PT J
AU Pei, LX
   Wang, G
   Yang, SH
   Zhou, SX
   Xu, TS
   Zhou, J
   Zhang, W
   Lu, KX
   Hu, LY
   Wang, Y
   Wang, K
   You, DF
   Wu, YQ
   Li, L
   Guo, J
   Sun, JH
AF Pei, Lixia
   Wang, Gang
   Yang, Sihao
   Zhou, Shuxin
   Xu, Tianshu
   Zhou, Jia
   Zhang, Wei
   Lu, Kaixin
   Hu, Linyan
   Wang, Yang
   Wang, Ke
   You, Dongfang
   Wu, Yaqian
   Li, Li
   Guo, Jing
   Sun, Jianhua
TI Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial
SO GASTROENTEROLOGY
LA English
DT Article
DE Gastric Cancer; Postoperative Ileus; Acupuncture; Recovery Time; Gastrointestinal Motility
ID quality-of-life; acupuncture; surgery; recovery; pain
AB BACKGROUND & AIMS: Electroacupuncture (EA) may reduce the duration of postoperative ileus (POI) after laparoscopic gastrectomy for gastric cancer, although evidence is limited. We investigated the efficacy of EA in reducing POI duration and enhancing gastrointestinal (GI) recovery in patients undergoing laparoscopic surgery for gastric cancer. METHODS: This multicenter randomized trial was conducted at 7 hospitals in China, enrolling 585 participants who underwent laparoscopic resection for gastric cancer from October 27, 2021, to December 21, 2023. Participants received perioperative standard care and were randomized to 4 sessions of EA, 4 sessions of sham EA (SA), or standard care only. The primary outcome was the time to first flatus. Secondary outcomes included time to first defecation, dietary recovery, quality of life, postoperative mobilization, and duration of hospital stay. RESULTS: A total of 578 participants were in the full analysis set. EA exhibited a shorter time to first flatus compared with both SA and standard care, with differences of-12.96 hours (95% confidence interval (CI), -19.17 to -6.75; P < .001) and-24.46 hours (95% CI, -30.61 to -18.30; P < .001), respectively. Similarly, EA significantly reduced the time to first defecation: -15.41 hours (95% CI, -27.73 to -3.09; P=.007) vs SA;-24.66 hours (95% CI, -36.76 to -12.55; P < .001) vs standard care. Incidence of prolonged POI was significantly lower in the EA group than in the SA and standard care groups, with group differences of -0.41 (95% CI, -0.66 to -0.16; P < .001) and -0.56 (95% CI, -0.82 to -0.31; P < .001), respectively. No severe adverse events were reported. CONCLUSIONS: EA was superior to SA and standard care only for reducing POI duration and the risk of prolonged POI in patients undergoing laparoscopic gastrectomy for gastric cancer.
C1 [Pei, Lixia; Hu, Linyan; Li, Li; Guo, Jing; Sun, Jianhua] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Clin Med Coll 1, Dept Acupuncture & Rehabil,Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Gang] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Gen Surg, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.
   [Yang, Sihao] Sichuan Univ, West China Hosp, Acupuncture Ctr, Chengdu, Sichuan, Peoples R China.
   [Yang, Sihao] West China Hosp, Yibin Hosp, Dept Integrated Tradit Chinese & Western Med, Yibin Peoples Hosp 2, Yibin, Sichuan, Peoples R China.
   [Zhou, Shuxin] Wenzhou Med Univ, Dept Acupuncture & Phys Therapy, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China.
   [Xu, Tianshu; Wang, Yang] Nanjing Univ, Sch Med, Dept Tradit Chinese Med, Affiliated Hosp,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
   [Zhou, Jia; Wang, Ke] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Acupuncture Anesthesia Clin Res Inst, Shanghai, Peoples R China.
   [Zhang, Wei] Hunan Univ Chinese Med, Dept Acupuncture Moxibust & Tuina, Affiliated Hosp 1, Changsha, Hunan, Peoples R China.
   [Lu, Kaixin] Subei Peoples Hosp Jiangsu Prov, Dept Acupuncture, Yangzhou, Jiangsu, Peoples R China.
   [You, Dongfang; Wu, Yaqian] Nanjing Med Univ, Sch Publ Hlth, Dept Biostat, Nanjing, Jiangsu, Peoples R China.
   [Guo, Jing] Nanjing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Sichuan University; Wenzhou Medical University; Nanjing University; Shanghai University of Traditional Chinese Medicine; Hunan University of Chinese Medicine; Nanjing Medical University; Nanjing University of Chinese Medicine
RP Sun, JH (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Clin Med Coll 1, Dept Acupuncture & Rehabil,Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.; Guo, J (corresponding author), Nanjing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM janiceguo@njucm.edu.cn; fsyy00657@njucm.edu.cn
FU Key Social Development Project of Jiangsu Provincial Science and Technology Department [BE2020788]; National Natural Science Foundation of China [82174489, 82274630, 82405589]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Blazeby JM, 2004, EUR J CANCER, V40, P2260, DOI 10.1016/j.ejca.2004.05.023
   Boeckxstaens GE, 2009, GUT, V58, P1300, DOI 10.1136/gut.2008.169250
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Chen HT, 2024, INT J SURG, V110, P1113, DOI 10.1097/JS9.0000000000000848
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   Chen KB, 2018, WORLD J GASTRO SURG, V10, P13, DOI 10.4240/wjgs.v10.i2.13
   Fei YT, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-064345
   Guerrini GP, 2020, INT J SURG, V82, P210, DOI 10.1016/j.ijsu.2020.07.053
   Han BF, 2024, J NATL CANCER CTR, V4, P47, DOI 10.1016/j.jncc.2024.01.006
   He FF, 2024, LANCET REG HEALTH-W, V44, P0, DOI 10.1016/j.lanwpc.2023.101003
   Hersberger L, 2020, CLIN NUTR, V39, P2720, DOI 10.1016/j.clnu.2019.11.041
   Jin T, 2023, SURGERY, V173, P375, DOI 10.1016/j.surg.2022.10.016
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Kong Q, 2024, INT J SURG, V110, P5713, DOI 10.1097/JS9.0000000000001641
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Lou SH, 2022, INT J SURG, V102, P0, DOI 10.1016/j.ijsu.2022.106678
   Murakami H, 2019, J NEUROGASTROENTEROL, V25, P286, DOI 10.5056/jnm18094
   Namikawa T, 2021, JGH OPEN, V5, P454, DOI 10.1002/jgh3.12515
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Qiu GT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5594263
   Reichert M, 2024, INT J SURG, V110, P4329, DOI 10.1097/JS9.0000000000001393
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Vilz TO, 2017, DTSCH ARZTEBL INT, V114, P508, DOI 10.3238/arztebl.2017.0508
   Wang CJ, 2021, GASTRIC CANCER, V24, P232, DOI 10.1007/s10120-020-01106-z
   Wang LP, 2022, MED ACUPUNCT, V34, P371, DOI 10.1089/acu.2021.0085
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Xu SB, 2020, BMJ-BRIT MED J, V368, P0, DOI 10.1136/bmj.m697
   Yan SY, 2023, UNITED EUR GASTROENT, V11, P564, DOI 10.1002/ueg2.12421
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   You XL, 2018, J CANCER, V9, P2266, DOI 10.7150/jca.24767
   Yuan L, 2024, J GASTROEN HEPATOL, V39, P2060, DOI 10.1111/jgh.16670
   Zhang WL, 2022, AM J CHINESE MED, V50, P961, DOI 10.1142/S0192415X22500392
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhu J, 2022, ACUPUNCT MED, V40, P415, DOI 10.1177/09645284221076517
NR 39
TC 18
Z9 19
U1 19
U2 30
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUL 15
PY 2025
VL 169
IS 1
BP 73
EP 84
DI 10.1053/j.gastro.2025.02.006
EA JUN 2025
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 5XA4C
UT WOS:001546358900006
PM 39978558
DA 2026-01-16
ER

PT J
AU Xu, YM
   Wu, JZ
   Jiang, QQ
   Lv, YY
   Zhou, J
   Wang, ZY
   Zhao, H
   Du, DP
AF Xu, Yongming
   Wu, Junzhen
   Jiang, Qingqing
   Lv, Yingying
   Zhou, Jin
   Wang, Zhiyu
   Zhao, Hui
   Du, Dongping
TI Efficacy of Transcutaneous Electrical Acupoint Stimulation on Modulating Upper Extremity Sympathetic Skin Response in Alleviating Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Propensity Score-Matched Cohort Study
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; chemotherapy-induced peripheral neuropathy; sympathetic skin response; cancer survivors; neuropathic pain
ID pain; paclitaxel; acupuncture
AB Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy and it is currently intractable We compared the efficacy of transcutaneous electrical acupoint stimulation (TEAS) against non-TEAS groups and investigated the variables that predict effective relief of upper extremity pain in cancer survivors with CIPN.<br /> Methods: We retrospectively collected data of cancer survivors who developed CIPN between May 2017 to March 2022. All eligible CIPN patients were divided into TEAS group (received TEAS) and non-TEAS group (did not receive TEAS) in our department. A 1:1 ratio propensity score matching (PSM) was used to balance the baseline features. The change of numerical rating scale (NRS), Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), and sympathetic skin response (SSR) parameters are all assessed after treatment. The procedure was considered a clinically effective relief if the patients' NRS scores were reduced by 50% or more, and overall patients with effective relief were all counted after treatment. Furthermore, a multivariable logistic regression model was utilized to evaluate the predictors of effective relief following CIPN treatment.<br /> Results: : A total of 102 cancer survivors with CIPN were analyzed after PSM (51 in each group). The change of NRS, SF-MPQ-2, SSR latency and SSR amplitude in TEAS group were significantly higher than those in non-TEAS group at 3 weeks after therapy (all P< 0.01). In addition, the effective relief rate was significantly higher in TEAS group than in non-TEAS group (P=0.026). Multivariate logistic regression on the total study cohort showed that TEAS group (OR 2.783, P = 0.025) and the baseline SSR amplitude of the upper extremity < 1265 mu V (OR 12.191, P = 0.000) were independent predictive factors for the clinical efficacy.<br /> Conclusions: : TEAS significantly decreased the severity of CIPN. TEAS group and baseline SSR amplitude of the upper extremity < 1265 mu V were the independent predictive factors for the clinical efficacy after treatment.
C1 [Xu, Yongming; Wu, Junzhen; Lv, Yingying; Zhou, Jin; Du, Dongping] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Pain Management Ctr, Sch Med, Shanghai, Peoples R China.
   [Jiang, Qingqing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurol, Sch Med, Shanghai, Peoples R China.
   [Wang, Zhiyu; Zhao, Hui] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Internal Oncol, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Du, DP (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Pain Management Ctr, Shanghai, Peoples R China.; Zhao, H (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhao-hui@sjtu.edu.cn; dudp@sjtu.edu.cn
FU National Natural Science Foundation of China [82271250]; Science Technology Department of School of Medicine, Shanghai Jiaotong University [TM202111]
CR Argyriou AA, 2005, EUR J NEUROL, V12, P858, DOI 10.1111/j.1468-1331.2005.01086.x
   ARUNODAYA GR, 1995, J NEUROL SCI, V129, P81, DOI 10.1016/0022-510X(94)00265-P
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Bulls HW, 2019, GYNECOL ONCOL, V152, P310, DOI 10.1016/j.ygyno.2018.12.002
   Chen S, 2024, PAIN THER, V13, P269, DOI 10.1007/s40122-024-00580-y
   Cheng Y, 2020, J CONTROL RELEASE, V318, P38, DOI 10.1016/j.jconrel.2019.12.011
   Cui X, 2023, J PAIN RES, V16, P2997, DOI 10.2147/JPR.S424841
   Cui X, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.822436
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   DSouza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   Fabry V, 2020, FRONT NEUROL, V11, P0, DOI 10.3389/fneur.2020.00342
   Fukuda Y, 2017, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00481
   Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Idiaquez J, 2023, NEUROPHYSIOL CLIN, V53, P0, DOI 10.1016/j.neucli.2022.102840
   Kang LM, 2021, J NEUROL, V268, P3269, DOI 10.1007/s00415-020-09942-w
   Karsidag S, 2005, DIABETES RES CLIN PR, V67, P211, DOI 10.1016/j.diabres.2004.07.017
   Kim DH, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-14359-z
   Lipov EG, 2009, MED HYPOTHESES, V72, P657, DOI 10.1016/j.mehy.2009.01.009
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lyu Z, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-023-08240-1
   Ma QF, 2022, CURR OPIN NEUROBIOL, V76, P0, DOI 10.1016/j.conb.2022.102602
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Ng DQ, 2020, FRONT NEUROL, V11, P0, DOI 10.3389/fneur.2020.604688
   Noguchi Y, 2018, BIOL PHARM BULL, V41, P1694, DOI 10.1248/bpb.b18-00444
   On AY, 2022, KOREAN J PAIN, V35, P327, DOI 10.3344/kjp.2022.35.3.327
   Saad M, 2014, CURR OPIN ONCOL, V26, P634, DOI 10.1097/CCO.0000000000000139
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2019, J PERIPHER NERV SYST, V24, PS26, DOI 10.1111/jns.12335
   Timmins HC, 2020, SUPPORT CARE CANCER, V28, P4459, DOI 10.1007/s00520-020-05299-y
   Vetrugno R, 2003, CLIN AUTON RES, V13, P256, DOI 10.1007/s10286-003-0107-5
   von Bischhoffshausen S, 2017, BRAIN, V140, P1238, DOI 10.1093/brain/awx069
   Wang YL, 2023, NEURAL PLAST, V2023, P0, DOI 10.1155/2023/9303419
   Westerhaus MJ, 2001, BRAIN RES, V903, P117, DOI 10.1016/S0006-8993(01)02453-2
   Xu YM, 2023, PAIN THER, V12, P785, DOI 10.1007/s40122-023-00499-w
   Yan WL, 2023, PAIN THER, V12, P631, DOI 10.1007/s40122-023-00496-z
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu XY, 2022, PAIN, V163, PE106, DOI 10.1097/j.pain.0000000000002321
   Zucker NA, 2017, PAIN MED, V18, P1582, DOI 10.1093/pm/pnx001
NR 46
TC 0
Z9 0
U1 5
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2025
VL 18
IS 
BP 293
EP 303
DI 10.2147/JPR.S500717
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA T3D6R
UT WOS:001403861000001
PM 39867541
DA 2026-01-16
ER

PT J
AU Bell, BK
   Cha, J
   Cavanaugh, KA
   O'Riordan, DL
   Rabow, MW
   Yang, AK
   Patel, S
   Park, SH
   McGrath, MK
   Whitaker, EM
   Nouri, SS
   Cheng, SW
AF Bell, Brieze K
   Cha, Jaeyoon
   Cavanaugh, Kathleen A
   O'Riordan, David L
   Rabow, Michael W
   Yang, Adrienne K
   Patel, Sohil
   Park, Sa Heen
   McGrath, Megan K
   Whitaker, Evans M
   Nouri, Sarah S
   Cheng, Stephanie W
TI Integrative Management of Cancer Pain: A Scoping Review of the Literature.
SO Cancer medicine
LA English
DT Journal Article
DE acupuncture; cancer pain; complementary and alternative medicine; integrative health; integrative medicine; integrative oncology; mindfulness
AB BACKGROUND: Cancer-related pain is common and debilitating. Patients frequently  use integrative medicine therapies to manage this, though safety and efficacy  evidence is incomplete. This scoping review aims to characterize the state of  integrative cancer pain therapy (ICPT) and identify priorities for future  research. METHODS: Following PRISMA guidelines, we searched PubMed, Embase, Web  of Science, PsycINFO, CINAHL, and Cochrane for ICPT studies published between  January 1, 1975 and May 26, 2022. Study findings were extracted and analyzed  using descriptive statistics and thematic analysis. Interventions were  categorized as follows: Whole Systems of Medicine (WSM); Mind-body Medicine  (MBM); Botanicals and Supplements (BAS); and Manual Therapies (MT). Quality  appraisal was performed using the Downs and Black checklist. Efficacy was  "positive" if there were statistically significant differences between study arms  (p < 0.05) favoring ICPT. RESULTS: Among 1246 studies reviewed, 151 met inclusion  criteria; 63.5% were excellent or good quality, and 68.9% were RCTs; 122 studies  (80.7%) were published since 2010. Studies occurred in 24 countries, in variable  settings, among participants with a wide range of cancers, disease status, and  age ranges. Studies investigating WSM and MBM interventions were most frequent  (35.7% for each), MT (20.59%), and BAS (7.9%). Overall, of the included studies,  127 (84.1%) found that the ICPT intervention reduced pain. CONCLUSIONS: Studies  on ICPT are increasingly common, and the majority of ICPT interventions  demonstrated a positive impact on cancer pain. Future rigorous research should  compare efficacy across integrative and biomedical interventions and explore how  to incorporate evidence-based ICPT into standard cancer treatment.
C1 University of California San Francisco, San Francisco, California, USA.
   Harvard Medical School, Boston, Massachusetts, USA.
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   The MERI Center for Education in Palliative Care, Supported by the Mount Zion 
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   Stanford University School of Medicine, Palo Alto, California, USA.
   University of California San Francisco, San Francisco, California, USA.
   University of California San Francisco, San Francisco, California, USA.
NR 0
TC 0
SN 2045-763
EI 
J9 Cancer Med
PD MAY 3
PY 2025
VL 14
IS 9
BP e70833
EP e70833
DI 10.1002/cam4.70833
PG 1
WC Humans; Cancer Pain; therapy; Pain Management; methods; Integrative Medicine; methods; Mind-Body Therapies; methods; Complementary Therapies; methods; Neoplasms; complications
UT PubMed:40317896
PM 40317896
DA 2025-05-03
ER

PT J
AU Ji, L
   Han, L
   Sharma, A
AF Ji, Lei
   Han, Lin
   Sharma, Aabha
TI Efficacy of acupuncture in managing radiotherapy/chemotherapy-induced oral mucositis: a systematic review and meta-analysis
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Oral mucositis; Radiotherapy; Chemotherapy; Acupuncture; Cancer; Meta-analysis
ID chemotherapy; radiotherapy; management; cancer
AB Purpose To evaluate the preventive and therapeutic efficacy of acupuncture modalities in radiation/chemotherapy-induced oral mucositis (RIOM/CIOM) management through evidence synthesis. Methods A systematic search was performed in eight biomedical databases: four English-language databases (PubMed, Embase, Web of Science, and Cochrane Library) and four Chinese-language databases (China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and SinoMed) for studies published up to July 25, 2025. Randomized controlled trials (RCTs) in English or Chinese investigating acupuncture for RIOM/CIOM were included. Dual independent extraction with standardized forms and quality appraisal using the Cochrane RoB 2.0 tool were implemented. The primary outcome was OM grading according to WHO, RTOG, or other recognized scales. The evidence quality was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. Results Eleven RCTs (n = 865) were included. Acupuncture significantly reduced moderate-to-severe OM incidence [RR = 0.58, 95% CI:0.45-0.76; P < 0.0001), with therapeutic interventions showing greater efficacy than preventive approaches (P < 0.0001). Auricular acupuncture showed substantial benefit (RR = 0.54 vs manual technique RR = 0.97). Other outcomes revealed significant ulcer duration reduction (SMD = -1.13, 95% CI -1.71-[-0.55]; P = 0.0001), pain score improvement (SMD = -1.89, P = 0.0005), and enhanced immune modulation (TGF-beta 1/IL-6 levels) with Karnofsky performance increase (MD = 5.83, P = 0.004). No severe adverse events were reported. The quality of evidence was rated as moderate due to significant heterogeneity observed across the studies. Conclusions The systematic review and meta-analysis found that acupuncture was effectively associated with preventing and treating RIOM/CIOM, shortening ulcer duration, reducing ulcer size, alleviating pain, and improving quality of life, although the evidence level was moderate. The finding suggests that more high-quality RCTs were needed for validation.
C1 [Ji, Lei; Han, Lin; Sharma, Aabha] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.
   [Ji, Lei; Han, Lin; Sharma, Aabha] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China.
   [Ji, Lei; Sharma, Aabha] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Han, L (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.; Han, L (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China.
EM tjhanlin@163.com
CR Aghamohammadi A, 2018, CLIN ORAL INVEST, V22, P2263, DOI 10.1007/s00784-017-2324-7
   Anderson C, 2025, SEMIN RADIAT ONCOL, V35, P271, DOI 10.1016/j.semradonc.2025.02.011
   Anshasi H, 2025, COMPLEMENT THER MED, V92, P0, DOI 10.1016/j.ctim.2025.103197
   Barati S, 2025, J PHOTOCH PHOTOBIO B, V264, P0, DOI 10.1016/j.jphotobiol.2025.113115
   Bissonnette C MK, 2020, J MICH DENT ASSOC, V0, P0
   [陈卫宏 Chen Weihong], 2022, 上海交通大学学报. 医学版 JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY .MEDICAL SCIENCE, V42, P635
   Chen YB, 2019, JOURNAL OF TRADITIONAL CHINESE MEDICINE, V0, P0
   Courtois E, 2021, BMC ORAL HEALTH, V21, P0, DOI 10.1186/s12903-021-01574-4
   de Sales PVA, 2025, ACTA CIR BRAS, V40, P0, DOI 10.1590/acb403125
   Duan YT, 2025, BMJ EVID-BASED MED, V0, P0, DOI DOI 10.1136/bmjebm-2024-113497
   Elad S, 2022, CA-CANCER J CLIN, V72, P57, DOI 10.3322/caac.21704
   Elsaadany B, 2024, BMC ORAL HEALTH, V24, P0, DOI 10.1186/s12903-024-04379-3
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Goel G, 2024, J CANCER RES THER, V20, P1564, DOI 10.4103/jcrt.jcrt_1200_23
   Higgins JT, 2019, J; CHANDLER, V0, P0
   Hu WJ, 2024, J QIQIHAR MED UNIV, V45, P1693
   Hu Y, 2024, CHINESE MODERN DOCTOR, V62, P82
   Hu ZX, 2013, JOURNAL OF NURSING SCIENCE, V0, P0
   Hua YC, 2022, SOUTHEAST NATIONAL DEFENSE MEDICAL JOURNAL, V24, P537
   Jiang S, 2020, GENERAL MEDICINE: CLINICAL AND EDUCATION, V18, P31
   [蒋瑛 Jiang Ying], 2023, 军事医学 MILITARY MEDICAL SCIENCES, V47, P657
   Jicman Stan D, 2022, MEDICINA (KAUNAS), V58, P0
   Juan Z, 2025, INT J SURG, V111, P2018, DOI 10.1097/JS9.0000000000002147
   Kim SY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9874207
   Kuang HJ, 2025, J INTEGR MED, V0, P0
   Lai Q, 2021, CLINICAL OBSERVATION ON THE THERAPEUTIC EFFECT OF FIRE NEEDLE IN CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN BREAST CANCER, V0, P0
   Li KX, 2017, ORAL ONCOL, V72, P32, DOI 10.1016/j.oraloncology.2017.06.026
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li X, 2023, ZHEJIANG JOURNAL OF TRAUMATIC SURGERY, V28, P0
   Li YX, 2024, FRONT CELL INFECT MI, V14, P0, DOI 10.3389/fcimb.2024.1477143
   Li YJ, 2024, STRAHLENTHER ONKOL, V200, P895, DOI 10.1007/s00066-024-02255-1
   [梁妍景 Liang Yanjing], 2023, 上海交通大学学报. 医学版 JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY .MEDICAL SCIENCE, V43, P208
   Liu DD, 2024, JOURNAL OF QIANNAN MEDICAL UNIVERSITY FOR NATIONALITIES, V37, P265
   LOCKHART PB, 1981, J DERMATOL SURG ONC, V7, P1019, DOI 10.1111/j.1524-4725.1981.tb00208.x
   Michel-Cherqui M, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08768-w
   Münstedt K, 2019, COMPLEMENT THER CLIN, V34, P145, DOI 10.1016/j.ctcp.2018.11.016
   Nicolatou-Galitis O, 2021, SUPPORT CARE CANCER, V29, P5701, DOI 10.1007/s00520-021-06048-5
   Niruthisard S, 2024, PAIN REP, V9, P0, DOI 10.1097/PR9.0000000000001188
   Nurhidayah I, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04710-z
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Parra-Rojas S, 2025, BIOMEDICINES, V13, P0, DOI 10.3390/biomedicines13020268
   Pereira-Riveros T, 2025, DENT J-BASEL, V13, P0, DOI 10.3390/dj13060254
   Qi J, 2018, J LIAONING UNIV TRADIT CHIN MED, V20, P216
   Shen BY, 2013, CHINESE JOURNAL OF TRADITIONAL CHINESE MEDICINE, V31, P0
   Sun Y, 2019, WORLD LATEST MEDICINE INFORMATION ABSTRACTS, V19, P1
   Villa A, 2021, SUPPORT CARE CANCER, V29, P6061, DOI 10.1007/s00520-021-06177-x
   Wang M, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1147718
   Wang ZH, 2025, NEUROSCIENCE, V573, P300, DOI 10.1016/j.neuroscience.2025.03.053
   Wu YQ, 2025, CANCER TREAT REV, V133, P0, DOI 10.1016/j.ctrv.2025.102883
   Xia J, 2025, INT J ORAL SCI, V17, P0, DOI 10.1038/s41368-025-00382-8
   Xie QH, 2024, CLINICAL RATIONAL DRUG USE, V17, P135
   Yang SK, 2015, JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE RESEARCH, V7, P0
   Yoshida K, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08836-1
   Yu YM, 2014, J NAVY MED UNIV, V117-118, P121
   Zhang ZX, 2025, BMC COMPLEMENT MED, V25, P0, DOI 10.1186/s12906-025-04930-x
NR 55
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD SEP 23
PY 2025
VL 33
IS 10
BP 
EP 
DI 10.1007/s00520-025-09931-7
PG 14
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 7SE6S
UT WOS:001578400700002
PM 40987848
DA 2026-01-16
ER

PT J
AU Wang, ZZ
   Zheng, XH
   Lin, J
   Zhou, B
   Zeng, ZM
   Gao, HW
   Chen, HX
   Tang, CZ
AF Wang, Zhenzhen
   Zheng, Xiahai
   Lin, Jing
   Zhou, Bin
   Zeng, Zhenming
   Gao, Haiwei
   Chen, Haoxiong
   Tang, Chunzhi
TI Electroacupuncture ameliorates cartilage damage in a rat model of knee osteoarthritis and regulates expression of miRNAs and the TLR4/NF-κB pathway
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE cartilage damage; inflammation; knee osteoarthritis; microRNA; TLR4; NF-kappa B
ID pain
AB Background: Electroacupuncture (EA) has been shown to be effective in the treatment of knee osteoarthritis (KOA); however, its underlying mechanism remains unclear.Methods: 40 KOA model rats were divided into control, untreated model, EA-treated model and celecoxib-treated model groups (n=10 each). Articular cartilage of the knee joint was stained with hematoxylin and eosin (HE), periodic acid-Schiff (PAS) and Alcian blue (AB)-PAS, and Moran/Mankin scores were used to evaluate articular cartilage injury across groups. Moreover, toll-like receptor (TLR)4/nuclear factor (NF)-kappa B pathway (TN-P)-related protein levels in the articular cartilage were detected using Western blotting. Oxidative stress and inflammatory biomarkers in the synovial fluid were measured by enzyme-linked immunosorbent assay (ELISA). MicroRNA (miRNA/miR) expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR).Results: Compared with the control group, Moran scores increased and Mankin scores decreased in the KOA model rats. In addition, compared with those in the control group, levels of superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and interleukin (IL)-10 were significantly decreased, while levels of IL-1 beta, IL-6, tumor necrosis factor (TNF)-alpha, malondialdehyde (MDA) and nitric oxide (NO) were significantly increased, in the synovial fluid of the KOA model group. Protein levels of TLR4, anti-myeloid differentiation primary response protein 88 (MyD88) and p65 NF-kappa B phosphorylation were significantly increased in the articular cartilage of the KOA model group. EA and celecoxib treatment reversed the trends of these protein levels. Moreover, expression of miR-15a/127/140/146a/216a-5p and miR-27a-3p in the articular cartilage were markedly increased in KOA rats, while EA and celecoxib treatment reduced their expression.Conclusions: EA reduces inflammation, oxidative stress and cartilage damage in KOA model rats, likely through regulation of the miRNA/TLR4/NF-kappa B pathway.
C1 [Wang, Zhenzhen; Zheng, Xiahai; Lin, Jing; Zhou, Bin; Zeng, Zhenming; Gao, Haiwei; Chen, Haoxiong] Guangzhou Univ Chinese Med, Dept Rehabil, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Wang, Zhenzhen; Tang, Chunzhi] Guangzhou Univ Chinese Med, Med Coll Acupuncture Moxibust & Rehabil, 12 Jichang Rd, Guangzhou 510000, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Tang, CZ (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acupuncture Moxibust & Rehabil, 12 Jichang Rd, Guangzhou 510000, Peoples R China.
EM jordan664@163.com
FU Project of Administration of Traditional Chinese Medicine of Guangdong Province of China [20202086]
CR Bisson DG, 2020, J CELL MOL MED, V24, P11355, DOI 10.1111/jcmm.15733
   Bu Y, 2022, CHIN J INTEGR MED, V28, P153, DOI 10.1007/s11655-021-3350-5
   Cao PH, 2020, EXPERT OPIN PHARMACO, V21, P797, DOI 10.1080/14656566.2020.1732924
   Chen N, 2017, AM J CHINESE MED, V45, P965, DOI 10.1142/S0192415X17500513
   Chou WC, 2022, ENVIRON TOXICOL, V37, P478, DOI 10.1002/tox.23414
   Geurts J, 2011, RHEUMATOLOGY, V50, P1216, DOI 10.1093/rheumatology/ker021
   Gregori D, 2018, JAMA-J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319
   Guo CG, 2020, GUT LIVER, V14, P179, DOI 10.5009/gnl19201
   Huang HT, 2021, PAIN MED, V22, P352, DOI 10.1093/pm/pnaa230
   Huang Z, 2023, IMMUNOPHARM IMMUNOT, V45, P61, DOI 10.1080/08923973.2022.2115924
   Jokar Z, 2024, SAGE OPEN NURS, V10, P0, DOI 10.1177/23779608241260822
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Li ZY, 2020, J MUSCULOSKEL NEURON, V20, P398
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   MORAN ME, 1992, J BONE JOINT SURG BR, V74, P659, DOI 10.1302/0301-620X.74B5.1527109
   Nasi S, 2014, JOINT BONE SPINE, V81, P320, DOI 10.1016/j.jbspin.2014.01.018
   Papathanasiou I, 2020, BIOCHEM BIOPH RES CO, V522, P783, DOI 10.1016/j.bbrc.2019.11.168
   Sahbaz T, 2024, REUMATISMO, V76, P121, DOI 10.4081/reumatismo.2024.1660
   Shi XW, 2020, BIOMED PHARMACOTHER, V123, P0, DOI 10.1016/j.biopha.2019.109724
   Sun SY, 2023, EVID-BASED COMPL ALT, V2023, P0, DOI 10.1155/2023/9050763
   Sun XS, 2019, INT J ENV RES PUB HE, V16, P0, DOI 10.3390/ijerph16234701
   Wan HS, 2022, J INT MED RES, V50, P0, DOI 10.1177/03000605221104764
   Wang KW, 2023, J ORTHOP SURG RES, V18, P0, DOI 10.1186/s13018-023-04201-w
   Wang Y, 2019, ARTIF CELL NANOMED B, V47, P1241, DOI 10.1080/21691401.2019.1596940
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
   Xu XT, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.951860
   Yu Yi-Nan, 2022, ZHEN CI YAN JIU, V47, P471, DOI 10.13702/j.1000-0607.20211269
   Zeng XJ, 2022, J ENVIRON PUBLIC HEA, V2022, P0, DOI 10.1155/2022/1933504
   Zhang GC, 2020, LIFE SCI, V261, P0, DOI 10.1016/j.lfs.2020.118429
   Zhang Xiao-Qin, 2023, ZHEN CI YAN JIU, V48, P185, DOI 10.13702/j.1000-0607.20220246
   Zhang YC, 2022, AUTOIMMUNITY, V55, P577, DOI 10.1080/08916934.2022.2103798
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
NR 32
TC 1
Z9 1
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD JUN 15
PY 2025
VL 43
IS 3
BP 164
EP 173
DI 10.1177/09645284251342259
EA MAY 2025
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3LT9J
UT WOS:001491070800001
PM 40390302
DA 2026-01-16
ER

PT J
AU Henry, NL
   Kidwell, KM
   Kozar, S
   Snyder, S
   Zick, SM
AF Henry, N Lynn
   Kidwell, Kelley M
   Kozar, Stephanie
   Snyder, Sara
   Zick, Suzanna M
TI Self-acupressure for patients with breast cancer experiencing aromatase
SO PloS one
LA English
DT Journal Article
AB BACKGROUND: Aromatase inhibitors (AI) reduce hormone receptor-positive breast  cancer recurrence risk by about 50%. However, half of AI-treated postmenopausal  women report new or worsened musculoskeletal symptoms (AIMSS), and 20%  discontinue therapy prematurely. Acupuncture is effective for reducing symptoms,  but many women are not able to access acupuncture therapy. We hypothesize that  self-administered acupressure will reduce AIMSS. MATERIALS AND METHODS:  Postmenopausal women who have been receiving treatment with an AI for more than 3  weeks but less than 2 years, and who report new or worsened joint pain or  myalgias since starting AI therapy with worst pain of at least 4 out of 10 on a  numerical rating scale, are eligible. Fifty participants will be enrolled and  randomized 1:1 to treatment with true or sham acupressure for 12 weeks.  Participants will self-apply pressure for 3 minutes to each of the 9 acupoints  daily. All participants will complete a pain assessment weekly, and a battery of  symptom questionnaires every 6 weeks. Optional stool samples will be collected  after 0 and 12 weeks of acupressure to examine changes in the gut microbiome. The  primary endpoint is change in worst pain on the Brief Pain Inventory-Short Form  with 12 weeks of the acupressure intervention, evaluated with generalized  estimating equations. CONCLUSION: Determination that self-administered  acupressure reduces AIMSS in this randomized phase 2 pilot trial will lead to a  larger randomized phase 3 clinical trial to confirm the efficacy of  self-acupressure. Reduction of AI-related arthralgias may improve persistence  with breast cancer therapy, breast cancer outcomes, and quality of life for  AI-treated patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT06228768.
C1 University of Michigan Medical School, Ann Arbor, MI, United States of America.
   University of Michigan School of Public Health, Ann Arbor, MI, United States of America.
   University of Michigan Medical School, Ann Arbor, MI, United States of America.
   University of Michigan Medical School, Ann Arbor, MI, United States of America.
   University of Michigan Medical School, Ann Arbor, MI, United States of America.
   University of Michigan School of Public Health, Ann Arbor, MI, United States of
NR 0
TC 0
SN 1932-620
EI 
J9 PLoS One
PD JAN 22
PY 2025
VL 20
IS 1
BP e0311044
EP e0311044
DI 10.1371/journal.pone.0311044
PG 1
WC Aged; Female; Humans; Middle Aged; Acupressure; methods; Aromatase Inhibitors; adverse effects; Arthralgia; therapy; Breast Neoplasms; drug therapy; Pilot Projects; Postmenopause; Randomized Controlled Trials as Topic
UT PubMed:39841658
PM 39841658
DA 2025-01-22
ER

PT J
AU Lu, LY
   Huang, XH
   Liu, C
   Wang, XY
   Lv, JQ
AF Lu, Lingyun
   Huang, Xianhao
   Liu, Ci
   Wang, Xiaoyu
   Lv, Jianqin
TI Perioperative intradermal acupuncture reduces postoperative nausea and vomiting after cerebellopontine angle tumor resection: a randomized clinical trial including mechanistic insights
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE intradermal acupuncture; metabolomics; PC6; postoperative nausea and vomiting; randomized controlled trial
ID heart-rate-variability; consensus guidelines; mass-spectrometry; management; electroacupuncture; modulation
AB Background: The aim of this study was to evaluate the impact of intradermal acupuncture (IA) at PC6 on postoperative nausea and vomiting (PONV) following cerebellopontine angle tumor resection, and to investigate possible mechanisms of action.Methods: Seventy patients scheduled for elective craniotomy were randomized into IA or sham IA (Sham) groups, with interventions applied 1 h before surgery and continued for 24 h postoperatively. Co-primary outcomes were the incidence of vomiting at 0-6 h and 6-24 h post-surgery. Secondary outcomes included the incidence of nausea and pain intensity. Electrogastrography (EGG) and heart rate variability (HRV) were used to assess gastric activity and autonomic nerve function, respectively. Untargeted metabolomic analysis of serum and cerebrospinal fluid (CSF) was also performed.Results: The incidence of vomiting at 6-24 h (but not 0-6 h) post-surgery was significantly lower in the IA group (12.1%) compared to the Sham group (36.4%; p = 0.022). IA significantly reduced the incidence of nausea at 0-6 h (48.5% vs 78.8%; p = 0.011) but not 6-24 h. HRV analysis showed a higher HF component in the IA group post-surgery. Metabolomic analyses revealed significant changes in multiple metabolites and pathways in serum and CSF.Conclusion: IA stimulation at PC6 effectively reduced postoperative vomiting at 6-24 h following cerebellopontine angle tumor resection and may also reduce early nausea (at 0-6 h). The mechanisms of action underlying these effects potentially include modulation of vagus nerve activity and regulation of metabolic pathways.Trial registration number: ChiCTR2100049992 (Chinese Clinical Trial Registry)
C1 [Lu, Lingyun; Huang, Xianhao; Liu, Ci; Lv, Jianqin] Sichuan Univ, West China Hosp, Inst Integrated Tradit Chinese & Western Med, Div Internal Med, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Xiaoyu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Lv, JQ (corresponding author), Sichuan Univ, West China Hosp, Inst Integrated Tradit Chinese & Western Med, Div Internal Med, Chengdu 610041, Sichuan, Peoples R China.
EM lvjianqin@wchscu.cn
FU National Outstanding Youth Science Fund Project of National Natural Science Foundation of China [82304958]
CR Agrusa AS, 2022, IEEE T BIO-MED ENG, V69, P3313, DOI 10.1109/TBME.2022.3167338
   Andrews PLR, 2002, CURR OPIN PHARMACOL, V2, P650, DOI 10.1016/S1471-4892(02)00227-8
   Babic T, 2014, EUR J PHARMACOL, V722, P38, DOI 10.1016/j.ejphar.2013.08.047
   BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0
   Billman GE, 2013, FRONT PHYSIOL, V4, P0, DOI 10.3389/fphys.2013.00026
   Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377
   Eberhart LHJ, 2007, BEST PRAC RES-CL ANA, V21, P575, DOI 10.1016/j.bpa.2007.06.007
   Gan TJ, 2020, ANESTH ANALG, V131, P411, DOI 10.1213/ANE.0000000000004833
   Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002
   Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259
   Horn CC, 2014, EUR J PHARMACOL, V722, P55, DOI 10.1016/j.ejphar.2013.10.037
   Hu XM, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1826-9
   Huang ST, 2005, AM J CHINESE MED, V33, P157, DOI 10.1142/S0192415X0500276X
   Kao TW, 2024, J TRADIT COMPL MED, V14, P666, DOI 10.1016/j.jtcme.2024.03.014
   Khaliulin I, 2019, NEUROBIOL STRESS, V11, P0, DOI 10.1016/j.ynstr.2019.100189
   Ko CW, 2020, NAT REV GASTRO HEPAT, V17, P169, DOI 10.1038/s41575-019-0250-7
   Latz B, 2011, J NEUROSURG, V114, P491, DOI 10.3171/2010.9.JNS10151
   Li Jin-Jin, 2016, ZHEN CI YAN JIU, V41, P240
   Liu S, 2008, NEUROGASTROENT MOTIL, V20, P1204, DOI 10.1111/j.1365-2982.2008.01164.x
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Maharjan A, 2022, NEUROMODULATION, V25, P1268, DOI 10.1016/j.neurom.2021.10.005
   Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383
   Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, PW388, DOI 10.1093/nar/gkab382
   SATO AKIO, 1966, BRAIN RES, V2, P399, DOI 10.1016/0006-8993(66)90011-4
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Tokumaru O, 2005, SCAND J GASTROENTERO, V40, P319, DOI 10.1080/00365520410009636
   Tu LD, 2024, COMPLEMENT THER CLIN, V54, P0, DOI 10.1016/j.ctcp.2023.101824
   Uchida S, 2017, AUTON NEUROSCI-BASIC, V203, P1, DOI 10.1016/j.autneu.2016.11.001
   Usichenko TI, 2014, ACUPUNCT MED, V32, P212, DOI 10.1136/acupmed-2014-010580
   Usichenko TI, 2013, BRIT J ANAESTH, V110, P87, DOI 10.1093/bja/aes352
   Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230
   Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004
   Weibel S, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012859.pub2
   Xu M, 2012, J NEUROSURG ANESTH, V24, P312, DOI 10.1097/ANA.0b013e31825eb5ef
   Yang Q, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-137
   Yu Z, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3182
   Zhang W, 2017, CHIN J SURG INTEGR T, V23, P144
   Zhou Y, 2014, J NEURAL TRANSM, V121, P799, DOI 10.1007/s00702-014-1180-8
NR 38
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD DEC 15
PY 2025
VL 43
IS 6
BP 330
EP 343
DI 10.1177/09645284251399690
EA NOV 2025
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA P8173
UT WOS:001626105400001
PM 41310932
DA 2026-01-16
ER

PT J
AU Shen, QY
   Deng, DH
   Li, GL
   Ruan, JY
   Shao, XY
   Wang, PP
   Li, XY
   Li, RR
   Bao, WL
   Chen, WJ
   Lu, C
AF Shen, Qiongying
   Deng, Dehou
   Li, Guangliang
   Ruan, Jiayin
   Shao, Xiying
   Wang, Peipei
   Li, Xiaoyu
   Li, Rongrong
   Bao, Wenlong
   Chen, Weiji
   Lu, Chao
TI Electroacupuncture frequency for chemotherapy-induced neuropathy in breast cancer: a randomized controlled trial
SO ONCOLOGIST
LA English
DT Article
DE electroacupuncture; breast cancer; chemotherapy-induced peripheral neuropathy
ID quality-of-life; induced peripheral neuropathy; acupuncture; pain; questionnaire; therapy; rats
AB Background Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent dose-limiting toxicity in breast cancer patients. Electroacupuncture (EA) shows promise but optimal stimulation parameters remain undefined. We conducted a randomized trial comparing EA frequencies for CIPN.Methods This single-center, single-blind trial randomized patients to 2, 100, and 2/100 Hz EA, or mecobalamin (Mecbl). The primary outcome was the patient neurotoxicity questionnaire (PNQ) response rate at Week 4. Secondary outcomes included PNQ scores, National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades at Weeks 4/8, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) and Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scales.Results 2/100 Hz EA achieved the highest overall response rate. Both 2 and 2/100 Hz EA improved PNQ sensory scores at Week 4. Sensory scores improved across groups, while motor scores decreased with 2 and 2/100 Hz EA. Only 2 Hz EA improved autonomic function. For quality-of-life, 2 Hz EA enhanced physical function, fatigue, pain and insomnia, while 2/100 Hz EA improved nausea/vomiting, constipation, appetite and global health with additional pain relief at Week 4. The 100 Hz EA group showed no significant benefits in these domains.Conclusions This study preliminarily explored EA's potential benefits for CIPN, with 2/100 Hz showing the highest response rate and 2 Hz demonstrating sensory improvement advantages. Different frequencies produced distinct therapeutic profiles. Further research should evaluate frequency-specific effects of EA for CIPN.
C1 [Shen, Qiongying; Li, Xiaoyu] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou 310053, Peoples R China.
   [Deng, Dehou; Wang, Peipei; Bao, Wenlong; Lu, Chao] Zhejiang Canc Hosp, Dept Tradit Chinese Med, 1 East Banshan Rd, Hangzhou 310022, Peoples R China.
   [Li, Guangliang; Shao, Xiying] Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou 310022, Peoples R China.
   [Ruan, Jiayin] Hong Kong Polytech Univ, Sch Nursing, Hong Kong 999077, Peoples R China.
   [Li, Rongrong; Chen, Weiji] Chinese Med Univ, Affiliated Hosp Zhejiang 3, Zhongshan Hosp Zhejiang Prov, Dept Acupuncture & Moxibust, Hangzhou 310009, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Hong Kong Polytechnic University; China Medical University
RP Lu, C (corresponding author), Zhejiang Canc Hosp, Dept Tradit Chinese Med, 1 East Banshan Rd, Hangzhou 310022, Peoples R China.
EM luchao@zjcc.org.cn
FU Zhejiang Traditional Chinese Medicine Administration [2022ZB058]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Basch E, 2014, JNCI-J NATL CANCER I, V106, P0, DOI 10.1093/jnci/dju244
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Chan KY, 2023, ACUPUNCT MED, V41, P268, DOI 10.1177/09645284221125421
   Cocks K, 2008, EUR J CANCER, V44, P1793, DOI 10.1016/j.ejca.2008.05.008
   Deng B, 2022, CHIN J INTEGR MED, V28, P579, DOI 10.1007/s11655-022-3575-y
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247
   Hiramoto S, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0261473
   Hu LY, 2019, CURR NEUROPHARMACOL, V17, P184, DOI 10.2174/1570159X15666170915143217
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu C, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.843886
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, PST1, DOI 10.1089/acm.2010.1610
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Nyrop KA, 2019, CANCER-AM CANCER SOC, V125, P2945, DOI 10.1002/cncr.32175
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Schwab L, 2023, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.1005083
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shimozuma K, 2012, SUPPORT CARE CANCER, V20, P3355, DOI 10.1007/s00520-012-1492-x
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Teare MD, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-264
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Xiong X, 2025, SIGNAL TRANSDUCT TAR, V10, P0, DOI 10.1038/s41392-024-02108-4
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yeh ML, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04603-1
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
NR 39
TC 0
Z9 0
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD SEP 15
PY 2025
VL 30
IS 9
BP 
EP 
DI 10.1093/oncolo/oyaf262
PG 11
WC Oncology
SC Oncology
GA 7MV5B
UT WOS:001574767000001
PM 40828899
DA 2026-01-16
ER

PT J
AU Henry, NL
   Kidwell, KM
   Kozar, S
   Snyder, S
   Zick, SM
AF Henry, N. Lynn
   Kidwell, Kelley M.
   Kozar, Stephanie
   Snyder, Sara
   Zick, Suzanna M.
TI Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trial
SO PLOS ONE
LA English
DT Article
ID acupuncture; pain; outcm; therapy; fatigue; women; discontinuation; multicenter; survivors
AB Background Aromatase inhibitors (AI) reduce hormone receptor-positive breast cancer recurrence risk by about 50%. However, half of AI-treated postmenopausal women report new or worsened musculoskeletal symptoms (AIMSS), and 20% discontinue therapy prematurely. Acupuncture is effective for reducing symptoms, but many women are not able to access acupuncture therapy. We hypothesize that self-administered acupressure will reduce AIMSS. Materials and methods Postmenopausal women who have been receiving treatment with an AI for more than 3 weeks but less than 2 years, and who report new or worsened joint pain or myalgias since starting AI therapy with worst pain of at least 4 out of 10 on a numerical rating scale, are eligible. Fifty participants will be enrolled and randomized 1:1 to treatment with true or sham acupressure for 12 weeks. Participants will self-apply pressure for 3 minutes to each of the 9 acupoints daily. All participants will complete a pain assessment weekly, and a battery of symptom questionnaires every 6 weeks. Optional stool samples will be collected after 0 and 12 weeks of acupressure to examine changes in the gut microbiome. The primary endpoint is change in worst pain on the Brief Pain Inventory-Short Form with 12 weeks of the acupressure intervention, evaluated with generalized estimating equations. Conclusion Determination that self-administered acupressure reduces AIMSS in this randomized phase 2 pilot trial will lead to a larger randomized phase 3 clinical trial to confirm the efficacy of self-acupressure. Reduction of AI-related arthralgias may improve persistence with breast cancer therapy, breast cancer outcomes, and quality of life for AI-treated patients.
C1 [Henry, N. Lynn; Kozar, Stephanie; Snyder, Sara; Zick, Suzanna M.] Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA.
   [Henry, N. Lynn; Kidwell, Kelley M.; Zick, Suzanna M.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of Michigan System; University of Michigan
RP Henry, NL (corresponding author), Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA.
EM norahh@med.umich.edu
FU Breast Cancer Research Foundation [23-206]
CR Baker JM, 2017, MATURITAS, V103, P45, DOI 10.1016/j.maturitas.2017.06.025
   Bao CH, 2022, ECLINICALMEDICINE, V45, P0, DOI 10.1016/j.eclinm.2022.101300
   Bao T, 2018, INTEGR CANCER THER, V17, P854, DOI 10.1177/1534735418754309
   Barron TI, 2013, BRIT J CANCER, V109, P1513, DOI 10.1038/bjc.2013.518
   Bauml J, 2015, BREAST CANCER RES, V17, P0, DOI 10.1186/s13058-015-0599-7
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011
   Chang YJ, 2007, SUPPORT CARE CANCER, V15, P891, DOI 10.1007/s00520-007-0219-x
   Chirgwin JH, 2016, J CLIN ONCOL, V34, P2452, DOI 10.1200/JCO.2015.63.8619
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Fibromyalgianess Wolfe F, 2009, ARTHRITIS RHEUM, V61, P715, DOI 10.1002/art.24553
   Greenlee H, 2015, J ACUPUNCT MERIDIAN, V8, P152, DOI 10.1016/j.jams.2015.03.006
   Hao XX, 2021, ARTHRITIS RES THER, V23, P0, DOI 10.1186/s13075-021-02427-9
   Henry NL, 2010, BRIT J CANCER, V103, P291, DOI 10.1038/sj.bjc.6605768
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2014, J PAIN, V15, P468, DOI 10.1016/j.jpain.2014.01.487
   Henry NL, 2013, BREAST CANCER RES TR, V138, P807, DOI 10.1007/s10549-013-2504-3
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Hertz DL, 2022, SUPPORT CARE CANCER, V30, P8059, DOI 10.1007/s00520-022-07243-8
   Jang JC, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/6249329
   Joyce E, 2023, BREAST CANCER RES TR, V197, P397, DOI 10.1007/s10549-022-06806-x
   Keefe JR, 2017, J PSYCHIATR RES, V84, P90, DOI 10.1016/j.jpsychires.2016.09.029
   Kelley ST, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0146509
   Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mao JJ, 2011, BREAST CANCER RES, V13, P0, DOI 10.1186/bcr2813
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246
   Wang TQ, 2021, FRONT CELL INFECT MI, V11, P0, DOI 10.3389/fcimb.2021.597431
   Wolfe F, 2011, J RHEUMATOL, V38, P1113, DOI 10.3899/jrheum.100594
   Zick SM, 2014, JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, V20, PA23, DOI 10.1089/acm.2014.5057.abstract
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
   Zick SM, 2021, CONTEMP CLIN TRIALS, V107, P0, DOI 10.1016/j.cct.2021.106477
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 42
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 
EI 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2025
VL 20
IS 1
BP 
EP 
DI 10.1371/journal.pone.0311044
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 2VJ3V
UT WOS:001492214200010
PM 39841658
DA 2026-01-16
ER

PT J
AU Yao, C
   Zeng, X
   Zhang, S
   Xiao, B
   Sun, P
   Kong, L
   Tao, J
   Fang, M
AF Yao, Chongjie
   Zeng, Xinyu
   Zhang, Shuaipan
   Xiao, Bin
   Sun, Pingping
   Kong, Lingjun
   Tao, Jiming
   Fang, Min
TI Acupoint massage: a comprehensive descriptive review of its forms, applications,
SO Chinese medicine
LA English
DT Review
DE Acupoint; Acupressure; Massage; Mechanism; Tuina
AB Acupoint massage is a non-invasive traditional therapy that has demonstrated  reliable clinical outcomes in pain management, mental health relief, sleep  disorder regulation, gastrointestinal treatment, and as an adjunct therapy for  cancer. Its convenience and cost-effectiveness further enhance its appeal.  However, the existing English literature lacks a systematic review that  encompasses the various forms of acupoint massage. The acupoint massage forms  adaptability is particularly notable when considering the diverse conditions, it  addresses, as well as its applicability across different age groups and gender  differences. Providing a comprehensive understanding, it is crucial to outline  common practices and explore specific applications in key areas. The  comprehensive understanding can create opportunities for effective collaboration  between preclinical and clinical studies. Defining and categorizing different  forms of acupoint massage is essential, alongside investigating the neural  circuits involved in touch sensation. Future efforts should enhance collaboration  with modern biology, facilitating the transition from empirical to evidence-based  practice. This review summarizes forms, applications, and mechanisms of  mainstream acupoint massage and provides insights for future research and  applications, promoting deeper integration into healthcare.
C1 Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional 
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional 
   School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
   Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. taoyecheng@163.com.
   Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. fm-tn0510@shutcm.edu.cn.
   Research Institute of Tuina, Shanghai Academy of Traditional Chinese Medicine,
NR 0
TC 0
SN 1749-854
EI 1749-854
J9 Chin Med
PD APR 24
PY 2025
VL 20
IS 1
BP 54
EP 54
DI 10.1186/s13020-025-01105-1
PG 0
UT PubMed:40270014
PM 40270014
DA 2025-04-24
ER

PT J
AU Naughton, MJ
   Zahrieh, DM
   Gnant, M
   Zdenkowski, N
   Lemieux, J
   Mao, JJ
   Bjelic-Radisic, V
   Shinn, E
   Balic, M
   Thomssen, C
   Meisel, JL
   Ruiz, GM
   Loibl, S
   Isaacs, C
   Cameron, D
   Henao-Carrasco, FM
   Goetz, MP
   Singer, CF
   Werutsky, G
   Rugo, HS
   Vetter, M
   Tseng, LM
   Miller, K
   Fitzal, F
   Gil, JMG
   Park, H
   Linderholm, B
   Bajetta, E
   Dayao, Z
   Prat, A
   Ehrhardt, K
   Metzger, O
   Arahmani, A
   Law, EH
   Partridge, AH
   Carey, LA
   Zoroufy, A
   Dueck, AC
   O'Brien, P
   Hlauschek, D
   Demichele, A
   Mayer, EL
AF Naughton, M. J.
   Zahrieh, D. M.
   Gnant, M.
   Zdenkowski, N.
   Lemieux, J.
   Mao, J. J.
   Bjelic-Radisic, V.
   Shinn, E.
   Balic, M.
   Thomssen, C.
   Meisel, J. L.
   Ruiz, G. M.
   Loibl, S.
   Isaacs, C.
   Cameron, D.
   Henao-Carrasco, F. M.
   Goetz, M. P.
   Singer, C. F.
   Werutsky, G.
   Rugo, H. S.
   Vetter, M.
   Tseng, L. -m.
   Miller, K.
   Fitzal, F.
   Gil, J. M. Gil
   Park, H.
   Linderholm, B.
   Bajetta, E.
   Dayao, Z.
   Prat, A.
   Ehrhardt, K.
   Metzger, O.
   Arahmani, A.
   Law, E. H.
   Partridge, A. H.
   Carey, L. A.
   Zoroufy, A.
   Dueck, A. C.
   O'Brien, P.
   Hlauschek, D.
   Demichele, A.
   Mayer, E. L.
TI Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
SO ESMO OPEN
LA English
DT Article
DE breast cancer; quality of life; symptoms; palbociclib; adjuvant endocrine therapy; PALLAS
ID inhibitor-related arthralgia; risk; electroacupuncture; validity; model
AB Background: The PALLAS phase III, randomized trial investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) improved invasive disease-free survival (iDFS) over adjuvant ET alone. This study reports the patient-reported outcomes (PROs) by treatment arm. Patients and methods: A total of 4688 of 5796 PALLAS patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II-III breast cancer completed PRO measures. Patients were randomly assigned (1 : 1) to either 2 years of palbociclib (125 mg/day, 3 weeks on 1 week off) plus ongoing provider or patient-choice adjuvant ET (palbociclib + ET) versus ongoing ET alone. Eight PRO endpoints were measured serially (i.e. day 1 of each monthly cycle for the first 3 months, then every 3 months for 2 years, and once at 3 years). These endpoints were the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/quality-of-life (QoL) score, the Brief Fatigue Inventory (BFI) score, the modified Brief Pain Inventory (mBFI) severity and pain interference scores, the EORTC Core Quality of Life Questionaire-Breast 23 (QLQ-BR23) alopecia score, and the Breast Cancer Prevention Trial (BCPT) hot flash symptoms, vaginal problems, and musculoskeletal pain scores. Treatment with palbociclib stopped after the second interim analysis (May 2020) due to futility, and patients transitioned to follow-up. Results: After adjustment for baseline covariates, on average, no significant differences between arms were observed on any of the eight endpoints over the study period. However, there were differences by treatment regimen in the worsening of symptoms over time, and by race and ethnicity. These findings have important implications for the management of symptoms in HR-positive/HER2-negative breast cancer survivors receiving endocrine and/or other therapies long term. Conclusions: No clinically significant differences in patient-reported QoL or symptom severity were found by treatment arm. However, the results of the PRO analyses may inform patient-centered communication and adherence efforts regarding treatment toxicity in subgroups of survivors.
C1 [Naughton, M. J.] Ohio State Univ, Columbus, OH USA.
   [Zahrieh, D. M.; Goetz, M. P.; Zoroufy, A.] Mayo Clin, Alliance Fdn Trials Stat, Rochester, MN USA.
   [Zahrieh, D. M.; Goetz, M. P.; Zoroufy, A.] Mayo Clin, Data Ctr, Rochester, MN USA.
   [Gnant, M.; Fitzal, F.] Med Univ Vienna AT, Vienna, Austria.
   [Gnant, M.; Fitzal, F.; Prat, A.; Ehrhardt, K.; Hlauschek, D.] Austrian Breast & Colorectal Canc Study Grp ABCSG, Vienna, Austria.
   [Zdenkowski, N.] Univ Newcastle, Callagan, Australia.
   [Lemieux, J.] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Mao, J. J.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Bjelic-Radisic, V.] Univ Witten Herdecke, Wuppertal, Germany.
   [Shinn, E.] MD Anderson Canc Ctr, Houston, TX USA.
   [Balic, M.] Med Univ Graz, Graz, Austria.
   [Thomssen, C.] Universitatsfrauenklin Halle, Wittenberg, Germany.
   [Meisel, J. L.] Emory Univ, Atlanta, GA USA.
   [Ruiz, G. M.] European Med Ctr, Moscow, Russia.
   [Loibl, S.] German Breast Grp, Neu Isenburg, Germany.
   [Isaacs, C.] Georgetown Univ, Washington, DC USA.
   [Cameron, D.] Canc Res UK Edinburgh Ctr, Edinburgh, Scotland.
   [Henao-Carrasco, F. M.] Hosp Virgen Macarena Sevilla, Seville, Spain.
   [Henao-Carrasco, F. M.] GEICAM Collaborat Grp, Seville, Spain.
   [Goetz, M. P.] Mayo Clin, Rochester, MN USA.
   [Singer, C. F.] Breast Ctr, Sankt Veit An Der Glan, Austria.
   [Werutsky, G.] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil.
   [Rugo, H. S.] Univ Calif San Francisco, San Francisco, CA USA.
   [Vetter, M.] Univ Hosp Basel, Basel, Switzerland.
   [Tseng, L. -m.] Taipei Vet Gen Hosp, Taipei, Taiwan.
   [Miller, K.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA.
   [Gil, J. M. Gil] Catalan Inst Oncol, Barcelona, Spain.
   [Park, H.] Washington Univ, Sch Med, St Louis, MO USA.
   [Linderholm, B.] Karolinska Inst, Solna, Sweden.
   [Bajetta, E.] Polyclin Hosp, Inst Oncol, Monza, Italy.
   [Dayao, Z.] Univ New Mexico Hosp, Albuquerque, NM USA.
   [Prat, A.] Hosp Clin Barcelona, Barcelona, Spain.
   [Metzger, O.; Mayer, E. L.] Dana Farber Canc Inst, Boston, MA USA.
   [Arahmani, A.] Breast Int Grp, Brussels, Belgium.
   [Law, E. H.] Pfizer Inc, New York, NY USA.
   [Carey, L. A.] Univ North Carolina, Chapel Hill, NC USA.
   [Dueck, A. C.; O'Brien, P.] Mayo Clin, Alliance Fdn Trials Stat, Phoenix, AZ USA.
   [Dueck, A. C.; O'Brien, P.] Mayo Clin, Data Ctr, Phoenix, AZ USA.
   [Demichele, A.] Univ Penn, Philadelphia, PA USA.
C3 University System of Ohio; Ohio State University; Mayo Clinic; Mayo Clinic; University of Newcastle; Laval University; Laval University Hospital; Memorial Sloan Kettering Cancer Center; Witten Herdecke University; University of Texas System; UTMD Anderson Cancer Center; Medical University of Graz; Emory University; German Breast Group; Georgetown University; Mayo Clinic; University of California System; University of California San Francisco; University of Basel; Taipei Veterans General Hospital; Indiana University System; Indiana University Indianapolis; Institut Catala d'Oncologia; Washington University (WUSTL); Karolinska Institutet; University of New Mexico; University of Barcelona; Hospital Clinic de Barcelona; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Breast International Group; Pfizer; Pfizer USA; University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of Pennsylvania
RP Naughton, MJ (corresponding author), Ohio State Univ, Dept Internal Med, Div Canc Prevent & Control, 3650 Olentangy River Rd,Suite 200, Columbus, OH 43214 USA.
EM Michelle.Naughton@osumc.edu
FU Austrian Breast and Colorectal Cancer Study Group; Alliance Foundation Trials, LLC; PrECOG, LLC; NSABP Foundation, Inc.; German Breast Group; Breast International Group; Pfizer
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Gnant M, 2022, J CLIN ONCOL, V40, P282, DOI 10.1200/JCO.21.02554
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Gundy CM, 2012, QUAL LIFE RES, V21, P1607, DOI 10.1007/s11136-011-0082-6
   Kieffer JM, 2014, QUAL LIFE RES, V23, P24
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2011, BREAST CANCER RES, V13, P0, DOI 10.1186/bcr2813
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Mayer EL, 2022, J CLIN ONCOL, V40, P449, DOI 10.1200/JCO.21.01918
   Mayer EL, 2021, LANCET ONCOL, V22, P212, DOI 10.1016/S1470-2045(20)30642-2
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Naughton MJ, 2021, CANCER-AM CANCER SOC, V127, P300, DOI 10.1002/cncr.33184
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   Rugo HS, 2022, ANN ONCOL, V33, P616, DOI 10.1016/j.annonc.2022.03.006
   Rugo HS, 2019, BREAST CANCER RES TR, V174, P719, DOI 10.1007/s10549-018-05125-4
   Rugo HS, 2018, ANN ONCOL, V29, P888, DOI 10.1093/annonc/mdy012
   Sloan J, 2003, J CANCER INTEGR MED, V1, P41
   Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3
   Stanton AL, 2005, JNCI-J NATL CANCER I, V97, P448, DOI 10.1093/jnci/dji069
   Tolaney SM, 2024, EUR J CANCER, V199, P0, DOI 10.1016/j.ejca.2024.113555
   Wheeler SB, 2019, JNCI-J NATL CANCER I, V111, P498, DOI 10.1093/jnci/djy136
   Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PD JUN 15
PY 2025
VL 10
IS 6
BP 
EP 
DI 10.1016/j.esmoop.2025.105120
EA JUN 2025
PG 11
WC Oncology
SC Oncology
GA 3SS3U
UT WOS:001508099600003
PM 40472660
DA 2026-01-16
ER

PT J
AU Chen, C
   Wang, Y
AF Chen, Chuihai
   Wang, Yujie
TI [Penetrating needling of three eye acupoints combined with sodium hyaluronate eye
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; dry eye; penetrating needling; randomized controlled trial (RCT); sodium hyaluronate eye drops; three eye acupoints
AB OBJECTIVE: To compare the clinical efficacy between penetrating needling of three  eye acupoints combined with sodium hyaluronate eye drops and sodium hyaluronate  eye drops alone for the treatment of dry eye. METHODS: A total of 156 patients  (312 eyes) with dry eye were randomly assigned to an observation group and a  control group, with 78 patients (156 eyes) in each group. The control group was  treated with sodium hyaluronate eye drops, one drop per eye, four times daily,  for 4 weeks. In addition to the sodium hyaluronate treatment, the observation  group received penetrating needling of three eye acupoints. Acupoints included  bilateral Cuanzhu (BL2), Sizhukong (TE23), Sibai (ST2), and Jingming (BL1).  Needling was performed once daily, four times a week, for 4 weeks. The subjective  ocular symptom scores, neuropathic pain symptom inventory-eye (NPSI-Eye) scores,  ocular surface disease index (OSDI) scores, corneal fluorescein staining (FL)  scores, tear break-up time (BUT), SchirmerⅠtest (SⅠT), central tear meniscus  height (TMH), and tear levels of interleukin-6 (IL-6) and tumor necrosis  factor-alpha (TNF-α) were evaluated before and after treatment in the two groups.  Clinical efficacy was also compared between the two groups. RESULTS: After  treatment, both groups showed significant improvements in subjective ocular  symptom scores, NPSI-Eye scores, OSDI scores, FL scores, and reductions in tear  IL-6 and TNF-α levels (P<0.01). Additionally, BUT, SⅠT, and TMH were increased  significantly in both groups (P<0.01). After treatment, the subjective ocular  symptom scores, NPSI-Eye score, OSDI score, FL score, and tear levels of IL-6 and  TNF-α in the observation group were lower than those in the control group  (P<0.01, P<0.05), while BUT, SⅠT, and TMH were significantly improved compared to  the control group (P<0.01). The markedly effective rate and total effective rate  in the observation group were 83.3% (65/78) and 100.0% (78/78), respectively,  which were higher than 52.6% (41/78, P<0.01) and 92.3% (72/78, P<0.05) in the  control group. CONCLUSION: The penetrating needling of three eye acupoints  combined with sodium hyaluronate eye drops can effectively alleviate symptoms of  dry eye, reduce inflammatory response, and has superior efficacy to sodium  hyaluronate eye drops alone.
C1 Ophthalmology Department, Bao'an District TCM Hospital, Shenzhen 518133, Guangdong Province, China.
   Pediatric Neurological Rehabilitation Department, Shenzhen Maternity and Child Healthcare Hospital.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 15
PY 2025
VL 45
IS 5
BP 633
EP 637
DI 10.13703/j.0255-2930.20240521-0002
PG 4
WC Humans; Hyaluronic Acid; administration & dosage; Male; Female; Dry Eye Syndromes; therapy; Middle Aged; Acupuncture Points; Ophthalmic Solutions; administration & dosage; Adult; Aged; Treatment Outcome; Acupuncture Therapy; Interleukin-6; metabolism; Young Adult; Tumor Necrosis Factor-alpha; metabolism
UT PubMed:40369920
PM 40369920
DA 2025-05-15
ER

PT J
AU Hao, YB
   Liu, YL
   Wang, XM
   Cheng, K
   Tu, QY
   Dai, F
   Yang, XB
AF Hao, Ya-Bo
   Liu, Yan-Lin
   Wang, Xiao-Mei
   Cheng, Kai
   Tu, Qing-Yu
   Dai, Fei
   Yang, Xi-Bing
TI Effects of Electroacupuncture at ST36 on Visceral Pain and Inflammatory Markers
SO Neurogastroenterology and motility
LA English
DT Journal Article
DE Zusanli; electroacupuncture; inflammatory biomarkers; visceral hypersensitivity; visceral pain
AB BACKGROUND: Irritable bowel syndrome (IBS) is characterized by recurrent visceral  pain associated with low-grade gut inflammation. Electroacupuncture (EA) at  acupoint ST36 (Zusanli) is reputed to alleviate gastrointestinal disorders, but  its effects on IBS-related visceral hypersensitivity and inflammation remain to  be fully elucidated. This study evaluated whether EA at ST36 attenuates visceral  pain and modulates key inflammatory mediators in the IBS rat model. METHODS:  Forty male rats were randomly assigned to Control, IBS model, IBS + EA, and  IBS + Sham groups (n = 10 each). IBS was induced by intracolonic acetic acid  enema combined with daily restraint stress for 1 week, validating the IBS-D  model. EA was applied at bilateral ST36 (2/100 Hz alternating frequency, ~0.5 mA,  20 min) every other day for 2 weeks; sham treatment used superficial needling  with no electrical current. Visceral pain was assessed by abdominal withdrawal  reflex (AWR) scores and electromyographic responses to graded colorectal  distension. Colonic tissues were analyzed for pro-inflammatory cytokines  (interleukin-1β, IL-6, tumor necrosis factor-α) by ELISA and for the expression  of pain or inflammation-related proteins (TRPV1 and nuclear factor kappa B,  NF-κB) by Western blot analyses. RESULTS: IBS model rats exhibited pronounced  visceral hypersensitivity, with AWR scores significantly elevated (e.g., score 3  threshold volume reduced by ~40% vs. controls, p < 0.01). EA at ST36 markedly  alleviated visceral pain, increasing pain threshold and reducing AWR scores by  ~30%-50% compared to untreated IBS (p < 0.05). EA also significantly  downregulated colonic IL-1β, IL-6, and TNF-α levels (by 45%-60% vs. IBS,  p < 0.01) and reduced TRPV1 and NF-κB expression toward normal levels.  CONCLUSION: EA at ST36 produced significant analgesic and anti-inflammatory  effects in IBS model rats. Visceral hypersensitivity was blunted and colonic  inflammatory biomarkers (cytokines, TRPV1, NF-κB) were suppressed by EA,  suggesting that EA at ST36 modulates neuro-immune pathways to relieve IBS-related  pain. These findings support the therapeutic potential of ST36-targeted  electroacupuncture for managing IBS visceral pain via inflammatory mechanism  attenuation.
C1 Acupuncture and Moxibustion Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
   Acupuncture and Moxibustion Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
   Acupuncture and Moxibustion Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
   Pediatrics Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
   Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
   Division of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
   Acupuncture and Moxibustion Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
NR 0
TC 0
SN 1365-298
EI 
J9 Neurogastroenterol Motil
PD DEC 19
PY 2025
VL 0
IS 
BP e70195
EP e70195
DI 10.1111/nmo.70195
PG 1
UT PubMed:41413920
PM 41413920
DA 2025-12-19
ER

PT J
AU Ding, ZW
   Wang, XH
   Han, DD
   Zhang, C
   Xie, KJ
   Zhou, HD
   Yuan, XH
   Mao, XC
   Yu, WF
   Huang, ZX
AF Ding, Zewu
   Wang, Xihui
   Han, Dongdong
   Zhang, Can
   Xie, Kangjie
   Zhou, Huidan
   Yuan, Xiaohong
   Mao, Xiaochun
   Yu, Weifeng
   Huang, Zhangxiang
TI Comparison of the analgesic efficacy of ultrasound-guided retrolaminar block with serratus anterior plane block in patients undergoing radical mastectomy
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Postoperative pain; nerve block; retrolaminar block; serratus anterior plane block; radical mastectomy
ID paravertebral block; cancer-surgery; breast surgery; pain
AB Objectives: The newly introduced retrolaminar block (RLB) offers anesthesiologists an alternative regional anesthetic technique for radical mastectomy. However, few clinical studies have compared the efficacy of RLB with that of serratus anterior plane block (SAPB). This study aimed to investigate the postoperative analgesia efficacy between ultrasound-guided RLB and SAPB in patients undergoing radical mastectomy. Methods: Seventy patients were included in this prospective, randomized controlled trial. Patients were assigned to receive either ultrasoundguided RLB or SAPB. The primary outcome was the visual analogue scale (VAS) score during coughing at 6 hours postoperatively. The secondary indicators included dermatomal spread of sensory block (from T2 to T6 at the medial and lateral nipple lines assessed by acupuncture), intraoperative hemodynamic changes, and analgesia-related adverse reactions. Results: The median VAS scores during coughing at 6 hours postoperatively were 2 (IQ1-IQ3: 1-3; P = 0.39) in both groups, indicating no significant difference. Similar analgesic effects were observed at other time points within 48 hours post-surgery. RLB provided broader sensory coverage on the medial side of the nipple compared to SAPB (median [IQR]: 3 (3-4) and 2 (1-2)) (P = 0.006). No significant differences in mean arterial pressure (MAP) or heart rate (HR) were observed immediately or 5 minutes after skin incision. The incidence of adverse events did not differ significantly between the two groups. Conclusions: Retrolaminar block and Serratus anterior plane block provide comparable postoperative analgesia following radical mastectomy. However, RLB offers a broader sensory block range, particularly over the medial chest wall.
C1 [Ding, Zewu; Xie, Kangjie; Zhou, Huidan; Yuan, Xiaohong] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Anesthesiol, Hangzhou 310005, Zhejiang, Peoples R China.
   [Wang, Xihui] Shaoxing Peoples Hosp, Dept Anesthesiol, Shaoxing 312300, Zhejiang, Peoples R China.
   [Han, Dongdong; Zhang, Can] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou 310005, Zhejiang, Peoples R China.
   [Mao, Xiaochun] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Thyroid Surg, Hangzhou 310005, Zhejiang, Peoples R China.
   [Yu, Weifeng] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, 145 Shandong Middle Rd, Shanghai 200001, Peoples R China.
   [Huang, Zhangxiang] Kunming Med Univ, Affiliated Hosp 1, Dept Pain, 295 Xichang Rd, Kunming 650000, Yunnan, Peoples R China.
C3 Zhejiang Cancer Hospital; Chinese Academy of Sciences; Hangzhou Institute of Medicine, CAS; Zhejiang Cancer Hospital; Wenzhou Medical University; Zhejiang Cancer Hospital; Chinese Academy of Sciences; Hangzhou Institute of Medicine, CAS; Shanghai Jiao Tong University; Kunming Medical University
RP Yu, WF (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, 145 Shandong Middle Rd, Shanghai 200001, Peoples R China.; Huang, ZX (corresponding author), Kunming Med Univ, Affiliated Hosp 1, Dept Pain, 295 Xichang Rd, Kunming 650000, Yunnan, Peoples R China.
EM ywf808@yeah.net; adams7777@163.com
FU Zhejiang Provincial Health Science and Technology Program Young Innovative Talents Project [2022RC015]; Zhejiang Traditional Chinese Medicine Science and Technology Plan [2023ZL302]; Zhejiang Medical Science and Technology Plan [2020-KY482]; National Natural Science Foundation of China [82160229]
CR Abdallah FW, 2021, ANAESTHESIA, V76, P1190, DOI 10.1111/anae.15373
   Alseoudy MM, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110421
   Ball L, 2016, CURR OPIN CRIT CARE, V22, P379, DOI 10.1097/MCC.0000000000000312
   Bennett GJ, 2000, J PAIN SYMPTOM MANAG, V19, P0
   Bican O, 2013, NEUROL CLIN, V31, P1, DOI 10.1016/j.ncl.2012.09.009
   Boezaart AP, 2009, CURR OPIN ANESTHESIO, V22, P637, DOI 10.1097/ACO.0b013e32832f3277
   Cho TH, 2021, REGION ANESTH PAIN M, V46, P699, DOI 10.1136/rapm-2021-102588
   Damjanovska M, 2018, J PAIN RES, V11, P293, DOI 10.2147/JPR.S153660
   Dubowitz J, 2021, CURR OPIN ANESTHESIO, V34, P317, DOI 10.1097/ACO.0000000000001002
   Ekinci M, 2022, PAIN MED, V23, P870, DOI 10.1093/pm/pnac004
   Elsharkawy H, 2020, KOREAN J ANESTHESIOL, V73, P550
   Heller GZ, 2016, SCAND J PAIN, V13, P67, DOI 10.1016/j.sjpain.2016.06.012
   Hwang BY, 2020, KOREAN J PAIN, V33, P378, DOI 10.3344/kjp.2020.33.4.378
   Jacobs A, 2020, ANAESTHESIA, V75, P664, DOI 10.1111/anae.14964
   Jayadeep I, 2022, CUREUS J MED SCIENCE, V14, P0, DOI 10.7759/cureus.30828
   Jüttner T, 2011, J CLIN ANESTH, V23, P443, DOI 10.1016/j.jclinane.2010.12.015
   Kamel AAF, 2022, PAIN PHYSICIAN, V25, P0
   Marshall K, 2020, THORAC SURG CLIN, V30, P339, DOI 10.1016/j.thorsurg.2020.03.001
   Massard G, 1998, CHEST SURG CLIN N AM, V8, P503
   Mayes J, 2016, ANAESTHESIA, V71, P1064, DOI 10.1111/anae.13549
   ONeill Archana, 2022, ANESTHESIOL CLIN, V40, P455, DOI 10.1016/j.anclin.2022.04.002
   Onishi E, 2018, TOHOKU J EXP MED, V245, P179, DOI 10.1620/tjem.245.179
   Pfeiffer G, 2006, ANAESTHESIST, V55, P423, DOI 10.1007/s00101-005-0969-0
   Qian B, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110410
   Ross JDW, 2021, HEART LUNG CIRC, V30, P1244, DOI 10.1016/j.hlc.2020.12.001
   Sabouri AS, 2018, REGION ANESTH PAIN M, V43, P864, DOI 10.1097/AAP.0000000000000828
   Shi KJ, 2021, ANN PALLIAT MED, V10, P6104, DOI 10.21037/apm-21-199
   Shibata Y, 2009, ANESTH ANALG, V109, P996, DOI 10.1213/ane.0b013e3181af7e7b
   Singariya G, 2023, INDIAN J ANAESTH, V67, PS12, DOI 10.4103/ija.ija_90_23
   Sotome S, 2021, J ANESTH, V35, P27, DOI 10.1007/s00540-020-02855-y
   Voscopoulos C, 2013, CAN J ANESTH, V60, P888, DOI 10.1007/s12630-013-9983-x
   Zhao YP, 2022, BRAZ J ANESTHESIOL, V72, P115, DOI 10.1016/j.bjane.2021.04.004
NR 32
TC 0
Z9 0
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2025
VL 17
IS 7
BP 5090
EP 5099
DI 10.62347/PUCP3777
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 5RB2M
UT WOS:001542299900016
PM 40821082
DA 2026-01-16
ER

PT J
AU Yao, CJ
   Zeng, XY
   Zhang, SP
   Xiao, B
   Sun, PP
   Kong, LJ
   Tao, JM
   Fang, M
AF Yao, Chongjie
   Zeng, Xinyu
   Zhang, Shuaipan
   Xiao, Bin
   Sun, Pingping
   Kong, Lingjun
   Tao, Jiming
   Fang, Min
TI Acupoint massage: a comprehensive descriptive review of its forms, applications, and underlying mechanisms
SO CHINESE MEDICINE
LA English
DT Review
DE Acupoint; Massage; Acupressure; Tuina; Mechanism
ID foot reflexology massage; quality-of-life; auricular acupressure; sleep quality; pleasant touch; rat model; acupuncture; pain; electroacupuncture; anxiety
AB Acupoint massage is a non-invasive traditional therapy that has demonstrated reliable clinical outcomes in pain management, mental health relief, sleep disorder regulation, gastrointestinal treatment, and as an adjunct therapy for cancer. Its convenience and cost-effectiveness further enhance its appeal. However, the existing English literature lacks a systematic review that encompasses the various forms of acupoint massage. The acupoint massage forms adaptability is particularly notable when considering the diverse conditions, it addresses, as well as its applicability across different age groups and gender differences. Providing a comprehensive understanding, it is crucial to outline common practices and explore specific applications in key areas. The comprehensive understanding can create opportunities for effective collaboration between preclinical and clinical studies. Defining and categorizing different forms of acupoint massage is essential, alongside investigating the neural circuits involved in touch sensation. Future efforts should enhance collaboration with modern biology, facilitating the transition from empirical to evidence-based practice. This review summarizes forms, applications, and mechanisms of mainstream acupoint massage and provides insights for future research and applications, promoting deeper integration into healthcare.
C1 [Yao, Chongjie; Zhang, Shuaipan; Xiao, Bin; Kong, Lingjun; Tao, Jiming; Fang, Min] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China.
   [Yao, Chongjie; Zeng, Xinyu; Xiao, Bin] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.
   [Sun, Pingping] Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, Shanghai 201203, Peoples R China.
   [Fang, Min] Shanghai Acad Tradit Chinese Med, Res Inst Tuina, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Tao, JM; Fang, M (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China.; Fang, M (corresponding author), Shanghai Acad Tradit Chinese Med, Res Inst Tuina, Shanghai 200437, Peoples R China.
EM taoyecheng@163.com; fm-tn0510@shutcm.edu.cn
FU National Natural Science Foundation of China [82305423, 82305424, 82030121]; China Postdoctoral Science Foundation [2023M732338]; Shanghai Post-doctoral Excellence Program [2022515]; Yangfan Special Project of Shanghai Science and Technology Innovation Action Plan [23YF1447600]; Shanghai health system key supported discipline [2023ZDFC0301]; Shanghai University of TCM Science and Technology Development Project [23 KFL009]; Shanghai Innovative Medical Device Application Demonstration Project [23SHS05400]; Pudong New Area Health Commission's Medical-Enterprise Integration Project [2024-PWYC-03]
CR Acupuncture AG, 1973, CHIN MED J, V86, P118
   Akgün M, 2020, INT J QUAL HEALTH C, V32, P609, DOI 10.1093/intqhc/mzaa107
   Çevik SA, 2021, HEALTH CARE WOMEN IN, V42, P710, DOI 10.1080/07399332.2020.1800014
   Alimoradi Zainab, 2023, COMPLEMENT THER CLIN PRACT, V52, P101762, DOI 10.1016/j.ctcp.2023.101762
   Alinia-najjar R, 2020, BURNS, V46, P1942, DOI 10.1016/j.burns.2020.04.035
   Alizadeh J, 2021, SUPPORT CARE CANCER, V29, P7307, DOI 10.1007/s00520-021-06304-8
   Andersen LB, 2012, ACTA OBSTET GYN SCAN, V91, P1261, DOI 10.1111/j.1600-0412.2012.01476.x
   Unknown -, 1986, PAIN SUPPL, V3, P0
   Areeudomwong P, 2022, COMPLEMENT THER CLIN, V48, P0, DOI 10.1016/j.ctcp.2022.101604
   Aust H, 2018, J PSYCHOSOM RES, V111, P133, DOI 10.1016/j.jpsychores.2018.05.012
   Baggley A, 2004, J MIDWIFERY WOM HEAL, V49, P350, DOI 10.1016/j.jmwh.2004.03.011
   Bagheri-Nesami M, 2014, COMPLEMENT THER CLIN, V20, P42, DOI 10.1016/j.ctcp.2013.10.006
   Ballegaard S, 1996, ACUPUNCTURE ELECTRO, V21, P187, DOI 10.3727/036012996816356834
   Bazarganipour F, 2017, COMPLEMENT THER MED, V34, P10, DOI 10.1016/j.ctim.2017.07.004
   Bernhardt IS, 2019, PSYCHOTHER RES, V29, P959, DOI 10.1080/10503307.2018.1490972
   Blunt Elizabeth, 2006, HOLIST NURS PRACT, V20, P257
   Booth B, 1994, NURS TIMES, V90, P38
   Bradley EH, 2017, QJM-INT J MED, V110, P61, DOI 10.1093/qjmed/hcw187
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Brown CA, 2014, J INTEGR MED-JIM, V12, P94, DOI 10.1016/S2095-4964(14)60010-8
   Buttagat V, 2024, COMPLEMENT THER MED, V83, P0, DOI 10.1016/j.ctim.2024.103056
   Cabo Fernando, 2018, INT J THER MASSAGE BODYWORK, V11, P4, DOI 10.3822/ijtmb.v11i2.391
   Cha HS, 2020, J PEDIATR NURS, V51, PE57, DOI 10.1016/j.pedn.2019.08.016
   Chang S, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00110
   Chen TR, 2019, J PSYCHIATR RES, V118, P73, DOI 10.1016/j.jpsychires.2019.08.014
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Choi EM, 2012, CHIN MED-UK, V7, P0, DOI 10.1186/1749-8546-7-4
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Chua IS, 2019, JAMA ONCOL, V5, P734, DOI 10.1001/jamaoncol.2019.0042
   Chung KF, 2015, J CLIN PSYCHIAT, V76, PE752, DOI 10.4088/JCP.14m09124
   Cockerham WC, 2017, AM J PREV MED, V52, PS5, DOI 10.1016/j.amepre.2016.09.010
   Collister D, 2019, CLIN KIDNEY J, V12, P559, DOI 10.1093/ckj/sfy129
   Cui JM, 2011, CHIN J INTEGR MED, V17, P464, DOI 10.1007/s11655-011-0631-4
   Cui X, 2018, J PAIN RES, V11, P483, DOI 10.2147/JPR.S152015
   Danner U, 2024, COMPLEMENT THER CLIN, V57, P0, DOI 10.1016/j.ctcp.2024.101884
   de Zambotti M, 2015, J CLIN ENDOCR METAB, V100, P1426, DOI 10.1210/jc.2014-3892
   Dieleman JL, 2020, JAMA-J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734
   Dieleman JL, 2017, JAMA-J AM MED ASSOC, V318, P1668, DOI 10.1001/jama.2017.15927
   Dong YJ, 2021, BIOMED PHARMACOTHER, V143, P0, DOI 10.1016/j.biopha.2021.112141
   Dopheide JA, 2020, AM J MANAG CARE, V26, PS76, DOI 10.37765/ajmc.2020.42769
   Du MH, 2015, J SURG RES, V195, P89, DOI 10.1016/j.jss.2014.12.043
   Duan DM, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/7950635
   Dupuis LL, 2018, CANCER-AM CANCER SOC, V124, P1188, DOI 10.1002/cncr.31198
   Einarson TR, 2013, J POPUL THER CLIN PH, V20, P0
   Fan TT, 2019, SLEEP, V42, P0, DOI 10.1093/sleep/zsy192
   Feng CW, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6678958
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   Flint J, 2014, NEURON, V81, P484, DOI 10.1016/j.neuron.2014.01.027
   Fu HY, 2018, LIFE SCI, V197, P109, DOI 10.1016/j.lfs.2018.02.005
   Gao P, 2015, EXP THER MED, V9, P1577, DOI 10.3892/etm.2015.2348
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Giannaki Christoforos D, 2017, WORLD J NEPHROL, V6, P236, DOI 10.5527/wjn.v6.i5.236
   Godley E, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101146
   Gong J, 2024, EXPLORE-NY, V20, P17, DOI 10.1016/j.explore.2023.06.015
   Gong MR, 2012, AM J CHINESE MED, V40, P511, DOI 10.1142/S0192415X12500395
   Guo DH, 2022, CLIN REHABIL, V36, P350, DOI 10.1177/02692155211049155
   Guo J, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.918652
   Guo Y, 2022, ACUPUNCT HERB MED, V2, P1, DOI 10.1097/HM9.0000000000000023
   Hamidzadeh A, 2022, EXPLORE-NY, V18, P567, DOI 10.1016/j.explore.2021.10.005
   Han KY, 2019, PAIN, V160, P712, DOI 10.1097/j.pain.0000000000001450
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   Han S, 2024, J HUM LACT, V40, P248, DOI 10.1177/08903344241228545
   Harorani M, 2021, HEART LUNG, V50, P893, DOI 10.1016/j.hrtlng.2021.07.013
   Heckroth M, 2021, J CLIN GASTROENTEROL, V55, P279, DOI 10.1097/MCG.0000000000001485
   Hmwe NTT, 2015, INT J NURS STUD, V52, P509, DOI 10.1016/j.ijnurstu.2014.11.002
   Hsu ES, 2010, AM J THER, V17, P476, DOI 10.1097/MJT.0b013e3181ea7821
   Hu S, 2015, WORLD J GASTROENTERO, V21, P1468, DOI 10.3748/wjg.v21.i5.1468
   Hu XM, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1826-9
   Hu YC, 2021, J CLIN NURS, V30, P3398, DOI 10.1111/jocn.15865
   Huang A, 2023, J ACUPUNCT MERIDIAN, V16, P109, DOI 10.51507/j.jams.2023.16.3.109
   Huang HC, 2021, J ADV NURS, V77, P1683, DOI 10.1111/jan.14699
   Huang YQ, 2020, COMPLEMENT THER CLIN, V40, P0, DOI 10.1016/j.ctcp.2020.101198
   Huyett P, 2021, J CLIN SLEEP MED, V17, P1981, DOI 10.5664/jcsm.9392
   Inangil D, 2020, J CLIN NURS, V29, P1094, DOI 10.1111/jocn.15172
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   Jiang SW, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/8041820
   Jiang ZF, 2023, FRONT PHYSIOL, V14, P0, DOI 10.3389/fphys.2023.1257660
   Jin HO, 1996, AM J PHYSIOL-GASTR L, V271, PG524, DOI 10.1152/ajpgi.1996.271.3.G524
   Jing XM, 2018, COMPLEMENT THER CLIN, V31, P282, DOI 10.1016/j.ctcp.2018.03.005
   Jueckstock JK, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-46
   Kagitani F, 2010, AUTON NEUROSCI-BASIC, V157, P2, DOI 10.1016/j.autneu.2010.03.004
   Keeratitanont K, 2015, COMPLEMENT THER CLIN, V21, P26, DOI 10.1016/j.ctcp.2015.01.006
   Kerautret Y, 2020, FRONT PHYSIOL, V11, P0, DOI 10.3389/fphys.2020.598898
   Kim YK, 2016, PROG NEURO-PSYCHOPH, V64, P277, DOI 10.1016/j.pnpbp.2015.06.008
   Kirca AS, 2021, EXPLORE-NY, V17, P463, DOI 10.1016/j.explore.2020.07.004
   Kobayashi D, 2019, COMPLEMENT THER MED, V45, P33, DOI 10.1016/j.ctim.2019.05.019
   Kong XL, 2023, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.1016222
   Kuo SY, 2016, INT J NURS STUD, V53, P17, DOI 10.1016/j.ijnurstu.2015.10.006
   Lanza G, 2018, COMPLEMENT THER MED, V38, P74, DOI 10.1016/j.ctim.2018.04.013
   Li H, 2018, NEW CHIN MED, V50, P20
   Li JQ, 2024, ASIAN J PSYCHIATR, V92, P0, DOI 10.1016/j.ajp.2023.103884
   Li JX, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07967-1
   Li MK, 2014, COMPLEMENT THER MED, V22, P266, DOI 10.1016/j.ctim.2014.01.010
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Li Q, 2019, PSYCHONEUROENDOCRINO, V101, P193, DOI 10.1016/j.psyneuen.2018.11.016
   Li SS, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.864046
   Li X, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8850653
   Li YL, 2024, DISPLAYS, V83, P0, DOI 10.1016/j.displa.2024.102743
   Liang C, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13318
   Liang FX, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/735297
   Liang Y, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919847810
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Liu BL, 2022, SCIENCE, V376, P483, DOI 10.1126/science.abn2479
   Liu K, 2023, ACUPUNCT HERB MED, V3, P55, DOI 10.1097/HM9.0000000000000058
   Liu LZ, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03235-z
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu ZF, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8528938
   Loeser JD, 1999, LANCET, V353, P1607, DOI 10.1016/S0140-6736(99)01311-2
   Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061
   Lu HB, 2022, HOLIST NURS PRACT, V36, PE27, DOI 10.1097/HNP.0000000000000532
   Luo D, 2017, MED SCI MONITOR, V23, P3080, DOI 10.12659/MSM.902549
   Luo T, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.00063
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   Marcolin ML, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-03873-5
   Marlow AM, 2014, ACUPUNCT MED, V32, P294, DOI 10.1136/ACUPMED-2014-010591
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Miyahara Y, 2024, FRONT NEUROL, V15, P0, DOI 10.3389/fneur.2024.1327448
   Miyahara Yuka, 2018, J TRADIT COMPLEMENT MED, V8, P261, DOI 10.1016/j.jtcme.2018.01.004
   Mo YP, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/179796
   Moloney ME, 2019, SSM-POPUL HLTH, V8, P0, DOI 10.1016/j.ssmph.2019.100388
   Monson E, 2019, J ALTERN COMPLEM MED, V25, P517, DOI 10.1089/acm.2018.0422
   Morehead A, 2020, NURS CLIN N AM, V55, P571, DOI 10.1016/j.cnur.2020.07.001
   Mosavi Z, 2023, BMC MED EDUC, V23, P0, DOI 10.1186/s12909-023-04825-w
   Hmwe NTT, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101163
   Netchanok Sritoomma, 2012, COMPLEMENT THER CLIN PRACT, V18, P227, DOI 10.1016/j.ctcp.2012.07.001
   Nieh HC, 2023, COMPLEMENT THER CLIN, V53, P0, DOI 10.1016/j.ctcp.2023.101801
   Park H, 2012, J PHYSIOL SCI, V62, P351, DOI 10.1007/s12576-012-0211-1
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Pedraz-Petrozzi B, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-66532-6
   Pei M, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.576050
   Peng ZH, 2024, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1341072
   Pereira PJS, 2017, NEURON, V93, P723, DOI 10.1016/j.neuron.2017.02.016
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Qin P, 2019, J INTEGR MED-JIM, V17, P24, DOI 10.1016/j.joim.2018.11.002
   Qin QG, 2014, WORLD J GASTROENTERO, V20, P18271, DOI 10.3748/wjg.v20.i48.18271
   Rice ASC, 2016, PAIN, V157, P791, DOI 10.1097/j.pain.0000000000000454
   Santoro A, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/457390
   Sarosiek I, 2017, J NEUROGASTROENTEROL, V23, P245, DOI 10.5056/jnm16097
   Schitter AM, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0229705
   Sharifi N, 2022, BMC PREGNANCY CHILDB, V22, P0, DOI 10.1186/s12884-022-04376-w
   Shi Y, 2016, COMPLEMENT THER MED, V25, P71, DOI 10.1016/j.ctim.2016.01.004
   Skrivanic P, 2016, THE FUTURE OF LIFE, V1, P193
   SNOOKS SJ, 1985, GASTROENTEROLOGY, V89, P977, DOI 10.1016/0016-5085(85)90196-9
   Song SN, 2019, MOL IMMUNOL, V106, P143, DOI 10.1016/j.molimm.2018.12.023
   Trento MMS, 2021, PFLUG ARCH EUR J PHY, V473, P573, DOI 10.1007/s00424-020-02503-0
   SPENCEJONES C, 1994, BRIT J OBSTET GYNAEC, V101, P147, DOI 10.1111/j.1471-0528.1994.tb13081.x
   Spencer RL, 2017, PHYSIOL BEHAV, V178, P43, DOI 10.1016/j.physbeh.2016.11.014
   Su MT, 2023, MULTIMEDIA SYST, V29, P2217, DOI 10.1007/s00530-023-01104-y
   Sun JH, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0863-5
   Sutton EL, 2021, ANN INTERN MED, V174, PITC33, DOI 10.7326/AITC202103160
   Tan JY, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03543-y
   Tan Z, 2024, J TRAD CHIN MED MANAG, V32, P140
   Tian CX, 2024, LECT NOTES COMPUT SC, V14719, P116, DOI 10.1007/978-3-031-60012-8_8
   Tsai LH, 2022, BIOMED J, V45, P533, DOI 10.1016/j.bj.2021.05.005
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tu CH, 2019, FRONT PSYCHIATRY, V10, P0, DOI 10.3389/fpsyt.2019.00014
   Usichenko T, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0238307
   Vriesman MH, 2020, NAT REV GASTRO HEPAT, V17, P21, DOI 10.1038/s41575-019-0222-y
   Waits A, 2018, SLEEP MED REV, V37, P24, DOI 10.1016/j.smrv.2016.12.004
   Wang WS, 2014, J NEUROSCI RES, V92, P1703, DOI 10.1002/jnr.23451
   Wang XH, 2024, ARCH GYNECOL OBSTET, V309, P1237, DOI 10.1007/s00404-023-07313-0
   Wang Y, 2025, INT J HUM-COMPUT INT, V41, P6011, DOI 10.1080/10447318.2024.2372893
   Wang YL, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-022-00636-1
   Wang ZW, 2019, ADV EXP MED BIOL, V1180, P193, DOI 10.1007/978-981-32-9271-0_10
   Westhoff CL, 2021, CONTRACEPTION, V103, P348, DOI 10.1016/j.contraception.2020.12.003
   Wu J, 2021, AM J TRANSL RES, V13, P8819
   Wu JM, 2024, FRONT NEUROSCI-SWITZ, V18, P0, DOI 10.3389/fnins.2024.1346635
   Wu Justin Cy, 2010, J NEUROGASTROENTEROL MOTIL, V16, P306, DOI 10.5056/jnm.2010.16.3.306
   Wu X, 2024, IEEE ACCESS, V12, P150564, DOI 10.1109/ACCESS.2024.3405645
   Wu Yang Yang, 2020, ZHEN CI YAN JIU, V45, P8, DOI 10.13702/j.1000-0607.1806066
   Xi J, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/6658321
   Xiao CB, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07976-0
   Xie C, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5527060
   Xie WX, 2023, INT J NURS STUD, V145, P0, DOI 10.1016/j.ijnurstu.2023.104531
   Xin JJ, 2016, FRONT MED-PRC, V10, P465, DOI 10.1007/s11684-016-0482-7
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yan XS, 2013, J BIOL CHEM, V288, P30544, DOI 10.1074/jbc.M113.495465
   Yang FM, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9430501
   Yang LH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/6383649
   Yang NN, 2022, CURR NEUROPHARMACOL, V20, P738, DOI 10.2174/1570159X19666210609162809
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yang SL, 2025, IEEE J BIOMED HEALTH, V29, P4599, DOI 10.1109/JBHI.2024.3511128
   Yang SN, 2011, J AFFECT DISORDERS, V132, P158, DOI 10.1016/j.jad.2011.02.009
   Yao CJ, 2023, J HEADACHE PAIN, V24, P0, DOI 10.1186/s10194-023-01612-2
   Yao CJ, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02568-x
   Yao CJ, 2022, AGING-US, V14, P2400, DOI 10.18632/aging.203949
   Yeung WF, 2022, PHYTOMEDICINE, V99, P0, DOI 10.1016/j.phymed.2022.153993
   Yeung WF, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.5830
   Yu Z, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3182
   Zeng Y, 2018, LISHIZHEN MED MATERIA MEDICA RES, V29, P1002, DOI 10.3969/j.issn.1008-0805
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhang F, 2017, GASTROENT RES PRACT, V2017, P0, DOI 10.1155/2017/5687496
   Zhang L, 2005, EUR J NEUROSCI, V22, P1141, DOI 10.1111/j.1460-9568.2005.04302.x
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang X, 2022, QJM-INT J MED, V115, P525, DOI 10.1093/qjmed/hcab230
   Zhang X, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/860631
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao FY, 2021, NAT SCI SLEEP, V13, P1823, DOI 10.2147/NSS.S332474
   Zhao WS, 2019, CHIN J INTEGR MED, V25, P462, DOI 10.1007/s11655-018-3057-4
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng Z, 2023, ACUPUNCT MED, V41, P16, DOI 10.1177/09645284221085282
   Zhi YK, 2024, AGE AGEING, V53, P0, DOI 10.1093/ageing/afae107
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zhou LR, 2022, COMPUT INTEL NEUROSC, V2022, P0, DOI 10.1155/2022/7678516
   Zhou Z, 2022, MICROMACHINES-BASEL, V13, P0, DOI 10.3390/mi13030370
   Zhu XW, 2017, ACUPUNCT MED, V35, P216, DOI 10.1136/acupmed-2016-011180
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 211
TC 7
Z9 7
U1 11
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD APR 23
PY 2025
VL 20
IS 1
BP 
EP 
DI 10.1186/s13020-025-01105-1
PG 21
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 1TC3S
UT WOS:001473011900001
PM 40270014
DA 2026-01-16
ER

PT J
AU Zhu, R
   Li, X
   Yan, Z
   Chen, C
   Zhai, W
   Zhang, H
   Ma, WJ
   Wang, F
   Liu, M
   Du, G
AF Zhu, Ruixin
   Li, Xing
   Yan, Zhaobo
   Chen, Cheng
   Zhai, Wei
   Zhang, Hengcai
   Ma, Wen juan
   Wang, Fukun
   Liu, Mi
   Du, Geshu
TI Efficacy and safety of acupuncture with moxibustion for knee osteoarthritis: a meta-analysis of randomized controlled trials
SO Systematic Reviews
LA English
DT Article
DE Acupuncture; Adverse events; Knee osteoarthritis; Meta-analysis; Moxibustion; Treatment
ID acupuncture; adverse event; article; drug efficacy; drug safety; follow up; human; knee osteoarthritis; meta analysis; moxibustion; outcome assessment; randomized controlled trial (topic); rigidity; sensitivity analysis; systematic review; treatment outcome; visual analog scale; multimodality cancer therapy; pain measurement; procedures; therapy; acupuncture therapy; combined modality therapy; humans; moxibustion; osteoarthritis, knee; pain measurement; randomized controlled trials as topic; treatment outcome
AB Background: Osteoarthritis (OA) is prevalent, yet its management remains challenging. This meta-analysis aims to evaluate the efficacy of acupuncture combined with moxibustion versus other standard treatments in patients with knee osteoarthritis (KOA) based on randomized controlled trials (RCTs). Methods: Searches were conducted in Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to retrieve relevant RCTs. Data on baseline characteristics, treatment efficacy, and adverse events were extracted. The analysis utilized pooled weighted mean differences (WMD) and risk ratios (RR) with 95% confidence intervals (CIs) to assess the superior treatment modality. Results: A total of 18 RCTs were included. Acupuncture combined with moxibustion demonstrated significant improvement in the visual analog scale (VAS) for pain and the long-term (> 60 weeks) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for pain, stiffness, and physical function compared to other treatments. In contrast, short- (< 4 weeks) and mid-term (6–60 weeks) WOMAC outcomes for pain, stiffness, and physical function indicated varied results. The overall efficacy rate also favored the combined therapy significantly in the short- and mid-term evaluations. Notably, this therapy was associated with fewer adverse events. Conclusion: The meta-analysis reveals that acupuncture combined with moxibustion is notably more effective and safer than other treatment modalities for KOA, particularly during mid- and long-term follow-up periods. © The Author(s) 2025.
C1 Hunan University of Chinese Medicine, Zhu, Ruixin, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Li, Xing, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Yan, Zhaobo, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Chen, Cheng, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Zhai, Wei, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Zhang, Hengcai, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Ma, Wen Juan, Department of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Wang, Fukun, Department of Acupuncture, Changsha, Hunan, China
   Hunan University of Chinese Medicine, Liu, Mi, School of Acupuncture, Changsha, Hunan, China
   Changsha Hospital of Traditional Chinese Medicine, Du, Geshu, Department of Acupuncture, Changsha, Hunan, China
CR Martel-Pelletier, 1900, 2016, V0, P0
   Woolf, 1900, 2003, V0, P0
   Jiang, 1900, OSTEOARTHRITIS YEAR IN REVIEW 2021: BIOLOGY, V0, P207-215
   Glyn-Jones, 1900, OSTEOARTHRITIS, V0, P376-387
   Carr, 1900, KNEE REPLACEMENT, V0, P1331-1340
   Pivec, 1900, HIP ARTHROPLASTY, V0, P1768-1777
   Bijlsma, 1900, 2011, V0, P0
   Singh, 1900, 2023, V0, P0
   Tao, 1900, EVALUATION OF TRADITIONAL CHINESE EXERCISE FOR KNEE OSTEOARTHRITIS (KOA): AN OVERVIEW OF SYSTEMATIC REVIEWS, V0, P1
   Yang, 1900, TRADITIONAL CHINESE MEDICINE FOR KNEE OSTEOARTHRITIS: AN OVERVIEW OF SYSTEMATIC REVIEW, V0, P12
NR 10
TC 3
SN 
EI 
J9 SYST REV
JI Syst. Rev.
PD JUN 15
PY 2025
VL 14
IS 1
BP 
EP 
DI 10.1186/s13643-025-02762-x
PG 0
UT Scopus:10.1186/s13643-025-02762-x
ER

PT J
AU Zhao, Y
   Cao, WD
   Zhang, HH
   Rong, QX
   He, MX
   Wu, MJ
   Zhao, Y
   Yang, P
AF Zhao, Yi
   Cao, Wendi
   Zhang, Hengheng
   Rong, Qingxi
   He, Mingxuan
   Wu, Meijie
   Zhao, Yi
   Yang, Ping
TI The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis
SO JOURNAL OF CANCER SURVIVORSHIP
LA English
DT Review; Early Access
DE Acupuncture; Peripheral nervous system diseases; Cancer supportive care; Systematic review; Meta-analysis
ID electroacupuncture; prevention; mechanisms; analgesia; quality; trials
AB PurposeChemotherapy-induced peripheral neuropathy (CIPN) is a common side effect in cancer patients, often emerging within the first month of chemotherapy. Severe CIPN can disrupt daily life, necessitating chemotherapy adjustments or discontinuation, which may increase cancer mortality. No standardized treatment exists, but acupuncture is widely used in China for CIPN.This study aimed to comprehensively assess the actual efficacy of acupuncture in treating CIPN in cancer patients.MethodsWe searched PubMed, Web of Science, Embase, and Cochrane Library up to October 2024 for randomized controlled trials (RCTs) on acupuncture for CIPN, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Methodological quality was assessed using the Cochrane risk-of-bias tool (RoB 2.0) and the modified Jadad scale. A random-effects model was used to analyze the Effect Size (ES) and 95% Confidence Interval (CI).Data analysis was performed using RevMan 5.3 software.ResultsThe final analysis incorporated 1,048 patients from 18 studies. The results presented in the forest plot demonstrated that, when compared to the control group, acupuncture exhibited superior efficacy in improving CIPN symptoms (RR = 1.11, 95%CI [1.01,1.21]), alleviating pain (SMD = -0.93, 95%CI [-1.63,-0.22]), enhancing quality of life (QoL) (MD = - 1.14, 95%CI [- 1.97, - 0.31]), and reducing chemotherapy-related neurotoxicity (MD = - 3.34, 95%CI [- 5.24, - 1.44]). Additionally, in alleviating CIPN-related pain, simple acupuncture demonstrates superior efficacy compared to electroacupuncture.ConclusionThis study clearly demonstrates that acupuncture offers more substantial benefits to CIPN patients compared to usual care, medication, vitamin, and sham acupuncture. This research serves as a valuable reference for cancer patients, physicians, nurses, and other professional medical practitioners.
C1 [Zhao, Yi; Cao, Wendi; Zhang, Hengheng; Rong, Qingxi; He, Mingxuan; Wu, Meijie; Zhao, Yi; Yang, Ping] Qinghai Univ, Breast Dis Diag & Treatment Ctr, Affiliated Hosp, Xining 810000, Peoples R China.
   [Zhao, Yi; Cao, Wendi; Zhang, Hengheng; Rong, Qingxi; He, Mingxuan; Wu, Meijie; Zhao, Yi; Yang, Ping] Qinghai Univ, Affiliated Canc Hosp, Xining 810000, Peoples R China.
C3 Qinghai University; Qinghai University
RP Zhao, Y; Yang, P (corresponding author), Qinghai Univ, Breast Dis Diag & Treatment Ctr, Affiliated Hosp, Xining 810000, Peoples R China.; Zhao, Y; Yang, P (corresponding author), Qinghai Univ, Affiliated Canc Hosp, Xining 810000, Peoples R China.
EM zywm0001@163.com; 1290912204@qq.com
CR American Cancer Chemotherapy Society, 2022, THE ROLE AND SIGNIFICANCE OF CHEMOTHERAPY IN CANCER MANAGEMENT, V0, P0
   Unknown -, 2024, SAUDI MED J, V45, P326
   Unknown -, 2021, THE GLOBAL HEALTH OBSERVATORY, V0, P0
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Brown C, 2020, CLINICAL NEUROLOGY REVIEW, V28, P112
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   DAlessandro EG, 2019, BMJ SUPPORT PALLIAT CARE, V0, P1
   Du JY, 2014, BRAIN RES BULL, V108, P27, DOI 10.1016/j.brainresbull.2014.06.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Green G, 2022, J CANCER SURVIV, V16, P337
   Green SCochrane Collaboration, 2008, J. WILEY-BLACKWELL, V0, PP1, DOI 10.1002/9780470712184
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jin Y, 2023, INTEGR CANCER THER, V22, P153473542312068
   Jordan K, 2018, CANCER TREAT REV, V63, P10
   Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   Lagerstedt K, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231178877
   Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016
   Lee JH, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018830
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lu Chao, 2024, ZHONGGUO ZHEN JIU, V44, P1139, DOI 10.13703/j.0255-2930.20240123-0001
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00038
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Smith A, 2019, J ONCOL NURS, V34, P98
   Smith AB, 2020, J CLIN ONCOL, V38, P1745
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Sui Minghong, 2016, ZHONGGUO ZHEN JIU, V36, P512
   Velasco R, 2021, ANTI-CANCER DRUG, V32, P88, DOI 10.1097/CAD.0000000000001005
   Visovsky CV, 2015, CLIN J ONCOL NURS, V19, P295
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wang X, 2023, J TRADIT CHIN MED REHABIL, V29, P147
   Wang Y, 2023, ONCOL REV, V17, P155
   Wilson E, 2021, CANCER EPIDEMIOL, V45, P167
   Windebank A, 2017, NAT REV NEUROL, V13, P15
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Wu SY, 2021, PAIN, V162, P550
   Wu ZQ, 2023, CLIN MED PROG, V13, P13922
   Xichun Hu, 2024, CHINA ONCOL, V34, P167
   Xie HY, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000031703
   Yan CC, 2023, J COMPUT BIOL, V30, P82, DOI 10.1089/cmb.2022.0063
   Yeh ML, 2015, HOLIST NURS PRACT, V29, P87, DOI 10.1097/HNP.0000000000000071
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhuang Y, 2022, J PAIN RES, V15, P2563
NR 61
TC 1
Z9 1
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1932-2259
EI 1932-2267
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD AUG 19
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1007/s11764-025-01869-3
EA AUG 2025
PG 13
WC Oncology; Social Sciences, Biomedical
SC Oncology; Biomedical Social Sciences
GA 6GF9B
UT WOS:001552622700001
PM 40830723
DA 2026-01-16
ER

PT J
AU Gianni, C
   Scarpi, E
   Bravaccini, S
   Pirini, F
   Vanni, S
   Dall'Agata, M
   Cortesi, M
   Fanini, F
   Cavalieri, S
   Mercatali, L
   Ulivi, P
   Poini, A
   Giovanardi, CM
   Rocca, A
   Fedeli, A
AF Gianni, Caterina
   Scarpi, Emanuela
   Bravaccini, Sara
   Pirini, Francesca
   Vanni, Silvia
   Dall'Agata, Monia
   Cortesi, Michela
   Fanini, Francesca
   Cavalieri, Sara
   Mercatali, Laura
   Ulivi, Paola
   Poini, Alessandra
   Giovanardi, Carlo Maria
   Rocca, Andrea
   Fedeli, Anna
TI Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Breast cancer; Acupuncture; Cytokines; Hot flushes; Menopause; TNF-alpha
ID vasomotor symptoms; hot flashes; women; interleukin-8; metaanalysis; mechanisms; model
AB Background Breast cancer (BC) remains a global health issue, with most women receiving adjuvant hormone therapy. Hot flushes and climacteric symptoms often compromise treatment adherence. Acupuncture has shown promise in alleviating these symptoms and improving quality of life (QoL). This prospective study aimed to investigate the mechanisms underlying acupuncture's effects on menopausal symptoms in breast cancer patients receiving endocrine therapy, with a secondary focus on inflammatory biomarker changes. Methods This open-label biological study enrolled 37 early BC patients receiving endocrine treatment, and acupuncture treatment provided at IRST within the integrative care pathway, of whom 27 completed all evaluations. Participants underwent a 10-session weekly acupuncture program based on Traditional Chinese Medicine, using fixed points (SP6, CV4, LI11, BL11, GB39). Blood samples for biochemical and cytokine analysis (IL-5, IL-6, IL-10, IL-8, IL-22, TNF alpha) were collected at baseline (T0), post-treatment (T1), and six months later (T2) during regular clinical and laboratory workups. Clinical outcomes were assessed using the Green Climacteric Scale (GCS), EQ-5D-5L, and Brief Pain Inventory (BPI). The study followed STRICTA guidelines. Results Acupuncture significantly improved vasomotor and climacteric symptoms, with reduced GCS and hot flash scores at T1 and T2 (p < 0.0001). QoL and pain scores also significantly improved at both time points. Among the cytokines measured over time, a significant reduction in TNF alpha levels was observed (p = 0.006), though no correlation emerged between cytokine changes and clinical outcomes. Conclusions Acupuncture proved effective in improving menopausal symptoms and QoL in BC patients receiving endocrine therapy. The modulation of TNF alpha suggests a potential biological role in the mechanism of symptom relief.
C1 [Gianni, Caterina] IRCCS Ist Romagnolo Studio Tumori IRST, Med Oncol & Breast Unit, Dino Amadori, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Scarpi, Emanuela; Dall'Agata, Monia] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Unit Biostat & Clin Trials, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Bravaccini, Sara] Univ Enna Kore, Dept Med & Surg, I-94100 Enna, Italy.
   [Pirini, Francesca; Cortesi, Michela; Ulivi, Paola] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Biosci Lab, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Vanni, Silvia] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Preclin & Osteoncol Unit, Biosci Lab, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Fanini, Francesca] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Immuno Gene Therapy Factory, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Cavalieri, Sara] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Med Oncol, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
   [Mercatali, Laura] IRCCS Ist Ortoped Rizzoli, Osteoncol Bone & Soft Tissue Sarcomas & Innovat Th, Via Barbiano 1-10, I-40136 Bologna, Italy.
   [Poini, Alessandra; Giovanardi, Carlo Maria; Fedeli, Anna] Assoc Med Acupuncturists Bologna AMAB, Res & Healthcare Inst, Via Antonio Canova 15-E, I-40138 Bologna, Italy.
   [Rocca, Andrea] Univ Trieste, Dept Med Surg & Hlth Sci, Piazza Univ 1, I-34127 Trieste, Italy.
C3 Universita Kore di ENNA; University of Trieste
RP Scarpi, E (corresponding author), IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Unit Biostat & Clin Trials, Via P Maroncelli 40, I-47014 Meldola, FC, Italy.
EM caterina.gianni@irst.emr.it; emanuela.scarpi@irst.emr.it; sara.bravaccini@unikore.it; francesca.pirini@irst.emr.it; silvia.vanni@irst.emr.it; monia.dallagata@irst.emr.it; michela.cortesi@irst.emr.it; francesca.fanini@irst.emr.it; sara.cavalieri@irst.emr.it; laura.mercatali@ior.it; paola.ulivi@irst.emr.it; alessandra.poini@gmail.com; carlomariagiovanardi@gmail.com; andrea.rocca@units.it; annafedeli60@gmail.com
FU Italian Ministry of Health within the research line "Precision, gender and ethnicity-based medicine and geroscience: genetic-molecular mechanisms in the development, characterization and treatment of tumors" [L3P1986]
CR Abildgaard J, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0235174
   Avis NE, 2008, MENOPAUSE, V15, P1070, DOI 10.1097/gme.0b013e31816d5b03
   Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad
   Brennan DJ, 2025, J CLIN ONCOL, V43, P508, DOI 10.1200/JCO.2025.43.16_suppl.508
   Bruun JM, 2003, HORM METAB RES, V35, P142, DOI 10.1055/s-2003-39074
   Caraceni A, 1996, PAIN, V65, P87, DOI 10.1016/0304-3959(95)00156-5
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chiu HY, 2015, MENOPAUSE, V22, P234, DOI 10.1097/gme.0000000000000260
   Cioffi M, 2002, MATURITAS, V41, P187, DOI 10.1016/S0378-5122(01)00286-9
   Di Maio M, 2022, ANN ONCOL, V33, P878, DOI 10.1016/j.annonc.2022.04.007
   Dudakov JA, 2015, ANNU REV IMMUNOL, V33, P747, DOI 10.1146/annurev-immunol-032414-112123
   Franzoi MA, 2021, LANCET ONCOL, V22, PE303, DOI 10.1016/S1470-2045(20)30666-5
   Freedman RR, 2014, J STEROID BIOCHEM, V142, P115, DOI 10.1016/j.jsbmb.2013.08.010
   Frisk JW, 2014, SUPPORT CARE CANCER, V22, P1409, DOI 10.1007/s00520-014-2126-2
   Giaquinto AN, 2022, CA-CANCER J CLIN, V72, P524, DOI 10.3322/caac.21754
   Greene JG, 1998, MATURITAS, V29, P25, DOI 10.1016/S0378-5122(98)00025-5
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Guli A, 2015, LE ACQUE LUNARI. LA MEDICINA CINESE E LA DONNA, V3rd, P0
   Harlow SD, 2012, J CLIN ENDOCR METAB, V97, P1159, DOI 10.1210/jc.2011-3362
   Huang WY, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0184011
   Jung J, 2021, BRAIN BEHAV IMMUN, V94, P424, DOI 10.1016/j.bbi.2021.02.003
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Karaoulanis SE, 2012, ANN GEN PSYCHIATR, V11, P0, DOI 10.1186/1744-859X-11-9
   Korpe B, 2024, MENOPAUSE, V31, P973, DOI 10.1097/GME.0000000000002433
   Kreimeier S, 2019, QUAL LIFE RES, V28, P1951, DOI 10.1007/s11136-019-02115-x
   Lambertini Matteo, 2023, AM SOC CLIN ONCOL EDUC BOOK, V43, Pe390442, DOI 10.1200/edbk_390442
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lin JG, 2018, CELL TRANSPLANT, V27, P551, DOI 10.1177/0963689717724795
   Maciocia G, 2011, OBSTETRICS AND GYNECOLOGY IN CHINESE MEDICINE, V2nd, P0
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Malutan A, 2013, ACTA ENDOCRINOL-BUCH, V9, P133, DOI 10.4183/aeb.2013.133
   Malutan AM, 2014, MENOPAUSE REV, V13, P162, DOI 10.5114/pm.2014.43818
   Mendieta D, 2016, J NEUROIMMUNOL, V290, P22, DOI 10.1016/j.jneuroim.2015.11.011
   Nelson HD, 2008, LANCET, V371, P760, DOI 10.1016/S0140-6736(08)60346-3
   Oh YI, 2012, KIDNEY BLOOD PRESS R, V35, P634, DOI 10.1159/000339640
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Rallis KS, 2022, FUTURE ONCOL, V18, P3349, DOI 10.2217/fon-2022-0063
   Ramires CC, 2021, ACUPUNCT MED, V39, P376, DOI 10.1177/0964528420938379
   Scalone L, 2013, VALUE HEALTH, V16, P814, DOI 10.1016/j.jval.2013.04.008
   Shivers KY, 2015, CYTOKINE, V72, P121, DOI 10.1016/j.cyto.2015.01.007
   Song AQ, 2018, CURR MED SCI, V38, P1109, DOI 10.1007/s11596-018-1991-1
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang L, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/8253904
   World Health Organization, 2025, ICD-11 FOR MORTALITY AND MORBIDITY STATISTICS (VERSION: 2025-01), V0, P0
   Wu LQ, 2019, COMPLEMENT THER CLIN, V37, P11, DOI 10.1016/j.ctcp.2019.08.002
   Yasui T, 2006, J CLIN ENDOCR METAB, V91, P4805, DOI 10.1210/jc.2006-1100
NR 46
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV 20
PY 2025
VL 33
IS 12
BP 
EP 
DI 10.1007/s00520-025-10181-w
PG 16
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA A6936
UT WOS:001619778600002
PM 41264030
DA 2026-01-16
ER

PT J
AU Seddio, AE
   Dhodapkar, MM
   Halperin, SJ
   Jabbouri, SS
   Gouzoulis, MJ
   Joo, PY
   Grauer, JN
AF Seddio, Anthony E
   Dhodapkar, Meera M
   Halperin, Scott J
   Jabbouri, Sahir S
   Gouzoulis, Michael J
   Joo, Peter Y
   Grauer, Jonathan N
TI Predictors of Physical, Chiropractic, and Acupuncture Therapy Utilization in the
SO Clinical spine surgery
LA English
DT Journal Article
DE acupuncture; chiropractic; conservative management; low back pain; national database study; physical therapy; resource utilization; therapy utilization
AB STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To assess the relative  utilization and predictors of physical therapy (PT), chiropractic therapy (CT),  and acupuncture therapy (AT) within 90 days of low back pain (LBP) diagnosis.  BACKGROUND: LBP is the most common musculoskeletal problem globally. Following  diagnosis, patients often seek treatments including PT, CT, and AT, however,  their relative use and drivers of therapeutic selection remain poorly  characterized. METHODS: Adults diagnosed with LBP who utilized PT, CT, or AT  within 90 days were identified from the PearlDiver M161 database. Exclusion  criteria included: therapy utilization before diagnosis and those presenting for  trauma, neoplasm, or infection. Patients utilizing each therapy type were  characterized based on clinical and nonclinical factors and compared by  univariable analyses and multivariable logistic regression. RESULTS: Of  10,046,167 LBP patients, no therapy/other was noted for 9,560,636 (94.78%), PT  for 413,554 (4.10%), CT for 103,444 (1.03%), and AT for 10,026  (0.10%).Independent predictors of CT utilization, relative to PT, were lower age  [per decade increase: odds ratio (OR): 0.986], male sex (OR: 1.046), lower  Elixhauser Comorbidity Index (ECI, per 1-point increase: OR: 0.882), lower mean  family income: (OR: 0.999), lower unemployment: (OR: 0.888), region (relative to  South: Northeast OR: 0.773, Midwest OR: 1.265), and insurance (relative to  commercial: Medicaid OR: 0.489, Medicare OR: 0.896; P <0.001 for all).Independent  predictors of AT utilization, relative to PT, were lower ECI (OR: 0.960), higher  mean family income (OR: 1.0000160), region (West OR: 2.214, Northeast OR: 1.390,  Midwest OR: 1.293), and insurance (Medicaid OR: 0.372, Medicare OR: 0.510; P  <0.001 for all). CONCLUSIONS: PT was more frequently utilized than both CT and AT  within 90 days of LBP diagnosis. However, clinical and nonclinical factors proved  to be significant predictors for patients who utilized CT and AT versus PT.  Understanding these drivers helps characterize therapy utilization patterns at a  national level, an area previously not well defined. LEVEL OF EVIDENCE: Level  III.
C1 Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT.
NR 0
TC 0
SN 2380-019
EI 
J9 Clin Spine Surg
PD JUN 16
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1097/BSD.0000000000001859
PG 0
UT PubMed:40521727
PM 40521727
DA 2025-06-16
ER

PT J
AU Tian, H
   Luo, Q
   Huang, LY
   Chen, G
   Sun, MS
   Liang, FR
AF Tian, Hao
   Luo, Qin
   Huang, Liuyang
   Chen, Guang
   Sun, Mingsheng
   Liang, Fanrong
TI Exploration of the quantitative-effectiveness association between acupuncture temporal parameters and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis of randomized controlled trials
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE acupuncture; chemotherapy-induced peripheral neuropathy; pain management; meta-analysis; dose-response
ID electroacupuncture
AB Background Chemotherapy-induced peripheral neuropathy (CIPN) is one of the commonly reported symptoms impacting cancer survivors. This study evaluated and compared the effectiveness of acupuncture treatments for CIPN. Methods We searched six databases from their inception to August 2024 to identify eligible randomized controlled trials (RCTs). Primary outcome were pain scores. Secondary outcomes were quality of life including FACT/GOG-Ntx and EORTC QLQ-C30. The robust error meta-regression (REMR) method was used to evaluate the dose-response relationship across treatment parameters, including number of sessions, frequency, and duration. Results In total, 11 RCTs featuring 740 participants were included. The meta-analysis demonstrated that the primary analysis achieved a significant reduction in pain scores, with a standardized mean difference of [SMD= -1.23, 95% CI = (-2.22, -0.24); P < 0.01; I-2 = 95%], improvement quality of life including FACT/GOG-Ntx [SMD = 0.95, 95% CI = (0.02, 1.88); P < 0.01; I-2 = 93%] and EORTC QLQ-C30 [SMD = 0.36, 95% CI = (0.03, 0.68); P = 0.14; I-2 = 46%]. The nonlinear dose-response analysis suggests that pain improvement achieves the MCID at 16 treatment sessions, over 8 weeks, with a frequency of twice per week. Furthermore, analysis of the treatment duration chart shows that acupuncture maintains therapeutic effects during the follow-up period. Sensitivity analysis confirmed the robustness of these findings. Conclusion Acupuncture demonstrates significant potential in managing CIPN, particularly through individualized treatment regimens. The identified time-dose-response relationship suggests that tailoring acupuncture frequency and duration can to optimize pain relief in CIPN patients. Future high-quality studies and large-scale multicenter clinical trials are needed to validate these findings.
C1 [Tian, Hao; Chen, Guang; Sun, Mingsheng; Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Clin Res Ctr Acupuncture & Moxibust Sichuan Prov, Coll Acupuncture & Tuina, Teaching Hosp 3,Coll Basic Med,Coll Int Educ, Chengdu, Sichuan, Peoples R China.
   [Luo, Qin] Sichuan Prov Orthoped Hosp, Dept Rheumatol & Orthoped, Chengdu, Sichuan, Peoples R China.
   [Huang, Liuyang] Hubei Univ Chinese Med, Coll Acupuncture & Orthoped, Wuhan, Peoples R China.
   [Huang, Liuyang] Hubei Univ Chinese Med, Hubei Prov Collaborat Innovat Ctr Prevent Treatmen, Wuhan, Peoples R China.
   [Huang, Liuyang] Hubei Univ Chinese Med, Hubei Shizhen Lab, Wuhan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Hubei University of Chinese Medicine; Hubei University of Chinese Medicine; Hubei University of Chinese Medicine
RP Sun, MS; Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Clin Res Ctr Acupuncture & Moxibust Sichuan Prov, Coll Acupuncture & Tuina, Teaching Hosp 3,Coll Basic Med,Coll Int Educ, Chengdu, Sichuan, Peoples R China.
EM sunmingsheng@cdutcm.edu.cn; acuresearch@126.com
FU National Natural Science Foundation of China [U21A20404]; Sichuan Provincial Department of Science and Technology Project, China [2021YFS0087]
CR Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   DSouza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   Gewandter JS, 2024, J PAIN, V25, P0, DOI 10.1016/j.jpain.2023.11.014
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hammond EA, 2019, NEUROREHAB NEURAL RE, V33, P792, DOI 10.1177/1545968319860486
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549-010-1278-0
   Higgins J, 2024, COCHRANE HDB SYSTEMA, V0, P0
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Huberts AS, 2024, EUR J ONCOL NURS, V72, P0, DOI 10.1016/j.ejon.2024.102685
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Lang PM, 2010, ANESTH ANALG, V110, P1448, DOI 10.1213/ANE.0b013e3181d3e7ef
   Li TFY, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.24139
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Luo Q, 2024, COMPLEMENT THER MED, V82, P0, DOI 10.1016/j.ctim.2024.103048
   Meng WJ, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1201544
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Papadopoulou M, 2023, IN VIVO, V37, P47, DOI 10.21873/invivo.13053
   Parsons SK, 2023, J PATIENT-REP OUTCOM, V7, P0, DOI 10.1186/s41687-023-00653-0
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Sabourin S, 2021, J NEUROSURG-SPINE, V35, P243, DOI 10.3171/2020.11.SPINE201431
   Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x
   Selvy M, 2021, SUPPORT CARE CANCER, V29, P4033, DOI 10.1007/s00520-020-05928-6
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Wang Y, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094696
   Xu C, 2018, INT J EVID-BASED HEA, V16, P138, DOI 10.1097/XEB.0000000000000132
   [徐畅 Xu Chang], 2015, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V15, P984
   [徐畅 Xu Chang], 2015, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V15, P479
   Yeh ML, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04603-1
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zheng Z, 2010, EUR J PAIN, V14, P725, DOI 10.1016/j.ejpain.2009.11.006
NR 40
TC 1
Z9 1
U1 5
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 12
PY 2025
VL 14
IS 
BP 
EP 
DI 10.3389/fonc.2024.1527331
PG 12
WC Oncology
SC Oncology
GA Z0Z5D
UT WOS:001436293600001
PM 40034252
DA 2026-01-16
ER

PT J
AU Huang, JH
   Zhao, LY
   Xie, YF
   Wang, C
   Yang, XJ
   Huang, HF
   Zhang, D
AF Huang, Jianhao
   Zhao, Liuyang
   Xie, Yufeng
   Wang, Chi
   Yang, Xinjing
   Huang, Haifu
   Zhang, Dian
TI Investigating the Analgesic Mechanisms of Acupuncture for Cancer Pain: Insights From Multimodal Bioelectrical Signal Analysis
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE cancer pain; acupuncture; multimodal bioelectrical signals; analgesic mechanism; deep learning
AB Purpose: Cancer pain management remains a significant clinical challenge. While acupuncture has shown potential in alleviating cancer pain, its underlying mechanisms are not yet fully understood. This study investigates the neurophysiological mechanisms underlying acupuncture's analgesic effects using multimodal bioelectrical signal analysis. Patients and Methods: Fifteen cancer pain patients underwent acupuncture while wearing portable, multi-sensor devices to capture bioelectrical signals. Pain levels were assessed using the Numerical Rating Scale (NRS) before and during needle retention. Neurophysiological changes were evaluated using Principal Component Analysis, Joint Time-Frequency Analysis, power spectrum analysis, spectral analysis, and dynamic functional network analysis. Results: There was a significant reduction in NRS scores from pre-treatment to the retention period, indicating pain relief. Principal component analysis showed significant differences in bioelectrical signals between these periods. Power spectrum analysis revealed decreased signal power during retention. Functional network analysis demonstrated a reduction in connectivity strength between electroencephalography and electromyography signals. Spectral analysis identified distinct real-time and staged characteristics of bioelectrical signals, with correlation analysis confirming a positive relationship between NRS score changes and bioelectrical signal alterations. Conclusion: Acupuncture alleviates cancer pain by reducing functional connectivity between injured tissues and the brain, with immediate effects. Prolonging needle retention may enhance therapeutic outcomes. These findings provide new insights into the neurophysiological basis of acupuncture's analgesic effects, supporting its role in cancer pain management.
C1 [Huang, Jianhao; Xie, Yufeng; Yang, Xinjing; Huang, Haifu] Guangzhou Univ Chinese Med, Shenzhen Hosp Fu Tian, Dept Acupuncture & Moxibust, Shenzhen, Peoples R China.
   [Zhao, Liuyang; Zhang, Dian] Shenzhen Univ, Sch Comp & Software, 3688,Nanhai Ave, Shenzhen, Peoples R China.
   [Xie, Yufeng] Macau Univ Sci & Technol, Fac Chinese Med, Taipa, Macao, Peoples R China.
   [Xie, Yufeng] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Wang, Chi] Ganzhou Tradit Chinese Med Hosp, Ganzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Shenzhen University; Macau University of Science & Technology; Macau University of Science & Technology
RP Zhang, D (corresponding author), Shenzhen Univ, Sch Comp & Software, 3688,Nanhai Ave, Shenzhen, Peoples R China.; Huang, HF (corresponding author), Guangzhou Univ Chinese Med, Shenzhen Hosp Fu Tian, 6001 Beihuan Ave, Futian Dist, Shenzhen, Peoples R China.
EM huanghaifu2004@163.com; zhangd@szu.edu.cn
FU Shenzhen Science and Technology Program Fund [JCYJ20220531091407016]; Futian Healthcare Research Project [FTWS069, FTWS055]
CR Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Cao YY, 2024, FRONT PHYSIOL, V15, P0, DOI 10.3389/fphys.2024.1487809
   Chan FHF, 2020, CLIN PSYCHOL REV, V80, P0, DOI 10.1016/j.cpr.2020.101884
   Chen WH, 2011, J BIOMED SCI, V18, P0, DOI 10.1186/1423-0127-18-82
   Chen Y, 2023, ZHONGGUO ZHEN JIU, V44, P89
   Chen YJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5281039
   de Almeida AS, 2021, EUR J PHARMACOL, V904, P0, DOI 10.1016/j.ejphar.2021.174185
   De Groef A, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07557-7
   de Paiva Neto APG, 2023, TRANSIT OF ELECTRIC CURRENTS IN THE HUMAN NERVOUS SYSTEM: HYPOTHESIS, V0, P0
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Evenepoel M, 2022, J PAIN SYMPTOM MANAG, V63, PE317, DOI 10.1016/j.jpainsymman.2021.09.011
   Falla D, 2020, J ELECTROMYOGR KINES, V52, P0, DOI 10.1016/j.jelekin.2020.102422
   Fan ZZ, 2024, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1239839
   Fang Jian-Qiao, 2018, ZHEN CI YAN JIU, V43, P459, DOI 10.13702/j.1000-0607.180380
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   Haroun R, 2023, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.1030899
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Kong YS, 2021, IEEE T BIO-MED ENG, V68, P3122, DOI 10.1109/TBME.2021.3065218
   Lacinova L, 2022, PFLUG ARCH EUR J PHY, V474, P365, DOI 10.1007/s00424-022-02679-7
   Li JJ, 2022, INFORM FUSION, V79, P229, DOI 10.1016/j.inffus.2021.10.018
   Lin Z, 2023, IEEE CVF C COMP VIS, V0, P0
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Mestdagh F, 2023, CURR ONCOL, V30, P6838, DOI 10.3390/curroncol30070500
   Moont R, 2010, PAIN, V150, P113, DOI 10.1016/j.pain.2010.04.009
   Mussigmann T, 2022, NEUROIMAGE, V258, P0, DOI 10.1016/j.neuroimage.2022.119351
   Qu ZY, 2020, BRAIN RES, V1730, P0, DOI 10.1016/j.brainres.2020.146670
   Sarnthein J, 2006, BRAIN, V129, P55, DOI 10.1093/brain/awh631
   Schmidt S, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0031138
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Wang J, 2015, WORLD J TRAD CHINESE, V1, P59, DOI 10.15806/j.issn.2311-8571.2014.0012
   White P, 2008, J ALTERN COMPLEM MED, V14, P373, DOI 10.1089/acm.2007.0714
   Yin T, 2023, CEREB CORTEX, V33, P3511, DOI 10.1093/cercor/bhac288
   Zhong Z, 2024, FRONT NEUROSCI-SWITZ, V18, P0, DOI 10.3389/fnins.2024.1386108
   Zhou Jia, 2024, ZHEN CI YAN JIU, V49, P1310, DOI 10.13702/j.1000-0607.20230928
NR 35
TC 1
Z9 1
U1 3
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2025
VL 18
IS 
BP 1435
EP 1450
DI 10.2147/JPR.S503975
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA 0LD6G
UT WOS:001449974500001
PM 40130202
DA 2026-01-16
ER

PT J
AU Zhao, QN
   Zhang, JF
   Shi, WR
   Qian, XY
   An, JX
AF Zhao, Qiannan
   Zhang, Jianfeng
   Shi, Wanrui
   Qian, Xiaoyan
   An, Jianxiong
TI Different mechanisms of electroacupuncture and pregabalin in neuropathic pain-induced ultrastructure damage in a rat model of brachial plexus neuralgia
SO NEUROLOGICAL RESEARCH
LA English
DT Article
DE Neuropathic pain; structural changes; electroacupuncture; pregabalin; morphology
ID mirror-image pain; injury; hyperalgesia; prevalence; guidelines; allodynia; nerve
AB Objectives: Brachial plexus neuralgia (BPN) can result from injury, trauma, or cancer, and it significantly impacts the patient's quality of life. This study investigated electroacupuncture (EA) vs. pregabalin on the structural changes in the peripheral nervous system (PNS) and central nervous system (CNS) in rats with BPN. Methods: Male Sprague-Dawley rats were randomized to the sham-operated (Con), BPN (using cobra venom), BPN+EA (EA), and BPN+pregabalin (PGB) groups (n = 8/group). EA or pregabalin was given from postoperative day (POD)14 to POD35. Structural alterations were determined by transmission electron microscopy in the primary sensory cortex, forelimb region (S1FL), anterior cingulate cortex (ACC), hippocampus, thalamus, cervical, thoracic, and lumbar spinal cords on POD40, and in the bilateral brachial plexus and dorsal root ganglions (DRG) at the cervical, thoracic and lumbar levels. Results: Compared with the CON group, BPN rats exhibited significant changes in mechanical withdrawal threshold (MWT) (p < 0.05). The MWT showed a significant increase compared with the BNP group after EA or pregabalin (p < 0.05), but the long-term analgesic effects of EA appeared superior to pregabalin (p < 0.05). Furthermore, EA alleviated myelin sheath damage at the spinal cord levels. Damage, including demyelination, was limited to the ipsilateral DRG at the corresponding segment and bilateral CNS. Conclusion: Neuropathic pain-induced damage is limited to the ipsilateral DRG at corresponding segment and bilateral CNS pain centers. EA and pregabalin each partially attenuate neuropathic pain and alleviate neuronal damage in BPN, but EA has a longer-term analgesic effect.
C1 [Zhao, Qiannan; Qian, Xiaoyan; An, Jianxiong] China Med Univ, Aviat Gen Hosp, Chinese Acad Sci, Dept Anesthesiol Pain & Sleep Med, Beijing, Peoples R China.
   [Zhao, Qiannan; Qian, Xiaoyan; An, Jianxiong] Beijing Inst Translat Med, Beijing, Peoples R China.
   [Zhang, Jianfeng] Peking Univ Peoples Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Shi, Wanrui] Peking Univ Third Hosp, Dept Ultrasound, Beijing, Peoples R China.
   [An, Jianxiong] Shandong Second Med Univ, Affiliated Hosp, Sch Anesthesiol, Dept Pain Med, Weifang, Shandong, Peoples R China.
C3 Chinese Academy of Sciences; China Medical University; Peking University; Shandong Second Medical University
RP An, JX (corresponding author), China Med Univ, Aviat Gen Hosp, Dept Anesthesiol Pain & Sleep Med, Beiyuan Rd 3, Beijing 100012, Peoples R China.; An, JX (corresponding author), Chinese Acad Sci, Beijing Inst Translat Med, Beiyuan Rd 3, Beijing 100012, Peoples R China.
EM anjianxiong@yeah.net
FU National Natural Science Foundation of China [82405553]; National Key R&D Program of China [2024YFC2510200]
CR Attia GM, 2019, FOLIA NEUROPATHOL, V57, P146, DOI 10.5114/fn.2019.84423
   Bidve P, 2020, J DRUG TARGET, V28, P11, DOI 10.1080/1061186X.2019.1587444
   Burjek NE, 2023, ANESTHES PERIOP SCI, V1, P0, DOI 10.1007/s44254-023-00024-4
   Cao Y, 2013, J PAIN, V14, P193, DOI 10.1016/j.jpain.2012.11.005
   Lovaglio AC, 2019, NEUROL INDIA, V67, PS32, DOI 10.4103/0028-3886.250699
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen Feng, 2009, ZHEN CI YAN JIU, V34, P363
   Chen RW, 2017, J PAIN RES, V10, P1887, DOI 10.2147/JPR.S140840
   Ciaramitaro P, 2017, PAIN MED, V18, P2428, DOI 10.1093/pm/pnw360
   Colloca L, 2017, NAT REV DIS PRIMERS, V3, P0, DOI 10.1038/nrdp.2017.2
   Davis G, 2016, HAND CLIN, V32, P257, DOI 10.1016/j.hcl.2015.12.011
   Derry S, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007076.pub3
   du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193
   Field MJ, 1999, PAIN, V83, P303, DOI 10.1016/S0304-3959(99)00111-6
   Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019
   Fiore NT, 2024, BRAIN BEHAV IMMUN, V122, P287, DOI 10.1016/j.bbi.2024.07.043
   Gadepalli A, 2024, NEUROTHERAPEUTICS, V21, P0, DOI 10.1016/j.neurot.2023.10.012
   Gao L, 2021, J PAIN RES, V14, P2893, DOI 10.2147/JPR.S322964
   Gilcrease-Garcia BM, 2020, RADIOGRAPHICS, V40, P1686, DOI 10.1148/rg.2020200012
   Ha KY, 2011, J KOREAN MED SCI, V26, P404, DOI 10.3346/jkms.2011.26.3.404
   Hong ES, 2021, J SPINAL CORD MED, V44, P364, DOI 10.30528/jolss.2019.9.3.001
   Huang DY, 2010, NEUROSCI BIOBEHAV R, V34, P528, DOI 10.1016/j.neubiorev.2009.10.011
   Hui L, 2016, PAIN PHYSICIAN, V19, P0
   Jancalek R, 2011, ANN NEUROSCI, V18, P123, DOI 10.5214/ans.0972.7531.11183010
   Jia LL, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/9187406
   Karsy M, 2019, WORLD NEUROSURG, V123, PE488, DOI 10.1016/j.wneu.2018.11.192
   Khandia R, 2019, CELLS-BASEL, V8, P0, DOI 10.3390/cells8070674
   Koltzenburg M, 1999, TRENDS NEUROSCI, V22, P122, DOI 10.1016/S0166-2236(98)01302-2
   Kumar N, 2010, J NEUROCHEM, V113, P552, DOI 10.1111/j.1471-4159.2010.06625.x
   Lao LX, 2004, BRAIN RES, V1020, P18, DOI 10.1016/j.brainres.2004.01.092
   Lau WK, 2010, NEUROSCIENCE, V170, P655, DOI 10.1016/j.neuroscience.2010.07.031
   Le W, 2015, NEUROSCI LETT, V589, P52, DOI 10.1016/j.neulet.2015.01.033
   Liu CC, 2015, PAIN MED, V16, P1680, DOI 10.1111/pme.12722
   Liu H, 2016, PAIN PHYSICIAN, V19, PE435, DOI 10.36076/ppj/2019.19.e435
   Liu JY, 2024, BRAIN RES BULL, V216, P0, DOI 10.1016/j.brainresbull.2024.111036
   Makabe K, 2024, ARTHRITIS RES THER, V26, P0, DOI 10.1186/s13075-024-03354-1
   Hoang NS, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-141
   Nozaki C, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-28507-6
   Oaklander AL, 2008, J PAIN, V9, PS10, DOI 10.1016/j.jpain.2007.10.003
   Onakpoya IJ, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-023600
   Qi DB, 2016, LIFE SCI, V160, P64, DOI 10.1016/j.lfs.2016.06.025
   Ribeiro H, 2022, BIOMEDICINES, V10, P0, DOI 10.3390/biomedicines10061255
   Santana MVB, 2016, ARQ NEURO-PSIQUIAT, V74, P895, DOI 10.1590/0004-282X20160149
   Sharma K, 2018, NEUROSCI LETT, V674, P162, DOI 10.1016/j.neulet.2018.03.030
   Tiwari V, 2020, PAIN, V161, P842, DOI 10.1097/j.pain.0000000000001768
   Tiwari V, 2014, NEUROSCI BIOBEHAV R, V45, P19, DOI 10.1016/j.neubiorev.2014.05.002
   Torres FD, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1221777
   Uniyal A, 2023, TRENDS PHARMACOL SCI, V44, P1009, DOI 10.1016/j.tips.2023.10.003
   Wang L, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02628-2
   Wang M, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/7536234
   Wu MF, 2015, NEURAL REGEN RES, V10, P1628, DOI 10.4103/1673-5374.167762
   Wu Y, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-03371-0
   Xin YY, 2022, ACUPUNCT MED, V40, P474, DOI 10.1177/09645284221076515
   Xu J, 2022, INVEST OPHTH VIS SCI, V63, P0, DOI 10.1167/iovs.63.12.7
   Yang S, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133130
   Yoon JS, 2011, NEUROBIOL DIS, V41, P624, DOI 10.1016/j.nbd.2010.11.011
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang XH, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.657507
   Zhao XL, 2013, NAT NEUROSCI, V16, P1024, DOI 10.1038/nn.3438
   Zhou MM, 2023, BIOMED PHARMACOTHER, V161, P0, DOI 10.1016/j.biopha.2023.114516
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
   Zou J, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/6637693
NR 63
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0161-6412
EI 1743-1328
J9 NEUROL RES
JI Neurol. Res.
PD DEC 2
PY 2025
VL 47
IS 12
BP 1139
EP 1152
DI 10.1080/01616412.2025.2515195
EA JUN 2025
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA K6088
UT WOS:001506320200001
PM 40494390
DA 2026-01-16
ER

PT J
AU Zhang, M
   Zhao, N
   Yang, G
   Zhang, HH
   Li, JL
AF Zhang, Meng
   Zhao, Nan
   Yang, Ge
   Zhang, Huan-Huan
   Li, Jian-Li
TI [Effects of transcutaneous electrical acupoint stimulation at Neiguan (PC6) and
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Autonomic nervous system; Elderly; Frailty; Heart rate variability; Transcutaneous electrical acupoint stimulation
AB OBJECTIVES: To explore the effects of transcutaneous electrical acupoint  stimulation (TEAS) at the bilateral acupoints Neiguan (PC6) and Jianshi (PC5) on  heart rate variability (HRV) and inflammatory factors in frail elderly patients  undergoing laparoscopic colorectal cancer surgery under general anesthesia.  METHODS: A total of 78 frail elderly patients undergoing elective laparoscopic  colorectal cancer surgery were randomized into the TEAS group (39 patients, with  2 patients dropping out) and the control group (39 patients, with 1 patient  dropping out). In the TEAS group, TEAS was applied to the bilateral PC6 and PC5  from 30 min before anesthesia induction until the end of the surgery. The control  group was connected to an electronic acupuncture instrument at the same acupoints  but did not receive electrical stimulation. A short-term Holter electrocardiogram  was used to collect HRV parameters in the frequency domain, including  low-frequency power (LF), high-frequency power (HF), and the LF/HF ratio. Serum  concentrations of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured  using ELISA. The Quality of Recovery-15 (Qor-15) score was recorded, along with  adverse reactions such as postoperative nausea and vomiting (PONV), palpitations,  chest tightness, and chest pain. RESULTS: Compared with 1 d before surgery, LF  and HF were significantly decreased (P<0.05), and the LF/HF ratio significantly  increased (P<0.05) at 1, 2, and 3 d after surgery in the control group. In the  TEAS group, both LF and the LF/HF ratio were significantly decreased (P<0.05) at  1, 2, and 3 d after surgery. Compared with the control group, LF and HF levels  were significantly increased (P<0.05), and the LF/HF ratio was significantly  decreased (P<0.05) in the TEAS group at 1, 2, and 3 d after surgery. Both groups  exhibited increased levels of CRP and IL-6 at 1, 3, and 5 d after surgery  compared to 1 d before surgery (P<0.05), with the TEAS group showing lower CRP  and IL-6 levels than the control group (P<0.05). Compared to baseline before  surgery, the Qor-15 scores of both groups were decreased at 1, 2, and 3 d after  surgery (P<0.05), with the TEAS group showing significantly higher Qor-15 scores  than those in the control group (P<0.05). The incidence of PONV, palpitations,  chest tightness, and chest pain in the TEAS group was lower than that in the  control group (P<0.05). CONCLUSIONS: TEAS at the PC6 and PC5 can regulate  autonomic nervous function, reduce the early postoperative sympathetic nerve  excitation, maintain parasympathetic nerve tension, reduce inflammatory  responses, improve the quality of postoperative recovery, and decrease the  incidence of postoperative adverse reactions in frail elderly patients after  laparoscopic colorectal cancer surgery.
C1 Department of Anesthesia, Hebei General Hospital, Shijiazhuang 050051, China.
   Department of Anesthesia, The Third Hospital of Hebei Medical University, Shijiazhuang 050051.
   Department of Anesthesia, Hebei General Hospital, Shijiazhuang 050051, China.
   Department of Anesthesia, Hebei General Hospital, Shijiazhuang 050051, China.
   Department of Anesthesia, Hebei General Hospital, Shijiazhuang 050051, China. hblijianli@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 22
PY 2025
VL 50
IS 7
BP 815
EP 821
DI 10.13702/j.1000-0607.20241107
PG 6
WC Humans; Acupuncture Points; Female; Male; Aged; Interleukin-6; blood; Transcutaneous Electric Nerve Stimulation; C-Reactive Protein; metabolism; Aged, 80 and over; Frail Elderly; Autonomic Nervous System; physiopathology; Heart Rate; Colorectal Neoplasms; surgery
UT PubMed:40691032
PM 40691032
DA 2025-07-22
ER

PT J
AU Marcondes, L
   Ferreira, PM
   Sawada, NO
   Chianca, TCM
   Felix, JVC
   Guimaraes, PRB
   Kalinke, LP
AF Marcondes, Larissa
   Ferreira, Poliana Martins
   Sawada, Namie Okino
   Chianca, Tania Couto Machado
   Felix, Jorge Vinicius Cestari
   Guimaraes, Paulo Ricardo Bittencourt
   Kalinke, Luciana Puchalski
TI Effect of Laser Auriculotherapy on Quality of Life, Fatigue, and Anxiety in Women with Advanced Breast Cancer: Randomized Clinical Trial
SO HEALTHCARE
LA English
DT Article
DE auriculotherapy; breast cancer; complementary therapies; oncology nursing; quality of life
ID acupuncture; pain
AB Objective: To evaluate the effect of laser auriculotherapy on health-related quality of life, cancer-related fatigue, and anxiety in women with advanced breast cancer undergoing palliative chemotherapy. Method: A randomized, parallel, single-blind, single-center clinical trial was conducted in a Brazilian oncology referral hospital. A total of 123 women were randomly divided into groups: 41 in the experimental group (10 weekly laser auriculotherapy sessions), 40 in the sham group (10 weekly sham sessions), and 42 in the control group. Outcomes were assessed at baseline, 5th week, and 11th week, using the Quality of Life Questionnaire Core-30, Functional Assessment of Cancer Therapy: Fatigue and State-Trait Anxiety Inventory. Statistical analyses included Kruskal-Wallis, Mann-Whitney, and Friedman tests. Results: The experimental group exhibited the highest mean overall quality of life, with a significant increase (p < 0.000001) between the second and third evaluations and a significant improvement in fatigue between the second and third evaluations (p = 0.00001). Conversely, women in the sham and control groups experienced a decline and worsening in both their quality of life and fatigue. Women in all three groups showed reduction an anxiety. Changes in anxiety in these women were not statistically significant. Conclusions: reduction improvement in health-related quality of life and a reduction in cancer-related fatigue in the experimental group. These results show a positive effect of auriculotherapy on cancer-related fatigue, demonstrating potential for application in clinical practice in women with advanced breast cancer and in palliative chemotherapy. Brazilian Registry of Clinical Trials: RBR-6hxffx4.
C1 [Marcondes, Larissa; Felix, Jorge Vinicius Cestari; Kalinke, Luciana Puchalski] Fed Univ Parana UFPR, Dept Nursing, BR-81210170 Curitiba, Brazil.
   [Ferreira, Poliana Martins; Sawada, Namie Okino] Fed Univ Alfenas UNIFAL, Dept Nursing, BR-37130001 Alfenas, Brazil.
   [Chianca, Tania Couto Machado] Univ Fed Minas Gerais, Dept Nursing, BR-30130100 Belo Horizonte, Brazil.
   [Guimaraes, Paulo Ricardo Bittencourt] Fed Univ Parana UFPR, Dept Stat, BR-81531990 Curitiba, Brazil.
C3 Universidade Federal de Alfenas; Universidade Federal de Minas Gerais
RP Marcondes, L (corresponding author), Fed Univ Parana UFPR, Dept Nursing, BR-81210170 Curitiba, Brazil.
EM marcondes.lari@gmail.com; poliana.martins@sou.unifal-mg.edu.br; namie.sawada@unifal-mg.edu.br; taniachianca@gmail.com; jvcfelix@hotmail.com; guimaraes.prb@gmail.com; kalinkeluciana@gmail.com
CR ae Kang Mi, 2019, THE KOREAN JOURNAL OF HEALTH SERVICE MANAGEMENT 보건의료산업학회지, V13, P81, DOI 10.12811/kshsm.2019.13.3.081
   Vallim ETA, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018043603525
   Unknown -, 2004, TABLE DAVID BOHM DIA, V0, P0
   Bao T, 2023, CANCER RES, V83, P0, DOI 10.1158/1538-7445.SABCS22-PD8-05
   Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1
   Biaggio AMB, 1979, MANUAL PARA O INVENTRIO DE ANSIEDADE TRAO-ESTADO (IDATE), V0, P0
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Chu YR, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221150907
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   European Organization For Research and Treatment Of Cancer (EORTC), 1995, FUNCTIONAL ASSESSMENT OF CANCER THERAPY: FATIGUE (FACT-F)VERSO 3.0, V0, P0
   Filler K, 2016, SUPPORT CARE CANCER, V24, P5, DOI 10.1007/s00520-015-2965-5
   Fonseca AA, 2017, REV. ELETRNICA ACERVO SADE, V5, P0
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Guo YQ, 2023, BMC NURS, V22, P0, DOI 10.1186/s12912-023-01184-1
   Hiensch AE, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06556-7
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Ishikawa NM, 2010, SUPPORT CARE CANCER, V18, P481, DOI 10.1007/s00520-009-0697-0
   Kumar JVR, 2015, ASIAN JOURNAL OF NURSING EDUCATION AND RESEARCH, V5, P513, DOI 10.5958/2349-2996.2015.00105.6
   Habimorad PHL, 2020, CIENC SAUDE COLETIVA, V25, P395, DOI 10.1590/1413-81232020252.11332018
   Li MJ, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2022-062407
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Ministrio da Sade do Brasil, 2022, ESTIMATIVA 2023: INCIDNCIA DE CNCER NO BRASIL, V0, P0
   National Cancer Institute, 2021, PALLIATIVE CARE IN CANCER, V0, P0
   Nogier PMF, 1983, FROM AURICULOTHERAPY TO AURICULOMEDICINE-HARDCOVER, V0, P0
   Riggio AI, 2021, BRIT J CANCER, V124, P13, DOI 10.1038/s41416-020-01161-4
   Rodrigues MD, 2019, COMPLEMENT THER MED, V42, P340, DOI 10.1016/j.ctim.2018.12.010
   Round R, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/984763
   Saligan LN, 2015, SUPPORT CARE CANCER, V23, P2853, DOI 10.1007/s00520-015-2815-5
   Sampaio H, 2016, TRIALS, V17, P0, DOI 10.1186/s13063-016-1540-9
   Silvrio-Lopes SS, 2020, ATLAS DE AURICULOTERAPIA DE A A Z, V4th, P0
   Soliman N, 1999, PHYS MED REHABIL CLIN N AM, V10, P547
   Spielberger CD, 1970, MANUAL STATE TRAIT A, V0, P0
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tsao Y, 2019, SUPPORT CARE CANCER, V27, P4155, DOI 10.1007/s00520-019-04682-8
   Xi Y, 2020, FRONTIERS OF NURSING, V7, P9, DOI 10.2478/fon-2020-0008
   Yang EM, 2022, J INTEGR COMPLEMENT, V28, P427, DOI 10.1089/jicm.2021.0256
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
NR 40
TC 3
Z9 3
U1 3
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD JAN 15
PY 2025
VL 13
IS 2
BP 
EP 
DI 10.3390/healthcare13020166
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA T5X2Z
UT WOS:001405723400001
PM 39857193
DA 2026-01-16
ER

PT J
AU Xie, TL
   Liu, C
   Wu, YD
   Li, XX
   Yang, QY
   Tan, J
AF Xie, Tianle
   Liu, Can
   Wu, Yudi
   Li, Xiuxiu
   Yang, Qianyun
   Tan, Jing
TI Efficacy and Safety of Different Acupuncture Treatments for Cancer-Related Pain: A Systematic Review and Network Meta-Analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; cancer; cancer pain; meta-analysis
ID electroacupuncture; moxibustion; therapy
AB Background: Cancer pain is a prevalent and persistent issue, and while there have been some observations of the possible benefits of acupuncture in managing cancer pain, there is still debate regarding its safety and effectiveness. This study aims to compare the efficacy and safety of different acupuncture modalities in the treatment of cancer pain through a network meta-analysis. Methods: Between the time each database was created and June 3, 2024, eight databases were queried: PubMed, Cochrane, Embase, Web of Science, CNKI, Wanfang, VIP, and China Biomedicine. Randomized controlled trials investigating the use of various acupuncture and moxibustion techniques in the treatment of cancer pain were identified. Publication bias and quality of randomized controlled trials were assessed using the Cochrane Risk of Bias tool and the Jadad scale, and network meta-analyses were performed using Stata 15 and R 4.3.2. Results: We incorporated 111 studies encompassing 9549 individuals diagnosed with cancer, examining 29 distinct therapies. Network meta-analysis showed that, compared to Usual Medicine, Acupuncture + Usual Medicine + Traditional Chinese medicine (MD = -1.83, 95% CI: -2.86 to -0.80) could reduce NRS scores, Acupuncture + Traditional Chinese medicine (OR = 30.86, 95% CI: 3.75-254.20) could improve cancer pain relief, Moxibustion + Usual Medicine (MD = 2.12, 95% CI: 0.43-3.80) could effectively improve KPS score, Acupuncture + Application of Chinese medicine (OR = 0.16, 95% CI: 0.04-0.66) is associated with a lower incidence of constipation, Electro-Acupuncture + Usual Medicine (OR = 0.11, 95% CI: 0.03-0.45) shows a lower incidence of nausea and vomiting, Acupuncture + Moxibustion + Usual Medicine (OR = 0.29, 95% CI: 0.09-0.90) is associated with a lower incidence of dizziness. Conclusion: Acupuncture + Traditional Chinese medicine is the best intervention for different acupuncture methods in the treatment of cancer pain, and Moxibustion + Usual Medicine is the best intervention to improve the quality of life of patients.
C1 [Xie, Tianle; Liu, Can; Wu, Yudi; Li, Xiuxiu; Yang, Qianyun; Tan, Jing] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
C3 Hunan University of Chinese Medicine
RP Tan, J (corresponding author), Hunan Univ Chinese Med, Coll Acupuncture Massage & Rehabil, Clin Applicat & Mech Acupuncture, Hanpu Campus, Changsha 410208, Hunan, Peoples R China.
EM hugotan0101@163.com
FU national outstanding youth science fund project of national natural science foundation of china [82205296]; Natural Science Foundation of China Youth Project [2022JJ1531]; Natural Science Foundation of Hunan Province Youth Project [21B0380]; Hunan Provincial Department of Education Scientific Research Outstanding Youth Project [S202310541034, 2020XJJJ008]; Innovation and Entrepreneurship Training Program for College Students in Hunan Province
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2000, ACUPUNCT RES, V0, P0
   Bao GA, 2019, J ACUPUNCT TUINA SCI, V17, P416, DOI 10.1007/s11726-019-1144-5
   Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Cao H, 2024, ADV MODERN BIOMED, V24, P553
   Chan YY, 2014, AM J CHINESE MED, V42, P569, DOI 10.1142/S0192415X14500372
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen J, 2020, SHAANXI TRADITIONAL CHINESE MEDICINE, V41, P105
   Chen LX, 2020, J ACUPUNCT TUINA SCI, V18, P276, DOI 10.1007/s11726-020-1188-6
   Chen Z, 2021, SHANG J ACUPUNCT, V40, P411
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Corder G, 2018, ANNU REV NEUROSCI, V41, P453, DOI 10.1146/annurev-neuro-080317-061522
   Cumpston M, 2019, COCHRANE HDB SYSTEMA, V10, P0
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Deng Y, 2015, J MODERN INTEGR MED, V24, P606
   Ding QG, 2015, CHIN MED MODERN DIST EDU CHIN, V13, P65
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Fan J, 2017, LIAON J TRADIT CHIN MED, V44, P371
   Feldman E, 2023, INTEGR MED ALERT, V26, P1
   Feng Y, 2020, MODERN J INTEGR TRADIT CHIN WEST MED, V29, P878
   [付烊 Fu Yang], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P768
   Gao J, 2020, SHAANXI TRADIT CHIN MED, V41, P0
   Gao J, 2019, SICHUAN TRADIT CHIN MED, V37, P93
   Gao J, 2018, CHIN HERALD MED, V15, P92
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Green CR, 2009, J PAIN SYMPTOM MANAG, V37, P831, DOI 10.1016/j.jpainsymman.2008.05.011
   Gu Y, 2017, J TRADIT CHIN MED, V32, P2307
   Guo Z, 2015, INT J TRAD CHIN MED, V37, P371
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Han Xue-Chang, 2020, ZHEN CI YAN JIU, V45, P845, DOI 10.13702/j.1000-0607.200131
   He J, 2024, J HUBEI UNIV CHIN MED, V26, P93
   He L, 2012, SHANDONG J TRADIT CHIN MED, V31, P254
   He YH, 2022, ACUPUNCT MED, V40, P133, DOI 10.1177/09645284211056016
   Hou Y, 2018, CLIN PRACT MODERN CHIN MED, V25, P17
   [胡梦云 Hu Mengyun], 2021, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V36, P6253
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   [惠建荣 Hui Jianrong], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P146
   Ji Jin-Feng, 2021, ZHONGGUO ZHEN JIU, V41, P725, DOI 10.13703/j.0255-2930.20200615-k0002
   Jiang H, 2021, LIAON J TRADIT CHIN MED, V48, P143
   Kang F, 2013, J HUNAN UNIV TRADIT CHIN MED, V33, P31
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kim CS, 2003, SHANG J TRADIT CHIN MED, V37, P48
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kroenke K, 2010, J PAIN SYMPTOM MANAG, V40, P327, DOI 10.1016/j.jpainsymman.2009.12.023
   Lee J, 2014, INTEGR CANCER THER, V13, P211, DOI 10.1177/1534735413510025
   Lewis CES, 2023, CURR OPIN SUPPORT PA, V17, P98, DOI 10.1097/SPC.0000000000000640
   Li D, 2021, SHANG J ACUPUNCT, V40, P406
   Li Dan, 2020, ZHONGGUO ZHEN JIU, V40, P257, DOI 10.13703/j.0255-2930.20190311-k0001
   Li FM, 2022, J PRAC MED, V38, P763
   Li J, 2016, CHINA ENV MONITOR, V32, P30, DOI 10.19316/j.issn.1002-6002.2016.05.06
   Li P, 2017, SHANDONG MED, V57, P43
   [李莎 Li Sha], 2023, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V42, P889
   Li Y, 2022, SICHUAN TRADIT CHIN MED, V40, P98
   Li Y, 2021, SHANG J ACUPUNCT, V40, P303
   Li Y, 2023, J PAIN RES, V16, P515, DOI 10.2147/JPR.S396696
   Li YH, 2014, SHANGHAI J ACUPUNCT, V33, P211
   Liu B, 2020, J SHANDONG UNIV TRADIT CHIN MED, V44, P0
   Liu H, 2010, HEBEI TRADIT CHIN MED, V32, P1384
   Liu J, 2001, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V21, P262
   Liu L, 2020, SHANG J ACUPUNCT, V39, P692
   Liu X, 2007, SHAANXI TRADIT CHIN MED, V28, P1225
   Liu X, 2008, SHAANXI TRADIT CHIN MED, V29, P347
   Lu Dian-Rong, 2021, ZHONGGUO ZHEN JIU, V41, P121, DOI 10.13703/j.0255-2930.20190320-0010
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Luo Z, 1900, V1992, V0, P94
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Mo Y, 2016, CHIN MED HERALD, V13, P108
   Ni W, 2020, J MODERN INTEGR MED, V29, P3008
   Ou J, 2018, J MODERN INTEGR MED, V27, P2319
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Peng J, 2012, SHANG J ACUPUNCT MOXIBUST, V31, P236
   Pergolizzi JV, 2021, FRONT PAIN RES, V2, P0, DOI 10.3389/fpain.2021.691720
   Prommer EE, 2015, CANCER CONTROL, V22, P412, DOI 10.1177/107327481502200407
   Qian Z, 1900, V2019, V0, P310
   Qiao D, 2008, J PRACT ONCOL, V22, P0
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Saraswati W, 2021, J ACUPUNCT MERIDIAN, V14, P5, DOI 10.51507/j.jams.2021.14.1.4
   Shen JM, 2013, JOURNAL OF LIAONING UNIVERSITY OF TCM, V15, P189
   Shen L, 2016, J MED RES, V45, P87
   Shen L, 2015, J INTRACT DIS, V14, P409
   Shen S, 2000, CHIN ACUPUNCT, V20, P143
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Sun T, 2024, J HUBEI UNIV CHIN MED, V26, P82
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tan GS, 2012, WORLD J INTEGR MED, V7, P147
   Tang H, 2015, SHANDONG MED, V55, P42
   Tang Y, 2019, BRAIN RES BULL, V151, P144, DOI 10.1016/j.brainresbull.2018.10.015
   Urits I, 2021, ADV THER, V38, P76, DOI 10.1007/s12325-020-01554-0
   Wang DF, 2016, CHIN NATUROP, V24, P83
   Wang L, 2021, SHANG J ACUPUNCT, V40, P1336
   Wang SC, 2010, CHIN J CANCER PREV TREAT, V17, P0
   Wang X, 2020, J SICHUAN TRADIT CHIN MED, V38, P191
   Wang Z, 2023, CHONGQ MED, V52, P123
   Wei R, 2018, CLIN J ACUPUNCT, V34, P10
   Wei S, 2020, LIAON J TRADIT CHIN MED, V47, P169
   Wu J, 2014, CHIN J TRADIT CHIN MED, V32, P1904
   Wu J, 2017, SHANG J TRADIT CHIN MED, V51, P48
   Wu QL, 1054, CHIN ACUPUNCT MOXIBUST, V39, P0
   Wu T, 2017, J MODERN INTEGR MED, V26, P3009
   Wu Y, 2015, J HUBEI U TRADIT CHI, V17, P87
   Xie Y, 2022, SICHUAN TRADIT CHIN MED, V40, P198
   Xu L, 2022, J INTEGR MED LIVER DIS, V32, P844
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   Xu P, 2021, LABORAT MED CLIN, V18, P2875
   Xu YL, 2021, J SICHUAN TRADIT CHIN MED, V39, P176
   Xue N, 2022, J MODERN INTEGR MED, V31, P0
   [杨海霞 Yang Haixia], 2018, 中国实验方剂学杂志 CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE, V24, P173
   Yang SF, 2015, SHANG J ACUPUNCT MOXIBUST, V34, P843
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yang Z, 2021, J TRADIT CHIN MED ONCOL, V3, P30, DOI 10.1007/s12032-021-01474-1
   Ye J, 2015, SHANGHAI J ACUP MOXIB, V34, P642
   Yin C, 2017, CURR OPIN ANESTHESIO, V30, P583, DOI 10.1097/ACO.0000000000000501
   Zhang D, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231210288
   Zhang H, 1900, V2015, V0, P742
   Zhang L, 2019, CHIN J TRADIT CHIN MED, V37, P2781
   Zhang M, 2016, CHIN ACUPUNCT MOXIBUST, V36, P346
   [张美芬 ZHANG Mei-fen], 2009, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V31, P674
   Zhang QL, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1166580
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang X, 2021, J LIAON UNIV TRADIT CHIN MED, V23, P178
   Zhang XY, 2022, LIAONING J TRADIT CHIN MED, V49, P165
   Zhang Z, 2012, J EMERG TRADIT CHIN MED, V21, P1848
   Zhao WL, 2018, J CLIN ACUPUNCT MOXIBUSTION, V34, P15, DOI 10.3969/j.issn.1005-0779.2018.06.006
   Zheng K, 2015, J LIAON UNIV TRADIT CHIN MED, V17, P19
   Zhou D, 2023, JOURNAL OF ONCOLOGY IN CHINESE MEDICINE, V5, P30
   Zhou J, 2017, J TRADIT CHIN MED, V32, P342
   Zhou Y, 2007, J ACUPUNCT TUINA SCI, V5, P162, DOI 10.1007/s11726-007-0162-x
   [朱元颖 Zhu Yuanying], 2013, 中国全科医学 CHINESE GENERAL PRACTICE, V16, P1923
   Zuo X, 2022, WORLD J INTEGR MED, V17, P1783
NR 133
TC 4
Z9 4
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2025
VL 24
IS 
BP 
EP 
DI 10.1177/15347354251314500
PG 17
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA T9T4Q
UT WOS:001408342500001
PM 39873173
DA 2026-01-16
ER

PT J
AU Chan, AL
   Nasr, R
   Arcos, D
   Kagramanov, D
   Asuzu, C
   Bao, T
   Cheung, YT
   Kwon, JH
   Lacey, J
   Lee, RT
   Lustberg, M
   Ohaeri, BM
   Rao, ST
   Soto-Perez-de-Celis, E
   Witt, CM
   Lopez, AM
AF Chan, Alexandre
   Nasr, Reem
   Arcos, Daniela
   Kagramanov, Dalia
   Asuzu, Chioma
   Bao, Ting
   Cheung, Yin Ting
   Kwon, Jung Hye
   Lacey, Judith
   Lee, Richard T.
   Lustberg, Maryam
   Ohaeri, Beatrice M.
   Rao, Santosh
   Soto-Perez-de-Celis, Enrique
   Witt, Claudia M.
   Lopez, Ana Maria
TI Evaluation of integrative oncology modalities for symptom management: a MASCC/SIO global survey
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Integrative oncology; Cancer supportive care; Oncology; Cancer; Global perspectives
ID medicine; education; care
AB BackgroundWith growing evidence pointing towards the potential of integrative oncology modalities (IOM) in addressing cancer and cancer-treatment related symptoms, research on IOM utilization and implementation is warranted. This study examines global stakeholder perspectives on integrative oncology (IO) utilization for supportive cancer care.MethodsMembers of the Multinational Association of Supportive Care in Cancer (MASCC) and the Society for Integrative Oncology (SIO) completed a survey on the utilization of IOM for supportive cancer care. Descriptive statistics were used to assess demographic data, IOM usage patterns, IOM education, and financial considerations for utilizing IOM.ResultsAmong 344 participants representing eight geographical regions, 70% reported having utilized or recommended IOM and 79% perceived IOM to be underutilized in cancer supportive care. Acupuncture (48%), exercise classes (39%), nutrition (38%), breathing/yoga (38%) and personalized exercise (38%) were among the most utilized IOM across regions. Relatedly, the symptoms for which IOM were most recommended for persons with a diagnosis of cancer in active treatment [AT] or completed treatment [CT] respectively were emotional (AT 23%; CT 26%), pain (AT 22%; CT 20%), gastrointestinal (AT 21%; CT 12%) and fatigue (AT 15%; CT 16%). The perceived availability of integrative medicine training was highest in North America (69%). Across regions, self-pay (20%-67%), private insurance (0%-26%) and government insurance (7%-40%) were the most common forms of payment for IOM. The IOM most recommended in high-income countries (acupuncture, exercise, massage, individual exercise) varied from the IOM most recommended in low-middle income countries (nutrition counseling, exercise classes, breathing, acupuncture).ConclusionThis study provides valuable insights into global utilization patterns of IOM in supportive cancer care, highlighting that while most respondents have utilized IOM, there is a perceived underutilization overall. Our results show significant regional differences in the availability of integrative oncology education and hint to financial barriers impacting IOM use. Further research is necessary to explore these aspects and inform strategies for supporting IOM implementation efforts.
C1 [Chan, Alexandre; Nasr, Reem; Arcos, Daniela; Kagramanov, Dalia] Univ Calif Irvine, Dept Clin Pharm Practice, 802 W Peltason Dr, Irvine, CA 92697 USA.
   [Asuzu, Chioma] Univ Ibadan, Dept Guidance & Counselling, Ibadan, Nigeria.
   [Bao, Ting] Dana Farber Canc Inst, Zakim Ctr Integrat Therapies & Hlth Living, Boston, MA USA.
   [Cheung, Yin Ting] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China.
   [Kwon, Jung Hye] Chung Ang Univ, Coll Med, Div Hemato oncol, Anseong, Gyeonggi Do, South Korea.
   [Lacey, Judith] Chris OBrien Lifehouse Comprehens Canc Ctr, Dept Support Care & Integrat Oncol, Sydney, NSW, Australia.
   [Lee, Richard T.] City Hope Comprehens Canc Ctr, Cherng Family Ctr Integrat Oncol, Duarte, CA USA.
   [Lustberg, Maryam] Yale Univ, Smilow Canc Hosp, Breast Canc Ctr, New Haven, CT USA.
   [Ohaeri, Beatrice M.] Univ Ibadan, Coll Med, Ibadan, Nigeria.
   [Rao, Santosh] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA.
   [Soto-Perez-de-Celis, Enrique] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Geriatr, Mexico City, Mexico.
   [Soto-Perez-de-Celis, Enrique] Univ Colorado, UC Hlth Diane OConnor Thompson Breast Ctr, Auschutz Med Campus, Aurora, CO USA.
   [Witt, Claudia M.] Univ Hosp Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Comprehens Canc Ctr, Philadelphia, PA USA.
C3 University of California System; University of California Irvine; University of Ibadan; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Chinese University of Hong Kong; Chung Ang University; Chung Ang University Hospital; Chris O'Brien Lifehouse; City of Hope; Yale University; University of Ibadan; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Zurich; University Zurich Hospital; Thomas Jefferson University
RP Chan, AL (corresponding author), Univ Calif Irvine, Dept Clin Pharm Practice, 802 W Peltason Dr, Irvine, CA 92697 USA.
EM a.chan@uci.edu
CR Armstrong K, 2018, SUPPORT CARE CANCER, V26, P2267, DOI 10.1007/s00520-017-4007-y
   Bower JE, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00541
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Chan A, 2024, CANCER MED-US, V13, P0, DOI 10.1002/cam4.70234
   Dans M, 2021, J NATL COMPR CANC NE, V19, P780, DOI 10.6004/jnccn.2021.0033
   ESMO, 2024, CLINICAL PRACTICE GUIDELINES, V0, P0
   Garchinski CM, 2014, FUTURE ONCOL, V10, P2603, DOI 10.2217/fon.14.186
   Gonzalez M, 2021, PSYCHO-ONCOLOGY, V30, P1196, DOI 10.1002/pon.5671
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Karim S, 2021, CURR ONCOL, V28, P853, DOI 10.3390/curroncol28010084
   Kim JEE, 2009, J PAIN SYMPTOM MANAG, V37, P715, DOI 10.1016/j.jpainsymman.2008.04.018
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Misiag W, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14174154
   Mumber MP, 2016, J CLIN ONCOL, V34, P0, DOI 10.1200/jco.2016.34.26_suppl.171
   Ng JY, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08785-9
   Ngamkham S, 2019, ASIA-PAC J ONCOL NUR, V6, P161, DOI 10.4103/apjon.apjon_67_18
   Semeniuk G, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12123946
   Society for Integrative Oncology, 2024, TRAINING MODULES, V0, P0
   Toledano A, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211004730
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
NR 24
TC 0
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD NOV 3
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12906-025-05157-6
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 9HW1B
UT WOS:001606725000001
PM 41184943
DA 2026-01-16
ER

PT J
AU Wei, W
   Yao, B
   Sun, XY
   Xing, SN
   Wang, KY
   He, FM
   Xu, QB
   Ren, CX
AF Wei, Wei
   Yao, Bei
   Sun, Xiaoying
   Xing, Shaona
   Wang, Kaiyi
   He, Fangmei
   Xu, Qiaobo
   Ren, Chunxiao
TI Invasive or noninvasive? A systematic review and network meta-analysis of acupuncture and acupressure to treat cancer pain
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Acupuncture; Acupressure; Cancer pain; Complementary therapies; Network meta-analysis
ID management; electroacupuncture; survivors; efficacy; society; trial; pilot; women
AB BackgroundBoth acupressure and acupuncture effectively alleviate pain in cancer patients. Acupuncture requires specialized practitioners and is invasive, while acupressure is noninvasive and can be self-administered. Current comparative evidence remains insufficient for clear clinical recommendations.AimsTo investigate the relative efficacy of acupuncture versus acupressure in alleviating pain among cancer patients.MethodsThis systematic review and network meta-analysis employed a Bayesian framework. Eight major Chinese and English databases were searched from inception to March 1, 2025. Two independent reviewers screened literature, extracted data, and assessed bias in selected studies using the Risk of Bias 2 tool. Network meta-analysis was conducted using R software version 4.4.1.ResultsThirty-seven RCTs including 3066 patients were analyzed to compare eight treatments: manual acupuncture, transcutaneous electrical acupoint stimulation, auricular acupressure, electro-acupuncture, acupoint massage, auricular acupuncture, moxibustion, and placebo. Network meta-analysis revealed auricular acupuncture provided the greatest pain score improvement compared to placebo, followed by auricular acupressure and acupoint massage.ConclusionBased on our analysis, we recommend auricular acupuncture, auricular acupressure, and acupoint massage for managing cancer pain. While current studies demonstrate potential benefits, limitations include concurrent pain medication use and methodological inconsistencies. Future research should include more robust, single-intervention clinical trials to definitively evaluate efficacy for oncology patients.
C1 [Wei, Wei; Sun, Xiaoying; Xing, Shaona; Wang, Kaiyi; He, Fangmei; Xu, Qiaobo; Ren, Chunxiao] Shaanxi Energy Inst, Xianyang 712000, Shaanxi, Peoples R China.
   [Yao, Bei] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS
RP Ren, CX (corresponding author), Shaanxi Energy Inst, Xianyang 712000, Shaanxi, Peoples R China.
EM 319068488@qq.com; 1030503107@qq.com; 252230368@qq.com; 12561895884@qq.com; 1258666562@qq.com; 1481705997@qq.com; xuqiaobo@sxny.cn; 2215222801@qq.com
FU Innovative Team for Smart Healthcare of Geriatric Diseases [:2024KYTD06]; Modern TCM Healthcare Technology Demonstration Platform
CR Alhusamiah B, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241239110
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Anekar AA, 2024, WHO ANALGESIC LADDER, V0, P0
   Turan GB, 2023, CANCER NURS, V46, P457, DOI 10.1097/NCC.0000000000001193
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen Hui, 2023, ZHONGGUO ZHEN JIU, V43, P322, DOI 10.13703/j.0255-2930.20220816-k0001
   Chen J, 2020, SHAANXI TRADITIONAL CHINESE MEDICINE, V41, P105
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Duan WH, 2023, THERAPEUTIC EFFECT OF ELECTROACUPUNCTURE ENCIRCLING NEEDLING COMBINED WITH EXTERNAL APPLICATION OF TRADITIONAL CHINESE MEDICINE FOR PROMOTING BLOOD CIRCULATION AND REMOVING BLOOD STASIS IN THE TREATMENT OF MODERATE AND SEVERE CANCER PAIN OF LUNG CANCER WITH BLOOD STASIS, V0, P0
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Gomes T, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.0217
   Gronkjær LL, 2021, JHEP REP, V3, P0, DOI 10.1016/j.jhepr.2021.100370
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Haroun R, 2023, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.1030899
   He YH, 2022, ACUPUNCT MED, V40, P133, DOI 10.1177/09645284211056016
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jeon JH, 2015, INTEGR CANCER THER, V14, P221, DOI 10.1177/1534735415570634
   Jia LT, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000040158
   Jung MS, 2025, CANCER NURS, V48, PE64, DOI 10.1097/NCC.0000000000001286
   Lee J, 2014, INTEGR CANCER THER, V13, P211, DOI 10.1177/1534735413510025
   Lu DR, 2021, CHINESE ACUPUNCTURE & MOXIBUSTION, V41, P126
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Lu LM, 2024, ANN INTERN MED, V177, P0, DOI 10.7326/M23-2721
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Luesma MJ, 2021, MED CLIN-BARCELONA, V157, P71, DOI 10.1016/j.medcli.2021.02.012
   Lyu Z, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-023-08240-1
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Miladinia M, 2018, EUR J CANCER CARE, V27, P0, DOI 10.1111/ecc.12762
   Ng DQ, 2024, BMC MED, V22, P0, DOI 10.1186/s12916-024-03626-2
   Paice JA, 2022, CURR OPIN SUPPORT PA, V16, P55, DOI 10.1097/SPC.0000000000000594
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Phillips RS, 2012, J NEUROPHYSIOL, V108, P2393, DOI 10.1152/jn.00563.2012
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Shen JM, 2013, JOURNAL OF LIAONING UNIVERSITY OF TCM, V15, P189
   Shen L, 2016, J MED RES, V45, P87
   Sterne J, 2019, BMJ, V366, P14898, DOI 10.1136/bmj.l4898
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tian W, 2024, J CANCER RES THER, V20, P1334, DOI 10.4103/jcrt.jcrt_2172_23
   Wang Y, 2017, ZHEJIANG J TRADIT CHIN MED, V52, P684
   Wang YJ, 2023, CHINESE SCIENCE AND TECHNOLOGY JOURNAL DATABASE MEDICINE, V8, P117
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Wu Qiu-Lan, 2019, ZHONGGUO ZHEN JIU, V39, P1051, DOI 10.13703/j.0255-2930.2019.10.005
   Yang J, 2020, J PAIN RES, V13, P411, DOI 10.2147/JPR.S244173
   Yang MX, 2023, J PAIN, V24, P1721, DOI 10.1016/j.jpain.2023.05.005
   Yao Jia-Lin, 2022, ZHONGGUO ZHEN JIU, V42, P1125, DOI 10.13703/j.0255-2930.20211203-k0001
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yeh Chao Hsing, 2020, GLOB ADV HEALTH MED, V9, P2164956120906092, DOI 10.1177/2164956120906092
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Zhou D, 2023, JOURNAL OF ONCOLOGY IN CHINESE MEDICINE, V5, P30
   朱利楠, 2013, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V35, P579
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 63
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT 31
PY 2025
VL 33
IS 11
BP 
EP 
DI 10.1007/s00520-025-10068-w
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 9ID1U
UT WOS:001606911700002
PM 41171390
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Gressel, O
   Keshet, Y
   Zaritsky, V
   Kassem, S
   Segev, Y
   Samuels, N
AF Ben-Arye, Eran
   Gressel, Orit
   Keshet, Yael
   Zaritsky, Vika
   Kassem, Sameer
   Segev, Yakir
   Samuels, Noah
TI War and Cancer: Exploring Patient Narratives in a Randomized Integrative Oncology
SO Psycho-oncology
LA English
DT Journal Article
DE cancer; integrative medicine; integrative oncology; pain; supportive and palliative care; war
AB STUDY OBJECTIVE: The current war in Israel has affected quality of life  (QoL)-related concerns among patients with cancer. Integrative oncology (IO)  provides complementary medicine within supportive and palliative care. The study  examined an IO program in northern Israel for cancer and war-related concerns.  METHODS: This qualitative study, nested within a prospective randomized  controlled trial, examined patients undergoing oncology and palliative care  expressing cancer and war-related QoL concerns referred by oncology healthcare  providers to an IO program. Patients were randomized to manual-relaxation with  (Group A) or without (Group B) acupuncture. Narratives were recorded in MYCaW  (Measure Yourself Concerns and Well-being) questionnaires immediately and after  24 h. Narrative excerpts were qualitatively analyzed using ATLAS.Ti software for  systematic coding. RESULTS: Patient narratives (Group A, 67; Group B, 58) focused  primarily on themes which included a sense of calmness and reduced emotional  distress (e.g., stress, anxiety, worries, nervousness), more prominently in Group  B (manual-relaxation only; 55/56 immediately/after 24 h); and reduced pain  severity, more so in Group A (with acupuncture; 19/24). Most excerpts described  improved QoL in both groups (142/147, 97%) immediately after IO treatments, less  so at 24 h (103/135). CONCLUSIONS: Narratives of patients facing cancer- and  war-related QoL challenges due to the ongoing war in Israel describe a beneficial  impact of IO treatments, both immediately and after 24 h. Manual-relaxation  without acupuncture was more likely to improve emotional concerns, with pain  relief more apparent with the addition of acupuncture. Further qualitative and  quantitative research is needed to explore these findings.
C1 Integrative Oncology Program, The Oncology Service
   Lin, Carmel, and Zebulun Medical Centers, Clalit Health Services, Haifa, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of 
   Integrative Oncology Program, The Oncology Service
   Lin, Carmel, and Zebulun Medical Centers, Clalit Health Services, Haifa, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of 
   Department of Sociology, Western Galilee Academic College, Acre, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
   Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
NR 0
TC 0
SN 1099-161
EI 1057-924
J9 Psychooncology
PD MAY 6
PY 2025
VL 34
IS 5
BP e70172
EP e70172
DI 10.1002/pon.70172
PG 1
WC Humans; Male; Neoplasms; psychology; Female; Quality of Life; psychology; Middle Aged; Israel; Acupuncture Therapy; Qualitative Research; Aged; Integrative Oncology; methods; Narration; Palliative Care; psychology; Prospective Studies; Adult; Relaxation Therapy; methods
UT PubMed:40326225
PM 40326225
DA 2025-05-06
ER

PT J
AU Zheng, K
   Hong, X
   Jiang, C
   Chen, Y
AF Zheng, Kanghua
   Hong, Xiaoping
   Jiang, Changyin
   Chen, Yong
TI Effects of warming needle moxibustion on postoperative rehabilitation, pain
SO American journal of cancer research
LA English
DT Journal Article
DE Functional rehabilitation training; immune function; radical mastectomy; upper limb lymphedema; warming needle moxibustion
AB This study aims to evaluate the effects of warm acupuncture combined with  conventional functional rehabilitation training (FRT) on the recovery of breast  cancer (BC) patients following radical mastectomy, focusing on immune function,  pain management, and quality of life (QoL). This retrospective study involved 118  BC patients who underwent radical surgery at the Second People's Hospital  Affiliated to Fujian University of Chinese Medicine between January 2022 and May  2024. The included patient were assigned into an experimental group (EG, n=62,  warm acupuncture in conjunction with conventional FRT) and a control group (CG;  n=56; conventional FRT only). Postoperative outcomes, including surgery duration,  intraoperative blood loss (IOBL), drainage volume (DV), length of hospital stay,  upper limb mobility, immune function indicators, and pain scores, were compared  between the two groups. Multivariate logistic regression was employed to identify  factors affecting treatment outcomes. The EG demonstrated significantly lower  visual analog scale (VAS) scores at post-operative 2, 4, and 8 weeks compared to  the CG (all P < 0.05). The incidence of upper limb lymphedema in the EG was  9.26%, notably lower than the 24.07% observed in the CG (P < 0.05). Immune  function indicators, including CD3(+), CD4(+), CD8(+), and the CD4(+)/CD8(+)  ratio, were significantly higher in the EG postoperatively (P < 0.05).  Furthermore, the EG reported significantly improved scores in role physical,  general health, vitality, social functioning, role emotional, mental health, and  physiological functioning, alongside significantly lower scores in bodily pain  compared to the CG (all P < 0.05). Multivariate logistic regression analysis  revealed CD3(+) and CD4(+)/CD8(+) ratio as independent factors affecting patient  treatment efficacy (both P < 0.05). In conclusion, the combination of warm  acupuncture and conventional FRT significantly enhances immune function, pain  management, and overall QoL in BC patients after surgery, with CD3(+) and  CD4(+)/CD8(+) ratios being crucial factors influencing recovery.
C1 Department of Rehabilitation, The Second People's Hospital Affiliated to Fujian University of Chinese Medicine Fuzhou 350003, Fujian, China.
   Department of Rehabilitation, The Second People's Hospital Affiliated to Fujian University of Chinese Medicine Fuzhou 350003, Fujian, China.
   Department of Rehabilitation, The Second People's Hospital Affiliated to Fujian University of Chinese Medicine Fuzhou 350003, Fujian, China.
   Department of Pathophysiology, College of Integrative Medicine, Fujian University of Traditional Chinese Medicine Fuzhou 350122, Fujian, China.
NR 0
TC 0
SN 2156-697
EI 2156-697
J9 Am J Cancer Res
PD APR 14
PY 2025
VL 15
IS 3
BP 991
EP 1001
DI 10.62347/YXHG6188
PG 10
UT PubMed:40226461
PM 40226461
DA 2025-04-14
ER

PT J
AU Li, XT
   Lampson, K
   Ahles, TA
   Root, JC
   Li, QS
   Li, YL
   Ahsan, A
   Mao, JJ
   Liou, KT
AF Li, Xiaotong
   Lampson, Kaitlin
   Ahles, Tim A.
   Root, James C.
   Li, Q. Susan
   Li, Yuelin
   Ahsan, Anam
   Mao, Jun J.
   Liou, Kevin T.
TI Feasibility and Preliminary Effects of Acupuncture for Cognitive Dysfunction in Diverse Cancer Survivors: A Pilot, Randomized, Placebo-Controlled Trial
SO CURRENT ONCOLOGY
LA English
DT Article
DE acupuncture; pilot study; cognitive dysfunction; cancer survivorship; feasibility
ID verbal-learning test; functional assessment; impairment; mechanisms; management; therapy; prevalence; efficacy; qlq-c30; model
AB (1) Background: This pilot study evaluates the feasibility and preliminary effects of acupuncture for cancer-related cognitive dysfunction (CRCD) in cancer survivors. (2) Methods: A randomized trial comparing real acupuncture (RA) to sham acupuncture (SA) and waitlist control (WLC) among cancer survivors reporting cognitive difficulties. Interventions were delivered weekly over 10 weeks. Feasibility was evaluated by recruitment, treatment adherence, and assessment completion. Subjective CRCD was assessed by the Functional Assessment of Cancer Therapy-Cognitive Function-Perceived Cognitive Impairment subscale (FACT-Cog PCI) and objective CRCD was assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R). (3) Results: 32 participants (57.1% of eligible patients) were enrolled. All participants in acupuncture groups completed >= 8 of 10 treatments. Assessment completion rate was 100% for all participants. From baseline to week 10, the RA group (n = 19) reported a clinically meaningful 17.3-point increase in FACT-Cog PCI (95% confidence interval [CI] 12.5 to 22.1), compared to 9.7 points (95% CI 2.8 to 16.7) in the SA group (n = 9), and 6.8 points (95% CI -3.7 to 17.2) in the WLC group (n = 4). In the subgroup analysis among patients with a below-average baseline HVLT-R (T-score < 50), the RA group (n = 8) increased FACT-Cog PCI scores by 20.4 (95% CI 13.6 to 27.3), compared to 11.1 points (95% CI 0.6 to 21.5) in the SA group (n = 5). The improvements from RA persisted through week 16 in both the total sample and the sub-group. Eleven mild adverse events were reported, with pain and bleeding at the needling sites being the most common. (4) Conclusions: The findings support the feasibility and safety of conducting a randomized, placebo-controlled trial to evaluate acupuncture for cognitive dysfunction in cancer survivors.
C1 [Li, Xiaotong; Lampson, Kaitlin; Li, Q. Susan; Mao, Jun J.; Liou, Kevin T.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
   [Ahles, Tim A.; Root, James C.; Li, Yuelin; Ahsan, Anam] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10065 USA.
   [Li, Yuelin] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Liou, KT (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
EM lix9@mskcc.org; lampsonk@mskcc.org; ahlest@mskcc.org; rootj@mskcc.org; liq2@mskcc.org; liy12@mskcc.org; anam.ahsann@gmail.com; maoj@mskcc.org; liouk@mskcc.org
FU MSK's Integrative Medicine and Translational Research Fund and in part by an NIH/NCI Cancer Center Support Grant; MSK's Integrative Medicine and Translational Research Fund [P30 CA008748]; NIH/NCI Cancer Center Support Grant [K08CA266927]; National Cancer Institute's Mentored Clinical Scientist Research Career Development Award
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Ahles TA, 2018, ANNU REV CLIN PSYCHO, V14, P425, DOI 10.1146/annurev-clinpsy-050817084903
   Unknown -, 2020, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: SURVIVORSHIP, V0, P0
   Unknown -, 2006, COMMON TERMINOLOGY C, V0, P0
   Bedillion MF, 2019, BREAST, V44, P73, DOI 10.1016/j.breast.2019.01.004
   Bell ML, 2018, J PATIENT-REP OUTCOM, V2, P0, DOI 10.1186/s41687-018-0071-4
   Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726
   Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822
   Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6
   Blatch-Jones AJ, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2018-022233
   Chan YT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9949777
   Cheng KJ, 2014, J ACUPUNCT MERIDIAN, V7, P105, DOI 10.1016/j.jams.2013.07.008
   Cramer H, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep36760
   Cui JW, 2021, VET SCI, V8, P0, DOI 10.3390/vetsci8080149
   Czajkowski SM, 2015, HEALTH PSYCHOL, V34, P971, DOI 10.1037/hea0000161
   Deng L, 1987, CHINESE ACUPUNCTURE AND MOXIBUSTION FOREIGN LANGUAGE PRESS, V0, P0
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Ercoli LM, 2015, PSYCHO-ONCOLOGY, V24, P1360, DOI 10.1002/pon.3769
   Ferguson Robert J, 2024, JOURNAL OF CLINICAL ONCOLOGY, V42, P0
   Franco-Rocha OY, 2023, J CANCER RES CLIN, V149, P12561, DOI 10.1007/s00432-023-05088-0
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Hamel LM, 2016, CANCER CONTROL, V23, P327, DOI 10.1177/107327481602300404
   Han XH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/156489
   Hardy Sara J, 2018, AM SOC CLIN ONCOL EDUC BOOK, V38, P795, DOI 10.1200/edbk_201179
   Hassan M, 2023, HEALTH QUAL LIFE OUT, V21, P0, DOI 10.1186/s12955-023-02095-0
   Henderson FME, 2019, HEALTH PSYCHOL OPEN, V6, P0, DOI 10.1177/2055102919832234
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Jacobs SR, 2007, J PAIN SYMPTOM MANAG, V33, P13, DOI 10.1016/j.jpainsymman.2006.06.011
   Janelsins MC, 2014, INT REV PSYCHIATR, V26, P102, DOI 10.3109/09540261.2013.864260
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   Kesler S, 2013, CLIN BREAST CANCER, V13, P299, DOI 10.1016/j.clbc.2013.02.004
   Kim RY, 2023, AM J RESP CRIT CARE, V207, P777, DOI 10.1164/rccm.202208-1590LE
   King S, 2015, FRONT ONCOL, V5, P0, DOI 10.3389/fonc.2015.00072
   Koffel E, 2018, J GEN INTERN MED, V33, P955, DOI 10.1007/s11606-018-4390-1
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Lange M, 2019, ANN ONCOL, V30, P1925, DOI 10.1093/annonc/mdz410
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lee B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/670536
   Leung MCP, 2014, J NEUROIMMUNE PHARM, V9, P492, DOI 10.1007/s11481-014-9550-4
   Liou KT, 2020, CANCER-AM CANCER SOC, V126, P3042, DOI 10.1002/cncr.32847
   Liu CZ, 2006, NEUROSCI LETT, V393, P45, DOI 10.1016/j.neulet.2005.09.049
   Lv LQ, 2020, J ONCOL, V2020, P0, DOI 10.1155/2020/3942439
   Lyu YR, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221098983
   Maeir T, 2023, DISABIL REHABIL, V45, P1056, DOI 10.1080/09638288.2022.2050954
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Mayo S, 2016, BONE MARROW TRANSPL, V51, P841, DOI 10.1038/bmt.2016.2
   Mayo SJ, 2021, SUPPORT CARE CANCER, V29, P2821, DOI 10.1007/s00520-020-05860-9
   Ng AH, 2021, JCO ONCOL PRACT, V17, P440, DOI 10.1200/OP.20.00625
   Oberste M, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-4992-3
   Orszaghova Z, 2021, FRONT MOL BIOSCI, V8, P0, DOI 10.3389/fmolb.2021.770413
   Reid-Arndt Stephanie A, 2012, COMPLEMENT THER CLIN PRACT, V18, P26, DOI 10.1016/j.ctcp.2011.02.005
   Santos MD, 2019, J. CLIN. ONCOL, V37, P11521, DOI 10.1200/JCO.2019.37.15suppl.11521
   Savard J, 2016, JAMA ONCOL, V2, P1263, DOI 10.1001/jamaoncol.2016.2047
   Schmidt JE, 2016, J CANCER SURVIV, V10, P302, DOI 10.1007/s11764-015-0476-5
   Selamat MH, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0108002
   Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749
   Teresi JA, 2022, MED CARE, V60, P95, DOI 10.1097/MLR.0000000000001664
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Van Dyk K, 2021, JAMA-J AM MED ASSOC, V326, P1736, DOI 10.1001/jama.2021.13309
   Vogel S, 2017, INT J OSTEOPATH MED, V23, P2, DOI 10.1016/j.ijosm.2017.02.001
   Von Ah D, 2016, ONCOL NURS FORUM, V43, P602, DOI 10.1188/16.ONF.602-616
   Von Ah D, 2015, J PAIN SYMPTOM MANAG, V49, P697, DOI 10.1016/j.jpainsymman.2014.08.012
   Von Ah D, 2012, BREAST CANCER RES TR, V135, P799, DOI 10.1007/s10549-012-2210-6
   Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1
   Wei DM, 2011, NEURAL REGEN RES, V6, P2357, DOI 10.3969/j.issn.1673-5374.2011.30.007
   Zhong B, 1993, ESSENTIALS OF CHINESE ACUPUNCTURE, V0, P0
NR 69
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 1198-0052
EI 1718-7729
J9 CURR ONCOL
JI Curr. Oncol.
PD JAN 15
PY 2025
VL 32
IS 1
BP 
EP 
DI 10.3390/curroncol32010027
PG 16
WC Oncology
SC Oncology
GA T4Z4V
UT WOS:001405104200001
PM 39851943
DA 2026-01-16
ER

PT J
AU Guo, S
   Lin, XP
   Jin, XR
   Tuo, KX
   Li, P
   Yang, WW
   Wang, Q
AF Guo, Shuai
   Lin, Xiang-Ping
   Jin, Xiang-Ren
   Tuo, Kang-Xiu
   Li, Pei
   Yang, Wei-Wei
   Wang, Qian
TI Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial
SO FRONTIERS IN SURGERY
LA English
DT Article
DE thumbtack needle; gastric cancer; GI function recovery; laparoscopic radical gastrectomy; ERAS
ID acupoints
AB Objectives: Postoperative gastrointestinal (GI) dysfunction is a common complication in patients undergoing gastric cancer surgery. This study aimed to evaluate the effect of thumbtack needle therapy on GI function recovery after laparoscopic radical gastrectomy. Methods: Participants were randomly assigned to either the treatment or control group. Both groups received perioperative enhanced recovery after surgery management. Participants in the treatment group received thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6). Primary outcomes included the time to bowel sound recovery and time to first flatus (all measured in hours). Secondary outcomes included the time to first defecation, time to removal of the nasogastric tube and intra-abdominal drains (all measured in hours), postoperative pain scores, nausea and vomiting scores, abdominal distension scores (all measured in points), length of hospital stay (days), incidence of complications (%), safety evaluation, and overall response rate (%). Results: A total of 103 participants were screened, and 80 were enrolled (40 per group). Baseline characteristics were similar between groups. Compared with the control group, the treatment group showed significantly shorter times to bowel sound recovery (difference, -4.0 h, 95% CI: -7.0 to -1.0, P = 0.010), first flatus (-11.0 h, 95% CI: -19.0 to -2.0, P = 0.017), first defecation (-8.0 h, 95% CI: -16.0 to -1.0, P = 0.026), nasogastric tube removal (-12.0 h, 95% CI: -27.0 to -2.0 P = 0.023), and intra-abdominal drain removal (-10.0 h, 95% CI: -21.0 to -1.0, P = 0.038). Pain scores were significantly lower in the treatment group on postoperative day (POD) 1 (-1, 95% CI: -1 to 0, P = 0.031), POD 2 (-1, 95% CI: -2 to -1, P < 0.001), and POD 3 (-1, 95% CI: -2 to 0, P < 0.001). Similar improvements were observed in nausea, vomiting, and abdominal distension scores on POD 1-3 (all showing a median difference of -1, all P < 0.05). The treatment group also had a significantly shorter hospital stay (difference, -1.7 days, 95% CI: -3.0 to -0.3, P = 0.015). There was no significant difference in the incidence of postoperative complications (difference, -5.0%, 95% CI: -18.6 to 8.0, P = 0.396), and no adverse reactions occurred in the treatment group. The overall response rate was significantly higher in the treatment group (difference, 17.5%, 95% CI: 0.18-34.0, P = 0.046). Conclusion: Thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6) is a safe and effective intervention that promotes early recovery of GI function after laparoscopic radical gastrectomy for gastric cancer. Clinical Trial Registration: http://www.chictr.org.cn, ChiCTR2400084712.
C1 [Guo, Shuai; Lin, Xiang-Ping; Tuo, Kang-Xiu; Yang, Wei-Wei] Guizhou Med Univ, Dept Pharm, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [Jin, Xiang-Ren; Li, Pei; Wang, Qian] Guizhou Med Univ, Affiliated Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Guo, S (corresponding author), Guizhou Med Univ, Dept Pharm, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.; Wang, Q (corresponding author), Guizhou Med Univ, Affiliated Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China.
EM guoshuai@gmc.edu.cn; wq5969@sina.com
FU Guizhou Administration of Traditional Chinese Medicine of China;  [QZYY-2024-061]
CR Blanke EN, 2021, NEURAL REGEN RES, V16, P254, DOI 10.4103/1673-5374.290883
   Buchanan L, 2025, STATPEARLS, V0, P0
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chinese ERAS Expert Group, 2016, ASIAN J. SURG, V15, P527
   Fleming MA, 2020, GASTROENT RES PRACT, V2020, P0, DOI 10.1155/2020/8024171
   Gottfried-Blackmore A, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13769
   Guo M, 2022, WORLD J CLIN CASES, V10, P11427, DOI 10.12998/wjcc.v10.i31.11427
   Hughes J, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101372
   Kannan V, 2025, PATIENT SAF SURG, V19, P0, DOI 10.1186/s13037-024-00425-9
   Kong Q, 2024, INT J SURG, V110, P5713, DOI 10.1097/JS9.0000000000001641
   Lin B, 2019, ZHONGGUO SHI YONG YI YAO, V14, P192
   Ljungqvist O, 2023, JAMA SURG, V158, P28, DOI 10.1001/jamasurg.2022.5683
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Lubbers T, 2010, WORLD J GASTROENTERO, V16, P1683, DOI 10.3748/wjg.v16.i14.1683
   Maisiyiti A, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1188781
   Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582
   Ou YX, 2024, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1464749
   Painovich J, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/309762
   Qiang CZ, 2013, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V33, P149
   Ren L, 2012, WORLD J SURG, V36, P407, DOI 10.1007/s00268-011-1348-4
   Schwenk W, 2021, CHIRURG, V92, P405, DOI 10.1007/s00104-020-01328-y
   Standardization Administration of the Peoples Republic of China, 2021, NATIONAL STANDARD OF THE PEOPLES REPUBLIC OF CHINA: NOMENCLATURE AND LOCATION OF MERIDIAN POINTS (GB/T 12346-2021), V0, P0
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tian M, 2020, OBES SURG, V30, P2980, DOI 10.1007/s11695-020-04626-w
   Urman RD, 2020, ENHANCED RECOVERY AFTER SURGERY: A COMPLETE GUIDE TO OPTIMIZING OUTCOMES, V0, P0
   Xv Y, 2025, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1494693
   Yu Xiang F, 2022, CLINICAL STUDY OF ELECTRO-ACUPUNCTURE PROMOTING EARLY GASTROINTESTINAL FUNCTION RECOVERY AFTER LAPAROSCOPIC GASTRIC CANCER SURGERY, V0, P0
   Zhang ZY, 2024, J NEUROINFLAMM, V21, P0, DOI 10.1186/s12974-024-03285-3
   Zhu HM, 2014, MED ACUPUNCT, V26, P264, DOI 10.1089/acu.2014.1057
NR 29
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-875X
EI 
J9 FRONT SURG
JI Front. Surg.
PD SEP 18
PY 2025
VL 12
IS 
BP 
EP 
DI 10.3389/fsurg.2025.1612766
PG 13
WC Surgery
SC Surgery
GA 8EG5S
UT WOS:001586594300001
PM 41050349
DA 2026-01-16
ER

PT J
AU Jiang, YY
   Li, X
   Hu, FX
   Wang, DN
   Zang, JM
   Liu, ZL
   Xu, F
   Cui, WQ
AF Jiang, Yi-Yang
   Li, Xue
   Hu, Feng-Xian
   Wang, Dan-Ni
   Zang, Ji-Miao
   Liu, Zhen-Ling
   Xu, Fei
   Cui, Wen-Qiang
TI Electroacupuncture alleviates chemotherapy-induced peripheral neuropathy and
SO Neuroscience
LA English
DT Journal Article
DE Anxiety; Chemotherapeutic neuropathy; Cisplatin; Electroacupuncture; Paraventricular thalamic nucleus
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and  dose-limiting side effect of neurotoxic cancer treatments, generally alongside  anxiety disorders. The paraventricular thalamic nucleus (PVT), as an integrative  node of sensory perceptions and emotional reactions, remains unclear in CIPN  modulation. This study aimed to investigate the role of PVT in CIPN and reveal  the mechanisms through which electroacupuncture (EA) alleviates CIPN. In this  study, a CIPN mouse model with emotional disorders was established through the  intervention of cisplatin for 21 d, which was validated by the von Frey test,  adhesive removal test, open-field test and elevated plus-maze test. Data showed  that the cisplatin-related CIPN was characterized by the increase of calcium  channel proteins TRPC6 and PKC, as well as the activation of glutamatergic  neurons in PVT. Inhibition of TRPC6 and PKC using SAR7334 significantly hindered  sensory neuron damage and the loss of intra-epidermal nerve fibers (IENFs) and  Merkel cells, while improving anxiety-like behaviors. EA treatment ameliorated  the symptoms of CIPN, including neuropathic pain, impairment of cutaneous  sensation, and loss of IENFs and Merkel cells in the acral skin, which exhibited  similar effects of SAR7334. Mechanically, EA treatment significantly inhibited  TRPC6 activation, reducing the Ca(2+) influx and attenuating p-PKC level, thereby  decreasing the release of excitatory neurotransmitter glutamate in the PVT. Our  findings revealed a novel mechanism through which calcium influx-mediated  glutamatergic neuron activation in PVT participated in the CIPN and provided  evidence that TRPC6/PKC may be potent targets for the EA effect.
C1 The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   School of Acupuncture and Tuina, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
   Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China.
EM qcui16@fudan.edu.cn
NR 0
TC 0
SN 1873-754
EI 
J9 Neuroscience
PD NOV 26
PY 2025
VL 592
IS 
BP 97
EP 110
DI 10.1016/j.neuroscience.2025.11.031
PG 13
WC Animals; Electroacupuncture; methods; Anxiety; therapy; Male; Protein Kinase C; metabolism; Mice; Peripheral Nervous System Diseases; chemically induced; Midline Thalamic Nuclei; metabolism; Glutamic Acid; metabolism; TRPC6 Cation Channel; metabolism; Neurons; metabolism; Disease Models, Animal; Antineoplastic Agents; toxicity; Mice, Inbred C57BL
UT PubMed:41290068
PM 41290068
DA 2025-11-26
ER

PT J
AU Li, DX
   Wu, Y
   Chang, LR
   Song, YZ
   Du, XQ
   Xue, FQ
   Liu, Y
   Wu, J
   Wang, TL
AF Li, Daxian
   Wu, Yan
   Chang, Lirong
   Song, Yizhi
   Du, Xiaoqiang
   Xue, Fenqin
   Liu, Yang
   Wu, Jie
   Wang, Tianlong
TI Therapeutic effects of melittin on paclitaxel-induced peripheral neuropathic pain and spinal neuronal hyperactivity in male rats
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE chemotherapy-induced peripheral neuropathy; bee venom; acupuncture; analgesia; wide dynamic range neuron; electrophysiological recording; noradrenergic system
ID substantia-gelatinosa neurons; mouse model; mechanisms; inhibition; management; allodynia; stimuli; system; adult
AB Introduction As a taxane-based cytostatic agent, paclitaxel holds a broad spectrum of life-saving properties. However, its use is frequently limited by painful neuropathy in the extremities, which severely hinders the ultimate prognosis of cancer survivors. While bee venom therapy has shown promise in alleviating chemotherapy-induced neuropathic pain, the analgesic potential of its primary bioactive components, such as melittin and phospholipase A2 (bvPLA2), remains uncharacterized. This study investigated the ameliorative effects of melittin against paclitaxel-induced peripheral neuropathy in rats through integrated behavioral, in vivo electrophysiological, and neuropharmacological approaches.Methods Paclitaxel was administered intraperitoneally (i.p.) at a total dose of 8 mg/kg. Cold and mechanical allodynia and hyperalgesia were quantified using the acetone drop and von Frey filament tests. To compare the therapeutic properties of bee venom ingredients, either melittin (0.5 mg/kg) or bvPLA2 (0.12 mg/kg) was administered subcutaneously at ST36 (Zusanli acupoint). In vivo extracellular recordings of wide dynamic range (WDR) neurons were performed in the spinal dorsal horn. Noradrenaline depletion was induced by the i.p. treatment with N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50 mg/kg), and serotonin depletion was conducted by the i.p. administration of para-chlorophenylalanine (PCPA, 450 mg/kg).Results ST36 treatment with melittin, but not bvPLA2, markedly impeded mechanical and cold hypersensitivity. Electrophysiological analysis revealed that paclitaxel induced spontaneous and stimulus-evoked hyperexcitation of spinal WDR neurons. Melittin selectively suppressed evoked neuronal activities (i.e., acute responses and after-discharges) without modulating the spontaneous firing of WDR neurons. Neuropharmacological investigation demonstrated that the effects of melittin were fully reversed by noradrenaline depletion, whereas serotonin depletion had no effect.Discussion Our findings establish that melittin treatment at ST36 could ease paclitaxel-induced neuropathic pain by partially attenuating the hyperexcitable state of spinal WDR neurons. Furthermore, these ameliorative actions were mediated by the specific recruitment of the endogenous noradrenergic system. This study provides novel evidence supporting melittin as a targeted symptomatic agent for paclitaxel-induced peripheral neuropathy, which would advance the development of promising analgesic strategies in oncological care.
C1 [Li, Daxian; Liu, Yang; Wu, Jie; Wang, Tianlong] Capital Med Univ, Xuanwu Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Li, Daxian; Liu, Yang; Wu, Jie; Wang, Tianlong] Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
   [Wu, Yan; Chang, Lirong; Song, Yizhi; Du, Xiaoqiang] Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Neural Regenerat & Repair, Dept Anat,Sch Basic Med Sci, Beijing, Peoples R China.
   [Wu, Yan] Beijing Agr Univ, Coll Vet Med, Beijing, Peoples R China.
   [Xue, Fenqin] Capital Med Univ, Core Facil Ctr, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Beijing University of Agriculture; Capital Medical University
RP Wang, TL (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Anesthesiol, Beijing, Peoples R China.; Wang, TL (corresponding author), Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
EM w_tl5595@hotmail.com
FU National Natural Science Foundation of China [82204932]
CR Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Beh ST, 2019, PAIN, V160, P1505, DOI 10.1097/j.pain.0000000000001547
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Boyette-Davis JA, 2015, PAIN MANAG, V5, P285, DOI 10.2217/PMT.15.19
   Cavaletti G, 2015, CURR OPIN NEUROL, V28, P500, DOI 10.1097/WCO.0000000000000234
   Chae HK, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11020432
   Chen YP, 2005, J PHARMACOL EXP THER, V315, P696, DOI 10.1124/jpet.105.091314
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Flatters SJL, 2006, NEUROSCI LETT, V397, P219, DOI 10.1016/j.neulet.2005.12.013
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Furue H, 1999, J PHYSIOL-LONDON, V521, P529, DOI 10.1111/j.1469-7793.1999.00529.x
   Gajski G, 2024, TOXINS, V16, P0, DOI 10.3390/toxins16030117
   Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Hershman DL, 2014, J ONCOL PRACT, V10, PE421, DOI 10.1200/JOP.2014.001776
   Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014
   JAIMETCHEVERRY G, 1980, BRAIN RES, V188, P513, DOI 10.1016/0006-8993(80)90049-9
   Kawashiri T, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168733
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim N, 2023, PLANTS-BASEL, V12, P0, DOI 10.3390/plants12122283
   Kim W, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Lee JH, 2022, CURR ISSUES MOL BIOL, V44, P718, DOI 10.3390/cimb44020050
   Li DX, 2021, KOREAN J PHYSIOL PHA, V25, P489, DOI 10.4196/kjpp.2021.25.5.489
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120775
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100620
   Li DX, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20071652
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Lin TY, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100618
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Maleki N, 2005, INT IMMUNOPHARMACOL, V5, P1723, DOI 10.1016/j.intimp.2005.05.012
   Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609
   McGgaraughty S, 2018, J NEUROPHYSIOL, V120, P1893, DOI 10.1152/jn.00325.2018
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Morisset V, 1998, EUR J NEUROSCI, V10, P3642, DOI 10.1046/j.1460-9568.1998.00370.x
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   PERTOVAARA A, 1993, PROG NEUROBIOL, V40, P691, DOI 10.1016/0301-0082(93)90011-G
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Reddi Danielle, 2013, BR J HOSP MED (LOND), V74 Suppl 12, P0
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Shim HS, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919840098
   Siau C, 2006, EXP NEUROL, V201, P507, DOI 10.1016/j.expneurol.2006.05.007
   Sikandar S, 2017, PHYSIOL REP, V5, P0, DOI 10.14814/phy2.13323
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Stela M, 2024, PHARMACEUTICALS-BASE, V17, P0, DOI 10.3390/ph17091211
   Sun XW, 2022, NAT SCI SLEEP, V14, P335, DOI 10.2147/NSS.S352035
   Sung SH, 2021, TOXINS, V13, P0, DOI 10.3390/toxins13090608
   Tasmuth T, 2002, EUR J PAIN-LONDON, V6, P17, DOI 10.1053/eujp.2001.0266
   Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947
   Tsai CH, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22179257
   Woo S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11080477
   Yamada A, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918817969
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   YOSHIMURA M, 1989, J NEUROPHYSIOL, V62, P96, DOI 10.1152/jn.1989.62.1.96
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   Yu DL, 2022, INT IMMUNOPHARMACOL, V105, P0, DOI 10.1016/j.intimp.2022.108555
   Zain M, 2019, PAIN, V160, P2199, DOI 10.1097/j.pain.0000000000001632
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zeng YJ, 2018, LASER MED SCI, V33, P295, DOI 10.1007/s10103-017-2367-7
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zhang ZY, 2024, J PAIN RES, V17, P441, DOI 10.2147/JPR.S446803
   Zheng FY, 2011, NEUROSCIENCE, V176, P447, DOI 10.1016/j.neuroscience.2010.12.052
   ZHU HG, 1991, J BIOL REG HOMEOS AG, V5, P52
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 70
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUL 2
PY 2025
VL 19
IS 
BP 
EP 
DI 10.3389/fnins.2025.1622553
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 4XZ0Q
UT WOS:001529336300001
PM 40672870
DA 2026-01-16
ER

PT J
AU Liu, W
   Zhang, Y
   Zhu, Q
   Wu, L
AF Liu, Wei
   Zhang, Ying
   Zhu, Qi
   Wu, Lan
TI A scientometric study on research trends and characteristics of burning mouth syndrome
SO JOURNAL OF DENTAL SCIENCES
LA English
DT Article
DE Burning mouth syndrome; Bibliometrics; Neurological factors; Psychological factors; Therapy strategy
AB Background/purpose: Burning mouth syndrome (BMS) is a chronic condition characterized by intraoral burning sensation and orofacial pain but without oral mucosal lesions. The purpose of this study was to analyze the scientometric characteristics and research trends of BMS. Materials and methods: All the papers on BMS were comprehensively retrieved from the Scopus database. The years of publication were divided into before 2015 and 2015-2024 in the analysis of research trends. Results: There were 924 papers on BMS, with total citations of 24,024 and the h index of 76. The related disorders of BMS were depression, xerostomia, pain, anxiety, glossodynia, taste disorder, nociception, paresthesia, analgesia, sleep disorder, diabetes mellitus, and neuralgia. Clonazepam was most common pharmacotherapy for BMS. After 2015, pharmacologic keywords including drug safety, aripiprazole, duloxetine, folic acid, hydrocortisone, and pregabalin were more frequent. Low level laser therapy, acupuncture, and cognitive behavioral therapy were the emerging nonpharmacologic strategies for BMS. Moreover, laboratory investigations on biomarkers, blood, genetics, interleukin 6, and tumor necrosis factor were more common. Various questionnaires, comorbidity, complication, anemia, hypertension, diabetes mellitus, and sleep were also more concerned after 2015. Conclusion: This scientometric study elucidated the current scenario and research trends of BMS, and would help in improving in reciprocal collaboration and communication for investiga-tions on this condition. <feminine ordinal indicator> 2025 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
C1 [Liu, Wei] Shanghai Ninth Peoples Hosp, Fengcheng Hosp Fengxian Dist, Dept Stomatol, Fengcheng Branch Hosp, Shanghai, Peoples R China.
   [Liu, Wei; Zhu, Qi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China.
   [Liu, Wei; Zhang, Ying; Zhu, Qi; Wu, Lan] Shanghai Jiao Tong Univ, Shanghai Res Inst Stomatol, Coll Stomatol, Natl Ctr Stomatol,Natl Clin Res Ctr Oral Dis,Shang, Shanghai, Peoples R China.
   [Zhang, Ying; Wu, Lan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oral Mucosal Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wu, L (corresponding author), Shanghai Ninth Peoples Hosp, Dept Oral Mucosal Dis, 500 Quxi Rd, Shanghai 200011, Peoples R China.; Zhu, Q (corresponding author), Shanghai Ninth Peoples Hosp, Dept Oral & Maxillofacial Head & Neck Oncol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM zhuqi70@hotmail.com; teana_wu@sina.com
FU Shanghai Municipal Health Committee [(2021-2023) -0207-01-04, 2022CX009]
CR Alhendi F, 2023, ORAL DIS, V29, P6, DOI 10.1111/odi.14051
   Alvarenga-Brant R, 2023, J DENT RES, V102, P135, DOI 10.1177/00220345221130025
   de Lima-Souza RA, 2024, OR SURG OR MED OR PA, V137, P119, DOI 10.1016/j.oooo.2023.10.002
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Farag AM, 2023, ORAL DIS, V29, P343, DOI 10.1111/odi.13817
   Fernández-Agra M, 2023, ORAL DIS, V29, P2600, DOI 10.1111/odi.14390
   Finfter O, 2024, ORAL DIS, V30, P4668, DOI 10.1111/odi.14900
   Goncalves S, 2023, ORAL DIS, V29, P3016, DOI 10.1111/odi.14297
   Kao CY, 2023, J DENT SCI, V18, P456, DOI 10.1016/j.jds.2022.08.028
   Kong MS, 2024, ORAL DIS, V30, P5360, DOI 10.1111/odi.14959
   Lin XY, 2024, FRONT NEUROL, V15, P0, DOI 10.3389/fneur.2024.1443817
   Liu H, 2023, J DENT SCI, V18, P1883, DOI 10.1016/j.jds.2023.05.016
   Lu CH, 2023, BMC ORAL HEALTH, V23, P0, DOI 10.1186/s12903-023-03441-w
   Lv K, 2024, INT DENT J, V0, P0, DOI DOI 10.1016/j.identj
   Pereira JV, 2021, OR SURG OR MED OR PA, V131, P186, DOI 10.1016/j.oooo.2020.11.019
   Sangalli L, 2024, ORAL DIS, V30, P3761, DOI 10.1111/odi.14914
   Wang GR, 2023, J DENT SCI, V18, P1378, DOI 10.1016/j.jds.2023.03.007
   Wu SS, 2022, ORAL DIS, V28, P1431, DOI 10.1111/odi.13868
   Wu YH, 2023, J DENT SCI, V18, P833, DOI 10.1016/j.jds.2023.01.009
   Zhang Y, 2024, J DENT SCI, V19, P1052, DOI 10.1016/j.jds.2023.06.003
   Zhou ZY, 2024, J DENT SCI, V19, P614, DOI 10.1016/j.jds.2023.06.004
NR 21
TC 0
Z9 0
U1 4
U2 9
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN
SN 1991-7902
EI 2213-8862
J9 J DENT SCI
JI J. Dental Sci.
PD APR 15
PY 2025
VL 20
IS 2
BP 1252
EP 1256
DI 10.1016/j.jds.2025.01.009
EA MAR 2025
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 0XE9C
UT WOS:001458158500001
PM 40224121
DA 2026-01-16
ER

PT J
AU Xue, Y
   Zhu, Q
   Zhang, J
   Wang, X
AF Xue, Yahong
   Zhu, Qinbing
   Zhang, Jing
   Wang, Xiaofeng
TI Electroacupuncture alleviates capsaicin-induced rectal visceral pain in rats via
SO Purinergic signalling
LA English
DT Journal Article
DE Disease; Electroacupuncture; P2X4 receptor; P38 mitogen-activated protein kinase; Rectal visceral pain; Transient receptor potential vanilloid-1
AB Electroacupuncture (EA), as a combination of traditional acupuncture and modern  electrotherapy, and has analgesic effects on various acute and chronic pain. It  has been proved to ameliorate chronic visceral pain, but its specific role in  rectal visceral pain remains underexplored. A capsaicin (CAP)-induced visceral  pain rat model was established, and behavioral pain responses were observed and  recorded. Measurement of mechanical pain threshold was performed using electronic  Von Frey system. Rectal tissues, and the activity of microglia cells were  detected by Hematoxylin/eosin staining and immunofluorescence, respectively.  Contents of interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) were  determined by enzyme-linked immunosorbent assay. Western blot was performed to  determine the expressions of P2X4 receptor (P2X4R), p38 mitogen-activated protein  kinase (p38), phosphorylated p38 (p-p38), transient receptor potential  vanilloid-1 (TRPV1) and ionized calcium binding adapter molecule 1 (Iba-1).  Transfection efficiency of TRPV1 overexpression plasmids was examined by  quantitative real-time polymerase chain reaction. EA abrogated CAP-induced  upregulation of behavioral pain responses and mechanical threshold, damage on  rectal tissue, activation of microglia, stimulation of inflammatory response and  promotion of P2X4R-p38-TRPV1 pathway expressions in rats, while P2X4R activation  reversed the effect of EA. P2X4R antagonist weakened CAP-induced upregulation of  P2X4R-p38-TRPV1 pathway expressions, microglia activation as well as increase of  IL-1β in HMO6 cells, which was reversed by TRPV1 overexpression. Collectively, EA  improves CAP-induced rectal visceral pain via inhibiting TRPV1 expression by  blocking the P2X4R-activated p38 pathway in microglia. However, the specificity  role of P2X4R needs to be confirmed by more experiment.
C1 Department of Anorectal, Nanjing Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, Jiangsu Province, China.xueyahong_1983@126.com.
   Graduate School of Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China.
   Graduate School of Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China.
   Department of Anorectal, Nanjing Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, Jiangsu Province, China.
NR 0
TC 0
SN 1573-954
EI 1573-953
J9 Purinergic Signal
PD JUN 25
PY 2025
VL 21
IS 4
BP 565
EP 576
DI 10.1007/s11302-025-10100-y
PG 11
WC Animals; Electroacupuncture; methods; TRPV Cation Channels; metabolism; Visceral Pain; chemically induced; Receptors, Purinergic P2X4; metabolism; Male; Rats; Rats, Sprague-Dawley; Capsaicin; toxicity; p38 Mitogen-Activated Protein Kinases; metabolism; Rectum; metabolism; MAP Kinase Signaling System; physiology
UT PubMed:40560521
PM 40560521
DA 2025-06-25
ER

PT J
AU Xue, YH
   Zhu, QB
   Zhang, J
   Wang, XF
AF Xue, Yahong
   Zhu, Qinbing
   Zhang, Jing
   Wang, Xiaofeng
TI Electroacupuncture alleviates capsaicin-induced rectal visceral pain in rats via inhibiting TRPV1 expression by blocking the P2X4R-activated p38 pathway
SO PURINERGIC SIGNALLING
LA English
DT Article
DE Electroacupuncture; P38 mitogen-activated protein kinase; Transient receptor potential vanilloid-1; Rectal visceral pain; Disease
ID acupuncture; mechanisms; hyperalgesia; blockade; receptor; axis
AB Electroacupuncture (EA), as a combination of traditional acupuncture and modern electrotherapy, and has analgesic effects on various acute and chronic pain. It has been proved to ameliorate chronic visceral pain, but its specific role in rectal visceral pain remains underexplored. A capsaicin (CAP)-induced visceral pain rat model was established, and behavioral pain responses were observed and recorded. Measurement of mechanical pain threshold was performed using electronic Von Frey system. Rectal tissues, and the activity of microglia cells were detected by Hematoxylin/eosin staining and immunofluorescence, respectively. Contents of interleukin (IL)-6, IL-1 beta and tumor necrosis factor-alpha (TNF-alpha) were determined by enzyme-linked immunosorbent assay. Western blot was performed to determine the expressions of P2X4 receptor (P2X4R), p38 mitogen-activated protein kinase (p38), phosphorylated p38 (p-p38), transient receptor potential vanilloid-1 (TRPV1) and ionized calcium binding adapter molecule 1 (Iba-1). Transfection efficiency of TRPV1 overexpression plasmids was examined by quantitative real-time polymerase chain reaction. EA abrogated CAP-induced upregulation of behavioral pain responses and mechanical threshold, damage on rectal tissue, activation of microglia, stimulation of inflammatory response and promotion of P2X4R-p38-TRPV1 pathway expressions in rats, while P2X4R activation reversed the effect of EA. P2X4R antagonist weakened CAP-induced upregulation of P2X4R-p38-TRPV1 pathway expressions, microglia activation as well as increase of IL-1 beta in HMO6 cells, which was reversed by TRPV1 overexpression. Collectively, EA improves CAP-induced rectal visceral pain via inhibiting TRPV1 expression by blocking the P2X4R-activated p38 pathway in microglia. However, the specificity role of P2X4R needs to be confirmed by more experiment.
C1 [Xue, Yahong; Wang, Xiaofeng] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Anorectal, Nanjing 210022, Jiangsu, Peoples R China.
   [Zhu, Qinbing; Zhang, Jing] Nanjing Univ Chinese Med, Grad Sch, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Xue, YH (corresponding author), Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Anorectal, Nanjing 210022, Jiangsu, Peoples R China.
EM xueyahong_1983@126.com
FU National Natural Science Foundation of China
CR Akhtari M, 2022, IRAN J ALLERGY ASTHM, V21, P73, DOI 10.18502/ijaai.v21i1.8618
   Arora V, 2021, PHARMACOL THERAPEUT, V220, P0, DOI 10.1016/j.pharmthera.2020.107743
   Basso AR, 2021, J ETHNOPHARMACOL, V269, P0, DOI 10.1016/j.jep.2020.113712
   Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Cui M, 2016, ADV PROTEIN CHEM STR, V104, P81, DOI 10.1016/bs.apcsb.2015.11.005
   Defaye M, 2022, CELL MOL GASTROENTER, V13, P977, DOI 10.1016/j.jcmgh.2021.12.012
   Deuis JR, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00284
   Ding YY, 2023, J INTEGR MED-JIM, V21, P496, DOI 10.1016/j.joim.2023.07.001
   Dodds KN, 2016, TRANSL PSYCHIAT, V6, P0, DOI 10.1038/tp.2016.168
   Ford AC, 2024, GASTROENTEROLOGY, V166, P976, DOI 10.1053/j.gastro.2024.01.045
   Frias B, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21060797
   Garcia-Nicas E, 2006, J NEUROPHYSIOL, V96, P661, DOI 10.1152/jn.00377.2006
   Hahm Tae Soo, 2009, KOREAN J ANESTHESIOL, V57, P3, DOI 10.4097/kjae.2009.57.1.3
   HOLZER P, 1991, PHARMACOL REV, V43, P143
   Hurt CM, 2016, J AM HEART ASSOC, V5, P0, DOI 10.1161/JAHA.116.003774
   Diaz-Rubio GI, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0246054
   Inoue K, 2022, NEUROCHEM RES, V47, P2454, DOI 10.1007/s11064-021-03516-6
   Jiang Zhenhua, 2022, NEURAL PLAST, V2022, P7670629, DOI 10.1155/2022/7670629
   Jin X, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8828846
   Kwon SG, 2014, NEUROPHARMACOLOGY, V79, P368, DOI 10.1016/j.neuropharm.2013.12.005
   Laird JMA, 2001, PAIN, V92, P335, DOI 10.1016/S0304-3959(01)00275-5
   Li ZY, 2017, WORLD J GASTROENTERO, V23, P6220, DOI 10.3748/wjg.v23.i34.6220
   Liu YT, 2018, J MOL NEUROSCI, V66, P279, DOI 10.1007/s12031-018-1172-5
   Liu YL, 2019, LIFE SCI, V233, P0, DOI 10.1016/j.lfs.2019.116707
   Liu YJ, 2021, PHYSIOL RES, V70, P635, DOI 10.33549/physiolres.934649
   Long JY, 2022, NEUROCHEM RES, V47, P545, DOI 10.1007/s11064-021-03486-9
   Lu HJ, 2023, NEUROSCI BULL, V39, P425, DOI 10.1007/s12264-022-00961-3
   Mai LJ, 2020, LIFE SCI, V256, P0, DOI 10.1016/j.lfs.2020.117885
   Mayer EA, 2011, ANNU REV MED, V62, P381, DOI 10.1146/annurev-med-012309-103958
   Moloney RD, 2016, CNS NEUROSCI THER, V22, P102, DOI 10.1111/cns.12490
   Morales-Soto W, 2019, CELL MOL GASTROENTER, V7, P433, DOI 10.1016/j.jcmgh.2018.11.005
   Parenti A, 2016, BRIT J PHARMACOL, V173, P953, DOI 10.1111/bph.13392
   Pusceddu MM, 2018, J BIOMED SCI, V25, P0, DOI 10.1186/s12929-018-0476-7
   Sattler K, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-93958-3
   Sun BX, 2023, PURINERG SIGNAL, V19, P297, DOI 10.1007/s11302-022-09879-x
   Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786
   Tsuda M, 2013, FRONT CELL NEUROSCI, V7, P0, DOI 10.3389/fncel.2013.00191
   Verma R, 2017, BRAIN BEHAV IMMUN, V66, P302, DOI 10.1016/j.bbi.2017.07.155
   Wang L, 2018, PURINERG SIGNAL, V14, P433, DOI 10.1007/s11302-018-9625-4
   Wang ZP, 2020, INT J MOL MED, V45, P1425, DOI 10.3892/ijmm.2020.4531
   Weng ZJ, 2023, PURINERG SIGNAL, V19, P43, DOI 10.1007/s11302-021-09830-6
   Whitehead WE, 1999, GUT, V45, P55
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Xue C, 2021, CHIN MED-UK, V16, P0, DOI 10.1186/s13020-021-00468-5
   Xue CC, 2024, J CELL MOL MED, V28, P0, DOI 10.1111/jcmm.18240
   Xue YH, 2022, J BIOL REG HOMEOS AG, V36, P1369, DOI 10.23812/j.biol.regul.homeost.agents.20223605.147
   Yang MX, 2021, CELL MOL NEUROBIOL, V41, P293, DOI 10.1007/s10571-020-00852-z
   Yu LL, 2018, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.00775
   Yue N, 2017, J NEUROINFLAMM, V14, P0, DOI 10.1186/s12974-017-0865-y
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang WJ, 2020, BIOMED PHARMACOTHER, V129, P0, DOI 10.1016/j.biopha.2020.110447
   Zheng YY, 2021, MOL MED REP, V23, P0, DOI 10.3892/mmr.2020.11814
NR 53
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-9538
EI 1573-9546
J9 PURINERG SIGNAL
JI Purinergic Signal.
PD AUG 15
PY 2025
VL 21
IS 4
BP 565
EP 576
DI 10.1007/s11302-025-10100-y
EA JUN 2025
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 7PA8H
UT WOS:001516518900001
PM 40560521
DA 2026-01-16
ER

PT J
AU Konda, Y
AF Konda, Y.
TI Integrative approach to pain management in prostate cancer: a case report on scalp and auricular acupuncture
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
C1 [Konda, Y.] Univ Indonesia, Med Acupuncture Study Program, Jakarta, Indonesia.
C3 University of Indonesia
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT 15
PY 2025
VL 36
IS 
BP S1742
EP S1742
DI 10.1016/j.annonc.2025.08.353
PG 1
WC Oncology
SC Oncology
GA O1031
UT WOS:001632241300106
DA 2026-01-16
ER

PT J
AU Liu, Q
   Qin, X
   Luo, C
   Zhao, Z
   Xie, W
   Du, X
   Qin, X
AF Liu, Qiang
   Qin, Xiaoguang
   Luo, Chenglin
   Zhao, Zhongting
   Xie, Wangjun
   Du, Xiaozheng
   Qin, Xin
TI Effects of warm needle acupuncture on behavioral pain threshold in a rat model of
SO Frontiers in neurology
LA English
DT Journal Article
DE 5-HT; CGRP; ET-1 protein; migraine; needle warming acupuncture
AB BACKGROUND: As a traditional Chinese treatment method, acupuncture has a long  history in the treatment of migraine and a rich literature base. As a traditional  acupuncture technique, warm needle acupuncture has clearly demonstrated clinical  efficacy in the treatment of migraine, although its mechanism of action remains  unclear. This study aimed to evaluate the efficacy and safety of warm needle  acupuncture in the treatment of migraine in a rat model of migraine by comparing  pain threshold and analgesic-related factors among different groups. METHODS:  Thirty Sprague-Dawley rats were randomly divided into control, model, and  acupuncture groups, with 10 animals in each group. On day 8, rat migraine models  were established by subcutaneous injection of nitroglycerin. The acupuncture  group was bilaterally needled once per day at Fengchi, Baihui, Fengfu, and Hegu.  Behavioral changes and biochemical alterations among the rats before and after  modeling were observed for 7 consecutive days after treatment. The expression of  Endothelin-1 (ET-1), interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α)  in the brain stem of the animals were assessed using ELISA. Expression levels of  calcitonin gene-related peptide (CGRP) mRNA were determined using real-time  quantitative polymerase chain reaction techniques. RESULTS: After treatment, the  expression of ET-1, IL-6, TNF-α, and CGRP in the brain stem of the model group  was significantly increased compared with that of the control group (p < 0.05),  while the expression of IL-6, TNF-α, and CGRP in the brain stem of the  acupuncture group was decreased. CONCLUSION: Warm needle acupuncture reduced ET-1  protein levels and promoted the expression of neurotransmitters, such as  5-hydroxytryptamine, in migraine rat model animals. In addition, needle warming  acupuncture decreased IL-6, TNF-α, and CGRP levels in the brain stem of the  migraine group, which may explain its mechanism of action in treating migraine.
C1 Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Department of Acupuncture and Moxibustion, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
   Medical Faculty, Northwest Minzu University, Lanzhou, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD OCT 17
PY 2025
VL 16
IS 
BP 1538182
EP 1538182
DI 10.3389/fneur.2025.1538182
PG 0
UT PubMed:41103513
PM 41103513
DA 2025-10-17
ER

PT J
AU Yu, QT
   Wang, XR
   Wu, JQ
   Zhang, QY
   Ying, XQ
   Ou, LM
   Hu, HT
   He, KL
   Wu, L
   Jin, ZD
   Shentu, J
   Dai, HF
   Ma, RJ
   Hu, QM
   Han, DX
AF Yu, Qintao
   Wang, Xinru
   Wu, Jiaqi
   Zhang, Qiyuan
   Ying, Xiaoqi
   Ou, Liming
   Hu, Hantong
   He, Kelin
   Wu, Lei
   Jin, Zongda
   Shentu, Jiajun
   Dai, Huifeng
   Ma, Ruijie
   Hu, Qimiao
   Han, Dexiong
TI Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and Biomarker Evaluation: A Study Protocol for a Multicenter, Randomized Trial
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE electroacupuncture; postherpetic neuralgia; biomarker; sham acupuncture; randomized controlled trial; study protocol
ID herpes-zoster
AB Introduction: Postherpetic neuralgia (PHN) is a persistent neuropathic pain condition that endures for at least 3 months following the onset of herpes zoster, significantly impairing life quality of patients. Current PHN treatments demonstrate limited efficacy, and the lack of reliable severity biomarkers hinders effective clinical management. Electroacupuncture represents a promising therapeutic approach for PHN, though comprehensive evidence supporting its efficacy and safety is still needed. Furthermore, as objective indicators, the role of serum biomarkers in assessments still requires further investigation. Methods: This multicenter, sham-controlled, randomized study will recruit 180 patients with PHN. Participants will be allocated in a 1:1:1 ratio to electroacupuncture, sham acupuncture, or waiting-list groups via multicenter stratified block randomization. Participants will receive 1-month of treatment and 3-month follow-ups. The electroacupuncture group and the sham acupuncture group will each receive 12 treatments. All participants will maintain their pre-enrollment medication. Primary outcome is Numerical Rating Scale; secondary outcomes include pain episode frequency, Hamilton Anxiety Scale, Hamilton Depression Scale, The Short-Form 36 Health Survey, and changes of biomarkers (Neuropeptide Y, Substance P, Tumor Necrosis Factor-alpha, Interleukin-10). A linear mixed-effects model will be used to analyze data at different time points to explore the efficacy of electroacupuncture and the correlation between serum biomarkers and pain intensity. The predictive value of biomarkers for refractory postherpetic neuralgia (NRS reduction <30% from baseline post-treatment) will be assessed using ROC curves. Conclusion: The expected outcomes will clarify the efficacy and safety of electroacupuncture for PHN. The study will also analyze the correlation between serum biomarkers and pain symptoms and determine whether serum biomarkers can serve as prognostic indicators for refractory postherpetic neuralgia.
C1 [Yu, Qintao; Wang, Xinru; Wu, Jiaqi; Zhang, Qiyuan; Ying, Xiaoqi; Ou, Liming] Zhejiang Chinese Med Univ, Sch Clin Med 3, Sch Rehabil Med, Hangzhou, Peoples R China.
   [Hu, Hantong; He, Kelin; Wu, Lei; Ma, Ruijie; Hu, Qimiao; Han, Dexiong] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Dept Acupuncture & Moxibust, 219 Moganshan Rd, Hangzhou, Peoples R China.
   [Jin, Zongda] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Dept Med Affairs, Hangzhou, Peoples R China.
   [Shentu, Jiajun] Hangzhou Third Peoples Hosp, Dept Acupuncture & Moxibust, Hangzhou, Zhejiang, Peoples R China.
   [Dai, Huifeng] Changxing Cty Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, Huzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Hu, QM; Han, DX (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 3, Dept Acupuncture & Moxibust, 219 Moganshan Rd, Hangzhou, Peoples R China.
EM huqimiao315@126.com; han_0213@163.com
FU Science and Technology Co-construction Project of the National Comprehensive Reform Demonstration Zone for Traditional Chinese Medicine [GZY-KJS-ZJ-2025-024]; Zhejiang Province Health High-level Talent Project [[2021] 40 (cxrc202102)]; Zhejiang Province High-Level Health Talent Project (Zhejiang Health Office [2021]) [40]
CR Ai J X, 2025, ZHONGHUA LIU XING BING XUE ZA ZHI, V46, P1204, DOI 10.3760/cma.j.cn112338-20250203-00067
   Ali U, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109898
   Barone M, 2022, PHYSIOTHER THEOR PR, V38, P1813, DOI 10.1080/09593985.2021.1878567
   Chen JH, 2024, SKIN RES TECHNOL, V30, P0, DOI 10.1111/srt.13815
   Chen L, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04564-z
   Chen S, 2024, PAIN THER, V13, P269, DOI 10.1007/s40122-024-00580-y
   Chen XJ, 2025, PAIN, V166, P916, DOI 10.1097/j.pain.0000000000003433
   Cui Y, 2023, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1056102
   DAmico F, 2025, J CLIN ANESTH, V102, P0, DOI 10.1016/j.jclinane.2025.111772
   Dai SP, 2024, ISCIENCE, V27, P0, DOI 10.1016/j.isci.2024.110955
   Dong WJ, 2025, EUR J NEUROL, V32, P0, DOI 10.1111/ene.16548
   Ferreira LL, 2022, BEHAV BRAIN RES, V424, P0, DOI 10.1016/j.bbr.2022.113803
   Gu J, 2023, MED SCI MONITOR, V29, P0, DOI 10.12659/MSM.941878
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
   He YJ, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000034502
   Pazili TH, 2023, WORLD J CLIN CASES, V11, P3619, DOI 10.12998/wjcc.v11.i15.3619
   Hu HT, 2023, J PAIN RES, V16, P1401, DOI 10.2147/JPR.S406841
   Huerta MA, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms241612987
   Kalava A, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.55168
   Kim JH, 2021, PAIN PRACT, V21, P794, DOI 10.1111/papr.13017
   Langford DJ, 2022, J PAIN, V23, P1945, DOI 10.1016/j.jpain.2022.07.001
   Lim S, 2010, EVID-BASED COMPL ALT, V7, P167, DOI 10.1093/ecam/nep006
   Liu QY, 2021, PAIN THER, V10, P1755, DOI 10.1007/s40122-021-00283-8
   Liu QP, 2024, SKIN RES TECHNOL, V30, P0, DOI 10.1111/srt.13867
   Lorente L, 2016, INT J MOL SCI, V17, P0, DOI 10.3390/ijms17060991
   Musa AF, 2021, HEALTH QUAL LIFE OUT, V19, P0, DOI 10.1186/s12955-020-01658-9
   Nagy Z, 2024, IDEGGYOGY SZEMLE, V77, P0, DOI 10.18071/isz.77.0131
   Nelson TS, 2024, ACS PHARMACOL TRANSL, V7, P3718, DOI 10.1021/acsptsci.4c00333
   Peng BX, 2023, FRONT PHARMACOL, V14, P0, DOI 10.3389/fphar.2023.1159753
   Qin ZS, 2024, GEN PSYCHIAT, V37, P0, DOI 10.1136/gpsych-2024-101578
   ROWBOTHAM MC, 1995, ANN NEUROL, V37, P246, DOI 10.1002/ana.410370216
   Ruan YJ, 2024, BMC PSYCHOL, V12, P0, DOI 10.1186/s40359-024-01744-3
   Ruengwongroj P, 2020, COMPLEMENT THER CLIN, V40, P0, DOI 10.1016/j.ctcp.2020.101202
   Seo YG, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000009837
   Sharma A, 2022, PROG NEURO-PSYCHOPH, V112, P0, DOI 10.1016/j.pnpbp.2021.110428
   Song XX, 2023, FRONT CELL NEUROSCI, V16, P0, DOI 10.3389/fncel.2022.1071012
   Tang JJ, 2025, JACC-CLIN ELECTROPHY, V11, P655, DOI 10.1016/j.jacep.2024.11.021
   Tang JY, 2023, CURR PAIN HEADACHE R, V27, P307, DOI 10.1007/s11916-023-01146-x
   Taracanova A, 2017, P NATL ACAD SCI USA, V114, PE4002, DOI 10.1073/pnas.1524845114
   Tsubaki Takayoshi, 2024, CUREUS, V16, Pe73132, DOI 10.7759/cureus.73132
   Wang Y, 2021, ACUPUNCT MED, V39, P358, DOI 10.1177/0964528420938376
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Werner RN, 2017, J EUR ACAD DERMATOL, V31, P9, DOI 10.1111/jdv.13995
   Wu D, 2024, INT J GEN MED, V17, P4805, DOI 10.2147/IJGM.S480411
   Wu QY, 2021, MOL PAIN, V17, P0, DOI 10.1177/1744806921997654
   Yang Yueyuan, 2024, ALTERN THER HEALTH MED, V30, P290
   Ye ZQ, 2022, FRONT PSYCHIATRY, V13, P0, DOI 10.3389/fpsyt.2022.830081
   Yen FS, 2023, J MED VIROL, V95, P0, DOI 10.1002/jmv.28278
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Zhang Y, 2021, CELL BIOSCI, V11, P0, DOI 10.1186/s13578-021-00657-7
   Zheng Y, 2024, CHIN MED-UK, V19, P0, DOI 10.1186/s13020-024-01030-9
   Zheng YY, 2021, MOL MED REP, V23, P0, DOI 10.3892/mmr.2020.11814
   Zhong CY, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.972536
NR 55
TC 1
Z9 1
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2025
VL 18
IS 
BP 5753
EP 5768
DI 10.2147/JPR.S559309
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA 9KQ8T
UT WOS:001608634800001
PM 41199896
DA 2026-01-16
ER

PT J
AU Ren, X
   Qu, YP
   Xia, T
   Tang, XF
AF Ren, Xu
   Qu, Yong-Ping
   Xia, Tian
   Tang, Xiu-Fen
TI Technical success, clinical efficacy, and safety of endoscopic minor papilla
SO World journal of gastroenterology
LA English
DT Journal Article
DE Abdominal pain improvement; Endoscopic minor papilla intervention; Obstructive chronic pancreatitis; Pancreas division; Symptomatic pancreatic diseases
AB BACKGROUND: Endoscopic minor papilla intervention (EMPI) is an option for  diagnosing or treating symptomatic pancreatic diseases in cases with failed  pancreatic duct deep cannulation via the major papilla, pancreas divisum with  obstruction of the minor papilla, or an abnormal patulous orifice of the minor  papilla during endoscopic retrograde cholangiopancreatography (ERCP). However,  the relatively low patency and small opening of the minor papillae pose technical  challenges. AIM: To evaluate the technical success, clinical success, stone  clearance, and safety profile of EMPI for diagnosis and treatment of symptomatic  pancreatic diseases. METHODS: Patients diagnosed with symptomatic pancreatic  diseases and EMPI between February 1996 and February 2023 were included. The  primary outcomes were the initial technical success, defined as successful deep  cannulation via the minor papilla (DCMP; access of the guidewire to the upstream  pancreatic duct via the minor papilla) alone, overall technical success, defined  as successful DCMP alone and successful DCMP with additional needle-knife precut  minor papillotomy (NKPMP), and immediate clinical success, defined as > 50%  improvement in abdominal pain after therapeutic EMPI. Secondary outcomes included  long-term clinical success at 1, 3, and 7 years, pancreatic stone clearance, and  procedure-related early and late adverse events (AEs). RESULTS: Overall, 43  patients, 32 with obstructive chronic pancreatitis, 8 with pancreatic divisum,  and 3 with intraductal papillary mucinous neoplasm were included. The initial and  overall technical success rates were 74.4% (32/43) and 88.4% (38/43),  respectively. The immediate clinical success rate was 79.1% (34/43), and the  long-term clinical success rates at 1, 3, and 7 years were 74.7%, 55.3%, and  41.5%, respectively, among the 22 patients with a follow-up period of 57.5  (7-266) months. Complete and partial success of pancreatic stone clearance was  achieved in 53.9% (7/13) and 15.4% (2/13), respectively. Early AEs included  post-ERCP pancreatitis (PEP, n = 5) and self-limiting bleeding (n = 1); surgery  therapy was required for 1 case with severe PEP and conservative management for  the other 4 with mild PEP. Late AEs included minor papilla stricture (n = 1)  after endoscopic minor papillotomy and pancreatic duct stricture (n = 1) after  double pancreatic stent placement; no specific treatment was implemented for  these events. CONCLUSION: EMPI is feasible, effective, and safe for symptomatic  pancreatic diseases, in terms of the technical and clinical success, stone  clearance, and incidence and severity of AEs. NKPMP appears to enhance technical  success. However, potential risks of developing PEP and late AEs should be kept  in mind.
C1 Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatmentof Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province, China.hljxhy2001@126.com.
   Digestive Endoscopy Center of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis andTreatment of Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province,China.
   Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center for Minimally Invasive Diagnosis and Treatmentof Pancreaticobiliary Diseases, Harbin 150001, Heilongjiang Province, China.
   First Department of Gastroenterology, Digestive Hospital of Heilongjiang Provincial Hospital, Heilongjiang Provincial Clinical Medical Research Center forMinimally Invasive Diagnosis and Treatment of Pancreaticobiliary Diseases, Harbin150001, Heilongjiang Province, China.
NR 0
TC 0
SN 2219-284
EI 1007-932
J9 World J Gastroenterol
PD JUN 11
PY 2025
VL 31
IS 20
BP 100192
EP 100192
DI 10.3748/wjg.v31.i20.100192
PG 0
WC Humans; Male; Female; Cholangiopancreatography, Endoscopic Retrograde; adverse effects; Middle Aged; Treatment Outcome; Pancreatic Ducts; surgery; Aged; Pancreatic Diseases; surgery; Sphincterotomy, Endoscopic; adverse effects; Adult; Retrospective Studies; Postoperative Complications; epidemiology
UT PubMed:40495942
PM 40495942
DA 2025-06-11
ER

PT J
AU Zhang, DT
   Shi, GX
   Jia, JY
   Tan, FW
   Qi, Y
   Liang, W
   Zhao, ZJ
   Yuan, P
   Gao, Y
   Zhang, GC
   Liu, XH
   Yang, JW
   Wang, LQ
   Wang, X
   Yang, NN
   Tu, JF
   Liu, CZ
AF Zhang, Dan-Tong
   Shi, Guang-Xia
   Jia, Jin-Ying
   Tan, Feng-Wei
   Qi, Yu
   Liang, Wei
   Zhao, Zhi-Jun
   Yuan, Ping
   Gao, Ya
   Zhang, Guo-Chao
   Liu, Xue-Hui
   Yang, Jing-Wen
   Wang, Li-Qiong
   Wang, Xiao
   Yang, Na-Na
   Tu, Jian-Feng
   Liu, Cun-Zhi
TI Electroacupuncture for acute postoperative pain during coughing after
SO PloS one
LA English
DT Journal Article
AB BACKGROUND: Despite the use of multimodal analgesia regimens following  video-assisted thoracoscopic surgery (VATS), acute postoperative pain persists.  Electroacupuncture (EA) may alleviate acute postoperative pain following VATS;  however, current evidence remains insufficient. OBJECTIVES: This trial will  assess the feasibility and efficacy of EA as an adjunctive treatment compared  with sham electroacupuncture (SA) for managing acute postoperative pain during  coughing after VATS. STUDY DESIGN AND METHODS: In this pilot randomized  controlled trial, 60 patients with non-small-cell lung cancer who will undergo  VATS will be randomly assigned to either the EA or SA group in a 1:1 ratio.  Patients will receive standard care combined with four sessions of EA or SA  within 72 h after surgery. The primary outcome will be the average postoperative  pain score during coughing, measured using a numeric rating scale within 72 h  after surgery. Secondary outcomes will include the average daily pain scores at  rest, during coughing, and while mobilizing; incidence of chronic post-surgical  pain; quality of life; cough symptom score; and analgesic consumption. All  adverse events will be recorded in detail. DISCUSSION: This study will determine  whether EA as an adjunctive treatment can reduce acute postoperative pain during  coughing following VATS. TRIAL REGISTRATION: ClinicalTrial.gov ITMCTR2024000170  (http://itmctr.ccebtcm.org.cn/zh-CN/Home/ProjectView?pid=f1a344f7-7e06-4665-ad9d-0917d588eba6).
C1 International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
   Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China.
   Medical College, Tianjin University, Tianjin, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
NR 0
TC 0
SN 1932-620
EI 
J9 PLoS One
PD MAR 27
PY 2025
VL 20
IS 3
BP e0316698
EP e0316698
DI 10.1371/journal.pone.0316698
PG 1
WC Adult; Aged; Female; Humans; Male; Middle Aged; Carcinoma, Non-Small-Cell Lung; surgery; Cough; complications; Electroacupuncture; methods; Lung Neoplasms; surgery; Pain, Postoperative; therapy; Pilot Projects; Quality of Life; Thoracic Surgery, Video-Assisted; adverse effects; Randomized Controlled Trials as Topic
UT PubMed:40138259
PM 40138259
DA 2025-03-27
ER

PT J
AU Hempen, M
   Hummelsberger, J
AF Hempen, Moritz
   Hummelsberger, Josef
TI The state of evidence in acupuncture: A review of metaanalyses and systematic reviews of acupuncture evidence (update 2017-2022)
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Review
DE Acupuncture; Acupuncture effectiveness; Acupuncture review; Acupuncture evidence
AB Introduction: Over the last decades, acupuncture research has increased drastically. As a result, it has become more and more difficult to oversee the amount of evidence concerning its effect in various medical conditions. Different comparative reviews aimed to roughly assess individual strength of acupuncture evidence, covering the years 2005-2017. Our review intends to assess the level of acupuncture evidence for any medical condition available, concerning the years 2017-2022. Methods: We searched the pubmed database for 'acupuncture' and filtered the results towards systematic reviews and metanalyses (SR/MA). Results were allocated towards medical disciplines and sorted to medical conditions. Each SR/MA was rated concerning quality of review (QoR), quality of data (QoD), and quality of evidence (QoE). To facilitate a rough overview, results were assessed into either of four categories: i) evidence of positive effect, ii) evidence of potential positive effect, iii) insufficient/unclear evidence, iv) no evidence of effect/evidence of no effect. Results: After considering exclusion criteria, 862 SR/MA remained for evaluation. Results were allocated and sorted as described, resulting in 184 medical conditions. Of these, in ten medical conditions SR/MA supported evidence of positive effect: chronic pain, low-back pain, knee osteoarthritis, postoperative nausea and vomiting (PONY), migraine, tension-type headache, cancer-related fatigue, menopausal symptoms, female infertility (additional to medical reproductive treatment), chronic prostatitis/chronic pelvic pain syndrome in men. In another 82 medical conditions SR/MA supported evidence of potential positive effect, in another 86 medical conditions SR/MA revealed unclear/insufficient evidence, and in another six medical conditions no evidence of effect/evidence of no effect was found. Compared with previous reviews until the year 2017, the number of medical conditions with higher quality evidence levels has increased, namely evidence of positive effect and evidence of potential positive effect. Discussion and conclusion: Compared to previous years, the amount and quality of acupuncture evidence has increased in the years 2017-2022. In total, 862 included SR/MA resulted in a comparative review of 184 medical conditions. Evidence of positive effect was revealed ten medical conditions, another 82 showed evidence of potential positive effect. 86 medical indications showed insufficient evidence for a firm conclusion, six conditions showed no evidence of effect/evidence of no effect. Although general quality of evidence has dramatically increased compared to the previous years, lack of underlying high-quality trials in some cases seems to compromise a consistent comparability between SR/MA. This issue should be addressed for future studies and guidelines such as STRICTA and CONSORT should strictly be obtained.
C1 [Hempen, Moritz; Hummelsberger, Josef] SMS Int Soc Chinese Med, Franz Joseph Str 38, D-80801 Munich, Germany.
RP Hempen, M (corresponding author), SMS Int Soc Chinese Med, Franz Joseph Str 38, D-80801 Munich, Germany.
EM m.hempen@tcm.edu
FU SMS - International Society for Chinese Medicine
CR Unknown -, 2024, DEUTSCHE GESELLSCHAFT FUR ORTHOPADIE UND UNFALLCHIRURGIE E.V. GONARTHROSE (LIVING GUIDELINE), V0, P0
   Australian Government Department of Veterans Affairs, 2010, ALTERNATIVE THERAPIES AND DEPARTMENT OF VETERANS AFFAIRS GOLD AND WHITE CARD ARRANGEMENTS, V0, P0
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   Candon M, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.42509
   Chang SC, 2017, NEUROUROL URODYNAM, V36, P474, DOI 10.1002/nau.22958
   DGfGuGeV (DGGG), 2021, PERIUND POSTMENOPAUSE-DIAGNOSTIK UND INTERVENTIONEN, V0, P0
   DGfNeV (DGN), 2023, S1-LEITLINIE DIAGNOSTIK UND THERAPIE DES KOPFSCHMERZES VOM SPANNUNGSTYP, V0, P0
   DGfPFuGeV (DGPFG), 2019, PSYCHOSOMATISCH ORIENTIERTE DIAGNOSTIK UND THERAPIE BEI FERTILITATSSTORUNGEN, V0, P0
   Fan SQ, 2021, J NEUROL, V268, P4128, DOI 10.1007/s00415-020-10178-x
   Fei YT, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-064345
   Franco JVA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012551.pub2
   Fu CW, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020301
   Gao Z, 2021, J PAIN RES, V14, P0, DOI 10.2147/JPR.S300911
   Hempel S, 2014, VA EVIDENCE-BASED SYNTHESIS PROGRAM REPORTS. EVIDENCE MAP OF ACUPUNCTURE, V0, P0
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Ji ZC, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03099-9
   John Bland, 1979, ACUPUNCTURE, V0, P2
   Kaptchuk TJ, 2020, MED ACUPUNCT, V32, P352, DOI 10.1089/acu.2020.1483
   Kolokotsios S, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.14237
   Lee B, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e25650
   Lee B, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15245875
   Li T, 2021, MENOPAUSE, V28, P564, DOI 10.1097/GME.0000000000001767
   Ma B, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0147244
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   McDonald J, 2017, THE ACUPUNCTURE EVIDENCE PROJECT: A COMPARATIVE LITERATURE REVIEW (REVISED EDITION), V0, P0
   Mu JL, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013814
   Naguit N, 2022, CUREUS J MED SCIENCE, V14, P0, DOI 10.7759/cureus.20888
   Qin ZS, 2022, EUR UROL OPEN SCI, V46, P55, DOI 10.1016/j.euros.2022.10.005
   Quan Kewei, 2022, EVID BASED COMPLEMENT ALTERNAT MED, V2022, P3595033, DOI 10.1155/2022/3595033
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Svenkerud S, 2018, ACUPUNCT MED, V36, P349, DOI 10.1136/acupmed-2017-011519
   Tian H, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/6561633
   Trinczek K, 2015, FORSCH KOMPLEMENTMED, V22, P118, DOI 10.1159/000381151
   Turkistani A, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.17601
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Xiao X, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5865697
   Yuan T, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/2653792
   Zhang GS, 2018, ACUPUNCT MED, V36, P204, DOI 10.1136/acupmed-2017-011484
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhao FY, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.666988
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zheng XY, 2022, FRONT PUBLIC HEALTH, V10, P0, DOI 10.3389/fpubh.2022.858587
   Zhu KX, 2024, FRONT PHARMACOL, V15, P0, DOI 10.3389/fphar.2024.1293468
NR 46
TC 3
Z9 5
U1 6
U2 12
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAY 15
PY 2025
VL 89
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103149
EA MAR 2025
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA Z7O8H
UT WOS:001440761300001
PM 40021024
DA 2026-01-16
ER

PT J
AU Segev, Y
   Abofol, S
   Samuels, N
   Schmidt, M
   Assaf, W
   Ben-Arye, E
AF Segev, Yakir
   Abofol, Sereen
   Samuels, Noah
   Schmidt, Meirav
   Assaf, Wisam
   Ben-Arye, Eran
TI Postoperative pain following intraoperative acupuncture: a randomized-controlled study
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article
DE Integrative Oncology; Pain; Supportive care
ID medicine
AB Context and objectives This study examined the impact of an integrative oncology intervention on postoperative care, primarily postoperative pain, in patients undergoing gynaecological oncology surgery.Methods Participants were randomised to three groups: group A, preoperative touch/relaxation modalities, followed by intraoperative acupuncture; group B, preoperative touch/relaxation only and group C, standard conventional care alone. Using an enhanced recovery after surgery (ERAS) protocol, medical personnel retrospectively assessed pain on each postoperative day (POD), using a Visual Analogue Scale (VAS; 0, no pain; 10, most severe pain). Use of analgesics, bowel movements, urination and number of days until discharge were also assessed.Results A total of 102 patients participated, with similar baseline demographic and surgery-related characteristics among the three groups (group A, 45; group B, 25 and group C, 32). Group A patients undergoing laparoscopic surgery reported significantly lower pain scores on POD1 than group C (p=0.018). Group B patients undergoing open laparotomy were discharged earlier than group C (p=0.031). No significant between-group differences were found for VAS pain scales, use of analgesics or report of first postoperative bowel movement or urination.Conclusions This prospective, controlled and pragmatic ERAS-based study suggests that intraoperative acupuncture may reduce postoperative pain on POD1, in patients undergoing laparoscopic gynaecological oncology surgery. The findings differ from a previous study which found no effect of acupuncture on pain-related haemodynamic parameters during laparoscopy. Further research using objective nociception parameters is needed to explore the effect of intraoperative acupuncture on postoperative pain.Trial registration number ClinicalTrials.gov (NCT03560388)
C1 [Segev, Yakir; Schmidt, Meirav; Assaf, Wisam] carmel Med Ctr, Gynecol Dept, Div Gynecol Oncol obster, H_efa, Israel.
   [Abofol, Sereen] Carmel Hosp, Obstet & Gynecol Dept, Haifa, Israel.
   [Samuels, Noah] Shaare Zedek Med Ctr, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Ben-Arye, Eran] LIN Med Ctr, H_aifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Tel Aviv, Israel.
C3 Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services
RP Segev, Y (corresponding author), carmel Med Ctr, Gynecol Dept, Div Gynecol Oncol obster, H_efa, Israel.
EM segevyakir@yahoo.com; Sereen.abofol@gmail.com; integrative@szmc.org.il; smeiravm@gmail.com; wissam_assaf_90@hotmail.com; ERANBE@clalit.org.il
FU The Israel Cancer Association; Israel Cancer Association
CR Baldawi M, 2022, J INTEGR COMPLEMENT, V28, P683, DOI 10.1089/jicm.2021.0429
   Ben-Arye E, 2023, J CANCER RES CLIN, V149, P8177, DOI 10.1007/s00432-023-04758-3
   Ben-Arye E, 2023, CURR ONCOL REP, V25, P559, DOI 10.1007/s11912-023-01359-8
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bondi A, 2021, J HOLIST NURS, V39, P58, DOI 10.1177/0898010120936437
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Felix MMD, 2018, REV LAT-AM ENFERM, V26, P0, DOI 10.1590/1518-8345.2850.3101
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Ozhanli Y, 2022, J PERIANESTH NURS, V37, P238, DOI 10.1016/j.jopan.2021.08.008
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Wiles MD, 2017, ANAESTHESIA, V72, P335, DOI 10.1111/anae.13785
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Xue FS, 2023, CANCER-AM CANCER SOC, V129, P1939, DOI 10.1002/cncr.34805
NR 18
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD SEP 15
PY 2025
VL 15
IS 5
BP 642
EP 647
DI 10.1136/spcare-2025-005485
EA JUN 2025
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 6YX0Q
UT WOS:001511423100001
PM 40537176
DA 2026-01-16
ER

PT J
AU Miron, O
   Wolff-Sagy, Y
   Levin, M
   Lubich, E
   Lewinski, J
   Shpunt, M
   Ahmad, WA
   Borochov, I
   Netzer, D
   Lavie, G
AF Miron, Oren
   Wolff-Sagy, Yael
   Levin, Mark
   Lubich, Esti
   Lewinski, Jordan
   Shpunt, Maya
   Ahmad, Wiessam Abu
   Borochov, Ilya
   Netzer, Doron
   Lavie, Gil
TI Fentanyl Initiation Rate Following the Requirement for Specialist Approval
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
ID safety
AB BackgroundHealthcare organizations attempt to address unwarranted fentanyl use, which often leads to increased risk of addiction and overdose.ObjectiveTo assess the impact of a requirement for a specialist's approval on fentanyl initiation for non-oncological pain.DesignA retrospective cohort study based on observational data.ParticipantsAll 4.4 million non-oncological members of Clalit Health Services were included, from July 20, 2021, to July 19, 2023.Main MeasuresThe rate of fentanyl initiation was assessed before and after the implementation of the requirement for specialist's approval, which was introduced on July 2022, and expanded 6 months later for continued use. A sub-group analysis by age group was performed, and patient characteristics and indications were assessed. We also compared total opioid dispensation in the 6th and 12th months after the implementation with the predicted rate based on pre-implementation rates.Key ResultsFentanyl initiation rate in the year before the requirement was 711 per million capita, which decreased following the requirement by - 81% (95% CI: - 77%; - 85%). The decrease attenuated with age. The prevalence of diagnosis with substance abuse disorders at the time of fentanyl initiation decreased from 6 to 3%. In the 6th and 12th months after the requirement was implemented, the morphine milligram equivalent (MME) from dispensation of total opioids was lower than predicted based on pre-implementation rates by 7% and 26%, respectively.ConclusionsRequiring specialist approval for fentanyl initiation for non-oncological chronic pain was associated with a decrease in fentanyl prescription initiations, especially among non-elderly patients. A decrease also occurred gradually in total opioid dispensations, further decreasing following the extension of the requirement to continuous fentanyl. The requirement for specialist approval upon fentanyl initiation and continuous fentanyl may present an effective tool for limiting the use of fentanyl and total opioids in healthcare systems.
C1 [Miron, Oren; Wolff-Sagy, Yael; Ahmad, Wiessam Abu; Lavie, Gil] Clalit Hlth Serv, Branch Planning & Strategy, Tel Aviv, Israel.
   [Miron, Oren] Bengurion Univ Negev, Dept Hlth Policy & Management, Beer Sheva, Israel.
   [Levin, Mark; Lubich, Esti; Lewinski, Jordan; Shpunt, Maya; Borochov, Ilya; Netzer, Doron] Clalit Hlth Serv, Community Med Serv Div, Tel Aviv, Israel.
   [Ahmad, Wiessam Abu] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Braun Sch Publ Hlth, Jerusalem, Israel.
   [Netzer, Doron] Ariel Univ, Adelson Sch Med, Ariel, Israel.
   [Lavie, Gil] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.
C3 Clalit Health Services; Ben-Gurion University of the Negev; Clalit Health Services; Hebrew University of Jerusalem; Hadassah University Medical Center; Hadassah University Hospital; Ariel University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine
RP Miron, O (corresponding author), Clalit Hlth Serv, Branch Planning & Strategy, Tel Aviv, Israel.
EM Orenmir@post.bgu.ac.il
CR Abouk R, 2021, ECON HUM BIOL, V42, P0, DOI 10.1016/j.ehb.2021.101000
   Aggarwal P, 2021, J AM ACAD DERMATOL, V85, P388, DOI 10.1016/j.jaad.2021.03.109
   Ahmad FB, 2024, PROVISIONAL DRUG OVERDOSE DEATH COUNTS, V0, P0, DOI DOI 10.5281/ZENODO.13352530
   Allen LD, 2024, JAMA-HEALTH FORUM, V5, P0, DOI 10.1001/jamahealthforum.2023.4731
   Unknown -, 2022, I24 NEWS 0105, V0, P0
   Dressler RL, 2023, ISR J HEALTH POLICY, V12, P0, DOI 10.1186/s13584-023-00581-w
   Evans WN, 2019, REV ECON STAT, V101, P1, DOI 10.1162/rest_a_00755
   Fox LM, 2018, ADDICTION, V113, P59, DOI 10.1111/add.13925
   Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961
   Israel Central Bureau of Statistics, 2021, CHARACTERIZATION CLA, V0, P0
   Jeffery MM, 2020, MED CARE, V58, P4, DOI 10.1097/MLR.0000000000001221
   Jeffery MM, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.2875
   McEvoy Theresa, 2014, HOSP PHARM, V49, P942, DOI 10.1310/hpj4910-942
   McGinty EE, 2022, ANN INTERN MED, V175, P617, DOI 10.7326/M21-4363
   Ministry of Health, 2016, GUIDELINES NARCOTICS, V0, P0
   Miron O, 2020, REGION ANESTH PAIN M, V0, P0
   Miron O, 2021, MEDRXIV, V0, P0
NR 18
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP 15
PY 2025
VL 40
IS 13
BP 3097
EP 3103
DI 10.1007/s11606-024-09160-4
EA NOV 2024
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 8IU9V
UT WOS:001347891300007
PM 39495456
DA 2026-01-16
ER

PT J
AU Li, H
   Doorenbos, AZ
   Chen, Z
   Choi, H
   Ma, W
   Danciu, O
   Patil, CL
   Gao, S
   Lif, N
   Schlaeger, JM
AF Li, Hongjin
   Doorenbos, Ardith Z
   Chen, Zhengjia
   Choi, Hannah
   Ma, Weiwei
   Danciu, Oana
   Patil, Crystal L
   Gao, Shuang
   Lif, Natalie
   Schlaeger, Judith M
TI Feasibility and Acceptability of Integrating Acupuncture for Management of
SO Cancers
LA English
DT Journal Article
DE acupuncture; breast cancer survivors; health disparities; medically underserved; symptom management
AB BACKGROUND/OBJECTIVES: Breast cancer survivors undergoing long-term endocrine  therapy often experience multiple symptoms, including pain, fatigue, sleep  disturbance, hot flashes, anxiety, and depression. This study explored the  feasibility and acceptability of integrating acupuncture for symptom management  in medically underserved breast cancer survivors. METHODS: This randomized  controlled trial was conducted at two clinics serving medically underserved  populations. Breast cancer survivors (N = 62) were randomized to receive  acupuncture (n = 31) or usual care (n = 31). The acupuncture group underwent 10  sessions over 5 weeks. Symptoms were assessed at baseline and Weeks 6 and 12.  RESULTS: The majority of participants (55%) were Black, mean age was 55.2 ± 9.3  years, and 62.9% had a household income below $55,000. Retention (90.3%),  engagement (93.1%), and acceptability (92.8%) rates were high, demonstrating that  integrating acupuncture into care for medically underserved breast cancer  survivors is both feasible and acceptable. At Week 6, the acupuncture group  showed significant reduction compared to the usual care group in pain, fatigue,  sleep disturbance, depression, anxiety, and the symptom cluster score. All  improvements persisted to Week 12 except for those in anxiety. CONCLUSIONS:  Integrating acupuncture for symptom management in medically underserved breast  cancer survivors is both feasible and acceptable. This approach offers potential  benefits for reducing multiple symptoms and addressing health disparities.
C1 College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, Chicago, IL 60612, USA.
   School of Nursing, University of Michigan, Ann Arbor, MI 48109, USA.
   College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
NR 0
TC 0
SN 2072-669
EI 2072-669
J9 Cancers (Basel)
PD JAN 25
PY 2025
VL 17
IS 2
BP 
EP 
DI 10.3390/cancers17020304
PG 0
UT PubMed:39858086
PM 39858086
DA 2025-01-25
ER

PT J
AU Tao, SY
   Yang, Y
   Tang, J
   Wang, X
   Jiang, NN
   Li, Y
   Wu, P
AF Tao, Siyu
   Yang, Yi
   Tang, Jie
   Wang, Xue
   Jiang, Nannan
   Li, Yuan
   Wu, Ping
TI The efficacy of moxibustion on the pressure pain threshold and substance P / leukotriene B4 contents in serum to patients with rheumatoid arthritis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Moxibustion; Rheumatoid arthritis; Pressure pain threshold; Substance P; Leukotriene B4; Interleukin-1 beta; Tumor necrosis factor-alpha; Trial registration number; ChiCTR-IOR-17012282
ID american-college; b-4 receptors; neuropeptides; modulation; mechanisms; blt1; il-6
AB Objective: To observe the effects of moxibustion on pressure-pain thresholds (PPTs) in affected joints and non-joint areas, as well as the contents of substance P (SP) and leukotriene B4 (LTB4) in serum of patients with rheumatoid arthritis (RA), and to explore the analgesic mechanism of moxibustion in RA patients. Methods: A total of 72 patients with RA were randomly and equally classified into the control and treatment groups. The control group was treated with routine drug therapy, while the treatment group received routine drug therapy and moxibustion. Both groups were treated for 8 weeks. The symptoms, measured by PPTs, Visual analogue scale (VAS), pain joint count (PJC), swollen joint count (SJC) and disease activity score of 28 joints (DAS28), and laboratory indicators, measured by the level of SP, LTB4, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), were compared in the two groups before and after intervention. Results: A total of 66 patients completed the trial, with 1 patients dropping out from the treatment group and 5 patients being excluded and dropped from the control group. Trial endpoints were change (triangle) in symptoms and laboratory indicators. The treatment group showed superior in triangle PPTs of the interphalangeal joints(1301.71 (95 %CI, 967.43-1636.00) vs 443.23(95 %CI, 99.51-786.95)), triangle SP(10.11 (95 %CI, 5.85-14.37) vs 3.10 (95 %CI, -1.13-7.34)), triangle LTB4(13.17 (95 %CI, 7.81-18.54) vs 3.37 (95 %CI, -5.73-12.48)), triangle TNF-alpha(4.57 (95 %CI, 2.60-6.55) vs 0.68 (95 %CI, -1.03-2.40)), triangle IL-1 beta(4.63 (95 %CI, 2.59-6.66) vs 1.63 (95 %CI, -0.53-3.80)), triangle PJC(7.14 (95 %CI, 5.17-8.58) vs 1.84 (95 %CI, 0.66-3.02)), triangle SJC(5.20 (95 %CI, 3.44-6.96) vs 1.00(95 %CI, 0.02-1.98)), triangle VAS(3.6 (95 %CI, 2.99-4.21) vs 0.9 (95 %CI, 0.24-1.57)), and triangle DAS(1.68 (95 %CI, 1.44-1.92) vs 0.41 (95 %CI, 0.08-0.73)) compared to the control group, at weeks 4. Furthermore, there was a significant negative correlation between triangle PPTs of the interphalangeal joints and triangle SP in the treatment group (r < 0, P < 0.05). Conclusion: Moxibustion combined with conventional western medicine can significantly improve PPTs in affected joints of RA patients, alleviate clinical symptoms, and reduce disease activity. The potential mechanism may be related to the down-regulation of SP and LTB4 levels and the reduction of the release of inflammatory factors Il-1 beta and TNF-alpha by moxibustion. The lack of double-blinding is a limitation of our study, which we plan to avoid by establishing a sham moxibustion group in the subsequent trials.
C1 [Tao, Siyu; Yang, Yi; Tang, Jie; Wang, Xue; Jiang, Nannan; Wu, Ping] Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
   [Li, Yuan] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Chengdu 610075, Sichuan, Peoples R China.
   [Wu, Ping] 1166 Liutai Ave, Chengdu 610075, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Wu, P (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.; Wu, P (corresponding author), 1166 Liutai Ave, Chengdu 610075, Sichuan, Peoples R China.
EM wuping_33@163.com
FU National Natural Science Foundation of China [81373738]; Education Department of Sichuan Province [2017JY0016, 2022YFS0386]
CR Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461
   Altawil R, 2016, ARTHRIT CARE RES, V68, P1061, DOI 10.1002/acr.22790
   Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817
   Chen Y, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6436420
   Cortes-Burgos LA, 2009, EUR J PHARMACOL, V617, P59, DOI 10.1016/j.ejphar.2009.06.058
   Douglas SD, 2011, ANN NY ACAD SCI, V1217, P83, DOI 10.1111/j.1749-6632.2010.05826.x
   Barbosa-Cobos RE, 2018, CLIN RHEUMATOL, V37, P901, DOI 10.1007/s10067-017-3929-6
   Fraenkel L, 2021, ARTHRITIS RHEUMATOL, V73, P1108, DOI 10.1002/art.41752
   Gong YY, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/4705247
   Graven-Nielsen T, 2010, NAT REV RHEUMATOL, V6, P599, DOI 10.1038/nrrheum.2010.107
   Gursel T, 1997, PROSTAG LEUKOTR ESS, V56, P205, DOI 10.1016/S0952-3278(97)90535-4
   He YS, 2010, SHANGHAI J ACUPUNCT MOXIBUSTION, V29, P449
   Heisler AC, 2020, ARTHRIT CARE RES, V72, P1122, DOI 10.1002/acr.23994
   Hermans L, 2018, PAIN PRACT, V18, P418, DOI 10.1111/papr.12613
   Hu HF, 2013, LISHIZHEN MED MATER MED RES, V24, P677
   Karlson EW, 2012, RHEUM DIS CLIN N AM, V38, P405, DOI 10.1016/j.rdc.2012.04.002
   Kubanov AA, 2015, B EXP BIOL MED+, V159, P318, DOI 10.1007/s10517-015-2951-4
   Kuo HP, 2000, AM J RESP CRIT CARE, V162, P1891, DOI 10.1164/ajrccm.162.5.9911065
   Lee YC, 2011, ARTHRITIS RES THER, V13, P0, DOI 10.1186/ar3353
   Leonard AV, 2013, J NEUROTRAUM, V30, P1812, DOI 10.1089/neu.2013.2993
   Li KX, 2020, CLIN EXP RHEUMATOL, V38, P543
   Liao CX, 2023, J PAIN RES, V16, P1739, DOI 10.2147/JPR.S408814
   Lisowska B, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0139206
   Liu J, 2017, CHIN J TRADIT MED SCI TECHNOL, V24, P483
   Majumdar R, 2016, PLOS BIOL, V14, P0, DOI 10.1371/journal.pbio.1002336
   Mashaghi A, 2016, CELL MOL LIFE SCI, V73, P4249, DOI 10.1007/s00018-016-2293-z
   Mathis SP, 2010, J IMMUNOL, V185, P3049, DOI 10.4049/jimmunol.1001031
   MITCHELL DM, 1986, ARTHRITIS RHEUM-US, V29, P706, DOI 10.1002/art.1780290602
   OConnor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Okubo M, 2010, GLIA, V58, P599, DOI 10.1002/glia.20948
   PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P520, DOI 10.1016/0006-291X(89)92630-2
   Schratzberger P, 1997, J IMMUNOL, V158, P3895
   SCOTT DL, 1987, LANCET, V1, P1108
   Skovbjerg S, 2017, J PAIN, V18, P274, DOI 10.1016/j.jpain.2016.10.022
   Studenic P, 2012, ARTHRITIS RHEUM-US, V64, P2814, DOI 10.1002/art.34543
   Tao S, 2021, PAIN RES MANAG, V2021, P0, DOI 10.1155/2021/7466313
   Tavano F, 2012, J CROHNS COLITIS, V6, P563, DOI 10.1016/j.crohns.2011.11.004
   Terenzi R, 2013, ANN RHEUM DIS, V72, P1107, DOI 10.1136/annrheumdis-2012-202846
   Tsilioni I, 2016, J PHARMACOL EXP THER, V356, P664, DOI 10.1124/jpet.115.230060
   UDDMAN R, 1986, PAIN, V27, P391, DOI 10.1016/0304-3959(86)90162-4
   Wang NH, 2004, NEURAL INJ FUNCT RECONSTR, V03, P97
   Wang QQ, 2019, BMC GENOMICS, V20, P0, DOI 10.1186/s12864-019-5510-y
   Wang YN, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6637554
   Wasserman A, 2018, AM FAM PHYSICIAN, V97, P455
   Wolfe F, 2007, J RHEUMATOL, V34, P1674
   Wu Xiao, 2018, ZHONGGUO ZHEN JIU, V38, P1189, DOI 10.13703/j.0255-2930.2018.11.014
   Yao J, 2013, WORLD J ACUPUNCT-MOX, V23, P29, DOI 10.1016/S1003-5257(13)60040-9
   Yokomizo T, 2015, J BIOCHEM, V157, P65, DOI 10.1093/jb/mvu078
   Yu ZY, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7150605
   Zhong YM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6108619
   Zhong Yu-Mei, 2020, ZHONGGUO ZHEN JIU, V40, P976, DOI 10.13703/j.0255-2930.20190729-0002
NR 52
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD SEP 15
PY 2025
VL 92
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103187
EA MAY 2025
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3JL2P
UT WOS:001501799100001
PM 40436210
DA 2026-01-16
ER

PT J
AU Zhao, Q
   Zhang, J
   Shi, W
   Qian, X
   An, J
AF Zhao, Qiannan
   Zhang, Jianfeng
   Shi, Wanrui
   Qian, Xiaoyan
   An, Jianxiong
TI Different mechanisms of electroacupuncture and pregabalin in neuropathic
SO Neurological research
LA English
DT Journal Article
DE Neuropathic pain; electroacupuncture; morphology; pregabalin; structural changes
AB OBJECTIVES: Brachial plexus neuralgia (BPN) can result from injury, trauma, or  cancer, and it significantly impacts the patient's quality of life. This study  investigated electroacupuncture (EA) vs. pregabalin on the structural changes in  the peripheral nervous system (PNS) and central nervous system (CNS) in rats with  BPN. METHODS: Male Sprague-Dawley rats were randomized to the sham-operated  (Con), BPN (using cobra venom), BPN+EA (EA), and BPN+pregabalin (PGB) groups  (n = 8/group). EA or pregabalin was given from postoperative day (POD)14 to  POD35. Structural alterations were determined by transmission electron microscopy  in the primary sensory cortex, forelimb region (S1FL), anterior cingulate cortex  (ACC), hippocampus, thalamus, cervical, thoracic, and lumbar spinal cords on  POD40, and in the bilateral brachial plexus and dorsal root ganglions (DRG) at  the cervical, thoracic and lumbar levels. RESULTS: Compared with the CON group,  BPN rats exhibited significant changes in mechanical withdrawal threshold (MWT)  (p < 0.05). The MWT showed a significant increase compared with the BNP group  after EA or pregabalin (p < 0.05), but the long-term analgesic effects of EA  appeared superior to pregabalin (p < 0.05). Furthermore, EA alleviated myelin  sheath damage at the spinal cord levels. Damage, including demyelination, was  limited to the ipsilateral DRG at the corresponding segment and bilateral CNS.  CONCLUSION: Neuropathic pain-induced damage is limited to the ipsilateral DRG at  corresponding segment and bilateral CNS pain centers. EA and pregabalin each  partially attenuate neuropathic pain and alleviate neuronal damage in BPN, but EA  has a longer-term analgesic effect.
C1 Department of Anesthesiology, Pain and Sleep Medicine, Chinese Academy of Sciences, Aviation General Hospital of China Medical University and BeijingInstitute of Translational Medicine, Beijing, China.
   Department of Anesthesiology, Peking University People's Hospital, Beijing, China.
   Department of Ultrasound, Peking University Third Hospital, Beijing, China.
   Department of Anesthesiology, Pain and Sleep Medicine, Chinese Academy of Sciences, Aviation General Hospital of China Medical University and BeijingInstitute of Translational Medicine, Beijing, China.
   Department of Anesthesiology, Pain and Sleep Medicine, Chinese Academy of Sciences, Aviation General Hospital of China Medical University and BeijingInstitute of Translational Medicine, Beijing, China.
   School of Anesthesiology, Department of Pain Medicine, Affiliated Hospital of
NR 0
TC 0
SN 1743-132
EI 
J9 Neurol Res
PD JUN 11
PY 2025
VL 47
IS 12
BP 1139
EP 1152
DI 10.1080/01616412.2025.2515195
PG 13
WC Animals; Pregabalin; therapeutic use; Electroacupuncture; methods; Rats, Sprague-Dawley; Male; Disease Models, Animal; Neuralgia; therapy; Analgesics; therapeutic use; Rats; Brachial Plexus Neuropathies; therapy; Brachial Plexus; pathology; Ganglia, Spinal; ultrastructure; Spinal Cord; ultrastructure; Pain Threshold; drug effects; Microscopy, Electron, Transmission
UT PubMed:40494390
PM 40494390
DA 2025-06-11
ER

PT J
AU Yang, LH
   Li, SY
   Yang, Y
   Yang, SN
   Guo, HL
   Hu, MM
   Duan, PB
   Xia, C
AF Yang, Li-Hua
   Li, Si-Yu
   Yang, Ya
   Yang, Sheng-Nan
   Guo, Hai-Li
   Hu, Ming-Ming
   Duan, Pei-Bei
   Xia, Chao
TI Effectiveness of Acupressure in Managing the Pain-Fatigue-Sleep Disturbance-Depression Symptom Cluster in Patients with Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE symptom cluster; acupressure; systematic review; meta-analysis
ID auricular point acupressure; interventions; mechanisms; care
AB Objective: To assess the effectiveness of acupressure in addressing the symptom cluster of pain, fatigue, sleep disturbances, and depression (P-F-S-D) in patients with cancer through a systematic review.Methods: A comprehensive search was conducted across three English-language medical databases (PubMed, Embase, and the Cochrane Library) and two Chinese databases (China National Knowledge Infrastructure and Wanfang). Only randomized controlled trials (RCTs) examining the impact of acupressure on the P-F-S-D symptom cluster were included. Two reviewers independently screened studies, evaluated the risk of bias, and extracted relevant data in parallel. The risk of bias in eligible RCTs was appraised using the revised Cochrane Risk of Bias tool (RoB 2.0). Meta-analysis was performed using Stata software.Results: A total of 20 studies (reported in 21 articles) met the inclusion criteria and were classified as either having a low risk of bias or some concerns regarding bias. Meta-analysis revealed that acupressure achieved large-effect reductions in the P-F-S-D symptom cluster compared to both sham acupoint (endpoint standardized mean difference [SMD] = -0.84 [-1.05, -0.63], 4-week follow-up SMD = -0.87 [-1.35, -0.39]) and usual care groups (endpoint SMD = -0.68 [-0.83, -0.53], 4-week follow-up SMD = -0.60 [-0.87, -0.33]) (all p = 0.000). Initial high heterogeneity (I2 = 65.6%-67.1%) resolved after sensitivity analysis (I2 = 19.7%-35.2%), confirming result robustness. Subgroup analysis further revealed that acupressure significantly benefited various symptom combinations, including P-F-S-D, P-F-S, F-S-D, F-S, P-S, and P-F. No serious adverse events were reported.Conclusions: The findings of this study suggest that acupressure should be considered for patients with cancer experiencing the P-F-S-D symptom cluster. However, given the considerable heterogeneity, potential bias, and lack of systematic adverse event reporting in the included studies, further large-scale, multicenter, high-quality RCTs are necessary to better evaluate the effectiveness and safety of acupressure for multisymptom relief.
C1 [Yang, Li-Hua; Yang, Ya; Yang, Sheng-Nan; Guo, Hai-Li; Hu, Ming-Ming] Jiangsu Hlth Vocat Coll, Sch Hlth Wellness & Educ, Nanjing, Peoples R China.
   [Li, Si-Yu] Nanjing Univ Chinese Med, Sch Nursing, Nanjing, Peoples R China.
   [Duan, Pei-Bei; Xia, Chao] Jiangsu Prov Hosp Chinese Med, Dept Oncol, 155 Hanzhong Rd, Nanjing 210029, Jiangsu Provinc, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Xia, C (corresponding author), Jiangsu Prov Hosp Chinese Med, Dept Oncol, 155 Hanzhong Rd, Nanjing 210029, Jiangsu Provinc, Peoples R China.
EM lajiao797@sina.com
CR Arai YCP, 2008, ANESTH ANALG, V107, P661, DOI 10.1213/ane.0b013e31817b8495
   Turan GB, 2023, CANCER NURS, V46, P457, DOI 10.1097/NCC.0000000000001193
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Dogan MD, 2024, INDIAN J PALLIAT CAR, V30, P10, DOI 10.25259/IJPC_95_2023
   Doong SH, 2015, BIOL RES NURS, V17, P237, DOI 10.1177/1099800414550394
   [费超男 Fei Chaonan], 2023, 护理学杂志 JOURNAL OF NURSING SCIENCE, V38, P65
   Goetze H, 2020, SUPPORT CARE CANCER, V28, P211, DOI 10.1007/s00520-019-04805-1
   He C, 2022, CHIN GEN PRACT, V19, P2414, DOI 10.11124/JBISRIR-2016-2476
   He CC, 2022, J GANNAN MED U, V42, P1193, DOI 10.3969/j.issn.1001-5779.2022.11.012
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   Ji YB, 2017, J PAIN SYMPTOM MANAG, V54, P843, DOI 10.1016/j.jpainsymman.2017.05.003
   [金艾香 Jin Aixiang], 2021, 中国护理管理 CHINESE NURSING MANAGEMENT, V21, P1510
   Kelly DL, 2016, SEMIN ONCOL NURS, V32, P351, DOI 10.1016/j.soncn.2016.08.002
   Kim HJ, 2012, CANCER NURS, V35, PE1, DOI 10.1097/NCC.0b013e318233a811
   Kim HJ, 2005, CANCER NURS, V28, P270
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Lee SN, 2021, COMPLEMENT THER CLIN, V44, P0, DOI 10.1016/j.ctcp.2021.101447
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li HJ, 2020, BIOL RES NURS, V22, P277, DOI 10.1177/1099800419899727
   Li LJ, 2020, CHIN MOD DOCT, V58, P92
   Li MY, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102380
   Li W, 2024, W J TRAD CHIN MED, V37, P143, DOI 10.12174/j.issn.2096-9600.2024.07.34
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Liu FY, 2020, CHIN MOD DOCT, V58, P129
   Liu QX, 2022, EUR J ONCOL NURS, V61, P0, DOI 10.1016/j.ejon.2022.102219
   Lu P, 2024, INT IMMUNOPHARMACOL, V127, P0, DOI 10.1016/j.intimp.2023.111415
   Matzka M, 2018, SUPPORT CARE CANCER, V26, P2685, DOI 10.1007/s00520-018-4102-8
   Miladinia M, 2017, CANCER NURS, V40, P31, DOI 10.1097/NCC.0000000000000353
   Miller AH, 2008, J CLIN ONCOL, V26, P971, DOI 10.1200/JCO.2007.10.7805
   Mohammed MA, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-010035
   Qing Peng, 2020, ZHONGGUO ZHEN JIU, V40, P505, DOI 10.13703/j.0255-2930.20190423-k0002
   Reyes-Gibby CC, 2013, SUPPORT CARE CANCER, V21, P3117, DOI 10.1007/s00520-013-1885-5
   Rha SY, 2021, J PAIN SYMPTOM MANAG, V61, P544, DOI 10.1016/j.jpainsymman.2020.08.008
   Salvetti MD, 2022, REV ESC ENFERM USP, V56, P0, DOI 10.1590/1980-220X-REEUSP-2021-0452en
   Santillan-Garcia A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419827087
   Sheikh-Wu SF, 2020, ONCOL NURS FORUM, V47, PE107, DOI 10.1188/20.ONF.E107-E119
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   So WKW, 2020, CANCER NURS, V43, PE304, DOI 10.1097/NCC.0000000000000730
   Tan JY, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph191911934
   Thong MSY, 2020, CURR TREAT OPTION ON, V21, P0, DOI 10.1007/s11864-020-0707-5
   Trentini JF III, 2005, AM J CHINESE MED, V33, P143, DOI 10.1142/S0192415X05002746
   Utli H, 2023, EXPLORE-NY, V19, P91, DOI 10.1016/j.explore.2022.11.007
   Wang CX, 2017, CHIN GEN PRACT NURS, V15, P1194, DOI 10.3969/J.ISSN.1674-4748.2017.10.015
   Wang FQ, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.1036634
   Wang XH, 2020, INTERVENTION STUDY A, V0, P0
   Wang YY, 2020, EFFECT AURICULAR POI, V0, P0
   Weaver M T, 1985, NURSE PRACT, V10, P38
   Wong WM, 2023, CANCER NURS, V46, PE70, DOI 10.1097/NCC.0000000000001048
   Wyatt G, 2015, SUPPORT CARE CANCER, V23, P3183, DOI 10.1007/s00520-015-2698-5
   Xie WX, 2023, INT J NURS STUD, V145, P0, DOI 10.1016/j.ijnurstu.2023.104531
   Yan JL, 2021, STUDY ON THE EFFECT OF ACUPOINT MASSAGE ON MILD TO MODERATE PAIN IN CANCER PATIENTS BASED ON HOLOGRAPHIC THEORY IN CHINESE, V0, P0
   Ye YX, 2025, CANCER NURS, V48, P352, DOI 10.1097/NCC.0000000000001316
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zhang B, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000007750
   Zhang CG, 2022, CHIN MOD DOCT, V60, P136
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 62
TC 0
Z9 0
U1 4
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD OCT 1
PY 2025
VL 31
IS 10
BP 860
EP 875
DI 10.1089/jicm.2024.0914
EA JUN 2025
PG 16
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 8SI4O
UT WOS:001516977700001
PM 40569723
DA 2026-01-16
ER

PT J
AU Zhang, D
   Zhao, X
   Li, H
   Chen, W
   Liu, C
AF Zhang, Dongxu
   Zhao, Xinhua
   Li, Hongping
   Chen, Wen
   Liu, Cunzhi
TI Effect of eight different acupuncture and moxibustion therapies on breast
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture and moxibustion therapies; Arm circumference; Breast cancer-related lymphedema; Network meta-analysis; Pain
AB BACKGROUND: Breast cancer is the most prevalent cancer worldwide, and nearly 30%  of affected patients experience breast cancer-related lymphedema (BCRL). Some  evidence suggests that acupuncture and moxibustion therapies are safe and  effective in the treatment of BCRL. Nevertheless, there is controversy regarding  the optimal acupuncture and moxibustion therapy for BCRL. OBJECTIVE: The aim of  this study was to compare and rank the efficacy of different acupuncture and  moxibustion therapies for BCRL, to identify the best acupuncture and moxibustion  therapy for BCRL, and to provide a reference for clinicians to choose the  treatment modality. METHODS: We searched PubMed, Embase, Cochrane Library, Web of  Science, Google Scholar, China National Knowledge Infrastructure, CQVIP, Wanfang  Data, and SINOMED Databases for randomized controlled trials (RCTs) of  acupuncture and moxibustion therapy for BCRL from inception to March 30, 2023.  The quality of the included literature was assessed using the Cochrane risk of  bias assessment, and data were analyzed and plotted using R4.3.2 and Stata 15.1  software. RESULTS: We included 27 RCTs including 8 acupuncture interventions with  a sample size of 1976 cases. The results of the network meta-analysis showed that  acupuncture + moxibustion, moxibustion, blood-letting puncture and cupping, and  electroacupuncture combined with conventional rehabilitation were superior to  conventional rehabilitation alone in reducing arm circumference. Moxibustion  combined with conventional rehabilitation was superior to conventional  rehabilitation alone in reducing the degree of edema. Electroacupuncture and  acupoint massage combined with conventional rehabilitation were superior to  conventional rehabilitation alone in reducing the visual analogue scale (VAS)  scores. And in terms of improving the mobility of the shoulder joint, moxibustion  and electroacupuncture combined with conventional rehabilitation were better than  conventional rehabilitation alone. CONCLUSION: The combination of acupuncture and  moxibustion therapy with conventional rehabilitation can improve the efficacy of  BCRL. Acupuncture + moxibustion was the best treatment modality to reduce arm  circumference, acupuncture was the best modality to reduce edema, and  electroacupuncture was the most effective modality for relieving BCRL pain  symptoms and was the best choice to improve abduction range of motion (ROM). Due  to the limitations of this study, this conclusion remains to be validated by  further high-quality clinical studies.
C1 Beijing University of Chinese Medicine, Beijing, China.
   Tumor Center, Beijing Anorectal Hospital, Beijing, China.
   Beijing University of Chinese Medicine, Beijing, China.
   Beijing University of Chinese Medicine, Beijing, China.
   Beijing University of Chinese Medicine, Beijing, China. lcz623780@126.com.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD SEP 13
PY 2025
VL 33
IS 10
BP 850
EP 850
DI 10.1007/s00520-025-09861-4
PG 0
WC Female; Humans; Acupuncture Therapy; methods; Bayes Theorem; Breast Cancer Lymphedema; therapy; Breast Neoplasms; complications; Moxibustion; methods; Randomized Controlled Trials as Topic
UT PubMed:40944772
PM 40944772
DA 2025-09-13
ER

PT J
AU Arias, F
   Zarandona, U
   Ibáñez-Beróiz, B
   Ibáñez, R
   Campo, M
   Cacicedo, J
   García-Rueda, N
   Baztán, B
   Villanueva, R
   Fresán, M
   Redín, I
   Osés, AT
   Hurtado, V
   Villafranca, I
   Iancu, V
   Almeida, P
   Moreno, N
   Cadena, S
   Carruesco, I
   Allegue, M
   González, AB
AF Arias, Fernando
   Zarandona, Uxue
   Ibanez-Beroiz, Berta
   Ibanez, Reyes
   Campo, Maider
   Cacicedo, Jon
   Garcia-Rueda, Noelia
   Baztan, Beatriz
   Villanueva, Raquel
   Fresan, Marta
   Redin, Inaki
   Oses, Ana T.
   Hurtado, Victoria
   Villafranca, Ines
   Iancu, Vasti
   Almeida, Pilar
   Moreno, Nieves
   Cadena, Soraya
   Carruesco, Irene
   Allegue, Marian
   Gonzalez, Ana B.
TI Prevalence and characterization of pain in radiation oncology: the PREDORT multicenter cross-sectional study
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Pain and radiotherapy services; Oncologic pain; Pain prevalence
ID cancer-treatment; radiotherapy; interference; moderate; mild
AB Background Pain in cancer patients has enormous impact on their quality-of-life. Radiation therapy (RT) is a cornerstone in cancer treatment. The objective of the PREDORT study is to estimate the prevalence of pain in patients attending at Radiation Oncology (RO) Services. Methods A prospective, multicenter study was designed for patients treated at the RO Services of reference hospitals. Patients were seen in their initial Nursing consultation, during which key data was collected, including demographic and comorbidities data, medical history, and oncological and pain characteristics. The study has received approval from the Ethics Committee of Navarra, and all patients signed the Informed Consent. Results Of the 860 participating patients, 306 reported some type of pain, which implies a prevalence of 35.6%. Of them, 213 identified a cause of oncological origin. The proportion of pain was similar among sexes, but the proportion of non-cancer pain was higher among women (p < 0.05). Regarding pain intensity, the magnitude of breakthrough pain in patients with oncological pain is nearly 1 point greater than in patients with non-oncological pain (7.53 vs 6.81; p = 0.064). Cancer pain is more likely to be limiting of normal life than non-cancer pain (59% versus 38%, p < 0.001). Regarding analgesic treatment, only 60/306 patients (19.6%) were receiving strong opioids. There were 68 patients with pain without any treatment (22.2%). Conclusions The prevalence of pain in cancer patients referred to RO services is 35.6%, with the prevalence of exclusively oncological pain being 24.8%. Understanding and addressing oncological pain is essential to provide comprehensive care to patients.
C1 [Arias, Fernando; Zarandona, Uxue; Garcia-Rueda, Noelia; Baztan, Beatriz; Villanueva, Raquel; Fresan, Marta; Redin, Inaki; Oses, Ana T.; Hurtado, Victoria; Villafranca, Ines; Iancu, Vasti; Almeida, Pilar; Moreno, Nieves] Univ Hosp Navarre, Radiat Oncol Dept, Irunlarrea 3, Pamplona, Spain.
   [Ibanez-Beroiz, Berta; Ibanez, Reyes] Univ Hosp Miguel Servet, Zaragoza, Spain.
   [Campo, Maider; Cadena, Soraya; Carruesco, Irene] Univ Hosp Alava, Vitoria, Spain.
   [Cacicedo, Jon; Allegue, Marian; Gonzalez, Ana B.] Univ Hosp Cruces, Bilbao, Spain.
C3 Servicio Navarro de Salud - Osasunbidea; Miguel Servet University Hospital; Hospital Universitario Cruces
RP Arias, F (corresponding author), Univ Hosp Navarre, Radiat Oncol Dept, Irunlarrea 3, Pamplona, Spain.
EM farias.delavega@outlook.es
FU Fundacin Grnenthal Espaa
CR Ahmed Y, 2017, ANN PALLIAT MED, V6, PS177, DOI 10.21037/apm.2017.08.09
   Amini Arya, 2021, CANCER TREAT RES, V182, P145, DOI 10.1007/978-3-030-81526-4_10
   Unknown -, 1996, CANC PAIN REL GUID O, V0, P0
   Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007
   Boveldt NT, 2013, PAIN PHYSICIAN, V16, P379
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Dolinsky Christopher, 2006, ANESTHESIOL CLIN, V24, P113, DOI 10.1016/j.atc.2005.11.002
   Gómez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9
   Hunter RD, 2004, RADIOTHER ONCOL, V70, P117, DOI 10.1016/j.radonc.2003.12.005
   Jamora Kurl E, 2022, ECANCERMEDICALSCIENCE, V16, P1483, DOI 10.3332/ecancer.2022.1483
   Jiang CC, 2019, JAMA ONCOL, V5, P1224, DOI 10.1001/jamaoncol.2019.1439
   Kapoor R, 2021, MED ONCOL, V38, P0, DOI 10.1007/s12032-021-01587-7
   Karri J, 2021, ADV THER, V38, P1425, DOI 10.1007/s12325-021-01640-x
   Mañas A, 2011, INT J RADIAT ONCOL, V81, P511, DOI 10.1016/j.ijrobp.2010.05.047
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Oldenburger E, 2022, RADIOTHER ONCOL, V173, P240, DOI 10.1016/j.radonc.2022.06.002
   Paice JA, 2023, J CLIN ONCOL, V41, P914, DOI 10.1200/JCO.22.02198
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Shi QL, 2017, PAIN, V158, P1108, DOI 10.1097/j.pain.0000000000000890
   Skarf LM, 2023, SEMIN RADIAT ONCOL, V33, P93, DOI 10.1016/j.semradonc.2023.01.002
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Valeberg BT, 2008, EUR J PAIN, V12, P582, DOI 10.1016/j.ejpain.2007.09.004
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Woo A, 2015, ANN PALLIAT MED, V4, P176, DOI 10.3978/j.issn.2224-5820.2015.09.04
   Wu JSY, 2010, J PAIN SYMPTOM MANAG, V39, P230, DOI 10.1016/j.jpainsymman.2009.07.006
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD FEB 15
PY 2025
VL 27
IS 2
BP 778
EP 784
DI 10.1007/s12094-024-03603-4
EA JUL 2024
PG 7
WC Oncology
SC Oncology
GA U2G5S
UT WOS:001283205100003
PM 39078470
DA 2026-01-16
ER

PT J
AU Masuyama, S
   Yamashita, H
   Amino, T
   Kawamoto, R
   Tsuji, R
   Nakanishi, H
   Yoshida, H
AF Masuyama, Shoko
   Yamashita, Hitoshi
   Amino, Tamami
   Kawamoto, Ryouko
   Tsuji, Ryota
   Nakanishi, Hiromoto
   Yoshida, Hiroshi
TI Acupuncture for patients with Cancer in a Japanese palliative care team: A
SO Integrative medicine research
LA English
DT Journal Article
DE Acupuncture; Cancer patient; Case series; Japan; Palliative care
AB BACKGROUND: The joint guidelines of the Society for Integrative Oncology and the  American Society of Clinical Oncology recommend acupuncture for pain symptoms in  some patients with cancer. This study assessed whether adding acupuncture to  usual palliative care alleviates the subjective symptoms of hospitalized patients  with cancer in Japan, at least in the short term. METHODS: Between 2015 and 2019,  we conducted a prospective case series study at a regional core hospital in  Osaka. Acupuncture was included in the usual care of patients with cancer. The  primary outcome was immediate changes in each patient's subjective symptoms  measured by a 10 cm visual analog scale (VAS). A 20 % reduction in VAS was set as  the minimal clinically important difference (MCID). RESULTS: A total of 83 cancer  patients (mean age: 66.1) were treated with acupuncture. A significant reduction  was observed in the VAS scores for pain, edema, nausea, neck/shoulder/back  stiffness, and breathlessness during at least one treatment session. The  percentage of patients that improved beyond the MCID was as follows: 67 % for  pain, 75 % for edema, 60 % for paresthesia, 80 % for nausea, 88 % for stiffness,  38 % for malaise, and 83 % for breathlessness, based on the maximum improvement  recorded per session. CONCLUSION: Japanese-style acupuncture, with relatively  finer needles and gentler stimulation, has shown promise as a palliative  treatment for patients with cancer, potentially offering temporary relief from  pain, edema, nausea, stiffness, and breathlessness. Based on our findings, a  pragmatic randomized controlled trial with an appropriate control group is  recommended.
C1 Graduate School of Health Sciences, Morinomiya University of Medical Sciences, Osaka, Japan.
   Department of Acupuncture, Morinomiya University of Medical Sciences, Osaka, 
   Graduate School of Health Sciences, Morinomiya University of Medical Sciences, Osaka, Japan.
   Department of Acupuncture, Morinomiya University of Medical Sciences, Osaka, 
   Osaka General Medical Center, Osaka, Japan.
   Osaka General Medical Center, Osaka, Japan.
   Department of Acupuncture, Morinomiya University of Medical Sciences, Osaka, Japan.
   Department of Acupuncture, Morinomiya University of Medical Sciences, Osaka, Japan.
   Osaka General Medical Center, Osaka, Japan.
NR 0
TC 0
SN 2213-423
EI 2213-422
J9 Integr Med Res
PD SEP 11
PY 2025
VL 15
IS 1
BP 101212
EP 101212
DI 10.1016/j.imr.2025.101212
PG 0
UT PubMed:40933787
PM 40933787
DA 2025-09-11
ER

PT J
AU Shi, HX
   Gao, YJ
   Wang, SR
AF Shi, Hao-Xin
   Gao, Yu-Jun
   Wang, Shu-Ren
TI Electroacupuncture in non-surgical management of lumbar spinal stenosis: mechanistic potential in attenuating ligamentum flavum thickening via inflammatory factor modulation
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE lumbar spinal stenosis; ligamentum flavum thickening; electroacupuncture; inflammation; signal pathway
ID b signaling pathway; low-back-pain; macrophage polarization; canal stenosis; acupuncture; hypertrophy; rat; pathomechanism; fibrosis; injury
AB Lumbar Spinal Stenosis (LSS) is a prevalent spinal disorder mainly induced by degenerative changes in the spine, which lead to nerve root compression. This results in symptoms such as lower back pain, numbness of the lower limbs, and difficulty in walking. The thickening of the ligamentum flavum (LF) is a crucial pathological feature of LSS and is closely linked to inflammatory responses. Electroacupuncture (EA), a form of traditional Chinese medical therapy, has garnered increasing recognition in modern medicine in recent years. It has shown notable efficacy in alleviating pain and enhancing function. EA achieves these effects by modulating inflammatory cytokines, reducing pro-inflammatory markers such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1le, and interleukin-6 (IL-6), while increasing anti-inflammatory cytokines like interleukin-10 (IL-10). Additionally, EA may inhibit LF thickening by suppressing signaling pathways, specifically the nuclear factor-kappa B (NF-kappa B) pathway, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, and the mitogen-activated protein kinase (MAPK) pathway. Clinical studies indicate that when EA is combined with other treatment modalities, it can significantly reduce pain and improve functional status in patients with LSS, thus enhancing their quality of life. Although the mechanisms underlying the effects of EA in the treatment of LSS warrant further exploration, its ability to regulate inflammatory responses through multiple pathways and promote tissue repair provides new perspectives and directions for the non-surgical management of LSS. This review encapsulates the application of EA in LSS and explores its potential mechanisms in mitigating LF thickening through the modulation of inflammatory cytokines. The aim is to offer a reference for future research and clinical practice.
C1 [Shi, Hao-Xin; Gao, Yu-Jun] Heilongjiang Univ Chinese Med, Grad Sch, Harbin, Peoples R China.
   [Wang, Shu-Ren] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Tradit Orthoped Therapy, Harbin, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine
RP Wang, SR (corresponding author), Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Tradit Orthoped Therapy, Harbin, Peoples R China.
EM wsr696969@126.com
CR Altun I, 2017, ASIAN SPINE J, V11, P71, DOI 10.4184/asj.2017.11.1.71
   Burt KG, 2023, JOR SPINE, V6, P0, DOI 10.1002/jsp2.1260
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Chang Q, 2021, BRAIN RES BULL, V170, P199, DOI 10.1016/j.brainresbull.2021.02.015
   Chu ECP, 2021, J FAM MED PRIM CARE, V10, P2757, DOI 10.4103/jfmpc.jfmpc_360_21
   Chu ECP, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.40941
   Chuang HC, 2020, AGING-US, V12, P24168, DOI 10.18632/aging.104105
   Cunha C, 2018, ARTHRITIS RES THER, V20, P0, DOI 10.1186/s13075-018-1743-4
   Du WB, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8138017
   Fang JQ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-285
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Genevay S, 2010, BEST PRACT RES CL RH, V24, P253, DOI 10.1016/j.berh.2009.11.001
   Hu R, 2025, INT J SURG, V111, P1526, DOI 10.1097/JS9.0000000000001979
   Huang ZH, 2019, ACUPUNCT MED, V37, P292, DOI 10.1136/acupmed-2017-011593
   Inoue M, 2008, EVID-BASED COMPL ALT, V5, P133, DOI 10.1093/ecam/nem050
   Inoue M, 2012, ACUPUNCT MED, V30, P103, DOI 10.1136/acupmed-2011-010122
   Jensen RK, 2020, EUR SPINE J, V29, P2143, DOI 10.1007/s00586-020-06339-1
   Jia LL, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/9187406
   Jia X, 2015, GUANGMING J CHIN MED, V30, P317, DOI 10.3969/j.issn.1003-8914.2015.02.050
   Jiang DX, 2015, NEURAL REGEN RES, V10, P237, DOI 10.4103/1673-5374.152377
   Jin Y, 2021, ACUPUNCT MED, V39, P708, DOI 10.1177/09645284211020766
   Katz JN, 2022, JAMA-J AM MED ASSOC, V327, P1688, DOI 10.1001/jama.2022.5921
   Kim H, 2022, BIOMED PHARMACOTHER, V156, P0, DOI 10.1016/j.biopha.2022.113776
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, P0, DOI 10.1101/cshperspect.a001651
   Lee JH, 2023, J PAIN RES, V16, P659, DOI 10.2147/JPR.S399132
   Lee WT, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.52957
   Li BW, 2021, COMPLEMENT MED RES, V28, P169, DOI 10.1159/000509336
   Liu R, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8163052
   Ma QH, 2025, FRONT IMMUNOL, V16, P0, DOI 10.3389/fimmu.2025.1541577
   Moon HJ, 2012, SPINE, V37, PE147, DOI 10.1097/BRS.0b013e3182269b19
   Nakamura T, 2015, EUR SPINE J, V24, P2001, DOI 10.1007/s00586-015-3835-z
   Park JO, 2013, J SPINAL DISORD TECH, V26, PE6, DOI 10.1097/BSD.0b013e3182698501
   Peiwei X, 2022, ASIA-PACIFIC TRADITIONAL MED, V18, P117, DOI 10.11954/ytctyy.202208022
   Sairyo K, 2005, SPINE, V30, P2649, DOI 10.1097/01.brs.0000188117.77657.ee
   Sairyo K, 2007, SPINE, V32, PE340, DOI 10.1097/01.brs.0000263407.25009.6e
   Shrikhande AA, 2011, MED ACUPUNCT, V23, P187, DOI 10.1089/acu.2011.0819
   Shu Q, 2016, WORLD J ACUPUNCT-MOX, V26, P63, DOI 10.1016/S1003-5257(17)30013-2
   Sidon E, 2019, J CELL BIOCHEM, V120, P11716, DOI 10.1002/jcb.28451
   Silwal P, 2024, BIOMOLECULES, V14, P0, DOI 10.3390/biom14101277
   Song SN, 2019, MOL IMMUNOL, V106, P143, DOI 10.1016/j.molimm.2018.12.023
   Sugimoto K, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0200872
   Toroski M, 2018, J ACUPUNCT MERIDIAN, V11, P62, DOI 10.1016/j.jams.2018.01.003
   Wang HF, 2021, BIOMED PHARMACOTHER, V140, P0, DOI 10.1016/j.biopha.2021.111655
   Wang M, 2025, INT IMMUNOPHARMACOL, V148, P0, DOI 10.1016/j.intimp.2025.114114
   Wang Y, 2021, ACUPUNCT MED, V39, P358, DOI 10.1177/0964528420938376
   Wang Y, 2019, J PAIN RES, V12, P1947, DOI 10.2147/JPR.S203867
   Wang ZG, 2017, INFLAMMATION, V40, P422, DOI 10.1007/s10753-016-0487-z
   Watanabe K, 2007, EUR SPINE J, V16, P1913, DOI 10.1007/s00586-007-0394-y
   Wei GJ, 2024, PEERJ, V12, P0, DOI 10.7717/peerj.17722
   Wei TH, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21134693
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
   Wu LK, 2021, BMC MUSCULOSKEL DIS, V22, P0, DOI 10.1186/s12891-021-04712-9
   Xia YY, 2019, J PAIN RES, V12, P2851, DOI 10.2147/JPR.S220201
   Xia YY, 2024, ACUPUNCT MED, V42, P275, DOI 10.1177/09645284241279874
   Xin P, 2020, INT IMMUNOPHARMACOL, V80, P0, DOI 10.1016/j.intimp.2020.106210
   Yan MY, 2019, EUR SURG RES, V60, P196, DOI 10.1159/000503130
   Yan S, 2024, ACUPUNCT MED, V0, P0, DOI DOI 10.1177/09645284241248465
   Young I, 2024, SPINE J, V24, P590, DOI 10.1016/j.spinee.2023.12.002
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, P0, DOI 10.1038/s41392-020-00312-6
   Yu ML, 2020, INFLAMMATION, V43, P1233, DOI 10.1007/s10753-020-01203-2
   Yu WL, 2023, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1086195
   Zhang QX, 2023, MOL PAIN, V19, P0, DOI 10.1177/17448069231202882
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang RX, 2005, J ALTERN COMPLEM MED, V11, P135, DOI 10.1089/acm.2005.11.135
   Zhu JJ, 2021, ANAT REC, V304, P2365, DOI 10.1002/ar.24625
NR 65
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
EI 
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 30
PY 2025
VL 16
IS 
BP 
EP 
DI 10.3389/fimmu.2025.1644394
PG 13
WC Immunology
SC Immunology
GA 9RK7M
UT WOS:001613242900001
PM 41246317
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Biron-Shental, T
   Rosa, WE
   Samuels, N
   Levy, O
   Keshet, Y
   Armon, S
   Gressel, O
   Kedar, R
   Messinger, A
   Lev, Ari R
   Lavie, A
   Atzil, N
   Ben, Zohar B
   Ferrer, Sokolovski C
   Solt, I
   Yaffe, H
   Shechter, Maor G
   Levy, M
   Maor-Sagie, E
   Katz, Shtern D
   Stoffman, G
   Ben, Ze'ev R
   Lahav, Sher M
   Zidenberg, B
   Sagi, S
   Schiff, E
AF Ben-Arye, Eran
   Biron-Shental, Tal
   Rosa, William E
   Samuels, Noah
   Levy, Oz
   Keshet, Yael
   Armon, Shunit
   Gressel, Orit
   Kedar, Reuven
   Messinger, Aviv
   Lev Ari, Revital
   Lavie, Anat
   Atzil, Neta
   Ben Zohar, Bosmat
   Ferrer Sokolovski, Cara
   Solt, Ido
   Yaffe, Hila
   Shechter Maor, Gil
   Levy, Moti
   Maor-Sagie, Esther
   Katz Shtern, Danit
   Stoffman, Gali
   Ben Ze'ev, Reut
   Lahav Sher, Maayan
   Zidenberg, Betty
   Sagi, Shlomi
   Schiff, Elad
TI Acupuncture in obstetrics: delivery room integrative medicine for anxiety and
SO BMJ supportive & palliative care
LA English
DT Journal Article
DE Complementary therapy; Integrative Medicine
AB OBJECTIVES: Supportive and palliative care include non-oncology settings where  patients suffer from pain and quality of life-related concerns. Integrative  medicine plays important roles in supportive care and symptom management,  including Integrative Obstetric (IOb) programmes within peri-partum settings.  Multidisciplinary approaches may help nurse-midwives and obstetricians improve  patient care and associated outcomes. This study presents a national perspective  on IOb programmes in Israel. METHODS: A qualitative research methodology was  codesigned by the Society for Complementary Medicine and Society of  Maternal-Fetal Medicine, Israel Medical Association. A questionnaire with 17  open-ended questions was distributed throughout obstetrics and gynaecology  departments across Israel. Respondent narratives were qualitatively analysed  using ATLAS.Ti software for systematic coding. RESULTS: 22 senior obstetricians  and IOb directors across 11 centres with IOb programmes completed the  questionnaire. Core themes considered essential for the design and operation of  IOb programmes included (1) determining major goals and indications for referral,  primarily pain and anxiety; (2) targeting patients most likely to benefit; (3)  identifying barriers and enablers to implementation and communication with the  obstetric team; (4) designing the referral process and (5) documenting outcomes  and safety of the IOb intervention in electronic medical files. CONCLUSIONS:  Designing and implementing IOb models of care that effectively support holistic  symptom management within obstetric settings requires identifying barriers and  enablers and establishing effective communication between obstetric and  integrative medical teams. Further research should explore other  multidisciplinary models of IOb care and structured referral development and  testing while assessing risks and effectiveness.
C1 Integrative Oncology Program, Oncology Service, LIN Medical Center, Haifa, Haifa District, Israel eranben@netvision.net.il.
   Meir Medical Center, Kefar Sava, Center District, Israel.
   Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
   Shaare Zedek Medical Center, Jerusalem, Jerusalem District, Israel.
   Western Galilee College, Acre, North District, Israel.
   Shaare Zedek Medical Center, Jerusalem, Jerusalem District, Israel.
   Integrative Obstetric Program, Carmel Medical Center, Haifa, Israel.
   Carmel Medical Center, Haifa, Israel.
   Sheba Medical Center, Tel HaShomer, Tel Aviv District, Israel.
   Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel.
   Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel.
   Hadassah Mount Scopus University Hospital, Jerusalem, Israel.
   Hadassah Mount Scopus University Hospital, Jerusalem, Israel.
   Rambam Health Care Campus, Haifa, Israel.
   Rambam Health Care Campus, Haifa, Israel.
   Hadassah University Medical Center Division of Obstetrics and Gynecology, Jerusalem, Israel.
   Meir Medical Center, Kefar Sava, Center District, Israel.
   Clalit Health Services, Tel Aviv-Yafo, Israel.
   Hillel Yaffe Medical Center, Hadera, Israel.
   Hillel Yaffe Medical Center, Hadera, Israel.
   Barzilai University Medical Center, Ashkelon, Israel.
   Barzilai Medical Center, Ashkelon, Israel.
   Carmel Medical Center, Haifa, Israel.
   Bnai Zion Medical Center, Haifa, Israel.
   Bnai Zion Medical Center, Haifa, Israel.
   Department of Internal Medicine, Bnai-Zion Hospital, Haifa, Israel.
NR 0
TC 0
SN 2045-436
EI 2045-435
J9 BMJ Support Palliat Care
PD APR 17
PY 2025
VL 15
IS 4
BP 535
EP 541
DI 10.1136/spcare-2025-005512
PG 6
WC Humans; Female; Pregnancy; Integrative Medicine; methods; Pain Management; methods; Anxiety; therapy; Israel; Acupuncture Therapy; methods; Qualitative Research; Obstetrics; methods; Surveys and Questionnaires
UT PubMed:40240122
PM 40240122
DA 2025-04-17
ER

PT J
AU Jia, RN
   Tu, JF
AF Jia, Ru-Nan
   Tu, Jian-Fei
TI Integrative Application of Traditional Chinese Medicine in Interventional Oncology: A Comprehensive Review
SO BRATISLAVA MEDICAL JOURNAL
LA English
DT Review
DE Acupuncture therapy; Bloodletting acupuncture therapy; Chinese medicine; Intradermal traditional Chinese medicine packaging; Interventional oncology; Wrist ankle acupuncture
ID cancer; radiology
AB The incidence and mortality associated with malignant tumors in China remain substantial, underscoring the critical need for effective strategies to improve quality of life and prolong survival among individuals diagnosed with cancer. Recent national healthcare policies have emphasized the importance of preserving, advancing, and incorporating traditional Chinese medicine (TCM) into clinical practice. Interventional oncology remains a cornerstone in the treatment of intermediate to advanced-stage malignancies; however, it is frequently associated with adverse drug reactions and procedure-related complications, including postoperative fever, nausea, vomiting, pain, and hepatotoxicity or nephrotoxicity. This review evaluates current evidence regarding the adjunctive application of TCM in the context of interventional oncology. Findings suggest that such integrative strategies may mitigate postoperative complications, support physiological recovery, and enhance overall well-being in patients undergoing cancer therapy. The incorporation of TCM into contemporary oncological interventions represents a potentially beneficial strategy for optimizing supportive care in cancer management.Clinical trial number Not applicable.
C1 [Jia, Ru-Nan; Tu, Jian-Fei] Lishui Cent Hosp, Dept Canc Ctr, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
RP Tu, JF (corresponding author), Lishui Cent Hosp, Dept Canc Ctr, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
EM tujianfeitjf@126.com
FU National Health Commission; Zhejiang Provincial Medicine and Health Major Science and Technology Programme Key Projects [WKJ-ZJ-1932]
CR Adel Nelly, 2017, AM J MANAG CARE, V23, P0
   Arnold MJ, 2019, AM FAM PHYSICIAN, V99, P547
   Cao XJ, 2016, CHINESE ARCH TRADITI, V34, P69
   Chapman EJ, 2020, PALLIATIVE MED, V34, P444, DOI 10.1177/0269216319896955
   Chen LT, 2020, ANN ONCOL, V31, P334, DOI 10.1016/j.annonc.2019.12.001
   Chen YL, 2017, CHIN ACUPUNCT MOXIB, V6, P76
   [崔倩倩 Cui Qianqian], 2024, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V43, P59
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gu KB, 2013, WORLD J INTEGRATED T, V8, P187
   [郭太品 Guo Taipin], 2017, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V23, P1126
   He Xin-Lu, 2023, ZHEN CI YAN JIU, V48, P764, DOI 10.13702/j.1000-0607.20230187
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Heckroth M, 2021, J CLIN GASTROENTEROL, V55, P279, DOI 10.1097/MCG.0000000000001485
   Hu JQ, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017109
   Jahn F, 2022, DTSCH ARZTEBL INT, V119, P382, DOI 10.3238/arztebl.m2022.0093
   Ji YL, 2022, CLIN RES TRADIT CHIN, V14, P97
   Jiang G, 2013, J XIAN JIAOTONG U ME, V34, P669
   Li QW, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-1927-2
   Li X, 2006, WORLD CHIN J DIG, V14, P1963, DOI 10.11569/WCJD.V14.I20.1963
   Zhang L, 2021, BIOMED PHARMACOTHER, V137, P0, DOI 10.1016/j.biopha.2021.111381
   Li ZM, 2021, J TRADIT CHIN MED, V36, P937
   Liu SN, 2022, NATURE, V601, PE9, DOI 10.1038/s41586-021-04290-9
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu XL, 2019, PHYTOMEDICINE, V62, P0, DOI 10.1016/j.phymed.2019.152930
   Mehran Shiva, 2021, BREAST DIS, V40, P117, DOI 10.3233/bd-201001
   Mosconi C, 2020, CHIN CLIN ONCOL, V9, P0, DOI 10.21037/cco.2019.12.15
   Qian Y, 1994, J BEIJING U TRADIT C, V0, P20
   Razvi Y, 2019, SUPPORT CARE CANCER, V27, P87, DOI 10.1007/s00520-018-4464-y
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Sun DQ, 2020, CHINESE J CANCER RES, V32, P129, DOI 10.21147/j.issn.1000-9604.2020.02.01
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tselikas L, 2021, CLIN CANCER RES, V27, P2698, DOI 10.1158/1078-0432.CCR-19-4073
   Wang HR, 2015, CHIN J GERONTOL, V0, P3614
   Wang Qiong, 2017, ZHONGGUO ZHEN JIU, V37, P509, DOI 10.13703/j.0255-2930.2017.05.016
   Wang SM, 2022, INT J CANCER, V151, P1447, DOI 10.1002/ijc.34158
   Wen XL, 2020, CHIN MED-UK, V38, P42
   Wood H, 2018, CLIN MED, V18, P17, DOI 10.7861/clinmedicine.18-1-17
   Wu S, 2020, J CLIN ACUPUNCT MOXIBUSTION, V36, P5, DOI 10.3969/j.issn.1005-0779.2020.11.003
   Xiang YN, 2019, CANCER MED-US, V8, P1958, DOI 10.1002/cam4.2108
   Yang YT, 2022, YUNNAN J TRADIT CHIN, V43, P28
   于弘, 2022, 中成药 CHINESE TRADITIONAL PATENT MEDICINE, V44, P2273
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhai WY, 2021, CHIN J EXP FORMULA S, V27, P227
   Zhang CJ, 2018, CHIN J BASIC TRADIT, V24, P532
   Zhang HJ, 2022, CURR ONCOL REP, V24, P223, DOI 10.1007/s11912-021-01166-z
   Zhu HC, 2023, INT J CANCER, V152, P1741, DOI 10.1002/ijc.34301
NR 48
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0006-9248
EI 1336-0345
J9 BRATISL MED J
JI Bratisl. Med. J.
PD AUG 15
PY 2025
VL 126
IS 8
BP 1647
EP 1654
DI 10.1007/s44411-025-00262-x
EA JUL 2025
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 5KW7W
UT WOS:001524605300001
DA 2026-01-16
ER

PT J
AU Satiamurthy, R
   Shah, NM
   Ab Muin, NF
   Azmi, N
   Ismail, CAN
   Yaakob, NS
AF Satiamurthy, Raajeswari
   Shah, Noraida Mohamed
   Ab Muin, Nur Fa'izah
   Azmi, Norazrina
   Ismail, Che Aishah Nazariah
   Yaakob, Nor Syafinaz
TI Exploring Cancer Patients' Perspectives on Chemotherapy-Induced Peripheral Neuropathy Experiences and Its Management: A Qualitative Study
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article; Early Access
DE CIPN management; Quality of life; Patient-centred education; Pain
ID cost-effectiveness; acupuncture; trial
AB Chemotherapy-induced peripheral neuropathy (CIPN) is often an overlooked side effect, affecting cancer patients' quality of life. Improving this requires an in-depth understanding of how patients perceived their CIPN experience, which this study had explored. This study also sought to identify potential barriers to current CIPN management among Malaysian cancer patients. Semi-structured one-to-one interviews were conducted among cancer patients who had a confirmed diagnosis of CIPN from one hospital and a local cancer organization. Interviews were conducted until theme saturation was achieved (N = 22). Interviews were audio-recorded, transcribed verbatim, and analysed using thematic analysis. Three main themes emerged: manageable CIPN experiences impacting activities of daily living despite limited awareness, current conventional treatments of CIPN were partially effective with side effects, and explorative of alternative treatment options for CIPN. The study results indicated that patients experienced CIPN, which was considerably mild and impacted their life activities to a small extent. The limited information provided about CIPN contributed to a sense of uncertainty among patients. They emphasized the importance of more accessible information and education about CIPN and its management. Although the conventional management of CIPN was able to partly control symptoms, patients experienced side effects from the prescribed medications. Interestingly, patients expressed openness to explore new treatments to help them cope better with CIPN. These findings highlighted the need for a comprehensive, patient-centred approach to CIPN management. Insights from patient experiences could guide the development of educational interventions, such as patient's assessment form on CIPN experiences and awareness activities to enhance CIPN care.
C1 [Satiamurthy, Raajeswari; Azmi, Norazrina; Yaakob, Nor Syafinaz] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia.
   [Shah, Noraida Mohamed] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Qual Management Med, Kuala Lumpur, Malaysia.
   [Ab Muin, Nur Fa'izah] Univ Kebangsaan Malaysia, Fac Med, Dept Radiotherapy & Oncol, Kuala Lumpur 56000, Malaysia.
   [Ismail, Che Aishah Nazariah] Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; Universiti Sains Malaysia
RP Yaakob, NS (corresponding author), Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia.
EM nsy@ukm.edu.my
FU Fundamental Research Grant Scheme (FRGS); National Cancer Society of Malaysia (NCSM)
CR Bakitas MA, 2007, NURS RES, V56, P323, DOI 10.1097/01.NNR.0000289503.22414.79
   Banach M, 2017, BRAIN BEHAV, V7, P0, DOI 10.1002/brb3.558
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Burnight T, 2011, J PAIN, V12, P84, DOI 10.1016/j.jpain.2011.02.343
   Cavaletti G, 2011, CURR TREAT OPTION NE, V13, P180, DOI 10.1007/s11940-010-0108-3
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, P0, DOI 10.1007/s11910-017-0757-7
   Jeong Ju Hyeon, 2013, KOREAN J WOMEN HEALTH NURS, V19, P201, DOI 10.4069/kjwhn.2013.19.4.201
   Kautio AL, 2009, ANTICANCER RES, V29, P2601
   Khatab NIO, 2017, CANCER INCIDENCE AND CHEMOTHERAPY-INDUCED ADVERSE EFFECTS IN ASIA, V16, P0
   Kim EY, 2023, SEMIN ONCOL NURS, V39, P0, DOI 10.1016/j.soncn.2023.151499
   Kim JH, 2013, ASIAN ONCOL NURS, V13, P145, DOI 10.5388/aon.2013.13.3.145
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   Ministry of Health Malaysia, 2021, NATIONAL STRATEGIC PLAN FOR CANCER CONTROL PROGRAMME 2021-2025, V0, P0
   Ministry of Health Malaysia National Cancer Registry, 2023, SUMMARY OF MALAYSIA NATIONAL CANCER REGISTRY REPORT 2017-2021, V0, P0
   Molassiotis A, 2021, ACUPUNCT MED, V39, P41, DOI 10.1177/0964528420920285
   Njobvu P, 1999, RHEUMATOLOGY, V38, P1184, DOI 10.1093/rheumatology/38.12.1184
   Prager K, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07688-5
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Reinhold T, 2013, ANN ALLERG ASTHMA IM, V111, P56, DOI 10.1016/j.anai.2013.04.008
   Salat K, 2017, NEUROPHARMACOLOGY, V125, P181, DOI 10.1016/j.neuropharm.2017.07.022
   Satiamurthy R, 2023, CURR MOL MED, V23, P341, DOI 10.2174/1566524022666220512122525
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Tanay MA, 2019, EUR J CANCER CARE, V28, P0, DOI 10.1111/ecc.13011
   Tanay MAL, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13517
NR 25
TC 1
Z9 1
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0885-8195
EI 1543-0154
J9 J CANCER EDUC
JI J. Cancer Educ.
PD APR 11
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1007/s13187-025-02624-z
EA APR 2025
PG 9
WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health
GA 1GO2U
UT WOS:001464512000001
PM 40214713
DA 2026-01-16
ER

PT J
AU Djaali, W
AF Djaali, W.
TI Integrating acupuncture in palliative care for elderly patients with cancer pain due to spinal metastasis
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
C1 [Djaali, W.] Univ Indonesia, Univ Indonesia Hosp, Fac Med, Med Acupuncture Study Program, Depok, Indonesia.
C3 University of Indonesia
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT 15
PY 2025
VL 36
IS 
BP S1738
EP S1738
DI 10.1016/j.annonc.2025.08.354
PG 1
WC Oncology
SC Oncology
GA O1031
UT WOS:001632241300105
DA 2026-01-16
ER

PT J
AU Duzova, US
   Can, G
   Duzova, M
   Basaran, H
   Yavas, C
AF Duzova, Ulku Saygili
   Can, Gulbeyaz
   Duzova, Mursel
   Basaran, Hamit
   Yavas, Cagdas
TI The effect of acupressure on anxiety, depression, pain, and vital signs in gynecological cancer patients receiving brachytherapy: A randomized controlled study
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Acupressure; Anxiety; Brachytherapy; Depression; Gynecological cancer; Pain
ID chemotherapy
AB Purpose: This study aimed to evaluate the effects of acupressure on pain, anxiety, depression, and physiological parameters in women undergoing brachytherapy for gynecological cancer. Methods: The research was conducted between December 2023 and September 2024 using a randomized controlled design. All patients receiving brachytherapy were randomly assigned to the acupressure group (n = 40) or the control group (n = 40). In addition to standard clinical care, the acupressure group received manual acupressure for 30 min before each brachytherapy session at specific acupressure points (SP6, PC6, LI4, HT7, LV4). The data were collected using the Personal Information Form, Visual Analog Scale (VAS), State-Trait Anxiety Inventory (STAI-I), Hospital Anxiety and Depression Scale (HADS), and Vital Signs Form. Results: The groups were comparable in terms of sociodemographic and clinical characteristics (p > 0.05). Significant reductions were observed in anxiety, depression, and pain levels in the acupressure group at post-test compared to baseline and the control group (p < 0.001). Additionally, diastolic blood pressure and body temperature significantly decreased in the intervention group (p < 0.001), whereas no significant differences were found for pulse and respiratory rate (p > 0.05). Conclusion: The results obtained from this study suggest that acupressure may be a beneficial complementary method for reducing anxiety, depression, and pain, as well as contributing to the regulation of certain physiological parameters in patients undergoing brachytherapy. These findings indicate that acupressure could be considered an intervention that may be integrated into clinical practice to support psychological and physiological well-being.
C1 [Duzova, Ulku Saygili] Selcuk Univ, Fac Nursing, Konya, Turkiye.
   [Can, Gulbeyaz] Istanbul Univ Cerrahpasa, Florence Nightingale Nursing Fac, Istanbul, Turkiye.
   [Duzova, Mursel; Basaran, Hamit; Yavas, Cagdas] Selcuk Univ, Fac Med, Dept Radiat Oncol, Konya, Turkiye.
C3 Selcuk University; Istanbul University - Cerrahpasa; Selcuk University
RP Duzova, US (corresponding author), Selcuk Univ, Fac Nursing, Konya, Turkiye.
EM ulkusaygili@selcuk.edu.tr; gulbeyaz@istanbul.edu.tr; mursel_duzova@hotmail.com; drhbasaran@gmail.com; drcagdasyavas@gmail.com
CR Amsbaugh AK, 2016, J CLIN ANESTH, V35, P509, DOI 10.1016/j.jclinane.2016.08.025
   Arslan DEFE, 2024, EXPLORE-NY, V20, P507, DOI 10.1016/j.explore.2023.11.008
   Arslan DE, 2025, SUPPORT CARE CANCER, V33, P0, DOI 10.1007/s00520-024-09059-0
   Avci A, 2024, EXPLORE-NY, V20, P0, DOI 10.1016/j.explore.2024.103070
   Aydemir O, 1997, TURK PSIKIYATRI DERG, V8, P280
   Becerra-Bolanos A, 2023, J PERS MED, V13, P0, DOI 10.3390/jpm13081187
   Benali K, 2022, JOURNAL OF CANCER THERAPY, V13, P405, DOI 10.4236/jct.2022.137035
   Blackburn L, 2021, ONCOL NURS FORUM, V48, P265, DOI 10.1188/21.ONF.265-276
   Cagli Ozturk S, 2019, QUALITATIVE DETERMINATION OF PHYSICAL AND PSYCHOLOGICAL EFFECTS OF BRACHYTHERAPY IN PATIENTS RECEIVING GYNECOLOGICAL CANCER TREATMENT, V0, P0
   Can G, 2024, BRAKITERAPI HEMSIRELIGINDE BAKIM STANDARTLARI-KONSENSUS, V0, P0
   Can G, 2011, EUR J ONCOL NURS, V15, P178, DOI 10.1016/j.ejon.2010.07.005
   Chen JJ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.677052
   Cihan YB, 2017, ACUPUNCT MED, V35, P386, DOI 10.1136/acupmed-2016-011286
   Darwish EAF, 2025, ALEX J MED, V61, P6, DOI 10.1080/20905068.2024.2414367
   Dzaka AD, 2016, SOUTH AFR J GYNAECOL, V8, P42, DOI 10.1080/20742835.2016.1257174
   Gao JL, 2020, EUR J CARDIOVASC NUR, V19, P20, DOI 10.1177/1474515119876778
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Ister ED, 2022, HOLIST NURS PRACT, V36, PE57, DOI 10.1097/HNP.0000000000000553
   Korenaga TRK, 2022, GYNECOL ONCOL, V164, P348, DOI 10.1016/j.ygyno.2021.11.015
   Lim KH, 2024, PAIN MANAG NURS, V25, Pe223, DOI 10.1016/j.pmn.2024.01.006
   Liu QX, 2022, EUR J ONCOL NURS, V61, P0, DOI 10.1016/j.ejon.2022.102219
   Néron S, 2014, CURR ONCOL, V21, PE89, DOI 10.3747/co.21.1741
   Oner N, 1990, SINAV KAYGISI ENVANTERI EL KITABI, V0, P0
   Özdemir Ü, 2023, ALTERN THER HEALTH M, V29, P57
   PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Shih YW, 2018, J NURS RES, V26, P411, DOI 10.1097/jnr.0000000000000257
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Toprak FÜ, 2024, SEMIN ONCOL NURS, V40, P0, DOI 10.1016/j.soncn.2023.151575
   Wiebe E, 2011, BRACHYTHERAPY, V10, P352, DOI 10.1016/j.brachy.2011.04.001
   Wilson JM, 2021, BRACHYTHERAPY, V20, P1164, DOI 10.1016/j.brachy.2021.07.008
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
NR 32
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUL 18
PY 2025
VL 33
IS 8
BP 
EP 
DI 10.1007/s00520-025-09754-6
PG 13
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 5BY6S
UT WOS:001532043600002
PM 40679634
DA 2026-01-16
ER

PT J
AU Tan, J
   Feng, Y
   Liu, H
   Zhou, YH
   Cai, JQ
   Jiang, YY
   Li, PY
   Gu, LB
   Song, ZH
AF Tan, Jing
   Feng, Yong
   Liu, Hui
   Zhou, Yihu
   Cai, Jiaqin
   Jiang, Yueyi
   Li, Pengyi
   Gu, Lianbing
   Song, Zhenghuan
TI Effect of press needle stimulation on postoperative pulmonary complications in video-assisted thoracoscopic surgery patients: a randomized controlled trial
SO ANNALS OF MEDICINE
LA English
DT Article
DE Press needle; video-assisted thoracoscopic surgery; postoperative pulmonary complications; postoperative pain control
ID inflammatory responses; acupuncture treatment; acupoint stimulation; thoracic-surgery; oxidative stress; lung injury; rats; electroacupuncture; lobectomy; ventilation
AB BackgroundPatients undergoing high-risk surgical procedures frequently experience postoperative pulmonary complications (PPCs) that impact outcomes. Acupuncture has demonstrated potential benefits during surgery. Press needle stimulation is increasingly recognized as an alternative to conventional techniques. We aimed to evaluate the effect of press needle stimulation on PPCs in patients with lung cancer undergoing video-assisted thoracoscopic surgery.MethodsEighty-seven patients undergoing video-assisted thoracoscopic surgery were randomized into press needle (n = 48) or sham needle (n = 39) groups. The press needle group underwent bilateral stimulation of acupoints LU9 (Taiyuan), RN17 (Danzhong), LU6 (Kongzui), and BL13 (Feishu) before anesthesia and during surgery. The sham group received a placebo stimulation. The primary endpoint was the incidence of PPCs within seven days post-surgery. The secondary endpoints included cytokine levels, intraoperative respiratory mechanics, postoperative pain score, analgesic consumption, and related complications.ResultsPress needle acupoint stimulation was associated with a significantly lower incidence of PPCs than the sham needle group. Perioperative data, tachycardia, cough, postoperative nausea, vomiting, and most inflammatory markers exhibited no significant differences, except for lower hypoxia-inducible factor-1 alpha levels in the press needle group. Hemodynamic and blood gas analyses indicated no significant cardiovascular or respiratory differences between groups. The press needle group exhibited reduced patient-controlled analgesia (PCA) pump utilization and lower total PCA usage, indicating improved pain management.ConclusionThis study indicates that press needle stimulation lowers PPC incidence and improves postoperative analgesia in patients with lung cancer undergoing video-assisted thoracoscopic lobectomy.
C1 [Tan, Jing; Liu, Hui; Li, Pengyi; Gu, Lianbing; Song, Zhenghuan] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing 21009, Peoples R China.
   [Tan, Jing; Liu, Hui; Cai, Jiaqin; Li, Pengyi; Gu, Lianbing; Song, Zhenghuan] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 21009, Peoples R China.
   [Tan, Jing; Liu, Hui; Cai, Jiaqin; Li, Pengyi; Gu, Lianbing; Song, Zhenghuan] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 21009, Peoples R China.
   [Tan, Jing; Cai, Jiaqin; Gu, Lianbing] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Radiol, Nanjing, Peoples R China.
   [Feng, Yong] Nanjing Med Univ, Nanjing, Peoples R China.
   [Zhou, Yihu; Jiang, Yueyi] Xuzhou Med Univ, Xuzhou, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University
RP Gu, LB; Song, ZH (corresponding author), Nanjing Med Univ, Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing 21009, Peoples R China.; Gu, LB; Song, ZH (corresponding author), Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 21009, Peoples R China.; Gu, LB; Song, ZH (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 21009, Peoples R China.
EM 13951947684@163.com; songzhenghuan@njmu.edu.cn
FU Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project [YB201986]
CR Al-Ameri M, 2018, J THORAC DIS, V10, P3499, DOI 10.21037/jtd.2018.05.177
   Alazawi W, 2016, ANN SURG, V264, P73, DOI 10.1097/SLA.0000000000001691
   Bailey KL, 2019, WORLD J SURG, V43, P1377, DOI 10.1007/s00268-018-04900-0
   Bastin AJ, 2016, RESPIROLOGY, V21, P180, DOI 10.1111/resp.12662
   Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301
   Bauml J, 2016, INTEGR CANCER THER, V15, P326, DOI 10.1177/1534735415624138
   Chen JQ, 2021, PAIN THER, V10, P1051, DOI 10.1007/s40122-021-00322-4
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   de la Gala F, 2017, BRIT J ANAESTH, V119, P655, DOI 10.1093/bja/aex230
   de Prost N, 2013, CRIT CARE, V17, P0, DOI 10.1186/cc12854
   Dulu A, 2006, CHEST, V130, P73, DOI 10.1016/S0012-3692(15)50955-0
   Fernandez FG, 2015, ANN THORAC SURG, V99, P368, DOI 10.1016/j.athoracsur.2014.05.104
   Fleckenstein J, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-33459-y
   Gao W, 2015, ANESTHESIOLOGY, V122, P1235, DOI 10.1097/ALN.0000000000000627
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Jobst K A, 1995, J ALTERN COMPLEMENT MED, V1, P57
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5
   Kim KM, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-53194-2
   Kong JT, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.22787
   Lagier D, 2020, ANESTHESIOLOGY, V133, P1029, DOI 10.1097/ALN.0000000000003539
   Lee D, 2019, EUR J PHYS REHAB MED, V55, P442, DOI 10.23736/S1973-9087.19.05334-6
   Li FS, 2012, J TRADIT CHIN MED, V32, P502, DOI 10.1016/S0254-6272(13)60062-X
   Li J, 2016, ACUPUNCT MED, V34, P107, DOI 10.1136/acupmed-2014-010674
   Li Y, 2019, J TRADIT CHIN MED, V39, P885
   Liu Tongshuai, 2016, ZHONGGUO ZHEN JIU, V36, P1135, DOI 10.13703/j.0255-2930.2016.11.005
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Lv JQ, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2019-032417
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   McDonald JL, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/975632
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Mo YC, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/8369737
   Ngai SPC, 2013, J ALTERN COMPLEM MED, V19, P558, DOI 10.1089/acm.2012.0097
   Noda Y, 2015, COMPLEMENT THER CLIN, V21, P193, DOI 10.1016/j.ctcp.2015.07.002
   Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162
   Pan P, 2010, EXP BIOL MED, V235, P642, DOI 10.1258/ebm.2010.009353
   Repac J, 2022, VET CLIN N AM-EQUINE, V38, P525, DOI 10.1016/j.cveq.2022.07.001
   Ruszkai Z, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-2116-z
   Shen MH, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9438650
   Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd
   Steinthorsdottir KJ, 2014, EUR J CARDIO-THORAC, V45, P959, DOI 10.1093/ejcts/ezt525
   Sun Yue, 2020, ZHONGGUO ZHEN JIU, V40, P1304, DOI 10.13703/j.0255-2930.20191204-k0007
   Tian HT, 2017, EUR REV MED PHARMACO, V21, P5515, DOI 10.26355/eurrev_201712_13943
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang Y, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094696
   Wei W, 2020, EXP THER MED, V19, P511, DOI 10.3892/etm.2019.8245
   Wei Y, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/340126
   Ye XX, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2979780
   Yin LM, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0947-z
   Yu F, 2020, EUR REV MED PHARMACO, V24, P5082, DOI 10.26355/eurrev_202005_21201
   Yu JB, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0104924
   Zhang XZ, 2014, NEUROCHEM INT, V65, P23, DOI 10.1016/j.neuint.2013.12.004
   Zhao FC, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9018701
   Zhao LZ, 2017, J TRADIT CHIN MED, V37, P789
NR 56
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD DEC 31
PY 2025
VL 57
IS 1
BP 
EP 
DI 10.1080/07853890.2025.2560684
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7JO2P
UT WOS:001572545900001
PM 40953233
DA 2026-01-16
ER

PT J
AU Sun, LY
   Ramalingam, MB
   Baser, R
   Teles, MS
   Seluzicki, C
   Li, QS
   Mao, JJ
AF Sun, Lingyun
   Ramalingam, Mothi Babu
   Baser, Raymond
   Santos Teles, Marco
   Seluzicki, Christina
   Li, Qing Susan
   Mao, Jun J.
TI Acupuncture Improves Functional Limitations for Cancer Patients with Chronic Pain: A Secondary Analysis of PEACE Randomized Clinical Trial
SO CURRENT ONCOLOGY
LA English
DT Article
DE cancer pain; acupuncture; rehabilitation; extremity function; randomized controlled trial
ID quality-of-life; breast-cancer; survival; rehabilitation; metaanalysis; medicine; therapy; women
AB Chronic pain significantly impairs functional performance in patients with cancer. Although acupuncture is effective for cancer-related pain, its impact on pain-related functional interference remains unclear. This secondary analysis of the PEACE randomized clinical trial included patients with prior cancer diagnoses and musculoskeletal pain for >= 3 months. Participants were randomized to groups undergoing 10 weeks of electro-acupuncture, auricular acupuncture, or a waitlist control. Functional performance was assessed using the Quick-Disability Arm/Shoulder/Hand (Q-DASH) for upper limbs and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) subscale for lower limbs (higher scores = worse function). Linear mixed models compared changes over time between groups, with week 12 as the primary endpoint. Functional changes were also compared between pain responders and non-responders in the acupuncture arms. Among 360 patients (mean [SD] age, 62.1 [12.7] years; 69.7% women), mean baseline Q-DASH and WOMAC scores were 33.2 (19.8) and 33.3 (20.3). At week 12, both electro-acupuncture and auricular acupuncture significantly improved function versus waitlist: Q-DASH by -7.18 and -9.64 points, respectively, and WOMAC by -6.89 and -7.61 points (all p < 0.001). No differences were found between the two acupuncture groups. Treatment effects on Q-DASH diminished during follow-up, while improvements on WOMAC persisted. Within the acupuncture groups, pain responders achieved greater functional gains than non-responders (Q-DASH, -6.74; WOMAC, -6.16; both p < 0.001). Electro-acupuncture and auricular acupuncture improved upper and lower extremity function in cancer patients with chronic pain. These findings support acupuncture as a potential adjunct in functional rehabilitation for cancer survivors.
C1 [Sun, Lingyun] China Acad Chinese Med Sci, Xiyuan Hosp, Oncol Dept, Beijing 100091, Peoples R China.
   [Sun, Lingyun; Santos Teles, Marco; Seluzicki, Christina; Li, Qing Susan; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.
   [Ramalingam, Mothi Babu] Singapore Gen Hosp, Dept Rehabil Med, Singapore 169856, Singapore.
   [Baser, Raymond] Mem Sloan Kettering Canc Ctr, Epidemiol Biostat, New York, NY 60637 USA.
C3 Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Memorial Sloan Kettering Cancer Center; Singapore General Hospital; Memorial Sloan Kettering Cancer Center
RP Sun, LY (corresponding author), China Acad Chinese Med Sci, Xiyuan Hosp, Oncol Dept, Beijing 100091, Peoples R China.; Sun, LY; Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.
EM slyslysun@126.com; maoj@mskcc.org
FU Department of Defense office of the Congressionally Directed Medical Research Programs [W81XWH-15-1-0245]; Scientific and Technological Innovation Project of the China Academy of Chinese Medical Science [C12021A01819]; National Cancer Institute Cancer Center Support Grant (CCSG) [P30 CA008748]
CR BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Bhavsar NA, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0251336
   Chan SC, 2020, INT J RHEUM DIS, V23, P1741, DOI 10.1111/1756-185X.13948
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Cheville AL, 2014, J CLIN ONCOL, V32, P1691, DOI 10.1200/JCO.2013.53.6680
   Clement ND, 2018, CLIN ORTHOP RELAT R, V476, P2005, DOI 10.1097/CORR.0000000000000444
   Courtney CA, 2017, J MAN MANIP THER, V25, P118, DOI 10.1080/10669817.2017.1300397
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Galardini L, 2024, PHYS THER, V104, P0, DOI 10.1093/ptj/pzae033
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Halabi S, 2008, J CLIN ONCOL, V26, P2544, DOI 10.1200/JCO.2007.15.0367
   Hjermstad MJ, 2016, BMJ SUPPORT PALLIAT, V6, P344, DOI 10.1136/bmjspcare-2015-000887
   Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L
   Isozaki AB, 2024, SEMIN ONCOL NURS, V40, P0, DOI 10.1016/j.soncn.2024.151672
   Johnson MC, 2024, EJSO-EUR J SURG ONC, V50, P0, DOI 10.1016/j.ejso.2024.108591
   Joshy G, 2023, BMC CANCER, V23, P0, DOI 10.1186/s12885-023-11214-5
   Kang JH, 2020, SUPPORT CARE CANCER, V28, P5177, DOI 10.1007/s00520-020-05329-9
   Li HL, 2024, FRONT MOL NEUROSCI, V17, P0, DOI 10.3389/fnmol.2024.1332876
   Li YX, 2020, ACUPUNCT MED, V38, P235, DOI 10.1136/acupmed-2017-011622
   Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330
   Maltser S, 2017, PM&R, V9, PS415, DOI 10.1016/j.pmrj.2017.08.403
   Mamipour H, 2023, J BODYW MOV THER, V35, P378, DOI 10.1016/j.jbmt.2023.04.033
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Markenson Joseph A, 1996, AMERICAN JOURNAL OF MEDICINE, V101, P0
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Recchia TL, 2017, REV BRAS GINECOL OBS, V39, P115, DOI 10.1055/s-0037-1598642
   Robinson CL, 2022, ORTHOP REV, V14, P0, DOI 10.52965/001c.38321
   Roy S, 2023, PROSTATE CANCER P D, V26, P96, DOI 10.1038/s41391-022-00529-2
   Shah KT, 2023, CURR ONCOL, V30, P8826, DOI 10.3390/curroncol30100637
   Shahidi B, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0276326
   Smyth EN, 2016, HEALTH QUAL LIFE OUT, V14, P0, DOI 10.1186/s12955-016-0449-z
   Stout NL, 2021, CA-CANCER J CLIN, V71, P149, DOI 10.3322/caac.21639
   Team RC, 2025, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0
   Tegegn HG, 2017, PAIN RES MANAG, V2017, P0, DOI 10.1155/2017/5698640
   Voulgarakis P, 2021, J ACUPUNCT MERIDIAN, V14, P231, DOI 10.51507/j.jams.2021.14.6.231
   Walsh EA, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07453-0
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou KN, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07802-7
NR 41
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 1198-0052
EI 1718-7729
J9 CURR ONCOL
JI Curr. Oncol.
PD NOV 16
PY 2025
VL 32
IS 11
BP 
EP 
DI 10.3390/curroncol32110640
PG 12
WC Oncology
SC Oncology
GA H4223
UT WOS:001625529600001
PM 41294702
DA 2026-01-16
ER

PT J
AU Chan, A
   Nasr, R
   Arcos, D
   Kagramanov, D
   Asuzu, C
   Bao, T
   Cheung, YT
   Kwon, JH
   Lacey, J
   Lee, RT
   Lustberg, M
   Ohaeri, BM
   Rao, S
   Soto-Perez-de-Celis, E
   Witt, CM
   Lopez, AM
AF Chan, Alexandre
   Nasr, Reem
   Arcos, Daniela
   Kagramanov, Dalia
   Asuzu, Chioma
   Bao, Ting
   Cheung, Yin Ting
   Kwon, Jung Hye
   Lacey, Judith
   Lee, Richard T
   Lustberg, Maryam
   Ohaeri, Beatrice M
   Rao, Santosh
   Soto-Perez-de-Celis, Enrique
   Witt, Claudia M
   Lopez, Ana Maria
TI Evaluation of integrative oncology modalities for symptom management: a MASCC/SIO
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE Cancer; Cancer supportive care; Global perspectives; Integrative oncology; Oncology
AB BACKGROUND: With growing evidence pointing towards the potential of integrative  oncology modalities (IOM) in addressing cancer and cancer-treatment related  symptoms, research on IOM utilization and implementation is warranted. This study  examines global stakeholder perspectives on integrative oncology (IO) utilization  for supportive cancer care. METHODS: Members of the Multinational Association of  Supportive Care in Cancer (MASCC) and the Society for Integrative Oncology (SIO)  completed a survey on the utilization of IOM for supportive cancer care.  Descriptive statistics were used to assess demographic data, IOM usage patterns,  IOM education, and financial considerations for utilizing IOM. RESULTS: Among 344  participants representing eight geographical regions, 70% reported having  utilized or recommended IOM and 79% perceived IOM to be underutilized in cancer  supportive care. Acupuncture (48%), exercise classes (39%), nutrition (38%),  breathing/yoga (38%) and personalized exercise (38%) were among the most utilized  IOM across regions. Relatedly, the symptoms for which IOM were most recommended  for persons with a diagnosis of cancer in active treatment [AT] or completed  treatment [CT] respectively were emotional (AT 23%; CT 26%), pain (AT 22%; CT  20%), gastrointestinal (AT 21%; CT 12%) and fatigue (AT 15%; CT 16%). The  perceived availability of integrative medicine training was highest in North  America (69%). Across regions, self-pay (20%-67%), private insurance (0%-26%) and  government insurance (7%-40%) were the most common forms of payment for IOM. The  IOM most recommended in high-income countries (acupuncture, exercise, massage,  individual exercise) varied from the IOM most recommended in low-middle income  countries (nutrition counseling, exercise classes, breathing, acupuncture).  CONCLUSION: This study provides valuable insights into global utilization  patterns of IOM in supportive cancer care, highlighting that while most  respondents have utilized IOM, there is a perceived underutilization overall. Our  results show significant regional differences in the availability of integrative  oncology education and hint to financial barriers impacting IOM use. Further  research is necessary to explore these aspects and inform strategies for  supporting IOM implementation efforts.
C1 Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.
   Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA.
   Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA.
   Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA.
   Department of Guidance and Counselling, University of Ibadan, Ibadan, Nigeria.
   Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, Boston, USA.
   School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, Shatin, China.
   Division of Hemato-oncology, Chung-Ang University College of Medicine, Gyeonggi-do, South Korea.
   Department of Supportive Care and Integrative Oncology, Chris O'Brien Lifehouse Comprehensive Cancer Centre, NSW, Sydney, Australia.
   Cherng Family Center for Integrative Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA.
   Breast Cancer Center, Smilow Cancer Hospital, Yale University, New Haven, USA.
   College of Medicine, University of Ibadan, Ibadan, Nigeria.
   University Hospitals Seidman Cancer Center, Cleveland, USA.
   Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Ciudad de Mexico, Mexico.
   UC Health Diane O'Connor Thompson Breast Center, Auschutz Medical Campus, 
   Institute for Complementary and Integrative Medicine, University Hospital Zurich, Zürich, Switzerland.
   Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, USA.
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD NOV 4
PY 2025
VL 25
IS 1
BP 406
EP 406
DI 10.1186/s12906-025-05157-6
PG 0
WC Humans; Neoplasms; therapy; Integrative Oncology; statistics & numerical data; Male; Female; Middle Aged; Adult; Surveys and Questionnaires; Aged
UT PubMed:41184943
PM 41184943
DA 2025-11-04
ER

PT J
AU Ding, YJ
   Cao, HZ
   Huang, Y
   Xue, H
   Cai, SQ
   Chen, XH
   Duan, ML
AF Ding, Yajun
   Cao, Hanzhong
   Huang, Ying
   Xue, Hong
   Cai, Shenquan
   Chen, Xiaohong
   Duan, Manlin
TI Fire Acupuncture Combined with Pulse Radiofrequency Relieves Tactile Allodynia in Rats with Postherpetic Neuralgia
SO INTERNATIONAL JOURNAL OF GENERAL MEDICINE
LA English
DT Article
DE postherpetic neuralgia; P13K/AKT; fire acupuncture; pulse radiofrequency
ID varicella-zoster-virus; protein-kinase b/akt; neuropathic pain; herpes-zoster; contributes; activation; 3-kinase; model
AB Background: Postherpetic neuralgia (PHN) remains challenging to treat, with 40%-50% of patients experiencing inadequate pain relief despite comprehensive interventions. Neuromodulation techniques such as pulsed radiofrequency (RF) and traditional methods such as fire acupuncture (FA) are increasingly used for PHN. This study investigated the combined effect of FA and RF on tactile allodynia in a rat model of PHN and explored its underlying mechanisms. Methods: Adult male rats were randomly divided into: Control, PHN, FA, RF, and combined FA_RF groups. PHN was induced by varicella-zoster virus inoculation. FA and/or RF interventions began on Day 15. Pain behavior was assessed via mechanical allodynia and thermal hyperalgesia tests. On Day 37, spinal cord tissues and cerebrospinal fluid were collected to evaluate astrocyte and microglial activation, neuronal apoptosis, expression of Insulin-Like Growth Factor 2 (IGF2), Peripheral Myelin Protein 2 (PMP2), Claudin-19 (CLDN19), Homeobox C8 (HOXC8), and levels of interleukin-1(3 (IL-1(3), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-alpha). The role of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway was verified using a PI3K/AKT agonist. Results: The results revealed that mechanical allodynia thresholds decreased on Day 8 post-inoculation. Compared to the PHN group, FA_RF combination significantly increased mechanical thresholds and prolonged thermal hyperalgesia latency, with superior effects versus FA or RF alone. The FA_RF group showed increased spinal IGF2, PMP2, and CLDN19 expression, decreased HOXC8, reduced astrocyte activation, and modulated cytokine levels (IL-1(3, IL-6, TNF-alpha, IL-10). The PI3K/AKT agonist reversed the analgesic effects of FA_RF. Conclusion: Combined fire acupuncture and pulsed radiofrequency alleviates tactile allodynia in PHN rats, possibly by inhibiting spinal astrocyte activation, modulating inflammatory responses, and promoting nerve repair via IGF2, PMP2, and CLDN19 expression. The PI3K/AKT pathway may be critically involved in this analgesic mechanism.
C1 [Ding, Yajun; Duan, Manlin] Nanjing Univ Chinese Med, Jinling Clin Med Coll, Dept Anesthesiol, Nanjing 210002, Peoples R China.
   [Ding, Yajun; Cao, Hanzhong; Chen, Xiaohong] Nantong Univ, Tumor Hosp, Nantong Tumor Hosp, Nantong 226361, Peoples R China.
   [Huang, Ying; Cai, Shenquan] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Pain Med, Affiliated Hosp,Med Sch, Nanjing 210008, Peoples R China.
   [Xue, Hong] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Anesthesiol, Huaian 223002, Peoples R China.
   [Xue, Hong] Huaian Second Peoples Hosp, Huaian 223002, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nantong University; Nanjing University; Xuzhou Medical University
RP Ding, YJ; Duan, ML (corresponding author), Nanjing Univ Chinese Med, Jinling Clin Med Coll, Dept Anesthesiol, Nanjing 210002, Peoples R China.; Ding, YJ (corresponding author), Nantong Univ, Tumor Hosp, Nantong Tumor Hosp, Nantong 226361, Peoples R China.
EM huangy0808@nju.edu.cn; dml1200@126.com
FU Nanjing Drum Tower Hospital integrated traditional Chinese and Western medicine characteristic technology development project [CZXM2022108]; Jiangsu province key research and development plan special funds [BE2018669]
CR Bach LA, 2015, AM J KIDNEY DIS, V65, P327, DOI 10.1053/j.ajkd.2014.05.024
   Bayat A, 2015, J TRANSL MED, V13, P0, DOI 10.1186/s12967-015-0695-6
   Cao X, 2023, PAIN THER, V12, P1, DOI 10.1007/s40122-022-00451-4
   CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen GW, 2022, MINERVA MED, V113, P1051, DOI 10.23736/S0026-4806.20.06843-3
   Chen T, 2022, J GUANGZHOU UNIV TRADIT CHIN MED., V39, P498
   Cui Y, 2023, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1056102
   Delaney A, 2009, NEUROTHERAPEUTICS, V6, P630, DOI 10.1016/j.nurt.2009.07.005
   Detloff MR, 2012, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/3247
   Devor M, 2018, PAIN REP, V3, P0, DOI 10.1097/PR9.0000000000000702
   Ding XT, 2026, MED GAS RES, V16, P76, DOI 10.4103/mgr.MEDGASRES-D-24-00150
   Dworkin RH, 2010, MAYO CLIN PROC, V85, PS3, DOI 10.4065/mcp.2009.0649
   Fan HR, 2023, PAIN THER, V12, P893, DOI 10.1007/s40122-023-00510-4
   FORNASARI D, 2022, EUR REV MED PHARMACO, V26, P3664, DOI 10.26355/eurrev_202205_28862
   Gao XM, 2023, J TRADIT CHIN MED, V43, P359, DOI 10.19852/j.cnki.jtcm.2023.02.007
   Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906
   Graeber MB, 2012, EXP NEUROL, V234, P255, DOI 10.1016/j.expneurol.2012.01.007
   Guedon JMG, 2014, GENE THER, V21, P694, DOI 10.1038/gt.2014.43
   Guedon JMG, 2015, VIROLOGY, V482, P167, DOI 10.1016/j.virol.2015.03.046
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Hornung R, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21165749
   Hornung R, 2020, NEUROSCI LETT, V736, P0, DOI 10.1016/j.neulet.2020.135287
   Jeong EY, 2013, NEUROSCI LETT, V548, P249, DOI 10.1016/j.neulet.2013.05.038
   Johnson RW, 2014, NEW ENGL J MED, V371, P1526, DOI 10.1056/NEJMcp1403062
   Kong CL, 2020, MOL MED, V26, P0, DOI 10.1186/s10020-020-00232-9
   Li XW, 2016, WORLD J INTEGR TRADIT WEST MED, V11, P38, DOI 10.13935/j.cnki.sjzx.160111
   Majava V, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0010300
   Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154
   Reinhold AK, 2019, BBA-MOL BASIS DIS, V1865, P1160, DOI 10.1016/j.bbadis.2019.01.008
   Schmeisser MJ, 2012, J NEUROSCI, V32, P5688, DOI 10.1523/JNEUROSCI.0111-12.2012
   Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576
   Stinson C, 2017, BMC NEUROL, V17, P0, DOI 10.1186/s12883-017-0882-6
   Sun R, 2007, NEUROSCIENCE, V144, P286, DOI 10.1016/j.neuroscience.2006.08.084
   Tanabe K, 2021, NEUROSCI LETT, V742, P0, DOI 10.1016/j.neulet.2020.135536
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   [王峰 Wang Feng], 2019, 临床麻醉学杂志 JOURNAL OF CLINICAL ANESTHESTOLOGY, V35, P1209
   Wang G, 2023, ARCH BIOCHEM BIOPHYS, V745, P0, DOI 10.1016/j.abb.2023.109720
   Wang L, 2020, J TRADIT CHIN MED, V40, P121
   Warner BE, 2021, PLOS PATHOG, V17, P0, DOI 10.1371/journal.ppat.1009689
   Westlund KN, 2024, J PAIN, V25, P428, DOI 10.1016/j.jpain.2023.09.015
   Xu JT, 2007, EXP NEUROL, V206, P269, DOI 10.1016/j.expneurol.2007.05.029
   Yu S, 2016, CHIN J PAIN MED, V22, P161
   Yue JY, 2024, J PAIN RES, V17, P887, DOI 10.2147/JPR.S449211
   Zhang Y, 2024, ARCH DERMATOL RES, V317, P0, DOI 10.1007/s00403-024-03628-3
   Zhu Q, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/9916978
   Zou J, 2019, NEUROTOX RES, V36, P387, DOI 10.1007/s12640-019-00052-8
NR 47
TC 0
Z9 0
U1 8
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 
EI 1178-7074
J9 INT J GEN MED
JI Int. J. Gen. Med.
PD JUN 15
PY 2025
VL 18
IS 
BP 
EP 
DI 10.2147/IJGM.S541807
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7PR7V
UT WOS:001576708300001
DA 2026-01-16
ER

PT J
AU Li, D
   Wu, Y
   Chang, L
   Song, Y
   Du, X
   Xue, F
   Liu, Y
   Wu, J
   Wang, T
AF Li, Daxian
   Wu, Yan
   Chang, Lirong
   Song, Yizhi
   Du, Xiaoqiang
   Xue, Fenqin
   Liu, Yang
   Wu, Jie
   Wang, Tianlong
TI Therapeutic effects of melittin on paclitaxel-induced peripheral neuropathic pain
SO Frontiers in neuroscience
LA English
DT Journal Article
DE acupuncture; analgesia; bee venom; chemotherapy-induced peripheral neuropathy; electrophysiological recording; noradrenergic system; wide dynamic range neuron
AB INTRODUCTION: As a taxane-based cytostatic agent, paclitaxel holds a broad  spectrum of life-saving properties. However, its use is frequently limited by  painful neuropathy in the extremities, which severely hinders the ultimate  prognosis of cancer survivors. While bee venom therapy has shown promise in  alleviating chemotherapy-induced neuropathic pain, the analgesic potential of its  primary bioactive components, such as melittin and phospholipase A2 (bvPLA2),  remains uncharacterized. This study investigated the ameliorative effects of  melittin against paclitaxel-induced peripheral neuropathy in rats through  integrated behavioral, in vivo electrophysiological, and neuropharmacological  approaches. METHODS: Paclitaxel was administered intraperitoneally (i.p.) at a  total dose of 8 mg/kg. Cold and mechanical allodynia and hyperalgesia were  quantified using the acetone drop and von Frey filament tests. To compare the  therapeutic properties of bee venom ingredients, either melittin (0.5 mg/kg) or  bvPLA2 (0.12 mg/kg) was administered subcutaneously at ST36 (Zusanli acupoint).  In vivo extracellular recordings of wide dynamic range (WDR) neurons were  performed in the spinal dorsal horn. Noradrenaline depletion was induced by the  i.p. treatment with N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50  mg/kg), and serotonin depletion was conducted by the i.p. administration of  para-chlorophenylalanine (PCPA, 450 mg/kg). RESULTS: ST36 treatment with  melittin, but not bvPLA2, markedly impeded mechanical and cold hypersensitivity.  Electrophysiological analysis revealed that paclitaxel induced spontaneous and  stimulus-evoked hyperexcitation of spinal WDR neurons. Melittin selectively  suppressed evoked neuronal activities (i.e., acute responses and  after-discharges) without modulating the spontaneous firing of WDR neurons.  Neuropharmacological investigation demonstrated that the effects of melittin were  fully reversed by noradrenaline depletion, whereas serotonin depletion had no  effect. DISCUSSION: Our findings establish that melittin treatment at ST36 could  ease paclitaxel-induced neuropathic pain by partially attenuating the  hyperexcitable state of spinal WDR neurons. Furthermore, these ameliorative  actions were mediated by the specific recruitment of the endogenous noradrenergic  system. This study provides novel evidence supporting melittin as a targeted  symptomatic agent for paclitaxel-induced peripheral neuropathy, which would  advance the development of promising analgesic strategies in oncological care.
C1 Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
   National Clinical Research Center for Geriatric Diseases, Beijing, China.
   Beijing Key Laboratory of Neural Regeneration and Repair, Department of Anatomy, School of Basic Medical Sciences, Beijing Institute of Brain Disorders, CapitalMedical University, Beijing, China.
   College of Veterinary Medicine, Beijing University of Agriculture, Beijing, 
   Beijing Key Laboratory of Neural Regeneration and Repair, Department of Anatomy, School of Basic Medical Sciences, Beijing Institute of Brain Disorders, CapitalMedical University, Beijing, China.
   Beijing Key Laboratory of Neural Regeneration and Repair, Department of Anatomy, School of Basic Medical Sciences, Beijing Institute of Brain Disorders, CapitalMedical University, Beijing, China.
   Beijing Key Laboratory of Neural Regeneration and Repair, Department of Anatomy, School of Basic Medical Sciences, Beijing Institute of Brain Disorders, CapitalMedical University, Beijing, China.
   Core Facilities Center, Capital Medical University, Beijing, China.
   Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
   National Clinical Research Center for Geriatric Diseases, Beijing, China.
   Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
   National Clinical Research Center for Geriatric Diseases, Beijing, China.
   Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China.
   National Clinical Research Center for Geriatric Diseases, Beijing, China.
NR 0
TC 0
SN 1662-453
EI 1662-454
J9 Front Neurosci
PD JUL 17
PY 2025
VL 19
IS 
BP 1622553
EP 1622553
DI 10.3389/fnins.2025.1622553
PG 0
UT PubMed:40672870
PM 40672870
DA 2025-07-17
ER

PT J
AU Raybin, JL
   Montgomery, K
   Janosy, N
   Mist, S
   Franklin, H
   Dieckmann, NF
   Hendricks-Ferguson, VL
   Jankowski, CM
AF Raybin, Jennifer L.
   Montgomery, Kathleen
   Janosy, Norah
   Mist, Scott
   Franklin, Heather
   Dieckmann, Nathan F.
   Hendricks-Ferguson, Verna L.
   Jankowski, Catherine M.
TI Study of Complementary and Integrative Interventions in Pediatric Patients With Serious Illness
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Integrative; complementary; quality of life; symptoms; childhood cancer
ID quality-of-life; creative arts therapy; acute lymphoblastic-leukemia; alternative medicine; symptom clusters; children; oncology; cancer; pain; management
AB Context. Pediatric patients report using complementary and integrative health interventions (CHI) for symptom management. Objective. Feasibility and initial effect sizes of CHI with patients at two children's hospitals. Methods. Using convenience sampling at two academic centers and accepting the wide age range of patients traditionally treated in children's hospitals, we examined feasibility of CHI and outcomes of quality of life (QOL) and symptoms with validated surveys and two physiologic measures. A priori feasibility thresholds were 90% accrual rate and 60% completion of at least two surveys and one CHI session. Results. Over 18 months we accrued 100 participants (Site 1, n = 34; Site 2, n = 66) who completed 811 assessments. Participants were aged 2-29 years (M = 13.5, SD = 5.6), 65% female, 23% from underrepresented populations, 52% with cancer versus other serious illness. Accrual rate was 94%, completion rate was 87%, acceptability was 96%. Ninety-nine participants received 191 total CHI sessions: acupuncture (39%), aromatherapy (35%), creative arts (20%), massage therapy (5%) and hypnosis (1%). After CHI heart rate decreased and symptom scores improved for anxiety, fatigue, nausea, pain, and sadness (Cohen's d effect sizes 0.22-0.99). Adjusted mixed-effects models suggested that the Faces Scale scores improved over time (b = 0.19, P< 0.01). Conclusion. Prospective two-site data collection in relationship to CHI exceeded feasibility thresholds and was acceptable. When given the choice, CHI were popular and may have contributed to improved QOL immediately and longitudinally. These preliminary findings support further study of CHI for targeted symptoms in distinct populations with rigor. (c) 2025 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Jankowski, Catherine M.] Univ Colorado, Coll Nursing, Auroroa, CO USA.
   [Jankowski, Catherine M.] Univ Colorad, Sch Med, Auroroa, CO USA.
   [Hendricks-Ferguson, Verna L.] St Louis Univ, Sch Nursing, St Louis, MO USA.
   [Raybin, Jennifer L.; Mist, Scott; Franklin, Heather; Dieckmann, Nathan F.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.
   [Raybin, Jennifer L.; Mist, Scott; Franklin, Heather; Dieckmann, Nathan F.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR USA.
   [Montgomery, Kathleen] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA.
C3 Saint Louis University; Oregon Health & Science University; Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison
RP Raybin, JL (corresponding author), Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.; Raybin, JL (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA.
EM raybin@ohsu.edu
FU Children ' s Oncology Group National Clinical Trials Network Operations Grant; University of Colorado Center for Integrative Medicine CAMPUS Award; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Advancing Translational Sciences (NCATS) [UL1TR002369]; National Institutes of Health (NIH); NIH Roadmap for Medical Research;  [U10CA180886]
CR Aguilar BA, 2017, J PEDIATR NURS, V36, P173, DOI 10.1016/j.pedn.2017.06.015
   Ahmadipour S, 2024, AM J PERINAT, V41, Pe3420, DOI 10.1055/s-0039-1685493
   Azadinia F, 2014, J SPINAL DISORD TECH, V27, P0
   Barrett E, 2018, PHYSIOTHER THEOR PR, V34, P301, DOI 10.1080/09593985.2017.1394411
   Barrett E, 2013, REHABIL RES PRACT, V2013, P0, DOI 10.1155/2013/475870
   Breau LM, 2001, CLIN J PAIN, V17, P178, DOI 10.1097/00002508-200106000-00011
   Burns DS, 2009, CANCER NURS, V32, PE8, DOI 10.1097/NCC.0b013e3181a4802c
   Chester SJ, 2018, PAIN, V159, P1790, DOI 10.1097/j.pain.0000000000001276
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   Czajkowski SM, 2015, HEALTH PSYCHOL, V34, P971, DOI 10.1037/hea0000161
   Darwin C, 1872, P374, V0, P0
   DeWalt DA, 2015, QUAL LIFE RES, V24, P2195, DOI 10.1007/s11136-015-0953-3
   Diorio C, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0529-3
   Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x
   Dupuis LL, 2016, CANCER-AM CANCER SOC, V122, P1116, DOI 10.1002/cncr.29876
   Dupuis LL, 2013, PEDIATR BLOOD CANCER, V60, P1073, DOI 10.1002/pbc.24508
   Evans A, 2018, J PEDIATR ONCOL NURS, V35, P392, DOI 10.1177/1043454218782133
   Garra G, 2010, ACAD EMERG MED, V17, P50, DOI 10.1111/j.1553-2712.2009.00620.x
   Geyer R, 2011, PEDIATR PHYS THER, V23, P375, DOI 10.1097/PEP.0b013e318235628c
   Hall M, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5110154
   Harris PA, 2019, J BIOMED INFORM, V95, P0, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hinds PS, 2019, PEDIATR BLOOD CANCER, V66, P0, DOI 10.1002/pbc.27606
   Hinds PS, 2013, PEDIATR BLOOD CANCER, V60, P402, DOI 10.1002/pbc.24233
   Hockenberry MJ, 2015, ONCOL NURS FORUM, V42, P542, DOI 10.1188/15.ONF.542-549
   Jacobs SS, 2014, CHILDREN-BASEL, V1, P424, DOI 10.3390/children1030424
   Jibb LA, 2015, ONCOL NURS FORUM, V42, PE339, DOI 10.1188/15.ONF.E339-E357
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kalaichandran A, 2018, PAED CHILD HEALT-CAN, V23, P12, DOI 10.1093/pch/pxx114
   Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173
   Knoerl R, 2022, J PAIN SYMPTOM MANAG, V63, PE357, DOI 10.1016/j.jpainsymman.2021.11.013
   Kohut SA, 2020, J CLIN PSYCHOL MED S, V27, P68, DOI 10.1007/s10880-019-09622-6
   Larson P, 1994, IMAGE, V26, P272, DOI 10.1111/J.1547-5069.1994.TB00333.X
   Lewis JS, 2010, BMC MUSCULOSKEL DIS, V11, P0, DOI 10.1186/1471-2474-11-39
   Li RR, 2022, CANCER NURS, V45, P96, DOI 10.1097/NCC.0000000000000920
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03271-9
   MacDonald C, 2019, CAN J DIABETES, V43, P377, DOI 10.1016/j.jcjd.2019.04.016
   Madden JR, 2010, J PEDIATR ONCOL NURS, V27, P133, DOI 10.1177/1043454209355452
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   McClafferty H, 2017, PEDIATRICS, V140, P0, DOI 10.1542/peds.2017-1961
   McGrath P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9
   McGrath PatriciaA, 1990, PAIN IN CHILDREN: NATURE, V0, P0
   Misra SM, 2019, CLIN PEDIATR, V58, P738, DOI 10.1177/0009922819839232
   Momani TG, 2017, J PEDIATR ONCOL NURS, V34, P173, DOI 10.1177/1043454216688638
   Montgomery KE, 2024, J PEDIAT HEMAT ONC N, V41, P157, DOI 10.1177/27527530231214544
   Montgomery KE, 2020, CANCER NURS, V43, P281, DOI 10.1097/NCC.0000000000000721
   Montgomery KE, 2022, CANCER CARE RESEARCH ONLINE, V2, P020
   Moore IM, 2004, JOURNAL OF PEDIATRIC ONCOLOGY NURSING, V21, P128, DOI 10.1177/1043454204264400
   Mora DC, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221105563
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Neu M, 2014, BIOL RES NURS, V16, P387, DOI 10.1177/1099800413516187
   Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930
   Niedenthal PM, 2009, J PERS SOC PSYCHOL, V96, P1120, DOI 10.1037/a0015574
   NIH, 2016, WHY STUDY COMPLEMENTARY HEALTH APPROACHES?, V0, P0
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P7, DOI 10.1177/1043454208323914
   Pour PS, 2017, J ACUPUNCT MERIDIAN, V10, P187, DOI 10.1016/j.jams.2017.04.001
   Rae C, 2018, J PEDIAT HEMATOL ONC, V40, P580, DOI 10.1097/MPH.0000000000001235
   Ramesh G, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5120168
   Raybin JL, 2024, CANCER NURS, V47, P12, DOI 10.1097/NCC.0000000000001186
   Raybin JL, 2022, J PEDIAT HEMAT ONC N, V39, P60, DOI 10.1177/27527530211059432
   Raybin JL, 2022, J PEDIAT HEMAT ONC N, V39, P155, DOI 10.1177/27527530211055988
   Raybin Jennifer L, 2021, PEDIATRIC BLOOD & CANCER, V68, Pe29388, DOI 10.1002/pbc.29388
   Raybin JL, 2020, J PEDIATR ONCOL NURS, V37, P82, DOI 10.1177/1043454219878397
   Reeve BB, 2020, JNCI-J NATL CANCER I, V112, P1143, DOI 10.1093/jnci/djaa016
   Reeve BB, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26261
   Shamsi MohammadBagher, 2014, ISRN ORTHOP, V2014, P159465, DOI 10.1155/2014/159465
   Stein E, 2019, SUPPORT CARE CANCER, V27, P3769, DOI 10.1007/s00520-019-04673-9
   Sullivan Gail M, 2012, J GRAD MED EDUC, V4, P279, DOI 10.4300/JGME-D-12-00156.1
   Thissen D, 2016, QUAL LIFE RES, V25, P13, DOI 10.1007/s11136-015-1058-8
   Thrane S, 2013, J PEDIATR ONCOL NURS, V30, P320, DOI 10.1177/1043454213511538
   Thrane SE, 2017, AM J HOSP PALLIAT ME, V34, P373, DOI 10.1177/1049909116630973
   Tomlinson D, 2011, SUPPORT CARE CANCER, V19, P1857, DOI 10.1007/s00520-010-1029-0
   Tsze DS, 2015, ACAD EMERG MED, V22, P415, DOI 10.1111/acem.12620
   Uman LS, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005179.pub3
   Varejao CD, 2019, J PEDIATR ONCOL NURS, V36, P44, DOI 10.1177/1043454218810140
   Victorson D, 2016, J ALTERN COMPLEM MED, V22, P778, DOI 10.1089/acm.2015.0121
   Walicka-Cuprys K, 2018, EUR SPINE J, V27, P497, DOI 10.1007/s00586-017-5409-8
   Wang JC, 2018, J PAIN SYMPTOM MANAG, V55, P359, DOI 10.1016/j.jpainsymman.2017.08.021
   Weaver MS, 2020, PALLIAT SUPPORT CARE, V18, P158, DOI 10.1017/S1478951519000555
   Weekly T, 2019, J PALLIAT CARE, V34, P164, DOI 10.1177/0825859718810727
   Wurz A, 2014, PEDIATR BLOOD CANCER, V61, P1828, DOI 10.1002/pbc.25096
   Zheng DJ, 2018, CANCER-AM CANCER SOC, V124, P571, DOI 10.1002/cncr.31085
   Zucchetti G, 2019, J PEDIATR ONCOL NURS, V36, P361, DOI 10.1177/1043454219845879
NR 84
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY 15
PY 2025
VL 69
IS 5
BP 515
EP 526
DI 10.1016/j.jpainsymman.2025.02.013
EA APR 2025
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 1PA2W
UT WOS:001470247800001
PM 39971211
DA 2026-01-16
ER

PT J
AU Liu, W
   Zhang, Y
   Zhu, Q
   Wu, L
AF Liu, Wei
   Zhang, Ying
   Zhu, Qi
   Wu, Lan
TI A scientometric study on research trends and characteristics of burning mouth
SO Journal of dental sciences
LA English
DT Journal Article
DE Bibliometrics; Burning mouth syndrome; Neurological factors; Psychological factors; Therapy strategy
AB BACKGROUND/PURPOSE: Burning mouth syndrome (BMS) is a chronic condition  characterized by intraoral burning sensation and orofacial pain but without oral  mucosal lesions. The purpose of this study was to analyze the scientometric  characteristics and research trends of BMS. MATERIALS AND METHODS: All the papers  on BMS were comprehensively retrieved from the Scopus database. The years of  publication were divided into before 2015 and 2015-2024 in the analysis of  research trends. RESULTS: There were 924 papers on BMS, with total citations of  24,024 and the h index of 76. The related disorders of BMS were depression,  xerostomia, pain, anxiety, glossodynia, taste disorder, nociception, paresthesia,  analgesia, sleep disorder, diabetes mellitus, and neuralgia. Clonazepam was most  common pharmacotherapy for BMS. After 2015, pharmacologic keywords including drug  safety, aripiprazole, duloxetine, folic acid, hydrocortisone, and pregabalin were  more frequent. Low level laser therapy, acupuncture, and cognitive behavioral  therapy were the emerging nonpharmacologic strategies for BMS. Moreover,  laboratory investigations on biomarkers, blood, genetics, interleukin 6, and  tumor necrosis factor were more common. Various questionnaires, comorbidity,  complication, anemia, hypertension, diabetes mellitus, and sleep were also more  concerned after 2015. CONCLUSION: This scientometric study elucidated the current  scenario and research trends of BMS, and would help in improving in reciprocal  collaboration and communication for investigations on this condition.
C1 Department of Stomatology, Fengcheng Hospital of Fengxian District, Shanghai Ninth People's Hospital Fengcheng Branch Hospital, Shanghai, China.
   Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth 
   College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai KeyLaboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai,China.
   College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai KeyLaboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai,China.
   Department of Oral Mucosal Diseases, Shanghai Ninth People's Hospital, Shanghai 
   Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,China.
   College of Stomatology, Shanghai Jiao Tong University, National Center for 
   College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai KeyLaboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai,China.
   Department of Oral Mucosal Diseases, Shanghai Ninth People's Hospital, Shanghai
NR 0
TC 0
SN 2213-886
EI 1991-790
J9 J Dent Sci
PD APR 14
PY 2025
VL 20
IS 2
BP 1252
EP 1256
DI 10.1016/j.jds.2025.01.009
PG 4
UT PubMed:40224121
PM 40224121
DA 2025-04-14
ER

PT J
AU McLarney, M
   Wechsler, SB
   Milani, SA
   Lyons, KD
   Pritchard, KT
AF McLarney, Mitra
   Wechsler, Stephen B
   Milani, Sadaf Arefi
   Lyons, Kathleen Doyle
   Pritchard, Kevin T
TI Trends in Opioids and Nonpharmacologic Pain Management Among U.S. Cancer
SO Archives of physical medicine and rehabilitation
LA English
DT Journal Article
DE Allied health personnel; Facilities and services use; Health policy; Neoplasms; Opioid; Pain; Rehabilitation
AB OBJECTIVE: It is unknown how the United States (U.S.) opioid epidemic influenced  the integration of nonpharmacologic pain treatments in cancer survivors. We  described annual trends and predictors of using opioids alone, nonpharmacologic  treatments alone, multimodal treatments (opioid + nonpharmacologic), and neither  treatment. DESIGN: A serial cross-sectional design. SETTING: Ambulatory.  PARTICIPANTS: Noninstitutionalized U.S. adults with prevalent cancer and pain in  the Medical Expenditure Panel Survey (2011-2020). INTERVENTIONS: Not applicable.  MAIN OUTCOME MEASURES: Period prevalence of self-reported and pharmacy-verified  use of opioids alone, nonpharmacologic treatments alone, both, or neither.  Nonpharmacologic treatments included physical therapy, occupational therapy,  chiropractic care, massage therapy, and acupuncture. RESULTS: Respondents with  cancer and pain represented a total of 41,064,668 adults from 2011 to 2020. Most  adults with cancer pain were >65 years of age (66.6%), women (52.1%), White  (91.4%), non-Hispanic (95.8%), had a high school diploma (42.2%), had an income  of 400% of the federal poverty line (46.6%), and lived in the U.S. South (37.7%).  Compared with 2011, the prevalence of multimodal treatments increased from 4%  (95% confidence interval [CI], 2%-6%) to 10% (95% CI, 6%-14%) in 2019, while the  prevalence of using neither pain treatment decreased from 62% (95% CI, 55%-68%)  to 46% (95% CI, 40%-52%). Compared with using neither treatment, the adjusted  relative risk ratio (RRR) for using nonpharmacologic treatments was stable from  2011 to 2015 (RRR=1.00; 95% CI, 0.93-1.08), but increased from 2016 to 2019  (RRR=1.22; 95% CI, 1.02-1.46) until 2020 (RRR=0.68; 95% CI, 0.43-1.46). Both  unadjusted and adjusted analyses found that pain treatments varied based on  income, educational attainment, race, and geographic region. CONCLUSIONS:  Nonpharmacologic and multimodal pain treatments increased from 2011 to 2020;  however, most cancer pain survivors remained untreated. Pain treatment varied  based on sociodemographic and socioeconomic factors.
C1 Department of Physical Medicine and Rehabilitation, Harvard Medical School/Spaulding Rehabilitation Hospital, Boston, MA.
   Department of Physical Therapy, Simmons University, Boston, MA.
   Department of Epidemiology, University of Texas Medical Branch, Galveston, TX.
   Department of Occupational Therapy, MGH Institute of Health Professions, Boston, MA.
   Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA
   Division of Pharmacoepidemiology and Pharmacoeconomics, Department ofMedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
EM kpritchard3@bwh.harvard.edu
NR 0
TC 0
SN 1532-821
EI 
J9 Arch Phys Med Rehabil
PD DEC 5
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1016/j.apmr.2025.11.019
PG 0
UT PubMed:41344550
PM 41344550
DA 2025-12-05
ER

PT J
AU Wan, R
   Zheng, Q
   Zeng, X
   Luo, Y
   Sun, L
   Chen, S
   Luo, F
   Zhang, Y
   Zhu, Z
   Chen, X
   Zhao, Y
   Li, Y
AF Wan, Renhong
   Zheng, Qianhua
   Zeng, Xiaorui
   Luo, Yalan
   Sun, Luqiang
   Chen, Shuai
   Luo, Fangli
   Zhang, Yupeng
   Zhu, Ziyue
   Chen, Xinyun
   Zhao, Yuanyuan
   Li, Ying
TI Differential placebo effect of sham acupuncture for chronic pain: a network meta-analysis of randomized controlled trials
SO BMC Complementary Medicine and Therapies
LA English
DT Article
DE Chronic pain; Manual acupuncture; Meta-analysis; Placebo; Randomized controlled trial; Sham acupuncture
ID acupuncture; acupuncture point; article; chronic pain; chronic prostatitis; clinical practice; electroacupuncture; human; meta analysis; network meta-analysis; neuropathic pain; outcome assessment; pain intensity; pelvis pain syndrome; placebo effect; preferred reporting items for systematic reviews and meta-analyses; quality of life; randomized controlled trial (topic); sensitivity analysis; visceral pain; visual analog scale; network meta analysis (topic); procedures; therapy; placebo; acupuncture therapy; chronic pain; humans; network meta-analysis as topic; placebo effect; placebos; randomized controlled trials as topic
AB Background: The clinical effects of acupuncture are often underestimated due to the placebo effect of sham acupuncture. While multiple sham acupuncture methods have been used in clinical practice, it is challenging to select the appropriate sham acupuncture technique due to the lack of head-to-head trials. Purpose: The purpose of this study was to compare the differential placebo effects of diverse sham acupuncture interventions, providing evidence-based guidance for selecting optimal placebo controls in clinical practice. Method: PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were systematically searched for randomized controlled trials comparing acupuncture with sham acupuncture for the treatment of chronic non-cancer pain (from inceptions to May 1, 2025). The primary outcome measure was pain variation, while secondary outcome measures included adverse events and the assessment of acupuncture blinding. Frequentist random-effect models were employed to perform indirect treatment comparison meta-analysis, and Confidence in Network Meta-Analysis (CINeMA) was utilized to evaluate the level of evidence. Results: A total of 45 randomized controlled trials (RCTs) were included, involving 7 sham acupuncture methods and 8287 participants. Regarding pain variation, the difference was noted between the waiting treatment group (mean difference 1.86 (95% confidence interval 1.36 to 2.35), SUCRA 97.4%; moderate confidence of evidence) and manual acupuncture group was most pronounced, followed by the difference between the acupoint and no penetration group (mean difference 1.14 (95% confidence interval 0.74 to 1.55), SUCRA 73.6%; low confidence of evidence) and the nonacupoint and no penetration group (mean difference 1.00 (95% confidence interval 0.35 to 1.65), SUCRA 64.8%; low confidence of evidence). Additionally, the rate of adverse events was comparable among the aforementioned sham acupuncture groups, and the blinding procedure was successfully implemented in the trials. Conclusions: The placebo effect of sham acupuncture is significant, among which the no penetration (acupoint or nonacupoint) groups exhibited the lowest placebo effect. Nevertheless, further head-to-head trials are warranted to obtain direct evidence. Systematic review registration: PROSPERO no. CRD42024535012. © The Author(s) 2025.
C1 Chengdu University of Traditional Chinese Medicine, Wan, Renhong, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zheng, Qianhua, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zeng, Xiaorui, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Luzhou Longmatan TCM Hospital, Luo, Yalan, Luzhou, China
   Chengdu University of Traditional Chinese Medicine, Sun, Luqiang, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Jiangxi University of Chinese Medicine, Chen, Shuai, Nanchang, Jiangxi, China
   Luo, Fangli, School of Integrated Traditional Chinese and Western Clinical Medicine, North Sichuan Medical College, Nanchang, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zhang, Yupeng, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zhu, Ziyue, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Chen, Xinyun, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zhao, Yuanyuan, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Li, Ying, Acupuncture and Tuina School, Chengdu, Sichuan, China
CR Beecher, 1900, 1955, V0, P0
   Kaptchuk, 1900, 2000, V0, P0
   Zhang, 1900, HOW TO DESIGN HIGH QUALITY ACUPUNCTURE TRIALS - A CONSENSUS INFORMED BY EVIDENCE, V0, PBMJ
   Streitberger, 1900, 1998, V0, P0
   Park, 1900, 2002, Validating a new non-penetrating sham acupuncture device: Two randomised controlled trials @ Acupuncture in Medicine, P0
   Takakura, 1900, A DOUBLE-BLIND PLACEBO NEEDLE FOR ACUPUNCTURE RESEARCH, V0, P7
   Wang, 1900, ANALYSIS OF PLACEBO EFFECT OF ACUPUNCTURE, V0, P875-879
   Zheng, 1900, ACUPUNCTURE FOR PATIENTS WITH CHRONIC TENSION-TYPE HEADACHE: A RANDOMIZED CONTROLLED TRIAL, V0, PE1560-E1569
   Zeng, 1900, PLACEBO RESPONSE VARIES BETWEEN DIFFERENT TYPES OF SHAM ACUPUNCTURE: A RANDOMIZED DOUBLE-BLIND TRIAL IN NECK PAIN PATIENTS, V0, P1006-1020
   Lee, 1900, ACURATE: A GUIDE FOR REPORTING SHAM CONTROLS IN TRIALS USING ACUPUNCTURE, V0, P82-90
NR 10
TC 1
SN 
EI 
J9 BMC COMPL MEDTHERAPIES
JI BMC Compl. Med.Therapies
PD JUN 15
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12906-025-05055-x
PG 0
UT Scopus:10.1186/s12906-025-05055-x
ER

PT J
AU Wang, XY
   Shen, QY
   Hu, XY
   Liang, Y
AF Wang, Xiaoying
   Shen, Qiongying
   Hu, Xinyi
   Liang, Yi
TI Comment on 'Efficacy and Safety of Different Acupuncture Treatments for Cancer-Related Pain: A Systematic Review and Network Meta-Analysis'
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Letter
C1 [Wang, Xiaoying; Shen, Qiongying; Hu, Xinyi; Liang, Yi] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou, Zhejiang, Peoples R China.
   [Liang, Yi] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Wang, XY (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou, Zhejiang, Peoples R China.
CR Beets MW, 2023, SYST REV-LONDON, V12, P0, DOI 10.1186/s13643-023-02184-7
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Sun N, 2019, ACUPUNCT MED, V37, P261, DOI 10.1136/acupmed-2017-011608
   Xie TL, 2025, INTEGR CANCER THER, V24, P0, DOI 10.1177/15347354251314500
NR 4
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2025
VL 24
IS 
BP 
EP 
DI 10.1177/15347354251344281
PG 2
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 3BH1P
UT WOS:001496236100001
PM 40417861
DA 2026-01-16
ER

PT J
AU Wu, HY
   Liu, Y
   Chen, YZ
   Xie, YZ
   Zhong, L
   Yu, Y
   Fan, XH
AF Wu, Haoyang
   Liu, Yuan
   Chen, Yuzhou
   Xie, Yizhou
   Zhong, Lei
   Yu, Yang
   Fan, Xiaohong
TI Effect of pestle needle therapy on the posterior cervical muscle in a rabbit model of cervical spondylosis
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE spondylosis; pestle needle; phosphatidylinositol 3-kinase; proto-oncogene proteins c-akt; TOR serine-threonine kinases; apoptosis; autophagy
ID pain; acupuncture; stimulation; degradation
AB OBJECTIVE: To investigate the effect of pestle needle therapy (PNT) on the posterior cervical muscle (PCM) in a rabbit model of cervical spondylosis (CS) and explore the underlying mechanisms. METHODS: Rabbits were divided into control, CS models I and II (CS1 and CS2), electroacupuncture (EA), PNT I and II (PN1 and PN2), activator (AVT), and PNT combined with activator (C-AVT) groups. A long-term neck immobilization technique was used to establish a rabbit model of CS. Following completion of modeling, the EA group received electroacupuncture intervention, whereas the CS1, CS2, and C-AVT groups received PNT intervention. The AVT and C-AVT groups received local 740 Y-P injections into the PCM daily. The inflammatory injury to PCM was evaluated based on pain threshold, morphological changes, and interleukin (IL)-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha levels. PCM fibrosis was evaluated by measuring the positive area (PA) of collagen fibrils (CFs) and collagen type 1 alpha 1 (Col1 alpha 1) using Masson's and immunohistochemical staining. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and transmission electron microscopy were used to identify apoptotic cells and assess autophagy, respectively. Western blotting was used to determine B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), cysteine aspartate-specific protease (caspase)-3, sequestosome-1 (P62), microtubuleassociated protein light chain 3 (LC3-I/II), phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) levels. Real-time quantitative polymerase chain reaction was used to determine mRNA expression levels of PI3K, AKT, mTOR, autophagy protein (ATG), and ATG7. RESULTS: PNT alleviated PCM cell degeneration and necrosis, inhibited inflammatory cell infiltration, decreased IL-1 beta, IL-6, and TNF-alpha levels, and decreased the PA of CFs and Col1 alpha 1. In the PN1 group, cell apoptosis in the PCM decreased, autophagy increased, Bcl-2 and LC3-II/I levels increased, Bax, Caspase-3, and P62 levels decreased, and the mRNA expression of ATG5 and ATG7 increased. PNT inhibits protein and mRNA expression of PI3K, AKT, and mTOR. Finally, the trend in the results of the rescue experiment was consistent with previous results. CONCLUSION: PNT inhibited apoptosis and promoted autophagy of PCM cells in CS rabbits and alleviated inflammation and fibrosis injury of PCM by inhibiting the PI3K/AKT/mTOR pathway.
C1 [Wu, Haoyang; Liu, Yuan; Chen, Yuzhou; Xie, Yizhou] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 610032, Peoples R China.
   [Zhong, Lei; Yu, Yang; Fan, Xiaohong] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed, Chengdu 610075, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Yu, Y; Fan, XH (corresponding author), Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed, Chengdu 610075, Peoples R China.
EM spine_yy@163.com; fxh202010@2980.com
FU Sichuan Provincial Administration of Traditional Chinese Medicine Key Project of Scientific Research in Traditional Chinese Medicine [2023zd025]; Scientific Research Project of Sichuan Provincial Science and Technology Department: Improvement of cartilage Degeneration in Knee Osteoarthritis by Regulating Zn2+ Homeostasis via Autophagy [23NFSC2298]
CR Almada AE, 2016, NAT REV MOL CELL BIO, V17, P267, DOI 10.1038/nrm.2016.7
   Blanpied Peter R, 2017, J ORTHOP SPORTS PHYS THER, V47, PA1, DOI 10.2519/jospt.2017.0302
   Cagnie B, 2012, EUR J APPL PHYSIOL, V112, P3305, DOI 10.1007/s00421-012-2322-z
   Chu Y, 2024, INT J MOL SCI, V25, P0, DOI 10.3390/ijms252211901
   Dingyue W, 2024, J TRADIT CHIN MED, V44, P629, DOI 10.19852/j.cnki.jtcm.20240322.001
   Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899
   Fiacco E, 2016, CELL DEATH DIFFER, V23, P1839, DOI 10.1038/cdd.2016.70
   Gao H, 2023, HUA ZHONG KE JI DA XUE XUE BAO, V52, P458
   García-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Goh Q, 2017, ELIFE, V6, P0, DOI 10.7554/eLife.20007
   Guo Y, 2016, EXPERIMENTAL ACUPUNCTURE, V0, P40
   Harrington JS, 2023, PHYSIOL REV, V103, P2349, DOI 10.1152/physrev.00058.2021
   Hu Y, 2018, CHENGDU ZHONG YI YAO DA XUE XUE BAO, V41, P112
   Japaries W, 2022, MED ACUPUNCT, V34, P400, DOI 10.1089/acu.2021.0051
   Ji YA, 2022, ANTIOXIDANTS-BASEL, V11, P0, DOI 10.3390/antiox11091686
   Jiang ZY, 2001, ZHONG GUO ZHEN JIU, V21, P30
   Jin S, 2019, PESTLE NEEDLE THERAPY AND SPORTS INJURIES, V0, P80
   Kazeminasab S, 2022, BMC MUSCULOSKEL DIS, V23, P0, DOI 10.1186/s12891-021-04957-4
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Li B, 2019, STEM CELL RES THER, V10, P0, DOI 10.1186/s13287-019-1219-8
   Li HT, 2021, ZHEN JIU LIN CHUANG ZA ZHI, V37, P85
   Li YC, 2022, ZHONG HUA ZHONG YI YAO XUE KAN, V40, P210
   Li ZB, 2012, J CELL SCI, V125, P3957, DOI 10.1242/jcs.090365
   Liu FS, 2012, EFFECTS OF ACUPOTOMY THERAPY ON APOPTOSIS IN POSTERIOR CERVICAL EXTENSOR MUSCLES IN RABBIT CERVICAL SPONDYLOSIS MODEL, V0, P43
   [刘福水 Liu Fushui], 2020, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V35, P918
   Liu JY, 2023, ZHONG GUO LIN CHUANG YAN JIU ZA ZHI, V36, P134
   Ma HF, 2023, ZHONG GUO ZU ZHI GONG CHENG YAN JIU, V27, P1842
   Mahdy MAA, 2019, CELL TISSUE RES, V375, P575, DOI 10.1007/s00441-018-2955-2
   McArthur K, 2018, SCIENCE, V359, P883, DOI 10.1126/science.aao6047
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev-immunol-042617-053010
   Rao RD, 2007, J BONE JOINT SURG AM, V89A, P1360
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Shen ZF, 2015, SHANGHAI ZHEN JIU ZA ZHI, V34, P575
   [史红美 Shi Hongmei], 2019, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V30, P1526
   Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580-018-0089-8
   Strom V, 2009, PAIN, V144, P147, DOI 10.1016/j.pain.2009.04.002
   Theodore N, 2020, NEW ENGL J MED, V383, P159, DOI 10.1056/NEJMra2003558
   Wang BY, 2024, J TRADIT CHIN MED, V44, P1091, DOI 10.19852/j.cnki.jtcm.20240926.001
   Wang X, 2020, J INTEGR MED-JIM, V18, P492, DOI 10.1016/j.joim.2020.08.001
   [Wang Yanzhi 王延之], 2016, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE 针灸推拿医学, V14, P284, DOI 10.1007/s11726-016-0937-z
   Wang YX, 2012, NAT REV MOL CELL BIO, V13, P127, DOI 10.1038/nrm3265
   Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211
   Xiong Shou-liang, 2013, ZHONGHUA YI XUE ZA ZHI, V93, P2474
   Xu HG, 2014, EXP THER MED, V7, P537, DOI 10.3892/etm.2013.1465
   Xu QF, 2023, MINERVA PEDIATR, V75, P930, DOI 10.23736/S2724-5276.23.07300-7
   [徐善达 Xu Shanda], 2020, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V35, P4739
   Yeh ML, 2010, ALTERN THER HEALTH M, V16, P10
   Zhang GL, 2019, SHI JIE ZUI XIN YI XUE XIN XI WEN ZHAI, V19, P142
   Zhang X, 2015, ZHONG HUA ZHONG YI YAO XUE KAN, V33, P913
   Zhen YL, 2003, SHANGHAI ZHEN JIU ZA ZHI, V0, P26
   Zhong L, 2017, DIAGRAM OF SICHUAN LIS CLINICAL EXPERIENCE ON PESTLE NEEDLING, V0, P23
   Zhong SC, 2006, THE PESTLE NEEDLE, V0, P83
NR 53
TC 0
Z9 0
U1 4
U2 4
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD JUN 15
PY 2025
VL 45
IS 4
BP 786
EP 795
DI 10.19852/j.cnki.jtcm.2025.04.009
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 5YP4E
UT WOS:001547438600001
PM 40810224
DA 2026-01-16
ER

PT J
AU Yang, M
   Zhong, L
   Fok, RWY
   Tjioe, YY
   Teo, BS
   Zhang, F
   Bao, T
AF Yang, Mingxiao
   Zhong, Linda
   Fok, Rose W Y
   Tjioe, Yan Yin
   Teo, Bo Siang
   Zhang, Furong
   Bao, Ting
TI Effects and safety of traditional Chinese medicine approaches in cancer symptom
SO Cancer
LA English
DT Journal Article
DE Tai Chi; acupuncture; herbal therapies; neoplasms; phase 3 clinical trials; symptom burden; systematic review; traditional Chinese medicine
AB Cancer-related symptoms are detrimental to the quality of life of people with  cancer. This review systematically evaluates phase 3 randomized clinical trials  (RCTs) assessing the effectiveness and safety of traditional Chinese medicine  (TCM) interventions in managing cancer-related symptoms throughout the cancer  care trajectory. A comprehensive literature search was conducted of PubMed,  Embase, and the Cochrane Library until April 27, 2025, to further identify  eligible RCTs involving patients with cancer or survivors and assessing TCM  interventions against valid control arms. Data extraction and quality assessments  were conducted in accordance with Cochrane standards and Preferred Reporting  Items for Systematic Reviews and Meta-Analyses guidelines. Nineteen phase 3 RCTs  involving 5387 participants (female, 3321; primarily breast, gastrointestinal,  and lung cancers) from six countries or regions were included. Nonpharmacological  interventions, namely acupuncture and Tai Chi, significantly reduced pain,  fatigue, insomnia, radiation-induced xerostomia, and hormonal therapy-related hot  flashes compared to usual care (UC). Their effects on preventing chemotherapy-  and radiotherapy-induced nausea and vomiting were mixed, which depended on  control arms and outcome measures. Conversely, evidence for pharmacological  interventions was limited, with inconclusive results regarding  chemotherapy-induced peripheral neuropathy and hematologic toxicities, although  promising outcomes were noted for preventing chemoradiotherapy-induced mucositis,  reducing colorectal adenoma recurrence, and enhancing chemotherapy completion  rates compared to placebo or UC. Safety data suggested similar adverse event  profiles across groups. These findings show strong evidence for the inclusion of  nonpharmacological interventions in oncology practice. However, pharmacological  interventions require more high-quality, multicenter research to fully understand  their effectiveness and safety. Implementing rigorous safety assessments and  standardized adverse event reporting protocols is crucial to enhance clinical  confidence in TCM modalities.
C1 School of Biological Sciences, Nanyang Technological University, Singapore.
   School of Biological Sciences, Nanyang Technological University, Singapore.
   Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
   School of Biological Sciences, Nanyang Technological University, Singapore.
   School of Biological Sciences, Nanyang Technological University, Singapore.
   College of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
NR 0
TC 0
SN 1097-014
EI 
J9 Cancer
PD NOV 11
PY 2025
VL 131
IS 22
BP e70170
EP e70170
DI 10.1002/cncr.70170
PG 1
WC Female; Humans; Acupuncture Therapy; adverse effects; Clinical Trials, Phase III as Topic; Medicine, Chinese Traditional; methods; Neoplasms; therapy; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:41217297
PM 41217297
DA 2025-11-11
ER

PT J
AU Li, YX
   Li, B
   Cui, Y
   Yang, XM
   Wang, SX
   Wang, XD
   Li, MY
   Tu, YF
   Jing, AN
   Zhou, YT
   Luo, M
AF Li, Yuxian
   Li, Bo
   Cui, Ying
   Yang, Xinming
   Wang, Sixuan
   Wang, Xiangdong
   Li, Mingyue
   Tu, Yufeng
   Jing, Anna
   Zhou, Yutong
   Luo, Mei
TI Acupuncture for chronic cancer pain: a systematic review and meta-analysis
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Review
DE Acupuncture; Chronic cancer pain; ICD-11; Meta-analysis; GRADE assessment
ID quality-of-life; breast-cancer; management; women
AB Introduction Pain is highly prevalent among cancer patients. Cancer pain is classified as chronic cancer pain (MG30.10) and chronic post-cancer treatment pain (MG30.11) in the International Classification of Diseases, 11th Revision (ICD-11). This research aims to ascertain the efficacy and safety of acupuncture in treating chronic cancer pain (MG30.10). Methods Eight Chinese and English databases were systematically searched from their inception to December 31, 2024, to identify randomized controlled trials (RCTs) that examined the efficacy of acupuncture in combination with active treatments versus active treatment alone (identical to the treatment group), no treatment, or sham acupuncture for cancer pain management. The risk of bias was assessed using the version 2 of the Cochrane risk-of-bias tool (ROB 2.0), and data analysis was conducted utilizing RevMan 5.4 and Stata 17.0. Additionally, the quality of evidence was evaluated using the grading of recommendations assessment, development, and evaluation (GRADE) approach. Results A total of 21 RCTs were included in the meta-analysis, involving 1432 patients. The meta-analysis revealed that compared to the control group, the treatment group exhibited significantly reduced Numeric Rating Scales (NRS) scores (mean difference (MD) = -0.93, 95 % confidence interval (CI) [-1.21, -0.64], P<0.00001, low certainty), fewer burst pain events (MD = -2.13, 95 % CI [-2.86, -1.39], P < 0.00001, low certainty), reduced analgesic consumption (standard mean difference (SMD) =-0.60, 95 % CI [-0.84, -0.37], P<0.00001, moderate certainty), improved quality of life (MD =6.37, 95 % CI [3.21, 9.54], P<0.0001, low certainty), and diminished side effects of taking analgesics, with no serious adverse effects of acupuncture treatment. Conclusion The integration of acupuncture with analgesic drugs has demonstrated considerable potential to significantly mitigate pain and ameliorate adverse effects of analgesics in patients with chronic cancer pain (MG30.11). However, further high-quality RCTs are required to elucidate the efficacy of acupuncture in cancer pain management and optimize treatment protocols. Registration CRD42024550206
C1 [Li, Yuxian; Li, Bo; Cui, Ying; Yang, Xinming; Wang, Sixuan; Wang, Xiangdong; Li, Mingyue; Tu, Yufeng; Jing, Anna; Zhou, Yutong; Luo, Mei] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, 88 Changling Rd, Tianjin 300381, Peoples R China.
   [Li, Yuxian; Li, Bo; Cui, Ying; Yang, Xinming; Wang, Sixuan; Wang, Xiangdong; Li, Mingyue; Tu, Yufeng; Jing, Anna; Zhou, Yutong; Luo, Mei] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Acupuncture & Moxibust, 314 Anshan Xi Rd, Tianjin 300193, Peoples R China.
   [Li, Yuxian; Cui, Ying; Yang, Xinming; Wang, Sixuan; Wang, Xiangdong; Li, Mingyue; Tu, Yufeng; Jing, Anna; Zhou, Yutong; Luo, Mei] Tianjin Univ Tradit Chinese Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
   [Li, Bo] Qinghai Prov Hosp Tradit Chinese Med, 338 Qiyi Rd, Xining 810000, Qinghai, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Li, B (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Acupuncture & Moxibust, 314 Anshan Xi Rd, Tianjin 300072, Peoples R China.
EM ibou119@163.com
FU Open Project of National Clinical Research Center for Chinese Medicine Acupuncture [NCRCOP2023009]
CR Bennett MI, 2019, PAIN, V160, P38, DOI 10.1097/j.pain.0000000000001363
   C.M.A.P.S. China Pain Medicine Association National Pain Specialty Medical Quality Control Center & Beijing Pain Treatment Quality Control and Improvement Center, 2023, CHIN. J. CANCER PAIN MED., V29, P881, DOI 10.3969/j.issn.1006-9852.2023.12.001
   Caraceni A, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040510
   Chams Cyril, 2022, REV MED SUISSE, V18, P1259, DOI 10.53738/revmed.2022.18.787.1259
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Cherny NI, 2000, CA-CANCER J CLIN, V50, P70, DOI 10.3322/canjclin.50.2.70
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Fan LY, 2017, FAM. MED., V0, PP1, DOI 10.3969/j.issn.1671-4954.2017.01.001
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Gao Xin, 2020, ZHONGGUO ZHEN JIU, V40, P601, DOI 10.13703/j.0255-2930.20190531-k0001
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Gu YY, 2024, J. CLIN. ACUPUNCT. MOXIBUSTION, V40, P106, DOI 10.19917/j.cnki.1005-0779.024020
   Guo ZB, 2015, INT. J. TRAD. CHIN. MED., V0, PP371, DOI 10.3760/cma.j.issn.1673-4246.2015.04.023
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   [惠建荣 Hui Jianrong], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P146
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kocot-Kepska M, 2021, WSPOLCZESNA ONKOL, V25, P88, DOI 10.5114/wo.2021.105969
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Lu Dian-Rong, 2021, ZHONGGUO ZHEN JIU, V41, P121, DOI 10.13703/j.0255-2930.20190320-0010
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Ma TY, 2023, ASIAN J SURG, V46, P5029, DOI 10.1016/j.asjsur.2023.06.060
   Mestdagh F, 2023, CURR ONCOL, V30, P6838, DOI 10.3390/curroncol30070500
   Ni J, 2021, HUNAN J TRADIT CHIN MED, V37, P114, DOI 10.16808/J.CNKI.ISSN1003-7705.2021.08.041
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Ramsey I, 2020, J PATIENT-REP OUTCOM, V4, P0, DOI 10.1186/s41687-020-00244-3
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Silberstein M, 2009, J THEOR BIOL, V261, P637, DOI 10.1016/j.jtbi.2009.09.008
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   von Moos R, 2017, EUR J CANCER, V71, P80, DOI 10.1016/j.ejca.2016.10.021
   Wang H, 2018, HENAN TRADIT. CHIN. MED., V38, P454, DOI 10.16367/J.ISSN.1003-5028.2018.03.0120
   Wang J, 2022, CLINICAL OBSERVATION ON THE TREATMENT OF MODERATE AND SEVERE CANCER PAIN OF QI-STAGNATION AND BLOOD-STASIS TYPE BY FILIFORM-FIRE NEEDLE COMBINED WITH THREE-STEP ANALGESIC THERAPY, V0, P0
   Wang JC, 2024, MOD. J. INTEGR. TRADIT. CHIN. WEST. MED., V33, P937
   Wang JC, 2024, CHIN. J. GERONTOL., V44, P5677
   Wang Y, 2016, CLINICAL STUDY OF ELECTROACUPUNCTURE COMBINED WITH OXYCODONE FOR ADVANCED NON-SMALL CELL LUNG CANCER PAIN, V0, P0
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Xue N, 2022, MOD. J. INTEGR. TRADIT. CHIN. WEST. MED., V31, P334
   Yan ZB, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.925013
   Yang ZL, 2020, CLINICAL OBSERVATION OF ACUPUNCTURE COMBINED WITH OPIOIDS IN THE TREATMENT OF MODERATE AND SEVERE CANCER PAIN, V0, P0
   Yi Y, 2024, J. ONCOL. CHIN. MED., V6, P54, DOI 10.19811/j.cnki
   Zhang N, 2022, CHINA PRACT MED, V17, P43, DOI 10.14163/j.cnki.11-5547/r.2022.19.010
   Zhang YZ, 2024, CLINICAL STUDY OF WRIST ANKLE ACUPUNCTURE COMBINED WITH OPIOID DRUGS IN THE TREATMENT OF MODERATE TO SEVERE CANCEROUS PAIN, V0, P0
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng X, 2021, J GANSU U CHIN MED C, V38, P64, DOI 10.16841/J.ISSN1003-8450.2021.06.13
   Zhou D, 2023, JOURNAL OF ONCOLOGY IN CHINESE MEDICINE, V5, P30
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
NR 55
TC 0
Z9 0
U1 7
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD AUG 15
PY 2025
VL 77
IS 
BP 
EP 
DI 10.1016/j.eujim.2025.102493
EA JUN 2025
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3RM8P
UT WOS:001507279200001
DA 2026-01-16
ER

PT J
AU Lu, L
   Huang, X
   Liu, C
   Wang, X
   Lv, J
AF Lu, Lingyun
   Huang, Xianhao
   Liu, Ci
   Wang, Xiaoyu
   Lv, Jianqin
TI Perioperative intradermal acupuncture reduces postoperative nausea and vomiting
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE PC6; intradermal acupuncture; metabolomics; postoperative nausea and vomiting; randomized controlled trial
AB BACKGROUND: The aim of this study was to evaluate the impact of intradermal  acupuncture (IA) at PC6 on postoperative nausea and vomiting (PONV) following  cerebellopontine angle tumor resection, and to investigate possible mechanisms of  action. METHODS: Seventy patients scheduled for elective craniotomy were  randomized into IA or sham IA (Sham) groups, with interventions applied 1 h  before surgery and continued for 24 h postoperatively. Co-primary outcomes were  the incidence of vomiting at 0-6 h and 6-24 h post-surgery. Secondary outcomes  included the incidence of nausea and pain intensity. Electrogastrography (EGG)  and heart rate variability (HRV) were used to assess gastric activity and  autonomic nerve function, respectively. Untargeted metabolomic analysis of serum  and cerebrospinal fluid (CSF) was also performed. RESULTS: The incidence of  vomiting at 6-24 h (but not 0-6 h) post-surgery was significantly lower in the IA  group (12.1%) compared to the Sham group (36.4%; p = 0.022). IA significantly  reduced the incidence of nausea at 0-6 h (48.5% vs 78.8%; p = 0.011) but not  6-24 h. HRV analysis showed a higher HF component in the IA group post-surgery.  Metabolomic analyses revealed significant changes in multiple metabolites and  pathways in serum and CSF. CONCLUSION: IA stimulation at PC6 effectively reduced  postoperative vomiting at 6-24 h following cerebellopontine angle tumor resection  and may also reduce early nausea (at 0-6 h). The mechanisms of action underlying  these effects potentially include modulation of vagus nerve activity and  regulation of metabolic pathways. TRIAL REGISTRATION NUMBER: ChiCTR2100049992  (Chinese Clinical Trial Registry).
C1 Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
   Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
   Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
   Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
   Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD NOV 28
PY 2025
VL 43
IS 6
BP 330
EP 343
DI 10.1177/09645284251399690
PG 13
WC Humans; Female; Male; Postoperative Nausea and Vomiting; therapy; Middle Aged; Acupuncture Therapy; Adult; Cerebellopontine Angle; surgery; Aged; Acupuncture Points
UT PubMed:41310932
PM 41310932
DA 2025-11-28
ER

PT J
AU Zhang, FF
   Zhang, XN
   Zhang, XH
   Nian, FH
   Yuan, B
   Li, F
   Hu, LL
   Li, XJ
   Wang, HD
   DU, XZ
AF Zhang, Feng-Fan
   Zhang, Xiao-Na
   Zhang, Xing-Hua
   Nian, Fang-Hong
   Yuan, Bo
   Li, Fang
   Hu, Le-le
   Li, Xiang-Jun
   Wang, Hai-Dong
   DU, Xiao-Zheng
TI [The effect of heat-reinforcing needling on the level of TRAF6-K63 ubiquitination
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Heat-reinforcing needling; Inflammatory response; Nuclear factor-κB pathway; Rheumatoid arthritis; TRAF6 ubiquitination
AB OBJECTIVES: To observe the effect of heat-reinforcing needling on the level of  tumor necrosis factor receptor associated factor 6 (TRAF6)-K63 ubiquitination and  the nuclear factor-κB (NF-κB) pathway in the synovial tissue of the knee joints  of a rabbit model with rheumatoid arthritis (RA) of cold syndrome, so as to  explore the mechanism by which the heat-reinforcing needling inhibits  inflammatory response in RA synovitis. METHODS: Eight out of 32 rabbits were  randomly selected and assigned to the normal group. The remaining rabbits were  induced to establish the RA cold syndrome model using ovalbumin combined with  complete Freund's adjuvant and low-temperature cryogenic methods. After modeling  evaluation, the rabbits were randomly divided into model group, inhibitor group,  and heat-reinforcing needling group, with 6 rabbits in each group. Rabbits in the  inhibitor group received intraperitoneal injection of C25-140 solution (2.5  mg/kg), twice a day for 14 days. Rabbits in the heat-reinforcing needling group  received acupuncture at "Zusanli"(ST36) according to the operation standard of  the heat-reinforcing needling and the needle was retained for 30 min, once a day,  for 14 days. After the intervention, knee joint circumference and pain threshold  of the rabbits were measured. Color Doppler ultrasound was used to observe  changes in knee joint imaging. HE staining was performed to observe morphological  changes in the synovial tissue. Immunohistochemical method was used to observe  the expression of inflammatory factors tumor necrosis factor (TNF)-α, interleukin  (IL)-1β, and IL-6 in the synovial tissue. Western blot was used to detect the  protein expression of ubiquitin-conjugating enzyme E2 13 (Ubc13) and NF-κB p65 in  the synovial tissue, and co-immunoprecipitation was used to detect the level of  TRAF6-K63 ubiquitination in the synovial tissue. RESULTS: Compared with the  normal group, the model group showed a decreased pain threshold (P<0.05),  increased knee joint circumference (P<0.05), and increased average optical  density of TNF-α, IL-1β, and IL-6 in the synovial tissue(P<0.05), as well as  elevated protein expression of NF-κB p65 and TRAF6-K63 ubiquitination levels  (P<0.05), while Ubc13 protein expression was decreased (P<0.05). Compared with  the model group, the heat-reinforcing needling group and the inhibitor group had  increased pain thresholds and reduced knee joint circumferences (P<0.05), and  significantly reduced average optical density of TNF-α, IL-1β, and IL-6 in the  synovial tissue (P<0.05), as well as decreased protein expression of NF-κB p65,  TRAF6-K63 ubiquitination levels (P<0.05), while Ubc13 protein expression was  increased (P<0.05). Compared to the heat-reinforcing needling group, the  inhibitor group showed reduced pain threshold (P<0.05), and lower average optical  density values of TNF-α, IL-1β, IL-6 in the synovial tissue (P<0.05), as well as  decreased expression of NF-κB p65 protein, TRAF6-K63 ubiquitination levels  (P<0.05), while Ubc13 protein expression was increased (P<0.05). The imaging  changes of the knee joints and the pathological morphological changes of the  synovial tissues in the two treatment groups are both less severe than those in  the model group. CONCLUSIONS: The heat-reinforcing needling may inhibit  inflammatory response in synovitis by suppressing TRAF6-K63 ubiquitination  levels, down-regulating the activity of the NF-κB pathway, and reducing the  secretion of downstream inflammatory factors.
C1 Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Jining Hospital of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Jining 272000, Shandong Province.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730000, China.
   Gansu University of Chinese Medicine, Lanzhou 730000. lz-duxiaozheng@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUN 24
PY 2025
VL 50
IS 6
BP 641
EP 648
DI 10.13702/j.1000-0607.20240329
PG 7
WC Animals; Rabbits; Arthritis, Rheumatoid; therapy; Knee Joint; metabolism; Acupuncture Therapy; NF-kappa B; genetics; Synovial Membrane; metabolism; Ubiquitination; Humans; TNF Receptor-Associated Factor 6; genetics; Male; Acupuncture Points; Female; Signal Transduction
UT PubMed:40551646
PM 40551646
DA 2025-06-24
ER

PT J
AU Zhang, DT
   Shi, GX
   Jia, JY
   Tan, FW
   Qi, Y
   Liang, W
   Zhao, ZJ
   Yuan, P
   Gao, Y
   Zhang, GC
   Liu, XH
   Yang, JW
   Wang, LQ
   Wang, X
   Yang, NN
   Tu, JF
   Liu, CZ
AF Zhang, Dan-Tong
   Shi, Guang-Xia
   Jia, Jin-Ying
   Tan, Feng-Wei
   Qi, Yu
   Liang, Wei
   Zhao, Zhi-Jun
   Yuan, Ping
   Gao, Ya
   Zhang, Guo-Chao
   Liu, Xue-Hui
   Yang, Jing-Wen
   Wang, Li-Qiong
   Wang, Xiao
   Yang, Na-Na
   Tu, Jian-Feng
   Liu, Cun-Zhi
TI Electroacupuncture for acute postoperative pain during coughing after video-assisted thoracoscopic surgery: study protocol for a pilot randomized controlled trial
SO PLOS ONE
LA English
DT Article
ID lung-cancer; thoracotomy
AB Background Despite the use of multimodal analgesia regimens following video-assisted thoracoscopic surgery (VATS), acute postoperative pain persists. Electroacupuncture (EA) may alleviate acute postoperative pain following VATS; however, current evidence remains insufficient.Objectives This trial will assess the feasibility and efficacy of EA as an adjunctive treatment compared with sham electroacupuncture (SA) for managing acute postoperative pain during coughing after VATS.Study design and methods In this pilot randomized controlled trial, 60 patients with non-small-cell lung cancer who will undergo VATS will be randomly assigned to either the EA or SA group in a 1:1 ratio. Patients will receive standard care combined with four sessions of EA or SA within 72 h after surgery. The primary outcome will be the average postoperative pain score during coughing, measured using a numeric rating scale within 72 h after surgery. Secondary outcomes will include the average daily pain scores at rest, during coughing, and while mobilizing; incidence of chronic post-surgical pain; quality of life; cough symptom score; and analgesic consumption. All adverse events will be recorded in detail.Discussion This study will determine whether EA as an adjunctive treatment can reduce acute postoperative pain during coughing following VATS.Trial registration ClinicalTrial.gov ITMCTR2024000170 (http://itmctr.ccebtcm.org.cn/zh-CN/Home/ProjectView?pid=f1a344f7-7e06-4665-ad9d-0917d588eba6).
C1 [Zhang, Dan-Tong; Shi, Guang-Xia; Yang, Jing-Wen; Wang, Li-Qiong; Wang, Xiao; Yang, Na-Na; Tu, Jian-Feng; Liu, Cun-Zhi] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Jia, Jin-Ying; Qi, Yu; Liang, Wei; Zhao, Zhi-Jun; Yuan, Ping; Gao, Ya] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Tan, Feng-Wei; Zhang, Guo-Chao] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing, Peoples R China.
   [Liu, Xue-Hui] Tianjin Univ, Med Coll, Tianjin, Peoples R China.
C3 Beijing University of Chinese Medicine; Zhengzhou University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Tianjin University
RP Yang, NN; Tu, JF (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
EM 1254614551@qq.com; tujianfeng1@126.com
FU National Administration of Traditional Chinese Medicine
CR Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016
   Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X
   Cao C, 2013, INTERACT CARDIOV TH, V16, P244, DOI 10.1093/icvts/ivs472
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen SS, 2019, INT J SURG, V69, P132, DOI 10.1016/j.ijsu.2019.05.013
   Chen TY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2126416
   Fletcher D, 2015, EUR J ANAESTH, V32, P725, DOI 10.1097/EJA.0000000000000319
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Hsu HC, 2022, J NURS SCHOLARSHIP, V54, P411, DOI 10.1111/jnu.12751
   Hutchinson PJ, 2023, NEW ENGL J MED, V388, P2219, DOI 10.1056/NEJMoa2214172
   James KE, 1996, STAT MED, V15, P1421
   Jiang YY, 2023, COMPLEMENT THER MED, V77, P0, DOI 10.1016/j.ctim.2023.102980
   Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9
   Lin RJ, 2022, GEN THORAC CARDIOVAS, V70, P735, DOI 10.1007/s11748-022-01791-w
   Liu JM, 2024, PAIN RES MANAG, V2024, P0, DOI 10.1155/2024/5365456
   Ma X, 2023, ACUPUNCT HERB MED, V3, P139, DOI 10.1097/HM9.0000000000000069
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, PST1, DOI 10.1089/acm.2010.1610
   Pang LN, 2023, ACUPUNCT HERB MED, V3, P285, DOI 10.1097/HM9.0000000000000087
   Shi W, 2021, J CLIN ANESTH, V75, P0, DOI 10.1016/j.jclinane.2021.110526
   Tu JF, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.25735
   Wang H, 2017, J CLIN NURS, V26, P2744, DOI 10.1111/jocn.13789
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Zhang AL, 2024, ACUPUNCT HERB MED, V4, P346, DOI 10.1097/HM9.0000000000000093
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhou Mintao, 2017, ZHONGGUO ZHEN JIU, V37, P705, DOI 10.13703/j.0255-2930.2017.07.006
NR 25
TC 0
Z9 0
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2025
VL 20
IS 3
BP 
EP 
DI 10.1371/journal.pone.0316698
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 0VD0K
UT WOS:001456749600020
PM 40138259
DA 2026-01-16
ER

PT J
AU Etchegaray, A
   Mudaliar, S
   Devereaux, B
AF Etchegaray, Amirah
   Mudaliar, Sanjivan
   Devereaux, Benedict
TI Endosonographically confirmed type III choledochal cyst managed with endoscopic
SO VideoGIE : an official video journal of the American Society for Gastrointestinal
LA English
DT Journal Article
AB BACKGROUND AND AIMS: Type III choledochal cysts consist of a cystic dilatation of  the intraduodenal portion of the common bile duct and represent the rarest  subtype, with a low risk of malignancy. Traditionally, choledochoceles are  treated with surgical resection or endoscopic choledochal cyst fenestration with  cannulation of the cyst via the native papilla and marsupialization using a  sphincterotome. We describe a novel approach to management of a type IIIA  choledochal cyst with endoscopic needle-knife division and marsupialization of a  type IIIA choledochal cyst. METHODS: A 19-year-old male nonsmoker with a 5-year  history of intermittent, colicky epigastric pain was referred to our tertiary  center for management of a large (69 × 53 × 89 mm) type IIIA choledochal cyst  confirmed on MRCP. Duodenoscopy revealed a large pendulous mass, with significant  medial displacement of the duodenum and intermittent gastric outlet obstruction,  that prevented clear visualization of the distally located papilla. After careful  multidisciplinary team discussion, it was decided that endoscopic needle-knife  division and marsupialization would be undertaken to reduce biliary stasis and  the chance of further ductal stone formation. RESULTS: Needle-knife division was  performed using a freehand technique using ENDO CUT I (30 W, 3d 3i). To  decompress the cyst, a large incision was made from the inferior to superior  position on the luminal aspect of the cyst. Further incisions were made to  marsupialize the cyst cavity and allow complete drainage of the cystic content  into the duodenum. The patient tolerated the procedure well, with no bleeding  postprocedure. Serial imaging demonstrated complete resolution of the large  choledochal cyst, with no adverse events at last follow-up (12 months after the  procedure). CONCLUSIONS: Endoscopic needle-knife division and marsupialization is  an effective novel approach for the treatment of symptomatic choledochoceles;  however, more data are required to evaluate the long-term safety of this  approach.
C1 Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Herston, Australia.
   University of Queensland, Brisbane, Australia.
   Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Herston, Australia.
   University of Queensland, Brisbane, Australia.
   Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Herston, Australia.
   University of Queensland, Brisbane, Australia.
NR 0
TC 0
SN 2468-448
EI 
J9 VideoGIE
PD JUL 24
PY 2025
VL 10
IS 8
BP 406
EP 409
DI 10.1016/j.vgie.2025.03.035
PG 3
UT PubMed:40704112
PM 40704112
DA 2025-07-24
ER

PT J
AU Li, FR
   Wan, HJ
   Liu, XH
   Deng, YT
   Tian, WY
   Zhao, ZL
AF Li, Fanrui
   Wan, Hejia
   Liu, Xiaohui
   Deng, Yuanting
   Tian, Wuyang
   Zhao, Zilin
TI Auricular Acupoint Therapy in Symptom Management of Cancer patients: A Scoping Review
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Review
DE auricular point therapy; cancer; symptom management; scoping review
ID single-blind; acupuncture; chemotherapy; acupressure; sleep
AB Background: The incidence of cancer is rising annually. With advances in diagnosis and treatment, cancer patients' long-term survival rates have improved, leading them to gradually enter a chronic disease state. However, they frequently experience physiological and psychological symptoms during treatment, which severely impact their survival and quality of life. Auricular acupoint therapy, a green non-pharmacological intervention characterized by ease of operation and low cost, can alleviate cancerrelated symptoms. Despite its widespread use, systematic summarization and comprehensive evaluation of this therapy remain insufficient. Objective: To systematically analyze the application of auricular therapy in cancer patients, identify its characteristics and intervention effects on symptoms, and provide a reference for symptom management in these patients. Methods: Relevant studies were systematically retrieved from PubMed, Web of Science, Cochrane Library, Embase, CINAHL, CNKI, CBM, WanFang Database, and VIP Database from their inception to April 20, 2025. Data from the included literature were extracted and analyzed. Results: A total of 42 studies were included. Auricular therapy is applicable across multiple stages of cancer care and exerts positive effects on cancer-related pain, fatigue, sleep disorders, anxiety, and chemotherapy-induced symptoms. Notably, the pain-fatigue-sleep disorder cluster is the most common and interrelated symptom group, with auricular acupressure as the most frequently used intervention. Conclusion: Owing to its simplicity and cost-effectiveness, auricular therapy offers unique advantages for managing symptoms in cancer patients. The current focus in this field has shifted from managing single symptoms or individual dimensions within symptom clusters to a comprehensive management of symptom clusters. Future research should pay attention to the dynamic progression of symptoms, focus on the core symptom clusters in cancer patients, and optimize intervention strategies to enhance the efficiency of symptom management.
C1 [Li, Fanrui; Wan, Hejia; Liu, Xiaohui; Deng, Yuanting; Tian, Wuyang; Zhao, Zilin] Henan Univ Chinese Med, Sch Nursing, Nursing Sch Smart Healthcare Ind, Zhengzhou, Henan, Peoples R China.
   [Liu, Xiaohui] Henan Univ Tradit Chinese Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Nursing Dept, Zhengzhou, Henan, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine
RP Liu, XH (corresponding author), Henan Univ Chinese Med, Sch Nursing, Nursing Sch Smart Healthcare Ind, Zhengzhou, Henan, Peoples R China.; Liu, XH (corresponding author), Henan Univ Tradit Chinese Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Nursing Dept, Zhengzhou, Henan, Peoples R China.
EM 1173652033@qq.com
FU Henan Provincial Science and Technology Association Popular Science Project [HNKP2025089]; Henan Provincial Health Commission TCM Culture and Management Research Project [TCM2023009]; Henan Provincial Health Commission TCM Clinical Research Base Special Project [2021JDZX2032]; Henan Provincial Health Commission TCM Scientific Research Special Project [20-21ZY2113]
CR Azevedo C, 2024, EUR J ONCOL NURS, V68, P0, DOI 10.1016/j.ejon.2023.102490
   Bermejo P, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/7830919
   Brant JM, 2016, ONCOL NURS FORUM, V43, P651, DOI 10.1188/16.ONF.651-654
   Brant JM, 2010, J ADV NURS, V66, P228, DOI 10.1111/j.1365-2648.2009.05179.x
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   China National Administration of Traditional Chinese Medicine Department of Medical Administration, 2015, HANDBOOK FOR THE USE OF TRADITIONAL CHINESE MEDICINE TECHNIQUES BY NURSING STAFF, V0, P0
   Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
   Menezes ASD, 2021, OR SURG OR MED OR PA, V131, P675, DOI 10.1016/j.oooo.2021.02.016
   de Moraes TL, 2023, BIOELECTRON MED-US, V9, P0, DOI 10.1186/s42234-023-00109-2
   de Rooij BH, 2021, CANCER-AM CANCER SOC, V127, P4665, DOI 10.1002/cncr.33852
   [邓元婷 Deng Yuanting], 2025, 护士进修杂志 JOURNAL OF NURSES TRAINING, V40, P550
   Dodd M J, 2001, ONCOL NURS FORUM, V28, P465
   Doern GV, 2020, CLIN MICROBIOL REV, V33, P0, DOI 10.1128/CMR.00009-19
   [杜卓雯 Du Zhuowen], 2024, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V43, P1029
   [费超男 Fei Chaonan], 2023, 护理学杂志 JOURNAL OF NURSING SCIENCE, V38, P65
   Han J, 2025, ANHUI MED PHARM J, V29, P1018
   [何桂双 He Guishuang], 2023, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V38, P6151
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Huang L, 1991, AURICULAR DIAGNOSIS AND THERAPY, V0, P0
   Jia T, 2017, CLINICAL STUDY ON SPECIFIC CHANGES OF EAR ACUPUNCTURE IN GASTRIC CANCER, V0, P0
   Jiang X, 2022, J NURS ADVANC, V37, P1929
   Jung MS, 2025, CANCER NURS, V48, PE64, DOI 10.1097/NCC.0000000000001286
   [孔晨 Kong Chen], 2018, 第二军医大学学报 ACADEMIC JOURNAL OF SECOND MILITARY MEDICAL UNIVERSITY, V39, P493
   [李冬梅 Li Dongmei], 2025, 军事护理 MILITARY NURSING, V42, P5
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Lin M, 2024, CHIN MED HERALD, V21, P178
   [刘立安 Liu Lian], 2024, 北京中医药大学学报 JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V47, P903
   Liu S, 1984, CHIN ACUPUNCT MOXIBUSTION, V1984, P43
   Liu Y, 2020, CLINICAL OBSERVATION OF SPECIFIC CHANGES IN AURICULAR POINTS OF THE RIGHT EAR IN PANCREATIC CANCER PATIENTS, V0, P0
   Lu D, 2020, J TRADIT CHIN MED ONCOL, V2, P15
   Lu N, 2024, TIANJIN J TRADITIONAL CHIN MED, V41, P1533
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Marcondes L, 2025, HEALTHCARE-BASEL, V13, P0, DOI 10.3390/healthcare13020166
   Mathew A, 2021, ADV NURS SCI, V44, PE93, DOI 10.1097/ANS.0000000000000347
   Miaskowski C, 2017, JNCI-J NATL CANCER I, V109, P0, DOI 10.1093/jnci/djw253
   Peters MDJ, 2021, JBI EVID IMPLEMENT, V19, P3, DOI 10.1097/XEB.0000000000000277
   Pirnia B, 2019, IRAN J PUBLIC HEALTH, V48, P1748
   Ru OY, 2023, MINERVA ANESTESIOL, V89, P149, DOI 10.23736/S0375-9393.22.16735-0
   Su Y, 2024, J CONTEMP UROL REPROD ONCO, V16, P347
   Tan JY, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03543-y
   van de Castle B, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231198086
   Veroniki AA, 2025, JBI EVID SYNTH, V23, P517, DOI 10.11124/JBIES-24-00308
   Viel E, 2021, MED ACUPUNCT, V33, P212, DOI 10.1089/acu.2020.1506
   Wang L, 2022, CHIN NURS RES, V36, P3156
   Wang M, 2023, EUR J ONCOL NURS, V67, P0, DOI 10.1016/j.ejon.2023.102458
   Wang YY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8637386
   Wu J, 2023, HEBEI J TRAD CHIN MED, V45, P796
   [吴巧红 Wu Qiaohong], 2020, 介入放射学杂志 JOURNAL OF INTERVENTIONAL RADIOLOGY, V29, P1047
   Yang J, 2019, WORLD CHIN MED, V14, P1298, DOI 10.3969/j.issn.1673-7202.2019.05.052
   杨丽, 2016, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V36, P1271
   [杨丽华 Yang Lihua], 2016, 护理学杂志 JOURNAL OF NURSING SCIENCE, V31, P34
   Yang YF, 2024, NEUROL SCI, V45, P2289, DOI 10.1007/s10072-023-07229-2
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Yu Y, 2014, J NAVY MED, V35, P117
   Zeng HM, 2024, J NATL CANCER CTR, V4, P203, DOI 10.1016/j.jncc.2024.06.005
   Zhang D, 2022, MOD J INTEGR TRADITIONAL CHINESE AND WESTERN MED, V31, P3448
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   Zhang S, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.51217
   [张素秋 Zhang Suqiu], 2024, 中国护理管理 CHINESE NURSING MANAGEMENT, V24, P1281
   Zhang Y, 2019, CHIN J GERONTOL, V39, P2958
   [赵卫梅 ZHAO Wei-mei], 2010, 南京中医药大学学报 JOURNAL OF NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V26, P111
   Zhu Hao-Han, 2024, ZHEN CI YAN JIU, V49, P403, DOI 10.13702/j.1000-0607.20221262
   Zhu W, 2012, J CLIN ACUPUNCT MOXIBUSTION, V28, P4
   Zhu W, 2016, SHANDONG J TRADIT CHIN MED, V35, P415
   Zhu Z, 2023, CANCER MED-US, V12, P663, DOI 10.1002/cam4.4904
NR 66
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
EI 
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PD JUN 15
PY 2025
VL 17
IS 
BP 3005
EP 3023
DI 10.2147/CMAR.S562388
PG 19
WC Oncology
SC Oncology
GA N4222
UT WOS:001631557800001
PM 41362632
DA 2026-01-16
ER

PT J
AU Wu, JW
   Li, LP
   Chen, YS
AF Wu, Jing-Wen
   Li, Li-Ping
   Chen, Yin-Song
TI Effects of bottle gourd moxibustion combined with umbilical therapy for
SO World journal of gastroenterology
LA English
DT Journal Article
DE Bottle gourd moxibustion; Cancer-induced bowel obstruction; Gastrointestinal recovery; Inflammatory cytokines; Pain management; Umbilical therapy
AB BACKGROUND: Cancer-induced incomplete bowel obstruction presents numerous  clinical challenges, notably pain management and inflammation control.  Conventional therapies provide limited relief, prompting investigation into  complementary approaches. This study compares the efficacy of bottle gourd  moxibustion combined with umbilical therapy (BGM-UT) plus standard palliative  care vs standard Western palliative care alone in symptom alleviation and  inflammation reduction. AIM: To compare the efficacy of BGM-UT plus standard  palliative care vs standard palliative care alone in reducing inflammatory  cytokine levels, alleviating symptoms, and improving gastrointestinal recovery in  cancer-induced incomplete bowel obstruction. METHODS: A retrospective analysis  was conducted on 109 patients aged 18-75 years with cancer-induced incomplete  bowel obstruction treated at the Foshan Hospital of Traditional Chinese Medicine  between October 2023 and September 2024. The participants were categorized into  two groups: (1) Regular group receiving standard palliative care; and (2) BGM-UT  group receiving additional moxibustion therapy. The inclusion criteria included  ongoing opioid use and a Karnofsky performance status score below 60. The  treatments were evaluated for 3 weeks in terms of opioid consumption,  gastrointestinal function recovery, brief pain inventory scores, traditional  Chinese medicine symptom scores, and inflammatory cytokine levels. RESULTS:  Initially, the groups were demographically and clinically comparable.  Post-treatment, the BGM-UT group showed significant reductions in opioid intake  (P = 0.027), improved gastrointestinal recovery times, and enhanced pain  management as reflected by their lower brief pain inventory scores (P < 0.05).  Similarly, the improvement in traditional Chinese medicine scores was greater in  the BGM-UT group than in the regular group (P < 0.05). Inflammatory markers  including interleukin-6, tumor necrosis factor-α, and C-reactive protein  decreased significantly in the BGM-UT group, indicating the superior  anti-inflammatory effects of this treatment (P < 0.05). CONCLUSION: The addition  of BGM-UT to standard palliative care enhances pain relief, accelerates  gastrointestinal recovery, and effectively reduces inflammatory cytokine levels  in patients with cancer-induced incomplete bowel obstruction. This combination  therapy offers a promising complementary approach to managing this challenging  condition. Further prospective studies are warranted to validate these findings  and explore underlying mechanisms.
C1 Department of Oncology, Foshan Hospital of Traditional Chinese Medicine, The Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan528000, Guangdong Province, China.
   Department of Oncology, Foshan Hospital of Traditional Chinese Medicine, The Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan528000, Guangdong Province, China. 13794038664@163.com.
   Department of Oncology, Foshan Hospital of Traditional Chinese Medicine, The Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan528000, Guangdong Province, China.
NR 0
TC 0
SN 2219-284
EI 1007-932
J9 World J Gastroenterol
PD NOV 19
PY 2025
VL 31
IS 41
BP 110753
EP 110753
DI 10.3748/wjg.v31.i41.110753
PG 0
WC Humans; Moxibustion; methods; Middle Aged; Male; Female; Retrospective Studies; Palliative Care; methods; Intestinal Obstruction; therapy; Adult; Aged; Neoplasms; complications; Cytokines; blood; Treatment Outcome; Combined Modality Therapy; methods; Young Adult; Pain Measurement; Adolescent; Pain Management; methods; Medicine, Chinese Traditional; methods
UT PubMed:41257282
PM 41257282
DA 2025-11-19
ER

PT J
AU Lukkahatai, N
   Benjasirisan, C
   Shen, A
   Li, J
   Allgood, SJ
   Thomas, F
   Karyukin, A
   Sheng, JY
   Engle, JP
   Lee, TY
   Saligan, LN
AF Lukkahatai, Nada
   Benjasirisan, Chitchanok
   Shen, Aomei
   Li, Junxin
   Allgood, Sarah j
   Thomas, Frank
   Karyukin, Artyom
   Sheng, Jennifer y
   Engle, Jessica p
   Lee, Ta ya
   Saligan, Leorey n
TI Combined technology-enhanced home exercise and acupressure (TEHEplus) program on symptoms among cancer patients receiving immunotherapy: a feasibility study
SO BMC Cancer
LA English
DT Article
DE Acupressure; Cancer; Exercise; Immunotherapy; Mobile health
ID nivolumab; pertuzumab; sipuleucel t; trastuzumab; acupressure; acupuncture point; adult; aged; anxiety; article; cancer patient; depression; exercise; fatigue; feasibility study; female; human; immunotherapy; male; pain; phase 1 clinical trial; phase 2 clinical trial; pilot study; randomization; short physical performance battery; sleep; social interaction; technology enhanced home exercise; very elderly; adverse event; clinical trial; controlled study; etiology; immunology; kinesiotherapy; middle aged; neoplasm; procedures; quality of life; randomized controlled trial; therapy; acupressure; aged; aged, 80 and over; exercise; exercise therapy; fatigue; feasibility study; female; humans; immunotherapy; male; middle aged; neoplasms; pilot projects; quality of life
AB Background: Cancer patients receiving immunotherapy often experience symptoms impacting their well-being. The present study aimed to develop and test the feasibility of a 12-week Technology-Enhanced Home Exercise and acupressure (TEHEplus) program to improve symptoms (fatigue, pain, sleep, anxiety, depression), social functioning, physical performance, and serum biomarkers (brain-derived neurotrophic factor, heat shock protein 90 levels.) Methods: A two-phase design was employed. Phase 1 involved program development; Phase 2 was a pilot feasibility study. Participants with solid tumor cancers were recruited from cancer centers in Maryland and randomly assigned to four groups: Usual Care Control (UC), Technology-Enhanced Home Exercise (TEHE) alone, Acupressure alone (ACU), and TEHEplus. Feasibility was measured by enrollment duration, intervention adherence, and daily survey response rates. Outcomes were measured at baseline and program completion. Results: In phase 1, four participants (age 56–82) provided feedback on online training, smartphone application, intervention duration, and outcome measures. In Phase 2, 40 participants (10 per group) were recruited over 12 months, with 43% (n = 17) completing all daily surveys. TEHEplus participants achieved 50% of exercise goals, and 78% adhered to the acupoint recommendations. TEHEplus participants showed significant improvements in fatigue (p = 0.02), pain inference (p = 0.30), and social functioning (p = 0.03); TEHE participants improved only in social functioning (p = 0.03). Conclusion: TEHEplus is feasible and shows promise for symptom alleviation. Preliminary findings suggest potential benefits in symptom management and functional outcomes. However, further studies with larger and more diverse samples are warranted to explore its efficacy and generalizability.Further studies with larger, more diverse populations are needed to confirm its efficacy. TEHEplus may enhance symptom management and improve functional outcomes for cancer survivors undergoing immunotherapy. Trial registration: ClinicalTrials.gov ID NCT03576274 Trial Registration Date: 06/07/2018. © The Author(s) 2025.
C1 Lukkahatai, Nada, Johns Hopkins School of Nursing, Baltimore, MD, United States
   Benjasirisan, Chitchanok, Johns Hopkins School of Nursing, Baltimore, MD, United States
   Tianjin Medical University Cancer Institute & Hospital, Shen, Aomei, Tianjin, Tianjin, China
   Li, Junxin, Johns Hopkins School of Nursing, Baltimore, MD, United States
   Johns Hopkins School of Nursing, Baltimore, MD, United States
   Thomas, Frank, Johns Hopkins School of Nursing, Baltimore, MD, United States
   Karyukin, Artyom, Johns Hopkins School of Nursing, Baltimore, MD, United States
   Johns Hopkins University School of Medicine, Baltimore, MD, United States
   Johns Hopkins University School of Medicine, Baltimore, MD, United States
   Johns Hopkins University School of Medicine, Lee, Ta Ya, Baltimore, MD, United States
   Rutgers School of Nursing, Newark, NJ, United States
CR Feng, 1900, SYMPTOMS, V0, P63
   Yin, 1900, IMMUNE-RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS: A REVIEW, V0, P14
   Wang, 1900, TREATMENT-RELATED ADVERSE EVENTS OF PD-1 AND PD-L1 INHIBITORS IN CLINICAL TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS, V0, P1008-1019
   Petrelli, 1900, IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL IN SOLID TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS, V0, P1-7
   Yang, 1900, SYMPTOM CLUSTERS AND SYMPTOM NETWORK ANALYSIS DURING IMMUNOTHERAPY IN LUNG CANCER PATIENTS, V0, P11
   Guven, 1900, THE BURDEN OF POLYPHARMACY AND DRUG–DRUG INTERACTIONS IN OLDER CANCER PATIENTS TREATED WITH IMMUNOTHERAPY, V0, P785-793
   Mao, 1900, 2022, V0, P0
   Mustian, 1900, 2017, V0, P0
   Hilfiker, 1900, EXERCISE AND OTHER NON-PHARMACEUTICAL INTERVENTIONS FOR CANCER-RELATED FATIGUE IN PATIENTS DURING OR AFTER CANCER TREATMENT: A SYSTEMATIC REVIEW INCORPORATING AN INDIRECT-COMPARISONS META-ANALYSIS, V0, P651-658
   Smith, 1900, CANCER SURVIVORS’ ATTITUDES TOWARDS AND KNOWLEDGE OF PHYSICAL ACTIVITY, V0, P4
NR 10
TC 0
SN 14712407
EI 
J9 BMC CANCER
JI BMC Cancer
PD JUN 15
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12885-025-14887-2
PG 0
UT Scopus:10.1186/s12885-025-14887-2
ER

PT J
AU Zhu, ZX
   Chen, C
   Zheng, YF
   Gong, WL
   Chen, Z
   Fang, SL
   Shao, DH
   Sun, CX
AF Zhu, Zhi-Xin
   Chen, Chen
   Zheng, Yong-Feng
   Gong, Wei-Li
   Chen, Zheng
   Fang, Shi-Lei
   Shao, Dong-Hua
   Sun, Cai-Xia
TI Buccal Acupuncture Alleviates Postoperative Pain in Patients Undergoing Radical
SO Chinese journal of integrative medicine
LA English
DT Journal Article
DE Chinese medicine; acupuncture analgesia; buccal acupuncture; gastrointestinal cancers; postoperative pain; recovery quality
AB OBJECTIVE: To preliminarily investigate the effect of buccal acupuncture therapy  on ameliorating postoperative pain and enhancing recovery quality among patients  undergoing radical resection of gastrointestinal cancers. METHODS: Fifty-two  participants were randomized at a 1:1 ratio to either the buccal acupuncture or  the control group. The acupuncture protocol entailed targeting 5 predetermined  acupoints [CA-2 (Upper jiao), CA-3 (Middle jiao), CA-4 (Lower jiao), CA-6 (back),  and CA-7 (waist) and two adjustable acupoints [CA-1 (head) and CA-8 (sacrum)] on  each side of the face. The outcomes included the Numeric Rating Scale (NRS)  scores for each day within 7 days postoperatively, 15-Item Quality of Recovery  Scale (QoR-15) scores, analgesics consumption during and after surgery,  incidences of postoperative nausea and vomiting, and perioperative levels of  interleukin-6 and glucose. Adverse events related to acupuncture were recorded.  RESULTS: Of the initial 52 participants, 46 completed the study and were included  in the analysis. Findings indicated that the buccal acupuncture group experienced  significantly reduced resting NRS scores in post-anesthesia care unit and  throughout the postoperative phase (P=0.001 and P=0.003, respectively), along  with enhanced QoR-15 scores on the 3rd postoperative day (P=0.008), compared to  the control group. No notable differences were identified in the remaining  indicators (P>0.05). CONCLUSION: Buccal acupuncture therapy demonstrated  significant effectiveness in reducing postoperative pain and improving recovery  quality for patients undergoing radical resection of gastrointestinal cancers,  presenting a viable intervention without associated adverse outcomes. (Trial  registration No. ChiCTR2200060441).
C1 Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Acupuncture and Moxibustion, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China.
   Department of Anesthesiology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212002, China. suncaixia_zj@126.com.
NR 0
TC 0
SN 1993-040
EI 
J9 Chin J Integr Med
PD MAR 14
PY 2025
VL 31
IS 6
BP 558
EP 565
DI 10.1007/s11655-025-4128-y
PG 7
WC Humans; Male; Pilot Projects; Female; Acupuncture Therapy; methods; Pain, Postoperative; therapy; Middle Aged; Gastrointestinal Neoplasms; surgery; Aged; Acupuncture Points; Adult
UT PubMed:40080251
PM 40080251
DA 2025-03-14
ER

PT J
AU Machi, A
   Patel, A
   Ottestad, E
AF Machi, Anthony
   Patel, Ankur
   Ottestad, Einar
TI Nerve stimulation and neuromodulation for painful nerves: a narrative review.
SO International orthopaedics
LA English
DT Review
DE Axon regeneration; Neuromodulation; Neuropathic pain; Percutaneous electrical nerve stimulation; Peripheral nerve stimulation; Transcutaneous electrical nerve stimulation
AB Nerve injury primarily leads to neuropathic pain but may also have overlapping  elements of nociplastic pain or ongoing nociceptive pain. Electrical stimulation  is particularly effective in the treatment of neuropathic pain and may be  effective for nociplastic and nociceptive pain. While multiple mechanisms  contribute to the analgesic effect of electrical stimulation, the most widely  accepted theory for the predominant effect is that of Melzack and Wall's gate  control theory. According to this theory, non-painful sensory input carried by  low-threshold large-diameter Aβ fibres disrupt the transmission of pain signals  in small pain fibers (Aδ and C fibres). This occurs through the activation of  inhibitory interneurons in the dorsal horn, which ultimately blocks pain signal  transmission.This theory has been employed for different forms of stimulation,  including transcutaneous electrical nerve stimulation (TENS), percutaneous  electrical nerve stimulation (PENS), and peripheral nerve stimulation (PNS). Each  of these methods offers a different approach to localized stimulation and  neuromodulation for the treatment of pain. TENS is a non-invasive technique, that  delivers electrical currents via surface electrodes placed on the skin. PENS, in  contrast, is a minimally invasive method that applies electrical currents through  small needles inserted near a target muscle or neural structure. PNS involves the  implantation of temporary or permanent electrodes to deliver electrical  stimulation directly to peripheral nerves. These modalities are widely used to  manage various pain conditions including non-malignant, chronic musculoskeletal  and neuropathic pain, such as chronic low back pain, neck pain, neuropathic pain,  myofascial pain, and post-operative pain. TENS is particularly notable as a  non-invasive device that is affordable, over-the-counter, self-administered, and  nonpharmacological option that does not pose the risk of toxicity or overdose.  PENS stands out for its ability to integrate electrical stimulation therapy with  electroacupuncture through a minimally invasive technique. PNS, on the other  hand, is unique in its capacity to precisely target specific nerves and provide a  range of stimulation options for extended treatment durations.This article  provides a narrative overview of TENS, PENS and PNS with a particular focus on  their application for neuropathic pain management and for athletes. We will  review mechanisms of action, indications, diagnostic and treatment algorithms, as  well as complications and limitations. The overview concludes with a complex case  study demonstrating the use of various electrical stimulation therapies,  ultimately to successful pain resolution for the patient.
C1 Stanford University, Stanford, USA. amachi@stanford.edu.
   Novant Health Spine Specialists, Winston Salem, USA.
   Stanford University, Stanford, USA.
NR 0
TC 0
SN 1432-519
EI 
J9 Int Orthop
PD MAR 20
PY 2025
VL 49
IS 5
BP 989
EP 996
DI 10.1007/s00264-025-06498-0
PG 7
WC Humans; Neuralgia; therapy; Transcutaneous Electric Nerve Stimulation; methods; Electric Stimulation Therapy; methods; Pain Management; methods
UT PubMed:40111452
PM 40111452
DA 2025-03-20
ER

PT J
AU Yeh, ML
   Hsu, CC
   Lin, MT
   Lin, CJ
   Lin, JG
AF Yeh, Mei-Ling
   Hsu, Chin-Che
   Lin, Matthew
   Lin, Chuan-Ju
   Lin, Jaung-Geng
TI Effects of acupuncture-related intervention on chemotherapy-induced peripheral neuropathy and quality of life: An umbrella review
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Pain; Quality of life; Umbrella review
ID nonpharmacological interventions
AB Background: Numerous studies have explored the role of acupuncture-related treatments in alleviating chemotherapy-induced peripheral neuropathy (CIPN) and improving the quality of life for patients with cancer, resulting in mixed findings. This umbrella review aimed to synthesize existing systematic reviews (SRs) to deliver an updated assessment of the certainty of evidence concerning the effects of acupuncture-related treatments on CIPN and quality of life among a diverse group of patients with cancer. Methods: This umbrella review considered eligible SRs published on one of nine electronic databases between inception and August 2024. It included adult patients with cancer of any stage who were undergoing chemotherapy. Interventions encompassed acupuncture, either alone or with electrical stimulation or moxibustion, and transcutaneous electrical acupoint/nerve stimulation (TEAS). The outcomes analyzed were changes in CIPN, nerve conduction velocity (NCV), and quality of life. Results: The outcomes were evaluated using data obtained from 14 SRs that demonstrated moderate to high methodological and reporting quality. The findings showed that acupuncture (either alone or combined with electrical stimulation) and TEAS effectively alleviated CIPN symptoms, reduced CIPN pain, improved NCV, and enhanced quality of life. Conclusion: The findings of this umbrella review indicate that these benefits were usually noticeable by the second week of treatment, persisted until the sixth week, and then gradually declined. Sensory nerve recovery occurred more rapidly than motor nerve recovery, often within 1.5 weeks. Although acupuncture combined with moxibustion or acupressure also enhanced patient outcomes, there was insufficient information available for further study analysis.
C1 [Yeh, Mei-Ling] Natl Taipei Univ Nursing & Hlth Sci, Taipei Med Univ Res Ctr Cochrane Taiwan, Sch Nursing, Minte Rd, Taipei 365, Taiwan.
   [Yeh, Mei-Ling] Taipei Med Univ Res Ctr Cochrane Taiwan, Taipei, Taiwan.
   [Hsu, Chin-Che] Kaohsiung Med Univ Hosp, 100 Tzyou 1st Rd, Kaohsiung, Taiwan.
   [Lin, Matthew] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, 365 Minte Rd, Taipei, Taiwan.
   [Lin, Chuan-Ju] Hsinchu Cathay Gen Hosp, 678,Sect 2,Zhonghua Rd, Hsinchu, Taiwan.
   [Lin, Chuan-Ju] Natl Taipei Univ Nursing & Hlth Sci, Taipei, Taiwan.
   [Lin, Jaung-Geng] China Med Univ, Sch Chinese Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
C3 National Taipei University of Nursing & Health Science (NTUNHS); Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Taipei University of Nursing & Health Science (NTUNHS); Cathay General Hospital; National Taipei University of Nursing & Health Science (NTUNHS); China Medical University Taiwan
RP Lin, CJ (corresponding author), Hsinchu Cathay Gen Hosp, 678,Sect 2,Zhonghua Rd, Hsinchu, Taiwan.; Lin, JG (corresponding author), China Med Univ, Sch Chinese Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM cgh306214@cgh.org.tw; jglin@mail.cmu.edu.tw
FU National Science of Technology Council [NSTC112-2314-B-227-007, NSTC113-2314-B-227-006]
CR Alsharif F, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6619243
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chow R, 2023, BMJ SUPPORT PALLIAT, V13, P27, DOI 10.1136/spcare-2022-003815
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   da Costa R, 2020, BRIT J PHARMACOL, V177, P3127, DOI 10.1111/bph.15086
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   Doyle TM, 2021, NEUROSCI LETT, V760, P0, DOI 10.1016/j.neulet.2021.136087
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Ibrahim EY, 2020, CRIT REV ONCOL HEMAT, V145, P0, DOI 10.1016/j.critrevonc.2019.102831
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Johnson MI, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-051073
   Kang GE, 2021, GAIT POSTURE, V88, P161, DOI 10.1016/j.gaitpost.2021.05.022
   Kannan P, 2023, CONTEMP CLIN TRIALS, V125, P0, DOI 10.1016/j.cct.2022.107055
   Kim TH, 2022, J ACUPUNCT MERIDIAN, V15, P333, DOI 10.51507/j.jams.2022.15.6.333
   Kim TH, 2020, ACUPUNCT MED, V38, P37, DOI 10.1136/acupmed-2018-011671
   Kuang B, 2019, TIANJIN J TRADIT CHIN MED, V0, PP673, DOI 10.11656/j.issn.1672-1519.2019.07.13
   Li SS, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.864046
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Liu YF, 2021, SHANGHAI J ACUPUNCT MOXIBUSTION, V40, P511, DOI 10.13460/j.issn.1005-0957.2021.04.0511
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   Maihöfner C, 2021, SUPPORT CARE CANCER, V29, P4223, DOI 10.1007/s00520-021-06042-x
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Papadopoulou M, 2023, IN VIVO, V37, P47, DOI 10.21873/invivo.13053
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Ronconi G, 2024, EUR J PHYS REHAB MED, V60, P505, DOI 10.23736/S1973-9087.24.08197-8
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Sreeram K, 2023, CANCER CAUSE CONTROL, V34, P459, DOI 10.1007/s10552-023-01676-0
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Vance CGT, 2022, MEDICINA-LITHUANIA, V58, P0, DOI 10.3390/medicina58101332
   Wang M, 2022, EUR J ONCOL NURS, V58, P0, DOI 10.1016/j.ejon.2022.102134
   Was H, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.750507
   Wiranata JA, 2024, JCO GLOB ONCOL, V10, P0, DOI 10.1200/GO.24.00160
   Wong ML, 2019, SUPPORT CARE CANCER, V27, P3905, DOI 10.1007/s00520-019-04695-3
   Xu RB, 2024, J PAIN RES, V17, P1423, DOI 10.2147/JPR.S448528
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yan Y, 2018, JIANGXI TRADIT CHIN MED, V49, P61
   Yeh ML, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04603-1
   Yeh ML, 2015, HOLIST NURS PRACT, V29, P87, DOI 10.1097/HNP.0000000000000071
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zeng HY, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-75922-9
   Zhou MM, 2023, BIOMED PHARMACOTHER, V161, P0, DOI 10.1016/j.biopha.2023.114516
NR 53
TC 4
Z9 4
U1 3
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAY 15
PY 2025
VL 89
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103131
EA FEB 2025
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA X2O8B
UT WOS:001423815200001
PM 39900253
DA 2026-01-16
ER

PT J
AU Kwag, E
   Joo, H
   Kim, SD
   Park, SJ
   Cho, JH
   Lee, NH
   Joo, JC
   Hyun, MH
   Chimonas, S
   Bao, T
   Mao, JJ
   Lee, JY
   Yoo, H
AF Kwag, Eunbin
   Joo, Haneum
   Kim, Soo-Dam
   Park, So Jung
   Cho, Jung Hyo
   Lee, Nam Hun
   Joo, Jong Cheon
   Hyun, Myung Han
   Chimonas, Susan
   Bao, Ting
   Mao, Jun J
   Lee, Jee Young
   Yoo, Hwaseung
TI Utilization Pattern of Acupuncture and Its Associated Predictors for Cancer Pain
SO Diseases (Basel, Switzerland)
LA English
DT Journal Article
DE Korean medicine; acupuncture; cancer pain; integrative oncology
AB BACKGROUND: Cancer-related pain is a common and distressing symptom among  patients with cancer. Although acupuncture is widely used and supported by  growing evidence, its real-world use and related patient attitudes remain  underexplored in South Korea. This study aimed to investigate patterns of  acupuncture use and identify factors influencing its use among Korean cancer  patients experiencing pain. METHODS: A cross-sectional survey was conducted from  October 2023 to May 2024 at six Korean medicine hospitals. A total of 201 cancer  patients with pain completed a questionnaire assessing acupuncture use, pain  severity and interference, and beliefs using a modified version of the ABCAM  (Attitudes and Beliefs about Complementary and Alternative Medicine) instrument.  Treatment concerns, logistical barriers, and social norms were analyzed. RESULTS:  Of the 201 participants, 80.6% reported using acupuncture for cancer-related  pain. Pain severity was the only significant predictor of acupuncture use (OR =  1.53, 95% CI: 1.10-2.12, p = 0.01). Acupuncture users reported fewer concerns  about safety and side effects, fewer logistical barriers, and stronger  encouragement from family, healthcare providers, and peers. CONCLUSIONS: This is  the first study to explore real-world use of acupuncture for cancer pain in South  Korea. Greater pain severity, perceived safety, ease of access, and social  support were associated with higher acupuncture use. These findings suggest that  improved patient education and integration of acupuncture into cancer care may  enhance pain management for Korean patients.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   East-West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, Daejeon 34520, Republic of Korea.
   KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
   Department of Korean Internal Medicine, School of Korean Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
   Korean Medicine Hospital, Pusan National University, Yangsan 50612, Republic of 
   East-West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, Daejeon 34520, Republic of Korea.
   East-West Cancer Center, Seoul Korean Medicine Hospital, Daejeon University, Seoul 05836, Republic of Korea.
   College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
   Integrative Cancer Center, CHA Ilsan Medical Center, CHA University, Goyang 10444, Republic of Korea.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Dana-Farber Cancer Institute Zakim, Center for Integrative Therapies and Healthy Living, Boston, MA 02215, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Integrative Cancer Center, CHA Ilsan Medical Center, CHA University, Goyang 10444, Republic of Korea.
   East-West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, Daejeon 34520, Republic of Korea.
NR 0
TC 0
SN 2079-972
EI 2079-972
J9 Diseases
PD SEP 26
PY 2025
VL 13
IS 9
BP 
EP 
DI 10.3390/diseases13090292
PG 0
UT PubMed:41002728
PM 41002728
DA 2025-09-26
ER

PT J
AU Lin, HC
   Hsu, HC
   Liao, HY
   Chen, ALP
   Lin, YW
AF Lin, Huan-Chin
   Hsu, Hsin-Cheng
   Liao, Hsien-Yin
   Chen, Arbee L P
   Lin, Yi-Wen
TI Electroacupuncture Modulates Programmed Cell Death 1 Ligand 1 on Peripheral and
SO Biomedicines
LA English
DT Journal Article
DE PD-L1; TRPV1; electroacupuncture; fibromyalgia; somatosensory cortex; spinal cord
AB Background: Fibromyalgia, a chronic condition that causes long-lasting pain over  several months, is a global medical issue with both personal and societal  implications. It is one of the hardest types of pain to heal, given the lack of  objective parameters for diagnosis and progression evaluation. The main symptoms  of fibromyalgia are long-lasting widespread pain alongside with anxiety, fatigue,  sleep disorders, cognitive dysfunction, and obesity. Programmed cell death 1  ligand 1 (PD-L1) has been used as a target in cancer immunotherapy. It can  inhibit acute and chronic pain by suppressing nociceptive neuron activity via  PD-1 receptors. Methods: The current study aimed to investigate the role of  PD-L1/PD1 in a mouse fibromyalgia pain model. Mice were exposed to intermittent  cold stress (ICS) to produce a murine fibromyalgia model characterized using von  Frey and Hargreaves tests. Results: The ICS-induced mice fibromyalgia pain model  showed mechanical (2.26 ± 0.18 g) and thermal (4.36 ± 0.31 s) hyperalgesia.  Nociceptive responses could be relieved with electroacupuncture, intracerebral  PD-L1 injection, or Trpv1 deletion. We also identified a lower PD-1 level in the  dorsal root ganglion, spinal cord, thalamus, and somatosensory cortex. In  contrast, levels of pain-related kinases increased after fibromyalgia induction,  an effect which could be reversed by EA, PD-L1, or Trpv1 deletion. Conclusions:  Our findings shed light on the contribution of PD-L1/PD1 to EA and fibromyalgia  pain, indicating its potential as a treatment target for fibromyalgia.
C1 College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 404328, Taiwan.
   Department of Traditional Chinese Medicine, Feng Yuan Hospital, Ministry of 
   Department of Traditional Chinese Medicine, China Medical University Hsinchu Hospital, China Medical University, Hsinchu 302056, Taiwan.
   College of Chinese Medicine, School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung 404328, Taiwan.
   Department of Computer Science and Information Engineering, Asia University, Taichung 413305, Taiwan.
   College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 404328, Taiwan.
   Chinese Medicine Research Center, China Medical University, Taichung 404328,
NR 0
TC 0
SN 2227-905
EI 2227-905
J9 Biomedicines
PD FEB 26
PY 2025
VL 13
IS 2
BP 
EP 
DI 10.3390/biomedicines13020396
PG 0
UT PubMed:40002809
PM 40002809
DA 2025-02-26
ER

PT J
AU Ben-Arye, E
   Gressel, O
   Keshet, Y
   Zaritsky, V
   Kassem, S
   Segev, Y
   Samuels, N
AF Ben-Arye, Eran
   Gressel, Orit
   Keshet, Yael
   Zaritsky, Vika
   Kassem, Sameer
   Segev, Yakir
   Samuels, Noah
TI War and Cancer: Exploring Patient Narratives in a Randomized Integrative Oncology Study
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE cancer; integrative medicine; integrative oncology; pain; supportive and palliative care; war
ID program
AB Study ObjectiveThe current war in Israel has affected quality of life (QoL)-related concerns among patients with cancer. Integrative oncology (IO) provides complementary medicine within supportive and palliative care. The study examined an IO program in northern Israel for cancer and war-related concerns.MethodsThis qualitative study, nested within a prospective randomized controlled trial, examined patients undergoing oncology and palliative care expressing cancer and war-related QoL concerns referred by oncology healthcare providers to an IO program. Patients were randomized to manual-relaxation with (Group A) or without (Group B) acupuncture. Narratives were recorded in MYCaW (Measure Yourself Concerns and Well-being) questionnaires immediately and after 24 h. Narrative excerpts were qualitatively analyzed using ATLAS.Ti software for systematic coding.ResultsPatient narratives (Group A, 67; Group B, 58) focused primarily on themes which included a sense of calmness and reduced emotional distress (e.g., stress, anxiety, worries, nervousness), more prominently in Group B (manual-relaxation only; 55/56 immediately/after 24 h); and reduced pain severity, more so in Group A (with acupuncture; 19/24). Most excerpts described improved QoL in both groups (142/147, 97%) immediately after IO treatments, less so at 24 h (103/135).ConclusionsNarratives of patients facing cancer- and war-related QoL challenges due to the ongoing war in Israel describe a beneficial impact of IO treatments, both immediately and after 24 h. Manual-relaxation without acupuncture was more likely to improve emotional concerns, with pain relief more apparent with the addition of acupuncture. Further qualitative and quantitative research is needed to explore these findings.
C1 [Ben-Arye, Eran; Gressel, Orit] Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Haifa, Israel.
   [Ben-Arye, Eran; Gressel, Orit] Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran; Gressel, Orit; Zaritsky, Vika; Kassem, Sameer] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Keshet, Yael] Western Galilee Acad Coll, Dept Sociol, Akko, Israel.
   [Kassem, Sameer] Lady Davis Carmel Med Ctr, Dept Internal Med, Haifa, Israel.
   [Segev, Yakir] Carmel Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Haifa, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Ctr Integrat Complementary Med, Shaare Zedek Med Ctr, Jerusalem, Israel.
C3 Clalit Health Services; Clalit Health Services; Technion Israel Institute of Technology; Western Galilee Academic College; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
EM eranben@technion.ac.il
FU Israel Cancer Association
CR Ben-Arye E, 2023, INT J GYNECOL CANCER, V33, P792, DOI 10.1136/ijgc-2022-004004
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Bower JE, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00541
   Budd S, 2023, MED ACUPUNCT, V35, P159, DOI 10.1089/acu.2023.0012
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Hommerberg C, 2020, BMC PALLIAT CARE, V19, P0, DOI 10.1186/s12904-020-00557-6
   Hovhannisyan A, 2024, PLOS GLOB PUBL HLTH, V4, P0, DOI 10.1371/journal.pgph.0003243
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Knoerl R, 2021, SUPPORT CARE CANCER, V29, P4191, DOI 10.1007/s00520-021-06174-0
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Marzouk M, 2024, SOC SCI MED, V361, P0, DOI 10.1016/j.socscimed.2024.117364
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI 10.1177/10775587221118156
   Skelton M, 2017, J GLOB ONCOL, V4, P0, DOI 10.1200/JGO.2016.008193
   Verma R, 2022, CURR ONCOL, V29, P589, DOI 10.3390/curroncol29020053
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD MAY 6
PY 2025
VL 34
IS 5
BP 
EP 
DI 10.1002/pon.70172
PG 6
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 2FR5U
UT WOS:001481547700001
PM 40326225
DA 2026-01-16
ER

PT J
AU Jin, RR
   Wu, BL
   Zhang, XD
   Hu, WY
   Wang, ZJ
   Xie, SR
AF Jin, Ru-Ru
   Wu, Bei-Lei
   Zhang, Xiao-Dan
   Hu, Wei-Yan
   Wang, Zhe-Jin
   Xie, Shang-Ren
TI Accelerated Rehabilitation Surgery Nursing Combined with Traditional Chinese Medicine Acupoint Application Therapy in Postoperative Rehabilitation of Elderly Patients with Liver Cancer
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article; Early Access
DE liver cancer; postoperative rehabilitation; pain management; opioid reduction; inflammatory markers; quality of life
ID integrative medicine; pain management; acupuncture
AB The purpose of the study is to evaluate the effectiveness of acupoint therapy in the comprehensive postoperative management of patients with liver cancer, aiming to reduce pain, decrease the need for opioid analgesics, and improve quality of life. The study was conducted in China at Wenzhou Central Hospital. A total of 156 patients who had undergone liver resection surgery for liver cancer were included. The patients were randomized into two groups: the experimental group (n = 79), which received standard postoperative rehabilitation combined with acupoint therapy, and the control group (n = 77), which received only standard postoperative rehabilitation. Patient assessment was conducted at three time points: before treatment initiation (T0), on the 4th day of therapy (T1), and 2 weeks after completion of the course (T2). Twelve nurses participated in the study and recorded sleep quality, appetite, need for assistance, behavioral distress signs, and frequency of PRN interventions. The results of this study confirm the effectiveness of acupoint therapy as an adjunctive method in the rehabilitation process following liver cancer surgery. The practical value lies in the potential for reducing the pharmacological burden, decreasing the frequency of opioid-related side effects, and accelerating patient recovery.
C1 [Jin, Ru-Ru; Wu, Bei-Lei; Wang, Zhe-Jin] Wenzhou Cent Hosp, Dept Hepatobiliary Surg, Wenzhou, Peoples R China.
   [Zhang, Xiao-Dan; Hu, Wei-Yan] Wenzhou Cent Hosp, Dept Emergency Surg, Wenzhou, Peoples R China.
   [Zhang, Xiao-Dan; Hu, Wei-Yan; Xie, Shang-Ren] Wenzhou Cent Hosp, Dept Tradit Chinese Med, Wenzhou, Peoples R China.
RP Wang, ZJ (corresponding author), Wenzhou Cent Hosp, Dept Hepatobiliary Surg, Wenzhou, Peoples R China.
EM zhejinwang78@outlook.com
FU Wenzhou City Scientific Research Project [Y20220704]
CR Cao C, 2020, INVESTIGACION CLINICA, V61, P1183
   Chang XL, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-04075-9
   Chen J, 2024, J INTEGR COMPLEMENT, V30, P493, DOI 10.1089/jicm.2023.0272
   Curseen KA, 2020, MED CLIN N AM, V104, P415, DOI 10.1016/j.mcna.2020.01.005
   Dudek P, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163662
   Echeverria-Villalobos M, 2020, CLIN J PAIN, V36, P219, DOI 10.1097/AJP.0000000000000792
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Giovannini S, 2021, DIAGNOSTICS, V11, P0, DOI 10.3390/diagnostics11040613
   Iliescu MG, 2024, J CLIN MED, V13, P0, DOI 10.3390/jcm13051190
   Invernizzi M, 2022, ANTI-CANCER AGENT ME, V22, P801, DOI 10.2174/1871520621666210609095602
   Isozaki AB, 2024, SEMIN ONCOL NURS, V40, P0, DOI 10.1016/j.soncn.2024.151672
   Li J, 2011, CHIN J INTEGR MED, V17, P243, DOI 10.1007/s11655-011-0712-4
   Liou KT, 2021, ACUPUNCT MED, V39, P637, DOI 10.1177/0964528421999395
   Liu XY, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06003-7
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   Majd I, 2025, ACUPUNCT MED, V43, P52, DOI 10.1177/09645284251314188
   Majid M, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.50633
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mayer RS, 2022, ANN REHABIL MED-ARM, V46, P60, DOI 10.5535/arm.22036
   Miyazaki T, 2024, J THORAC DIS, V16, P3422, DOI 10.21037/jtd-24-158
   Niyonkuru E, 2025, PAIN THER, V14, P121, DOI 10.1007/s40122-024-00688-1
   Pugh TM, 2021, FRONT PAIN RES, V2, P0, DOI 10.3389/fpain.2021.688511
   Sun LX, 2024, INT J COLORECTAL DIS, V39, P0, DOI 10.1007/s00384-024-04768-8
   Taleban S, 2016, DIGEST LIVER DIS, V48, P1105, DOI 10.1016/j.dld.2016.05.006
   Tang ZY, 2012, CHIN J INTEGR MED, V18, P323, DOI 10.1007/s11655-012-1103-1
   Tong QY, 2025, J PERIANESTH NURS, V40, P535, DOI 10.1016/j.jopan.2024.06.110
   Wang J, 2023, PAIN THER, V12, P707, DOI 10.1007/s40122-023-00493-2
   Wang LJ, 2024, BMC NURS, V23, P0, DOI 10.1186/s12912-024-02144-z
   Wang XB, 2022, CLIN NURS RES, V31, P1100, DOI 10.1177/10547738221090556
   Wei W, 2024, FRONT ONCOL, V14, P0, DOI 10.3389/fonc.2024.1322196
   Yan YQ, 2023, CANCER MED-US, V12, P12504, DOI 10.1002/cam4.5962
   Zhang YJ, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1169458
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD DEC 3
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/03601293251397402
EA DEC 2025
PG 15
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA L4632
UT WOS:001629588700001
DA 2026-01-16
ER

PT J
AU Ren, X
   Qu, YP
   Xia, T
   Tang, XF
AF Ren, Xu
   Qu, Yong-Ping
   Xia, Tian
   Tang, Xiu-Fen
TI Technical success, clinical efficacy, and safety of endoscopic minor papilla interventions for symptomatic pancreatic diseases
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Endoscopic minor papilla intervention; Symptomatic pancreatic diseases; Obstructive chronic pancreatitis; Pancreas division; Abdominal pain improvement
ID shock-wave lithotripsy; guided electrohydraulic lithotripsy; duct stones; balloon sphincteroplasty; therapy; diagnosis
AB BACKGROUND Endoscopic minor papilla intervention (EMPI) is an option for diagnosing or treating symptomatic pancreatic diseases in cases with failed pancreatic duct deep cannulation via the major papilla, pancreas divisum with obstruction of the minor papilla, or an abnormal patulous orifice of the minor papilla during endoscopic retrograde cholangiopancreatography (ERCP). However, the relatively low patency and small opening of the minor papillae pose technical challenges. AIM To evaluate the technical success, clinical success, stone clearance, and safety profile of EMPI for diagnosis and treatment of symptomatic pancreatic diseases. METHODS Patients diagnosed with symptomatic pancreatic diseases and EMPI between February 1996 and February 2023 were included. The primary outcomes were the initial technical success, defined as successful deep cannulation via the minor papilla (DCMP; access of the guidewire to the upstream pancreatic duct via the minor papilla) alone, overall technical success, defined as successful DCMP alone and successful DCMP with additional needle-knife precut minor papillotomy (NKPMP), and immediate clinical success, defined as > 50% improvement in abdominal pain after therapeutic EMPI. Secondary outcomes included long-term clinical success at 1, 3, and 7 years, pancreatic stone clearance, and procedure-related early and late adverse events (AEs). RESULTS Overall, 43 patients, 32 with obstructive chronic pancreatitis, 8 with pancreatic divisum, and 3 with intraductal papillary mucinous neoplasm were included. The initial and overall technical success rates were 74.4% (32/43) and 88.4% (38/43), respectively. The immediate clinical success rate was 79.1% (34/43), and the long-term clinical success rates at 1, 3, and 7 years were 74.7%, 55.3%, and 41.5%, respectively, among the 22 patients with a follow-up period of 57.5 (7-266) months. Complete and partial success of pancreatic stone clearance was achieved in 53.9% (7/13) and 15.4% (2/13), respectively. Early AEs included post-ERCP pancreatitis (PEP, n = 5) and self-limiting bleeding (n = 1); surgery therapy was required for 1 case with severe PEP and conservative management for the other 4 with mild PEP. Late AEs included minor papilla stricture (n = 1) after endoscopic minor papillotomy and pancreatic duct stricture (n = 1) after double pancreatic stent placement; no specific treatment was implemented for these events. CONCLUSION EMPI is feasible, effective, and safe for symptomatic pancreatic diseases, in terms of the technical and clinical success, stone clearance, and incidence and severity of AEs. NKPMP appears to enhance technical success. However, potential risks of developing PEP and late AEs should be kept in mind.
C1 [Ren, Xu; Xia, Tian] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Hosp, 405 Guogeli St, Harbin 150001, Heilongjiang, Peoples R China.
   [Qu, Yong-Ping] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Endoscopy Ctr, Harbin 150001, Heilongjiang, Peoples R China.
   [Tang, Xiu-Fen] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Dept Gastroenterol 1, Digest Hosp, Harbin 150001, Heilongjiang, Peoples R China.
RP Ren, X (corresponding author), Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Hosp, 405 Guogeli St, Harbin 150001, Heilongjiang, Peoples R China.
EM hljxhy2001@126.com
FU Heilongjiang Provincial Natural Science Foundation Team Project [TD2020H002]
CR Bansal RK, 2017, ENDOSC INT OPEN, V5, PE1229, DOI 10.1055/s-0043-119752
   Basturk O, 2019, WHO CLASSIFICATION OF TUMOURS EDITORIAL BOARD. DIGESTIVE SYSTEM TUMOURS, V1, P310
   Bellocchi MCC, 2021, PANCREATOLOGY, V21, P805, DOI 10.1016/j.pan.2021.01.019
   Bhurwal A, 2021, PANCREATOLOGY, V21, P990, DOI 10.1016/j.pan.2021.03.021
   Boninsegna E, 2015, EUR RADIOL, V25, P2437, DOI 10.1007/s00330-015-3644-0
   Brauer BC, 2013, GASTROINTEST ENDOSC, V78, P545, DOI 10.1016/j.gie.2013.05.005
   Brown NG, 2017, GASTROINTEST ENDOSC, V85, P365, DOI 10.1016/j.gie.2016.07.066
   de Rijk FEM, 2023, ENDOSC INT OPEN, V11, PE296, DOI 10.1055/a-2035-8969
   Dickson ZA, 2020, GASTROINTEST ENDOSC, V91, P1396, DOI 10.1016/j.gie.2020.01.005
   Dirweesh A, 2022, DIGEST DIS SCI, V67, P1624, DOI 10.1007/s10620-022-07391-1
   Dumonceau JM, 2019, ENDOSCOPY, V51, P179, DOI 10.1055/a-0822-0832
   Ertan A, 2000, GASTROINTEST ENDOSC, V52, P9, DOI 10.1067/mge.2000.106311
   Gardner TB, 2020, AM J GASTROENTEROL, V115, P322, DOI 10.14309/ajg.0000000000000535
   Gonoi W, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0037652
   Gonoi W, 2011, GUT, V60, P1103, DOI 10.1136/gut.2010.230011
   Gourgiotis S, 2007, EJSO-EUR J SURG ONC, V33, P678, DOI 10.1016/j.ejso.2006.11.031
   Han S, 2022, PANCREATOLOGY, V22, P1120, DOI 10.1016/j.pan.2022.09.245
   Han S, 2019, DIGEST DIS SCI, V64, P1059, DOI 10.1007/s10620-019-05502-z
   Inamdar Sumant, 2023, GASTROINTEST ENDOSC CLIN N AM, V33, P789, DOI 10.1016/j.giec.2023.04.012
   Iwano K, 2020, ENDOSCOPY, V52, PE213, DOI 10.1055/a-1071-7649
   Jagtap SV, 2018, ANNALS OF PATHOLOGY AND LABORATORY MEDICINE, V5, PC82, DOI 10.21276/apalm.1809
   James TW, 2018, ENDOSC INT OPEN, V6, PE735, DOI 10.1055/a-0607-2484
   Kamisawa T, 2007, PANCREAS, V34, P96
   Kamisawa Terumi, 2004, JOP, V5, P107
   Kondo H, 2014, DIGEST LIVER DIS, V46, P639, DOI 10.1016/j.dld.2014.02.017
   Korpela T, 2016, SCAND J GASTROENTERO, V51, P866, DOI 10.3109/00365521.2016.1150502
   Kwon CI, 2017, ENDOSCOPY, V49, P371, DOI 10.1055/s-0042-120996
   Löhr JM, 2017, UNITED EUR GASTROENT, V5, P153, DOI 10.1177/2050640616684695
   Machado NO, 2015, N AM J MED SCI, V7, P160, DOI 10.4103/1947-2714.157477
   Mandai K, 2022, ENDOSCOPY, V54, PE1051, DOI 10.1055/a-1913-7425
   Maydeo A, 2009, GASTROINTEST ENDOSC, V70, P798, DOI 10.1016/j.gie.2009.05.004
   Meldrum JT, 2020, J CLIN IMAG SCI, V10, P0, DOI 10.25259/JCIS_17_2020
   Michailidis L, 2017, ANN GASTROENTEROL, V30, P550, DOI 10.20524/aog.2017.0159
   Moole H, 2016, PANCREAS, V45, P651, DOI 10.1097/MPA.0000000000000512
   Müller PC, 2017, SURG LAPARO ENDO PER, V27, PE44, DOI 10.1097/SLE.0000000000000414
   Mukai H, 1998, ENDOSCOPY, V30 Suppl 1, PA99, DOI 10.1055/s-2007-1001486
   Muramoto Yuya, 2021, VIDEOGIE, V6, P419, DOI 10.1016/j.vgie.2021.05.014
   Okamoto Takeshi, 2021, VIDEOGIE, V6, P512, DOI 10.1016/j.vgie.2021.08.004
   Pancreatology Speciality Committee of Chinese Medical Doctor Association, 2018, ZHONGHUA YIXIANBING ZAZHI, V35, P814
   Ren X, 2000, ZHONGHUA XIAOHUANEIJING ZAZHI, V17, P271
   Ren X, 2019, WORLD J CLIN CASES, V7, P102, DOI 10.12998/wjcc.v7.i1.102
   Shintani Shuhei, 2020, VIDEOGIE, V5, P673, DOI 10.1016/j.vgie.2020.07.004
   Siddappa PK, 2021, GASTROENTEROL REP, V9, P105, DOI 10.1093/gastro/goab001
   Singh A, 2023, PANCREATOLOGY, V23, P858, DOI 10.1016/j.pan.2023.09.141
   Song MH, 2004, GASTROINTEST ENDOSC, V59, P901, DOI 10.1016/S0016-5107(04)00457-2
   Takeshita K, 2020, DIGEST ENDOSC, V32, PE98, DOI 10.1111/den.13697
   Tandan M, 2019, PANCREATOLOGY, V19, P916, DOI 10.1016/j.pan.2019.08.001
   Tringali A, 2019, SCAND J GASTROENTERO, V54, P359, DOI 10.1080/00365521.2019.1584640
   van der Wiel SE, 2022, GASTROINTEST ENDOSC, V95, P905, DOI 10.1016/j.gie.2021.11.047
   Zhang PY, 1993, ZHONGHUA XIAOHUA ZAZHI, V13, P14
NR 50
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 28
PY 2025
VL 31
IS 20
BP 
EP 
DI 10.3748/wjg.v31.i20.100192
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 3IW8T
UT WOS:001501422800011
PM 40495942
DA 2026-01-16
ER

PT J
AU Al-Ajlouni, YA
   Al, Ta'ani O
   Zweig, SA
   Bak, M
   Tanashat, M
   Gabr, A
   Khamis, Z
   Al-Bitar, F
   Islam, M
AF Al-Ajlouni, Yazan A
   Al Ta'ani, Omar
   Zweig, Sophia A
   Bak, Magdalena
   Tanashat, Mohammad
   Gabr, Ahmed
   Khamis, Zaid
   Al-Bitar, Farah
   Islam, Mohammad
TI Assessing the Therapeutic Role of Rehabilitation Programs in Chemotherapy-Induced
SO Healthcare (Basel, Switzerland)
LA English
DT Review
DE chemotherapy-induced peripheral neuropathy; neuropathic symptoms; pain management; rehabilitation programs; scoping review
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common,  debilitating side effect of cancer treatment. Characterized by symptoms like  pain, numbness, and muscle weakness, CIPN significantly impacts patients' quality  of life. Current management strategies vary, with limited consensus on effective  treatments. This scoping review aims to explore comprehensive rehabilitation  interventions for CIPN, focusing on enhancing patient well-being and functional  abilities. Methods: A scoping review, guided by Arksey and O'Malley's framework  and Levac et al.'s refinements, was conducted to assess rehabilitation programs  for CIPN. Searches across six databases were performed, with inclusion and  exclusion criteria focusing on studies with physical rehabilitation  interventions. Data were charted, detailing interventions, demographics, and  outcomes. Results were synthesized descriptively and presented narratively with  tables. Results: The review included 24 studies covering diverse cancer types and  treatments, involving a total of 1167 participants. Various interventions for  CIPN were assessed, and results were thematically categorized according to  exercise category. Physical modalities like ultrasound and exercise showed  promise in symptom relief for colorectal and breast cancer patients. No distinct  advantage was found in the timing of exercise interventions. Complementary  therapies such as acupuncture and yoga demonstrated effectiveness in managing  CIPN symptoms. Conclusions: This review highlights the effectiveness of diverse  physical and complementary interventions in managing CIPN, advocating for their  integration into standard protocols. It emphasizes the need for holistic,  patient-centered approaches that combine exercises, physical therapy, and  complementary therapies to improve patient outcomes. These findings set a  direction for future research and clinical practices focused on comprehensive and  personalized CIPN management strategies.
C1 School of Medicine, New York Medical College, Valhalla, NY 10595, USA.
   Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New 
   Department of Medicine, Staten Island University Hospital, Staten Island, NY 10305, USA.
   Alleghany Health Network, Pittsburgh, PA 15212, USA.
   School of Medicine, SUNY Downstate College of Medicine, Brooklyn, NY 11203, USA.
   School of Sciences, New York University Abu Dhabi (NYUAD), Abu Dhabi P.O. Box 129188, United Arab Emirates.
   Faculty of Medicine, Yarmouk University, Irbid 21163, Jordan.
   School of Medicine, New York Medical College, Valhalla, NY 10595, USA.
   Department of Medicine, Staten Island University Hospital, Staten Island, NY 10305, USA.
   Homer Stryker M.D. School of Medicine, Western Michigan University, Kalamazoo, MI 49007, USA.
   Department of Physical Medicine and Rehabilitation, Metropolitan Hospital, New York, NY 10029, USA.
NR 0
TC 0
SN 2227-903
EI 2227-903
J9 Healthcare (Basel)
PD JUL 13
PY 2025
VL 13
IS 13
BP 
EP 
DI 10.3390/healthcare13131526
PG 0
UT PubMed:40648551
PM 40648551
DA 2025-07-13
ER

PT J
AU Yeh, ML
   Hsu, CC
   Lin, M
   Lin, CJ
   Lin, JG
AF Yeh, Mei-Ling
   Hsu, Chin-Che
   Lin, Matthew
   Lin, Chuan-Ju
   Lin, Jaung-Geng
TI Effects of acupuncture-related intervention on chemotherapy-induced peripheral
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy (CIPN); Pain; Quality of life; Umbrella review
AB BACKGROUND: Numerous studies have explored the role of acupuncture-related  treatments in alleviating chemotherapy-induced peripheral neuropathy (CIPN) and  improving the quality of life for patients with cancer, resulting in mixed  findings. This umbrella review aimed to synthesize existing systematic reviews  (SRs) to deliver an updated assessment of the certainty of evidence concerning  the effects of acupuncture-related treatments on CIPN and quality of life among a  diverse group of patients with cancer. METHODS: This umbrella review considered  eligible SRs published on one of nine electronic databases between inception and  August 2024. It included adult patients with cancer of any stage who were  undergoing chemotherapy. Interventions encompassed acupuncture, either alone or  with electrical stimulation or moxibustion, and transcutaneous electrical  acupoint/nerve stimulation (TEAS). The outcomes analyzed were changes in CIPN,  nerve conduction velocity (NCV), and quality of life. RESULTS: The outcomes were  evaluated using data obtained from 14 SRs that demonstrated moderate to high  methodological and reporting quality. The findings showed that acupuncture  (either alone or combined with electrical stimulation) and TEAS effectively  alleviated CIPN symptoms, reduced CIPN pain, improved NCV, and enhanced quality  of life. CONCLUSION: The findings of this umbrella review indicate that these  benefits were usually noticeable by the second week of treatment, persisted until  the sixth week, and then gradually declined. Sensory nerve recovery occurred more  rapidly than motor nerve recovery, often within 1.5 weeks. Although acupuncture  combined with moxibustion or acupressure also enhanced patient outcomes, there  was insufficient information available for further study analysis.
C1 School of Nursing, National Taipei University of Nursing & Health Sciences, Taipei Medical University Research Center of Cochrane Taiwan, 365 Minte Road,Taipei, Taiwan
   Taipei Medical University Research Center of Cochrane Taiwan.
   Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung, Taiwan.
   School of Nursing, National Taipei University of Nursing & Health Sciences, 365 Minte Road, Taipei, Taiwan.
   Hsinchu Cathay General Hospital, No. 678, Section 2, Zhonghua Road, Hsinchu, Taiwan
   National Taipei University of Nursing and Health Sciences. Electronicaddress: cgh306214@cgh.org.tw.
   School of Chinese Medicine, China Medical University, 91 Hsueh-Shih Road, Taichung, Taiwan.
EM jglin@mail.cmu.edu.tw
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD FEB 4
PY 2025
VL 89
IS 
BP 103131
EP 103131
DI 10.1016/j.ctim.2025.103131
PG 0
WC Humans; Quality of Life; Acupuncture Therapy; methods; Peripheral Nervous System Diseases; therapy; Antineoplastic Agents; adverse effects; Neoplasms; drug therapy; Transcutaneous Electric Nerve Stimulation; Adult
UT PubMed:39900253
PM 39900253
DA 2025-02-04
ER

PT J
AU Feng, YH
   Kong, LY
   Sun, Y
   Gao, F
AF Feng, Yuan-Hui
   Kong, Ling-Yu
   Sun, Ying
   Gao, Fang
TI [Therapeutic effect of the combination of Tiaodu Lijin acupuncture therapy and
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Cervical spondylotic radiculopathy; Lijin reduction tuina manipulation; Tiaodu Lijin acupuncture therapy
AB OBJECTIVES: To explore the therapeutic effect of the combined measures of Tiaodu  Lijin acupuncture therapy (for regulating the governor vessel and tendons) and  Lijin reduction tuina manipulation (for regulating tendons and reduction) in  treatment of cervical spondylotic radiculopathy (CSR). METHODS: From August 2021  to December 2023, 160 CSR patients were selected and randomly divided into a  control group (80 cases) and a trial group (80 cases) using a random number table  method. In the control group, the conventional acupuncture and Lijin reduction  tuina manipulation were operated, and in the trial group, Tiaodu Lijin  acupuncture therapy and Lijin reduction tuina manipulation were combined. The  treatment was delivered once daily in each group, 5 interventions a week and  lasted for 4 weeks. Before and after treatment, the score of clinical assessment  scale of cervical spondylosis (CASCS), cervical dysfunction index (NDI) and the  score of visual analog scale (VAS) were compared in the two groups. Using ELISA,  the contents of interleukin (IL)-6, leukotriene D4 (LTD4), tumor necrosis factor  (TNF)-α and C-reactive protein (CRP) in the serum were detected. Transcranial  color Doppler ultrasound was used to detect the mean peak velocity (VM),  resistance index (RI) and pulsation index (PI) of vertebral-basilar artery at  systole. The effective rate was calculated in the two groups. RESULTS: Every  indicator after treatment was improved in comparison with that before treatment  in each group (P<0.05). After 4-week treatment, compared with the control group,  NDI and VAS scores were lower (P<0.05), and the serum contents of IL-6, LTD4,  TNF-α and CRP were reduced (P<0.05), RI and PI of vertebral-basilar artery were  lower (P<0.05), and CASCS score and VM were higher (P<0.05) in the trial group.  The overall effective rate in the trial group (95.00%, 76/80) was higher (P<0.05)  than that (81.25%, 65/80) in the control group. CONCLUSIONS: The combined  measures of Tiaodu Lijin acupuncture therapy and Lijin reduction tuina  manipulation obtain the satisfactory therapeutic effect on CSR, which alleviates  pain, reduces inflammatory indicators and improves vertebral basilar arterial  blood flow and cervical spine function.
C1 Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, Hebei Province, China.
   Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, Hebei Province, China. 506905766@qq.com.
   Tangshan Fengnan District Hospital of Traditional Chinese Medicine, Tangshan 063300, Hebei Province.
   Tangshan Fengnan District Hospital of Traditional Chinese Medicine, Tangshan 063300, Hebei Province.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD SEP 18
PY 2025
VL 50
IS 9
BP 1088
EP 1094
DI 10.13702/j.1000-0607.20250309
PG 6
WC Humans; Acupuncture Therapy; Male; Middle Aged; Female; Spondylosis; therapy; Radiculopathy; therapy; Adult; Acupuncture Points; Aged; Tumor Necrosis Factor-alpha; blood; Interleukin-6; blood; Treatment Outcome; C-Reactive Protein; metabolism; Combined Modality Therapy
UT PubMed:40962733
PM 40962733
DA 2025-09-18
ER

PT J
AU Zheng, KH
   Hong, XP
   Jiang, CY
   Chen, Y
AF Zheng, Kanghua
   Hong, Xiaoping
   Jiang, Changyin
   Chen, Yong
TI Effects of warming needle moxibustion on postoperative rehabilitation, pain degree, immune function, and upper limb lymphedema in patients with breast cancer undergoing radical mastectomy
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Functional rehabilitation training; warming needle moxibustion; radical mastectomy; upper limb lymph edema; immune function
ID acupuncture
AB This study aims to evaluate the effects of warm acupuncture combined with conventional functional rehabilitation training (FRT) on the recovery of breast cancer (BC) patients following radical mastectomy, focusing on immune function, pain management, and quality of life (QoL). This retrospective study involved 118 BC patients who underwent radical surgery at the Second People's Hospital Affiliated to Fujian University of Chinese Medicine between January 2022 and May 2024. The included patient were assigned into an experimental group (EG, n=62, warm acupuncture in conjunction with conventional FRT) and a control group (CG; n=56; conventional FRT only). of hospital stay, upper limb mobility, immune function indicators, and pain scores, were compared between the two groups. Multivariate logistic regression was employed to identify factors affecting treatment outcomes. The EG demonstrated significantly lower visual analog scale (VAS) scores at post-operative 2, 4, and 8 weeks compared to the CG (all P < 0.05). The incidence of upper limb lymphedema in the EG was 9.26%, notably lower than the 24.07% observed in the CG (P < 0.05). Immune function indicators, including CD3(+), CD4(+), CD8(+), and the CD4(+)/CD8(+) ratio, were significantly higher in the EG postoperatively (P < 0.05). Furthermore, the EG reported significantly improved scores in role physical, general health, vitality, social functioning, role emotional, mental health, and physiological functioning, alongside significantly lower scores in bodily pain compared to the CG (all P < 0.05). Multivariate logistic regression analysis revealed CD3(+) and CD4(+)/CD8(+) ratio as independent factors affecting patient treatment efficacy (both P < 0.05). In conclusion, the combination of warm acupuncture and conventional FRT significantly enhances immune function, pain management, and overall QoL in BC patients after surgery, with CD3(+) and CD4(+)/CD8(+) ratios being crucial factors influencing recovery.
C1 [Zheng, Kanghua; Hong, Xiaoping; Jiang, Changyin] Fujian Univ Chinese Med, Peoples Hosp 2, Dept Rehabil, Fuzhou 350003, Fujian, Peoples R China.
   [Chen, Yong] Fujian Univ Tradit Chinese Med, Coll Integrat Med, Dept Pathophysiol, 1 Qiuyang Rd, Fuzhou 350122, Fujian, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine
RP Chen, Y (corresponding author), Fujian Univ Tradit Chinese Med, Coll Integrat Med, Dept Pathophysiol, 1 Qiuyang Rd, Fuzhou 350122, Fujian, Peoples R China.
EM chenyong1209c@163.com
CR Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Ben-Dror J, 2022, GENES-BASEL, V13, P0, DOI 10.3390/genes13060960
   Boere I, 2022, BEST PRACT RES CL OB, V82, P46, DOI 10.1016/j.bpobgyn.2022.05.001
   Choi SB, 2022, BREAST CANCER RES TR, V192, P343, DOI 10.1007/s10549-022-06519-1
   El Masri J, 2022, CLIN OBSTET GYNECOL, V65, P461, DOI 10.1097/GRF.0000000000000721
   Friedman R, 2023, LYMPHAT RES BIOL, V21, P488, DOI 10.1089/lrb.2022.0001
   Ghorbani A, 2024, CANCER GENET-NY, V282, P14, DOI 10.1016/j.cancergen.2023.12.006
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Herzog SK, 2022, BRIT J CANCER, V126, P174, DOI 10.1038/s41416-021-01564-x
   Jagsi R, 2022, BREAST CANCER RES TR, V192, P235, DOI 10.1007/s10549-021-06434-x
   Jin ZS, 2022, RECENT PAT ANTI-CANC, V17, P326, DOI 10.2174/1574892817666220119121204
   Kashyap D, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/9605439
   Katsura C, 2022, BRIT J HOSP MED, V83, P0, DOI 10.12968/hmed.2021.0459
   Liu HR, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.952290
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Mouabbi JA, 2022, BREAST CANCER RES TR, V193, P253, DOI 10.1007/s10549-022-06572-w
   Qi QL, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/1164355
   Shen K, 2023, REDOX BIOL, V62, P0, DOI 10.1016/j.redox.2023.102655
   Wang HZ, 2023, J PAIN RES, V16, P4165, DOI 10.2147/JPR.S442151
   Wilkinson L, 2022, BRIT J RADIOL, V95, P0, DOI 10.1259/bjr.20211033
   Yang EM, 2022, J INTEGR COMPLEMENT, V28, P427, DOI 10.1089/jicm.2021.0256
   Yang J, 2024, BMC WOMENS HEALTH, V24, P0, DOI 10.1186/s12905-024-03165-1
   Zannetti A, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24032542
   Zhang H, 2022, INT J BIOL SCI, V18, P3337, DOI 10.7150/ijbs.69141
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang XP, 2019, BIOSCIENCE REP, V39, P0, DOI 10.1042/BSR20190231
NR 26
TC 0
Z9 0
U1 1
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
EI 
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PD JUN 15
PY 2025
VL 15
IS 3
BP 991
EP 1001
DI 10.62347/YXHG6188
PG 11
WC Oncology
SC Oncology
GA 2BZ8G
UT WOS:001479045400009
PM 40226461
DA 2026-01-16
ER

PT J
AU Zhao, FY
   Zhang, WD
   Chow, CM
   Xu, PJ
   Yue, LP
   Ho, YS
   Fu, QQ
   Conduit, R
AF Zhao, Fei-Yi
   Zhang, Wen-Ding
   Chow, Chin Moi
   Xu, Peijie
   Yue, Li-Ping
   Ho, Yuen-Shan
   Fu, Qiang-Qiang
   Conduit, Russell
TI From Needles to Photons: Clinical Efficacy, Safety, and Mechanistic Insights of Laser Acupuncture in Insomnia Management
SO NATURE AND SCIENCE OF SLEEP
LA English
DT Article
DE traditional Chinese medicine; non-pharmacological treatment; auricular therapy; auriculotherapy; sleep disorder; sleep disturbance
ID quality-of-life; sleep; risk; pain; complementary; symptoms; therapy; anxiety
AB Insomnia constitutes a significant worldwide public health burden. Limitations of conventional treatments, such as cognitive-behavioral therapy and hypnotic medications, have fueled growing interest in complementary and alternative medicine approaches, including laser acupuncture (LA). This comprehensive mini-review evaluates LA's effects and mechanisms for insomnia management. Clinical evidence indicates that LA alleviates both primary insomnia and comorbid cases (eg, with cancer, hypertension, and perimenopausal syndrome). LA demonstrates efficacy comparable to traditional needle acupuncture in improving subjective and objective sleep quality, while also reducing affective symptoms and enhancing quality of life. This provides an appealing alternative for needle-phobia patients. LA appears generally safe, with only mild, transient adverse effects reported. Mechanistic investigations suggest that LA may act via neurotransmitter modulation, autonomic nervous system regulation, and alterations in brain wave activity. reporting, and insufficient follow-ups -- compromise the current evidence base. Future research should adopt multicenter, large-scale, placebo-controlled randomized trials, complemented by advanced techniques such as neuroimaging, polysomnography, and neurochemical assays, to further validate the therapeutic potential of LA and elucidate its underlying mechanisms.
C1 [Zhao, Fei-Yi; Yue, Li-Ping] Shanghai Sanda Univ, Sch Int Med Technol, Dept Nursing, Shanghai 201209, Peoples R China.
   [Zhao, Fei-Yi; Conduit, Russell] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic 3083, Australia.
   [Zhao, Fei-Yi; Chow, Chin Moi] Univ Sydney, Fac Med & Hlth, Sydney Sch Hlth Sci, Camperdown, NSW 2050, Australia.
   [Zhao, Fei-Yi; Zhang, Wen-Ding] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai 200071, Peoples R China.
   [Chow, Chin Moi] Univ Sydney, Charles Perkins Ctr, Sleep Res Grp, Camperdown, NSW 2050, Australia.
   [Xu, Peijie] RMIT Univ, Sch Comp Technol, Melbourne, Vic 3000, Australia.
   [Ho, Yuen-Shan] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Sch Nursing, Hong Kong, Peoples R China.
   [Fu, Qiang-Qiang] Tongji Univ, Yangpu Hosp, Sch Med, Shanghai 200090, Peoples R China.
C3 Sanda University; Royal Melbourne Institute of Technology (RMIT); University of Sydney; Shanghai University of Traditional Chinese Medicine; University of Sydney; Royal Melbourne Institute of Technology (RMIT); Hong Kong Polytechnic University; Tongji University
RP Ho, YS (corresponding author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Sch Nursing, Hong Kong, Peoples R China.; Fu, QQ (corresponding author), Tongji Univ, Yangpu Hosp, Sch Med, Shanghai 200090, Peoples R China.
EM janice.ys.ho@polyu.edu.hk; qiangqiang.fu@tongji.edu.cn
FU Scientific Research Fund Project of Shanghai Sanda University [2024BSZX03]
CR Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1
   Benjafield AV, 2025, SLEEP MED REV, V82, P0, DOI 10.1016/j.smrv.2025.102121
   Bolge SC, 2009, QUAL LIFE RES, V18, P415, DOI 10.1007/s11136-009-9462-6
   Chang YP, 2024, LASER MED SCI, V39, P0, DOI 10.1007/s10103-024-04114-y
   Chaput JP, 2023, SLEEP HEALTH, V9, P185, DOI 10.1016/j.sleh.2022.09.010
   Chen CK, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8136967
   Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003
   Chokroverty S, 2010, INDIAN J MED RES, V131, P126
   Chon TY, 2019, MED ACUPUNCT, V31, P164, DOI 10.1089/acu.2019.1343
   Ciano C, 2017, JOGNN-J OBST GYN NEO, V46, P804, DOI 10.1016/j.jogn.2017.07.011
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, P0, DOI 10.1109/JSTQE.2016.2561201
   Dong XY, 2023, J MED THEORY PRACT, V36, P3762
   Feng SL, 2018, SHANDONG J TRAD CHIN MED, V37, P494
   Geiger-Brown JM, 2015, SLEEP MED REV, V23, P54, DOI 10.1016/j.smrv.2014.11.007
   Grandner MA, 2012, J SLEEP RES, V21, P427, DOI 10.1111/j.1365-2869.2011.00990.x
   Grimaldi D, 2021, SLEEP, V44, P0, DOI 10.1093/sleep/zsaa274
   Hettinga DM, 2008, PHYSIOTHERAPY, V94, P97, DOI 10.1016/j.physio.2007.10.008
   Irwin M, 2003, BRAIN BEHAV IMMUN, V17, P365, DOI 10.1016/S0889-1591(03)00031-X
   Jansson-Fröjmark M, 2008, J PSYCHOSOM RES, V64, P443, DOI 10.1016/j.jpsychores.2007.10.016
   Jieun Jung, 2025, SLEEP MEDICINE RESEARCH, V15, P218, DOI 10.17241/smr.2024.02593
   Karia Sagar B, 2016, IND PSYCHIATRY J, V25, P155, DOI 10.4103/ipj.ipj_86_15
   Kyle SD, 2010, BEHAV SLEEP MED, V8, P123, DOI 10.1080/15402002.2010.487450
   Lan KC, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8997051
   Law D, 2015, J ACUPUNCT MERIDIAN, V8, P2
   Leung AK, 2015, CLINICAL STUDY ON LASER ACUPOINT THERAPY FOR TREATING INSOMNIA WITH YIN DEFICIENCY WITH EFFULGENT FIRE MASTER, V0, P0
   Liang GY, 2006, CHIN J PRACT MED, V5, P648
   Lin JG, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/740508
   Liu T, 2007, EVID-BASED COMPL ALT, V4, P3, DOI 10.1093/ecam/nel061
   Liu WL, 2025, NAT SCI SLEEP, V17, P947, DOI 10.2147/NSS.S501619
   Miglis MG, 2016, SLEEP MED, V19, P40, DOI 10.1016/j.sleep.2015.10.001
   Mira PCD, 2024, LASER MED SCI, V39, P0, DOI 10.1007/s10103-024-03999-z
   Monti Jaime M, 2004, CURRENT MEDICINAL CHEMISTRY - CENTRAL NERVOUS SYSTEM AGENTS, V4, P119, DOI 10.2174/1568015043357039
   Moreno Claudia R C, 2025, HANDB CLIN NEUROL, V206, P89, DOI 10.1016/B978-0-323-90918-1.00015-0
   Moskvin SV, 2020, J LASERS MED SCI, V11, P381, DOI 10.34172/jlms.2020.61
   Naeser MA, 2002, ARCH PHYS MED REHAB, V83, P978, DOI 10.1053/apmr.2002.33096
   Namazi N, 2017, ACUPUNCT MED, V35, P452, DOI 10.1136/acupmed-2017-011401
   Neckelmann D, 2007, SLEEP, V30, P873, DOI 10.1093/sleep/30.7.873
   Neubauer DN, 2018, J CENT NERV SYST DIS, V10, P0, DOI 10.1177/1179573518770672
   Oishi Y, 2017, BRAIN STRUCT FUNCT, V222, P2907, DOI 10.1007/s00429-017-1365-7
   Page JM, 2025, PSYCHO-ONCOLOGY, V34, P0, DOI 10.1002/pon.70079
   Patel D, 2018, J CLIN SLEEP MED, V14, P1017, DOI 10.5664/jcsm.7172
   Pearson NJ, 2006, ARCH INTERN MED, V166, P1775, DOI 10.1001/archinte.166.16.1775
   Sarris J, 2011, SLEEP MED REV, V15, P99, DOI 10.1016/j.smrv.2010.04.001
   Sheppard N, 2022, J SLEEP RES, V31, P0, DOI 10.1111/jsr.13677
   Sterne J, 2019, BMJ, V366, P14898, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i4919
   Suen LKP, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/3651268
   Ton G, 2022, MED ACUPUNCT, V34, P228, DOI 10.1089/acu.2022.0002
   Wang Y, 2015, LIAONING J TRADIT CHIN MED, V42, P1087
   Wang Y, 2016, HENAN TRADITIONAL CHIN MED, V36, P1258
   Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8
   Winsper C, 2014, INT REV PSYCHIATR, V26, P189, DOI 10.3109/09540261.2014.881330
   Wu JH, 2009, PHOTOMED LASER SURG, V27, P273, DOI 10.1089/pho.2007.2235
   Wu SY, 2017, J CHIN MED, V28, P0
   Yang J, 2020, MED ACUPUNCT, V32, P209, DOI 10.1089/acu.2020.1419
   Zhang L, 2018, J SHAANXI UNIV TRADIT CHIN MED, V41, P53
   Zhang Xuejiao, 2024, J CLIN SLEEP MED, V20, P1975, DOI 10.5664/jcsm.11326
   Zhao FY, 2025, WORLD J PSYCHIATR, V15, P0, DOI 10.5498/wjp.v15.i5.105802
   Zhao FY, 2024, SLEEP MED REV, V74, P0, DOI 10.1016/j.smrv.2023.101892
   Zhao FY, 2021, SLEEP MED, V80, P244, DOI 10.1016/j.sleep.2021.01.053
   Zhou P, 2012, CHIN J CLIN HEALTHC, V15, P50
NR 61
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1608
EI 
J9 NAT SCI SLEEP
JI NAT. SCI. SLEEP
PD JUN 15
PY 2025
VL 17
IS 
BP 3105
EP 3114
DI 10.2147/NSS.S570796
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA M6402
UT WOS:001630773400001
PM 41356808
DA 2026-01-16
ER

PT J
AU Zhou, R
   Zhu, YJ
   He, YH
   Lin, JJ
   Zhang, ZX
   Zhao, WJ
   Ma, HC
   Chang, XS
   Chen, YD
   Li, WZ
   Chen, X
   Chai, XS
   Zhang, HB
AF Zhou, Rui
   Zhu, Yan-juan
   He, Yi-han
   Lin, Jia-jia
   Zhang, Ze-xin
   Zhao, Wen-jie
   Ma, Hao-chuan
   Chang, Xue-song
   Chen, Ya-dong
   Li, Wen-zhu
   Chen, Xian
   Chai, Xiao-shu
   Zhang, Hai-bo
TI The association between acupuncture and response to immune checkpoint inhibitors in non-small cell lung cancer
SO CHINESE MEDICINE
LA English
DT Article
DE Acupuncture; Immune checkpoint inhibitors; Non-small cell lung cancer; Immunotherapy
ID efficacy; events; pain
AB Background Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, yet low response rates and resistance remain challenges. Emerging evidence suggests acupuncture may enhance ICI effectiveness by reprogramming immunosuppressive tumor microenvironments. Methods A retrospective analysis was conducted on 217 ICI-treated NSCLC patients. Patients who initiated acupuncture before median progression-free survival (mPFS, 8.87 months) of the overall population were classified as the acupuncture group (n = 97). Cox regression analysis was employed to evaluate the association between clinical characteristics and outcomes. Propensity score matching (PSM) was performed to mitigate selection bias. Subgroup and interaction analyses were conducted to evaluate potential effect modifiers. Results Acupuncture was significantly associated with improved mPFS (10.23 vs. 7.87 months, P = 0.036), while a numerical trend favoring acupuncture was observed in overall survival (mOS: 24.1 vs. 20.9 months, P = 0.352). Obvious benefits emerged in bone metastasis patients, with the acupuncture group reducing progression risk by 76% (HR = 0.24, 95% CI 0.14-0.42, P < 0.001) and death risk by 53% (HR = 0.47, 95% CI 0.21-1.03, P = 0.049). Conversely, PD-L1-positive subgroups exhibited no trend of improvement (subgroup HR > 1.0), with interaction HRs > 2.0 indicating potential impairment of ICI efficacy. The results of post-PSM data suggest that acupuncture was independently associated with improved PFS (aHR = 0.62, 95% CI 0.41-0.94, P = 0.024). Conclusion Our findings suggest a positive association between acupuncture and improved outcomes in ICI-treated NSCLC patients, particularly in those with bone metastasis, underscoring the potential role of acupuncture in the integrative management of cancer. However, biomarker-guided patient stratification is essential for integrating acupuncture into oncology care.
C1 [Zhou, Rui; Zhu, Yan-juan; He, Yi-han; Ma, Hao-chuan; Chang, Xue-song; Chen, Ya-dong; Li, Wen-zhu; Chen, Xian; Chai, Xiao-shu; Zhang, Hai-bo] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Hosp Tradit Chinese Med, Dept Oncol, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [Zhu, Yan-juan; Zhang, Hai-bo] Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China.
   [Zhu, Yan-juan; Zhang, Hai-bo] Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
   [Lin, Jia-jia; Zhang, Ze-xin; Zhao, Wen-jie] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Zhang, Hai-bo] Second Affiliated Hosp Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zhu, YJ; Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Hosp Tradit Chinese Med, Dept Oncol, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.; Zhu, YJ; Zhang, HB (corresponding author), Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China.; Zhu, YJ; Zhang, HB (corresponding author), Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.; Zhang, HB (corresponding author), Second Affiliated Hosp Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China.
EM zyjsophy@gzucm.edu.cn; haibozh@gzucm.edu.cn
FU National Key Research and Development Program of China [2023YFC3503303]; Major Innovation Technology Construction Project of Synergistic Chinese Medicine and Western Medicine of Guangzhou [2023-2318]; Project of Guangdong Provincial Hospital of Chinese Medicine [YN2024GZRPY019]; Traditional Chinese Medicine Bureau of Guangdong Province [20233014]
CR Boland JW, 2020, EUR J CLIN PHARMACOL, V76, P393, DOI 10.1007/s00228-019-02801-2
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen SX, 2024, FRONT IMMUNOL, V15, P0, DOI 10.3389/fimmu.2024.1335366
   Concato J, 1995, J CLIN EPIDEMIOL, V48, P1495, DOI 10.1016/0895-4356(95)00510-2
   Enfield KSS, 2024, CANCER DISCOV, V14, P1018, DOI 10.1158/2159-8290.CD-23-1380
   Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Garon EB, 2019, J CLIN ONCOL, V37, P0, DOI 10.1200/JCO.19.00934
   Guo H, 2024, CELL BIOL TOXICOL, V40, P0, DOI 10.1007/s10565-024-09892-3
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Jing B, 2020, CANCER RES, V80, P784, DOI 10.1158/0008-5472.CAN-19-2013
   Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588
   Liang MM, 2023, J EXP CLIN CANC RES, V42, P0, DOI 10.1186/s13046-023-02862-3
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Morad G, 2022, CELL, V185, P576, DOI 10.1016/j.cell.2022.01.008
   Negrao MV, 2021, J IMMUNOTHER CANCER, V9, P0, DOI 10.1136/jitc-2021-002891
   ODonnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8
   Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8
   Schoenfeld AJ, 2020, ANN ONCOL, V31, P599, DOI 10.1016/j.annonc.2020.01.065
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Turpin A, 2020, TRANSL ONCOL, V13, P308, DOI 10.1016/j.tranon.2019.10.012
   Wang Y, 2024, CANCER IMMUNOL RES, V12, P26, DOI 10.1158/2326-6066.CIR-23-0309
   Xiang LS, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20040999
   Xu LL, 2022, J HEMATOL ONCOL, V15, P0, DOI 10.1186/s13045-022-01307-2
   Yi JS, 2010, IMMUNOLOGY, V129, P474, DOI 10.1111/j.1365-2567.2010.03255.x
   Zhang ZY, 2021, LIFE SCI, V272, P0, DOI 10.1016/j.lfs.2021.119259
   Zhu YJ, 2022, LUNG CANCER, V166, P189, DOI 10.1016/j.lungcan.2022.03.006
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
   Zhu YJ, 2021, CLIN LUNG CANCER, V22, PE98, DOI 10.1016/j.cllc.2020.09.003
NR 30
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD SEP 19
PY 2025
VL 20
IS 1
BP 
EP 
DI 10.1186/s13020-025-01148-4
PG 12
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 7OR5E
UT WOS:001576021600002
PM 40973957
DA 2026-01-16
ER

PT J
AU Yang, MX
   Zhong, LD
   Fok, RWY
   Tjioe, YY
   Teo, BS
   Zhang, FR
   Bao, T
AF Yang, Mingxiao
   Zhong, Linda
   Fok, Rose W. Y.
   Tjioe, Yan Yin
   Teo, Bo Siang
   Zhang, Furong
   Bao, Ting
TI Effects and safety of traditional Chinese medicine approaches in cancer symptom care: A systematic review of phase 3 randomized clinical trials
SO CANCER
LA English
DT Review
DE acupuncture; herbal therapies; neoplasms; phase 3 clinical trials; symptom burden; systematic review; Tai Chi; traditional Chinese medicine
ID herbal medicine; breast-cancer; double-blind; acupuncture; therapy; fatigue
AB Cancer-related symptoms are detrimental to the quality of life of people with cancer. This review systematically evaluates phase 3 randomized clinical trials (RCTs) assessing the effectiveness and safety of traditional Chinese medicine (TCM) interventions in managing cancer-related symptoms throughout the cancer care trajectory. A comprehensive literature search was conducted of PubMed, Embase, and the Cochrane Library until April 27, 2025, to further identify eligible RCTs involving patients with cancer or survivors and assessing TCM interventions against valid control arms. Data extraction and quality assessments were conducted in accordance with Cochrane standards and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Nineteen phase 3 RCTs involving 5387 participants (female, 3321; primarily breast, gastrointestinal, and lung cancers) from six countries or regions were included. Nonpharmacological interventions, namely acupuncture and Tai Chi, significantly reduced pain, fatigue, insomnia, radiation-induced xerostomia, and hormonal therapy-related hot flashes compared to usual care (UC). Their effects on preventing chemotherapy- and radiotherapy-induced nausea and vomiting were mixed, which depended on control arms and outcome measures. Conversely, evidence for pharmacological interventions was limited, with inconclusive results regarding chemotherapy-induced peripheral neuropathy and hematologic toxicities, although promising outcomes were noted for preventing chemoradiotherapy-induced mucositis, reducing colorectal adenoma recurrence, and enhancing chemotherapy completion rates compared to placebo or UC. Safety data suggested similar adverse event profiles across groups. These findings show strong evidence for the inclusion of nonpharmacological interventions in oncology practice. However, pharmacological interventions require more high-quality, multicenter research to fully understand their effectiveness and safety. Implementing rigorous safety assessments and standardized adverse event reporting protocols is crucial to enhance clinical confidence in TCM modalities.
C1 [Yang, Mingxiao; Zhong, Linda; Tjioe, Yan Yin; Teo, Bo Siang] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
   [Fok, Rose W. Y.] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
   [Zhang, Furong] Chengdu Univ Tradit Chinese Med, Coll Hlth Preservat & Rehabil, Chengdu, Sichuan, Peoples R China.
   [Bao, Ting] Dana Farber Canc Inst, Boston, MA USA.
   [Bao, Ting] Harvard Med Sch, Boston, MA USA.
C3 Nanyang Technological University; National Cancer Centre Singapore (NCCS); Chengdu University of Traditional Chinese Medicine; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School
RP Yang, MX (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
EM mingxiao.yang@ntu.edu.sg
FU Nanyang Technological University [025273-00001]
CR Bergerot CD, 2025, JCO GLOB ONCOL, V11, P0, DOI 10.1200/GO-24-00625
   Bower JE, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00541
   Bubis LD, 2018, J CLIN ONCOL, V36, P1103, DOI 10.1200/JCO.2017.76.0876
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Cheng CW, 2017, ANN INTERN MED, V167, P112, DOI 10.7326/M16-2977
   Cleeland Charles S, 2007, J NATL CANCER INST MONOGR, V0, P16
   Cochrane Collaboration, 2020, REVIEW MANAGER (REVMAN), V0, P0
   Cohen L, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.10421
   Duan XY, 2025, CHIN MED-UK, V20, P0, DOI 10.1186/s13020-025-01156-4
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Fai CK, 2011, RECENT PATENTS INFLA, V5, P169, DOI 10.2174/187221311795399237
   Fasinu PS, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.01356
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Gupta S, 2023, CANCER MED-US, V12, P11773, DOI 10.1002/cam4.5837
   Henry DH, 2008, SUPPORT CARE CANCER, V16, P791, DOI 10.1007/s00520-007-0380-2
   Herrstedt J, 2024, ESMO OPEN, V9, P0, DOI 10.1016/j.esmoop.2023.102195
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins J, 2023, METHODOLOGICAL EXPECTATIONS OF COCHRANE INTERVENTION REVIEWS, V0, P0
   Konno Y, 2025, INTEGR CANCER THER, V24, P0, DOI 10.1177/15347354251329346
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Liu YM, 2023, PHYTOMEDICINE, V113, P0, DOI 10.1016/j.phymed.2023.154723
   Lopez G, 2024, NAT REV CANCER, V24, P739, DOI 10.1038/s41568-024-00735-1
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu CL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211031650
   Luo YK, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8692343
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mok TSK, 2007, ANN ONCOL, V18, P768, DOI 10.1093/annonc/mdl465
   Molassiotis A, 2013, HEALTH TECHNOL ASSES, V17, P0, DOI 10.3310/hta17260
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ni MX, 2024, PHYTOMEDICINE, V127, P0, DOI 10.1016/j.phymed.2024.155496
   Oki E, 2015, INT J CLIN ONCOL, V20, P767, DOI 10.1007/s10147-015-0784-9
   Shah S, 2022, COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS, V784, P0
   Sun LY, 2024, EUR J CANCER, V213, P0, DOI 10.1016/j.ejca.2024.115109
   Takemura N, 2024, JAMA ONCOL, V10, P176, DOI 10.1001/jamaoncol.2023.5248
   Tilburt JC, 2008, B WORLD HEALTH ORGAN, V86, P594, DOI 10.2471/BLT.07.042820
   Viviana Cortlana Ms, 2025, ONCOLOGY (WILLISTON PARK), V39, P105, DOI 10.46883/2025.25921037
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Zhang YL, 2024, CHIN J INTEGR MED, V30, P963, DOI 10.1007/s11655-024-4114-9
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
NR 42
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD NOV 15
PY 2025
VL 131
IS 22
BP 
EP 
DI 10.1002/cncr.70170
PG 11
WC Oncology
SC Oncology
GA 9YN2J
UT WOS:001618067800016
PM 41217297
DA 2026-01-16
ER

PT J
AU Li, SJ
   Shen, H
   Zhang, SC
   Shen, F
AF Li, Shi-Jie
   Shen, Hao
   Zhang, Shi-Chao
   Shen, Feng
TI [Research progress of acupuncture and moxibustion in treatment of primary liver
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Review
DE Acupuncture and moxibustion; Cancer pain; Cancer-related insomnia; Immunosuppression; Intractable hiccups; Primary liver cancer
AB The theoretical foundation of acupuncture and moxibustion is solid to support the  treatment of liver cancer and its related complications. A large number of  clinical and basic studies have deliberated the therapeutic effects of  acupuncture and moxibustion on liver cancer. The effects of  acupuncture-moxibustion therapy were summarized in terms of controlling tumor  lesion growth, alleviating cancer pain, reducing ascites production, attenuating  immunosuppression, inhibiting angiogenesis in tumors, alleviating postoperative  or chemotherapy-related side effects, and relieving cancer-related insomnia in  this review. Some problems existing in the current researches were explained and  the direction of future studies was explored.
C1 Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou 510006, China.
   Clinical Research Institute of The Third Affiliated Hospital, Naval Medical 
   The Fourth Department of Hepatic Surgery of The Third Affiliated Hospital, Naval Medical University, Shanghai 200438.
   Clinical Research Institute of The Third Affiliated Hospital, Naval Medical University, Shanghai 200438.
   The Fourth Department of Hepatic Surgery of The Third Affiliated Hospital, Naval 
   Clinical Research Institute of The Third Affiliated Hospital, Naval Medical University, Shanghai 200438.
   The Fourth Department of Hepatic Surgery of The Third Affiliated Hospital, Naval 
   Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou 510006, China. shenfengehbh@sina.com.
   Clinical Research Institute of The Third Affiliated Hospital, Naval Medical 
   The Fourth Department of Hepatic Surgery of The Third Affiliated Hospital, Naval Medical University, Shanghai 200438. shenfengehbh@sina.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAY 20
PY 2025
VL 50
IS 5
BP 605
EP 612
DI 10.13702/j.1000-0607.20240053
PG 7
WC Humans; Moxibustion; Acupuncture Therapy; Liver Neoplasms; therapy; Animals
UT PubMed:40390619
PM 40390619
DA 2025-05-20
ER

PT J
AU Hadoush, H
   Almhasis, R
   Kassab, M
   Almasri, NA
   Al-Wardat, M
AF Hadoush, Hikmat
   Almhasis, Reem
   Kassab, Manal
   Almasri, Nihad A
   Al-Wardat, Mohammad
TI Effectiveness of Non-pharmacological interventions on pain and fatigue management
SO Journal of bodywork and movement therapies
LA English
DT Journal Article
DE Cancer; Fatigue; Non-pharmacological; Rehabilitation; pain
AB Pain and fatigue are the primary symptoms that cancer survivors frequently  report. The goal of this meta-analysis was to evaluate how effective  non-pharmacological interventions are in managing pain and fatigue in cancer  survivors. Approach: This research consisted solely of randomized controlled  trials (RCTs) that enlisted participants aged 18-80 years who had been diagnosed  with any form of cancer. The risk of bias was evaluated through the Cochrane risk  of bias tool. The process of meta-analyses involved calculating the standardized  mean difference (SMD) within a 95 % confidence interval (CI) using Review Manager  software. Outcome: Five studies involving 283 participants in the treatment group  demonstrated a noteworthy benefit of acupuncture and reflexology in pain relief  (SMD -0.69, 95 % CI -1.29 to -0.10, Z = 2.28, p = 0.02, and I(2) = 82 %).  Nonetheless, five studies with 370 participants (221 in the intervention group)  found a minor impact on pain control from engaging in physical activity (SMD  -0.29, 95 % CI -0.74 to 0.16, Z = 1.27, p = 0.20, I(2) = 76 %). Regarding fatigue  management, four studies involving 368 participants (intervention group = 221)  found a minor impact of physical activity on fatigue management (SMD - 0.06, 95 %  CI - 0.46 to 0.33, Z = 0.30, p = 0.76, I2 = 72 %). In conclusion, data that was  pooled and analyzed found that non-pharmacological interventions were found to  have a positive therapeutic impact on pain management among cancer survivors.  However, the same interventions showed little to no therapeutic effect on  fatigue. Therefore, it is strongly recommended to conduct more high-quality  studies.
C1 Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan. 
   Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan.
   Department of Maternal and Child Health, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan.
   Department of Rehabilitation Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
   Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan.
EM mhadoush@just.edu.jo
NR 0
TC 0
SN 1532-928
EI 
J9 J Bodyw Mov Ther
PD SEP 16
PY 2025
VL 44
IS 
BP 251
EP 260
DI 10.1016/j.jbmt.2025.05.046
PG 9
WC Humans; Acupuncture Therapy; methods; Cancer Survivors; Exercise; Fatigue; therapy; Massage; methods; Neoplasms; complications; Pain Management; methods; Randomized Controlled Trials as Topic
UT PubMed:40954588
PM 40954588
DA 2025-09-16
ER

PT J
AU Chen, Z
   Xu, T
   Yin, Z
   Li, Q
   Shu, Y
   Zhou, X
   Zhao, L
   Sun, M
   Liang, F
AF Chen, Zi-Wen
   Xu, Tao
   Yin, Zi-Han
   Li, Qi-Fu
   Shu, Yun-Jie
   Zhou, Xue-Li
   Zhao, Ling
   Sun, Ming-Sheng
   Liang, Fan-Rong
TI Electroacupuncture for chemotherapy-induced gastrointestinal symptoms in colorectal cancer: protocol for a multicenter, three-arm, randomized controlled trial
SO International Journal of Colorectal Disease
LA English
DT Article
DE Chemotherapy; Colorectal cancer; Electroacupuncture; Gastrointestinal toxicity; Randomized controlled trial
ID adsorbent; corticosteroid; loperamide; serotonin 3 agonist; antineoplastic agent; abdominal distension; abdominal pain; acupuncturist; adult; aged; article; bile reflux; bleeding; blind evaluation scale; chemical ionization mass spectrometry; colorectal cancer; constipation; controlled study; cross validation; diarrhea; dizziness; ecog performance status; efficacy parameters; electroacupuncture; electrostimulation; female; follow up; functional assessment of cancer therapy colorectal scores; gastrointestinal symptom rating scale; gastrointestinal toxicity; hematoma; human; indigestion; infection; intention to treat analysis; internal consistency; intervention study; karnofsky performance status; linear mixed effects model; major clinical study; male; middle aged; multicenter study; nausea and vomiting; needle insertion; neiguan acupoint; outcome assessment; pain; pallor; protocol; quality control; quchi acupoint; randomized controlled trial; sample size; shangjuxu acupoint; standard care; sweating; zung self rating depression scale; zusanli acupoint; colorectal tumor; drug therapy; gastrointestinal disease; multicenter study (topic); quality of life; randomized controlled trial (topic); therapy; treatment outcome; adult; aged; antineoplastic agents; colorectal neoplasms; electroacupuncture; female; gastrointestinal diseases; humans; male; middle aged; multicenter studies as topic; quality of life; randomized controlled trials as topic; treatment outcome
AB Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality globally. While chemotherapy remains a cornerstone of CRC treatment, gastrointestinal (GI) toxicity—manifesting as abdominal pain, diarrhea, constipation, and reflux—affects 40%–100% of patients, severely impairing quality of life. Despite the prevalence of these symptoms, there is a lack of effective non-pharmacological interventions. This study aims to evaluate the efficacy of electroacupuncture (EA) in alleviating chemotherapy-induced GI dysfunction in CRC patients. Methods: In this multicenter, three-arm, randomized controlled trial (RCT), 231 CRC patients with post-chemotherapy GI symptoms will be centrally randomized to EA plus standard care, sham acupuncture (SA) plus standard care, or standard care alone. The EA and SA groups will receive three 30-min sessions over consecutive days, delivered by certified acupuncturists (EA: LI11, PC6, ST36 and ST37 with electrical stimulation; SA: non-acupoints with blunt-tip needles without stimulation). The primary outcome is the change in Gastrointestinal Symptom Rating Scale (GSRS) total scores from baseline to post-treatment (day 3). Secondary outcomes include GSRS subscale scores, Functional Assessment of Cancer Therapy-Colorectal (FACT-C) scores, and Self-Rating Anxiety Scale/Self-Rating Depression Scale (SAS/SDS) scores. All outcomes will be assessed at baseline (T0), post-intervention (T1: day 3), and follow-up (T2: day 10). Statistical analysis will employ intention-to-treat linear mixed-effects models. Conclusion: This multicenter RCT is designed to generate high-quality evidence on the comprehensive efficacy of EA in addressing chemotherapy-induced GI toxicity in CRC patients. If proven effective, EA could provide a safe, non-pharmacological adjunct to standard care, helping to reduce symptom burden and improve patient adherence to chemotherapy. Trial registration ChiCTR2200062317. Registered on 1 August 2022. © The Author(s) 2025.
C1 Chengdu University of Traditional Chinese Medicine, Chen, Ziwen, Acupuncture and Tuina School, Chengdu, Sichuan, China, Sichuan Provincial Acupuncture Clinical Medicine Research Center, Chengdu, Sichuan, China
   Sichuan Orthopedic Hospital, Xu, Tao, Department of Research, Chengdu, China
   Chengdu University of Traditional Chinese Medicine, Yin, Zihan, Acupuncture and Tuina School, Chengdu, Sichuan, China, Sichuan Provincial Acupuncture Clinical Medicine Research Center, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Li, Qifu, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Shu, Yunjie, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zhou, Xueli, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Zhao, Ling, Acupuncture and Tuina School, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Sun, Mingsheng, Acupuncture and Tuina School, Chengdu, Sichuan, China, Sichuan Provincial Acupuncture Clinical Medicine Research Center, Chengdu, Sichuan, China
   Chengdu University of Traditional Chinese Medicine, Liang, Fanrong, Acupuncture and Tuina School, Chengdu, Sichuan, China, Sichuan Provincial Acupuncture Clinical Medicine Research Center, Chengdu, Sichuan, China
CR Global Cancer Burden Growing Amidst Mounting Need for Services, 1900, 2024, V0, P0
   Eng, 1900, A COMPREHENSIVE FRAMEWORK FOR EARLY-ONSET COLORECTAL CANCER RESEARCH, V0, Pe116-e128
   Patel, 1900, 2024, V0, P0
   Baxter, 1900, ADJUVANT THERAPY FOR STAGE II COLON CANCER: ASCO GUIDELINE UPDATE, V0, P892-910
   Hu, 1900, NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, V0, P2978-2988
   Patel, 1900, 2022, V0, P0
   Akbarali, 1900, 2022, V0, P0
   Chen, 1900, SYNERGISTIC ANTITUMOR ACTIVITY OF RAPAMYCIN AND EF24 VIA INCREASING ROS FOR THE TREATMENT OF GASTRIC CANCER, V0, P78-89
   Lee, 1900, GASTRO-INTESTINAL TOXICITY OF CHEMOTHERAPEUTICS IN COLORECTAL CANCER: THE ROLE OF INFLAMMATION, V0, P3751-3761
   Dahlgren, 1900, CHEMOTHERAPEUTICS-INDUCED INTESTINAL MUCOSITIS: PATHOPHYSIOLOGY AND POTENTIAL TREATMENT STRATEGIES, V0, P12
NR 10
TC 0
SN 01791958
EI 
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD JUN 15
PY 2025
VL 40
IS 1
BP 
EP 
DI 10.1007/s00384-025-05008-3
PG 0
UT PubMed:41144022
ER

PT J
AU Chien, TJ
   Chang, YI
   Liao, LL
   Hsu, YN
   Huang, CW
AF Chien, Tsai-Ju
   Chang, Yuan-I.
   Liao, Li-Lan
   Hsu, Yu-Ni
   Huang, Chien-Wen
TI Comparative Efficacy of Low-Level Laser Acupuncture and Electroacupuncture in Women With Dysmenorrhea and Autonomic Imbalance: A Pilot Randomized-Controlled Trial
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Article
DE autonomic dysfunction; dysmenorrhea; electroacupuncture; heart rate variation; low-level laser acupuncture
ID heart-rate-variability; quality-of-life; kuan-sin-yin; therapy; acupressure; symptoms; cancer; pain
AB Background Electroacupuncture (EA) has been widely applied in treating dysmenorrhea and autonomic dysfunction. Low-level laser acupuncture (LLLA), a noninvasive acupuncture, has been used clinically, but efficacy is uncertain. This study aimed to explore the efficacy of LLLA, EA, and sham-controlled LLLA on pain, heart rate variability (HRV) activity, and symptom improvement in dysmenorrhea with autonomic imbalance. Method In a randomized, controlled design, a total of 114 women with dysmenorrhea and autonomic imbalance were randomly allocated to three groups: sham LLLA, LLLA, and EA. The primary outcomes are pain (VAS), and HRV parameters, and the secondary outcomes are symptom assessment (verbal multidimensional scoring system), prostaglandin E, progesterone levels, and the SF-12 quality-of-life assessment. Results Contrast to the sham acupuncture, LLLA and EA effectively reconciled the pain and sympathetic/parasympathetic tone significantly, no matter the vagus or sympathetic deviated status (low or high LF/HF group). LLLA was superior to EA in terms of SDNN, RMMSD, and PNN50 (p < 0.001) in the low LF/HF group in intergroup analysis. For all participants' analysis, the effects of LLLA and EA were similar for pain assessment (VAS) and quality of life (SF-12) (p < 0.05). In proinflammatory cytokine measurement, EA showed a significant decrease in prostaglandin E2 (PGE2) levels (p = 0.022). Conclusion This pilot study showed both LLLA and EA effectively relieve dysmenorrhea without a placebo effect, LLLA is noninferior to EA in autonomic dysfunction, and the effect is even more prominent in low LF/HF status (a relatively lower energy status). Given its noninvasiveness, LLLA could be an alternative treatment and warrants further large-scale study.
C1 [Chien, Tsai-Ju; Hsu, Yu-Ni] Taipei City Hosp, Dept Internal Med, Div Hematooncol, Branch Zhong Xing, Taipei, Taiwan.
   [Chien, Tsai-Ju; Liao, Li-Lan] Natl Yang Ming Chiao Tung Univ, Inst Tradit Med, Taipei, Taiwan.
   [Chang, Yuan-I.] Natl Yang Ming Chiao Tung Univ, Dept & Inst Physiol, Coll Med, Taipei, Taiwan.
   [Liao, Li-Lan] Taipei City Hosp, Dept Tradit Med, Branch Kunming, Taipei, Taiwan.
   [Huang, Chien-Wen] Sunhawk Vis Biotech Inc, Taipei, Taiwan.
C3 Taipei City Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei City Hospital
RP Chien, TJ (corresponding author), Taipei City Hosp, Dept Internal Med, Div Hematooncol, Branch Zhong Xing, Taipei, Taiwan.; Chien, TJ (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Tradit Med, Taipei, Taiwan.
EM silence021@gmail.com
FU Ministry of Science and Technology of the People's Republic of China
CR Adly AS, 2022, LASER MED SCI, V37, P499, DOI 10.1007/s10103-021-03287-0
   Akita T, 2022, J INTEGR COMPLEMENT, V28, P791, DOI 10.1089/jicm.2022.0526
   Armour M, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180177
   Burduli NM, 2012, TERAPEVT ARKH, V84, P58
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Chang YC, 2022, LIFE-BASEL, V12, P0, DOI 10.3390/life12121951
   Chien TJ, 2020, CLIMACTERIC, V23, P130, DOI 10.1080/13697137.2019.1664460
   Chien TJ, 2024, J INTEGR COMPLEMENT, V30, P560, DOI 10.1089/jicm.2023.0183
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chien TJ, 2016, COMPLEMENT THER MED, V29, P204, DOI 10.1016/j.ctim.2016.10.001
   Chien TJ, 2016, INTEGR CANCER THER, V15, P113, DOI 10.1177/1534735415617282
   Chon TY, 2019, MED ACUPUNCT, V31, P164, DOI 10.1089/acu.2019.1343
   Dai L, 2019, CHIN J INTEGR MED, V25, P71, DOI 10.1007/s11655-018-2999-x
   Dai RX, 2024, LIFE SCI, V357, P0, DOI 10.1016/j.lfs.2024.123102
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, P0, DOI 10.1109/JSTQE.2016.2561201
   de Jesus JF, 2015, LASER MED SCI, V30, P153, DOI 10.1007/s10103-014-1636-y
   Doret M, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0136661
   Fu ZT, 2024, CHIN MED-UK, V19, P0, DOI 10.1186/s13020-024-01028-3
   Hong GY, 2016, INT J GYNECOL OBSTET, V133, P37, DOI 10.1016/j.ijgo.2015.08.004
   Iorno V, 2008, EVID-BASED COMPL ALT, V5, P227, DOI 10.1093/ecam/nem020
   Jensen MK, 2022, SENSORS-BASEL, V22, P0, DOI 10.3390/s22207884
   Jeon H, 2025, CHIN MED-UK, V20, P0, DOI 10.1186/s13020-025-01104-2
   Jittiwat J, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1204709
   Kastyro IV, 2021, DOKL BIOCHEM BIOPHYS, V500, P300, DOI 10.1134/S1607672921050112
   Kouzuma N, 2022, MED ACUPUNCT, V34, P299, DOI 10.1089/acu.2022.0004
   Li T, 2025, COMPLEMENT THER MED, V92, P0, DOI 10.1016/j.ctim.2025.103184
   Li YW, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1038945
   Liang WC, 2009, SENSORS-BASEL, V9, P6913, DOI 10.3390/s90906913
   Lim S, 2010, EVID-BASED COMPL ALT, V7, P167, DOI 10.1093/ecam/nep006
   Liu LL, 2019, LASER MED SCI, V34, P263, DOI 10.1007/s10103-018-2581-y
   Liu WT, 2022, CLIN NURS RES, V31, P1362, DOI 10.1177/10547738221086984
   Manente R, 2023, LASER MED SCI, V38, P0, DOI 10.1007/s10103-023-03754-w
   Meyer-Hamme G, 2018, BMC NEUROL, V18, P0, DOI 10.1186/s12883-018-1037-0
   Mussttaf RA, 2019, INT J RADIAT BIOL, V95, P120, DOI 10.1080/09553002.2019.1524944
   Ouyang XJ, 2020, NEUROMODULATION, V23, P1137, DOI 10.1111/ner.13154
   Pedron-Nuevo N, 1998, GINECOL OBSTET MEX, V66, P492
   Qorbanalipour K, 2018, INT J WOMEN HEAL REP, V6, P471, DOI 10.15296/ijwhr.2018.78
   Roomruangwong C, 2021, J PSYCHOSOM RES, V142, P0, DOI 10.1016/j.jpsychores.2020.110355
   Shaffer F, 2017, FRONT PUBLIC HEALTH, V5, P0, DOI 10.3389/fpubh.2017.00258
   Shi GX, 2011, CLIN J PAIN, V27, P258, DOI 10.1097/AJP.0b013e3181fb27ae
   Sriprasert I, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/735690
   STEINBERGER A, 1981, AM J CHINESE MED, V9, P57, DOI 10.1142/S0192415X81000081
   Sun DC, 2006, P 9 C ENG TECHN APPL, V0, P0
   Uchida C, 2018, MED ACUPUNCT, V30, P89, DOI 10.1089/acu.2017.1266
   Wang SS, 2020, J PAIN RES, V13, P1471, DOI 10.2147/JPR.S251948
   Wang YJ, 2016, BIOL RES NURS, V18, P465, DOI 10.1177/1099800416640875
   Wehrwein EA, 2016, COMPR PHYSIOL, V6, P1239, DOI 10.1002/cphy.c150037
   Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8
   Wu JH, 2009, PHOTOMED LASER SURG, V27, P273, DOI 10.1089/pho.2007.2235
   Yang HH, 2023, J INTEGR MED-JIM, V21, P26, DOI 10.1016/j.joim.2022.10.004
   Yu JS, 2013, INT REV NEUROBIOL, V111, P125, DOI 10.1016/B978-0-12-411545-3.00006-7
   Zhang DX, 2021, NEUROL SCI, V42, P1453, DOI 10.1007/s10072-020-04682-1
NR 52
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD JUN 15
PY 2025
VL 2025
IS 1
BP 
EP 
DI 10.1155/prm/3494216
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA 8YC9P
UT WOS:001600103300001
PM 41179650
DA 2026-01-16
ER

PT J
AU Xu, Y
   Chen, YT
   Feng, YF
   Zhang, Q
   Zhou, T
   Wo, CX
   Zhang, MM
AF Xu, Yun
   Chen, Yunting
   Feng, Yongfu
   Zhang, Qian
   Zhou, Tao
   Wo, Chunxin
   Zhang, Minmin
TI Silver needle thermal conduction therapy relieves pain in rats with myofascial pain syndrome
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Myofascial pain syndrome; silver needle thermal conduction therapy; chronic pain; acupuncture effect; thermal effect
ID gene-related peptide; 5-ht3
AB Objective: To assess the effects of silver needle thermal conduction therapy on spinal neurotransmitter activation and inflammation reduction in the myofascial trigger point musculature of a rat model with myofascial pain syndrome (MPS). Methods: The MPS rat model was induced by a combination of impact and exercise fatigue. MPS rats were then subjected to silver needle thermal conduction therapy for 14 days. Thermal and mechanical pain thresholds were assessed using the thermal hyperalgesia and mechanical hyperalgesia tests. Transverse and longitudinal sections of the right medial thigh muscle were prepared for histological analysis using HE staining. Western blot and immunohistochemistry were used to measure the expression of calcitonin gene-related peptide (CGRP), substance P (SP), and 5-hydroxytryptamine (5-HT) in the L4-6 segment of the spinal cord. Additionally, the levels of inflammatory cytokines, including interleukin 1-(3 (IL-1(3) and tumor necrosis factor alpha (TNF-alpha), in the right medial femoral muscle were assessed via ELISA. Results: MPS rats exhibited a decreased thermal and mechanical pain threshold compared to control rats. Muscle fiber atrophy and deformation were observed in the MPS rats. Levels of IL-1(3 and TNF-alpha were elevated in the right medial femoral muscle, while CGRP and SP expression were increased, and 5-HT expression was decreased in the spinal cord. Silver needle thermal conduction therapy effectively reversed these pathological changes in the MPS rats. Conclusions: Silver needle thermal conduction therapy alleviated MPS in rats by modulating spinal neurotransmitter expression and reducing muscle inflammation.
C1 [Xu, Yun; Feng, Yongfu; Zhang, Qian; Zhou, Tao] Guizhou Med Univ, Affiliated Hosp 2, Dept Pain, Kaili 556000, Guizhou, Peoples R China.
   [Chen, Yunting; Wo, Chunxin; Zhang, Minmin] Guizhou Med Univ, Affiliated Hosp, Dept Pain, 28 Guiyi St, Guiyang 550004, Guizhou, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Wo, CX; Zhang, MM (corresponding author), Guizhou Med Univ, Affiliated Hosp, Dept Pain, 28 Guiyi St, Guiyang 550004, Guizhou, Peoples R China.
EM wochunxin@163.com; zmm1987@hotmail.com
FU Guizhou Province Science and Technology Planning Project [ZK [2021]]; National Natural Science Foundation of China [82160226]; Regional Foundation of China;  [Qianke He Foundation-ZK [2023] Key 044]
CR Barbero M, 2019, CURR OPIN SUPPORT PA, V13, P270, DOI 10.1097/SPC.0000000000000445
   Chang WH, 2021, BIOMED J, V44, P739, DOI 10.1016/j.bj.2020.05.020
   Corum M, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101319
   Baltazar MCD, 2022, BMC WOMENS HEALTH, V22, P0, DOI 10.1186/s12905-022-01910-y
   de Magalhaes SF, 2021, EUR J NEUROSCI, V53, P376, DOI 10.1111/ejn.14985
   Duarte FCK, 2023, CLIN J PAIN, V39, P188, DOI 10.1097/AJP.0000000000001102
   Fan AY, 2017, CHIN J INTEGR MED, V23, P83, DOI 10.1007/s11655-017-2800-6
   Fernández-de-las-Peñas C, 2023, LIFE-BASEL, V13, P0, DOI 10.3390/life13030694
   Fernández-de-Las-Peñas C, 2019, J PAIN RES, V12, P1899, DOI 10.2147/JPR.S154728
   Fernández-Lázaro D, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12020501
   Galasso A, 2020, CURR PAIN HEADACHE R, V24, P0, DOI 10.1007/s11916-020-00877-5
   Green DP, 2019, NEURON, V101, P412, DOI 10.1016/j.neuron.2019.01.012
   Iyengar S, 2017, PAIN, V158, P543, DOI 10.1097/j.pain.0000000000000831
   Lauritano D, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24054811
   Lee S, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.947884
   Li CJ, 2022, MOL NEUROBIOL, V59, P7253, DOI 10.1007/s12035-022-03034-8
   Lu FY, 2023, J PAIN RES, V16, P1025, DOI 10.2147/JPR.S401875
   Lv XL, 2022, NEUROL INDIA, V70, PS288, DOI 10.4103/0028-3886.360917
   Mansoori SS, 2021, J REHABIL MED, V53, P0, DOI 10.2340/16501977-2781
   Menéndez-Torre A, 2023, CHIROPR MAN THER, V31, P0, DOI 10.1186/s12998-023-00489-x
   Paige C, 2022, J NEUROSCI, V42, P1930, DOI 10.1523/JNEUROSCI.1137-21.2022
   Paoletta M, 2022, MEDICINA-LITHUANIA, V58, P0, DOI 10.3390/medicina58081014
   Shah JP, 2008, ARCH PHYS MED REHAB, V89, P16, DOI 10.1016/j.apmr.2007.10.018
   Srinivasan M, 2022, PHYS MED REH CLIN N, V33, P307, DOI 10.1016/j.pmr.2022.01.011
   Taskesen F, 2023, CRANIO, V41, P96, DOI 10.1080/08869634.2020.1820686
   Urits I, 2020, BEST PRAC RES-CL ANA, V34, P427, DOI 10.1016/j.bpa.2020.08.003
   Wei S, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02151-w
   Xiong JW, 2024, FRONT NEUROL, V15, P0, DOI 10.3389/fneur.2024.1374542
   Yamaguchi C, 2021, BIOL PHARM BULL, V44, P1067, DOI 10.1248/bpb.b21-00178
   Yehoshua I, 2022, BMC PRIM CARE, V23, P0, DOI 10.1186/s12875-022-01951-0
   Yuan Y, 2022, MOL PAIN, V18, P0, DOI 10.1177/17448069221093016
   Zha MY, 2022, J MED CASE REP, V16, P0, DOI 10.1186/s13256-021-03239-w
   Zhang Q, 2020, ARCH PHYS MED REHAB, V101, P1437, DOI 10.1016/j.apmr.2020.02.013
NR 33
TC 0
Z9 0
U1 2
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2025
VL 17
IS 4
BP 2604
EP 2613
DI 10.62347/QQBB3856
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 2GC3M
UT WOS:001481829200014
PM 40385020
DA 2026-01-16
ER

PT J
AU Su, WH
   Li, XL
   Wang, YR
AF Su, Wenhao
   Li, Xueling
   Wang, Yanru
TI Efficacy of pharmacological and non-pharmacological therapy on chronic cancer pain intensity of adults with cancer: A network meta-analysis protocol
SO PLOS ONE
LA English
DT Article
ID quality-of-life; management; acupuncture; guidelines; relief
AB Background Chronic cancer pain is very common symptom in cancer patients, but this issue has not been satisfactorily resolved by the conventional three-step analgesic therapy. There are multiple non-pharmacological interventions for managing chronic cancer pain, but we haven't reached a consensus on which non pharmacological treatment is the best and these treatments are lack of high-quality evidence. In order to identify the most effective non-pharmaceutical therapy alternatives and investigate further possible medication interventions, this study will use network meta-analysis to assess the therapeutic effects of pharmacological and non-pharmacological treatments on chronic cancer pain patients and support clinical decision-making by prioritizing therapies according to the most valuable clinical outcomes for these patients.Methods and analysis We will carry out a systematic search of published randomized controlled trials (group, crossover, and parallel) in the PubMed, Web of Science, Cochrane Library, MEDLINE, Embase, and CINAHL databases, without language or date restrictions, in accordance with the PRISMA for Network Meta-Analyses (PRISMA-NMA) guidelines. Included studies must evaluate the effects of pharmacological and non-pharmacological treatments in patients with chronic cancer pain. Adult chronic cancer pain patients (>= 18 years old) receiving pharmacological or non-pharmacological treatment will be our target participants. Our primary outcomes will be pain intensity, total effective rate of treatment, onset time, and quality of Life (QoL); Adverse reaction will be our secondary outcome. We'll utilize the mean difference (MD) for continuous variables, the odds ratio (OR) for binary variables, and the 95% confidence interval (CI) for interval estimates. The Cochrane Bias Risk Tool (RoB2.0) will be used to assess the bias risk of every RCT trial included in NMA. We will use Review Manager 5.3 software to conduct heterogeneity testing and meta-analysis. The network meta-analysis will be performed by ADDIS1.16.8 software. The Confidence in Network Meta-analysis (CINeMA) framework will be used to evaluate the level of confidence in the NMA results. Besides, we will use SUCRA for ranking the network meta-analysis results, and we will also apply normalized entropy to verify the accuracy of the SUCRA ranking outcomes.Discussion This network meta-analysis will compare the efficacy of pharmacological versus non-pharmacological treatments for pain intensity in chronic cancer pain patients. The final analysis results may be significantly heterogeneous, because the population with cancerous pain suffers from different types of cancers. Owing to the databases primary reliance on our listed databases for inclusion, potentially valuable research will be overlooked.Registration This study has been registered in the PROSPERO database (CRD42024505214)
C1 [Su, Wenhao] Wenzhou Med Univ, Quzhou Peoples Hosp, Nursing Dept, Quzhou, Zhejiang, Peoples R China.
   [Li, Xueling] Hainan Vocat Univ Sci & Technol, Sch Nursing, Haikou, Hainan, Peoples R China.
   [Wang, Yanru] Zhejiang Chinese Med Univ, Sch Nursing, Hangzhou, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Hainan Vocational University of Science & Technology; Zhejiang Chinese Medical University
RP Wang, YR (corresponding author), Zhejiang Chinese Med Univ, Sch Nursing, Hangzhou, Zhejiang, Peoples R China.
EM Wangyanru001@outlook.com
CR Shaheed CA, 2024, CA-CANCER J CLIN, V74, P286, DOI 10.3322/caac.21823
   Algera MH, 2019, BRIT J ANAESTH, V122, PE168, DOI 10.1016/j.bja.2018.12.023
   Araujo AM, 2004, ANALES SIS SAN NAVARRA, V27, P63
   Arthur J, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08323-7
   Bennett MI, 2019, PAIN, V160, P38, DOI 10.1097/j.pain.0000000000001363
   Bradt J, 2021, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911.pub4
   Bruera Eduardo, 2015, AM SOC CLIN ONCOL EDUC BOOK, V0, PPE593, DOI 10.14694/edbook_am.2015.35.e593
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   Carlson RW, 2014, J NATL COMPR CANC NE, V12, P643, DOI 10.6004/jnccn.2014.0068
   Cascella AAAJMHM, 2023, WHO ANALGESIC LADDER, V0, P0
   Cillessen L, 2019, PSYCHO-ONCOLOGY, V28, P2257, DOI 10.1002/pon.5214
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Eccleston C, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010152.pub2
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Farmer AD, 2019, UNITED EUR GASTROENT, V7, P7, DOI 10.1177/2050640618818305
   Feng BB, 2022, EUR J PAIN, V26, P61, DOI 10.1002/ejp.1849
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Fink J, 2020, J ALTERN COMPLEM MED, V26, P820, DOI 10.1089/acm.2019.0371
   Fonseca LS, 2023, SYST REV-LONDON, V12, P0, DOI 10.1186/s13643-023-02369-0
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Gentile D, 2018, J ALTERN COMPLEM MED, V24, P968, DOI 10.1089/acm.2018.0192
   George B, 2019, SUPPORT CARE CANCER, V27, P3105, DOI 10.1007/s00520-019-04828-8
   Huang RZ, 2019, J CLIN ONCOL, V37, P1742, DOI 10.1200/JCO.18.01567
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jin H, 2024, MEDICINE, V103, P0
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Kruizinga R, 2016, PSYCHO-ONCOLOGY, V25, P253, DOI 10.1002/pon.3910
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lu XK, 2023, FRONT PHARMACOL, V14, P0, DOI 10.3389/fphar.2023.1073939
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mercadante S, 2023, CURR TREAT OPTION ON, V24, P1367, DOI 10.1007/s11864-023-01117-9
   Ngamkham S, 2019, ASIA-PAC J ONCOL NUR, V6, P161, DOI 10.4103/apjon.apjon_67_18
   Nikolakopoulou A, 2020, PLOS MED, V17, P0, DOI 10.1371/journal.pmed.1003082
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Ream E, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007568.pub2
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Sande TA, 2019, J PALLIAT MED, V22, P90, DOI 10.1089/jpm.2018.0260
   Sine H, 2022, CANCER INVEST, V40, P235, DOI 10.1080/07357907.2021.1998520
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Wang B, 2023, INT J QUAL HEALTH C, V35, P0, DOI 10.1093/intqhc/mzad017
   Yangöz ST, 2019, J ADV NURS, V75, P3362, DOI 10.1111/jan.14184
   Zhang QL, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1166580
NR 49
TC 0
Z9 0
U1 5
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 
EI 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 15
PY 2025
VL 20
IS 7
BP 
EP 
DI 10.1371/journal.pone.0322651
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 5SR7Z
UT WOS:001543410900003
PM 40674370
DA 2026-01-16
ER

PT J
AU Akutay, S
   Yüceler, Kaçmaz H
   Ceyhan, Ö
AF Akutay, Seda
   Yüceler Kaçmaz, Hatice
   Ceyhan, Özlem
TI The healing power of transcutaneous electrical nerve stimulation: a systematic
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Breast cancer; Pain; Postoperative care; Transcutaneous electrical nerve stimulation
AB BACKGROUND: Transcutaneous electrical stimulation after breast cancer surgery has  been utilized for various purposes, but the full efficacy of this treatment  approach on postoperative symptoms remains unclear. AIM: This study aimed to  answer the question: Does transcutaneous electrical nerve stimulation  significantly impact postoperative patient outcomes in individuals undergoing  breast cancer surgery? METHODS: A systematic review of randomized controlled  trials was conducted. Because of the limited number of studies included, it was  not feasible to perform a meta-analysis. English-language publications from 2013  and 2024 that investigated the effects of transcutaneous electrical stimulation  in breast cancer surgery patients were included. Electronic databases such as Web  of Science, PubMed, Scopus, EBSCO, ScienceDirect, Cochrane Central Register of  Controlled Trials, and Wiley Online Library were searched. Two independent  investigators assessed the studies using the revised JBI risk of bias tool. Data  from randomized trials were extracted by two researchers using the Cochrane data  collection tool. RESULTS: Our comprehensive literature review identified 251  studies. After rigorous assessment, 12 articles met our inclusion criteria. Title  and abstract screening excluded seven studies that did not involve surgery, used  treatments other than TENS, included acupuncture, or did not measure pain  outcomes. Among these, five studies involving 776 patients examined the effects  of transcutaneous electrical stimulation on pain management in breast cancer  surgery. In all of the studies reviewed, transcutaneous electrical stimulation  had a beneficial effect on postoperative pain. CONCLUSION: Transcutaneous  electrical stimulation has significantly alleviated pain associated with breast  cancer surgery. This therapeutic modality has improved patient satisfaction with  analgesia by relieving pain; reducing analgesic use; reducing postoperative  nausea and vomiting; increasing blood levels of IL-2, IFN-γ, and IL-2/IL-4 ratio;  and reducing skin sensitivity. Transcutaneous electrical stimulation devices may  improve postoperative patient outcomes and enhance the recovery process in people  undergoing breast cancer surgery. The results of this study are limited by  heterogeneity and the small number of included studies. Future research should  prioritize standardization of intervention procedures and investigation of the  long-term effects of TENS in postoperative care. REGISTRATION: This study was  registered in the PROSPERO registration system under the number CRD42024523558.
C1 Department of Surgical Nursing, Faculty of Health Sciences, Erciyes University, Kayseri, Turkey. sedaakutay@erciyes.edu.tr.
   Department of Surgical Nursing, Faculty of Health Sciences, Erciyes University, Kayseri, Turkey.
   Department of Internal Nursing, Faculty of Health Sciences, Erciyes University, Kayseri, Turkey.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD JAN 13
PY 2025
VL 33
IS 2
BP 90
EP 90
DI 10.1007/s00520-024-09129-3
PG 0
WC Humans; Transcutaneous Electric Nerve Stimulation; methods; Breast Neoplasms; surgery; Female; Randomized Controlled Trials as Topic; Pain, Postoperative; therapy; Mastectomy
UT PubMed:39804405
PM 39804405
DA 2025-01-13
ER

PT J
AU Cao, YL
   Jing, F
   Jiang, LY
   Tian, MT
   Qiu, JJ
   Tang, LC
   Hu, Y
AF Cao, Yuling
   Jing, Feng
   Jiang, Lingyun
   Tian, Maoting
   Qiu, Jiajia
   Tang, Lichen
   Hu, Yan
TI The experience of musculoskeletal symptoms among patients with breast cancer during aromatase inhibitor therapy: A qualitative study
SO ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE Breast cancer; Aromatase inhibitor therapy; Musculoskeletal symptoms; Qualitative study; Symptom experience; Symptom management
ID adjuvant endocrine therapy; social support; of-life; chinese; management; adherence; survivors; women
AB Objective: To examine the musculoskeletal symptom experiences of Chinese patients with breast cancer receiving aromatase inhibitor (AI) therapy and identify patient-centered strategies for symptom management. Methods: A descriptive qualitative study was conducted from June to August 2023 at a tertiary hospital in Shanghai, China. Using purposive sampling with maximum variation, 37 women with hormone receptor-positive (HR+) breast cancer (stages I-III) undergoing AI therapy participated in semi-structured telephone interviews. Data were audio-recorded, transcribed verbatim, and analyzed thematically. Results: Four themes were identified: (1) Symptom burden-persistent joint pain, stiffness, and fatigue interfered with daily activities; (2) Emotional impact-symptoms provoked anxiety, frustration, and reduced well-being; (3) Social challenges-decreased participation in social and family life led to feelings of isolation; and (4) Coping strategies-pharmacological measures (e.g., calcium and vitamin D supplementation) and nonpharmacological interventions (e.g., exercise, acupuncture) were adopted, though access to reliable information and professional guidance was often inadequate. Conclusions: Musculoskeletal symptoms related to AI therapy impose considerable physical, emotional, and social burdens on Chinese patients with breast cancer, potentially undermining treatment adherence. Culturally appropriate, patient-centered management incorporating both pharmacological and non-pharmacological interventions is essential to optimize symptom control and quality of life.
C1 [Cao, Yuling; Jing, Feng; Jiang, Lingyun; Tian, Maoting; Hu, Yan] Fudan Univ, Sch Nursing, Shanghai, Peoples R China.
   [Jing, Feng; Qiu, Jiajia; Tang, Lichen] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Hu, Y (corresponding author), Fudan Univ, Sch Nursing, Shanghai, Peoples R China.
EM huyan@fudan.edu.cn
FU National Natural Science Foundation of China (NSFC) [(1) 2023 JBI, (2) 2023];  [2023-82272922]
CR Alizadeh Saeedeh, 2018, ASIAN PAC J CANCER PREV, V19, P2469
   Armstrong Terri S, 2003, ONCOL NURS FORUM, V30, P601, DOI 10.1188/03.ONF.601-606
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Berkowitz MJ, 2021, J CANCER SURVIV, V15, P29, DOI 10.1007/s11764-020-00908-5
   Bevers TB, 2018, J NATL COMPR CANC NE, V16, P1362, DOI 10.6004/jnccn.2018.0083
   Chan CWH, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17082950
   Clancy C, 2020, EUR J ONCOL NURS, V44, P0, DOI 10.1016/j.ejon.2019.101706
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Firouzbakht M, 2020, INT HEALTH, V12, P354, DOI 10.1093/inthealth/ihz108
   Harrow A, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-005285
   Hata K, 2020, PSYCHO-ONCOLOGY, V29, P663, DOI 10.1002/pon.5303
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Holz SC, 2023, CURR ONCOL REP, V25, P825, DOI 10.1007/s11912-023-01413-5
   Hyder T, 2021, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.713700
   Jacobs JM, 2022, CANCER-AM CANCER SOC, V128, P3541, DOI 10.1002/cncr.34409
   Jacobs JM, 2020, INT J BEHAV MED, V27, P687, DOI 10.1007/s12529-020-09908-2
   Kim MS, 1999, HEALTH COMMUN, V11, P249, DOI 10.1207/S15327027HC110307
   Kroenke CH, 2013, BREAST CANCER RES TR, V139, P515, DOI 10.1007/s10549-013-2477-2
   Laroche F, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0187165
   Lee EY, 2023, CANCER RES TREAT, V55, P1065, DOI 10.4143/crt.2023.846
   Li YL, 2019, CANCER RES TREAT, V51, P1098, DOI 10.4143/crt.2018.386
   Liu BS, 2021, NURS OPEN, V8, P1981, DOI 10.1002/nop2.876
   Lu XY, 2023, J MED INTERNET RES, V25, P0, DOI 10.2196/38848
   Luckett T, 2011, LANCET ONCOL, V12, P1240, DOI 10.1016/S1470-2045(11)70212-1
   Lund-Jacobsen T, 2024, JMIR RES PROTOC, V13, P0, DOI 10.2196/49549
   Luo AJ, 2022, J MED INTERNET RES, V24, P0, DOI 10.2196/23354
   Ma Y, 2024, ASIA-PAC J ONCOL NUR, V11, P0, DOI 10.1016/j.apjon.2023.100364
   Macía P, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0252075
   Macía P, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0236572
   Mellado BH, 2016, INT J GYNECOL OBSTET, V133, P199, DOI 10.1016/j.ijgo.2015.08.024
   Meng H, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028982
   Milbury K, 2017, SUPPORT CARE CANCER, V25, P2103, DOI 10.1007/s00520-017-3612-0
   Qing SS, 2020, J CHINESE SOCIOL, V7, P0, DOI 10.1186/s40711-020-00123-w
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013167.pub2
   Song Y, 2014, INT J EQUITY HEALTH, V13, P0, DOI 10.1186/1475-9276-13-8
   Taiwong A, 2024, BELITUNG NURS J, V10, P252, DOI 10.33546/bnj.3343
   Toivonen KI, 2021, CURR ONCOL, V28, P2496, DOI 10.3390/curroncol28040227
   Wagner LI, 2018, BREAST CANCER RES TR, V169, P537, DOI 10.1007/s10549-018-4713-2
   Wang LJ, 2023, BMJ OPEN, V13, P0, DOI 10.1136/bmjopen-2023-073915
   Wang LJ, 2020, SUPPORT CARE CANCER, V28, P3259, DOI 10.1007/s00520-019-05161-w
   Wang XS, 2010, JNCI-J NATL CANCER I, V102, P732, DOI 10.1093/jnci/djq097
   Wells KJ, 2016, SUPPORT CARE CANCER, V24, P4123, DOI 10.1007/s00520-016-3229-8
   Wheeler SB, 2024, PATIENT EDUC COUNS, V127, P0, DOI 10.1016/j.pec.2024.108349
   Xu XF, 2018, PALLIAT SUPPORT CARE, V16, P785, DOI 10.1017/S1478951517001171
   Yang EJ, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0245987
   Yeung NCY, 2018, CANCER NURS, V41, P53, DOI 10.1097/NCC.0000000000000422
   You J, 2017, J GLOB ONCOL, V4, P0, DOI 10.1200/JGO.2016.008763
   Zhang XT, 2017, BMC MED INFORM DECIS, V17, P0, DOI 10.1186/s12911-017-0470-0
   Zhu JM, 2018, JMIR MHEALTH UHEALTH, V6, P0, DOI 10.2196/mhealth.9438
   Zhu JM, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-017-3276-7
NR 51
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2347-5625
EI 2349-6673
J9 ASIA-PAC J ONCOL NUR
JI Asia-Pac. J. Oncol. Nurs.
PD DEC 15
PY 2025
VL 12
IS 
BP 
EP 
DI 10.1016/j.apjon.2025.100784
EA SEP 2025
PG 10
WC Nursing
SC Nursing
GA 7SO4D
UT WOS:001578654700001
PM 41048407
DA 2026-01-16
ER

PT J
AU Luo, XC
   Liu, JL
   Yao, MH
   Chen, YM
   Fan, AY
   Liang, FR
   Zhao, JP
   Zhao, L
   Zhou, X
   Zhong, XY
   Yang, JIH
   Li, B
   Zhang, Y
   Sun, X
   Li, L
AF Luo, Xiao-chao
   Liu, Jia-li
   Yao, Ming-hong
   Chen, Ye-meng
   Fan, Arthur Yin
   Liang, Fan-rong
   Zhao, Ji-ping
   Zhao, Ling
   Zhou, Xu
   Zhong, Xiao-ying
   Yang, J. Ia-hui
   Li, Bo
   Zhang, Ying
   Sun, Xin
   Li, Ling
TI Specific effect of inserted sham acupuncture and its impact on the estimation of acupuncture treatment effect in randomized controlled trials: A systematic survey
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Review
DE Acupuncture; Placebos; Randomized controlled trial; Treatment outcome
ID low-back-pain; knee osteoarthritis; adjunctive therapy; breast-cancer; placebo; migraine; women; electroacupuncture; metaanalysis; multicenter
AB Background: The use of inserted sham acupuncture as a placebo in randomized controlled trials (RCTs) is controversial, because it may produce specific effects that cause an underestimation of the effect of acupuncture treatment. Objective: This systematic survey investigates the magnitude of insert-specific effects of sham acupuncture and whether they affect the estimation of acupuncture treatment effects. Search strategy: PubMed, Embase and Cochrane Central Register of Controlled Trials were searched to identify acupuncture RCTs from their inception until December 2022. Inclusion criteria: RCTs that evaluated the effects of acupuncture compared to sham acupuncture and no treatment. Data extraction and analysis: The total effect measured for an acupuncture treatment group in RCTs were divided into three components, including the natural history and/or regression to the mean effect (controlled for no-treatment group), the placebo effect, and the specific effect of acupuncture. The first two constituted the contextual effect of acupuncture, which is mimicked by a sham acupuncture treatment group. The proportion of acupuncture total effect size was considered to be 1. The proportion of natural history and/or regression to the mean effect (PNE) and proportional contextual effect (PCE) of included RCTs were pooled using meta-analyses with a random-effect model. The proportion of acupuncture placebo effect was the difference between PCE and PNE in RCTs with non-inserted sham acupuncture. The proportion of insert-specific effect of sham acupuncture (PIES) was obtained by subtracting the proportion of acupuncture placebo effect and PNE from PCE in RCTs with inserted sham acupuncture. The impact of PIES on the estimation of acupuncture's treatment effect was evaluated by quantifying the percentage of RCTs that the effect of outcome changed from no statistical difference to statistical differ-ence after removing PIES in the included studies, and the impact of PIES was externally validated in other acupuncture RCTs with an inserted sham acupuncture group that were not used to calculate PIES. Results: This analysis included 32 studies with 5492 patients. The overall PNE was 0.335 (95% confidence interval [CI], 0.255-0.415) and the PCE of acupuncture was 0.639 (95% CI, 0.567-0.710) of acupuncture's total effect. The proportional contribution of the placebo effect to acupuncture's total effect was 0.191, and the PIES was 0.189. When we modeled the exclusion of the insert-specific effect of sham acupunc-ture, the acupuncture treatment effect changed from no difference to a significant difference in 45.45% of the included RCTs, and in 40.91% of the external validated RCTs. Conclusion: The insert-specific effect of sham acupuncture in RCTs represents 18.90% of acupuncture's total effect and significantly affects the evaluation of the acupuncture treatment effect. More than 40% of RCTs that used inserted sham acupuncture would draw different conclusions if the PIES had been con-trolled for. Considering the impact of the insert-specific effect of sham acupuncture, caution should be taken when using inserted sham acupuncture placebos in R CTs. Please cite this article as: Luo XC, Liu JL, Yao MH, Chen YM, Fan AY, Liang FR, Zhao JP, Zhao L, Zhou X, Zhong XY, Yang JH, Li B, Zhang Y, Sun X, Li L. Specific effect of inserted sham acupuncture and its impact on the estimation of acupuncture treatment effect in randomized controlled trials: A systematic survey. J Integr Med. 2025; 23(6):630-640. (c) 2025 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Luo, Xiao-chao; Liu, Jia-li; Yao, Ming-hong; Sun, Xin; Li, Ling] Sichuan Univ, West China Hosp, Inst Integrated Tradit Chinese & Western Med, Chengdu 610041, Sichuan, Peoples R China.
   [Luo, Xiao-chao; Liu, Jia-li; Yao, Ming-hong; Sun, Xin; Li, Ling] Sichuan Univ, Chinese Evidence Based Med Ctr, Cochrane China Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Luo, Xiao-chao; Liu, Jia-li; Yao, Ming-hong; Sun, Xin; Li, Ling] Sichuan Univ, West China Hosp, MAGIC China Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Luo, Xiao-chao; Liu, Jia-li; Yao, Ming-hong; Sun, Xin; Li, Ling] NMPA Key Lab Real World Data Res & Evaluat Hainan, Chengdu 610041, Sichuan, Peoples R China.
   [Luo, Xiao-chao; Liu, Jia-li; Yao, Ming-hong; Sun, Xin; Li, Ling] Sichuan Ctr Technol Innovat Real World Data, Chengdu 610041, Sichuan, Peoples R China.
   [Chen, Ye-meng] New York Coll Tradit Chinese Med, Mineola, NY 11501 USA.
   [Fan, Arthur Yin] McLean Ctr Complementary & Alternat Med PLC, Vienna, VA 22182 USA.
   [Liang, Fan-rong; Zhao, Ling] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 611137, Sichuan, Peoples R China.
   [Zhao, Ji-ping] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Acupuncture & Moxibust, Beijing 100700, Peoples R China.
   [Zhou, Xu] Jiangxi Univ Tradit Chinese Med, Evidence Based Med Res Ctr, Sch Basic Sci, Nanchang 330004, Jiangxi, Peoples R China.
   [Zhong, Xiao-ying] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ, Beijing 100700, Peoples R China.
   [Yang, J. Ia-hui] Jiangxi Univ Tradit Chinese Med, Coll Acupuncture & Massage, Nanchang 330004, Jiangxi, Peoples R China.
   [Li, Bo] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin 300381, Peoples R China.
   [Li, Bo] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin 300381, Peoples R China.
   [Zhang, Ying] Guanganmen Hosp, China Acad Chinese Med Sci, Dept Oncol, Beijing 100053, Peoples R China.
   [Sun, Xin] Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol & Biostat, Chengdu 610041, Sichuan, Peoples R China.
   [Sun, Xin] Sichuan Univ, West China Hosp 4, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Ling] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4K1, Canada.
C3 Sichuan University; Sichuan University; Sichuan University; Chengdu University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences; Sichuan University; Sichuan University; McMaster University
RP Sun, X; Li, L (corresponding author), Sichuan Univ, West China Hosp, Inst Integrated Tradit Chinese & Western Med, Chengdu 610041, Sichuan, Peoples R China.; Sun, X; Li, L (corresponding author), Sichuan Univ, Chinese Evidence Based Med Ctr, Cochrane China Ctr, Chengdu 610041, Sichuan, Peoples R China.; Sun, X; Li, L (corresponding author), Sichuan Univ, West China Hosp, MAGIC China Ctr, Chengdu 610041, Sichuan, Peoples R China.; Sun, X; Li, L (corresponding author), NMPA Key Lab Real World Data Res & Evaluat Hainan, Chengdu 610041, Sichuan, Peoples R China.; Sun, X; Li, L (corresponding author), Sichuan Ctr Technol Innovat Real World Data, Chengdu 610041, Sichuan, Peoples R China.
EM sunxin@wchscu.cn; liling@wchscu.cn
FU National Key R&D Program of China [2023YFC3503300, 2023YFC3503304]; National Natural Science Foundation of China for Distinguished Young Scholars [82225049, 82305045]; Fundamental Research Funds for the Central Public Welfare Research Institutes [2020YJSZX-3]
CR Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Birch S, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100725
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   Ceballos-Laita L, 2021, ARCH PHYS MED REHAB, V102, P959, DOI 10.1016/j.apmr.2021.01.077
   Chen AT, 2020, OSTEOARTHR CARTILAGE, V28, P1154, DOI 10.1016/j.joca.2020.05.007
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Choi JY, 2010, J ASTHMA, V47, P774, DOI 10.3109/02770903.2010.485665
   Choi SM, 2013, ALLERGY, V68, P365, DOI 10.1111/all.12053
   Colquhoun D, 2013, ANESTH ANALG, V116, P1360, DOI 10.1213/ANE.0b013e31828f2d5e
   Deng SZ, 2015, EXP THER MED, V10, P1247, DOI 10.3892/etm.2015.2653
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   Evers AWM, 2018, PSYCHOTHER PSYCHOSOM, V87, P204, DOI 10.1159/000490354
   Fei YT, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-064345
   FISHER S, 1965, PSYCHOPHARMACOLOGIA, V7, P57, DOI 10.1007/BF00404165
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Gaubeca-Gilarranz A, 2018, ACUPUNCT MED, V36, P302, DOI 10.1136/acupmed-2017-011566
   Gol AS, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101466
   Haflidadóttir SH, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05454-8
   Harbach H, 2007, EUR J ANAESTH, V24, P370, DOI 10.1017/S0265021506001906
   Hedges LV, 1999, ECOLOGY, V80, P1150, DOI 10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins J, 2023, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 6.4, V0, P0
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Kim TH, 2022, J ACUPUNCT MERIDIAN, V15, P333, DOI 10.51507/j.jams.2022.15.6.333
   Kim TH, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.834112
   KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8
   Krause F, 2020, ADDICT BEHAV, V110, P0, DOI 10.1016/j.addbeh.2020.106488
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Li GY, 2013, EXP THER MED, V6, P699, DOI 10.3892/etm.2013.1225
   Li L, 2020, J CLIN EPIDEMIOL, V123, P80, DOI 10.1016/j.jclinepi.2020.03.017
   Li ZJ, 2017, CEPHALALGIA, V37, P161, DOI 10.1177/0333102416641665
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Liu JL, 2022, J CLIN EPIDEMIOL, V152, P1, DOI 10.1016/j.jclinepi.2022.09.008
   Liu JL, 2022, ACUPUNCT MED, V40, P524, DOI 10.1177/09645284221117848
   Liu K, 2023, ACUPUNCT HERB MED, V3, P55, DOI 10.1097/HM9.0000000000000058
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   MacPherson H, 2008, NEUROSCI LETT, V434, P144, DOI 10.1016/j.neulet.2008.01.058
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   McGeeney BE, 2015, HEADACHE, V55, P465, DOI 10.1111/head.12524
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Moura CD, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018009003418
   Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Prisco MK, 2013, MED ACUPUNCT, V25, P407, DOI 10.1089/acu.2013.0989
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Shi GX, 2011, CLIN J PAIN, V27, P258, DOI 10.1097/AJP.0b013e3181fb27ae
   Smith C, 2002, COMPLEMENT THER MED, V10, P210, DOI 10.1016/S0965-2299(02)00072-9
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Sun X, 2011, BMJ-BRIT MED J, V342, P0, DOI 10.1136/bmj.d1569
   Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Whiteside N, 2018, CLIN RHEUMATOL, V37, P1375, DOI 10.1007/s10067-017-3948-3
   Wild B, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0236004
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Wu XK, 2017, JAMA-J AM MED ASSOC, V317, P2502, DOI 10.1001/jama.2017.7217
   Xu SB, 2020, BMJ-BRIT MED J, V368, P0, DOI 10.1136/bmj.m697
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Zeng D, 2022, EUR J PAIN, V26, P1006, DOI 10.1002/ejp.1924
   Zhang CS, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140825
   Zhang WY, 2018, CLIN IMMUNOL, V186, P82, DOI 10.1016/j.clim.2017.07.018
   Zhang WT, 2004, NEUROSCI LETT, V354, P50, DOI 10.1016/j.neulet.2003.09.080
   Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/429412
   Zhao FY, 2022, WORLD J ACUPUNCT-MOX, V32, P1, DOI 10.1016/j.wjam.2021.07.005
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zheng H, 2019, J CLIN HYPERTENS, V21, P412, DOI 10.1111/jch.13490
   Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387
NR 73
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD NOV 15
PY 2025
VL 23
IS 6
BP 630
EP 640
DI 10.1016/j.joim.2025.07.011
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA A5832
UT WOS:001619667500004
PM 40796482
DA 2026-01-16
ER

PT J
AU Wang, B
   Li, WL
   Su, SJ
AF Wang, Bo
   Li, Weilin
   Su, Shengjie
TI Changes of serum miR-21-5p level in patients with acute spinal cord injury treated with ganglioside and methylprednisolone pulse therapy and its correlation with therapeutic effect
SO NEUROLOGY ASIA
LA English
DT Article
DE Acute spinal cord injury; ganglioside; methylprednisolone; inflammatory factors; miR-21-5p
ID gene-expression; plasticity; ischemia; beta; il-6; pcr
AB Background: Acute spinal cord injury (ASCI) is a serious central nervous system condition that carries a high rate of disability and mortality, making it a primary focus of clinical research. The commonly used drugs for ASCI are ganglioside (GM-1) and methylprednisolone (MP). There are few studies available on the impact of GM-1 combined with MP pulse therapy on the clinical outcomes of patients with ASCI and the underlying mechanisms involved. Methods: In a randomized controlled trial, the 100 patients with ASCI who were treated at our hospital from 2021 to 2024 were selected for this study. They were arbitrarily separated into two equal cohorts, a control cohort and an observation cohort, each containing 50 patients. While the control cohort underwent treatment solely with GM-1, the observation cohort additionally received MP pulse therapy, both treatments administered over a span of six months. The general information of patients was recorded. The motor score, acupuncture pain score, light touch score, Barthel Index (BI) for evaluating daily living capabilities, American Spinal Injury Association (ASIA) neurological function score, and visual analogue scale (VAS) score were analyzed between the two groups before and after treatment to evaluate the recovery of neurological function. Additionally, quantitative real-time PCR (qRT-PCR) was used to assess the serum levels of miR-21-5p in both groups. Moreover, the concentrations of serum inflammatory markers, such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), along with nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), were quantified using ELISA. The Pearson method was employed to evaluate the correlation between miR-21-5p and the levels of CRP, TNF-alpha, IL-6, NGF, and BDNF. The receiver operating characteristic (ROC) curve was employed to evaluate the predictive ability of serum miR-21-5p regarding treatment effectiveness in patients with ASCI. Results: Three patients dropped out of the control group, and no patient dropped out of the observation group. There were no significant variations in the baseline data, index scores, or factor levels between the two groups prior to treatment (P > 0.05). After undergoing therapy, the observation group exhibited significantly higher BI index, ASIA motor and sensory scores, as well as increased in serum miR-21-5p levels, BDNF, and NGF compared to the reference group (P < 0.05). Furthermore, the observation group exhibited marked decreases in VAS ratings as well as serum CRP, TNF-alpha, and IL-6 levels, in stark contrast to the control group (P < 0.05). Furthermore, the level of miR-21-5p exhibited a negative correlation with the levels of CRP, TNF-alpha, and IL-6 (P < 0.05), while showing a positive correlation with the levels of BDNF and NGF (P < 0.05). The ROC curve analysis indicated that miR-21-5p possesses strong diagnostic potential for assessing ASCI efficacy, with an area under the curve (AUC) of 0.987, a sensitivity rate of 91.49%, and a specificity rate of 100.00%. Conclusions: The combination of GM-1 and MP pulse therapy can significantly enhance neurological symptoms and facilitate the restoration of neurological function in patients with ASCI. This effect may be ascribed to the increased levels of miR-21-5p, BDNF, and NGF, along with a reduction in serum inflammatory factors.
C1 [Wang, Bo] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Joint Surg, Haikou, Hainan, Peoples R China.
   [Li, Weilin] Southeast Univ, Nanjing Pukou Peoples Hosp, Liangjiang Hosp, Dept Spine, Nanjing, Jiangsu, Peoples R China.
   [Su, Shengjie] Baoji City Tradit Chinese Med Hosp, Shaanxi Prov Baoji City Orthoped Hosp, Orthoped Ctr Ward 3, Baoji, Shaanxi, Peoples R China.
C3 Hainan Medical University; Southeast University - China
RP Su, SJ (corresponding author), 43 Baofu Rd, Baoji 721001, Shaanxi, Peoples R China.
EM wbo129129@hotmail.com
CR Al Mamun A, 2021, IMMUNOBIOLOGY, V226, P0, DOI 10.1016/j.imbio.2020.152033
   Alizadeh A, 2019, FRONT NEUROL, V10, P0, DOI 10.3389/fneur.2019.00282
   Alves MA, 2023, SPINAL CORD SER CASE, V9, P0, DOI 10.1038/s41394-023-00571-9
   Baichurina I, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23010114
   Chen C, 2021, AM J TRANSL RES, V13, P14005
   Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011
   Cui YJ, 2024, SCI REP-UK, V14, P0, DOI 10.1038/s41598-024-52080-w
   de Laorden EH, 2023, FRONT CELL DEV BIOL, V11, P0, DOI 10.3389/fcell.2023.1328261
   Dolci S, 2022, PHARMACOL RES, V178, P0, DOI 10.1016/j.phrs.2022.106149
   Fabbri Isabella, 2023, ENEUROLOGICALSCI, V31, P100467, DOI 10.1016/j.ensci.2023.100467
   Fan BY, 2022, BONE RES, V10, P0, DOI 10.1038/s41413-022-00199-9
   Garcia E, 2016, MEDIAT INFLAMM, V2016, P0, DOI 10.1155/2016/9476020
   Gheorghe RO, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms242115831
   Guo ZW, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24119558
   Hellenbrand DJ, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02337-2
   Ho PTB, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23137167
   Huang HY, 2020, J ORTHOP TRANSL, V20, P14, DOI 10.1016/j.jot.2019.10.006
   Jiang L, 2021, BRAZ J MED BIOL RES, V54, P0, DOI 10.1590/1414-431X2021e11530
   Jin W, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9010257
   Kim YT, 2009, BIOMATERIALS, V30, P2582, DOI 10.1016/j.biomaterials.2008.12.077
   Lau D, 2019, NEUROSURG FOCUS, V46, P0, DOI 10.3171/2018.12.FOCUS18555
   Li YY, 2022, FRONT AGING NEUROSCI, V14, P0, DOI 10.3389/fnagi.2022.986443
   Li Z, 2024, MOL NEUROBIOL, V61, P2197, DOI 10.1007/s12035-023-03702-3
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   LINDSAY RM, 1985, J CELL SCI, V0, P115
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv X, 2020, PANMINERVA MED, V66, P256, DOI 10.23736/S0031-0808
   MAHADIK SP, 1993, NEUROCHEM INT, V23, P163, DOI 10.1016/0197-0186(93)90094-L
   MAHADIK SP, 1989, J NEUROSCI RES, V24, P402, DOI 10.1002/jnr.490240310
   Ngwa DN, 2022, MOL IMMUNOL, V146, P50, DOI 10.1016/j.molimm.2022.04.003
   Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, P0, DOI 10.3389/fncel.2014.00053
   Park DY, 2013, GLOB SPINE J, V3, P1, DOI 10.1055/s-0033-1337118
   Pattwell SS, 2012, J NEUROSCI, V32, P2410, DOI 10.1523/JNEUROSCI.5205-11.2012
   Plebani M, 2023, CLIN CHEM LAB MED, V61, P1540, DOI 10.1515/cclm-2023-0086
   Razzouk J, 2023, SPINE, V48, PE302, DOI 10.1097/BRS.0000000000004708
   Rizo-Téllez SA, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1237729
   Roberts TT, 2017, CLIN ORTHOP RELAT R, V475, P1499, DOI 10.1007/s11999-016-5133-4
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Siddiqui AM, 2015, PROG BRAIN RES, V218, P15, DOI 10.1016/bs.pbr.2014.12.007
   Sproston NR, 2018, FRONT IMMUNOL, V9, P0, DOI 10.3389/fimmu.2018.00754
   Tsitsiou E, 2009, CURR OPIN PHARMACOL, V9, P514, DOI 10.1016/j.coph.2009.05.003
   Tsutsumi S, 2006, SPINE, V31, P2992, DOI 10.1097/01.brs.0000250273.28483.5c
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
   Wang JC, 2021, AM J TRANSL RES, V13, P646
   Wang Wenzhao, 2020, ZHONGGUO XIU FU CHONG JIAN WAI KE ZA ZHI, V34, P213, DOI 10.7507/1002-1892.201905079
   Wang WZ, 2018, INT J BIOL SCI, V14, P178, DOI 10.7150/ijbs.24074
   Yang ZH, 2018, MOL NEUROBIOL, V55, P2174, DOI 10.1007/s12035-017-0424-7
   Yoshii A, 2010, DEV NEUROBIOL, V70, P304, DOI 10.1002/dneu.20765
   Zhang HY, 2014, J TRANSL MED, V12, P0, DOI 10.1186/1479-5876-12-130
   Zhou YJ, 2023, INT J SPINE SURG, V17, P678, DOI 10.14444/8527
NR 50
TC 0
Z9 0
U1 4
U2 4
PU ASEAN NEUROLOGICAL ASSOC
PI KUALA LUMPUR
PA UNIV MALAYA MEDICAL CENTRE, NEUROLOGY LABORATORY, KUALA LUMPUR, 59100, MALAYSIA
SN 1823-6138
EI 
J9 NEUROL ASIA
JI Neurol. Asia
PD SEP 15
PY 2025
VL 30
IS 3
BP 881
EP 891
DI 10.54029/2025xwv
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 9ET2P
UT WOS:001604605400001
DA 2026-01-16
ER

PT J
AU Ye, AL
   Abdi, S
AF Ye, Alice L
   Abdi, Salahadin
TI Beyond p-values: a cross-sectional umbrella review of chemotherapy-induced
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Journal Article
DE chemotherapy-induced peripheral neuropathy; clinical research methodology; effect size analysis; p-values; randomized controlled trials; systematic reviews; umbrella review
AB INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side  effect of neurotoxic chemotherapy agents, significantly impacting the daily lives  of many cancer survivors. Despite thousands of articles published on CIPN, we  remain no closer to a successful treatment regimen for the condition. In recent  years, several new clinical trials and systematic reviews have been published,  many exploring nonpharmaceutical interventions, prompting the need for a  comprehensive synthesis of this emerging evidence. METHODS: We conducted an  umbrella review to identify and appraise the 19 systematic reviews (SRs)  published in 2023 that examined randomized controlled trials (RCTs) for  established CIPN treatment. We focused our analysis on the three most researched  treatment options: oral drugs, exercise, and acupuncture. RCTs not previously  synthesized together were reviewed, and effect size analyses were performed to  allow readers to interpret the existing literature beyond binary p-values.  RESULTS: Our analysis of RCTs revealed the following key findings. For cancer  survivors with CIPN after completing chemotherapy, serotonin-norepinephrine  reuptake inhibitors (SNRIs) as well as acupuncture provided at least short-term  relief for pain and sensory symptoms. For patients with CIPN who were actively  undergoing chemotherapy, home-based balance and strength training exercises  appeared to alleviate symptoms. Effect size analyses highlighted variability in  treatment responses, underscoring the limitations of relying solely on p-values  to assess intervention efficacy. DISCUSSION: Through an umbrella review approach,  we demonstrate that SRs are often less systematic than expected. None of the 19  SRs captured all relevant RCTs within their search timeframe. However, by  cross-referencing SRs, we identified 41 RCTs across 42 publications, illustrating  the feasibility of an umbrella review approach to uncover relevant trials.  Furthermore, many SRs exhibited methodological concerns that limit the  interpretability of their findings. Finally, we discuss multiple opportunities  for refining methods and reporting in future CIPN treatment trials. SYSTEMATIC  REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024508283,  PROSPERO (42024508283).
C1 Department of Pain Medicine, The University of Texas MD Anderson Texas Center, Houston, TX, United States.
   Department of Pain Medicine, The University of Texas MD Anderson Texas Center, Houston, TX, United States.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD APR 3
PY 2025
VL 6
IS 
BP 1564662
EP 1564662
DI 10.3389/fpain.2025.1564662
PG 0
UT PubMed:40176845
PM 40176845
DA 2025-04-03
ER

PT J
AU Huang, XR
   Xu, M
   Xu, Y
   Wang, SJ
   Ni, FL
AF Huang, Xin-Rui
   Xu, Min
   Xu, Yan
   Wang, Shu-Jie
   Ni, Fei-Lin
TI Auricular acupressure for insomnia in women with breast cancer: A systematic
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Breast cancer as the malignant tumor with the highest incidence and  mortality rate among the global female population. Insomnia is a common complaint  in breast cancer patients, more than one-third (38-47%) of breast cancer patients  suffer it. Auricular acupressure (AA), a non-pharmacological therapy, has been  used in the studies to intervene in insomnia in breast cancer patients. The  objective of this systematic review and meta-analysis is to investigate the  efficacy and safety of AA therapy in intervening with insomnia in breast cancer.  METHODS: A systematic literature search was performed for 10 databases up to  January of 2024 to identify randomized control trials (RCTs). The methodological  quality of RCTs was assessed independently using the Cochrane Handbook for  Systematic Reviews of Interventions. The quality of evidence was evaluated with  the Grading of Recommendations Assessment, Development and Evaluation approach.  Data were screened and extracted independently using predesigned forms. The  meta-analysis was conducted using RevMan 5.3 software, P-value < .05 means  statistically significant. RESULTS: This review included 15 studies from 3  different countries with a total of 1125 adult participants. The pooled results  showed that AA significantly in improving sleep quality (mean difference  [MD] = -3.36, 95% confidence interval [CI]: [-4.65, -2.07], P < .001) and life  quality (MD = -7.82, 95% CI: [-14.76, -0.88], P = .03). Based on data from sleep  monitoring devices, AA was valuable for improving sleep efficiency (MD = -3.63,  95% CI: [-4.19,-3.07], P = .03) in breast cancer patients. Adverse events were  reported in 5 RCTs. Common adverse reactions include auricular skin allergic  reaction (10/259, 3.9%), bruising (7/259, 2.7%), pain (3/259, 1.2%), and local  pressure ulcers on the auricular points (2/259, 0.8%). The evidence grade was  moderate because of the substantial heterogeneity among studies. Heart, Shenmen,  and Subcortex were the 3 most numerous auricular points, with a total share of up  to 71.70%. CONCLUSION: This systematic review and meta-analysis demonstrates the  efficacy and safety of AA in intervening insomnia in breast cancer patients,  providing a basis for the selection of clinical auricular points. However, the  high-quality RCTs in existence are not enough, and more rigorous trials are  needed to identify the efficacy of AA and insomnia.
C1 Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou,Zhejiang Province, China.
   Office of the Dean, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ZhejiangProvince, China.
   College of Nursing, Zhejiang University of Chinese Medicine, Hangzhou, Zhejiang Province, China.
   Department of Breast Diseases, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou,Zhejiang Province, China.
   Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou,Zhejiang Province, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD FEB 17
PY 2025
VL 104
IS 7
BP e41498
EP e41498
DI 10.1097/MD.0000000000041498
PG 1
WC Humans; Female; Sleep Initiation and Maintenance Disorders; therapy; Breast Neoplasms; complications; Acupressure; methods; Randomized Controlled Trials as Topic; Acupuncture, Ear; methods
UT PubMed:39960920
PM 39960920
DA 2025-02-17
ER

PT J
AU Chen, ML
   Zhao, H
   He, L
AF Chen, Menglin
   Zhao, Hua
   He, Ling
TI Comment On: "Acupuncture Treatment for Liver Cancer Pain: A Meta-Analysis"
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Letter
C1 [Chen, Menglin; He, Ling] Jiangxi Univ Chinese Med, Sch Clin Med, Nanchang, Peoples R China.
   [Chen, Menglin; He, Ling] Jiangxi Univ Chinese Med, Affiliated Hosp, Gastroenterol Div, Nanchang, Peoples R China.
   [Zhao, Hua] Zhejiang Chinese Med Univ, Sch Basic Med, Hangzhou, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Zhejiang Chinese Medical University
RP He, L (corresponding author), Jiangxi Univ Chinese Med, Sch Clin Med, Nanchang, Peoples R China.; He, L (corresponding author), Jiangxi Univ Chinese Med, Affiliated Hosp, Gastroenterol Div, Nanchang, Peoples R China.
EM heling118@126.com
CR Cai W, 2017, J CLIN ACUPUNCTURE M, V33, P76
   He Y, 2024, J SURG ONCOL, V130, P83, DOI 10.1002/jso.27691
   Yang X, 2024, LIAONING J TRADITION, V51, P156
NR 3
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD FEB 15
PY 2025
VL 131
IS 2
BP 106
EP 107
DI 10.1002/jso.27918
EA SEP 2024
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 1ZZ2P
UT WOS:001316690500001
PM 39300895
DA 2026-01-16
ER

PT J
AU Yang, LH
   Li, SY
   Yang, Y
   Yang, SN
   Guo, HL
   Hu, MM
   Duan, PB
   Xia, C
AF Yang, Li-Hua
   Li, Si-Yu
   Yang, Ya
   Yang, Sheng-Nan
   Guo, Hai-Li
   Hu, Ming-Ming
   Duan, Pei-Bei
   Xia, Chao
TI Effectiveness of Acupressure in Managing the Pain-Fatigue-Sleep
SO Journal of integrative and complementary medicine
LA English
DT Journal Article
DE acupressure; meta-analysis; symptom cluster; systematic review
AB Objective: To assess the effectiveness of acupressure in addressing the symptom  cluster of pain, fatigue, sleep disturbances, and depression (P-F-S-D) in  patients with cancer through a systematic review. Methods: A comprehensive search  was conducted across three English-language medical databases (PubMed, Embase,  and the Cochrane Library) and two Chinese databases (China National Knowledge  Infrastructure and Wanfang). Only randomized controlled trials (RCTs) examining  the impact of acupressure on the P-F-S-D symptom cluster were included. Two  reviewers independently screened studies, evaluated the risk of bias, and  extracted relevant data in parallel. The risk of bias in eligible RCTs was  appraised using the revised Cochrane Risk of Bias tool (RoB 2.0). Meta-analysis  was performed using Stata software. Results: A total of 20 studies (reported in  21 articles) met the inclusion criteria and were classified as either having a  low risk of bias or some concerns regarding bias. Meta-analysis revealed that  acupressure achieved large-effect reductions in the P-F-S-D symptom cluster  compared to both sham acupoint (endpoint standardized mean difference [SMD] =  -0.84 [-1.05, -0.63], 4-week follow-up SMD = -0.87 [-1.35, -0.39]) and usual care  groups (endpoint SMD = -0.68 [-0.83, -0.53], 4-week follow-up SMD = -0.60 [-0.87,  -0.33]) (all p = 0.000). Initial high heterogeneity (I(2) = 65.6%-67.1%) resolved  after sensitivity analysis (I(2) = 19.7%-35.2%), confirming result robustness.  Subgroup analysis further revealed that acupressure significantly benefited  various symptom combinations, including P-F-S-D, P-F-S, F-S-D, F-S, P-S, and P-F.  No serious adverse events were reported. Conclusions: The findings of this study  suggest that acupressure should be considered for patients with cancer  experiencing the P-F-S-D symptom cluster. However, given the considerable  heterogeneity, potential bias, and lack of systematic adverse event reporting in  the included studies, further large-scale, multicenter, high-quality RCTs are  necessary to better evaluate the effectiveness and safety of acupressure for  multisymptom relief.
C1 School of Health Wellness and Education, Jiangsu Health Vocational College, Nanjing, China.
   School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China.
   School of Health Wellness and Education, Jiangsu Health Vocational College, Nanjing, China.
   School of Health Wellness and Education, Jiangsu Health Vocational College, Nanjing, China.
   School of Health Wellness and Education, Jiangsu Health Vocational College, Nanjing, China.
   School of Health Wellness and Education, Jiangsu Health Vocational College, Nanjing, China.
   Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
   Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
NR 0
TC 0
SN 2768-361
EI 
J9 J Integr Complement Med
PD JUN 26
PY 2025
VL 31
IS 10
BP 860
EP 875
DI 10.1089/jicm.2024.0914
PG 15
WC Humans; Acupressure; Neoplasms; complications; Fatigue; therapy; Depression; therapy; Randomized Controlled Trials as Topic; Sleep Wake Disorders; therapy; Pain Management; methods; Cancer Pain; therapy
UT PubMed:40569723
PM 40569723
DA 2025-06-26
ER

PT J
AU Zhao, JC
   Li, JH
   Zhou, JF
   Li, M
AF Zhao, Junchao
   Li, Jiahui
   Zhou, Jinfeng
   Li, Ming
TI Comment on: "Acupuncture Treatment for Liver Cancer Pain: A Meta-Analysis"
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Letter
C1 [Zhao, Junchao; Li, Jiahui; Zhou, Jinfeng] Haiyan Hosp Tradit Chinese Med, Jiaxing, Peoples R China.
   [Li, Ming] Cent Hosp Haining, Jiaxing, Peoples R China.
RP Li, M (corresponding author), Cent Hosp Haining, Jiaxing, Peoples R China.
EM liminghaining@126.com
FU This work was funded by Administration of Traditional Chinese Medicine of Zhejiang Province (2024ZL173). [2024ZL173]; Administration of Traditional Chinese Medicine of Zhejiang Province
CR Llovet Josep M, 2021, NAT REV DIS PRIMERS, V7, P6, DOI 10.1038/s41572-021-00245-6
   He Y, 2024, J SURG ONCOL, V130, P83, DOI 10.1002/jso.27691
NR 2
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD APR 15
PY 2025
VL 131
IS 5
BP 765
EP 766
DI 10.1002/jso.28035
EA DEC 2024
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 3FU6J
UT WOS:001368905600001
PM 39623460
DA 2026-01-16
ER

PT J
AU Li, X
   Lampson, K
   Rosa, WE
   Li, QS
   Ramalingam, MB
   Epstein, AS
   Mao, JJ
AF Li, Xiaotong
   Lampson, Kaitlin
   Rosa, William E
   Li, Q Susan
   Ramalingam, Mothi Babu
   Epstein, Andrew S
   Mao, Jun J
TI Effect of acupuncture on fatigue in cancer survivors with chronic pain: a
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Cancer survivors; Chronic pain; Clinical trial; Fatigue
AB PURPOSE: Fatigue is one of the most common and troublesome symptoms in cancer  survivors and is strongly correlated with pain. We evaluated the effect of  acupuncture versus usual care for fatigue among cancer survivors with chronic  pain. METHODS: We analyzed data from a randomized clinical trial comparing the  effect of electro-acupuncture (EA) or battlefield acupuncture (BFA) versus  waitlist control (WLC) for chronic musculoskeletal pain in cancer survivors.  Analysis included participants who reported moderate or severe fatigue at  baseline. Interventions were delivered over 10 weeks. Fatigue severity was  measured using the Brief Fatigue Inventory (BFI). RESULTS: Among 274 participants  (mean age 61.0 years [standard deviation (SD)] 12.8; 73.0% women), the baseline  BFI worst fatigue score was 7.1 (SD 1.7). EA and BFA were associated with  reductions in worst fatigue score of 2.4 points (95% confidence interval  [CI]: - 2.9 to - 1.9) and 2.0 points (95% CI: - 2.5 to - 1.5) from baseline to  week 12. There was no significant between-group difference. A higher proportion  of patients in both EA and BFA experienced clinically meaningful fatigue  improvement compared to WLC (61.2% and 51.6% vs. 37.3%, p = 0.019). Fatigue  reductions persisted at week 24 (EA: -2.1 points [95% CI: -2.6 to -1.7]; BFA:  -2.2 points [95% CI: -2.8 to -1.7]). CONCLUSION: Cancer survivors with chronic  pain experienced clinically meaningful and durable fatigue reductions when  receiving either EA or BFA. IMPLICATIONS FOR CANCER SURVIVORS: These findings  support the clinical utility of acupuncture as an evidence-based option for  managing fatigue in cancer survivors with pain. TRIAL REGISTRATION:  ClinicalTrials.gov Identifier: NCT02979574; November 30, 2016.
C1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Rehabilitation Medicine, Singapore General Hospital, Singapore, Singapore.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Weill Cornell Medical College, Cornell University, New York, NY, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. maoj@mskcc.org.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD DEC 13
PY 2025
VL 34
IS 1
BP 31
EP 31
DI 10.1007/s00520-025-10219-z
PG 0
WC Humans; Fatigue; therapy; Female; Middle Aged; Male; Chronic Pain; therapy; Cancer Survivors; Acupuncture Therapy; methods; Aged; Neoplasms; complications; Electroacupuncture; methods; Severity of Illness Index
UT PubMed:41389238
PM 41389238
DA 2025-12-13
ER

PT J
AU Zhang, WZ
   Chin, KY
   Zakaria, R
   Hassan, NH
AF Zhang, Wei-Zheng
   Chin, Kok-Yong
   Zakaria, Roshaya
   Hassan, Nor Haty
TI Strategies for Pain Management in Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolisation: A Scoping Review of Current Evidence
SO HEALTHCARE
LA English
DT Review
DE hepatocellular carcinoma; transarterial chemoembolisation (TACE); pain management; scoping review
ID transcatheter arterial chemoembolization; postembolization syndrome; intraarterial lidocaine; liver-cancer; relief; dexamethasone; acupuncture; efficacy; steroids; therapy
AB Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with transarterial chemoembolisation (TACE) being a primary treatment for intermediate-stage disease. However, post-procedural pain remains a significant challenge due to inconsistent management practices and a lack of standardised protocols. This scoping review synthesises current evidence on pain management strategies in HCC patients undergoing TACE, evaluates their effectiveness, identifies practice gaps, and proposes optimisation strategies. Methods: A comprehensive database search according to the methodological approach given by Arksey and O'Malley with the aid of the PRISMA-ScR guidelines across Cochrane Library, Web of Science, CINAHL, PubMed, and Scopus was performed. The terms associated with pain, TACE, and liver cancer were included in the search strategy. Two independent researchers systematically screened study titles, abstracts, and full texts and extracted key study characteristics and approaches to pain management. Results: Of 1515 identified studies, 29 met the inclusion criteria. Most (72.7%) focused on pharmacological interventions, with dexamethasone and lidocaine being the most frequently investigated agents. Non-pharmacological approaches, including psychological interventions, physical therapies, music therapy, health education, and comprehensive nursing, were also reported. Pain was primarily assessed using the visual analogue scale (VAS) and numeric rating scale (NRS). Conclusions: Pharmacological interventions, particularly dexamethasone and lidocaine, remain the cornerstone of pain management in TACE, yet consensus on their optimal use is lacking. Non-pharmacological strategies provide complementary benefits. standardised, evidence-based pain management protocols integrating both approaches are needed. Future large-scale, multicentre trials are essential to establish the most effective strategies for optimising patient outcomes.
C1 [Zhang, Wei-Zheng; Zakaria, Roshaya; Hassan, Nor Haty] Univ Kebangsaan Malaysia, Fac Med, Dept Nursing, Kuala Lumpur 56000, Malaysia.
   [Chin, Kok-Yong] Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Kuala Lumpur 56000, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia
RP Hassan, NH (corresponding author), Univ Kebangsaan Malaysia, Fac Med, Dept Nursing, Kuala Lumpur 56000, Malaysia.
EM p119154@siswa.ukm.edu.my; chinky@ukm.edu.my; roshaya@hctm.ukm.edu.my; norhaty@hctm.ukm.edu.my
FU Universiti Kabangsaan Malaysia
CR Abusedera MA, 2014, EGYPT J RADIOL NUC M, V45, P403, DOI 10.1016/j.ejrnm.2014.03.005
   Alruwaili MOS, 2024, GLAND SURG, V9, P316
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Bian LF, 2020, WORLD J GASTROENTERO, V26, P4442, DOI 10.3748/wjg.v26.i30.4442
   Chadwick A, 2021, J PAIN RES, V14, P3145, DOI 10.2147/JPR.S320863
   Chang KT, 2020, INT J NURS STUD, V109, P0, DOI 10.1016/j.ijnurstu.2020.103641
   Chang Y, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21218165
   Chapman EJ, 2020, PALLIATIVE MED, V34, P444, DOI 10.1177/0269216319896955
   Du QQ, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102355
   Feng YL, 2009, J ALTERN COMPLEM MED, V15, P175, DOI 10.1089/acm.2008.0093
   Gao LL, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000035929
   GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177
   Guo JG, 2018, HEPATOB PANCREAT DIS, V17, P510, DOI 10.1016/j.hbpd.2018.08.001
   Hartnell GG, 1999, CARDIOVASC INTER RAD, V22, P293, DOI 10.1007/s002709900391
   Khuntee W, 2022, BELITUNG NURS J, V8, P396, DOI 10.33546/bnj.2210
   Kim MS, 2024, CANCER NURS, V47, PE226, DOI 10.1097/NCC.0000000000001211
   Kogut MJ, 2013, J VASC INTERV RADIOL, V24, P326, DOI 10.1016/j.jvir.2012.11.019
   Kuwaki K, 2019, ACTA MED OKAYAMA, V73, P333, DOI 10.18926/AMO/56935
   Labgaa I, 2020, LIVER CANCER, V9, P138, DOI 10.1159/000505093
   Lee SH, 2001, CARDIOVASC INTER RAD, V24, P368, DOI 10.1007/s00270-001-0073-z
   Liang J, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/6169183
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Lin LF, 2021, J HEMATOL ONCOL, V14, P0, DOI 10.1186/s13045-021-01213-z
   Lin ZG, 2022, J ACUPUNCT TUINA SCI, V20, P383, DOI 10.1007/s11726-022-1320-x
   Lu HH, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000035433
   Lu HH, 2021, BMC GASTROENTEROL, V21, P0, DOI 10.1186/s12876-021-01839-w
   Lv N, 2016, EUR RADIOL, V26, P3492, DOI 10.1007/s00330-016-4207-8
   Lyu N, 2022, J AM COLL RADIOL, V19, P61, DOI 10.1016/j.jacr.2021.09.029
   Makary MS, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12071914
   McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288
   Molgaard C P, 1990, J VASC INTERV RADIOL, V1, P81, DOI 10.1016/S1051-0443(90)72508-0
   Munn Z, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-018-0611-x
   Nielsen A, 2022, PAIN MED, V23, P1582, DOI 10.1093/pm/pnac056
   Niyonkuru E, 2025, PAIN THER, V14, P121, DOI 10.1007/s40122-024-00688-1
   Francisco ASPG, 2021, PAIN MANAG NURS, V22, P121, DOI 10.1016/j.pmn.2020.07.006
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Sainamthip P, 2021, WORLD J CLIN CASES, V9, P9059, DOI 10.12998/wjcc.v9.i30.9059
   Simasingha N, 2023, WORLD J GASTROENTERO, V29, P890, DOI 10.3748/wjg.v29.i5.890
   Sinatti P, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph19106194
   Tang HK, 2021, SUPPORT CARE CANCER, V29, P7299, DOI 10.1007/s00520-021-06152-6
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Turk DC, 2002, J CONSULT CLIN PSYCH, V70, P678, DOI 10.1037//0022-006X.70.3.678
   Vanderbecq Q, 2023, DIAGN INTERV IMAG, V104, P123, DOI 10.1016/j.diii.2022.10.013
   Varsi C, 2021, BMC HEALTH SERV RES, V21, P0, DOI 10.1186/s12913-021-06278-7
   Velikova G, 2022, PROGRAMME GRANTS FOR APPLIED RESEARCH, V10, P1, DOI 10.3310/fdde8516
   Vitale A, 2020, HEPATOLOGY, V72, P2206, DOI 10.1002/hep.31187
   Wally MK, 2022, J ORTHOP TRAUMA, V36, PS19, DOI 10.1097/BOT.0000000000002457
   Wang LZ, 2021, J HEPATOCELL CARCINO, V8, P1221, DOI 10.2147/JHC.S331779
   Wang ZX, 2018, J PAIN RES, V11, P2115, DOI 10.2147/JPR.S166333
   Wang ZX, 2008, WORLD J GASTROENTERO, V14, P931, DOI 10.3748/wjg.14.931
   Xu H, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6269518
   Xu LT, 2016, INTEGR CANCER THER, V15, P349, DOI 10.1177/1534735415617020
   Yang H, 2017, J VASC INTERV RADIOL, V28, P1503, DOI 10.1016/j.jvir.2017.07.021
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yu JM, 2020, INT J CLIN EXP MED, V13, P1687
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhou B, 2012, RADIOLOGY, V262, P1014, DOI 10.1148/radiol.11110552
   Zhou ZG, 2016, ONCOTARGET, V7, P27938, DOI 10.18632/oncotarget.8560
NR 58
TC 2
Z9 2
U1 4
U2 6
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD APR 25
PY 2025
VL 13
IS 9
BP 
EP 
DI 10.3390/healthcare13090994
PG 19
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 2MO0Y
UT WOS:001486212700001
PM 40361772
DA 2026-01-16
ER

PT J
AU Xu, YY
   Wu, GR
   Zhang, GM
   Li, DX
   Zhang, LY
   Yang, W
AF Xu, Yuanyuan
   Wu, Guangrong
   Zhang, Guomin
   Li, Dongxue
   Zhang, Lunyou
   Yang, Wei
TI Rare Emphysematous Osteomyelitis of the Femoral Head: A Case Report and Literature Review
SO INFECTION AND DRUG RESISTANCE
LA English
DT Review
DE emphysematous osteomyelitis; MRI; CT; acupotomy; diabetes
ID bone
AB Emphysematous osteomyelitis (EO) is a perilous infection of the femoral head. In this case, we present a 66-year-old male patient of Han ethnicity, who had lumbar disc herniation and type 2 diabetes mellitus. The patient reported severe pain in his lower back and right lower limb, which had worsened over the past 20 days. Despite undergoing invasive procedures such as regional anesthetic blocks and other traditional Chinese medical methods such as acupuncture and acupotomy, his condition deteriorated. Pain in the lumbar region was not relieved, and there was a new onset of pain in the right hip, groin, and thighs. Preliminary medical evaluation revealed normal body temperature but elevated levels of the inflammatory marker high-sensitivity C-reactive protein (hsCRP). In the imaging tests, computed tomography revealed air bubbles within the right femoral head, corresponding to the EO. Diabetes mellitus and malignant neoplasms have been well-established as predominant risk factors for EO, while iatrogenic interventions may serve as potential precipitating factors in disease pathogenesis. Our report underlines the critical role of radiologists in identifying EO through distinctive imaging features, such as the "pumice stone" sign. This highlights the need for further research to enhance our understanding, diagnosis, and management of EO.
C1 [Xu, Yuanyuan; Wu, Guangrong; Zhang, Guomin; Li, Dongxue; Yang, Wei] Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Radiol, Zunyi, Guizhou, Peoples R China.
   [Zhang, Lunyou] Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Pathol, Zunyi, Guizhou, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University
RP Yang, W (corresponding author), Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Radiol, Zunyi, Guizhou, Peoples R China.
EM coxsackie@163.com
CR Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838
   Campoccia D, 2010, BIOMATERIALS, V31, P6363, DOI 10.1016/j.biomaterials.2010.05.005
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Charles JF, 2014, CURR OSTEOPOROS REP, V12, P1, DOI 10.1007/s11914-014-0195-2
   Chen JLY, 2016, QJM-INT J MED, V109, P427, DOI 10.1093/qjmed/hcw030
   Di Stasi Martina, 2020, RADIOL CASE REP, V15, P1552, DOI 10.1016/j.radcr.2020.05.078
   Fang H, 2019, BMC INFECT DIS, V19, P0, DOI 10.1186/s12879-019-4255-1
   Khan UH, 2024, J CLIN INFECT DIS, V0, PP77, DOI 10.4103/cids.cids6223
   Kim YK, 2018, INFECT CHEMOTHER, V50, P268, DOI 10.3947/ic.2018.50.3.268
   Kosai K, 2008, INTERNAL MED, V47, P1121, DOI 10.2169/internalmedicine.47.0937
   Larsen J, 2015, LANCET INFECT DIS, V15, P486, DOI 10.1016/S1473-3099(14)71017-5
   Lauer MF, 2019, ORTHOPEDICS, V42, PE128, DOI 10.3928/01477447-20181023-08
   Lee J, 2017, INFECT CHEMOTHER, V49, P151, DOI 10.3947/ic.2017.49.2.151
   Loomans CJM, 2009, MOL MED, V15, P152, DOI 10.2119/molmed.2009.00032
   Luey C, 2012, INT J INFECT DIS, V16, PE216, DOI 10.1016/j.ijid.2011.11.007
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579-022-00686-0
   Mautone Marcela, 2014, CASE REP RADIOL, V2014, P616184, DOI 10.1155/2014/616184
   Moon TJ, 2023, JAAOS GLOB RES REV, V7, P0, DOI 10.5435/JAAOSGlobal-D-21-00088
   Ono R, 2018, INTERNAL MED, V57, P2081, DOI 10.2169/internalmedicine.0219-17
   Potocki J, 2003, SKELETAL RADIOL, V32, P46, DOI 10.1007/s00256-002-0567-z
   Qin X, 2022, J HEALTHC ENG, V2022, P0, DOI 10.1155/2022/1076112
   RAM PC, 1981, AM J ROENTGENOL, V137, P721, DOI 10.2214/ajr.137.4.721
   Sachdev IS, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.16782
   Sax AJ, 2020, SKELETAL RADIOL, V49, P1487, DOI 10.1007/s00256-020-03470-4
   Schierenbeck M, 2023, DIAGNOSTICS, V13, P0, DOI 10.3390/diagnostics13172745
   Small JE, 2022, CURR PROBL DIAGN RAD, V51, P666, DOI 10.1067/j.cpradiol.2018.05.008
   Sulyma Vadym, 2020, ORTOP TRAUMATOL REHABIL, V22, P153, DOI 10.5604/01.3001.0014.3231
NR 27
TC 1
Z9 1
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
EI 
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PD JUN 15
PY 2025
VL 18
IS 
BP 1279
EP 1285
DI 10.2147/IDR.S479261
PG 7
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA Z2U8A
UT WOS:001437529900001
PM 40059938
DA 2026-01-16
ER

PT J
AU Li, MY
   Wang, T
   Liu, XL
   Deng, RL
   Kwok, WH
   Yao, LQ
   Tan, JY
AF Li, Mengyuan
   Wang, Tao
   Liu, Xian-Liang
   Deng, Ren-Li
   Kwok, Wai Hang
   Yao, Li-Qun
   Tan, Jing-Yu (Benjamin)
TI Somatic acupressure for the management of the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a study protocol for a phase III randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE Breast tumours; Fatigue; Depression & mood disorders; Insomnia; Nursing research
ID traditional chinese medicine; version; acupuncture; pain; validation
AB Introduction The fatigue-sleep disturbance-depression symptom cluster (FSDSC) is commonly experienced by breast cancer (BC) survivors, leading to a deteriorated quality of life (QoL). Somatic acupressure (SA) has been recommended as a promising non-pharmacological intervention for cancer-related fatigue (the core symptom of the FSDSC) in the guidelines, showing its encouraging role in relieving cancer-related sleep disorders, fatigue and depression. This phase III randomised controlled trial (RCT) is designed to evaluate the effects, safety and cost-effectiveness of SA for managing the FSDSC in BC survivors. Methods This phase III RCT will be a partial-blinded, sham-controlled, three-arm, parallel clinical trial, involving a 7-week SA intervention period and a 12-week follow-up period. 108 BC survivors will be randomly allocated in a ratio of 1:1:1 to either a true SA group (self-administered acupressure plus usual care), a sham SA group (self-administered light acupressure at non-acupoints plus usual care) or a usual care group. The primary outcomes will be the effectiveness of SA on the FSDSC at both the individual symptom level and cluster symptom level. Each individual symptom will be specifically measured by the Brief Fatigue Inventory (fatigue), the Pittsburgh Sleep Quality Index (sleep disturbance) and the Hospital Anxiety and Depression Scale-Depression (depression). The cluster symptom level will be measured by using an FSDSC composite score, an averaging score of three separated 0-10 numeric rating scales for fatigue, depression and sleep disturbance. The secondary outcomes will include QoL (measured by the Functional Assessment of Cancer Therapy-Breast), adverse events and cost-effectiveness. Outcomes will be assessed at baseline (week 0), immediately after intervention (week 7) and follow-up (week 19). All outcomes will be analysed based on the intention-to-treat principle using the Statistical Package for Social Science (SPSS 25) software. Ethics and dissemination Ethical approvals of this study have been granted by the Human Research Ethics Committee at Charles Darwin University (H22110) and the Clinical Trial Ethics Committee at the Affiliated Hospital of Zunyi Medical University (KLL-2023-594), and the Second Affiliated Hospital of Zunyi Medical University (KYLL-2023-058). Findings from this trial will be published in peer-reviewed journals and presented at professional conferences. Trial registration number NCT06412107.
C1 [Li, Mengyuan; Wang, Tao] Charles Darwin Univ, Fac Hlth, Brisbane, Qld, Australia.
   [Wang, Tao; Tan, Jing-Yu (Benjamin)] Univ Southern Queensland, Sch Nursing & Midwifery, Ipswich, Qld, Australia.
   [Liu, Xian-Liang] Hong Kong Metropolitan Univ, Sch Nursing & Hlth Sci, Hong Kong, Peoples R China.
   [Deng, Ren-Li] Zunyi Med Univ, Sch Nursing, Zunyi, Guizhou, Peoples R China.
   [Deng, Ren-Li; Kwok, Wai Hang] Charles Darwin Univ, Fac Hlth, Darwin, NT, Australia.
   [Kwok, Wai Hang] Edith Cowan Univ, Sch Nursing & Midwifery, Joondalup, WA, Australia.
   [Yao, Li-Qun] Fujian Univ Tradit Chinese Med, Coll Nursing, Fuzhou, Fujian, Peoples R China.
   [Tan, Jing-Yu (Benjamin)] Univ Southern Queensland, Ctr Hlth Res, Springfield, Qld, Australia.
C3 Charles Darwin University; University of Southern Queensland; Hong Kong Metropolitan University; Zunyi Medical University; Charles Darwin University; Edith Cowan University; Fujian University of Traditional Chinese Medicine; University of Southern Queensland
RP Tan, JY (corresponding author), Univ Southern Queensland, Sch Nursing & Midwifery, Ipswich, Qld, Australia.; Tan, JY (corresponding author), Univ Southern Queensland, Ctr Hlth Res, Springfield, Qld, Australia.
EM mengyuanli@students.cdu.edu.au; alison.wang@cdu.edu.au; dxliu@hkmu.edu.hk; rengli.deng@cdu.edu.au; w.kwok@ecu.edu.au; yaoliqunpt@163.com; benjamin.tan@unisq.edu.au
FU Charles Darwin International PhD Scholarship (CDIPS), Charles Darwin University, Australia
CR Unknown -, 2005, THE USE OF THE WHO-UMC SYSTEM FOR STANDARDIZED CASE CAUSALITY ASSESSMENT, V0, P0
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Chen R, 2010, EVID-BASED COMPL ALT, V7, P3, DOI 10.1093/ecam/nen017
   Chen X, 2020, COMPUT METH PROG BIO, V196, P0, DOI 10.1016/j.cmpb.2020.105710
   Cheung DST, 2023, WORLDV EVID-BASED NU, V20, P202, DOI 10.1111/wvn.12617
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Cohen J, 1992, CURR DIR PSYCHOL SCI, V1, P98, DOI 10.1111/1467-8721.EP10768783
   Danhauer SC, 2019, CANCER-AM CANCER SOC, V125, P1979, DOI 10.1002/cncr.31979
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   de Rooij BH, 2023, J CANCER SURVIV, V17, P1405, DOI 10.1007/s11764-022-01189-w
   Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9
   Dodd MJ, 2010, EUR J ONCOL NURS, V14, P101, DOI 10.1016/j.ejon.2009.09.005
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Donovan Kristine A, 2007, SEMIN ONCOL NURS, V23, P127, DOI 10.1016/j.soncn.2007.01.004
   Drummond MF, 2005, METHODS FOR THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES, V0, P0, DOI DOI 10.1093/OSO/9780198529446.001.0001
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Fu L, 2022, J PAIN SYMPTOM MANAG, V63, P230, DOI 10.1016/j.jpainsymman.2021.09.003
   Hampson JP, 2015, NEUROIMAGE-CLIN, V8, P305, DOI 10.1016/j.nicl.2015.04.022
   Harris RE, 2017, FRONT NEUROL, V8, P0, DOI 10.3389/fneur.2017.00298
   He X, 2019, ANN ONCOL, V30, P840
   Higgins JPT, 1900, DOI 10.1002/9781119536604, V0, P0
   Ho RTH, 2014, SLEEP MED, V15, P565, DOI 10.1016/j.sleep.2013.10.019
   Ho SY, 2015, J PAIN SYMPTOM MANAG, V49, P707, DOI 10.1016/j.jpainsymman.2014.09.009
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Illi J, 2012, CYTOKINE, V58, P437, DOI 10.1016/j.cyto.2012.02.015
   Jain S, 2015, BREAST CANCER-TARGET, V7, P267, DOI 10.2147/BCTT.S25014
   Kelly DL, 2016, SEMIN ONCOL NURS, V32, P351, DOI 10.1016/j.soncn.2016.08.002
   Khanghah AG, 2019, J ACUPUNCT MERIDIAN, V12, P103
   Kwekkeboom KL, 2020, ONCOL NURS FORUM, V47, P498, DOI 10.1188/20.ONF.498-511
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Lee LJ, 2020, ONCOL NURS FORUM, V47, P89, DOI 10.1188/20.ONF.89-100
   Li MY, 2024, ASIA-PAC J ONCOL NUR, V11, P0, DOI 10.1016/j.apjon.2024.100380
   Li MY, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102380
   Li QP, 2016, EUR J ONCOL NURS, V25, P16, DOI 10.1016/j.ejon.2016.09.004
   Li S, 2007, CLIN APPL COMMONLY U, V0, P0
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Llewellyn-Bennett R, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-018-2653-0
   Lu AP, 2004, WORLD J GASTROENTERO, V10, P1854
   Nguyen LT, 2018, J PAIN SYMPTOM MANAG, V55, P1459, DOI 10.1016/j.jpainsymman.2018.02.019
   MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5
   Murphy SL, 2012, AM J OCCUP THER, V66, P387, DOI 10.5014/ajot.2010.005405
   Mustian KM, 2016, SEMIN ONCOL NURS, V32, P383, DOI 10.1016/j.soncn.2016.09.002
   National Comprehensive Cancer Network, 2022, PLYM M PA NAT COMPR, V0, P0
   National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2024, CANCER-RELATED FATIGUE, V0, P0
   NCI, 2017, NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V5.0, V0, P0
   Ohlsson-Nevo E, 2019, ACTA ONCOL, V58, P1676, DOI 10.1080/0284186X.2019.1633017
   Palesh O, 2018, BREAST J, V24, P167, DOI 10.1111/tbj.12862
   PDQ Supportive and Palliative Care Editorial Board, 2023, PDQ SLEEP DISORDERS, V0, P0
   Qiao SN, 2019, PATIENT PREFER ADHER, V13, P923, DOI 10.2147/PPA.S203900
   Rong Peijing, 2011, FRONT MED, V5, P151, DOI 10.1007/s11684-011-0129-7
   Schlaeger JM, 2017, J MIDWIFERY WOM HEAL, V62, P12, DOI 10.1111/jmwh.12545
   Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9
   Skivington K, 2021, BMJ-BRIT MED J, V374, P0, DOI 10.1136/bmj.n2061
   So WKW, 2020, CANCER NURS, V43, PE304, DOI 10.1097/NCC.0000000000000730
   Sui YL, 2020, EUR J ONCOL NURS, V45, P0, DOI 10.1016/j.ejon.2019.101707
   Tan JY, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0132989
   Tan JY, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph191911934
   Tan JY, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101490
   Trudel-Fitzgerald C, 2013, ANN BEHAV MED, V45, P329, DOI 10.1007/s12160-012-9459-1
   Wan CH, 2007, BREAST CANCER RES TR, V106, P413, DOI 10.1007/s10549-007-9511-1
   Wang T, 2023, COMPLEMENT THER CLIN, V51, P0, DOI 10.1016/j.ctcp.2023.101735
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   Wong WM, 2023, CANCER NURS, V46, PE70, DOI 10.1097/NCC.0000000000001048
   Yang Q, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1224-8
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yorke J, 2015, SUPPORT CARE CANCER, V23, P3373, DOI 10.1007/s00520-015-2810-x
   Yuan HW, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/430851
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
   Zick SM, 2014, BRAIN IMAGING BEHAV, V8, P506, DOI 10.1007/s11682-013-9270-z
NR 71
TC 0
Z9 0
U1 5
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD MAR 3
PY 2025
VL 15
IS 3
BP 
EP 
DI 10.1136/bmjopen-2024-089515
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA Z2K3I
UT WOS:001437256100001
PM 40032405
DA 2026-01-16
ER

PT J
AU Li, YY
   Xu, RY
   Chen, MY
   Zheng, KG
   Nie, HM
   Yin, CY
   Liu, BY
   Tai, Y
   Du, JY
   Wang, J
   Fang, JQ
   Liu, BY
AF Li, Yuanyuan
   Xu, Ruoyao
   Chen, Muyan
   Zheng, Kaige
   Nie, Huimin
   Yin, Chengyu
   Liu, Boyu
   Tai, Yan
   Du, Junying
   Wang, Jie
   Fang, Jianqiao
   Liu, Boyi
TI Electroacupuncture alleviates paclitaxel-induced peripheral neuropathy by reducing CCL2-mediated macrophage infiltration in sensory ganglia and sciatic nerve
SO CHINESE MEDICINE
LA English
DT Article
DE Paclitaxel; Chemotherapy; Neuropathy; Macrophages; Acupuncture; Pain
ID mouse model; chemotherapy; pain; acupuncture; contributes; neurons; mediate; cells; rats
AB BackgroundPaclitaxel-induced peripheral neuropathy (PIPN) is prevalent among patients receiving paclitaxel chemotherapy, which results in sensory abnormality as well as neuropathic pain. Conventional medications lack effectiveness on PIPN. Clinical trials identified beneficial effects of acupuncture on PIPN among patients receiving chemotherapy. Here we explored the mechanisms underlying how acupuncture might alleviate PIPN.MethodsA mouse model of PIPN was established by repeated paclitaxel application. Electroacupuncture (EA) was applied at ST36 and BL60 acupoints of model mice. Immunostaining, flow cytometry, behavioral assay, in vivo imaging were utilized for effects determination and mechanism exploration.ResultsEA ameliorated mechanical and cold pain hypersensitivities, reduced sensory neuron damage and improved loss in intra-epidermal nerve fibers (IENFs) in model mice. Macrophages infiltration were detected in DRG and sciatic nerve of model mice, which was reduced by EA. EA affected M1-like pro-inflammatory macrophage infiltration in DRG, whereas it did not affect M2-like macrophages. DRG neurons released chemoattractant CCL2 that recruited macrophages via CCR2 to DRG. EA reduced CCL2 overproduction by DRG neurons and reduced macrophage infiltration. Blocking CCR2 mimicked EA's anti-allodynic effect, whereas exogenously applying recombinant CCL2 reversed the ameliorative effect of EA on macrophage infiltration and abolished EA's anti-allodynia on model mice. EA ameliorated other signs of PIPN, including sensory neuron damage, sciatic nerve morphology impairment and IENFs loss. In mice inoculated with breast cancer cells, EA didn't affect paclitaxel-induced antitumor effect.ConclusionsThese findings suggest EA alleviates PIPN by reducing CCL2/CCR2 mediated-pro-inflammatory macrophage infiltration into sensory ganglia as well as the sciatic nerve. Our study supports EA could be used as a potential non-pharmacological therapy for PIPN.
C1 [Li, Yuanyuan; Xu, Ruoyao; Chen, Muyan; Zheng, Kaige; Nie, Huimin; Yin, Chengyu; Liu, Boyu; Du, Junying; Fang, Jianqiao; Liu, Boyi] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.
   [Tai, Yan] Zhejiang Chinese Med Univ, Acad Chinese Med Sci, Hangzhou, Peoples R China.
   [Wang, Jie] Zhejiang Univ, Affiliated Hosp 2, Dept Rehabil Tradit Chinese Med, Sch Med, Hangzhou, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang University
RP Fang, JQ; Liu, BY (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.; Wang, J (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Rehabil Tradit Chinese Med, Sch Med, Hangzhou, Peoples R China.
EM wangjiee@zju.edu.cn; fangjianqiao7532@163.com; boyi.liu@foxmail.com
FU Key Technologies Research and Development Program; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University
CR Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Beh ST, 2019, PAIN, V160, P1505, DOI 10.1097/j.pain.0000000000001547
   Bianconi V, 2018, CURR OPIN HEMATOL, V25, P44, DOI 10.1097/MOH.0000000000000389
   Boyette-Davis J, 2011, PAIN, V152, P308, DOI 10.1016/j.pain.2010.10.030
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Caceres AI, 2017, BRIT J PHARMACOL, V174, P867, DOI 10.1111/bph.13760
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen O, 2020, CURR OPIN NEUROBIOL, V62, P17, DOI 10.1016/j.conb.2019.11.006
   Chen RX, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02131-0
   Chen RX, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01834-0
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Dietzel J, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12062103
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Forsyth PA, 1997, J NEURO-ONCOL, V35, P47, DOI 10.1023/A:1005805907311
   Huang ZZ, 2014, BRAIN BEHAV IMMUN, V40, P155, DOI 10.1016/j.bbi.2014.03.014
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Koyanagi M, 2021, CANCER RES, V81, P2207, DOI 10.1158/0008-5472.CAN-20-2799
   Li YY, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02098-y
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liu BY, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0165200
   Liu BY, 2016, P NATL ACAD SCI USA, V113, PE7572, DOI 10.1073/pnas.1606608113
   Liu BY, 2013, PAIN, V154, P2169, DOI 10.1016/j.pain.2013.06.043
   Liu BY, 2022, CELL MOL BIOL LETT, V27, P0, DOI 10.1186/s11658-022-00316-w
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Luo X, 2019, J NEUROSCI, V39, P6848, DOI 10.1523/JNEUROSCI.3257-18.2019
   Ma X, 2023, ACUPUNCT HERB MED, V3, P139, DOI 10.1097/HM9.0000000000000069
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Mody MD, 2016, JAMA OTOLARYNGOL, V142, P898, DOI 10.1001/jamaoto.2016.1238
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Song SN, 2019, MOL IMMUNOL, V106, P143, DOI 10.1016/j.molimm.2018.12.023
   Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang J, 2023, J NEUROINFLAMM, V20, P0, DOI 10.1186/s12974-023-02778-x
   Wei HN, 2023, CHIN MED-UK, V18, P0, DOI 10.1186/s13020-023-00800-1
   Wernicke Joachim F, 2005, EXPERT OPIN DRUG SAF, V4, P987, DOI 10.1517/14740338.4.6.987
   Xu RY, 2024, THERANOSTICS, V14, P5281, DOI 10.7150/thno.97856
   Yeh ML, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04603-1
   Yin CY, 2024, THERANOSTICS, V14, P3082, DOI 10.7150/thno.95611
   Yin CY, 2024, NAT COMMUN, V15, P0, DOI 10.1038/s41467-024-47640-7
   Yin CY, 2020, THERANOSTICS, V10, P12189, DOI 10.7150/thno.48028
   Yu NN, 2023, ACUPUNCT MED, V41, P96, DOI 10.1177/09645284221085278
   Zeng DY, 2024, BIOMED PHARMACOTHER, V170, P0, DOI 10.1016/j.biopha.2023.115957
   Zhang HJ, 2013, J PAIN, V14, P1031, DOI 10.1016/j.jpain.2013.03.012
   Zhang HM, 2016, J PAIN, V17, P775, DOI 10.1016/j.jpain.2016.02.011
   Zhang L, 2021, BRAIN BEHAV IMMUN, V91, P556, DOI 10.1016/j.bbi.2020.11.015
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhao YX, 2021, J PAIN RES, V14, P993, DOI 10.2147/JPR.S296150
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zuo WJ, 2023, CELL MOL BIOL LETT, V28, P0, DOI 10.1186/s11658-023-00491-4
NR 55
TC 4
Z9 6
U1 11
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD JAN 13
PY 2025
VL 20
IS 1
BP 
EP 
DI 10.1186/s13020-024-01023-8
PG 18
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA S2S2N
UT WOS:001396778800001
PM 39806462
DA 2026-01-16
ER

PT J
AU Zhang, XC
   Shen, DL
   Shi, JL
   Gong, GW
   Wang, G
   Jiang, ZW
   Jin, HY
   Deng, ZM
AF Zhang, Xiao-Chun
   Shen, Dan-Li
   Shi, Jia-Ling
   Gong, Guan-Wen
   Wang, Gang
   Jiang, Zhi-Wei
   Jin, Hei-Ying
   Deng, Zheng-Ming
TI Development of a Nomogram for Predicting Postoperative Prolonged Ileus in Gastric
SO The American surgeon
LA English
DT Journal Article
DE electroacupuncture; gastric cancer; nomogram; postoperative ileus; risk prediction
AB ObjectiveTo develop and validate a nomogram for predicting the risk of  postoperative prolonged ileus (PPOI) in patients undergoing gastric cancer (GC)  surgery, providing a personalized risk assessment tool for early identification  and optimized postoperative management.MethodsA retrospective cohort (January  2019-December 2023) was used to develop and internally test the nomogram, while a  prospective cohort (January-December 2024) was used for external validation.  Univariate and multivariate logistic regression with backward stepwise selection  identified independent predictors. Model performance was assessed through  receiver operating characteristic (ROC) curves, calibration curves,  decision-curve analysis (DCA), and clinical impact curve analysis (CICA).  Patients were stratified into low, medium, and high-risk groups based on nomogram  scores for further analysis.ResultsA total of 780 patients in the training cohort  and 294 in the validation cohort were included, with postoperative prolonged  ileus rates of 11.54% and 16.33%, respectively (χ(2) = 4.371, P =.037).  Independent predictors included electroacupuncture, pain self-efficacy  questionnaire (PSEQ) score, preoperative serum albumin (Alb), body fat,  postoperative day 1 Visual Analog Scale (Pod1 VAS), and intensive care unit (ICU)  admission. The nomogram demonstrated strong discriminatory ability and  calibration, with clinical utility confirmed through DCA and CICA. Higher  nomogram scores correlated with increased PPOI incidence.ConclusionsThe developed  nomogram is a valuable tool for early identification of PPOI in GC patients,  supporting clinicians and nurses in implementing personalized preventive  strategies.
C1 Department of Colorectal Surgery, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of Surgical Nursing, College of Nursing, Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 66478
   Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of Colorectal Surgery, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
   Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. RINGGOLD: 531909
NR 0
TC 0
SN 1555-982
EI 
J9 Am Surg
PD SEP 29
PY 2025
VL 0
IS 
BP 31348251383475
EP 31348251383475
DI 10.1177/00031348251383475
PG 1
UT PubMed:41021978
PM 41021978
DA 2025-09-29
ER

PT J
AU Xu, X
   Zhou, MM
   Hao, HY
   Chen, HY
AF Xu, Xiao
   Zhou, Ming-Ming
   Hao, Hai-Yan
   Chen, Hai-Yan
TI Enhancing peri-operative pain management in urological cancer: exploring the role of acupuncture
SO BJU INTERNATIONAL
LA English
DT Letter
C1 [Xu, Xiao; Zhou, Ming-Ming] Nantong Hlth Coll Jiangsu Prov, Res Ctr Mol Med, PhD Lab, Nantong, Peoples R China.
   [Xu, Xiao; Zhou, Ming-Ming] Nantong Hlth Coll Jiangsu Prov, Dept Nursing, Nantong, Peoples R China.
   [Hao, Hai-Yan] Nantong Univ, Affiliated Hosp, Clin Res Unit, Nantong, Peoples R China.
   [Chen, Hai-Yan] Nanjing Univ Chinese Med, Nantong Hosp Tradit Chinese Med, Affiliated Nantong Hosp, Dept Urol, Nantong 226001, Peoples R China.
C3 Nantong University; Nanjing University of Chinese Medicine
RP Hao, HY (corresponding author), Nantong Univ, Affiliated Hosp, Clin Res Unit, Nantong, Peoples R China.; Chen, HY (corresponding author), Nanjing Univ Chinese Med, Nantong Hosp Tradit Chinese Med, Affiliated Nantong Hosp, Dept Urol, Nantong 226001, Peoples R China.
EM haohaiyan001@outlook.com; chaiy2022@outlook.com
FU Nantong Municipal Health Commission [MS2023004]
CR Doan LV, 2020, CURR ANESTHESIOL REP, V10, P28, DOI 10.1007/s40140-020-00367-9
   He BJ, 2013, PAIN MED, V14, P1608, DOI 10.1111/pme.12197
   Lee YS, 2018, ACUPUNCT MED, V36, P197, DOI 10.1136/acupmed-2017-011516
   Maurer J, 2024, BJU INT, V133, P725, DOI 10.1111/bju.16288
NR 4
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD JUN 15
PY 2025
VL 135
IS 6
BP 1060
EP 1061
DI 10.1111/bju.16700
EA MAR 2025
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 2GI8O
UT WOS:001447455300001
PM 40104920
DA 2026-01-16
ER

PT J
AU Jung, MS
   Kim, M
   Sohn, EH
   Lee, JS
AF Jung, Mi Sook
   Kim, Mijung
   Sohn, Eun Hee
   Lee, Jin Sun
TI The Effectiveness and Safety of Nurse-Led Auricular Acupressure on Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer: A Randomized, Double-Blind, Sham-Controlled Trial
SO CANCER NURSING
LA English
DT Article
DE Auriculotherapy; Breast neoplasms; Drug toxicity; Peripheral nervous system disease
ID point acupressure; outcome measures; pain; neurotoxicity; acupuncture; prevalence; prevention; management; consensus; toxicity
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major symptom of distress among chemotherapy-treated cancer survivors. Although various interventions have been attempted, there is no criterion-standard treatment. Objective: The aim of this study was to examine the efficacy and safety of auricular acupressure (AA) in improving peripheral neuropathy symptoms in breast cancer patients undergoing taxane-based treatment. Methods: A total of 51 eligible participants were enrolled and randomly allocated (1:1) to AA or sham control groups. The intervention was performed weekly for 3 weeks using different ear points, depending on the group. The Total Neuropathy Score was used to measure CIPN objectively. The Numerical Rating Scale and the European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy-20 were used to measure the subjective symptoms of CIPN. Outcomes were compared between groups by time interaction using generalized estimating equations based on the intention-to-treat principle. Results: Only 1 participant dropped out because of nausea and mild fever. The results of generalized estimating equations showed significant improvement in Numerical Rating Scale scores on the hands and feet and total Chemotherapy-Induced Peripheral Neuropathy-20 in the experimental group compared with the sham control group (all Ps < .05). Although the experimental group showed a greater reduction in Total Neuropathy Score scores than the sham control group, no significant differences were found. Conclusion: Auricular acupressure is an effective and safe nurse-led intervention for managing CIPN symptoms in breast cancer patients. Implications for Practice: The findings help nurses to integrate AA easily and usefully into nursing care, contributing to managing symptoms of CIPN in cancer patients and survivors.
C1 [Jung, Mi Sook] Chungnam Natl Univ, Coll Nursing, Daejeon, South Korea.
   [Kim, Mijung] Catholic Kkottongnae Univ, Dept Nursing, 133 Sangsam Gil, Chungju 28211, South Korea.
   [Sohn, Eun Hee] Chungnam Natl Univ Hosp, Dept Neurol, Daejeon, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Dept Surg, Daejeon, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Res Inst Med Sci, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University; Chungnam National University Hospital; Chungnam National University; Chungnam National University
RP Jung, MS (corresponding author), Catholic Kkottongnae Univ, Dept Nursing, 133 Sangsam Gil, Chungju 28211, South Korea.
EM msj713@gmail.com; seh337@daum.net; leejin123@cnu.ac.kr
FU National Research Foundation of Korea [2017R1A2B4004328]
CR AL-Atiyyat N, 2017, INT J PALLIAT NURS, V23, P13, DOI 10.12968/ijpn.2017.23.1.13
   Alberti P, 2014, ANN ONCOL, V25, P257, DOI 10.1093/annonc/mdt409
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Alimi D, 2002, MED ACUPUNCT, V13, P18
   Armstrong T, 2005, ONCOL NURS FORUM, V32, P305, DOI 10.1188/05.ONF.305-311
   Arts A, 2007, AURICULAR MEDICINE AND AURICULAR THERAPY: A PRACTICAL APPROACH, V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Cunningham JA, 2013, BMC MED RES METHODOL, V13, P0, DOI 10.1186/1471-2288-13-150
   Di Maio M, 2015, J CLIN ONCOL, V33, P910, DOI 10.1200/JCO.2014.57.9334
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Jouya S, 2018, EVID BASED CARE J, V7, P55
   Jung MS, 2021, ANN PALLIAT MED, V10, P721, DOI 10.21037/apm-20-1469
   Kim SY, 2021, ASIAN ONCOL NURS, V21, P129, DOI 10.5388/aon.2021.21.3.129
   Li T, 2022, QUAL LIFE RES, V31, P3091, DOI 10.1007/s11136-022-03154-7
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   mijung Kim, 2020, THE JOURNAL OF FUNDAMENTALS OF NURSING, V0, P0
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/430796
   Visovsky Constance, 2007, CLIN J ONCOL NURS, V11, P901
   White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Willson ML, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004421.pub3
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238
   Zheng SH, 2018, FRONTIERS OF NURSING, V5, P227, DOI 10.1515/fon-2018-0030
   Zhong Baoliang, 2009, J THORAC DIS, V1, P51
NR 51
TC 4
Z9 6
U1 12
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD MAR-APR 15
PY 2025
VL 48
IS 2
BP E64
EP E74
DI 10.1097/NCC.0000000000001286
EA OCT 2023
PG 11
WC Oncology; Nursing
SC Oncology; Nursing
GA 9ZY6Q
UT WOS:001619046600001
PM 37851514
DA 2026-01-16
ER

PT J
AU Zhang, XC
   Shen, DL
   Shi, JL
   Gong, GW
   Wang, G
   Jiang, ZW
   Jin, HY
   Deng, ZM
AF Zhang, Xiao-Chun
   Shen, Dan-Li
   Shi, Jia-Ling
   Gong, Guan-Wen
   Wang, Gang
   Jiang, Zhi-Wei
   Jin, Hei-Ying
   Deng, Zheng-Ming
TI Development of a Nomogram for Predicting Postoperative Prolonged Ileus in Gastric Cancer Patients: A Retrospective and Prospective Cohort Study
SO AMERICAN SURGEON
LA English
DT Article; Early Access
DE postoperative ileus; gastric cancer; nomogram; risk prediction; electroacupuncture
ID inflammation; activation; infection
AB Objective To develop and validate a nomogram for predicting the risk of postoperative prolonged ileus (PPOI) in patients undergoing gastric cancer (GC) surgery, providing a personalized risk assessment tool for early identification and optimized postoperative management.Methods A retrospective cohort (January 2019-December 2023) was used to develop and internally test the nomogram, while a prospective cohort (January-December 2024) was used for external validation. Univariate and multivariate logistic regression with backward stepwise selection identified independent predictors. Model performance was assessed through receiver operating characteristic (ROC) curves, calibration curves, decision-curve analysis (DCA), and clinical impact curve analysis (CICA). Patients were stratified into low, medium, and high-risk groups based on nomogram scores for further analysis.Results A total of 780 patients in the training cohort and 294 in the validation cohort were included, with postoperative prolonged ileus rates of 11.54% and 16.33%, respectively (chi 2 = 4.371, P =.037). Independent predictors included electroacupuncture, pain self-efficacy questionnaire (PSEQ) score, preoperative serum albumin (Alb), body fat, postoperative day 1 Visual Analog Scale (Pod1 VAS), and intensive care unit (ICU) admission. The nomogram demonstrated strong discriminatory ability and calibration, with clinical utility confirmed through DCA and CICA. Higher nomogram scores correlated with increased PPOI incidence.Conclusions The developed nomogram is a valuable tool for early identification of PPOI in GC patients, supporting clinicians and nurses in implementing personalized preventive strategies.
C1 [Zhang, Xiao-Chun; Jin, Hei-Ying] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Colorectal Surg, Nanjing, Peoples R China.
   [Shen, Dan-Li; Gong, Guan-Wen; Wang, Gang; Jiang, Zhi-Wei; Deng, Zheng-Ming] Nanjing Univ Chinese Med, Dept Gen Surg, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210023, Jiangsu, Peoples R China.
   [Shi, Jia-Ling] Nanjing Univ Chinese Med, Coll Nursing, Dept Surg Nursing, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Deng, ZM (corresponding author), Nanjing Univ Chinese Med, Dept Gen Surg, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM dengzhengming2024@163.com
FU Jiangsu Province 14th Five-Year medical key discipline: Traditional Chinese surgery [ZDXK202251]
CR Bik CK, 2016, J TRADIT CHIN MED, V36, P271, DOI 10.1016/S0254-6272(16)30038-3
   Buscail E, 2022, BRIT J PHARMACOL, V179, P3283, DOI 10.1111/bph.15800
   Chao Hui-Lin, 2013, ONCOL NURS FORUM, V40, PE61, DOI 10.1188/13.ONF.E61-E68
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   Chung MY, 2011, J INT MED RES, V39, P2370, DOI 10.1177/147323001103900637
   Dubé MO, 2021, PAIN REP, V6, P0, DOI 10.1097/PR9.0000000000000972
   Fan ZQ, 2024, BIOMARK MED, V0, P0, DOI DOI 10.2217/bmm-2023-0355
   Gayer CP, 2009, CELL SIGNAL, V21, P1237, DOI 10.1016/j.cellsig.2009.02.011
   Hou LL, 2016, J TRADIT CHIN MED, V36, P450
   Ju H, 2024, KOREAN J ANESTHESIOL, V77, P133, DOI 10.4097/kja.22792
   Kalff JC, 2003, ANN SURG, V237, P301, DOI 10.1097/00000658-200303000-00003
   Khoury MK, 2024, J VASC SURG, V80, P0, DOI 10.1016/j.jvs.2024.07.094
   Kim G, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0981-x
   Liang WQ, 2020, WORLD J GASTROENTERO, V26, P1185, DOI 10.3748/wjg.v26.i11.1185
   Liang WQ, 2019, WORLD J GASTROENTERO, V25, P5838, DOI 10.3748/wjg.v25.i38.5838
   Lieffers JR, 2012, BRIT J CANCER, V107, P931, DOI 10.1038/bjc.2012.350
   Lin ZM, 2022, BMC CANCER, V22, P0, DOI 10.1186/s12885-022-10377-x
   Pei LX, 2025, GASTROENTEROLOGY, V169, P73, DOI 10.1053/j.gastro.2025.02.006
   Petch-in P, 2023, DRUGS-REAL WOR OUTC, V10, P341, DOI 10.1007/s40801-023-00364-4
   Ross RK, 2020, AM J EPIDEMIOL, V189, P1583, DOI 10.1093/aje/kwaa124
   Sasaki M, 2022, BMC SURG, V22, P0, DOI 10.1186/s12893-022-01887-3
   Sparreboom CL, 2016, WORLD J GASTROENTERO, V22, P7226, DOI 10.3748/wjg.v22.i32.7226
   Sui C, 2025, FRONT IMMUNOL, V16, P0, DOI 10.3389/fimmu.2025.1552944
   Tang XD, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms222313009
   The FO, 2008, GUT, V57, P33, DOI 10.1136/gut.2007.120238
   Vather R, 2014, CLIN EXP PHARMACOL P, V41, P358, DOI 10.1111/1440-1681.12220
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wang ZB, 2024, FRONT NUTR, V11, P0, DOI 10.3389/fnut.2024.1345570
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Xiu WC, 2024, INT J COLORECTAL DIS, V39, P0, DOI 10.1007/s00384-024-04693-w
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
NR 32
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-1348
EI 1555-9823
J9 AM SURGEON
JI Am. Surg.
PD SEP 29
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/00031348251383475
EA SEP 2025
PG 16
WC Surgery
SC Surgery
GA 8AL5T
UT WOS:001584001900001
PM 41021978
DA 2026-01-16
ER

PT J
AU Yan, L
   Sun, B
   Zhou, M
   Zhang, Y
   Gao, F
   Zhao, Q
   Wang, L
AF Yan, Li
   Sun, Bin
   Zhou, Meiyan
   Zhang, Yan
   Gao, Fei
   Zhao, Qianwen
   Wang, Liwei
TI [Effect of transcutaneous electrical acupoint stimulation on postoperative pain
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE breast cancer; inflammatory factors; modified radical mastectomy for breast cancer; postoperative acute pain; postoperative chronic pain; randomized controlled trial (RCT); transcutaneous electrical acupoint stimulation
AB OBJECTIVE: To observe the effect of transcutaneous electrical acupoint  stimulation (TEAS) on postoperative pain in patients undergoing modified radical  mastectomy for breast cancer. METHODS: A total of 140 female patients scheduled  for unilateral modified radical mastectomy for breast cancer undergoing general  anesthesia were randomized into a TEAS group (70 cases) and a sham TEAS group (70  cases, 2 cases dropped out). Patients in both groups received TEAS or sham TEAS  at bilateral Neiguan (PC6), Zusanli (ST36), and Danzhong (CV17), respectively,  from 30 min before anesthesia induction until the end of surgery, and on 1st,  2nd, and 3rd days after surgery for 30 min a time, once a day. On 1st, 2nd, and  3rd days after surgery, the pain visual analogue scale (VAS) score was observed;  on 3, 6, 12 months after surgery, the incidence rate of chronic pain was  observed; before surgery, and on 1st, 3rd, and 7th days after surgery, the serum  levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10 were  detected; the number of analgesia pump press, rescue analgesia, and the  occurrence of adverse reaction after surgery were recorded in the two groups.  RESULTS: In the TEAS group, the VAS scores on 1st and 2nd days after surgery, and  the incidence rates of chronic pain on 3 and 6 months after surgery were lower  than those in the sham TEAS group (P<0.05). On 1st, 3rd, and 7th days after  surgery, the serum levels of TNF-α, IL-6, and IL-10 were increased compared with  those before surgery in both groups (P<0.05, P<0.01); the above indexes in the  TEAS group were lower than those in the sham TEAS group (P<0.05). The number of  analgesia pump press and the incidence rate of rescue analgesia after surgery in  the TEAS group were lower than those in the sham TEAS group (P<0.05). There was  no statistically significant difference in the incidence of adverse reactions  after surgery between the two groups (P>0.05). CONCLUSION: TEAS can effectively  improve both the postoperative acute pain and chronic pain in patients undergoing  modified radical mastectomy for breast cancer, the mechanism may relate to  inhibiting the inflammatory reaction.
C1 Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
   Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou221009, Jiangsu Province.
   Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province.
   Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province.
   Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province.
   Department of Acupuncture-Moxibustion and Encephalopathy, Xuzhou Hospital of TCM.
   Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China.
   Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
   Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou221009, Jiangsu Province.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 13
PY 2025
VL 45
IS 2
BP 162
EP 6
DI 10.13703/j.0255-2930.20240206-k0002
PG -156
WC Humans; Female; Acupuncture Points; Pain, Postoperative; therapy; Middle Aged; Breast Neoplasms; surgery; Adult; Transcutaneous Electric Nerve Stimulation; Mastectomy, Modified Radical; adverse effects; Interleukin-6; blood; Tumor Necrosis Factor-alpha; blood; Interleukin-10; blood; Aged
UT PubMed:39943756
PM 39943756
DA 2025-02-13
ER

PT J
AU Lin, HC
   Hsu, HC
   Liao, HY
   Chen, ALP
   Lin, YW
AF Lin, Huan-Chin
   Hsu, Hsin-Cheng
   Liao, Hsien-Yin
   Chen, Arbee L. P.
   Lin, Yi-Wen
TI Electroacupuncture Modulates Programmed Cell Death 1 Ligand 1 on Peripheral and Central Nervous Systems in a Mouse Fibromyalgia Pain Model
SO BIOMEDICINES
LA English
DT Article
DE electroacupuncture; fibromyalgia; PD-L1; TRPV1; spinal cord; somatosensory cortex
AB Background: Fibromyalgia, a chronic condition that causes long-lasting pain over several months, is a global medical issue with both personal and societal implications. It is one of the hardest types of pain to heal, given the lack of objective parameters for diagnosis and progression evaluation. The main symptoms of fibromyalgia are long-lasting widespread pain alongside with anxiety, fatigue, sleep disorders, cognitive dysfunction, and obesity. Programmed cell death 1 ligand 1 (PD-L1) has been used as a target in cancer immunotherapy. It can inhibit acute and chronic pain by suppressing nociceptive neuron activity via PD-1 receptors. Methods: The current study aimed to investigate the role of PD-L1/PD1 in a mouse fibromyalgia pain model. Mice were exposed to intermittent cold stress (ICS) to produce a murine fibromyalgia model characterized using von Frey and Hargreaves tests. Results: The ICS-induced mice fibromyalgia pain model showed mechanical (2.26 +/- 0.18 g) and thermal (4.36 +/- 0.31 s) hyperalgesia. Nociceptive responses could be relieved with electroacupuncture, intracerebral PD-L1 injection, or Trpv1 deletion. We also identified a lower PD-1 level in the dorsal root ganglion, spinal cord, thalamus, and somatosensory cortex. In contrast, levels of pain-related kinases increased after fibromyalgia induction, an effect which could be reversed by EA, PD-L1, or Trpv1 deletion. Conclusions: Our findings shed light on the contribution of PD-L1/PD1 to EA and fibromyalgia pain, indicating its potential as a treatment target for fibromyalgia.
C1 [Lin, Huan-Chin; Lin, Yi-Wen] China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 404328, Taiwan.
   [Lin, Huan-Chin] Minist Hlth & Welf, Feng Yuan Hosp, Dept Tradit Chinese Med, Taichung, Taiwan.
   [Hsu, Hsin-Cheng] China Med Univ, Hsinchu Hosp, Dept Tradit Chinese Med, Hsinchu 302056, Taiwan.
   [Liao, Hsien-Yin] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung 404328, Taiwan.
   [Chen, Arbee L. P.] Asia Univ, Dept Comp Sci & Informat Engn, Taichung 413305, Taiwan.
   [Lin, Yi-Wen] China Med Univ, Chinese Med Res Ctr, Taichung 404328, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan
RP Lin, YW (corresponding author), China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 404328, Taiwan.; Chen, ALP (corresponding author), Asia Univ, Dept Comp Sci & Informat Engn, Taichung 413305, Taiwan.; Lin, YW (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung 404328, Taiwan.
EM peishiuan1010@gmail.com; 002762@tool.caaumed.org.tw; 017215@tool.caaumed.org.tw; arbeec@mail.asia.edu.tw; yiwenlin@mail.cmu.edu.tw
FU Ministry of Education in Taiwan; NSTC [113-2314-B-039-047, CMU113-ASIA-15, CMUHCH-DRM-113-025]; Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program
CR Assavarittirong C, 2022, OXID MED CELL LONGEV, V2022, P0, DOI 10.1155/2022/1582432
   Benítez-Angeles M, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21103421
   Brown EN, 2018, ANESTH ANALG, V127, P1246, DOI 10.1213/ANE.0000000000003668
   Chen G, 2017, NAT NEUROSCI, V20, P917, DOI 10.1038/nn.4571
   Farag HM, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.12939
   Fernández-Carvajal A, 2022, FRONT MOL NEUROSCI, V15, P0, DOI 10.3389/fnmol.2022.930964
   Ghowsi M, 2021, BIOMEDICINE-TAIWAN, V11, P13, DOI 10.37796/2211-8039.1174
   Guo L, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e30819
   Hsiao IH, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11182869
   Hsiao IH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/2242074
   Janssen LP, 2021, AN ACAD BRAS CIENC, V93, P0, DOI 10.1590/0001-3765202120210618
   Kaur A, 2019, BIOCHEM PHARMACOL, V166, P56, DOI 10.1016/j.bcp.2019.05.012
   Koivisto AP, 2024, CURR OPIN PHARMACOL, V75, P0, DOI 10.1016/j.coph.2024.102447
   Kong FQ, 2021, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.670646
   Liao HY, 2021, CHIN MED-UK, V16, P0, DOI 10.1186/s13020-021-00451-0
   Lin YW, 2020, BRAIN BEHAV IMMUN, V89, P604, DOI 10.1016/j.bbi.2020.06.033
   Liu BL, 2020, JCI INSIGHT, V5, P0, DOI 10.1172/jci.insight.137386
   Liu F, 2023, BRAIN RES, V1820, P0, DOI 10.1016/j.brainres.2023.148578
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Lu SF, 2019, FRONT PSYCHIATRY, V10, P0, DOI 10.3389/fpsyt.2019.00353
   Menzies V, 2010, BIOL RES NURS, V11, P387, DOI 10.1177/1099800409348328
   Fischer SPM, 2020, NEUROCHEM INT, V134, P0, DOI 10.1016/j.neuint.2020.104673
   Peck MM, 2020, CUREUS J MED SCIENCE, V12, P0, DOI 10.7759/cureus.10276
   Qin YX, 2013, ACUPUNCT MED, V31, P214, DOI 10.1136/acupmed-2012-010289
   Shi SM, 2020, CEPHALALGIA, V40, P288, DOI 10.1177/0333102419883374
   Siracusa R, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22083891
   Stone JAM, 2010, CURR TREAT OPTION ON, V11, P118, DOI 10.1007/s11864-010-0128-y
   Tan HL, 2021, ANESTH ANALG, V133, P1321, DOI 10.1213/ANE.0000000000005737
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Wang G, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-020-15229-5
   Wang Y, 2024, CANCER IMMUNOL RES, V12, P26, DOI 10.1158/2326-6066.CIR-23-0309
   Xie LS, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.689629
   Yang B, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.716684
   Yang Y, 2022, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.811584
   Yen LT, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep46663
   Yüksel E, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-17715-1
   Zhang C, 2024, NEUROTHERAPEUTICS, V21, P0, DOI 10.1016/j.neurot.2024.e00369
   Zhao L, 2022, P NATL ACAD SCI USA, V119, P0, DOI 10.1073/pnas.2204114119
   Zhou X, 2024, BRAIN SCI, V14, P0, DOI 10.3390/brainsci14040380
NR 39
TC 1
Z9 1
U1 5
U2 10
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB 15
PY 2025
VL 13
IS 2
BP 
EP 
DI 10.3390/biomedicines13020396
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Research & Experimental Medicine; Pharmacology & Pharmacy
GA Y2L7J
UT WOS:001430510500001
PM 40002809
DA 2026-01-16
ER

PT J
AU Ying, Y
   Yang, G
   Li, X
   Wang, F
   Zhang, G
AF Ying, Yi
   Yang, Guodong
   Li, Xiaoyu
   Wang, Feifei
   Zhang, Guobing
TI Analgesic effects of electroacupuncture via the EphBs-p38 MAPK signaling pathway
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE EphBs; electroacupuncture; microglia; neuropathic pain; p38 mitogen-activated protein kinase
AB OBJECTIVE: To explore the analgesic effects of electroacupuncture (EA) and its  impact on the EphBs-p38 mitogen-activated protein kinase (MAPK) pathway and  microglia in a rat model of neuropathic pain (NP). METHODS: Following adaptive  training, 60 male Sprague Dawley (SD) rats were allocated to one of two  experiments. In experiment 1, rats received intrathecal SB203580 (p38 MAPK  inhibitor), intramuscular EphB1-Fc (EphBs inhibitor) or no injection before  undergoing chronic constrictive injury (CCI). In experiment 2, CCI model rats  received EA either alone or combined with either anisomycin (p38 MAPK agonist) or  EphrinB1-Fc (EphBs agonist) versus minimal acupuncture (MA) as a control  intervention. A sham surgery group was included in both experiments as a control  for CCI. All groups consisted of n = 6 rats (four in experiment 1 and six in  experiment 2). Behavioral hyperalgesia was examined and the spinal L5-6 region  was harvested and subjected to enzyme-linked immunosorbent assay to assess tumor  necrosis factor (TNF)-α and interleukin (IL)-1β levels. Western blotting and  immunofluorescence were used to assess protein expression of B-cell lymphoma  (Bcl)-2, Bcl-2 associated X-protein (BAX), EphB1, EphrinB1, p38 MAPK,  phosphorylated (p)-p38 MAPK and ionized calcium binding adaptor molecule (Iba)-1.  RESULTS: CCI induced behavioral hyperalgesia, as demonstrated by altered paw  withdrawal latency (PWL), paw withdrawal threshold (PWT) and cytokine levels, and  increased p38 MAPK phosphorylation and microglial activation. However, inhibitors  SB203580 and EphB1-Fc reversed these effects. Notably, EA showed similar  beneficial effects, but these were counteracted when combined with anisomycin and  EphrinB1-Fc. CONCLUSIONS: The analgesic effects of EA in this rat model of NP  appear to be linked to diminished p-p38 MAPK expression and subsequent microglial  deactivation. EA has a potential role as a complementary therapy for NP.
C1 Department of Traditional Chinese Medicine, XianJu People's Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People's Hospital, Affiliated Xianju'sHospital, Hangzhou Medical College, Taizhou, China.
   Department of Orthopedics, XianJu People's Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People's Hospital, Affiliated Xianju's Hospital, HangzhouMedical College, Taizhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medical(School of Rehabilitation Medicine), Zhejiang Chinese Medical University,Hangzhou, China.
   Department of Rehabilitation, XianJu People's Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People's Hospital, Affiliated Xianju's Hospital, HangzhouMedical College, Taizhou, China.
   Department of Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD AUG 23
PY 2025
VL 43
IS 5
BP 278
EP 289
DI 10.1177/09645284251363987
PG 11
WC Animals; Electroacupuncture; Rats, Sprague-Dawley; Male; Neuralgia; therapy; p38 Mitogen-Activated Protein Kinases; metabolism; Microglia; metabolism; Rats; Disease Models, Animal; Humans; MAP Kinase Signaling System; Interleukin-1beta; genetics; Signal Transduction; Tumor Necrosis Factor-alpha; genetics; Acupuncture Analgesia
UT PubMed:40847801
PM 40847801
DA 2025-08-23
ER

PT J
AU Gómez-Neva, ME
   Pulido-Ramirez, E
   Ibañez-Rodriguez, LJ
   Caroprese, O
   Buitrago-Lopez, A
AF Gómez-Neva, María Elizabeth
   Pulido-Ramirez, Edwin
   Ibañez-Rodriguez, Leidy Johana
   Caroprese, Oscar
   Buitrago-Lopez, Adriana
TI Non-pharmacological interventions for side effects of antineoplastic chemotherapy
SO Revista Cuidarte
LA English
DT Journal Article
DE Complementary Therapies; Drug-Related Side Effects and Adverse Reactions; Integrative Oncology; Signs and Symptoms
AB INTRODUCTION: Different non-pharmacological interventions have been studied to  manage symptoms derived from chemotherapy, but their effectiveness is unknown.  OBJECTIVE: To describe non-pharmacological interventions for managing symptoms  secondary to antineoplastic chemotherapy in adults. MATERIALS AND METHODS:  Systematic review of analytical experimental and observational studies (2021 to  2023). The studies were selected, and data was extracted in parallel.  Discrepancies were resolved with a third reviewer. The risk of bias was assessed  using the Risk of Bias (RoB) tool and The Newcastle-Ottawa Scale (NOS). The  literature was synthesized descriptively based on prioritized outcomes. RESULTS:  The prioritized outcomes were neutropenia, pain, neuropathy, nausea, vomiting,  alopecia, anorexia, and sleep disorders. Out of 7520 references found, 62 were  included for analysis. Acupressure showed a possible effect in controlling  symptoms such as nausea and vomiting. The intervention with cold on the scalp  showed differences in the stages of alopecia severity. Other interventions showed  heterogeneity. DISCUSSION: Non-pharmacological interventions have been widely  described in observational and experimental studies in the control of side  effects of chemotherapy; however, there is homogeneity and a high risk of bias.  CONCLUSION: Acupressure, muscle massage, music therapy, foot baths, and other  interventions have been studied for nausea, vomiting, sleep disorders,  neutropenia, alopecia, anorexia, pain, and neuropathy as secondary symptoms  prioritized by patients. It is necessary to standardize both the interventions  and how measure the outcomes.
C1 Pontificia Universidad Javeriana, Facultad de Enfermería. Bogotá, Colombia. E-mail: m.gomezn@javeriana.edu.co Pontificia Universidad Javeriana PontificiaUniversidad Javeriana Facultad de Enfermería Bogotá Colombiam.gomezn@javeriana.edu.co.
   Pontificia Universidad Javeriana. Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina. Bogotá, Colombia. E-mail:pulidoedwin@javeriana.edu.co Pontificia Universidad Javeriana PontificiaUniversidad Javeriana Departamento de Epidemiología Clínica y BioestadísticaFacultad de Medicina Bogotá Colombia pulidoedwin@javeriana.edu.co.
   Hospital Universitario San Ignacio. Bogotá, Colombia. E-mail: leidy.ibanez@javeriana.edu.co Hospital Universitario San Ignacio Bogotá Colombialeidy.ibanez@javeriana.edu.co.
   Subred Integrada de Servicios de Salud Norte. Bogotá, Colombia. E-mail: ocaropresse@g mail.com Subred Integrada de Servicios de Salud Norte BogotáColombia ocaropresse@g mail.com.
   Pontificia Universidad Javeriana, Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina. Bogotá, Colombia. E-mail:buitragod@javeriana.edu.co Pontificia Universidad Javeriana PontificiaUniversidad Javeriana Departamento de Epidemiología Clínica y BioestadísticaFacultad de Medicina Bogotá Colombia buitragod@javeriana.edu.co.
NR 0
TC 0
SN 2346-341
EI 2216-097
J9 Rev Cuid
PD MAR 21
PY 2025
VL 15
IS 3
BP e3612
EP e3612
DI 10.15649/cuidarte.3612
PG 1
UT PubMed:40115309
PM 40115309
DA 2025-03-21
ER

PT J
AU Duzova, US
   Can, G
   Duzova, M
   Basaran, H
   Yavas, C
AF Duzova, Ulku Saygili
   Can, Gulbeyaz
   Duzova, Mursel
   Basaran, Hamit
   Yavas, Cagdas
TI The effect of acupressure on anxiety, depression, pain, and vital signs in
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupressure; Anxiety; Brachytherapy; Depression; Gynecological cancer; Pain
AB PURPOSE: This study aimed to evaluate the effects of acupressure on pain,  anxiety, depression, and physiological parameters in women undergoing  brachytherapy for gynecological cancer. METHODS: The research was conducted  between December 2023 and September 2024 using a randomized controlled design.  All patients receiving brachytherapy were randomly assigned to the acupressure  group (n = 40) or the control group (n = 40). In addition to standard clinical  care, the acupressure group received manual acupressure for 30 min before each  brachytherapy session at specific acupressure points (SP6, PC6, LI4, HT7, LV4).  The data were collected using the Personal Information Form, Visual Analog Scale  (VAS), State-Trait Anxiety Inventory (STAI-I), Hospital Anxiety and Depression  Scale (HADS), and Vital Signs Form. RESULTS: The groups were comparable in terms  of sociodemographic and clinical characteristics (p > 0.05). Significant  reductions were observed in anxiety, depression, and pain levels in the  acupressure group at post-test compared to baseline and the control group  (p < 0.001). Additionally, diastolic blood pressure and body temperature  significantly decreased in the intervention group (p < 0.001), whereas no  significant differences were found for pulse and respiratory rate (p > 0.05).  CONCLUSION: The results obtained from this study suggest that acupressure may be  a beneficial complementary method for reducing anxiety, depression, and pain, as  well as contributing to the regulation of certain physiological parameters in  patients undergoing brachytherapy. These findings indicate that acupressure could  be considered an intervention that may be integrated into clinical practice to  support psychological and physiological well-being. TRIAL REGISTRATION:  NCT06531551. Date of Registration: 1 August 2024.
C1 Faculty of Nursing, Selcuk University, Konya, Turkey. ulkusaygili@selcuk.edu.tr.
   Florence Nightingale Nursing Faculty, Istanbul University Cerrahpaşa, Istanbul, Turkey.
   Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey.
   Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey.
   Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD JUL 18
PY 2025
VL 33
IS 8
BP 698
EP 698
DI 10.1007/s00520-025-09754-6
PG 0
WC Humans; Female; Brachytherapy; adverse effects; Acupressure; methods; Anxiety; therapy; Genital Neoplasms, Female; radiotherapy; Middle Aged; Depression; therapy; Vital Signs; Adult; Pain Measurement; Aged
UT PubMed:40679634
PM 40679634
DA 2025-07-18
ER

PT J
AU Li, XT
   Lampson, K
   Rosa, WE
   Li, QS
   Ramalingam, MB
   Epstein, AS
   Mao, JJ
AF Li, Xiaotong
   Lampson, Kaitlin
   Rosa, William E.
   Li, Q. Susan
   Ramalingam, Mothi Babu
   Epstein, Andrew S.
   Mao, Jun J.
TI Effect of acupuncture on fatigue in cancer survivors with chronic pain: a secondary analysis
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Acupuncture; Fatigue; Cancer survivors; Chronic pain; Clinical trial
ID quality-of-life; breast-cancer; psychological distress; mechanisms; sleep
AB PurposeFatigue is one of the most common and troublesome symptoms in cancer survivors and is strongly correlated with pain. We evaluated the effect of acupuncture versus usual care for fatigue among cancer survivors with chronic pain.MethodsWe analyzed data from a randomized clinical trial comparing the effect of electro-acupuncture (EA) or battlefield acupuncture (BFA) versus waitlist control (WLC) for chronic musculoskeletal pain in cancer survivors. Analysis included participants who reported moderate or severe fatigue at baseline. Interventions were delivered over 10 weeks. Fatigue severity was measured using the Brief Fatigue Inventory (BFI).ResultsAmong 274 participants (mean age 61.0 years [standard deviation (SD)] 12.8; 73.0% women), the baseline BFI worst fatigue score was 7.1 (SD 1.7). EA and BFA were associated with reductions in worst fatigue score of 2.4 points (95% confidence interval [CI]: - 2.9 to - 1.9) and 2.0 points (95% CI: - 2.5 to - 1.5) from baseline to week 12. There was no significant between-group difference. A higher proportion of patients in both EA and BFA experienced clinically meaningful fatigue improvement compared to WLC (61.2% and 51.6% vs. 37.3%, p = 0.019). Fatigue reductions persisted at week 24 (EA: -2.1 points [95% CI: -2.6 to -1.7]; BFA: -2.2 points [95% CI: -2.8 to -1.7]).ConclusionCancer survivors with chronic pain experienced clinically meaningful and durable fatigue reductions when receiving either EA or BFA.Implications for cancer survivorsThese findings support the clinical utility of acupuncture as an evidence-based option for managing fatigue in cancer survivors with pain.Trial registrationClinicalTrials.gov Identifier: NCT02979574; November 30, 2016.
C1 [Li, Xiaotong; Lampson, Kaitlin; Li, Q. Susan; Epstein, Andrew S.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
   [Rosa, William E.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY USA.
   [Ramalingam, Mothi Babu] Singapore Gen Hosp, Dept Rehabil Med, Singapore, Singapore.
   [Epstein, Andrew S.] Cornell Univ, Weill Cornell Med Coll, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Singapore General Hospital; Cornell University; Weill Cornell Medicine
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
EM maoj@mskcc.org
FU National Cancer Institute [P30 CA008748]
CR Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Beijer S, 2008, INT J CANCER, V123, P232, DOI 10.1002/ijc.23497
   Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Bower JE, 1900, DOI 10.1200/, V0, P0
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cramer H, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep36760
   Dagnelie PC, 2007, ANN ONCOL, V18, P940, DOI 10.1093/annonc/mdm057
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Gunn HJ, 2024, NEURO-ONCOL PRACT, V11, P633, DOI 10.1093/nop/npae034
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Jones JM, 2016, J CANCER SURVIV, V10, P51, DOI 10.1007/s11764-015-0450-2
   Kang YE, 2023, SCI REP-UK, V13, P0, DOI 10.1038/s41598-023-39046-0
   Koffel E, 2018, J GEN INTERN MED, V33, P955, DOI 10.1007/s11606-018-4390-1
   Kukanich B, 2015, VETERINARY ANESTHESIA AND ANALGESIA: THE FIFTH EDITION OF LUMB AND JONES, V0, P207
   Levy CE, 2018, AM J PHYS MED REHAB, V97, Pe18, DOI 10.1097/PHM.0000000000000766
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li PJ, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231188947
   Li YF, 2020, ONCOTARGETS THER, V13, P11743, DOI 10.2147/OTT.S272747
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu D, 2023, INT J NURS SCI, V10, P111, DOI 10.1016/j.ijnss.2022.12.006
   Maass SWMC, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13061301
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Ng AH, 2021, JCO ONCOL PRACT, V17, P440, DOI 10.1200/OP.20.00625
   Nielsen A, 2020, PAIN MED, V21, P1276, DOI 10.1093/pm/pnz379
   Niemtzow RC, 2007, MED ACUPUNCT, V19, P225, DOI 10.1089/acu.2007.0603
   Park JH, 2020, ACUPUNCT MED, V38, P407, DOI 10.1177/0964528420920287
   Romero SAD, 2017, J CLIN ONCOL, V35, P0, DOI 10.1200/JCO.2017.35.5_suppl.162
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Sloan Jeff A, 2017, TRENDS CANCER RES, V12, P97
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   van de Castle B, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231198086
   Wang XS, 2014, CANCER-AM CANCER SOC, V120, P425, DOI 10.1002/cncr.28434
   Wu CX, 2019, WORLDV EVID-BASED NU, V16, P102, DOI 10.1111/wvn.12352
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD DEC 13
PY 2025
VL 34
IS 1
BP 
EP 
DI 10.1007/s00520-025-10219-z
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA U6739
UT WOS:001638835500003
PM 41389238
DA 2026-01-16
ER

PT J
AU Ji, Z
   Niu, HY
   He, AQ
   Li, KY
   Jia, JY
   Zhang, MR
   Liu, G
AF Ji, Zhe
   Niu, Heyuan
   He, Anqi
   Li, Kaiyu
   Jia, Jinyan
   Zhang, Maorun
   Liu, Gang
TI Research Hotspots and Trends in Acupuncture for Cancer:A bibliometric analysis from 2004 to 2024
SO JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
LA English
DT Article
DE acupuncture; bibliometric analysis; cancer; citespace; VOSviewer
ID postoperative ileus pathophysiology; signaling pathway
AB Background: Acupuncture is increasingly recognized as a promising intervention modality in cancer treatment. Nevertheless, there has been a paucity of systematic analysis and visualisation of relevant publications through bibliometric methods. This paper conducts a bibliometric analysis of research on acupuncture within the realm of oncological applications, aiming to explore its prospects and emerging trends. Methods: In this study, we analyzed 2117 documents obtained from the Web of Science Core Collection (WOSCC) to examine the correlations among authors, journals, institutions, countries, and keywords. This analysis was conducted using the Bibliometric R package, CiteSpace, and VOSviewer software. Results: The evolution of acupuncture can be broadly divided into three time periods: 2004-2008, 2009-2017 and 2018-2024. The WOSCC retrieved 2117 publications on acupuncture for cancer over the past 20 years. Among the top 10 institutions, seven were from the United States, two from China, and one from Korea. Memorial Sloan Kettering Cancer Center had the highest number of publications. At the same time, the journal INTEGRATIVE CANCER THERAPIES published the most articles in this field. Keyword co-occurrence analysis revealed four distinct clusters: "Alternative and Complementary Medicine for Cancer", "Acupuncture for cancer-related fatigue and pain", "Acupressure for anxiety, depression, and insomnia", "Improving quality of life for breast cancer patients". The most recent keyword outbreaks included "sleep", "radiation induced xerostomia", "recovery", "insomnia", and "induced peripheral neuropathy." Breast cancer is the type of cancer for which acupuncture is most commonly used. Conclusion: The future research focus will be on acupuncture as a treatment for sleep disorders, the alleviation of radiotherapy complications and the improvement of postoperative quality of life. Research on acupuncture in the field of breast cancer is more extensive compared to other cancers. Therefore, it is necessary to strengthen research on acupuncture in different cancer types.
C1 [Ji, Zhe; Niu, Heyuan; He, Anqi; Li, Kaiyu; Jia, Jinyan; Zhang, Maorun; Liu, Gang] Tianjin Med Univ, Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Liu, G (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Gen Surg, Tianjin, Peoples R China.
EM lg1059@tmu.edu.cn
FU Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-005A]
CR Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bhide SA, 2009, CLIN ONCOL-UK, V21, P737, DOI 10.1016/j.clon.2009.09.002
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Chang QQ, 2019, RADIOL ONCOL, V53, P443, DOI 10.2478/raon-2019-0048
   Chen CM, 2004, P NATL ACAD SCI USA, V101, P5303, DOI 10.1073/pnas.0307513100
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   de Winter JCF, 2014, SCIENTOMETRICS, V98, P1547, DOI 10.1007/s11192-013-1089-2
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Deng P, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.910400
   Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302
   Dörfler J, 2023, HEAD NECK-J SCI SPEC, V45, P1026, DOI 10.1002/hed.27297
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Fang Junfan, 2017, ZHONGGUO ZHEN JIU, V37, P291, DOI 10.13703/j.0255-2930.2017.03.020
   Feng YY, 2018, BIOMED RES INT, V2018, P0, DOI 10.1155/2018/3128378
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Harnsberger CR, 2019, CLIN COLON RECT SURG, V32, P166, DOI 10.1055/s-0038-1677003
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hicks D, 2015, NATURE, V520, P429, DOI 10.1038/520429a
   Hu D, 2021, J CELL MOL MED, V25, P2900, DOI 10.3233/jifs-202844
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Huang ZH, 2019, ACUPUNCT MED, V37, P292, DOI 10.1136/acupmed-2017-011593
   Jiang ST, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.1096806
   Jiang ST, 2023, INT J SURG, V109, P2774, DOI 10.1097/JS9.0000000000000492
   Lasch K, 2009, CURR MED RES OPIN, V25, P1699, DOI 10.1185/03007990902973201
   Li MY, 2022, BMC ORAL HEALTH, V22, P0, DOI 10.1186/s12903-022-02269-0
   Lin SS, 2023, CELL DEATH DIS, V14, P0, DOI 10.1038/s41419-023-05839-4
   Liu CY, 2021, ANN TRANSL MED, V9, P0, DOI 10.21037/atm-21-3845
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Lu WD, 2024, CANCER-AM CANCER SOC, V130, P3219, DOI 10.1002/cncr.35374
   Ma QF, 2022, CURR OPIN NEUROBIOL, V76, P0, DOI 10.1016/j.conb.2022.102602
   Maeda H, 2018, CLIN TRANSL MED, V7, P0, DOI 10.1186/s40169-018-0185-6
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Peters EG, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13862
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shen GS, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00099
   Stakenborg N, 2017, HANDB EXP PHARMACOL, V239, P39, DOI 10.1007/164_2016_108
   Synnestvedt Marie B, 2005, AMIA ANNU SYMP PROC, V0, P724
   Team RC Team R, 2005, A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0
   van der Zweerde T, 2019, SLEEP MED REV, V48, P0, DOI 10.1016/j.smrv.2019.08.002
   van Eck NJ, 2017, SCIENTOMETRICS, V111, P1053, DOI 10.1007/s11192-017-2300-7
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Van Eck NJ, 2014, MEASURING SCHOLARLY, V0, PP285, DOI 10.1007/978-3-319-10377-8_13
   van Elk M, 2016, INT J PHARMACEUT, V515, P132, DOI 10.1016/j.ijpharm.2016.10.013
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   Wang B, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3170803
   Wang LL, 2020, LIFE SCI, V261, P0, DOI 10.1016/j.lfs.2020.118473
   Wang XM, 2012, CYTOKINE, V59, P3, DOI 10.1016/j.cyto.2012.03.027
   Wang XJ, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/396396
   Wang YK, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02969-6
   Wang YH, 2024, FRONT ONCOL, V14, P0, DOI 10.3389/fonc.2024.1291524
   Wei SS, 2018, ONCOL REP, V40, P3213, DOI 10.3892/or.2018.6723
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Zhang B, 2022, BIOSCI TRENDS, V16, P73, DOI 10.5582/bst.2022.01039
   Zhang JH, 2020, COMPLEMENT THER CLIN, V41, P0, DOI 10.1016/j.ctcp.2020.101253
   Zhang XY, 2019, ACUPUNCT MED, V37, P16, DOI 10.1136/acupmed-2018-011668
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 59
TC 2
Z9 2
U1 10
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2390
EI 
J9 J MULTIDISCIP HEALTH
JI J. Multidiscip. Healthc.
PD JUN 15
PY 2025
VL 18
IS 
BP 531
EP 547
DI 10.2147/JMDH.S494138
PG 17
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA W1F4G
UT WOS:001416115800001
PM 39911755
DA 2026-01-16
ER

PT J
AU Wang, F
   Ye, ZH
   Yin, XJ
   Zhou, CC
   Zhong, M
   Zhao, GF
AF Wang, Feng
   Ye, Zhihui
   Yin, Xiuju
   Zhou, Chengcheng
   Zhong, Min
   Zhao, Gaofeng
TI Electroacupuncture at 5/100 Hz alleviates neuropathic pain in rats by inhibiting the CCL3/CCR5 axis in the spinal cord
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE CCL3; CCR5; electroacupuncture; glial cells; neuropathic pain; proinflammatory factors
ID receptor 5; acupuncture; chemokines
AB Objective: Typically, neuropathic pain (NP) is difficult to manage as it is refractory to conventional medications. Electroacupuncture (EA) at 5/100 Hz has emerged as an effective and promising treatment for NP; however, its mechanism of action is still uncertain. Accordingly, this study investigated the alleviatory mechanism of EA in chronic compression injury (CCI)-induced chronic pain via the C-C chemokine ligand 3 / C-C chemokine receptor type 5 (CCL3/CCR5) axis.Methods: The CCI model was established in rats to induce NP. Mechanical and thermal hyperalgesia were assessed with von Frey and Hargreaves tests, respectively. From day 8 after CCI, EA (5/100 Hz) was performed for 1 week (30 min/day). CCL3 and CCR5 expression was detected with Western blotting and immunofluorescence. Glial cell activation was determined through co-labeling of neurons and glial cells with antibodies against CCL3 and CCR5. The release of interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF)-alpha was tested with enzyme-linked immunosorbent assay (ELISA).Results: EA markedly ameliorated CCI-induced chronic NP in rats and reduced CCL3 and CCR5 expression in the rat spinal cord. CCL3 and CCR5 were co-expressed by neurons and microglia in the central nervous system. In addition, EA also repressed the activation of glial cells and levels of IL-1 beta, IL-6 and TNF-alpha.Conclusion: EA may mitigate chronic NP in rats by blocking the CCL3/CCR5 axis in the spinal cord. In addition, EA appeared to exert anti-inflammatory and analgesic effects by suppressing glial cell activation. These findings add to our understanding of the mechanism of EA-induced analgesia.
C1 [Wang, Feng; Zhong, Min; Zhao, Gaofeng] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, 11 Dade Rd, Guangzhou 510000, Guangdong, Peoples R China.
   [Ye, Zhihui; Yin, Xiuju; Zhou, Chengcheng] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zhao, GF (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, 11 Dade Rd, Guangzhou 510000, Guangdong, Peoples R China.
EM zhaogaofengzyy@163.com
FU Natural Science Foundation of Guangdong Province [2020A1515010957]
CR Alles SRA, 2018, PHARMACOL REV, V70, P315, DOI 10.1124/pr.117.014399
   Arman A, 2020, BRAIN BEHAV IMMUN, V88, P442, DOI 10.1016/j.bbi.2020.04.009
   Bannister K, 2020, ANNU REV PHARMACOL, V60, P257, DOI 10.1146/annurev-pharmtox-010818-021524
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Bonin RP, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-26
   Cheng KI, 2021, PHYTOMEDICINE, V92, P0, DOI 10.1016/j.phymed.2021.153734
   Choi SR, 2019, FRONT MOL NEUROSCI, V12, P0, DOI 10.3389/fnmol.2019.00153
   Colloca L, 2017, NAT REV DIS PRIMERS, V3, P0, DOI 10.1038/nrdp.2017.2
   Dutta R, 2018, ARTHRITIS RES THER, V20, P0, DOI 10.1186/s13075-018-1661-5
   Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Hu QM, 2020, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/60562
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Ji RR, 2013, PAIN, V154, PS10, DOI 10.1016/j.pain.2013.06.022
   Kiguchi N, 2010, PAIN, V149, P305, DOI 10.1016/j.pain.2010.02.025
   Kong JT, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.22787
   Kwiatkowski K, 2016, PROG NEURO-PSYCHOPH, V64, P68, DOI 10.1016/j.pnpbp.2015.07.005
   Lee YK, 2013, NEUROPHARMACOLOGY, V67, P57, DOI 10.1016/j.neuropharm.2012.10.030
   Li YH, 2019, J PAIN RES, V12, P2663, DOI 10.2147/JPR.S205987
   Manni L, 2011, DIABETOLOGIA, V54, P1900, DOI 10.1007/s00125-011-2117-5
   Matsushita K, 2014, ANESTHESIOLOGY, V120, P1491, DOI 10.1097/ALN.0000000000000190
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Pottorf TS, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11132083
   Raghuraman S, 2020, P NATL ACAD SCI USA, V117, P26414, DOI 10.1073/pnas.1922618117
   Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234
   Sun SY, 2016, MOL IMMUNOL, V77, P184, DOI 10.1016/j.molimm.2016.08.006
   Wang JY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2134-8
   Wong CE, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02513-y
   Yang JH, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10102647
   Yuan JJ, 2019, PAIN, V160, P375, DOI 10.1097/j.pain.0000000000001405
   Zhang GX, 2022, J ETHNOPHARMACOL, V289, P0, DOI 10.1016/j.jep.2022.115051
   Zhang MX, 2018, ARQ NEURO-PSIQUIAT, V76, P736, DOI 10.1590/0004-282X20180128
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang ZJ, 2017, CELL MOL LIFE SCI, V74, P3275, DOI 10.1007/s00018-017-2513-1
NR 36
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD APR 15
PY 2025
VL 43
IS 2
BP 95
EP 103
DI 10.1177/09645284251327197
EA MAR 2025
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0WR6R
UT WOS:001450518800001
PM 40119762
DA 2026-01-16
ER

PT J
AU Jayatilleke, A
AF Jayatilleke, Arundathi
TI Arthritis: Rheumatoid Arthritis.
SO FP essentials
LA English
DT Review
AB Key principles of rheumatoid arthritis (RA) management include early patient  evaluation by a rheumatologist and early initiation of pharmacologic therapy in  patients at risk for chronic disease. Early diagnosis and appropriate management  are essential to prevent joint damage. Patients with RA usually report pain and  swelling in multiple joints and prolonged stiffness in the morning that improves  with activity. Joint involvement typically is bilateral and symmetric. RA affects  large and small joints, particularly the metacarpophalangeal and proximal  interphalangeal joints of the hands. Patients with RA may be started on  nonsteroidal anti-inflammatory drugs, glucocorticoids, or conventional synthetic  disease-modifying antirheumatic drugs (DMARDs) before evaluation by a  rheumatologist. Patients who have a poor response to conventional synthetic  DMARDs or aggressive arthritis at initial evaluation may be prescribed biologic  or targeted synthetic DMARDs. Anti-tumor necrosis factor alpha agents also may be  used. Patients typically are managed with a treat-to-target strategy to achieve  and maintain low disease activity or remission. Regular monitoring visits using  formal assessment of disease activity have been shown to improve outcomes. RA and  the medications used in its treatment are associated with increased risks of  infections and malignancy. Integrative medicine therapies with limited evidence  include acupuncture, mind-body therapies (eg, yoga, tai chi), and dietary  supplements.
C1 Department of Medicine at Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
NR 0
TC 0
SN 
EI 2159-300
J9 FP Essent
PD JAN 22
PY 2025
VL 548
IS 
BP 25
EP 30
DI 
PG 5
WC Humans; Arthritis, Rheumatoid; diagnosis; Antirheumatic Agents; therapeutic use; Glucocorticoids; therapeutic use; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Tumor Necrosis Factor-alpha; antagonists & inhibitors
UT PubMed:39836893
PM 39836893
DA 2025-01-22
ER

PT J
AU Giron, PS
   Haddad, CA
   Rizzi, SKLA
   Elias, S
   Nazario, ACP
   Facina, G
AF Giron, Patricia Santolia
   Haddad, Cinira Assad
   Rizzi, Samantha Karlla Lopes De Almeida
   Elias, Simone
   Nazario, Afonso Celso Pinto
   Facina, Gil
TI Exercise Therapy, Systemic Acupuncture and Silicon Oxide Tablets in the
SO Asian Pacific journal of cancer prevention : APJCP
LA English
DT Journal Article
DE Pain; Post Breast Cancer Surgery; Range of Motion; Rehabilitation; depression
AB OBJECTIVE: To compare three rehabilitation treatments, exercise therapy,  acupuncture, and silicon oxide tablets (Stiper®), in women undergoing breast  cancer surgery, assessing pain, depression, upper limb function, and range of  motion parameters (ROM). METHODS: Seventy-nine women with pain above 3 on the  visual analog pain scale (VAS) were divided into three groups: exercise group was  treated with exercise therapy, acupuncture group was treated with acupuncture,  and Stiper® group was treated with silicon oxide tablets in place of needles.  RESULTS: Sixty-seven patients completed the treatment, 26 from exercise group, 23  from acupuncture group, and 18 from Stiper® group . There was an improvement of  pain over time in all groups, the first session compared with the fifth (p <  0.001) and with the tenth (p < 0.001), but not between groups. There was a  statistically significant difference in depressive symptoms using the Beck  questionnaire over time in the three groups, between the first and tenth sessions  (p = 0.001), between the first and fifth sessions (p = 0.052), but not between  groups. Regarding the DASH questionnaire for shoulder function, there were  significant differences over time at all evaluated moments (p<0.001), but not  between groups. There was a statistically significant difference in ROM over time  in the three groups, but not between groups. CONCLUSION: The rehabilitation of  physical dysfunctions in women who survived breast cancer through exercise  therapy, acupuncture, and silicon oxide tablets in pain, depression, upper limb  function, and ROM, proved to be effective, without statistical difference between  the groups.
C1 Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
SN 2476-762
EI 1513-736
J9 Asian Pac J Cancer Prev
PD MAR 29
PY 2025
VL 26
IS 3
BP 809
EP 817
DI 10.31557/APJCP.2025.26.3.809
PG 8
WC Humans; Female; Breast Neoplasms; rehabilitation; Middle Aged; Acupuncture Therapy; methods; Exercise Therapy; methods; Cancer Survivors; Tablets; Range of Motion, Articular; Adult; Follow-Up Studies; Prognosis; Aged
UT PubMed:40156397
PM 40156397
DA 2025-03-29
ER

PT J
AU Xu, Y
   Chen, Y
   Feng, Y
   Zhang, Q
   Zhou, T
   Wo, C
   Zhang, M
AF Xu, Yun
   Chen, Yunting
   Feng, Yongfu
   Zhang, Qian
   Zhou, Tao
   Wo, Chunxin
   Zhang, Minmin
TI Silver needle thermal conduction therapy relieves pain in rats with myofascial
SO American journal of translational research
LA English
DT Journal Article
DE Myofascial pain syndrome; acupuncture effect; chronic pain; silver needle thermal conduction therapy; thermal effect
AB OBJECTIVE: To assess the effects of silver needle thermal conduction therapy on  spinal neurotransmitter activation and inflammation reduction in the myofascial  trigger point musculature of a rat model with myofascial pain syndrome (MPS).  METHODS: The MPS rat model was induced by a combination of impact and exercise  fatigue. MPS rats were then subjected to silver needle thermal conduction therapy  for 14 days. Thermal and mechanical pain thresholds were assessed using the  thermal hyperalgesia and mechanical hyperalgesia tests. Transverse and  longitudinal sections of the right medial thigh muscle were prepared for  histological analysis using HE staining. Western blot and immunohistochemistry  were used to measure the expression of calcitonin gene-related peptide (CGRP),  substance P (SP), and 5-hydroxytryptamine (5-HT) in the L4-6 segment of the  spinal cord. Additionally, the levels of inflammatory cytokines, including  interleukin 1-β (IL-1β) and tumor necrosis factor α (TNF-α), in the right medial  femoral muscle were assessed via ELISA. RESULTS: MPS rats exhibited a decreased  thermal and mechanical pain threshold compared to control rats. Muscle fiber  atrophy and deformation were observed in the MPS rats. Levels of IL-1β and TNF-α  were elevated in the right medial femoral muscle, while CGRP and SP expression  were increased, and 5-HT expression was decreased in the spinal cord. Silver  needle thermal conduction therapy effectively reversed these pathological changes  in the MPS rats. CONCLUSIONS: Silver needle thermal conduction therapy alleviated  MPS in rats by modulating spinal neurotransmitter expression and reducing muscle  inflammation.
C1 Department of Pain, The Second Affiliated Hospital of Guizhou Medical University Kaili 556000, Guizhou, China.
   Department of Pain, Affiliated Hospital of Guizhou Medical University Guiyang 550004, Guizhou, China.
   Department of Pain, The Second Affiliated Hospital of Guizhou Medical University Kaili 556000, Guizhou, China.
   Department of Pain, The Second Affiliated Hospital of Guizhou Medical University Kaili 556000, Guizhou, China.
   Department of Pain, The Second Affiliated Hospital of Guizhou Medical University Kaili 556000, Guizhou, China.
   Department of Pain, Affiliated Hospital of Guizhou Medical University Guiyang 550004, Guizhou, China.
   Department of Pain, Affiliated Hospital of Guizhou Medical University Guiyang 550004, Guizhou, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD MAY 19
PY 2025
VL 17
IS 4
BP 2604
EP 2613
DI 10.62347/QQBB3856
PG 9
UT PubMed:40385020
PM 40385020
DA 2025-05-19
ER

PT J
AU Gianni, C
   Scarpi, E
   Bravaccini, S
   Pirini, F
   Vanni, S
   Dall'Agata, M
   Cortesi, M
   Fanini, F
   Cavalieri, S
   Mercatali, L
   Ulivi, P
   Poini, A
   Giovanardi, CM
   Rocca, A
   Fedeli, A
AF Gianni, Caterina
   Scarpi, Emanuela
   Bravaccini, Sara
   Pirini, Francesca
   Vanni, Silvia
   Dall'Agata, Monia
   Cortesi, Michela
   Fanini, Francesca
   Cavalieri, Sara
   Mercatali, Laura
   Ulivi, Paola
   Poini, Alessandra
   Giovanardi, Carlo Maria
   Rocca, Andrea
   Fedeli, Anna
TI Investigating biochemical markers of Acupuncture's effectiveness in managing
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Breast cancer; Cytokines; Hot flushes; Menopause; TNF-α
AB BACKGROUND: Breast cancer (BC) remains a global health issue, with most women  receiving adjuvant hormone therapy. Hot flushes and climacteric symptoms often  compromise treatment adherence. Acupuncture has shown promise in alleviating  these symptoms and improving quality of life (QoL). This prospective study aimed  to investigate the mechanisms underlying acupuncture's effects on menopausal  symptoms in breast cancer patients receiving endocrine therapy, with a secondary  focus on inflammatory biomarker changes. METHODS: This open-label biological  study enrolled 37 early BC patients receiving endocrine treatment, and  acupuncture treatment provided at IRST within the integrative care pathway, of  whom 27 completed all evaluations. Participants underwent a 10-session weekly  acupuncture program based on Traditional Chinese Medicine, using fixed points  (SP6, CV4, LI11, BL11, GB39). Blood samples for biochemical and cytokine analysis  (IL-5, IL-6, IL-10, IL-8, IL-22, TNFα) were collected at baseline (T0),  post-treatment (T1), and six months later (T2) during regular clinical and  laboratory workups. Clinical outcomes were assessed using the Green Climacteric  Scale (GCS), EQ-5D-5L, and Brief Pain Inventory (BPI). The study followed STRICTA  guidelines. RESULTS: Acupuncture significantly improved vasomotor and climacteric  symptoms, with reduced GCS and hot flash scores at T1 and T2 (p < 0.0001). QoL  and pain scores also significantly improved at both time points. Among the  cytokines measured over time, a significant reduction in TNFα levels was observed  (p = 0.006), though no correlation emerged between cytokine changes and clinical  outcomes. CONCLUSIONS: Acupuncture proved effective in improving menopausal  symptoms and QoL in BC patients receiving endocrine therapy. The modulation of  TNFα suggests a potential biological role in the mechanism of symptom relief.
C1 Medical Oncology and Breast Unit, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST), Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC,Italy. emanuela.scarpi@irst.emr.it.
   Department of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
   Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014,Meldola, FC, Italy.
   Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC,Italy.
   Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Immuno-Gene Therapy Factory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori IRST "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori IRST "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Di Barbiano 1/10, 40136, Bologna, Italy.
   Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
   Research and Healthcare Institute of Association of Medical Acupuncturists of Bologna (A.M.A.B.), Via Antonio Canova, 15/E, 40138, Bologna, Italy.
   Research and Healthcare Institute of Association of Medical Acupuncturists of Bologna (A.M.A.B.), Via Antonio Canova, 15/E, 40138, Bologna, Italy.
   Department of Medical, Surgical and Health Sciences, University of Trieste, Piazza Università 1, 34127, Trieste, Italy.
   Research and Healthcare Institute of Association of Medical Acupuncturists of Bologna (A.M.A.B.), Via Antonio Canova, 15/E, 40138, Bologna, Italy.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD NOV 20
PY 2025
VL 33
IS 12
BP 1099
EP 1099
DI 10.1007/s00520-025-10181-w
PG 0
WC Humans; Female; Breast Neoplasms; therapy; Middle Aged; Acupuncture Therapy; methods; Prospective Studies; Hot Flashes; therapy; Quality of Life; Cytokines; blood; Biomarkers; blood; Aged; Menopause; Adult; Treatment Outcome
UT PubMed:41264030
PM 41264030
DA 2025-11-20
ER

PT J
AU Zhang, J
   Zhang, H
   Zheng, J
   Niu, C
   Zhu, S
   Hu, H
   Lu, Y
   Zhu, M
AF Zhang, Jiamin
   Zhang, Hao
   Zheng, Junfei
   Niu, Cong
   Zhu, Shu
   Hu, Haiqing
   Lu, Ye
   Zhu, Meihua
TI Safety and Effectiveness of Electroacupuncture During Colon Endoscopic Submucosal
SO Journal of pain research
LA English
DT Journal Article
DE electroacupuncture; endoscopic submucosal dissection; propofol; remifentanil
AB BACKGROUND: Endoscopic treatment of early colon neoplasms has evolved as a valid  and less traumatic alternative to surgical resection. It can usually be performed  with sedation on an outpatient basis. The present study was performed to  determine the safety and effectiveness of electroacupuncture (EA) versus propofol  sedation during endoscopic submucosal dissection (ESD) for early colon neoplasm.  METHODS: A total of 150 adult outpatients undergoing ESD were selected and  divided into the EA combined with propofol group (EP group), remifentanil  combined with propofol group (RP group), and propofol group (SP group), with 50  patients in each group. All patients received standard sedation with propofol.  Acupuncture was performed before intravenous propofol injection in the EP group.  A density wave of 1-3 mA, 2/100 hz current was administered for 20 min before the  induction of anesthesia. The effectiveness of sedation was measured by  satisfaction levels, and pain and sedation scores were measured by  questionnaires. Respiratory and hemodynamic complications were monitored and  compared as indices of safety. RESULTS: Demographic data were comparable among  the three groups. The total dose of propofol and the percentage of body movement  in the EP group were lower than in the SP and RP groups (P<0.01). The incidence  of hypotension and bradycardia in the SP and RP groups was higher than in the EP  group. Patients who received the EA intervention showed a significant reduction  in hypoxemia. The endoscopists felt that the procedure was more favorable in the  EP group, but, there was no significant difference of patient satisfaction scores  among three groups. CONCLUSION: Sedation with EA is effective and safe for  patients undergoing ESD, and could improve the satisfaction levels of patients  and gastroendoscopists.
C1 Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, People's Republic of China.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
   Department of Surgery, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic of China.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210017, People's Republic ofChina.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD MAR 19
PY 2025
VL 18
IS 
BP 1221
EP 1229
DI 10.2147/JPR.S501941
PG 8
UT PubMed:40104825
PM 40104825
DA 2025-03-19
ER

PT J
AU Li, Z
   Gao, Y
   Yan, D
   Feng, YH
AF Li, Zhe
   Gao, Yu
   Yan, Dong
   Feng, Yi-Hui
TI Efficacy of electroacupuncture for cervical spondylosis-related pain in patients
SO World journal of psychiatry
LA English
DT Journal Article
DE Cervical spondylosis; Electroacupuncture; Generalized anxiety disorder; Neuroinflammation; Pain management
AB BACKGROUND: Cervical spondylosis (CS) frequently co-occurs with generalized  anxiety disorder (GAD), presenting a complex clinical challenge. Managing  CS-related pain in patients with GAD is particularly challenging because of the  bidirectional relationship between pain and anxiety, necessitating integrated  treatment strategies. AIM: To evaluate the efficacy of electroacupuncture (EA) in  treating CS-related pain and anxiety in patients with GAD. METHODS: This  retrospective cohort study analyzed data from 83 patients with CS-related pain  and GAD who received EA treatment over 2-year period. Pain intensity was assessed  using the visual analog scale, and anxiety symptoms were measured using the  Hamilton Anxiety Rating Scale. Additionally, neuroinflammatory markers, including  interleukin-6, tumor necrosis factor-alpha, and high-sensitivity C-reactive  protein, were examined. Outcomes were evaluated at baseline, after 4 weeks, and  after 8 weeks of treatment. RESULTS: EA treatment significantly reduced  CS-related pain (mean visual analog scale reduction: 3.24 ± 1.18; P < 0.001) and  improved anxiety symptoms (mean Hamilton Anxiety Rating Scale reduction: 7.83 ±  2.65; P < 0.001) after 8 weeks of treatment. Neuroinflammatory markers also  showed significant reductions, with interleukin-6 and tumor necrosis factor-alpha  levels decreasing by 32.7% and 28.5%, respectively (P < 0.01). Pain reduction was  significantly correlated with improvements in anxiety symptoms (r = 0.68; P <  0.001) and a decrease in inflammatory markers (r = 0.54; P < 0.01). CONCLUSION:  EA demonstrates significant efficacy in reducing CS-related pain in patients with  comorbid GAD, along with concurrent improvements in anxiety symptoms and  neuroinflammatory profiles. These findings suggest that EA may offer a valuable  integrative approach for managing this complex clinical presentation, potentially  addressing both pain and anxiety through the modulation of neuroinflammatory  pathways.
C1 Department of Pain Disease Treatment, Zhengzhou Orthopaedic Hospital, Zhengzhou 450052, Henan Province, China.
   Department of Cervicolumbar, Zhengzhou Orthopaedic Hospital, Zhengzhou 450052, Henan Province, China.
   Department of Cervicolumbar, Zhengzhou Orthopaedic Hospital, Zhengzhou 450052, Henan Province, China.
   Department of Acupuncture and Moxibustion, University of Health and Rehabilitation Sciences, Qingdao 266042, Shandong Province, China.walgzzh@126.com.
NR 0
TC 0
SN 2220-320
EI 2220-320
J9 World J Psychiatry
PD NOV 24
PY 2025
VL 15
IS 11
BP 108288
EP 108288
DI 10.5498/wjp.v15.i11.108288
PG 0
UT PubMed:41281520
PM 41281520
DA 2025-11-24
ER

PT J
AU Giambrone, G
   Catone, G
   Marino, G
   Sfacteria, A
   Miloro, R
   Vullo, C
AF Giambrone, Giada
   Catone, Giuseppe
   Marino, Gabriele
   Sfacteria, Alessandra
   Miloro, Renato
   Vullo, Cecilia
TI Perioperative Pain Management for Mastectomy in Dogs: A Narrative Review.
SO Animals : an open access journal from MDPI
LA English
DT Review
DE dog; mastectomy; pain management
AB Mammary tumours are the most common neoplasia in adult female dogs. Mastectomy  leads to moderate to severe pain. Effective pain management is crucial in  veterinary medicine. This review outlines analgesic techniques for managing  perioperative pain in dogs undergoing mastectomy. A literature search on dog  mastectomy analgesia was conducted from January 2001 to January 2025. Pre-emptive  meloxicam reduces postoperative cardiovascular changes without affecting renal  function. When combined with gabapentin, it lowers the need for rescue analgesic  opioids, similar to robenacoxib. With regard to tramadol, it offers contrasting  analgesia in the studies considered when used alone, while its effect appears  enhanced when used in combination with meloxicam/dipyrone. However, methadone  provides superior pain control, especially when given preoperatively or  intraoperatively. The combination of ketamine, lidocaine, and maropitant enhances  pain management, while fentanyl, alone or with lidocaine and ketamine, is  effective for intraoperative pain control. Local infiltration with  lidocaine/bupivacaine provides effective pain control, and devices like  Comfont-in(®) or WSC facilitate this process. Tumescent anaesthesia using  lidocaine/ropivacaine allows for extensive infiltration of the mammary gland.  Epidural analgesia, paravertebral blocks, and TAP blocks are beneficial in  multimodal protocols. Transdermal patches containing fentanyl/buprenorphine offer  prolonged analgesia, while electroacupuncture can help reduce the need for rescue  analgesics. Multimodal analgesic protocols are crucial for effective pain  management in dog mastectomy surgeries, minimising the need for rescue opioids.
C1 Department of Veterinary Sciences, University of Messina, Via G. Palatucci, 98168 Messina, Italy.
   Department of Veterinary Sciences, University of Messina, Via G. Palatucci, 98168 Messina, Italy.
   Department of Veterinary Sciences, University of Messina, Via G. Palatucci, 98168 Messina, Italy.
   Department of Veterinary Sciences, University of Messina, Via G. Palatucci, 98168 Messina, Italy.
   Department of Veterinary Sciences, University of Messina, Via G. Palatucci, 98168 Messina, Italy.
   Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina,Italy.
NR 0
TC 0
SN 2076-261
EI 2076-261
J9 Animals (Basel)
PD MAY 14
PY 2025
VL 15
IS 9
BP 
EP 
DI 10.3390/ani15091214
PG 0
UT PubMed:40362030
PM 40362030
DA 2025-05-14
ER

PT J
AU Benameur, E
   Olsen, A
   Rosthoj, S
   Tjonneland, A
   Bidstrup, PE
   Kyro, C
AF Benameur, Elias
   Olsen, Anja
   Rosthoj, Susanne
   Tjonneland, Anne
   Bidstrup, Pernille E.
   Kyro, Cecilie
TI Use of complementary and alternative medicine in Denmark among women with and without breast cancer: a cross-sectional study
SO SCANDINAVIAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article; Early Access
DE Complementary medicine; alternative medicine; cross-sectional study; breast cancer; health determinants; quality of life
ID health-related quality; of-life; chemotherapy; diagnosis; therapy; anxiety; impact; pain
AB Aims: The study aim was to describe the use of complementary and alternative medicine (CAM) among women with breast cancer and without breast cancer in Denmark. Furthermore, the aim was to investigate whether use was related to lifestyle factors, socioeconomic factors, comorbidities, and health-related quality of life (HRQoL).Methods: A cross-sectional design was applied, and data from 1452 women aged 63-82 years collected in 2010-2011 from the Danish Diet, Cancer, and Health cohort was used. Some 717 of the women had breast cancer and 735 were without breast cancer. Multivariable logistic regression was applied with CAM use as the outcome variable and lifestyle factors, socioeconomic factors, comorbidities, and HRQoL as explanatory variables. Adjustments were made for potential confounders.Results: CAM was used by 34.3% (95% CI [30.1, 37.7]) of the women without breast cancer and 38.6% (95% CI [35.1, 42.2]) of the women with breast cancer. The most frequently used CAMs were massage, acupuncture/acupressure, relaxation techniques, reflexology, medicinal tea, herbs and plant extracts, and most CAM users used a single modality. CAM users were more likely to be younger, divorced, and less likely to smoke. Breast cancer status, body mass index, alcohol use, and comorbidity status were not significantly associated with CAM use. CAM users had lower means across all HRQoL dimensions compared to non-users.Conclusions: CAM use is common among Danish women, with no significant difference found when comparing women with and without breast cancer. CAM users seemingly had lower HRQoL, and were more likely to be younger, divorced, and less likely to smoke.
C1 [Benameur, Elias; Olsen, Anja; Rosthoj, Susanne; Tjonneland, Anne; Bidstrup, Pernille E.; Kyro, Cecilie] Danish Canc Inst, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Olsen, Anja] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark.
   [Tjonneland, Anne] Univ Copenhagen, Fac Hlth & Med Sci, Dept Publ Hlth, Copenhagen, Denmark.
C3 Aarhus University; University of Copenhagen
RP Kyro, C (corresponding author), Danish Canc Inst, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
EM Ceciliek@cancer.dk
FU National Budget of Denmark 2018 (Finansloven 2018); Danish Cancer Institute
CR Unknown -, 2021, COMPLEMENTARY, V0, P0
   Arvidsson G, 2024, NORDCAN: CANCER INCIDENCE, V0, P0
   Ballatori E, 2007, SUPPORT CARE CANCER, V15, P179, DOI 10.1007/s00520-006-0109-7
   Belloni S, 2023, CLIN THER, V45, PE54, DOI 10.1016/j.clinthera.2022.12.001
   Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023
   Boström B, 2003, J CLIN NURS, V12, P726, DOI 10.1046/j.1365-2702.2003.00777.x
   Cheung DST, 2023, WORLDVIEWS EVID BASED NURS, V20, P0
   Commar A, 2018, WHO GLOBAL REPORT ON TRENDS IN PREVALENCE OF TOBACCO SMOKING 2000-2025, V0, P0
   Demark-Wahnefried W, 2005, J CLIN ONCOL, V23, P5814, DOI 10.1200/JCO.2005.01.230
   Deng C, 2022, CLIN BREAST CANCER, V22, P115, DOI 10.1016/j.clbc.2021.05.006
   Fortner BV, 2002, J PAIN SYMPTOM MANAG, V24, P471, DOI 10.1016/S0885-3924(02)00500-6
   Fosså SD, 2002, J PSYCHOSOM RES, V52, P79, DOI 10.1016/S0022-3999(01)00308-7
   Fox P, 2013, EUR J ONCOL NURS, V17, P490, DOI 10.1016/j.ejon.2012.10.008
   Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562
   Goldrosen MH, 2004, NAT REV IMMUNOL, V4, P912, DOI 10.1038/nri1486
   Hanssen B, 2005, SCAND J PRIM HEALTH, V23, P57, DOI 10.1080/02813430510018419
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Johnson SB, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx145
   Jung AY, 2019, AM J CLIN NUTR, V109, P69, DOI 10.1093/ajcn/nqy223
   Karlsen RV, 2016, ACTA ONCOL, V55, P720, DOI 10.3109/0284186X.2015.1127415
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869
   Kraeftens Bekaempelse [Danish Cancer Society], 2023, THE NEEDS AND EXPERIENCES OF CANCER PATIENTS WITH THE HEALTHCARE SYSTEM IN FOLLOW-UP AND AFTERCARE, V0, P0
   Kraeftens Bekaempelses [Danish Cancer Society], 2019, BAROMETER SURVEY, V0, P0
   Kraeftens Bekaempelses [Danish Cancer Society], 2017, BAROMETER SURVEY, V0, P0
   Kremser T, 2008, BREAST, V17, P387, DOI 10.1016/j.breast.2007.12.006
   Kuo YH, 2018, J ALTERN COMPLEMENT MED, V24, P0
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Lovelace DL, 2019, J MIDWIFERY WOM HEAL, V64, P713, DOI 10.1111/jmwh.13012
   Luo QL, 2017, INTEGR CANCER THER, V16, P104, DOI 10.1177/1534735416643384
   Micke O, 2009, EUR J INTEGR MED, V1, P19, DOI 10.1016/j.eujim.2009.02.001
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Moller SR, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-023-04327-8
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Nissen N, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-388
   Ong CK, 2002, AM J PUBLIC HEALTH, V92, P1653, DOI 10.2105/AJPH.92.10.1653
   Pedersen C G, 2009, EUR J CANCER, V45, P0
   Salamonsen A, 2012, QUAL HEALTH RES, V22, P1497, DOI 10.1177/1049732312457077
   Shan SN, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07926-w
   Shmueli A, 2007, EVID BASED COMPLEMENT ALTERNAT MED, V4, P0
   Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003
   Stöcker A, 2023, PLOS ONE, V18, P0, DOI 10.1371/journal.pone.0285718
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   Ware JE, 2007, USERS MANUAL SF 36V2, V2nd, P0
   Wolf C, 2022, J CANCER RES CLIN ONCOL, V148, P0
NR 47
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1403-4948
EI 1651-1905
J9 SCAND J PUBLIC HEALT
JI Scand. J. Public Health
PD AUG 20
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/14034948251363843
EA AUG 2025
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 6IP7E
UT WOS:001554242200001
PM 40836388
DA 2026-01-16
ER

PT J
AU Liu, ZC
   Qiao, F
   Liu, DJ
   Kong, XZ
   Liu, KW
   Gu, HW
   Zhang, YQ
   Meng, QB
   Cheng, L
AF Liu, Zhenchuan
   Qiao, Fei
   Liu, Dejian
   Kong, Xiangzhen
   Liu, Kaiwen
   Gu, Hanwen
   Zhang, Yuanqiang
   Meng, Qunbo
   Cheng, Lei
TI Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD
SO PHYTOMEDICINE
LA English
DT Article
DE Intervertebral disc degeneration; Periplocin; TNF-alpha; inflammation; LRP4; Molecular docking
ID intervertebral disc degeneration; low-back-pain; kappa-b; alpha
AB Background: Intervertebral disc degeneration (IVDD) is characterized by deteriorating intervertebral discs, leading primarily to low back pain and leg pain. Most current treatments for IVDD primarily address symptoms without targeting the underlying degenerative process. Moreover, tumor necrosis factor-alpha (TNF-alpha)-mediated inflammation and degradation of the nucleus pulposus (NP) extracellular matrix (ECM) influence this pathological process. Periplocin, a cardiotonic steroid extracted from periplocin forrestii, has demonstrated a wide range of medical benefits, including cardiotonic, anticancer, anti-inflammatory, and wound healing properties. Nevertheless, the effects of periplocin on IVDD remain unexplored. Objective: Our study explores the mechanism of action and the potential target of periplocin in mitigating IVDD pathology. Methods: Rat models of IVDD were established using acupuncture, and the affected discs underwent analysis via Safranin O-Fast Green (S-O) and Hematoxylin and Eosin (H&E) staining. Nucleus pulposus cells (NPCs) were harvested from IVDD patients and experimental animals for examination. A variety of techniques, including Western blot analysis, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) assay, immunofluorescence staining, Alcian Blue staining and Immunohistochemistry (IHC) staining, were utilized to evaluate inflammationrelated proteins, mRNAs and the ECM metabolism. In order to ascertain the potential protein targets of periplocin, the binding site of periplocin to LRP4 was elucidated through the utilisation of molecular docking experiments. Subsequently, the expression of low-density lipoprotein receptor-related protein 4 (LRP4) in NPCs was modified through the use of small interfering RNA (siRNA) knockdown and overexpression vectors, which were employed for the purposes of target validation. Results: We conclude from the present study that periplocin alleviates the progression of IVDD mainly through the following aspects: periplocin inhibits TNF-alpha-induced inflammatory; periplocin reduces matrix degradation; periplocin promotes matrix anabolism and regulates metabolic homeostasis. Moreover, the present study demonstrates that LRP4 is involved as a potential target in the multiple pathways mentioned above to protect the intervertebral disc. Conclusion: Our research suggests that periplocin may serve as a promising treatment for IVDD, offering antiinflammatory benefits, preventing ECM degradation, and promoting ECM anabolism.
C1 [Liu, Zhenchuan; Qiao, Fei; Liu, Dejian; Kong, Xiangzhen; Liu, Kaiwen; Gu, Hanwen; Zhang, Yuanqiang; Meng, Qunbo; Cheng, Lei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Orthoped Surg, Jinan 250012, Shandong, Peoples R China.
   [Qiao, Fei] Dalian Women & Childrens Med Ctr Grp, Dept Pediat Orthoped, Dalian 116012, Liaoning, Peoples R China.
C3 Shandong University
RP Zhang, YQ; Meng, QB; Cheng, L (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Orthoped Surg, Jinan 250012, Shandong, Peoples R China.
EM drzhyq@126.com; mengqunbo@126.com; chenglei@email.sdu.edu.cn
FU National Natural Science Foundation of China [82272548]; Natural Science Foundation of Shandong Province, China [ZR2023MH194]
CR Asai N, 2014, BIOCHEM BIOPH RES CO, V451, P302, DOI 10.1016/j.bbrc.2014.07.125
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Chai Q, 2023, CARTILAGE, V14, P506, DOI 10.1177/19476035231157341
   Chang HY, 2021, CELL DEATH DIS, V12, P0, DOI 10.1038/s41419-021-03990-4
   Chen JX, 2023, ADV SCI, V10, P0, DOI 10.1002/advs.202206306
   Chen L, 2021, J ETHNOPHARMACOL, V271, P0, DOI 10.1016/j.jep.2021.113892
   Duan L, 2015, AM J TRANSL RES, V7, P194
   Fijalkowski I, 2016, J BONE MINER RES, V31, P874, DOI 10.1002/jbmr.2782
   Francisco V, 2022, NAT REV RHEUMATOL, V18, P47, DOI 10.1038/s41584-021-00713-z
   Gawri R, 2014, ARTHRITIS RES THER, V16, P0, DOI 10.1186/ar4449
   Han B, 2008, SPINE, V33, P1925, DOI 10.1097/BRS.0b013e31817c64a9
   Hao JM, 2023, J CARDIOVASC TRANSL, V16, P127, DOI 10.1007/s12265-022-10277-2
   Hayashi S, 2008, SPINE, V33, P1542, DOI 10.1097/BRS.0b013e318178e5ea
   He ZL, 2018, BIOCHEM BIOPH RES CO, V506, P94, DOI 10.1016/j.bbrc.2018.10.069
   Jha R, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12216907
   Jiang XJ, 2020, J EXP CLIN CANC RES, V39, P0, DOI 10.1186/s13046-020-01709-5
   Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9
   Koneczny I, 2019, CELLS-BASEL, V8, P0, DOI 10.3390/cells8070671
   Lara-Castillo N, 2015, REV ENDOCR METAB DIS, V16, P141, DOI 10.1007/s11154-015-9315-2
   Lin RG, 2019, CELL MOL BIOL LETT, V24, P0, DOI 10.1186/s11658-019-0167-8
   Liu KW, 2021, FRONT CELL DEV BIOL, V9, P0, DOI 10.3389/fcell.2021.687024
   Ma HW, 2022, CELL DEATH DISCOV, V8, P0, DOI 10.1038/s41420-022-01002-8
   Molinos M, 2015, J R SOC INTERFACE, V12, P0, DOI 10.1098/rsif.2014.1191
   Molladavoodi S, 2020, CELL TISSUE RES, V379, P429, DOI 10.1007/s00441-019-03136-1
   Ni WY, 2020, FRONT CELL DEV BIOL, V8, P0, DOI 10.3389/fcell.2020.579658
   Ogata N, 2000, CARDIOVASC RES, V45, P513, DOI 10.1016/S0008-6363(99)00364-8
   Qiu XJ, 2022, INT J BIOL SCI, V18, P2202, DOI 10.7150/ijbs.65973
   Rim Dae Cheol, 2016, KOREAN J SPINE, V13, P1, DOI 10.14245/kjs.2016.13.1.1
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Séguin CA, 2005, SPINE, V30, P1940, DOI 10.1097/01.brs.0000176188.40263.f9
   Shang P, 2020, J CELL MOL MED, V24, P3701, DOI 10.1111/jcmm.15074
   Shao Z, 2021, OSTEOARTHR CARTILAGE, V29, P413, DOI 10.1016/j.joca.2020.11.006
   Sun J, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms241813695
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Vo NV, 2013, SPINE J, V13, P331, DOI 10.1016/j.spinee.2012.02.027
   Vos T, 2013, LANCET, V381, P628
   Wallwork SB, 2024, CAN MED ASSOC J, V196, PE29, DOI 10.1503/cmaj.230542
   Wang KD, 2022, ANN RHEUM DIS, V81, P544, DOI 10.1136/annrheumdis-2021-221380
   Zhang GZ, 2021, CELL PROLIFERAT, V54, P0, DOI 10.1111/cpr.13057
   Zhang P, 2023, BIOMED PHARMACOTHER, V165, P0, DOI 10.1016/j.biopha.2023.115252
   Zhang XD, 2023, BIOCHEM PHARMACOL, V211, P0, DOI 10.1016/j.bcp.2023.115516
   Zhang Y, 2008, INT J BIOL SCI, V4, P283
   Zhao YP, 2020, THERANOSTICS, V10, P7015, DOI 10.7150/thno.45359
   Zhou MH, 2024, JOR SPINE, V7, P0, DOI 10.1002/jsp2.1289
NR 44
TC 3
Z9 3
U1 9
U2 11
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL 25
PY 2025
VL 143
IS 
BP 
EP 
DI 10.1016/j.phymed.2025.156885
EA MAY 2025
PG 15
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 3IK7W
UT WOS:001501105100002
PM 40440911
DA 2026-01-16
ER

PT J
AU Ji, L
   Han, L
   Sharma, A
AF Ji, Lei
   Han, Lin
   Sharma, Aabha
TI Efficacy of acupuncture in managing radiotherapy/chemotherapy-induced oral
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Cancer; Chemotherapy; Meta-analysis; Oral mucositis; Radiotherapy
AB PURPOSE: To evaluate the preventive and therapeutic efficacy of acupuncture  modalities in radiation/chemotherapy-induced oral mucositis (RIOM/CIOM)  management through evidence synthesis. METHODS: A systematic search was performed  in eight biomedical databases: four English-language databases (PubMed, Embase,  Web of Science, and Cochrane Library) and four Chinese-language databases (China  National Knowledge Infrastructure (CNKI), Wanfang, VIP, and SinoMed) for studies  published up to July 25, 2025. Randomized controlled trials (RCTs) in English or  Chinese investigating acupuncture for RIOM/CIOM were included. Dual independent  extraction with standardized forms and quality appraisal using the Cochrane RoB  2.0 tool were implemented. The primary outcome was OM grading according to WHO,  RTOG, or other recognized scales. The evidence quality was assessed using the  Grading of Recommendations Assessment, Development, and Evaluation (GRADE)  methodology. RESULTS: Eleven RCTs (n = 865) were included. Acupuncture  significantly reduced moderate-to-severe OM incidence [RR = 0.58, 95%  CI:0.45-0.76; P < 0.0001), with therapeutic interventions showing greater  efficacy than preventive approaches (P < 0.0001). Auricular acupuncture showed  substantial benefit (RR = 0.54 vs manual technique RR = 0.97). Other outcomes  revealed significant ulcer duration reduction (SMD = -1.13, 95% CI -1.71-[-0.55];  P = 0.0001), pain score improvement (SMD = -1.89, P = 0.0005), and enhanced  immune modulation (TGF-β1/IL-6 levels) with Karnofsky performance increase  (MD = 5.83, P = 0.004). No severe adverse events were reported. The quality of  evidence was rated as moderate due to significant heterogeneity observed across  the studies. CONCLUSIONS: The systematic review and meta-analysis found that  acupuncture was effectively associated with preventing and treating RIOM/CIOM,  shortening ulcer duration, reducing ulcer size, alleviating pain, and improving  quality of life, although the evidence level was moderate. The finding suggests  that more high-quality RCTs were needed for validation.
C1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. tjhanlin@163.com.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin, China.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD SEP 24
PY 2025
VL 33
IS 10
BP 873
EP 873
DI 10.1007/s00520-025-09931-7
PG 0
WC Humans; Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; Neoplasms; radiotherapy; Radiation Injuries; therapy; Randomized Controlled Trials as Topic; Stomatitis; therapy
UT PubMed:40987848
PM 40987848
DA 2025-09-24
ER

PT J
AU Segev, Y
   Abofol, S
   Samuels, N
   Schmidt, M
   Assaf, W
   Ben-Arye, E
AF Segev, Yakir
   Abofol, Sereen
   Samuels, Noah
   Schmidt, Meirav
   Assaf, Wisam
   Ben-Arye, Eran
TI Postoperative pain following intraoperative acupuncture: a randomized‑controlled
SO BMJ supportive & palliative care
LA English
DT Journal Article
DE Integrative Oncology; Pain; Supportive care
AB CONTEXT AND OBJECTIVES: This study examined the impact of an integrative oncology  intervention on postoperative care, primarily postoperative pain, in patients  undergoing gynaecological oncology surgery. METHODS: Participants were randomised  to three groups: group A, preoperative touch/relaxation modalities, followed by  intraoperative acupuncture; group B, preoperative touch/relaxation only and group  C, standard conventional care alone. Using an enhanced recovery after surgery  (ERAS) protocol, medical personnel retrospectively assessed pain on each  postoperative day (POD), using a Visual Analogue Scale (VAS; 0, no pain; 10, most  severe pain). Use of analgesics, bowel movements, urination and number of days  until discharge were also assessed. RESULTS: A total of 102 patients  participated, with similar baseline demographic and surgery-related  characteristics among the three groups (group A, 45; group B, 25 and group C,  32). Group A patients undergoing laparoscopic surgery reported significantly  lower pain scores on POD1 than group C (p=0.018). Group B patients undergoing  open laparotomy were discharged earlier than group C (p=0.031). No significant  between-group differences were found for VAS pain scales, use of analgesics or  report of first postoperative bowel movement or urination. CONCLUSIONS: This  prospective, controlled and pragmatic ERAS-based study suggests that  intraoperative acupuncture may reduce postoperative pain on POD1, in patients  undergoing laparoscopic gynaecological oncology surgery. The findings differ from  a previous study which found no effect of acupuncture on pain-related  haemodynamic parameters during laparoscopy. Further research using objective  nociception parameters is needed to explore the effect of intraoperative  acupuncture on postoperative pain. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov  (NCT03560388).
C1 Division Of Gynecology Oncology at the obsterics and Gynecology department, carmel medical center, Haifa, Israel segevyakir@yahoo.com.
   Obstetrics and Gynecology Department, Carmel Medical Center, Haifa, Israel.
   Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
   Division Of Gynecology Oncology at the obsterics and Gynecology department, carmel medical center, Haifa, Israel.
   Division Of Gynecology Oncology at the obsterics and Gynecology department, carmel medical center, Haifa, Israel.
   LIN Medical Center, Haifa, Israel.
   Clalit Health Services, Tel Aviv-Yafo, Israel.
NR 0
TC 0
SN 2045-436
EI 
J9 BMJ Support Palliat Care
PD JUN 20
PY 2025
VL 15
IS 5
BP 642
EP 647
DI 10.1136/spcare-2025-005485
PG 5
WC Humans; Female; Pain, Postoperative; therapy; Middle Aged; Acupuncture Therapy; methods; Adult; Pain Measurement; Aged; Prospective Studies; Intraoperative Care; methods; Gynecologic Surgical Procedures; adverse effects
UT PubMed:40537176
PM 40537176
DA 2025-06-20
ER

PT J
AU Ben-Arye, E
   Biron-Shental, T
   Rosa, WE
   Samuels, N
   Levy, O
   Keshet, Y
   Armon, S
   Gressel, O
   Kedar, R
   Messinger, A
   Ari, RL
   Lavie, A
   Atzil, N
   Ben Zohar, B
   Sokolovski, CF
   Solt, I
   Yaffe, H
   Maor, GS
   Levy, M
   Maor-Sagie, E
   Shtern, DK
   Stoffman, G
   Ben Ze'ev, R
   Sher, ML
   Zidenberg, B
   Sagi, S
   Schiff, E
AF Ben-Arye, Eran
   Biron-Shental, Tal
   Rosa, William E.
   Samuels, Noah
   Levy, Oz
   Keshet, Yael
   Armon, Shunit
   Gressel, Orit
   Kedar, Reuven
   Messinger, Aviv
   Ari, Revital Lev
   Lavie, Anat
   Atzil, Neta
   Ben Zohar, Bosmat
   Sokolovski, Cara Ferrer
   Solt, Ido
   Yaffe, Hila
   Maor, Gil Shechter
   Levy, Moti
   Maor-Sagie, Esther
   Shtern, Danit Katz
   Stoffman, Gali
   Ben Ze'ev, Reut
   Sher, Maayan Lahav
   Zidenberg, Betty
   Sagi, Shlomi
   Schiff, Elad
TI Acupuncture in <bold>obstetrics</bold>: <bold>delivery room integrative medicine for anxiety and pain</bold>
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article
DE Integrative Medicine; Complementary therapy
ID alternative medicine; complementary; pregnancy; period; women
AB Objectives Supportive and palliative care include non-oncology settings where patients suffer from pain and quality of life-related concerns. Integrative medicine plays important roles in supportive care and symptom management, including Integrative Obstetric (IOb) programmes within peri-partum settings. Multidisciplinary approaches may help nurse-midwives and obstetricians improve patient care and associated outcomes. This study presents a national perspective on IOb programmes in Israel.Methods A qualitative research methodology was codesigned by the Society for Complementary Medicine and Society of Maternal-Fetal Medicine, Israel Medical Association. A questionnaire with 17 open-ended questions was distributed throughout obstetrics and gynaecology departments across Israel. Respondent narratives were qualitatively analysed using ATLAS.Ti software for systematic coding.Results 22 senior obstetricians and IOb directors across 11 centres with IOb programmes completed the questionnaire. Core themes considered essential for the design and operation of IOb programmes included (1) determining major goals and indications for referral, primarily pain and anxiety; (2) targeting patients most likely to benefit; (3) identifying barriers and enablers to implementation and communication with the obstetric team; (4) designing the referral process and (5) documenting outcomes and safety of the IOb intervention in electronic medical files.Conclusions Designing and implementing IOb models of care that effectively support holistic symptom management within obstetric settings requires identifying barriers and enablers and establishing effective communication between obstetric and integrative medical teams. Further research should explore other multidisciplinary models of IOb care and structured referral development and testing while assessing risks and effectiveness.
C1 [Ben-Arye, Eran] LIN Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Biron-Shental, Tal; Maor, Gil Shechter] Meir Med Ctr, Kefar Sava, Israel.
   [Rosa, William E.] Mem Sloan Kettering Canc Ctr, Psychiat & Behav Sci, New York, NY USA.
   [Samuels, Noah] Shaare Zedek Med Ctr, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Levy, Oz; Armon, Shunit] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Keshet, Yael] Western Galilee Coll, Akko, Israel.
   [Gressel, Orit] Carmel Hosp, Integrat Obstet Program, Haifa, Israel.
   [Kedar, Reuven; Sher, Maayan Lahav] Carmel Hosp, Haifa, Israel.
   [Messinger, Aviv] Sheba Med Ctr, Tel Hashomer, Israel.
   [Ari, Revital Lev; Lavie, Anat] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
   [Atzil, Neta; Ben Zohar, Bosmat] Hadassah Mt Scopus Univ Hosp, Jerusalem, Israel.
   [Sokolovski, Cara Ferrer; Solt, Ido] Rambam Hlth Care Campus, Haifa, Israel.
   [Yaffe, Hila] Hadassah Univ, Div Obstet & Gynecol, Med Ctr, Jerusalem, Israel.
   [Levy, Moti] Clalit Hlth Serv, Tel Aviv, Israel.
   [Maor-Sagie, Esther; Shtern, Danit Katz] Hillel Yaffe Med Ctr, Hadera, Israel.
   [Stoffman, Gali] Barzilai Univ, Med Ctr, Ashqelon, Israel.
   [Ben Ze'ev, Reut] Barzilai Govt Hosp, Ashqelon, Israel.
   [Zidenberg, Betty; Sagi, Shlomi] Bnai Zion Med Ctr, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
C3 Clalit Health Services; Tel Aviv University; Sackler Faculty of Medicine; Memorial Sloan Kettering Cancer Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Western Galilee Academic College; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Hebrew University of Jerusalem; Hadassah University Hospital; Rambam Health Care Campus; Hebrew University of Jerusalem; Hadassah University Medical Center; Clalit Health Services; Ben-Gurion University of the Negev; Barzilai Medical Center; Ben-Gurion University of the Negev; Barzilai Medical Center; Bnai Zion Medical Center; Bnai Zion Medical Center
RP Ben-Arye, E (corresponding author), LIN Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
EM eranben@netvision.net.il; Tal.Biron-Shental@clalit.org.il; rosaw@mskcc.org; noahs@szmc.org.il; ozlevy@szmc.org.il; yaelk@wgalil.ac.il; shunita@szmc.org.il; oritgresselraz@gmail.com; Reuven.kedar@gmail.com; aviv@briat.co.il; revlev@gmail.com; anatlavier@gmail.com; Neta.atzil@gmail.com; Bosmatbosmat100@gmail.com; CARA.TCM@GMAIL.COM; Ido.solt@gmail.com; yaffehila@gmail.com; gilshec@gmail.com; motil@clalit.org.il; estimaorsagie@gmail.com; Danit.k.s11@gmail.com; gali@pandaclinic.co.il; reutb@bmc.gov.il; maayanlahavsher@gmail.com; Betty.ziden@gmail.com; Mdsagi.s@gmail.com; elad.schiff@b-zion.org.il
FU Department of Obstetrics and Gynecology, Sheba Medical Center
CR Abadi F, 2017, J ACUPUNCT MERIDIAN, V10, P114, DOI 10.1016/j.jams.2016.11.008
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Birdee GS, 2014, J WOMENS HEALTH, V23, P824, DOI 10.1089/jwh.2013.4568
   Carr DJ, 2015, ACUPUNCT MED, V33, P413, DOI 10.1136/acupmed-2015-010936
   Emiru Yohannes Kelifa, 2021, INT J REPROD MED, V2021, P8829313, DOI 10.1155/2021/8829313
   Fok D, 2016, BIRTH-ISS PERINAT C, V43, P247, DOI 10.1111/birt.12233
   Jodie F, 2025, J PAIN SYMPTOM MANAG, V69, P102, DOI 10.1016/j.jpainsymman.2024.07.024
   Johnson PJ, 2016, WOMEN HEALTH ISS, V26, P40, DOI 10.1016/j.whi.2015.08.009
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Lokugamage AU, 2020, J OBSTET GYNAECOL, V40, P1096, DOI 10.1080/01443615.2019.1694878
   Madden K, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009356.pub2
   Marc I, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007559.pub2
   Michel J, 2007, J ETHNOPHARMACOL, V114, P92, DOI 10.1016/j.jep.2007.07.033
   Mollart LJ, 2015, WOMEN BIRTH, V28, P199, DOI 10.1016/j.wombi.2015.03.007
   Pallivalapila AR, 2015, OBSTET GYNECOL, V125, P204, DOI 10.1097/AOG.0000000000000596
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI 10.1177/10775587221118156
   Schürger N, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2249-y
   Schytt E, 2011, ACTA OBSTET GYN SCAN, V90, P77, DOI 10.1111/j.1600-0412.2010.01027.x
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Skouteris H, 2008, AUST NZ J OBSTET GYN, V48, P384, DOI 10.1111/j.1479-828X.2008.00865.x
   Smith C, 2002, COMPLEMENT THER MED, V10, P78, DOI 10.1054/ctim.2002.0523
   Smith CA, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009232.pub2
   Smith CA, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009290.pub2
   Smith CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009514
   Tan MY, 2023, FRONT PUBLIC HEALTH, V11, P0, DOI 10.3389/fpubh.2023.1108756
   Usichenko TI, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.0517
   Zamawe C, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2018-022499
   Zeng YC, 2014, COMPLEMENT THER MED, V22, P1047, DOI 10.1016/j.ctim.2014.10.009
   Zhang N H, 1988, MIDWIVES CHRON, V101, P100
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/7341920
   Zimpel SA, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011216.pub2
NR 32
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD JUL 15
PY 2025
VL 15
IS 4
BP 535
EP 541
DI 10.1136/spcare-2025-005512
EA APR 2025
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 4PS8Q
UT WOS:001468809800001
PM 40240122
DA 2026-01-16
ER

PT J
AU Zhang, Y
   Wu, B
   Qin, P
   Cheng, Y
   Chen, Y
AF Zhang, Yuxing
   Wu, Bangqi
   Qin, Peng
   Cheng, Yupei
   Chen, Yuyan
TI Alternative therapies in chronic non-cancer pain management: A scoping review of
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Chronic non-cancer pain; Complementary therapies; Pain management; Personalized treatment. Non-pharmacological therapy; Scoping review
AB BACKGROUND: Chronic pain is one of the most challenging health problems in modern  society, placing significant burdens on individuals and healthcare systems. While  pharmacological treatments remain the primary approach to pain management, their  limitations often restrict choices for both clinicians and patients. In contrast,  complementary therapies are gaining recognition for their potential effectiveness  and safety. However, the current literature lacks a comprehensive summary of the  role of complementary therapies in chronic pain management. OBJECTIVE: This  review aims to summarize the complementary therapies used in chronic non-cancer  pain management, assess their practical applications, identify research gaps and  limitations, and provide a comprehensive perspective for the development of  chronic non-cancer pain management and personalized pain management strategies.  METHODS: This scoping review followed the PRISMA-ScR guidelines. Randomized  controlled trials (RCTs) published in the last decade were retrieved from PubMed  and Web of Science using the keywords "chronic pain" and "complementary therapy."  Non-English studies were excluded. RESULTS: A total of 848 RCTs were identified,  of which 128 met the inclusion criteria. The included studies addressed chronic  musculoskeletal pain (102 studies), chronic visceral pain (5 studies), chronic  neuropathic pain (7 studies), and 13 studies that did not specify the pain type.  The complementary therapies investigated included acupuncture, manual therapy,  exercise therapy, psychological interventions, mind-body therapies, and physical  modalities. CONCLUSION: This review provides preliminary evidence supporting the  efficacy and safety of complementary therapies in the management of chronic  non-cancer pain. However, methodological and quality-related limitations were  identified in the included studies. Future high-quality RCTs are needed to  validate the long-term efficacy of these therapies, explore their mechanisms of  action, and provide stronger evidence for their clinical application.  REGISTRATION: This scoping review is registered on the Open Science Framework  (OSF) under the following DOI: https://doi.org/10.17605/OSF.IO/67K32.
C1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, Tianjin 300381, China
   Tianjin University of Traditional ChineseMedicine, Tianjin 301617, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, Tianjin 300381, China. 
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, Tianjin 300381, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, Tianjin 300381, China
   Tianjin University of Traditional ChineseMedicine, Tianjin 301617, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, Tianjin 300381, China
   Tianjin University of Traditional ChineseMedicine, Tianjin 301617, China.
EM wbqwbq1980@outlook.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAR 14
PY 2025
VL 90
IS 
BP 103154
EP 103154
DI 10.1016/j.ctim.2025.103154
PG 0
WC Humans; Chronic Pain; therapy; Complementary Therapies; methods; Randomized Controlled Trials as Topic; Pain Management; methods
UT PubMed:40081508
PM 40081508
DA 2025-03-14
ER

PT J
AU Booher, AG
   Rico, C
   Nouvini, R
   Killoran, K
   Drullinsky, P
   Maxwell, S
   Li, S
   Jutagir, D
   McConnell, K
   Godfrey, H
   Cadwell, M
   Casaw, C
   Rosa, WE
   Muñiz, RC
   Liou, KT
AF Booher, Allison G
   Rico, Charles
   Nouvini, Rosa
   Killoran, Kathleen
   Drullinsky, Pamela
   Maxwell, Shaun
   Li, Susan
   Jutagir, Devika
   McConnell, Kelly
   Godfrey, Henry
   Cadwell, Malik
   Casaw, Camila
   Rosa, William E
   Muñiz, Rosario Costas
   Liou, Kevin T
TI Program Evaluation of Acupuncture and Massage Services Delivered for Symptom
SO JCO oncology practice
LA English
DT Journal Article
AB PURPOSE: High symptom burden disproportionately affects minoritized racial and  ethnic groups during cancer treatments and exacerbates health disparities related  to quality of life, treatment adherence, and overall survival. Acupuncture and  massage have a growing evidence base for cancer symptom management, as shown in  recent guidelines from ASCO and the Society for Integrative Oncology. However,  access remains limited in community-based, underserved settings. METHODS: We  conducted a program evaluation of integrative medicine services at a community  cancer clinic in East Harlem, New York. Auricular acupuncture and massage were  offered 1 day a week to patients with cancer in the chemoinfusion suites at no  additional cost. We collected demographics and clinical characteristics of  patient visits, as well as types of treatments delivered and reasons treatments  were not received. We assessed pain, fatigue, anxiety, and nausea immediately  pre- and post-treatment, as well as patient satisfaction. RESULTS: From 2022 to  2024, we offered acupuncture or massage at 635 patient visits, which were  predominantly non-White (82.4%), Hispanic (44.9%), Spanish-speaking (31.7%), and  Medicaid-insured (45.5%). Of these 635 patient visits, 396 (62.4%) received  acupuncture or massage. Of the 239 who did not receive treatment, the most common  reasons were lack of time (54.4%) and lack of interest (38.9%). Rates of  treatment receipt were higher among female, Hispanic, Spanish-speaking,  Medicare-insured, and chemotherapy patient visits (all P < .05). Patients  reported reductions in pain, fatigue, anxiety, and nausea immediately  post-treatment. More than 90% of treatment recipients reported satisfaction with  the program. CONCLUSION: This program reached a diverse, underserved population  with historically limited access to integrative therapies. The findings highlight  the barriers and facilitators to bringing acupuncture and massage services to  community-based oncology settings.
C1 Geisel School of Medicine at Dartmouth College, Hanover, NH.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Weill Cornell Medical College, New York, NY.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   Weill Cornell Medical College, New York, NY.
NR 0
TC 0
SN 2688-153
EI 2688-152
J9 JCO Oncol Pract
PD DEC 4
PY 2025
VL 0
IS 
BP OP2500321
EP OP2500321
DI 10.1200/OP-25-00321
PG 1
UT PubMed:41343752
PM 41343752
DA 2025-12-04
ER

PT J
AU Shrateh, ON
   Habib, A
   Ur, Rehman Shamsi H
   Kumar, KA
   Mousa, Omar BM
   Mansour, A
   Mohsen, M
   Hamad, AM
   Mair, M
   Sahota, B
AF Shrateh, Oadi N
   Habib, Ashna
   Ur Rehman Shamsi, Hammad
   Kumar, Kanwal Ashok
   Mousa Omar, Belal Mohammad
   Mansour, Ahmad
   Mohsen, Mahmoud
   Hamad, Ali M
   Mair, Manish
   Sahota, Bindy
TI Treatment options for radiation-induced xerostomia in patients with head and neck
SO The British journal of oral & maxillofacial surgery
LA English
DT Review
DE head and neck cancer; radiotherapy; salivary gland dysfunction; xerostomia
AB Radiation-induced xerostomia is a frequent and debilitating complication in  patients undergoing radiotherapy for head and neck cancer. This study aimed to  compare the effectiveness of available treatment modalities in preventing or  managing radiation-induced xerostomia and associated complications in head and  neck cancer patients. A detailed search of PubMed and Google Scholar was  conducted. Only randomised controlled trials (RCTs) involving  radiotherapy-treated head and neck cancer patients were included. The  interventions that were analysed encompassed pharmacological agents (for example,  pilocarpine, and amifostine), antioxidants, herbal formulations, acupuncture,  low-level laser therapy (LLLT), and regenerative approaches. Primary outcomes  included severity of xerostomia, rates of salivary flow, mucositis, oral pain,  dysphagia, and fatigue. Thirty-one randomised clinical trials met the inclusion  criteria. Pooled analysis showed no significant reduction in severity of  xerostomia at weeks 3, 4, or 6, or 6 months. Stimulated salivary flow did not  significantly improve (mean difference (MD): 0.22; p = 0.15), while unstimulated  salivary flow showed a significant benefit (MD: 0.13; 95% CI: 0.09 to 0.17;  p < 0.00001). A significant reduction in the severity of oral pain was also noted  (MD: -2.25; p < 0.0001). No significant differences were found for the incidence  or duration of mucositis, dysphagia, or fatigue. Considerable heterogeneity was  observed across the studies and no single intervention demonstrated consistent  efficacy in managing radiation-induced xerostomia. Some therapies have shown  promise in improving unstimulated salivary flow and reducing oral pain; however,  the overall evidence remains inconclusive. To address this persistent clinical  challenge, future trials should adopt standardised outcome measures, assess  combination therapies, and investigate novel regenerative strategies.
C1 Faculty of Medicine, Al-Quds University, Jerusalem, Palestine. 
   Dow University of Health Sciences, Karachi, Pakistan.
   Dow University of Health Sciences, Karachi, Pakistan.
   Dow University of Health Sciences, Karachi, Pakistan.
   Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
   Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
   Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
   Basildon University Hospital, Basildon, United Kingdom.
   University Hospitals of Leicester, Leicester, United Kingdom.
   University Hospitals of Leicester, Leicester, United Kingdom
   University of Leicester, Leicester, United Kingdom
   University of Derby, Derby, United Kingdom.
EM oadi.nawaf97@gmail.com
NR 0
TC 0
SN 1532-194
EI 
J9 Br J Oral Maxillofac Surg
PD NOV 19
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1016/j.bjoms.2025.10.003
PG 0
UT PubMed:41253620
PM 41253620
DA 2025-11-19
ER

PT J
AU Yan, S
   Yan, F
   Liangyu, P
   Fei, X
AF Yan, Shen
   Yan, Feng
   Liangyu, Pei
   Fei, Xu
TI Assessment of non-pharmacological nursing strategies for pain management in tumor
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Journal Article
DE acupressure; acupuncture; aromatherapy; cancer-related pain; massage; reflexology
AB SUMMARY BACKGROUND: Cancer is a multifactorial disease associated with intense  pain and fatigue. Pain is the main discomfort experienced during cancer  treatment, particularly as a major side effect of chemotherapy. OBJECTIVE: This  study has aimed to investigate the effectiveness of non-pharmacological nursing  strategies, including reflexology, aromatherapy, acupressure, massage therapy and  acupuncture, in the management of cancer-associated pain. Moreover, it provides  evidence-based recommendations for integrating these interventions into standard  pain management protocols. SEARCH METHODOLOGY: We gathered data from three major  online databases; PubMed, the Cochrane Library and Embase. For the analysis, we  exclusively targeted randomized controlled trials (RCTs) assessing the  effectiveness of non-pharmacological interventions in managing cancer-related  pain. No language restrictions were applied, and pain was considered the primary  outcome measure. RESULTS: Seventeen RCTs (n = 1,070) were included in this  meta-analysis from 166 eligible studies. The pooled effect size demonstrated that  all evaluated non-pharmacological nursing strategies, including aromatherapy,  massage, reflexology, acupressure and acupuncture significantly reduced  cancer-related pain compared to usual care (p < 0.001). Moreover, the reflexology  and massage showed negligible heterogeneity among other interventions.  CONCLUSION: This meta-analysis found the significant effectiveness of  non-pharmacological nursing strategies, particularly reflexology and massage in  reducing cancer-related pain. The findings support their integration into  clinical practice, providing evidence-based recommendations for enhancing  standard pain management protocols.
C1 Department of Cancer V, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Department of Cancer V, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Department of Cancer V, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Department of Cancer V, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD APR 30
PY 2025
VL 6
IS 
BP 1447075
EP 1447075
DI 10.3389/fpain.2025.1447075
PG 0
UT PubMed:40303318
PM 40303318
DA 2025-04-30
ER

PT J
AU Wang, XY
   Shen, QY
   Hu, XY
   Yu, XS
   Erasmus, SR
   Gong, LY
   Liu, JH
   Fan, W
   Liang, Y
AF Wang, Xiaoying
   Shen, Qiongying
   Hu, Xinyi
   Yu, Xiaoshuai
   Erasmus, Shannah Rose
   Gong, Liyan
   Liu, Jianhao
   Fan, Wei
   Liang, Yi
TI Efficacy and Safety of Acupuncture Combined with Conventional Drug Therapy for the Treatment of Cancer-Induced Bone Pain: A Network Meta-Analysis of Randomized Controlled Trials
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE cancer-induced bone pain; acupuncture; supplementary alternative therapy; network meta-analysis
AB Background: Cancer-induced bone pain (CIBP) involves both nociceptive and neuropathic components, causing significant suffering in cancer patients. Acupuncture has shown beneficial effects on CIBP. However, given the diverse acupuncture techniques, their therapeutic efficacy may vary. Objective: To evaluate the efficacy and safety of various acupuncture modalities integrated with conventional drug therapy for CIBP. Methods: Randomized controlled trials (RCTs) of acupuncture combined with conventional analgesics for CIBP were searched across eight Chinese and English databases and clinical trial registries up to September 2024. Two researchers independently performed literature screening, data extraction, and bias assessment. Data were analyzed using Stata 14.0 and R 4.2.3. Results: Twenty-two RCTs involving 1,738 patients were included, assessing techniques including manual acupuncture (MA), electroacupuncture (EA), moxibustion (MOX), acupoint injection (AI), acupoint catgut embedding (ACE), auricular-plaster therapy (AP), thumbtack needle (TN) and transcutaneous electrical acupoint stimulation (TEAS). The outcomes were assessed across 20 studies for the clinical effective rate, 13 for nausea and vomiting, and 11 for constipation.The results indicated that for the primary outcome of pain relief (as measured by clinical effective rate), TN demonstrated the highest probability of being the most effective acupuncture technique (SUCRA = 75.2%). In terms of mitigating opioid-induced adverse reactions, ACE was most effective for reducing nausea and vomiting (SUCRA = 87.7%), while EA+AP was optimal for alleviating constipation (SUCRA = 93.5%). MA +MOX achieved the best overall balance between efficacy and the incidence of adverse reactions. Conclusion: Acupuncture combined with conventional drug therapy significantly improves pain relief in CIBP and reduces opioidrelated side effects. However, due to methodological limitations and the modest sample sizes of available studies, further high-quality, multicenter trials with larger samples are needed to confirm these findings and inform clinical practice.
C1 [Wang, Xiaoying; Shen, Qiongying; Hu, Xinyi; Yu, Xiaoshuai; Erasmus, Shannah Rose; Liang, Yi] Zhejiang Chinese Med Univ, Clin Med Coll 3, 548 Binwen Rd Binjiang District, Hangzhou, Zhejiang, Peoples R China.
   [Gong, Liyan] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Jianhao; Fan, Wei] Sanya Tradit Chinese Med Hosp, Sanya, Hainan, Peoples R China.
   [Liang, Yi] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University
RP Liang, Y (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, 548 Binwen Rd Binjiang District, Hangzhou, Zhejiang, Peoples R China.
EM liangyiwww@126.com
FU Key Project of Health Science and Technology Program of National Health Commission [WKJ-ZJ-2436]; Key Foundation of Chinese Medicine Research Program of Zhejiang Province [2021ZZ017]; Key Research and Development Project of Hainan Province [ZDYF2022SHFZ129]
CR Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Chen Y, 2020, CHIN MED J, V0, P144
   Chen YY, 2021, CHIN J CLIN RATIONAL DRUG USE, V14, P29, DOI 10.15887/j.cnki.13-1389/r.2021.24.009
   Chen Z, 2021, SHANGHAI J ACUPUNCT MOXIBUSTION, V40, P411, DOI 10.13460/j.issn.1005-0957.2021.04.0411
   Chu X, 2018, J CHENGDU UNIV TRADIT CHIN MED, V41, P41, DOI 10.13593/j.cnki.51-1501/r.2018.03.041
   Colosia A, 2022, J PAIN RES, V15, P3399, DOI 10.2147/JPR.S371337
   Du WB, 2019, CHIN GEN PRACT, V22, P3997, DOI 10.12114/j.issn.1007-9572.2019.00.078
   Ellingson HM, 2020, CURR OPIN SUPPORT PA, V14, P107, DOI 10.1097/SPC.0000000000000496
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Gou J, 2021, J SHAANXI UNIV CHIN MED, V44, P89, DOI 10.13424/j.cnki.jsctcm.2021.06.018
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Jiang YF, 2014, DISSERTATION, V0, P0
   Kane CM, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h315
   Li B, 2013, CHIN J TRADIT MED SCI TECHNOL, V20, P286, DOI 10.3969/j.issn.1005-7072.2013.03.054
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li Yan-Qiu, 2024, ZHEN CI YAN JIU, V49, P79, DOI 10.13702/j.1000-0607.20221211
   Liu DL, 2023, DISSERTATION, V0, P0, DOI DOI 10.26922/d.cnki.ganzc.2023.000507
   Liu W, 2019, JILIN J CHIN MED, V39, P911, DOI 10.13463/j.cnki.jlzyy.2019.07.020
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Mantyh PW, 2014, CURR OPIN SUPPORT PA, V8, P83, DOI 10.1097/SPC.0000000000000048
   National Comprehensive Cancer Network (NCCN), 2024, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: ADULT CANCER PAIN, V0, P0
   Ni J, 2021, HUNAN J TRADIT CHIN MED, V37, P114, DOI 10.16808/J.CNKI.ISSN1003-7705.2021.08.041
   Shen YH, 2015, CANCER-AM CANCER SOC, V121, P84, DOI 10.1002/cncr.28973
   司尚坤, 2023, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V42, P318
   Wang H, 2021, CHIN J FRONT MED SCI, V13, P60, DOI 10.12037/YXQY.2021.01-05
   Wang P, 2024, ACTA CHIN MED, V39, P102, DOI 10.16368/j.issn.1674-8999.2024.01.017
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wang XT, 2019, CURR MED SCI, V39, P52, DOI 10.1007/s11596-019-1999-1
   Wang XJ, 2025, J PAIN RES, V18, P315, DOI 10.2147/JPR.S498466
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   World Health Organization, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Wu S, 2020, J CLIN ACUPUNCT MOXIBUSTION, V36, P5, DOI 10.3969/j.issn.1005-0779.2020.11.003
   Xie YW, 2022, J SICHUAN TRADIT CHIN MED, V40, P198, DOI 10.3969/j.issn.1000-3649.2022.11.sczy202211056
   Xu YL, 2021, J SICHUAN TRADIT CHIN MED, V39, P176
   Yan LF, 2021, J BAOTOU MED COLL, V37, P96, DOI 10.16833/j.cnki.jbmc.2021.04.026
   Yan ZB, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.925013
   Yang FM, 2020, CHIN J INTEGR MED, V26, P310, DOI 10.1007/s11655-019-3150-3
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yao ZQ, 2022, COMPLEMENT THER CLIN, V46, P0, DOI 10.1016/j.ctcp.2021.101527
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20236047
   Zang C, 2013, CHIN J EVID BASED MED, V13, P1258, DOI 10.7507/1672-2531.20130215
   Zhang C, 2019, CHINA FOREIGN WOMENS HEALTH RESEARCH, V0, P0
   Zhang N, 2022, CHINA PRACT MED, V17, P43, DOI 10.14163/j.cnki.11-5547/r.2022.19.010
   Zhang QL, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1166580
   Zhao WL, 2018, J CLIN ACUPUNCT MOXIBUSTION, V34, P15, DOI 10.3969/j.issn.1005-0779.2018.06.006
   Zhao ZN, 2023, THER CLIN RISK MANAG, V19, P811, DOI 10.2147/TCRM.S429469
   Zhen GH, 2022, BONE RES, V10, P0, DOI 10.1038/s41413-022-00217-w
   Zheng XQ, 2022, J ADV RES, V35, P117, DOI 10.1016/j.jare.2021.06.006
   Zhu ZF, 2024, CHINA MOD MED, V31, P21, DOI 10.3969/j.issn.1674-4721.2024.06.007
   迪丽努尔 ·, 2023, ADVANCES IN CLINICAL MEDICINE, V13, P14750, DOI 10.12677/acm.2023.1392063
NR 55
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2025
VL 18
IS 
BP 6807
EP 6826
DI 10.2147/JPR.S550454
PG 20
WC Clinical Neurology
SC Neurosciences & Neurology
GA Z7858
UT WOS:001642959800001
PM 41438386
DA 2026-01-16
ER

PT J
AU Shushtari, SSG
   Kennedy, AB
   Jahangiri, M
   White, SJ
   Miladinia, M
   Karimpourian, H
AF Shushtari, Sima Sadat Ghaemizade
   Kennedy, Ann Blaire
   Jahangiri, Mina
   White, Sharon Jackson
   Miladinia, Mojtaba
   Karimpourian, Hossein
TI Comparing Massage, Acupressure, and Combined Therapy for Managing Cancer-related
SO International journal of therapeutic massage & bodywork
LA English
DT Journal Article
DE Complementary medicine; oncology; palliative medicine; supportive care; symptom management
AB BACKGROUND: Massage and acupressure are highly popular among cancer patients as  non-invasive methods with different mechanisms that can target multiple  coexisting symptoms. However, the comparative effectiveness between these two  techniques is still unclear, particularly among patients with advanced cancer.  Furthermore, it is unclear whether both approaches would have a synergistic  effect if applied simultaneously. The main objective is to compare the efficacy  of massage alone versus acupressure alone versus combined therapy (massage plus  acupressure) for managing cancer-related symptom cluster of fatigue, pain, and  sleep disturbance. METHODS: The 2-FAM-2 study is a four-arm, longitudinal,  randomized trial comparing the efficacy of two complementary medicine techniques  (massage alone vs. acupressure alone vs. combined therapy vs. control) for  managing a fatigue-pain-sleep symptom cluster in patients with advanced cancer  that will use a 2 × 2 factorial design with an equal allocation ratio. One  hundred adult patients with advanced cancer who have all three symptoms of pain,  fatigue, and sleep disturbance will be recruited. Four weeks of intervention and  4 weeks of follow-up with repeated measures will be part of the 8-week study  period. The main outcome is the longitudinal trajectory (trend) in the intensity  of the pain-sleep-fatigue symptom cluster over time, assessed via generalized  estimating equations (GEE) at baseline, weekly during intervention (weeks 1-4),  and at weeks 6 and 8 as follow-up. Self-reported fatigue, sleep disturbance, and  pain items (0-10 scale) will be averaged to compute the symptom cluster intensity  (SCI). Furthermore, a machine learning technique based on decision tree  algorithms will be carried out to conduct a subgroup analysis aimed at predicting  clinical outcomes for different interventions in homogeneous subgroups.  DISCUSSION: The trial's findings could be helpful in the development of clinical  guidelines, individualization of intervention, as well as guiding clinical  decisions and improving the quality of life of patients.
C1 Nursing Care Research Center in Chronic Diseases, School of Nursing, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
   Department of Biomedical Sciences, School of Medicine Greenville, University of South Carolina, Greenville, SC, USA.
   Department of Family Medicine, Prisma Health, Greenville, SC, USA.
   Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
   Emory University, Nell Hodgson Woodruff School of Nursing, Atlanta, GA, USA.
   Nursing Care Research Center in Chronic Diseases, School of Nursing, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
   Department of Medical Oncology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
NR 0
TC 0
SN 1916-257
EI 1916-257
J9 Int J Ther Massage Bodywork
PD DEC 8
PY 2025
VL 18
IS 4
BP 31
EP 44
DI 10.3822/ijtmb.v18i4.1269
PG 13
UT PubMed:41356775
PM 41356775
DA 2025-12-08
ER

PT J
AU Chen, ZW
   Xu, T
   Yin, ZH
   Li, QF
   Shu, YJ
   Zhou, XL
   Zhao, L
   Sun, MS
   Liang, FR
AF Chen, Zi-Wen
   Xu, Tao
   Yin, Zi-Han
   Li, Qi-fu
   Shu, Yun-Jie
   Zhou, Xue-Li
   Zhao, Ling
   Sun, Ming-Sheng
   Liang, Fan-Rong
TI Electroacupuncture for chemotherapy-induced gastrointestinal symptoms in colorectal cancer: protocol for a multicenter, three-arm, randomized controlled trial
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Chemotherapy; Gastrointestinal toxicity; Colorectal cancer; Electroacupuncture; Randomized controlled trial
ID acupuncture; inflammation; pathway
AB BackgroundColorectal cancer (CRC) is the second leading cause of cancer-related mortality globally. While chemotherapy remains a cornerstone of CRC treatment, gastrointestinal (GI) toxicity-manifesting as abdominal pain, diarrhea, constipation, and reflux-affects 40%-100% of patients, severely impairing quality of life. Despite the prevalence of these symptoms, there is a lack of effective non-pharmacological interventions. This study aims to evaluate the efficacy of electroacupuncture (EA) in alleviating chemotherapy-induced GI dysfunction in CRC patients.MethodsIn this multicenter, three-arm, randomized controlled trial (RCT), 231 CRC patients with post-chemotherapy GI symptoms will be centrally randomized to EA plus standard care, sham acupuncture (SA) plus standard care, or standard care alone. The EA and SA groups will receive three 30-min sessions over consecutive days, delivered by certified acupuncturists (EA: LI11, PC6, ST36 and ST37 with electrical stimulation; SA: non-acupoints with blunt-tip needles without stimulation). The primary outcome is the change in Gastrointestinal Symptom Rating Scale (GSRS) total scores from baseline to post-treatment (day 3). Secondary outcomes include GSRS subscale scores, Functional Assessment of Cancer Therapy-Colorectal (FACT-C) scores, and Self-Rating Anxiety Scale/Self-Rating Depression Scale (SAS/SDS) scores. All outcomes will be assessed at baseline (T0), post-intervention (T1: day 3), and follow-up (T2: day 10). Statistical analysis will employ intention-to-treat linear mixed-effects models.ConclusionThis multicenter RCT is designed to generate high-quality evidence on the comprehensive efficacy of EA in addressing chemotherapy-induced GI toxicity in CRC patients. If proven effective, EA could provide a safe, non-pharmacological adjunct to standard care, helping to reduce symptom burden and improve patient adherence to chemotherapy.Trial registration ChiCTR2200062317. Registered on 1 August 2022.ConclusionThis multicenter RCT is designed to generate high-quality evidence on the comprehensive efficacy of EA in addressing chemotherapy-induced GI toxicity in CRC patients. If proven effective, EA could provide a safe, non-pharmacological adjunct to standard care, helping to reduce symptom burden and improve patient adherence to chemotherapy.Trial registration ChiCTR2200062317. Registered on 1 August 2022.
C1 [Chen, Zi-Wen; Yin, Zi-Han; Li, Qi-fu; Shu, Yun-Jie; Zhou, Xue-Li; Zhao, Ling; Sun, Ming-Sheng; Liang, Fan-Rong] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.
   [Chen, Zi-Wen; Yin, Zi-Han; Sun, Ming-Sheng; Liang, Fan-Rong] Sichuan Prov Acupuncture Clin Med Res Ctr, Chengdu, Sichuan, Peoples R China.
   [Xu, Tao] Sichuan Orthoped Hosp, Res Dept, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Sichuan, Peoples R China.; Liang, FR (corresponding author), Sichuan Prov Acupuncture Clin Med Res Ctr, Chengdu, Sichuan, Peoples R China.
EM sunmingsheng@163.com; acuresearch@126.com
FU Major Project of Sichuan Provincial Department of Science and Technology
CR Akbarali HI, 2022, ADV CANCER RES, V155, P131, DOI 10.1016/bs.acr.2022.02.007
   Unknown -, 2015, STRATEGIC PRIORITIES: SYMPTOM MANAGEMENT AND QUALITY OF LIFE STEERING COMMITTEE, V0, P0
   Bao T, 2009, J NATL COMPR CANC NE, V7, P606, DOI 10.6004/jnccn.2009.0041
   Baxter NN, 2022, J CLIN ONCOL, V40, P892, DOI 10.1200/JCO.21.02538
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen WQ, 2016, REDOX BIOL, V10, P78, DOI 10.1016/j.redox.2016.09.006
   Chen Y, 2021, J INFLAMM RES, V14, P325, DOI 10.2147/JIR.S285146
   Dahlgren D, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.681417
   Deleemans JM, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241240141
   Eng C, 2022, LANCET ONCOL, V23, PE116, DOI 10.1016/S1470-2045(21)00588-X
   Escalante J, 2017, MATURITAS, V105, P23, DOI 10.1016/j.maturitas.2017.04.021
   Fan AY, 2023, J INTEGR MED-JIM, V21, P320, DOI 10.1016/j.joim.2023.06.001
   Farrell D, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012005.pub2
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   He YJ, 2023, BIOCHEM PHARMACOL, V216, P0, DOI 10.1016/j.bcp.2023.115787
   Hu B, 2016, SCIENCE, V354, P765, DOI 10.1126/science.aaf7532
   Hu HB, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.23.01889
   Lee CS, 2014, WORLD J GASTROENTERO, V20, P3751, DOI 10.3748/wjg.v20.i14.3751
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Liu SC, 2024, BIOMED PHARMACOTHER, V173, P0, DOI 10.1016/j.biopha.2024.116387
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Patel SG, 2024, ANN INTERN MED, V177, P0, DOI 10.7326/AITC202404160
   Patel SG, 2022, LANCET GASTROENTEROL, V7, P262, DOI 10.1016/S2468-1253(21)00426-X
   Qiu Y, 2023, CHIN GEN PRACT, V26, P2277, DOI 10.12114/J.ISSN.1007-9572.2022.0820
   Shen GS, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00099
   Wang J, 2022, J CANCER RES THER, V18, P1835, DOI 10.4103/jcrt.jcrt_1444_22
   WHO, 2024, GLOBAL CANC BURDEN G, V0, P0
   Yan YQ, 2023, CANCER MED-US, V12, P12504, DOI 10.1002/cam4.5962
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yeung WF, 2021, NAT SCI SLEEP, V13, P1195, DOI 10.2147/NSS.S318874
   Zhang C, 2024, NEUROTHERAPEUTICS, V21, P0, DOI 10.1016/j.neurot.2024.e00369
   Zhang LL, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.930489
   Zhong XL, 2022, DIS MARKERS, V2022, P0, DOI 10.1155/2022/5113473
NR 33
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0179-1958
EI 1432-1262
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD OCT 27
PY 2025
VL 40
IS 1
BP 
EP 
DI 10.1007/s00384-025-05008-3
PG 9
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 8ZF1J
UT WOS:001600839900001
PM 41144022
DA 2026-01-16
ER

PT J
AU Zhao, JY
   Yuan, GM
   Li, PY
   Wang, XM
   Liu, ZX
   Xu, Y
   Guo, YM
   Li, Y
AF Zhao, Ji-Yu
   Yuan, Gong-Ming
   Li, Pei-Yun
   Wang, Xin-Meng
   Liu, Zi-Xuan
   Xu, Yuan
   Guo, Yong-Ming
   Li, Yuan
TI [Effects of acupuncture on the efferocytosis pathway of Mer receptor tyrosine
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Adjuvant arthritis; Efferocytosis; Mer receptor tyrosine kinase
AB OBJECTIVES: To observe the effect of acupuncture at "Zusanli" (ST36) on the  expression of Mer receptor tyrosine kinase (MerTK)-related efferocytosis  regulatory molecules in mice with adjuvant arthritis induced by complete Freund's  adjuvant (CFA), so as to explore the potential mechanism of acupuncture on  efferocytosis in adjuvant arthritis. METHODS: C57BL/6J mice were randomly divided  into a saline group, a model group, and an acupuncture group (10 mice/group). The  right hind footpad of mice in the saline group was injected with 0.9% sodium  chloride solution, while those in the model group and the acupuncture group were  injected with CFA (50 μL) to establish the model of adjuvant arthritis. Mice in  the acupuncture group received acupuncture at bilateral ST36 once a day for a  total of 7 times, and mice in the saline group and the model group were fixed in  the same way. During the experiment, paw swelling degree and the paw withdrawal  thermal latency (PWTL) of mice were measured before modeling, on the day of  modeling (D0) and on the 1(st), 3(rd), 5(th) and 7(th) day of acupuncture (D1,  D3, D5, D7) to evaluate paw swelling and pain conditions. The mRNA expressions of  tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β in spinal cord  tissue were detected by real-time quantitative PCR. The protein expressions of  MerTK, phosphorylated (p)-signal transducer and activator of transcription 3  (STAT3), STAT3, and programmed death-ligand 1 (PD-L1) in footpad and spinal cord  tissue were detected by Western blot. RESULTS: After modeling, compared with the  saline group, the PWTL on D0-D7, the protein expression of PD-L1 in spinal cord  and protein expressions of MerTK and PD-L1 in footpad, the phosphorylation level  of STAT3 in spinal cord and footpad were decreased (P<0.01) in the model group,  while the degree of paw swelling, mRNA expressions of TNF-α, IL-6, and IL-1β in  spinal cord tissue were increased (P<0.01, P<0.05). Compared with the model  group, the PWTL on D1-D7, the protein expressions of MerTK, PD-L1 and  phosphorylation level of STAT3 in spinal cord and footpad were increased (P<0.01)  in the acupuncture group after acupuncture intervention, while the degree of paw  swelling on D7, the mRNA expressions of TNF-α, IL-6, and IL-1β in spinal cord  tissue were significantly decreased(P<0.01, P<0.05). CONCLUSIONS: Acupuncture can  improve the symptoms of mice with adjuvant arthritis, which may be related to  promoting MerTK-mediated efferocytosis and thus exerting an anti-inflammatory  effect.
C1 Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture-Moxibustion and Tuina & Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing 210023.liyuan@njucm.edu.cn.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education,
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD SEP 18
PY 2025
VL 50
IS 9
BP 1021
EP 1028
DI 10.13702/j.1000-0607.20240585
PG 7
WC Animals; Mice; Mice, Inbred C57BL; Humans; c-Mer Tyrosine Kinase; genetics; Acupuncture Therapy; Male; Arthritis, Experimental; therapy; Acupuncture Points; Interleukin-1beta; genetics; Receptor Protein-Tyrosine Kinases; genetics; Tumor Necrosis Factor-alpha; genetics; Female; STAT3 Transcription Factor; genetics; Interleukin-6; genetics; Efferocytosis
UT PubMed:40962725
PM 40962725
DA 2025-09-18
ER

PT J
AU Sun, D
   Chang, HY
   Luo, DC
   Du, GC
   Wang, H
   Yan, B
AF Sun, Di
   Chang, Hongyuan
   Luo, Dicheng
   Du, Guanchao
   Wang, Hao
   Yan, Bin
TI A narrative review of acupuncture in prostate diseases: perspectives from traditional Chinese medicine, current evidence and future directions
SO REVISTA INTERNACIONAL DE ANDROLOGIA
LA English
DT Review
DE Acupuncture; Prostate diseases; Chronic prostatitis/chronic pelvic pain syndrome; Benign prostatic hyperplasia; Prostate cancer; Traditional Chinese medicine
ID pelvic pain syndrome; vasomotor symptoms; hot flushes; men; electroacupuncture; cancer; hyperplasia; efficacy; inflammation; expression
AB Prostate diseases, including chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), benign prostatic hyperplasia (BPH) and prostate cancer, are among the most common conditions in andrology and urology. These diseases significantly affect patients' life quality and have profound impacts on the mental and psychological health of patients. Acupuncture has been widely used to treat prostate diseases, demonstrating notable efficacy and safety. This review synthesizes traditional Chinese medicine (TCM) perspectives on prostate diseases and evaluates the clinical application of acupuncture while summarizing mechanisms and proposing future research directions. Our review included twenty clinical trials involving CP/CPPS, BPH and prostate cancer. Acupuncture demonstrates significant efficacy in symptom relief (pain reduction and improvement of urinary symptoms) and disease modification (prostate volume reduction). The most frequently targeted meridians were the bladder meridian of foot-taiyang, the spleen meridian of foot-taiyin, ren meridian, the pericardium meridian of hand-jueyin, the liver meridian of foot-jueyin, the heart meridian of handshaoyin, the gallbladder meridian of foot-shaoyang and the kidney meridian of footshaoyin. In addition, acupuncture treatment for each disease exhibited distinct TCM characteristics and mechanisms of action. Patients with prostate disease may benefit from acupuncture treatment, however, high-quality clinical evidence, standardized guidelines and exploration of the mechanisms of acupuncture for prostate diseases are needed in the future.
C1 [Sun, Di; Chang, Hongyuan; Luo, Dicheng; Du, Guanchao; Wang, Hao; Yan, Bin] Chinese Med Sci, Xiyuan Hosp China Acad, Dept Androl, Beijing 100091, Peoples R China.
   [Sun, Di] Chongqing Univ, Three Gorges Hosp, Dept Androl, Chongqing 404000, Peoples R China.
C3 Chongqing University
RP Wang, H; Yan, B (corresponding author), Chinese Med Sci, Xiyuan Hosp China Acad, Dept Androl, Beijing 100091, Peoples R China.
EM wanghao0066@126.com; yanbinxyyy@126.com
FU State Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project [zyyzdxk-2023238]; Capacity Enhancement Project of Xiyuan Hospital, China Academy of Traditional Chinese Medicine [XYZX0405-31]
CR ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Ashamalla H, 2011, INT J RADIAT ONCOL, V79, P1358, DOI 10.1016/j.ijrobp.2010.01.025
   Azevedo C, 2024, EUR J ONCOL NURS, V68, P0, DOI 10.1016/j.ejon.2023.102490
   Beer TM, 2010, UROLOGY, V76, P1182, DOI 10.1016/j.urology.2010.03.033
   Bergengren O, 2023, EUR UROL, V84, P191, DOI 10.1016/j.eururo.2023.04.021
   Birch S, 2003, J ALTERN COMPLEM MED, V9, P91, DOI 10.1089/107555303321222973
   Bo HJ, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000030925
   Capodice Jillian L, 2007, CHIN MED, V2, P1, DOI 10.1186/1749-8546-2-1
   Chen Guo, 2016, ZHONGGUO ZHEN JIU, V36, P1247, DOI 10.13703/j.0255-2930.2016.12.006
   Chen H, 2023, BMJ SUPPORT PALLIAT, V13, PE10, DOI 10.1136/bmjspcare-2020-002450
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Chung IM, 2008, NEUROSCI LETT, V439, P18, DOI 10.1016/j.neulet.2008.04.100
   Co arcan SK, 2024, MEDICINE, V103, P0
   Daher M, 2023, BMC UROL, V23, P0, DOI 10.1186/s12894-023-01365-9
   Dai LL, 2023, EXPLORE-NY, V19, P475, DOI 10.1016/j.explore.2022.08.009
   Downing A, 2019, LANCET ONCOL, V20, P436, DOI 10.1016/S1470-2045(18)30780-0
   Frisk J, 2009, EUR UROL, V55, P156, DOI 10.1016/j.eururo.2008.02.002
   Glazener C, 2011, LANCET, V378, P328, DOI 10.1016/S0140-6736(11)60751-4
   Habermacher GM, 2006, ANNU REV MED, V57, P195, DOI 10.1146/annurev.med.57.011205.135654
   Hammar M, 1999, J UROLOGY, V161, P853, DOI 10.1016/S0022-5347(01)61789-0
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Harding C, 2009, BJU INT, V103, P186, DOI 10.1111/j.1464-410X.2008.07884.x
   Haverkamp J, 2008, J CELL BIOCHEM, V103, P1344, DOI 10.1002/jcb.21536
   Honjo H, 2004, INT J UROL, V11, P607, DOI 10.1111/j.1442-2042.2004.00868.x
   Hou J, 2022, GLAND SURG, V11, P1464, DOI 10.21037/gs-22-438
   Huang XF, 2020, TRANSL ANDROL UROL, V9, P485, DOI 10.21037/tau.2020.01.25
   Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022
   Jang JH, 2024, PAIN REP, V9, P0, DOI 10.1097/PR9.0000000000001200
   Krieger JN, 2003, WORLD J UROL, V21, P70, DOI 10.1007/s00345-003-0329-0
   Küçük EV, 2015, UROLOGY, V85, P636, DOI 10.1016/j.urology.2014.11.004
   Lee MS, 2009, SUPPORT CARE CANCER, V17, P763, DOI 10.1007/s00520-009-0589-3
   Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047
   Lee SWH, 2008, AM J MED, V121, P0, DOI 10.1016/j.amjmed.2007.07.033
   Lei Y, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019609
   Ma Y, 2016, FRONT MED-PRC, V10, P28, DOI 10.1007/s11684-016-0434-2
   Maurer J, 2024, BJU INT, V133, P725, DOI 10.1111/bju.16288
   McPherson SJ, 2008, DIFFERENTIATION, V76, P660, DOI 10.1111/j.1432-0436.2008.00291.x
   Nguyen PL, 2015, EUR UROL, V67, P825, DOI 10.1016/j.eururo.2014.07.010
   Nickel JC, 2008, EUR UROL, V54, P1379, DOI 10.1016/j.eururo.2007.11.026
   Pan L, 2023, J STEROID BIOCHEM, V234, P0, DOI 10.1016/j.jsbmb.2023.106402
   Parker CC, 2024, LANCET, V403, P2416, DOI 10.1016/S0140-6736(24)00549-X
   Peng Yi-yu, 2015, ZHEN CI YAN JIU, V40, P493
   Qin ZS, 2018, J UROLOGY, V200, P815, DOI 10.1016/j.juro.2018.05.001
   Qin ZS, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003095
   Sahin S, 2015, PROSTATE CANCER P D, V18, P249, DOI 10.1038/pcan.2015.13
   Sandhu JS, 2024, J UROLOGY, V211, P11, DOI 10.1097/JU.0000000000003698
   Song LM, 2016, BOSNIAN J BASIC MED, V16, P201, DOI 10.17305/bjbms.2016.1209
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   Tawfik A, 2024, WORLD J UROL, V42, P0, DOI 10.1007/s00345-023-04735-y
   Tugcu V, 2010, PAIN MED, V11, P518, DOI 10.1111/j.1526-4637.2009.00794.x
   Ullah R, 2021, WIEN KLIN WOCHENSCHR, V133, P153, DOI 10.1007/s00508-020-01692-z
   Wang AM, 2024, ACTA CHINESE MEDICINE AND PHARMACOLOGY, V52, P47, DOI 10.19664/j.cnki.1002-2392.240136
   王浩, 2022, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V63, P1091
   Wang H, 2023, ACTA CHINESE MEDICINE AND PHARMACOLOGY, V51, P1
   Wang H, 2024, J ORAL FACIAL PAIN H, V38, P11, DOI 10.22514/jofph.2024.035
   Wang H, 2023, BASIC CLIN ANDROL, V33, P0, DOI 10.1186/s12610-023-00215-w
   Wang H, 2023, INT J GEN MED, V16, P4039, DOI 10.2147/IJGM.S417066
   Wang H, 2023, INTEGR MED NEPHROL A, V10, P0, DOI 10.1097/imna-d-22-00001
   Wang H, 2023, NEUROPSYCH DIS TREAT, V19, P1273, DOI 10.2147/NDT.S413205
   Wang H, 2023, INT J GEN MED, V16, P1137, DOI 10.2147/IJGM.S406194
   Wang XL, 2024, WORLD J UROL, V42, P0, DOI 10.1007/s00345-024-04791-y
   Wang Y, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0059449
   Wazir J, 2019, INT UROL NEPHROL, V51, P2093, DOI 10.1007/s11255-019-02267-2
   Widia F, 2023, LUTS, V15, P107, DOI 10.1111/luts.12477
   Xia CF, 2022, CHINESE MED J-PEKING, V135, P584, DOI 10.1097/CM9.0000000000002108
   Xie Hong-Wu, 2012, ZHEN CI YAN JIU, V37, P140
   Xu C, 2022, J PAIN RES, V15, P2067, DOI 10.2147/JPR.S364972
   Yano T, 2004, NEUROCHEM RES, V29, P283, DOI 10.1023/B:NERE.0000010457.00855.8c
   Yao ZY, 2021, BRAIN RES BULL, V169, P43, DOI 10.1016/j.brainresbull.2021.01.005
   Yebes A, 2023, CURR UROL REP, V24, P241, DOI 10.1007/s11934-023-01150-z
   Yu Jung-Sheng, 2011, EVID BASED COMPLEMENT ALTERNAT MED, V2011, P303198, DOI 10.1155/2011/303198
   Zhang W, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0174586
   Zhou MJ, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1768-2
   Zhu DZ, 2024, UROL PRACT, V11, P0, DOI 10.1097/UPJ.0000000000000573
   Zhu LL, 2023, INTEGR MED RES, V12, P0, DOI 10.1016/j.imr.2023.100943
   Zhu Y, 2021, CHIN J INTEGR MED, V27, P384, DOI 10.1007/s11655-020-3483-y
   Zlotta AR, 2014, EUR UROL, V66, P619, DOI 10.1016/j.eururo.2014.06.026
NR 77
TC 0
Z9 0
U1 0
U2 0
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08-01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 1698-031X
EI 
J9 REV INT ANDROL
JI Rev. Int. Androl.
PD SEP 15
PY 2025
VL 23
IS 3
BP 22
EP 33
DI 10.22514/j.androl.2025.027
PG 12
WC Andrology
SC Endocrinology & Metabolism
GA 8NN1L
UT WOS:001592887000002
DA 2026-01-16
ER

PT J
AU Chen, XM
   Pang, LN
   Ke, YC
   Huang, QL
   Lan, YY
   Yu, XM
   Ye, XQ
   Wang, ZF
AF Chen, Xiao-Mei
   Pang, Li-Na
   Ke, Yi-Chen
   Huang, Qiu-Ling
   Lan, Yan-Yan
   Yu, Xiang-Mei
   Ye, Xiao-Qian
   Wang, Zhi-Fu
TI [Exploring the mechanism of wrist-ankle acupuncture in treating
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Chemotherapy-induced neuropathic pain; Electroacupuncture; Wrist-ankle acupuncture; α7 nicotinic acetylcholine receptor / Janus kinase 2/signal transducer and
AB OBJECTIVES: To investigate the effect of wrist-ankle acupuncture on the α7  nicotinic acetylcholine receptor (α7nAChR)/Janus kinase 2 (JAK2)/signal  transducer and activator of transcription 3 (STAT3) signaling pathway in the  spinal dorsal horn of mice with chemotherapy-induced neuropathic pain (CINP), and  to explore the mechanisms by which low-intensity wrist-ankle electroacupuncture  alleviates pain hypersensitivity in CINP mice. METHODS: C57BL/6 mice were  randomly divided into a blank group, a model group, a wrist-ankle acupuncture  group, and a wrist-ankle acupuncture + antagonist group, with 8 mice in each  group. A CINP model was established by intraperitoneal injection of paclitaxel (2  mg/kg). The wrist-ankle acupuncture group received electroacupuncture at the  "Lower 4" and "Lower 5" points in the wrist-ankle region for 30 min per session,  once every other day, for a total of 7 sessions. The wrist-ankle acupuncture +  antagonist group received intrathecal injections of the α7nAChR antagonist α-BGT  (0.5 μg/kg) on day 1, 7, and 13, in addition to acupuncture. The mechanical and  thermal pain thresholds were assessed using Von Frey filaments and hot plate  tests. The expression level of α7nAChR protein in the spinal dorsal horn (L4-L6)  was determined by Western blot. Immunofluorescence staining was used to detect  the expression of ionized calcium-binding adapter molecule 1 (Iba-1) in the  spinal dorsal horn. ELISA was used to measure the relative levels of  phosphorylated (p)-JAK2 and p-STAT3 in the spinal dorsal horn. Quantitative PCR  was used to detect the relative mRNA expression levels of tumor necrosis factor-α  (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). RESULTS: Compared with  the blank group, the model group exhibited decreased mechanical and thermal pain  thresholds (P<0.001), reduced α7nAChR protein expression (P<0.05), increased  Iba-1 expression (P<0.05), elevated relative contents of p-JAK2 and p-STAT3  (P<0.05), and increased mRNA expression levels of TNF-α, IL-1β, and IL-6  (P<0.05). Compared with the model group, the wrist-ankle acupuncture group showed  increased mechanical and thermal pain thresholds (P<0.05), elevated α7nAChR  protein expression (P<0.05), decreased Iba-1 expression (P<0.05), reduced  relative contents of p-JAK2 and p-STAT3 (P<0.05), and decreased mRNA expression  levels of TNF-α, IL-1β, and IL-6 (P<0.05). Compared with the wrist-ankle  acupuncture group, the wrist-ankle acupuncture + antagonist group showed  decreased mechanical and thermal pain thresholds (P<0.05), lower α7nAChR protein  expression (P<0.05), increased Iba-1 expression (P<0.05), higher relative  contents of p-JAK2 and p-STAT3 (P<0.05), and elevated mRNA expression levels of  TNF-α, IL-1β, and IL-6 (P<0.05). CONCLUSIONS: Wrist-ankle acupuncture may  alleviate pain hypersensitivity in CINP mice by regulating the α7nAChR/JAK2/STAT3  signaling pathway in the spinal dorsal horn, inhibiting microglial activation,  and reducing neuroinflammation.
C1 College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
   College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 
   College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
   College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
   College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
   College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
   College of Integrated Traditional Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122.
   Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou 350122. 357635952@qq.com.
   College of Acupuncture-Moxibustion and Tuina, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. 2007015@fjtcm.edu.cn.
   People's Hospital Affiliated to Fujian University of Traditional Chinese
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 22
PY 2025
VL 50
IS 7
BP 735
EP 742
DI 10.13702/j.1000-0607.20241267
PG 7
WC Animals; alpha7 Nicotinic Acetylcholine Receptor; genetics; Mice; Neuralgia; therapy; Humans; Mice, Inbred C57BL; Male; Spinal Cord Dorsal Horn; immunology; Acupuncture Points; STAT3 Transcription Factor; genetics; Acupuncture Therapy; Janus Kinase 2; genetics; Antineoplastic Agents; adverse effects; Paclitaxel; adverse effects; Signal Transduction; Electroacupuncture
UT PubMed:40691023
PM 40691023
DA 2025-07-22
ER

PT J
AU Li, Z
   Gao, Y
   Yan, D
   Feng, YH
AF Li, Zhe
   Gao, Yu
   Yan, Dong
   Feng, Yi-Hui
TI Efficacy of electroacupuncture for cervical spondylosis-related pain in patients with generalized anxiety disorder
SO WORLD JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Electroacupuncture; Cervical spondylosis; Generalized anxiety disorder; Neuroinflammation; Pain management
ID acupuncture; osteoarthritis; knee
AB BACKGROUND Cervical spondylosis (CS) frequently co-occurs with generalized anxiety disorder (GAD), presenting a complex clinical challenge. Managing CS-related pain in patients with GAD is particularly challenging because of the bidirectional relationship between pain and anxiety, necessitating integrated treatment strategies. AIM To evaluate the efficacy of electroacupuncture (EA) in treating CS-related pain and anxiety in patients with GAD. METHODS This retrospective cohort study analyzed data from 83 patients with CS-related pain and GAD who received EA treatment over 2-year period. Pain intensity was assessed using the visual analog scale, and anxiety symptoms were measured using the Hamilton Anxiety Rating Scale. Additionally, neuroinflammatory markers, including interleukin-6, tumor necrosis factor-alpha, and high-sensitivity C-reactive protein, were examined. Outcomes were evaluated at baseline, after 4 weeks, and after 8 weeks of treatment. RESULTS EA treatment significantly reduced CS-related pain (mean visual analog scale reduction: 3.24 +/- 1.18; P < 0.001) and improved anxiety symptoms (mean Hamilton Anxiety Rating Scale reduction: 7.83 +/- 2.65; P < 0.001) after 8 weeks of treatment. Neuroinflammatory markers also showed significant reductions, with interleukin-6 and tumor necrosis factor-alpha levels decreasing by 32.7% and 28.5%, respectively (P < 0.01). Pain reduction was significantly correlated with improvements in anxiety symptoms (r = 0.68; P < 0.001) and a decrease in inflammatory markers (r = 0.54; P < 0.01). CONCLUSION EA demonstrates significant efficacy in reducing CS-related pain in patients with comorbid GAD, along with concurrent improvements in anxiety symptoms and neuroinflammatory profiles. These findings suggest that EA may offer a valuable integrative approach for managing this complex clinical presentation, potentially addressing both pain and anxiety through the modulation of neuroinflammatory pathways.
C1 [Li, Zhe] Zhengzhou Orthopaed Hosp, Dept Pain Dis Treatment, Zhengzhou 450052, Henan, Peoples R China.
   [Gao, Yu; Yan, Dong] Zhengzhou Orthopaed Hosp, Dept Cervicolumbar, Zhengzhou 450052, Henan, Peoples R China.
   [Feng, Yi-Hui] Univ Hlth & Rehabil Sci, Dept Acupuncture & Moxibust, 369 Dengyun Rd, Qingdao 266042, Shandong, Peoples R China.
C3 University of Health & Rehabilitation Sciences
RP Feng, YH (corresponding author), Univ Hlth & Rehabil Sci, Dept Acupuncture & Moxibust, 369 Dengyun Rd, Qingdao 266042, Shandong, Peoples R China.
EM walgzzh@126.com
CR Araya-Quintanilla F, 2022, J BODYW MOV THER, V29, P117, DOI 10.1016/j.jbmt.2021.10.012
   Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004
   Atalay SG, 2021, PAIN PHYSICIAN, V24, PE269, DOI 10.36076/ppj.2021/24/e269
   Bäumler P, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-045961
   Bailes AH, 2021, SPINE J, V21, P1440, DOI 10.1016/j.spinee.2021.03.031
   Berger Amnon A, 2021, ANESTH PAIN MED, V11, Pe113627, DOI 10.5812/aapm.113627
   Borrella-Andrés S, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/9936981
   Cezar-Vaz MR, 2023, HEALTHCARE-BASEL, V11, P0, DOI 10.3390/healthcare11030365
   de la Rosa JS, 2024, PAIN, V165, P666, DOI 10.1097/j.pain.0000000000003056
   Fang JF, 2024, CURR PAIN HEADACHE R, V28, P957, DOI 10.1007/s11916-024-01267-x
   Felger JC, 2018, CURR NEUROPHARMACOL, V16, P533, DOI 10.2174/1570159X15666171123201142
   Foster NE, 2021, ACUPUNCT MED, V39, P83, DOI 10.1177/0964528420920303
   Guo L, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e30819
   Hernández-Secorún M, 2023, PAIN RES MANAG, V2023, P0, DOI 10.1155/2023/1523834
   Huo LY, 2022, GLOB SPINE J, V12, P1912, DOI 10.1177/21925682221075290
   Ji HY, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000031515
   Kim MW, 2023, ASIAN SPINE J, V17, P213, DOI 10.31616/asj.2022.0440
   Kwon CY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026871
   Lee B, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6429836
   Lei W, 2022, NEUROMODULATION, V25, P1122, DOI 10.1016/j.neurom.2022.02.001
   Li MC, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000030076
   Li YM, 2021, ACUPUNCT MED, V39, P208, DOI 10.1177/0964528420922232
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Luo XC, 2023, J EVID-BASED MED, V16, P237, DOI 10.1111/jebm.12526
   Ma X, 2021, J NEUROPATH EXP NEUR, V80, P844, DOI 10.1093/jnen/nlab046
   Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5
   Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081
   Prablek M, 2023, NEUROL CLIN, V41, P77, DOI 10.1016/j.ncl.2022.07.003
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Treede RD, 2022, PAIN, V163, PS99, DOI 10.1097/j.pain.0000000000002740
   Valera-Calero JA, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph19169904
   Vázquez-Justes D, 2022, NEUROLOGIA, V37, P806, DOI 10.1016/j.nrl.2019.09.010
   Walker AK, 2014, PHARMACOL REV, V66, P80, DOI 10.1124/pr.113.008144
   Yin MC, 2021, GLOB SPINE J, V11, P988, DOI 10.1177/2192568220948832
   Zhang ML, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1451342
NR 35
TC 0
Z9 0
U1 1
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2220-3206
EI 
J9 WORLD J PSYCHIATR
JI World J. Psychiatr.
PD NOV 19
PY 2025
VL 15
IS 11
BP 
EP 
DI 10.5498/wjp.v15.i11.108288
PG 12
WC Psychiatry
SC Psychiatry
GA C0345
UT WOS:001620120100015
PM 41281520
DA 2026-01-16
ER

PT J
AU Qi, P
   Zhou, M
   Han, W
   Li, H
   Min, L
   Li, J
   Sun, Z
   Yin, H
AF Qi, Pengfei
   Zhou, Mingyuan
   Han, Wenqing
   Li, Hongxiang
   Min, Lu
   Li, Jiaxin
   Sun, Zhongren
   Yin, Hongna
TI Mechanism of the analgesic effect of electroacupuncture on bone cancer pain
SO Frontiers in neurology
LA English
DT Review
DE animal model; bone cancer pain; electroacupuncture; immunity; mechanism; morphine tolerance; neuroscience
AB This article summarizes the mechanism of the analgesic effect of  electroacupuncture (EA) on BCP by analyzing the progress of animal experimental  research on the treatment of bone cancer pain (BCP). As a kind of chronic  specific pain that both overlaps and incompletely coincides with inflammatory  pain and neuropathic pain, BCP is mostly clinically treated with opioids such as  morphine as the first-line analgesic for BCP, but the long-term application is  prone to a series of unavoidable side-effects, such as tolerance, dependence, as  well as cognitive impairment, nausea, constipation, and nephrotoxicity.  Therefore, there is an urgent need to seek safer and more effective treatment  measures. As a safe, reliable and consistently efficacious analgesic, EA produces  analgesic effects in inflammatory pain, neuropathic pain and BCP. EA not only  attenuates the nociceptive sensitization of BCP by modulating the release of  nociception-related neurotransmitters and receptors in the nervous system, but  also exerts analgesic effects on BCP by modulating the expression of inflammatory  factors in the immune system, inhibiting glial cell activation, and T cell  proliferation. At present, EA research on the analgesic mechanism of BCP has made  some progress, but there are still problems that need to be solved, such as the  lack of standardization of acupoints and parameters, weak clinical validation, a  single research model, and limitations in the perspective of analgesic mechanism  research. It is suggested that future studies should be based on databases such  as AcuEBase v1.0 to develop standardized EA acupoint combinations and frequency  parameters to provide a scientific basis for EA standardization. At the same  time, the sample size should be expanded and the experimental design should be  improved in order to promote the transformation of animal experiments into  clinical applications. In addition, it should be expanded to more types of cancer  bone metastasis pain models to verify the consistency of the analgesic effect of  EA in different BCP models. Future studies could also explore the multi-target  synergistic analgesic effects of EA from a microbial-immune axis perspective with  the help of tools such as MicrobeTCM. And optimize the treatment plan of BCP  through EA combined with drug therapy. It is believed that with the progress of  science and technology as well as the continuous exploration of human beings, the  complex mechanism of BCP will be overcome by human beings eventually.
C1 Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Second Hospital of Heilongjiang University of Traditional Chinese Medicine,
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD DEC 26
PY 2025
VL 16
IS 
BP 1693978
EP 1693978
DI 10.3389/fneur.2025.1693978
PG 0
UT PubMed:41451423
PM 41451423
DA 2025-12-26
ER

PT J
AU Chen, C
   He, L
AF Chen, Cai-Yi
   Lin, Yuan-Quan
   Wang, Zhang-Ying
   He, Ling-Ling
   Wang, Xuan
TI Effects of different intensities of electroacupuncture and manual acupuncture at "Shangjuxu" (ST37) on acute inflammatory visceral pain and their relationship with α7nAChR/PI3K/AKT signaling pathway
SO Zhen Ci Yan Jiu
LA Chinese
DT Article
DE Acute inflammatory visceral pain; Electroacupuncture; Manual acupuncture; Shangjuxu(ST37); α7nAChR/PI3K/AKT signaling pathway
ID bungarotoxin receptor; phosphatidylinositol 3 kinase; protein kinase b; acupuncture; acupuncture point; animal; electroacupuncture; genetics; human; immunology; male; metabolism; rat; signal transduction; sprague dawley rat; therapy; visceral pain; acupuncture points; acupuncture therapy; alpha7 nicotinic acetylcholine receptor; animals; electroacupuncture; humans; male; phosphatidylinositol 3-kinases; proto-oncogene proteins c-akt; rats; rats, sprague-dawley; signal transduction; visceral pain
AB 目的: 对比不同刺激强度电针与手针治疗急性炎性内脏痛的效应差异;观察手针与（等效）电针通过α7烟碱乙酰胆碱受体（α7nAChR）/磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（AKT）通路治疗急性炎性内脏痛的机制差异。方法: 将SD大鼠随机分为正常组、模型组、电针1 mA组、电针2 mA组、电针3 mA组、电针4 mA组、电针6 mA组、手针组，每组12只。用2%乙酸灌肠制作急性炎性内脏痛大鼠模型。电针组分别采用对应电流强度电针（2 Hz）刺激“上巨虚”，手针组针刺“上巨虚”，刺激频率为2次/s，均持续干预2 min。HE染色法检测结肠黏膜组织病理形态变化，腹部撤回反射（AWR）评分和腹外斜肌放电幅值测定大鼠内脏痛，对比手针与不同强度电针的效应差异。选取与手针组等效的电针2 mA组，以及应用甲基乌头碱（MLA，α7nAChR阻断剂，4 mg/kg）的手针+MLA组和电针2 mA+MLA组，对比加用阻断剂后电针和手针镇痛效应的变化，ELISA法检测大鼠血清肿瘤坏死因子α（TNF-α）、白细胞介素-1β（IL-1β）含量，Western blot法检测大鼠结肠α7nAChR、PI3K、AKT蛋白表达。结果: 与正常组比较，模型组大鼠AWR评分和腹外斜肌放电幅值升高（P<0.05）;与模型组比较，1、2 mA电针组及与电针各组相同频率相同刺激时间的手针组大鼠AWR评分和腹外斜肌放电幅值降低（P<0.05），结肠黏膜炎性浸润及形态异常均有所改善。与正常组比较，模型组大鼠血清TNF-α、IL-1β含量，结肠PI3K、AKT蛋白表达升高（P<0.05），结肠α7nAChR蛋白表达降低（P<0.05）;与模型组比较，与2 mA等效的手针组和电针2 mA组大鼠血清TNF-α、IL-1β含量，结肠PI3K、AKT蛋白的表达降低（P<0.05），结肠α7nAChR蛋白表达升高（P<0.05），且手针和2 mA电针降低AWR评分，血清TNF-α、IL-1β含量，结肠PI3K、AKT蛋白表达及升高结肠α7nAChR蛋白表达的效应均能被α7nAChR的阻断剂MLA抑制（P<0.05）。结论: 1 mA、2 mA强度电针及与其相同频率（2 Hz）相同刺激时间（2 min）的手针具有类似的急性炎性内脏痛镇痛效应，此效应优于较高强度（3、4、6 mA）的电针;手针与电针“上巨虚”缓解急性炎性内脏痛的作用机制，可能与α7nAChR/PI3K/AKT信号通路密切相关。.; OBJECTIVES: To compare the effects of electroacupuncture (EA) and manual acupuncture (MA) at different stimulation intensities on acute inflammatory visceral pain, and to analyze their mechanisms underlying relief of inflammatory visceral pain mediated by α7 nicotinic acetylcholine receptor (α7nAChR)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. METHODS: Male SD rats were randomly divided into normal control, visceral pain model, EA 1 mA, EA 2 mA, EA 3 mA, EA 4 mA, EA 6 mA, and MA groups (with the same frequency as EA, 2 times/s, for 2 min), with 12 rats in each group. The acute inflammatory visceral pain model was established by intracolonic instillation of 2% acetic acid. EA (2 Hz, 1, 2, 3, 4, 6 mA) or MA (120 twirlings/min, with the needle rotated at a magnitude of about 90°-180°) was applied to the right Shangjuxu (ST37) for 2 min. The abdominal withdrawal reflex (AWR) score and external oblique muscle electromyogram amplitude were used to assess the visceral pain reaction. Histopathological changes of the colonic mucosal tissue were detected by H.E. staining. For observing the involvement of colonic α7nAChR in visceral pain relief of both EA and MA, intraperitoneal injection of methylaconitine (MLA, α7nAChR blocker, 4 mg/kg) was given to rats of MA+MLA and EA 2 mA+MLA groups (with 6 rats in each group) before each intervention. The contents of serum tumor necrosis factor-α(TNF-ɑ) and interleukin-1β(IL-1β) were detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of α7nAChR, PI3K and AKT in the colon tissue were detected by Western blot. RESULTS: In comparison with the normal control group, both the AWR scores and the amplitude of EMG at colorectal dilation (CRD) pressure of 20, 40, 60 and 80 mmHg were significantly increased in the model group (P<0.05). Compared with the model group, both the AWR scores and the amplitude of EMG at CRD pressure of 20, 40, 60 and 80 mmHg were significantly decreased in the EA 1 mA, EA 2 mA and MA groups (P<0.05), rather than in the EA 3 mA, EA 4 mA and EA 6 mA groups, suggesting that the higher stimulation intensity of EA had no analgesic effect. H.E. staining showed slightly hyperemic and edematous injury of the colonic mucosa tissue, with obvious inflammatory infiltration and abnormal morphological changes in the model group, which was obviously milder in the injury in the MA and EA 1 mA, EA 2 mA groups, rather than in the EA 3 mA, 4 mA and 6 mA groups. In comparison with the normal control group, the contents of serum TNF-ɑ and IL-1β, and expression levels of PI3K and AKT proteins in colon were significantly increased (P<0.05), and the expression of α7nAChR protein was remarkably down-regulated (P<0.05) in the model group. Compared with the model group, the contents of serum TNF-ɑ and IL-1β, and the expression levels of PI3K and AKT proteins were strikingly down-regulated (P<0.05), and the expression of α7nAChR was considerably up-regulated (P<0.05) in both EA 2 mA and MA groups. Moreover, the effects of reducing the corresponding AWR scores at various CRD pressure levels, serum TNF-α and IL-1β contents, and the protein expressions of PI3K and AKT in colon, as well as increasing the protein expression of α7nAChR in colon in rats of MA and EA 2 mA groups can be inhibited by MLA (P<0.05), a blocker of α7nAChR. CONCLUSIONS: Both MA and 2 mA EA (not 3, 4, 6 mA EA) stimulation of ST37 have a similar analgesic effect in acute inflammatory visceral pain rats, which may be related to their function in suppressing the activities of α7nAChR/PI3K/AKT signaling pathway.
C1 Fujian Normal University, Chen, Caiyi, Acupuncture and moxibustion Massage College, Fuzhou, Fujian, China
   Fujian Normal University, null, null, Acupuncture and moxibustion Massage College, Fuzhou, Fujian, China
   Fujian Normal University, null, null, Acupuncture and moxibustion Massage College, Fuzhou, Fujian, China
   Fujian Normal University, He, Lingling, Acupuncture and moxibustion Massage College, Fuzhou, Fujian, China
   Fujian Normal University, null, null, College of Education, Fuzhou, Fujian, China
NR 0
TC 0
SN 10000607
EI 
J9 ZHEN CI YAN JIU
JI Zhen Ci Yan Jiu
PD JUN 15
PY 2025
VL 50
IS 12
BP 1365
EP 1375
DI 10.13702/j.1000-0607.20250327
PG 11
UT PubMed:41443910
ER

PT J
AU Shi, Z
   Sun, H
   Wu, J
   Jin, Y
   Cao, S
   Cai, J
AF Shi, Zhengqin
   Sun, Hong
   Wu, Junlei
   Jin, Yude
   Cao, Sujie
   Cai, Jianli
TI Chinese acupoint therapies in cancer pain management: research advances and
SO Pain management
LA English
DT Review
DE Cancer pain; acupuncture; analgesic therapies; electroacupuncture; moxibustion; traditional Chinese medicine
AB Cancer pain management (CPM) is crucial in oncology care, with current approaches  including pharmacotherapy, radiotherapy, chemotherapy, nerve blocks, and  psychological support. However, long-term drug use risks adverse effects and  addiction, while physiotherapies often lack sustained efficacy. Therefore,  identifying safer adjuvant analgesic therapies has become an urgent issue.  Traditional Chinese Medicine (TCM) acupoint therapies (acupuncture, moxibustion,  and acupoint injection) offer safer adjuvant analgesia with growing clinical  validation. This narrative review aims to introduce the research progress of  acupoint therapy in alleviating cancer pain and the role of emerging technologies  in advancing acupoint therapy. All literature selections were sourced exclusively  from PubMed and CNKI databases. First, we briefly introduce the mechanisms of  cancer pain, outline relevant evaluation methods, and summarize the limitations  of existing CPM strategies. Additionally, we discuss the therapeutic effects,  underlying mechanisms, and potential improvements of acupoint therapies in CPM.  Notably, recent advancements in information technology, artificial intelligence,  and materials science, along with the development of noninvasive stimulation  methods and innovative devices, have significantly advanced the understanding of  acupoint treatment mechanisms and expanded their clinical applications. Finally,  we highlight the challenges and future directions for TCM acupoint therapies.  This study provides clinical insights and recommendations for CPM.
C1 Department of Thyroid and Breast Minimally Invasive Surgery, Huzhou First People's Hospital, Huzhou, China.
   Department of General Surgery, Huzhou First People's Hospital, Huzhou, China.
   Department of Thyroid and Breast Minimally Invasive Surgery, Huzhou First People's Hospital, Huzhou, China.
   Department of General Surgery, Huzhou First People's Hospital, Huzhou, China.
   Department of Information Technology, Huzhou First People's Hospital, Huzhou, China.
   Nursing Department, Huzhou First People's Hospital, Huzhou, China.
NR 0
TC 0
SN 1758-187
EI 1758-186
J9 Pain Manag
PD MAY 22
PY 2025
VL 15
IS 6
BP 345
EP 358
DI 10.1080/17581869.2025.2510191
PG 13
WC Humans; Cancer Pain; therapy; Acupuncture Points; Pain Management; methods; Medicine, Chinese Traditional; methods; Acupuncture Therapy; methods
UT PubMed:40402471
PM 40402471
DA 2025-05-22
ER

PT J
AU Yu, T
   Liu, H
   Liu, Z
   Chen, R
   Xie, D
AF Yu, Ting
   Liu, Huawei
   Liu, Zuqin
   Chen, Rixin
   Xie, Dingyi
TI [Heat-sensitive moxibustion assisted in palliative treatment to improve the
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE heat-sensitive moxibustion; immunologic function; malignant tumor, elderly; palliative treatment; quality of life
AB OBJECTIVE: To observe the effect of heat-sensitive moxibustion on the quality of  life in the elderly patients with malignant tumor based on palliative treatment.  METHODS: A total of 100 elderly patients with malignant tumor were randomly  divided into an observation group (50 cases, 3 cases dropped out) and a control  group (50 cases, 4 cases dropped out). The conventional palliative treatment was  performed in the control group. On the basis of conventional palliative  treatment, heat-sensitive moxibustion was added at Shenque (CV8) and Zhongwan  (CV12) in the observation group, once a day, 5 times a week, one course of  treatment was composed of 2 weeks, and 2 consecutive courses of treatment were  given. In the observation group, 15 patients voluntarily continued heat-sensitive  moxibustion treatment, which was collected in the sub-observation group No.1,  these patients were treated 3 times a week and for 6 months consecutively. Using  the propensity score matching method, 15 patients who only completed 2 courses of  treatment were assigned into the sub-observation group No.2. Before and after  treatment, the scores of European Organization for Research and Treatment of  Cancer quality of life questionnaire (EORTC QLQ-C30), the Karnofsky performance  status (KPS), and the anorexia/cachexia subscale-12 (A/CS-12), as well as the  immune indexes (the contents of serum immune globulin [Ig]G, IgA, IgM and  complements C3 and C4) were observed in the patients of the observation group and  the control group. The monthly survivals were recorded in the two sub-observation  groups after 6 months of treatment completion. The coordination was analyzed on  the score of deqi scale of heat-sensitive moxibustion at the probing stage before  treatment and the change in the score of EORTC QLQ-C30 before and after treatment  in the patients of the observation group. RESULTS: After treatment, except the  score related to the financial difficulties, the score of every items in EORTC  QLQ-C30 was greater than that before treatment in the observation group (P<0.05);  the scores for overall health, nausea/vomiting, pain, short breath, constipation  and diarrhea of the scale were higher than those before treatment in the control  group (P<0.05). The score for each item of the scale in the observation group was  higher when compared with that in the control group, except the score for  financial difficulties (P<0.05). After treatment, KPS score increased in the  observation group when compared with that before treatment (P<0.05), and the  score was higher than that of the control group (P<0.05). After treatment,  A/CS-12 score was elevated in comparison with that before treatment in each group  (P<0.05), and the score in the observation group was higher than that of the  control group (P<0.05). After treatment, in the observation group, the contents  of serum IgG, IgA and IgM, and C3 and C4 increased in comparison with those  before treatment (P<0.05); and in the control group, the contents of serum IgG,  C3 and C4 were declined (P<0.05). After treatment, the contents of serum IgG, IgA  and IgM, and C3 and C4 in the observation group were higher than those in the  control group (P<0.05). After 6 months of treatment completion, the survival rate  in the sub-observation group No.1 was higher than that of the sub-observation  group No.2 (P<0.05). In the observation group, the positive coordination was  presented between the score of deqi scale of heat-sensitive moxibustion and the  change in the score of EORTC QLQ-C30 in the observation group (r>0, P<0.001).  CONCLUSION: On the basis of palliative treatment, heat-sensitive moxibustion can  improve the quality of life, appetite and the immunity of the elderly patients  with malignant tumor. Consecutive long-term moxibustion is contributed to  prolonging the life span. The stronger deqi is felt during moxibustion delivery,  the more significant the therapeutic effect is obtained.
C1 Department of TCM, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
   First Department of Internal Medicine, Bo'xing County Hospital of TCM.
   Department of Moxibustion, Bo'xing County Hospital of TCM
   4College of Acupuncture-Moxibustion and Tuina, Jiangxi University of CM
   5AdministrationOffice of Heat-Sensitive Moxibustion, Affiliated Hospital of Jiangxi Universityof CM, Nanchang 330025.
   College of Acupuncture-Moxibustion and Tuina, Jiangxi University of CM.
   Administration Office of Heat-Sensitive Moxibustion, Affiliated Hospital of Jiangxi University of CM, Nanchang 330025.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 13
PY 2025
VL 45
IS 2
BP 167
EP 72
DI 10.13703/j.0255-2930.20240403-k0002
PG -95
WC Humans; Moxibustion; Male; Female; Aged; Quality of Life; Neoplasms; therapy; Palliative Care; Aged, 80 and over; Middle Aged; Acupuncture Points
UT PubMed:39943757
PM 39943757
DA 2025-02-13
ER

PT J
AU Jafari, M
   Shabani, F
   Fathollahi, MS
   Barghi, TS
   Peighambari, SB
   Zargaz, SEH
AF Jafari, Mahya
   Shabani, Fidan
   Fathollahi, Mahmood Sheikh
   Barghi, Tohid Seif
   Peighambari, Seyed Babak
   Zargaz, Seyyed Ebrahim Hosseini
TI Effect of Acupressure on Pain and Sleep Quality of Patients with Cancer after
SO Iranian journal of nursing and midwifery research
LA English
DT Journal Article
DE Acupressure; neoplasms; pain; sleep quality; surgery
AB BACKGROUND: Pain and sleep disturbances are among the most common symptoms and  complications in cancer patients. This study aims to evaluate the effect of  acupressure at the LI4 and SP6 points on pain and sleep quality in cancer  patients after surgery. MATERIALS AND METHODS: In this single-blind randomized  clinical trial, cancer patients admitted to the intensive care unit at the Cancer  Institute of Imam Khomeini Hospital in Tehran, Iran in 2022, following surgery,  were divided into two equal groups of 39: an intervention group and a control  group. On the second and third days after surgery, in the morning and evening,  acupressure was applied bilaterally at the LI4 (hand) and SP6 (foot) points, in  the experimental group. In the control group, surface touch was applied to the  same points. Patients' pain was assessed using the visual analog scale of pain,  and sleep quality was measured using the Richard-Campbell Sleep Questionnaire.  Data were analyzed using the two-way repeated measures analysis of variance.  RESULTS: Statistical analysis showed that the interaction effect of group and  time was statistically significant (p < 0.001), indicating that pain reduction  was significantly greater in the experimental group compared to the control  patients. A paired t-test demonstrated a significant increase in sleep quality  after the acupressure intervention in the experimental group (p < 0.001), whereas  no significant change was observed in the control group (p = 0.124). CONCLUSIONS:  Acupressure was found to effectively reduce pain and improve sleep quality in  cancer patients after surgery.
C1 Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
   Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
   National Center for Health Insurance Research, Tehran, Iran.
   Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
   Department of Biomedical Engineering, Texas A and M University, Texas, USA.
   Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
NR 0
TC 0
SN 2228-550
EI 1735-906
J9 Iran J Nurs Midwifery Res
PD AUG 20
PY 2025
VL 30
IS 4
BP 531
EP 537
DI 10.4103/ijnmr.ijnmr_368_23
PG 6
UT PubMed:40832492
PM 40832492
DA 2025-08-20
ER

PT J
AU Tian, H
   Luo, Q
   Huang, L
   Chen, G
   Sun, M
   Liang, F
AF Tian, Hao
   Luo, Qin
   Huang, Liuyang
   Chen, Guang
   Sun, Mingsheng
   Liang, Fanrong
TI Exploration of the quantitative-effectiveness association between acupuncture
SO Frontiers in oncology
LA English
DT Review
DE acupuncture; chemotherapy-induced peripheral neuropathy; dose-response; meta-analysis; pain management
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the  commonly reported symptoms impacting cancer survivors. This study evaluated and  compared the effectiveness of acupuncture treatments for CIPN. METHODS: We  searched six databases from their inception to August 2024 to identify eligible  randomized controlled trials (RCTs). Primary outcome were pain scores. Secondary  outcomes were quality of life including FACT/GOG-Ntx and EORTC QLQ-C30. The  robust error meta-regression (REMR) method was used to evaluate the dose-response  relationship across treatment parameters, including number of sessions,  frequency, and duration. RESULTS: In total, 11 RCTs featuring 740 participants  were included. The meta-analysis demonstrated that the primary analysis achieved  a significant reduction in pain scores, with a standardized mean difference of  [SMD= -1.23, 95% CI = (-2.22, -0.24); P < 0.01; I² = 95%], improvement quality of  life including FACT/GOG-Ntx [SMD = 0.95, 95% CI = (0.02, 1.88); P < 0.01; I² =  93%] and EORTC QLQ-C30 [SMD = 0.36, 95% CI = (0.03, 0.68); P = 0.14; I² = 46%].  The nonlinear dose-response analysis suggests that pain improvement achieves the  MCID at 16 treatment sessions, over 8 weeks, with a frequency of twice per week.  Furthermore, analysis of the treatment duration chart shows that acupuncture  maintains therapeutic effects during the follow-up period. Sensitivity analysis  confirmed the robustness of these findings. CONCLUSION: Acupuncture demonstrates  significant potential in managing CIPN, particularly through individualized  treatment regimens. The identified time-dose-response relationship suggests that  tailoring acupuncture frequency and duration can to optimize pain relief in CIPN  patients. Future high-quality studies and large-scale multicenter clinical trials  are needed to validate these findings.
C1 College of Acupuncture and Tuina/The 3rd Teaching Hospital/College of Basic Medicine/College of International Education, Chengdu University of TraditionalChinese Medicine/Clinical Research Center for Acupuncture and Moxibustion inSichuan Province, Chengdu, Sichuan, China.
   Department of Rheumatology and Orthopedics, Sichuan Province Orthopedic Hospital, Chengdu, Sichuan, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, China.
   Hubei Provincial Collaborative Innovation Center of Preventive Treatment by 
   Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan, China.
   College of Acupuncture and Tuina/The 3rd Teaching Hospital/College of Basic Medicine/College of International Education, Chengdu University of TraditionalChinese Medicine/Clinical Research Center for Acupuncture and Moxibustion inSichuan Province, Chengdu, Sichuan, China.
   College of Acupuncture and Tuina/The 3rd Teaching Hospital/College of Basic Medicine/College of International Education, Chengdu University of TraditionalChinese Medicine/Clinical Research Center for Acupuncture and Moxibustion inSichuan Province, Chengdu, Sichuan, China.
   College of Acupuncture and Tuina/The 3rd Teaching Hospital/College of Basic Medicine/College of International Education, Chengdu University of TraditionalChinese Medicine/Clinical Research Center for Acupuncture and Moxibustion inSichuan Province, Chengdu, Sichuan, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD MAR 4
PY 2025
VL 14
IS 
BP 1527331
EP 1527331
DI 10.3389/fonc.2024.1527331
PG 0
UT PubMed:40034252
PM 40034252
DA 2025-03-04
ER

PT J
AU Yang, M
   Chen, Y
   Wan, Y
   Shen, C
   Huang, J
AF Yang, Ming
   Chen, Yue
   Wan, Yuxiang
   Shen, Chen
   Huang, Jinchang
TI Acupuncture and moxibustion in integrative oncology and new progress in China.
SO Integrative medicine research
LA English
DT Review
DE Acupuncture; Evidence-based medicine; Integrative oncology; Moxibustion; Traditional Chinese Medicine
AB Acupuncture and moxibustion are increasingly gaining recognition in the clinical  and research fields of integrative oncology. This review synthesizes findings  from clinical guidelines, systematic reviews, meta-analyses, and randomized  controlled trials (RCTs) of acupuncture and moxibustion for cancer care. Clinical  evidence highlights acupuncture's efficacy in managing symptoms such as hot  flashes, pain, insomnia, fatigue, and constipation. Acupuncture also demonstrates  potential effects in reducing chemotherapy and radiotherapy-induced side effects.  Recent advancements in China shows integrated therapies combining acupuncture  with chemotherapy to enhance therapeutic outcomes. Additionally, laboratory  studies reveal the potential of acupuncture and moxibustion to modulate the tumor  microenvironment, boost chemotherapy efficacy, and strengthen immunity. Despite  these promising results, there is a pressing need for well-designed trials and  real-world studies to evaluate the long-term effects of standardized acupuncture  and moxibustion treatments in cancer care.
C1 Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, PR China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, PR China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, PR China.
   Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, PR China.
   Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, PR China.
NR 0
TC 0
SN 2213-423
EI 2213-422
J9 Integr Med Res
PD JUN 6
PY 2025
VL 14
IS 2
BP 101149
EP 101149
DI 10.1016/j.imr.2025.101149
PG 0
UT PubMed:40475037
PM 40475037
DA 2025-06-06
ER

PT J
AU Li, M
   Zhang, J
   Liang, W
   Bai, W
   Lei, X
AF Li, Mengzhong
   Zhang, Jianguo
   Liang, Wenjie
   Bai, Wenjie
   Lei, Xiaoping
TI [Thermo-electroacupuncture at yaosanzhen for chronic lumbar muscle strain of cold
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE chronic lumbar muscle strain, cold dampness; randomized controlled trial (RCT); thermo-electroacupuncture comprehensive therapy device; visual analogue scale (VAS); yaosanzhen
AB OBJECTIVE: To compare the clinical efficacy between thermo-electroacupuncture at  yaosanzhen and oral celecoxib in the treatment of chronic lumbar muscle strain  with cold dampness. METHODS: A total of 80 patients with chronic lumbar muscle  strain of cold dampness were randomly divided into an observation group (40  cases, 1 case dropped out) and a control group (40 cases, 2 cases were excluded).  The observation group was treated with thermo-electroacupuncture at yaosanzhen  (bilateral Shenshu [BL23], Dachangshu [BL25], Weizhong [BL40]), disperse-dense  wave was selected, with a pulse cycle of 0.08 s, current intensity of 1-3 mA,  with needles heated to approximately 45 ℃, the duration was 25 min per session,  once a day. The control group was given oral celecoxib capsules, once daily, 200  mg each time. Six sessions as one course, with a 1-day interval between courses,  2 courses were required in both groups. The TCM syndrome score, visual analogue  scale (VAS) score, Oswestry disability index (ODI) score, and Japanese Orthopedic  Association (JOA) score before and after treatment in both groups were compared.  The serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6),  thromboxane B2 (TXB2) and C-reactive protein (CRP) were detected using ELISA  method before and after treatment in both groups. The clinical efficacy was  evaluated in both groups after treatment. RESULTS: After treatment, the TCM  syndrome scores, VAS scores, ODI scores and serum levels of TNF-α, IL-6, TXB2,  CRP in both groups were reduced compared with those before treatment (P<0.01),  while the JOA scores were increased (P<0.01)；the TCM syndrome score, VAS score,  ODI score and serum levels of TNF-α, IL-6, TXB2, CRP in the observation group  were lower than those in the control group (P<0.01, P<0.05), and the JOA score  was higher than that in the control group (P<0.01). The total effective rate of  the observation group was 92.3% (36/39), which was superior to 78.9% (30/38) in  the control group (P<0.05). CONCLUSION: Thermo-electroacupuncture at yaosanzhen  can alleviate pain symptom in patients with chronic lumbar muscle strain of cold  dampness, regulate lumbar function, reduce the levels of inflammatory factors,  and the therapeutic effect is superior to oral celecoxib.
C1 Guangxi University of CM, Nanning 530001, China.
   Department of Acupuncture and Moxibustion, Ruikang Hospital Affiliated to Guangxi University of CM, Nanning 530011.
   Guangxi University of CM, Nanning 530001, China.
   Guangxi University of CM, Nanning 530001, China.
   Department of Acupuncture and Moxibustion, Ruikang Hospital Affiliated to Guangxi University of CM, Nanning 530011.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD OCT 11
PY 2025
VL 45
IS 10
BP 1421
EP 1426
DI 10.13703/j.0255-2930.20240924-k0001
PG 5
WC Humans; Male; Female; Middle Aged; Adult; Electroacupuncture; Acupuncture Points; Sprains and Strains; therapy; Cold Temperature; Tumor Necrosis Factor-alpha; blood; Interleukin-6; blood; Aged; Treatment Outcome; Young Adult; C-Reactive Protein; metabolism; Chronic Disease; therapy; Lumbosacral Region; physiopathology
UT PubMed:41074517
PM 41074517
DA 2025-10-11
ER

PT J
AU Wu, HWV
   Li, XT
   Li, QS
   Baser, RE
   Panageas, KS
   Chimonas, S
   Tap, WD
   Bender, JG
   Moskowitz, CS
   Mao, JJ
AF Wu, Han-Wei V.
   Li, Xiaotong
   Li, Qing S.
   Baser, Raymond E.
   Panageas, Katherine S.
   Chimonas, Susan
   Tap, William D.
   Glade Bender, Julia
   Moskowitz, Chaya S.
   Mao, Jun J.
TI Effect of Acupuncture and Massage on Pain in Adolescent and Young Adult Patients with Advanced Cancer: Subgroup Analysis of a Randomized Clinical Trial
SO JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY
LA English
DT Article; Early Access
DE pain management; health-related quality of life; supportive care; quality of life
ID integrative medicine; oncology society; electroacupuncture; management; therapy; mechanisms; symptoms; sarcoma; touch
AB Purpose: Pain management remains challenging for adolescent and young adult (AYA) cancer patients. Acupuncture and massage have been recommended for cancer-related pain management, but no prospective trials have been conducted in AYA patients. We explored the effects of acupuncture and massage on pain in AYAs. Methods: This subgroup analysis focused on AYA patients (aged 18-39 years) enrolled in a randomized controlled trial comparing acupuncture and massage for pain management in advanced cancer. Interventions were delivered weekly for 10 weeks, followed by monthly booster treatments through week 26. The primary outcome was the worst pain score from the Brief Pain Inventory, analyzed using a linear mixed-effects model. Results: Thirty participants met eligibility criteria (13 acupuncture; 17 massage), with a mean age of 31.1 years (standard deviation, 5.8); 57% were female; 67% were White; and 53% had solid tumors. Both groups experienced reduced pain over time. Relative to baseline, patients receiving acupuncture had a mean change of -1.26 points (95% confidence interval [CI], -2.54 to 0.01) at 10 weeks and a mean change of -1.46 points (95% CI, -2.78 to -0.14) at 26 weeks. Patients receiving massage experienced a mean change of -2.81 points (95% CI, -3.92 to -1.70) at week 10 and a mean change of -3.79 points (95% CI, -4.85 to -2.73) at week 26. Conclusion: AYA patients with advanced cancer who received either acupuncture or massage experienced clinically meaningful and sustained reductions in pain. These findings provide a promising foundation for future trials aimed at evaluating integrative pain management strategies in AYAs.
C1 [Wu, Han-Wei V.; Glade Bender, Julia] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA.
   [Li, Xiaotong; Li, Qing S.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,Room 456, New York, NY 10065 USA.
   [Baser, Raymond E.; Panageas, Katherine S.; Chimonas, Susan; Moskowitz, Chaya S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA.
   [Tap, William D.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,Room 456, New York, NY 10065 USA.
EM maoj@mskcc.org
FU NIH/National Cancer Institute (NCI) Cancer Center [P30 CA008748]; NCI [T32 CA275764]; PCORI award [SMPAI-2018C2-12883]; Memorial Sloan Kettering Cancer Center
CR Abdelaal M, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13040770
   Ameringer S, 2022, CANCER NURS, V45, P306, DOI 10.1097/NCC.0000000000001047
   Audino AN, 2013, PEDIATR BLOOD CANCER, V60, P415, DOI 10.1002/pbc.24231
   Beauchemin MP, 2022, CANCER-AM CANCER SOC, V128, P2777, DOI 10.1002/cncr.34238
   Bettini E, 2023, CANCER NURS, V46, PE204, DOI 10.1097/NCC.0000000000001135
   Bhatia S, 2023, J NATL COMPR CANC NE, V21, P851, DOI 10.6004/jnccn.2023.0040
   Bleyer A, 2008, NAT REV CANCER, V8, P288, DOI 10.1038/nrc2349
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Buckenmaier C, 2016, PAIN MED, V17, P1211, DOI 10.1093/pm/pnw092
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   ctepcancer, 2009, COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) VERSION 5.0, V0, P0
   Dalal Shalini, 2019, AM SOC CLIN ONCOL EDUC BOOK, V39, P24, DOI 10.1200/edbk_100020
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   Fortier MA, 2020, PEDIATR BLOOD CANCER, V67, P0, DOI 10.1002/pbc.28124
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Gentile D, 2018, J ALTERN COMPLEM MED, V24, P968, DOI 10.1089/acm.2018.0192
   Harper A, 2023, JNCI CANCER SPECT, V7, P0, DOI 10.1093/jncics/pkad049
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hsiung H, 2022, CUREUS J MED SCIENCE, V14, P0, DOI 10.7759/cureus.27361
   Hudgins JD, 2019, PLOS MED, V16, P0, DOI 10.1371/journal.pmed.1002922
   Hughes N, 2018, CANCER TREAT REV, V67, P45, DOI 10.1016/j.ctrv.2018.05.001
   Hughes RE, 2015, J ADOLESC YOUNG ADUL, V4, P70, DOI 10.1089/jayao.2014.0015
   Janardan SK, 2021, JCO ONCOL PRACT, V17, P299, DOI 10.1200/OP.21.00178
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kitzman JM, 2024, ANESTH ANALG, V139, P1244, DOI 10.1213/ANE.0000000000006623
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Li XT, 2023, INTEGR MED RES, V12, P0, DOI 10.1016/j.imr.2023.100922
   Licciardone JC, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.6026
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Lindgren L, 2012, NEUROIMAGE, V59, P3427, DOI 10.1016/j.neuroimage.2011.11.013
   Link C, 2023, J ADOLESC YOUNG ADUL, V12, P199, DOI 10.1089/jayao.2021.0213
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   Maggi G, 2021, FUTURE ONCOL, V17, P817, DOI 10.2217/fon-2020-0572
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2017, J ONCOL PRACT, V13, PE207, DOI 10.1200/JOP.2016.015081
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2023, JCO ONCOL PRACT, V19, P45, DOI 10.1200/OP.22.00622
   Miller KD, 2020, CA-CANCER J CLIN, V70, P443, DOI 10.3322/caac.21637
   National Cancer Institute, 2024, CANCER STAT FACTS: CANCER AMONG ADOLESCENTS AND YOUNG ADULTS (AYAS) (AGES 15-39), V0, P0
   Paice JA, 2023, J CLIN ONCOL, V41, P914, DOI 10.1200/JCO.22.02198
   Perez Giselle K, 2020, AM SOC CLIN ONCOL EDUC BOOK, V40, P1, DOI 10.1200/edbk_279787
   R Core Team, 2025, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0
   Rodgers-Melnick SN, 2023, PEDIATR BLOOD CANCER, V70, P0, DOI 10.1002/pbc.30243
   Romero SAD, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-058281
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Statistics NCfH, 2022, U.S. OVERDOSE DEATHS IN 2021 INCREASED HALF AS MUCH AS IN 2020-BUT ARE STILL UP 15%, V0, P0
   Steineck A, 2022, J PAIN SYMPTOM MANAG, V64, P244, DOI 10.1016/j.jpainsymman.2022.05.017
   Stöckigt B, 2019, COMPLEMENT MED RES, V26, P195, DOI 10.1159/000496063
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Yaster M, 2020, CURR OPIN ANESTHESIO, V33, P327, DOI 10.1097/ACO.0000000000000865
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang YY, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033939
NR 59
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2156-5333
EI 2156-535X
J9 J ADOLESC YOUNG ADUL
JI J. Adolesc. Young Adult Oncol.
PD AUG 13
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/21565333251368891
EA AUG 2025
PG 9
WC Oncology
SC Oncology
GA 6DR2H
UT WOS:001550878700001
PM 40803676
DA 2026-01-16
ER

PT J
AU Sun, L
   Ramalingam, MB
   Baser, R
   Santos, Teles M
   Seluzicki, C
   Li, QS
   Mao, JJ
AF Sun, Lingyun
   Ramalingam, Mothi Babu
   Baser, Raymond
   Santos Teles, Marco
   Seluzicki, Christina
   Li, Qing Susan
   Mao, Jun J
TI Acupuncture Improves Functional Limitations for Cancer Patients with Chronic
SO Current oncology (Toronto, Ont.)
LA English
DT Journal Article
DE acupuncture; cancer pain; extremity function; randomized controlled trial; rehabilitation
AB Chronic pain significantly impairs functional performance in patients with  cancer. Although acupuncture is effective for cancer-related pain, its impact on  pain-related functional interference remains unclear. This secondary analysis of  the PEACE randomized clinical trial included patients with prior cancer diagnoses  and musculoskeletal pain for ≥3 months. Participants were randomized to groups  undergoing 10 weeks of electro-acupuncture, auricular acupuncture, or a waitlist  control. Functional performance was assessed using the Quick-Disability  Arm/Shoulder/Hand (Q-DASH) for upper limbs and the Western Ontario and McMaster  Universities Osteoarthritis (WOMAC) subscale for lower limbs (higher scores =  worse function). Linear mixed models compared changes over time between groups,  with week 12 as the primary endpoint. Functional changes were also compared  between pain responders and non-responders in the acupuncture arms. Among 360  patients (mean [SD] age, 62.1 [12.7] years; 69.7% women), mean baseline Q-DASH  and WOMAC scores were 33.2 (19.8) and 33.3 (20.3). At week 12, both  electro-acupuncture and auricular acupuncture significantly improved function  versus waitlist: Q-DASH by -7.18 and -9.64 points, respectively, and WOMAC by  -6.89 and -7.61 points (all p < 0.001). No differences were found between the two  acupuncture groups. Treatment effects on Q-DASH diminished during follow-up,  while improvements on WOMAC persisted. Within the acupuncture groups, pain  responders achieved greater functional gains than non-responders (Q-DASH, -6.74;  WOMAC, -6.16; both p < 0.001). Electro-acupuncture and auricular acupuncture  improved upper and lower extremity function in cancer patients with chronic pain.  These findings support acupuncture as a potential adjunct in functional  rehabilitation for cancer survivors.
C1 Oncology Department, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering 
   Department of Rehabilitation Medicine, Singapore General Hospital, Singapore 169856, Singapore.
   Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 60637, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
NR 0
TC 0
SN 1718-772
EI 1198-005
J9 Curr Oncol
PD NOV 26
PY 2025
VL 32
IS 11
BP 
EP 
DI 10.3390/curroncol32110640
PG 0
WC Humans; Female; Male; Middle Aged; Chronic Pain; therapy; Acupuncture Therapy; methods; Aged; Neoplasms; complications; Cancer Pain; therapy
UT PubMed:41294702
PM 41294702
DA 2025-11-26
ER

PT J
AU Ma, WG
   Si, YX
   Zhang, YL
   Gao, WF
   Dong, YG
   Li, YQ
   Xu, ZF
   Xi, Q
   Li, ZZ
AF Ma, Wei-Gang
   Si, Yu-Xin
   Zhang, Yong-Long
   Gao, Wei-Fang
   Dong, Yu-Ge
   Li, Yan-Qi
   Xu, Zhi-Fang
   Xi, Qiang
   Li, Zhong-Zheng
TI Combining acupuncture and mesenchymal stem cell therapy offers promise as a treatment for inflammatory bowel disease
SO WORLD JOURNAL OF STEM CELLS
LA English
DT Review
DE Acupuncture; Mesenchymal stem cell; Inflammatory bowel disease; Anti-inflammatory; Oxidative stress
ID reactive oxygen metabolites; bone-marrow; electroacupuncture promotes; ulcerative-colitis; crohns-disease; macrophage polarization; effector function; interferon-gamma; th17 cells; differentiation
AB Inflammatory bowel disease (IBD) is a persistent gastrointestinal ailment driven by a range of immunological and pathophysiological factors, and often exposes patients to persistent pain and a greater risk of tumor development. In clinical settings, sulfasalazine is among the most common treatments used to manage IBD, but such treatment can result in a range of side effects in addition to leading to relatively poor efficacy. In certain refractory cases, patients must undergo surgical resection of affected tissues, underscoring the need to devise safer and more efficacious forms of alternative treatment. Mesenchymal stem cells (MSCs) have recently been shown to exhibit been shown to exhibit robust immunomodulatory activity and potential for differentiation such that they may be an effective tool for treating IBD. Acupuncture has also shown promise as an efficacious treatment option for IBD, performing better than drug-based treatments in certain clinical trials. Acupuncture is capable of enhancing endogenous MSC proliferation and homing, enabling these cells to more effectively migrate toward target lesion sites and to promote tissue repair. In light of these findings, this review was formulated to survey the potential therapeutic advantages of combining MSCs and acupuncture when attempting to treat IBD.
C1 [Ma, Wei-Gang; Si, Yu-Xin; Zhang, Yong-Long; Gao, Wei-Fang; Dong, Yu-Ge; Xu, Zhi-Fang] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin 301617, Peoples R China.
   [Li, Yan-Qi; Xi, Qiang] Tianjin Univ Tradit Chinese Med, Dept Clin Practice, Tianjin 301617, Peoples R China.
   [Li, Zhong-Zheng] Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Tuina, Res Ctr Expt Acupuncture Sci, 10 Poyanghu Rd West Area, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Li, ZZ (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Tuina, Res Ctr Expt Acupuncture Sci, 10 Poyanghu Rd West Area, Tianjin 301617, Peoples R China.
EM lizhzh2008@163.com
FU National Natural Science Foundation of China [82174524]
CR Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Ahn SM, 2019, MOL NEUROBIOL, V56, P157, DOI 10.1007/s12035-018-1067-z
   Albarenque SM, 2011, STEM CELL RES, V7, P163, DOI 10.1016/j.scr.2011.05.002
   An JH, 2018, BMC VET RES, V14, P0, DOI 10.1186/s12917-018-1684-9
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, P0, DOI 10.1155/2014/360438
   Bank S, 2019, ALIMENT PHARM THER, V49, P890, DOI 10.1111/apt.15187
   Bao CH, 2022, ECLINICALMEDICINE, V45, P0, DOI 10.1016/j.eclinm.2022.101300
   Bitton A, 2016, INFLAMM BOWEL DIS, V22, P416, DOI 10.1097/MIB.0000000000000608
   Bobis-Wozowicz S, 2011, EXP HEMATOL, V39, P686, DOI 10.1016/j.exphem.2011.03.004
   Boshagh MA, 2019, J INFLAMM RES, V12, P167, DOI 10.2147/JIR.S203714
   BUFFINTON GD, 1995, FREE RADICAL BIO MED, V19, P911, DOI 10.1016/0891-5849(95)94362-H
   Cao H, 2022, AM J TRANSL RES, V14, P4443
   Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342
   Casado JG, 2013, STEM CELL REV REP, V9, P184, DOI 10.1007/s12015-013-9430-y
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197
   Che J, 2024, CNS NEUROSCI THER, V30, P0, DOI 10.1111/cns.14454
   Chen Huan, 2018, ZHEN CI YAN JIU, V43, P353, DOI 10.13702/j.1000-0607.170986
   Chen QQ, 2013, WORLD J GASTROENTERO, V19, P4702, DOI 10.3748/wjg.v19.i29.4702
   Chou KJ, 2017, EXP CELL RES, V350, P91, DOI 10.1016/j.yexcr.2016.11.010
   Chung ES, 2015, EUR HEART J, V36, P2228, DOI 10.1093/eurheartj/ehv254
   Dai N, 2021, BRAIN BEHAV, V11, P0, DOI 10.1002/brb3.2328
   Danese S, 2006, WORLD J GASTROENTERO, V12, P4807
   Deng L, 2021, STEM CELL REV REP, V0, P0, DOI DOI 10.1007/s12015-021-10144-8
   Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830
   Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010
   Ding DC, 2007, CELL TRANSPLANT, V16, P273, DOI 10.3727/000000007783464777
   Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Ding Y, 2009, BMC NEUROSCI, V10, P0, DOI 10.1186/1471-2202-10-35
   Du YZ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023803
   Fabian Ondrej, 2022, CESK PATOL, V58, P27
   Fang Jian-Qiao, 2013, ZHEN CI YAN JIU, V38, P35
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Fox JM, 2007, BRIT J HAEMATOL, V137, P491, DOI 10.1111/j.1365-2141.2007.06610.x
   Gao HY, 2023, LIFE SCI, V331, P0, DOI 10.1016/j.lfs.2023.122031
   Geng YX, 2016, INFLAMMATION, V39, P1414, DOI 10.1007/s10753-016-0373-8
   Gonzalez-Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534
   GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2
   Gu L, 2021, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.660614
   Guo XY, 2019, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00047
   Han KH, 2022, COMPLEMENT THER MED, V71, P0, DOI 10.1016/j.ctim.2022.102872
   Han M, 2021, BIOMED PHARMACOTHER, V133, P0, DOI 10.1016/j.biopha.2020.111048
   Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319
   Hong G, 2023, ALTERN THER HEALTH M, V29, P228
   Hu T, 2019, INT J MOL MED, V43, P807, DOI 10.3892/ijmm.2018.4035
   Huang TI, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6624976
   Hwang NS, 2009, WIRES SYST BIOL MED, V1, P97, DOI 10.1002/wsbm.26
   Ji J, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/158352
   Jiang LH, 2023, J INTEGR MED-JIM, V21, P518, DOI 10.1016/j.joim.2023.11.005
   Jiang YD, 2021, LIFE SCI, V275, P0, DOI 10.1016/j.lfs.2021.119254
   Jin H, 2024, NATURE, V630, P0, DOI 10.1038/s41586-024-07469-y
   Jin H, 2019, STEM CELL REP, V12, P274, DOI 10.1016/j.stemcr.2018.12.015
   Jo H, 2018, GUT LIVER, V12, P664, DOI 10.5009/gnl18072
   Kaplan GG, 2021, NAT REV GASTRO HEPAT, V18, P56, DOI 10.1038/s41575-020-00360-x
   KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G
   Koutroubakis IE, 2004, DIGEST DIS SCI, V49, P1433, DOI 10.1023/B:DDAS.0000042242.22898.d9
   Kraitchman DL, 2005, CIRCULATION, V112, P1451, DOI 10.1161/CIRCULATIONAHA.105.537480
   Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008
   Kuo WT, 2021, GASTROENTEROLOGY, V161, P1924, DOI 10.1053/j.gastro.2021.08.047
   Lan TX, 2021, J HEMATOL ONCOL, V14, P0, DOI 10.1186/s13045-021-01208-w
   Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338
   Lee CH, 2001, AM J CHINESE MED, V29, P211, DOI 10.1142/S0192415X01000241
   Lee DS, 2021, GUT LIVER, V15, P70
   Lee SH, 2018, INTEST RES, V16, P26, DOI 10.5217/ir.2018.16.1.26
   Lee YS, 2024, CLIN EXP PEDIATR, V67, P152, DOI 10.3345/cep.2023.01151
   Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596
   Li FF, 2017, FRONT CARDIOVASC MED, V4, P0, DOI 10.3389/fcvm.2017.00032
   Li H, 2023, CHIN J INTEGR MED, V29, P847, DOI 10.1007/s11655-022-3531-x
   Li JL, 2023, NEUROCHEM RES, V48, P862, DOI 10.1007/s11064-022-03797-5
   Li J, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016301
   Li J, 2020, PEERJ, V8, P0, DOI 10.7717/peerj.9928
   Li W, 2015, J EXP CLIN CANC RES, V34, P0, DOI 10.1186/s13046-015-0172-3
   Li YX, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/3825617
   Liao HY, 2023, BRAIN BEHAV IMMUN, V110, P339, DOI 10.1016/j.bbi.2023.03.016
   Lin WC, 2019, J TRANSL MED, V17, P0, DOI 10.1186/s12967-019-02164-3
   Liu F, 2024, QJM-INT J MED, V117, P167, DOI 10.1093/qjmed/hcad134
   Liu GH, 2022, BIOLOGY-BASEL, V11, P0, DOI 10.3390/biology11070962
   Liu GH, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2087903
   Liu LZ, 2016, CELL PHYSIOL BIOCHEM, V38, P1605, DOI 10.1159/000443101
   Liu Z, 2011, CURR MED CHEM, V18, P5165, DOI 10.2174/092986711797636144
   Liu ZJ, 2009, WORLD J GASTROENTERO, V15, P5784, DOI 10.3748/wjg.15.5784
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054
   Lou YY, 2020, MOL MED REP, V22, P3225, DOI 10.3892/mmr.2020.11429
   Luz-Crawford P, 2013, STEM CELL RES THER, V4, P0, DOI 10.1186/scrt216
   Maerten P, 2004, CLIN EXP IMMUNOL, V135, P310, DOI 10.1111/j.1365-2249.2004.02362.x
   Mao LM, 2018, FRONT IMMUNOL, V9, P0, DOI 10.3389/fimmu.2018.02566
   Martinez-Fierro ML, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017208
   Meisel R, 2011, LEUKEMIA, V25, P648, DOI 10.1038/leu.2010.310
   Naji A, 2019, CELL MOL LIFE SCI, V76, P3323, DOI 10.1007/s00018-019-03125-1
   Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080
   Nguyen Geoffrey C, 2019, J CAN ASSOC GASTROENTEROL, V2, PS68, DOI 10.1093/jcag/gwy051
   Nitzsche F, 2017, STEM CELLS, V35, P1446, DOI 10.1002/stem.2614
   Pais I, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/217397
   Park HJ, 2018, BIOCHEM BIOPH RES CO, V498, P988, DOI 10.1016/j.bbrc.2018.03.096
   Patel M, 2020, BEST PRAC RES-CL ANA, V34, P603, DOI 10.1016/j.bpa.2020.08.005
   Pope JL, 2014, GUT, V63, P622, DOI 10.1136/gutjnl-2012-304241
   POTTEN CS, 1990, DEVELOPMENT, V110, P1001
   Ramos GP, 2019, MAYO CLIN PROC, V94, P155, DOI 10.1016/j.mayocp.2018.09.013
   Raza A, 2012, EXPERT REV CLIN IMMU, V8, P161, DOI 10.1586/ECI.11.96
   Regmi S, 2019, EUR J CELL BIOL, V98, P0, DOI 10.1016/j.ejcb.2019.04.002
   Ricart E, 2012, DIGEST DIS, V30, P387, DOI 10.1159/000338134
   Saadh MJ, 2023, EUR J MED RES, V28, P0, DOI 10.1186/s40001-023-01008-7
   Salazar TE, 2017, STEM CELLS, V35, P1303, DOI 10.1002/stem.2613
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   Sémont A, 2010, CELL DEATH DIFFER, V17, P952, DOI 10.1038/cdd.2009.187
   Shang HX, 2015, WORLD J GASTROENTERO, V21, P4986, DOI 10.3748/wjg.v21.i16.4986
   Shao YR, 2019, BIOMED PHARMACOTHER, V109, P1233, DOI 10.1016/j.biopha.2018.10.108
   Shen JL, 2024, BRAIN RES, V1826, P0, DOI 10.1016/j.brainres.2023.148715
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   SIMMONDS NJ, 1992, GASTROENTEROLOGY, V103, P186, DOI 10.1016/0016-5085(92)91112-H
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Song IH, 2018, NEPHROLOGY, V23, P483, DOI 10.1111/nep.13047
   Song SN, 2019, MOL IMMUNOL, V106, P143, DOI 10.1016/j.molimm.2018.12.023
   Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004-0359
   Stavely R, 2024, SCI REP-UK, V14, P0, DOI 10.1038/s41598-024-57070-6
   Stavely R, 2020, STEM CELL TRANSL MED, V9, P985, DOI 10.1002/sctm.19-0446
   Sun MZ, 2023, J TRADIT CHIN MED, V43, P494, DOI 10.19852/j.cnki.jtcm.2023.03.001
   Tak LJ, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22126431
   Tang YS, 2019, NEURAL PLAST, V2019, P0, DOI 10.1155/2019/2823679
   Tavakoli S, 2020, J CELL PHYSIOL, V235, P9185, DOI 10.1002/jcp.29803
   Troncone E, 2017, EXPERT OPIN DRUG SAF, V16, P779, DOI 10.1080/14740338.2017.1340936
   Ullah M, 2019, ISCIENCE, V15, P421, DOI 10.1016/j.isci.2019.05.004
   Wang Cheng-yu-lin, 2016, ZHEN CI YAN JIU, V41, P55
   Wang L, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/8253904
   Wang M, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1147718
   Wang T, 2020, BIOMATERIALS, V257, P0, DOI 10.1016/j.biomaterials.2020.120264
   Wang XJ, 2023, BIOCHEM BIOPHYS REP, V35, P0, DOI 10.1016/j.bbrep.2023.101497
   Wang YL, 2014, BRAIN RES, V1575, P78, DOI 10.1016/j.brainres.2014.05.035
   Wang ZX, 2024, REPROD SCI, V31, P2318, DOI 10.1007/s43032-024-01465-3
   Wang ZX, 2015, MOL CELL BIOCHEM, V400, P163, DOI 10.1007/s11010-014-2272-3
   Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014
   Watanabe S, 2014, J GASTROENTEROL, V49, P270, DOI 10.1007/s00535-013-0901-3
   Windsor Joseph W, 2019, CURR GASTROENTEROL REP, V21, P40, DOI 10.1007/s11894-019-0705-6
   Wu HG, 1999, WORLD J GASTROENTERO, V5, P515
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526
   Xian PP, 2019, THERANOSTICS, V9, P5956, DOI 10.7150/thno.33872
   Xiao K, 2020, CELL DEATH DIS, V11, P0, DOI 10.1038/s41419-020-03034-3
   Xu J, 2020, THERANOSTICS, V10, P12204, DOI 10.7150/thno.47683
   Xuan SS, 2023, ACUPUNCT MED, V41, P354, DOI 10.1177/09645284231169485
   Xue XH, 2014, NEUROSCI LETT, V558, P14, DOI 10.1016/j.neulet.2013.10.029
   Yan Q, 2011, EXP TOXICOL PATHOL, V63, P151, DOI 10.1016/j.etp.2009.11.002
   Yang FY, 2018, CELL TRANSPLANT, V27, P1352, DOI 10.1177/0963689718780304
   Yang XY, 2023, COMPLEMENT THER MED, V74, P0, DOI 10.1016/j.ctim.2023.102946
   Yang Y, 2021, CNS NEUROSCI THER, V27, P776, DOI 10.1111/cns.13638
   Yu JB, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0104924
   Yu Y, 1997, JPN J PHYSIOL, V47, P173, DOI 10.2170/jjphysiol.47.173
   Yu Y, 2019, J TISSUE ENG REGEN M, V13, P1792, DOI 10.1002/term.2930
   Yun WS, 2018, INT J MOL SCI, V19, P0, DOI 10.3390/ijms19051376
   Zhang H, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.861799
   Zhang K, 2014, STEM CELL REV REP, V10, P612, DOI 10.1007/s12015-014-9513-4
   Zhang Q, 2023, ISCIENCE, V26, P0, DOI 10.1016/j.isci.2023.107868
   Zhao JJ, 2021, J IMMUNOL RES, V2021, P0, DOI 10.1155/2021/8816041
   Zhao TT, 2022, OXID MED CELL LONGEV, V2022, P0, DOI 10.1155/2022/4455183
   Zhao Y, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271098
   Zhou CH, 2019, FRONT CELL NEUROSCI, V13, P0, DOI 10.3389/fncel.2019.00275
   Zhou YF, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-045090
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
NR 158
TC 0
Z9 0
U1 6
U2 6
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948-0210
EI 
J9 WORLD J STEM CELLS
JI World J. Stem Cells
PD JUL 26
PY 2025
VL 17
IS 7
BP 
EP 
DI 10.4252/wjsc.v17.i7.105371
PG 18
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 5LL8H
UT WOS:001538500300002
PM 40740536
DA 2026-01-16
ER

PT J
AU Cheng, J
   Hu, S
   Fang, Y
   Cao, G
   Jiang, T
   Wang, Y
AF Cheng, Jing
   Hu, Shiyi
   Fang, Yuru
   Cao, Guixia
   Jiang, Tao
   Wang, Yiqiao
TI [Effect of perioperative transcutaneous electrical acupoint stimulation on
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE elderly patients; inflammatory response; laparoscopic radical gastrectomy; oxidative stress; pain; postoperative fatigue syndrome; transcutaneous electrical acupoint stimulation
AB OBJECTIVE: To observe the effect of perioperative transcutaneous electrical  acupoint stimulation (TEAS) on postoperative fatigue syndrome (POFS) in elderly  patients undergoing laparoscopic radical gastrectomy. METHODS: A total of 80  elderly patients scheduled for laparoscopic radical gastrectomy were randomized  into a TEAS group and a sham TEAS group, 40 cases in each one. In the TEAS group,  TEAS intervention was applied at bilateral Hegu (LI4), Neiguan (PC6), Zusanli  (ST36) and Sanyinjiao (SP6) from 30 min before anesthesia induction until surgery  completion, and at 18:00 on 1st, 2nd and 3rd days after surgery, once a day, 30  min a time. In the sham TEAS group, the same acupoints were selected and  connected to the electroacupuncture device at the same time, without electrical  stimulation. One day before surgery and 1, 3, 7 days after surgery, the 10-item  short form of identity consequence fatigue scale (ICFS-10) score was observed,  and the POFS incidence rate of 1, 3, 7 days after surgery was assessed in the two  groups. One day before surgery, surgery completion, and 1, 3 days after surgery,  the serum levels of superoxide dismutase (SOD), β-endorphin (β-EP) were detected;  1 day before surgery and 1, 3, 7 days after surgery, the serum level of tumor  necrosis factor-α (TNF-α) was detected in the two groups. The pain visual analog  scale (VAS) score was observed at 24, 48 and 72 h after surgery; the  intraoperative dosage of propofol and remifentanil, and the incidence rate of  postoperative nausea and vomiting, itching, respiratory depression were recorded  in the two groups. RESULTS: In the TEAS group, on 1, 3, 7 days after surgery,  except for the scores of item 8-10, the item scores and the total scores of  ICFS-10 were lower than those in the sham TEAS group (P<0.001); on 3 and 7 days  after surgery, the POFS incidence rates were lower than those in the sham TEAS  group (P<0.05). In the TEAS group, on 1 and 3 days after surgery, the serum  levels of SOD were higher than those in the sham TEAS group (P<0.05, P<0.01); at  surgery completion, and on 1, 3 days after surgery, the serum levels of β-EP were  higher than those in the sham TEAS group (P<0.001, P<0.01); on 1, 3, 7 days after  surgery, the serum levels of TNF-α were lower than those in the sham TEAS group  (P<0.01, P<0.001). In the TEAS group, at 24, 48 and 72 h after surgery, the pain  VAS scores were lower than those in the sham TEAS group (P<0.001, P<0.01,  P<0.05); the intraoperative dosage of remifentanil was lower than that in the  sham TEAS group (P<0.001); the incidence rate of postoperative nausea and  vomiting was lower than that in the sham TEAS group (P<0.01). CONCLUSION:  Perioperative TEAS intervention can effectively reduce the incidence rate of  POFS, improve fatigue symptom and mental state in elderly patients undergoing  laparoscopic radical gastrectomy, its mechanism may related to enhancing  endogenous β-EP release, inhibiting inflammatory response, and reducing central  oxidative stress, thereby promoting postoperative recovery.
C1 Graduate School, Bengbu Medical University, Bengbu 233030, Anhui Province, China.
   Graduate School, Bengbu Medical University, Bengbu 233030, Anhui Province, China.
   Graduate School, Bengbu Medical University, Bengbu 233030, Anhui Province, China.
   Department of Anesthesiology, Anhui No.2 Provincial People's Hospital, Hefei 230041.
   Department of Anesthesiology, Anhui No.2 Provincial People's Hospital, Hefei 230041.
   Graduate School, Bengbu Medical University, Bengbu 233030, Anhui Province, China
   Department of Anesthesiology, Anhui No.2 Provincial People's Hospital, Hefei230041.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD AUG 19
PY 2025
VL 45
IS 8
BP 1071
EP 1077
DI 10.13703/j.0255-2930.20240814-k0004
PG 6
WC Humans; Acupuncture Points; Male; Female; Aged; Transcutaneous Electric Nerve Stimulation; Postoperative Complications; therapy; Middle Aged; Fatigue; therapy; Gastrectomy; adverse effects; beta-Endorphin; blood; Tumor Necrosis Factor-alpha; blood
UT PubMed:40825690
PM 40825690
DA 2025-08-19
ER

PT J
AU Wu, J
   Tang, Q
   Tan, X
AF Wu, Jia
   Tang, Qiong
   Tan, Xiaofei
TI Sodium hyaluronate and acupotomy bone decompression alleviates inflammatory
SO Inflammopharmacology
LA English
DT Journal Article
DE Bone marrow edema; Inflammation; Knee osteoarthritis; MRI; Needle-knife bone decompression surgery; Sodium hyaluronate
AB OBJECTIVE: Knee osteoarthritis (KOA), predominantly affecting middle-aged and  elderly populations, induces localized joint pain and functional impairment. It  was to evaluate the effectiveness of acupotomy bone decompression (ABD) combined  with sodium hyaluronate (SH) intra-articular injection on inflammatory responses  in treating KOA. METHODS: Clinical data from 128 patients with KOA were  retrospectively collected, categorized into SH group (n = 55) and ABD + SH group  (n = 73). Pain was assessed using the visual analogue scale (VAS), knee joint  function was evaluated, and knee joint balance and gait parameters were measured.  The status of articular cartilage and bone marrow edema was evaluated using  quantitative magnetic resonance imaging (MRI). Interleukin (IL)-6, IL-1β, tumor  necrosis factor (TNF)-α, matrix metalloproteinase (MMP)-3, MMP-9, and  hypersensitive C-reactive protein (hs-CRP) were detected. RESULTS: ABD + SH group  showed drastic reductions in VAS scores, decreased indices of different axial  balances, and increased stride length and walking speed versus the SH group  (P < 0.05). Quantitative MRI examination revealed that relative to the SH group,  ABD + SH group exhibited increased thickness of articular cartilage and reduced  area of bone marrow edema post-treatment (P < 0.05). Post-treatment levels of  hs-CRP, IL-6, IL-1β, TNF-α, MMP-3, and MMP-9 were markedly lower in the ABD + SH  group versus SH group (P < 0.05). Moreover, the clinical effective rate in the  ABD + SH group was drastically superior to the SH group (95.9% vs. 78.2%,  P < 0.05). CONCLUSION: Combining ABD with SH treatment for KOA effectively  alleviates patient pain and inflammatory responses.
C1 Department of Rheumatoid Osteoarthrosis, Sichuan Orthopedics Hospital, Sichuan Province, Chengdu, 610000, China.
   Department of Radiology, The People's Hospital of Chongqing Liang Jiang New Area, Chongqing, 401120, China.
   Department of Orthopedic, Yunyang County Traditional Chinese Medicine Hospital, Chongqing, 404500, China. 796458@finmail.com.
NR 0
TC 0
SN 1568-560
EI 
J9 Inflammopharmacology
PD FEB 20
PY 2025
VL 33
IS 4
BP 1997
EP 2005
DI 10.1007/s10787-025-01667-4
PG 8
WC Humans; Osteoarthritis, Knee; therapy; Male; Female; Hyaluronic Acid; administration & dosage; Middle Aged; Aged; Retrospective Studies; Inflammation; drug therapy; Decompression, Surgical; methods; Acupuncture Therapy; methods; Magnetic Resonance Imaging; methods; Knee Joint; Injections, Intra-Articular; Treatment Outcome; Pain Measurement; methods
UT PubMed:39976668
PM 39976668
DA 2025-02-20
ER

PT J
AU Williams, JE
   Kim, Y
   Moramarco, J
AF Williams, James E
   Kim, Yun
   Moramarco, Jacques
TI Research Supports the Integration of Acupuncture in Mainstream Health Care for
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; acupuncture-physician (AP); acupuncturist; biopuncture; doctor of acupuncture and herbal medicine (DAHM); doctor of oriental medicine (DOM/OMD); integrative therapies; medical acupuncture; medical doctor (MD); osteopathic doctor (DO); translational research
AB PURPOSE: To address the role of acupuncture in mainstream health care for symptom  relief, condition outcome, pain management, and shared therapy in resolving  chronic diseases. This article explores how acupuncture education can adapt to  meet the standards required for inclusion in conventional health care.  OBJECTIVES: To discuss the future of acupuncture education and its part in  training providers for inclusion in a comprehensive health care system that  involves physician acupuncturists and licensed acupuncturists for treating and  managing specific chronic diseases. To strategize the future of acupuncture  education at an advanced clinical level that fosters incorporating acupuncture  therapy into selected allopathic settings. To encourage the recognition of  translational research for promoting the acceptance of acupuncture by providers  and insurers. CONCLUSION: Translational research employs clinical evidence to  support acupuncture therapy when incorporated into selected areas of allopathic  practices, including pain management, palliative care for patients with end-stage  cancer, sleep disorders, anxiety disorders, post-traumatic stress, female  hormonal conditions such as premenstrual syndrome and menopausal syndrome, as  well as chronic fatigue syndromes including Myalgic encephalomyeltitis/chronic  fatigue syndrome (ME/CFS) and Long COVID. Advanced clinical training in  acupuncture schools and postgraduate certification courses are required to  prepare acupuncturists to safely and effectively provide the specialized  integrative acupuncture services needed in these clinical areas.
C1 Emperor's College, Culver City, CA, USA.
   Emperor's College, Culver City, CA, USA.
   Emperor's College, Culver City, CA, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD MAY 1
PY 2025
VL 37
IS 2
BP 106
EP 111
DI 10.1089/acu.2024.0108
PG 5
UT PubMed:40308724
PM 40308724
DA 2025-05-01
ER

PT J
AU Shen, Q
   Deng, D
   Li, G
   Ruan, J
   Shao, X
   Wang, P
   Li, X
   Li, R
   Bao, W
   Chen, W
   Lu, C
AF Shen, Qiongying
   Deng, Dehou
   Li, Guangliang
   Ruan, Jiayin
   Shao, Xiying
   Wang, Peipei
   Li, Xiaoyu
   Li, Rongrong
   Bao, Wenlong
   Chen, Weiji
   Lu, Chao
TI Electroacupuncture frequency for chemotherapy-induced neuropathy in breast
SO The oncologist
LA English
DT Journal Article
DE breast cancer; chemotherapy-induced peripheral neuropathy; electroacupuncture
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent  dose-limiting toxicity in breast cancer patients. Electroacupuncture (EA) shows  promise but optimal stimulation parameters remain undefined. We conducted a  randomized trial comparing EA frequencies for CIPN. METHODS: This single-center,  single-blind trial randomized patients to 2, 100, and 2/100 Hz EA, or mecobalamin  (Mecbl). The primary outcome was the patient neurotoxicity questionnaire (PNQ)  response rate at Week 4. Secondary outcomes included PNQ scores, National Cancer  Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades at  Weeks 4/8, and European Organization for Research and Treatment of Cancer Quality  of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC  QLQ-CIPN20) and Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scales.  RESULTS: 2/100 Hz EA achieved the highest overall response rate. Both 2 and  2/100 Hz EA improved PNQ sensory scores at Week 4. Sensory scores improved across  groups, while motor scores decreased with 2 and 2/100 Hz EA. Only 2 Hz EA  improved autonomic function. For quality-of-life, 2 Hz EA enhanced physical  function, fatigue, pain and insomnia, while 2/100 Hz EA improved nausea/vomiting,  constipation, appetite and global health with additional pain relief at Week 4.  The 100 Hz EA group showed no significant benefits in these domains. CONCLUSIONS:  This study preliminarily explored EA's potential benefits for CIPN, with 2/100 Hz  showing the highest response rate and 2 Hz demonstrating sensory improvement  advantages. Different frequencies produced distinct therapeutic profiles. Further  research should evaluate frequency-specific effects of EA for CIPN.
C1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   School of Nursing, The Hong Kong Polytechnic University, Hong Kong Special Administrative Region 999077, China.
   Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang, Chinese Medical University (Zhongshan Hospital of Zhejiang Province),Hangzhou 310009, China.
   Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang, Chinese Medical University (Zhongshan Hospital of Zhejiang Province),Hangzhou 310009, China.
   Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China.
NR 0
TC 0
SN 1549-490
EI 1083-715
J9 Oncologist
PD AUG 19
PY 2025
VL 30
IS 9
BP 
EP 
DI 10.1093/oncolo/oyaf262
PG 0
WC Humans; Electroacupuncture; methods; Female; Breast Neoplasms; drug therapy; Middle Aged; Peripheral Nervous System Diseases; therapy; Quality of Life; Aged; Adult; Antineoplastic Agents; adverse effects; Single-Blind Method; Vitamin B 12; analogs & derivatives
UT PubMed:40828899
PM 40828899
DA 2025-08-19
ER

PT J
AU Hamachi, A
   Matriz, J
   Fukui, J
AF Hamachi, April
   Matriz, Jobel
   Fukui, Jami
TI The use of complementary and alternative medicine among cancer patients in
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE Alternative; CAM; Cancer symptom management; Complementary; Integrative medicine
AB Complementary and alternative medicine (CAM) are medical products and practices  that are not part of standard medical care. Various studies demonstrate benefits  of CAM use in alleviating cancer related side effects. However, data involving  the use of CAM therapies among cancer patients is limited. Hawaii has a unique  and diverse population and trends in CAM use could reveal important aspects of  cancer care. We distributed questionnaires to various cancer treatment centers  across Oahu. The questionnaires were optional and anonymous. We evaluated 126  questionnaires and analyzed CAM use. We collected participant data including:  cancer type, treatments used (surgery, radiation, chemotherapy) and patient  demographics (age, gender, ethnicity, income, religion). We found that at least  one CAM therapy is used by a majority of patients 72/126 (57.1%), while 54  (42.9%) do not use any CAM therapy. Among the CAM therapies, meditation and  herbal supplements were most commonly used 26 (36.1%), followed by massage 25  (34.7%), yoga 18 (25%), CBD 17 (23.6%), THC 16 (22.2%), and acupuncture 14  (19.4%). Stress reduction was the most common symptom benefit noted for  meditation, herbal supplement, massage, and yoga. Anxiety was another symptom  benefit reported for meditation. THC and CBD are used for sleep, however, CBS was  also used for pain reduction together with acupuncture. Among the patients who  use CAM therapy (n = 72), 80.6% are female (n = 58) while only 8.3% are male  (n = 6). Furthermore only, 18.3% (n = 23) of our respondents have spoken to a  clinician about CAM. We discovered that stress reduction is a symptom benefit  associated with the most commonly used CAM therapies by cancer patients in  Hawaii. Other symptom benefits involve anxiety, pain, and sleep. The modalities  utilized were similar to nonpharmacologic therapies recommended by the NCCN  guidelines for cancer survivorship, with the exception of herbal supplements.  There is a lack of physician discussion regarding CAM use, which could impact the  cancer burden in Hawaii.
C1 John A. Burns School of Medicine, University of Hawaii, Honolulu, USA. ahamachi@hawaii.edu.
   John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.
   University of Hawaii Cancer Center, Honolulu, USA.
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD MAY 9
PY 2025
VL 25
IS 1
BP 167
EP 167
DI 10.1186/s12906-025-04912-z
PG 0
WC Humans; Complementary Therapies; statistics & numerical data; Hawaii; Male; Female; Neoplasms; therapy; Middle Aged; Adult; Aged; Surveys and Questionnaires; Young Adult; Aged, 80 and over
UT PubMed:40340689
PM 40340689
DA 2025-05-09
ER

PT J
AU Li, Y
   Li, F
   Xiao, C
   Cao, J
   Xia, D
   Wu, Y
AF Li, Yanhua
   Li, Fangfei
   Xiao, Caizhi
   Cao, Jie
   Xia, Dongqin
   Wu, Yongzhong
TI Electroacupuncture therapy and bone cancer pain relief: experimental study on
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Journal Article
DE analgesia; astrocytes; bone cancer pain; electroacupuncture; neuroimmune inflammation
AB BACKGROUND: Bone cancer pain is a common complication of advanced malignant  tumors.Chemotherapeutic drugs, regardless of their origin or type, are often  associated with various adverse effects such as gastrointestinal toxicity, immune  suppression, and acquired drug resistance, which can compromise patients' quality  of life and treatment compliance. Electroacupuncture, known for its safety and  analgesic effects, has been increasingly studied in bone cancer pain but the  underlying mechanism is not fully understood. OBJECTIVE: To explore the mechanism  of electroacupuncture in rats with bone cancer pain. METHODS: Forty-eight SD rats  were divided into four groups: blank control, sham electroacupuncture,  electroacupuncture-1, and electroacupuncture-2, with 12 rats in each group.  Except the control group, rats were inoculated with cancer cells in the left  tibia to induce bone cancer pain. The electroacupuncture groups received  interventions starting on the 6th day after modeling. Mechanical pain sensitivity  (PWT) and thermal pain sensitivity (PWL) were assessed, and the expression of  phosphorylated glycogen synthase kinase-3 (p-GSK-3) and glial fibrillary acidic  protein (GFAP) in the spinal cord were analyzed. HE staining was used to observe  tibial pathological changes. RESULTS: From the 6th day, PWT and PWL were  significantly reduced in the control group compared to the sham group (P < 0.05).  Electroacupuncture-1 significantly increased PWT and PWL compared to the sham  group (P < 0.05), while no significant changes were observed in  electroacupuncture-2 compared to the control. On day 12, spinal p-GSK-3 levels  were significantly lower and GFAP levels significantly higher in the model and  control groups compared to the electroacupuncture-1 group (P < 0.05). The  electroacupuncture-2 group showed no significant changes. Inflammatory cytokines  IL-1, IL-6, and TNF-α were significantly elevated in the model group compared to  the control (P < 0.05), but significantly reduced in the electroacupuncture-1  group (P < 0.05). HE staining showed cancer cell infiltration and bone tissue  damage in the sham and electroacupuncture groups. CONCLUSION: Electroacupuncture  significantly reduced the pain threshold in rats with bone cancer pain. This  effect is likely due to the down-regulation of GSK-3 activity, inhibition of  astrocyte activation, and reduction in inflammatory responses.
C1 Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
   Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
   Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
   Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
   Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
   Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD OCT 20
PY 2025
VL 6
IS 
BP 1597472
EP 1597472
DI 10.3389/fpain.2025.1597472
PG 0
UT PubMed:41112967
PM 41112967
DA 2025-10-20
ER

PT J
AU Wu, J
   Tang, Q
   Tan, XF
AF Wu, Jia
   Tang, Qiong
   Tan, Xiaofei
TI Sodium hyaluronate and acupotomy bone decompression alleviates inflammatory responses in patients with knee osteoarthritis
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE Knee osteoarthritis; Needle-knife bone decompression surgery; Sodium hyaluronate; Bone marrow edema; MRI; Inflammation
ID hip
AB Objective Knee osteoarthritis (KOA), predominantly affecting middle-aged and elderly populations, induces localized joint pain and functional impairment. It was to evaluate the effectiveness of acupotomy bone decompression (ABD) combined with sodium hyaluronate (SH) intra-articular injection on inflammatory responses in treating KOA. Methods Clinical data from 128 patients with KOA were retrospectively collected, categorized into SH group (n = 55) and ABD + SH group (n = 73). Pain was assessed using the visual analogue scale (VAS), knee joint function was evaluated, and knee joint balance and gait parameters were measured. The status of articular cartilage and bone marrow edema was evaluated using quantitative magnetic resonance imaging (MRI). Interleukin (IL)-6, IL-1 beta, tumor necrosis factor (TNF)-alpha, matrix metalloproteinase (MMP)-3, MMP-9, and hypersensitive C-reactive protein (hs-CRP) were detected. Results ABD + SH group showed drastic reductions in VAS scores, decreased indices of different axial balances, and increased stride length and walking speed versus the SH group (P < 0.05). Quantitative MRI examination revealed that relative to the SH group, ABD + SH group exhibited increased thickness of articular cartilage and reduced area of bone marrow edema post-treatment (P < 0.05). Post-treatment levels of hs-CRP, IL-6, IL-1 beta, TNF-alpha, MMP-3, and MMP-9 were markedly lower in the ABD + SH group versus SH group (P < 0.05). Moreover, the clinical effective rate in the ABD + SH group was drastically superior to the SH group (95.9% vs. 78.2%, P < 0.05). Conclusion Combining ABD with SH treatment for KOA effectively alleviates patient pain and inflammatory responses.
C1 [Wu, Jia] Sichuan Orthoped Hosp, Dept Rheumatoid Osteoarthrosis, Chengdu 610000, Sichuan, Peoples R China.
   [Tang, Qiong] Peoples Hosp Chongqing Liang Jiang New Area, Dept Radiol, Chongqing 401120, Peoples R China.
   [Tan, Xiaofei] Yunyang Cty Tradit Chinese Med Hosp, Dept Orthoped, Chongqing 404500, Peoples R China.
RP Tan, XF (corresponding author), Yunyang Cty Tradit Chinese Med Hosp, Dept Orthoped, Chongqing 404500, Peoples R China.
EM 796458@finmail.com
CR Alghadir AH, 2019, BMC MUSCULOSKEL DIS, V20, P0, DOI 10.1186/s12891-019-2537-9
   Åström M, 2023, QUAL LIFE RES, V32, P2719, DOI 10.1007/s11136-023-03411-3
   Benner RW, 2019, ORTHOP CLIN N AM, V50, P425, DOI 10.1016/j.ocl.2019.05.001
   Deyle GD, 2020, NEW ENGL J MED, V382, P1420, DOI 10.1056/NEJMoa1905877
   Dulic O, 2021, MEDICINA-LITHUANIA, V57, P0, DOI 10.3390/medicina57111193
   Gilbert AL, 2021, ARTHRIT CARE RES, V73, P559, DOI 10.1002/acr.24159
   Giorgino R, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24076405
   Hall M, 2022, OSTEOARTHR CARTILAGE, V30, P32, DOI 10.1016/j.joca.2021.09.010
   Hesper T, 2014, SKELETAL RADIOL, V43, P1429, DOI 10.1007/s00256-014-1852-3
   Ivkovic A, 2023, BIOMEDICINES, V11, P0, DOI 10.3390/biomedicines11071799
   Kan HS, 2019, HONG KONG MED J, V25, P0, DOI 10.12809/hkmj187600
   Kang N, 2022, SPORTS MED HLTH SCI, V4, P239, DOI 10.1016/j.smhs.2022.10.001
   Ko JH, 2019, KNEE, V26, P317, DOI 10.1016/j.knee.2019.01.010
   Li XY, 2017, BIOCHEM BIOPH RES CO, V493, P100, DOI 10.1016/j.bbrc.2017.09.068
   Liew JW, 2023, OSTEOARTHR CARTILAGE, V31, P1234, DOI 10.1016/j.joca.2023.04.015
   Lozano-Meca J, 2024, MUSCULOSKEL SCI PRAC, V72, P0, DOI 10.1016/j.msksp.2024.102983
   Moshi MR, 2023, CALCIFIED TISSUE INT, V112, P631, DOI 10.1007/s00223-023-01078-z
   Primorac D, 2020, GENES-BASEL, V11, P0, DOI 10.3390/genes11080854
   Raeissadat SA, 2021, BMC MUSCULOSKEL DIS, V22, P0, DOI 10.1186/s12891-021-04017-x
   Rampersaud YR, 2008, SPINE J, V8, P296, DOI 10.1016/j.spinee.2007.05.003
   Schwarting J, 2024, EUR RADIOL, V34, P3115, DOI 10.1007/s00330-023-10327-6
   Sukerkar PA, 2022, RADIOL CLIN N AM, V60, P605, DOI 10.1016/j.rcl.2022.03.004
   Sun CG, 2020, J ORTHOP SURG RES, V15, P0, DOI 10.1186/s13018-020-01838-9
   Sun G, 2019, BIOSCIENCE REP, V39, P0, DOI 10.1042/BSR20181346
   Tang JZ, 2020, J ORTHOP SURG RES, V15, P0, DOI 10.1186/s13018-020-01919-9
   Thomas DT, 2022, BMC MUSCULOSKEL DIS, V23, P0, DOI 10.1186/s12891-022-05557-6
   Tsubosaka M, 2024, J BIOMED MATER RES B, V112, P0, DOI 10.1002/jbm.b.35360
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Watrin A, 2001, RADIOLOGY, V219, P395, DOI 10.1148/radiology.219.2.r01ma32395
   Webner D, 2021, CARTILAGE, V13, P1619S, DOI 10.1177/19476035211017320
   Welsch GH, 2022, KNEE SURG SPORT TR A, V30, P1161, DOI 10.1007/s00167-022-06897-5
   Xu Q, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028540
   Yang ZY, 2015, ORTHOPEDICS, V38, PE1110, DOI 10.3928/01477447-20151120-08
   Yenamandra AK, 2022, CANCER GENET-NY, V268, P1, DOI 10.1016/j.cancergen.2022.07.006
NR 34
TC 2
Z9 2
U1 3
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925-4692
EI 1568-5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD APR 15
PY 2025
VL 33
IS 4
BP 1997
EP 2005
DI 10.1007/s10787-025-01667-4
EA FEB 2025
PG 9
WC Immunology; Pharmacology & Pharmacy; Toxicology
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA 1HE5C
UT WOS:001427380200001
PM 39976668
DA 2026-01-16
ER

PT J
AU Ling, WH
   Yang, CX
   Ho, MH
   Lee, JJ
AF Ling, Weihong
   Yang, Chenxi
   Ho, Mu-Hsing
   Lee, Jung Jae
TI Effectiveness of Acupressure on Sleep Quality Among Inpatients: A Systematic Review and Meta-Analysis
SO NURSING & HEALTH SCIENCES
LA English
DT Review
DE acupressure; adults; inpatients; meta-analysis; sleep quality; systematic review
ID auricular acupressure; chinese medicine; cancer; diagnosis; insomnia; therapy; patient
AB Sleep quality in adult inpatients is frequently and severely disturbed by various factors such as noise, pain, and unfamiliar surroundings, which can impair disease recovery. Acupressure is widely used to improve sleep quality in hospitalized patients, but its overall effectiveness is unclear. This meta-analysis aims to analyze the efficacy of acupressure therapy on sleep quality and sleep parameters in adult inpatients. Eight electronic databases were searched for randomized controlled trials published before April 2024. Two researchers independently screened, assessed, and extracted data from the included studies. A total of 41 studies involving 3680 subjects were included. The meta-analysis showed a significant difference between the acupressure and control groups in sleep quality (SMD = -1.58, 95% CI [-1.85, -1.31]), total sleep time (SMD = 1.12, 95% CI [0.40, 1.83]), sleep efficiency (SMD = 0.90, 95% CI [0.29, 1.52]), sleep onset latency (SMD = -0.73, 95% CI [-1.14, -0.33]), and wake after sleep onset (SMD = -1.32, 95% CI [-2.55, -0.09]). The meta-regression results suggested that the number of sessions daily and the duration of each session were significant factors influencing heterogeneity. Acupressure is an effective intervention to improve sleep quality and sleep parameters in inpatients.
C1 [Ling, Weihong; Yang, Chenxi; Ho, Mu-Hsing; Lee, Jung Jae] Univ Hong Kong, LKS Fac Med, Sch Nursing, Hong Kong, Peoples R China.
   [Ling, Weihong] Chongqing Univ, Chongqing Gen Hosp, Dept Gen Surg, Chongqing, Peoples R China.
   [Lee, Jung Jae] George Inst Global Hlth, Sydney, Australia.
C3 University of Hong Kong; Chongqing University; George Institute for Global Health
RP Lee, JJ (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Nursing, Hong Kong, Peoples R China.; Lee, JJ (corresponding author), George Inst Global Hlth, Sydney, Australia.
EM leejay@hku.hk
CR Unknown -, 1993, STANDARD ACUPUNCTURE NOMENCLATURE, V2nd, P0
   Unknown -, 2012, CHINESE JOURNAL OF MODERN NURSING, V0, P0, DOI DOI 10.3760/CMA.J.ISSN.1674-2907.2012.33.009
   Asgari MR, 2020, COMPLEMENT THER CLIN, V38, P0, DOI 10.1016/j.ctcp.2019.101066
   Ashghab A, 2024, INTENSIVE CARE RESEARCH, V4, P55, DOI 10.1007/s44231-024-00056-9
   Bagheri-Nesami Masoumeh, 2015, J TRADIT COMPLEMENT MED, V5, P241, DOI 10.1016/j.jtcme.2014.11.005
   Bang YY, 2020, APPL NURS RES, V53, P0, DOI 10.1016/j.apnr.2020.151269
   Bellon F, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-26412-7
   Bellon F, 2021, INT J NURS STUD, V115, P0, DOI 10.1016/j.ijnurstu.2020.103855
   Beswick AD, 2023, SLEEP MED, V107, P243, DOI 10.1016/j.sleep.2023.05.004
   Birling Y, 2021, CHINESE HERBAL MEDICINE FOR INSOMNIA: EVIDENCE AND EXPERIENCE., V0, P0
   Cheisson G, 2018, ANAESTH CRIT CARE PA, V37, PS5, DOI 10.1016/j.accpm.2018.02.019
   Chen B, 2021, NEW MOM AND NEW BORN, V32, P181
   Chen H, 2022, CHIN J INTEGR MED, V28, P1096, DOI 10.1007/s11655-022-3581-0
   Chen L, 2014, CHINA MODERN DOCTOR, V52, P128
   Cheng HL, 2023, J PAIN SYMPTOM MANAG, V66, PE109, DOI 10.1016/j.jpainsymman.2023.03.002
   Cho HJ, 2022, J GEN INTERN MED, V37, P2454, DOI 10.1007/s11606-021-07269-4
   Dsouza OL, 2019, INDIAN J MED SPEC, V10, P201, DOI 10.4103/INJMS.INJMS_17_19
   Dincer B, 2022, EXPLORE-NY, V18, P635, DOI 10.1016/j.explore.2021.11.010
   Eckstein M, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.555058
   Foley HM, 2019, COMPLEMENT THER MED, V42, P65, DOI 10.1016/j.ctim.2018.11.003
   Fu M, 2021, JOURNAL OF GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V38, P880, DOI 10.13359/j.cnki.gzxbtcm.2021.05.004
   Garbarino S, 2021, COMMUN BIOL, V4, P0, DOI 10.1038/s42003-021-02825-4
   Godson DR, 2019, J ACUPUNCT MERIDIAN, V12, P52, DOI 10.1016/j.jams.2018.10.009
   Gonzalez MC, 2017, J CACHEXIA SARCOPENI, V8, P187, DOI 10.1002/jcsm.12159
   Guo KX, 2024, FRONT NEUROSCI-SWITZ, V18, P0, DOI 10.3389/fnins.2024.1426618
   Haiyan Q, 2016, WESTERN J TRADITIONAL CHIN MED, V29, P112, DOI 10.3969/J.ISSN.1004-6852.2016.04.039
   Han L, 2021, ZHONGHUA YANGSHENG BAOJIAN, V39, P58
   Han X, 2019, MATERNAL AND CHILD HEALTH CARE OF CHINA, V34, P2640, DOI 10.7620/zgfybj.j.issn.1001-4411.2019.11.71
   Hendy P, 2012, CLIN MED, V12, P320, DOI 10.7861/clinmedicine.12-4-320
   Herzig SJ, 2021, SLEEP, V44, P0, DOI 10.1093/sleep/zsab064
   Higgins JPT, 2022, COCHRANE, V0, P0
   Hillman DR, 2021, ANESTH ANALG, V132, P1314, DOI 10.1213/ANE.0000000000005323
   Hou J, 2017, CHINA MODERN MEDICINE, V24, P111
   Hsieh SH, 2021, CANCER NURS, V44, PE578, DOI 10.1097/NCC.0000000000000997
   Hu Hiroe, 2019, GLOB ADV HEALTH MED, V8, P2164956119880143, DOI 10.1177/2164956119880143
   Huang F, 2014, LIAONING JOURNAL OF TRADITIONAL CHINESE MEDICINE, V41, P1726, DOI 10.13192/j.issn.1000-1719.2014.08.072
   Huang X, 2021, DRUG DES DEV THER, V15, P2161, DOI 10.2147/DDDT.S304162
   Hutsalenko OO, 2022, ACTA BALNEOL, V64, P342, DOI 10.36740/ABAL202204112
   Jain A, 2019, INTERNATIONAL JOURNAL OF CHEMICAL STUDIES, V7, P323
   Jaiswal SJ, 2017, J HOSP MED, V12, P798, DOI 10.12788/jhm.2826
   Jiang-Siebert Q, 2025, INT NURS REV, V72, P0, DOI 10.1111/inr.12989
   Jones LA, 2020, INT J BIOCHEM CELL B, V125, P0, DOI 10.1016/j.biocel.2020.105776
   Jun JH, 2021, INTENS CRIT CARE NUR, V67, P0, DOI 10.1016/j.iccn.2021.103124
   Kanji S, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2016-012108
   Kulpatcharapong Santi, 2020, SLEEP DISORD, V2020, P8518396, DOI 10.1155/2020/8518396
   Lee BH, 2021, P NATL ACAD SCI USA, V118, P0, DOI 10.1073/pnas.2113852118j1of9
   Lee SN, 2021, COMPLEMENT THER CLIN, V44, P0, DOI 10.1016/j.ctcp.2021.101447
   Li CL, 2023, ALTERN THER HEALTH M, V29, P186
   [李静 Li Jing], 2021, 世界科学技术：中医药现代化 MODERNIZATION OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA--WORLD SCIENCE AND TECHNOLOGY, V23, P2086
   Li SY, 2021, NAT SCI SLEEP, V13, P375, DOI 10.2147/NSS.S300803
   Li X, 2019, CHINESE AND FOREIGN MEDICAL RESEARCH, V17, P97, DOI 10.14033/j.cnki.cfmr.2019.23.038
   Li Zhi-Qiang, 2024, HELIYON, V10, Pe38675, DOI 10.1016/j.heliyon.2024.e38675
   Liang Y, 2021, CHINAS NATUROPATHY, V29, P59, DOI 10.19621/j.cnki.11-3555/r.2021.0224
   Lin CH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/1399258
   Lin L, 2023, WORLD JOURNAL OF SLEEP MEDICINE, V10, P732, DOI 10.3969/j.issn.2095-7130.2023.04.011
   Lin L, 2020, PATIENT PREFER ADHER, V14, P1275, DOI 10.2147/PPA.S261466
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Lindquist R, 2022, COMPLEMENTARY THERAPIES IN NURSING: PROMOTING INTEGRATIVE CARE, V0, P0, DOI DOI 10.4037/ccn2014754
   Liu MM, 2021, PAIN MANAG NURS, V22, P268, DOI 10.1016/j.pmn.2020.07.007
   Liu SQ, 2020, WORLD J SLEEP MED, V7, P1327, DOI 10.3969/J.ISSN.2095-7130.2020.08.011
   Liu Y, 2021, CHINESE AND FOREIGN MEDICAL RESEARCH, V19, P169, DOI 10.14033/j.cnki.cfmr.2021.06.065
   Liu YH, 2016, CHINESE NURSING RES, V30, P4573, DOI 10.3969/j.issn.1009-6493.2016.36.033
   Liu Y, 2024, INT J CLIN PRACT, V2024, P0, DOI 10.1155/2024/6763996
   Lozano F, 2014, ACUPUNCTURE FOR PAIN MANAGEMENT, V0, PP13, DOI 10.1007/978-1-4614-5275-12
   Lu HB, 2022, HOLIST NURS PRACT, V36, PE27, DOI 10.1097/HNP.0000000000000532
   Lu MJ, 2013, NURS RES, V62, P130, DOI 10.1097/NNR.0b013e3182781524
   Luo T, 2016, JOURNAL OF EXTERNAL THERAPY OF TRADITIONAL CHINESE MEDICINE, V25, P6
   Matos LC, 2021, HEALTHCARE-BASEL, V9, P0, DOI 10.3390/healthcare9030257
   Mehta Piyush, 2017, J TRADIT COMPLEMENT MED, V7, P251, DOI 10.1016/j.jtcme.2016.06.004
   Meng H, 2017, JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES, V23, P100, DOI 10.3969/j.issn.1672-187X.2017.03.034-0100-03
   Montakab HD, 2014, MED ACUPUNCT, V26, P315, DOI 10.1089/acu.2014.1064
   Morin CM, 2021, SLEEP MED, V81, P124, DOI 10.1016/j.sleep.2021.01.023
   Morse AM, 2019, CLOCKS SLEEP, V1, P151, DOI 10.3390/clockssleep1010014
   Moses MW, 2019, LANCET PUBLIC HEALTH, V4, PE49, DOI 10.1016/S2468-2667(18)30213-5
   National Technical Committee on Acupuncture, 2008, NOMENCLATURE AND LOCATION OF AURICULAR POINTS. (GB/T 137342008)., V0, P0
   Nelson KL, 2022, NURS FORUM, V57, P144, DOI 10.1111/nuf.12659
   Nerbass FB, 2015, ORGANIZADORES. PROFISIO PROGRAMA DE ATUALIZAO EM FISIOTERAPIA EM TERAPIA INTENSIVA ADULTO. CICLO, V0, P99
   Ni M, 2016, MODERN NURSE, V12, P104
   Nielsen A, 2020, PAIN MED, V21, P1276, DOI 10.1093/pm/pnz379
   Nys LD, 2022, PSYCHONEUROENDOCRINO, V143, P0, DOI 10.1016/j.psyneuen.2022.105843
   Ohki S, 2022, CHEM PHARM BULL, V70, P375, DOI 10.1248/cpb.c21-00982
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Ramar K, 2021, J CLIN SLEEP MED, V17, P2115, DOI 10.5664/jcsm.9476
   Relton C, 2013, COMPLEMENT THER MED, V21, P121, DOI 10.1016/j.ctim.2012.12.011
   Salajegheh Z, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-023-04292-2
   Sato-Suzuki I, 2019, AUTON NEUROSCI-BASIC, V220, P0, DOI 10.1016/j.autneu.2019.102557
   Schünemann HJ, 2020, J CLIN EPIDEMIOL, V122, P142, DOI 10.1016/j.jclinepi.2019.12.021
   Sha YS, 2016, TIANJIN J NURSING, V24, P496, DOI 10.3969/J.ISSN.1006-9143.2016.06.010
   Sun M, 2022, REFLEXOLOGY AND REHABILITATION MEDICINE, V3, P51
   Sun S, 2021, JOURNAL OF NEW CHINESE MEDICINE, V53, P186, DOI 10.13457/j.cnki.jncm.2021.16.048
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Tan JY, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0132989
   Tian M, 2021, FRONT CHEM, V9, P0, DOI 10.3389/fchem.2021.666280
   Vedantam D, 2022, CUREUS J MED SCIENCE, V14, P0, DOI 10.7759/cureus.26714
   Vin-Raviv N, 2018, SUPPORT CARE CANCER, V26, P1833, DOI 10.1007/s00520-017-4012-1
   Waits A, 2018, SLEEP MED REV, V37, P24, DOI 10.1016/j.smrv.2016.12.004
   Wang J, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033213
   Wang XT, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101151
   Wang Y, 2024, TEXTBOOK OF TRADITIONAL CHINESE MEDICINE: VOLUME 1: INTRODUCTION, V0, P0
   Wang Y, 2023, SMART HEALTH, V9, P158, DOI 10.19335/j.cnki.2096-1219.2023.14.039
   Wei Q, 2014, CHINESE JOURNAL OF ETHNOMEDICINE AND ETHNOPHARMACY, V14, P42
   Wei Y, 2021, JOURNAL OF CHANGCHUN UNIVERSITY OF CHINESE MEDICINE, V37, P1134, DOI 10.13463/j.cnki.cczyy.2021.05.049
   White B, 2023, J PHARM PRACT, V36, P126, DOI 10.1177/08971900211017857
   Wu J, 2017, SHAANXI J TRAD CHIN MED, V38, P103, DOI 10.3969/j.issn.1000-7369.2017.01.051
   Wu L, 2015, CHINESE RURAL HEALTH SERVICE ADMINISTRATION, V35, P662
   Xiao A, 2015, JOURNAL OF EXTERNAL THERAPY OF TRADITIONAL CHINESE MEDICINE, V24, P15, DOI 10.3969/j.issn.1006-978X.2015.02.007
   Xie WX, 2023, INT J NURS STUD, V145, P0, DOI 10.1016/j.ijnurstu.2023.104531
   Xie ZZ, 2017, NEUROL RES, V39, P559, DOI 10.1080/01616412.2017.1315864
   2023, 1900, V4, V0, P0, DOI DOI 10.38007/ijwm.2023.040209
   Yang X, 2021, JOURNAL OF MEDICAL THEORY AND PRACTICE, V34, P1583, DOI 10.19381/j.issn.1001-7585.2021.09.070
   Yang Y, 2019, MEDICAL FORUM, V23, P771, DOI 10.19435/j.1672-1721.2019.06.016
   Yao J, 2023, MATERNAL AND CHILD HEALTH CARE OF CHINA, V38, P3126, DOI 10.19829/j.zgfybj.issn.10014411.2023.16.046
   Ye Yu-Fei, 2019, ZHONGGUO ZHEN JIU, V39, P605, DOI 10.13703/j.0255-2930.2019.06.010
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yin R, 2014, SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V8, P710, DOI 10.13460/j.issn.1005-0957.2014.08.0710
   Yoon DE, 2022, AM J CHINESE MED, V50, P653, DOI 10.1142/S0192415X22500264
   Younis MB, 2018, CRIT CARE NURS Q, V41, P170, DOI 10.1097/CNQ.0000000000000196
   Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238
   Zhang Z, 2023, HENAN MEDICAL RESEARCH, V32, P4363, DOI 10.3969/j.issn.1004-437x.2023.23.034
   Zhao L, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/543943
   Zhou Z, 2023, JOURNAL OF MEDICAL THEORY AND PRACTICE, V36, P343, DOI 10.19381/j.issn.1001-7585.2023.02.065
   Zhu Y, 2020, CHINA MODERN DOCTOR, V58, P173
NR 122
TC 0
Z9 1
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1441-0745
EI 1442-2018
J9 NURS HEALTH SCI
JI Nurs. Health Sci.
PD MAR 6
PY 2025
VL 27
IS 1
BP 
EP 
DI 10.1111/nhs.70075
PG 22
WC Nursing
SC Nursing
GA Z4Q1U
UT WOS:001438764300001
PM 40049603
DA 2026-01-16
ER

PT J
AU Li, BY
   Liu, CZ
   Zhou, H
   Wei, XY
   Jia, JY
   Wang, J
   Guo, XY
   Liang, W
   Tu, JF
   Wang, LQ
   Shi, GX
   Yang, JW
   Yang, NN
AF Li, Bin-Yan
   Liu, Cun-Zhi
   Zhou, Hang
   Wei, Xiao-Ya
   Jia, Jin-Ying
   Wang, Jun
   Guo, Xiao-Yan
   Liang, Wei
   Tu, Jian-Feng
   Wang, Li-Qiong
   Shi, Guangxia
   Yang, Jing-Wen
   Yang, Na-Na
TI Acupuncture for preventing chemotherapy-induced peripheral neuropathy: study protocol for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE Acupuncture; CHEMOTHERAPY; Clinical Trial; Neurological injury
ID clinical-practice guidelines; integrative oncology; lung-cancer; severity; women; pain; cipn
AB Introduction Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent non-haematological, dose-limiting adverse event associated with platinum derivatives and taxanes. Currently, no effective prophylactic interventions for CIPN have been established. However, several studies have shown that acupuncture may alleviate symptoms of peripheral neuropathy, proposing it as a potentially effective strategy for CIPN prevention. This pilot trial will help determine the feasibility and efficacy of acupuncture for preventing CIPN. The results will provide valuable insights for designing a larger clinical trial and conducting power calculations.Methods and analysis This is a randomised sham-controlled trial. A cohort of 60 patients scheduled to receive chemotherapy will be enrolled and randomly assigned to either the electroacupuncture group or the sham acupuncture group. Eligible patients will receive nine treatment sessions administered over the course of three chemotherapy cycles. The primary outcome is the change in CIPN-related quality of life (QOL) measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) CIPN20 from baseline to the end of cycle three. Secondary outcomes include: neurotoxicity symptoms assessed by the Numeric Rating Scale, incidence of CIPN, chemotherapy status, insomnia symptoms measured by the Insomnia Severity Index, depression symptoms evaluated using the Beck Depression Inventory-II, anxiety symptoms assessed with the Generalised Anxiety Disorder-7 and fatigue symptoms measured by the Brief Fatigue Inventory. Adverse events will be meticulously recorded.Ethics and dissemination The study protocol (V.1.0, 29 July 2024) has been approved by the First Affiliated Hospital of Zhengzhou University (2024-KY-0853-001). All patients will provide oral informed consent and written informed consent before participating in this study. Trial results will be disseminated in peer-reviewed publications.Trial registration number ITMCTR2024000390 (International Traditional Medicine Clinical Trial Registry, http://itmctr.ccebtcm.org.cn/zh-CN/Home/ProjectView?pid=16387992-8971-4218-9cd0-b623af91f9f3), registered on 3 September 2024.
C1 [Li, Bin-Yan; Liu, Cun-Zhi; Zhou, Hang; Wei, Xiao-Ya; Tu, Jian-Feng; Wang, Li-Qiong; Shi, Guangxia; Yang, Jing-Wen; Yang, Na-Na] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Jia, Jin-Ying; Wang, Jun; Guo, Xiao-Yan; Liang, Wei] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
C3 Beijing University of Chinese Medicine; Zhengzhou University
RP Yang, NN (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
EM lby05192022@163.com; lcz623780@126.com; 2721955078@qq.com; xiaoya0414@vip.qq.com; 436008247@qq.com; zywj1968@163.com; guo_xiaoyan88@163.com; lllwww2016@163.com; tujianfeng1@126.com; wangliqiongwork@163.com; shiguangxia2008@126.com; yangjw0626@126.com; 1254614551@qq.com
FU Qihuang Scholar Project of the National Administration of Traditional Chinese Medicine
CR Unknown -, 1988, NUTR REV, V46, P12
   Bang H, 2016, CONT CLIN TRIAL COMM, V3, P117, DOI 10.1016/j.conctc.2016.05.003
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13
   Beijers AJM, 2020, ANN ONCOL, V31, P131, DOI 10.1016/j.annonc.2019.09.006
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Chan KY, 2023, ACUPUNCT MED, V41, P268, DOI 10.1177/09645284221125421
   Chine VB, 2019, MOL NEUROBIOL, V56, P3244, DOI 10.1007/s12035-018-1301-8
   Das M, 2017, LANCET ONCOL, V18, PE202, DOI 10.1016/S1470-2045(17)30182-1
   De Falco V, 2019, ESMO OPEN, V4, P0, DOI 10.1136/esmoopen-2020-000813
   Denduluri N, 2018, CLIN BREAST CANCER, V18, P380, DOI 10.1016/j.clbc.2018.02.003
   Desai N, 2022, JAMA INTERN MED, V182, P766, DOI 10.1001/jamainternmed.2022.1812
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Gewandter JS, 2020, SUPPORT CARE CANCER, V28, P2553, DOI 10.1007/s00520-019-05063-x
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   James KE, 1996, STAT MED, V15, P1421
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Joseph N, 2015, GYNECOL ONCOL, V137, P401, DOI 10.1016/j.ygyno.2015.03.052
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Li TFY, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.24139
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Ma YY, 2023, J EXP CLIN CANC RES, V42, P0, DOI 10.1186/s13046-023-02804-z
   Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Park SB, 2009, J CLIN ONCOL, V27, P1243, DOI 10.1200/JCO.2008.19.3425
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Singh N, 2010, J THORAC ONCOL, V5, P236, DOI 10.1097/JTO.0b013e3181c3f5f7
   Smith EML, 2013, QUAL LIFE RES, V22, P2787, DOI 10.1007/s11136-013-0379-8
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yang YH, 2012, SUPPORT CARE CANCER, V20, P1491, DOI 10.1007/s00520-011-1237-2
   Yeo F, 2019, SUPPORT CARE CANCER, V27, P4753, DOI 10.1007/s00520-019-04771-8
   Yusufov M, 2019, PSYCHO-ONCOLOGY, V28, P540, DOI 10.1002/pon.4973
NR 48
TC 0
Z9 0
U1 16
U2 16
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUL 29
PY 2025
VL 15
IS 7
BP 
EP 
DI 10.1136/bmjopen-2025-102588
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 5MR6F
UT WOS:001539330200001
PM 40730402
DA 2026-01-16
ER

PT J
AU Huang, XR
   Xu, M
   Xu, Y
   Wang, SJ
   Ni, FL
AF Huang, Xin-Rui
   Xu, Min
   Xu, Yan
   Wang, Shu-Jie
   Ni, Fei-Lin
TI Auricular acupressure for insomnia in women with breast cancer A systematic review and meta-analysis of randomized controlled trials
SO MEDICINE
LA English
DT Review
DE auricular acupressure; auricular point; lymphoma; non-pharmacological therapy; sleep disorder; systematic review; Traditional Chinese Medicine therapy
ID single-blind; acupuncture; sleep; association; prevalence; efficacy; quality; anxiety; pain
AB Background: Breast cancer as the malignant tumor with the highest incidence and mortality rate among the global female population. Insomnia is a common complaint in breast cancer patients, more than one-third (38-47%) of breast cancer patients suffer it. Auricular acupressure (AA), a non-pharmacological therapy, has been used in the studies to intervene in insomnia in breast cancer patients. The objective of this systematic review and meta-analysis is to investigate the efficacy and safety of AA therapy in intervening with insomnia in breast cancer. Methods: A systematic literature search was performed for 10 databases up to January of 2024 to identify randomized control trials (RCTs). The methodological quality of RCTs was assessed independently using the Cochrane Handbook for Systematic Reviews of Interventions. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. Data were screened and extracted independently using predesigned forms. The meta-analysis was conducted using RevMan 5.3 software, P-value <.05 means statistically significant. Results: This review included 15 studies from 3 different countries with a total of 1125 adult participants. The pooled results showed that AA significantly in improving sleep quality (mean difference [MD] = -3.36, 95% confidence interval [CI]: [-4.65, -2.07], P <.001) and life quality (MD = -7.82, 95% CI: [-14.76, -0.88], P =.03). Based on data from sleep monitoring devices, AA was valuable for improving sleep efficiency (MD = -3.63, 95% CI: [-4.19,-3.07], P =.03) in breast cancer patients. Adverse events were reported in 5 RCTs. Common adverse reactions include auricular skin allergic reaction (10/259, 3.9%), bruising (7/259, 2.7%), pain (3/259, 1.2%), and local pressure ulcers on the auricular points (2/259, 0.8%). The evidence grade was moderate because of the substantial heterogeneity among studies. Heart, Shenmen, and Subcortex were the 3 most numerous auricular points, with a total share of up to 71.70%. Conclusion: This systematic review and meta-analysis demonstrates the efficacy and safety of AA in intervening insomnia in breast cancer patients, providing a basis for the selection of clinical auricular points. However, the high-quality RCTs in existence are not enough, and more rigorous trials are needed to identify the efficacy of AA and insomnia.
C1 [Huang, Xin-Rui] Zhejiang Chinese Med Univ, Dept Neurol, Zhejiang Prov Hosp Chinese Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
   [Xu, Min] Zhejiang Chinese Med Univ, Off Dean, Zhejiang Prov Hosp Chinese Med, Affiliated Hosp 1, Dean, Hangzhou, Zhejiang, Peoples R China.
   [Xu, Yan] Zhejiang Univ Chinese Med, Coll Nursing, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Shu-Jie] Zhejiang Chinese Med Univ, Dept Breast Dis, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Hangzhou, Zhejiang, Peoples R China.
   [Ni, Fei-Lin] Zhejiang Chinese Med Univ, Dept Neurol, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Xu, M (corresponding author), Zhejiang Chinese Med Univ, Off Dean, Zhejiang Prov Hosp Chinese Med, Affiliated Hosp 1, Dean, Hangzhou, Zhejiang, Peoples R China.
EM yudi1212@163.com
CR Abdo J, 2023, SURG CLIN N AM, V103, P155, DOI 10.1016/j.suc.2022.08.014
   Araújo T, 2017, SLEEP MED REV, V31, P58, DOI 10.1016/j.smrv.2016.01.003
   Blake MJ, 2018, CLIN PSYCHOL REV, V63, P25, DOI 10.1016/j.cpr.2018.05.006
   Boldyrev L, 2022, AM SURGEON, V88, P2730, DOI 10.1177/00031348221078949
   Buysse DJ, 2013, JAMA-J AM MED ASSOC, V309, P706, DOI 10.1001/jama.2013.193
   Cao W, 2021, CHINESE MED J-PEKING, V134, P783, DOI 10.1097/CM9.0000000000001474
   Chen H, 2022, CHIN J INTEGR MED, V28, P1096, DOI 10.1007/s11655-022-3581-0
   Cunnington D, 2013, MED J AUSTRALIA, V199, PS36, DOI 10.5694/mja13.10718
   Fa XY, 2021, CHINA FOREIGN MED TREATMENT, V40, P159
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Han J, 2023, COMPLEMENT THER MED, V75, P0, DOI 10.1016/j.ctim.2023.102954
   Hazard-Jenkins HW, 2022, OBSTET GYN CLIN N AM, V49, P209, DOI 10.1016/j.ogc.2021.11.008
   Huang JY, 2022, MAGNETIC BEAD AURICULAR ACUPUNCTURE POINTS COMBINED WITH CHINESE MEDICINES FOR THE TREATMENT OF LIVER DEPRESSION AND BLOOD DEFICIENCY A CLINICAL STUDY OF BREAST CANCER WITH ANXIETY AND DEPRESSION, V0, P0
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Kay-Stacey M, 2016, BMJ-BRIT MED J, V354, P0, DOI 10.1136/bmj.i2123
   Kim SA, 2021, AM J CHINESE MED, V49, P1135, DOI 10.1142/S0192415X21500543
   Ko YL, 2016, J CLIN NURS, V25, P332, DOI 10.1111/jocn.13053
   Kong XL, 2023, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.1016222
   Kuo SY, 2016, INT J NURS STUD, V53, P17, DOI 10.1016/j.ijnurstu.2015.10.006
   Kwak A, 2020, BREAST CANCER RES TR, V181, P269, DOI 10.1007/s10549-020-05635-0
   Lei SY, 2021, CANCER COMMUN, V41, P1183, DOI 10.1002/cac2.12207
   Li XY, 2019, HEBEI J TCM, V41, P1526
   Liang YY, 2020, LABORATORY MED CLINIC, V17, P1118
   Lin J, 2018, FUJIAN J TCM, V49, P75, DOI 10.13260/j.cnki.jfjtcm.011643
   Liu MM, 2021, PAIN MANAG NURS, V22, P268, DOI 10.1016/j.pmn.2020.07.007
   Liu SM, 2023, J QILU NURS., V29, P29
   Madari S, 2021, NEUROTHERAPEUTICS, V18, P44, DOI 10.1007/s13311-021-01010-z
   Mokhatri-Hesari P, 2020, HEALTH QUAL LIFE OUT, V18, P0, DOI 10.1186/s12955-020-01591-x
   Pei M, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.576050
   Plevritis SK, 2018, JAMA-J AM MED ASSOC, V319, P154, DOI 10.1001/jama.2017.19130
   Qin XY, 2015, CLINICAL J CHIN MED, V11, P61
   Sator-Katzenschlager SM, 2004, ANESTH ANALG, V98, P1359, DOI 10.1213/01.ANE.0000107941.16173.F7
   Schieber K, 2019, SLEEP MED, V58, P107, DOI 10.1016/j.sleep.2019.02.018
   Singh D, 2023, LANCET GLOB HEALTH, V11, PE197, DOI 10.1016/S2214-109X(22)00501-0
   Stedman Margaret R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP244, DOI 10.1093/jncimonographs/lgu015
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sutton EL, 2021, ANN INTERN MED, V174, PITC33, DOI 10.7326/AITC202103160
   Waits A, 2018, SLEEP MED REV, V37, P24, DOI 10.1016/j.smrv.2016.12.004
   Wan QY, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.856093
   Wang LJ, 2020, J NANOPART RES, V22, P0, DOI 10.1007/s11051-019-4724-x
   Wang Y, 2014, J NURS (CHINA), V21, P68
   Wang YY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8637386
   Wong WS, 2011, J SLEEP RES, V20, P117, DOI 10.1111/j.1365-2869.2010.00822.x
   Wu J, 2017, SHAANXI J TRAD CHIN MED, V38, P103, DOI 10.3969/j.issn.1000-7369.2017.01.051
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zeng ZH, 2019, THERAPEUTIC EFFICACY OF MAGNETIC BEAD AURICULAR ACUPOINT THERAPY ON INSOMNIA IN BREAST CANCER PATIENTS WITH LIVERDEPRESSION AND SPLEEN-DEFICIENCY TYPE OF BREAST CANCER, V0, P0
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   Zhao DM, 2020, ZHONGHUA XIANDAI HULI ZAZHI, V26, P505, DOI 10.3760/cma.j.issn.1674-2907.2020.04.015
NR 52
TC 4
Z9 5
U1 6
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB 14
PY 2025
VL 104
IS 7
BP 
EP 
DI 10.1097/MD.0000000000041498
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 2YJ5N
UT WOS:001494259000101
PM 39960920
DA 2026-01-16
ER

PT J
AU Giambrone, G
   Catone, G
   Marino, G
   Sfacteria, A
   Miloro, R
   Vullo, C
AF Giambrone, Giada
   Catone, Giuseppe
   Marino, Gabriele
   Sfacteria, Alessandra
   Miloro, Renato
   Vullo, Cecilia
TI Perioperative Pain Management for Mastectomy in Dogs: A Narrative Review
SO ANIMALS
LA English
DT Review
DE mastectomy; pain management; dog
ID abdominis plane block; postoperative pain; local-anesthesia; mammary-tumors; tumescent technique; analgesia; lidocaine; tramadol; bitches; methadone
AB Mammary tumours are the most common neoplasia in adult female dogs. Mastectomy leads to moderate to severe pain. Effective pain management is crucial in veterinary medicine. This review outlines analgesic techniques for managing perioperative pain in dogs undergoing mastectomy. A literature search on dog mastectomy analgesia was conducted from January 2001 to January 2025. Pre-emptive meloxicam reduces postoperative cardiovascular changes without affecting renal function. When combined with gabapentin, it lowers the need for rescue analgesic opioids, similar to robenacoxib. With regard to tramadol, it offers contrasting analgesia in the studies considered when used alone, while its effect appears enhanced when used in combination with meloxicam/dipyrone. However, methadone provides superior pain control, especially when given preoperatively or intraoperatively. The combination of ketamine, lidocaine, and maropitant enhances pain management, while fentanyl, alone or with lidocaine and ketamine, is effective for intraoperative pain control. Local infiltration with lidocaine/bupivacaine provides effective pain control, and devices like Comfont-in (R) or WSC facilitate this process. Tumescent anaesthesia using lidocaine/ropivacaine allows for extensive infiltration of the mammary gland. Epidural analgesia, paravertebral blocks, and TAP blocks are beneficial in multimodal protocols. Transdermal patches containing fentanyl/buprenorphine offer prolonged analgesia, while electroacupuncture can help reduce the need for rescue analgesics. Multimodal analgesic protocols are crucial for effective pain management in dog mastectomy surgeries, minimising the need for rescue opioids.
C1 [Giambrone, Giada; Catone, Giuseppe; Marino, Gabriele; Sfacteria, Alessandra; Miloro, Renato] Univ Messina, Dept Vet Sci, Via G Palatucci, I-98168 Messina, Italy.
   [Vullo, Cecilia] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno Alcontres 31, I-98166 Messina, Italy.
C3 University of Messina; University of Messina
RP Giambrone, G (corresponding author), Univ Messina, Dept Vet Sci, Via G Palatucci, I-98168 Messina, Italy.
EM ggiambrone97@gmail.com; giuseppe.catone@unime.it; gabriele.marino@unime.it; alessandra.sfacteria@unime.it; renato.miloro@gmail.com; cecilia.vullo@unime.it
CR Abdallah FW, 2012, REGION ANESTH PAIN M, V37, P193, DOI 10.1097/AAP.0b013e3182429531
   Abelson AL, 2009, VET ANAESTH ANALG, V36, P597, DOI 10.1111/j.1467-2995.2009.00487.x
   Abimussi CJX, 2014, VET ANAESTH ANALG, V41, P516, DOI 10.1111/vaa.12178
   de la Torre PA, 2014, AESTHET SURG J, V34, P198, DOI 10.1177/1090820X13515902
   Allen C, 2004, NOUS, V38, P617, DOI 10.1111/j.0029-4624.2004.00486.x
   Unknown -, 2005, VADE-MECUM DANESTHESIE DES CARNIVORES DOMESTIQUES, V0, P0
   Unknown -, 2022, AAHA PAIN MANAGEMENT GUIDELINES FOR DOGS AND CATS, V0, P0
   Antonucci F, 2008, J NEUROSCI, V28, P3689, DOI 10.1523/JNEUROSCI.0375-08.2008
   Bacarin CD, 2022, J ACUPUNCT MERIDIAN, V15, P121, DOI 10.51507/j.jams.2022.15.2.121
   Bach-Rojecky L, 2009, PHARMACOL BIOCHEM BE, V94, P234, DOI 10.1016/j.pbb.2009.08.012
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Becerra JRH, 2022, VET ANAESTH ANALG, V49, P126, DOI 10.1016/j.vaa.2021.10.001
   Beier SL, 2015, SEMIN-CIENC AGRAR, V36, P3139, DOI 10.5433/1679-0359.2015v36n5p3139
   Bergh A, 2021, ANIMALS-BASEL, V11, P0, DOI 10.3390/ani11123356
   Berry SH, 2015, VET CLIN N AM-SMALL, V45, P1013, DOI 10.1016/j.cvsm.2015.04.007
   Boeer B, 2023, ARCH GYNECOL OBSTET, V308, P935, DOI 10.1007/s00404-023-06938-5
   Camu Frederic, 2002, BEST PRACT RES CLIN ANAESTHESIOL, V16, P475, DOI 10.1053/bean.2002.0262
   Caramalac SM, 2022, AN ACAD BRAS CIENC, V94, P0, DOI 10.1590/0001-3765202220210082
   Cardozo HG, 2024, VET ANAESTH ANALG, V51, P381, DOI 10.1016/j.vaa.2024.04.006
   Carpenter RE, 2004, VET ANAESTH ANALG, V31, P46, DOI 10.1111/j.1467-2995.2004.00137.x
   Chrisman C, 2007, XIES VETERINARY ACUPUNCTURE, V0, PP129, DOI 10.1002/9780470344569.ch5
   Cicirelli V, 2022, VET MED SCI, V8, P469, DOI 10.1002/vms3.691
   Costa GL, 2024, ANIMALS-BASEL, V14, P0, DOI 10.3390/ani14131902
   Crociolli GC, 2015, J VET MED SCI, V77, P1011, DOI 10.1292/jvms.14-0602
   Cui ML, 2004, PAIN, V107, P125, DOI 10.1016/j.pain.2003.10.008
   de Moura RS, 2022, BMC VET RES, V18, P0, DOI 10.1186/s12917-022-03244-1
   Della Rocca G, 2018, VET ITAL, V54, P251, DOI 10.12834/VetIt.699.3421.3
   Dewey CW, 2021, OPEN VET J, V11, P203, DOI 10.5455/OVJ.2021.v11.i2.3
   Donati PA, 2021, VET ANAESTH ANALG, V48, P283, DOI 10.1016/j.vaa.2021.01.003
   Engwerda EEC, 2011, DIABETES CARE, V34, P1804, DOI 10.2337/dc11-0182
   Enomoto H, 2022, J VET PHARMACOL THER, V45, P358, DOI 10.1111/jvp.13056
   Fernandez-Parra R, 2017, VET ANAESTH ANALG, V44, P356, DOI 10.1016/j.vaa.2016.03.010
   Firth AM, 1999, J AM VET MED ASSOC, V214, P651
   Friton G, 2017, J VET INTERN MED, V31, P832, DOI 10.1111/jvim.14698
   Gach K, 2011, N-S ARCH PHARMACOL, V384, P221, DOI 10.1007/s00210-011-0672-4
   Gakiya HH, 2011, ACTA CIR BRAS, V26, P346, DOI 10.1590/S0102-86502011000500004
   Galosi M, 2022, ANIMALS-BASEL, V12, P0, DOI 10.3390/ani12243468
   GILBERTSON SR, 1983, VET PATHOL, V20, P127, DOI 10.1177/030098588302000201
   Groeben Harald, 2006, J ANESTH, V20, P290, DOI 10.1007/s00540-006-0425-6
   Credie LDGA, 2013, BMC VET RES, V9, P0, DOI 10.1186/1746-6148-9-178
   Gupta K, 2002, CANCER RES, V62, P4491
   Hill R, 2000, TRENDS PHARMACOL SCI, V21, P244, DOI 10.1016/S0165-6147(00)01502-9
   Horta RS, 2015, ACTA VET SCAND, V57, P0, DOI 10.1186/s13028-015-0121-3
   Interlandi C, 2022, ANIMALS-BASEL, V12, P0, DOI 10.3390/ani12223134
   Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033
   Kinobe RT, 2020, VET J, V259-26, P0, DOI 10.1016/j.tvjl.2020.105471
   Klein JA, 1999, DERMATOL CLIN, V17, P751, DOI 10.1016/S0733-8635(05)70124-8
   KLEIN JA, 1993, PLAST RECONSTR SURG, V92, P1085, DOI 10.1097/00006534-199311000-00014
   Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316
   Lehnhardt Marcus, 2008, PLAST RECONSTR SURG, V121, P396e, DOI 10.1097/PRS.0b013e318170817a
   Lemke KA, 2010, TOP COMPANION ANIM M, V25, P70, DOI 10.1053/j.tcam.2009.12.003
   Marquesa EJ, 2023, TOP COMPANION ANIM M, V52, P0, DOI 10.1016/j.tcam.2022.100759
   Marquez M, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140734
   Martins TL, 2010, AM J VET RES, V71, P1019, DOI 10.2460/ajvr.71.9.1019
   Moe L, 2001, J REP FER S, V0, P439
   Moiniche S, 1998, BRIT J ANAESTH, V81, P377, DOI 10.1093/bja/81.3.377
   Monteiro BP, 2023, J SMALL ANIM PRACT, V64, P177, DOI 10.1111/jsap.13566
   Nakagawa K, 2007, J VET MED SCI, V69, P939, DOI 10.1292/jvms.69.939
   Novosad CA, 2003, CLIN TECH SMALL AN P, V18, P107, DOI 10.1053/svms.2003.36625
   Ochroch EA, 2003, DRUGS, V63, P2709, DOI 10.2165/00003495-200363240-00002
   Oderda G, 2012, PHARMACOTHERAPY, V32, P6S, DOI 10.1002/j.1875-9114.2012.01177.x
   Ostad A, 1996, DERMATOL SURG, V22, P921, DOI 10.1111/j.1524-4725.1996.tb00634.x
   Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6
   Pinheiro AV, 2023, ANIMALS-BASEL, V13, P0, DOI 10.3390/ani13213392
   Polton G, 2009, IRISH VET J, V62, P50
   Portela DA, 2014, VET ANAESTH ANALG, V41, P319, DOI 10.1111/vaa.12122
   Rocha FD, 2022, ACTA SCI VET, V50, P0, DOI 10.22456/1679-9216.120564
   Rocha FD, 2020, ACTA SCI VET, V48, P0, DOI 10.22456/1679-9216.102649
   Rutherford KMD, 2002, ANIM WELFARE, V11, P31
   Salas Y, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0127381
   Sanches Mariana Cardoso, 2020, CIÊNC. ANIM. BRAS., V21, Pe, DOI 10.1590/1809-6891v21e-53552
   Santamaria LB, 2010, SURG ONCOL, V19, P63, DOI 10.1016/j.suronc.2009.03.007
   Santoro F, 2022, JAVMA-J AM VET MED A, V260, PS53, DOI 10.2460/javma.21.04.0188
   Sarrau S, 2007, J SMALL ANIM PRACT, V48, P670, DOI 10.1111/j.1748-5827.2007.00362.x
   Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444
   Shimizu N, 2007, DTSCH. Z. AKUPUNKT, V50, P6, DOI 10.1078/0415-6412-00258
   Shipton EA, 2000, ANAESTH INTENS CARE, V28, P363, DOI 10.1177/0310057X0002800403
   Sleeckx N, 2011, REPROD DOMEST ANIM, V46, P1112, DOI 10.1111/j.1439-0531.2011.01816.x
   Slingsby LS, 2000, RES VET SCI, V69, P147, DOI 10.1053/rvsc.2000.0406
   Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3
   Soares PCLR, 2021, VET MED INT, V2021, P0, DOI 10.1155/2021/4747301
   Sorenmo K, 2003, VET CLIN N AM-SMALL, V33, P573, DOI 10.1016/S0195-5616(03)00020-2
   Sorenmo KU, 2013, WITHROW MACEWENS SMALL ANIMAL CLINICAL ONCOLOGY, V5th, P538, DOI 10.1016/B978-1-4377-2362-5.00027-X
   Steagall PVM, 2017, FRONT VET SCI, V4, P0, DOI 10.3389/fvets.2017.00068
   Steagall PV, 2020, BMC VET RES, V16, P0, DOI 10.1186/s12917-020-02364-w
   Suárez-Redondo M, 2024, VET RES COMMUN, V48, P2707, DOI 10.1007/s11259-024-10377-1
   Sztark F, 1998, ANESTHESIOLOGY, V88, P1340, DOI 10.1097/00000542-199805000-00026
   Tan C, 2004, AUST VET J, V82, P65, DOI 10.1111/j.1751-0813.2004.tb14646.x
   Tayari H, 2022, ANIMALS-BASEL, V12, P0, DOI 10.3390/ani12050587
   Taylor R, 2013, PAIN PRACT, V13, P332, DOI 10.1111/j.1533-2500.2012.00595.x
   Teixeira LG, 2018, PESQUI VET BRASIL, V38, P315, DOI 10.1590/1678-5150-PVB-5007
   Teixeira RCR, 2013, VET ANAESTH ANALG, V40, P641, DOI 10.1111/vaa.12080
   Thomas J, 2001, AESTHET PLAST SURG, V25, P343, DOI 10.1007/s002660010146
   Uscategui RAR, 2017, PAK VET J, V37, P345
   Uscategui RAR, 2017, REV COLOMB CIENC PEC, V30, P39, DOI 10.17533/udea.rccp.v30n1a05
   Vettorato E, 2010, VET J, V183, P310, DOI 10.1016/j.tvjl.2008.11.002
   Vilhegas S, 2015, VET REC, V177, P0, DOI 10.1136/vr.102993
   Vullo C, 2021, ANIMALS-BASEL, V11, P0, DOI 10.3390/ani11051280
   YOUNG LE, 1990, J SMALL ANIM PRACT, V31, P554, DOI 10.1111/j.1748-5827.1990.tb00685.x
NR 99
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 2076-2615
EI 
J9 ANIMALS-BASEL
JI Animals
PD APR 25
PY 2025
VL 15
IS 9
BP 
EP 
DI 10.3390/ani15091214
PG 21
WC Agriculture, Dairy & Animal Science; Veterinary Sciences; Zoology
SC Agriculture; Veterinary Sciences; Zoology
GA 2MH6G
UT WOS:001486044500001
PM 40362030
DA 2026-01-16
ER

PT J
AU Akutay, S
   Kaçmaz, HY
   Ceyhan, Ö
AF Akutay, Seda
   Kacmaz, Hatice Yuceler
   Ceyhan, Ozlem
TI The healing power of transcutaneous electrical nerve stimulation: a systematic review on its effects after breast surgery
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Breast cancer; Transcutaneous electrical nerve stimulation; Pain; Postoperative care
ID acupoint stimulation; postoperative nausea; pain; tens; mechanisms; recovery; quality
AB BackgroundTranscutaneous electrical stimulation after breast cancer surgery has been utilized for various purposes, but the full efficacy of this treatment approach on postoperative symptoms remains unclear.AimThis study aimed to answer the question: Does transcutaneous electrical nerve stimulation significantly impact postoperative patient outcomes in individuals undergoing breast cancer surgery?MethodsA systematic review of randomized controlled trials was conducted. Because of the limited number of studies included, it was not feasible to perform a meta-analysis. English-language publications from 2013 and 2024 that investigated the effects of transcutaneous electrical stimulation in breast cancer surgery patients were included. Electronic databases such as Web of Science, PubMed, Scopus, EBSCO, ScienceDirect, Cochrane Central Register of Controlled Trials, and Wiley Online Library were searched. Two independent investigators assessed the studies using the revised JBI risk of bias tool. Data from randomized trials were extracted by two researchers using the Cochrane data collection tool.ResultsOur comprehensive literature review identified 251 studies. After rigorous assessment, 12 articles met our inclusion criteria. Title and abstract screening excluded seven studies that did not involve surgery, used treatments other than TENS, included acupuncture, or did not measure pain outcomes. Among these, five studies involving 776 patients examined the effects of transcutaneous electrical stimulation on pain management in breast cancer surgery. In all of the studies reviewed, transcutaneous electrical stimulation had a beneficial effect on postoperative pain.ConclusionTranscutaneous electrical stimulation has significantly alleviated pain associated with breast cancer surgery. This therapeutic modality has improved patient satisfaction with analgesia by relieving pain; reducing analgesic use; reducing postoperative nausea and vomiting; increasing blood levels of IL-2, IFN-gamma, and IL-2/IL-4 ratio; and reducing skin sensitivity. Transcutaneous electrical stimulation devices may improve postoperative patient outcomes and enhance the recovery process in people undergoing breast cancer surgery. The results of this study are limited by heterogeneity and the small number of included studies. Future research should prioritize standardization of intervention procedures and investigation of the long-term effects of TENS in postoperative care.RegistrationThis study was registered in the PROSPERO registration system under the number CRD42024523558.
C1 [Akutay, Seda; Kacmaz, Hatice Yuceler] Erciyes Univ, Fac Hlth Sci, Dept Surg Nursing, Kayseri, Turkiye.
   [Ceyhan, Ozlem] Erciyes Univ, Fac Hlth Sci, Dept Internal Nursing, Kayseri, Turkiye.
C3 Erciyes University; Erciyes University
RP Akutay, S (corresponding author), Erciyes Univ, Fac Hlth Sci, Dept Surg Nursing, Kayseri, Turkiye.
EM sedaakutay@erciyes.edu.tr; haticeyclr@erciyes.edu.tr; ozlemg@erciyes.edu.tr
FU Scientific and Technological Research Council of Turkiye (TUBITAK)
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Barker TH, 2023, JBI EVID SYNTH, V21, P494, DOI 10.11124/JBIES-22-00430
   Bennett MI, 2011, PAIN, V152, P1226, DOI 10.1016/j.pain.2010.12.009
   Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8
   Castro-Martín E, 2017, ARCH PHYS MED REHAB, V98, P832, DOI 10.1016/j.apmr.2016.11.019
   Elshinnawy AM, 2024, PHYSIOTHER RES INT, V29, P0, DOI 10.1002/pri.2051
   Erden S, 2022, J PERIANESTH NURS, V37, P485, DOI 10.1016/j.jopan.2021.08.017
   Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, V0, PP1, DOI 10.1007/978-1-4419-0685-4_1
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Han ZX, 2023, MED SCI MONITOR, V29, P0, DOI 10.12659/MSM.941262
   Hemmati M, 2022, BMC MUSCULOSKEL DIS, V23, P0, DOI 10.1186/s12891-022-05780-1
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   HUGHES GS, 1984, PHYS THER, V64, P1062, DOI 10.1093/ptj/64.7.1062
   Johnson MI, 2022, MEDICINA-LITHUANIA, V58, P0, DOI 10.3390/medicina58060803
   Johnson MI, 2021, MEDICINA-LITHUANIA, V57, P0, DOI 10.3390/medicina57040378
   Kalra A, 2001, J PHARMACOL EXP THER, V298, P257
   Kannan P, 2022, QUAL LIFE RES, V31, P951, DOI 10.1007/s11136-021-02926-x
   Keelan S, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.622621
   Lu LY, 2023, PLOS ONE, V18, P0, DOI 10.1371/journal.pone.0285943
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Lukasiewicz S, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13174287
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Mendonça Andreza Carvalho Rabelo, 2017, FISIOTER. MOV., V30, P285, DOI 10.1590/1980-5918.030.s01.ao28
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Reeves BC, 2024, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0
   SALAR G, 1981, PAIN, V10, P169, DOI 10.1016/0304-3959(81)90192-5
   Shinbara H, 2015, ACUPUNCT MED, V33, P65, DOI 10.1136/acupmed-2014-010634
   Silva JG, 2014, J PHYS THER SCI, V26, P349, DOI 10.1589/jpts.26.349
   Sluka KA, 2003, J PAIN, V4, P109, DOI 10.1054/jpai.2003.434
   Szmit M, 2023, ADV CLIN EXP MED, V32, P1063, DOI 10.17219/acem/159703
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Tong QY, 2022, CLIN BREAST CANCER, V22, P724, DOI 10.1016/j.clbc.2022.04.010
   Toth MJ, 2020, J APPL PHYSIOL, V128, P1654, DOI 10.1152/japplphysiol.00203.2020
   Vance CGT, 2022, MEDICINA-LITHUANIA, V58, P0, DOI 10.3390/medicina58101332
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Viderman D, 2024, J CLIN MED, V13, P0, DOI 10.3390/jcm13020427
   Wang XQ, 2010, J NEUROSURG ANESTH, V22, P128, DOI 10.1097/ANA.0b013e3181c9fbde
   Yan WL, 2023, PAIN THER, V12, P631, DOI 10.1007/s40122-023-00496-z
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
   Zhang YY, 2023, SURGERY, V174, P787, DOI 10.1016/j.surg.2023.06.014
NR 42
TC 0
Z9 1
U1 5
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD FEB 15
PY 2025
VL 33
IS 2
BP 
EP 
DI 10.1007/s00520-024-09129-3
PG 16
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA S3I4Q
UT WOS:001397200600003
PM 39804405
DA 2026-01-16
ER

PT J
AU Shi, HX
   Gao, YJ
   Wang, SR
AF Shi, Hao-Xin
   Gao, Yu-Jun
   Wang, Shu-Ren
TI Electroacupuncture in non-surgical management of lumbar spinal stenosis:
SO Frontiers in immunology
LA English
DT Review
DE electroacupuncture; inflammation; ligamentum flavum thickening; lumbar spinal stenosis; signal pathway
AB Lumbar Spinal Stenosis (LSS) is a prevalent spinal disorder mainly induced by  degenerative changes in the spine, which lead to nerve root compression. This  results in symptoms such as lower back pain, numbness of the lower limbs, and  difficulty in walking. The thickening of the ligamentum flavum (LF) is a crucial  pathological feature of LSS and is closely linked to inflammatory responses.  Electroacupuncture (EA), a form of traditional Chinese medical therapy, has  garnered increasing recognition in modern medicine in recent years. It has shown  notable efficacy in alleviating pain and enhancing function. EA achieves these  effects by modulating inflammatory cytokines, reducing pro-inflammatory markers  such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1le, and  interleukin-6 (IL-6), while increasing anti-inflammatory cytokines like  interleukin-10 (IL-10). Additionally, EA may inhibit LF thickening by suppressing  signaling pathways, specifically the nuclear factor-κB (NF-κB) pathway, the Janus  kinase/signal transducer and activator of transcription (JAK/STAT) pathway, and  the mitogen-activated protein kinase (MAPK) pathway. Clinical studies indicate  that when EA is combined with other treatment modalities, it can significantly  reduce pain and improve functional status in patients with LSS, thus enhancing  their quality of life. Although the mechanisms underlying the effects of EA in  the treatment of LSS warrant further exploration, its ability to regulate  inflammatory responses through multiple pathways and promote tissue repair  provides new perspectives and directions for the non-surgical management of LSS.  This review encapsulates the application of EA in LSS and explores its potential  mechanisms in mitigating LF thickening through the modulation of inflammatory  cytokines. The aim is to offer a reference for future research and clinical  practice.
C1 Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
   Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
   Department of Traditional Orthopedic Therapy, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
NR 0
TC 0
SN 1664-322
EI 
J9 Front Immunol
PD NOV 17
PY 2025
VL 16
IS 
BP 1644394
EP 1644394
DI 10.3389/fimmu.2025.1644394
PG 0
WC Humans; Electroacupuncture; methods; Spinal Stenosis; therapy; Ligamentum Flavum; pathology; Cytokines; metabolism; Animals; Inflammation Mediators; metabolism; Lumbar Vertebrae; pathology; Signal Transduction
UT PubMed:41246317
PM 41246317
DA 2025-11-17
ER

PT J
AU Yu, Q
   Wang, X
   Wu, J
   Zhang, Q
   Ying, X
   Ou, L
   Hu, H
   He, K
   Wu, L
   Jin, Z
   Shentu, J
   Dai, H
   Ma, R
   Hu, Q
   Han, D
AF Yu, Qintao
   Wang, Xinru
   Wu, Jiaqi
   Zhang, Qiyuan
   Ying, Xiaoqi
   Ou, Liming
   Hu, Hantong
   He, Kelin
   Wu, Lei
   Jin, Zongda
   Shentu, Jiajun
   Dai, Huifeng
   Ma, Ruijie
   Hu, Qimiao
   Han, Dexiong
TI Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and
SO Journal of pain research
LA English
DT Journal Article
DE biomarker; electroacupuncture; postherpetic neuralgia; randomized controlled trial; sham acupuncture; study protocol
AB INTRODUCTION: Postherpetic neuralgia (PHN) is a persistent neuropathic pain  condition that endures for at least 3 months following the onset of herpes  zoster, significantly impairing life quality of patients. Current PHN treatments  demonstrate limited efficacy, and the lack of reliable severity biomarkers  hinders effective clinical management. Electroacupuncture represents a promising  therapeutic approach for PHN, though comprehensive evidence supporting its  efficacy and safety is still needed. Furthermore, as objective indicators, the  role of serum biomarkers in assessments still requires further investigation.  METHODS: This multicenter, sham-controlled, randomized study will recruit 180  patients with PHN. Participants will be allocated in a 1:1:1 ratio to  electroacupuncture, sham acupuncture, or waiting-list groups via multicenter  stratified block randomization. Participants will receive 1-month of treatment  and 3-month follow-ups. The electroacupuncture group and the sham acupuncture  group will each receive 12 treatments. All participants will maintain their  pre-enrollment medication. Primary outcome is Numerical Rating Scale; secondary  outcomes include pain episode frequency, Hamilton Anxiety Scale, Hamilton  Depression Scale, The Short-Form 36 Health Survey, and changes of biomarkers  (Neuropeptide Y, Substance P, Tumor Necrosis Factor-α, Interleukin-10). A linear  mixed-effects model will be used to analyze data at different time points to  explore the efficacy of electroacupuncture and the correlation between serum  biomarkers and pain intensity. The predictive value of biomarkers for refractory  postherpetic neuralgia (NRS reduction <30% from baseline post-treatment) will be  assessed using ROC curves. CONCLUSION: The expected outcomes will clarify the  efficacy and safety of electroacupuncture for PHN. The study will also analyze  the correlation between serum biomarkers and pain symptoms and determine whether  serum biomarkers can serve as prognostic indicators for refractory postherpetic  neuralgia. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06990854.  Registered on June 3, 2025. (https://clinicaltrials.gov/study/NCT06990854).
C1 The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Medical Affairs, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture and Moxibustion, Changxing County Traditional Chinese Medicine Hospital, Huzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD NOV 7
PY 2025
VL 18
IS 
BP 5753
EP 5768
DI 10.2147/JPR.S559309
PG 15
UT PubMed:41199896
PM 41199896
DA 2025-11-07
ER

PT J
AU Ben-Arye, E
   Vagedes, J
   Kassem, S
   Samuels, N
   Lavie, O
   Zaritsky, V
   Gressel, O
AF Ben-Arye, Eran
   Vagedes, Jan
   Kassem, Sameer
   Samuels, Noah
   Lavie, Ofer
   Zaritsky, Vika
   Gressel, Orit
TI Adding Acupuncture to Touch/Relaxation for Pain in Wartime: A Randomized
SO Journal of pain and symptom management
LA English
DT Journal Article
DE Integrative oncology; acupuncture; cancer; heart rate variability; integrative medicine
AB CONTEXT AND OBJECTIVES: Patients with cancer living in war zones face significant  quality of life (QoL)-related challenges. This study examined an integrative  oncology (IO) intervention in northern Israel for pain and autonomic response.  METHODS: This prospective, randomized, controlled and pragmatic study examined an  IO intervention with manual-relaxation, with acupuncture (Group A) or without  (Group B). ESAS (Edmonton Symptom Assessment Scale), EORTC QLQ-C30 (European  Organization for Research and Treatment of Cancer QoL Questionnaire), and MYCAW  (Measure Yourself Concerns and Wellbeing) tools were used to examine QoL. Heart  rate and variability (HRV) were measured at baseline and 15 minutes  post-treatment, comparing frequency-domain variable changes (e.g., LN Power  Total, Power HF, Power LF, Power VLF). RESULTS: Of 125 patients, Groups A (67)  and B (58) had similar demographic and cancer-related characteristics. ESAS pain  scores improved in both groups post-treatment (A, P < 0.001; B, P = 0.002), as  did anxiety, depression, and fatigue. At three weeks, Group B reported greater  improvement on ESAS pain (P = 0.039) and MYCAW pain-related concerns (P = 0.025),  both showing within-group improvement on EORTC pain. HRV showed greater change in  Group A, with decreased LN Power Total (P = 0.006), LN Power LF (P = 0.02), and  LN Power VLF (P = 0.026). While Relative Power HF increased marginally (P =  0.054), heart rate decreasing more significantly in Group B (P = 0.005).  CONCLUSIONS: IO treatments led to reduced pain among patients with cancer living  in a war zone, with no additive effect of acupuncture. HRV changes suggest  enhanced parasympathetic activity, with acupuncture-treated patients showing  additional frequency-domain changes attributed to decreased sympathetic tone.
C1 Ruth and Bruce Rappaport Faculty of Medicine (E.B.A., S.K., O.L., V.Z., O.G.), Technion-Israel Institute of Technology, Haifa, Israel
   Integrative OncologyProgram, The Oncology Service (E.B.A., O.G.), Lin, Carmel, and Zebulun Medicalcenters, Clalit Health Services, Haifa, Israel. 
   ARCIM Institute (J.V.), Research Institute, Filderstadt, Germany
   Department of Neonatology (J.V.), University Hospital Tuebingen, University Tuebingen,Tuebingen, Germany.
   Ruth and Bruce Rappaport Faculty of Medicine (E.B.A., S.K., O.L., V.Z., O.G.), Technion-Israel Institute of Technology, Haifa, Israel
   Department of InternalMedicine (S.K.), Lady Davis Carmel Medical Center, Haifa, Israel.
   Center for Integrative Complementary Medicine (N.S.), Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
   Ruth and Bruce Rappaport Faculty of Medicine (E.B.A., S.K., O.L., V.Z., O.G.), Technion-Israel Institute of Technology, Haifa, Israel
   Unit of GynecologicOncology (O.L.), Department of Obstetrics and Gynecology, Carmel Medical Center,Haifa, Israel.
   Ruth and Bruce Rappaport Faculty of Medicine (E.B.A., S.K., O.L., V.Z., O.G.), Technion-Israel Institute of Technology, Haifa, Israel.
   Ruth and Bruce Rappaport Faculty of Medicine (E.B.A., S.K., O.L., V.Z., O.G.), Technion-Israel Institute of Technology, Haifa, Israel
   Integrative OncologyProgram, The Oncology Service (E.B.A., O.G.), Lin, Carmel, and Zebulun Medicalcenters, Clalit Health Services, Haifa, Israel.
EM ranben@technion.ac.il
NR 0
TC 0
SN 1873-651
EI 
J9 J Pain Symptom Manage
PD DEC 12
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1016/j.jpainsymman.2025.12.001
PG 0
UT PubMed:41380985
PM 41380985
DA 2025-12-12
ER

PT J
AU Zhao, Y
   Cao, W
   Zhang, H
   Rong, Q
   He, M
   Wu, M
   Zhao, Y
   Yang, P
AF Zhao, Yi
   Cao, Wendi
   Zhang, Hengheng
   Rong, Qingxi
   He, Mingxuan
   Wu, Meijie
   Zhao, Yi
   Yang, Ping
TI The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral
SO Journal of cancer survivorship : research and practice
LA English
DT Review
DE Acupuncture; Cancer supportive care; Meta-analysis; Peripheral nervous system diseases; Systematic review
AB PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side  effect in cancer patients, often emerging within the first month of chemotherapy.  Severe CIPN can disrupt daily life, necessitating chemotherapy adjustments or  discontinuation, which may increase cancer mortality. No standardized treatment  exists, but acupuncture is widely used in China for CIPN.This study aimed to  comprehensively assess the actual efficacy of acupuncture in treating CIPN in  cancer patients. METHODS: We searched PubMed, Web of Science, Embase, and  Cochrane Library up to October 2024 for randomized controlled trials (RCTs) on  acupuncture for CIPN, following the Preferred Reporting Items for Systematic  Reviews and Meta-Analyses (PRISMA). Methodological quality was assessed using the  Cochrane risk-of-bias tool (RoB 2.0) and the modified Jadad scale. A  random-effects model was used to analyze the Effect Size (ES) and 95% Confidence  Interval (CI).Data analysis was performed using RevMan 5.3 software. RESULTS: The  final analysis incorporated 1,048 patients from 18 studies. The results presented  in the forest plot demonstrated that, when compared to the control group,  acupuncture exhibited superior efficacy in improving CIPN symptoms (RR = 1.11,  95%CI [1.01,1.21]), alleviating pain (SMD = -0.93, 95%CI [-1.63,-0.22]),  enhancing quality of life (QoL) (MD =  - 1.14, 95%CI [- 1.97, - 0.31]), and  reducing chemotherapy-related neurotoxicity (MD =  - 3.34, 95%CI  [- 5.24, - 1.44]). Additionally, in alleviating CIPN-related pain, simple  acupuncture demonstrates superior efficacy compared to electroacupuncture.  CONCLUSION: This study clearly demonstrates that acupuncture offers more  substantial benefits to CIPN patients compared to usual care, medication,  vitamin, and sham acupuncture. This research serves as a valuable reference for  cancer patients, physicians, nurses, and other professional medical  practitioners.
C1 Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China. zywm0001@163.com.
   Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000,China. 1290912204@qq.com.
NR 0
TC 0
SN 1932-226
EI 
J9 J Cancer Surviv
PD AUG 20
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1007/s11764-025-01869-3
PG 0
UT PubMed:40830723
PM 40830723
DA 2025-08-20
ER

PT J
AU DU, XZ
   Liu, LM
   Liu, C
   Jing, WY
   Yuan, B
   Zhang, XH
   Zhang, FF
   Li, XJ
   Liu, Q
   Wang, HD
AF DU, Xiao-Zheng
   Liu, Li-Mei
   Liu, Cui
   Jing, Wei-Yao
   Yuan, Bo
   Zhang, Xing-Hua
   Zhang, Feng-Fan
   Li, Xiang-Jun
   Liu, Qiang
   Wang, Hai-Dong
TI [Effect of heat-reinforcing needling on expression profile of LncRNAs in synovial
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Heat-reinforcing needling; Long noncoding RNA; Rheumatoid arthritis
AB OBJECTIVES: To observe the effect of heat-reinforcing needling on the expression  profile of long non-coding RNA (LncRNA) in the synovial tissue of rabbits with  cold-syndrome type rheumatoid arthritis (RA), so as to explore its mechanisms  underlying improvement of RA. METHODS: A total of 18 New Zealand rabbits were  randomly divided into normal, model and heat-reinforcing needling (acupuncture)  groups, with 6 rabbits in each group. The RA model was established by injection  of mixed solution (emulsifier) of ovalbumin powder(80 mg) + NaCl (20 mL)  +Freund's complete adjuvant (20 mL), combined with cold compress (ice cube  +crystal calcium chloride) of the knee-joint. In addition, rabbits of the normal  and model groups received regular grasping and fixation in the same way as those  of the acupuncture group. For rabbits of the acupuncture group, the  heat-reinforcing needling stimulation was applied to bilateral "Zusanli" (ST36)  for about 1 min, followed by retaining the needle for 30 min, once a day, for a  total of 7 d. The rabbits' general condition was observed, and the knee joint  circumference and pain threshold after intervention were measured. The knee-joint  cavity effusion, synovial thickness, and internal blood flow signals were  observed using a color Doppler ultrasound apparatus. Histopathological changes of  synovium were observed using H.E. staining. The contents of serum tumor necrosis  factor α (TNF-α), interleukin (IL)-1β and IL-6 were detected using enzyme linked  immunosorbent assay (ELISA), and the differential LncRNAs and biological  functions in the synovial tissues were detected and analyzed using  high-throughput sequencing technology. The expression levels of 5 significantly  differentially expressed LncRNAs were verified using qPCR. RESULTS: Compared with  the normal group, the model group of rabbits showed a significant increase in the  knee joint circumference (P<0.05) and the content of serum TNF-α, IL-1β, IL-6  (P<0.05), and a significant decrease in the pain threshold (P<0.05), and diffuse  synovial hyperplasia of the synovial membrane, joint effusion and abnormal blood  flow signals, proliferated and thickened synovial lining, with visible capillary  formation beneath the lining and a large number of inflammatory cell clustering.  In comparison with the model group, the knee joint circumference, and the serum  contents of TNF-α, IL-1β and IL-6 were obviously decreased (P<0.05), while the  pain threshold was notably increased (P<0.05), and H.E. staining showed a  reduction in the hyperplasia of synovial lining, with a milder inflammatory cell  infiltration. High-throughput sequencing and bioinformatics analysis displayed  that a total of 142 LncRNAs were found to have opposite expression trends between  the acupuncture group and the model group, of which 83 LncRNAs were up-regulated  in the model group vs the normal group and down-regulated in the acupuncture  group vs the model group, mainly involving the core functional clusters of cell  cycle, mitogen-activated protein kinase (MAPK) signaling and cell senescence, and  59 LncRNAs were down-regulated in the model group vs the normal group, and  up-regulated in the acupuncture group vs the model group, mainly involving the  metabolic pathway, peroxisome proliferator-activated receptor (PPAR) signaling  and AMP-dependent protein kinase (AMPK) signaling. The results of qPCR showed  that compared with the normal group, the expression levels of MSTRG.15448.1 and  MSTRG.17571.1 in the synovial tissue of knee joint were significantly decreased  (P<0.05), and those of MSTRG.5134.1, MSTRG.13294.1 and MSTRG.15972.1 were  significantly increased (P<0.05) in the model group. Compared with the model  group, the expression levels of MSTRG.15448.1 and MSTRG.17571.1 were  significantly increased (P<0.05), and those of MSTRG.5134.1, MSTRG.13294.1 and  MSTRG.15972.1 were significantly decreased (P<0.05) in the acupuncture group.  CONCLUSIONS: The heat-reinforcing needling can regulate the expression profile of  LncRNAs in the RA synovial tissue, which may be one of the mechanisms underlying  inhibition of synovial inflammatory response and improvement of symptoms.
C1 College of Acupuncture-moxibusition and Massage, Gansu University of Chinese Medicine, Lanzhou 730000, China.
   Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000.
   College of Acupuncture-moxibusition and Massage, Gansu University of Chinese Medicine, Lanzhou 730000, China.
   College of Acupuncture-moxibusition and Massage, Gansu University of Chinese Medicine, Lanzhou 730000, China.
   Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050.
   College of Acupuncture-moxibusition and Massage, Gansu University of Chinese Medicine, Lanzhou 730000, China.
   Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050. whaidong5859@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD FEB 18
PY 2025
VL 50
IS 1
BP 65
EP 75
DI 10.13702/j.1000-0607.20240026
PG 10
WC Animals; Rabbits; RNA, Long Noncoding; genetics; Arthritis, Rheumatoid; genetics; Acupuncture Therapy; instrumentation; Synovial Membrane; metabolism; Humans; Male; Acupuncture Points; Female; Tumor Necrosis Factor-alpha; genetics; Interleukin-6; genetics
UT PubMed:39961760
PM 39961760
DA 2025-02-18
ER

PT J
AU Xu, X
   Zhou, MM
   Hao, HY
   Chen, HY
AF Xu, Xiao
   Zhou, Ming-Ming
   Hao, Hai-Yan
   Chen, Hai-Yan
TI Enhancing peri-operative pain management in urological cancer: exploring the role
SO BJU international
LA English
DT Letter
C1 Research Center of Molecular Medicine (Ph.D. Lab), Nantong Health College of Jiangsu Province, Nantong, China.
   Department of Nursing, Nantong Health College of Jiangsu Province, Nantong, 
   Research Center of Molecular Medicine (Ph.D. Lab), Nantong Health College of Jiangsu Province, Nantong, China.
   Department of Nursing, Nantong Health College of Jiangsu Province, Nantong, 
   Clinical Research Unit, Affiliated Hospital of Nantong University, Nantong, China.
   Department of Urology, Nantong Hospital of Traditional Chinese Medicine, Affiliated Nantong Hospital of Nanjing University of Chinese Medicine, Nantong,China.
NR 0
TC 0
SN 1464-410
EI 
J9 BJU Int
PD MAR 19
PY 2025
VL 135
IS 6
BP 1060
EP 1061
DI 10.1111/bju.16700
PG 1
UT PubMed:40104920
PM 40104920
DA 2025-03-19
ER

PT J
AU Jing, M
   Zhang, Y
   Shen, Y
   Peng, Y
   Wang, H
AF Jing, Mengjiao
   Zhang, Yuanyuan
   Shen, Yuanjuan
   Peng, Yongjun
   Wang, Hesheng
TI [Effects of thumbtack-needle embedding therapy of auricular acupuncture on
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE 16S rRNA; gastric cancer; gastrointestinal function; intestinal microflora; thumbtack-needle embedding therapy of auricular acupuncture
AB OBJECTIVE: To observe the effects of thumbtack-needle embedding therapy of  auricular acupuncture on gastrointestinal function and intestinal microflora in  the patients with gastric cancer after operation, and to explore its mechanism.  METHODS: A total of 80 patients with gastric cancer after radical operation were  randomly divided into an observation group (40 cases, 3 cases discontinued) and a  control group (40 cases, 3 cases discontinued). The patients of both groups  received the perioperative care for accelerating recovery. Additionally, in the  observation group, the thumbtack-needle embedding therapy of auricular  acupuncture was delivered at the auricular points of unilateral side, including  Wei (CO(4)), Pi (CO(13)), Dachang (CO(7)), Xiaochang (CO(6)), Yuanzhong  (AT(2,3,4i)), Erzhong (HX(1)), Sanjiao (CO(17)) and Jiaowozhong (TF(3)), and the  needles were embedded and retained for 72 h. The postoperative recovery time of  gastrointestinal function (the postoperative bowel sound recovery time, the first  exhaust time, the first defecation time), the postoperative hospital stay and  pain visual analogue scale (VAS) score were observed in the two groups. Before  operation and on day 5 after operation, the serum gastrin level was detected in  the two groups. The third-generation 16S rRNA sequencing technology was used to  detect the composition and relative abundance of intestinal flora in the two  groups before and after operation. RESULTS: Compared with the control group, the  postoperative bowel sound recovery time, the first exhaust time and the first  defecation time were shortened in the observation group (P<0.05). In the  observation group, the VAS scores at 24 h, 48 h, and 72 h after surgery were  lower than those of the control group, respectively (P<0.05). There was no  significant differences in postoperative hospital stay and serum gastrin level  between the two groups (P>0.05). The alpha diversity analysis showed that the  differences in Shannon index, Simpson index, Pielou_J index and Pd_fath index  were not significant statistically after intervention between the two groups  (P>0.05). After intervention, the community structure of the fecal sample was  similar at each taxonomic level between the two groups, and although the  proportion between species was various, the difference was not significant  (P>0.05). After intervention, there were 55 species with the differences between  the two groups, 17 species of them presented significant difference in relative  abundance in the observation group and 38 species in the control group. Regarding  the level of genus, the levels of Klebsiell and Enterobacter increased (P<0.05)  and the level of Streptococcus decreased (P<0.05) in the observation group. The  main microbial groups that played an important role were Coprobacillaceae,  Sutterellaceae and Yersiniaceae in the observation group. KEGG function  prediction indicated that the function of intestinal microflora was mainly  associated with the cofactor and vitamin metabolism, carbohydrate metabolism, and  amino acid metabolism. CONCLUSION: The thumbtack-needle embedding therapy of  auricular acupuncture improves the postoperative gastrointestinal function of the  patients with gastric cancer probably through regulating the structure and  relative abundance of intestinal microflora and affecting the energy metabolism.
C1 Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Nursing, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Nursing, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAR 18
PY 2025
VL 45
IS 3
BP 300
EP 311
DI 10.13703/j.0255-2930.20240813-k0005
PG 11
WC Humans; Male; Female; Middle Aged; Acupuncture, Ear; instrumentation; Gastrointestinal Microbiome; Aged; Stomach Neoplasms; microbiology; Adult; Acupuncture Points; Gastrointestinal Tract; physiopathology; Intestines; microbiology; Postoperative Period; Acupuncture Therapy
UT PubMed:40097211
PM 40097211
DA 2025-03-18
ER

PT J
AU Xia, FY
   Liu, Y
   Zhong, Y
   He, XQ
   Yu, YL
   Li, HL
   Zhang, XY
AF Xia, Fei-Yan
   Liu, Yu
   Zhong, Yan
   He, Xi-Qin-Bing
   Yu, Yi-Lin
   Li, Han-Lin
   Zhang, Xin-Yi
TI [Effect of electroacupuncture on cannabinoid-related receptor CB2R and TRPV1 and
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Cannabinoid receptor type 2; Electroacupuncture; Microglia; Neuroinflammation; Pain hyperalgesia; Primary dysmenorrhea; Transient receptor potential vanilloid 1
AB OBJECTIVES: To observe the effect of electroacupuncture (EA) on the expression of  cannabinoid receptor type 2 (CB2R), atypical cannabinoid receptor transient  receptor potential vanilloid 1 (TRPV1), and spinal microglial polarization in  rats with primary dysmenorrhea (PDM), so as to explore the underlying mechanism  of EA alleviating PDM pain hyperalgesia. METHODS: Thirty female SD rats were  randomly divided into control, model, and EA groups (n=10 rats per group). The  PDM model was established by subcutaneous injection of estradiol diphenhydrate  combined with intraperitoneal injection of oxytocin. Rats in the EA group were  treated with EA (50 Hz) at "Guanyuan" (CV4) and bilateral "Sanyinjiao" (SP6) for  20 min, once a day for 10 consecutive days. The number of writhing, writhing  score, and writhing latency were observed. The uterine histopathological changes  were observed by H.E. staining. The contents of prostaglandin F2α (PGF2α),  prostaglandin E2 (PGE2) in serum and interleukin-6 (IL-6), interleukin-1β  (IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) in spinal  cord were detected by ELISA. The protein expressions of CB2R and TRPV1 in spinal  cord and uterus, and inducible nitric oxide synthase (iNOS) and arginase-1 (Arg1)  in spinal cord were detected by Western blot. RESULTS: Compared with the control  group, the number and score of writhing, pathological injury score, contents of  PGF2α and ratio of PGF2α/PGE2 in serum and IL-1β, TNF-α and IL-6 contents in  spinal cord, the protein expressions of TRPV1 in both uterine and spinal cord,  and iNOS in spinal cord were significantly increased in the model group  (P<0.001), while contents of PGE2 in serum and IL-10 in spinal cord, the  expression levels of CB2R in both uterine and spinal cord, and Arg1 in spinal  cord were significantly decreased (P<0.001). In comparison with the model group,  the number of writhing, pathological injury score, contents of PGF2α and ratio of  PGF2α/PGE2 in serum and IL-1β, TNF-α and IL-6 contents in spinal cord, the  protein expressions of TRPV1 in both uterine and spinal cord and iNOS in spinal  cord were obviously decreased (P<0.001, P<0.05, P<0.01), whereas the writhing  latency was considerably prolonged (P<0.05), with elevated contents of PGE2 in  serum and IL-10 in spinal cord, and elevated protein expression levels of CB2R in  both uterine and spinal cord, and Arg1 in spinal cord (P<0.01, P<0.001) in the EA  group. H.E. staining showed degeneration, swelling, and necrosis of endometrial  epithelial cells, dilation of glands, stromal hyperemia, and granulocyte  infiltration in the model group, which were relatively milder in the EA group.  CONCLUSIONS: EA can alleviate uterine inflammatory response, pathological damage  and pain sensitization in PDM rats, which may be related to activating peripheral  and central CB2R expression, inhibiting TRPV1 expression, promoting spinal cord  microglia polarization from M1 to M2, thus reducing neuroinflammation.
C1 Hunan University of Chinese Medicine, Changsha 410208, China.
   Hunan University of Chinese Medicine, Changsha 410208, China. 125790602@qq.com.
   Hunan University of Chinese Medicine, Changsha 410208, China.
   Hunan University of Chinese Medicine, Changsha 410208, China.
   Hunan University of Chinese Medicine, Changsha 410208, China.
   Hunan University of Chinese Medicine, Changsha 410208, China.
   Hunan University of Chinese Medicine, Changsha 410208, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD NOV 20
PY 2025
VL 50
IS 11
BP 1248
EP 1256
DI 10.13702/j.1000-0607.20250615
PG 8
WC Animals; Electroacupuncture; Female; TRPV Cation Channels; genetics; Rats; Receptor, Cannabinoid, CB2; genetics; Rats, Sprague-Dawley; Dysmenorrhea; therapy; Humans; Microglia; metabolism; Acupuncture Points; Spinal Cord; metabolism
UT PubMed:41261023
PM 41261023
DA 2025-11-20
ER

PT J
AU Li, F
   Wan, H
   Liu, X
   Deng, Y
   Tian, W
   Zhao, Z
AF Li, Fanrui
   Wan, Hejia
   Liu, Xiaohui
   Deng, Yuanting
   Tian, Wuyang
   Zhao, Zilin
TI Auricular Acupoint Therapy in Symptom Management of Cancer patients: A Scoping
SO Cancer management and research
LA English
DT Review
DE auricular point therapy; cancer; scoping review; symptom management
AB BACKGROUND: The incidence of cancer is rising annually. With advances in  diagnosis and treatment, cancer patients' long-term survival rates have improved,  leading them to gradually enter a chronic disease state. However, they frequently  experience physiological and psychological symptoms during treatment, which  severely impact their survival and quality of life. Auricular acupoint therapy, a  green non-pharmacological intervention characterized by ease of operation and low  cost, can alleviate cancer-related symptoms. Despite its widespread use,  systematic summarization and comprehensive evaluation of this therapy remain  insufficient. OBJECTIVE: To systematically analyze the application of auricular  therapy in cancer patients, identify its characteristics and intervention effects  on symptoms, and provide a reference for symptom management in these patients.  METHODS: Relevant studies were systematically retrieved from PubMed, Web of  Science, Cochrane Library, Embase, CINAHL, CNKI, CBM, WanFang Database, and VIP  Database from their inception to April 20, 2025. Data from the included  literature were extracted and analyzed. RESULTS: A total of 42 studies were  included. Auricular therapy is applicable across multiple stages of cancer care  and exerts positive effects on cancer-related pain, fatigue, sleep disorders,  anxiety, and chemotherapy-induced symptoms. Notably, the pain-fatigue-sleep  disorder cluster is the most common and interrelated symptom group, with  auricular acupressure as the most frequently used intervention. CONCLUSION: Owing  to its simplicity and cost-effectiveness, auricular therapy offers unique  advantages for managing symptoms in cancer patients. The current focus in this  field has shifted from managing single symptoms or individual dimensions within  symptom clusters to a comprehensive management of symptom clusters. Future  research should pay attention to the dynamic progression of symptoms, focus on  the core symptom clusters in cancer patients, and optimize intervention  strategies to enhance the efficiency of symptom management.
C1 School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
   School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
   School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
   Nursing Department, Henan Provincial Hospital of Traditional Chinese Medicine 
   School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
   School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
   School of Nursing (Nursing School of Smart Healthcare Industry), Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.
NR 0
TC 0
SN 1179-132
EI 1179-132
J9 Cancer Manag Res
PD DEC 9
PY 2025
VL 17
IS 
BP 3005
EP 3023
DI 10.2147/CMAR.S562388
PG 18
UT PubMed:41362632
PM 41362632
DA 2025-12-09
ER

PT J
AU Chen, XJ
   Mi, WL
   Gao, TC
   Ding, FF
   Wang, W
AF Chen, Xuejiao
   Mi, Wenli
   Gao, Tianchi
   Ding, Fengfei
   Wang, Wei
TI Astrocytes in the rostral ventromedial medulla mediate the analgesic effect of electroacupuncture in a rodent model of chemotherapy-induced peripheral neuropathic pain
SO PAIN
LA English
DT Article
DE Paclitaxel; Electroacupuncture; Neuropathic pain; Rostral ventromedial medulla; Astrocyte
ID mechanical allodynia; activation; inhibition; paclitaxel; receptor; rats; acupuncture; stimulation; involvement; contribute
AB Chemotherapy-induced peripheral neuropathic pain aggravates cancer survivors' life burden. Electroacupuncture (EA) has exhibited promising analgesic effects on neuropathic pain in previous studies. We investigated whether EA was effective in a paclitaxel-induced neuropathic pain mouse model. We further explored the functional role of astrocytes in the rostral ventromedial medulla (RVM), a well-established pain modulation center, in the process of neuropathic pain as well as the analgesic effect of EA. We found that paclitaxel induced mechanical allodynia, astrocytic calcium signaling, and neuronal activation in the RVM and spinal cord, which could be suppressed by EA treatment. Electroacupuncture effectively alleviated paclitaxel-induced mechanical allodynia, and the effect was attenuated by the chemogenetic activation of astrocytes in the RVM. In addition, inhibiting astrocytic calcium activity by using either IP3R2 knockout (IP3R2 KO) mice or microinjection of AAV-mediated hPMCA2 w/b into the RVM to reduce non-IP3R2-dependent Ca2+ signaling in astrocytes exhibited an analgesic effect on neuropathic pain, which mimicked the EA effect. The current study revealed the pivotal role of the RVM astrocytes in mediating the analgesic effects of EA on chemotherapy-induced peripheral neuropathic pain.
C1 [Chen, Xuejiao; Wang, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, 1905 Jiefang Rd, Wuhan 430010, Hubei, Peoples R China.
   [Mi, Wenli; Gao, Tianchi] Fudan Univ, Inst Integrat Med, Sch Basic Med Sci, Dept Integrat Med & Neurobiol,Shanghai Key Lab Acu, Shanghai, Peoples R China.
   [Mi, Wenli; Gao, Tianchi] Fudan Univ, Inst Brain Sci, Shanghai Med Coll, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China.
   [Ding, Fengfei] Fudan Univ, Inst Brain Sci, Shanghai Med Coll, Frontiers Ctr Brain Sci,Sch Basic Med Sci,Dept Pha, Shanghai, Peoples R China.
   [Ding, Fengfei] Fudan Univ, Inst Brain Sci, Shanghai Med Coll, Frontiers Ctr Brain Sci,Minist Educ, Shanghai, Peoples R China.
   [Wang, Wei] Huazhong Univ Sci & Technol, Hubei Key Lab Neural Injury & Funct Reconstruct, Wuhan, Peoples R China.
   [Wang, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Minist Educ,Key Lab Neurol Dis Chinese, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Fudan University; Fudan University; Fudan University; Fudan University; Huazhong University of Science & Technology; Huazhong University of Science & Technology
RP Wang, W (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, 1905 Jiefang Rd, Wuhan 430010, Hubei, Peoples R China.
EM xuejiaochen_2020@163.com; wenlimi@fudan.edu.cn; 21211010084@m.fudan.edu.cn; wwang@vip.126.com
CR Agulhon C, 2010, SCIENCE, V327, P1250, DOI 10.1126/science.1184821
   Alves RC, 2018, CRIT REV ANAL CHEM, V48, P110, DOI 10.1080/10408347.2017.1416283
   Cavaletti G, 2024, PAIN, V165, P2482, DOI 10.1097/j.pain.0000000000003268
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chen Y, 2022, BIOL RES, V55, P0, DOI 10.1186/s40659-022-00374-6
   Chen Z, 2015, NEUROSCIENCE, V291, P272, DOI 10.1016/j.neuroscience.2015.02.021
   Cho J, 2020, FRONT CELL NEUROSCI, V14, P0, DOI 10.3389/fncel.2020.594216
   Dai SH, 2014, MED HYPOTHESES, V83, P772, DOI 10.1016/j.mehy.2014.10.008
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Guerra-Gomes S, 2021, EUR J NEUROSCI, V54, P5673, DOI 10.1111/ejn.14724
   Guo W, 2006, J NEUROSCI, V26, P126, DOI 10.1523/JNEUROSCI.3686-05.2006
   Hansen RR, 2013, EUR J PHARMACOL, V716, P120, DOI 10.1016/j.ejphar.2013.03.023
   Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009
   Huang ZX, 2014, PAIN, V155, P783, DOI 10.1016/j.pain.2014.01.011
   Imbe H, 2007, BRAIN RES, V1134, P131, DOI 10.1016/j.brainres.2006.11.091
   Ji R R, 1993, INT J NEUROSCI, V72, P183, DOI 10.3109/00207459309024107
   Ji RR, 2019, NAT REV NEUROSCI, V20, P667, DOI 10.1038/s41583-019-0218-1
   Ji RR, 2013, PAIN, V154, PS10, DOI 10.1016/j.pain.2013.06.022
   Li J, 1990, ZHEN CI YAN JIU, V15, P181
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Lin SS, 2023, CELL DEATH DIS, V14, P0, DOI 10.1038/s41419-023-05839-4
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   LIU X, 1990, ACTA PHYSIOLOGICA SINICA, V42, P523
   Liu X, 1996, ZHEN CI YAN JIU, V21, P4
   Liu XJ, 2012, J HUAZHONG U SCI-MED, V32, P291, DOI 10.1007/s11596-012-0051-5
   Lu HJ, 2023, NEUROSCI BULL, V39, P425, DOI 10.1007/s12264-022-00961-3
   Luo H, 2019, CELL REP, V29, P2384, DOI 10.1016/j.celrep.2019.10.085
   Luo R, 2023, GLIA, V71, P1592, DOI 10.1002/glia.24358
   Ma X, 2022, ANESTH ANALG, V134, P204, DOI 10.1213/ANE.0000000000005768
   MENDELL LM, 1965, NATURE, V206, P97, DOI 10.1038/206097a0
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Michel A, 2023, AM SOC CLIN ONCOL EDUC BOOK, V0, P0, DOI DOI 10.1200/EDBK_390428
   Mo SY, 2022, J ORAL REHABIL, V49, P207, DOI 10.1111/joor.13211
   Nam Y, 2016, CELL REP, V17, P3049, DOI 10.1016/j.celrep.2016.11.043
   Nguyen E, 2023, TRENDS NEUROSCI, V46, P539, DOI 10.1016/j.tins.2023.04.002
   Noh K, 2023, NAT NEUROSCI, V26, P1541, DOI 10.1038/s41593-023-01406-4
   Pan ZZ, 2000, NEURON, V26, P515, DOI 10.1016/S0896-6273(00)81183-6
   Paxinos G, 2001, MOUSE BRAIN STEREOTA, V0, P0
   Petravicz J, 2008, J NEUROSCI, V28, P4967, DOI 10.1523/JNEUROSCI.5572-07.2008
   Qi De-bo, 2012, ZHONG XI YI JIE HE XUE BAO, V10, P416
   Shen SY, 2022, NEUROBIOL DIS, V169, P0, DOI 10.1016/j.nbd.2022.105743
   Shigetomi E, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20040996
   Sivanesan E, 2023, NEUROMODULATION, V26, P938, DOI 10.1016/j.neurom.2023.03.006
   Takanashi K, 2021, PHARMACOL RES PERSPE, V9, P0, DOI 10.1002/prp2.850
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Trendafilova T, 2022, NEURON, V110, P2571, DOI 10.1016/j.neuron.2022.05.017
   Wang JW, 2023, FRONT BEHAV NEUROSCI, V17, P0, DOI 10.3389/fnbeh.2023.1239024
   Wang JY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2134-8
   Wang JY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8403064
   Wang Q, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-23843-0
   Wang XY, 2023, NAT COMMUN, V14, P0, DOI 10.1038/s41467-023-40860-3
   Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008
   White K, 2018, VET J, V237, P16, DOI 10.1016/j.tvjl.2018.05.005
   Xie Chuangbo Ai J, 2023, NEW CHINESE MED, V55, P191
   Xin JJ, 2016, FRONT MED-PRC, V10, P465, DOI 10.1007/s11684-016-0482-7
   Xu YH, 2022, EUR J PHARMACOL, V933, P0, DOI 10.1016/j.ejphar.2022.175288
   Xu ZZ, 2015, NAT MED, V21, P1326, DOI 10.1038/nm.3978
   Yan B, 2023, PAIN MED, V24, P11, DOI 10.1093/pm/pnac115
   Yan XS, 2015, MOL PAIN, V11, P0, DOI 10.1186/s12990-015-0005-6
   Yang QF, 2023, BIOACT MATER, V26, P194, DOI 10.1016/j.bioactmat.2023.02.024
   Zhang MX, 2018, ARQ NEURO-PSIQUIAT, V76, P736, DOI 10.1590/0004-282X20180128
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 63
TC 8
Z9 9
U1 10
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD APR 15
PY 2025
VL 166
IS 4
BP 916
EP 926
DI 10.1097/j.pain.0000000000003433
PG 11
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 0GY4Z
UT WOS:001447121700010
PM 39432736
DA 2026-01-16
ER

PT J
AU Zhang, SW
   Li, YY
   Liang, ZD
   Dai, JX
   Huang, H
   Zhang, HH
   Yang, B
   Wang, JH
   Tang, DX
AF Zhang, Shaowang
   Li, Yuanyin
   Liang, Zhide
   Dai, Jiaxing
   Huang, Hong
   Zhang, Huanghui
   Yang, Bing
   Wang, Jinghui
   Tang, Dongxin
TI Comparing the effects of different non-pharmacological traditional Chinese medicine therapies on cancer survivors: A Bayesian Network Meta-analysis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Non-pharmacological traditional Chinese; medicine therapies; Network Meta-Analysis; Cancer survivors; Pain; Fatigue
ID quality-of-life; massage therapy; tai chi; interventions; management; qigong; inconsistency; statement; fatigue; pain
AB Objectives: Several studies have demonstrated the positive impact of non-pharmacological Traditional Chinese Medicine (TCM) therapies on pain, fatigue, sleep quality, and quality of life in cancer survivors. However, no research has compared the effectiveness of these therapies. This study aims to compare various interventions and identify the most effective non-pharmacological TCM therapies to provide evidence-based recommendations for cancer survivors. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, CNKI, and Wanfang Data. RCTs investigating the effects of Taichi, Qigong, acupuncture, acupressure, TCM emotional therapy, and mixed therapies as interventions for cancer survivors were screened was conducted. Data from the creation of the database to February 2025 were included. Two independent reviewers evaluated the study quality. A Bayesian Network Meta-analysis was conducted to carry out a random effects model. Results: Seventy-one RCTs involving 6473 patients were included in the analysis. Network meta-analysis showed significance for all five intervention therapies in pain control in cancer patients. The best efficacy was observed for acupressure (SMD=-1.1 [-1.55,-0.66]) and Taichi/Qigong (SMD=-1.08[-1.64,-0.53]), followed by TCM emotional therapy (SMD=-0.93 [-1.42,-0.44]) and acupuncture (SMD=-0.54 [-0.93,-0.15]), with the latter showing comparatively lower efficacy. None of the interventions demonstrated superior efficacy in improving fatigue compared to the control group. Mixed therapies (SMD=-1.36[-2.56,-0.28]) demonstrated the greatest effect in improving sleep quality. Taichi/Qigong (SMD=1.87 [0.96, 2.83]) demonstrated certain advantages in improving quality of life. However, acupuncture and TCM emotional therapy had no significant effect on sleep quality or overall quality of life. Conclusion: The evidence from this study suggests that acupressure and Taichi/Qigong are recommended as the most effective therapies for pain relief and quality of life improvement, respectively. The efficacy of these therapies for fatigue remains inconclusive. However, due to the limited number of included studies and the high risk of bias, these results should be interpreted with caution. Future studies should include more rigorously designed high-quality randomized controlled trials to confirm their long-term efficacy and safety. Registration: PROSPERO CRD42024601976
C1 [Zhang, Shaowang; Li, Yuanyin; Dai, Jiaxing; Huang, Hong; Zhang, Huanghui; Yang, Bing; Wang, Jinghui; Tang, Dongxin] Guizhou Univ Tradit Chinese Med, Huaxi Campus, Guiyang 550000, Peoples R China.
   [Yang, Bing; Wang, Jinghui; Tang, Dongxin] Guizhou Univ Tradit Chinese Med, Affiliated Hosp 1, Guiyang 550000, Peoples R China.
   [Zhang, Shaowang; Li, Yuanyin; Dai, Jiaxing; Huang, Hong; Zhang, Huanghui; Yang, Bing; Wang, Jinghui; Tang, Dongxin] Talent Base TCM Tumor Inheritance & Sci & Technol, Guiyang 550000, Peoples R China.
   [Liang, Zhide] Qingdao Univ, Coll Phys Educ, Dept Phys Educ, Qingdao 266071, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine; Guizhou University of Traditional Chinese Medicine; Qingdao University
RP Wang, JH; Tang, DX (corresponding author), Guizhou Univ Tradit Chinese Med, Huaxi Campus, Guiyang 550000, Peoples R China.; Wang, JH (corresponding author), Guizhou Univ Chinese Med, Affiliated Hosp 1, Dept Oncol, Guiyang 550000, Peoples R China.
EM zhangsw1114@163.com; 1240722076@qq.com; liangzhide123@163.com; 1229607910@qq.com; 1527005190@qq.com; 1257379762@qq.com; 1006019442@qq.com; 547917662@qq.com; hemingankang@sina.com
FU Guizhou Provincial Higher Education Traditional Chinese and Medicine Ethnic Medicine Cancer Prevention and Treatment Medical Transformation Engineering Research Center (Qian Jijiao [2023]) [037]; Talent Base of Traditional Chinese Medicine Tumor Inheritance and Scientific and Technological Innovation in Guizhou Province (Guizhou Qianren Lingfa [2018]) [3]; Talent Team of Traditional Chinese Medicine Tumor Inheritance and Scientific and Technological Innovation in Guizhou Province (Guizhou Science and Technology Cooperative Talent [2020]) [5013]; Guizhou Science and Technology Cooperation Academic New Seedling ([2023]) [03]
CR Baddour LM, 2005, CIRCULATION, V111, PE394, DOI 10.1161/CIRCULATIONAHA.105.165564
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Carmady B, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-22
   Chang PS, 2019, ASIA-PAC J ONCOL NUR, V6, P315, DOI 10.4103/apjon.apjon_34_19
   Chien C-R, 2013, AM SOC CLIN ONCOL, V0, P0
   de Rooij BH, 2021, CANCER-AM CANCER SOC, V127, P4665, DOI 10.1002/cncr.33852
   Dias S, 2013, MED DECIS MAKING, V33, P641, DOI 10.1177/0272989X12455847
   Emery J, 2022, LANCET, V399, P1537, DOI 10.1016/S0140-6736(22)00242-2
   Field T, 2014, COMPLEMENT THER CLIN, V20, P224, DOI 10.1016/j.ctcp.2014.07.002
   Fisher AA, 2022, PHILOS T R SOC B, V377, P0, DOI 10.1098/rstb.2021.0242
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   He C, 2022, CHIN GEN PRACT, V19, P2414, DOI 10.11124/JBISRIR-2016-2476
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Hosokawa M, 2022, ANN PALLIAT MED, V11, P3382, DOI 10.21037/apm-22-655
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Klein Penelope, 2017, MEDICINES (BASEL), V4, P0, DOI 10.3390/medicines4010002
   Kröz M, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-017-3142-7
   Labata-Lezaun N, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12092607
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li XL, 2024, BMJ EVID-BASED MED, V29, P162, DOI 10.1136/bmjebm-2023-112434
   Lin LF, 2018, J GEN INTERN MED, V33, P1260, DOI 10.1007/s11606-018-4425-7
   Ling Y, 2013, ANN PALLIAT MED, V2, P141, DOI 10.3978/j.issn.2224-5820.2013.04.05
   Liu LZ, 2020, COMPLEMENT THER CLIN, V38, P0, DOI 10.1016/j.ctcp.2019.101078
   Long YY, 2024, INT J NURS STUD, V160, P0, DOI 10.1016/j.ijnurstu.2024.104904
   Luo Y, 2024, FRONT NEUROL, V15, P0, DOI 10.3389/fneur.2024.1421469
   Ma HL, 2016, EUR J INTEGR MED, V8, P707, DOI 10.1016/j.eujim.2016.05.007
   Mazzocco K, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15041176
   Miaskowski C, 2017, JNCI-J NATL CANCER I, V109, P0, DOI 10.1093/jnci/djw253
   Miller KD, 2022, CA-CANCER J CLIN, V72, P409, DOI 10.3322/caac.21731
   Owen RK, 2019, RES SYNTH METHODS, V10, P569, DOI 10.1002/jrsm.1373
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Paul AK, 2021, PHARMACEUTICALS-BASE, V14, P0, DOI 10.3390/ph14111091
   Roura S, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0260642
   Schmidt ME, 2022, INT J CANCER, V151, P1280, DOI 10.1002/ijc.34152
   Shan SN, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07926-w
   Sheikh-Wu SF, 2020, ONCOL NURS FORUM, V47, PE107, DOI 10.1188/20.ONF.E107-E119
   Siegel RL, 2024, CA-CANCER J CLIN, V74, P12, DOI 10.3322/caac.21820
   So WKW, 2020, CANCER NURS, V43, PE304, DOI 10.1097/NCC.0000000000000730
   Su MZ, 2020, CANCER-AM CANCER SOC, V126, P3312, DOI 10.1002/cncr.32943
   Sutradhar R, 2017, CANCER-AM CANCER SOC, V123, P4286, DOI 10.1002/cncr.30839
   Tang Y, 2024, CANCER NURS, V47, P20, DOI 10.1097/NCC.0000000000001155
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   Thom H, 2019, RES SYNTH METHODS, V10, P113, DOI 10.1002/jrsm.1329
   Tu YK, 2016, VALUE HEALTH, V19, P957, DOI 10.1016/j.jval.2016.07.005
   Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x
   Wang J, 2024, J PAIN SYMPTOM MANAG, V0, P0
   Wang T, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9967574
   Wang YP, 2024, STAT METHODS MED RES, V33, P745, DOI 10.1177/09622802241231496
   Wen YR, 2022, FRONT AGING NEUROSCI, V14, P0, DOI 10.3389/fnagi.2022.921069
   Yang T, 2021, COMPLEMENT THER CLIN, V44, P0, DOI 10.1016/j.ctcp.2021.101416
   Yao CJ, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6678184
   Yennurajalingam S, 2021, BMJ SUPPORT PALLIAT, V11, P170, DOI 10.1136/bmjspcare-2019-001877
   Zeng YC, 2014, COMPLEMENT THER MED, V22, P173, DOI 10.1016/j.ctim.2013.11.010
   Zhang J, 2024, WORLD NEUROSURG, V191, P58, DOI 10.1016/j.wneu.2024.08.017
NR 58
TC 1
Z9 1
U1 3
U2 16
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD JUN 15
PY 2025
VL 90
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103164
EA MAR 2025
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0ZL1V
UT WOS:001459676900001
PM 40157553
DA 2026-01-16
ER

PT J
AU Li, HJ
   Doorenbos, AZ
   Chen, ZJ
   Choi, H
   Ma, WW
   Danciu, O
   Patil, CL
   Gao, S
   Lif, N
   Schlaeger, JM
AF Li, Hongjin
   Doorenbos, Ardith Z.
   Chen, Zhengjia
   Choi, Hannah
   Ma, Weiwei
   Danciu, Oana
   Patil, Crystal L.
   Gao, Shuang
   Lif, Natalie
   Schlaeger, Judith M.
TI Feasibility and Acceptability of Integrating Acupuncture for Management of Multiple Symptoms in Medically Underserved Breast Cancer Survivors
SO CANCERS
LA English
DT Article
DE acupuncture; health disparities; medically underserved; breast cancer survivors; symptom management
ID pain
AB Background/Objectives: Breast cancer survivors undergoing long-term endocrine therapy often experience multiple symptoms, including pain, fatigue, sleep disturbance, hot flashes, anxiety, and depression. This study explored the feasibility and acceptability of integrating acupuncture for symptom management in medically underserved breast cancer survivors. Methods: This randomized controlled trial was conducted at two clinics serving medically underserved populations. Breast cancer survivors (N = 62) were randomized to receive acupuncture (n = 31) or usual care (n = 31). The acupuncture group underwent 10 sessions over 5 weeks. Symptoms were assessed at baseline and Weeks 6 and 12. Results: The majority of participants (55%) were Black, mean age was 55.2 +/- 9.3 years, and 62.9% had a household income below $55,000. Retention (90.3%), engagement (93.1%), and acceptability (92.8%) rates were high, demonstrating that integrating acupuncture into care for medically underserved breast cancer survivors is both feasible and acceptable. At Week 6, the acupuncture group showed significant reduction compared to the usual care group in pain, fatigue, sleep disturbance, depression, anxiety, and the symptom cluster score. All improvements persisted to Week 12 except for those in anxiety. Conclusions: Integrating acupuncture for symptom management in medically underserved breast cancer survivors is both feasible and acceptable. This approach offers potential benefits for reducing multiple symptoms and addressing health disparities.
C1 [Li, Hongjin; Doorenbos, Ardith Z.; Choi, Hannah; Lif, Natalie; Schlaeger, Judith M.] Univ Illinois, Coll Nursing, Chicago, IL 60612 USA.
   [Li, Hongjin; Doorenbos, Ardith Z.; Chen, Zhengjia; Ma, Weiwei; Danciu, Oana] Univ Illinois, Canc Ctr, Chicago, IL 60612 USA.
   [Patil, Crystal L.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
   [Gao, Shuang] Univ Illinois, Coll Med, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Li, HJ (corresponding author), Univ Illinois, Coll Nursing, Chicago, IL 60612 USA.; Li, HJ (corresponding author), Univ Illinois, Canc Ctr, Chicago, IL 60612 USA.
EM hongjin@uic.edu; ardith@uic.edu; znchen@uic.edu; hchoi213@uic.edu; wma29@uic.edu; ocdanciu@uic.edu; clpatil@med.umich.edu; sgao20@uic.edu; nlif2@uic.edu; jschlaeg@uic.edu
FU National Center for Complementary and Integrative Health;  [R34 AT012084];  [K24 AT011995-01]
CR Alcalá HE, 2014, BMC PUBLIC HEALTH, V14, P0, DOI 10.1186/1471-2458-14-930
   Alnaim L, 2022, EUR J BREAST HEALTH, V18, P292, DOI 10.4274/ejbh.galenos.2022.2022-5-8
   Unknown -, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/BMJ.C332
   Bjerkeset E, 2020, BREAST CANCER RES TR, V180, P63, DOI 10.1007/s10549-020-05522-8
   Caraballo C, 2022, JAMA-HEALTH FORUM, V3, P0, DOI 10.1001/jamahealthforum.2022.3856
   Carmen A, 2023, BREAST CANCER RES TR, V198, P475, DOI 10.1007/s10549-022-06808-9
   Cella D, 2019, VALUE HEALTH, V22, P537, DOI 10.1016/j.jval.2019.02.004
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Deyo RA, 2016, PAIN MED, V17, P314, DOI 10.1093/pm/pnv046
   Eliassen FM, 2023, BMC CANCER, V23, P0, DOI 10.1186/s12885-023-11122-8
   Elshafie S, 2025, CANCER-AM CANCER SOC, V131, P0, DOI 10.1002/cncr.35550
   Harris PA, 2019, J BIOMED INFORM, V95, P0, DOI 10.1016/j.jbi.2019.103208
   Kang D, 2022, CANCER RES TREAT, V54, P10, DOI 10.4143/crt.2020.1200
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Li HJ, 2024, CONTEMP CLIN TRIALS, V136, P0, DOI 10.1016/j.cct.2023.107387
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Ma Y, 2024, ASIA-PAC J ONCOL NUR, V11, P0, DOI 10.1016/j.apjon.2023.100364
   Mandelblatt JS, 2020, CANCER-AM CANCER SOC, V126, P1183, DOI 10.1002/cncr.32663
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Miller David W, 2021, GLOB ADV HEALTH MED, V10, P21649561211042574, DOI 10.1177/21649561211042574
   SAS Institute, 2019, SAS CERTIFIED PROFESSIONAL PREP GUIDE: ADVANCED PROGRAMMING USING SAS 9.4, V0, P0
   Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280
   Tangkiatkumjai M, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03157-2
   Tarver WL, 2025, J CANCER SURVIV, V19, P1956, DOI 10.1007/s11764-024-01609-z
   Teets R, 2023, GLOB ADV INTEGR MED, V12, P0, DOI 10.1177/27536130231202515
   Terwee CB, 2021, QUAL LIFE RES, V30, P2729, DOI 10.1007/s11136-021-02925-y
   Tonorezos E, 2024, JNCI-J NATL CANCER I, V116, P1784, DOI 10.1093/jnci/djae135
   Vallerand AH, 2005, PAIN MED, V6, P242, DOI 10.1111/j.1526-4637.2005.05038.x
   Whisenant MS, 2022, CANCER NURS, V45, P253, DOI 10.1097/NCC.0000000000001019
   Wilkie DJ, 2003, J PAIN SYMPTOM MANAG, V25, P213, DOI 10.1016/S0885-3924(02)00638-3
   Wilkie DJ, 2001, FAM COMMUNITY HEALTH, V24, P48, DOI 10.1097/00003727-200110000-00007
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
NR 34
TC 2
Z9 2
U1 2
U2 4
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN 15
PY 2025
VL 17
IS 2
BP 
EP 
DI 10.3390/cancers17020304
PG 14
WC Oncology
SC Oncology
GA T2W9A
UT WOS:001403685100001
PM 39858086
DA 2026-01-16
ER

PT J
AU Spraker-Perlman, HL
   Busby, KM
   Ly, A
   Meyer, M
   Baker, JN
   Levine, DR
AF Spraker-Perlman, Holly L.
   Busby, Kenneth M.
   Ly, Amy
   Meyer, Maggi
   Baker, Justin N.
   Levine, Deena R.
TI Pediatric Hematology-Oncology Provider Attitudes and Beliefs About the Use of Acupuncture for Their Patients
SO CHILDREN-BASEL
LA English
DT Article
DE pediatrics; children; oncology; cancer; acupuncture; survey; needs assessment; integrative medicine
ID integrative medicine; pain management; safety; children
AB Background/Objectives: Children with cancer suffer due to the underlying disease and prescribed cancer-directed therapies, and non-pharmacologic modalities may offer improved symptom control without additional medications. We sought to elicit knowledge, attitudes, and beliefs of Pediatric Hematology Oncology (PHO) providers surrounding the incorporation of acupuncture for symptom management for their patients. Methods: A cross-sectional survey instrument was created, formatted, and delivered to physicians and advanced practice providers (APPs) at a single US pediatric cancer center. Survey responses were summarized by descriptive statistics. Results: A total of 78 PHO clinicians participated (response rate 29%). Most participants were interested in learning more about acupuncture (n = 42, 56.0%), yet rarely (n = 17, 22.7%) or never (n = 46, 61.3%) recommend acupuncture to patients. Most (n = 51, 73.9%) noted that they would support institutional development of an acupuncture program. Over half (n = 37, 52.2%) indicated their threshold for minimum hematologic indices for acupuncture includes a platelet count greater than 20,000 and absolute neutrophil count (ANC) greater than 500 (n = 37, 54.4%). Approximately two-thirds (n = 52, 66.7%) of participants noted that acupuncture could improve their patient's quality of life, and most (n = 46, 67.6%) were not worried about harm. Conclusions: Acupuncture for symptom management is an evidenced-based, guideline-concordant recommendation for adults with cancer, but robust data in the pediatric oncology population are lacking. PHO providers do not routinely recommend acupuncture for patients but note that it may improve quality of life. Given their high symptom burden, rigorous studies of non-pharmacologic strategies for pediatric symptom management are vital. Acupuncture should be examined as a potential beneficial adjunct.
C1 [Spraker-Perlman, Holly L.] Univ Utah, Primary Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol & Pediat Palliat Care, Salt Lake City, UT 84113 USA.
   [Busby, Kenneth M.] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA.
   [Ly, Amy] St Jude Childrens Res Hosp, Dept Pediat Med, Div Pediat Neurol, Memphis, TN 38105 USA.
   [Meyer, Maggi] St Jude Childrens Res Hosp, Dept Rehabil Med, Memphis, TN 38105 USA.
   [Baker, Justin N.] Stanford Univ, Dept Pediat, Div Qual Life & Pediat Palliat Care, Sch Med, Palo Alto, CA 94305 USA.
   [Levine, Deena R.] St Jude Childrens Res Hosp, Dept Oncol, Div Qual Life & Palliat Care, Memphis, TN 38105 USA.
C3 Utah System of Higher Education; University of Utah; Stanford University; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Stanford University; St Jude Children's Research Hospital
RP Spraker-Perlman, HL (corresponding author), Univ Utah, Primary Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol & Pediat Palliat Care, Salt Lake City, UT 84113 USA.
EM holly.spraker-perlman@hsc.utah.edu; kmbusby@stanford.edu; amy.ly@stjude.org; maggi.meyer@stjude.org; jusbaker@stanford.edu; deena.levine@stjude.org
FU American Lebanese Syrian Associated charities (ALSAC)
CR Ast A, 2021, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V6, P0, DOI 10.21926/obm.icm.2101005
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Barnhart BJ, 2021, EVAL HEALTH PROF, V44, P245, DOI 10.1177/01632787211019445
   Beer TM, 2010, UROLOGY, V76, P1182, DOI 10.1016/j.urology.2010.03.033
   Bodner K, 2018, COMPLEMENT THER MED, V38, P79, DOI 10.1016/j.ctim.2018.05.001
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   de Valois B, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08386-6
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   García EM, 2024, CANCERS, V16, P0, DOI 10.3390/cancers16183197
   Highfield ES, 2006, J ALTERN COMPLEM MED, V12, P317, DOI 10.1089/acm.2006.12.317
   Johnson A, 2015, ALTERN COMPLEMENT TH, V21, P255, DOI 10.1089/act.2015.29022.ajo
   Kayo T, 2024, J INTEGR COMPLEMENT, V30, P77, DOI 10.1089/jicm.2022.0710
   Kemper K, 2004, CONTEMPORARY PEDIATRICS, V21, P61
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lin YC, 2020, J TRADIT COMPL MED, V10, P315, DOI 10.1016/j.jtcme.2019.08.004
   Lu WD, 2024, CANCER-AM CANCER SOC, V130, P3219, DOI 10.1002/cncr.35374
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Martin CS, 2019, ACTA ANAESTH SCAND, V63, P292, DOI 10.1111/aas.13288
   Metcalf RA, 2025, JAMA-J AM MED ASSOC, V334, P606, DOI 10.1001/jama.2025.7529
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Morey SS, 1998, AM FAM PHYSICIAN, V57, P2545
   Murphy CC, 2020, BMC MED RES METHODOL, V20, P0, DOI 10.1186/s12874-020-01014-x
   National Comprehensive Cancer Center National Comprehensive Cancer Network, 2025, CLINICAL PRACTICE GUIDELINES IN ONCOLOGY-SURVIVORSHIP-PHYSICIAN GUIDELINES, V0, P0
   PDQ Integrative Alternative and Complementary Therapies Editorial Board, 2002, ACUPUNCTURE (PDQ®): HEALTH PROFESSIONAL VERSION. PDQ CANCER INFORMATION SUMMARIES, V0, P0
   Roth M, 2009, J PEDIAT HEMATOL ONC, V31, P177, DOI 10.1097/MPH.0b013e3181984f5a
   Schneider Craig D, 2003, BMC MED EDUC, V3, P5, DOI 10.1186/1472-6920-3-5
   Spraker-Perlman HL, 2025, J NATL COMPR CANC NE, V23, P0, DOI 10.6004/jnccn.2025.7021
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 33
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9067
J9 CHILDREN-BASEL
JI Children-Basel
PD JUL 22
PY 2025
VL 12
IS 8
BP 
EP 
DI 10.3390/children12080961
PG 11
WC Pediatrics
SC Pediatrics
GA 6NC2T
UT WOS:001557294200001
PM 40868413
DA 2026-01-16
ER

PT J
AU Gu, YM
   Meng, X
   Liang, JY
   Xia, Y
   Huang, JW
   Wang, K
   Ju, ZY
AF Gu, Yi-Ming
   Meng, Xiang
   Liang, Jia-Yi
   Xia, Yong
   Huang, Jun-Wei
   Wang, Ke
   Ju, Zi-Yong
TI Electroacupuncture intervention relieves pain by stimulating the STING/IFN-I
SO Molecular pain
LA English
DT Journal Article
DE IFN-I; STING; analgesic effects; cancer-induced bone pain; electroacupuncture
AB This study aimed to evaluate the effects of electroacupuncture (EA) on  cancer-induced bone pain (CIBP) and investigate its interaction with the  STING/IFN-I pathway. A CIBP model was established in female rats. EA was  administered for six consecutive days at bilateral L3-L5 Jia Ji points (EX-B2).  EA-induced antinociception was evaluated through mechanical, thermal, and cold  sensitivity assessments. EA significantly increased the paw withdrawal threshold  (PWT) and paw withdrawal latency (PWL) in rats with CIBP (p < 0.01). In the  spinal cord of CIBP model rats, western blot analysis demonstrated that the  application of EA upregulated the expression of STING, IRF3, and IFNAR (p <  0.05). The ELISA results indicated that EA significantly increased the expression  of IFN-α (p < 0.005) and IFN-β (p < 0.01) and reduced the expression of TNF-α and  IL-1β (p < 0.05). Immunofluorescence analysis revealed that STING was  predominantly localized in microglia, with a minimal presence in neuronal cells.  Furthermore, intrathecal administration of the STING antagonist C-176 attenuated  the analgesic effects of EA in CIBP (p < 0.05). Both EA and STING agonist were  effective in alleviating pain in rats with CIBP, possibly through the activation  of the STING/IFN-I pathway. Notably, EA treatment reduced pro-inflammatory  cytokines and increased anti-inflammatory cytokines. In contrast, while the STING  agonist exhibited analgesic effects, it was associated with elevated levels of  pro-inflammatory cytokines. These finding underscore the therapeutic potential of  EA in the management of CIBP.
C1 Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 1744-806
EI 
J9 Mol Pain
PD MAY 7
PY 2025
VL 21
IS 
BP 17448069251342240
EP 17448069251342240
DI 10.1177/17448069251342240
PG 1
WC Animals; Electroacupuncture; methods; Female; Cancer Pain; therapy; Rats, Sprague-Dawley; Disease Models, Animal; Signal Transduction; Bone Neoplasms; complications; Rats; Membrane Proteins; metabolism
UT PubMed:40331681
PM 40331681
DA 2025-05-07
ER

PT J
AU Ding, Y
   Cao, H
   Huang, Y
   Xue, H
   Cai, S
   Chen, X
   Duan, M
AF Ding, Yajun
   Cao, Hanzhong
   Huang, Ying
   Xue, Hong
   Cai, Shenquan
   Chen, Xiaohong
   Duan, Manlin
TI Fire Acupuncture Combined with Pulse Radiofrequency Relieves Tactile Allodynia in
SO International journal of general medicine
LA English
DT Journal Article
DE P13K/AKT; fire acupuncture; postherpetic neuralgia; pulse radiofrequency
AB BACKGROUND: Postherpetic neuralgia (PHN) remains challenging to treat, with  40%-50% of patients experiencing inadequate pain relief despite comprehensive  interventions. Neuromodulation techniques such as pulsed radiofrequency (RF) and  traditional methods such as fire acupuncture (FA) are increasingly used for PHN.  This study investigated the combined effect of FA and RF on tactile allodynia in  a rat model of PHN and explored its underlying mechanisms. METHODS: Adult male  rats were randomly divided into: Control, PHN, FA, RF, and combined FA_RF groups.  PHN was induced by varicella-zoster virus inoculation. FA and/or RF interventions  began on Day 15. Pain behavior was assessed via mechanical allodynia and thermal  hyperalgesia tests. On Day 37, spinal cord tissues and cerebrospinal fluid were  collected to evaluate astrocyte and microglial activation, neuronal apoptosis,  expression of Insulin-Like Growth Factor 2 (IGF2), Peripheral Myelin Protein 2  (PMP2), Claudin-19 (CLDN19), Homeobox C8 (HOXC8), and levels of interleukin-1β  (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis  factor-α (TNF-α). The role of the phosphatidylinositol 3-kinase (PI3K)/protein  kinase B (AKT) pathway was verified using a PI3K/AKT agonist. RESULTS: The  results revealed that mechanical allodynia thresholds decreased on Day 8  post-inoculation. Compared to the PHN group, FA_RF combination significantly  increased mechanical thresholds and prolonged thermal hyperalgesia latency, with  superior effects versus FA or RF alone. The FA_RF group showed increased spinal  IGF2, PMP2, and CLDN19 expression, decreased HOXC8, reduced astrocyte activation,  and modulated cytokine levels (IL-1β, IL-6, TNF-α, IL-10). The PI3K/AKT agonist  reversed the analgesic effects of FA_RF. CONCLUSION: Combined fire acupuncture  and pulsed radiofrequency alleviates tactile allodynia in PHN rats, possibly by  inhibiting spinal astrocyte activation, modulating inflammatory responses, and  promoting nerve repair via IGF2, PMP2, and CLDN19 expression. The PI3K/AKT  pathway may be critically involved in this analgesic mechanism.
C1 Department of Anesthesiology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210002, People's Republic of China.
   Tumor Hospital Affiliated to Nantong University, Nantong Tumor Hospital, Nantong, 
   Tumor Hospital Affiliated to Nantong University, Nantong Tumor Hospital, Nantong, 226361, People's Republic of China.
   Department of Pain Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People's Republic of China.
   Department of Anesthesiology, The Affiliated Huaian Hospital of Xuzhou Medical University and Huaian Second People's Hospital, Huai'an, 223002, People'sRepublic of China.
   Department of Pain Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People's Republic of China.
   Tumor Hospital Affiliated to Nantong University, Nantong Tumor Hospital, Nantong, 226361, People's Republic of China.
   Department of Anesthesiology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210002, People's Republic of China.
NR 0
TC 0
SN 1178-707
EI 1178-707
J9 Int J Gen Med
PD SEP 25
PY 2025
VL 18
IS 
BP 5699
EP 5716
DI 10.2147/IJGM.S541807
PG 17
UT PubMed:40994884
PM 40994884
DA 2025-09-25
ER

PT J
AU Raybin, JL
   Montgomery, K
   Janosy, N
   Mist, S
   Franklin, H
   Dieckmann, NF
   Hendricks-Ferguson, VL
   Jankowski, CM
AF Raybin, Jennifer L
   Montgomery, Kathleen
   Janosy, Norah
   Mist, Scott
   Franklin, Heather
   Dieckmann, Nathan F
   Hendricks-Ferguson, Verna L
   Jankowski, Catherine M
TI Study of Complementary and Integrative Interventions in Pediatric Patients With
SO Journal of pain and symptom management
LA English
DT Journal Article
DE Integrative; childhood cancer; complementary; quality of life; symptoms
AB CONTEXT: Pediatric patients report using complementary and integrative health  interventions (CHI) for symptom management. OBJECTIVE: Feasibility and initial  effect sizes of CHI with patients at two children's hospitals. METHODS: Using  convenience sampling at two academic centers and accepting the wide age range of  patients traditionally treated in children's hospitals, we examined feasibility  of CHI and outcomes of quality of life (QOL) and symptoms with validated surveys  and two physiologic measures. A priori feasibility thresholds were 90% accrual  rate and 60% completion of at least two surveys and one CHI session. RESULTS:  Over 18 months we accrued 100 participants (Site 1, n = 34; Site 2, n = 66) who  completed 811 assessments. Participants were aged 2-29 years (M = 13.5, SD =  5.6), 65% female, 23% from underrepresented populations, 52% with cancer versus  other serious illness. Accrual rate was 94%, completion rate was 87%,  acceptability was 96%. Ninety-nine participants received 191 total CHI sessions:  acupuncture (39%), aromatherapy (35%), creative arts (20%), massage therapy (5%)  and hypnosis (1%). After CHI heart rate decreased and symptom scores improved for  anxiety, fatigue, nausea, pain, and sadness (Cohen's d effect sizes 0.22-0.99).  Adjusted mixed-effects models suggested that the Faces Scale scores improved over  time (b = -0.19, P < 0.01). CONCLUSION: Prospective two-site data collection in  relationship to CHI exceeded feasibility thresholds and was acceptable. When  given the choice, CHI were popular and may have contributed to improved QOL  immediately and longitudinally. These preliminary findings support further study  of CHI for targeted symptoms in distinct populations with rigor.
C1 Oregon Health and Sciences University Schools of Nursing and Medicine (J.L.R., S.M., H.F., N.F.D), Portland, Oregon. 
   University of Wisconsin-Madison School of Nursing (K.M.), Madison, Wisconsin.
   University of Colorado College of Nursing and School of Medicine (C.M.J.), Auroroa, Colorado.
   Oregon Health and Sciences University Schools of Nursing and Medicine (J.L.R., S.M., H.F., N.F.D), Portland, Oregon.
   Oregon Health and Sciences University Schools of Nursing and Medicine (J.L.R., S.M., H.F., N.F.D), Portland, Oregon.
   Oregon Health and Sciences University Schools of Nursing and Medicine (J.L.R., S.M., H.F., N.F.D), Portland, Oregon.
   Saint Louis University School of Nursing (V.L.H.F.), St Louis, Missouri.
   University of Colorado College of Nursing and School of Medicine (C.M.J.), Auroroa, Colorado.
EM raybin@ohsu.edu
NR 0
TC 0
SN 1873-651
EI 0885-392
J9 J Pain Symptom Manage
PD FEB 20
PY 2025
VL 69
IS 5
BP 515
EP 526
DI 10.1016/j.jpainsymman.2025.02.013
PG 11
WC Humans; Female; Child; Male; Adolescent; Complementary Therapies; methods; Child, Preschool; Quality of Life; Young Adult; Adult; Feasibility Studies; Integrative Medicine; Treatment Outcome; Critical Illness; therapy
UT PubMed:39971211
PM 39971211
DA 2025-02-20
ER

PT J
AU Houran, L
   Pucka, AQ
   Jiang, MC
   Liu, Z
   O'brien, AR
   Harte, SE
   Harris, RE
   Pakbaz, Z
   Wang, Y
AF Houran, Lina
   Pucka, Andrew q
   Jiang, Mio cate
   Liu, Ziyue
   O'brien, Andrew rw
   Harte, Steve e
   Harris, Richard edmund
   Pakbaz, Zahra
   Wang, Ying
TI Acupressure alleviates pain and clinical symptoms in patients with sickle cell disease
SO Blood Advances
LA English
DT Article
DE 
ID hydroxyurea; placebo; acupressure; adolescent; adult; anxiety; article; body mass; breast cancer; cancer survivor; clinical article; controlled study; depression; dysmenorrhea; fatigue; female; follow up; human; low back pain; male; opioid induced hyperalgesia; pain severity; quality of life; randomized controlled trial; sickle cell anemia; sickle cell crisis; sleep disorder
AB [No abstract available]
C1 Indiana University School of Medicine, Houran, Lina, Department of Anesthesiology, Indianapolis, IN, United States
   Indiana University School of Medicine, Department of Anesthesiology, Indianapolis, IN, United States
   Jiang, Mio Cate, UCI School of Medicine, Irvine, CA, United States
   Indiana University School of Medicine, Liu, Ziyue, Department of Biostatistics and Health Data Science, Indianapolis, IN, United States
   Indiana University School of Medicine, O'Brien, Andrew Rw, Division of Hematology and Oncology, Indianapolis, IN, United States
   University of Michigan Medical School, Department of Anesthesiology, Ann Arbor, MI, United States
   University of Michigan Medical School, Harris, Richard Edmund, Department of Anesthesiology, Ann Arbor, MI, United States, Department of Anesthesiology and Perioperative Care, UCI School of Medicine, Irvine, CA, United States, UCI School of Medicine, Irvine, CA, United States
   Pakbaz, Zahra, UCI School of Medicine, Irvine, CA, United States
   Indiana University School of Medicine, Wang, Ying, Department of Anesthesiology, Indianapolis, IN, United States, Division of Hematology and Oncology, Indianapolis, IN, United States
CR Song, 1900, EFFECT OF SELF-ACUPRESSURE FOR SYMPTOM MANAGEMENT: A SYSTEMATIC REVIEW, V0, P68-78
   He, 1900, CLINICAL EVIDENCE FOR ASSOCIATION OF ACUPUNCTURE AND ACUPRESSURE WITH IMPROVED CANCER PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS, V0, P271-278
   Karakuş Selçuk, 1900, EFFECT OF ACUPRESSURE ON PRIMARY DYSMENORRHEA: REVIEW OF EXPERIMENTAL STUDIES, V0, P33-49
   Alimoardi, 1900, EFFECTS OF EAR AND BODY ACUPRESSURE ON LABOR PAIN AND DURATION OF LABOR ACTIVE PHASE: A RANDOMIZED CONTROLLED TRIAL, V0, P51
   Murphy, 1900, 2019, V0, P0
   Zick, 1900, 2016, V0, P0
   Osunkwo, 1900, OPTIMIZING THE MANAGEMENT OF CHRONIC PAIN IN SICKLE CELL DISEASE, V0, P562-569
   Smith, 1900, 2008, V0, P0
   Zaidi, 1900, A SYSTEMATIC LITERATURE REVIEW OF FREQUENCY OF VASO-OCCLUSIVE CRISES IN SICKLE CELL DISEASE, V0, P1
NR 9
TC 0
SN 24739529
EI 
J9 BLOOD ADV
JI Blood Adv.
PD JUN 15
PY 2025
VL 9
IS 23
BP 6126
EP 6129
DI 10.1182/bloodadvances.2025016995
PG 4
UT Scopus:10.1182/bloodadvances.2025016995
ER

PT J
AU Bermúdez, LIH
   Palacios, LD
   Rosero, ID
   Guil, R
   Ordoñez-Mora, LT
AF Henao Bermudez, Laura Isabel
   Dominguez Palacios, Lawrence
   Rosero, Ilem D.
   Guil, Rocio
   Ordonez-Mora, Leidy Tatiana
TI Effect of educational interventions in pain intensity and related outcomes in adults with oncological pain: a systematic review and meta-analysis
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article; Early Access
DE Palliative Care; Pain; Education and training; Supportive care
ID randomized controlled-trial; patient-related barriers; cancer pain; self-management; clinical-trial; home-care; program; impact; outpatients; quality
AB Background Pain is the second most prevalent symptom in patients with cancer after fatigue and is highly debilitating. There is an increasing emphasis on the prescription of non-pharmacological interventions, among which pain education is a prominent option. This study aimed to determine the effects of educational interventions on pain intensity and related outcomes in patients with oncological pain.Methods A systematic review was conducted following Cochrane and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, with registration in PROSPERO CRD42022343205 from searches in the main databases such as PubMed, Science Direct, Taylor and Francis, Cochrane (CENTRAL) and Scopus without language restriction, including randomised clinical trials and observational studies using the following keywords: "Pain Education" AND "Cancer". The PEDro (Physiotherapy Evidence Database scale) scale and MINORS (methodological index for non-randomised studies) criteria were used to analyse the risk of bias.Results 35 articles involving the use of educational interventions for patients with cancer pain were analysed in this study. Most protocols involved sessions implementing audiovisual aids, which the patient could easily access. The protocols showed significant results in terms of improvement in pain intensity, stress, quality of life and catastrophising in the intervened groups. Due to the heterogeneity of the interventions in the quantitative analysis, it was only possible to include six articles, which yielded significant results in improving pain (-0.65 (-1.18 to -0.12)).Conclusions It is concluded that educational interventions can be effective in the treatment of cancer pain and should be considered as a complement to palliative care treatment.PROSPERO registration number CRD42022343205.
C1 [Henao Bermudez, Laura Isabel; Dominguez Palacios, Lawrence] Univ Santiago de Cali, Med Program Palmira, Cali, Colombia.
   [Rosero, Ilem D.; Ordonez-Mora, Leidy Tatiana] Univ Santiago de Cali, Dept Hlth, Physiotherapy Program, Cali, Colombia.
   [Guil, Rocio] Univ Cadiz, Dept Psychol, Cadiz, Spain.
C3 Universidad de Cadiz
RP Ordoñez-Mora, LT (corresponding author), Univ Santiago de Cali, Dept Hlth, Physiotherapy Program, Cali, Colombia.
EM laurahenao_99@hotmail.com; law0ren3ce12@gmail.com; ilemdayana@gmail.com; rocio.guil@uca.es; tatiana.ormora@gmail.com
FU General Directorate of Investigations of Universidad Santiago de Cali [DGI 01- 2025]
CR Anderson KO, 2004, J CLIN ONCOL, V22, P4918, DOI 10.1200/JCO.2004.06.115
   Unknown -, 2022, J CANCER EDUC, V37, PS1, DOI 10.1007/s13187-022-02218-z
   Unknown -, 2024, EL DOLOR EN EL PACIENTE ONCOLOGICO, V0, P0
   Aubin M, 2006, ONCOL NURS FORUM, V33, P1183, DOI 10.1188/06.ONF.1183-1188
   Barlési F, 2004, PRESSE MED, V33, P1313, DOI 10.1016/S0755-4982(04)98915-4
   Barre VP, 2015, INDIAN J PALLIAT CAR, V21, P203, DOI 10.4103/0973-1075.156503
   Bentez del Rosario MA, 2002, ATENCIN PRIMARIA, V29, P374, DOI 10.1016/S0212-6567(02)70586-6
   Bilmiç E, 2023, EUR J ONCOL NURS, V67, P0, DOI 10.1016/j.ejon.2023.102422
   Cancer, 2024, ABOUT US, V0, P0
   Chang MC, 2002, CANCER NURS, V25, P470, DOI 10.1097/00002820-200212000-00012
   Chou PL, 2011, J CLIN NURS, V20, P1858, DOI 10.1111/j.1365-2702.2011.03740.x
   DALTON JA, 1987, PATIENT EDUC COUNS, V9, P155, DOI 10.1016/0738-3991(87)90077-2
   De Groef A, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07557-7
   de Wit R, 2001, J ADV NURS, V36, P742, DOI 10.1046/j.1365-2648.2001.02047.x
   de Wit R, 2001, EUR J PAIN, V5, P241, DOI 10.1053/eujp.2001.0239
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Fletcher C, 2016, PHYSIOTHER THEOR PR, V32, P271, DOI 10.3109/09593985.2015.1138010
   Geerling JI, 2023, RADIOTHER ONCOL, V185, P0, DOI 10.1016/j.radonc.2023.109687
   Gonzalez Margarita, 2014, REVISTA MEDICA CLINICA LAS CONDES, V25, P610, DOI 10.1016/S0716-8640(14)70081-1
   González-Martín AM, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15164123
   GRADEpro, 2024, ABOUT US, V0, P0
   Hartshorn G, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2022-064363
   Higgins J, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000049
   Hochstenbach LMJ, 2015, BMC CANCER, V15, P0, DOI 10.1186/s12885-015-1428-1
   IARC, 2024, CANCER TODAY, V0, P0
   iasp-pain, 2024, PAIN MANAGEMENT CENTER-CHAPTER 1-INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (IASP), V0, P0
   Jahn P, 2014, PAIN, V155, P746, DOI 10.1016/j.pain.2014.01.006
   Jarelnape AA, 2024, SAUDI J HEALTH SYST, V4, P1, DOI 10.1159/000534482
   Jho HJ, 2013, SUPPORT CARE CANCER, V21, P1963, DOI 10.1007/s00520-013-1756-0
   Jose Cid C, 2014, REV. MEDICA CLINICA LAS CONDES, V25, P687, DOI 10.1016/S0716-8640(14)70090-2
   Keefe FJ, 2005, J PAIN SYMPTOM MANAG, V29, P263, DOI 10.1016/j.jpainsymman.2004.06.014
   Koh SJ, 2018, PAIN MED, V19, P2546, DOI 10.1093/pm/pny039
   Koller A, 2013, EUR J ONCOL NURS, V17, P284, DOI 10.1016/j.ejon.2012.08.002
   Kravitz RL, 2011, PAIN, V152, P1572, DOI 10.1016/j.pain.2011.02.047
   Lahousse A, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11010195
   Lai YH, 2004, SUPPORT CARE CANCER, V12, P645, DOI 10.1007/s00520-004-0626-1
   Lee YJ, 2014, ASIAN PAC J CANCER P, V15, P4787, DOI 10.7314/APJCP.2014.15.12.4787
   Lin CC, 2000, PAIN, V88, P7, DOI 10.1016/S0304-3959(00)00303-1
   Lovell MR, 2014, J CLIN ONCOL, V32, P1712, DOI 10.1200/JCO.2013.52.4850
   Luckett T, 2018, BMC HEALTH SERV RES, V18, P0, DOI 10.1186/s12913-018-3318-0
   Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713
   Marie N, 2013, SUPPORT CARE CANCER, V21, P3529, DOI 10.1007/s00520-013-1995-0
   Melton Laura, 2017, J ADV PRACT ONCOL, V8, P188, DOI 10.6004/jadpro.2017.8.2.6
   Miaskowski C, 2004, J CLIN ONCOL, V22, P1713, DOI 10.1200/JCO.2004.06.140
   Niedzwiedz CL, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-6181-4
   Nijs J, 2023, BRIT J ANAESTH, V130, P611, DOI 10.1016/j.bja.2022.12.013
   Nijs J, 2019, BRAZ J PHYS THER, V23, P367, DOI 10.1016/j.bjpt.2018.12.003
   OBrien M, 2022, PAIN MANAG NURS, V23, P504, DOI 10.1016/j.pmn.2021.10.007
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Oldenmenger WH, 2011, PAIN, V152, P2632, DOI 10.1016/j.pain.2011.08.009
   Oliver JW, 2001, J CLIN ONCOL, V19, P2206, DOI 10.1200/JCO.2001.19.8.2206
   Ordoñez-Mora LT, 2023, BMJ OPEN, V13, P0, DOI 10.1136/bmjopen-2022-071493
   Page MJ, 2020, THE PRISMA 2020A STATEMENT: AN UPDATED GUIDELINE FOR REPORTING SYSTEMATIC REVIEWS, V0, P0, DOI DOI 10.31222/OSF.IO/V7GM2
   Pas R, 2020, J BODYW MOV THER, V24, P239, DOI 10.1016/j.jbmt.2020.06.027
   Phillips JL, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3152-z
   Prevost V, 2022, J CANCER EDUC, V37, P1089, DOI 10.1007/s13187-020-01924-w
   Prevost V, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5836-5
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   RIMER B, 1987, PATIENT EDUC COUNS, V10, P267, DOI 10.1016/0738-3991(87)90128-5
   Rostaing-Rigattieri S, 2014, PRESSE MED, V43, P252, DOI 10.1016/j.lpm.2013.05.005
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Smith MY, 2010, PATIENT EDUC COUNS, V81, P79, DOI 10.1016/j.pec.2009.11.021
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Street RL, 2014, PSYCHO-ONCOLOGY, V23, P1111, DOI 10.1002/pon.3518
   Street RL, 2010, PATIENT EDUC COUNS, V80, P42, DOI 10.1016/j.pec.2009.10.009
   Syrjala KL, 2008, PAIN, V135, P175, DOI 10.1016/j.pain.2007.10.026
   Valenta S, 2018, BMC NURS, V17, P0, DOI 10.1186/s12912-018-0323-x
   Vallières I, 2006, INT J RADIAT ONCOL, V66, P234, DOI 10.1016/j.ijrobp.2005.12.057
   van der Peet EH, 2009, SUPPORT CARE CANCER, V17, P1089, DOI 10.1007/s00520-008-0564-4
   Ward S, 2000, RES NURS HEALTH, V23, P393, DOI 10.1002/1098-240X(200010)23:5<393::AID-NUR6>3.0.CO;2-O
   Ward S, 2008, HEALTH PSYCHOL, V27, P59, DOI 10.1037/0278-6133.27.1.59
   Wells N, 2003, J PAIN SYMPTOM MANAG, V25, P344, DOI 10.1016/S0885-3924(02)00685-1
   Yates P, 2004, PATIENT EDUC COUNS, V53, P227, DOI 10.1016/S0738-3991(03)00165-4
   Yildirim YK, 2009, PAIN MANAG NURS, V10, P220, DOI 10.1016/j.pmn.2007.09.004
NR 76
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD JUN 17
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1136/spcare-2024-005219
EA JUN 2025
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 3XP3Y
UT WOS:001511426500001
PM 40527587
DA 2026-01-16
ER

PT J
AU Xu, Y
   Wu, G
   Zhang, G
   Li, D
   Zhang, L
   Yang, W
AF Xu, Yuanyuan
   Wu, Guangrong
   Zhang, Guomin
   Li, Dongxue
   Zhang, Lunyou
   Yang, Wei
TI Rare Emphysematous Osteomyelitis of the Femoral Head: A Case Report and
SO Infection and drug resistance
LA English
DT Journal Article
DE CT; MRI; acupotomy; diabetes; emphysematous osteomyelitis
AB Emphysematous osteomyelitis (EO) is a perilous infection of the femoral head. In  this case, we present a 66-year-old male patient of Han ethnicity, who had lumbar  disc herniation and type 2 diabetes mellitus. The patient reported severe pain in  his lower back and right lower limb, which had worsened over the past 20 days.  Despite undergoing invasive procedures such as regional anesthetic blocks and  other traditional Chinese medical methods such as acupuncture and acupotomy, his  condition deteriorated. Pain in the lumbar region was not relieved, and there was  a new onset of pain in the right hip, groin, and thighs. Preliminary medical  evaluation revealed normal body temperature but elevated levels of the  inflammatory marker high-sensitivity C-reactive protein (hsCRP). In the imaging  tests, computed tomography revealed air bubbles within the right femoral head,  corresponding to the EO. Diabetes mellitus and malignant neoplasms have been  well-established as predominant risk factors for EO, while iatrogenic  interventions may serve as potential precipitating factors in disease  pathogenesis. Our report underlines the critical role of radiologists in  identifying EO through distinctive imaging features, such as the "pumice stone"  sign. This highlights the need for further research to enhance our understanding,  diagnosis, and management of EO.
C1 Department of Radiology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
   Department of Radiology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
   Department of Radiology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
   Department of Radiology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
   Department of Pathology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
   Department of Radiology, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, Guizhou, People'sRepublic of China.
NR 0
TC 0
SN 1178-697
EI 1178-697
J9 Infect Drug Resist
PD MAR 10
PY 2025
VL 18
IS 
BP 1279
EP 1285
DI 10.2147/IDR.S479261
PG 6
UT PubMed:40059938
PM 40059938
DA 2025-03-10
ER

PT J
AU Li, FF
   Zhang, LN
   Tang, F
   Liu, YC
AF Li, Fang-Fang
   Zhang, Li-Na
   Tang, Fen
   Liu, Yu-Chen
TI Randomized Controlled Trial of Wrist-Ankle Acupuncture for Postoperative
SO Cancer nursing
LA English
DT Journal Article
DE Day surgery; Pain; Randomized controlled trial; Thyroid cancer; Traditional Chinese medicine; Wrist-ankle acupuncture therapy
AB BACKGROUND: Postoperative pharyngeal pain is common in patients with thyroid  cancer undergoing day-case surgery, with approximately 60%-90% affected.  Wrist-ankle acupuncture (WAA) offers a potential alternative but lacks clinical  validation in day surgery settings. OBJECTIVE: This study aimed to assess the  effectiveness and safety of WAA in reducing postoperative pharyngeal pain in  patients with thyroid cancer undergoing day-case surgery. METHODS: Seventy-two  patients undergoing thyroidectomy were randomized into the WAA experimental group  (n = 36) or the control group (n = 36). The WAA experimental group received  standardized care plus subcutaneous needle insertion at wrist points (Upper 1 and  Upper 6) postoperatively, whereas the control group received standard care alone.  Pain was assessed using the visual analog scale at 3, 4, 9, and 27 hours, and  predischarge. Secondary outcomes included the Houston Pain Outcome Instrument and  the 15-item Quality of Recovery scale. RESULTS: At 9 and 27 hours post surgery,  the experimental group reported significantly lower pain scores ( P < .001);  satisfaction with pain control was also significantly higher ( P < .001). The WAA  group had minor adverse events and no serious complications. Additionally, the  experimental group experienced better postoperative sleep and overall health ( P  < .05). CONCLUSIONS: Wrist-ankle acupuncture significantly relieves postoperative  sore throat in patients with thyroid cancer during day surgery. This work  establishes a foundation for integrating WAA into modern surgical recovery  pathways. However, larger randomized controlled trials are needed to determine  effectiveness across different institutions and populations. IMPLICATIONS FOR  PRACTICE: Wrist-ankle acupuncture offers a nonpharmacological alternative for  pain management in thyroid cancer surgery. Further studies are needed to confirm  its broader applicability and effectiveness in diverse patient populations.
C1 Author Affiliations: Ambulatory Surgery Center (Mss Li, Zhang, and Tang) and Department of Otolaryngology, Head and Neck Surgery (Dr Liu), The FirstAffiliated Hospital of Anhui Medical University, Hefei, China.
NR 0
TC 0
SN 1538-980
EI 
J9 Cancer Nurs
PD SEP 30
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1097/NCC.0000000000001547
PG 0
UT PubMed:41026681
PM 41026681
DA 2025-09-30
ER

PT J
AU Pan, WT
   Ji, MH
   Ma, DQ
   Yang, JJ
AF Pan, Wei-Tong
   Ji, Mu-huo
   Ma, Daqing
   Yang, Jian-Jun
TI Effect of perioperative autonomic nervous system imbalance on surgical outcomes: a systematic review
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE autonomic nervous system; perioperative autonomic imbalance; parasympathetic tone; perioperative
ID heart-rate-variability; beta-blockers; surgery; dexmedetomidine; hypertension; inflammation; innervation; mechanisms; responses; immunity
AB The autonomic nervous system (ANS) is essential for maintaining physiological homeostasis. Autonomic nervous system imbalance, characterised by sympathetic hyperactivation and low parasympathetic tone, can occur during the perioperative period. These changes drive systemic stress responses, cardiovascular instability, impaired tissue repair, and immunosuppression, which in turn increase infection risk, neurocognitive decline, and multiorgan dysfunction. Surgical trauma, anaesthesia, pain, hypothermia, and psychological stressors all contribute to this dysregulation, and consequently low parasympathetic tone results in the cholinergic anti-inflammatory pathway being less effective. High sympathetic nervous system activity promotes catecholamine surges and pro-inflammatory cytokine release. Pharmacological interventions, including dexmedetomidine and beta-blockers, together with nonpharmacological strategies, such as electroacupuncture and temperature management, are measures that have potential to restore ANS balance. This systematic review covers ANS-mediated organ regulation, pathophysiological consequences of perioperative dysautonomia, and evidence-based therapeutic strategies. By integrating findings from multiple basic and clinical studies, the pivotal roles of ANS modulation in mitigating postoperative complications, including neurocognitive disorders, immunosuppression, and cancer recurrence, are discussed. Maintaining balance of the sympathetic and parasympathetic nervous systems is an important prospect in perioperative medicine that could benefit surgical patients' short- or long
C1 [Pan, Wei-Tong; Yang, Jian-Jun] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol Pain & Perioperat Med, Zhengzhou, Henan, Peoples R China.
   [Pan, Wei-Tong; Yang, Jian-Jun] Zhengzhou Univ Acad Med Sci, Neurosci Res Inst, Zhengzhou, Henan, Peoples R China.
   [Ji, Mu-huo] Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.
   [Ma, Daqing] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Perioperat & Syst Med Lab,Sch Med, Hangzhou, Peoples R China.
   [Ma, Daqing] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Anesthesiol,Sch Med, Hangzhou, Peoples R China.
   [Ma, Daqing] Ningbo Univ, Affiliated Hosp 1, Dept Anesthesiol, Ningbo, Zhejiang, Peoples R China.
   [Ma, Daqing] Imperial Coll London, Chelsea & Westminster Hosp, Dept Surg & Canc, Fac Med,Div Anaesthet Pain Med & Intens Care, London, England.
C3 Zhengzhou University; Nanjing Medical University; Zhejiang University; Zhejiang University; Ningbo University; Imperial College London
RP Yang, JJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol Pain & Perioperat Med, Zhengzhou, Henan, Peoples R China.; Yang, JJ (corresponding author), Zhengzhou Univ Acad Med Sci, Neurosci Res Inst, Zhengzhou, Henan, Peoples R China.; Ma, DQ (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Perioperat & Syst Med Lab,Sch Med, Hangzhou, Peoples R China.; Ma, DQ (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Anesthesiol,Sch Med, Hangzhou, Peoples R China.; Ma, DQ (corresponding author), Ningbo Univ, Affiliated Hosp 1, Dept Anesthesiol, Ningbo, Zhejiang, Peoples R China.; Ma, DQ (corresponding author), Imperial Coll London, Chelsea & Westminster Hosp, Dept Surg & Canc, Fac Med,Div Anaesthet Pain Med & Intens Care, London, England.
EM d.ma@imperial.ac.uk; yjyangjj@126.com
FU National Natural Science Foundation of China [U23A20421]; European Society of Anesthesiology and Intensive Care; Ningbo Top Medial and Health Research Program [2024010317]; British Journal of Anaesthesia
CR Ackermann W, 2018, FRONT SURG, V5, P0, DOI 10.3389/fsurg.2018.00064
   Adachi A, 2024, PEDIATR SURG INT, V40, P0, DOI 10.1007/s00383-024-05802-0
   Alam A, 2018, EBIOMEDICINE, V37, P547, DOI 10.1016/j.ebiom.2018.10.021
   Alazawi W, 2016, ANN SURG, V264, P73, DOI 10.1097/SLA.0000000000001691
   Angka L, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18081787
   Bain CR, 2023, ANAESTHESIA, V78, P356, DOI 10.1111/anae.15896
   Bari DS, 2020, J BIOL PHYS, V46, P177, DOI 10.1007/s10867-020-09547-4
   Bayoumy K, 2021, NAT REV CARDIOL, V18, P581, DOI 10.1038/s41569-021-00522-7
   Bazoukis G, 2023, J AM HEART ASSOC, V12, P0, DOI 10.1161/JAHA.123.030539
   Buse S, 2017, RESUSCITATION, V118, P35, DOI 10.1016/j.resuscitation.2017.07.003
   Caravaca AS, 2022, P NATL ACAD SCI USA, V119, P0, DOI 10.1073/pnas.2023285119
   Carrara M, 2021, ANN INTENSIVE CARE, V11, P0, DOI 10.1186/s13613-021-00869-7
   Cero C, 2021, JCI INSIGHT, V6, P0, DOI 10.1172/jci.insight.139160
   Chang E, 2024, MED, V0, P0
   Chang WC, 2016, INT J GYNECOL CANCER, V26, P156, DOI 10.1097/IGC.0000000000000578
   Chen BK, 2023, J ORTHOP SURG RES, V18, P0, DOI 10.1186/s13018-023-03516-y
   Chen C, 2025, BASIC CLIN PHARMACOL, V136, P0, DOI 10.1111/bcpt.70032
   Chen HY, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0257816
   Chen ML, 2022, J ANESTH, V36, P5, DOI 10.1007/s00540-021-02982-0
   Chen Q, 2016, ONCOTARGET, V7, P55990, DOI 10.18632/oncotarget.10809
   Chen XT, 2024, CLIN INTERV AGING, V19, P981, DOI 10.2147/CIA.S455987
   Cheng C, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02656-y
   Cheng H, 2017, SURG INFECT, V18, P722, DOI 10.1089/sur.2017.089
   Claassen JAHR, 2021, PHYSIOL REV, V101, P1487, DOI 10.1152/physrev.00022.2020
   Dellacqua LO, 2024, J APPL PHYSIOL, V136, P189, DOI 10.1152/japplphysiol.00433.2023
   Deng M, 2024, ANESTHES PERIOP SCI, V2, P0, DOI 10.1007/s44254-024-00078-y
   Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7
   Devereaux PJ, 2015, NEW ENGL J MED, V373, P2258, DOI 10.1056/NEJMra1502824
   Dick TE, 2014, PROG BRAIN RES, V209, P191, DOI 10.1016/B978-0-444-63274-6.00010-2
   Dingová D, 2025, AM J PHYSIOL-HEART C, V328, PH526, DOI 10.1152/ajpheart.00672.2024
   Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5
   Duan HW, 2025, ADV SCI, V12, P0, DOI 10.1002/advs.202411433
   Erdem S, 2021, INT OPHTHALMOL, V41, P2555, DOI 10.1007/s10792-021-01814-0
   Evered L, 2022, ANAESTHESIA, V77, P34, DOI 10.1111/anae.15613
   Faber CL, 2020, DIABETOLOGIA, V63, P2086, DOI 10.1007/s00125-020-05204-6
   Fonseca RC, 2019, BRAIN BEHAV IMMUN, V81, P444, DOI 10.1016/j.bbi.2019.06.041
   Frost S, 2024, J APPL PHYSIOL, V137, P364, DOI 10.1152/japplphysiol.00128.2024
   Fukuda K, 2015, CIRC RES, V116, P2005, DOI 10.1161/CIRCRESAHA.116.304679
   Gabanyi I, 2016, CELL, V164, P378, DOI 10.1016/j.cell.2015.12.023
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Germán-Salló Z, 2016, PROC TECH, V22, P645, DOI 10.1016/j.protcy.2016.01.134
   Gordan R, 2015, WORLD J CARDIOL, V7, P204, DOI 10.4330/wjc.v7.i4.204
   Grassi G, 2019, J HYPERTENS, V37, P1746, DOI 10.1097/HJH.0000000000002093
   Gu JT, 2011, CRIT CARE, V15, P0, DOI 10.1186/cc10283
   Gullett N, 2023, INT J PSYCHOPHYSIOL, V192, P35, DOI 10.1016/j.ijpsycho.2023.08.001
   Gumbert SD, 2020, ANESTHESIOLOGY, V132, P180, DOI 10.1097/ALN.0000000000002968
   Guo QH, 2023, J CLIN HYPERTENS, V25, P227, DOI 10.1111/jch.14616
   Han TK, 2019, BRAIN RES, V1707, P154, DOI 10.1016/j.brainres.2018.11.035
   Han ZX, 2023, MED SCI MONITOR, V29, P0, DOI 10.12659/MSM.941262
   Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005
   He HL, 2024, WORLD J MENS HEALTH, V42, P1, DOI 10.5534/wjmh.220248
   Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194
   Hu J, 2022, BMC ANESTHESIOL, V22, P0, DOI 10.1186/s12871-022-01589-6
   Huang L, 2020, CELL MOL IMMUNOL, V17, P1092, DOI 10.1038/s41423-020-00522-6
   Huffman WJ, 2019, BRAIN STIMUL, V12, P19, DOI 10.1016/j.brs.2018.10.005
   Hunt T, 2025, BRIT J ANAESTH, V134, P1671, DOI 10.1016/j.bja.2025.02.031
   Johner N, 2024, EUR J CLIN INVEST, V54, P0, DOI 10.1111/eci.14309
   Kao LC, 2016, PSYCHIAT INVEST, V13, P397
   Kay MW, 2022, PHYSIOLOGY, V37, P39, DOI 10.1152/physiol.00023.2021
   Khan AA, 2019, EUR J CLIN INVEST, V49, P0, DOI 10.1111/eci.13174
   Kim EH, 2016, J CLIN ANESTH, V35, P332, DOI 10.1016/j.jclinane.2016.09.012
   Koenig J, 2016, CLIN J PAIN, V32, P218, DOI 10.1097/AJP.0000000000000242
   Kolmus K, 2015, BRAIN BEHAV IMMUN, V45, P297, DOI 10.1016/j.bbi.2014.10.007
   Kong YS, 2021, IEEE T BIO-MED ENG, V68, P3122, DOI 10.1109/TBME.2021.3065218
   Koziol-White C, 2020, AM J PHYSIOL-LUNG C, V318, PL345, DOI 10.1152/ajplung.00393.2019
   Kulkarni K, 2016, IEEE ENG MED BIO, V0, PP149, DOI 10.1109/EMBC.2016.7590662
   Kumari R, 2024, CELL REP, V43, P0, DOI 10.1016/j.celrep.2024.113674
   Lee LY, 2014, COMPR PHYSIOL, V4, P287, DOI 10.1002/cphy.c130020
   Li S, 2021, CELL DEATH DISCOV, V7, P0, DOI 10.1038/s41420-021-00431-1
   Li XC, 2023, ISCIENCE, V26, P0, DOI 10.1016/j.isci.2023.108128
   Li XL, 2023, AM J HEALTH BEHAV, V47, P65, DOI 10.5993/AJHB.47.1.8
   Lindgren M, 2021, DIABETES RES CLIN PR, V176, P0, DOI 10.1016/j.diabres.2021.108833
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Ma JB, 2020, ANESTH ANALG, V130, P1054, DOI 10.1213/ANE.0000000000003820
   Mahfoud F, 2024, CURR MED RES OPIN, V40, P25, DOI 10.1080/03007995.2024.2318003
   Margraf A, 2020, ANESTH ANALG, V131, P1693, DOI 10.1213/ANE.0000000000005175
   Martelli D, 2014, AUTON NEUROSCI-BASIC, V182, P65, DOI 10.1016/j.autneu.2013.12.007
   Nakamura Y, 2023, COMMUN BIOL, V6, P0, DOI 10.1038/s42003-023-05051-2
   Nazari MA, 2023, LANCET DIABETES ENDO, V11, P942, DOI 10.1016/S2213-8587(23)00256-5
   Nilsson MB, 2020, J NEUROIMMUNE PHARM, V15, P27, DOI 10.1007/s11481-019-09891-w
   ONeill E, 2020, BRIT J PHARMACOL, V177, P282, DOI 10.1111/bph.14862
   Oliver E, 2019, REV ESP CARDIOL, V72, P853, DOI 10.1016/j.rec.2019.04.006
   Ommen SR, 2024, CIRCULATION, V149, Pe1239, DOI 10.1161/CIR.0000000000001250
   Patel ABU, 2022, BRIT J ANAESTH, V128, P135, DOI 10.1016/j.bja.2021.08.037
   Petersen MC, 2017, NAT REV ENDOCRINOL, V13, P572, DOI 10.1038/nrendo.2017.80
   Pinto ML, 2017, BIOMATERIALS, V124, P211, DOI 10.1016/j.biomaterials.2017.02.004
   Poveda-Jaramillo R, 2018, J CARDIOTHOR VASC AN, V32, P1415, DOI 10.1053/j.jvca.2017.11.039
   Prete A, 2018, CLIN ENDOCRINOL, V89, P554, DOI 10.1111/cen.13820
   Price LC, 2021, BRIT J ANAESTH, V126, P774, DOI 10.1016/j.bja.2021.01.005
   Qin ZJ, 2019, BMC ANESTHESIOL, V19, P0, DOI 10.1186/s12871-019-0859-7
   Rahimzadeh P, 2014, HEPAT MON, V14, P0, DOI 10.5812/hepatmon.19881
   Ribeiro IMR, 2018, AM J PHYSIOL-GASTR L, V315, PG538, DOI 10.1152/ajpgi.00290.2017
   Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046
   Salvador AF, 2021, NAT REV IMMUNOL, V21, P526, DOI 10.1038/s41577-021-00508-z
   Sander M, 2020, KOREAN J ANESTHESIOL, V73, P103, DOI 10.4097/kja.20022
   Scridon A, 2022, FRONT PHYSIOL, V13, P0, DOI 10.3389/fphys.2022.1058427
   Sharma AE, 2025, CANCERS, V17, P0, DOI 10.3390/cancers17081357
   Simegn GD, 2021, ANN MED SURG, V72, P0, DOI 10.1016/j.amsu.2021.103059
   Singh A, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.43894
   Stern T, 2015, JAMA-J AM MED ASSOC, V313, P2486, DOI 10.1001/jama.2015.3086
   Su X, 2016, LANCET, V388, P1893, DOI 10.1016/S0140-6736(16)30580-3
   Sun QZ, 2024, BIOMED PHARMACOTHER, V174, P0, DOI 10.1016/j.biopha.2024.116462
   Tang L, 2024, EXP GERONTOL, V194, P0, DOI 10.1016/j.exger.2024.112507
   Tatsumi S, 2025, PHYSIOL BEHAV, V288, P0, DOI 10.1016/j.physbeh.2024.114721
   Travica N, 2022, NEUROBIOL LEARN MEM, V193, P0, DOI 10.1016/j.nlm.2022.107656
   Turan A, 2020, LANCET, V396, P177, DOI 10.1016/S0140-6736(20)30631-0
   Udit S, 2022, NAT REV NEUROSCI, V23, P157, DOI 10.1038/s41583-021-00555-4
   van Herk L, 2024, NEUROBIOL STRESS, V31, P0, DOI 10.1016/j.ynstr.2024.100659
   Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656
   Wang D, 2024, BMC ANESTHESIOL, V24, P0, DOI 10.1186/s12871-024-02453-5
   Wang HY, 2021, FRONT PHYSIOL, V12, P0, DOI 10.3389/fphys.2021.705153
   Wang K, 2019, BRIT J ANAESTH, V123, P777, DOI 10.1016/j.bja.2019.07.027
   Wang LZ, 2018, EXP THER MED, V16, P3869, DOI 10.3892/etm.2018.6665
   Wang Y, 2022, FRONT PHYSIOL, V13, P0, DOI 10.3389/fphys.2022.799183
   Wang Z, 2017, EXP THER MED, V14, P5851, DOI 10.3892/etm.2017.5265
   Wang ZD, 2022, CELL SIGNAL, V91, P0, DOI 10.1016/j.cellsig.2021.110227
   Wehrwein EA, 2016, COMPR PHYSIOL, V6, P1239, DOI 10.1002/cphy.c150037
   Werner LM, 2025, AM J EMERG MED, V88, P64, DOI 10.1016/j.ajem.2024.11.029
   Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185
   Willows JW, 2023, COMPR PHYSIOL, V13, P4985, DOI 10.1002/j.2040-4603.2023.tb00277.x
   Worek F, 2016, TOXICOL LETT, V249, P22, DOI 10.1016/j.toxlet.2016.03.007
   Xue BH, 2019, REV ASSOC MED BRAS, V65, P1181, DOI 10.1590/1806-9282.65.9.1181
   Yan Y, 2021, CRIT CARE, V25, P0, DOI 10.1186/s13054-021-03793-1
   Yang LQ, 2024, INT J SURG, V110, P5518, DOI 10.1097/JS9.0000000000001669
   Yang T, 2025, ACS SENSORS, V10, P100, DOI 10.1021/acssensors.4c03314
   Yu J, 2021, RESP PHYSIOL NEUROBI, V287, P0, DOI 10.1016/j.resp.2020.103595
   Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072
   Zhai Q, 2023, BRIT J ANAESTH, V131, P542, DOI 10.1016/j.bja.2023.04.044
   Zhang DF, 2019, ANN SURG, V270, P356, DOI 10.1097/SLA.0000000000002801
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhou Q, 2018, NATURE, V557, P351, DOI 10.1038/s41586-018-0088-0
   Zhu LL, 2023, IEEE J BIOMED HEALTH, V27, P2155, DOI 10.1109/JBHI.2023.3239305
NR 132
TC 1
Z9 2
U1 4
U2 4
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD SEP 15
PY 2025
VL 135
IS 3
BP 608
EP 622
DI 10.1016/j.bja.2025.06.004
EA AUG 2025
PG 15
WC Anesthesiology
SC Anesthesiology
GA 8MG5N
UT WOS:001592033200007
PM 40615330
DA 2026-01-16
ER

PT J
AU Ji, Z
   Niu, H
   He, A
   Li, K
   Jia, J
   Zhang, M
   Liu, G
AF Ji, Zhe
   Niu, Heyuan
   He, Anqi
   Li, Kaiyu
   Jia, Jinyan
   Zhang, Maorun
   Liu, Gang
TI Research Hotspots and Trends in Acupuncture for Cancer:A bibliometric analysis
SO Journal of multidisciplinary healthcare
LA English
DT Journal Article
DE VOSviewer; acupuncture; bibliometric analysis; cancer; citespace
AB BACKGROUND: Acupuncture is increasingly recognized as a promising intervention  modality in cancer treatment. Nevertheless, there has been a paucity of  systematic analysis and visualisation of relevant publications through  bibliometric methods. This paper conducts a bibliometric analysis of research on  acupuncture within the realm of oncological applications, aiming to explore its  prospects and emerging trends. METHODS: In this study, we analyzed 2117 documents  obtained from the Web of Science Core Collection (WOSCC) to examine the  correlations among authors, journals, institutions, countries, and keywords. This  analysis was conducted using the Bibliometric R package, CiteSpace, and VOSviewer  software. RESULTS: The evolution of acupuncture can be broadly divided into three  time periods: 2004-2008, 2009-2017 and 2018-2024. The WOSCC retrieved 2117  publications on acupuncture for cancer over the past 20 years. Among the top 10  institutions, seven were from the United States, two from China, and one from  Korea. Memorial Sloan Kettering Cancer Center had the highest number of  publications. At the same time, the journal INTEGRATIVE CANCER THERAPIES  published the most articles in this field. Keyword co-occurrence analysis  revealed four distinct clusters: "Alternative and Complementary Medicine for  Cancer", "Acupuncture for cancer-related fatigue and pain", "Acupressure for  anxiety, depression, and insomnia", "Improving quality of life for breast cancer  patients". The most recent keyword outbreaks included "sleep", "radiation induced  xerostomia", "recovery", "insomnia", and "induced peripheral neuropathy." Breast  cancer is the type of cancer for which acupuncture is most commonly used.  CONCLUSION: The future research focus will be on acupuncture as a treatment for  sleep disorders, the alleviation of radiotherapy complications and the  improvement of postoperative quality of life. Research on acupuncture in the  field of breast cancer is more extensive compared to other cancers. Therefore, it  is necessary to strengthen research on acupuncture in different cancer types.
C1 Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
   Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
NR 0
TC 0
SN 1178-239
EI 1178-239
J9 J Multidiscip Healthc
PD FEB 6
PY 2025
VL 18
IS 
BP 531
EP 547
DI 10.2147/JMDH.S494138
PG 16
UT PubMed:39911755
PM 39911755
DA 2025-02-06
ER

PT J
AU Giron, PS
   Haddad, CAS
   Lopes, De Almeida Rizzi SK
   Elias, S
   Nazário, ACP
   Facina, G
AF Giron, Patricia Santolia
   Haddad, Cinira Assad Simão
   Lopes De Almeida Rizzi, Samantha Karlla
   Elias, Simone
   Nazário, Afonso Celso Pinto
   Facina, Gil
TI Effect of Exercise Therapy, Systemic Acupuncture and Silicon Oxide Tablets on
SO Asian Pacific journal of cancer prevention : APJCP
LA English
DT Journal Article
DE Acupuncture; Lymphedema; Quality of Life; Rehabilitation; muscle strength
AB OBJECTIVE: The purpose of this study was to compare the effectiveness of three  different rehabilitation treatments (exercise therapy, acupuncture, and silicon  oxide tablets (Stiper®) in women who have undergone breast cancer surgery. The  study assessed the impact of these treatments on strength, lymphedema, and  quality of life. METHODS: The study included seventy-nine women who reported pain  levels above 3 on the visual analog pain scale (VAS) and had undergone surgery  more than 90 days prior. Group I received exercise therapy for 30 minutes, Group  II received acupuncture for 30 minutes using predefined points, and Group III  received acupuncture at the same points as Group II using silicon oxide instead  of needles at the same points as Group II. RESULTS: The results showed an  improvement in upper limb muscle strength over time in all groups, except for  abduction and internal rotation movements. During treatment, there was no  increase in the number of patients with lymphedema, and there was no statistical  difference between the groups. Nine out of the fifteen factors analyzed in the  EORTC QLQ-C30 quality of life questionnaire showed significant differences  between sessions. The factors that did not show significant differences between  the three groups were Social Function, Nausea and Vomiting, Dyspnea, Loss of  Appetite, Constipation, and Diarrhea. CONCLUSION: The rehabilitation of physical  dysfunctions in women who survived breast cancer through exercise therapy,  acupuncture, and silicon oxide tablets in upper limb muscle strength, lymphedema,  and quality of life, proved to be effective, without difference between groups.
C1 Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
   Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
SN 2476-762
EI 1513-736
J9 Asian Pac J Cancer Prev
PD MAR 29
PY 2025
VL 26
IS 3
BP 799
EP 808
DI 10.31557/APJCP.2025.26.3.799
PG 9
WC Humans; Female; Quality of Life; Breast Neoplasms; rehabilitation; Muscle Strength; Middle Aged; Acupuncture Therapy; methods; Exercise Therapy; methods; Cancer Survivors; Lymphedema; etiology; Adult; Follow-Up Studies; Tablets; Prognosis; Aged
UT PubMed:40156396
PM 40156396
DA 2025-03-29
ER

PT J
AU Wang, ZY
   Liu, CZ
   Pei, W
   Zhang, TZ
   Zhang, J
   Fan, WW
   Wei, XY
   Tu, JF
   Wang, L
   Wang, X
   Yang, NN
AF Wang, Ze-Yi
   Liu, Cun-Zhi
   Pei, Wei
   Zhang, Tian-Zhen
   Zhang, Jing
   Fan, Wen-Wen
   Wei, Xiao-Ya
   Tu, Jian-Feng
   Wang, Lu
   Wang, Xu
   Yang, Na-Na
TI Investigating the efficacy of electroacupuncture for postoperative ileus in patients with colorectal cancer: study protocol for a multicentre clinical trial with neuroimaging assessment
SO BMJ OPEN
LA English
DT Article
DE Acupuncture; Functional bowel disorders; Motility disorders; Colorectal surgery; Functional Magnetic Resonance Imaging; COMPLEMENTARY MEDICINE
ID opioid receptor antagonist; gastric-cancer; gastrectomy; surgery; alvimopan; fmri; connectivity; acupuncture; network; pain
AB Introduction Postoperative ileus (POI) is a prevalent complication following abdominal surgeries, significantly compromising patients' quality of life and imposing a socioeconomic burden. Electroacupuncture (EA), a widely used therapeutic approach in China, has shown promise as an effective intervention for POI. However, the neural mechanism underlying its therapeutic effects remains unclear. Thus, this study aims to evaluate the efficacy of EA treatment for POI and investigate its central mechanism by functional MRI (fMRI).Methods and analysis This randomised controlled clinical trial will be conducted across three hospitals in China. A total of 50 eligible patients with colorectal cancer scheduled for elective laparoscopic surgery will be randomly assigned to either the EA or sham electroacupuncture (SA) group in a 1:1 ratio. All patients will undergo 5 sessions of 30 min EA or SA over 5 consecutive days post-surgery (once daily). Resting-state fMRI (rs-fMRI) scans will be performed at baseline and the end of treatment to examine brain functional changes related to EA treatment. The primary outcome is the time to first defecation. Secondary outcomes include the time to first flatus, ambulation, tolerability of semiliquid and solid food; length of postoperative hospital stay; severity of postoperative pain, abdominal distension and nausea; frequency of postoperative nausea and vomiting episodes; rate of readmission. Postoperative complications will be monitored and documented throughout the trial duration. Credibility and expectancy evaluation, along with blinding assessment, will be conducted after the first treatment session. Pearson/Spearman correlation analysis will be performed to determine the relationship between clinical variables and rs-fMRI metrics.Ethics and dissemination This protocol has been approved by the ethics committees of Beijing University of Chinese Medicine (number 2024BZYLL0113), Cancer Hospital Chinese Academy of Medical Sciences (number 24/323-4603), Beijing Friendship Hospital Affiliated to Capital Medical University (number 2024-P2-081-01) and Beijing Chaoyang Huanxing Cancer Hospital (number 2024-011-02). Participants will sign the paper-based informed consent form before enrolment. The results will be disseminated through peer-reviewed publications.Trial registration number ITMCTR2024000504.
C1 [Wang, Ze-Yi; Liu, Cun-Zhi; Wei, Xiao-Ya; Tu, Jian-Feng; Wang, Lu; Yang, Na-Na] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Pei, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Colorectal Surg,Canc Hosp, Beijing, Peoples R China.
   [Zhang, Tian-Zhen] Capital Med Univ, Affiliated Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China.
   [Zhang, Tian-Zhen] Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China.
   [Zhang, Tian-Zhen] Capital Med Univ, State Key Lab Digest Hlth, Affiliated Beijing Friendship Hosp, Beijing, Peoples R China.
   [Zhang, Jing] Huanxing Canc Hosp, Dept Surg, Beijing, Peoples R China.
   [Fan, Wen-Wen] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Radiol,Natl Canc Ctr,Natl Clin Res Ctr, Beijing, Peoples R China.
   [Wang, Xu] Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Cancer Institute & Hospital - CAMS; Capital Medical University; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Beijing University of Chinese Medicine
RP Yang, NN (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.; Wang, X (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
EM 18810201536@163.com; lcz623780@126.com; peiwei@cicams.ac.cn; tianzhen_zhang@126.com; 13436383665@163.com; 2024.fwwhy@163.com; xiaoya0414@vip.qq.com; tujianfeng1@126.com; wanglucomeonctgu@163.com; wangx@bucm.edu.cn; 1254614551@qq.com
FU National Natural Science Foundation of China [82330126]
CR Artinyan A, 2008, WORLD J SURG, V32, P1495, DOI 10.1007/s00268-008-9491-2
   Asgeirsson T, 2010, J AM COLL SURGEONS, V210, P228, DOI 10.1016/j.jamcollsurg.2009.09.028
   Barkhof F, 2014, RADIOLOGY, V272, P28, DOI 10.1148/radiol.14132388
   Basaia S, 2020, NEUROLOGY, V95, PE2552, DOI 10.1212/WNL.0000000000010731
   Buscail E, 2022, BRIT J PHARMACOL, V179, P3283, DOI 10.1111/bph.15800
   Cao J, 2020, NEUROIMAGE, V221, P0, DOI 10.1016/j.neuroimage.2020.117176
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Chapman SJ, 2018, BRIT J SURG, V105, P797, DOI 10.1002/bjs.10781
   Chen HT, 2024, INT J SURG, V110, P1113, DOI 10.1097/JS9.0000000000000848
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   Chen KB, 2018, WORLD J GASTRO SURG, V10, P13, DOI 10.4240/wjgs.v10.i2.13
   Desmond JE, 2002, J NEUROSCI METH, V118, P115, DOI 10.1016/S0165-0270(02)00121-8
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Ditzel FL, 2023, BRIT J ANAESTH, V130, PE281, DOI 10.1016/j.bja.2022.07.054
   Drake TM, 2016, J GASTROINTEST SURG, V20, P1253, DOI 10.1007/s11605-016-3140-0
   FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4
   Gkegkes ID, 2020, DIGEST SURG, V37, P22, DOI 10.1159/000496431
   Guo CH, 2025, SCI REP-UK, V15, P0, DOI 10.1038/s41598-025-99406-w
   Harnsberger CR, 2019, CLIN COLON RECT SURG, V32, P166, DOI 10.1055/s-0038-1677003
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Hou YQ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3051-3
   Irving G, 2011, J PAIN, V12, P175, DOI 10.1016/j.jpain.2010.06.013
   Jia WD, 2019, ASIAN J SURG, V42, P11, DOI 10.1016/j.asjsur.2018.01.007
   Jiang S, 2024, NUCLEIC ACIDS RES, V53, PD1670, DOI 10.1093/nar/gkae973
   Jovicich J, 2016, NEUROIMAGE, V124, P442, DOI 10.1016/j.neuroimage.2015.07.010
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Kauf TL, 2014, J UROLOGY, V191, P1721, DOI 10.1016/j.juro.2013.12.015
   Kehlet H, 2008, NAT CLIN PRACT GASTR, V5, P552, DOI 10.1038/ncpgasthep1230
   Keller DS, 2016, AM J SURG, V212, P851, DOI 10.1016/j.amjsurg.2016.02.016
   Kong Q, 2024, INT J SURG, V110, P5713, DOI 10.1097/JS9.0000000000001641
   Kraft MD, 2008, EXPERT OPIN INV DRUG, V17, P1365, DOI 10.1517/13543784.17.9.1365
   Landrum Laurie, 2006, QUAL MANAG HEALTH CARE, V15, P83
   Lee IS, 2016, NEUROGASTROENT MOTIL, V28, P793, DOI 10.1111/nmo.12793
   Li ZJ, 2014, FORSCH KOMPLEMENTMED, V21, P99, DOI 10.1159/000360804
   Liu PH, 2020, J AFFECT DISORDERS, V273, P95, DOI 10.1016/j.jad.2020.03.107
   Liu Q, 2017, INT J SURG, V47, P107, DOI 10.1016/j.ijsu.2017.07.107
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976
   Ma K, 2020, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.608688
   Mumford JA, 2008, NEUROIMAGE, V39, P261, DOI 10.1016/j.neuroimage.2007.07.061
   Pei LX, 2025, GASTROENTEROLOGY, V169, P73, DOI 10.1053/j.gastro.2025.02.006
   Qin RJ, 2025, ACUPUNCT HERB MED, V5, P36, DOI 10.1097/HM9.0000000000000142
   Qiu K, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3685785
   Ravikumar R, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j1455
   Reichert M, 2024, INT J SURG, V110, P4329, DOI 10.1097/JS9.0000000000001393
   Rollins KE, 2019, ANN SURG, V270, P43, DOI 10.1097/SLA.0000000000003145
   Stakenborg N, 2017, HANDB EXP PHARMACOL, V239, P39, DOI 10.1007/164_2016_108
   Sultan S, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012111.pub2
   Sun RR, 2021, BRAIN IMAGING BEHAV, V15, P216, DOI 10.1007/s11682-019-00249-7
   Teixeira FM, 2012, BRAZ J MED BIOL RES, V45, P1209, DOI 10.1590/S0100-879X2012007500133
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vilz TO, 2017, DTSCH ARZTEBL INT, V114, P508, DOI 10.3238/arztebl.2017.0508
   Wang L, 2024, BMC GASTROENTEROL, V24, P0, DOI 10.1186/s12876-024-03124-y
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wang YW, 2023, NEUROIMAGE, V274, P0, DOI 10.1016/j.neuroimage.2023.120089
   Wu ZQ, 2015, EUR SURG RES, V54, P127, DOI 10.1159/000369529
   Yang H, 2007, NEUROIMAGE, V36, P144, DOI 10.1016/j.neuroimage.2007.01.054
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   You XL, 2018, J CANCER, V9, P2266, DOI 10.7150/jca.24767
   Yu MC, 2018, HUM BRAIN MAPP, V39, P4213, DOI 10.1002/hbm.24241
   Yu Z, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3182
   Yuan L, 2024, J GASTROEN HEPATOL, V39, P2060, DOI 10.1111/jgh.16670
   Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030
   Zennami K, 2024, BJU INT, V134, P426, DOI 10.1111/bju.16340
   Zhao TT, 2021, FRONT HUM NEUROSCI, V15, P0, DOI 10.3389/fnhum.2021.736512
   Zhou JZ, 2017, NEUROMODULATION, V20, P767, DOI 10.1111/ner.12602
   Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652
   Zou X, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-050000
NR 71
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD DEC 31
PY 2025
VL 15
IS 12
BP 
EP 
DI 10.1136/bmjopen-2025-108722
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AM4LU
UT WOS:001651591400001
PM 41475813
DA 2026-01-16
ER

PT J
AU Zhang, H
   Guo, QY
   Song, RL
   He, JR
   Jia, NN
   Shi, H
   Chen, SQ
AF Zhang, Hong
   Guo, Qian-Yu
   Song, Rui-Ling
   He, Jiao-Rong
   Jia, Ning-Ning
   Shi, Hong
   Chen, Su-Qing
TI Efficacy of Moxibustion Combined With Refined Nursing Care on Pain Reduction in Gouty Arthritis
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article; Early Access
DE Arthritis; gout; pain; refined nursing; traditional Chinese medicine nursing
ID intervention
AB Objective: This study aimed to evaluate the therapeutic efficacy of moxibustion with moxa sticks combined with refined nursing care in alleviating pain in individuals with gouty arthritis. Methods: A randomized controlled trial was conducted from March 2022 to January 2024, involving 96 patients diagnosed with gouty arthritis who were admitted to our hospital. The participants were randomly assigned to either the observation group (n = 48, treated with moxibustion intervention) or the control group (n = 48). The observation group received moxibustion treatment, while the control group underwent standard Western medical treatment. Both groups received refined nursing care during the intervention. Pain improvement, laboratory indicators, swelling levels, and clinical efficacy of both groups were compared. Results: The observation group demonstrated significantly lower visual analog scale (VAS) scores at 3- and 7-day postintervention, compared with the control group (P < 0.05). Additionally, C-reactive protein (CRP), tumor necrosis factor alpha (TNF-alpha), and uric acid (UA) levels and limb swelling were all markedly reduced in the observation group 7 days after treatment (P < 0.05). The observation group also exhibited a higher overall effective rate compared with the control group (P < 0.05). Conclusion: The combination of moxibustion and refined nursing care in the treatment of gouty arthritis provides significant therapeutic benefits, including the reduction of joint swelling, pain, and uric acid levels. This integrated approach may represent an effective strategy for managing gouty arthritis.
C1 [Zhang, Hong; Guo, Qian-Yu; Song, Rui-Ling; He, Jiao-Rong; Jia, Ning-Ning; Shi, Hong] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp,Hosp 3, Shanxi Acad Med Sci,Dept Rheumatol & Immunol, Taiyuan, Peoples R China.
   [Chen, Su-Qing] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp,Hosp 3, Shanxi Acad Med Sci,Dept Otorhinolaryngol Head & N, 99 Longcheng Ave, Taiyuan 030032, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University
RP Chen, SQ (corresponding author), Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp,Hosp 3, Shanxi Acad Med Sci,Dept Otorhinolaryngol Head & N, 99 Longcheng Ave, Taiyuan 030032, Peoples R China.
EM suqingchencsq@126.com
CR Chen J, 2022, ZHONG YI YAN JIU, V35, P40
   Chen Y, 2021, JOURNAL OF CHANGCHUN UNIVERSITY OF CHINESE MEDICINE, V37, P430
   Dalbeth N, 2021, LANCET, V397, P1843, DOI 10.1016/S0140-6736(21)00569-9
   Daoussis D, 2022, RHEUMATOL INT, V42, P949, DOI 10.1007/s00296-022-05128-x
   Deng KF, 2022, SHI JIE ZHEN JIU ZA ZHI, V32, P49
   Hao F, 2022, J TRADIT CHIN MED, V42, P73, DOI 10.19852/j.cnki.jtcm.20210324.002
   Hu Z, 2023, AM J TRANSL RES, V15, P2738
   Jiang L, 2022, XIAN DAI YIN XUE YU JIAN KANG YAN JIU, V6, P126
   Keller SF, 2021, MED CLIN N AM, V105, P297, DOI 10.1016/j.mcna.2020.09.013
   Ren JJ, 2022, WORLD J TRAD CHINESE, V8, P199, DOI 10.4103/2311-8571.335136
   Schlee S, 2018, Z GERONTOL GERIATR, V51, P453, DOI 10.1007/s00391-017-1197-3
   So A, 2008, ARTHRITIS RES THER, V10, P0, DOI 10.1186/ar2509
   Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9
   Wang SW, 2024, J ETHNOPHARMACOL, V330, P0, DOI 10.1016/j.jep.2024.118182
   Yang D, 2021, LIN CHUANG YI XUE YAN JIU YU SHI JIAN, V6, P139, DOI 10.19347/j.cnki.2096-1413.202135044
   Yu QN, 2021, AM J TRANSL RES, V13, P11671
   Zhang WF, 2022, ZHONG YI WAI ZHI ZA ZHI, V31, P68
NR 17
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUL 31
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/03601293251362861
EA JUL 2025
PG 15
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA 5QA4A
UT WOS:001541601700001
DA 2026-01-16
ER

PT J
AU Liu, T
   Zhi, WQ
   Wang, XQ
   Pei, Q
   Guo, XF
   Huang, Q
AF Liu, Tong
   Zhi, Wenqian
   Wang, Xiaoquan
   Pei, Qian
   Guo, Xianfeng
   Huang, Qiang
TI Effectiveness of Fu's subcutaneous needling on pain and physical function in patients with knee osteoarthritis: A systematic review and meta-analysis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Fu's subcutaneous needling; Knee osteoarthritis; Inflammatory cytokines; Randomized controlled trials; Pain assessment; Meta-analysis
ID randomized controlled-trials; vagal modulation; acupuncture
AB Objectives This study aims to evaluate the efficacy of Fu's subcutaneous needling (FSN) for knee osteoarthritis (KOA) via a meta-analysis. Methods Randomized controlled trials (RCTs) of FSN for KOA were searched in PubMed, Cochrane Library, Embase, Web of Science, and other databases up to July 20, 2024. Stata 15.0 was leveraged for data analysis. Results 30 RCTs were included, involving 2169 individuals. Compared to electroacupuncture, acupuncture, and other therapies, FSN demonstrated significant benefits in reducing the Western Ontario and McMaster Universities Arthritis Index score (WOMAC, improved physical function) [SMD= -1.69 (-2.15 to -1.23), I-2 = 89.8 %, P < 0.001] and relieving pain (the visual analog scale) [SMD = -1.77( -2.14 to -1.40); I-2 = 89.8 %, P < 0.001]. Additionally, FSN was more effective in reducing inflammatory cytokine levels, such as interleukin 1 beta [SMD = -1.65 (-2.36, -0.94); I-2 = 91.9 %, P < 0.001], interleukin-6 [SMD = -3.93 (-5.08, -2.78); I-2 = 96.7 %, P < 0.001], and tumor necrosis factor-alpha [SMD = -2.65 (-3.46, -1.83); I-2 = 94.8 %, P < 0.001], and increasing the total effective rate [OR = 4.17, 95 % CI: 3.05-5.68; I-2 = 0.0 %, P < 0.001]. Conclusions FSN shows promise as an adjuvant therapy for KOA, with moderate-quality evidence supporting its short-term efficacy in pain relief and functional improvement. Further validation through standardized protocols is required to determine its long-term benefits.
C1 [Liu, Tong; Zhi, Wenqian; Wang, Xiaoquan; Pei, Qian; Guo, Xianfeng; Huang, Qiang] Capital Med Univ, Beijing Jishuitan Hosp, Dept Rehabil Med, 31 Xinjiekou East St, Beijing, Peoples R China.
C3 Capital Medical University
RP Huang, Q (corresponding author), Capital Med Univ, Beijing Jishuitan Hosp, Dept Rehabil Med, 31 Xinjiekou East St, Beijing, Peoples R China.
EM hq2349@vip.sina.com
FU Beijing Municipal Administration of Hospitals Incubating Program [PX2024018]
CR Ali N, 2022, MOL CELL PROTEOMICS, V21, P0, DOI 10.1016/j.mcpro.2022.100200
   Angst F, 2018, RMD OPEN, V4, P0, DOI 10.1136/rmdopen-2018-000685
   Bassi GS, 2020, NEUROSCI BIOBEHAV R, V112, P363, DOI 10.1016/j.neubiorev.2020.02.011
   Bjarnason I, 2018, GASTROENTEROLOGY, V154, P500, DOI 10.1053/j.gastro.2017.10.049
   Chen J, 2023, MOD DRUG APPL CHINA, V17, P0
   Chen P, 2021, CHIN PHARM SCI, V11, P195
   Chen Q, 2021, SHENZHEN J INTEGR MED, V31, P73, DOI 10.16458/j.cnki.1007-0893.2021.10.033
   Cheng J, 2022, LIAONING J CHIN MED, V49, P0
   Chiu PE, 2024, TRANSL RES, V273, P46, DOI 10.1016/j.trsl.2024.06.005
   Chiu PE, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11237184
   Dong W, 2023, JILIN CHIN MED, V43, P1480, DOI 10.13463/j.cnki.jlzyy.2023.12.026
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Fu ZH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/353916
   Gelber AC, 2024, ANN INTERN MED, V177, P0, DOI 10.7326/ANNALS-24-01249
   Gong M, 2025, CHIN ACUPUNCT MOXIBUSTION, V45, P13
   Hauck M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-13633-4
   Hayashi D, 2025, OSTEOARTHR CARTILAGE, V33, P88, DOI 10.1016/j.joca.2024.10.009
   Hayashi D, 2022, THER ADV MUSCULOSKEL, V14, P0, DOI 10.1177/1759720X221146621
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Huang CH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/5951327
   Huang D, 2021, CHIN NATL HEALTH MED, V33, P110
   Huang Z, 2020, INN MONG TRADIT CHIN MED, V39, P104, DOI 10.16040/j.cnki.cn15-1101.2020.01.062
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Irimes MB, 2024, MED RES REV, V44, P23, DOI 10.1002/med.21978
   Ji M, 2021, CHIN FOLK REM, V29, P35, DOI 10.19621/j.cnki.11-3555/r.2021.0715
   Jia L, 2022, CHIN PHARM SCI, V12, P127
   Jiang Y, 2019, J PRACT CHIN MED, V0, P870
   Kan HS, 2019, HONG KONG MED J, V25, P0, DOI 10.12809/hkmj187600
   Katz N, 2021, PAIN, V162, P1935, DOI 10.1097/j.pain.0000000000002204
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Lei L, 2020, LAB MED CLIN, V17, P807
   Li H, 2022, SHANGHAI ACUPUNCT MOXIBUSTION J, V41, P907, DOI 10.13460/j.issn.1005-0957.2022.09.0907
   Li YP, 2022, MOL PAIN, V18, P0, DOI 10.1177/17448069221108717
   Liang J, 2025, FRONT NEUROL, V16, P0, DOI 10.3389/fneur.2025.1509291
   Liu W, 2021, J PAIN RES, V14, P2209, DOI 10.2147/JPR.S315956
   Liu Z, 2020, WORLD J ACUPUNCT-MOX, V30, P29, DOI 10.1016/j.wjam.2020.02.001
   Long HB, 2022, ARTHRITIS RHEUMATOL, V74, P1172, DOI 10.1002/art.42089
   Malemud CJ, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18030484
   Mou JJ, 2024, EXPLORE-NY, V20, P562, DOI 10.1016/j.explore.2023.12.015
   Niu Z, 2023, SHANGHAI ACUPUNCT MOXIBUSTION J, V42, P170, DOI 10.13460/j.issn.1005-0957.2023.02.0170
   Page MJ, 2021, BMJ, V372, Pn71, DOI 10.1136/bmj.n71
   Paz-González R, 2024, ANN RHEUM DIS, V83, P661, DOI 10.1136/ard-2023-225090
   Peng HN, 2021, ORTHOP SURG, V13, P1465, DOI 10.1111/os.13021
   Sheng G, 2022, MASSAGE REHABIL MED, V13, P1, DOI 10.19787/j.issn.1008-1879.2022.02.001
   Sheu ML, 2021, NEUROSURGERY, V89, PE49, DOI 10.1093/neuros/nyab105
   Tang Hui, 2019, CHINESE MEDICAL SCIENCES JOURNAL, V34, P147, DOI 10.24920/003466
   Taylor P, 2014, PAIN PRACT, V14, P599, DOI 10.1111/papr.12116
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Wang M, 2023, GUANGMING CHIN MED, V38, P3173
   [王琼 Wang Qiong], 2024, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V43, P416
   Wang Z, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1309751
   Wen X, 2019, INN MONG TRADIT CHIN MED, V38, P82, DOI 10.16040/j.cnki.cn15-1101.2019.06.054
   Wietek J, 2024, NAT METHODS, V21, P0, DOI 10.1038/s41592-024-02285-8
   Xiao B, 2019, CHIN MED CLIN RES, V11, P17
   Xie Y, 2020, J AEROSP MED, V31, P985
   Yang J, 2021, PRACT INTEGR CHIN WEST MED CLIN, V21, P79, DOI 10.13638/j.issn.1671-4040.2021.12.038
   Yang XL, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000038274
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, P0, DOI 10.1038/s41392-023-01330-w
   Zhai P, 2022, YI KANG, V3, P124, DOI 10.12332/j.issn.2095-6525.2022.03.042
   Zhang D, 2020, J HUBEI UNIV TRADIT CHIN MED., V22, P96
   Zhang L, 2019, MEDIAT INFLAMM, V2019, P0, DOI 10.1155/2019/2165918
   Zhang N, 2021, J PAIN RES, V14, P2369, DOI 10.2147/JPR.S319195
   Zhang Q, 2020, J PRACT CHIN MED, V34, P109, DOI 10.13729/j.issn.1671-7813.z20200793
   Zhang Y, 2021, MED FOOD THER HEALTH, V19, P78
   Zheng J, 2022, WORLD J SLEEP MED, V9, P642
   Zhou D, 2020, CHIN DISABIL MED, V28, P56, DOI 10.13214/j.cnki.cjotadm.2020.22.037
   Zhou Z, 2016, ACS BIOMATER SCI ENG, V2, P929, DOI 10.1021/acsbiomaterials.6b00021
   Zhu J, 2019, GUANGMING CHIN MED, V34, P0
NR 69
TC 0
Z9 0
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD OCT 15
PY 2025
VL 93
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103233
EA AUG 2025
PG 27
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 7OF7Q
UT WOS:001575715100001
PM 40846208
DA 2026-01-16
ER

PT J
AU Li, FF
   Zhang, LN
   Tang, F
   Liu, YC
AF Li, Fang-Fang
   Zhang, Li-Na
   Tang, Fen
   Liu, Yu-Chen
TI Randomized Controlled Trial of Wrist-Ankle Acupuncture for Postoperative Pharyngeal Pain in Patients Undergoing Day Surgery Thyroidectomy
SO CANCER NURSING
LA English
DT Article; Early Access
DE Day surgery; Pain; Randomized controlled trial; Thyroid cancer; Traditional Chinese medicine; Wrist-ankle acupuncture therapy
ID mechanisms; recovery; quality; scale
AB Background: Postoperative pharyngeal pain is common in patients with thyroid cancer undergoing day-case surgery, with approximately 60%-90% affected. Wrist-ankle acupuncture (WAA) offers a potential alternative but lacks clinical validation in day surgery settings. Objective: This study aimed to assess the effectiveness and safety of WAA in reducing postoperative pharyngeal pain in patients with thyroid cancer undergoing day-case surgery. Methods: Seventy-two patients undergoing thyroidectomy were randomized into the WAA experimental group (n = 36) or the control group (n = 36). The WAA experimental group received standardized care plus subcutaneous needle insertion at wrist points (Upper 1 and Upper 6) postoperatively, whereas the control group received standard care alone. Pain was assessed using the visual analog scale at 3, 4, 9, and 27 hours, and predischarge. Secondary outcomes included the Houston Pain Outcome Instrument and the 15-item Quality of Recovery scale. Results: At 9 and 27 hours post surgery, the experimental group reported significantly lower pain scores (P < .001); satisfaction with pain control was also significantly higher (P < .001). The WAA group had minor adverse events and no serious complications. Additionally, the experimental group experienced better postoperative sleep and overall health (P < .05). Conclusions: Wrist-ankle acupuncture significantly relieves postoperative sore throat in patients with thyroid cancer during day surgery. This work establishes a foundation for integrating WAA into modern surgical recovery pathways. However, larger randomized controlled trials are needed to determine effectiveness across different institutions and populations. Implications for Practice: Wrist-ankle acupuncture offers a nonpharmacological alternative for pain management in thyroid cancer surgery. Further studies are needed to confirm its broader applicability and effectiveness in diverse patient populations.
C1 [Li, Fang-Fang; Zhang, Li-Na; Tang, Fen] Anhui Med Univ, Affiliated Hosp, Ambulatory Surg Ctr, Hefei, Peoples R China.
   [Liu, Yu-Chen] Anhui Med Univ, Affiliated Hosp, Dept Otolaryngol Head & Neck Surg, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University
RP Liu, YC (corresponding author), Anhui Med Univ, Affiliated Hosp, Dept Otolaryngol Head & Neck Surg, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
EM 3091305084@qq.com; 81147677@qq.com; 13855178172@163.com; 136856076@qq.com
CR Bérubé M, 2024, PAIN, V165, PE162, DOI 10.1097/j.pain.0000000000003288
   Boucai L, 2024, JAMA-J AM MED ASSOC, V331, P425, DOI 10.1001/jama.2023.26348
   Cao HT, 2023, CHIN J INTEGR MED, V29, P253, DOI 10.1007/s11655-022-3463-5
   Chou RG, 2022, THYROID, V32, P351, DOI 10.1089/thy.2021.0539
   DOrazi V, 2019, BMC SURG, V18, P0, DOI 10.1186/s12893-018-0447-7
   da Costa BR, 2021, OSTEOARTHR CARTILAGE, V29, P304, DOI 10.1016/j.joca.2020.10.004
   de la Fuente Bartolome Marta, 2022, CIR ESP (ENGL ED), V100, P601, DOI 10.1016/j.cireng.2022.06.018
   El-Boghdadly K, 2016, ANAESTHESIA, V71, P706, DOI 10.1111/anae.13438
   Fei YT, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-064345
   Gao LL, 2025, EUR ARCH OTO-RHINO-L, V282, P427, DOI 10.1007/s00405-024-08943-z
   Goudman L, 2024, ANAESTHESIA, V79, P128, DOI 10.1111/anae.16151
   Han XR, 2023, J INTEGR MED-JIM, V21, P168, DOI 10.1016/j.joim.2023.02.001
   Huang XA, 2025, ENDOSCOPY, V57, P158, DOI 10.1055/a-2373-0513
   Jensen MP, 2024, ANAESTHESIA, V79, P114, DOI 10.1111/anae.16150
   Jin YS, 2022, EUR ARCH OTO-RHINO-L, V279, P5877, DOI 10.1007/s00405-022-07513-5
   John H, 2000, J UROLOGY, V163, P1761, DOI 10.1016/S0022-5347(05)67537-4
   Kim D, 2019, CAN J ANESTH, V66, P934, DOI 10.1007/s12630-019-01371-2
   Lang-Illievich K, 2020, BRIT J ANAESTH, V124, PE228, DOI 10.1016/j.bja.2020.02.011
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Liu YQ, 2015, CHIN J INTEGR MED, V21, P697, DOI 10.1007/s11655-014-2009-x
   March JP, 2022, JAMA OTOLARYNGOL, V148, P561, DOI 10.1001/jamaoto.2022.0952
   Mazzotta E, 2023, FRONT PHARMACOL, V14, P0, DOI 10.3389/fphar.2023.1284071
   Mongelli MN, 2020, SURGERY, V167, P631, DOI 10.1016/j.surg.2019.11.014
   Myles PS, 2022, BRIT J ANAESTH, V128, P1029, DOI 10.1016/j.bja.2022.03.009
   Nabhan F, 2021, INT J CANCER, V149, P984, DOI 10.1002/ijc.33690
   Nakanishi H, 2024, AM J SURG, V236, P0, DOI 10.1016/j.amjsurg.2024.02.037
   Rao SN, 2023, BEST PRACT RES CL EN, V37, P0, DOI 10.1016/j.beem.2022.101678
   Shi P, 2020, IEEE T BIOMED CIRC S, V14, P1431, DOI 10.1109/TBCAS.2020.3039063
   Sorrenti S, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15123102
   Valentine S, 2021, ANN EMERG MED, V77, P82, DOI 10.1016/j.annemergmed.2020.03.029
   Van den Eynde F, 2023, LANGENBECK ARCH SURG, V408, P0, DOI 10.1007/s00423-023-02982-6
   Wang Qiong, 2017, ZHONGGUO ZHEN JIU, V37, P509, DOI 10.13703/j.0255-2930.2017.05.016
   Want SC, 2024, BODY IMAGE, V51, P0, DOI 10.1016/j.bodyim.2024.101788
   Wattier JM, 2016, ANAESTH CRIT CARE PA, V35, P197, DOI 10.1016/j.accpm.2015.10.006
   Xu JS, 2013, NEURAL REGEN RES, V8, P2633, DOI 10.3969/j.issn.1673-5374.2013.28.005
   Xu TF, 2024, SURG ENDOSC, V38, P1995, DOI 10.1007/s00464-024-10689-y
   Xue FR, 2025, MEDICINE, V104, P0, DOI 10.1097/md.0000000000041837
   Yao W, 2013, J TRADIT CHIN MED, V33, P538, DOI 10.1016/S0254-6272(13)60162-4
   Yoon S, 2020, BRIT J ANAESTH, V125, P614, DOI 10.1016/j.bja.2020.06.040
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang EW, 2023, PAIN, V164, P2642, DOI 10.1097/j.pain.0000000000003004
   Zhang ML, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1451342
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou Q, 2023, J ACUPUNCT TUINA SCI, V21, P368, DOI 10.1007/s11726-023-1394-0
NR 46
TC 0
Z9 0
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD SEP 29
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1097/NCC.0000000000001547
EA SEP 2025
PG 8
WC Oncology; Nursing
SC Oncology; Nursing
GA 8AS5X
UT WOS:001584184300001
PM 41026681
DA 2026-01-16
ER

PT J
AU Tao, S
   Yang, Y
   Tang, J
   Wang, X
   Jiang, N
   Li, Y
   Wu, P
AF Tao, Siyu
   Yang, Yi
   Tang, Jie
   Wang, Xue
   Jiang, Nannan
   Li, Yuan
   Wu, Ping
TI The efficacy of moxibustion on the pressure pain threshold and substance P /
SO Complementary therapies in medicine
LA English
DT Journal Article
DE ChiCTR-IOR-17012282; Interleukin-1β; Leukotriene B4; Moxibustion; Pressure pain threshold; Rheumatoid arthritis; Substance P; Trial registration number; Tumor necrosis factor-α
AB OBJECTIVE: To observe the effects of moxibustion on pressure-pain thresholds  (PPTs) in affected joints and non-joint areas, as well as the contents of  substance P (SP) and leukotriene B4 (LTB4) in serum of patients with rheumatoid  arthritis (RA), and to explore the analgesic mechanism of moxibustion in RA  patients. METHODS: A total of 72 patients with RA were randomly and equally  classified into the control and treatment groups. The control group was treated  with routine drug therapy, while the treatment group received routine drug  therapy and moxibustion. Both groups were treated for 8 weeks. The symptoms,  measured by PPTs, Visual analogue scale (VAS), pain joint count (PJC), swollen  joint count (SJC) and disease activity score of 28 joints (DAS28), and laboratory  indicators, measured by the level of SP, LTB4, tumor necrosis factor- α (TNF-α)  and interleukin-1β (IL-1β), were compared in the two groups before and after  intervention. RESULTS: A total of 66 patients completed the trial, with 1  patients dropping out from the treatment group and 5 patients being excluded and  dropped from the control group. Trial endpoints were change (∆) in symptoms and  laboratory indicators. The treatment group showed superior in ∆PPTs of the  interphalangeal joints(1301.71 (95 %CI, 967.43-1636.00) vs 443.23(95 %CI,  99.51-786.95)), ∆SP(10.11 (95 %CI, 5.85-14.37) vs 3.10 (95 %CI, -1.13-7.34)), ∆  LTB4(13.17 (95 %CI, 7.81-18.54) vs 3.37 (95 %CI, -5.73-12.48)), ∆TNF-α(4.57  (95 %CI, 2.60-6.55) vs 0.68 (95 %CI, -1.03-2.40)), ∆IL-1β(4.63 (95 %CI,  2.59-6.66) vs 1.63 (95 %CI, -0.53-3.80)), ∆PJC(7.14 (95 %CI, 5.17-8.58) vs 1.84  (95 %CI, 0.66-3.02)), ∆SJC(5.20 (95 %CI, 3.44-6.96) vs 1.00(95 %CI, 0.02-1.98)),  ∆VAS(3.6 (95 %CI, 2.99-4.21) vs 0.9 (95 %CI, 0.24-1.57)), and ∆DAS(1.68 (95 %CI,  1.44-1.92) vs 0.41 (95 %CI, 0.08-0.73)) compared to the control group, at weeks  4. Furthermore, there was a significant negative correlation between ∆PPTs of the  interphalangeal joints and ∆SP in the treatment group (r < 0, P < 0.05).  CONCLUSION: Moxibustion combined with conventional western medicine can  significantly improve PPTs in affected joints of RA patients, alleviate clinical  symptoms, and reduce disease activity. The potential mechanism may be related to  the down-regulation of SP and LTB4 levels and the reduction of the release of  inflammatory factors Il-1β and TNF-α by moxibustion. The lack of double-blinding  is a limitation of our study, which we plan to avoid by establishing a sham  moxibustion group in the subsequent trials.
C1 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, Sichuan province 610075, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province 610075, China.
EM wuping_33@163.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAY 29
PY 2025
VL 92
IS 
BP 103187
EP 103187
DI 10.1016/j.ctim.2025.103187
PG 0
WC Humans; Moxibustion; methods; Female; Male; Arthritis, Rheumatoid; therapy; Middle Aged; Leukotriene B4; blood; Substance P; blood; Adult; Pain Threshold; physiology; Aged; Interleukin-1beta; blood; Pain Measurement
UT PubMed:40436210
PM 40436210
DA 2025-05-29
ER

PT J
AU Ben-Arye, E
   Greenberg, D
   Samuels, N
   Lopez, AM
   Simon-Tuval, T
AF Ben-Arye, Eran
   Greenberg, Dan
   Samuels, Noah
   Lopez, Ana Maria
   Simon-Tuval, Tzahit
TI Adherence to Integrative Care, Oncology Healthcare Utilization, Opioid Use and Hospitalization
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology; pain; palliative care; cancer; patients; adherence; healthcare utilization
ID complementary medicine; cancer; acupuncture; program; management; impact; breast
AB Research on the relationship between integrative oncology (IO) programs and dispensing of chemotherapy agents and supportive care drugs, and hospitalization rates is limited. The present study examined these outcomes in chemotherapy-treated patients with cancer, comparing patients highly adherent to integrative care (high-AIC) to those with low adherence (low-AIC). Data from patients with cancer treated with taxane and/or platinum-based agents participating in an ongoing prospective, controlled pragmatic trial were examined retrospectively. Patients were referred to an IO consultation and weekly treatments at 3 medical centers in Northern Israel, with high-AIC defined as attending >= 4 sessions at 6 weeks; low-AIC, 0-3 sessions. Cancer-related parameters; dispensing of medication (chemotherapy agents, analgesics, anxiolytics and opioids); rates of hospitalizations and emergency room visits were analyzed using generalized linear regression models. Of 615 patients attending the IO consultation, 367 (59.7%) were high-AIC, with both groups having mostly similar baseline characteristics. Dispensing rates for taxanes (P = .336), platinum agents (P = .403), non-opioid analgesics (P = .201), and anxiolytics (P = .350), and number of emergency room visits were similar in both groups at 12 weeks. However, high-AIC patients had fewer dispensed opioid prescriptions (RR = 0.50, 95% CI = 0.30-0.85, P = .010); lower rates of hospitalization (OR = 0.59, 95% CI = 0.39-0.88, P = .010); and fewer hospitalization days (RR = 0.53, 95% CI = 0.31-0.90, P = .019). In conclusion, dispensing of chemotherapy drugs was similar between groups, though high-AIC patients used less opioids and had fewer hospitalizations at 12 weeks. Further research is needed with randomized and prospective studies exploring the relationship between adherence to IO care; adherence to chemotherapy; quality of life; opioid use; and hospitalization.
C1 [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Integrat Oncol Program, Lin Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Carmel Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Zebulun Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Greenberg, Dan; Simon-Tuval, Tzahit] Ben Gurion Univ Negev, Guilford Glazer Fac Business & Management, Dept Hlth Policy & Management, Beer Sheva, Israel.
   [Greenberg, Dan; Simon-Tuval, Tzahit] Bengur Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sydney Kimmel comprehens Canc Ctr, Philadelphia, PA USA.
C3 Clalit Health Services; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Technion Israel Institute of Technology; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Thomas Jefferson University; Thomas Jefferson University
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, IL-35152 Haifa, Israel.
EM eranben@technion.ac.il
CR Ben-Arye E, 2024, J PAIN SYMPTOM MANAG, V68, P10, DOI 10.1016/j.jpainsymman.2024.03.018
   Ben-Arye E, 2024, J PAIN SYMPTOM MANAG, V67, P69, DOI 10.1016/j.jpainsymman.2023.09.022
   Ben-Arye E, 2023, J CANCER RES CLIN, V149, P8177, DOI 10.1007/s00432-023-04758-3
   Ben-Arye E, 2024, BMJ SUPPORT PALLIAT, V14, P178, DOI 10.1136/spcare-2022-004117
   Ben-Arye E, 2022, SUPPORT CARE CANCER, V30, P4345, DOI 10.1007/s00520-022-06865-2
   Ben-Arye E, 2022, PSYCHO-ONCOLOGY, V31, P207, DOI 10.1002/pon.5794
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2018, SUPPORT CARE CANCER, V26, P4039, DOI 10.1007/s00520-018-4271-5
   Ben-Arye E, 2015, CLIN NUTR, V34, P1215, DOI 10.1016/j.clnu.2014.12.011
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Bower JE, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.24.00541
   Cao LX, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3271
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Central Bureau of Statistics of Israel, 2017, CHARACTERIZATION AND CLASSIFICATION OF STATISTICAL AREAS WITHIN MUNICIPALITIES AND LOCAL COUNCILS BY THE SOCIO-ECONOMIC LEVEL OF THE POPULATION, V0, P0
   Estores IM, 2018, EXPLORE-NY, V14, P212, DOI 10.1016/j.explore.2018.02.002
   Herman PM, 2018, J ALTERN COMPLEM MED, V24, P1025, DOI 10.1089/acm.2018.0155
   Kerner H, 2020, BMJ SUPPORT PALLIAT, V10, P0, DOI 10.1136/bmjspcare-2017-001351
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Molassiotis A, 2021, ACUPUNCT MED, V39, P41, DOI 10.1177/0964528420920285
   Ng DQ, 2024, BMC MED, V22, P0, DOI 10.1186/s12916-024-03626-2
   Oberoi DV, 2021, J ALTERN COMPLEM MED, V27, P390, DOI 10.1089/acm.2020.0386
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Shalom-Sharabi I, 2017, SUPPORT CARE CANCER, V25, P3181, DOI 10.1007/s00520-017-3726-4
   Shalom-Sharabi I, 2017, MED ONCOL, V34, P0, DOI 10.1007/s12032-017-1016-0
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P1243, DOI 10.1007/s00432-017-2368-8
   Sim Chin-Keng, 2002, ACUPUNCT MED, V20, P56
   Thronicke A, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0236426
   Tillery R, 2018, EUR J ONCOL NURS, V36, P1, DOI 10.1016/j.ejon.2018.06.004
   Wang PR, 2023, PHOTODIAGN PHOTODYN, V42, P0, DOI 10.1016/j.pdpdt.2023.103611
   World Health Organization, 2025, ANATOMICAL THERAPEUTIC CHEMICAL (ATC) CLASSIFICATION, V0, P0
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2025
VL 24
IS 
BP 
EP 
DI 10.1177/15347354251387955
PG 9
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 9CB2Y
UT WOS:001602773600001
PM 41147326
DA 2026-01-16
ER

PT J
AU Wang, X
   Shen, Q
   Hu, X
   Liang, Y
AF Wang, Xiaoying
   Shen, Qiongying
   Hu, Xinyi
   Liang, Yi
TI Comment on 'Efficacy and Safety of Different Acupuncture Treatments for
SO Integrative cancer therapies
LA English
DT Letter
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAY 26
PY 2025
VL 24
IS 
BP 15347354251344281
EP 15347354251344281
DI 10.1177/15347354251344281
PG 1
UT PubMed:40417861
PM 40417861
DA 2025-05-26
ER

PT J
AU Cho, N
   Choi, Y
   Kim, H
   Yun, J
   Jun, H
   Yang, C
   Kim, S
   Leem, J
AF Cho, Nahyun
   Choi, Younkuk
   Kim, Heekyung
   Yun, Jeongmi
   Jun, Hyungsun
   Yang, Changsop
   Kim, Sungha
   Leem, Jungtae
TI Pain Treatment in Primary Care Through Eight Constitution Medicine: A
SO Medicina (Kaunas, Lithuania)
LA English
DT Journal Article
DE acupuncture; healthy lifestyle; musculoskeletal pain; precision medicine; retrospective studies
AB Background and Objectives: Musculoskeletal pain is a global public health issue.  Eight Constitution Medicine (ECM), a type of East Asian Traditional Medicine,  offers personalized, minimally invasive treatment through Eight Constitution  Acupuncture (ECA) and Eight Constitution Lifestyle Intervention (ECLI). Despite  its clinical use, scientific evidence supporting ECM's effectiveness remains  limited. This study aimed to evaluate the effectiveness in treating  musculoskeletal pain in primary care settings. Materials and Methods: This  retrospective study analyzed medical records from three ECM clinics  (Gangnam-Shingwang, Yeson, and Yebon) between January 2018 and August 2023. A  total of 163 patients were included, with 44 providing follow-up data. Pain  intensity, quality of life, and functional outcomes were assessed using validated  instruments including the PainDETECT questionnaire, Korean Cancer Pain Assessment  Tool (KCPAT) somatic pain scores, EuroQol 5-Dimension 5-Level (EQ-5D-5L), Western  Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Oswestry  Disability Index (ODI), Neck Disability Index (NDI), and Shoulder Pain and  Disability Index (SPADI). Pre- and post-treatment scores were statistically  analyzed. Results: Significant decreases were observed in KCPAT somatic pain  scores (11.77 ± 4.77 to 9.77 ± 5.32) and significant improvements in EQ-5D-5L  scores (0.74 ± 0.12 to 0.80 ± 0.07). WOMAC and ODI scores also showed significant  improvements. However, the changes in the NDI, SPADI, and PainDETECT scores were  not statistically significant. No adverse events were reported. Conclusions: ECM,  through ECA and ECLI, may offer effective personalized treatment for  musculoskeletal pain, improving both pain intensity and quality of life. Despite  its small sample size and retrospective design, this study offers valuable  preliminary evidence for ECM. Further large-scale prospective studies are needed  to confirm these findings.
C1 Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
   East-West Cancer Center, Cheonan Korean Medical Hospital, Daejeon University, 
   Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Gangnam-gu,Seoul 06355, Republic of Korea.
   Gangnam-Shingwang ECM Clinic, Seocho-gu, Seoul 06612, Republic of Korea.
   Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Gangnam-gu,Seoul 06355, Republic of Korea.
   Yebon ECM Clinic, Songpa-gu, Seoul 05510, Republic of Korea.
   Yeson ECM Clinic, Yangcheon-gu, Seoul 07999, Republic of Korea.
   Department of Diagnostics, College of Korean Medicine, Dongshin University, Naju 58245, Republic of Korea.
   KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
   Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
   Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
   Research Center of Traditional Korean Medicine, College of Korean Medicine, 
   Department of Il-won Integrated Medicine, Wonkwang University Korean Medicine Hospital, 895, Muwang-ro, Iksan 54538, Republic of Korea.
NR 0
TC 0
SN 1648-914
EI 1010-660
J9 Medicina (Kaunas)
PD SEP 27
PY 2025
VL 61
IS 9
BP 
EP 
DI 10.3390/medicina61091564
PG 0
WC Humans; Retrospective Studies; Female; Male; Middle Aged; Primary Health Care; statistics & numerical data; Republic of Korea; Pain Management; methods; Adult; Musculoskeletal Pain; therapy; Aged; Pain Measurement; methods; Quality of Life; psychology; Surveys and Questionnaires; Acupuncture Therapy; methods
UT PubMed:41010955
PM 41010955
DA 2025-09-27
ER

PT J
AU Murari, J
   Sharma, I
   Atwal, SA
   Sharma, A
   Bandyopadhyay, S
   Shalini, B
   Kumar, M
AF Murari, Jerish
   Sharma, Ish
   Atwal, Siddharth Arjun
   Sharma, Aparna
   Bandyopadhyay, Sukanta
   Shalini, B
   Kumar, Manish
TI Understanding Cancer-Related Pain: Pathophysiology, Classification, and Treatment
SO Cureus
LA English
DT Review
DE artificial intelligence; cancer-related pain; mechanism-based treatment; precision oncology; translational pain research
AB Cancer-related pain (CRP) is a complex, multidimensional challenge in oncology  that undermines quality of life, psychological well-being, and treatment  adherence. This narrative, mechanism-informed review synthesizes pathophysiology,  classification systems, and multidisciplinary management strategies to provide  clinical insights and research priorities. It connects nociceptive, neuropathic,  and mixed pain mechanisms to practical interventions, emphasizing peripheral and  central sensitization in chronicity. Major frameworks, including the WHO  analgesic ladder, International Classification of Diseases, 11th Revision,  Edmonton Classification System for Cancer Pain, and European Pain Federation  standards, are appraised alongside assessment tools such as the Visual Analogue  Scale, Brief Pain Inventory, and Hospital Anxiety and Depression Scale, with  examples of their clinical application. Management is framed within a flexible,  mechanism-based, multimodal model that integrates pharmacologic, adjuvant,  interventional, and psychosocial approaches, delivered through coordinated,  multidisciplinary teams. Evidence for complementary modalities, such as  acupuncture and mindfulness-based stress reduction, remains preliminary and  heterogeneous, requiring further high-quality trials, whereas opioid-based  pharmacologic approaches and structured psychosocial interventions such as  cognitive behavioral therapy are supported by more robust, established evidence.  Similarly, innovations like AI-driven monitoring and pharmacogenomics hold  promise but are still in the early validation phase, underscoring the need to  distinguish between evolving and well-established domains of cancer pain  management. The principal actionable priorities are to adopt mechanism-based  classification, embed multidisciplinary collaboration, expand multimodal access  in low-resource settings, and rigorously validate emerging pharmacogenomic and  digital health innovations before widespread clinical integration.
C1 Department of General Medicine, Chettinad Hospital and Research Institute, Kelambakkam, IND.
   Department of Ayurvedic Pathology, Babe Ke Ayurvedic Medical College and Hospital, Daudhar, IND.
   Department of Emergency Medicine, Civil Hospital Malerkotla, Malerkotla, IND.
   Department of Ayurvedic Eye and Ear, Nose, and Throat (ENT), National Institute of Ayurveda, Jaipur, IND.
   Department of Biochemistry, Rama Medical College Hospital and Research Centre, Kanpur, IND.
   Department of Pediatric Medicine, National Institute of Siddha, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, IND.
   Department of Microbiology, School of Science, YBN University, Ranchi, IND.
   Department of Cancer Biology, ESIC Medical College and Hospital, Ranchi, IND.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD OCT 3
PY 2025
VL 17
IS 9
BP e91395
EP e91395
DI 10.7759/cureus.91395
PG 1
UT PubMed:41040753
PM 41040753
DA 2025-10-03
ER

PT J
AU Guo, ZN
   Wang, LY
   Wang, YT
   Liu, WH
   Zhao, Y
   Tang, XR
   Lin, R
   Wu, ZN
   Cui, SY
   Xu, NG
AF Guo, Zining
   Wang, Liying
   Wang, Yuting
   Liu, Wenhao
   Zhao, Yi
   Tang, Xiaorong
   Lin, Run
   Wu, Zhennan
   Cui, Shaoyang
   Xu, Nenggui
TI Acupuncture for cancer-related insomnia: An evidence mapping
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Review
DE Acupoint; Acupuncture; Cancer; Evidence mapping; Insomnia
ID sleep disturbances; severity index; chemotherapy; acupressure; depression; validation; management; fatigue; pain
AB Background: Acupuncture shows promise in treating cancer-related insomnia (CRI); however, the evidence level for its effectiveness remains low. This study systematically examined research quality and used evidence mapping (EM) to map and present evidence information to identify gaps and inform future research. Methods: Two reviewers searched eight databases from inception to May 2024, screened eligible randomized controlled trials (RCTs), and extracted key characteristics from included studies. The quality of studies was assessed using the Cochrane Risk of Bias 2.0 (RoB 2.0) tool, and key characteristics visualized EM. Finally, Acupoint data were systematically summarized. Results: 37 RCTs were included in this study. RoB 2.0 results showed only three studies at "low risk," while most had notable quality issues. EM indicated that common comparisons involved manual acupuncture (MA), alone or combined, versus sleep medications. Measures involved six assessment tools, with Pittsburgh Sleep Quality Index (PSQI) most frequently used. Meanwhile, EM revealed considerable uncertainty regarding acupuncture for CRI efficacy. Acupoint analysis identified Yintang (GV24 +), Shenting (GV24), Baihui (GV20), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7) as core acupoints. Analysis identified five key gaps: study reliability, participant selection, placebo effect, outcome measurement, and acupoint selection. Conclusions: Research on acupuncture for CRI has various gaps, and more high-quality evidence is still needed. This study comprehensively mapped the current evidence on acupuncture for CRI and identified five key gaps, providing directions and references for future research. Protocol registration: INPLASY, INPLASY202460052.
C1 [Guo, Zining; Wang, Liying; Lin, Run; Cui, Shaoyang] Guangzhou Univ Chinese Med, Shenzhen Hosp Fu Tian, Shenzhen, Peoples R China.
   [Wang, Yuting; Liu, Wenhao; Zhao, Yi; Tang, Xiaorong; Wu, Zhennan; Xu, Nenggui] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou 510000, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xu, NG (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou 510000, Peoples R China.; Cui, SY (corresponding author), Guangzhou Univ Chinese Med, Shenzhen Hosp, Shenzhen 518000, Guangdong, Peoples R China.
EM herb107@126.com; ngxu8018@163.com
FU Sanming Project of Medicine in Shenzhen [SZZYSM202311011]; Guangzhou University of Traditional Chinese Medicine Joint Science and Technology Innovation Fund [GZYFT2024Y09]; Basic and Applied Basic Research Program of Guangzhou Municipal Health Commission Foundation [SL2022A03J00189]
CR Unknown -, 2008, WHO STANDARD ACUPUNCTURE POINT LOCATIONS IN THE WESTERN PACIFIC REGION, V0, P0
   Unknown -, 1993, ICD 10 CLASSIFICATIO, V0, P0
   Unknown -, 2016, DSM-5 CLASSIFICATION, V0, P0
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Cai YQ, 2025, INTEGR MED RES, V14, P0, DOI 10.1016/j.imr.2025.101144
   Chen SY, 2021, INTELL HEALTH, V7, P167
   Chen YF, 2002, PSYCHOPATHOLOGY, V35, P171, DOI 10.1159/000065140
   Chi WC, 2019, CHIN MED J, V16, P114
   Ciani O, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2022.51564
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   DAlessandro EG, 2022, MED ACUPUNCT, V34, P58, DOI 10.1089/acu.2021.0073
   Dan ZJ, 2013, MSD THESIS, V0, P0
   de Jonge SW, 2023, JAMA SURG, V158, P89, DOI 10.1001/jamasurg.2022.4892
   Duan CX, 2018, ELECTRON J CLIN MED LIT, V5, P14
   Efverman A, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241300068
   Fan GH, 2020, J NURSES TRAIN, V35, P1803
   Fan JQ, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.32133
   Fang WJ, 2023, SHANGHAI J ACUPUNCT MOXIBUSTION, V42, P1157
   Feng F, 2021, MED AESTHET COSMETOL, V0, P120
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Fernandes-Taylor S, 2023, JAMA OTOLARYNGOL, V149, P276, DOI 10.1001/jamaoto.2022.4733
   Guiteras AF, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18168509
   Gamble C, 2017, JAMA-J AM MED ASSOC, V318, P2337, DOI 10.1001/jama.2017.18556
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Gnanasakthy A, 2022, VALUE HEALTH, V25, P647, DOI 10.1016/j.jval.2021.10.006
   Grassi L, 2023, ESMO OPEN, V8, P0, DOI 10.1016/j.esmoop.2023.102047
   Guo ZN, 2024, COMPLEMENT THER MED, V85, P0, DOI 10.1016/j.ctim.2024.103074
   Hendy A, 2025, BMC CANCER, V25, P0, DOI 10.1186/s12885-025-14538-6
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Hopewell S, 2025, BMJ-BRIT MED J, V389, P0, DOI 10.1136/bmj-2024-081123
   Howell D, 2014, ANN ONCOL, V25, P791, DOI 10.1093/annonc/mdt506
   Hu XY, 2023, WORLD J ACUPUNCT-MOX, V33, P325, DOI 10.1016/j.wjam.2023.09.004
   Huang YJ, 2020, MSD THESIS, V0, P0
   Jakobsen G, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14163933
   Kim DH, 2025, INTEGR MED RES, V14, P0, DOI 10.1016/j.imr.2024.101098
   Lam TF, 2024, BMC COMPLEMENT MED, V24, P0, DOI 10.1186/s12906-024-04340-5
   Lee B, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03561-w
   Li J, 2023, BMC MED RES METHODOL, V23, P0, DOI 10.1186/s12874-023-01904-w
   Liao J, 2018, WORLD SCI TECHNOL-MOD CHIN MED., V20, P219
   Liu GL, 2016, TRADIT MED ASIA PAC, V12, P112
   Liu Y, 2024, MSD THESIS, V0, P0
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Lyman GH, 2018, J ONCOL PRACT, V14, P495, DOI 10.1200/JOP.18.00283
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   McGeeney BE, 2015, HEADACHE, V55, P465, DOI 10.1111/head.12524
   McGlothlin AE, 2014, JAMA-J AM MED ASSOC, V312, P1342, DOI 10.1001/jama.2014.13128
   McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411
   Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P786, DOI 10.1016/j.jpainsymman.2015.06.018
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mogavero MP, 2021, SLEEP MED REV, V56, P0, DOI 10.1016/j.smrv.2020.101409
   Oh JY, 2024, ADV SCI, V11, P0, DOI 10.1002/advs.202403245
   Peng XH, 2016, J TRADIT CHIN MED, V31, P2409
   Ren XL, 2020, MSD THESIS, V0, P0
   Riemann D, 2023, J SLEEP RES, V32, P0, DOI 10.1111/jsr.14035
   Riley KE, 2021, INT J BEHAV MED, V28, P683, DOI 10.1007/s12529-021-09962-4
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Schieber K, 2019, SLEEP MED, V58, P107, DOI 10.1016/j.sleep.2019.02.018
   Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487
   Shi Y, 2020, J SHANDONG UNIV TRADIT CHIN MED., V44, P164
   Shi Y, 2014, GUIDE CHINA MED, V12, P286
   Shi Y, 2020, MOD ONCOL, V28, P469
   Song JR, 2015, SICHUAN J TRADIT CHIN MED, V33, P163
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Taljaard M, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.f2838
   Tu JF, 2024, JAMA INTERN MED, V184, P1417, DOI 10.1001/jamainternmed.2024.5463
   Wang GH, 2024, MSD THESIS, V0, P0
   Wang HJ, 2024, CHINA J TRADIT CHIN MED PHARM, V42, P210
   Wang YF, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.956854
   Wang YY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8637386
   Wong AK, 2023, J PAIN SYMPTOM MANAG, V66, Pe335, DOI 10.1016/j.jpainsymman.2023.05.020
   Wu Xiao-Dong, 2022, ZHONGGUO ZHEN JIU, V42, P579, DOI 10.13703/j.0255-2930.20220117-k0001
   Yao LL, 2023, NAT COMMUN, V14, P0, DOI 10.1038/s41467-023-36448-6
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yin S, 2021, SHANGHAI J ACUPUNCT MOXIBUSTION, V40, P21
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   Zhang LF, 2022, J QIQIHAR MED UNIV, V43, P2394
   Zhang XP, 2022, MSD THESIS, V0, P0
   Zhang XX, 2022, NEW CHIN MED, V54, P197
   Zhang YL, 2016, MSD THESIS, V0, P0
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067476
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2022-070533
   Zhao FY, 2024, SLEEP MED REV, V74, P0, DOI 10.1016/j.smrv.2023.101892
   Zhao WZ, 2021, MSD THESIS, V0, P0
   Zheng Jun-Wei, 2023, SICHUAN DA XUE XUE BAO YI XUE BAN, V54, P231, DOI 10.12182/20230260302
   Zhou ES, 2017, J CANCER SURVIV, V11, P74, DOI 10.1007/s11764-016-0564-1
   Zhuang GH, 2022, MASSAGE REHABIL MED, V13, P28
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 94
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD DEC 15
PY 2025
VL 14
IS 4
BP 
EP 
DI 10.1016/j.imr.2025.101225
EA AUG 2025
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 6SB5S
UT WOS:001560670800001
PM 40896346
DA 2026-01-16
ER

PT J
AU Wei, W
   Yao, B
   Sun, X
   Xing, S
   Wang, K
   He, F
   Xu, Q
   Ren, C
AF Wei, Wei
   Yao, Bei
   Sun, Xiaoying
   Xing, Shaona
   Wang, Kaiyi
   He, Fangmei
   Xu, Qiaobo
   Ren, Chunxiao
TI Invasive or noninvasive? A systematic review and network meta-analysis of
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupressure; Acupuncture; Cancer pain; Complementary therapies; Network meta-analysis
AB BACKGROUND: Both acupressure and acupuncture effectively alleviate pain in cancer  patients. Acupuncture requires specialized practitioners and is invasive, while  acupressure is noninvasive and can be self-administered. Current comparative  evidence remains insufficient for clear clinical recommendations. AIMS: To  investigate the relative efficacy of acupuncture versus acupressure in  alleviating pain among cancer patients. METHODS: This systematic review and  network meta-analysis employed a Bayesian framework. Eight major Chinese and  English databases were searched from inception to March 1, 2025. Two independent  reviewers screened literature, extracted data, and assessed bias in selected  studies using the Risk of Bias 2 tool. Network meta-analysis was conducted using  R software version 4.4.1. RESULTS: Thirty-seven RCTs including 3066 patients were  analyzed to compare eight treatments: manual acupuncture, transcutaneous  electrical acupoint stimulation, auricular acupressure, electro-acupuncture,  acupoint massage, auricular acupuncture, moxibustion, and placebo. Network  meta-analysis revealed auricular acupuncture provided the greatest pain score  improvement compared to placebo, followed by auricular acupressure and acupoint  massage. CONCLUSION: Based on our analysis, we recommend auricular acupuncture,  auricular acupressure, and acupoint massage for managing cancer pain. While  current studies demonstrate potential benefits, limitations include concurrent  pain medication use and methodological inconsistencies. Future research should  include more robust, single-intervention clinical trials to definitively evaluate  efficacy for oncology patients.
C1 Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   China Academy of Chinese Medical Sciences, Institute of Basic Research in Clinical Medicine, Beijing, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China.
   Shaanxi Energy Institute, Xianyang City, 712000, Shaanxi Province, China. 2215222801@qq.com.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD OCT 31
PY 2025
VL 33
IS 11
BP 997
EP 997
DI 10.1007/s00520-025-10068-w
PG 0
WC Humans; Cancer Pain; therapy; Acupressure; methods; Acupuncture Therapy; methods; Randomized Controlled Trials as Topic; Neoplasms; complications; Bayes Theorem; Pain Management; methods
UT PubMed:41171390
PM 41171390
DA 2025-10-31
ER

PT J
AU Gao, L
   Chen, SY
   Gao, TL
   Yang, LY
   Tai, XT
AF Gao, Lin
   Chen, Suyu
   Gao, Tianlei
   Yang, Liuying
   Tai, Xiantao
TI A bibliometric analysis of the development trend of Tuina research: Based on the Web of Science (WOS) platform
SO MEDICINE
LA English
DT Article
DE bibliometric analysis; Chinese massage; research review; Tuina
ID low-back-pain; therapeutic-efficacy; cancer-patients; neck pain; tai chi; manipulation; massage; acupuncture; medicine; complementary
AB Background:Tuina has been proven to significantly relieve symptoms, demonstrating its clinical value. With the growth of related research, a comprehensive review is urgently needed to promote its development. This study aims to clarify the collaboration and current research status in the field of Tuina research using bibliometric analysis, and to discuss future directions.Methods:On February 4, 2023, the Web of Science Core Collection (WoSCC) database was searched using the keywords "tuina," "tui-na," "tui na," and "Chinese massage" to collect literature related to Tuina from its inception until December 31, 2022. The collected literature included all types of research articles and reviews. VOSviewer, CiteSpace, Pajek, and Scimago Graphica were utilized to perform a visual analysis of annual publication volume, as well as publication volume and collaboration networks of different countries, institutions, and authors, along with journal publication volume and keyword network analysis.Results:A total of 761 publications were included in the analysis, with the total number of papers showed an increasing trend over time. The countries and institutions with the most publications were China and Shanghai University of Traditional Chinese Medicine, respectively. The authors who contributed the most were Min Fang, Qingguang Zhu, Zhiwei Wu, Lingjun Kong and Yufeng Wang. The most widely published journal in the field was the Journal of Acupuncture and Tuina Science. The clinical efficacy evaluation of Tuina therapy for musculoskeletal and spinal diseases, apoplexy sequelae, chronic diseases, and pediatric diseases were research hotspots and developing trends in this field.Conclusion:The research on Tuina has been increasing year by year. Currently, the focus of Tuina research lies in clinical studies, including the treatment of skeletal muscle and spinal diseases, stroke sequelae, chronic diseases, and pediatric illnesses, with pediatric Tuina emerging as a hot topic of research. Basic research in this field is relatively scarce, and the mechanisms of action of this therapy have not yet been fully elucidated. Future efforts in this area should aim to strengthen basic research and promote cooperation among international institutions.
C1 [Gao, Lin; Chen, Suyu] Yunnan Univ Chinese Med, Clin Med Coll 1, Kunming, Peoples R China.
   [Gao, Tianlei; Yang, Liuying; Tai, Xiantao] Yunnan Univ Chinese Med, Clin Med Coll 2, Kunming, Peoples R China.
C3 Yunnan University of Chinese Medicine; Yunnan University of Chinese Medicine
RP Tai, XT (corresponding author), Yunnan Univ Chinese Med, Affiliated Hosp 2, Sch Clin Med 2, Kunming 650500, Peoples R China.
EM 1587920143@qq.com; 515064283@qq.com; 1587920143@qq.com; m18468028906@163.com; taixiantao@163.com
FU Yunnan Province Innovation Team for the Prevention and Treatment of Brain Diseases with Acupuncture and Tuina [202405AS350007]; Yunnan Provincial Department of Education Scientific Research Fund Project [2022Y367]
CR Carmady B, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-22
   Chen B, 2019, IRAN J BIOTECHNOL, V17, P80, DOI 10.21859/ijb.1863
   Chen LL, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028833
   Chen LF, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021664
   Chen SC, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154191
   Chen WJ, 2020, J TRADIT CHIN MED, V40, P1026, DOI 10.19852/j.cnki.jtcm.2020.06.014
   Cheng ZJ, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05557-2
   Fan ZY, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2020.101293
   Fan ZY, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011979
   Fang L, 2018, CHIN J INTEGR MED, V24, P531, DOI 10.1007/s11655-016-2275-x
   Fang L, 2015, J TRADIT CHIN MED, V35, P558
   Feng X, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06030-4
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   FLAWS B, 1993, AM J ACUPUNCTURE, V21, P267
   Fu SF, 2022, FRONT PEDIATR, V10, P0, DOI 10.3389/fped.2022.1043322
   Gong ZC, 2023, J PAIN RES, V16, P2063, DOI 10.2147/JPR.S410603
   Guan HY, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000030699
   Guo GX, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06633-x
   Guo M, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000035980
   Guo TP, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000009697
   Huang F, 2022, COMPLEMENT THER CLIN, V49, P0, DOI 10.1016/j.ctcp.2022.101627
   Huang F, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101115
   Ji YY, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028780
   Jia Y, 2017, OPEN LIFE SCI, V12, P285, DOI 10.1515/biol-2017-0033
   Jiang SC, 2016, EXP THER MED, V11, P1367, DOI 10.3892/etm.2016.3055
   Jiang Z, 2021, INT J ORAL SCI, V13, P0, DOI 10.1038/s41368-021-00117-5
   Kim E, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000032086
   Kong LJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/578305
   Li HN, 2017, J TRADIT CHIN MED, V37, P819
   Li T, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/8862399
   Li X, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023016
   Li Y, 2021, INDIAN J PHARM SCI, V83, P205, DOI 10.36468/pharmaceutical-sciences.spl.395
   Li Z, 2024, HELIYON, V10, Pe38675, DOI 10.1016/J.HELIYON.2024.E38675
   Liang SB, 2020, COMPLEMENT THER MED, V51, P0, DOI 10.1016/j.ctim.2020.102411
   Lin JH, 2013, MANUAL THER, V18, P308, DOI 10.1016/j.math.2012.11.005
   Liu MQ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023738
   Lu TY, 2021, HEALTH QUAL LIFE OUT, V19, P0, DOI 10.1186/s12955-020-01636-1
   Mao H, 2022, COMPLEMENT THER MED, V71, P0, DOI 10.1016/j.ctim.2022.102882
   Meng M, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026013
   Morandi G, 2023, ALTERN THER HEALTH M, V29, P258
   Niu JF, 2019, COMPLEMENT THER MED, V42, P322, DOI 10.1016/j.ctim.2018.10.017
   Öztekin DS, 2007, TOHOKU J EXP MED, V211, P49, DOI 10.1620/tjem.211.49
   Ploner M, 2011, CEREB CORTEX, V21, P719, DOI 10.1093/cercor/bhq146
   Ren J, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000027700
   Song PF, 2018, J TRADIT CHIN MED, V38, P834
   Tan MGE, 2013, ANN ACAD MED SINGAP, V42, P133
   Tang SJ, 2016, COMPLEMENT THER MED, V25, P45, DOI 10.1016/j.ctim.2016.01.001
   Tao JM, 2022, FRONT PSYCHIATRY, V13, P0, DOI 10.3389/fpsyt.2022.923721
   Tao JM, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05469-1
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   Wang FY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026222
   Wang HR, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1007432
   Wang JK, 2024, COMPLEMENT THER MED, V86, P0, DOI 10.1016/j.ctim.2024.103092
   Wang MY, 2008, J CLIN NURS, V17, P2531, DOI 10.1111/j.1365-2702.2008.02446.x
   Wen Y, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.974792
   WOLFE HL, 1995, AM J ACUPUNCTURE, V23, P219
   Wu HY, 2021, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.787228
   Wu ZW, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3096-3
   Xu H, 2023, PAIN MED, V24, P244, DOI 10.1093/pm/pnac127
   Yang YC, 2022, NEUROPSYCH DIS TREAT, V18, P187, DOI 10.2147/NDT.S339762
   Zhang PY, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8828826
   Zhang QS, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2020-038705
   Zhang QS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020368
   Zhang SP, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-4198-2
   Zhang XH, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06678-y
   Zhang XH, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010574
   Zhao S, 2024, ASIAN J SURG, V0, P0
   Zhou BW, 2021, J ACUPUNCT TUINA SCI, V19, P104, DOI 10.1007/s11726-021-1232-1
   Zhou RJ, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1006830
   Zhou X, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.952346
   Zhou X, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028883
   ZHU BY, 2022, J ACUPUNCT TUINA SCI, V20, P187, DOI 10.1007/s11726-022-1311-y
   Zhu DC, 2022, J PAIN RES, V15, P3043, DOI 10.2147/JPR.S384757
   Zhu QG, 2016, J TRADIT CHIN MED, V36, P314
   Zhu QG, 2015, J TRADIT CHIN MED, V35, P411, DOI 10.1016/S0254-6272(15)30117-5
NR 75
TC 0
Z9 0
U1 6
U2 33
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 17
PY 2025
VL 104
IS 3
BP 
EP 
DI 10.1097/MD.0000000000041070
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA S8Z9W
UT WOS:001401048300048
PM 39833056
DA 2026-01-16
ER

PT J
AU Qi, PF
   Zhou, MY
   Han, WQ
   Li, HX
   Min, L
   Li, JX
   Sun, ZR
   Yin, HN
AF Qi, Pengfei
   Zhou, Mingyuan
   Han, Wenqing
   Li, Hongxiang
   Min, Lu
   Li, Jiaxin
   Sun, Zhongren
   Yin, Hongna
TI Mechanism of the analgesic effect of electroacupuncture on bone cancer pain through the neuro-immune system: progress based on animal experiments
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE electroacupuncture; bone cancer pain; morphine tolerance; mechanism; neuroscience; immunity; animal model
ID opioid receptor desensitization; gene-related peptide; rat model; astrocyte activation; morphine-tolerance; prostate-cancer; p2x3 receptors; spinal-cord; endothelin; inhibition
AB This article summarizes the mechanism of the analgesic effect of electroacupuncture (EA) on BCP by analyzing the progress of animal experimental research on the treatment of bone cancer pain (BCP). As a kind of chronic specific pain that both overlaps and incompletely coincides with inflammatory pain and neuropathic pain, BCP is mostly clinically treated with opioids such as morphine as the first-line analgesic for BCP, but the long-term application is prone to a series of unavoidable side-effects, such as tolerance, dependence, as well as cognitive impairment, nausea, constipation, and nephrotoxicity. Therefore, there is an urgent need to seek safer and more effective treatment measures. As a safe, reliable and consistently efficacious analgesic, EA produces analgesic effects in inflammatory pain, neuropathic pain and BCP. EA not only attenuates the nociceptive sensitization of BCP by modulating the release of nociception-related neurotransmitters and receptors in the nervous system, but also exerts analgesic effects on BCP by modulating the expression of inflammatory factors in the immune system, inhibiting glial cell activation, and T cell proliferation. At present, EA research on the analgesic mechanism of BCP has made some progress, but there are still problems that need to be solved, such as the lack of standardization of acupoints and parameters, weak clinical validation, a single research model, and limitations in the perspective of analgesic mechanism research. It is suggested that future studies should be based on databases such as AcuEBase v1.0 to develop standardized EA acupoint combinations and frequency parameters to provide a scientific basis for EA standardization. At the same time, the sample size should be expanded and the experimental design should be improved in order to promote the transformation of animal experiments into clinical applications. In addition, it should be expanded to more types of cancer bone metastasis pain models to verify the consistency of the analgesic effect of EA in different BCP models. Future studies could also explore the multi-target synergistic analgesic effects of EA from a microbial-immune axis perspective with the help of tools such as MicrobeTCM. And optimize the treatment plan of BCP through EA combined with drug therapy. It is believed that with the progress of science and technology as well as the continuous exploration of human beings, the complex mechanism of BCP will be overcome by human beings eventually.
C1 [Qi, Pengfei; Zhou, Mingyuan; Han, Wenqing; Li, Hongxiang; Min, Lu; Li, Jiaxin; Sun, Zhongren; Yin, Hongna] Heilongjiang Univ Chinese Med, Haerbin, Peoples R China.
   [Yin, Hongna] Heilongjiang Univ Tradit Chinese Med, Hosp 2, Harbin, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine
RP Yin, HN (corresponding author), Heilongjiang Univ Chinese Med, Haerbin, Peoples R China.; Yin, HN (corresponding author), Heilongjiang Univ Tradit Chinese Med, Hosp 2, Harbin, Peoples R China.
EM hljzyydxfsey@163.com
FU Heilongjiang Provincial Natural Science Foundation of China [LH2024H231]
CR Abbas AK, 2018, SCI IMMUNOL, V3, P0, DOI 10.1126/sciimmunol.aat1482
   Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood-2011-04-325225
   Andriessen AS, 2021, PAIN REP, V6, P0, DOI 10.1097/PR9.0000000000000867
   Arranz L, 2017, BLOOD REV, V31, P306, DOI 10.1016/j.blre.2017.05.001
   Baamonde A, 2005, N-S ARCH PHARMACOL, V372, P213, DOI 10.1007/s00210-005-0013-6
   Bennett MI, 2019, PAIN, V160, P38, DOI 10.1097/j.pain.0000000000001363
   Carducci MA, 2006, CLIN CANCER RES, V12, P6296S, DOI 10.1158/1078-0432.CCR-06-0929
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   Chartier SR, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917745465
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chen J, 2019, JCPSP-J COLL PHYSICI, V29, P528, DOI 10.29271/jcpsp.2019.06.528
   Chen YF, 2024, PHARMACOL RES, V201, P0, DOI 10.1016/j.phrs.2024.107080
   Currie GL, 2014, CURR PAIN HEADACHE R, V18, P0, DOI 10.1007/s11916-014-0423-6
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   Dang VC, 2012, BRIT J PHARMACOL, V165, P1704, DOI 10.1111/j.1476-5381.2011.01482.x
   Dang VC, 2011, J NEUROSCI, V31, P7122, DOI 10.1523/JNEUROSCI.5999-10.2011
   Dhaun N, 2023, LANCET, V402, P1945, DOI 10.1016/S0140-6736(23)02419-4
   Dong C, 2021, ANNU REV IMMUNOL, V39, P51, DOI 10.1146/annurev-immunol-061020-053702
   Donovan-Rodriguez T, 2006, NEUROSCI LETT, V393, P237, DOI 10.1016/j.neulet.2005.09.073
   Du Jun Ying, 2020, ZHEN CI YAN JIU, V45, P87, DOI 10.13702/j.1000-0607.1900036
   Falk S, 2015, NEUROSCIENCE, V291, P93, DOI 10.1016/j.neuroscience.2015.02.011
   Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019
   Fiore NT, 2023, NAT REV NEUROL, V19, P199, DOI 10.1038/s41582-023-00777-3
   Fu J, 2021, PPAR RES, V2021, P0, DOI 10.1155/2021/6086265
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Gadepalli A, 2021, ACS CHEM NEUROSCI, V12, P4195, DOI 10.1021/acschemneuro.1c00414
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Ge MM, 2022, BIOMED PHARMACOTHER, V149, P0, DOI 10.1016/j.biopha.2022.112912
   Ghilardi JR, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-87
   Hamamoto DT, 2008, J NEUROPHYSIOL, V100, P2300, DOI 10.1152/jn.01337.2007
   Hamza FN, 2024, PHARMACEUTICALS-BASE, V17, P0, DOI 10.3390/ph17121591
   Han MM, 2018, NEUROPEPTIDES, V68, P36, DOI 10.1016/j.npep.2018.01.003
   Hansen RR, 2016, PAIN, V157, P666, DOI 10.1097/j.pain.0000000000000416
   Hansen RR, 2012, EUR J PHARMACOL, V688, P27, DOI 10.1016/j.ejphar.2012.05.008
   He JJ, 2020, EXP NEUROL, V334, P0, DOI 10.1016/j.expneurol.2020.113482
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Hökfelt T, 2003, LANCET NEUROL, V2, P463, DOI 10.1016/S1474-4422(03)00482-4
   Huang LY, 2023, COMPLEMENT THER MED, V72, P0, DOI 10.1016/j.ctim.2023.102915
   Iakovou I, 2014, CANCER BIOTHER RADIO, V29, P116, DOI 10.1089/cbr.2013.1551
   Illes P, 2021, BRIT J PHARMACOL, V178, P489, DOI 10.1111/bph.15299
   Ishchenko Y, 2017, J PHARMACOL EXP THER, V361, P472, DOI 10.1124/jpet.116.238840
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464-410X.2010.09638.x
   Jiang W, 2017, PHYTOTHER RES, V31, P1298, DOI 10.1002/ptr.5849
   Kan BF, 2024, ANESTHESIOLOGY, V140, P765, DOI 10.1097/ALN.0000000000004880
   Köles L, 2007, CURR PHARM DESIGN, V13, P2368
   Lalich M, 2007, CANCER INVEST, V25, P785, DOI 10.1080/07357900701522588
   Laws S, 2019, J PALLIAT MED, V22, P1468, DOI 10.1089/jpm.2019.0481
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Liu L, 2025, MOL PAIN, V21, P0, DOI 10.1177/17448069251348778
   Liu QQ, 2020, PHARMACOL RES, V159, P0, DOI 10.1016/j.phrs.2020.104949
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu Wen-Hao, 2024, ZHEN CI YAN JIU, V49, P667, DOI 10.13702/j.1000-0607.20231005
   Liu XJ, 2012, J HUAZHONG U SCI-MED, V32, P291, DOI 10.1007/s11596-012-0051-5
   Liu XF, 2021, INT J BIOL SCI, V17, P4005, DOI 10.7150/ijbs.59032
   Liu ZQ, 2020, PROSTATE, V80, P782, DOI 10.1002/pros.23993
   Mantyh PW, 2019, BRIT J CLIN PHARMACO, V85, P1103, DOI 10.1111/bcp.13801
   Mao YT, 2020, ANESTHESIOLOGY, V132, P357, DOI 10.1097/ALN.0000000000003078
   Mao-Ying QL, 2012, MOL BRAIN, V5, P0, DOI 10.1186/1756-6606-5-16
   Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004
   Meng XW, 2019, EXP THER MED, V18, P4379, DOI 10.3892/etm.2019.8097
   Mestdagh F, 2023, CURR ONCOL, V30, P6838, DOI 10.3390/curroncol30070500
   Monteiro AC, 2024, BONE, V178, P0, DOI 10.1016/j.bone.2023.116932
   Ni HD, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919831909
   Pang J, 2023, BRAIN SCI, V13, P0, DOI 10.3390/brainsci13010152
   Parajulee A, 2023, BMB REP, V56, P527, DOI 10.5483/BMBRep.2023-0147
   Peters CM, 2004, NEUROSCIENCE, V126, P1043, DOI 10.1016/j.neuroscience.2004.04.027
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Qi PF, 2025, FRONT NEUROL, V16, P0, DOI 10.3389/fneur.2025.1587471
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Ren BX, 2012, ANESTHESIOLOGY, V116, P122, DOI 10.1097/ALN.0b013e31823de68d
   Romero-Morelos P, 2021, CURR NEUROPHARMACOL, V19, P308, DOI 10.2174/1570159X18666201111112748
   Russell FA, 2014, PHYSIOL REV, V94, P1099, DOI 10.1152/physrev.00034.2013
   Russo AF, 2023, PHYSIOL REV, V103, P1565, DOI 10.1152/physrev.00059.2021
   Sharp T, 2020, NEUROPHARMACOLOGY, V177, P0, DOI 10.1016/j.neuropharm.2020.108155
   Shi Ren-Yi, 2019, ZHEN CI YAN JIU, V44, P161, DOI 10.13702/j.1000-0607.180635
   Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y
   Tang J, 2022, DIS MARKERS, V2022, P0, DOI 10.1155/2022/8563202
   Tang YX, 2016, NEUROSCI LETT, V617, P108, DOI 10.1016/j.neulet.2016.01.053
   Tian SX, 2023, PURINERG SIGNAL, V19, P13, DOI 10.1007/s11302-022-09861-7
   Tu HA, 2021, TISSUE CELL, V68, P0, DOI 10.1016/j.tice.2020.101438
   VANDEKAR LD, 1991, ANNU REV PHARMACOL, V31, P289
   Versijpt J, 2025, LANCET, V405, P1014, DOI 10.1016/s0140-6736(25)00109-6
   Wang XJ, 2025, J PAIN RES, V18, P315, DOI 10.2147/JPR.S498466
   Wang YG, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918788681
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942
   Wu JX, 2012, EUR J PAIN, V16, P1378, DOI 10.1002/j.1532-2149.2012.00149.x
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yan ZB, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.925013
   Yang H, 2018, FRONT CELL NEUROSCI, V12, P0, DOI 10.3389/fncel.2018.00129
   Yetisir A, 2024, REV ASSOC MED BRAS, V70, P0, DOI 10.1590/1806-9282.20230264
   Yhdego H, 2021, 2021 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE, V0, P3137, DOI 10.1109/bibm52615.2021.9669795
   Yoneda T, 2021, J BONE ONCOL, V30, P0, DOI 10.1016/j.jbo.2021.100387
   Yuan Jiao, 2017, ZHONG NAN DA XUE XUE BAO YI XUE BAN, V42, P1257, DOI 10.11817/j.issn.1672-7347.2017.11.003
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20236047
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang JJ, 2023, J PHARM ANAL, V13, P0, DOI 10.1016/j.jpha.2023.06.008
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhao D, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919857981
   Zhao YX, 2024, MOL PAIN, V20, P0, DOI 10.1177/17448069241240692
   Zhong Xue-Mei, 2020, ZHONGGUO ZHEN JIU, V40, P405, DOI 10.13703/j.0255-2930.20190822-k0002
   Zhou KX, 2019, BRAIN RES BULL, V149, P137, DOI 10.1016/j.brainresbull.2019.04.009
NR 104
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD DEC 10
PY 2025
VL 16
IS 
BP 
EP 
DI 10.3389/fneur.2025.1693978
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AD0ZQ
UT WOS:001645272200001
PM 41451423
DA 2026-01-16
ER

PT J
AU Hershey, B
AF Hershey, Betsy
TI Integrative Veterinary Oncology Part II - Homeopathy, Acupuncture, Manual Therapies, Oxygen Therapies, Energy Work and Phototherapies
SO VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE
LA English
DT Article
DE Integrative veterinary oncology; Supportive care veterinary oncology; Palliative care veterinary oncology
ID massage therapy; singing bowl; cancer-patients; ozone therapy; fatigue; trial; metaanalysis; meditation; pain
C1 [Hershey, Betsy] Integrat Vet Oncol, 2501 N 32nd St, Phoenix, AZ 85008 USA.
RP Hershey, B (corresponding author), Integrat Vet Oncol, 2501 N 32nd St, Phoenix, AZ 85008 USA.
EM bhershey32@yahoo.com
CR Aghabati N, 2010, EVID-BASED COMPL ALT, V7, P375, DOI 10.1093/ecam/nen006
   Unknown -, 2008, INTEGRATING COMPLEMENTARY MEDICINE INTO VETERINARY PRACTICE, V0, P0
   Anschau F, 2019, LASER MED SCI, V34, P1053, DOI 10.1007/s10103-019-02722-7
   Bagot JL, 2021, SUPPORT CARE CANCER, V29, P5873, DOI 10.1007/s00520-021-06137-5
   Bennett MH, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004739.pub2
   Bidin L, 2016, EUR J INTEGR MED, V8, P747, DOI 10.1016/j.eujim.2016.06.003
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Chen Xiaowei, 2020, NAN FANG YI KE DA XUE XUE BAO, V40, P1488, DOI 10.12122/j.issn.1673-4254.2020.10.15
   Chitapanarux I, 2025, CANCER REP-US, V8, P0, DOI 10.1002/cnr2.70109
   Choi KH, 2017, J ACUPUNCT MERIDIAN, V10, P211, DOI 10.1016/j.jams.2017.04.005
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Ciborowski M, 2012, J PROTEOME RES, V11, P6231, DOI 10.1021/pr3008946
   Clavo B, 2005, J ALTERN COMPLEM MED, V11, P539, DOI 10.1089/acm.2005.11.539
   Clavo B, 2025, INTEGR CANCER THER, V24, P0, DOI 10.1177/15347354241307038
   Clavo B, 2021, PAIN MED, V22, P2138, DOI 10.1093/pm/pnaa459
   Clavo B, 2013, J PAIN SYMPTOM MANAG, V46, P106, DOI 10.1016/j.jpainsymman.2012.06.017
   Cole JS, 2024, GLOB ADV INTEGR MED, V13, P0, DOI 10.1177/27536130241245099
   Collinge W, 2013, SUPPORT CARE CANCER, V21, P1405, DOI 10.1007/s00520-012-1682-6
   Di Fede O, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11185307
   Evans Ronald C, 2005, SEMIN ONCOL NURS, V21, P184, DOI 10.1016/j.soncn.2005.04.007
   Frass M, 2020, ONCOLOGIST, V25, PE1930, DOI 10.1002/onco.13548
   Freitas KABDS, 2020, REVISTA NURSING, V23, P4975
   Freitas KABD, 2021, REV ESC ENFERM USP, V55, P0, DOI 10.1590/1980-220X-REEUSP-2020-0527
   Frenkel M, 2015, CURR ONCOL REP, V17, P0, DOI 10.1007/s11912-015-0467-8
   Goldsby TL, 2017, J EVID-BASED INTEGR, V22, P401, DOI 10.1177/2156587216668109
   Grognet J, 2014, JOURNAL OF THE AMERICAN HOLISTIC VETERINARY MEDICAL ASSOCIATION, V35, P28
   Heudel PE, 2019, SUPPORT CARE CANCER, V27, P1879, DOI 10.1007/s00520-018-4449-x
   Izzotti A, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14051174
   Jiang Y, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028860
   Johnston MF, 2007, INTEGR CANCER THER, V6, P36, DOI 10.1177/1534735406298903
   Jonas WB, 2006, INTEGR CANCER THER, V5, P343, DOI 10.1177/1534735406294225
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Kawasoe Y, 2009, ONCOL REP, V22, P1045, DOI 10.3892/or_00000534
   Kilmartin L, 2020, LASER MED SCI, V35, P95, DOI 10.1007/s10103-019-02798-1
   Kinkead B, 2018, CANCER-AM CANCER SOC, V124, P546, DOI 10.1002/cncr.31064
   Lana SE, 2006, J AM ANIM HOSP ASSOC, V42, P361, DOI 10.5326/0420361
   Landry JM, 2014, AM J HEALTH PROMOT, V28, P306, DOI 10.4278/ajhp.121031-ARB-528
   Laoudikou Maria Tsampika, 2020, J CAN CHIROPR ASSOC, V64, P32
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Li YC, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241226667
   Martin R, 2003, PRACTICAL PAIN MANAG, V3, P20
   Matourypour P, 2016, J NURS MIDWIFERY RES, V21, P255
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Nwabudike LC, 2019, HOMEOPATHY, V108, P277, DOI 10.1055/s-0039-1687822
   Paglioni MD, 2019, ORAL ONCOL, V93, P21, DOI 10.1016/j.oraloncology.2019.04.004
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Rio-Alamos C, 2023, EUR J INVEST HEALTH, V13, P317, DOI 10.3390/ejihpe13020024
   Ripamonti CI, 2012, J BONE ONCOL, V1, P81, DOI 10.1016/j.jbo.2012.08.001
   Ripamonti CI, 2011, ORAL ONCOL, V47, P185, DOI 10.1016/j.oraloncology.2011.01.002
   Robijns J, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.927685
   Rose WJ, 2017, ANIM HEALTH RES REV, V18, P177, DOI 10.1017/S1466252317000068
   Rostock M, 2011, BMC CANCER, V11, P0, DOI 10.1186/1471-2407-11-19
   Saha S, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-230
   Samadder A, 2013, J ACUPUNCT MERIDIAN, V6, P180
   Samuel SR, 2021, J CANCER SURVIV, V15, P799, DOI 10.1007/s11764-020-00972-x
   Schlappack O, 2004, HOMEOPATHY, V93, P210, DOI 10.1016/j.homp.2004.06.004
   Serra-Añó P, 2019, SUPPORT CARE CANCER, V27, P2633, DOI 10.1007/s00520-018-4544-z
   Silva LP, 2024, ANTIOXIDANTS-BASEL, V13, P0, DOI 10.3390/antiox13060673
   Sorrentino L, 2017, J INTERCULT ETHNOPHA, V6, P1, DOI 10.5455/jice.20161229055245
   Tirelli U, 2023, EUR REV MED PHARMACO, V27, P11643, DOI 10.26355/eurrev_202312_34602
   Tirelli U, 2018, EUR REV MED PHARMACO, V22, P8030, DOI 10.26355/eurrev_201811_16432
   Tsang KL, 2007, INTEGR CANCER THER, V6, P25, DOI 10.1177/1534735406298986
   Wang T, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9967574
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Yan ZB, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.925013
   Zhang YY, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033939
NR 66
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0195-5616
EI 1878-1306
J9 VET CLIN N AM-SMALL
JI Vet. Clin. N. Am.-Small Anim. Pract.
PD NOV 15
PY 2025
VL 55
IS 6
BP 1177
EP 1191
DI 10.1016/j.cvsm.2025.07.004
EA OCT 2025
PG 15
WC Veterinary Sciences
SC Veterinary Sciences
GA 9NQ5Y
UT WOS:001610670500015
PM 40883158
DA 2026-01-16
ER

PT J
AU Tan, J
   Feng, Y
   Liu, H
   Zhou, Y
   Cai, J
   Jiang, Y
   Li, P
   Gu, L
   Song, Z
AF Tan, Jing
   Feng, Yong
   Liu, Hui
   Zhou, Yihu
   Cai, Jiaqin
   Jiang, Yueyi
   Li, Pengyi
   Gu, Lianbing
   Song, Zhenghuan
TI Effect of press needle stimulation on postoperative pulmonary complications in
SO Annals of medicine
LA English
DT Journal Article
DE Press needle; postoperative pain control; postoperative pulmonary complications; video-assisted thoracoscopic surgery
AB BACKGROUND: Patients undergoing high-risk surgical procedures frequently  experience postoperative pulmonary complications (PPCs) that impact outcomes.  Acupuncture has demonstrated potential benefits during surgery. Press needle  stimulation is increasingly recognized as an alternative to conventional  techniques. We aimed to evaluate the effect of press needle stimulation on PPCs  in patients with lung cancer undergoing video-assisted thoracoscopic surgery.  METHODS: Eighty-seven patients undergoing video-assisted thoracoscopic surgery  were randomized into press needle (n = 48) or sham needle (n = 39) groups. The  press needle group underwent bilateral stimulation of acupoints LU9 (Taiyuan),  RN17 (Danzhong), LU6 (Kongzui), and BL13 (Feishu) before anesthesia and during  surgery. The sham group received a placebo stimulation. The primary endpoint was  the incidence of PPCs within seven days post-surgery. The secondary endpoints  included cytokine levels, intraoperative respiratory mechanics, postoperative  pain score, analgesic consumption, and related complications. RESULTS: Press  needle acupoint stimulation was associated with a significantly lower incidence  of PPCs than the sham needle group. Perioperative data, tachycardia, cough,  postoperative nausea, vomiting, and most inflammatory markers exhibited no  significant differences, except for lower hypoxia-inducible factor-1α levels in  the press needle group. Hemodynamic and blood gas analyses indicated no  significant cardiovascular or respiratory differences between groups. The press  needle group exhibited reduced patient-controlled analgesia (PCA) pump  utilization and lower total PCA usage, indicating improved pain management.  CONCLUSION: This study indicates that press needle stimulation lowers PPC  incidence and improves postoperative analgesia in patients with lung cancer  undergoing video-assisted thoracoscopic lobectomy.
C1 Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
   Department of Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer 
   Nanjing Medical University, Nanjing, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
   Xuzhou Medical University, Xuzhou, People's Republic of China.
   Department of Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
   Xuzhou Medical University, Xuzhou, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
   Department of Radiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer 
   Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, People's Republic of China.
NR 0
TC 0
SN 1365-206
EI 0785-389
J9 Ann Med
PD SEP 15
PY 2025
VL 57
IS 1
BP 2560684
EP 2560684
DI 10.1080/07853890.2025.2560684
PG 0
WC Humans; Thoracic Surgery, Video-Assisted; adverse effects; Male; Female; Middle Aged; Aged; Lung Neoplasms; surgery; Postoperative Complications; prevention & control; Acupuncture Therapy; methods; Pain, Postoperative; prevention & control; Acupuncture Points; Lung Diseases; etiology; Needles; Treatment Outcome
UT PubMed:40953233
PM 40953233
DA 2025-09-15
ER

PT J
AU Pan, WT
   Ji, MH
   Ma, D
   Yang, JJ
AF Pan, Wei-Tong
   Ji, Mu-Huo
   Ma, Daqing
   Yang, Jian-Jun
TI Effect of perioperative autonomic nervous system imbalance on surgical outcomes:
SO British journal of anaesthesia
LA English
DT Journal Article
DE autonomic nervous system; parasympathetic tone; perioperative autonomic imbalance; perioperative outcomes; vagus nerve stimulation
AB The autonomic nervous system (ANS) is essential for maintaining physiological  homeostasis. Autonomic nervous system imbalance, characterised by sympathetic  hyperactivation and low parasympathetic tone, can occur during the perioperative  period. These changes drive systemic stress responses, cardiovascular  instability, impaired tissue repair, and immunosuppression, which in turn  increase infection risk, neurocognitive decline, and multiorgan dysfunction.  Surgical trauma, anaesthesia, pain, hypothermia, and psychological stressors all  contribute to this dysregulation, and consequently low parasympathetic tone  results in the cholinergic anti-inflammatory pathway being less effective. High  sympathetic nervous system activity promotes catecholamine surges and  pro-inflammatory cytokine release. Pharmacological interventions, including  dexmedetomidine and β-blockers, together with nonpharmacological strategies, such  as electroacupuncture and temperature management, are measures that have  potential to restore ANS balance. This systematic review covers ANS-mediated  organ regulation, pathophysiological consequences of perioperative dysautonomia,  and evidence-based therapeutic strategies. By integrating findings from multiple  basic and clinical studies, the pivotal roles of ANS modulation in mitigating  postoperative complications, including neurocognitive disorders,  immunosuppression, and cancer recurrence, are discussed. Maintaining balance of  the sympathetic and parasympathetic nervous systems is an important prospect in  perioperative medicine that could benefit surgical patients' short- or long-term  recovery.
C1 Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Neuroscience Research Institute, Zhengzhou University Academy of MedicalSciences, Zhengzhou, Henan, China.
   Department of Anesthesiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
   Perioperative and Systems Medicine Laboratory and Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National ClinicalResearch Center for Child Health, Hangzhou, Zhejiang, China
   Department ofAnesthesiology, The First Affiliated Hospital, Ningbo University, Ningbo,Zhejiang, China
   Division of Anaesthetics, Pain Medicine & Intensive Care,Department of Surgery & Cancer, Faculty of Medicine, Imperial College London,Chelsea & Westminster Hospital, London, UK. 
   Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Neuroscience Research Institute, Zhengzhou University Academy of MedicalSciences, Zhengzhou, Henan, China.
EM yjyangjj@126.com
NR 0
TC 0
SN 1471-677
EI 0007-091
J9 Br J Anaesth
PD JUL 5
PY 2025
VL 135
IS 3
BP 608
EP 622
DI 10.1016/j.bja.2025.06.004
PG 14
WC Humans; Autonomic Nervous System; physiopathology; Postoperative Complications; physiopathology; Perioperative Care; methods; Autonomic Nervous System Diseases; physiopathology; Treatment Outcome
UT PubMed:40615330
PM 40615330
DA 2025-07-05
ER

PT J
AU Wei, R
   Huang, Z
AF Wei, Ran
   Huang, Zuozhen
TI Acupuncture-induced pain relief and anti-inflammatory effects in chronic pelvic
SO American journal of translational research
LA English
DT Review
DE Acupuncture and moxibustion; anti-inflammatory; chronic pelvic inflammatory disease; pain relief; pelvic mass regression; smooth fallopian tubes
AB OBJECTIVE: To systematically evaluate the effects of acupuncture and moxibustion  on pain relief, inflammatory biomarkers, and reproductive outcomes in patients  with chronic pelvic inflammatory disease (CPID). METHOD: A systematic search was  conducted in PubMed, Embase, Cochrane Library, CNKI, and Wanfang for studies  published between January 2010 and December 2023. Randomized controlled trials  (RCTs) comparing acupuncture with sham/conventional control interventions in CPID  patients were included. The primary outcomes included pain intensity (visual  analog scale, VAS), inflammatory biomarkers (C-reactive protein [CRP],  interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α]), and CPID specific  indicators (fallopian tube patency and pelvic mass regression). Data were  analyzed using a random-effects model (RevMan 5.3/Stata 16). RESULT: Thirteen  RCTs involving 658 patients were included. Acupuncture significantly reduced pain  intensity (standardized mean deviation [SMD]=-1.42, 95% confidence interval [CI]:  -1.66 to -1.18), CRP (SMD=-3.89), IL-6 (SMD=-5.00), TNF-α (SMD=0.60) (all  P<0.001). CPID-specific outcomes were improved, with higher rates of fallopian  tube patency (hazard ratio [RR] =1.35) and pelvic mass regression (RR=1.44; both  P<0.01). Moreover, acupuncture improved quality of life (SMD=0.55, P<0.0001),  increased pregnancy rate (RR=1.32), and reduced recurrence rates (RR=0.68; both  P<0.05). Electroacupuncture combined with herbal medicine (≥8 weeks) showed the  most pronounced therapeutic benefits. CONCLUSION: Electroacupuncture combined  with herbal medicine significantly alleviates pelvic pain, reduces systemic  inflammation, and enhances reproductive outcomes in patients with CPID.
C1 College of Ancient Chinese Studies, Beijing University of Chinese Medicine Beijing 100029, China.
   College of Ancient Chinese Studies, Beijing University of Chinese Medicine Beijing 100029, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD DEC 19
PY 2025
VL 17
IS 11
BP 8985
EP 8998
DI 10.62347/GLPQ2895
PG 13
UT PubMed:41415097
PM 41415097
DA 2025-12-19
ER

PT J
AU Li, S
   Dai, AH
   Zhou, YH
   Chen, X
   Chen, YZ
   Zhou, L
   Yang, XL
   Yue, MQ
   Shi, J
   Qiu, Y
AF Li, Song
   Dai, Anhong
   Zhou, Yihao
   Chen, Xu
   Chen, Yizhou
   Zhou, Li
   Yang, Xiaolin
   Yue, Mengqi
   Shi, Jing
   Qiu, Yong
TI Hotspots and trends in acupuncture combined with non-invasive neuromodulation technology in the past 20 years: a bibliometric analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE acupuncture; non-invasive neuromodulation technology; transcutaneous electrical acupoint stimulation; analgesia; visualization analysis; bibliometric
ID electrical acupoint stimulation; transcranial magnetic stimulation; general-anesthesia; pain; therapy; electroacupuncture; recovery; cancer; pretreatment; modulation
AB Background: Non-invasive neuromodulation (NIN) technology, a promising approach in the field of neuromodulation, has been employed to address a diverse array of disorders, with an increasing volume of research emerging. Traditional Chinese acupuncture has also been utilized as a complementary and preventive therapy for various ailments. Nevertheless, the publication trends and research hotspots at the intersection of acupuncture and NIN technology remain largely unexplored. This study aims to systematically analyze the publication trends and research hotspots related to the convergence of acupuncture and NIN over the past two decades using bibliometric methods. Methods: We collected literature data on the combination of acupuncture and NIN technology from January 1, 2004, to December 31, 2023, utilizing the Web of Science Core Collection (WOSCC) database. This data was imported into CiteSpace (version 6.2. R4) and RStudio to facilitate a visual analysis of research hotspots and trends, categorized by author, country/region, affiliation, annual publication, keywords, and journal. Results: A total of 803 articles were retrieved, encompassing contributions from 55 countries, 468 research institutions, and 360 academic journals. The People's Republic of China leads in publication volume with 390 articles, followed by Capital Medical University and Peking University, each contributing 27 articles. Among the authors, HAN JS has the highest number of co-citations, totaling 142. Additionally, the journal Evidence-Based Complementary and Alternative Medicine is noted for publishing the most papers in this field. Recent research hotspots regarding acupuncture combined with NIN technology primarily focus on topics such as "postoperative gastrointestinal function," "postoperative analgesia," "postoperative nausea and vomiting," "acupuncture analgesia," "reproductive medicine," "inflammation," "chronic low back pain," and "postoperative pain." The predominant intervention method identified is TEAS technology, which integrates acupuncture with modern electrical stimulation as an innovative clinical treatment approach. Conclusion: The publications on acupuncture combined with NIN technology have made significant progress; however, there is still a need to strengthen international academic exchanges and cooperation among scientific researchers and institutions to promote interdisciplinary collaboration and academic innovation. Furthermore, future studies should focus on enhancing the overall quality of research outcomes in this field and reinforcing research programs.
C1 [Li, Song] Heilongjiang Univ Chinese Med, Clin Med Coll 2, Harbin, Peoples R China.
   [Li, Song; Zhou, Yihao; Shi, Jing] Yunnan Univ Chinese Med, Affiliated Hosp 1, Yunnan Prov Hosp Tradit Chinese Med, Dept Acupuncture & Moxibust, Kunming, Peoples R China.
   [Dai, Anhong] Kunming Med Univ, Yanan Hosp, Dept Rehabil Med, Kunming, Peoples R China.
   [Chen, Xu; Chen, Yizhou; Zhou, Li; Yang, Xiaolin; Yue, Mengqi; Qiu, Yong] Yunnan Univ Tradit Chinese Med, Kunming, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Yunnan University of Chinese Medicine; Kunming Medical University; Yunnan University of Chinese Medicine
RP Shi, J (corresponding author), Yunnan Univ Chinese Med, Affiliated Hosp 1, Yunnan Prov Hosp Tradit Chinese Med, Dept Acupuncture & Moxibust, Kunming, Peoples R China.; Qiu, Y (corresponding author), Yunnan Univ Tradit Chinese Med, Kunming, Peoples R China.
EM 2662831291@qq.com; 2225851674@qq.com
FU National Natural Science Foundation of China [81760893]; Fundamental Research Key Project of Yunnan Science and Technology Department [202101AZ070001-165]; Special Project for Famous Doctors of "Xingdian Talent Support Program" in Yunnan Province
CR Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Bange M, 2025, NPJ PARKINSONS DIS, V11, P0, DOI 10.1038/s41531-025-00908-1
   Botzanowski B, 2025, BIOELECTRON MED-US, V11, P0, DOI 10.1186/s42234-025-00169-6
   Brenner B, 2022, CURR PAIN HEADACHE R, V26, P709, DOI 10.1007/s11916-022-01081-3
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Deng XY, 2024, INTERN EMERG MED, V19, P839, DOI 10.1007/s11739-024-03562-2
   Ding LLQ, 2023, J SPINAL CORD MED, V46, P798, DOI 10.1080/10790268.2022.2088498
   Feng B, 2019, PSYCHIAT CLIN NEUROS, V73, P179, DOI 10.1111/pcn.12810
   George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87
   Grenouillet S, 2025, SUPPORT CARE CANCER, V33, P0, DOI 10.1007/s00520-025-09378-w
   Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024
   Gu T, 2018, J PAIN RES, V11, P889, DOI 10.2147/JPR.S162696
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Han JZ, 2024, AGEING RES REV, V99, P0, DOI 10.1016/j.arr.2024.102355
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hong ES, 2021, J SPINAL CORD MED, V44, P364, DOI 10.30528/jolss.2019.9.3.001
   Hou LL, 2016, J TRADIT CHIN MED, V36, P450
   Hu R, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8859672
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Huo CC, 2024, NEURAL REGEN RES, V19, P1517, DOI 10.4103/1673-5374.387970
   Jayathilake NJ, 2025, EXP MOL MED, V57, P501, DOI 10.1038/s12276-025-01409-0
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Kanai R, 2008, CURR BIOL, V18, P1839, DOI 10.1016/j.cub.2008.10.027
   Kwon M, 2014, PAIN PRACT, V14, P656, DOI 10.1111/papr.12145
   Lamos M, 2025, MOVEMENT DISORD, V40, P1051, DOI 10.1002/mds.30134
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Li RR, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1045763
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Li YX, 2023, J PAIN RES, V16, P1835, DOI 10.2147/JPR.S400362
   Ling FY, 2023, J PAIN RES, V16, P985, DOI 10.2147/JPR.S395421
   Liu LS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019610
   Liu YQ, 2024, J PAIN RES, V17, P1107, DOI 10.2147/JPR.S452971
   Luff CE, 2024, BRAIN STIMUL, V17, P92, DOI 10.1016/j.brs.2023.12.010
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   Markenson Joseph A, 1996, AMERICAN JOURNAL OF MEDICINE, V101, P0
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Missey F, 2023, BIOELECTRON MED-US, V9, P0, DOI 10.1186/s42234-023-00120-7
   Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x
   Park KS, 2023, BIOMED ENG LETT, V13, P329
   Paulasir S, 2015, DIS COLON RECTUM, V58, P870, DOI 10.1097/DCR.0000000000000430
   Pei P, 2019, ACUPUNCT MED, V37, P47, DOI 10.1136/acupmed-2017-011410
   Polania R, 2018, NAT NEUROSCI, V21, P174, DOI 10.1038/s41593-017-0054-4
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Rong PJ, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-255
   SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489
   Song QF, 2023, NEURAL REGEN RES, V18, P1861, DOI 10.4103/1673-5374.367838
   Steinhoff MS, 2014, PHYSIOL REV, V94, P265, DOI 10.1152/physrev.00031.2013
   Szymoniuk M, 2023, NEUROSURG REV, V46, P0, DOI 10.1007/s10143-023-02032-1
   Tsuda M, 2013, GLIA, V61, P55, DOI 10.1002/glia.22379
   Uzair M, 2022, NEURAL REGEN RES, V17, P251, DOI 10.4103/1673-5374.317962
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang J, 2019, ADV EXP MED BIOL, V1101, P207, DOI 10.1007/978-981-13-2050-7_8
   Wang Q, 2024, MOL PAIN, V20, P0, DOI 10.1177/17448069241254201
   Wang X, 2016, NEURAL REGEN RES, V11, P2004, DOI 10.4103/1673-5374.197145
   Wang Y, 2024, INT J SURG, V110, P3962, DOI 10.1097/JS9.0000000000001251
   Wei H, 2022, CHIN J INTEGR MED, V28, P730, DOI 10.1007/s11655-022-3516-1
   Wei Z, 2018, FRONT MOL NEUROSCI, V11, P0, DOI 10.3389/fnmol.2018.00411
   Wu MY, 2024, AUTOPHAGY, V20, P1442, DOI 10.1142/S0192415X2450037X
   Xu HY, 2021, J NEUROTRAUM, V38, P734, DOI 10.1089/neu.2020.7155
   Xue ZZ, 2019, LIFE SCI, V233, P0, DOI 10.1016/j.lfs.2019.116749
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhang J, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.1035895
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
   Zhang TT, 2021, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.756366
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou RJ, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1006830
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhou ZD, 2020, MOL MED REP, V22, P751, DOI 10.3892/mmr.2020.11161
NR 71
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 9
PY 2025
VL 16
IS 
BP 
EP 
DI 10.3389/fneur.2025.1511655
PG 18
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 7RN2X
UT WOS:001577946900001
PM 40994712
DA 2026-01-16
ER

PT J
AU Qu, SY
   Wang, HZ
   Hu, QQ
   Ma, YQ
   Kang, YR
   Ma, LQ
   Li, X
   Chen, LH
   Liu, BY
   Shao, XM
   Liu, BY
   Du, JY
   Liang, Y
   Zhao, HL
   Jiang, YL
   Fang, JQ
   He, XF
AF Qu, Si-ying
   Wang, Han-zhi
   Hu, Qun-qi
   Ma, Yi-qi
   Kang, Yu-rong
   Ma, Li-qian
   Li, Xiang
   Chen, Lu-hang
   Liu, Bo-yu
   Shao, Xiao-mei
   Liu, Bo-yi
   Du, Jun-ying
   Liang, Yi
   Zhao, Hong-li
   Jiang, Yong-liang
   Fang, Jian-qiao
   He, Xiao-fen
TI Electroacupuncture may alleviate diabetic neuropathic pain by inhibiting the microglia P2X4R and neuroinflammation
SO PURINERGIC SIGNALLING
LA English
DT Article
DE Electroacupuncture; Diabetic neuropathic pain; Spinal cord; Microglia
ID peripheral-nerve injury; spinal microglia; up-regulation; mechanical allodynia; p2x(4) receptors; rat model; streptozotocin; activation; cord; expression
AB Diabetic neuropathic pain (DNP) is a common and destructive complication of diabetes mellitus. The discovery of effective therapeutic methods for DNP is vitally imperative because of the lack of effective treatments. Although 2 Hz electroacupuncture (EA) was a successful approach for relieving DNP, the mechanism underlying the effect of EA on DNP is still poorly understood. Here, we established a rat model of DNP that was induced by streptozotocin (STZ) injection. P2X4R was upregulated in the spinal cord after STZ-injection. The upregulation of P2X4R was mainly expressed on activated microglia. Intrathecal injection of a P2X4R antagonist or microglia inhibitor attenuated STZ-induced nociceptive thermal hyperalgesia and reduced the overexpression of brain-derived neurotrophic factor (BDNF), interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in the spinal cord. We also assessed the effects of EA treatment on the pain hypersensitivities of DNP rats, and further investigated the possible mechanism underlying the analgesic effect of EA. EA relieved the hyperalgesia of DNP. In terms of mechanism, EA reduced the upregulation of P2X4R on activated microglia and decreased BDNF, IL-1 beta and TNF-alpha in the spinal cord. Mechanistic research of EA's analgesic impact would be beneficial in ensuring its prospective therapeutic effect on DNP as well as in extending EA's applicability.
C1 [Qu, Si-ying; Wang, Han-zhi; Hu, Qun-qi; Ma, Yi-qi; Kang, Yu-rong; Ma, Li-qian; Li, Xiang; Chen, Lu-hang; Liu, Bo-yu; Shao, Xiao-mei; Liu, Bo-yi; Du, Jun-ying; Liang, Yi; Jiang, Yong-liang; Fang, Jian-qiao; He, Xiao-fen] Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China.
   [Wang, Han-zhi; Zhao, Hong-li] Zhejiang Chinese Med Univ, Hangzhou Hosp Tradit Chinese Med, Dept TCM Gynecol, Hangzhou 310000, Peoples R China.
   [Liu, Bo-yu; Shao, Xiao-mei; Liu, Bo-yi; Du, Jun-ying; Liang, Yi; Jiang, Yong-liang; Fang, Jian-qiao; He, Xiao-fen] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Jiang, YL; Fang, JQ; He, XF (corresponding author), Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China.; Jiang, YL; Fang, JQ; He, XF (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou 310053, Zhejiang, Peoples R China.
EM jyl2182@126.com; fangjianqiao7532@163.com; zjhxf1986@163.com
FU National Natural Science Foundation of China [81804181, 81774389]; Natural Science Foundation of Zhejiang Province of China [LY22H270006]; Research Fund for Zhejiang Traditional Chinese Medicine University Affiliated Hospital [2022FSYYZZ09]; Key Laboratory of Acupuncture and Neurology of Zhejiang Province [2019E10011]
CR Abbott CA, 2011, DIABETES CARE, V34, P2220, DOI 10.2337/dc11-1108
   Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605
   Butovsky O, 2018, NAT REV NEUROSCI, V19, P622, DOI 10.1038/s41583-018-0057-5
   Chen XM, 2015, BRIT J ANAESTH, V114, P150, DOI 10.1093/bja/aeu199
   Cheng KI, 2014, EUR J PAIN, V18, P162, DOI 10.1002/j.1532-2149.2013.00356.x
   Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7
   Deng ZY, 2018, BRAIN RES BULL, V142, P138, DOI 10.1016/j.brainresbull.2018.07.003
   El-Hossary N, 2016, DIABETES RES CLIN PR, V121, P102, DOI 10.1016/j.diabres.2016.09.008
   Erbas O, 2016, DIABETES RES CLIN PR, V114, P106, DOI 10.1016/j.diabres.2015.12.016
   Fan WJ, 2017, CARDIOVASC ENDOCRINO, V6, P8, DOI 10.1097/XCE.0000000000000116
   Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, P0, DOI 10.3389/fncel.2013.00045
   Gu YX, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8861994
   Hao LJ, 2021, NEUROSCIENCE, V463, P216, DOI 10.1016/j.neuroscience.2021.03.009
   He XF, 2017, J ZHEJIANG UNIV-SC B, V18, P239, DOI 10.1631/jzus.B1600247
   Hu QQ, 2023, PURINERG SIGNAL, V19, P29, DOI 10.1007/s11302-022-09844-8
   Inoue K, 2021, PURINERG SIGNAL, V17, P41, DOI 10.1007/s11302-020-09743-w
   Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Khakh BS, 2012, NEURON, V76, P51, DOI 10.1016/j.neuron.2012.09.024
   Kim C, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21091253
   Lee JY, 2019, J GINSENG RES, V43, P58
   Li J, 2017, PURINERG SIGNAL, V13, P13, DOI 10.1007/s11302-016-9537-0
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Manitz MP, 2016, BRAIN RES, V1636, P172, DOI 10.1016/j.brainres.2016.02.004
   Miao JY, 2012, NEUROSCI RES, V74, P269, DOI 10.1016/j.neures.2012.09.001
   Morrow Thomas J, 2004, CURR PROTOC NEUROSCI, VChapter 9, P0, DOI 10.1002/0471142301.ns0918s29
   Peltier A, 2014, BMJ-BRIT MED J, V348, P0, DOI 10.1136/bmj.g1799
   Qin ZL, 2020, SAUDI J BIOL SCI, V27, P2485, DOI 10.1016/j.sjbs.2020.05.043
   Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397
   Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Shin KM, 2018, DIABETES CARE, V41, PE141, DOI 10.2337/dc18-1254
   Smith PA, 2014, NEUROSCIENCE, V283, P107, DOI 10.1016/j.neuroscience.2014.05.044
   Snyder MJ, 2016, AM FAM PHYSICIAN, V94, P227
   Sun JS, 2015, MOL MED REP, V12, P2677, DOI 10.3892/mmr.2015.3735
   Szkudelski T, 2001, PHYSIOL RES, V50, P537
   Teng YB, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1631-0
   Tozaki-Saitoh H, 2019, GLIA, V67, P729, DOI 10.1002/glia.23570
   Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009
   Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786
   Tsuda M, 2016, NEUROPHARMACOLOGY, V104, P76, DOI 10.1016/j.neuropharm.2015.08.042
   Tsuda M, 2016, J DIABETES INVEST, V7, P17, DOI 10.1111/jdi.12379
   Tsuda M, 2013, J PHARMACOL SCI, V121, P89, DOI 10.1254/jphs.12R14CP
   Tsuda M, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-28
   Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008
   Vázquez-Villoldo N, 2014, GLIA, V62, P171, DOI 10.1002/glia.22596
   Wang FX, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep19396
   Yan Y, 2019, NEUROSCI LETT, V701, P100, DOI 10.1016/j.neulet.2019.02.024
   Zabala A, 2018, EMBO MOL MED, V10, P0, DOI 10.15252/emmm.201708743
   Zhang JQ, 2020, SAUDI J BIOL SCI, V27, P3138, DOI 10.1016/j.sjbs.2020.07.013
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
   Zhang Z, 2008, NEUROSCIENCE, V152, P495, DOI 10.1016/j.neuroscience.2007.12.042
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
   Zhou R, 2018, J PAIN RES, V11, P615, DOI 10.2147/JPR.S154437
NR 55
TC 15
Z9 15
U1 4
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-9538
EI 1573-9546
J9 PURINERG SIGNAL
JI Purinergic Signal.
PD AUG 15
PY 2025
VL 21
IS 4
BP 533
EP 547
DI 10.1007/s11302-023-09972-9
EA OCT 2023
PG 15
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 7PA8H
UT WOS:001087983000001
PM 37870716
DA 2026-01-16
ER

PT J
AU Fan, D
   Ren, H
AF Fan, Dihui
   Ren, Hongbin
TI Clinical value of warm acupuncture combined with Jiaji acupoint Tongbian scraping
SO Medicine
LA English
DT Journal Article
DE Jiaji acupoint Tongbian scraping therapy; myofascial pain syndrome; warm acupuncture; wind-cold-dampness obstruction syndrome
AB This study investigates the clinical value of warm acupuncture combined with  Jiaji acupoint Tongbian scraping therapy in patients with myofascial pain  syndrome (MPS) of the lumbar and dorsal muscles with wind-cold-dampness  obstruction syndrome. A total of 112 patients with wind-cold-dampness  obstruction-type MPS admitted to our hospital from January 2024 to October 2024  were enrolled. According to different treatment methods, they were assigned into  the control group (n = 35, Jiaji acupoint Tongbian scraping therapy), observation  group (n = 35, warm acupuncture), and combination group (n = 42, warm acupuncture  combined with Jiaji acupoint Tongbian scraping therapy). The following indicators  were compared before and after treatment: Traditional Chinese Medicine (TCM)  syndrome scores, visual analog scale (VAS) scores, Oswestry Disability Index  (ODI) scores, Modified Barthel Index (MBI) scores, serum inflammatory cytokines  (interleukin-6, tumor necrosis factor-α, interleukin-1β), clinical efficacy, and  incidence of adverse reactions. After treatment, serum inflammatory cytokine  levels, TCM syndrome scores, VAS, and ODI scores were significantly lower in the  combination group than in the control and observation groups, while the MBI score  was significantly higher (F = 22.340, 11.200, 17.130, 40.120, 4.850, 20.960,  14.680; P < .05). The overall effective rate in the combination group (95.24%)  was significantly higher than that in the control group (74.29%) and the  observation group (77.14%) (χ2 = 7.205, P < .05). The incidence of adverse  reactions in the combination group (16.67%) showed no significant difference  compared with the control group (11.43%) and the observation group (14.29%)  (χ2 = 0.428, P > .05). Warm acupuncture combined with Jiaji acupoint Tongbian  scraping therapy can effectively improve clinical symptoms and functional  impairment, reduce pain and inflammatory levels, and enhance activities of daily  living, without significantly increasing adverse reactions. This combined  approach demonstrates high clinical efficacy.
C1 Department of Acupuncture and Moxibustion, Jiaxing Traditional Chinese Medicine Hospital, Jiaxing, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD DEC 30
PY 2025
VL 104
IS 52
BP e46161
EP e46161
DI 10.1097/MD.0000000000046161
PG 1
WC Humans; Male; Female; Acupuncture Therapy; methods; Myofascial Pain Syndromes; therapy; Acupuncture Points; Middle Aged; Adult; Treatment Outcome; Pain Measurement; Medicine, Chinese Traditional; methods; Combined Modality Therapy; Lumbosacral Region
UT PubMed:41465915
PM 41465915
DA 2025-12-30
ER

PT J
AU Bauer-Büntzel, C
   Büntzel, J
AF Bauer-Buntzel, Christoph
   Buntzel, Judith
TI Complementary approaches to treating radiation-induced side effects in the pelvis and chemotherapy-associated neuropathy
SO ONKOLOGIE
LA German
DT Review; Early Access
DE Neuropathic pain; Pelvic organ toxicity after radiotherapy; Peripheral nerve damage; Integrative oncology; Integrative oncology; Pelvic organ toxicity after radiotherapy; Peripheral nerve damage; Supportive care; Integrative oncology
ID placebo-controlled trial; induced peripheral neuropathy; double-blind; breast-cancer; radiotherapy; multicenter; prevention; women
AB Background: In uro-oncological diseases such as prostate cancer and urothelial carcinoma, multimodal treatment concepts combining radiation and systemic therapy are frequently applied. These approaches often lead to radiogenic side effects in the pelvis and chemotherapy-induced peripheral neuropathies (CIPN). Complementary and integrative medicine is increasingly used to alleviate therapy-related toxicities. Methods: Based on current German S3 guidelines and published clinical studies, complementary and integrative approaches for managing radiogenic adverse effects and CIPN were reviewed and evaluated for evidence and clinical relevance. Results: For radiogenic proctitis, enteritis, and cystitis, amifostine, probiotic combinations, and selenium showed beneficial effects, while Aloe vera may provide symptom relief. Cranberries are not recommended due to negative trial results. In CIPN, functional training and cryotherapy appear effective in prevention. Acupuncture and topical phytotherapeutics such as menthol, capsaicin, or Nigella sativa can reduce neuropathic pain. Vitamin E and carnitine are not indicated due to lack of efficacy. Conclusion: Complementary approaches can meaningfully contribute to alleviating therapy-related adverse effects. Their evidence-based integration into supportive oncology may improve quality of life and treatment tolerance in cancer patients.
C1 [Bauer-Buntzel, Christoph] Klinikum Fulda, Med Klin Nephrol 3, Fulda, Germany.
   [Buntzel, Judith] Univ Med Gottingen, Klin Hamatol & Med Onkol, Robert Koch Str 40, D-37075 Gottingen, Germany.
C3 Klinikum Fulda; University of Gottingen
RP Büntzel, J (corresponding author), Univ Med Gottingen, Klin Hamatol & Med Onkol, Robert Koch Str 40, D-37075 Gottingen, Germany.
EM judith.buentzel@med.uni-goettingen.de
CR Athanassiou H, 2003, INT J RADIAT ONCOL, V56, P1154, DOI 10.1016/S0360-3016(03)00187-1
   AWMF, 2025, S3-LEITLINIE KOMPLEMENTARMEDIZIN IN DER BEHANDLUNG VON ONKOLOGISCHEN PATIENTINNEN. AWMF LANGVERSION 2.0:630, V0, P0
   Bairati I, 2005, JNCI-J NATL CANCER I, V97, P481, DOI 10.1093/jnci/dji095
   Bauer-Büntzel C, 2024, ZEITSCHRIFT FÜR KOMPLEMENTÄRMEDIZIN, V16, P16, DOI 10.1055/a-2284-0057
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Bonetta Alberto, 2012, CANCER MANAG RES, V4, P281, DOI 10.2147/CMAR.S35342
   Chitapanarux I, 2010, RADIAT ONCOL, V5, P0, DOI 10.1186/1748-717X-5-31
   Cowan CC, 2012, CLIN ONCOL-UK, V24, PE31, DOI 10.1016/j.clon.2011.05.009
   Dalsania Raj M, 2021, AM SOC CLIN ONCOL EDUC BOOK, V41, P1, DOI 10.1200/edbk_323525
   Deutsche Gesellschaft fur Urologie eV, 2024, S3-LEITLINIE EPIDEMIOLOGIE, V0, P231
   Deutschen Krebshilfe (DKH), 2025, S3-LEITLINIE SUPPORTIVE THERAPIE BEI ONKOLOGISCHEN PATIENTINNEN-LANGVERSION 2.0, V0, P0
   Ehrenpreis ED, 2005, DIS COLON RECTUM, V48, P1, DOI 10.1007/s10350-004-0821-7
   Emami H, 2014, J RES MED SCI, V19, P445
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Guo SN, 2023, J CANCER SURVIV, V17, P318, DOI 10.1007/s11764-022-01182-3
   Helissey C, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10010021
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Herst PM, 2020, RADIOTHER ONCOL, V149, P117, DOI 10.1016/j.radonc.2020.05.006
   Huber R, 2019, MIND-MAPS PHYTOTHERAPIE, V0, P0, DOI DOI 10.1055/b-006-163252
   Huebner J, 2014, BREAST CARE, V9, P60, DOI 10.1159/000360381
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Katsanos KH, 2010, J EXP CLIN CANC RES, V29, P0, DOI 10.1186/1756-9966-29-68
   Khodaie SA, 2023, INFLAMMOPHARMACOLOGY, V31, P2885, DOI 10.1007/s10787-023-01338-2
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF), 2025, S3-LEITLINIE PROSTATAKARZINOM. LANGVERSION 81, V0, P0
   Linn YH, 2019, PROBIOTICS ANTIMICRO, V11, P638, DOI 10.1007/s12602-018-9408-9
   Lube-Diedrich B, 2020, ARZNEIPFLANZEN-ARZNEIDROGEN: BOTANIK-EIGENSCHAFTEN-ANWENDUNG. AVOXA-MEDIENGRUPPE DEUTSCHER, V0, P0
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Muecke R, 2014, INTEGR CANCER THER, V13, P463, DOI 10.1177/1534735414541963
   Muecke R, 2010, INT J RADIAT ONCOL, V78, P828, DOI 10.1016/j.ijrobp.2009.08.013
   OTCHY DP, 1993, SURG CLIN N AM, V73, P1017
   Ronconi G, 2024, EUR J PHYS REHAB MED, V60, P505, DOI 10.23736/S1973-9087.24.08197-8
   Rosenbaek F, 2020, SUPPORT CARE CANCER, V28, P3763, DOI 10.1007/s00520-019-05196-z
   Sahebnasagh A, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02935-2
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Simpson DM, 2017, J PAIN, V18, P42, DOI 10.1016/j.jpain.2016.09.008
   Wedlake L, 2017, AM J CLIN NUTR, V106, P849, DOI 10.3945/ajcn.116.150565
   Wiese F, 2023, INT J VITAM NUTR RES, V93, P72, DOI 10.1024/0300-9831/a000698
NR 39
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2731-7226
EI 2731-7234
J9 ONKOLOGIE-GER
JI Onkologie
PD DEC 15
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1007/s00761-025-01874-2
EA DEC 2025
PG 7
WC Oncology
SC Oncology
GA W5237
UT WOS:001639688900001
DA 2026-01-16
ER

PT J
AU Dai, N
   Liu, XH
   Wan, HJ
AF Dai, Nan
   Liu, Xiaohui
   Wan, Hejia
TI Practical Applications and Safety of Battlefield Acupuncture for Pain Management: A Systematic Literature Review
SO JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
LA English
DT Review
DE pain management; acupuncture therapy; analgesics
ID ear acupuncture; therapy; cancer
AB Background: Pain is complex and subjective, causing physical and psychological damage. Western medical treatments are prone to dependence, gastrointestinal problems, and organ damage. Battlefield acupuncture (BFA) integrates traditional Chinese medicine with contemporary military medicine, achieving a rapid analgesic effect. In the domain of pain management, it is effective. Despite controversy, it is recommended as an analgesic for pain populations. Purpose: The present study evaluated the clinical efficacy and safety of BFA, with a view to informing pain management strategies and validating its credibility. Methods: Databases including PubMed, Cochrane Library, Web of Science, and Embase were searched from 2015-2025. Randomized controlled studies(RCTs) on BFA for pain were included. Outcome measurements were pain scores and adverse event rates. Two authors independently assessed studies using the Cochrane risk of bias tool for randomized trials(RoB-1). Heterogeneity was addressed via narrative synthesis. Results: Of 800 articles screened, 11 RCTs (n=1,232; BFA: 530 patients) matched criteria. BFA was compared with opioids, non-opioids, exercise or physical therapies for various types of pain. Four studies reported lower BFA pain scores, and four found no difference. No severe adverse event rates were noted, but mild reactions were recorded. RoB grades: two A, eight B, Conclusion: Evidence supports the efficacy and safety of BFA for acute pain. The utilisation of BFA in the context of alleviating mild to moderate pain is recommended, particularly in conjunction with electroacupuncture therapies.However, limitations include small sample sizes, blinding issues, and inconsistent protocols. Research into specific pain types and long-term efficacy should be focused on.
C1 [Dai, Nan; Liu, Xiaohui; Wan, Hejia] Henan Univ Chinese Med, Sch Nursing, Smart Healthcare Ind, Nursing Sch, Zhengzhou, Peoples R China.
   [Liu, Xiaohui] Henan Univ Tradit Chinese Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Zhengzhou, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine
RP Liu, XH (corresponding author), Henan Univ Chinese Med, Sch Nursing, Smart Healthcare Ind, Nursing Sch, Zhengzhou, Peoples R China.; Liu, XH (corresponding author), Henan Univ Tradit Chinese Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Zhengzhou, Peoples R China.
EM 1173652033@qq.com
FU The 2023 Chinese Medicine Culture and Management Research Program of Henan Provincial Health Commission [TCM2023009]; The 2023 Professional Degree Graduate Student Fine Teaching Case Project of Education Department of Henan Province [YJS2023AL053]; The 2022 Chinese Medicine Clinical Research Base Special Projects of Henan Provincial Health Commission [2021JDZX2032]; The 2020 Chinese Medicine Scientific Research Special Projects of Henan Provincial Health Commission [20-21ZY2113]
CR Alimoradi Z, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3896-0
   Bahrololoomi Zahra, 2019, IRAN ENDOD J, V14, P104, DOI 10.22037/iej.v14i2.22799
   Baldawi M, 2022, J INTEGR COMPLEMENT, V28, P683, DOI 10.1089/jicm.2021.0429
   Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Bedi GS, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.59935
   Castañeda G, 2021, MED ACUPUNCT, V33, P159, DOI 10.1089/acu.2020.1459
   Collinsworth KM, 2019, MED ACUPUNCT, V31, P228, DOI 10.1089/acu.2019.1372
   Crowell MS, 2025, MIL MED, V190, Pe1509, DOI 10.1093/milmed/usae577
   Djaali W, 2020, MED ACUPUNCT, V32, P157, DOI 10.1089/acu.2020.1410
   Estores I, 2017, J SPINAL CORD MED, V40, P432, DOI 10.1080/10790268.2016.1141489
   Eucker SA, 2024, ANN EMERG MED, V84, P337, DOI 10.1016/j.annemergmed.2024.03.014
   Fox LM, 2018, AM J EMERG MED, V36, P1045, DOI 10.1016/j.ajem.2018.02.038
   Gely C, 2020, GASTROENT HEPAT-BARC, V43, P9, DOI 10.1016/j.gastrohep.2019.06.008
   Giannitrapani KF, 2020, MED CARE, V58, PS88, DOI 10.1097/MLR.0000000000001332
   Higgins J, 2024, COCHRANE HDB SYSTEMA, V0, P0
   Jan AL, 2020, MED ACUPUNCT, V32, P253, DOI 10.1089/acu.2020.1436
   Jan AL, 2021, EMERG MED AUSTRALAS, V33, P434, DOI 10.1111/1742-6723.13642
   Johnston K, 2021, J EMERG MED, V61, P406, DOI 10.1016/j.jemermed.2021.07.017
   Kang YJ, 2024, BMJ-BRIT MED J, V384, P0, DOI 10.1136/bmj-2022-072362
   Kim M, 2019, EXPLORE-NY, V15, P409, DOI 10.1016/j.explore.2019.05.001
   King JD, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.46872
   Levy CE, 2018, AM J PHYS MED REHAB, V97, Pe18, DOI 10.1097/PHM.0000000000000766
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Minotti B, 2022, ACAD EMERG MED, V29, P954, DOI 10.1111/acem.14517
   Money S, 2018, CURR EMERG HOSP ME R, V6, P141, DOI 10.1007/s40138-018-0170-9
   Montgomery AD, 2020, MED ACUPUNCT, V32, P38, DOI 10.1089/acu.2019.1382
   Niemtzow RC, 2020, MED ACUPUNCT, V32, P377, DOI 10.1089/acu.2020.1470
   Niemtzow RC, 2007, MED ACUPUNCT, V19, P225, DOI 10.1089/acu.2007.0603
   Office of the Secretary Department of Defense (DoD), 2016, FED REGIST, V81, P61067
   Opoku-Agyakwa M, 2023, EJHAEM, V4, P582, DOI 10.1002/jha2.704
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Plunkett A, 2018, PAIN MANAG, V8, P287, DOI 10.2217/pmt-2018-0007
   Salaffi F, 2020, INT J RHEUM DIS, V23, P480, DOI 10.1111/1756-185X.13803
   Salamone FJ, 2021, SOUTH MED J, V114, P239, DOI 10.14423/SMJ.0000000000001232
   Shah AN, 2020, LARYNGOSCOPE, V130, P1907, DOI 10.1002/lary.28338
   Steven BZ, 2020, ROUTINE CLIN CARE MED CARE, V58, PS101, DOI 10.1097/mlr.0000000000001368
   Taylor SL, 2021, PAIN MED, V22, P1721, DOI 10.1093/pm/pnaa474
   Taylor SL, 2018, MED ACUPUNCT, V30, P252, DOI 10.1089/acu.2018.1286
   Toney BT, 2023, JAAPA-J AM ACAD PHYS, V36, P1, DOI 10.1097/01.JAA.0000902880.99336.60
   UMEH B, 1988, AM J CHINESE MED, V16, P67, DOI 10.1142/S0192415X88000108
   Yang J, 2021, AM J CHINESE MED, V49, P25, DOI 10.1142/S0192415X21500026
   You E, 2019, PAIN MANAG NURS, V20, P17, DOI 10.1016/j.pmn.2018.07.010
NR 43
TC 2
Z9 2
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2390
EI 
J9 J MULTIDISCIP HEALTH
JI J. Multidiscip. Healthc.
PD JUN 15
PY 2025
VL 18
IS 
BP 2749
EP 2769
DI 10.2147/JMDH.S517946
PG 21
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 2VS5N
UT WOS:001492456300001
PM 40401079
DA 2026-01-16
ER

PT J
AU Xu, JQ
   Zhang, Q
   Xue, N
   Zhang, C
   Xu, WR
AF Xu, Jinqun
   Zhang, Qing
   Xue, Na
   Zhang, Cui
   Xu, Weiru
TI The therapeutic effect of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy: a randomized controlled trial
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE acupuncture; chemotherapy; peripheral neuropathy; therapeutic; randomized controlled trial
ID electroacupuncture; pilot; pain; prevention; management; needle
AB Introduction: Effective treatments for preventing and treating chemotherapy-induced peripheral neuropathy (CIPN) are still under exploration. Acupuncture in the treatment of CIPN requires more clinical trial data. This study aimed to evaluate the therapeutic effect of acupuncture on CIPN and explore its efficacy and safety in improving peripheral neuropathy. Methods: A randomized controlled trial was conducted from May 2021 to June 2023. Eligible patients were randomly divided into a verum acupuncture group and a sham acupuncture group at a 1:1 ratio with sealed opaque envelopes. The patients of both the two groups took oral mecobalamin tablets, 0.5 mg, three times a day for 2 weeks. Participants received acupuncture treatment three times a week for 2 weeks. The primary outcome was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 3.0. The secondary outcomes were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-CIPN twenty-item subscale (QLQ-CIPN20), Numerical Rating Scale (NRS), Traditional Chinese Medicine (TCM) syndrome score, and nerve conduction study (NCS) testing. Assessments were conducted at baseline, 1 week, and 2 weeks. Results: All 70 participants were recruited and randomized. In the end, 68 patients were included in the datasets and received verum acupuncture (n = 34) or sham acupuncture (n = 34). After 2 weeks of treatment and follow-up, a statistically significant difference was found in the NCI-CTCAE scores between the two groups (p = 0.02). Baseline-to-2-week assessment scores improved significantly in the intervention group (vs. controls) on EORTC QLQ-CIPN20 (p = 0.02), NRS scores (p = 0.03), TCM syndrome scores (p = 0.04), and sensory nerve action potential (SNAP) of median and peroneal nerves, sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) of peroneal nerves (p < 0.05). No serious adverse events were reported. Conclusion: This study supports the feasibility of acupuncture combined with medication as an intervention for patients with CIPN and confirms its efficacy and safety in improving peripheral neuropathy.
C1 [Xu, Jinqun; Zhang, Qing; Xue, Na; Zhang, Cui; Xu, Weiru] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing, Peoples R China.
   [Xu, Jinqun] Yibin Hosp Tradit Chinese Med, Dept Oncol, Yibin, Peoples R China.
C3 Capital Medical University
RP Xu, WR (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing, Peoples R China.
EM xuweiru@bjzhongyi.com
FU Beijing Municipal Administration of Hospitals Incubating Program [PZ2020019]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20161001]
CR Abu Sharour L, 2021, APPL NEUROPSYCH-ADUL, V28, P614, DOI 10.1080/23279095.2019.1677232
   Bae EH, 2021, NEUROTHERAPEUTICS, V18, P2384, DOI 10.1007/s13311-021-01142-2
   Banach M, 2017, BRAIN BEHAV, V7, P0, DOI 10.1002/brb3.558
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Cai YY, 2021, J PAIN SYMPTOM MANAG, V61, P305, DOI 10.1016/j.jpainsymman.2020.07.034
   Cao LC, 2024, FRONT ONCOL, V14, P0, DOI 10.3389/fonc.2024.1326970
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Dai L, 2019, GUANGZHOU UNIV CHIN MED, V0, P0, DOI DOI 10.27044/D.CNKI.GGZZU.2019.000473
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   DONOFRIO PD, 1990, MUSCLE NERVE, V13, P889, DOI 10.1002/mus.880131002
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Huo JG, 2023, CHIN J ONCOL SURG, V15, P521, DOI 10.3969/J.ISSN.1674-4136.2023.06.001
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Knoerl R, 2021, AM J NURS, V121, P26, DOI 10.1097/01.naj.0000742060.56042.e7
   Kutcher AM, 2022, WESTERN J NURS RES, V44, P169, DOI 10.1177/0193945921992538
   Li XJ, 2024, FRONT ONCOL, V14, P0, DOI 10.3389/fonc.2024.1440205
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Linbo L, 2024, CHIN J CLIN ONCOL REHABIL, V31, P561, DOI 10.13455/J.CNKI.CJCOR.113494-2024-2024-0167
   Litscher G, 2005, FORSCH KOMP KLAS NAT, V12, P190, DOI 10.1159/000087044
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Ma F, 2020, CHIN J FRONT MED SCI, V12, P41, DOI 10.12037/YXQY.2020.03-07
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Pu T, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1156308
   Rattanakrong Nida, 2022, ASIAN PAC J CANCER PREV, V23, P1547, DOI 10.31557/apjcp.2022.23.5.1547
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Schwab L, 2023, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.1005083
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stillman Mark, 2006, CURR PAIN HEADACHE REP, V10, P279
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Valentini J, 2024, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1371056
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Weiru X, 2022, J GUANGZHOU UNIV TRADITIONAL CHIN MED, V39, P24, DOI 10.13359/J.CNKI.GZXBTCM.2022.01.005
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yuan Y, 2024, WORLD CHINESE MED, V19, P1348, DOI 10.3969/J.ISSN.1673-7202.2024.09.023
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
NR 50
TC 0
Z9 0
U1 8
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 16
PY 2025
VL 15
IS 
BP 
EP 
DI 10.3389/fonc.2025.1500410
PG 12
WC Oncology
SC Oncology
GA 2BR2N
UT WOS:001478822500001
PM 40308502
DA 2026-01-16
ER

PT J
AU Yang, M
   Chen, Y
   Wan, YX
   Shen, C
   Huang, JC
AF Yang, Ming
   Chen, Yue
   Wan, Yuxiang
   Shen, Chen
   Huang, Jinchang
TI Acupuncture and moxibustion in integrative oncology and new progress in China
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Review
DE Acupuncture; Moxibustion; Integrative oncology; Evidence-based medicine; Traditional Chinese Medicine
ID electrical acupoint stimulation; cancer-related fatigue; breast-cancer; double-blind; auricular acupuncture; ons guidelines(tm); gastric-cancer; hot flashes; pain; xerostomia
AB Acupuncture and moxibustion are increasingly gaining recognition in the clinical and research fields of integrative oncology. This review synthesizes findings from clinical guidelines, systematic reviews, meta-analyses, and randomized controlled trials (RCTs) of acupuncture and moxibustion for cancer care. Clinical evidence highlights acupuncture's efficacy in managing symptoms such as hot flashes, pain, insomnia, fatigue, and constipation. Acupuncture also demonstrates potential effects in reducing chemotherapy and radiotherapy-induced side effects. Recent advancements in China shows integrated therapies combining acupuncture with chemotherapy to enhance therapeutic outcomes. Additionally, laboratory studies reveal the potential of acupuncture and moxibustion to modulate the tumor microenvironment, boost chemotherapy efficacy, and strengthen immunity. Despite these promising results, there is a pressing need for well-designed trials and real-world studies to evaluate the long-term effects of standardized acupuncture and moxibustion treatments in cancer care.
C1 [Yang, Ming; Chen, Yue; Wan, Yuxiang; Huang, Jinchang] Beijing Univ Chinese Med, Affiliated Hosp 3, An Wai Xiao Guan Jie 51, Beijing 100029, Peoples R China.
   [Shen, Chen] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Huang, JC (corresponding author), Beijing Univ Chinese Med, Affiliated Hosp 3, An Wai Xiao Guan Jie 51, Beijing 100029, Peoples R China.
EM zryhhuang@163.com
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bordeleau L, 2007, CLIN THER, V29, P230, DOI 10.1016/j.clinthera.2007.02.006
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Cheng Hai-Bo, 2024, ZHEN CI YAN JIU, V49, P693, DOI 10.13702/j.1000-0607.20230985
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Davis MP, 2014, CANCER J, V20, P330, DOI 10.1097/PPO.0000000000000071
   Deng GY, 2021, J ACUPUNCT TUINA SCI, V19, P206, DOI 10.1007/s11726-021-1241-0
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Dymackova R, 2020, BIOMED PAP, V164, P454, DOI 10.5507/bp.2020.021
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han K, 2021, CANCER MED-US, V10, P4721, DOI 10.1002/cam4.4020
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   Hao J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420945027
   Haumann J, 2017, CURR OPIN SUPPORT PA, V11, P99, DOI 10.1097/SPC.0000000000000261
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Hsieh SH, 2021, CANCER NURS, V44, PE578, DOI 10.1097/NCC.0000000000000997
   Huang J, 2018, ZHONG GUO ZHEN JIU, V38, P1123
   Huang JC, 2020, CHIN J CLINIC, V48, P1006, DOI 10.3969/j.issn.2095-8552.2020.08.042
   Hübner J, 2021, ONKOLOGE, V27, P917, DOI 10.1007/s00761-021-00990-z
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Iovoli AJ, 2020, J ALTERN COMPLEM MED, V26, P323, DOI 10.1089/acm.2019.0131
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Ji YJ, 2021, EVID BASED COMPLEMENT ALTERNAT MED, V2021, P0
   Jones KF, 2022, J PALLIAT MED, V25, P964, DOI 10.1089/jpm.2021.0512
   Kaplan M, 2020, ONCOL NURS FORUM, V47, P374, DOI 10.1188/20.ONF.374-399
   Kong M, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420908327
   Lam WC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1038206
   Lee B, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03561-w
   Li LJ, 2021, J INTEGR MED-JIM, V19, P251, DOI 10.1016/j.joim.2021.02.001
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Li YF, 2020, ONCOTARGETS THER, V13, P11743, DOI 10.2147/OTT.S272747
   Ling CQ, 2018, J INTEGR MED-JIM, V16, P236, DOI 10.1016/j.joim.2018.05.002
   Liu TL, 2021, CLIN INTERV AGING, V16, P757, DOI 10.2147/CIA.S309082
   Liu WH, 2023, J ONCOL CHIN MED, V5, P1, DOI 10.19811/j.cnki
   Liu XL, 2020, EVID BASED COMPLEMENT ALTERNAT MED, V2020, P0
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Majem M, 2022, CLIN TRANSL ONCOL, V24, P712, DOI 10.1007/s12094-022-02802-1
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2023, J INTEGR COMPLEMENT, V29, P209, DOI 10.1089/jicm.2023.0018
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Mercadante V, 2021, J CLIN ONCOL, V39, P2825, DOI 10.1200/JCO.21.01208
   Molassiotis A, 2024, SUPPORT CARE CANCER, V32, P1
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Pei LX, 2025, GASTROENTEROLOGY, V169, P73, DOI 10.1053/j.gastro.2025.02.006
   Qiu GT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5594263
   Qiu Xingsheng, 2004, J TRADIT CHIN MED, V24, P56
   Rogers B, 2020, ONCOL NURS FORUM, V47, P671, DOI 10.1188/20.ONF.671-691
   Song YF, 2023, AM J CANCER RES, V13, P394
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Sun LY, 2020, ANN PALLIAT MED, V9, P1804, DOI 10.21037/apm.2020.04.24
   Tan JY, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101490
   Tian YH, 2022, J CHEM NEUROANAT, V124, P0, DOI 10.1016/j.jchemneu.2022.102133
   Tian YX, 1987, CHINESE ACUPUNCT MOXIBUST, V4, P44
   Tola YO, 2021, J CLIN NURS, V30, P3369, DOI 10.1111/jocn.15827
   Tong QY, 2022, CLIN BREAST CANCER, V22, P724, DOI 10.1016/j.clbc.2022.04.010
   von Trott P, 2020, J PAIN SYMPTOM MANAG, V59, P327, DOI 10.1016/j.jpainsymman.2019.09.007
   Wan YX, 2024, CANCER LETT, V598, P0, DOI 10.1016/j.canlet.2024.217094
   Wang B, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3170803
   Wang D, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/7570533
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wang XQ, 2022, EXPLORE-NY, V18, P36, DOI 10.1016/j.explore.2021.09.007
   Wang YX, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3996101
   Wu P, 2001, J TRADIT CHIN MED, V21, P68
   Xing RY, 2022, PAIN THER, V11, P1327, DOI 10.1007/s40122-022-00429-2
   Xu ZYR, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1001918
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang M, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.00576
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Yang Yuan-Zhen, 2024, ZHEN CI YAN JIU, V49, P634, DOI 10.13702/j.1000-0607.20230001
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zhang HB, 2023, ANN ONCOL, V34, PS1080, DOI 10.1016/j.annonc.2023.09.817
   Zhang Jian, 2022, PROCEEDINGS OF THE 5TH INTERNATIONAL CONFERENCE ON ELECTRICAL ENGINEERING AND INFORMATION TECHNOLOGIES FOR RAIL TRANSPORTATION (EITRT) 2021: NOVEL TRACTION DRIVE TECHNOLOGIES OF RAIL TRANSPORTATION. LECTURE NOTES IN ELECTRICAL ENGINEERING (864), V0, PP102, DOI 10.1007/978-981-16-9905-4_12
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang WN, 2024, EXPLORE-NY, V20, P0, DOI 10.1016/j.explore.2024.103031
   Zhang Y, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.765458
   Zhang ZJ, 2020, BRAIN BEHAV IMMUN, V88, P88, DOI 10.1016/j.bbi.2020.04.035
   Zhang ZY, 2021, LIFE SCI, V272, P0, DOI 10.1016/j.lfs.2021.119259
   Zhao YX, 2024, MOL PAIN, V20, P0, DOI 10.1177/17448069241240692
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
NR 98
TC 1
Z9 1
U1 11
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD JUN 15
PY 2025
VL 14
IS 2
BP 
EP 
DI 10.1016/j.imr.2025.101149
EA MAY 2025
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 2TY1A
UT WOS:001491235900001
PM 40475037
DA 2026-01-16
ER

PT J
AU Zhang, S
   Li, Y
   Liang, Z
   Dai, J
   Huang, H
   Zhang, H
   Yang, B
   Wang, J
   Tang, D
AF Zhang, Shaowang
   Li, Yuanyin
   Liang, Zhide
   Dai, Jiaxing
   Huang, Hong
   Zhang, Huanghui
   Yang, Bing
   Wang, Jinghui
   Tang, Dongxin
TI Comparing the effects of different non-pharmacological traditional Chinese
SO Complementary therapies in medicine
LA English
DT Review
DE Cancer survivors; Fatigue; Network Meta-Analysis; Non-pharmacological traditional Chinese medicine therapies; Pain
AB OBJECTIVES: Several studies have demonstrated the positive impact of  non-pharmacological Traditional Chinese Medicine (TCM) therapies on pain,  fatigue, sleep quality, and quality of life in cancer survivors. However, no  research has compared the effectiveness of these therapies. This study aims to  compare various interventions and identify the most effective non-pharmacological  TCM therapies to provide evidence-based recommendations for cancer survivors.  METHODS: A systematic search was conducted in PubMed, Embase, Web of Science,  CNKI, and Wanfang Data. RCTs investigating the effects of Taichi, Qigong,  acupuncture, acupressure, TCM emotional therapy, and mixed therapies as  interventions for cancer survivors were screened was conducted. Data from the  creation of the database to February 2025 were included. Two independent  reviewers evaluated the study quality. A Bayesian Network Meta-analysis was  conducted to carry out a random effects model. RESULTS: Seventy-one RCTs  involving 6473 patients were included in the analysis. Network meta-analysis  showed significance for all five intervention therapies in pain control in cancer  patients. The best efficacy was observed for acupressure (SMD=-1.1 [-1.55,  -0.66]) and Taichi/Qigong (SMD=-1.08[-1.64, -0.53]), followed by TCM emotional  therapy (SMD=-0.93 [-1.42, -0.44]) and acupuncture (SMD=-0.54 [-0.93, -0.15]),  with the latter showing comparatively lower efficacy. None of the interventions  demonstrated superior efficacy in improving fatigue compared to the control  group. Mixed therapies (SMD=-1.36[-2.56, -0.28]) demonstrated the greatest effect  in improving sleep quality. Taichi/Qigong (SMD=1.87 [0.96, 2.83]) demonstrated  certain advantages in improving quality of life. However, acupuncture and TCM  emotional therapy had no significant effect on sleep quality or overall quality  of life. CONCLUSION: The evidence from this study suggests that acupressure and  Taichi/Qigong are recommended as the most effective therapies for pain relief and  quality of life improvement, respectively. The efficacy of these therapies for  fatigue remains inconclusive. However, due to the limited number of included  studies and the high risk of bias, these results should be interpreted with  caution. Future studies should include more rigorously designed high-quality  randomized controlled trials to confirm their long-term efficacy and safety.  REGISTRATION: PROSPERO CRD42024601976.
C1 Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science and Technology Innovation of GuizhouProvince, Guiyang 550000, China. 
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science and Technology Innovation of GuizhouProvince, Guiyang 550000, China. 
   Department of Physical Education, College of Physical Education, Qingdao University, Qingdao 266071, China. 
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science and Technology Innovation of GuizhouProvince, Guiyang 550000, China. 
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science and Technology Innovation of GuizhouProvince, Guiyang 550000, China. 
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science and Technology Innovation of GuizhouProvince, Guiyang 550000, China. 
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science andTechnology Innovation of Guizhou Province, Guiyang 550000, China. Electronicaddress: 1006019442@qq.com.
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science andTechnology Innovation of Guizhou Province, Guiyang 550000, China. Electronicaddress: 547917662@qq.com.
   Guizhou University of Traditional Chinese Medicine, Guiyang 550000, China
   The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang 550000, China
   Talent Base for TCM Tumor Inheritance and Science andTechnology Innovation of Guizhou Province, Guiyang 550000, China. Electronicaddress: hemingankang@sina.com.
EM 1257379762@qq.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAR 30
PY 2025
VL 90
IS 
BP 103164
EP 103164
DI 10.1016/j.ctim.2025.103164
PG 0
WC Humans; Acupressure; Acupuncture Therapy; Bayes Theorem; Cancer Survivors; Fatigue; therapy; Medicine, Chinese Traditional; methods; Neoplasms; therapy; Qigong; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:40157553
PM 40157553
DA 2025-03-30
ER

PT J
AU Liu, Z
   Qiao, F
   Liu, D
   Kong, X
   Liu, K
   Gu, H
   Zhang, Y
   Meng, Q
   Cheng, L
AF Liu, Zhenchuan
   Qiao, Fei
   Liu, Dejian
   Kong, Xiangzhen
   Liu, Kaiwen
   Gu, Hanwen
   Zhang, Yuanqiang
   Meng, Qunbo
   Cheng, Lei
TI Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation
SO Phytomedicine : international journal of phytotherapy and phytopharmacology
LA English
DT Journal Article
DE Intervertebral disc degeneration; LRP4; Molecular docking; Periplocin; TNF-α; inflammation
AB BACKGROUND: Intervertebral disc degeneration (IVDD) is characterized by  deteriorating intervertebral discs, leading primarily to low back pain and leg  pain. Most current treatments for IVDD primarily address symptoms without  targeting the underlying degenerative process. Moreover, tumor necrosis factor-α  (TNF-α)-mediated inflammation and degradation of the nucleus pulposus (NP)  extracellular matrix (ECM) influence this pathological process. Periplocin, a  cardiotonic steroid extracted from periplocin forrestii, has demonstrated a wide  range of medical benefits, including cardiotonic, anticancer, anti-inflammatory,  and wound healing properties. Nevertheless, the effects of periplocin on IVDD  remain unexplored. OBJECTIVE: Our study explores the mechanism of action and the  potential target of periplocin in mitigating IVDD pathology. METHODS: Rat models  of IVDD were established using acupuncture, and the affected discs underwent  analysis via Safranin O-Fast Green (S-O) and Hematoxylin and Eosin (H&E)  staining. Nucleus pulposus cells (NPCs) were harvested from IVDD patients and  experimental animals for examination. A variety of techniques, including Western  blot analysis, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) assay,  immunofluorescence staining, Alcian Blue staining and Immunohistochemistry (IHC)  staining, were utilized to evaluate inflammation-related proteins, mRNAs and the  ECM metabolism. In order to ascertain the potential protein targets of  periplocin, the binding site of periplocin to LRP4 was elucidated through the  utilisation of molecular docking experiments. Subsequently, the expression of  low-density lipoprotein receptor-related protein 4 (LRP4) in NPCs was modified  through the use of small interfering RNA (siRNA) knockdown and overexpression  vectors, which were employed for the purposes of target validation. RESULTS: We  conclude from the present study that periplocin alleviates the progression of  IVDD mainly through the following aspects: periplocin inhibits TNF-α-induced  inflammatory; periplocin reduces matrix degradation; periplocin promotes matrix  anabolism and regulates metabolic homeostasis. Moreover, the present study  demonstrates that LRP4 is involved as a potential target in the multiple pathways  mentioned above to protect the intervertebral disc. CONCLUSION: Our research  suggests that periplocin may serve as a promising treatment for IVDD, offering  anti-inflammatory benefits, preventing ECM degradation, and promoting ECM  anabolism.
C1 Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China
   Department of PediatricOrthopedic, Dalian Women and Children's Medical Center(group), Dalian, Liaoning,116012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China. 
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China. 
   Department of Orthopedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
EM henglei@email.sdu.edu.cn
NR 0
TC 0
SN 1618-095
EI 
J9 Phytomedicine
PD MAY 29
PY 2025
VL 143
IS 
BP 156885
EP 156885
DI 10.1016/j.phymed.2025.156885
PG 0
WC Animals; Intervertebral Disc Degeneration; drug therapy; Homeostasis; drug effects; Male; Humans; Rats; Rats, Sprague-Dawley; Anti-Inflammatory Agents; pharmacology; Nucleus Pulposus; drug effects; Molecular Docking Simulation; Tumor Necrosis Factor-alpha; metabolism; Female; Inflammation; drug therapy; Disease Models, Animal; Middle Aged
UT PubMed:40440911
PM 40440911
DA 2025-05-29
ER

PT J
AU Liu, T
   Zhi, W
   Wang, X
   Pei, Q
   Guo, X
   Huang, Q
AF Liu, Tong
   Zhi, Wenqian
   Wang, Xiaoquan
   Pei, Qian
   Guo, Xianfeng
   Huang, Qiang
TI Effectiveness of Fu's subcutaneous needling on pain and physical function in
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Fu's subcutaneous needling; Inflammatory cytokines; Knee osteoarthritis; Meta-analysis; Pain assessment; Randomized controlled trials
AB OBJECTIVES: This study aims to evaluate the efficacy of Fu's subcutaneous  needling (FSN) for knee osteoarthritis (KOA) via a meta-analysis. METHODS:  Randomized controlled trials (RCTs) of FSN for KOA were searched in PubMed,  Cochrane Library, Embase, Web of Science, and other databases up to July 20,  2024. Stata 15.0 was leveraged for data analysis. RESULTS: 30 RCTs were included,  involving 2169 individuals. Compared to electroacupuncture, acupuncture, and  other therapies, FSN demonstrated significant benefits in reducing the Western  Ontario and McMaster Universities Arthritis Index score (WOMAC, improved physical  function) [SMD= -1.69 (-2.15 to -1.23), I² = 89.8 %, P < 0.001] and relieving  pain (the visual analog scale) [SMD = -1.77( -2.14 to -1.40); I² = 89.8 %,  P < 0.001]. Additionally, FSN was more effective in reducing inflammatory  cytokine levels, such as interleukin 1β [SMD = -1.65 (-2.36, -0.94); I² = 91.9 %,  P < 0.001], interleukin-6 [SMD = -3.93 (-5.08, -2.78); I² = 96.7 %, P < 0.001],  and tumor necrosis factor-α [SMD = -2.65 (-3.46, -1.83); I² = 94.8 %, P < 0.001],  and increasing the total effective rate [OR = 4.17, 95 % CI: 3.05-5.68; I²  = 0.0 %, P < 0.001]. CONCLUSIONS: FSN shows promise as an adjuvant therapy for  KOA, with moderate-quality evidence supporting its short-term efficacy in pain  relief and functional improvement. Further validation through standardized  protocols is required to determine its long-term benefits.
C1 Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
   Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
   Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
   Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
   Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
   Department of Rehabilitation Medicine, Beijing Jishuitan Hospital, Capital Medical University, No. 31, Xinjiekou East Street, Xicheng District, Beijing,China.
EM hq2349@vip.sina.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD AUG 23
PY 2025
VL 93
IS 
BP 103233
EP 103233
DI 10.1016/j.ctim.2025.103233
PG 0
WC Humans; Osteoarthritis, Knee; therapy; Acupuncture Therapy; methods; Randomized Controlled Trials as Topic; Pain Management; methods
UT PubMed:40846208
PM 40846208
DA 2025-08-23
ER

PT J
AU Günes, D
   Karabulutlu, EY
AF Gunes, Demet
   Karabulutlu, Elanur Yilmaz
TI The Effects of Su Jok Therapy on Pain, Fatigue, Insomnia, Nausea, and Vomiting Experienced by Patients With Gastrointestinal System Cancer
SO HOLISTIC NURSING PRACTICE
LA English
DT Article
DE fatigue; gastrointestinal system cancer; insomnia; nausea; nursing; pain; Su Jok complementary and integrative practice; vomiting
ID chemotherapy-induced nausea; severity index; acupressure; complementary; validation; scale
AB Su Jok therapy is used as an energy-based complementary and alternative method in cancer patients. The study was conducted to determine the effects of Su Jok therapy on pain, fatigue, insomnia, nausea, and vomiting experienced by patients with gastrointestinal cancer. This randomized controlled trial was conducted with 48 patients. Data were collected by the researcher by using an introductory information form, the short form McGill pain questionnaire, the cancer fatigue scale, the insomnia severity index, the Rhodes index of nausea, vomiting, and retching, and the visual analog scale. It was found that, after the application of Su Jok seed treatment, there was a significant decrease in the mean scores of the intervention group on the McGill pain scale, the cancer fatigue scale, the insomnia severity index, and the Rhodes index of nausea, vomiting, Su Jok therapy was effective in reducing the pain, fatigue, insomnia, nausea, and vomiting scores of patients with gastrointestinal cancer.
C1 [Gunes, Demet] Erzincan Binali Yildirim Univ, Fac Hlth Sci, Dept Nursing, Erzincan Merkez, TR-24100 Erzincan, Turkiye.
   [Karabulutlu, Elanur Yilmaz] Ataturk Univ, Fac Hlth Sci, Dept Internal Med Nursing, Erzurum, Turkiye.
C3 Erzincan Binali Yildirim University; Ataturk University
RP Günes, D (corresponding author), Erzincan Binali Yildirim Univ, Fac Hlth Sci, Dept Nursing, Erzincan Merkez, TR-24100 Erzincan, Turkiye.
EM demetimm24@gmail.com
CR Admi H, 2017, ONCOL NURS FORUM, V44, P553, DOI 10.1188/17.ONF.553-561
   Akin B, 2021, J HACETTEPE UNIV FAC NURS, V8, P117, DOI 10.31125/HUNHEMSIRE.908072
   Arslan M, 2015, TURK ONCOL DERG, V30, P82, DOI 10.5505/tjoncol.2015.1204
   Atalikoglu BS, 2022, SYMPTOM MANAGEMENT IN ONCOLOGY NURSING, V0, P159
   Aydemir T, 2018, THE EFFECT OF ACUPRESSURE ON PAIN, V0, Physical function and quality of life in individuals with knee osteoarthritis
   Bahar A, 2019, V6, V0, P42
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Bean HR, 2022, SLEEP, V45, P0, DOI 10.1093/sleep/zsab246
   Bicici B, 2010, RELIABILITY AND VALIDITY OF THE TURKISH VERSION SHORT-FORM MCGILL PAIN QUESTIONNAIRE, V0, P0
   Boysan M, 2010, ANADOLU PSIKIYATR DE, V11, P248
   Buyukbayram Z, 2021, EXPLORE-NY, V17, P22, DOI 10.1016/j.explore.2020.07.009
   Buyukozturk S, 2020, THE HANDBOOK OF DATA ANALYSIS FOR SOCIAL SCIENCES, V0, P0, DOI DOI 10.14527/9789756802748
   Chen YW, 2014, PAIN MANAG NURS, V15, P539, DOI 10.1016/j.pmn.2012.12.005
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Vu DV, 2017, COMPLEMENT THER CLIN, V29, P111, DOI 10.1016/j.ctcp.2017.09.005
   Dikmen HA, 2019, PAIN MANAG NURS, V20, P47, DOI 10.1016/j.pmn.2018.03.001
   Şimşek HE, 2020, JOURNAL OF TRADITIONAL MEDICAL COMPLEMENTARY THERAPIES, V3, P265, DOI 10.5336/jtracom.2019-72803
   Ertürk NE, 2021, COMPLEMENT THER MED, V56, P0, DOI 10.1016/j.ctim.2020.102587
   Genç F, 2015, PALLIAT SUPPORT CARE, V13, P275, DOI 10.1017/S1478951514000248
   Gjuzeleva T, 2019, KNOWLEDGE-INTERNATIONAL J, V30, P1011
   Goktas S, 2023, J CLIN MED KAZAKHSTAN, V20, P17, DOI 10.23950/JCMK/13691
   Guyton K, 2019, CANCER: PREVENTION, V0, P0
   Hajbaghery MA, 2018, JOURNAL OF COMPLEMENTARY MEDICINE & ALTERNATIVE HEALTHCARE, V5, P0, DOI 10.19080/jcmah.2018.05.555666
   Han CJ, 2019, J PAIN SYMPTOM MANAG, V58, P224, DOI 10.1016/j.jpainsymman.2019.04.035
   Hassanpour SH, 2017, JOURNAL OF CANCER RESEARCH AND PRACTICE, V4, P127, DOI 10.1016/j.jcrpr.2017.07.001
   Huber JCOT, 2016, MEDISAN, V20, P5009
   Ivanov P, 2018, SU JOK AND MOXA. A SELF-TREAT A SELF-TREATMENT MANUAL, V0, P0
   Kahraman A, 2022, COMPLEMENT MED RES, V29, P402, DOI 10.1159/000526903
   Karakus Z, 2022, OURNAL HACETTEPE UNIV FAC NURS, V9, P64
   Kocatakan P, 2021, MED J ANKARA TRAIN RES HOSP, V54, P59, DOI 10.20492/aeahtd.806164
   Kreitzer MJ, 2015, RAMBAM MAIMONIDES ME, V6, P0, DOI 10.5041/RMMJ.10200
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Miao J, 2017, INT J NURS STUD, V70, P27, DOI 10.1016/j.ijnurstu.2017.02.014
   Nurjannah I, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101337
   Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4
   Pérez Cruz Julio César, 2018, CCM, V22, P549
   Rhodes V A, 1984, CANCER NURS, V7, P33
   Sahin S, 2018, TURK J MED SCI, V48, P124, DOI 10.3906/sag-1707-125
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Schulz KF, 2010, EPIDEMIOL BIOSTAT PU, V7, P325
   Seth SS, 2013, ALTERN INTEGR MED, V2, P91
   Simsek HE, 2022, COMPLEMENT THER CLIN, V49, P0, DOI 10.1016/j.ctcp.2022.101642
   Stavropoulou A, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18168512
   Tan JY, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03543-y
   Tantoy IY, 2018, J PAIN SYMPTOM MANAG, V55, P808, DOI 10.1016/j.jpainsymman.2017.10.004
   Uysal N, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12532
   Wang Ya-Ling, 2019, ZHONGGUO ZHEN JIU, V39, P1269, DOI 10.13703/j.0255-2930.2019.12.004
   Wei TT, 2020, SUPPORT CARE CANCER, V28, P4031, DOI 10.1007/s00520-020-05409-w
   Woo PJ, 2000, SEED THERAPY, V0, P0
   Woo PJ, 1991, SU JOK FOR EVERYBODY, V0, P0
   World Health Organization, 2022, ALL CANCERS, V0, P0
   World health organization, 2022, CANCER TODAY, V0, P0
   Yagil Z, 2019, QUADERNO, V14, P51
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zorba P, 2018, CANCER NURS, V41, P359, DOI 10.1097/NCC.0000000000000496
NR 55
TC 1
Z9 1
U1 19
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0887-9311
EI 1550-5138
J9 HOLIST NURS PRACT
JI Holist. Nurs. Pract.
PD SEP-OCT 15
PY 2025
VL 39
IS 5
BP 283
EP 294
DI 10.1097/HNP.0000000000000713
PG 12
WC Integrative & Complementary Medicine; Nursing
SC Integrative & Complementary Medicine; Nursing
GA 6II2G
UT WOS:001554044400002
PM 39642275
DA 2026-01-16
ER

PT J
AU Liu, Q
   Qin, XG
   Luo, CL
   Zhao, ZT
   Xie, WJ
   Du, XZ
   Qin, X
AF Liu, Qiang
   Qin, Xiaoguang
   Luo, Chenglin
   Zhao, Zhongting
   Xie, Wangjun
   Du, Xiaozheng
   Qin, Xin
TI Effects of warm needle acupuncture on behavioral pain threshold in a rat model of migraine
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE needle warming acupuncture; migraine; ET-1 protein; 5-HT; CGRP
ID 5-hydroxytryptamine; prophylaxis; activation
AB Background: As a traditional Chinese treatment method, acupuncture has a long history in the treatment of migraine and a rich literature base. As a traditional acupuncture technique, warm needle acupuncture has clearly demonstrated clinical efficacy in the treatment of migraine, although its mechanism of action remains unclear. This study aimed to evaluate the efficacy and safety of warm needle acupuncture in the treatment of migraine in a rat model of migraine by comparing pain threshold and analgesic-related factors among different groups. Methods: Thirty Sprague-Dawley rats were randomly divided into control, model, and acupuncture groups, with 10 animals in each group. On day 8, rat migraine models were established by subcutaneous injection of nitroglycerin. The acupuncture group was bilaterally needled once per day at Fengchi, Baihui, Fengfu, and Hegu. Behavioral changes and biochemical alterations among the rats before and after modeling were observed for 7 consecutive days after treatment. The expression of Endothelin-1 (ET-1), interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha) in the brain stem of the animals were assessed using ELISA. Expression levels of calcitonin gene-related peptide (CGRP) mRNA were determined using real-time quantitative polymerase chain reaction techniques. Results: After treatment, the expression of ET-1, IL-6, TNF-alpha, and CGRP in the brain stem of the model group was significantly increased compared with that of the control group (p < 0.05), while the expression of IL-6, TNF-alpha, and CGRP in the brain stem of the acupuncture group was decreased. Conclusion: Warm needle acupuncture reduced ET-1 protein levels and promoted the expression of neurotransmitters, such as 5-hydroxytryptamine, in migraine rat model animals. In addition, needle warming acupuncture decreased IL-6, TNF-alpha, and CGRP levels in the brain stem of the migraine group, which may explain its mechanism of action in treating migraine.
C1 [Liu, Qiang; Qin, Xiaoguang; Luo, Chenglin; Zhao, Zhongting; Xie, Wangjun; Du, Xiaozheng] Gansu Univ Tradit Chinese Med, Dept Acupuncture & Moxibust, Lanzhou, Peoples R China.
   [Qin, Xin] Northwest Minzu Univ, Med Fac, Lanzhou, Peoples R China.
C3 Gansu University of Chinese Medicine; Northwest Minzu University
RP Du, XZ (corresponding author), Gansu Univ Tradit Chinese Med, Dept Acupuncture & Moxibust, Lanzhou, Peoples R China.; Qin, X (corresponding author), Northwest Minzu Univ, Med Fac, Lanzhou, Peoples R China.
EM lz-duxiaozheng@163.com; qinxin111209@163.com
FU Gansu Provincial Department of Education [2020B-52]
CR Arzani M, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-020-1078-9
   Baloh RW, 2020, SEMIN NEUROL, V40, P76, DOI 10.1055/s-0039-3402735
   Chen YQ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023036
   Cooper W, 2020, POSTGRAD MED, V132, P581, DOI 10.1080/00325481.2020.1767402
   de Vries T, 2020, PHARMACOL THERAPEUT, V211, P0, DOI 10.1016/j.pharmthera.2020.107528
   Deen M, 2019, CEPHALALGIA, V39, P526, DOI 10.1177/0333102418793642
   Deen M, 2018, NEUROIMAGE-CLIN, V18, P97, DOI 10.1016/j.nicl.2018.01.016
   Edvinsson L, 2019, HANDB EXP PHARMACOL, V255, P121, DOI 10.1007/164_2018_201
   Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1
   Evers S, 1999, PAEDIATR DRUGS, V1, P7, DOI 10.2165/00128072-199901010-00002
   FOZARD JR, 1994, N-S ARCH PHARMACOL, V350, P225
   Ha H, 2019, AM FAM PHYSICIAN, V99, P17
   Hämäläinen ML, 2006, CNS DRUGS, V20, P813
   Hougaard A, 2020, HEADACHE, V60, P724, DOI 10.1111/head.13753
   Huang YS, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024401
   Iyengar S, 2019, HEADACHE, V59, P659, DOI 10.1111/head.13529
   Ji SZ, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8876873
   Jo HR, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/4159172
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Li Y, 2012, CAN MED ASSOC J, V184, P401, DOI 10.1503/cmaj.110551
   Li YX, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/3825617
   Lin SJ, 2020, J TRADIT CHIN MED, V40, P267
   Liu GF, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6868625
   Liu L, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-020653
   Natbony LR, 2020, CURR PAIN HEADACHE R, V24, P0, DOI 10.1007/s11916-020-00864-w
   Nye BL, 2015, HEADACHE, V55, P359, DOI 10.1111/head.12536
   Oliveira AB, 2017, NEUROIMMUNOMODULAT, V24, P293, DOI 10.1159/000487141
   Peters GL, 2019, AM J MANAG CARE, V25, P0
   Qi J, 2014, NEURAL REGEN RES, V9, P293, DOI 10.4103/1673-5374.128227
   Redon S, 2021, REV NEUROL-FRANCE, V177, P773, DOI 10.1016/j.neurol.2021.07.002
   Silberstein SD, 2004, LANCET, V363, P381, DOI 10.1016/S0140-6736(04)15440-8
   Sugimoto K, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-020-01194-3
   Villalon CM, 2017, MINI-REV MED CHEM, V17, P928, DOI 10.2174/1389557516666160728121050
   Wei Y, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023596
   Xie XY, 2020, CELL MOL BIOL, V66, P34, DOI 10.14715/cmb/2020.66.6.7
   Xue JY, 2023, J TRADIT CHIN MED, V43, P337, DOI 10.19852/j.cnki.jtcm.20221206.002
   Zhang F, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018900
   Zhang J, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024126
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao ZD, 2020, ELIFE, V9, P0, DOI 10.7554/eLife.61965
   Zhou PJ, 2015, J TRADIT CHIN MED, V35, P301
NR 41
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 1
PY 2025
VL 16
IS 
BP 
EP 
DI 10.3389/fneur.2025.1538182
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 8PI2D
UT WOS:001594114100001
PM 41103513
DA 2026-01-16
ER

PT J
AU Hua, K
   Cummings, M
   Bernatik, M
   Brinkhaus, B
   Usichenko, T
   Willich, SN
   Scheibenbogen, C
   Dietzel, J
AF Hua, Kevin
   Cummings, Mike
   Bernatik, Miriam
   Brinkhaus, Benno
   Usichenko, Taras
   Willich, Stefan N.
   Scheibenbogen, Carmen
   Dietzel, Joanna
TI Effects of Auricular Stimulation on Inflammatory Parameters: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO NEUROMODULATION
LA English
DT Review
DE Auriculotherapy; ear; acupuncture; in fl ammation; meta-analysis; transauricular vagus nerve stimulation
ID frequency cranial electrostimulation; rest-activity rhythm; electrotherapy stimulation; salivary cortisol; single-blind; pain; acupressure; auriculotherapy; acupuncture; fatigue
AB Background: The number of randomized controlled trials (RCTs) using auricular stimulation (AS) techniques, such as trans-auricular vagus nerve stimulation, auricular electrostimulation, auricular acupuncture, and acupressure in experimental and clinical settings has increased markedly over the last three decades. This systematic review evaluates the effects of AS on biomarkers of inflammation and stress responses. Materials and Methods: The following data bases were searched: MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, and Scopus Data base. Data collection and analysis were conducted independently by two reviewers. Quality and risk assessments of the included studies were performed, and a meta-analysis of the effects of the most frequently assessed biomarkers was conducted using RevMan statistical software. Results: A total of 1122 patients and healthy volunteers from 27 RCTs were included in this systematic review; 81% of the participants were female, with a median age of 51 years. Pooled data of 18 studies showed a significant effect of AS regarding a reduction of serum C-reactive protein, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-10. Although IL-4, IL1 beta, cortisol, substance P and calcitonin gene-related peptide, and adrenocorticotropic hormone did not show any changes, salivary amylase increased under AS. Conclusions: The influence of inflammatory cytokines seems to be mediated by AS. More research is needed to investigate the effects of AS on the immunologic system in addition to its clinical significance in high-quality RCT.
C1 [Hua, Kevin; Brinkhaus, Benno; Willich, Stefan N.; Dietzel, Joanna] Charite, Inst Social Med Epidemiol & Hlth Econ, Luisenstr 57, D-10117 Berlin, Germany.
   [Hua, Kevin; Brinkhaus, Benno; Willich, Stefan N.; Dietzel, Joanna] Free Univ Berlin, Berlin, Germany.
   [Hua, Kevin; Brinkhaus, Benno; Willich, Stefan N.; Dietzel, Joanna] Humboldt Univ, Berlin, Germany.
   [Hua, Kevin; Brinkhaus, Benno; Willich, Stefan N.; Dietzel, Joanna] Berlin Inst Hlth, Berlin, Germany.
   [Cummings, Mike] British Med Acupuncture Soc, London, England.
   [Bernatik, Miriam] Int Soc Chinese Med, Munich, Germany.
   [Usichenko, Taras] Univ Hosp Greifswald, Dept Anaesthesiol, Greifswald, Germany.
   [Usichenko, Taras] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Scheibenbogen, Carmen] Charite, Inst Med Immunol, Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Humboldt University of Berlin; Free University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; McMaster University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Dietzel, J (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, Luisenstr 57, D-10117 Berlin, Germany.
EM Joanna.Dietzel@charite.de
CR Addorisio ME, 2019, JOURNAL OF IMMUNOLOGY, V5, P0
   Andersson Ulf, 2012, CEREBRUM, V2012, P3
   Andreas M, 2019, CIRC-ARRHYTHMIA ELEC, V12, P0, DOI 10.1161/CIRCEP.119.007711
   Aranow C, 2021, ANN RHEUM DIS, V80, P203, DOI 10.1136/annrheumdis-2020-217872
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Baker MC, 2023, ARTHRITIS RHEUMATOL, V75, P2107, DOI 10.1002/art.42637
   Bellavance MA, 2014, FRONT IMMUNOL, V5, P0, DOI 10.3389/fimmu.2014.00136
   Bellocchi C, 2023, RMD OPEN, V9, P0, DOI 10.1136/rmdopen-2023-003265
   Bernateck M, 2008, FORSCH KOMPLEMENTMED, V15, P187, DOI 10.1159/000141929
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   Butt MF, 2020, J ANAT, V236, P588, DOI 10.1111/joa.13122
   Cha NH, 2017, HOLIST NURS PRACT, V31, P102, DOI 10.1097/HNP.0000000000000197
   Corrêa HP, 2020, REV ESC ENFERM USP, V54, P0, DOI 10.1590/S1980-220X2019006703626
   Costa-Cavalcanti RG, 2018, J ACUPUNCT MERIDIAN, V11, P145
   Elimam H, 2019, DIABETES METAB SYND, V13, P800, DOI 10.1016/j.dsx.2018.11.061
   Haddad-Rodrigues M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/169184
   Hasan A, 2015, EUR ARCH PSY CLIN N, V265, P589, DOI 10.1007/s00406-015-0618-9
   Ito H, 2015, BMJ OPEN GASTROENTER, V2, P0, DOI 10.1136/bmjgast-2014-000013
   Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30
   Jin H, 2024, NATURE, V630, P0, DOI 10.1038/s41586-024-07469-y
   Koch A, 2007, INFLAMM RES, V56, P32, DOI 10.1007/s00011-007-6088-4
   Koenig J, 2021, PSYCHOL MED, V51, P511, DOI 10.1017/S0033291719003490
   Kraychete DC, 2010, SAO PAULO MED J, V128, P259, DOI 10.1590/S1516-31802010000500003
   Kressel AM, 2020, P NATL ACAD SCI USA, V117, P29803, DOI 10.1073/pnas.2008213117
   Kuo SY, 2016, INT J NURS STUD, V53, P17, DOI 10.1016/j.ijnurstu.2015.10.006
   Lee EJ, 2022, J ADDICT DIS, V40, P415, DOI 10.1080/10550887.2021.2016011
   Lee SH, 2013, J INT MED RES, V41, P1788, DOI 10.1177/0300060513500749
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Nater UM, 2006, PSYCHONEUROENDOCRINO, V31, P49, DOI 10.1016/j.psyneuen.2005.05.010
   Peuker ET, 2002, CLIN ANAT, V15, P35, DOI 10.1002/ca.1089
   Peuker ET, 2003, DTSCH Z AKUPUNKT, V46, P6, DOI 10.1078/0415-6412-00015
   Pirnia B, 2019, IRAN J PSYCHIATRY BE, V13, P0, DOI 10.5812/ijpbs.12498
   Renner V, 2022, TRANSL PSYCHIAT, V12, P0, DOI 10.1038/s41398-022-01921-1
   Roh HT, 2017, TECHNOL HEALTH CARE, V25, P403, DOI 10.3233/THC-161275
   Salama M, 2020, WORLD J SURG, V44, P3167, DOI 10.1007/s00268-020-05543-w
   Scherder E, 2003, NEUROREHAB NEURAL RE, V17, P101, DOI 10.1177/0888439003017002004
   Scherder E, 2006, DEMENT GERIATR COGN, V22, P267, DOI 10.1159/000095108
   Stavrakis S, 2022, J AM HEART ASSOC, V11, P0, DOI 10.1161/JAHA.121.023582
   Stavrakis S, 2020, JACC-CLIN ELECTROPHY, V6, P282, DOI 10.1016/j.jacep.2019.11.008
   Stavrakis S, 2015, J AM COLL CARDIOL, V65, P867, DOI 10.1016/j.jacc.2014.12.026
   Thau L, 2019, PHYSIOLOGY, V0, P0
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Turkheimer FE, 2021, BRAIN BEHAV IMMUN, V91, P487, DOI 10.1016/j.bbi.2020.10.025
   Uehara L, 2022, EXPERT REV MED DEVIC, V19, P915, DOI 10.1080/17434440.2022.2154147
   Usichenko T, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0238307
   Usichenko TI, 2022, J CLIN ANESTH, V76, P0, DOI 10.1016/j.jclinane.2021.110581
   Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021
   Veiz E, 2022, NEUROIMMUNOMODULAT, V29, P450, DOI 10.1159/000524646
   Ventura-Bort C, 2018, FRONT HUM NEUROSCI, V12, P0, DOI 10.3389/fnhum.2018.00202
   Wu ZY, 2023, BRAIN STIMUL, V16, P507, DOI 10.1016/j.brs.2023.02.008
   Xia BJ, 2018, PAIN MED, V19, P193, DOI 10.1093/pm/pnx112
   Xian J, 2023, ACUPUNCT MED, V41, P3, DOI 10.1177/09645284221086288
   Yan CN, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/593196
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Yu LL, 2017, JACC-CARDIOVASC INTE, V10, P1511, DOI 10.1016/j.jcin.2017.04.036
NR 59
TC 4
Z9 4
U1 6
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD JUN 15
PY 2025
VL 28
IS 4
BP 627
EP 640
DI 10.1016/j.neurom.2024.12.007
EA JUN 2025
PG 14
WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences
SC Research & Experimental Medicine; Neurosciences & Neurology
GA 3UA2O
UT WOS:001508988300010
PM 39998453
DA 2026-01-16
ER

PT J
AU Qu, J
   Peng, Y
   Shen, X
   Xiong, J
   Wang, H
   Xiao, X
   Wang, Y
AF Qu, Jinyu
   Peng, Yingchun
   Shen, Xuefang
   Xiong, Jin
   Wang, Huan
   Xiao, Xiang
   Wang, Yili
TI Electroacupuncture of Guanyuan (CV4) Acupoint Improved Pelvic Inflammatory
SO Immunity, inflammation and disease
LA English
DT Journal Article
DE Guanyuan acupoint; electroacupuncture; neuroinflammation; pelvic inflammatory disease; sympathetic activity
AB OBJECTIVE: To investigate the underlying mechanisms through which  electroacupuncture (EA) at the Guanyuan (CV4) acupoint inhibits sympathetic  activity and neurogenic inflammatory responses to relieve pain in rats with  pelvic inflammatory disease (PID). METHODS: Escherichia coli and Staphylococcus  aureus were used to establish a PID rat model. EA was evaluated at frequencies of  2, 100, and 2/100 Hz, and 2/100 Hz was selected for subsequent investigation. The  rats were randomly divided into the control, model, EA-guanyuan (2/100 Hz), and  EA-nonsensitized groups (n = 6). Mechanical withdrawal threshold (MWT) and  thermal withdrawal latency (TWL) were assessed using von Frey filaments.  Hematoxylin and eosin staining was performed to evaluate the histopathology. The  tyrosine hydroxylase (TH) expression was analyzed using immunofluorescence (IF)  staining. The levels of tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2),  transforming growth factor-β1 (TGF-β1), intercellular cell adhesion molecule-1  (ICAM-1), 5-hydroxytryptamine receptor 3 (5-HT3R), substance P (SP), hyaluronic  acid (HA), and bradykinin (BK) were measured using an enzyme-linked immunosorbent  assay (ELISA). Western blot analysis was performed to measure the expression of  5-HT3R, calcitonin gene-related peptide (CGRP), HA, Kininogen 1 (KNG1),  prostaglandin I2 (PGI2), and trefoil factor 2 (TFF2). Transmission electron  microscopy (TEM) was used to observe synaptic connections. RESULTS: EA at CV4  reduced the behavioral pain score (p < 0.05), increased MWT and TWL, and  alleviated uterine tissue pathological damage in rats. EA at CV4 reduced the  levels of 5-HT3R, CGRP, BK, HA, KNG1, PGI2SP, TGF-β1, ICAM-1, and TNF-α, and  increased IL-2 levels (p < 0.05). Furthermore, EA at CV4 inhibited sympathetic  activity by decreasing TH expression (p < 0.05). Additionally, EA at CV4 restored  the synaptic connections between the pelvic nerves of the dorsal commissural  neuron (DCN). CONCLUSION: EA at CV4 alleviated the pathological damage and pain  sensitization of uterine tissue in rats with PID by inhibiting sympathetic  activity and neurogenic inflammatory response.
C1 Department of Neurology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Neurology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Neurology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Neurology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Rehabilitation Medicine, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Nephrology, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
   Department of Rehabilitation Medicine, the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
NR 0
TC 0
SN 2050-452
EI 
J9 Immun Inflamm Dis
PD NOV 6
PY 2025
VL 13
IS 11
BP e70299
EP e70299
DI 10.1002/iid3.70299
PG 1
WC Humans; Pelvic Inflammatory Disease; pathology; Neuroinflammatory Diseases; therapy; Sympathetic Nervous System; Animals; Rats; Disease Models, Animal; Pain Management; Acupuncture Points; Female; Rats, Sprague-Dawley; Uterus; pathology; Chromosome Pairing; Acupuncture Therapy
UT PubMed:41194515
PM 41194515
DA 2025-11-06
ER

PT J
AU Bell, BK
   Cha, JY
   Cavanaugh, KA
   O'Riordan, DL
   Rabow, MW
   Yang, AK
   Patel, S
   Park, SH
   Mcgrath, MK
   Whitaker, EM
   Nouri, SS
   Cheng, SW
AF Bell, Brieze K.
   Cha, Jaeyoon
   Cavanaugh, Kathleen A.
   O'Riordan, David L.
   Rabow, Michael W.
   Yang, Adrienne K.
   Patel, Sohil
   Park, Sa Heen
   Mcgrath, Megan K.
   Whitaker, Evans M.
   Nouri, Sarah S.
   Cheng, Stephanie W.
TI Integrative Management of Cancer Pain: A Scoping Review of the Literature
SO CANCER MEDICINE
LA English
DT Review
DE acupuncture; cancer pain; complementary and alternative medicine; integrative health; integrative medicine; integrative oncology; mindfulness
ID progressive muscle-relaxation; breast-cancer; musculoskeletal symptoms; aromatase inhibitors; guided imagery; double-blind; acupuncture; complementary; medicine; women
AB Background: Cancer-related pain is common and debilitating. Patients frequently use integrative medicine therapies to manage this, though safety and efficacy evidence is incomplete. This scoping review aims to characterize the state of integrative cancer pain therapy (ICPT) and identify priorities for future research. Methods: Following PRISMA guidelines, we searched PubMed, Embase, Web of Science, PsycINFO, CINAHL, and Cochrane for ICPT studies published between January 1, 1975 and May 26, 2022. Study findings were extracted and analyzed using descriptive statistics and thematic analysis. Interventions were categorized as follows: Whole Systems of Medicine (WSM); Mind-body Medicine (MBM); Botanicals and Supplements (BAS); and Manual Therapies (MT). Quality appraisal was performed using the Downs and Black checklist. Efficacy was "positive" if there were statistically significant differences between study arms (p < 0.05) favoring ICPT. Results: Among 1246 studies reviewed, 151 met inclusion criteria; 63.5% were excellent or good quality, and 68.9% were RCTs; 122 studies (80.7%) were published since 2010. Studies occurred in 24 countries, in variable settings, among participants with a wide range of cancers, disease status, and age ranges. Studies investigating WSM and MBM interventions were most frequent (35.7% for each), MT (20.59%), and BAS (7.9%). Overall, of the included studies, 127 (84.1%) found that the ICPT intervention reduced pain. Conclusions: Studies on ICPT are increasingly common, and the majority of ICPT interventions demonstrated a positive impact on cancer pain. Future rigorous research should compare efficacy across integrative and biomedical interventions and explore how to incorporate evidence-based ICPT into standard cancer treatment.
C1 [Bell, Brieze K.; Cavanaugh, Kathleen A.; O'Riordan, David L.; Rabow, Michael W.; Yang, Adrienne K.; Patel, Sohil; Park, Sa Heen; Mcgrath, Megan K.; Nouri, Sarah S.; Cheng, Stephanie W.] Univ Calif San Francisco, San Francisco, CA 94115 USA.
   [Cha, Jaeyoon] Harvard Med Sch, Boston, MA USA.
   [Rabow, Michael W.] Supported Mt Zion Hlth Fund, MERI Ctr Educ Palliat Care, San Francisco, CA USA.
   [Whitaker, Evans M.] Stanford Univ, Sch Med, Palo Alto, CA USA.
C3 University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Stanford University
RP Bell, BK (corresponding author), Univ Calif San Francisco, San Francisco, CA 94115 USA.
EM brieze.bell@ucsf.edu
FU Mount Zion Health Fund; MERI Center for Education in Palliative Care
CR Unknown -, 2023, PRODUCTSVITAL STATISTICS RAPID RELEASEPROVISIONAL DRUG OVERDOSE DATA, V0, P0
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bauer BA, 2020, ALTERN THER HEALTH M, V26, P8
   Brier MJ, 2017, CANCER-AM CANCER SOC, V123, P169, DOI 10.1002/cncr.30318
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Calcagni N, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0223564
   Carson JW, 2007, J PAIN SYMPTOM MANAG, V33, P331, DOI 10.1016/j.jpainsymman.2006.08.009
   Carson JW, 2021, J PAIN SYMPTOM MANAG, V61, P1227, DOI 10.1016/j.jpainsymman.2020.10.009
   Chen FJ, 2021, PAIN MANAG NURS, V22, P791, DOI 10.1016/j.pmn.2021.04.009
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen SF, 2015, IRAN RED CRESCENT ME, V17, P0, DOI 10.5812/ircmj.31277
   De Paolis G, 2019, COMPLEMENT THER CLIN, V34, P280, DOI 10.1016/j.ctcp.2018.12.014
   Demmer Craig, 2004, J PALLIAT MED, V7, P510, DOI 10.1089/1096621041838335
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dydyk AM, 2022, OPIOID USE DISORDER, V0, P0
   Dymackova R, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10051111
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Haddaway NR, 2022, CAMPBELL SYST REV, V18, P0, DOI 10.1002/cl2.1230
   Harte J, 2019, INT J PALLIAT NURS, V25, P108, DOI 10.12968/ijpn.2019.25.3.108
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Hsiao AF, 2006, SOC SCI MED, V62, P2973, DOI 10.1016/j.socscimed.2005.11.056
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Jensen MP, 2012, INT J CLIN EXP HYP, V60, P135, DOI 10.1080/00207144.2012.648057
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Johnson JR, 2013, J PAIN SYMPTOM MANAG, V46, P207, DOI 10.1016/j.jpainsymman.2012.07.014
   Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008
   Kasymjanova G, 2013, CURR ONCOL, V20, P152, DOI 10.3747/co.20.1312
   Kwckkeboom KL, 2008, J PAIN SYMPTOM MANAG, V36, P604, DOI 10.1016/j.jpainsymman.2007.12.011
   Lacroix C, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419869494
   Larochelle MR, 2021, AM J PUBLIC HEALTH, V111, P1851, DOI 10.2105/AJPH.2021.306431
   Lichtman AH, 2018, J PAIN SYMPTOM MANAG, V55, P179, DOI 10.1016/j.jpainsymman.2017.09.001
   Lopes LC Jr, 2020, REV LAT-AM ENFERM, V28, P0, DOI 10.1590/1518-8345.4213.3377
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Maqsood S, 2019, ANAESTH PAIN INTENSI, V23, P0, DOI 10.35975/apic.v23i1.1088
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Ngamkham S, 2021, ASIA-PAC J ONCOL NUR, V8, P58, DOI 10.4103/apjon.apjon_43_20
   NOYES R, 1975, J CLIN PHARMACOL, V15, P139, DOI 10.1002/j.1552-4604.1975.tb02348.x
   Parás-Bravo P, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2200-2
   Pawasarat IM, 2020, J PALLIAT MED, V23, P809, DOI 10.1089/jpm.2019.0374
   Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003
   Rodriguez C, 2019, J HOSP PALLIAT NURS, V21, P116, DOI 10.1097/NJH.0000000000000507
   Saleh A, 2020, ENFERM CLIN, V30, P45, DOI 10.1016/j.enfcli.2019.07.025
   Sanford NN, 2019, JAMA ONCOL, V5, P735, DOI 10.1001/jamaoncol.2019.0349
   Schleider LBL, 2018, EUR J INTERN MED, V49, P37, DOI 10.1016/j.ejim.2018.01.023
   Serçe S, 2018, INTEGR CANCER THER, V17, P728, DOI 10.1177/1534735418769153
   Shamloo MBB, 2019, COMPLEMENT THER CLIN, V35, P78, DOI 10.1016/j.ctcp.2019.01.016
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Sohl SJ, 2015, CANCER-AM CANCER SOC, V121, P900, DOI 10.1002/cncr.29138
   Sohrabi C, 2021, INT J SURG, V86, P57, DOI 10.1016/j.ijsu.2020.12.008
   SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Tsai PS, 2007, CANCER NURS, V30, P347, DOI 10.1097/01.NCC.0000290805.38335.7b
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Viscuse PV, 2017, CURR OPIN ONCOL, V29, P235, DOI 10.1097/CCO.0000000000000376
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zeng YS, 2018, J PAIN SYMPTOM MANAG, V56, P781, DOI 10.1016/j.jpainsymman.2018.07.016
   Zhang H, 2018, JAMA OTOLARYNGOL, V144, P1017, DOI 10.1001/jamaoto.2018.0486
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
NR 69
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
EI 
J9 CANCER MED-US
JI Cancer Med.
PD MAY 3
PY 2025
VL 14
IS 9
BP 
EP 
DI 10.1002/cam4.70833
PG 10
WC Oncology
SC Oncology
GA 2EI2N
UT WOS:001480621300001
PM 40317896
DA 2026-01-16
ER

PT J
AU Shen, Q
   Zhu, YW
   Xu, WH
   Tang, MY
   Xie, HJ
   Chen, JDZ
   Wu, GJ
AF Shen, Qin
   Zhu, Ying-wei
   Xu, Wen-hui
   Tang, Ming-yu
   Xie, Hong-jun
   Chen, Jiande D. Z.
   Wu, Gao-jue
TI Integrative Effects of Transcutaneous Electrical Acustimulation and Autonomic-Endocrine Mechanisms on Postprocedural Recovery in Patients With Endoscopic Retrograde Cholangio-Pancreatography
SO NEUROMODULATION
LA English
DT Article
DE Autonomic function; endoscopic retrograde cholangio-pancreatography (ERCP); gastrointestinal motility; ghrelin; transcutaneous electrical acustimulation
ID nerve-stimulation; pain; ercp
AB Objectives: This study aimed to investigate the integrative effects and mechanisms of transcutaneous electrical acustimulation (TEA) on postprocedural recovery from endoscopic retrograde cholangio-pancreatography (ERCP). Materials and Methods: A total of 86 patients for elective ERCP were randomly ordered to receive TEA (n = 43) at acupoints PC6 and ST36 or Sham-TEA (n = 43) at sham points from 24 hours before ERCP (pre-ERCP) to 24 hours after ERCP (PE24). Scores of gastrointestinal (GI) motility-related symptoms and abdominal pain, gastric slow waves, and autonomic functions were recorded through the spectral analysis of heart rate variability; meanwhile, circulatory levels of inflammation cytokines of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-10 and GI hormones of motilin, ghrelin, cholecystokinin (CCK), and vasoactive intestinal peptide (VIP) were assessed by enzyme-linked immunosorbent assay. Results: 1) TEA, but not Sham-TEA, decreased the post-ERCP GI motility-related symptom score (2.4 +/- 2.6 vs 7.9 +/- 4.6, p < 0.001) and abdominal pain score (0.5 +/- 0.7 vs 4.1 +/- 2.7, p < 0.001) at PE24, and decreased the post-ERCP hospital day by 20.0% (p < 0.05 vs Sham-TEA); 2) TEA improved the average gastric percentage of normal slow waves and dominant frequency by 34.6% and 33.3% at PE24, respectively (both p < 0.001 vs Sham-TEA); 3) TEA, but not Sham-TEA, reversed the ERCP-induced increase of TNF alpha but not IL-10 at PE24, reflected as a significantly lower level of TNF-alpha in the TEA group than in the Sham-TEA group (1.6 +/- 0.5 pg/mL vs 2.1 +/- 0.9 pg/mL, p < 0.01); 4) compared with Sham-TEA, TEA increased vagal activity by 37.5% (p < 0.001); and 5) TEA caused a significantly higher plasma level of ghrelin (1.5 +/- 0.8 ng/ml vs 1.1 +/- 0.7 ng/ml, p < 0.05) but not motilin, VIP, or CCK than did Sham-TEA at PE24. Conclusion: TEA at PC6 and ST36 accelerates the post-ERCP recovery, reflected as the improvement in GI motility and amelioration of abdominal pain, and suppression of the inflammatory cytokine TNF-alpha may mediate through both autonomic and ghrelin-related mechanisms.
C1 [Shen, Qin; Zhu, Ying-wei; Xu, Wen-hui; Tang, Ming-yu; Xie, Hong-jun; Wu, Gao-jue] Jiangnan Univ, Wuxi 2 Peoples Hosp, Dept Gastroenterol, Med Ctr, 68 Zhongshan Rd, Wuxi 214002, Jiangsu Provinc, Peoples R China.
   [Shen, Qin; Zhu, Ying-wei; Tang, Ming-yu; Wu, Gao-jue] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu Provinc, Peoples R China.
   [Chen, Jiande D. Z.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI USA.
C3 Jiangnan University; Jiangnan University; University of Michigan System; University of Michigan
RP Wu, GJ (corresponding author), Jiangnan Univ, Wuxi 2 Peoples Hosp, Dept Gastroenterol, Med Ctr, 68 Zhongshan Rd, Wuxi 214002, Jiangsu Provinc, Peoples R China.
EM wugaojue@aliyun.com
FU Top Talent Support Program for young and middle-aged people of Wuxi Health Committee [BJ2023031]; Science and Technology Bureau of Wuxi City [Y20212028]; Wuxi City, Jiangsu Province, China
CR Alam MJ, 2023, DIAGNOSTICS, V13, P0, DOI 10.3390/diagnostics13040627
   Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7
   Boeckxstaens GE, 2009, GUT, V58, P1300, DOI 10.1136/gut.2008.169250
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   CHEN JD, 1993, IEEE T BIO-MED ENG, V40, P128, DOI 10.1109/10.212066
   Chen MJ, 2022, HEPATOB PANCREAT DIS, V21, P285, DOI 10.1016/j.hbpd.2021.12.002
   Davis EA, 2020, CURR BIOL, V30, P0, DOI 10.1016/j.cub.2020.08.069
   Dumonceau JM, 2020, ENDOSCOPY, V52, P127, DOI 10.1055/a-1075-4080
   Harrison E, 2013, FRONTLINE GASTROENTE, V4, P282, DOI 10.1136/flgastro-2013-100309
   Huang ZH, 2022, AM J GASTROENTEROL, V117, P1491, DOI 10.14309/ajg.0000000000001882
   Jiao ZT, 2022, NUTRIENTS, V14, P0, DOI 10.3390/nu14194191
   Jin HF, 2019, NEUROGASTROENT MOTIL, V31, P0, DOI 10.1111/nmo.13615
   Kitazawa T, 2019, FRONT ENDOCRINOL, V10, P0, DOI 10.3389/fendo.2019.00278
   KRAUSE AW, 1987, PHYS THER, V67, P507, DOI 10.1093/ptj/67.4.507
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Liu S, 2008, NEUROGASTROENT MOTIL, V20, P1204, DOI 10.1111/j.1365-2982.2008.01164.x
   Lu ZK, 2012, MOL BIOL REP, V39, P3557, DOI 10.1007/s11033-011-1129-z
   Maple JT, 2009, GASTROINTEST ENDOSC, V70, P278, DOI 10.1016/j.gie.2008.12.050
   Matsushita M, 2017, GASTROINTEST ENDOSC, V86, P747, DOI 10.1016/j.gie.2017.05.007
   Niu F, 2019, VIDEOSURGERY MINIINV, V14, P394, DOI 10.5114/wiitm.2019.82871
   Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x
   Petrov MS, 2017, SCAND J GASTROENTERO, V52, P615, DOI 10.1080/00365521.2017.1296182
   Priebe HJ, 2016, BEST PRACT RES-CLIN, V30, P171, DOI 10.1016/j.bpa.2016.03.001
   Prodam F, 2014, ARCH IMMUNOL THER EX, V62, P369, DOI 10.1007/s00005-014-0287-9
   Qi DB, 2016, LIFE SCI, V160, P64, DOI 10.1016/j.lfs.2016.06.025
   Shrestha YB, 2009, PEPTIDES, V30, P1187, DOI 10.1016/j.peptides.2009.02.001
   Su Yang-Shuai, 2022, ZHEN CI YAN JIU, V47, P1, DOI 10.13702/j.1000-0607.20211341
   Tolentino Bento da Silva M, 2021, PHYSIOL BEHAV, V233, P0, DOI 10.1016/j.physbeh.2021.113355
   Traut U, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004930.pub3
   Wang HW, 2020, BIOMED PHARMACOTHER, V129, P0, DOI 10.1016/j.biopha.2020.110343
   Wu JN, 2017, EXP THER MED, V14, P4655, DOI 10.3892/etm.2017.5159
   Xiao Y, 2022, CLIN TRANSL GASTROEN, V13, P0, DOI 10.14309/ctg.0000000000000485
   Xuan JL, 2022, NEUROGASTROENT MOTIL, V34, P0, DOI 10.1111/nmo.14249
   Yin JY, 2023, EXPERT REV GASTROENT, V17, P1221, DOI 10.1080/17474124.2023.2288156
   Yin JY, 2013, J NEUROGASTROENTEROL, V19, P5, DOI 10.5056/jnm.2013.19.1.5
   Zhang B, 2021, AM J GASTROENTEROL, V116, P1495, DOI 10.14309/ajg.0000000000001203
   Zhang B, 2019, NEUROMODULATION, V22, P546, DOI 10.1111/ner.12856
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
NR 39
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD JAN 15
PY 2025
VL 28
IS 1
BP 174
EP 184
DI 10.1016/j.neurom.2024.06.503
EA JAN 2025
PG 11
WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences
SC Research & Experimental Medicine; Neurosciences & Neurology
GA S7T7U
UT WOS:001400206700001
PM 39115505
DA 2026-01-16
ER

PT J
AU Xie, T
   Liu, C
   Wu, Y
   Li, X
   Yang, Q
   Tan, J
AF Xie, Tianle
   Liu, Can
   Wu, Yudi
   Li, Xiuxiu
   Yang, Qianyun
   Tan, Jing
TI Efficacy and Safety of Different Acupuncture Treatments for Cancer-Related Pain:
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer; cancer pain; meta-analysis
AB BACKGROUND: Cancer pain is a prevalent and persistent issue, and while there have  been some observations of the possible benefits of acupuncture in managing cancer  pain, there is still debate regarding its safety and effectiveness. This study  aims to compare the efficacy and safety of different acupuncture modalities in  the treatment of cancer pain through a network meta-analysis. METHODS: Between  the time each database was created and June 3, 2024, eight databases were  queried: PubMed, Cochrane, Embase, Web of Science, CNKI, Wanfang, VIP, and China  Biomedicine. Randomized controlled trials investigating the use of various  acupuncture and moxibustion techniques in the treatment of cancer pain were  identified. Publication bias and quality of randomized controlled trials were  assessed using the Cochrane Risk of Bias tool and the Jadad scale, and network  meta-analyses were performed using Stata 15 and R 4.3.2. RESULTS: We incorporated  111 studies encompassing 9549 individuals diagnosed with cancer, examining 29  distinct therapies. Network meta-analysis showed that, compared to Usual  Medicine, Acupuncture + Usual Medicine + Traditional Chinese medicine  (MD = -1.83, 95% CI: -2.86 to -0.80) could reduce NRS scores,  Acupuncture + Traditional Chinese medicine (OR = 30.86, 95% CI: 3.75-254.20)  could improve cancer pain relief, Moxibustion + Usual Medicine (MD = 2.12, 95%  CI: 0.43-3.80) could effectively improve KPS score, Acupuncture + Application of  Chinese medicine (OR = 0.16, 95% CI: 0.04-0.66) is associated with a lower  incidence of constipation, Electro-Acupuncture + Usual Medicine (OR = 0.11, 95%  CI: 0.03-0.45) shows a lower incidence of nausea and vomiting,  Acupuncture + Moxibustion + Usual Medicine (OR = 0.29, 95% CI: 0.09-0.90) is  associated with a lower incidence of dizziness. CONCLUSION:  Acupuncture + Traditional Chinese medicine is the best intervention for different  acupuncture methods in the treatment of cancer pain, and Moxibustion + Usual  Medicine is the best intervention to improve the quality of life of patients.
C1 Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Hunan University of Chinese Medicine, Changsha, Hunan, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JAN 28
PY 2025
VL 24
IS 
BP 15347354251314500
EP 15347354251314500
DI 10.1177/15347354251314500
PG 1
WC Humans; Acupuncture Therapy; methods; Cancer Pain; therapy; Medicine, Chinese Traditional; methods; Moxibustion; methods; Neoplasms; complications; Pain Management; methods; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:39873173
PM 39873173
DA 2025-01-28
ER

PT J
AU Wang, F
   Ye, Z
   Yin, X
   Zhou, C
   Zhong, M
   Zhao, G
AF Wang, Feng
   Ye, Zhihui
   Yin, Xiuju
   Zhou, Chengcheng
   Zhong, Min
   Zhao, Gaofeng
TI Electroacupuncture at 5/100 Hz alleviates neuropathic pain in rats by inhibiting
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE CCL3; CCR5; electroacupuncture; glial cells; neuropathic pain; proinflammatory factors
AB OBJECTIVE: Typically, neuropathic pain (NP) is difficult to manage as it is  refractory to conventional medications. Electroacupuncture (EA) at 5/100 Hz has  emerged as an effective and promising treatment for NP; however, its mechanism of  action is still uncertain. Accordingly, this study investigated the alleviatory  mechanism of EA in chronic compression injury (CCI)-induced chronic pain via the  C-C chemokine ligand 3 / C-C chemokine receptor type 5 (CCL3/CCR5) axis. METHODS:  The CCI model was established in rats to induce NP. Mechanical and thermal  hyperalgesia were assessed with von Frey and Hargreaves tests, respectively. From  day 8 after CCI, EA (5/100 Hz) was performed for 1 week (30 min/day). CCL3 and  CCR5 expression was detected with Western blotting and immunofluorescence. Glial  cell activation was determined through co-labeling of neurons and glial cells  with antibodies against CCL3 and CCR5. The release of interleukin (IL)-1β, IL-6  and tumor necrosis factor (TNF)-α was tested with enzyme-linked immunosorbent  assay (ELISA). RESULTS: EA markedly ameliorated CCI-induced chronic NP in rats  and reduced CCL3 and CCR5 expression in the rat spinal cord. CCL3 and CCR5 were  co-expressed by neurons and microglia in the central nervous system. In addition,  EA also repressed the activation of glial cells and levels of IL-1β, IL-6 and  TNF-α. CONCLUSION: EA may mitigate chronic NP in rats by blocking the CCL3/CCR5  axis in the spinal cord. In addition, EA appeared to exert anti-inflammatory and  analgesic effects by suppressing glial cell activation. These findings add to our  understanding of the mechanism of EA-induced analgesia.
C1 Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD MAR 22
PY 2025
VL 43
IS 2
BP 95
EP 103
DI 10.1177/09645284251327197
PG 8
WC Animals; Electroacupuncture; Receptors, CCR5; genetics; Neuralgia; therapy; Spinal Cord; metabolism; Rats; Male; Chemokine CCL3; genetics; Rats, Sprague-Dawley; Humans; Disease Models, Animal
UT PubMed:40119762
PM 40119762
DA 2025-03-22
ER

PT J
AU Shainhouse, J
   Hwang, PSY
   Fontes, M
   Bao, T
AF Shainhouse, Jill
   Hwang, Pauline Sok Yin
   Fontes, Mark
   Bao, Ting
TI Integrative medicine in breast cancer survivorship care.
SO Annals of palliative medicine
LA English
DT Review
DE Integrative medicine; breast cancer; lifestyle; symptoms
AB Integrative medicine use is prevalent among breast cancer survivors to improve  lifestyle and manage symptoms associated with cancer or its treatment. This  review provides an overview of integrative therapies used for lifestyle  improvement and symptom management in breast cancer patients, including diet and  exercise recommendations, mind-body approaches including mindfulness-based  intervention, acupuncture, yoga, massage, and dietary supplements. A balanced  diet with an emphasis on plant-based foods and limited consumption of red meat,  processed meats, alcohol, and refined sugar is recommended for cancer patients  and survivors. Physical activity is also important, with recommendations of 30  minutes of moderate exercise daily, aiming for 150 minutes per week. Mind-body  approaches such as meditation, yoga have been shown to improve emotional  self-regulation, anxiety, depression, and other symptoms. Acupuncture has  demonstrated potential benefits for aromatase inhibitor-induced musculoskeletal  symptoms, hot flashes, peripheral neuropathy, and fatigue. Massage may help  address pain, anxiety, stress, and improve quality of life (QoL). Supplement use  should be approached with caution, especially during active treatment, due to  potential interactions with cancer therapies. The review highlights the role of  specialized integrative medicine practitioners, such as naturopathic doctors and  acupuncturists, in safely incorporating these therapies into standard cancer  care. This collaborative approach supports survivors' diverse needs and empowers  them to actively participate in their recovery, ultimately improving health  outcomes and QoL. Integrative therapy programs within cancer care institutions  can provide structure, guidance, and support for patients to safely incorporate  these modalities into their treatment and recovery plans.
C1 Integrative Cancer Care, Insight Naturopathic Clinic, Toronto, ON, Canada.
   Internal Medicine, Nanjing University of Chinese Medicine, Hillgreen Oncology Acupuncture & Herbs, Toronto, ON, Canada.
   Integrative Cancer Care, Insight Naturopathic Clinic, Toronto, ON, Canada.
   Medical Oncology Department, Dana-Farber Cancer Institute, Boston, MA, USA.
NR 0
TC 0
SN 2224-583
EI 
J9 Ann Palliat Med
PD JUN 13
PY 2025
VL 14
IS 3
BP 283
EP 294
DI 10.21037/apm-24-176
PG 11
WC Humans; Breast Neoplasms; therapy; Integrative Medicine; methods; Female; Cancer Survivors; psychology; Quality of Life; Mind-Body Therapies; Complementary Therapies
UT PubMed:40511571
PM 40511571
DA 2025-06-13
ER

PT J
AU Atreya, CE
   Leach, H
   Asiimwe, E
   Bahri, N
   Le, BK
   Macaire, G
   Wood, KC
   Van, Blarigan EL
   Lee, RT
AF Atreya, Chloe E
   Leach, Heather
   Asiimwe, Edgar
   Bahri, Natasha
   Le, Bryan Khuong
   Macaire, Greta
   Wood, Kelley C
   Van Blarigan, Erin L
   Lee, Richard T
TI Integrative Oncology: Incorporating Evidence-Based Approaches for Patients With
SO American Society of Clinical Oncology educational book. American Society of
LA English
DT Review
AB Data have matured to support incorporation of integrative oncology modalities  into comprehensive cancer care. Clinical practice guidelines have recently been  published by ASCO for diet and exercise (2022) and use of cannabinoids and  cannabis (2024) and jointly by ASCO and the Society for Integrative Oncology  (SIO) for application of integrative approaches in the management of pain (2022),  anxiety and depression (2023), and fatigue (2024) among adults with cancer.  Following the ASCO-SIO guidelines, clinicians should recommend mindfulness-based  interventions (MBIs) to patients with symptoms of anxiety or depression and MBIs  and exercise for management of fatigue during or after completion of cancer  treatment. We will review the basis of these recommendations and evidence to  support use of other mind-body approaches, exercise, nutrition,  acupuncture/acupressure, and natural products in the specific contexts of GI  cancers. For example, optimizing physical activity and diet is associated with  improved survival after a colorectal cancer (CRC) diagnosis, in addition to  conferring symptom management benefits. We will also highlight gaps in research,  including that most studies enrolling patients with GI malignancies have focused  on CRC. A limitation of nonpharmacologic evidence-based guidelines is that they  list broad categories (eg, yoga or acupuncture) and lack implementation details.  How to safely and equitably incorporate integrative approaches into conventional  cancer care will be addressed. This ASCO Educational Book article aims to be both  evidence-informed and practical, with attention to unique considerations for  people with GI cancers.
C1 Department of Medicine, University of California, San Francisco, CA.
   Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
   Osher Center for Integrative Health, San Francisco, CA.
   Department of Health and Exercise Science, Colorado State University, Fort Collins, CO.
   Department of Medicine, University of California, San Francisco, CA.
   National Clinician Scholars Program, University of California, San Francisco, CA.
   City of Hope National Medical Center, Duarte, CA.
   Department of Medicine, University of California, San Francisco, CA.
   Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
   Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
   ReVital Cancer Rehabilitation, Select Medical, Mechanicsburg, PA.
   Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
   Department of Epidemiology and Biostatistics, University of California, San 
   Department of Urology, University of California, San Francisco, CA.
   City of Hope National Medical Center, Duarte, CA.
NR 0
TC 0
SN 1548-875
EI 
J9 Am Soc Clin Oncol Educ Book
PD JAN 22
PY 2025
VL 45
IS 1
BP e471734
EP e471734
DI 10.1200/EDBK-25-471734
PG 1
WC Humans; Integrative Oncology; methods; Gastrointestinal Neoplasms; therapy; Evidence-Based Medicine
UT PubMed:39841946
PM 39841946
DA 2025-01-22
ER

PT J
AU Yu, RF
   Guo, XF
   Zhu, YJ
   Chen, Y
   Zhang, CY
   Chai, XS
   Wang, YQ
AF Yu, Ruifang
   Guo, Xinfeng
   Zhu, Yanjuan
   Chen, Yue
   Zhang, Canyang
   Chai, Xiaoshu
   Wang, Yingqi
TI Acupuncture reduced incidence of insomnia symptoms in patients with lung cancer: a retrospective cohort study
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Insomnia symptoms; Lung cancer; Prevention; Acupuncture
ID breast-cancer; sleep quality; electroacupuncture; fatigue; prevalence; prevention; efficacy; adults
AB Purpose About 30-50% of lung cancer patients suffer from insomnia with limited prevention options. We conducted a retrospective cohort study to investigate whether acupuncture for cancer-related symptoms such as pain could reduce the incidence of insomnia symptoms. Methods We included newly diagnosed lung cancer patients without prior insomnia symptoms from Guangdong Provincial Hospital of Chinese Medicine (2012-2021) and followed up until January 31, 2022. Cases were propensity score-matched by sex, age, ECOG PS score, pathological diagnosis, therapy, and comorbidities. The main outcome was the incidence of insomnia symptoms, identified by psychiatric diagnosis or insomnia symptoms in medical records. Results Among 1295 lung cancer survivors, 918 patients were matched (459 per group). Over an average follow-up of 218.6 days, insomnia symptoms were observed in 20.9% of the acupuncture group and 42.2% of the non-acupuncture group. Acupuncture was linked to a lower incidence of insomnia symptoms (adjusted HR 0.31, 95% CI 0.23-0.39). Higher frequency and more numerous acupuncture sessions further reduced the risk of insomnia symptoms (adjusted HR 0.15 for frequency of 1 day/session, adjusted HR 0.15 for sessions > 16). The acupuncture group had a significantly lower cumulative incidence of insomnia (log-rank test, P < 0.01). Conclusion Our results suggest that acupuncture may prevent the incidence of insomnia symptoms in patients with lung cancer. Daily sessions and a cumulative total of 16 or more treatments may enhance the benefit.
C1 [Yu, Ruifang; Zhang, Canyang] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou, Peoples R China.
   [Yu, Ruifang; Guo, Xinfeng; Zhang, Canyang] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Guo, Xinfeng] Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
   [Guo, Xinfeng] Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China.
   [Zhu, Yanjuan; Chai, Xiaoshu] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Dept Oncol, Guangzhou, Peoples R China.
   [Chen, Yue] Guangzhou Univ Chinese Med, Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China.
   [Wang, Yingqi] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Chai, XS (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Dept Oncol, Guangzhou, Peoples R China.; Wang, YQ (corresponding author), Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Peoples R China.
EM chaixiaoshu@126.com; wyq950101@126.com
FU the State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine [No. SZ2021ZZ0401]; Science and Technology Planning Project of Guangdong Province [No. 2023B1212060063]; Fuding for Young Top Talents of Guangzhou University of Chinese Medicines [A1-2601-25-415-111Z68]; Fuding for Young Top Talents of Guangdong Provincial Hospital of Traditional Chinese Medicine,International Collaborative Research Program of Guangdong Provincial Hospital of Traditional Chinese Medicine [YN2024HL05]
CR Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Chinese Society of Clinical Oncology Guideline Working Committee, 2021, J CLIN ONCOL (CHINA), V26, P638, DOI 10.3969/j.issn.1009-0460.2021.07.011
   Feeney T, 2025, BMJ-BRIT MED J, V388, P0, DOI 10.1136/bmj-2023-078226
   Gamus D, 2025, AUTOIMMUN REV, V24, P0, DOI 10.1016/j.autrev.2024.103709
   Gao JH, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0521-y
   Guo J, 2024, FRONT MICROBIOL, V15, P0, DOI 10.3389/fmicb.2024.1456848
   Han XK, 2021, CHIN MED-UK, V16, P0, DOI 10.1186/s13020-020-00421-y
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Heide-Jorgensen U, 2018, CLIN EPIDEMIOL, V10, P1325, DOI 10.2147/CLEP.S164456
   Howell D, 2013, SUPPORT CARE CANCER, V21, P2695, DOI 10.1007/s00520-013-1823-6
   Huang W, 2009, SLEEP MED REV, V13, P73, DOI 10.1016/j.smrv.2008.04.002
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Jakobsen G, 2019, BMJ SUPPORT PALLIAT, V9, P307, DOI 10.1136/bmjspcare-2017-001399
   Jiang Tian-Xin, 2024, ZHEN CI YAN JIU, V49, P845, DOI 10.13702/j.1000-0607.20230316
   Le JJ, 2016, NEUROSCI LETT, V615, P66, DOI 10.1016/j.neulet.2016.01.004
   Li GF, 2025, FRONT MED-LAUSANNE, V12, P0, DOI 10.3389/fmed.2025.1513888
   Lina Qiao, 2023, J TRADIT CHIN MED, V43, P704, DOI 10.19852/j.cnki.jtcm.20230308.001
   Lis CG, 2008, SUPPORT CARE CANCER, V16, P261, DOI 10.1007/s00520-007-0314-z
   Liu LQ, 2012, BRAIN BEHAV IMMUN, V26, P706, DOI 10.1016/j.bbi.2012.02.001
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Marion LP, 2021, BEHAV SLEEP MED, V19, P70, DOI 10.1080/15402002.2019.1707203
   Mercadante S, 2004, SUPPORT CARE CANCER, V12, P355, DOI 10.1007/s00520-004-0623-4
   Mercadante S, 2021, INT J CLIN PRACT, V0, P0, DOI DOI 10.1111/ijcp.14521
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Nishiura M, 2015, PALLIAT SUPPORT CARE, V13, P575, DOI 10.1017/S1478951513001119
   Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Ozminkowski RJ, 2007, SLEEP, V30, P263, DOI 10.1093/sleep/30.3.263
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Papadopoulos D, 2019, PSYCHO-ONCOLOGY, V28, P1879, DOI 10.1002/pon.5167
   Pearl J, 2016, CAUSAL INFERENCE IN STATISTICS: A PRIMER, V0, P58
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Rosenberg Russell P, 2023, PRIM CARE COMPANION CNS DISORD, V25, P0, DOI 10.4088/pcc.22nr03385
   Ruel S, 2020, HEALTH PSYCHOL, V39, P358, DOI 10.1037/hea0000811
   Savard J, 2009, J CLIN ONCOL, V27, P5233, DOI 10.1200/JCO.2008.21.6333
   Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487
   Sephton SE, 2013, BRAIN BEHAV IMMUN, V30, PS163, DOI 10.1016/j.bbi.2012.07.019
   Shergis JL, 2016, COMPLEMENT THER MED, V26, P11, DOI 10.1016/j.ctim.2016.02.007
   Teng Dainjun, 2003, J TRADIT CHIN MED, V23, P45
   Tong QY, 2022, CLIN BREAST CANCER, V22, P724, DOI 10.1016/j.clbc.2022.04.010
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Vaughn CM, 2025, CANCERS, V17, P0, DOI 10.3390/cancers17060911
   Wang Peng, 2024, ZHONGGUO ZHEN JIU, V44, P521, DOI 10.13703/j.0255-2930.20231027-k0005
   Xue XH, 2014, NEUROSCI LETT, V558, P14, DOI 10.1016/j.neulet.2013.10.029
   Yujuan YE, 2023, J TRADIT CHIN MED, V43, P523, DOI 10.19852/j.cnki.jtcm.20230404.005
   Yadav K, 2021, JAMA-J AM MED ASSOC, V325, P686, DOI 10.1001/jama.2020.9151
   Yang JW, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/739708
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang Q, 2022, NEUROCHEM RES, V47, P1751, DOI 10.1007/s11064-022-03567-3
   Zhang SQ, 2021, ANAT REC, V304, P2381, DOI 10.1002/ar.24784
   Zhang SY, 2011, J NEUROL SCI, V307, P139, DOI 10.1016/j.jns.2011.04.021
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang XN, 2025, FRONT PSYCHIATRY, V16, P0, DOI 10.3389/fpsyt.2025.1501321
   Zhao HS, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000038476
NR 57
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD DEC 19
PY 2025
VL 34
IS 1
BP 
EP 
DI 10.1007/s00520-025-10256-8
PG 16
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA AA6HP
UT WOS:001643600000001
PM 41417088
DA 2026-01-16
ER

PT J
AU Yang, Q
   Xu, HQ
   Chen, H
   Chen, XY
   Ji, WT
   Cai, MJ
   Fu, H
   Li, H
   Hou, CM
   Gao, J
AF Yang, Qing
   Xu, Huiqiong
   Chen, Huan
   Chen, Xinyu
   Ji, Wenting
   Cai, Minjin
   Fu, Han
   Li, Hang
   Hou, Chaoming
   Gao, Jing
TI Summary of evidence on Traditional Chinese Medicine nursing interventions in hospice care for patients with advanced cancer
SO GERIATRIC NURSING
LA English
DT Article
DE Advanced cancer; Hospice care; Traditional Chinese medicine nursing; interventions; Evidence summary; Evidence-based care
ID integrative palliative care; health; acupuncture; pain
AB Background: Patients with advanced cancer experience physical and psychological pain that affects their quality of life. This review aimed to systematically search, evaluate, and summarize the best evidence on Traditional Chinese Medicine (TCM) nursing interventions in hospice care for patients with advanced cancer and to provide an evidence-based foundation for clinical care. The time limit for the search was from 2010 to September 2024. Methods: A top-down search of relevant literature was conducted according to the "6S" evidence model, including clinical decisions, guidelines, best practices, evidence summaries, systematic reviews, expert consensus, and randomized controlled trials (RCTs). The literature was evaluated, and evidence was extracted independently by two researchers. The evidence was appraised using the Appraisal of Guidelines Research and Evaluation (AGREE) tool and integrated with an evidence-based team consisting of six members. Results: Thirty-three publications were included, including four guidelines, two expert consensus, two clinical decisions, two evidence summaries, twenty-one systematic reviews, and two RCTs. Thirty-six indicators of best evidence were summarized from eight areas: TCM therapy, acupuncture therapy, moxibustion therapy, acupressure therapy, music therapy, traditional Chinese exercise therapy, auricular therapy, and aromatherapy. Conclusion: This review summarizes the best evidence for TCM nursing interventions in hospice care for patients with advanced cancer, which can be used by clinical healthcare professionals to develop appropriate TCM nursing interventions in combination with the actual situation and with full consideration of the needs and wishes of the patients and their families to improve the patients' quality of life in advanced stages. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Yang, Qing; Xu, Huiqiong; Chen, Huan; Chen, Xinyu; Ji, Wenting; Cai, Minjin; Fu, Han; Li, Hang; Hou, Chaoming; Gao, Jing] Chengdu Univ Tradit Chinese Med, Coll Nursing, 1166 Liutai Rd, Chengdu 611137, Sichuan, Peoples R China.
   [Hou, Chaoming] Sichuan Univ, West China Hosp, Canc Ctr,Dept Med Oncol, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Sichuan University
RP Hou, CM; Gao, J (corresponding author), Chengdu Univ Tradit Chinese Med, Coll Nursing, 1166 Liutai Rd, Chengdu 611137, Sichuan, Peoples R China.
EM 983729484@qq.com; 19942021@cdutcm.edu.cn
FU Project of Sichuan Mental Health Education Research Center [XLJKJY2203A]; Sichuan Provincial Administration of Traditional Chinese Medicine [2023MS442]
CR Akazawa T, 2010, J PAIN SYMPTOM MANAG, V40, P224, DOI 10.1016/j.jpainsymman.2009.12.015
   Alessandra S, 2024, REHABILITATION AND INTEGRATIVE TREATMENT OF CANCER PAIN, V0, P0
   Alhusamiah B, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241239110
   Alper Brian S, 2016, EVID BASED MED, V21, P123, DOI 10.1136/ebmed-2016-110447
   Unknown -, 2021, BREAST CANCER: WORLD HEALTH ORGANIZATION INTERNET, V0, P0
   Unknown -, 1992, INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS, V0, P0
   Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055
   Bradt J, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007169.pub2
   Brouwers MC, 2010, CAN MED ASSOC J, V182, PE839, DOI 10.1503/cmaj.090449
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Chu XL, 2020, ARTIF INTELL MED, V103, P0, DOI 10.1016/j.artmed.2020.101810
   Corasaniti MT, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24087085
   Crawford GB, 2021, ESMO OPEN, V6, P0, DOI 10.1016/j.esmoop.2021.100225
   Dan X, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08466-7
   de Valois B, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08386-6
   Department of Medical Affairs. National Administration of Traditional Chinese Medicine, 2024, MANUAL OF TCM SKILLS FOR NURSING STAFF, V0, P0
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Foster MJ, 2013, J MED LIBR ASSOC, V101, P192, DOI 10.3163/1536-5050.101.3.008
   Gao YY, 2019, J PAIN SYMPTOM MANAG, V57, P319, DOI 10.1016/j.jpainsymman.2018.10.504
   Gu Xujie, 2023, CHINESE J CONVALESC MED, V32, P1028
   Guo HR, 2017, J N SICHUAN MED COLL, V32, P163
   Guo ZN, 2024, COMPLEMENT THER MED, V85, P0, DOI 10.1016/j.ctim.2024.103074
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hall S, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007132.pub2
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Health Sciences Library, 2024, CENTER FOR EVIDENCE BASED MANAGEMENT, V0, P0
   Hongsheng L, 2016, CHINESE J INTEGR MED, V36, P269, DOI 10.7661/CJIM.2016.03.0269
   Hu Y, 2021, EVIDENCE-BASED NURSING: THEORY AND PRACTICE OF EVIDENCE CLINICAL TRANSLATION M, V1st, P0
   Hui KK, 2006, INTEGR CANCER THER, V5, P56, DOI 10.1177/1534735405286109
   Inayat S, 2024, CREAT NURS, V30, P12, DOI 10.1177/10784535231213843
   Ji ZC, 2022, ACUPUNCT HERB MED, V2, P184, DOI 10.1097/HM9.0000000000000045
   Jiang YL, 2018, NURS RES, V32, P2723, DOI 10.12102/J.ISSN.1009-6493.2018.17.020
   Kang H, 2024, J PAIN SYMPTOM MANAG, V68, Pe434, DOI 10.1016/j.jpainsymman.2024.07.010
   Khangura S, 2012, SYST REV, V1, P0, DOI 10.1186/2046-4053-1-10
   Klionsky DJ, 2021, AUTOPHAGY, V17, P1, DOI 10.1080/15548627.2020.1797280
   Lam WC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1038206
   Leng G, 2013, ACUPUNCT MED, V31, P16, DOI 10.1136/acupmed-2012-010230
   Li Y, 2023, J PAIN RES, V16, P515, DOI 10.2147/JPR.S396696
   Li YC, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0203111
   Li Z, 2017, CHINA J MOD MED, V26, P2521, DOI 10.3969/j.issn.1008-8849.2017.23.005
   Liu TT, 2022, GEN HOSP PSYCHIAT, V77, P118, DOI 10.1016/j.genhosppsych.2022.05.004
   Liu XY, 2022, CHIN NATUROP, V30, P60
   Liu YT, 2024, CANCER NURS, V0, P0, DOI DOI 10.1097/NCC.0000000000001384
   Ma Shu-Ya, 2022, ZHONGGUO ZHEN JIU, V42, P473, DOI 10.13703/j.0255-2930.20210806-k0001
   Magtoto Leaderlou S, 2024, PALLIATIVE CARE: MUSIC THERAPY, V0, P0
   Mattai SAD, 2021, CHIN J INTEGR MED, V27, P723, DOI 10.1007/s11655-021-3500-9
   Mazzocco K, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15041176
   Munn Z, 2015, WORLDV EVID-BASED NU, V12, P131, DOI 10.1111/wvn.12094
   NCCN, 2019, NAT COMPR CANC NETW, V0, P0
   Pearson A, 2005, INT J EVID-BASED HEA, V3, P207, DOI 10.1111/j.1479-6988.2005.00026.x
   Pérez-Eizaguirre M, 2021, J PALLIAT CARE, V36, P194, DOI 10.1177/0825859720957803
   Petkovic J, 2016, IMPLEMENT SCI, V11, P0, DOI 10.1186/s13012-016-0530-3
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Wang L, 2019, CURR ONCOL, V26, PE188, DOI 10.3747/co.26.4679
   Wang XQ, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07977-z
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Wong CHL, 2021, HEALTH EXPECT, V24, P1487, DOI 10.1111/hex.13289
   World Health Organisation (WHO), 1900, AMIDST MOUNTING NEED FOR SERVICES, V0, P0
   Xiao H, 2020, CHINE NURS RES, V34, P4379
   Xing WJ, 2020, J NURS TRAIN, V35, P1129, DOI 10.16821/j.cnki.hsjx.2020.12.016
   Xiue L, 2024, CHINA MED PHARM, V14, P118, DOI 10.20116/j.issn2095-0616.2024.15.28.+155
   Zeng SQ, 2020, J ALTERN COMPLEM MED, V26, P770, DOI 10.1089/acm.2020.0160
   Zeng YC, 2019, CURR ONCOL REP, V21, P0, DOI 10.1007/s11912-019-0786-2
   Zeng YS, 2018, J PAIN SYMPTOM MANAG, V56, P781, DOI 10.1016/j.jpainsymman.2018.07.016
   Zhang HW, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010559.pub2
   [张璐 Zhang Lu], 2023, 护理学杂志 JOURNAL OF NURSING SCIENCE, V38, P75
NR 68
TC 4
Z9 4
U1 14
U2 36
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4572
EI 1528-3984
J9 GERIATR NURS
JI Geriatr. Nurs.
PD JAN-FEB 15
PY 2025
VL 61
IS 
BP 240
EP 249
DI 10.1016/j.gerinurse.2024.11.007
EA NOV 2024
PG 10
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA N0B6F
UT WOS:001361091500001
PM 39566235
DA 2026-01-16
ER

PT J
AU Liu, ZM
   Lu, H
   Zhang, XJ
   Tang, S
   Lin, AT
   Han, S
   Ma, XX
AF Liu, Zhiming
   Lu, Hui
   Zhang, Xianjuan
   Tang, Shuai
   Lin, Antao
   Han, Shuo
   Ma, Xuexiao
TI NOXA exacerbates endoplasmic-reticulum-stress-induced intervertebral disc degeneration by activating apoptosis and ECM degradation
SO CELL DEATH DISCOVERY
LA English
DT Article
ID nucleus pulposus cells; global burden; therapy; expression; survival; reveals; disease; cancer; injury; death
AB Intervertebral disc degeneration (IVDD) is a prevalent condition leading to low back pain. Endoplasmic reticulum stress (ERS) is strongly linked to IVDD progression, although the underlying mechanisms remain unclear. In this study, we investigated the effects of NOXA on ERS-induced IVDD. Primary nucleus pulposus cells (NPCs) were stimulated with Thapsigargin to mimic the ERS microenvironment in IVDD. Western blot analysis, PCR, immunofluorescence, and immunohistochemistry assay were performed to measure the expression levels of PERK, NOXA, and cell apoptosis- and extracellular-matrix-degradation-relevant proteins. JC-1 fluorescent probes, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and flow cytometry were used to measure mitochondrial function and apoptosis in NPCs under ERS conditions. Magnetic resonance imaging, Safranin O staining, alcian blue staining, and immunohistochemistry were performed to estimate the effects of NOXA knockdown on acupuncture-mediated IVDD in rats at both imaging and histological levels. The results showed that ERS induced and activated the PERK pathway during IVDD development. Mechanically, ERS induced NPC apoptosis and ECM degradation by upregulating PERK expression and activating NOXA expression. The genetic overexpression of NOXA inhibited cell proliferation and increased apoptosis, whereas its knockdown decreased MCL-1 expression and alleviated IVDD degeneration in human NPCs and rat models. NOXA plays a crucial role in the PERK/NOXA/MCL-1 axis, mediating the link between ERS and IVDD. Targeting NOXA expression may be an effective method for treating IVDD, laying the foundation for future research on molecular mechanisms and the development of new therapies.
C1 [Liu, Zhiming; Lu, Hui; Tang, Shuai; Lin, Antao; Han, Shuo; Ma, Xuexiao] Qingdao Univ, Dept Spinal Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Zhang, Xianjuan] Qingdao Univ, Affiliated Hosp, Dept Clin Lab, Qingdao, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University
RP Han, S; Ma, XX (corresponding author), Qingdao Univ, Dept Spinal Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
EM 576110131@qq.com; maxuexiaospinal@163.com
FU Taishan Scholar Foundation of Shandong Province
CR Alcorta-Sevillano N, 2020, CELLS-BASEL, V9, P0, DOI 10.3390/cells9122630
   Carlton JG, 2020, NAT REV MOL CELL BIO, V21, P151, DOI 10.1038/s41580-019-0208-1
   Cazzanelli P, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21103601
   Cheng XF, 2018, ANN RHEUM DIS, V77, P770, DOI 10.1136/annrheumdis-2017-212056
   Diallo JS, 2007, CLIN CANCER RES, V13, P7044, DOI 10.1158/1078-0432.CCR-07-1224
   Fujii T, 2018, J ORTHOP RES, V36, P1334, DOI 10.1002/jor.23787
   GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
   Ghiotto F, 2009, CANCER BIOL THER, V8, P263, DOI 10.4161/cbt.8.3.7424
   Gonen N, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-38705-5
   Gupta A, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep18304
   Hauck P, 2009, MOL CANCER THER, V8, P883, DOI 10.1158/1535-7163.MCT-08-1118
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Kang HL, 2022, BIOCHEM PHARMACOL, V197, P0, DOI 10.1016/j.bcp.2022.114932
   Kelly KR, 2015, ONCOTARGET, V6, P41275, DOI 10.18632/oncotarget.5753
   Kepler CK, 2013, SPINE J, V13, P318, DOI 10.1016/j.spinee.2012.12.003
   Le Maitre CL, 2007, BIOCHEM SOC T, V35, P652, DOI 10.1042/BST0350652
   Lee EF, 2008, J CELL BIOL, V180, P341, DOI 10.1083/jcb.200708096
   Liang HZ, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23031715
   Liao ZW, 2019, THERANOSTICS, V9, P4084, DOI 10.7150/thno.33638
   Lin H, 2021, OXID MED CELL LONGEV, V2021, P0, DOI 10.1155/2021/8810698
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Luo RJ, 2019, FEBS J, V286, P4356, DOI 10.1111/febs.14972
   Luo RJ, 2019, LIFE SCI, V228, P85, DOI 10.1016/j.lfs.2019.04.064
   Majumder M, 2012, MOL CELL BIOL, V32, P992, DOI 10.1128/MCB.06665-11
   Marshall AD, 2013, NEOPLASIA, V15, P738, DOI 10.1593/neo.121888
   Masuda K, 2005, SPINE, V30, P5, DOI 10.1097/01.brs.0000148152.04401.20
   Matsuhashi T, 2017, EBIOMEDICINE, V20, P27, DOI 10.1016/j.ebiom.2017.05.016
   Meroni R, 2021, DISABIL REHABIL, V43, P1029, DOI 10.1080/09638288.2019.1645888
   Morsi RZ, 2018, CURR CANCER DRUG TAR, V18, P914, DOI 10.2174/1568009618666180308105048
   Mukherjee N, 2017, ONCOTARGET, V8, P46801, DOI 10.18632/oncotarget.8695
   Nakajima W, 2014, CELL DEATH DIS, V5, P0, DOI 10.1038/cddis.2014.6
   OKeeffe M, 2020, LANCET, V396, P1560, DOI 10.1016/s0140-6736(20)32325-4
   Ochoa CD, 2018, MOL ASPECTS MED, V63, P18, DOI 10.1016/j.mam.2018.03.002
   Ong G, 2024, CELL DEATH DIS, V15, P0, DOI 10.1038/s41419-024-06663-0
   Pattappa G, 2012, J ANAT, V221, P480, DOI 10.1111/j.1469-7580.2012.01521.x
   Pietkiewicz S, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061438
   Qiu XB, 2019, J TRANSL MED, V17, P0, DOI 10.1186/s12967-019-1886-3
   Raj P Prithvi, 2008, PAIN PRACT, V8, P18, DOI 10.1111/j.1533-2500.2007.00171.x
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sakai D, 2015, ADV DRUG DELIVER REV, V84, P159, DOI 10.1016/j.addr.2014.06.009
   Sampara P, 2018, GENE THER, V25, P67, DOI 10.1038/s41434-018-0004-0
   Shpilka T, 2018, NAT REV MOL CELL BIO, V19, P109, DOI 10.1038/nrm.2017.110
   Simonin K, 2013, APOPTOSIS, V18, P492, DOI 10.1007/s10495-012-0799-x
   Smith E, 2014, ANN RHEUM DIS, V73, P1462, DOI 10.1136/annrheumdis-2013-204680
   Stewart ML, 2010, NAT CHEM BIOL, V6, P595, DOI 10.1038/nchembio.391
   Teng C, 2024, PHYTOTHER RES, V38, P2114, DOI 10.1002/ptr.8057
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228
   Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748
   Vo NV, 2013, SPINE J, V13, P331, DOI 10.1016/j.spinee.2012.02.027
   Wang D, 2022, FRONT CELL DEV BIOL, V9, P0, DOI 10.3389/fcell.2021.819139
   Wang WJ, 2015, CLIN CHIM ACTA, V448, P238, DOI 10.1016/j.cca.2015.06.023
   Wang WZ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6719460
   Wen ZQ, 2023, MILITARY MED RES, V10, P0, DOI 10.1186/s40779-023-00485-5
   Xi YM, 2020, CELL BIOL INT, V44, P583, DOI 10.1002/cbin.11258
   Xu DL, 2017, PHARMACOL RES, V117, P357, DOI 10.1016/j.phrs.2017.01.005
   Xu M, 2016, STEM CELL TRANSL MED, V5, P1171, DOI 10.5966/sctm.2015-0384
   Yang CH, 2020, EUR REV MED PHARMACO, V24, P11295, DOI 10.26355/eurrev_202011_23619
   Yao DB, 2024, CELL SIGNAL, V114, P0, DOI 10.1016/j.cellsig.2023.110986
   Zhang LN, 2013, CANCER GENE THER, V20, P1, DOI 10.1038/cgt.2012.84
   Zhang M, 2017, CELL HOST MICROBE, V22, P766, DOI 10.1016/j.chom.2017.11.005
   Zhang S, 2022, CELL TISSUE RES, V390, P1, DOI 10.1007/s00441-022-03662-5
   Zhang XB, 2021, INT J MED SCI, V18, P2799, DOI 10.7150/ijms.59171
   Zhao CQ, 2010, AGE, V32, P161, DOI 10.1007/s11357-009-9121-4
   ,, 2018, LANCET (BRITISH EDITION), V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
NR 66
TC 2
Z9 2
U1 2
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD MAY 28
PY 2025
VL 11
IS 1
BP 
EP 
DI 10.1038/s41420-025-02539-0
PG 12
WC Cell Biology
SC Cell Biology
GA 3DY7J
UT WOS:001498057700001
PM 40436859
DA 2026-01-16
ER

PT J
AU Lukkahatai, N
   Benjasirisan, C
   Shen, AM
   Li, JX
   Allgood, S
   Thomas, F
   Karyukin, A
   Sheng, JY
   Engle, J
   Lee, TY
   Saligan, LN
AF Lukkahatai, Nada
   Benjasirisan, Chitchanok
   Shen, Aomei
   Li, Junxin
   Allgood, Sarah
   Thomas, Frank
   Karyukin, Artyom
   Sheng, Jennifer Y.
   Engle, Jessica
   Lee, Ta-Ya
   Saligan, Leorey N.
TI Combined technology-enhanced home exercise and acupressure (TEHEplus) program on symptoms among cancer patients receiving immunotherapy: a feasibility study
SO BMC CANCER
LA English
DT Article
DE Cancer; Immunotherapy; Exercise; Acupressure; Mobile health
ID physical-activity; intervention; reliability; management; therapy; fatigue; health; sleep; lung
AB BackgroundCancer patients receiving immunotherapy often experience symptoms impacting their well-being. The present study aimed to develop and test the feasibility of a 12-week Technology-Enhanced Home Exercise and acupressure (TEHEplus) program to improve symptoms (fatigue, pain, sleep, anxiety, depression), social functioning, physical performance, and serum biomarkers (brain-derived neurotrophic factor, heat shock protein 90 levels.)MethodsA two-phase design was employed. Phase 1 involved program development; Phase 2 was a pilot feasibility study. Participants with solid tumor cancers were recruited from cancer centers in Maryland and randomly assigned to four groups: Usual Care Control (UC), Technology-Enhanced Home Exercise (TEHE) alone, Acupressure alone (ACU), and TEHEplus. Feasibility was measured by enrollment duration, intervention adherence, and daily survey response rates. Outcomes were measured at baseline and program completion.ResultsIn phase 1, four participants (age 56-82) provided feedback on online training, smartphone application, intervention duration, and outcome measures. In Phase 2, 40 participants (10 per group) were recruited over 12 months, with 43% (n = 17) completing all daily surveys. TEHEplus participants achieved 50% of exercise goals, and 78% adhered to the acupoint recommendations. TEHEplus participants showed significant improvements in fatigue (p = 0.02), pain inference (p = 0.30), and social functioning (p = 0.03); TEHE participants improved only in social functioning (p = 0.03).ConclusionTEHEplus is feasible and shows promise for symptom alleviation. Preliminary findings suggest potential benefits in symptom management and functional outcomes. However, further studies with larger and more diverse samples are warranted to explore its efficacy and generalizability.Further studies with larger, more diverse populations are needed to confirm its efficacy. TEHEplus may enhance symptom management and improve functional outcomes for cancer survivors undergoing immunotherapy.Trial registrationClinicalTrials.gov ID NCT03576274 Trial Registration Date: 06/07/2018.
C1 [Lukkahatai, Nada; Benjasirisan, Chitchanok; Li, Junxin; Allgood, Sarah; Thomas, Frank; Karyukin, Artyom] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.
   [Shen, Aomei] Tianjin Med Univ, Natl Clin Res Ctr Canc, Canc Inst & Hosp, Minist Educ, Tianjin, Peoples R China.
   [Sheng, Jennifer Y.; Engle, Jessica; Lee, Ta-Ya] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Saligan, Leorey N.] Rutgers State Univ, Sch Nursing, Newark, NJ USA.
C3 Johns Hopkins University; Tianjin Medical University; Johns Hopkins University; Johns Hopkins Medicine; Rutgers University System; Rutgers University New Brunswick; Rutgers University Newark
RP Lukkahatai, N (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.
EM nada.lukkahatai@jhu.edu; cbenjas1@jh.edu; shenaomei0239@gmail.com; junxin.li@jhu.edu; sallgoo1@jhmi.edu; fthoma12@jhmi.edu; adk2187@cumc.columbia.edu; jsheng7@jhmi.edu; jengli18@jhmi.edu; tlee19@jhmi.edu; ls1684@sn.rutgers.edu
FU Oncology Nursing Foundation
CR Aiyegbusi OL, 2020, QUAL LIFE RES, V29, P325, DOI 10.1007/s11136-019-02329-z
   Turan GB, 2023, CANCER NURS, V46, P457, DOI 10.1097/NCC.0000000000001193
   Bilek F, 2023, EXPLORE-NY, V19, P84, DOI 10.1016/j.explore.2022.03.002
   Binda Dhanesh D, 2022, GLOB ADV HEALTH MED, V11, P2164957X221096640, DOI 10.1177/2164957x221096640
   Blackwood Jennifer, 2021, J FRAILTY SARCOPENIA FALLS, V6, P139, DOI 10.22540/jfsf-06-139
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Coppieters MW, 2021, MUSCULOSKEL SCI PRAC, V54, P0, DOI 10.1016/j.msksp.2021.102387
   Denecke K, 2022, J MED INTERNET RES, V24, P0, DOI 10.2196/27791
   Eldridge SM, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i5239
   Feng LN, 2023, EUR J ONCOL NURS, V63, P0, DOI 10.1016/j.ejon.2023.102288
   Forkmann T, 2018, J ABNORM PSYCHOL, V127, P758, DOI 10.1037/abn0000381
   Garland SN, 2019, CANCER J, V25, P337, DOI 10.1097/PPO.0000000000000398
   GURALNIK JM, 1994, J GERONTOL, V49, PM85, DOI 10.1093/geronj/49.2.M85
   Guven DC, 2022, J ONCOL PHARM PRACT, V28, P785, DOI 10.1177/10781552211012038
   Hays RD, 2018, QUAL LIFE RES, V27, P1885, DOI 10.1007/s11136-018-1842-3
   Haywood D, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15225331
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hilfiker R, 2018, BRIT J SPORT MED, V52, P651, DOI 10.1136/bjsports-2016-096422
   Hoang HTX, 2022, SLEEP BREATH, V26, P457, DOI 10.1007/s11325-021-02411-2
   Hopkins ME, 2010, NEUROBIOL LEARN MEM, V94, P278, DOI 10.1016/j.nlm.2010.06.006
   Hwang MC, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000037251
   Jammes Y, 2009, J INTERN MED, V266, P196, DOI 10.1111/j.1365-2796.2009.02079.x
   Lee KC, 2022, CANCER NURS, V45, PE1, DOI 10.1097/NCC.0000000000000870
   Li JX, 2022, J AGING PHYS ACTIV, V30, P261, DOI 10.1123/japa.2020-0463
   Li MY, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102380
   Lin D, 2014, INT J MOL SCI, V15, P3234, DOI 10.3390/ijms15023234
   Lin L, 2020, PATIENT PREFER ADHER, V14, P1275, DOI 10.2147/PPA.S261466
   2023, 1900, V6, V0, P0, DOI DOI 10.29011/2688-9501.101488
   Lukkahatai N, 2025, BIOMEDICINES, V13, P0, DOI 10.3390/biomedicines13020332
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   Malekan M, 2023, J CANCER RES CLIN, V149, P2621, DOI 10.1007/s00432-022-04365-8
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Marsh AP, 2015, J GERONTOL A-BIOL, V70, P1233, DOI 10.1093/gerona/glv029
   Mustian KM, 2017, JAMA ONCOL, V3, P961, DOI 10.1001/jamaoncol.2016.6914
   Nazari G, 2019, PHYSIOTHER CAN, V71, P197, DOI 10.3138/ptc.2018-25
   Neckers Len, 2003, CURRENT OPINION IN ONCOLOGY, V15, P419, DOI 10.1097/00001622-200311000-00003
   Noble EG, 2012, AUTOIMMUN DIS, V2012, P0, DOI 10.1155/2012/836519
   Norman-Nott N, 2024, EUR J PAIN, V28, P1276, DOI 10.1002/ejp.2268
   Park SE, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-08017-6
   Petrelli F, 2020, J IMMUNOTHER, V43, P1, DOI 10.1097/CJI.0000000000000300
   Plinsinga ML, 2023, SPORTS MED, V53, P1737, DOI 10.1007/s40279-023-01862-9
   Reid RER, 2017, J SCI MED SPORT, V20, P578, DOI 10.1016/j.jsams.2016.10.015
   Rogers ML, 2021, PSYCHOL ASSESSMENT, V33, P1215, DOI 10.1037/pas0001054
   Samara A, 2015, INT J WOMENS HEALTH, V7, P279, DOI 10.2147/IJWH.S80680
   Sander AP, 2012, PHYS THER, V92, P525, DOI 10.2522/ptj.20110115
   Shi YK, 2014, CLIN CANCER RES, V20, P6016, DOI 10.1158/1078-0432.CCR-14-0174
   Smith L, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12641
   Solheim TS, 2017, J CACHEXIA SARCOPENI, V8, P778, DOI 10.1002/jcsm.12201
   Vink M, 2019, HEALTH PSYCHOL OPEN, V6, P0, DOI 10.1177/2055102919840614
   Walsh EI, 2020, AGEING RES REV, V60, P0, DOI 10.1016/j.arr.2020.101044
   Wang YL, 2024, CLIN PSYCHOL PSYCHOT, V31, P0, DOI 10.1002/cpp.3023
   Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393
   Yang XY, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08918-0
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yin QA, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1167975
   Zhang Q, 2018, INT J NURS STUD, V78, P52, DOI 10.1016/j.ijnurstu.2017.08.010
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/570431
   Zimmer P, 2018, INTEGR CANCER THER, V17, P306, DOI 10.1177/1534735417713301
NR 59
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 1
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12885-025-14887-2
PG 15
WC Oncology
SC Oncology
GA 8EH4L
UT WOS:001586617000001
PM 41034793
DA 2026-01-16
ER

PT J
AU Cho, N
   Choi, Y
   Kim, H
   Yun, J
   Jun, H
   Yang, C
   Kim, S
   Leem, J
AF Cho, Nahyun
   Choi, Younkuk
   Kim, Heekyung
   Yun, Jeongmi
   Jun, Hyungsun
   Yang, Changsop
   Kim, Sungha
   Leem, Jungtae
TI Pain Treatment in Primary Care Through Eight Constitution Medicine: A Retrospective Real-World Study from South Korea
SO MEDICINA-LITHUANIA
LA English
DT Article
DE acupuncture; precision medicine; musculoskeletal pain; healthy lifestyle; retrospective studies
ID cross-cultural adaptation; neck disability index; western ontario; validation; questionnaire; version; osteoarthritis; reliability; paindetect; womac
AB Background and Objectives: Musculoskeletal pain is a global public health issue. Eight Constitution Medicine (ECM), a type of East Asian Traditional Medicine, offers personalized, minimally invasive treatment through Eight Constitution Acupuncture (ECA) and Eight Constitution Lifestyle Intervention (ECLI). Despite its clinical use, scientific evidence supporting ECM's effectiveness remains limited. This study aimed to evaluate the effectiveness in treating musculoskeletal pain in primary care settings. Materials and Methods: This retrospective study analyzed medical records from three ECM clinics (Gangnam-Shingwang, Yeson, and Yebon) between January 2018 and August 2023. A total of 163 patients were included, with 44 providing follow-up data. Pain intensity, quality of life, and functional outcomes were assessed using validated instruments including the PainDETECT questionnaire, Korean Cancer Pain Assessment Tool (KCPAT) somatic pain scores, EuroQol 5-Dimension 5-Level (EQ-5D-5L), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Oswestry Disability Index (ODI), Neck Disability Index (NDI), and Shoulder Pain and Disability Index (SPADI). Pre- and post-treatment scores were statistically analyzed. Results: Significant decreases were observed in KCPAT somatic pain scores (11.77 +/- 4.77 to 9.77 +/- 5.32) and significant improvements in EQ-5D-5L scores (0.74 +/- 0.12 to 0.80 +/- 0.07). WOMAC and ODI scores also showed significant improvements. However, the changes in the NDI, SPADI, and PainDETECT scores were not statistically significant. No adverse events were reported. Conclusions: ECM, through ECA and ECLI, may offer effective personalized treatment for musculoskeletal pain, improving both pain intensity and quality of life. Despite its small sample size and retrospective design, this study offers valuable preliminary evidence for ECM. Further large-scale prospective studies are needed to confirm these findings.
C1 [Cho, Nahyun; Leem, Jungtae] Wonkwang Univ, Coll Korean Med, Dept Diagnost, Iksan 54538, South Korea.
   [Cho, Nahyun] Daejeon Univ, Cheonan Korean Med Hosp, East West Canc Ctr, Daejeon 34520, South Korea.
   [Choi, Younkuk; Kim, Heekyung] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Clin Res Design & Evaluat, Seoul 06355, South Korea.
   [Choi, Younkuk] Gangnam Shingwang ECM Clin, Seoul 06612, South Korea.
   [Kim, Heekyung] Yebon ECM Clin, Seoul 05510, South Korea.
   [Yun, Jeongmi] Yeson ECM Clin, Seoul 07999, South Korea.
   [Jun, Hyungsun] Dongshin Univ, Coll Korean Med, Dept Diagnost, Naju 58245, South Korea.
   [Yang, Changsop] Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
   [Kim, Sungha] Korea Inst Oriental Med, Clin Med Div, Daejeon 34054, South Korea.
   [Leem, Jungtae] Wonkwang Univ, Coll Korean Med, Res Ctr Tradit Korean Med, Iksan 54538, South Korea.
   [Leem, Jungtae] Wonkwang Univ, Dept Ilwon Integrated Med, Korean Med Hosp, 895 Muwang Ro, Iksan 54538, South Korea.
C3 Wonkwang University; Daejeon University; Samsung; Sungkyunkwan University (SKKU); Dongshin University; Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental Medicine (KIOM); Wonkwang University; Wonkwang University
RP Leem, J (corresponding author), Wonkwang Univ, Coll Korean Med, Dept Diagnost, Iksan 54538, South Korea.; Kim, S (corresponding author), Korea Inst Oriental Med, Clin Med Div, Daejeon 34054, South Korea.; Leem, J (corresponding author), Wonkwang Univ, Coll Korean Med, Res Ctr Tradit Korean Med, Iksan 54538, South Korea.; Leem, J (corresponding author), Wonkwang Univ, Dept Ilwon Integrated Med, Korean Med Hosp, 895 Muwang Ro, Iksan 54538, South Korea.
EM jnh528@naver.com; pyrologos@gmail.com; yebon8@gmail.com; yeson1004@naver.com; hs14231423@naver.com; yangunja@kiom.re.kr; bozzol@kiom.re.kr; julcho0908@wku.ac.kr
FU Bio&Medical Technology Development Program of the National Research Foundation (NRF) [RS-2023-00261934]; Bio&Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [RS-2022-NR072366]; National Research Foundation of Korea - Korea government [KSN2122211]; Korea Institute of Oriental Medicine
CR Al-Boloushi Z, 2019, J BODYW MOV THER, V23, P122, DOI 10.1016/j.jbmt.2018.05.002
   Almutairi NM, 2022, HEALTHCARE-BASEL, V10, P0, DOI 10.3390/healthcare10071176
   Bae SC, 2001, OSTEOARTHR CARTILAGE, V9, P746, DOI 10.1053/joca.2001.0471
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Bilton K, 2016, J ALTERN COMPLEM MED, V22, P599, DOI 10.1089/acm.2016.0056
   채상진, 2004, JOURNAL OF ACUPUNCTURE RESEARCH, V21, P65
   Chae S-J, 2001, J. ACUPUNCT. RES, V18, P48
   Chen J, 2023, J ORTHOP SURG RES, V18, P0, DOI 10.1186/s13018-023-04403-2
   Cho N, 2025, FRONT MED-LAUSANNE, V12, P0, DOI 10.3389/fmed.2025.1545687
   Choi YS, 2006, J PAIN SYMPTOM MANAG, V31, P553, DOI 10.1016/j.jpainsymman.2005.10.008
   Choi Y, 2024, INTEGR MED REP, V3, P19, DOI 10.1089/imr.2023.0039
   Coretti S, 2014, EXPERT REV PHARM OUT, V14, P221, DOI 10.1586/14737167.2014.894462
   Ehrich EW, 2000, J RHEUMATOL, V27, P2635
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488
   Green S, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005319
   Gwinnutt JM, 2023, ANN RHEUM DIS, V82, P48, DOI 10.1136/annrheumdis-2021-222020
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Ho RST, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100771
   김희경, 2009, THE JOURNAL OF KOREAN MEDICINE OPHTHALMOLOGY&OTORHINOLARYNGOLOGY&DERMATOLOGY 한방안이비인후피부과학회지, V22, P251
   Hsu Elisabeth, 2010, PULSE DIAGNOSIS IN EARLY CHINESE MEDICINE, V0, P0
   Jeon CH, 2006, J KOREAN MED SCI, V21, P1092, DOI 10.3346/jkms.2006.21.6.1092
   조병제, 2013, JOURNAL OF KOREAN MEDICINE 대한한의학회지, V34, P143
   Kim Chang-Keun, 2020, JOURNAL OF KOREAN MEDICINE 대한한의학회지, V41, P41, DOI 10.13048/jkm.20042
   Kim HJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019074
   Kim MK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2376581
   Kim SH, 2016, QUAL LIFE RES, V25, P1845, DOI 10.1007/s11136-015-1205-2
   Kim Y, 2003, J. ACUPUNCT. RES, V20, P202
   Kim YE, 2019, J KOREAN MED SCI, V34, P0, DOI 10.3346/jkms.2019.34.e75
   Kuon D, 1974, J. MYONG JI UNIV, V7, P583
   Kuon D, 2011, ADV MED BIOL, V5, P243
   Mu JL, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013814
   Oh IH, 2011, BMC MUSCULOSKEL DIS, V12, P0, DOI 10.1186/1471-2474-12-157
   Park J, 2022, MED. POLICY FORUM, V20, P19
   Paul A, 2004, ANN RHEUM DIS, V63, P1293, DOI 10.1136/ard.2003.012088
   Pinto JW, 2021, J ALTERN COMPLEM MED, V27, P238, DOI 10.1089/acm.2020.0365
   Pool JJM, 2007, SPINE, V32, P3047, DOI 10.1097/BRS.0b013e31815cf75b
   Ramaswami R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/annurev-publhealth-040617-014158
   Roach K E, 1991, ARTHRITIS CARE RES, V4, P143, DOI 10.1002/art.1790040403
   Safiri S, 2021, ARTHRITIS RHEUMATOL, V73, P702, DOI 10.1002/art.41571
   Seo Hyun-Du, 2012, 특수교육재활과학연구, V51, P319
   Shin Yong-Sup, 2009, ORIENTAL PHARMACY AND EXPERIMENTAL MEDICINE, V9, P14
   Song KJ, 2010, SPINE, V35, PE1045, DOI 10.1097/BRS.0b013e3181df78e9
   Sung JK, 2017, PAIN PRACT, V17, P494, DOI 10.1111/papr.12472
   Tangkiatkumjai M, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03157-2
   The Society of Korean Medicine Diagnostics Department of Biofunctional Medicine of Korean Medical University, 2008, BIOFUNCTIONAL MEDICINE, V0, P0
   Ussai S, 2015, DRUG DES DEV THER, V9, P2073, DOI 10.2147/DDDT.S80686
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   Yoo SK, 2013, SPRINGERPLUS, V2, P0, DOI 10.1186/2193-1801-2-406
   Yu WJ, 2017, AM J CHINESE MED, V45, P1, DOI 10.1142/S0192415X1750001X
   Yuan QL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0117146
   Yun HM, 2001, J. DONG-EUI ORIENT. MED, V5, P67
   Yun J, 2022, PROTOCOL DEVELOPMENT OF EIGHT CONSTITUTION MEDICINE REGISTRY FOR CHRONIC LOW BACK PAIN, V0, P0
NR 54
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD AUG 30
PY 2025
VL 61
IS 9
BP 
EP 
DI 10.3390/medicina61091564
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7VD2T
UT WOS:001580396900001
PM 41010955
DA 2026-01-16
ER

PT J
AU Wang, X
   Shen, Q
   Hu, X
   Yu, X
   Erasmus, SR
   Gong, L
   Liu, J
   Fan, W
   Liang, Y
AF Wang, Xiaoying
   Shen, Qiongying
   Hu, Xinyi
   Yu, Xiaoshuai
   Erasmus, Shannah Rose
   Gong, Liyan
   Liu, Jianhao
   Fan, Wei
   Liang, Yi
TI Efficacy and Safety of Acupuncture Combined with Conventional Drug Therapy for
SO Journal of pain research
LA English
DT Review
DE acupuncture; cancer-induced bone pain; network meta-analysis; supplementary alternative therapy
AB BACKGROUND: Cancer-induced bone pain (CIBP) involves both nociceptive and  neuropathic components, causing significant suffering in cancer patients.  Acupuncture has shown beneficial effects on CIBP. However, given the diverse  acupuncture techniques, their therapeutic efficacy may vary. OBJECTIVE: To  evaluate the efficacy and safety of various acupuncture modalities integrated  with conventional drug therapy for CIBP. METHODS: Randomized controlled trials  (RCTs) of acupuncture combined with conventional analgesics for CIBP were  searched across eight Chinese and English databases and clinical trial registries  up to September 2024. Two researchers independently performed literature  screening, data extraction, and bias assessment. Data were analyzed using Stata  14.0 and R 4.2.3. RESULTS: Twenty-two RCTs involving 1,738 patients were  included, assessing techniques including manual acupuncture (MA),  electroacupuncture (EA), moxibustion (MOX), acupoint injection (AI), acupoint  catgut embedding (ACE), auricular-plaster therapy (AP), thumbtack needle (TN) and  transcutaneous electrical acupoint stimulation (TEAS). The outcomes were assessed  across 20 studies for the clinical effective rate, 13 for nausea and vomiting,  and 11 for constipation.The results indicated that for the primary outcome of  pain relief (as measured by clinical effective rate), TN demonstrated the highest  probability of being the most effective acupuncture technique (SUCRA = 75.2%). In  terms of mitigating opioid-induced adverse reactions, ACE was most effective for  reducing nausea and vomiting (SUCRA = 87.7%), while EA+AP was optimal for  alleviating constipation (SUCRA = 93.5%). MA+MOX achieved the best overall  balance between efficacy and the incidence of adverse reactions. CONCLUSION:  Acupuncture combined with conventional drug therapy significantly improves pain  relief in CIBP and reduces opioid-related side effects. However, due to  methodological limitations and the modest sample sizes of available studies,  further high-quality, multicenter trials with larger samples are needed to  confirm these findings and inform clinical practice.
C1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
   Sanya Traditional Chinese Medicine Hospital, Sanya, Hainan Province, People's Republic of China.
   Sanya Traditional Chinese Medicine Hospital, Sanya, Hainan Province, People's Republic of China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
   The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD DEC 24
PY 2025
VL 18
IS 
BP 6807
EP 6826
DI 10.2147/JPR.S550454
PG 19
UT PubMed:41438386
PM 41438386
DA 2025-12-24
ER

PT J
AU Fan, BK
   Xia, YF
   Feng, YY
   Yang, XL
   Lin, P
   Fang, JQ
   Zhang, ZY
   Li, SM
AF Fan, Binke
   Xia, Yunfan
   Feng, Yuanyuan
   Yang, Xilong
   Lin, Ping
   Fang, Jianqiao
   Zhang, Zuyong
   Li, Shimin
TI Research trends of acupuncture therapy for painful peripheral nervous system diseases from 2004 to 2023: a bibliometric and meta-analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE acupuncture therapy; peripheral nervous system diseases; pain management; peripheral neuropathy; bibliometric analysis; CiteSpace
ID postherpetic neuralgia; trigeminal neuralgia; integrative oncology; pilot trial; neuropathy; chemotherapy; electroacupuncture; medicine; efficacy; safety
AB Background Peripheral nervous system diseases (PNSD) have represented a major global health burden, leading to significant economic impacts and diminished productivity. This bibliometric analysis was performed to summarize the current research trends and hotspots over the past two decades, aiming to provide a comprehensive perspective for future research. Methods All data were sourced from the Web of Science Core Collection (WoSCC) on March 1, 2024, for publications between January 1, 2004, and December 31, 2023. Data visualization and analyses, including descriptive statistics, co-occurrence mapping, and cluster analysis, were performed using CiteSpace (Version 6.1.R6) and Excel 2021. Results Our search yielded 678 references, with the annual publication count demonstrating an increasing trend over the past 20 years. The most productive country and institution were China and Kyung Hee University, respectively. Fang Jianqiao, was the most prolific author with the highest publications. Among journals, "Pain," was the most frequently cited, while the top-cited reference was a randomized controlled pilot trial by Lu Weidong in 2020. "Acupuncture" emerged as the keyword with the highest frequency. The meta-analysis indicated that acupuncture was more effective than standard care for pain associated with Diabetic Peripheral Neuropathy [MD = -2.03, 95% CI (-2.86, -1.21), 2 RCTs, 102 participants, p < 0.0001]. Conclusion Our bibliometric review revealed key insights into the focal areas of PNSD research, underscoring the urgent need for continued and targeted high-quality investigations.
C1 [Fan, Binke; Lin, Ping; Zhang, Zuyong; Li, Shimin] Zhejiang Chinese Med Univ, Affiliated Hangzhou Hosp 3, Hangzhou, Zhejiang, Peoples R China.
   [Xia, Yunfan; Feng, Yuanyuan; Yang, Xilong; Fang, Jianqiao] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Zhang, ZY; Li, SM (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hangzhou Hosp 3, Hangzhou, Zhejiang, Peoples R China.
EM 20168028@zcmu.edu.cn; lishimin004@126.com
FU Medical and Health Science and Technology Program of Hangzhou
CR Ang L, 2023, COMPLEMENT THER CLIN, V52, P0, DOI 10.1016/j.ctcp.2023.101763
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   Chao MT, 2019, PAIN MED, V20, P2292, DOI 10.1093/pm/pnz117
   Chen DY, 2021, FRONT NEUROL, V12, P0, DOI 10.3389/fneur.2021.637310
   Cheuk DKL, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005472.pub3
   Coyle ME, 2017, DERMATOL THER, V30, P0, DOI 10.1111/dth.12468
   Cruccu G, 2008, EUR J NEUROL, V15, P1013, DOI 10.1111/j.1468-1331.2008.02185.x
   de Sousa TR, 2023, J CLIN NURS, V32, P6917, DOI 10.1111/jocn.16812
   Dietzel J, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12062103
   Dimitrova A, 2017, J ALTERN COMPLEM MED, V23, P164, DOI 10.1089/acm.2016.0155
   Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019
   Gao J, 2019, J NERV MENT DIS, V207, P171, DOI 10.1097/NMD.0000000000000937
   Gao XM, 2023, J TRADIT CHIN MED, V43, P359, DOI 10.19852/j.cnki.jtcm.2023.02.007
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Goo B, 2023, J PAIN RES, V16, P623, DOI 10.2147/JPR.S396264
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He KL, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/4478444
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hicks CW, 2019, CURR DIABETES REP, V19, P0, DOI 10.1007/s11892-019-1212-8
   Hu HT, 2019, COMPLEMENT THER CLIN, V34, P254, DOI 10.1016/j.ctcp.2018.12.013
   Hu QM, 2020, J PAIN, V21, P1060, DOI 10.1016/j.jpain.2020.01.007
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Ichida MC, 2017, CHIN J INTEGR MED, V23, P829, DOI 10.1007/s11655-017-2786-0
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Kong JT, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.22787
   Kutcher AM, 2022, WESTERN J NURS RES, V44, P169, DOI 10.1177/0193945921992538
   Lee JH, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018830
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Li XT, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221149992
   Li Y, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13040766
   Liu K, 2019, J PAIN RES, V12, P2359, DOI 10.2147/JPR.S210471
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Lu C, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.843886
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mezzanotte JN, 2022, CURR TREAT OPTION ON, V23, P29, DOI 10.1007/s11864-021-00926-0
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Nicolian S, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0214195
   Papadopoulou M, 2023, IN VIVO, V37, P47, DOI 10.21873/invivo.13053
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Pei WY, 2019, J PAIN RES, V12, P2155, DOI 10.2147/JPR.S199950
   Qi T, 2022, ANN PALLIAT MED, V11, P756, DOI 10.21037/apm-22-109
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Ruengwongroj P, 2020, COMPLEMENT THER CLIN, V40, P0, DOI 10.1016/j.ctcp.2020.101202
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Smith TJ, 2023, NEW ENGL J MED, V389, P158, DOI 10.1056/NEJMra2110098
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Sun J, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019710
   Teng C, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07463-y
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Ursini T, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-46
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang L, 2020, J TRADIT CHIN MED, V40, P121
   Wang Y, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011986
   Watson JC, 2015, MAYO CLIN PROC, V90, P940, DOI 10.1016/j.mayocp.2015.05.004
   Wu CH, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-18
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yang K, 2022, BIOMED PHARMACOTHER, V148, P0, DOI 10.1016/j.biopha.2022.112717
   Yang W, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1209262
   Yeung WF, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.5830
   Yin ZH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/3178154
   Zhang T, 2023, ALTERN THER HEALTH M, V29, P898
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj.o487
   Zhang YW, 2022, FRONT CELL NEUROSCI, V16, P0, DOI 10.3389/fncel.2022.826777
   Zhao WX, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6886465
NR 77
TC 0
Z9 0
U1 4
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 14
PY 2025
VL 16
IS 
BP 
EP 
DI 10.3389/fneur.2025.1510331
PG 19
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 0SX6C
UT WOS:001455251100001
PM 40162011
DA 2026-01-16
ER

PT J
AU Fan, DH
   Ren, HB
AF Fan, Dihui
   Ren, Hongbin
TI Clinical value of warm acupuncture combined with Jiaji acupoint Tongbian scraping therapy in the treatment of myofascial pain syndrome of the lumbar and dorsal muscles with wind-cold-dampness obstruction syndrome
SO MEDICINE
LA English
DT Article
DE Jiaji acupoint Tongbian scraping therapy; myofascial pain syndrome; warm acupuncture; wind-cold-dampness obstruction syndrome
AB This study investigates the clinical value of warm acupuncture combined with Jiaji acupoint Tongbian scraping therapy in patients with myofascial pain syndrome (MPS) of the lumbar and dorsal muscles with wind-cold-dampness obstruction syndrome. A total of 112 patients with wind-cold-dampness obstruction-type MPS admitted to our hospital from January 2024 to October 2024 were enrolled. According to different treatment methods, they were assigned into the control group (n = 35, Jiaji acupoint Tongbian scraping therapy), observation group (n = 35, warm acupuncture), and combination group (n = 42, warm acupuncture combined with Jiaji acupoint Tongbian scraping therapy). The following indicators were compared before and after treatment: Traditional Chinese Medicine (TCM) syndrome scores, visual analog scale (VAS) scores, Oswestry Disability Index (ODI) scores, Modified Barthel Index (MBI) scores, serum inflammatory cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta), clinical efficacy, and incidence of adverse reactions. After treatment, serum inflammatory cytokine levels, TCM syndrome scores, VAS, and ODI scores were significantly lower in the combination group than in the control and observation groups, while the MBI score was significantly higher (F = 22.340, 11.200, 17.130, 40.120, 4.850, 20.960, 14.680; P < .05). The overall effective rate in the combination group (95.24%) was significantly higher than that in the control group (74.29%) and the observation group (77.14%) (chi(2) = 7.205, P < .05). The incidence of adverse reactions in the combination group (16.67%) showed no significant difference compared with the control group (11.43%) and the observation group (14.29%) (chi(2) = 0.428, P > .05). Warm acupuncture combined with Jiaji acupoint Tongbian scraping therapy can effectively improve clinical symptoms and functional impairment, reduce pain and inflammatory levels, and enhance activities of daily living, without significantly increasing adverse reactions. This combined approach demonstrates high clinical efficacy.
C1 [Fan, Dihui; Ren, Hongbin] Jiaxing Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, Jiaxing 314000, Peoples R China.
RP Fan, DH (corresponding author), Jiaxing Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, Jiaxing 314000, Peoples R China.
EM verysupersb@163.com; me6095@163.com
FU Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project [2024ZL1047]
CR Cheng L, 2022, CHIN J TRADIT CHIN MED EMERG, V31, P317
   Dou Ting-Ting, 2023, ZHONGGUO ZHEN JIU, V43, P639, DOI 10.13703/j.0255-2930.20220719-k0003
   Gao L, 2016, CHIN GEN PRACT, V19, P3589
   Ge H, 2023, J REHABIL, V33, P65
   Jiang L, 2021, BULL TRADIT CHIN MED, V20, P50
   Jiang Z, 2024, MOD J INTEGR TRADIT CHIN WEST MED, V33, P1770
   Kellis E, 2024, J SPORT SCI MED, V23, P436, DOI 10.52082/jssm.2024.436
   Kohpe Kapseu Stephane, 2022, INT J SURG CASE REP, V98, P107545, DOI 10.1016/j.ijscr.2022.107545
   Li Q, 2024, CHIN J TRADIT CHIN MED EMERG, V33, P870
   Li Y, 2023, TIANJIN J TRADIT CHIN MED, V40, P1018
   Lin Q, 2023, CHIN J TRADIT CHIN MED EMERG, V32, P1764
   Lin W, 2023, SHAANXI J TRADIT CHIN MED, V44, P112
   Liu L, 2019, WEST J TRADIT CHIN MED, V32, P117
   Liu S, 2022, GUIDING J TRADIT CHIN MED PHARM, V28, P64
   Liu Y, 2020, J LIAONING UNIV TRADIT CHIN MED, V22, P155
   Ma JY, 2024, FRONT SPORTS ACT LIV, V6, P0, DOI 10.3389/fspor.2024.1383228
   Ma M, 2023, J NURS, V38, P52
   Medani K, 2021, INT J OCCUP MED ENV, V34, P111, DOI 10.13075/ijomeh.1896.01602
   Ren J, 2021, SICHUAN J TRADIT CHIN MED, V39, P179
   Wang F, 2023, J ORTHOP SURG RES, V18, P0, DOI 10.1186/s13018-023-04140-6
   Wang S, 2020, CHINESE J REHABIL, V35, P179
   [肖薇 Xiao Wei], 2020, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V26, P1743
   Ye Y, 2021, NEW J TRADIT CHIN MED, V53, P178
   You Y, 2019, GUIDING J TRADIT CHIN MED PHARM, V25, P22
   Zhan Z, 2016, LIAONING J TRADIT CHIN MED, V43, P2624
NR 25
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 26
PY 2025
VL 104
IS 52
BP 
EP 
DI 10.1097/MD.0000000000046161
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AJ5YN
UT WOS:001649664100042
PM 41465915
DA 2026-01-16
ER

PT J
AU Wang, HD
   Wang, HY
   Yang, LY
   Liu, JJ
   Zhang, T
   Zheng, J
AF Wang, Huang-Dong
   Wang, Hua-Yu
   Yang, Li-Yue
   Liu, Ji-Jun
   Zhang, Tao
   Zheng, Jia
TI [Acupotomy at trigger points combined with meridian sinew manipulation in
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupotomy; Clinical efficacy; Inflammatory response; Knee osteoarthritis; Randomized controlled trial; Trigger point
AB OBJECTIVES: To observe the clinical efficacy of acupotomy at trigger points  combined with meridian sinew manipulation in treatment of early and mid-term knee  osteoarthritis (KOA), and investigate whether its therapeutic mechanism is  related to the regulation of inflammatory response. METHODS: Seventy-four  patients with early and mid-term KOA were randomly divided into the control group  (37 cases, with 2 cases dropouts) and the observation group (37 cases, with 1  case dropout). The control group was treated with meridian sinew manipulation for  30 min each time, 5 times a week, for 4 consecutive weeks. The observation group  was given acupotomy at trigger points on the basis of the treatment of control  group, once a week, for 4 consecutive weeks. Western Ontario and McMaster  University osteoarthritis index (WOMAC) scores, short-form McGill pain  questionnaire (SF-MPQ) scores, the medical outcome 36-item short form health  survey (SF-36) scores, serum inflammatory factors content before and after  treatment were compared between the two groups. The clinical efficacy were  assessed after the treatment. RESULTS: Compared with those before treatment, the  total scores and the scores of pain, stiffness and activity impairment of WOMAC,  the pain rating index (PRI), visual analog scale (VAS) and present pain intensity  (PPI) scores of SF-MPQ, and the contents of serum tumor necrosis factor (TNF)-α,  interleukin (IL)-6 and IL-10 in both groups were significantly decreased after  treatment (P<0.05), while the scores of the physical component summary (PCS) and  the mental component summary (MCS) of SF-36 were significantly increased  (P<0.05). Compared with the control group, the total scores, scores of pain,  stiffness and activity impairment of WOMAC, the PRI, VAS and PPI scores of  SF-MPQ, and the contents of serum TNF-α, IL-6 and IL-10 in the observation group  were significantly decreased after treatment (P<0.05), while the scores of PCS  and MCS of SF-36 were significantly increased (P<0.05). The total effective rate  of the observation group was 94.4% (34/36) after treatment, which was  significantly higher than that of the control group (74.3%, 26/35, P<0.05).  CONCLUSIONS: Acupotomy at trigger points combined with meridian sinew  manipulation can significantly improve the clinical symptoms such as joint pain,  stiffness and limited activity in patients with KOA, improve the quality of life,  and its mechanism may be related to reducing the inflammatory response.
C1 Graduate School, Anhui University of Chinese Medicine, Hefei 230012, China.
   The Department of Joint and Bone, Lu'an Hospital of Traditional Chinese Medicine, 
   The Department of Joint and Bone, Lu'an Hospital of Traditional Chinese Medicine, Lu'an 237000, Anhui Province. why2834463@163.com.
   The 2rd Department of Joint and Bone, Wuhu Hospital of Traditional Chinese Medicine, Wuhu 241000, Anhui Province.
   Graduate School, Anhui University of Chinese Medicine, Hefei 230012, China.
   Graduate School, Anhui University of Chinese Medicine, Hefei 230012, China.
   Graduate School, Anhui University of Chinese Medicine, Hefei 230012, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 22
PY 2025
VL 50
IS 7
BP 822
EP 828
DI 10.13702/j.1000-0607.20240549
PG 6
WC Humans; Osteoarthritis, Knee; therapy; Female; Male; Middle Aged; Aged; Acupuncture Therapy; Acupuncture Points; Meridians; Treatment Outcome; Interleukin-6; blood; Tumor Necrosis Factor-alpha; blood; Interleukin-10; blood; Adult
UT PubMed:40691033
PM 40691033
DA 2025-07-22
ER

PT J
AU Machi, A
   Patel, A
   Ottestad, E
AF Machi, Anthony
   Patel, Ankur
   Ottestad, Einar
TI Nerve stimulation and neuromodulation for painful nerves: a narrative review
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Review
DE Transcutaneous electrical nerve stimulation; Percutaneous electrical nerve stimulation; Peripheral nerve stimulation; Neuromodulation; Neuropathic pain; Axon regeneration
ID electrical-stimulation; neuropathic pain; tens; metaanalysis; inhibition; management; efficacy
AB Nerve injury primarily leads to neuropathic pain but may also have overlapping elements of nociplastic pain or ongoing nociceptive pain. Electrical stimulation is particularly effective in the treatment of neuropathic pain and may be effective for nociplastic and nociceptive pain. While multiple mechanisms contribute to the analgesic effect of electrical stimulation, the most widely accepted theory for the predominant effect is that of Melzack and Wall's gate control theory. According to this theory, non-painful sensory input carried by low-threshold large-diameter A beta fibres disrupt the transmission of pain signals in small pain fibers (A delta and C fibres). This occurs through the activation of inhibitory interneurons in the dorsal horn, which ultimately blocks pain signal transmission.This theory has been employed for different forms of stimulation, including transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS), and peripheral nerve stimulation (PNS). Each of these methods offers a different approach to localized stimulation and neuromodulation for the treatment of pain. TENS is a non-invasive technique, that delivers electrical currents via surface electrodes placed on the skin. PENS, in contrast, is a minimally invasive method that applies electrical currents through small needles inserted near a target muscle or neural structure. PNS involves the implantation of temporary or permanent electrodes to deliver electrical stimulation directly to peripheral nerves. These modalities are widely used to manage various pain conditions including non-malignant, chronic musculoskeletal and neuropathic pain, such as chronic low back pain, neck pain, neuropathic pain, myofascial pain, and post-operative pain. TENS is particularly notable as a non-invasive device that is affordable, over-the-counter, self-administered, and nonpharmacological option that does not pose the risk of toxicity or overdose. PENS stands out for its ability to integrate electrical stimulation therapy with electroacupuncture through a minimally invasive technique. PNS, on the other hand, is unique in its capacity to precisely target specific nerves and provide a range of stimulation options for extended treatment durations.This article provides a narrative overview of TENS, PENS and PNS with a particular focus on their application for neuropathic pain management and for athletes. We will review mechanisms of action, indications, diagnostic and treatment algorithms, as well as complications and limitations. The overview concludes with a complex case study demonstrating the use of various electrical stimulation therapies, ultimately to successful pain resolution for the patient.
C1 [Machi, Anthony; Ottestad, Einar] Stanford Univ, Stanford, CA 94305 USA.
   [Patel, Ankur] Novant Hlth Spine Specialists, Winston Salem, NC USA.
C3 Stanford University
RP Machi, A (corresponding author), Stanford Univ, Stanford, CA 94305 USA.
EM amachi@stanford.edu; patel.ankur.anil@gmail.com; ottestad@stanford.edu
CR Unknown -, 2022, NALU PRODUCT CATALOG, V0, P0
   Unknown -, 2023, NEUROMODULATION NEUR, V0, P0
   Unknown -, 2023, SYSTEM SPRINTPNS, V0, P0
   Astokorki AHY, 2017, EUR J APPL PHYSIOL, V117, P483, DOI 10.1007/s00421-016-3532-6
   Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8
   Bouhassira D, 2018, PAIN, V159, P576, DOI 10.1097/j.pain.0000000000001136
   Chakravarthy KV, 2019, NEUROMODULATION, V22, P235, DOI 10.1111/ner.12859
   Chow RM, 2023, CURR PAIN HEADACHE R, V27, P321, DOI 10.1007/s11916-023-01143-0
   CHUNG JM, 1984, PAIN, V19, P277, DOI 10.1016/0304-3959(84)90005-8
   Deer TR, 2019, BRAIN SCI, V9, P0, DOI 10.3390/brainsci9020023
   Eldabe S, 2016, PAIN MED, V17, P325, DOI 10.1093/pm/pnv025
   Finnerup Nanna B, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Fitzcharles MA, 2022, PAIN REP, V7, P0, DOI 10.1097/PR9.0000000000001024
   Fitzcharles MA, 2021, LANCET, V397, P2098, DOI 10.1016/S0140-6736(21)00392-5
   Gallego-Sendarrubias GM, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10040690
   García-Collado A, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11133753
   Ghoname ESA, 1999, JAMA-J AM MED ASSOC, V281, P818, DOI 10.1001/jama.281.9.818
   Gilmore CA, 2021, PAIN PRACT, V21, P877, DOI 10.1111/papr.13055
   Gordon T, 2010, EXP NEUROL, V223, P192, DOI 10.1016/j.expneurol.2009.09.020
   Heidland August, 2013, CLIN NEPHROL, V79 Suppl 1, P0
   Helm S, 2021, PAIN THER, V10, P985, DOI 10.1007/s40122-021-00306-4
   Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017
   Johnson Mark, 2007, REV PAIN, V1, P7, DOI 10.1177/204946370700100103
   Johnson MI, 2017, PAIN MANAG, V7, P1, DOI 10.2217/pmt-2016-0030
   Johnson MI, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006142.pub3
   Johnson M, 2007, PAIN, V130, P157, DOI 10.1016/j.pain.2007.02.007
   Juckett L, 2022, BIOMOLECULES, V12, P0, DOI 10.3390/biom12121856
   Keane GC, 2022, HAND-AM ASSOC HAND S, V17, P540, DOI 10.1177/1558944720939200
   Kosek E, 2016, PAIN, V157, P1382, DOI 10.1097/j.pain.0000000000000507
   Kupers R, 2011, EUR J PAIN, V15, P0, DOI 10.1016/j.ejpain.2010.06.015
   Hernandez JVL, 2021, PAIN PHYSICIAN, V24, P135, DOI 10.36076/ppj.2021.24.135-143
   Lin T, 2020, PAIN MED, V21, PS6, DOI 10.1093/pm/pnaa164
   Manchikanti Laxmaiah, 2024, PAIN PHYSICIAN, V27, P0
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Meyer-Friessem CH, 2019, CLIN J PAIN, V35, P111, DOI 10.1097/AJP.0000000000000661
   Plaza-Manzano G, 2020, EUR J PAIN, V24, P1023, DOI 10.1002/ejp.1559
   Power HA, 2020, NEUROSURGERY, V86, P769, DOI 10.1093/neuros/nyz322
   Sawant A, 2015, MULT SCLER RELAT DIS, V4, P219, DOI 10.1016/j.msard.2015.03.006
   StimRouter, 2022, STIMROUTER PNS PRODU, V0, P0
   Strand N, 2022, J PAIN RES, V15, P2483, DOI 10.2147/JPR.S362204
   Strand NH, 2021, CURR PAIN HEADACHE R, V25, P0, DOI 10.1007/s11916-021-00962-3
   TOREBJORK HE, 1974, J NEUROL NEUROSUR PS, V37, P653, DOI 10.1136/jnnp.37.6.653
   Udina E, 2008, EXP NEUROL, V210, P238, DOI 10.1016/j.expneurol.2007.11.007
   van Hecke O, 2014, PAIN, V155, P654, DOI 10.1016/j.pain.2013.11.013
   Vance CGT, 2014, PAIN MANAG, V4, P197, DOI 10.2217/PMT.14.13
   WALL PD, 1974, NATURE, V248, P740, DOI 10.1038/248740a0
   WALL PD, 1967, SCIENCE, V155, P108, DOI 10.1126/science.155.3758.108
   Woolf CJ, 2011, PAIN, V152, PS2, DOI 10.1016/j.pain.2010.09.030
   Xu JJ, 2021, PAIN PHYSICIAN, V24, PE131, DOI 10.36076/ppj.2021.24.e131-e152
   Yang F, 2014, EUR J PAIN, V18, P978, DOI 10.1002/j.1532-2149.2013.00443.x
   Yokoyama M, 2004, ANESTH ANALG, V98, P1552, DOI 10.1213/01.ANE.0000112312.94043.DF
NR 51
TC 4
Z9 4
U1 7
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341-2695
EI 1432-5195
J9 INT ORTHOP
JI Int. Orthop.
PD MAY 15
PY 2025
VL 49
IS 5
BP 989
EP 996
DI 10.1007/s00264-025-06498-0
EA MAR 2025
PG 8
WC Orthopedics
SC Orthopedics
GA 3YI7C
UT WOS:001467600600001
PM 40111452
DA 2026-01-16
ER

PT J
AU Gu, YM
   Meng, X
   Liang, JY
   Xia, Y
   Huang, JW
   Wang, K
   Ju, ZY
AF Gu, Yi-Ming
   Meng, Xiang
   Liang, Jia-Yi
   Xia, Yong
   Huang, Jun-Wei
   Wang, Ke
   Ju, Zi-Yong
TI Electroacupuncture intervention relieves pain by stimulating the STING/IFN-I pathway in rat models of cancer-induced bone pain
SO MOLECULAR PAIN
LA English
DT Article
DE STING; IFN-I; analgesic effects; electroacupuncture; cancer-induced bone pain
ID prevalence; management; society; injury
AB This study aimed to evaluate the effects of electroacupuncture (EA) on cancer-induced bone pain (CIBP) and investigate its interaction with the STING/IFN-I pathway. A CIBP model was established in female rats. EA was administered for six consecutive days at bilateral L3-L5 Jia Ji points (EX-B2). EA-induced antinociception was evaluated through mechanical, thermal, and cold sensitivity assessments. EA significantly increased the paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) in rats with CIBP (p < 0.01). In the spinal cord of CIBP model rats, western blot analysis demonstrated that the application of EA upregulated the expression of STING, IRF3, and IFNAR (p < 0.05). The ELISA results indicated that EA significantly increased the expression of IFN-alpha (p < 0.005) and IFN-beta (p < 0.01) and reduced the expression of TNF-alpha and IL-1 beta (p < 0.05). Immunofluorescence analysis revealed that STING was predominantly localized in microglia, with a minimal presence in neuronal cells. Furthermore, intrathecal administration of the STING antagonist C-176 attenuated the analgesic effects of EA in CIBP (p < 0.05). Both EA and STING agonist were effective in alleviating pain in rats with CIBP, possibly through the activation of the STING/IFN-I pathway. Notably, EA treatment reduced pro-inflammatory cytokines and increased anti-inflammatory cytokines. In contrast, while the STING agonist exhibited analgesic effects, it was associated with elevated levels of pro-inflammatory cytokines. These finding underscore the therapeutic potential of EA in the management of CIBP.
C1 [Gu, Yi-Ming; Meng, Xiang; Liang, Jia-Yi; Xia, Yong; Huang, Jun-Wei; Ju, Zi-Yong] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.
   [Wang, Ke] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & Weste, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Ju, ZY (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.
EM juziyong@hotmail.com
FU National Nature Science Foundation of China [81874506, 82474639]
CR Bhatt K, 2024, ANN ONCOL, V35, P473, DOI 10.1016/j.annonc.2024.01.006
   Brigatte P, 2007, J PAIN, V8, P412, DOI 10.1016/j.jpain.2006.11.006
   Chen SY, 2010, INNER MONGOLIA J TRADIT CHIN MED, V29, P117
   Cheng ZL, 2020, SIGNAL TRANSDUCT TAR, V5, P0, DOI 10.1038/s41392-020-0198-7
   Costantini M, 2009, ANN ONCOL, V20, P729, DOI 10.1093/annonc/mdn700
   Ding YY, 2023, J INTEGR MED-JIM, V21, P496, DOI 10.1016/j.joim.2023.07.001
   Donnelly CR, 2021, NATURE, V591, P275, DOI 10.1038/s41586-020-03151-1
   [杜俊英 Du Junying], 2014, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V29, P1454
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hou PP, 2021, CELL MOL IMMUNOL, V18, P2358, DOI 10.1038/s41423-021-00758-w
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317
   Kane CM, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h315
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Lee SH, 2012, MOL MED REP, V6, P157, DOI 10.3892/mmr.2012.879
   Li Q, 2024, MEDCOMM (2020), V5, P0
   Li WW, 2020, SCI TRANSL MED, V12, P0, DOI 10.1126/scitranslmed.aay9013
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang JY, 2024, J LIAONING UNIV TRADIT CHIN MED, V26, P61
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Liu QY, 2021, PAIN THER, V10, P1755, DOI 10.1007/s40122-021-00283-8
   Liu S, 2020, J PAIN, V21, P836, DOI 10.1016/j.jpain.2019.11.010
   Liu YD, 2022, FRONT SYNAPTIC NEURO, V14, P0, DOI 10.3389/fnsyn.2022.891803
   Martini RS, 2024, CURR ONCOL REP, V26, P691, DOI 10.1007/s11912-024-01536-3
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pan L, 2024, ASIAN J SURG, V47, P3288, DOI 10.1016/j.asjsur.2024.03.152
   Prudente AS, 2024, BRAIN BEHAV IMMUN, V117, P51, DOI 10.1016/j.bbi.2024.01.003
   Samson N, 2022, NAT CANCER, V0, P0, DOI DOI 10.1038/s43018-022-00468-w
   Shenoy PA, 2016, FRONT PHARMACOL, V7, P0, DOI 10.3389/fphar.2016.00286
   Sun J, 2022, J NEUROIMMUNE PHARM, V17, P453, DOI 10.1007/s11481-021-10031-6
   Tan PH, 2021, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.783725
   Tian SX, 2023, PURINERG SIGNAL, V19, P13, DOI 10.1007/s11302-022-09861-7
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang KY, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-24867-2
   Wang W, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.593043
   Wang Y, 2020, GUIDING J TRADIT CHIN MED PHARM, V26, P90
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   Woller SA, 2019, BRAIN BEHAV IMMUN, V76, P151, DOI 10.1016/j.bbi.2018.11.014
   Woolf CJ, 2010, J CLIN INVEST, V120, P3742, DOI 10.1172/JCI45178
   Wu WY, 2022, NEUROPHARMACOLOGY, V217, P0, DOI 10.1016/j.neuropharm.2022.109206
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xu J, 2016, ANESTH ANALG, V122, P882, DOI 10.1213/ANE.0000000000001097
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang LY, 2021, FRONT MOL BIOSCI, V8, P0, DOI 10.3389/fmolb.2021.647647
   Zhang XX, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14215188
   Zhang YX, 2023, INFLAMM RES, V72, P117, DOI 10.1007/s00011-022-01663-2
   Zhang ZY, 2021, LIFE SCI, V272, P0, DOI 10.1016/j.lfs.2021.119259
   Zhao JG, 2017, ACUPUNCT MED, V35, P224, DOI 10.1136/acupmed-2016-011107
   Zhao YX, 2024, MOL PAIN, V20, P0, DOI 10.1177/17448069241240692
   Zhu YY, 2019, MOL CANCER, V18, P0, DOI 10.1186/s12943-019-1087-y
NR 52
TC 0
Z9 0
U1 3
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 
EI 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD JUN 15
PY 2025
VL 21
IS 
BP 
EP 
DI 10.1177/17448069251342240
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 3MD4S
UT WOS:001503634600001
PM 40331681
DA 2026-01-16
ER

PT J
AU Nie, HM
   Liu, BY
   Yin, CY
   Dong, ZS
   Pan, YS
   Li, PY
   Hu, QM
   Wang, J
   Tai, Y
   Shao, XM
   Tian, GH
   Wang, C
   Fang, JQ
   Liu, BY
AF Nie, Huimin
   Liu, Boyu
   Yin, Chengyu
   Dong, Zishan
   Pan, Yushuang
   Li, Peiyi
   Hu, Qimiao
   Wang, Jie
   Tai, Yan
   Shao, Xiaomei
   Tian, Guihua
   Wang, Chuan
   Fang, Jianqiao
   Liu, Boyi
TI Neuronal Reg3β/macrophage TNF-α-mediated positive feedback signaling contributes to pain chronicity in a rat model of CRPS-I
SO SCIENCE ADVANCES
LA English
DT Article
ID complex regional pain; tumor-necrosis-factor; sensory neurons; mouse model; tyrosine kinase; sodium-channels; drg neurons; macrophages; expression; electroacupuncture
AB Complex regional pain syndrome type I (CRPS-I) develops after an initial injury. It causes prolonged pain that persists beyond the usual expected time for tissue healing. Mechanisms underlying pain chronicity of CRPS-I remain unknown. Here, we identified the presence of long-lasting infiltration of macrophages in local dorsal root ganglia (DRG) of a rat model of CRPS-I. We demonstrate that regenerating islet-derived 3 beta (Reg3 beta) is specifically produced by DRG neurons upon model establishment and functions as an important signaling molecule to drive proinflammatory macrophage infiltration in local DRG. Infiltrated macrophages produce TNF-alpha, which causes hyperexcitability of nociceptive DRG neurons and reciprocally promotes Reg3 beta overexpression and secretion from DRG neurons to recruit more macrophages. Our work reveals a positive feedback signaling conveyed by neuronal Reg3 beta/macrophage TNF-alpha that contributes to neuroinflammation in DRG, resulting in persistent pain in a rat model of CRPS-I. This finding provides insights into the neuroimmune interaction in local DRG that contributes to pain chronicity of CRPS-I.
C1 [Nie, Huimin; Liu, Boyu; Yin, Chengyu; Pan, Yushuang; Li, Peiyi; Hu, Qimiao; Shao, Xiaomei; Fang, Jianqiao; Liu, Boyi] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.
   [Yin, Chengyu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China.
   [Dong, Zishan] Hebei Med Univ, Dept Pathophysiol, Hebei Key Lab Crit Dis Mech & Intervent, Shijiazhuang, Peoples R China.
   [Wang, Jie] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Rehabil Tradit Chinese Med, Hangzhou, Peoples R China.
   [Tai, Yan] Zhejiang Chinese Med Univ, Acad Chinese Med Sci, Hangzhou, Peoples R China.
   [Tian, Guihua] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China.
   [Wang, Chuan] Hebei Med Univ, Dept Pharmacol, Key Lab Neural & Vasc Biol, Minist Educ, Shijiazhuang, Peoples R China.
   [Wang, Chuan] Hebei Univ, Coll Pharmaceut Sci, Baoding, Peoples R China.
C3 Zhejiang Chinese Medical University; Huazhong University of Science & Technology; Hebei Medical University; Zhejiang University; Zhejiang Chinese Medical University; Capital Medical University; Hebei Medical University; Hebei University
RP Fang, JQ; Liu, BY (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.; Wang, C (corresponding author), Hebei Med Univ, Dept Pharmacol, Key Lab Neural & Vasc Biol, Minist Educ, Shijiazhuang, Peoples R China.; Wang, C (corresponding author), Hebei Univ, Coll Pharmaceut Sci, Baoding, Peoples R China.
EM wangchuan@hebmu.edu.cn; fangjianqiao7532@163.com; boyi.liu@foxmail.com
FU National Natural Science Foundation of China [82474625, 82305368, 82305369, 81770407, 82105014]; Zhejiang Provincial Natural Science [LZ23H270001]; Natural Science Foundation of Hebei Province [H2024206491]; National High Level Traditional Chinese Medicine Hospital Clinical Research Funding [DZM-XZYY-23001]
CR Averill S, 2002, J NEUROSCI, V22, P7493
   Birklein F, 2018, NAT REV NEUROL, V14, P272, DOI 10.1038/nrneurol.2018.20
   Caceres AI, 2017, BRIT J PHARMACOL, V174, P867, DOI 10.1111/bph.13760
   Caxaria S, 2023, P NATL ACAD SCI USA, V120, P0, DOI 10.1073/pnas.2211631120
   Chakrabarti S, 2020, ARTHRITIS RHEUMATOL, V72, P1749, DOI 10.1002/art.41314
   Chan KY, 2017, NAT NEUROSCI, V20, P1172, DOI 10.1038/nn.4593
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen L, 2025, SCI ADV, V11, P0, DOI 10.1126/sciadv.adu2159
   Chen Ouyang, 2023, MED REV (2021), V3, P381, DOI 10.1515/mr-2023-0034
   Chen O, 2020, CURR OPIN NEUROBIOL, V62, P17, DOI 10.1016/j.conb.2019.11.006
   Chen RX, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02131-0
   Chen RX, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01834-0
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Chen W, 2018, ANAL BIOCHEM, V561, P59, DOI 10.1016/j.ab.2018.09.002
   Coderre TJ, 2004, PAIN, V112, P94, DOI 10.1016/j.pain.2004.08.001
   Cruceriu D, 2020, CELL ONCOL, V43, P1, DOI 10.1007/s13402-019-00489-1
   Dawes JM, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093338
   De Logu F, 2020, BRAIN BEHAV IMMUN, V88, P535, DOI 10.1016/j.bbi.2020.04.037
   Dirckx M, 2013, PAIN PRACT, V13, P633, DOI 10.1111/papr.12078
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Eisenberg E, 2013, PAIN PRACT, V13, P649, DOI 10.1111/papr.12070
   Fassio A, 2022, RHEUMATOLOGY, V61, P3534, DOI 10.1093/rheumatology/keac060
   Gao Yong-Jing, 2009, OPEN PAIN J, V2, P11
   Guimares RM, 2023, ELIFE, V12, P0, DOI 10.7554/eLife.78515
   Haberberger RV, 2023, CELL TISSUE RES, V393, P17, DOI 10.1007/s00441-023-03770-w
   He SQ, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-23
   Hensellek S, 2007, MOL CELL NEUROSCI, V36, P381, DOI 10.1016/j.mcn.2007.07.010
   Hu QM, 2020, J PAIN, V21, P1060, DOI 10.1016/j.jpain.2020.01.007
   Hu QM, 2020, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/60562
   Hu QM, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00453
   Ino Y, 2023, J NEUROINFLAMM, V20, P0, DOI 10.1186/s12974-023-02882-y
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Jin XC, 2006, J NEUROSCI, V26, P246, DOI 10.1523/JNEUROSCI.3858-05.2006
   Jin Y, 2021, J INFLAMM RES, V14, P2841, DOI 10.2147/JIR.S315774
   Kaminow B, 1900, DOI 10.1101/2021.05.05.442755, V0, P0
   Li JY, 2020, J NEUROSCI, V40, P297, DOI 10.1523/JNEUROSCI.1414-19.2019
   Li XJ, 2022, OXID MED CELL LONGEV, V2022, P0, DOI 10.1155/2022/8035109
   Li YZ, 2004, J NEUROSCI, V24, P9623, DOI 10.1523/JNEUROSCI.2392-04.2004
   Liu BY, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0165200
   Liu BY, 2016, P NATL ACAD SCI USA, V113, PE7572, DOI 10.1073/pnas.1606608113
   Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084
   Liu BY, 2022, CELL MOL BIOL LETT, V27, P0, DOI 10.1186/s11658-022-00316-w
   Liu F, 2023, ADV SCI, V10, P0, DOI 10.1002/advs.202205397
   Liu F, 2020, ARTHRITIS RHEUMATOL, V72, P1668, DOI 10.1002/art.41386
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lörchner H, 2018, CARDIOVASC RES, V114, P1667, DOI 10.1093/cvr/cvy126
   Lörchner H, 2015, NAT MED, V21, P353, DOI 10.1038/nm.3816
   Lopez-Santiago LF, 2006, J NEUROSCI, V26, P7984, DOI 10.1523/JNEUROSCI.2211-06.2006
   Marinus J, 2011, LANCET NEUROL, V10, P637, DOI 10.1016/S1474-4422(11)70106-5
   Marvaldi L, 2020, SCIENCE, V369, P842, DOI 10.1126/science.aaz5875
   Miclescu AA, 2013, PAIN PRACT, V13, P641, DOI 10.1111/papr.12027
   Ott S, 2018, J PAIN, V19, P599, DOI 10.1016/j.jpain.2018.01.004
   Pu SF, 2023, NEUROSCI BULL, V39, P177, DOI 10.1007/s12264-022-00910-0
   Raoof R, 2021, J NEUROSCI, V41, P8249, DOI 10.1523/JNEUROSCI.1787-20.2021
   Ren JH, 2024, ACUPUNCT HERB MED, V4, P525, DOI 10.1097/HM9.0000000000000140
   Sharma A, 2009, REGION ANESTH PAIN M, V34, P110, DOI 10.1097/AAP.0b013e3181958f90
   Silva JR, 2017, J NEUROSCI, V37, P6408, DOI 10.1523/JNEUROSCI.2233-16.2017
   Sun C, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22137196
   Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066
   Taylor SS, 2021, PAIN THER, V10, P875, DOI 10.1007/s40122-021-00279-4
   Uckun FM, 2010, P NATL ACAD SCI USA, V107, P2902, DOI 10.1073/pnas.0909086107
   Üçeyler N, 2007, PAIN, V132, P195, DOI 10.1016/j.pain.2007.07.031
   Wang J, 2023, J NEUROINFLAMM, V20, P0, DOI 10.1186/s12974-023-02778-x
   Wang J, 2020, FRONT NEUROL, V11, P0, DOI 10.3389/fneur.2020.580997
   Wang Q, 2021, J ADV RES, V31, P97, DOI 10.1016/j.jare.2020.12.009
   Wei HN, 2023, CHIN MED-UK, V18, P0, DOI 10.1186/s13020-023-00800-1
   Xu RY, 2024, THERANOSTICS, V14, P5281, DOI 10.7150/thno.97856
   Yin CY, 2024, THERANOSTICS, V14, P3082, DOI 10.7150/thno.95611
   Yin CY, 2024, NAT COMMUN, V15, P0, DOI 10.1038/s41467-024-47640-7
   Yin CY, 2020, THERANOSTICS, V10, P12189, DOI 10.7150/thno.48028
   Yin CY, 2020, BRIT J PHARMACOL, V177, P2042, DOI 10.1111/bph.14967
   Yin CY, 2019, J PAIN RES, V12, P1201, DOI 10.2147/JPR.S188758
   Yu XB, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-019-13839-2
   Zhang L, 2021, BRAIN BEHAV IMMUN, V91, P556, DOI 10.1016/j.bbi.2020.11.015
   Zuo WJ, 2023, CELL MOL BIOL LETT, V28, P0, DOI 10.1186/s11658-023-00491-4
NR 75
TC 1
Z9 1
U1 15
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 
EI 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD AUG 1
PY 2025
VL 11
IS 31
BP 
EP 
DI 10.1126/sciadv.adu4270
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 5RE8Q
UT WOS:001542395300015
PM 40749060
DA 2026-01-16
ER

PT J
AU Cao, Y
   Jing, F
   Jiang, L
   Tian, M
   Qiu, J
   Tang, L
   Hu, Y
AF Cao, Yuling
   Jing, Feng
   Jiang, Lingyun
   Tian, Maoting
   Qiu, Jiajia
   Tang, Lichen
   Hu, Yan
TI The experience of musculoskeletal symptoms among patients with breast cancer
SO Asia-Pacific journal of oncology nursing
LA English
DT Journal Article
DE Aromatase inhibitor therapy; Breast cancer; Musculoskeletal symptoms; Qualitative study; Symptom experience; Symptom management
AB OBJECTIVE: To examine the musculoskeletal symptom experiences of Chinese patients  with breast cancer receiving aromatase inhibitor (AI) therapy and identify  patient-centered strategies for symptom management. METHODS: A descriptive  qualitative study was conducted from June to August 2023 at a tertiary hospital  in Shanghai, China. Using purposive sampling with maximum variation, 37 women  with hormone receptor-positive (HR+) breast cancer (stages I-III) undergoing AI  therapy participated in semi-structured telephone interviews. Data were  audio-recorded, transcribed verbatim, and analyzed thematically. RESULTS: Four  themes were identified: (1) Symptom burden-persistent joint pain, stiffness, and  fatigue interfered with daily activities; (2) Emotional impact-symptoms provoked  anxiety, frustration, and reduced well-being; (3) Social challenges-decreased  participation in social and family life led to feelings of isolation; and (4)  Coping strategies-pharmacological measures (e.g., calcium and vitamin D  supplementation) and non-pharmacological interventions (e.g., exercise,  acupuncture) were adopted, though access to reliable information and professional  guidance was often inadequate. CONCLUSIONS: Musculoskeletal symptoms related to  AI therapy impose considerable physical, emotional, and social burdens on Chinese  patients with breast cancer, potentially undermining treatment adherence.  Culturally appropriate, patient-centered management incorporating both  pharmacological and non-pharmacological interventions is essential to optimize  symptom control and quality of life.
C1 School of Nursing, Fudan University, Shanghai, China.
   School of Nursing, Fudan University, Shanghai, China.
   Fudan University Shanghai Cancer Center, Shanghai, China.
   School of Nursing, Fudan University, Shanghai, China.
   School of Nursing, Fudan University, Shanghai, China.
   Fudan University Shanghai Cancer Center, Shanghai, China.
   Fudan University Shanghai Cancer Center, Shanghai, China.
   School of Nursing, Fudan University, Shanghai, China.
NR 0
TC 0
SN 2349-667
EI 2347-562
J9 Asia Pac J Oncol Nurs
PD OCT 6
PY 2025
VL 12
IS 
BP 100784
EP 100784
DI 10.1016/j.apjon.2025.100784
PG 0
UT PubMed:41048407
PM 41048407
DA 2025-10-06
ER

PT J
AU Laycock, H
   Ramdin, C
   Grayer, J
   Brown, MRD
AF Laycock, Helen
   Ramdin, Candice
   Grayer, Justin
   Brown, Matthew R. D.
TI Causes and management of acute oncological pain: a narrative review
SO ANAESTHESIA
LA English
DT Review
DE acute pain; cancer; mucositis; neuropathy; opioids; radiotherapy
ID induced oral mucositis; induced bone pain; palliative radiotherapy; postoperative pain; normal tissue; cancer pain; opioids; prevalence; metastases; surgery
AB IntroductionAcute pain in cancer is an important but often overlooked feature of many patients' oncological journey. Cancer-related pain is associated commonly with more persistent pain states caused by both the disease and its treatment, but there are numerous causes of acute pain which can develop in patients with cancer. This pain is frequently severe, can be challenging to manage and its suboptimal control can directly impact on oncological outcomes. This narrative review provides an overview of several causes of acute pain in patients with cancer and management approaches.MethodsA focused literature review was conducted to encompass the search terms 'acute pain', 'oncology' and 'cancer' in adult and paediatric populations.ResultsAcute pain is common in patients with cancer with a number of pain generators identified. Broadly, these are disease- and treatment-related but commonality in pain mechanisms and features are present. Importantly, these pain states do not occur in isolation; a patient may experience multiple acute pain episodes during their oncology journey.DiscussionAs the oncological treatment landscape shifts and increasing numbers of novel treatments are employed, the number of causes of acute pain in patients with cancer rises. This pain is often managed by non-pain specialists and suboptimal control has a variety of deleterious effects. It is important that awareness of acute pain in the oncological population is increased and treatment approaches, which adopt a biopsychosocial structure, are optimised.
C1 [Laycock, Helen] Great Ormond St Hosp Sick Children, Dept Pain Med, London, England.
   [Ramdin, Candice] San Fernando Gen Hosp, Southwest Reg Hlth Author, Dept Pain Med, San Fernando, Trinidad Tobago.
   [Grayer, Justin] Royal Marsden Hosp, Adult Psychol Support Serv, London, England.
   [Brown, Matthew R. D.] Royal Marsden Hosp, Dept Pain Med, London, England.
   [Brown, Matthew R. D.] Inst Canc Res, London, England.
C3 University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK
RP Brown, MRD (corresponding author), Royal Marsden Hosp, Dept Pain Med, London, England.; Brown, MRD (corresponding author), Inst Canc Res, London, England.
EM matthew.brown@rmh.nhs.uk
FU NHS; Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre; Boston Scientific Corporation; Medtronic plc
CR Al-Ansari Sali, 2015, CURR ORAL HEALTH REP, V2, P202, DOI 10.1007/s40496-015-0069-4
   Anghelescu DL, 2019, PEDIATR DRUGS, V21, P59, DOI 10.1007/s40272-018-00324-4
   Unknown -, 1996, CANCER PAIN RELIEF, V2nd, P0
   Attal N, 2009, PAIN, V144, P245, DOI 10.1016/j.pain.2009.03.024
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2
   Baumann L, 2023, CURR PAIN HEADACHE R, V27, P437, DOI 10.1007/s11916-023-01127-0
   Baxter J, 2019, CURR OPIN SUPPORT PA, V13, P81, DOI 10.1097/SPC.0000000000000428
   Boland JW, 2014, BRIT J CANCER, V111, P866, DOI 10.1038/bjc.2014.384
   Brown MRD, 2014, BRIT J PAIN, V8, P139, DOI 10.1177/2049463714542605
   Burton AW, 2004, PAIN MED, V5, P239, DOI 10.1111/j.1526-4637.2004.04037.x
   Cavaletti G, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12061370
   Chiu N, 2016, ANN PALLIAT MED, V5, P50, DOI 10.3978/j.issn.2224-5820.2015.08.01
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Coley KC, 2002, J CLIN ANESTH, V14, P349, DOI 10.1016/S0952-8180(02)00371-9
   Corbacioglu S, 2019, BIOL BLOOD MARROW TR, V25, P1271, DOI 10.1016/j.bbmt.2019.02.018
   Craig TJ, 2024, CURR OPIN SUPPORT PA, V18, P113, DOI 10.1097/SPC.0000000000000714
   Cronin-Fenton DP, 2015, CANCER-AM CANCER SOC, V121, P3507, DOI 10.1002/cncr.29532
   Deer TR, 2012, NEUROMODULATION, V15, P436, DOI 10.1111/j.1525-1403.2012.00476.x
   Descoeur J, 2011, EMBO MOL MED, V3, P266, DOI 10.1002/emmm.201100134
   Docimo R, 2022, EUR ARCH PAEDIATR DE, V23, P501, DOI 10.1007/s40368-022-00727-5
   Eccleston CW, 2009, COCHRANE DATABASE SYSTEMATIC REVIEW, V2, P0, DOI 10.1002/14651858.CD007407.PUB2
   Ekholm O, 2014, PAIN, V155, P2486, DOI 10.1016/j.pain.2014.07.006
   Elad S, 2020, CANCER-AM CANCER SOC, V126, P4423, DOI 10.1002/cncr.28592
   Emvalomati A, 2023, DERMATOL PRACT CONCE, V13, P0, DOI 10.5826/dpc.1301a64
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Farr KP, 2011, CASE REP ONCOL, V4, P229, DOI 10.1159/000327767
   Faulkner S, 2019, CANCER DISCOV, V9, P702, DOI 10.1158/2159-8290.CD-18-1398
   Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3
   Ferrara JLM, 2003, INT J HEMATOL, V78, P181, DOI 10.1007/BF02983793
   Forget P, 2010, EUR J ANAESTH, V27, P233, DOI 10.1097/EJA.0b013e32832d540e
   Furman WL, 2021, BIOL-TARGETS THER, V15, P205, DOI 10.2147/BTT.S267278
   Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066
   Gavioli E, 2017, SUPPORT CARE CANCER, V25, P817, DOI 10.1007/s00520-016-3465-y
   Gomez-Iturriaga A, 2015, BMC PALLIAT CARE, V14, P0, DOI 10.1186/s12904-015-0045-8
   Graus F, 2004, J NEUROL NEUROSUR PS, V75, P1135, DOI 10.1136/jnnp.2003.034447
   Haroutounian S, 2018, PAIN REP, V3, P0, DOI 10.1097/PR9.0000000000000640
   Hendry JH, 2006, REVISTA PANAMERICANA DE SALUD PUBLICA/PAN AMERICAN JOURNAL OF PUBLIC HEALTH, V20, P151
   Hou QZ, 2011, PAIN, V152, P2036, DOI 10.1016/j.pain.2011.04.033
   Hubenak JR, 2014, PLAST RECONSTR SURG, V133, P49E, DOI 10.1097/01.prs.0000440818.23647.0b
   Jepegnanam C, 2021, BRIT J PAIN, V15, P163, DOI 10.1177/2049463720926212
   Johnson JW, 2015, CURR OPIN PHARMACOL, V20, P54, DOI 10.1016/j.coph.2014.11.006
   Karthaus M, 1999, BONE MARROW TRANSPL, V24, P1095, DOI 10.1038/sj.bmt.1702024
   Kharasch ED, 2020, ANESTHESIOLOGY, V133, P251, DOI 10.1097/ALN.0000000000003394
   Kirshner JJ, 2012, J CLIN ONCOL, V30, P1974, DOI 10.1200/JCO.2011.37.8364
   Kurita GP, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040443
   Kwakman JJM, 2020, ONCOL REV, V14, P57, DOI 10.4081/oncol.2020.442
   Kyle BN, 2014, PAIN RES MANAG, V19, P159, DOI 10.1155/2014/536859
   Lambertini M, 2014, CRIT REV ONCOL HEMAT, V89, P112, DOI 10.1016/j.critrevonc.2013.08.006
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Livraghi T, 2012, CARDIOVASC INTER RAD, V35, P868, DOI 10.1007/s00270-011-0241-8
   Loblaw DA, 2007, SUPPORT CARE CANCER, V15, P451, DOI 10.1007/s00520-006-0166-y
   Lodge D, 2015, BRIT J PHARMACOL, V172, P4254, DOI 10.1111/bph.13222
   Magee D, 2019, PAIN MANAG, V9, P63, DOI 10.2217/pmt-2018-0031
   Magee DJ, 2021, CURR OPIN SUPPORT PA, V15, P77, DOI 10.1097/SPC.0000000000000549
   Maria OM, 2017, FRONT ONCOL, V7, P0, DOI 10.3389/fonc.2017.00089
   McCracken LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-057212
   McDonald R, 2014, J BONE ONCOL, V3, P84, DOI 10.1016/j.jbo.2014.10.001
   Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X
   Naidu MUR, 2004, NEOPLASIA, V6, P423, DOI 10.1593/neo.04169
   Padmanaban V, 2024, NATURE, V633, P207, DOI 10.1038/s41586-024-07767-5
   Page GG, 2005, J PAIN SYMPTOM MANAG, V29, PS25, DOI 10.1016/j.jpainsymman.2005.01.006
   Paice JA, 2023, J CLIN ONCOL, V41, P914, DOI 10.1200/JCO.22.02198
   Pelosof LC, 2010, MAYO CLIN PROC, V85, P838, DOI 10.4065/mcp.2010.0099
   Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Sadeghi-Naini M, 2018, CLIN SPINE SURG, V31, P203, DOI 10.1097/BSD.0000000000000601
   SALKOVSKIS PM, 1992, AM J MED, V92, PS114, DOI 10.1016/0002-9343(92)80066-9
   Sayed D, 2019, PAIN PHYSICIAN, V22, PE441, DOI 10.36076/ppj/2019.22.e441
   Shkodra M, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14081992
   Sonis Stephen T, 2004, SEMIN ONCOL NURS, V20, P11
   Spain L, 2017, ANN ONCOL, V28, P377, DOI 10.1093/annonc/mdw558
   Spill F, 2016, CURR OPIN BIOTECH, V40, P41, DOI 10.1016/j.copbio.2016.02.007
   Tighe P, 2015, PAIN MED, V16, P1806, DOI 10.1111/pme.12760
   Tomasian A, 2020, SEMIN INTERVENT RAD, V37, P192, DOI 10.1055/s-0040-1709205
   Tonev DG, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/6153955
   Treede RD, 2019, PAIN, V160, P19, DOI 10.1097/j.pain.0000000000001384
   Tutelman PR, 2018, CLIN J PAIN, V34, P198, DOI 10.1097/AJP.0000000000000531
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Walker SM, 2022, PEDIATR ANESTH, V32, P17, DOI 10.1111/pan.14324
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang H, 2021, CELL DEATH DISCOV, V7, P0, DOI 10.1038/s41420-021-00450-y
   Wei JL, 2019, CANCER MANAG RES, V11, P167, DOI 10.2147/CMAR.S188655
   Weisman SJ, 2021, OXFORD TXB PEDIAT PA, V0, PP168, DOI 10.1093/med/9780198818762.003.0018
   Wild CP, 2020, WORLD CANCER REPORT: CANCER RESEARCH FOR CANCER PREVENTION, V0, P0
   Yaniv D, 2024, NAT REV DRUG DISCOV, V23, P780, DOI 10.1038/s41573-024-01017-z
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
   Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472
   Zoccarato M, 2021, FRONT NEUROL, V12, P0, DOI 10.3389/fneur.2021.706169
NR 90
TC 1
Z9 1
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD FEB 15
PY 2025
VL 80
IS 
BP 95
EP 105
DI 10.1111/anae.16512
EA JAN 2025
PG 11
WC Anesthesiology
SC Anesthesiology
GA U6I7Q
UT WOS:001391285700001
PM 39777687
DA 2026-01-16
ER

PT J
AU Ying, Y
   Yang, GD
   Li, XY
   Wang, FF
   Zhang, GB
AF Ying, Yi
   Yang, Guodong
   Li, Xiaoyu
   Wang, Feifei
   Zhang, Guobing
TI Analgesic effects of electroacupuncture via the EphBs-p38 MAPK signaling pathway and microglial suppression in the chronic constriction injury rat model of neuropathic pain
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE electroacupuncture; EphBs; microglia; neuropathic pain; p38 mitogen-activated protein kinase
ID spinal dorsal-horn; synaptic plasticity; p38 mapk; mechanisms; activation; hyperalgesia; inflammation; acupuncture; allodynia; receptor
AB Objective: To explore the analgesic effects of electroacupuncture (EA) and its impact on the EphBs-p38 mitogen-activated protein kinase (MAPK) pathway and microglia in a rat model of neuropathic pain (NP).Methods: Following adaptive training, 60 male Sprague Dawley (SD) rats were allocated to one of two experiments. In experiment 1, rats received intrathecal SB203580 (p38 MAPK inhibitor), intramuscular EphB1-Fc (EphBs inhibitor) or no injection before undergoing chronic constrictive injury (CCI). In experiment 2, CCI model rats received EA either alone or combined with either anisomycin (p38 MAPK agonist) or EphrinB1-Fc (EphBs agonist) versus minimal acupuncture (MA) as a control intervention. A sham surgery group was included in both experiments as a control for CCI. All groups consisted of n = 6 rats (four in experiment 1 and six in experiment 2). Behavioral hyperalgesia was examined and the spinal L5-6 region was harvested and subjected to enzyme-linked immunosorbent assay to assess tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta levels. Western blotting and immunofluorescence were used to assess protein expression of B-cell lymphoma (Bcl)-2, Bcl-2 associated X-protein (BAX), EphB1, EphrinB1, p38 MAPK, phosphorylated (p)-p38 MAPK and ionized calcium binding adaptor molecule (Iba)-1.Results: CCI induced behavioral hyperalgesia, as demonstrated by altered paw withdrawal latency (PWL), paw withdrawal threshold (PWT) and cytokine levels, and increased p38 MAPK phosphorylation and microglial activation. However, inhibitors SB203580 and EphB1-Fc reversed these effects. Notably, EA showed similar beneficial effects, but these were counteracted when combined with anisomycin and EphrinB1-Fc.Conclusions: The analgesic effects of EA in this rat model of NP appear to be linked to diminished p-p38 MAPK expression and subsequent microglial deactivation. EA has a potential role as a complementary therapy for NP.
C1 [Ying, Yi] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, XianJu Peoples Hosp, Affiliated Xianjus Hosp,Dept Tradit Chinese Med, Zhejiang Southeast Campus, Taizhou, Peoples R China.
   [Yang, Guodong] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Xianjus Hosp, XianJu Peoples Hosp,Dept Orthoped, Zhejiang Southeast Campus, Taizhou, Peoples R China.
   [Li, Xiaoyu] Zhejiang Chinese Med Univ, Sch Clin Med 3, Key Lab Acupuncture & Neurol Zhejiang Prov, Dept Neurobiol & Acupuncture Res,Sch Rehabil Med, Hangzhou, Peoples R China.
   [Wang, Feifei] Hangzhou Med Coll, XianJu Peoples Hosp, Zhejiang Prov Peoples Hosp, Affiliated Xianjus Hosp,Dept Rehabil, Zhejiang Southeast Campus, Taizhou, Peoples R China.
   [Zhang, Guobing] Zhejiang Hosp Integrated Tradit Chinese & Western, Dept Pharm, Hangzhou 310014, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Zhejiang Chinese Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital
RP Zhang, GB (corresponding author), Zhejiang Hosp Integrated Tradit Chinese & Western, Dept Pharm, Hangzhou 310014, Peoples R China.
EM 13675851802@163.com
FU Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project [2021ZA145]
CR Austin PJ, 2012, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/3393
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Cao JL, 2008, PAIN, V139, P617, DOI 10.1016/j.pain.2008.06.023
   Cheng KI, 2021, PHYTOMEDICINE, V92, P0, DOI 10.1016/j.phymed.2021.153734
   Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014
   Chu HC, 2012, INT J NEUROSCI, V122, P74, DOI 10.3109/00207454.2011.630542
   Dong CR, 2022, BIOMED PHARMACOTHER, V150, P0, DOI 10.1016/j.biopha.2022.113029
   Edlich F, 2018, BIOCHEM BIOPH RES CO, V500, P26, DOI 10.1016/j.bbrc.2017.06.190
   Finnerup Nanna B, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Huang Q, 2017, BRAIN BEHAV IMMUN, V62, P64, DOI 10.1016/j.bbi.2017.02.005
   HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4
   Jensen Troels S, 2014, LANCET NEUROL, V13, P924, DOI 10.1016/S1474-4422(14)70102-4
   Jin FH, 2020, MOL PAIN, V16, P0, DOI 10.1177/1744806920984079
   Ju ZY, 2013, NEURAL REGEN RES, V8, P2350, DOI 10.3969/j.issn.1673-5374.2013.25.006
   Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16
   Kaur S, 2024, FUND CLIN PHARMACOL, V38, P4, DOI 10.1111/fcp.12937
   Khan A, 2023, INT IMMUNOPHARMACOL, V118, P0, DOI 10.1016/j.intimp.2023.110046
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Li Y, 2019, CURR NEUROVASC RES, V16, P465, DOI 10.2174/1567202616666191111104145
   Liang RY, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3056963
   Liang Y, 2016, CHIN J INTEGR MED, V22, P704, DOI 10.1007/s11655-015-2045-1
   Liu Y, 2017, J NEUROSCI, V37, P871, DOI 10.1523/JNEUROSCI.2235-16.2016
   Malcangio M, 2020, SCAND J PAIN, V20, P33, DOI 10.1515/sjpain-2019-0138
   Mukai M, 2022, BMC NEUROSCI, V23, P0, DOI 10.1186/s12868-022-00719-7
   Pan H, 2020, HUM EXP TOXICOL, V39, P563, DOI 10.1177/0960327119895561
   Ruan JP, 2010, ANESTHESIOLOGY, V112, P1234, DOI 10.1097/ALN.0b013e3181d3e0df
   Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122
   Song XJ, 2008, EUR J PAIN, V12, P1031, DOI 10.1016/j.ejpain.2008.01.011
   Tan B, 2022, MOLECULES, V27, P0, DOI 10.3390/molecules27123956
   Taylor H, 2017, CURR BIOL, V27, PR90, DOI 10.1016/j.cub.2017.01.003
   Tian J, 2020, J MOL NEUROSCI, V70, P84, DOI 10.1007/s12031-019-01403-y
   Tozaki-Saitoh H, 2019, BIOCHEM PHARMACOL, V169, P0, DOI 10.1016/j.bcp.2019.08.016
   Tsuda M, 2017, J NEUROCHEM, V141, P486, DOI 10.1111/jnc.14001
   Wang BB, 2018, NEUROCHEM RES, V43, P287, DOI 10.1007/s11064-017-2420-8
   Wang BB, 2018, J HEADACHE PAIN, V19, P0, DOI 10.1186/s10194-018-0836-4
   Wu JP, 2020, MOL MED REP, V21, P291, DOI 10.3892/mmr.2019.10829
   Ye GY, 2021, J PAIN RES, V14, P1289, DOI 10.2147/JPR.S298727
   Yu C, 2020, DRUG DES DEV THER, V14, P4725, DOI 10.2147/DDDT.S276424
   Zhang D, 2023, CNS NEUROSCI THER, V29, P1000, DOI 10.1111/cns.14060
   Zhang Fei-E, 2005, SHENGLI XUEBAO, V57, P545
   Zhou LJ, 2019, CELL REP, V27, P3844, DOI 10.1016/j.celrep.2019.05.087
   Zilliox Lindsay A, 2017, CONTINUUM (MINNEAP MINN), V23, P512, DOI 10.1212/con.0000000000000462
NR 42
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD OCT 15
PY 2025
VL 43
IS 5
BP 278
EP 289
DI 10.1177/09645284251363987
EA AUG 2025
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 8IX9P
UT WOS:001555278700001
PM 40847801
DA 2026-01-16
ER

PT J
AU Yin, J
   Feng, MM
   Xu, HY
AF Yin, Jie
   Feng, Mengmeng
   Xu, Haiyang
TI Cai's gynecology chronic pelvic formula with acupuncture alleviates chronic pelvic pain and reduces recurrence in patients with pelvic inflammatory disease sequelae
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Cai's gynecology chronic pelvic formula; acupuncture; chronic pelvic pain; recurrence rate; clinical efficacy; cox regression analysis
AB Objective: To assess the efficacy of Cai's Gynecology Chronic Pelvic Formula combined with acupuncture in managing chronic pelvic pain (CPP) secondary to pelvic inflammatory disease (PID) sequelae, and its effect on recurrence. Methods: A retrospective study assessed medical records from 240 CPP patients undergoing treatment between February 2019 and February 2024. Patients were divided into a control group (standard treatment, n = 120) and an observation group (standard treatment plus Cai's Chronic Pelvic Formula combined with acupuncture, n = 120), with treatment lasted for 28 days and follow-up for 6 months. The symptom scores (Visual Analog Scale, Self-rating Anxiety Scale and Self-rating Depression Scale), inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cancer antigen 125 (CA125)], efficacy rates, and recurrence rates were all employed to measure treatment outcomes. Cox regression was leveraged to identify recurrence risk factors, while a nomogram model was developed and validated by Receiver Operating Characteristic (ROC), calibration curves, and decision curve analysis (DCA). Results: The observation group had significantly lower post-treatment Traditional Chinese Medicine symptom scores, inflammatory markers (CRP: P < 0.001; TNF-alpha: P = 0.003; IL-6: P = 0.004), and CA125 (P < 0.001) versus the control group. The observation group also demonstrated shorter symptom resolution time (P < 0.05), with higher total treatment efficacy in comparison to the control group (93.46% vs. 79.70%; P = 0.002). In addition, the observation group showed lower recurrence rates (14.2% vs. 28.3%; P = 0.008) as well as postponed recurrence time when compared to the control group. Cox regression analysis identified treatment protocol (HR = 0.41, 95% CI: 0.24-0.71), disease duration (HR = 1.32, 95% CI: 1.08-1.62), and pre-treatment CRP level (HR = 1.18, 95% CI: 1.02-1.36) as independent recurrence predictors. In addition, the nomogram demonstrated high accuracy in predicting disease recurrence (C-index = 0.852), with both ROC (AUC = 0.837) and calibration curves confirming its reliability. DCA indicated high clinical net benefit of the studying treatment protocol. Conclusion: Cai's Gynecology Chronic Pelvic Formula combined with acupuncture could significantly alleviate CPP and inflammation, and decrease recurrence rates. The nomogram may be used as a validated tool for predicting the disease recurrence, with benefits when integrated into clinical practice as a novel therapeutic strategy.
C1 [Yin, Jie] Shangluo Tradit Chinese Med Hosp, Dept Gynaecol, 148 Beixin St, Shangluo 726000, Shaanxi, Peoples R China.
   [Feng, Mengmeng] Shangluo Vocat & Tech Coll, Tradit Chinese Med Teaching & Res Off, West Sect Shangyang Ave, Shangluo 726000, Shaanxi, Peoples R China.
   [Xu, Haiyang] Xian Int Med Ctr Hosp, Dept Postpartum & Pelv Floor Rehabil, 777 Xitai Rd, Xian 710100, Shaanxi, Peoples R China.
RP Xu, HY (corresponding author), Xian Int Med Ctr Hosp, Dept Postpartum & Pelv Floor Rehabil, 777 Xitai Rd, Xian 710100, Shaanxi, Peoples R China.
EM xuhaiyang9992025@163.com
CR Abdulaziz KS, 2021, J MUSCULOSKEL NEURON, V21, P121
   Armour M, 2021, J ALTERN COMPLEM MED, V27, P841, DOI 10.1089/acm.2021.0004
   Bittelbrunn CC, 2023, ARCH GYNECOL OBSTET, V307, P663, DOI 10.1007/s00404-022-06514-3
   Chang H, 2023, BIOMED PHARMACOTHER, V157, P0, DOI 10.1016/j.biopha.2022.113795
   Grinberg K, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17093005
   He SH, 2022, JAMA-J AM MED ASSOC, V328, P208, DOI 10.1001/jama.2022.7489
   Lamvu G, 2021, JAMA-J AM MED ASSOC, V325, P2381, DOI 10.1001/jama.2021.2631
   Li Bo, 2023, ZHONGGUO ZHEN JIU, V43, P654, DOI 10.13703/j.0255-2930.20221113-k0006
   Li DH, 2018, CHINESE MANIPULATION & REHABILITATION MEDICINE, V0, P0
   Liang Zhuo, 2021, ZHONGGUO ZHEN JIU, V41, P395, DOI 10.13703/j.0255-2930.20200329-k0003
   Liao C, 2024, CHIN J INTEGR TRADIT WEST MED DIG, V32, P711
   Liao CX, 2023, PAIN RES MANAG, V2023, P0, DOI 10.1155/2023/3315090
   Lin KYH, 2023, HEALTHCARE-BASEL, V11, P0, DOI 10.3390/healthcare11060830
   Liu L, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000025281
   Liu LQ, 2019, J TRADIT CHIN MED, V39, P440
   Liu Ying-Hua, 2021, ZHONGGUO ZHEN JIU, V41, P31, DOI 10.13703/j.0255-2930.20191218-k0002
   Parsons BA, 2022, BJU INT, V129, P572, DOI 10.1111/bju.15609
   Peng T, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023916
   Qin ZS, 2018, J UROLOGY, V200, P815, DOI 10.1016/j.juro.2018.05.001
   Ravel J, 2021, AM J OBSTET GYNECOL, V224, P251, DOI 10.1016/j.ajog.2020.10.019
   Shroff S, 2023, MED CLIN N AM, V107, P299, DOI 10.1016/j.mcna.2022.10.009
   Song SY, 2023, BIOMEDICINES, V11, P0, DOI 10.3390/biomedicines11102868
   Su D, 2022, PHYTOMEDICINE, V94, P0, DOI 10.1016/j.phymed.2021.153833
   Wang YY, 2024, J ETHNOPHARMACOL, V319, P0, DOI 10.1016/j.jep.2023.117373
   Yi LC, 2024, PLOS ONE, V19, P0, DOI 10.1371/journal.pone.0292166
   Zhang Jie-Yi, 2021, ZHONGGUO ZHEN JIU, V41, P757, DOI 10.13703/j.0255-2930.20200713-0002
   Zhang LJ, 2017, J ETHNOPHARMACOL, V208, P57, DOI 10.1016/j.jep.2017.06.034
   Zheng J, 2022, J HEALTHC ENG, V2022, P0, DOI 10.1155/2022/8770510
   Zhu GH, 2025, GINEKOL POL, V96, P304, DOI 10.5603/gp.a2021.0066
NR 29
TC 1
Z9 1
U1 5
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2025
VL 17
IS 7
BP 5241
EP 5256
DI 10.62347/YVFO2330
PG 16
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 5RB2M
UT WOS:001542299900031
PM 40821053
DA 2026-01-16
ER

PT J
AU Vella, R
   Giardino, A
   Pizzocaro, E
   Frigerio, I
   Bannone, E
   Vieni, S
   Butturini, G
AF Vella, Roberta
   Giardino, Alessandro
   Pizzocaro, Erica
   Frigerio, Isabella
   Bannone, Elisa
   Vieni, Salvatore
   Butturini, Giovanni
TI Unconventional Treatments for Pancreatic Cancer: A Systematic Review
SO CANCERS
LA English
DT Review
DE pancreatic cancer; systematic review; complementary medicine; unconventional treatment; precision oncology
ID quality-of-life; factor-kappa-b; viscum-album l; phase-i; chinese medicine; curcumin; pain; survival; gemcitabine; chemotherapy
AB Objective: This study aims to review the existing literature on the efficacy and safety of unconventional treatments among pancreatic cancer patients, including the use of natural products, dietary supplements, probiotics, whole medical systems, and body-based therapies. Methods: An electronic, systematic, and comprehensive literature review was conducted searching for studies up to November 2024 following the PRISMA 2020 guidelines. Randomized controlled trials and prospective and retrospective studies assessing the efficacy and safety of unconventional treatments for pancreatic cancer were considered eligible. Data on overall survival, quality of life, and treatment tolerability were extracted. Results: A total of 21 studies, providing data from 3095 patients, met the inclusion criteria. Various types of unconventional treatments are used in pancreatic cancer patients, including Chinese herbal medicine (CHM), mistletoe extract (ME), curcumin, and electroacupuncture. Among these, the use of CHM and curcumin concomitant with standard therapy was associated with survival and quality-of-life benefits. Electroacupuncture reduced pancreatic cancer pain intensity in a cost-effective manner. The data on ME are mixed and of insufficient quality for drawing definitive conclusions. Conclusions: Some unconventional treatments showed potential benefits in improving overall survival and quality of life in pancreatic cancer patients within an integrative oncology setting. Further high-quality studies are needed to provide robust, rigorous, and ethical evidence to support their integration into future guidelines, ensuring a holistic approach to cancer treatment.
C1 [Vella, Roberta; Giardino, Alessandro; Pizzocaro, Erica; Frigerio, Isabella; Bannone, Elisa; Butturini, Giovanni] Pederzoli Hosp, HPB Surg, I-37019 Peschiera Del Garda, Verona, Italy.
   [Vella, Roberta; Vieni, Salvatore] Univ Palermo, Dept Precis Med Med Surg & Crit Care, Me Pre CC, I-90133 Palermo, Italy.
   [Pizzocaro, Erica] Univ Tor Vergata, PhD Sch Appl Med Surg Sci, I-00133 Rome, Italy.
   [Frigerio, Isabella] SAN Univ, Coll Med, PL-90012 Lodz, Poland.
C3 University of Palermo; University of Rome Tor Vergata
RP Pizzocaro, E (corresponding author), Pederzoli Hosp, HPB Surg, I-37019 Peschiera Del Garda, Verona, Italy.; Pizzocaro, E (corresponding author), Univ Tor Vergata, PhD Sch Appl Med Surg Sci, I-00133 Rome, Italy.
EM roberta.vella02@unipa.it; alessandro.giardino@ospedalepederzoli.it; erica.pizzocaro@gmail.com; isabella.frigerio@ospedalepederzoli.it; elisa.bannone@ospedalepederzoli.it; salvatore.vieni@unipa.it; giovanni.butturini@ospedalepederzoli.it
CR Unknown -, 2025, JAMA-J AM MED ASSOC, V333, P71, DOI 10.1001/jama.2024.21972
   Unknown -, 1999, BMJ, V318, P224
   Unknown -, 2022, SURVEILLANCE, V0, P0
   Atanasov AG, 2021, NAT REV DRUG DISCOV, V20, P200, DOI 10.1038/s41573-020-00114-z
   Axtner J, 2016, BMC CANCER, V16, P0, DOI 10.1186/s12885-016-2594-5
   Baars EW, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/4904930
   Bapat AA, 2011, NAT REV CANCER, V11, P695, DOI 10.1038/nrc3131
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Boland JW, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14225720
   Bosetti C, 2012, MOL CARCINOGEN, V51, P3, DOI 10.1002/mc.20785
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Bussing A, 1996, CANCER LETT, V99, P59, DOI 10.1016/0304-3835(95)04038-2
   Cao ND, 2015, INTEGR CANCER THER, V14, P133, DOI 10.1177/1534735414564185
   Caraceni A, 1996, CANCER-AM CANCER SOC, V78, P639
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Cheng KJ, 2014, J ACUPUNCT MERIDIAN, V7, P105, DOI 10.1016/j.jams.2013.07.008
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Ciociola AA, 2014, AM J GASTROENTEROL, V109, P620, DOI 10.1038/ajg.2013.407
   Coveler AL, 2021, ONCOLOGIST, V26, PE971, DOI 10.1002/onco.13796
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   di Mola FF, 2008, LANGENBECK ARCH SURG, V393, P919, DOI 10.1007/s00423-007-0277-z
   Didier AJ, 2024, CANCER CAUSE CONTROL, V35, P1509, DOI 10.1007/s10552-024-01906-z
   Dilhuydy JM, 2003, B CANCER, V90, P623
   El-Ghlban S, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/152659
   El-Qassas J, 2024, BIORESOUR BIOPROCESS, V11, P0, DOI 10.1186/s40643-024-00805-0
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Esatbeyoglu T, 2012, ANGEW CHEM INT EDIT, V51, P5308, DOI 10.1002/anie.201107724
   Global Cancer Observatory, 2024, CANCER TODAY (VERSION 1.1), V0, P0
   Goldstein D, 2015, JNCI-J NATL CANCER I, V107, P0, DOI 10.1093/jnci/dju413
   Hameed Mariam, 2010, CANCERS (BASEL), V3, P43, DOI 10.3390/cancers3010043
   Hashimoto D, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-021-05934-x
   Heusser P, 1998, PRAXIS (BERN 1994), V87, P975
   Hoenders R, 2024, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1395698
   Hong CE, 2024, INT J MOL SCI, V25, P0, DOI 10.3390/ijms25158459
   Kanai M, 2013, CANCER CHEMOTH PHARM, V71, P1521, DOI 10.1007/s00280-013-2151-8
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kummar S, 2011, CLIN COLORECTAL CANC, V10, P85, DOI 10.1016/j.clcc.2011.03.003
   Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257
   Kuo YT, 2018, INTEGR CANCER THER, V17, P411, DOI 10.1177/1534735417722224
   Lee S, 2011, ONCOLOGY-BASEL, V81, P312, DOI 10.1159/000334695
   Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605
   Li M, 2018, CHIN J INTEGR MED, V24, P178, DOI 10.1007/s11655-017-2971-1
   Li Y, 2011, BIOCHEM SYST ECOL, V39, P849, DOI 10.1016/j.bse.2011.04.004
   Magrì A, 2020, SCI TRANSL MED, V12, P0, DOI 10.1126/scitranslmed.aay8707
   Meng Z, 2012, BRIT J CANCER, V107, P411, DOI 10.1038/bjc.2012.283
   Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0
   Ouyang HQ, 2011, PANCREAS, V40, P120, DOI 10.1097/MPA.0b013e3181e6e398
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Pastorelli D, 2018, PHARMACOL RES, V132, P72, DOI 10.1016/j.phrs.2018.03.013
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Perrone D, 2015, EXP THER MED, V10, P1615, DOI 10.3892/etm.2015.2749
   Saif MW, 2010, PHYTOMEDICINE, V17, P161, DOI 10.1016/j.phymed.2009.12.016
   Saif MW, 2014, CANCER CHEMOTH PHARM, V73, P373, DOI 10.1007/s00280-013-2359-7
   Schad F, 2014, INTEGR CANCER THER, V13, P332, DOI 10.1177/1534735413513637
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Song LB, 2017, CHIN J INTEGR MED, V23, P937, DOI 10.1007/s11655-017-2279-1
   Staupe H, 2023, J CANCER RES CLIN, V149, P5559, DOI 10.1007/s00432-022-04511-2
   Thronicke A, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3543568
   Tian W, 2024, J CANCER RES THER, V20, P1334, DOI 10.4103/jcrt.jcrt_2172_23
   Tröger W, 2014, DTSCH ARZTEBL INT, V111, P493, DOI 10.3238/arztebl.2014.0493
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Wode Kathrin, 2024, DTSCH ARZTEBL INT, V121, P347, DOI 10.3238/arztebl.m2024.0080
   Wong GY, 2004, JAMA-J AM MED ASSOC, V291, P1092, DOI 10.1001/jama.291.9.1092
   Wong W, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419828836
   Yang PY, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-41444-2
   Yang X, 2015, MEDICINE, V94, P0, DOI 10.1097/MD.0000000000001008
   Yen Y, 2009, ANTICANCER RES, V29, P4083
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang X, 2001, LEGAL STATUS TRADITI, V0, P0
   Zhang X, 2005, TRADITIONAL MEDICINE STRATEGY 2002, V0, P0
   Zhernov YV, 2021, ENVIRON RES, V193, P0, DOI 10.1016/j.envres.2020.110312
   Zhong ZF, 2022, MED RES REV, V42, P1246, DOI 10.1002/med.21876
NR 72
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR 25
PY 2025
VL 17
IS 9
BP 
EP 
DI 10.3390/cancers17091437
PG 24
WC Oncology
SC Oncology
GA 2MH0N
UT WOS:001486029600001
PM 40361364
DA 2026-01-16
ER

PT J
AU David, A
   Eilon, S
   Lev-Ari, S
   Frenkel, M
AF David, Adi
   Eilon, Sharon
   Lev-Ari, Shaked
   Frenkel, Moshe
TI [THERAPY IN PATIENTS AFFECTED BY BREAST AND PROSTATE CANCER].
SO Harefuah
LA heb
DT Review
AB OBJECTIVES: This study aims to identify and evaluate the treatment gaps in  patients undergoing endocrine therapy for breast and prostate tumors, and to  propose integrative solutions for unmet needs. METHODS: The article provides a  narrative review of three significant side effects of endocrine therapy among  breast and prostate cancer patients: vasomotor effects, joint pain and stiffness,  and sexual disorders. It also offers treatment options for these effects from the  field of complementary and integrative medicine. RESULTS: The adverse  consequences of endocrine treatments in breast and prostate cancer patients  reduce treatment compliance and significantly impair the patients' quality of  life. Evidence-based complementary and integrative medicine modalities, including  nutritional counseling, dietary supplements, homeopathic remedies, touch  therapies, acupuncture, and mind-body treatments, may improve the patients'  quality of life and alleviate the burden of side effects. CONCLUSIONS: There is a  need to improve the management of side effects unique to endocrine therapy.  Integrating supportive care with complementary and integrative medicine offers a  viable option to enhance the quality of life for these patients.
C1 Tal Center for Integrative Medicine, Supportive Care Unit, Chaim Sheba Medical Center, Ramat-Gan, Israel.
   Integrative Medicine Unit for Cancer Patients, Davidoff Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
   Ella Lemelbaum Institute for Immuno-Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
   Complementary and Integrative Medicine Service, Oncology Division, Rambam Health Care Campus, Haifa, Israel.
NR 0
TC 0
SN 
EI 0017-776
J9 Harefuah
PD JUL 24
PY 2025
VL 164
IS 7
BP 441
EP 446
DI 
PG 5
WC Humans; Quality of Life; Prostatic Neoplasms; therapy; Male; Breast Neoplasms; therapy; Complementary Therapies; methods; Female; Antineoplastic Agents, Hormonal; adverse effects; Integrative Medicine; methods
UT PubMed:40704870
PM 40704870
DA 2025-07-24
ER

PT J
AU Chen, H
   Fang, JF
   Liu, SX
   Gao, S
   Shi, HY
   Ma, JZ
   Shen, XY
   Wang, WM
   Liu, ZS
AF Chen, He
   Fang, Jiufei
   Liu, Sixing
   Gao, Shuai
   Shi, Hangyu
   Ma, Ji-Zheng
   Shen, Xinyu
   Wang, Weiming
   Liu, Zhishun
TI Efficacy and safety of two-step acupuncture therapy for symptom relief in adults with mild to moderate ulcerative colitis: rationale and design of the TSA-UC randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE Acupuncture; Inflammatory bowel disease; Randomized Controlled Trial
ID inflammatory-bowel-disease; clinically meaningful improvement; rectal bleeding remission; stool frequency remission; evidence-based consensus; quality-of-life; relative association; colorectal-cancer; urgency remission; questionnaire
AB Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterised by episodes of symptoms including rectal bleeding, increased stool frequency and abdominal pain, impacting quality of life significantly. Conventional treatments often come with potential side effects and may not be sufficient. Acupuncture is increasingly recognised for its potential benefits in UC. This study aims to assess the efficacy and safety of acupuncture for symptom relief in mild to moderate UC.Methods and analysis This single-centre, parallel-arm, randomised, sham-controlled, the two-step acupuncture (TSA)-UC trial, will involve 64 adults with mild to moderate UC, randomly assigned in a 1:1 ratio to either the acupuncture or sham acupuncture group. Participants will receive 20 sessions of two-step acupuncture or sham acupuncture therapy over 8 weeks. Blinding will be applied to participants, outcome assessors and statisticians. The primary outcome measure is the change in Patient-Reported Outcome 2 (PRO2) from baseline at week 8. Secondary outcomes include changes from baseline in the following scales: PRO2 at other time points, weekly average Numeric Rating Scale (NRS) for bowel urgency, weekly average NRS for abdominal pain (both associated and not associated with bowel movement), the 32-item Inflammatory Bowel Disease Questionnaire, Work Productivity and Activity Impairment Questionnaire-IBD, Pittsburgh Sleep Quality Index and Hospital Anxiety and Depression Scale. The Patient Global Impression of Change will also be assessed. Long-term effects of acupuncture will be explored. Adverse events and additional treatments will be monitored throughout the study. The modified intention-to-treat population including participants who complete baseline assessments and receive at least one treatment session will be analysed.Ethics and dissemination The study has received ethical approval from the Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences (2024-190-KY). The results will be published in a peer-reviewed medical journal.Trial registration number NCT06615765.
C1 [Chen, He; Fang, Jiufei; Gao, Shuai; Wang, Weiming; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, Beijing, Peoples R China.
   [Liu, Sixing; Shen, Xinyu] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Shi, Hangyu] Westlake Univ, Sch Life Sci, Hangzhou, Zhejiang, Peoples R China.
   [Ma, Ji-Zheng] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Gastroenterol, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Beijing University of Chinese Medicine; Westlake University; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences
RP Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, Beijing, Peoples R China.
EM chenhenick@gmail.com; 1365623648@qq.com; sixingliu@sina.cn; gaoshuai980314@163.com; 18811735839@163.com; majizheng1116@yeah.net; shxinyu2001@163.com; wangweiming1a1@163.com; zhishunjournal@163.com
FU High Level Chinese Medical Hospital Promotion Project [HLCMHPP2023089]
CR Achleitner U, 2012, J CROHNS COLITIS, V6, P507, DOI 10.1016/j.crohns.2011.11.003
   Alrubaiy L, 2015, J CROHNS COLITIS, V9, P284, DOI 10.1093/ecco-jcc/jjv002
   Unknown -, 2024, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0
   Armuzzi A, 2021, DIGEST LIVER DIS, V53, P803, DOI 10.1016/j.dld.2021.03.002
   Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016
   Bao CH, 2022, ECLINICALMEDICINE, V45, P0, DOI 10.1016/j.eclinm.2022.101300
   Bhala N, 2023, FRONTLINE GASTROENTE, V14, P25, DOI 10.1136/flgastro-2022-102104
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen XL, 2017, HEALTH QUAL LIFE OUT, V15, P0, DOI 10.1186/s12955-017-0753-2
   DHaens G, 2007, GASTROENTEROLOGY, V132, P763, DOI 10.1053/j.gastro.2006.12.038
   Danese S, 2023, INFLAMM BOWEL DIS, V29, P1723, DOI 10.1093/ibd/izad016
   Danese S, 2019, DIGEST DIS, V37, P266, DOI 10.1159/000496739
   De Simone B, 2021, WORLD J EMERG SURG, V16, P0, DOI 10.1186/s13017-021-00362-3
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Dignass A, 2012, J CROHNS COLITIS, V6, P965, DOI 10.1016/j.crohns.2012.09.003
   Dragasevic S, 2020, GASTROENT RES PRACT, V2020, P0, DOI 10.1155/2020/2065383
   Dubinsky MC, 2022, CROHNS COLITIS 360, V4, P0, DOI 10.1093/crocol/otac016
   Dubinsky MC, 2022, J PATIENT-REP OUTCOM, V6, P0, DOI 10.1186/s41687-022-00439-w
   Fumery M, 2018, CLIN GASTROENTEROL H, V16, P343, DOI 10.1016/j.cgh.2017.06.016
   Greuter T, 2021, GUT, V70, P796, DOI 10.1136/gutjnl-2020-322129
   Gros B, 2023, JAMA-J AM MED ASSOC, V330, P951, DOI 10.1001/jama.2023.15389
   GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0
   Harbord M, 2016, J CROHNS COLITIS, V10, P239, DOI 10.1093/ecco-jcc/jjv213
   Horta D, 2020, INFLAMM BOWEL DIS, V26, P484, DOI 10.1093/ibd/izz091
   Jairath V, 2015, ALIMENT PHARM THER, V42, P1200, DOI 10.1111/apt.13408
   Jones Jennifer L, 2019, J CAN ASSOC GASTROENTEROL, V2, PS42, DOI 10.1093/jcag/gwy048
   Joos S, 2006, SCAND J GASTROENTERO, V41, P1056, DOI 10.1080/00365520600580688
   Kane SV, 2001, AM J GASTROENTEROL, V96, P2929
   Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020
   Kilic Y, 2024, INFLAMM BOWEL DIS, V30, P230, DOI 10.1093/ibd/izad061
   Kobayashi T, 2020, NAT REV DIS PRIMERS, V6, P0, DOI 10.1038/s41572-020-0205-x
   Kuenzig ME, 2020, CAN MED ASSOC J, V192, PE1394, DOI 10.1503/cmaj.190976
   Lewis JD, 2008, INFLAMM BOWEL DIS, V14, P1660, DOI 10.1002/ibd.20520
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Li C, 2024, JOURNAL OF KUNMING MEDICAL UNIVERSITY, V45, P72
   Lichtenstein GR, 2020, CLIN GASTROENTEROL H, V18, P889, DOI 10.1016/j.cgh.2019.07.022
   Lutgens MWMD, 2013, INFLAMM BOWEL DIS, V19, P789, DOI 10.1097/MIB.0b013e31828029c0
   Lynch WD, 2024, STATPEARLS, V0, P0
   Maaser C, 2019, J CROHNS COLITIS, V13, P144, DOI 10.1093/ecco-jcc/jjy113
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Magro F, 2017, J CROHNS COLITIS, V11, P649, DOI 10.1093/ecco-jcc/jjx008
   Marín-Jiménez I, 2016, AM J GASTROENTEROL, V111, P261, DOI 10.1038/ajg.2015.403
   McGing JJ, 2021, ALIMENT PHARM THER, V54, P368, DOI 10.1111/apt.16465
   ODONNELL LJD, 1990, BMJ-BRIT MED J, V300, P439, DOI 10.1136/bmj.300.6722.439
   Olén O, 2020, LANCET, V395, P123, DOI 10.1016/S0140-6736(19)32545-0
   [千圣楠 Qian Shengnan], 2024, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V43, P381
   Raine T, 2022, GASTROENTEROLOGY, V162, P1507, DOI 10.1053/j.gastro.2021.09.078
   Rubin DT, 2019, AM J GASTROENTEROL, V114, P384, DOI 10.14309/ajg.0000000000000152
   Sands BE, 2023, J CROHNS COLITIS, V17, P523, DOI 10.1093/ecco-jcc/jjac190.0521
   Sands BE, 2023, J CROHNS COLITIS, V17, P775, DOI 10.1093/ecco-jcc/jjac190.0776
   SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603
   Sninsky Jared A, 2022, AM J GASTROENTEROL, V117, P769, DOI 10.14309/ajg.0000000000001685
   Standardization Administration of the Peoples Republic of China, 2021, GB/T 12346-2021, V0, P0
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   Tinsley A, 2011, ALIMENT PHARM THER, V34, P1328, DOI 10.1111/j.1365-2036.2011.04871.x
   Tsai L, 2022, DIGEST DIS SCI, V67, P2451, DOI 10.1007/s10620-021-07200-1
   Tsai L, 2021, CLIN GASTROENTEROL H, V19, P2031, DOI 10.1016/j.cgh.2020.10.039
   Turner D, 2021, GASTROENTEROLOGY, V160, P1570, DOI 10.1053/j.gastro.2020.12.031
   Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2
   Wang D, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e27524
   Wang X, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03101-4
   Williet N, 2014, CLIN GASTROENTEROL H, V12, P1246, DOI 10.1016/j.cgh.2014.02.016
   Yang XY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/319734
   Yarlas A, 2020, J PATIENT-CENTER RES, V7, P189, DOI 10.17294/2330-0698.1722
   Yarlas A, 2018, J CROHNS COLITIS, V12, P600, DOI 10.1093/ecco-jcc/jjy024
   Zhang SS, 2024, PHYTOTHER RES, V38, P970, DOI 10.1002/ptr.8087
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhu LL, 2024, ANN INTERN MED, V177, P1048, DOI 10.7326/M23-2749
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 70
TC 0
Z9 0
U1 4
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD FEB 27
PY 2025
VL 15
IS 2
BP 
EP 
DI 10.1136/bmjopen-2024-094301
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA Z0T5M
UT WOS:001436138500001
PM 40021194
DA 2026-01-16
ER

PT J
AU Zhang, YX
   Wu, BQ
   Qin, P
   Cheng, YP
   Chen, YY
AF Zhang, Yuxing
   Wu, Bangqi
   Qin, Peng
   Cheng, Yupei
   Chen, Yuyan
TI Alternative therapies in chronic non-cancer pain management: A scoping review of randomized controlled trials
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Chronic non-cancer pain; Complementary therapies; Pain management; Scoping review; Personalized treatment. Non-pharmacological; therapy
ID low-back-pain; chronic neck pain; electrical nerve-stimulation; connective-tissue massage; tension-type headache; quality-of-life; mindfulness meditation; controlled pilot; manual therapy; pressure pain
AB Background: Chronic pain is one of the most challenging health problems in modern society, placing significant burdens on individuals and healthcare systems. While pharmacological treatments remain the primary approach to pain management, their limitations often restrict choices for both clinicians and patients. In contrast, complementary therapies are gaining recognition for their potential effectiveness and safety. However, the current literature lacks a comprehensive summary of the role of complementary therapies in chronic pain management. Objective: This review aims to summarize the complementary therapies used in chronic non-cancer pain management, assess their practical applications, identify research gaps and limitations, and provide a comprehensive perspective for the development of chronic non-cancer pain management and personalized pain management strategies. Methods: This scoping review followed the PRISMA-ScR guidelines. Randomized controlled trials (RCTs) pub- lished in the last decade were retrieved from PubMed and Web of Science using the keywords "chronic pain" and "complementary therapy." Non-English studies were excluded. Results: A total of 848 RCTs were identified, of which 128 met the inclusion criteria. The included studies addressed chronic musculoskeletal pain (102 studies), chronic visceral pain (5 studies), chronic neuropathic pain (7 studies), and 13 studies that did not specify the pain type. The complementary therapies investigated included acupuncture, manual therapy, exercise therapy, psychological interventions, mind-body therapies, and physical modalities. Conclusion: This review provides preliminary evidence supporting the efficacy and safety of complementary therapies in the management of chronic non-cancer pain. However, methodological and quality-related limita- tions were identified in the included studies. Future high-quality RCTs are needed to validate the long-term efficacy of these therapies, explore their mechanisms of action, and provide stronger evidence for their clin- ical application. Registration: This scoping review is registered on the Open Science Framework (OSF) under the following DOI: https://doi.org/10.17605/OSF.IO/67K32.
C1 [Zhang, Yuxing; Wu, Bangqi; Qin, Peng; Cheng, Yupei; Chen, Yuyan] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, 88 Changling Rd, Tianjin 300381, Peoples R China.
   [Zhang, Yuxing; Cheng, Yupei; Chen, Yuyan] Tianjin Univ Tradit Chinese Med, Tianjin 301617, Peoples R China.
   [Wu, Bangqi] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.
   [Wu, Bangqi] 88 Changling Rd, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Wu, BQ (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, 88 Changling Rd, Tianjin 300381, Peoples R China.; Wu, BQ (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.; Wu, BQ (corresponding author), 88 Changling Rd, Tianjin, Peoples R China.
EM wbqwbq1980@outlook.com
CR Abdulaziz KS, 2021, J MUSCULOSKEL NEURON, V21, P121
   Adhia DB, 2023, SCI REP-UK, V13, P0, DOI 10.1038/s41598-023-28344-2
   Al-Eidi SM, 2019, J ACUPUNCT MERIDIAN, V12, P173, DOI 10.1016/j.jams.2019.04.005
   Alfuth M, 2016, ORTHOPADE, V45, P579, DOI 10.1007/s00132-016-3233-1
   Ardigo S, 2016, BMC GERIATR, V16, P0, DOI 10.1186/s12877-016-0180-y
   Auger K, 2021, J OSTEOPATH MED, V121, P561, DOI 10.1515/jom-2020-0132
   Avila L, 2024, PHYS THER, V104, P0, DOI 10.1093/ptj/pzad105
   Bakar Y, 2014, J MANIP PHYSIOL THER, V37, P415, DOI 10.1016/j.jmpt.2014.05.004
   Bellido-Fernández L, 2022, DISABIL REHABIL, V44, P4233, DOI 10.1080/09638288.2021.1884903
   Beltran-Alacreu H, 2015, AM J PHYS MED REHAB, V94, P887, DOI 10.1097/PHM.0000000000000293
   Bernal-Utrera C, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04610-w
   Bicego A, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0256001
   Bradt J, 2016, J MUSIC THER, V53, P178, DOI 10.1093/jmt/thw004
   Brochado FT, 2018, BRAZ ORAL RES, V32, P0, DOI 10.1590/1807-3107bor-2018.vol32.0050
   Brück K, 2021, J BACK MUSCULOSKELET, V34, P997, DOI 10.3233/BMR-191731
   Buttagat V, 2021, J BODYW MOV THER, V27, P647, DOI 10.1016/j.jbmt.2021.05.007
   Büyükturan B, 2021, MUSCULOSKEL SCI PRAC, V55, P0, DOI 10.1016/j.msksp.2021.102417
   Cabrera-Martos I, 2022, PHYSIOTHER THEOR PR, V38, P1145, DOI 10.1080/09593985.2020.1821418
   Sánchez AMC, 2019, DISABIL REHABIL, V41, P2235, DOI 10.1080/09638288.2018.1461259
   Ceballos-Laita L, 2022, J BACK MUSCULOSKELET, V35, P393, DOI 10.3233/BMR-200322
   Celenay ST, 2016, MANUAL THER, V21, P144, DOI 10.1016/j.math.2015.07.003
   Chatchawan U, 2014, J ALTERN COMPLEM MED, V20, P486, DOI 10.1089/acm.2013.0176
   Chen L, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j1284
   Dayanir IO, 2020, J ALTERN COMPLEM MED, V26, P291, DOI 10.1089/acm.2019.0435
   Deyo RA, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.g6380
   Onieva-Zafra MD, 2015, HOLIST NURS PRACT, V29, P13, DOI 10.1097/HNP.0000000000000062
   Domingues L, 2019, CLIN REHABIL, V33, P1908, DOI 10.1177/0269215519876675
   Er G, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033516
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133
   Eshuis TAH, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0259394
   Eskander JP, 2019, CURR PAIN HEADACHE R, V23, P0, DOI 10.1007/s11916-019-0790-0
   Eslamian F, 2020, ARCH PHYS MED REHAB, V101, P770, DOI 10.1016/j.apmr.2019.12.009
   Gausel AM, 2019, J MANIP PHYSIOL THER, V42, P601, DOI 10.1016/j.jmpt.2018.12.006
   Gkolias V, 2020, EUR J PAIN, V24, P1716, DOI 10.1002/ejp.1615
   Gonçalves AV, 2017, J ALTERN COMPLEM MED, V23, P45, DOI 10.1089/acm.2015.0343
   Groisman S, 2020, J BODYW MOV THER, V24, P189, DOI 10.1016/j.jbmt.2019.11.002
   Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147
   Haller H, 2016, CLIN J PAIN, V32, P441, DOI 10.1097/AJP.0000000000000290
   Herman PM, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0217831
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Huang ZL, 2019, PAIN MED, V20, P2303, DOI 10.1093/pm/pnz167
   Hussain N, 2019, J EVID-BASED INTEGR, V24, P0, DOI 10.1177/2515690X19876599
   Itoh K, 2014, J ACUPUNCT MERIDIAN, V7, P59, DOI 10.1016/j.jams.2013.02.002
   Ives TJ, 2006, BMC HEALTH SERV RES, V6, P0, DOI 10.1186/1472-6963-6-46
   Jeitler M, 2015, J PAIN, V16, P77, DOI 10.1016/j.jpain.2014.10.009
   Jensen MP, 2020, PAIN, V161, P2284, DOI 10.1097/j.pain.0000000000001943
   Juel J, 2017, PANCREAS, V46, P170, DOI 10.1097/MPA.0000000000000749
   Kanter G, 2016, INT UROGYNECOL J, V27, P1705, DOI 10.1007/s00192-016-3022-8
   Kasimis K, 2024, MEDICINA-LITHUANIA, V60, P0, DOI 10.3390/medicina60040556
   Kasimis K, 2023, MEDICINA-LITHUANIA, V59, P0, DOI 10.3390/medicina59071275
   Kent P, 2015, BMC MUSCULOSKEL DIS, V16, P0, DOI 10.1186/s12891-015-0591-5
   Kim JH, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0269282
   Kim M, 2021, J ALTERN COMPLEM MED, V27, P160, DOI 10.1089/acm.2020.0413
   Kim YK, 2021, J BACK MUSCULOSKELET, V34, P895, DOI 10.3233/BMR-200369
   Kizhakkeveettil A, 2017, J MANIP PHYSIOL THER, V40, P201, DOI 10.1016/j.jmpt.2017.01.002
   Klassen E, 2019, Z ORTHOP UNFALLCHIR, V157, P263, DOI 10.1055/a-0715-2332
   Kobayashi D, 2019, COMPLEMENT THER MED, V45, P33, DOI 10.1016/j.ctim.2019.05.019
   Konrad KL, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0236780
   Kumar S, 2017, J ALTERN COMPLEM MED, V23, P109, DOI 10.1089/acm.2015.0272
   Kuvacic G, 2018, COMPLEMENT THER CLIN, V31, P262, DOI 10.1016/j.ctcp.2018.03.008
   la Cour P, 2015, PAIN MED, V16, P641, DOI 10.1111/pme.12605
   Lai CH, 2014, J ALTERN COMPLEM MED, V20, P123, DOI 10.1089/acm.2013.0122
   Lauche R, 2016, J PAIN, V17, P1013, DOI 10.1016/j.jpain.2016.06.004
   Leca S, 2022, FRONT INTEGR NEUROSC, V16, P0, DOI 10.3389/fnint.2022.920271
   Lee HJ, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-018-3049-x
   Lee J, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.13757
   Lin ZW, 2020, ANN THORAC CARDIOVAS, V26, P196, DOI 10.5761/atcs.oa.20-00022
   Lluch E, 2014, J MANIP PHYSIOL THER, V37, P660, DOI 10.1016/j.jmpt.2014.08.007
   López-de-Uralde-Villanueva I, 2020, PHYSIOTHER THEOR PR, V36, P45, DOI 10.1080/09593985.2018.1480678
   MacPherson H, 2015, ANN INTERN MED, V163, P653, DOI 10.7326/M15-0667
   Maicki T, 2017, J BACK MUSCULOSKELET, V30, P1095, DOI 10.3233/BMR-169718
   Mardani-Kivi M, 2019, CHIN J INTEGR MED, V25, P502, DOI 10.1007/s11655-018-2996-0
   Castro-Sánchez AM, 2016, J ALTERN COMPLEM MED, V22, P650, DOI 10.1089/acm.2016.0068
   Martí-Salvador M, 2018, ARCH PHYS MED REHAB, V99, P1720, DOI 10.1016/j.apmr.2018.04.022
   Menezes FD, 2022, COMPLEMENT THER CLIN, V48, P0, DOI 10.1016/j.ctcp.2022.101578
   Michalsen A, 2021, J PAIN, V22, P1233, DOI 10.1016/j.jpain.2021.03.154
   Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007
   Minakawa Y, 2022, J ACUPUNCT MERIDIAN, V15, P143
   Morais BX, 2023, REV LAT-AM ENFERM, V31, P0, DOI 10.1590/1518-8345.6641.3953
   Moraska AF, 2015, CLIN J PAIN, V31, P159, DOI 10.1097/AJP.0000000000000091
   Morone NE, 2016, JAMA INTERN MED, V176, P329, DOI 10.1001/jamainternmed.2015.8033
   Moura CD, 2022, J ACUPUNCT MERIDIAN, V15, P130, DOI 10.51507/j.jams.2022.15.2.130
   Moura CD, 2019, J CLIN NURS, V28, P3796, DOI 10.1111/jocn.14983
   Moura CdC, 2018, REV LAT AM ENFERM, V2610, P0
   Murphy SL, 2019, PAIN MED, V20, P2588, DOI 10.1093/pm/pnz138
   Najafabadi MM, 2020, APPL NURS RES, V51, P0, DOI 10.1016/j.apnr.2019.05.020
   Nambi G, 2018, EUR J PHYS REHAB MED, V54, P880, DOI 10.23736/S1973-9087.18.05005-0
   Namiranian P, 2022, J ACUPUNCT MERIDIAN, V15, P163, DOI 10.51507/j.jams.2022.15.3.163
   Nandini B, 2018, EXPLORE-NY, V14, P373, DOI 10.1016/j.explore.2018.01.002
   Neyaz O, 2019, J ALTERN COMPLEM MED, V25, P938, DOI 10.1089/acm.2019.0140
   Niggemann B, 2006, J ALLERGY CLIN IMMUN, V118, P569, DOI 10.1016/j.jaci.2006.06.021
   Özkul Ç, 2015, J BACK MUSCULOSKELET, V28, P709, DOI 10.3233/BMR-140573
   Pan RY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000004634
   Peacock KS, 2019, MILITARY MED RES, V6, P0, DOI 10.1186/s40779-019-0227-4
   Polaski AM, 2021, PAIN MED, V22, P444, DOI 10.1093/pm/pnaa403
   Przekop P, 2016, J BODYW MOV THER, V20, P715, DOI 10.1016/j.jbmt.2015.02.003
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Qin ZS, 2018, J UROLOGY, V200, P815, DOI 10.1016/j.juro.2018.05.001
   Reid KJ, 2011, CURR MED RES OPIN, V27, P449, DOI 10.1185/03007995.2010.545813
   Rizzo RRN, 2018, J PAIN, V19, P0, DOI 10.1016/j.jpain.2018.03.013
   Roclofs PDDM, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000396.pub3
   Rodríguez-Sánchez JL, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17061920
   Rohe BG, 2015, J ALTERN COMPLEM MED, V21, P223, DOI 10.1089/acm.2014.0036
   Roseen EJ, 2023, J GEN INTERN MED, V38, P2113, DOI 10.1007/s11606-023-08037-2
   Roseen EJ, 2020, J GEN INTERN MED, V35, P167, DOI 10.1007/s11606-019-05329-4
   Roslyakova T, 2021, PSYCHOL HEALTH, V36, P1403, DOI 10.1080/08870446.2020.1856844
   Rotter G, 2022, J INTEGR COMPLEMENT, V28, P474, DOI 10.1089/jicm.2021.0361
   Saha FJ, 2017, COMPLEMENT MED RES, V24, P26, DOI 10.1159/000454872
   Sancakli E, 2015, BMC ORAL HEALTH, V15, P0, DOI 10.1186/s12903-015-0116-5
   Sanei M, 2020, J BODYW MOV THER, V24, P123, DOI 10.1016/j.jbmt.2020.02.015
   Saper RB, 2017, ANN INTERN MED, V167, P85, DOI 10.7326/M16-2579
   Saracoglu I, 2022, PHYSIOTHER THEOR PR, V38, P868, DOI 10.1080/09593985.2020.1809046
   Schmid AA, 2019, J EVID-BASED INTEGR, V24, P0, DOI 10.1177/2515690X19863763
   Seguin-Fowler R, 2020, BMC GERIATR, V20, P0, DOI 10.1186/s12877-020-01818-y
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Shi Y, 2023, BMC MED, V21, P0, DOI 10.1186/s12916-023-03076-2
   Skillgate E, 2020, MUSCULOSKEL SCI PRAC, V45, P0, DOI 10.1016/j.msksp.2019.102070
   Stieven FF, 2020, J ORTHOP SPORT PHYS, V50, P447, DOI 10.2519/jospt.2020.9389
   Sung WS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022526
   Sutton D, 2019, ACUPUNCTURE FOR CHRONIC NON-CANCER PAIN: A REVIEW OF CLINICAL EFFECTIVENESS, V0, P0
   Tamer S, 2017, J BACK MUSCULOSKELET, V30, P419, DOI 10.3233/BMR-150424
   Tan G, 2015, EUR J PAIN, V19, P271, DOI 10.1002/ejp.545
   Teut M, 2016, J PAIN, V17, P796, DOI 10.1016/j.jpain.2016.03.003
   Townsend CS, 2014, HOLIST NURS PRACT, V28, P78, DOI 10.1097/HNP.0000000000000012
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Turk DC, 2008, CAN J PSYCHIAT, V53, P213, DOI 10.1177/070674370805300402
   Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9
   Ulger O, 2023, HOLIST NURS PRACT, V37, PE59, DOI 10.1097/HNP.0000000000000593
   Valiente-Castrillo P, 2021, ACUPUNCT MED, V39, P91, DOI 10.1177/0964528420920300
   Vas J, 2014, ACUPUNCT MED, V32, P227, DOI 10.1136/acupmed-2013-010507
   Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1
   Vining R, 2020, J ALTERN COMPLEM MED, V26, P592, DOI 10.1089/acm.2020.0107
   Vittorio S, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12030821
   Weissenfels A, 2019, BIOMED RES INT, V2019, P0, DOI 10.1155/2019/5745409
   Williams RM, 2022, PAIN, V163, P1905, DOI 10.1097/j.pain.0000000000002586
   Wu YL, 2021, PAIN MANAG NURS, V22, P755, DOI 10.1016/j.pmn.2021.01.004
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Yeldan I, 2024, APPL PSYCHOPHYS BIOF, V49, P103, DOI 10.1007/s10484-023-09606-1
   Yetwin AK, 2022, J PEDIATR NURS, V66, P151, DOI 10.1016/j.pedn.2022.06.008
   Yuen JWM, 2017, COMPLEMENT THER MED, V32, P25, DOI 10.1016/j.ctim.2017.03.010
   Zgierska AE, 2016, J ALTERN COMPLEM MED, V22, P610, DOI 10.1089/acm.2015.0314
   Zollman C, 1999, BRIT MED J, V319, P836, DOI 10.1136/bmj.319.7213.836
NR 144
TC 1
Z9 1
U1 13
U2 18
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD JUN 15
PY 2025
VL 90
IS 
BP 
EP 
DI 10.1016/j.ctim.2025.103154
EA MAR 2025
PG 19
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0JS5H
UT WOS:001449007800001
PM 40081508
DA 2026-01-16
ER

PT J
AU Hamachi, A
   Matriz, J
   Fukui, J
AF Hamachi, April
   Matriz, Jobel
   Fukui, Jami
TI The use of complementary and alternative medicine among cancer patients in Hawaii
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE CAM; Complementary; Alternative; Integrative medicine; Cancer symptom management
ID breast-cancer; women
AB Complementary and alternative medicine (CAM) are medical products and practices that are not part of standard medical care. Various studies demonstrate benefits of CAM use in alleviating cancer related side effects. However, data involving the use of CAM therapies among cancer patients is limited. Hawaii has a unique and diverse population and trends in CAM use could reveal important aspects of cancer care.We distributed questionnaires to various cancer treatment centers across Oahu. The questionnaires were optional and anonymous. We evaluated 126 questionnaires and analyzed CAM use. We collected participant data including: cancer type, treatments used (surgery, radiation, chemotherapy) and patient demographics (age, gender, ethnicity, income, religion).We found that at least one CAM therapy is used by a majority of patients 72/126 (57.1%), while 54 (42.9%) do not use any CAM therapy. Among the CAM therapies, meditation and herbal supplements were most commonly used 26 (36.1%), followed by massage 25 (34.7%), yoga 18 (25%), CBD 17 (23.6%), THC 16 (22.2%), and acupuncture 14 (19.4%). Stress reduction was the most common symptom benefit noted for meditation, herbal supplement, massage, and yoga. Anxiety was another symptom benefit reported for meditation. THC and CBD are used for sleep, however, CBS was also used for pain reduction together with acupuncture. Among the patients who use CAM therapy (n = 72), 80.6% are female (n = 58) while only 8.3% are male (n = 6). Furthermore only, 18.3% (n = 23) of our respondents have spoken to a clinician about CAM.We discovered that stress reduction is a symptom benefit associated with the most commonly used CAM therapies by cancer patients in Hawaii. Other symptom benefits involve anxiety, pain, and sleep. The modalities utilized were similar to nonpharmacologic therapies recommended by the NCCN guidelines for cancer survivorship, with the exception of herbal supplements. There is a lack of physician discussion regarding CAM use, which could impact the cancer burden in Hawaii.
C1 [Hamachi, April; Matriz, Jobel] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
   [Fukui, Jami] Univ Hawaii, Canc Ctr, Honolulu, HI USA.
C3 University of Hawaii System; Cancer Research Center of Hawaii; University of Hawaii System
RP Hamachi, A (corresponding author), Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
EM ahamachi@hawaii.edu
FU University of Hawaii Cancer Center [P30 CA071789-18]
CR AARP/NCCAM, 2007, CONSUMER SURVEY REPORT, V0, P0
   Bennett JA, 2009, J GEN INTERN MED, V24, P1089, DOI 10.1007/s11606-009-0979-8
   Complementary and Alternative Medicine (CAM), 1980, NCI, V0, P0
   Fukui Jami, 2021, J PSYCHOSOC ONCOL RES PRACT, V3, P0, DOI 10.1097/or9.0000000000000055
   Harrigan Rosanne, 2006, HAWAII MED J, V65, P130
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hierl M, 2017, ONCOLOGY-BASEL, V93, P157, DOI 10.1159/000464248
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Källman M, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-03876-2
   Kim Min Jae, 2004, KOREAN JOURNAL OF INTERNAL MEDICINE, V19, P250
   Krogstad JM, 2015, HAWAII IS HOME TO THE NATIONS LARGEST SHARE OF MULTIRACIAL AMERICANS, V0, P0
   Kwon JH, 2019, CANCER RES TREAT, V51, P851, DOI 10.4143/crt.2019.137
   Metin ZG, 2019, EUR J ONCOL NURS, V42, P116, DOI 10.1016/j.ejon.2019.09.003
   Oneha Mary Frances, 2023, HAWAII J HEALTH SOC WELF, V82, P72
   Sanford NN, 2019, JAMA ONCOL, V5, P735, DOI 10.1001/jamaoncol.2019.0349
   Taso CJ, 2014, J NURS RES, V22, P155, DOI 10.1097/jnr.0000000000000044
   Wolf CPJG, 2022, J CANCER RES CLIN, V148, P461, DOI 10.1007/s00432-021-03625-3
   Wu A, 2023, JCO GLOB ONCOL, V9, P0, DOI 10.1200/GO.22.00303
NR 18
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD MAY 8
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12906-025-04912-z
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 2KY4L
UT WOS:001485122000001
PM 40340689
DA 2026-01-16
ER

PT J
AU Yin, J
   Feng, M
   Xu, H
AF Yin, Jie
   Feng, Mengmeng
   Xu, Haiyang
TI Cai's gynecology chronic pelvic formula with acupuncture alleviates chronic
SO American journal of translational research
LA English
DT Journal Article
DE Cai’s gynecology chronic pelvic formula; acupuncture; chronic pelvic pain; clinical efficacy; cox regression analysis; recurrence rate
AB OBJECTIVE: To assess the efficacy of Cai's Gynecology Chronic Pelvic Formula  combined with acupuncture in managing chronic pelvic pain (CPP) secondary to  pelvic inflammatory disease (PID) sequelae, and its effect on recurrence.  METHODS: A retrospective study assessed medical records from 240 CPP patients  undergoing treatment between February 2019 and February 2024. Patients were  divided into a control group (standard treatment, n = 120) and an observation  group (standard treatment plus Cai's Chronic Pelvic Formula combined with  acupuncture, n = 120), with treatment lasted for 28 days and follow-up for 6  months. The symptom scores (Visual Analog Scale, Self-rating Anxiety Scale and  Self-rating Depression Scale), inflammatory markers [C-reactive protein (CRP),  tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cancer antigen 125  (CA125)], efficacy rates, and recurrence rates were all employed to measure  treatment outcomes. Cox regression was leveraged to identify recurrence risk  factors, while a nomogram model was developed and validated by Receiver Operating  Characteristic (ROC), calibration curves, and decision curve analysis (DCA).  RESULTS: The observation group had significantly lower post-treatment Traditional  Chinese Medicine symptom scores, inflammatory markers (CRP: P < 0.001; TNF-α: P =  0.003; IL-6: P = 0.004), and CA125 (P < 0.001) versus the control group. The  observation group also demonstrated shorter symptom resolution time (P < 0.05),  with higher total treatment efficacy in comparison to the control group (93.46%  vs. 79.70%; P = 0.002). In addition, the observation group showed lower  recurrence rates (14.2% vs. 28.3%; P = 0.008) as well as postponed recurrence  time when compared to the control group. Cox regression analysis identified  treatment protocol (HR = 0.41, 95% CI: 0.24-0.71), disease duration (HR = 1.32,  95% CI: 1.08-1.62), and pre-treatment CRP level (HR = 1.18, 95% CI: 1.02-1.36) as  independent recurrence predictors. In addition, the nomogram demonstrated high  accuracy in predicting disease recurrence (C-index = 0.852), with both ROC (AUC =  0.837) and calibration curves confirming its reliability. DCA indicated high  clinical net benefit of the studying treatment protocol. CONCLUSION: Cai's  Gynecology Chronic Pelvic Formula combined with acupuncture could significantly  alleviate CPP and inflammation, and decrease recurrence rates. The nomogram may  be used as a validated tool for predicting the disease recurrence, with benefits  when integrated into clinical practice as a novel therapeutic strategy.
C1 Department of Gynaecology, Shangluo Traditional Chinese Medicine Hospital No. 148, Beixin Street, Shangzhou District, Shangluo 726000, Shaanxi, China.
   Traditional Chinese Medicine Teaching and Research Office, Shangluo Vocational and Technical College Dannan New District, West Section of Shangyang Avenue,Shangluo 726000, Shaanxi, China.
   Department of Postpartum and Pelvic Floor Rehabilitation, Xi'an International Medical Center Hospital No. 777 Xitai Road, Chang'an District, Xi'an 710100,Shaanxi, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD AUG 18
PY 2025
VL 17
IS 7
BP 5241
EP 5256
DI 10.62347/YVFO2330
PG 15
UT PubMed:40821053
PM 40821053
DA 2025-08-18
ER

PT J
AU Hempen, M
   Hummelsberger, J
AF Hempen, Moritz
   Hummelsberger, Josef
TI The state of evidence in acupuncture: A review of metaanalyses and systematic
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Acupuncture; Acupuncture effectiveness; Acupuncture evidence; Acupuncture review
AB INTRODUCTION: Over the last decades, acupuncture research has increased  drastically. As a result, it has become more and more difficult to oversee the  amount of evidence concerning its effect in various medical conditions. Different  comparative reviews aimed to roughly assess individual strength of acupuncture  evidence, covering the years 2005-2017. Our review intends to assess the level of  acupuncture evidence for any medical condition available, concerning the years  2017-2022. METHODS: We searched the pubmed database for 'acupuncture' and  filtered the results towards systematic reviews and metanalyses (SR/MA). Results  were allocated towards medical disciplines and sorted to medical conditions. Each  SR/MA was rated concerning quality of review (QoR), quality of data (QoD), and  quality of evidence (QoE). To facilitate a rough overview, results were assessed  into either of four categories: i) evidence of positive effect, ii) evidence of  potential positive effect, iii) insufficient/unclear evidence, iv) no evidence of  effect/evidence of no effect. RESULTS: After considering exclusion criteria, 862  SR/MA remained for evaluation. Results were allocated and sorted as described,  resulting in 184 medical conditions. Of these, in ten medical conditions SR/MA  supported evidence of positive effect: chronic pain, low-back pain, knee  osteoarthritis, postoperative nausea and vomiting (PONV), migraine, tension-type  headache, cancer-related fatigue, menopausal symptoms, female infertility  (additional to medical reproductive treatment), chronic prostatitis/chronic  pelvic pain syndrome in men. In another 82 medical conditions SR/MA supported  evidence of potential positive effect, in another 86 medical conditions SR/MA  revealed unclear/insufficient evidence, and in another six medical conditions no  evidence of effect/evidence of no effect was found. Compared with previous  reviews until the year 2017, the number of medical conditions with higher quality  evidence levels has increased, namely evidence of positive effect and evidence of  potential positive effect. DISCUSSION AND CONCLUSION: Compared to previous years,  the amount and quality of acupuncture evidence has increased in the years  2017-2022. In total, 862 included SR/MA resulted in a comparative review of 184  medical conditions. Evidence of positive effect was revealed ten medical  conditions, another 82 showed evidence of potential positive effect. 86 medical  indications showed insufficient evidence for a firm conclusion, six conditions  showed no evidence of effect/evidence of no effect. Although general quality of  evidence has dramatically increased compared to the previous years, lack of  underlying high-quality trials in some cases seems to compromise a consistent  comparability between SR/MA. This issue should be addressed for future studies  and guidelines such as STRICTA and CONSORT should strictly be obtained.
C1 SMS - International Society for Chinese Medicine, Munich, Germany. 
   SMS - International Society for Chinese Medicine, Munich, Germany.
EM m.hempen@tcm.edu
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAR 1
PY 2025
VL 89
IS 
BP 103149
EP 103149
DI 10.1016/j.ctim.2025.103149
PG 0
WC Acupuncture Therapy; Humans; Systematic Reviews as Topic; Evidence-Based Medicine
UT PubMed:40021024
PM 40021024
DA 2025-03-01
ER

PT J
AU Yu, X
   Gong, SY
   Luo, Q
   Xu, GX
   Tian, H
   Li, Q
   Chen, M
   Yang, S
   Yu, SG
AF Yu, Xin
   Gong, Si-yao
   Luo, Qin
   Xu, Gui-xing
   Tian, Hao
   Li, Qian
   Chen, Ming
   Yang, Sha
   Yu, Shu-guang
TI Effectiveness of Acupuncture in Improving Quality of Life for Patients with Advanced Cancer: A Systematic Review and Meta-Analysis
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Review
DE acupuncture; advanced cancer; palliative care; meta-analysis; quality of life
ID palliative care; lung-cancer; chemotherapy; symptoms; therapy
AB ObjectiveTo investigate the effect of acupuncture on advanced cancer patients by meta-analysis.MethodsNine databases (the Cochrane Central Register of Controlled Trials, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure, the Cumulative Index to Nursing and Allied Health Literature, Chinese Biomedical Literature Database, China Science and Technology Journal Database, and WanFang Data) were searched for randomized controlled trials (RCTs) on acupuncture in advanced cancer patients published from inception to February 13, 2023 and updated to June 1, 2023. Primary outcomes were quality of life (QOL), while secondary outcomes were pain, fatigue, and adverse events (side effects). Data synthesis was performed using RevMan V.5.3 to calculate pooled effect sizes. RoB-2 was used for the risk of bias, and the quality of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool.ResultsTotally 17 RCTs involving 1,178 participants were included, 15 of which were pooled for meta-analysis. Most studies demonstrated some concern for the overall risk of bias. The pooled data indicated that acupuncture was associated with improved QOL [mean difference (MD)=6.67, 95% confidence interval (CI): 5.09 to 8.26], pain (MD=-1.18, 95% CI -2.28 to -0.08), and adverse events (risk ratio=0.30, 95% CI: 0.26 to 0.57) compared with control groups. Fatigue outcome was not included. Heterogeneity was substantial, and GRADE evidence was very low for both QOL and pain.ConclusionsAcupuncture could benefit patients with advanced cancer and is considered safe compared with usual care. However, the evidence regarding QOL and pain outcomes requires further validation. It is crucial to encourage the development of high-quality studies to strengthen this evidence. (Registry No. CRD42023423539)
C1 [Yu, Xin; Gong, Si-yao; Luo, Qin; Xu, Gui-xing; Tian, Hao; Li, Qian; Chen, Ming; Yang, Sha; Yu, Shu-guang] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Peoples R China.
   [Li, Qian] Panzhihua Univ, Sch Hlth & Wellness, Panzhihua 617099, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Panzhihua University
RP Yang, S (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu 610075, Peoples R China.
EM yangsha@cdutcm.edu.cn
FU National Natural Science Foundation of China [82004487, 82230127]; Central Guidance for Local Projects of Sichuan Province [2022ZYD0101]
CR Buss MK, 2017, MAYO CLIN PROC, V92, P280, DOI 10.1016/j.mayocp.2016.11.007
   Chae Y, 2017, ACUPUNCT MED, V35, P148, DOI 10.1136/acupmed-2016-011178
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Crawford GB, 2021, ESMO OPEN, V6, P0, DOI 10.1016/j.esmoop.2021.100225
   Cui Y, 2004, BREAST CANCER RES TR, V85, P263, DOI 10.1023/B:BREA.0000025422.26148.8d
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng Xiao-Yue, 2019, ZHONGGUO ZHEN JIU, V39, P379, DOI 10.13703/j.0255-2930.2019.04.009
   Deng XY, 2018, J ZHEJIANG U TRADIT, V42, P748, DOI 10.16466/J.ISSN1005-5509.2018.09.018
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474
   Fulton JJ, 2019, PALLIATIVE MED, V33, P123, DOI 10.1177/0269216318812633
   Gan D, 2020, SICHUAN J TRADIT CHI, V38, P210
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Geerse OP, 2021, J PALLIAT MED, V24, P53, DOI 10.1089/jpm.2019.0615
   Giesinger JM, 2011, J PALLIAT MED, V14, P904, DOI 10.1089/jpm.2011.0086
   Granger C, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012020.pub3
   [何佩珊 He Peishan], 2020, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V35, P5313
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kiss Z, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1207295
   Langevin Helene M, 2016, CANCER RES, V76, P6159, DOI 10.1158/0008-5472.can-16-0753
   LeBlanc TW, 2015, LANCET ONCOL, V16, PE333, DOI 10.1016/S1470-2045(15)00080-7
   Li YH, 2014, SHANGHAI J ACUPUNCT, V33, P211
   Liu YQ, 2015, CHIN J INTEGR MED, V21, P697, DOI 10.1007/s11655-014-2009-x
   Lu L, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.28776
   Luo XC, 2023, J EVID-BASED MED, V16, P237, DOI 10.1111/jebm.12526
   Ma J, 2021, CHIN MED MODERN DIST, V19, P119
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Miao XM, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8701779
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Ni WM, 2018, SHANGHAI ZHENJIU ZAZ, V37, P1020
   Noorlandt H, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13638
   Oh B, 2018, INTEGR CANCER THER, V17, P458, DOI 10.1177/1534735417734912
   Okuyama T, 2017, CANCER TREAT REV, V56, P16, DOI 10.1016/j.ctrv.2017.03.012
   Page Matthew J, 2021, BMJ, V372, Pn71, DOI 10.1016/j.ijsu.2021.105906
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Papadopoulou M, 2023, IN VIVO, V37, P47, DOI 10.21873/invivo.13053
   Peng GY, 2016, J GUANGDONG COLL PHA, V32, P522
   Puhan MA, 2014, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g5630
   Saraswati W, 2021, J ACUPUNCT MERIDIAN, V14, P5, DOI 10.51507/j.jams.2021.14.1.4
   Schenker Y, 2021, JAMA INTERN MED, V181, P1451, DOI 10.1001/jamainternmed.2021.5185
   Su CF, 2018, J INTEGR MED-JIM, V16, P208, DOI 10.1016/j.joim.2018.04.003
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swetz KM, 2018, ANN INTERN MED, V168, PITC33, DOI 10.7326/AITC201803060
   Verma N, 2021, J CLIN HYPERTENS, V23, P1275, DOI 10.1111/jch.14236
   von Trott P, 2020, J PAIN SYMPTOM MANAG, V59, P327, DOI 10.1016/j.jpainsymman.2019.09.007
   Wang WM, 2021, ACUPUNCT MED, V39, P272, DOI 10.1177/0964528420947739
   Wang XP, 2017, J NAVAL MED CHIN, V38, P353
   Wang Y, 2017, ZHEJIANG J TRADIT CHIN MED, V52, P684
   *WHO, 2020, PALL CAR, V0, P0
   Xie LF, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-03926-9
   Yang HN, 2023, LIAONING J TRADIT CH, V50, P159
   Yin S, 2021, SHANGHAI J ACUPUNCT, V40, P21, DOI 10.13460/J.ISSN.1005-0957.2008.12.009
   Yu Z, 2014, J TRADIT CHIN MED, V34, P754, DOI 10.1016/S0254-6272(15)30092-3
   Zeng YC, 2018, INTEGR CANCER THER, V17, P737, DOI 10.1177/1534735418777109
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
   Zhang X, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1206196
   Zheng X, 2021, J GANSU U CHIN MED C, V38, P64, DOI 10.16841/J.ISSN1003-8450.2021.06.13
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2
NR 62
TC 1
Z9 2
U1 7
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD APR 15
PY 2025
VL 31
IS 4
BP 360
EP 371
DI 10.1007/s11655-024-4119-4
EA OCT 2024
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 1JM2D
UT WOS:001334459000001
PM 39417952
DA 2026-01-16
ER

PT J
AU Wu, HV
   Li, X
   Li, QS
   Baser, RE
   Panageas, KS
   Chimonas, S
   Tap, WD
   Glade, Bender J
   Moskowitz, CS
   Mao, JJ
AF Wu, Han-Wei V
   Li, Xiaotong
   Li, Qing S
   Baser, Raymond E
   Panageas, Katherine S
   Chimonas, Susan
   Tap, William D
   Glade Bender, Julia
   Moskowitz, Chaya S
   Mao, Jun J
TI Effect of Acupuncture and Massage on Pain in Adolescent and Young Adult Patients
SO Journal of adolescent and young adult oncology
LA English
DT Journal Article
DE health-related quality of life; pain management; quality of life; supportive care
AB Purpose: Pain management remains challenging for adolescent and young adult (AYA)  cancer patients. Acupuncture and massage have been recommended for cancer-related  pain management, but no prospective trials have been conducted in AYA patients.  We explored the effects of acupuncture and massage on pain in AYAs. Methods: This  subgroup analysis focused on AYA patients (aged 18-39 years) enrolled in a  randomized controlled trial comparing acupuncture and massage for pain management  in advanced cancer. Interventions were delivered weekly for 10 weeks, followed by  monthly booster treatments through week 26. The primary outcome was the worst  pain score from the Brief Pain Inventory, analyzed using a linear mixed-effects  model. Results: Thirty participants met eligibility criteria (13 acupuncture; 17  massage), with a mean age of 31.1 years (standard deviation, 5.8); 57% were  female; 67% were White; and 53% had solid tumors. Both groups experienced reduced  pain over time. Relative to baseline, patients receiving acupuncture had a mean  change of -1.26 points (95% confidence interval [CI], -2.54 to 0.01) at 10 weeks  and a mean change of -1.46 points (95% CI, -2.78 to -0.14) at 26 weeks. Patients  receiving massage experienced a mean change of -2.81 points (95% CI, -3.92 to  -1.70) at week 10 and a mean change of -3.79 points (95% CI, -4.85 to -2.73) at  week 26. Conclusion: AYA patients with advanced cancer who received either  acupuncture or massage experienced clinically meaningful and sustained reductions  in pain. These findings provide a promising foundation for future trials aimed at  evaluating integrative pain management strategies in AYAs.
C1 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
NR 0
TC 0
SN 2156-535
EI 
J9 J Adolesc Young Adult Oncol
PD AUG 14
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1177/21565333251368891
PG 0
UT PubMed:40803676
PM 40803676
DA 2025-08-14
ER

PT J
AU Yu, R
   Guo, X
   Zhu, Y
   Chen, Y
   Zhang, C
   Chai, X
   Wang, Y
AF Yu, Ruifang
   Guo, Xinfeng
   Zhu, Yanjuan
   Chen, Yue
   Zhang, Canyang
   Chai, Xiaoshu
   Wang, Yingqi
TI Acupuncture reduced incidence of insomnia symptoms in patients with lung cancer:
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Insomnia symptoms; Lung cancer; Prevention
AB PURPOSE: About 30-50% of lung cancer patients suffer from insomnia with limited  prevention options. We conducted a retrospective cohort study to investigate  whether acupuncture for cancer-related symptoms such as pain could reduce the  incidence of insomnia symptoms. METHODS: We included newly diagnosed lung cancer  patients without prior insomnia symptoms from Guangdong Provincial Hospital of  Chinese Medicine (2012-2021) and followed up until January 31, 2022. Cases were  propensity score-matched by sex, age, ECOG PS score, pathological diagnosis,  therapy, and comorbidities. The main outcome was the incidence of insomnia  symptoms, identified by psychiatric diagnosis or insomnia symptoms in medical  records. RESULTS: Among 1295 lung cancer survivors, 918 patients were matched  (459 per group). Over an average follow-up of 218.6 days, insomnia symptoms were  observed in 20.9% of the acupuncture group and 42.2% of the non-acupuncture  group. Acupuncture was linked to a lower incidence of insomnia symptoms (adjusted  HR 0.31, 95% CI 0.23-0.39). Higher frequency and more numerous acupuncture  sessions further reduced the risk of insomnia symptoms (adjusted HR 0.15 for  frequency of 1 day/session, adjusted HR 0.15 for sessions > 16). The acupuncture  group had a significantly lower cumulative incidence of insomnia (log-rank test,  P < 0.01). CONCLUSION: Our results suggest that acupuncture may prevent the  incidence of insomnia symptoms in patients with lung cancer. Daily sessions and a  cumulative total of 16 or more treatments may enhance the benefit.
C1 Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital 
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese 
   State Key Laboratory of Dampness, Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou,China.
   Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou, China.
   College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
   Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital 
   Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou, China. chaixiaoshu@126.com.
   First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China. wyq950101@126.com.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD DEC 19
PY 2025
VL 34
IS 1
BP 45
EP 45
DI 10.1007/s00520-025-10256-8
PG 0
WC Humans; Sleep Initiation and Maintenance ; Retrospective Studies; Male; Female; Acupuncture Therapy; methods; Lung Neoplasms; complications; Middle Aged; Incidence; Aged; Adult; Cohort Studies; China; epidemiology
UT PubMed:41417088
PM 41417088
DA 2025-12-19
ER

PT J
AU Raybin, JL
   Montgomery, KE
   Skeens, M
   Janosy, N
   Mist, S
   Franklin, H
   Dieckmann, NF
   Hendricks-Ferguson, VL
   Jankowski, CM
AF Raybin, Jennifer L
   Montgomery, Kathleen E
   Skeens, Micah
   Janosy, Norah
   Mist, Scott
   Franklin, Heather
   Dieckmann, Nathan F
   Hendricks-Ferguson, Verna L
   Jankowski, Catherine M
TI Integrative and Complementary Interventions Result in Significant Positive Effect
SO Research square
LA English
DT Journal Article
DE childhood cancer; complementary; creative arts; integrative; quality of life; symptoms
AB PURPOSE: Children with cancer report intractable symptoms and endorse using  complementary and integrative health interventions (CHI) without strong published  evidence. We conducted a prospective study of CHI in 100 participants at two  children's hospitals. The secondary aim was to estimate outcome effect sizes.  Here we report preliminary effect size estimates of CHI on quality of life (QOL)  and symptom burden in pediatric participants with cancer and other serious  illness. METHODS: We used standardized patient reported outcome (PRO) measures in  response to CHI sessions. Data were collected at baseline, pre/post CHI, and  monthly up to 6 months. Outcomes were QOL and symptom burden. RESULTS:  Participants (n=100) were aged 2-29 years (M=13.5, SD=5.6), 65% identified as  female, 23% were from underrepresented populations, 52% were receiving treatment  for cancer versus other serious illness. Participants completed 191 CHI sessions  with 811 PRO assessments. CHI included acupuncture (39%), aromatherapy (35%),  creative arts (20%), massage therapy (5%), and hypnosis (1%). Mixed-effects  models controlling for cancer diagnosis revealed improvement in anxiety, fatigue,  pain, sadness, and mood (Cohen's d effect sizes 0.20-1.45; all p<0.05). Creative  arts were associated with improvement in all symptoms except for nausea  (0.31-1.45; all p<0.03). QOL improved over time (b = 0.21; p<0.05) and was  clinically significant compared to standard clinical cut offs. CONCLUSION:  Patients (or proxy) reported improvement in QOL and symptom burden with CHI. The  positive effect size estimates support for the need for additional efficacy  studies of targeted CHI among children with serious illnesses including cancer,  especially creative arts interventions.
C1 University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
   University of Colorado College of Nursing and School of Medicine (Drs. Jankowski and Janosy)
   Saint Louis University School of Nursing (Dr. Hendricks-Ferguson);Oregon Health and Sciences University Schools of Nursing and Medicine (Drs.Raybin, Mist, Franklin, and Dieckmann)
   University of Wisconsin-Madison School ofNursing (Dr. Montgomery)
   College of Medicine, The Ohio State University.
NR 0
TC 0
SN 2693-501
EI 
J9 Res Sq
PD SEP 18
PY 2025
VL 0
IS 
BP 
EP 
DI 10.21203/rs.3.rs-7208100/v1
PG 0
UT PubMed:40964042
PM 40964042
DA 2025-09-18
ER

PT J
AU Haoyang, WU
   Yuan, L
   Yuzhou, C
   Yizhou, X
   Lei, Z
   Yang, YU
   Xiaohong, F
AF Haoyang, W U
   Yuan, Liu
   Yuzhou, Chen
   Yizhou, Xie
   Lei, Zhong
   Yang, Y U
   Xiaohong, Fan
TI Effect of pestle needle therapy on the posterior cervical muscle in a rabbit
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE TOR serine-threonine kinases; apoptosis; autophagy; pestle needle; phosphatidylinositol 3-kinase; proto-oncogene proteins c-akt; spondylosis
AB OBJECTIVE: To investigate the effect of pestle needle therapy (PNT) on the  posterior cervical muscle (PCM) in a rabbit model of cervical spondylosis (CS)  and explore the underlying mechanisms. METHODS: Rabbits were divided into  control, CS models I and II (CS1 and CS2), electroacupuncture (EA), PNT I and II  (PN1 and PN2), activator (AVT), and PNT combined with activator (C-AVT) groups. A  long-term neck immobilization technique was used to establish a rabbit model of  CS. Following completion of modeling, the EA group received electroacupuncture  intervention, whereas the CS1, CS2, and C-AVT groups received PNT intervention.  The AVT and C-AVT groups received local 740 Y-P injections into the PCM daily.  The inflammatory injury to PCM was evaluated based on pain threshold,  morphological changes, and interleukin (IL)-1β, IL-6, and tumor necrosis factor  (TNF)-α levels. PCM fibrosis was evaluated by measuring the positive area (PA) of  collagen fibrils (CFs) and collagen type 1 alpha 1 (Col1α1) using Masson's and  immunohistochemical staining. Terminal deoxynucleotidyl transferase-mediated dUTP  nick-end labeling assay and transmission electron microscopy were used to  identify apoptotic cells and assess autophagy, respectively. Western blotting was  used to determine B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax),  cysteine aspartate-specific protease (caspase)-3, sequestosome-1 (P62),  microtubule-associated protein light chain 3 (LC3-I/II), phosphatidylinositol  3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR)  levels. Real-time quantitative polymerase chain reaction was used to determine  mRNA expression levels of PI3K, AKT, mTOR, autophagy protein (ATG), and ATG7.  RESULTS: PNT alleviated PCM cell degeneration and necrosis, inhibited  inflammatory cell infiltration, decreased IL-1β, IL-6, and TNF-α levels, and  decreased the PA of CFs and Col1α1. In the PN1 group, cell apoptosis in the PCM  decreased, autophagy increased, Bcl-2 and LC3-II/I levels increased, Bax,  Caspase-3, and P62 levels decreased, and the mRNA expression of ATG5 and ATG7  increased. PNT inhibits protein and mRNA expression of PI3K, AKT, and mTOR.  Finally, the trend in the results of the rescue experiment was consistent with  previous results. CONCLUSION: PNT inhibited apoptosis and promoted autophagy of  PCM cells in CS rabbits and alleviated inflammation and fibrosis injury of PCM by  inhibiting the PI3K/AKT/mTOR pathway.
C1 College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.
   College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.
   College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.
   College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, China.
   Department of Orthopaedics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   Department of Orthopaedics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   Department of Orthopaedics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
NR 0
TC 0
SN 2589-451
EI 0255-292
J9 J Tradit Chin Med
PD AUG 14
PY 2025
VL 45
IS 4
BP 786
EP 795
DI 10.19852/j.cnki.jtcm.2025.04.009
PG 9
WC Animals; Rabbits; Spondylosis; therapy; Male; Humans; Disease Models, Animal; Acupuncture Therapy; instrumentation; Apoptosis; Tumor Necrosis Factor-alpha; genetics; Neck Muscles; metabolism; Interleukin-6; genetics; Interleukin-1beta; genetics; Electroacupuncture
UT PubMed:40810224
PM 40810224
DA 2025-08-14
ER

PT J
AU Kaul, I
   Busby, K
   Yeh, AM
AF Kaul, Ila
   Busby, Ken
   Yeh, Ann Ming
TI Integrative medicine consults in a pediatric hospital: A case series
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Case series; Acupressure; Massage; Aromatherapy; Hypnosis
ID acupuncture; oncology; children; therapy; cancer; pain
AB Pediatric integrative medicine (PIM) is a holistic approach to health care that combines conventional pediatric treatments with evidence-based complementary therapies to support the physical, emotional, and spiritual wellbeing of children and their caretakers. It encompasses a wide range of modalities, including acupuncture, massage therapy, mindfulness, guided imagery, and nutritional counseling, tailored to meet the developmental and medical needs of pediatric patients. The goal of PIM is to support treatment by integrating family values, lifestyle, and stress management into care plans through different therapies. In this report, the existing literature of pediatric inpatient integrative medicine interventions is reviewed, and three patient case studies illustrate the impact of a pilot integrative medicine consultation service in a tertiary care children's hospital. These cases will reflect integrative medicine modalities to provide non-pharmacologic symptom management through approaches such as massage, acupressure, clinical hypnosis, guided imagery, and breathing techniques.
C1 [Kaul, Ila] Dartmouth Coll, Geisel Sch Med, Lebanon, NH 03755 USA.
   [Busby, Ken] Emory Univ, Sch Med, Dept Pediat, Pediat Hematol & Oncol, Atlanta, GA USA.
   [Yeh, Ann Ming] Stanford Univ, Sch Med, Dept Pediat, Pediat Gastroenterol Hepatol & Nutr, Palo Alto, CA USA.
C3 Dartmouth College; Emory University; Stanford University
RP Kaul, I (corresponding author), Dartmouth Coll, Geisel Sch Med, Lebanon, NH 03755 USA.
EM ila.k.kaul.med@dartmouth.edu
CR Bryl K, 2023, CURR ONCOL, V30, P6497, DOI 10.3390/curroncol30070477
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Ismail SA, 2021, J PAIN RES, V14, P273, DOI 10.2147/JPR.S285322
   Ladas EJ, 2014, PEDIATR BLOOD CANCER, V61, P687, DOI 10.1002/pbc.24791
   Misra SM, 2019, CLIN PEDIATR, V58, P738, DOI 10.1177/0009922819839232
   Reindl TK, 2006, SUPPORT CARE CANCER, V14, P172, DOI 10.1007/s00520-005-0846-z
   Roth I, 2021, COMPLEMENT THER MED, V58, P0, DOI 10.1016/j.ctim.2021.102698
   Shanafelt TD, 1900, V4, V0, P0, DOI DOI 10.1016/j.mayocp.2024.11.031.S0025-6196(24)00668-2
   Torres-Luna R, 2025, AN PEDIATR, V102, P0, DOI 10.1016/j.anpede.2025.503831
   Tsao GJ, 2015, LARYNGOSCOPE, V125, P1972, DOI 10.1002/lary.25252
   Vohra S, 2021, CHILDREN-BASEL, V8, P0, DOI 10.3390/children8040311
   Vohra S, 2012, BMC PEDIATR, V12, P0, DOI 10.1186/1471-2431-12-123
NR 12
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD NOV-DEC 15
PY 2025
VL 21
IS 6
BP 
EP 
DI 10.1016/j.explore.2025.103259
EA SEP 2025
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 7KR1I
UT WOS:001573298100001
PM 40945035
DA 2026-01-16
ER

PT J
AU Zhang, DX
   Zhao, XH
   Li, HP
   Chen, W
   Liu, CZ
AF Zhang, Dongxu
   Zhao, Xinhua
   Li, Hongping
   Chen, Wen
   Liu, Cunzhi
TI Effect of eight different acupuncture and moxibustion therapies on breast cancer-related lymphedema: a Bayesian network meta-analysis
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Breast cancer-related lymphedema; Acupuncture and moxibustion therapies; Arm circumference; Pain; Network meta-analysis
ID survivors
AB BackgroundBreast cancer is the most prevalent cancer worldwide, and nearly 30% of affected patients experience breast cancer-related lymphedema (BCRL). Some evidence suggests that acupuncture and moxibustion therapies are safe and effective in the treatment of BCRL. Nevertheless, there is controversy regarding the optimal acupuncture and moxibustion therapy for BCRL.ObjectiveThe aim of this study was to compare and rank the efficacy of different acupuncture and moxibustion therapies for BCRL, to identify the best acupuncture and moxibustion therapy for BCRL, and to provide a reference for clinicians to choose the treatment modality.MethodsWe searched PubMed, Embase, Cochrane Library, Web of Science, Google Scholar, China National Knowledge Infrastructure, CQVIP, Wanfang Data, and SINOMED Databases for randomized controlled trials (RCTs) of acupuncture and moxibustion therapy for BCRL from inception to March 30, 2023. The quality of the included literature was assessed using the Cochrane risk of bias assessment, and data were analyzed and plotted using R4.3.2 and Stata 15.1 software.ResultsWe included 27 RCTs including 8 acupuncture interventions with a sample size of 1976 cases. The results of the network meta-analysis showed that acupuncture + moxibustion, moxibustion, blood-letting puncture and cupping, and electroacupuncture combined with conventional rehabilitation were superior to conventional rehabilitation alone in reducing arm circumference. Moxibustion combined with conventional rehabilitation was superior to conventional rehabilitation alone in reducing the degree of edema. Electroacupuncture and acupoint massage combined with conventional rehabilitation were superior to conventional rehabilitation alone in reducing the visual analogue scale (VAS) scores. And in terms of improving the mobility of the shoulder joint, moxibustion and electroacupuncture combined with conventional rehabilitation were better than conventional rehabilitation alone.ConclusionThe combination of acupuncture and moxibustion therapy with conventional rehabilitation can improve the efficacy of BCRL. Acupuncture + moxibustion was the best treatment modality to reduce arm circumference, acupuncture was the best modality to reduce edema, and electroacupuncture was the most effective modality for relieving BCRL pain symptoms and was the best choice to improve abduction range of motion (ROM). Due to the limitations of this study, this conclusion remains to be validated by further high-quality clinical studies.
C1 [Zhang, Dongxu; Li, Hongping; Chen, Wen; Liu, Cunzhi] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Zhao, Xinhua] Beijing Anorectal Hosp, Tumor Ctr, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine
RP Liu, CZ (corresponding author), Beijing Univ Chinese Med, Beijing, Peoples R China.
EM lcz623780@126.com
FU National Key Research and Development Program
CR Unknown -, 2012, CHIN J CLIN RES, V0, P0
   Unknown -, 2019, WORLD CHIN MED, V0, P0
   Avraham T, 2013, FASEB J, V27, P1114, DOI 10.1096/fj.12-222695
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Berdzuli N, 2023, BMJ-BRIT MED J, V380, P0, DOI 10.1136/bmj.p290
   Boeer B, 2023, ARCH GYNECOL OBSTET, V307, P1529, DOI 10.1007/s00404-022-06609-x
   Breast Cancer Specialized Committee of the Chinese Anti-Cancer Association, 2021, CHINESE JOURNAL OF CANCER, V31, P954, DOI 10.19401/j.cnki.1007-3639.2021.10.013
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Chen J, 2016, ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, V51, P905, DOI 10.13633/j.cnki.zjtcm.2016.12.033
   Cheng MH, 2022, J SURG ONCOL, V126, P1162, DOI 10.1002/jso.27054
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Dayan JH, 2018, ANNU REV MED, V69, P263, DOI 10.1146/annurev-med-060116-022900
   Dylke E, 2022, J PHYSIOTHER, V68, P238, DOI 10.1016/j.jphys.2022.09.008
   Farley CR, 2022, ANN SURG ONCOL, V29, P6370, DOI 10.1245/s10434-022-12142-7
   Fearn N, 2023, J CANCER SURVIV, V17, P1669, DOI 10.1007/s11764-022-01278-w
   Feng XM, 2023, J MODERN ONCOL, V31, P1252
   Gao Yin-Lai, 2020, ZHONGGUO ZHEN JIU, V40, P1108, DOI 10.13703/j.0255-2930.20190821-0008
   Gelman A, 1996, STAT METHODS MED RES, V5, P339, DOI 10.1177/096228029600500402
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han Y, 2019, CLINICAL STUDY OF ACUPUNCTURE COMBINED WITH REHA- BILITATION MEDICAL GYMNASTICS FOR THE TREATMENT OF SHOULDER JOINT DYSFUNCTION AFTER BREAST CANCER SURGERY, V0, P0
   Hayes SC, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14235998
   He L, 2020, ONCOL LETT, V19, P2085, DOI 10.3892/ol.2020.11307
   Huang JH, 2020, ANALYSIS OF RISK FACTORS OF LYMPHEDEMA IN UPPER LIMBS AFTER BREAST CANCER SURGERY AND THE EFFICACY OF ACUPOINT ELECTRICAL STIMULATION COMBINED WITH COMPREHENSIVE DECONGESTION THERAPY, V0, P0
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Hyland CJ, 2022, CANCER-AM CANCER SOC, V128, P3284, DOI 10.1002/cncr.34374
   Jia Lan-Yu, 2019, ZHEN CI YAN JIU, V44, P715, DOI 10.13702/j.1000-0607.180823
   Jiao HF, 2017, INNER MONGOLIA JOURNAL OF TRADITIONAL CHINESE MEDICINE, V36, P130, DOI 10.16040/j.cnki.cn15-1101.2017.z2.103
   Jin HM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3237451
   Karst M, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16929
   Leysen L, 2017, SUPPORT CARE CANCER, V25, P3607, DOI 10.1007/s00520-017-3824-3
   Li BH, 2020, ANN TRANSL MED, V8, P0, DOI 10.21037/atm-20-6605
   Li SM, 2012, CLINICAL STUDY OF MOXIBUSTION THERAPY FOR THE PRE- VENTION AND TREATMENT OF EDEMA IN THE AFFECTED LIMBS DURING POST- OPERATIVE CHEMOTHERAPY FOR BREAST CANCER, V0, P0
   Li XH, 2021, J SICHUAN TRADIT CHIN MED, V39, P182
   Li XL, 2019, MODERN NURSE, V26, P79
   Liu YN, 2019, SHANGHAI J ACU-MOX, V38, P634, DOI 10.13460/j.issn.1005-0957.2019.06.0634
   Lu LM, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-056803
   Mallory MJ, 2016, J INTEGR MED-JIM, V14, P311, DOI 10.1016/S2095-4964(16)60269-8
   McEvoy MP, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.1062472
   McLaughlin SA, 2017, ANN SURG ONCOL, V24, P2818, DOI 10.1245/s10434-017-5982-4
   Naoum GE, 2021, INT J RADIAT ONCOL, V110, P1159, DOI 10.1016/j.ijrobp.2021.01.056
   Paramanandam VS, 2022, J CLIN ONCOL, V40, P2004, DOI 10.1200/JCO.21.02567
   Qiao L, 2020, AM J CHINESE MED, V48, P245, DOI 10.1142/S0192415X20500135
   Rafn BS, 2022, J CLIN ONCOL, V40, P1009, DOI 10.1200/JCO.21.01681
   Ren YM, 2022, CANCER-AM CANCER SOC, V128, P4119, DOI 10.1002/cncr.34489
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Shi S, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1649605
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Sun XH, 2017, CHINESE JOURNAL OF SURGERY OF INTEGRATED TRADITIONAL AND WEST- ERN MEDICINE, V23, P167
   Wan H, 2019, CHIN COMMUNITY DOCT, V35, P100, DOI 10.3969/j.issn.1007-614x.2019.20.071
   Wan J, 2018, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.00902
   Wang CH, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866919
   Wang HJ, 2012, CHINESE JOURNAL OF TRADITIONAL MEDICAL SCIENCE AND TECHNOLOGY, V19, P453
   Wang L, 2023, J CLIN NURS, V32, P2208, DOI 10.1111/jocn.16437
   Wang M, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1147718
   Wang SH, 2023, GLAND SURG, V0, P0, DOI DOI 10.21037/gs-22-767
   Wen JY, 2021, AM J CHINESE MED, V49, P1, DOI 10.1142/S0192415X21500014
   Xiang TT, 2022, J MED THEOR & PRAC, V35, P1781, DOI 10.19381/j.issn.1001-7585.2022.10.072
   Xu ZH, 2021, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.596780
   Yang HZ, 2020, J EXTERNAL THER TCM, V29, P50
   Yang M, 2017, BEIJING UNI- VERSITY OF CHINESE MEDICINE, V0, P0
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Ye XZ, 2016, J LIAONING UNIV TRA- DIT CHIN MED, V18, P133, DOI 10.13194/j.issn.1673-842x.2016.10.040
   Yu Liu, 2016, GUANGMING JOURNAL OF CHINESE MEDICINE, V31, P879
   Zhang FR, 2020, WORLD JOURNAL OF INTEGRATED TRADITIONAL AND WEST- ERN MEDICINE, V15, P1934, DOI 10.13935/J.CNKI.SJZX.201038
   Zhang JW, 2019, JOURNAL OF CHENGDU UNIVERSITY OF TCM, V42, P51, DOI 10.16295/j.cnki.0257-358x.2019.08.006
   Zhang JY, 2023, LIAONING JOURNAL OF TRADITIONAL CHINESE MEDICINE, V50, P205, DOI 10.13192/j.issn.1000-1719.2023.06.057
   Zhang KY, 2023, PLOS ONE, V18, P0, DOI 10.1371/journal.pone.0280821
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang YR, 2016, 03C0NG IN THE TREATMENT OF POSTOPERATIVE UPPER LIMB EDEMA IN BREAST CAN- CER, V0, P0
   Zheng LF, 2019, CHINA MODERN DOCTOR, V57, P142
   Zhou CP, 2022, CELL RES, V32, P543, DOI 10.1038/s41422-022-00639-5
NR 74
TC 0
Z9 0
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD SEP 13
PY 2025
VL 33
IS 10
BP 
EP 
DI 10.1007/s00520-025-09861-4
PG 17
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 7GJ9V
UT WOS:001570397400003
PM 40944772
DA 2026-01-16
ER

PT J
AU Al-Ajlouni, YA
   Al Ta'ani, O
   Zweig, SA
   Bak, M
   Tanashat, M
   Gabr, A
   Khamis, Z
   Al-Bitar, F
   Islam, M
AF Al-Ajlouni, Yazan A.
   Al Ta'ani, Omar
   Zweig, Sophia A.
   Bak, Magdalena
   Tanashat, Mohammad
   Gabr, Ahmed
   Khamis, Zaid
   Al-Bitar, Farah
   Islam, Mohammad
TI Assessing the Therapeutic Role of Rehabilitation Programs in Chemotherapy-Induced Peripheral Neuropathy (CIPN)-A Scoping Review
SO HEALTHCARE
LA English
DT Review
DE chemotherapy-induced peripheral neuropathy; rehabilitation programs; pain management; neuropathic symptoms; scoping review
ID quality-of-life; colorectal-cancer; controlled-trial; breast; strength; yoga; prevention; survivors; pain
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of cancer treatment. Characterized by symptoms like pain, numbness, and muscle weakness, CIPN significantly impacts patients' quality of life. Current management strategies vary, with limited consensus on effective treatments. This scoping review aims to explore comprehensive rehabilitation interventions for CIPN, focusing on enhancing patient well-being and functional abilities. Methods: A scoping review, guided by Arksey and O'Malley's framework and Levac et al.'s refinements, was conducted to assess rehabilitation programs for CIPN. Searches across six databases were performed, with inclusion and exclusion criteria focusing on studies with physical rehabilitation interventions. Data were charted, detailing interventions, demographics, and outcomes. Results were synthesized descriptively and presented narratively with tables. Results: The review included 24 studies covering diverse cancer types and treatments, involving a total of 1167 participants. Various interventions for CIPN were assessed, and results were thematically categorized according to exercise category. Physical modalities like ultrasound and exercise showed promise in symptom relief for colorectal and breast cancer patients. No distinct advantage was found in the timing of exercise interventions. Complementary therapies such as acupuncture and yoga demonstrated effectiveness in managing CIPN symptoms. Conclusions: This review highlights the effectiveness of diverse physical and complementary interventions in managing CIPN, advocating for their integration into standard protocols. It emphasizes the need for holistic, patient-centered approaches that combine exercises, physical therapy, and complementary therapies to improve patient outcomes. These findings set a direction for future research and clinical practices focused on comprehensive and personalized CIPN management strategies.
C1 [Al-Ajlouni, Yazan A.; Gabr, Ahmed] New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
   [Al-Ajlouni, Yazan A.; Islam, Mohammad] Metropolitan Hosp, Dept Phys Med & Rehabil, New York, NY 10029 USA.
   [Al-Ajlouni, Yazan A.; Khamis, Zaid] Staten Isl Univ Hosp, Dept Med, Staten Isl, NY 10305 USA.
   [Al Ta'ani, Omar] Alleghany Hlth Network, Pittsburgh, PA USA.
   [Zweig, Sophia A.] SUNY Downstate Coll Med, Sch Med, Brooklyn, NY 11203 USA.
   [Bak, Magdalena] New York Univ Abu Dhabi NYUAD, Sch Sci, POB 129188, Abu Dhabi, U Arab Emirates.
   [Tanashat, Mohammad] Yarmouk Univ, Fac Med, Irbid 21163, Jordan.
   [Al-Bitar, Farah] Western Michigan Univ, Homer Stryker MD Sch Med, Kalamazoo, MI 49007 USA.
C3 New York Medical College; Metropolitan Hospital Center; Northwell Health; State University of New York (SUNY) System; SUNY Downstate Health Sciences University; Yarmouk University; Western Michigan University
RP Al-Ajlouni, YA (corresponding author), New York Med Coll, Sch Med, Valhalla, NY 10595 USA.; Al-Ajlouni, YA (corresponding author), Metropolitan Hosp, Dept Phys Med & Rehabil, New York, NY 10029 USA.; Al-Ajlouni, YA (corresponding author), Staten Isl Univ Hosp, Dept Med, Staten Isl, NY 10305 USA.
EM alajlouni.yazan@gmail.com
CR Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Anshu A, 2022, INTERNATIONAL JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, V0, PP17, DOI 10.46797/ijacm.v3i2.341
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Bös C, 2023, FRONT PSYCHOL, V14, P0, DOI 10.3389/fpsyg.2023.1096848
   Bonakdar Robert, 2019, GLOB ADV HEALTH MED, V8, P2164956119855629, DOI 10.1177/2164956119855629
   Bower JE, 2012, CANCER-AM CANCER SOC, V118, P3766, DOI 10.1002/cncr.26702
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Buckner SL, 2017, SPORTS MED, V47, P193, DOI 10.1007/s40279-016-0580-3
   Cartwright T, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-031848
   Cramer H, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-412
   De Melo MN, 2022, CURR ONCOL REP, V24, P1363, DOI 10.1007/s11912-022-01296-y
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Dixit S, 2023, LIFE-BASEL, V13, P0, DOI 10.3390/life13020262
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Fremion E, 2020, J PEDIATR REHAB MED, V13, P513, DOI 10.3233/PRM-200718
   Galantino ML, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850627
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Grgic J, 2020, SPORTS MED, V50, P1983, DOI 10.1007/s40279-020-01331-7
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Guizelini PC, 2018, EXP GERONTOL, V102, P51, DOI 10.1016/j.exger.2017.11.020
   Haffer H, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-92788-7
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Huang YJ, 2024, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1252259
   Ikio Y, 2022, SUPPORT CARE CANCER, V30, P4981, DOI 10.1007/s00520-022-06846-5
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Levac D, 2010, IMPLEMENT SCI, V5, P0, DOI 10.1186/1748-5908-5-69
   Li Y, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13040766
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Maestas NA, 2021, J DISABIL POLICY STU, V32, P13, DOI 10.1177/1044207320933211
   Quintao NLM, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00907
   Osmani K, 2012, J NEUROL, V259, P1936, DOI 10.1007/s00415-012-6442-5
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Ross A, 2013, COMPLEMENT THER MED, V21, P313, DOI 10.1016/j.ctim.2013.04.001
   Rosson Gedge D, 2006, CLIN PODIATR MED SURG, V23, P637
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shibata Yosuke, 2020, J PHYS THER SCI, V32, P428, DOI 10.1589/jpts.32.428
   Simão Delma Aurélia da Silva, 2015, REV. DOR, V16, P215, DOI 10.5935/1806-0013.20150043
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Streckmann F, 2014, ANN ONCOL, V25, P493, DOI 10.1093/annonc/mdt568
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Tamburin S, 2022, CRIT REV ONCOL HEMAT, V171, P0, DOI 10.1016/j.critrevonc.2021.103575
   Tanay MAL, 2023, J CANCER SURVIV, V17, P254, DOI 10.1007/s11764-021-00997-w
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Villemure C, 2015, FRONT HUM NEUROSCI, V9, P0, DOI 10.3389/fnhum.2015.00281
   Vollmers PL, 2018, J CANCER RES CLIN, V144, P1785, DOI 10.1007/s00432-018-2686-5
   Waibel S, 2021, ANN CLIN TRANSL NEUR, V8, P1680, DOI 10.1002/acn3.51426
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Zhang X, 2017, BIOMED REP, V6, P267, DOI 10.3892/br.2017.851
   Zhao HT, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph192315491
   Zhi WI, 2021, CANCER RES, V81, P0
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 60
TC 0
Z9 0
U1 5
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD JUN 26
PY 2025
VL 13
IS 13
BP 
EP 
DI 10.3390/healthcare13131526
PG 21
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 4TL0Z
UT WOS:001526255100001
PM 40648551
DA 2026-01-16
ER

PT J
AU Jin, X
   Zhang, Y
   Chang, B
   Ren, J
   Hao, J
   Cao, Y
   Wang, H
   Ji, L
AF Jin, Xu
   Zhang, Yanlin
   Chang, Boya
   Ren, Jia
   Hao, Jianheng
   Cao, Yuxia
   Wang, Haijun
   Ji, Laixi
TI [Analgesic effect of "Zhibian" (BL54)-toward-"Shuidao" (ST28) needling technique
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE NOD1/RIP2/NF-κB signaling pathway; Zhibian (BL54)-toward-Shuidao (ST28); acupuncture; inflammatory response; pain; primary dysmenorrhea
AB OBJECTIVE: To observe the effect of "Zhibian" (BL54)-toward-"Shuidao" (ST28)  needling technique on the relative protein expression of the signaling pathway of  nucleotide-binding oligomerization domain-containing protein 1 (NOD1)/  receptor-interacting protein 2 (RIP2)/nuclear factor kappa-B (NF-κB) and the  expression of proinflammatory cytokines in the rats with primary dysmenorrhea  (PD), so as to explore the underlying mechanism of this acupuncture technique for  pain alleviation in PD. METHODS: Thirty female SD rats of SPF grade with normal  estrous cycle were randomized into a blank group, a model group and an  acupuncture group, 10 rats in each one. Using the intraperitoneal injection with  estradiol benzoate combined with oxytocin, PD model was prepared in the model  group and the acupuncture group. In the acupuncture group, during model  preparation, the intervention with "Zhibian" (BL54)-toward-"Shuidao" (ST28)  needling technique was delivered simultaneously, 20 min each time, once daily for  consecutive 10 days. On day 11, within 30 min after the intraperitoneal injection  with oxytocin, the writhing reaction (latency, frequency and score) was recorded;  the morphology of uterine tissue was observed with HE staining, the contents of  prostaglandin E(2) (PGE(2)), prostaglandin F(2α) (PGF(2α)), interleukin (IL)-1β,  IL-18, cyclooxygenase-2 (COX-2), and tumor necrosis factor-α(TNF-α) in the serum  were detected using ELISA method; the relative protein expression of NOD1, RIP2,  NF-κB p65, phosphorylation-NF-κB p65 (p-NF-κB p65) was detected in the uterine  tissue using Western blot method; and the mRNA expression of NOD1, RIP2 and NF-κB  p65 was detected with the quantitative real-time PCR employed. RESULTS: Compared  with the blank group, in the model group, the writhing latency was prolonged  (P<0.01), the writhing frequency and score increased (P<0.01) in the rats; the  endometrial epithelial cells showed massive degeneration and necrosis, with  severe endometrial edema and widespread shedding, combined with neutrophil  infiltration; the serum PGE(2) content was dropped (P<0.01), while those of  PGF(2α), IL-1β, IL-18, COX-2, and TNF-α elevated (P<0.01); the protein expression  of NOD1, RIP2, NF-κB p65 and p-NF-κB p65, and the mRNA expression of NOD1, RIP2  and NF-κB p65 in uterine tissue increased (P<0.01). In comparison with the model  group, in the acupuncture group, the writhing latency was prolonged (P<0.01), the  writhing frequency and score were reduced (P<0.01) in the rats; there was less  degeneration and necrosis of endometrial epithelial cells, with mild endometrial  edema and very little neutrophil infiltration; the serum PGE(2) content increased  (P<0.01), while those of PGF(2α), IL-1β, IL-18, COX-2, and TNF-α decreased  (P<0.01); the protein expression of NOD1, RIP2, NF-κB p65 and p-NF-κB p65 and the  mRNA expression of NOD1, RIP2 and NF-κB p65 in uterine tissue were dropped  (P<0.05, P<0.01). CONCLUSION: "Zhibian" (BL54)-toward-"Shuidao" (ST28) needling  technique can alleviate the pain symptom of PD rats, and its action mechanism may  be related to inhibiting the active expression of NOD1/RIP2/NF-κB signaling  pathway in the uterine tissue, thereby reducing the inflammatory response.
C1 Second Clinical College, Shanxi University of CM, Jinzhong 030619, China.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM.
   Second Clinical College, Shanxi University of CM, Jinzhong 030619, China.
   Second Clinical College, Shanxi University of CM, Jinzhong 030619, China.
   Second Clinical College, Shanxi University of CM, Jinzhong 030619, China.
   Affiliated Hospital of Acupuncture-Moxibustion and Tuina, Shanxi University of CM, Taiyuan 030012.
   Affiliated Hospital of Acupuncture-Moxibustion and Tuina, Shanxi University of CM, Taiyuan 030012.
   Affiliated Hospital of Acupuncture-Moxibustion and Tuina, Shanxi University of CM, Taiyuan 030012.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 13
PY 2025
VL 45
IS 2
BP 209
EP 16
DI 10.13703/j.0255-2930.20240331-k0001
PG -193
WC Animals; Female; Rats, Sprague-Dawley; Rats; Signal Transduction; Dysmenorrhea; therapy; NF-kappa B; genetics; Acupuncture Points; Humans; Acupuncture Analgesia; Nod1 Signaling Adaptor Protein; genetics; Receptor-Interacting Protein Serine-Threonine Kinase 2; genetics; Acupuncture Therapy
UT PubMed:39943763
PM 39943763
DA 2025-02-13
ER

PT J
AU Wu, JW
   Li, LP
   Chen, YS
AF Wu, Jing-Wen
   Li, Li-Ping
   Chen, Yin-Song
TI Effects of bottle gourd moxibustion combined with umbilical therapy for cancer-related incomplete bowel obstruction on inflammatory cytokine levels
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Cancer-induced bowel obstruction; Bottle gourd moxibustion; Umbilical therapy; Pain management; Inflammatory cytokines; Gastrointestinal recovery
ID validity; outcm
AB BACKGROUND Cancer-induced incomplete bowel obstruction presents numerous clinical challenges, notably pain management and inflammation control. Conventional therapies provide limited relief, prompting investigation into complementary approaches. This study compares the efficacy of bottle gourd moxibustion combined with umbilical therapy (BGM-UT) plus standard palliative care vs standard Western palliative care alone in symptom alleviation and inflammation reduction.AIM To compare the efficacy of BGM-UT plus standard palliative care vs standard palliative care alone in reducing inflammatory cytokine levels, alleviating symptoms, and improving gastrointestinal recovery in cancer-induced incomplete bowel obstruction.METHODS A retrospective analysis was conducted on 109 patients aged 18-75 years with cancer-induced incomplete bowel obstruction treated at the Foshan Hospital of Traditional Chinese Medicine between October 2023 and September 2024. The participants were categorized into two groups: (1) Regular group receiving standard palliative care; and (2) BGM-UT group receiving additional moxibustion therapy. The inclusion criteria included ongoing opioid use and a Karnofsky performance status score below 60. The treatments were evaluated for 3 weeks in terms of opioid consumption, gastrointestinal function recovery, brief pain inventory scores, traditional Chinese medicine symptom scores, and inflammatory cytokine levels.RESULTS Initially, the groups were demographically and clinically comparable. Post-treatment, the BGM-UT group showed significant reductions in opioid intake (P = 0.027), improved gastrointestinal recovery times, and enhanced pain management as reflected by their lower brief pain inventory scores (P < 0.05). Similarly, the improvement in traditional Chinese medicine scores was greater in the BGM-UT group than in the regular group (P < 0.05). Inflammatory markers including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein decreased significantly in the BGM-UT group, indicating the superior anti-inflammatory effects of this treatment (P < 0.05).CONCLUSION The addition of BGM-UT to standard palliative care enhances pain relief, accelerates gastrointestinal recovery, and effectively reduces inflammatory cytokine levels in patients with cancer-induced incomplete bowel obstruction. This combination therapy offers a promising complementary approach to managing this challenging condition. Further prospective studies are warranted to validate these findings and explore underlying mechanisms.
C1 [Wu, Jing-Wen; Li, Li-Ping; Chen, Yin-Song] Guangzhou Univ Chinese Med, Foshan Hosp Tradit Chinese Med, Clin Med Coll 8, Dept Oncol, 6 Qinren Rd, Foshan 528000, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Li, LP (corresponding author), Guangzhou Univ Chinese Med, Foshan Hosp Tradit Chinese Med, Clin Med Coll 8, Dept Oncol, 6 Qinren Rd, Foshan 528000, Guangdong, Peoples R China.
EM 13794038664@163.com
FU Medical Research Project of Foshan Health Bureau [20240243]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Ahmed M, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.67026
   Ahmed M, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.14817
   Aliabadi T, 2022, EUR J TRANSL MYOL, V32, P0, DOI 10.4081/ejtm.2022.10813
   Bauscherta L, 2022, J MYCOL MED, V32, P0, DOI 10.1016/j.mycmed.2022.101312
   Ben Jabra S, 2023, INT J SURG CASE REP, V106, P0, DOI 10.1016/j.ijscr.2023.108159
   Blask AR, 2021, PEDIATR RADIOL, V51, P1332, DOI 10.1007/s00247-021-04969-1
   Carroll W, 2021, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012619.pub3
   Chen MK, 2012, SAUDI J GASTROENTERO, V18, P225, DOI 10.4103/1319-3767.98420
   Chen PP, 2022, FRONT SURG, V9, P0, DOI 10.3389/fsurg.2022.855904
   Chiang Hsueh-Chien, 2021, RADIOL CASE REP, V16, P2505, DOI 10.1016/j.radcr.2021.05.075
   Chien Tsai-Ju, 2012, J TRADIT COMPLEMENT MED, V2, P204
   De Dyn S, 2023, ACTA CHIR BELG, V123, P699, DOI 10.1080/00015458.2022.2136047
   Doll A, 2023, AM SURGEON, V89, P2803, DOI 10.1177/00031348211054550
   Elzeneini WMA, 2023, PEDIATR INT, V65, P0, DOI 10.1111/ped.15495
   Farooq R, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.36902
   Figueroa-Giralt M, 2022, ABCD-ARQ BRAS CIR DI, V35, P0, DOI 10.1590/0102-672020210002e1654
   Green J, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012798.pub2
   Guo JF, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/2775434
   Hong SM, 2021, DIAGNOSTICS, V11, P0, DOI 10.3390/diagnostics11101842
   Hoter A, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20215331
   Jazayeri-Moghadass BS, 2022, CASE REP NEPHROL DIA, V12, P6, DOI 10.1159/000521350
   Kadhim S, 2018, J ANESTH, V32, P756, DOI 10.1007/s00540-018-2534-4
   Kaneishi K, 2020, J PALLIAT MED, V23, P880, DOI 10.1089/jpm.2020.0101
   Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005
   Li EK, 2024, PLOS PATHOG, V20, P0, DOI 10.1371/journal.ppat.1012609
   Liang JT, 2024, INT J SURG, V110, P1577, DOI 10.1097/JS9.0000000000000980
   Liao FF, 2014, PAIN MED, V15, P1272, DOI 10.1111/pme.12512
   Lim JH, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.914299
   Madariaga A, 2022, SUPPORT CARE CANCER, V30, P4711, DOI 10.1007/s00520-022-06889-8
   Mejri A, 2021, INT J SURG CASE REP, V81, P0, DOI 10.1016/j.ijscr.2021.105814
   Merrill C, 2025, ABDOM RADIOL, V50, P555, DOI 10.1007/s00261-024-04496-1
   MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
   Pan S, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6864195
   Saalabian K, 2022, CHILDREN-BASEL, V9, P0, DOI 10.3390/children9020160
   Schudrowitz N, 2023, J AM COLL SURGEONS, V236, P649, DOI 10.1097/XCS.0000000000000593
   Sugarbaker PH, 2022, J SURG ONCOL, V126, P1462, DOI 10.1002/jso.27087
   Yao F, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8645727
   Zhao ZN, 2023, THER CLIN RISK MANAG, V19, P811, DOI 10.2147/TCRM.S429469
NR 39
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 7
PY 2025
VL 31
IS 41
BP 
EP 
DI 10.3748/wjg.v31.i41.110753
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 9WO7T
UT WOS:001616747800001
PM 41257282
DA 2026-01-16
ER

PT J
AU Liu, XM
   Qi, YX
   Zheng, JY
   Hao, SQ
   Hao, WW
   Du, Y
   Li, WJ
   An, LX
AF Liu, Xu-ming
   Qi, Yu-xuan
   Zheng, Jian-yong
   Hao, Si-qi
   Hao, Wen-wen
   Du, Yi
   Li, Wen-jing
   An, Li-xin
TI Transcutaneous Electrical Acupoint Stimulation Reduces Postoperative Abdominal Pain after Endoscopic Submucosal Dissection: A Single-Center, Prospective, and Randomized Controlled Trial
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article; Early Access
DE transcutaneous electrical acupoint stimulation; endoscopic submucosal dissection; postoperative abdominal pain; randomized controlled trial
ID relief
AB Objective: To evaluate the efficacy of perioperative transcutaneous electrical acupoint stimulation (TEAS) for reducing postoperative abdominal pain in patients after endoscopic submucosal dissection (ESD) for early gastric and esophageal neoplasms. Methods: A total of 129 patients undergoing ESD were assigned randomly to the TEAS group (64 cases) or the sham group (65 cases) using computer-generated random numbers and stratified by the surgical type (i.e., gastric or esophageal ESD). Patients in the TEAS group were treated bilaterally at the acupoints Hegu (LI 4), Neiguan (PC 6), Zusanli (ST 36), and Shangjuxu (ST 37), with the stimulation current frequency 2/100 Hz and intensity to the patient's maximum tolerance level. Patients in the sham group were treated at sham acupoints, and no electrical stimulation was given from the HANS stimulator. The TEAS and sham stimulations are both given from 30 min before ESD to the end of surgery. The primary outcome was the incidence of moderate-to-severe pain within 24 h. Secondary outcomes included the area under the curve (AUC) of Numeric Rating Scale (NRS) pain score from 1 to 48 h, morphine consumption after ESD, intraoperative hemodynamic parameters and postoperative nausea and vomiting (PONV).Results: The incidence of moderate-to-severe pain within 24 h postoperative period was significantly decreased by TEAS [22 (37.9%) vs. 40 (64.5%), P=0.004]. Patients needing morphine were also reduced by TEAS treatment [19 (32.7%) vs. 40 (64.5%), P<0.01]. TEAS significantly decreased the proportion and incidence of PONV compared with the sham group (P=0.06). Intraoperative hemodynamic parameters, recovery of gastrointestinal function, postoperative adverse events were similar between the two groups. According to the results of multivariate logistic regression, TEAS treatment was a protective factor associated with reduced incidence of NRS scores >= 4 (OR=0.227; 95% CI: 0.100 to 0.512; P<0.01), whereas patients undergoing gastric ESD had a much lower incidence of NRS scores >= 4 than esophageal ESD (OR=0.287; 95% CI: 0.133 to 0.621; P=0.002).Conclusions: TEAS can effectively reduce the incidence of moderate-to-severe pain in patients after ESD. TEAS demonstrates an morphine-sparing effect and reduces the occurrence of PONV.
C1 [Liu, Xu-ming; Qi, Yu-xuan; Hao, Si-qi; Hao, Wen-wen; Li, Wen-jing; An, Li-xin] Capital Med Univ, Beijing Friendship Hosp, Dept Anesthesiol, Beijing 100050, Peoples R China.
   [Zheng, Jian-yong] Peking Univ Canc Hosp, Dept Anesthesiol, Beijing 100053, Peoples R China.
   [Du, Yi] Capital Med Univ, Beijing Friendship Hosp, Dept Tradit Chinese Med, Beijing 100050, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP An, LX (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Anesthesiol, Beijing 100050, Peoples R China.
EM anlixin8120@163.com
FU Beijing Municipal Administration of Traditional Chinese Medicine [BJZYQN-2023-22]; Beijing Tongzhou District Science and Technology Program, China [WS2024036]
CR Chang XL, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-04075-9
   Hayashi T, 2017, GASTROINTEST ENDOSC, V86, P358, DOI 10.1016/j.gie.2016.11.032
   Hou LL, 2016, J TRADIT CHIN MED, V36, P450
   Jung DH, 2015, ENDOSCOPY, V47, P1119, DOI 10.1055/s-0034-1392537
   Kim B, 2015, SURG ENDOSC, V29, P714, DOI 10.1007/s00464-014-3730-4
   Kim HI, 2024, J CLIN MED, V13, P0, DOI 10.3390/jcm13113119
   Kim JE, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003593
   Kim JW, 2019, SURG ENDOSC, V33, P794, DOI 10.1007/s00464-018-6345-3
   Kim SY, 2016, DIGEST DIS SCI, V61, P3560, DOI 10.1007/s10620-016-4325-9
   Li D, 2019, CLIN COLON RECT SURG, V32, P138, DOI 10.1055/s-0038-1676480
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Li YJ, 2023, ANAESTH CRIT CARE PA, V42, P0, DOI 10.1016/j.accpm.2023.101273
   Liu Q, 2020, INT J SURG, V73, P28, DOI 10.1016/j.ijsu.2019.11.027
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Luo X, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12051816
   Maple JT, 2015, GASTROINTEST ENDOSC, V81, P1311, DOI 10.1016/j.gie.2014.12.010
   Misumi Y, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10112511
   Pyo JH, 2016, GUT LIVER, V10, P549, DOI 10.5009/gnl15302
   Shah S, 2022, CURR PAIN HEADACHE R, V26, P453, DOI 10.1007/s11916-022-01048-4
   Tanabe S, 2017, GASTRIC CANCER, V20, PS45, DOI 10.1007/s10120-016-0664-7
   Uozumi T, 2023, CLIN ENDOSC, V56, P409, DOI 10.5946/ce.2023.024
   Wang D, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/7570533
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Yu CH, 2024, BIOMEDICINES, V12, P0, DOI 10.3390/biomedicines12081660
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD DEC 15
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1007/s11655-025-3844-7
EA DEC 2025
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA W5324
UT WOS:001639697600001
PM 41396394
DA 2026-01-16
ER

PT J
AU Ma, WG
   Si, YX
   Zhang, YL
   Gao, WF
   Dong, YG
   Li, YQ
   Xu, ZF
   Xi, Q
   Li, ZZ
AF Ma, Wei-Gang
   Si, Yu-Xin
   Zhang, Yong-Long
   Gao, Wei-Fang
   Dong, Yu-Ge
   Li, Yan-Qi
   Xu, Zhi-Fang
   Xi, Qiang
   Li, Zhong-Zheng
TI Combining acupuncture and mesenchymal stem cell therapy offers promise as a
SO World journal of stem cells
LA English
DT Review
DE Acupuncture; Anti-inflammatory; Inflammatory bowel disease; Mesenchymal stem cell; Oxidative stress
AB Inflammatory bowel disease (IBD) is a persistent gastrointestinal ailment driven  by a range of immunological and pathophysiological factors, and often exposes  patients to persistent pain and a greater risk of tumor development. In clinical  settings, sulfasalazine is among the most common treatments used to manage IBD,  but such treatment can result in a range of side effects in addition to leading  to relatively poor efficacy. In certain refractory cases, patients must undergo  surgical resection of affected tissues, underscoring the need to devise safer and  more efficacious forms of alternative treatment. Mesenchymal stem cells (MSCs)  have recently been shown to exhibit been shown to exhibit robust immunomodulatory  activity and potential for differentiation such that they may be an effective  tool for treating IBD. Acupuncture has also shown promise as an efficacious  treatment option for IBD, performing better than drug-based treatments in certain  clinical trials. Acupuncture is capable of enhancing endogenous MSC proliferation  and homing, enabling these cells to more effectively migrate toward target lesion  sites and to promote tissue repair. In light of these findings, this review was  formulated to survey the potential therapeutic advantages of combining MSCs and  acupuncture when attempting to treat IBD.
C1 Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Department of Clinical Practice, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Department of Clinical Practice, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, School of Acupuncture and Tuina, Tianjin 301617,China. lizhzh2008@163.com.
NR 0
TC 0
SN 1948-021
EI 1948-021
J9 World J Stem Cells
PD JUL 31
PY 2025
VL 17
IS 7
BP 105371
EP 105371
DI 10.4252/wjsc.v17.i7.105371
PG 0
UT PubMed:40740536
PM 40740536
DA 2025-07-31
ER

PT J
AU Penati, R
   Vecchio, R
   Gatto, R
   Odone, A
   Deandrea, S
AF Penati, Rachele
   Vecchio, Riccardo
   Gatto, Roberto
   Odone, Anna
   Deandrea, Silvia
TI High Outcome-Reporting Bias in Randomized-Controlled Trials of Acupuncture for Cancer Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Epidemiological Study
SO CURRENT ONCOLOGY
LA English
DT Review
DE bias; complementary therapies; nausea; vomiting; chemotherapy; acupuncture therapy
ID electroacupuncture; pain
AB Selective outcome-reporting bias refers to the selective reporting of a subset of study findings. This methodological limitation may occur in cancer-related acupuncture studies, where valid empirical studies on psychometric performance are still lacking. We assessed the risk of selective outcome reporting bias in studies published in English that were included in a systematic review on acupuncture for preventing cancer chemotherapy-induced nausea and vomiting. For each study, we searched for registry availability and, if present, assessed its validity. We described each study outcome (nausea, vomiting, or both) according to the following seven items: type of outcome, domain, specific measurement, specific metric, type of data, methods of aggregation, and timepoint unit and time. Eleven studies published between 1987 and 2019 in English were evaluated. Only four (36%) had a registry, of which only two were prospective and therefore considered valid. Discrepancies were found in the specific measurement of the outcome in two studies and in the specific metric. In many other cases, discrepancies were not evaluable due to missing information. No study reported complete outcomes as planned in the published protocol. Communication about the importance of prospective trial registration, including outcome details, should be enforced to reduce the risk of selective outcome reporting bias in oncology acupuncture studies.
C1 [Penati, Rachele] Valduce Hosp, Villa Beretta Rehabil Ctr, I-23845 Costa Masnaga, Italy.
   [Penati, Rachele; Gatto, Roberto; Deandrea, Silvia] Ctr So Wen ETS, I-20146 Milan, Italy.
   [Vecchio, Riccardo; Odone, Anna; Deandrea, Silvia] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy.
C3 University of Pavia
RP Deandrea, S (corresponding author), Ctr So Wen ETS, I-20146 Milan, Italy.; Deandrea, S (corresponding author), Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy.
EM silvia.deandrea@unipv.it
CR Beith JM, 2012, MED ACUPUNCT, V24, P241, DOI 10.1089/acu.2012.0876
   Boutron I, 2023, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0
   Brinkhaus B, 2019, BREAST CANCER RES TR, V178, P617, DOI 10.1007/s10549-019-05431-5
   Chen T, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.7242
   Chow YM, 2022, BALI J ANESTH, V6, P1, DOI 10.4103/bjoa.bjoa_153_21
   Decker Georgia M, 2006, J SUPPORT ONCOL, V4, P35
   DUNDEE JW, 1988, BRIT J CLIN PHARMACO, V25, P0
   DUNDEE JW, 1987, LANCET, V1, P1083
   Greville-Harris M, 2016, COMPLEMENT THER MED, V29, P164, DOI 10.1016/j.ctim.2016.10.005
   Herrstedt J, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-023-08219-y
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c365
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li T, 2022, QUAL LIFE RES, V31, P3091, DOI 10.1007/s11136-022-03154-7
   Liu JP, 2013, BMJ OPEN, V3, P0, DOI 10.1136/bmjopen-2013-002968
   Mayo-Wilson E, 2017, J CLIN EPIDEMIOL, V91, P95, DOI 10.1016/j.jclinepi.2017.07.014
   McKeon C, 2015, ACUPUNCT MED, V33, P277, DOI 10.1136/acupmed-2015-010781
   Molassiotis A, 2007, J PAIN SYMPTOM MANAG, V34, P148, DOI 10.1016/j.jpainsymman.2006.10.018
   Nankervis H, 2012, J INVEST DERMATOL, V132, P2727, DOI 10.1038/jid.2012.231
   Odone Anna, 2024, ANN IG, V36, P144, DOI 10.7416/ai.2024.2604
   Page Matthew J, 2021, BMJ, V372, Pn71, DOI 10.1016/j.ijsu.2021.105906
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Saldanha IJ, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0109400
   Saraswati W, 2019, MED ACUPUNCT, V31, P29, DOI 10.1089/acu.2018.1316
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Singh B, 2021, MEDRXIV, V0, P0, DOI DOI 10.1101/2021.03.12.21253378
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Su CX, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-014-0545-5
   Vera-Badillo FE, 2016, EUR J CANCER, V61, P29, DOI 10.1016/j.ejca.2016.03.066
   Vernooij M, 2017, COMPLEMENT THER CLIN, V28, P192, DOI 10.1016/j.ctcp.2017.06.005
   Walker Kate F, 2014, JRSM OPEN, V5, P2042533313517688, DOI 10.1177/2042533313517688
   Yan YQ, 2023, CANCER MED-US, V12, P12504, DOI 10.1002/cam4.5962
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
NR 32
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 1198-0052
EI 1718-7729
J9 CURR ONCOL
JI Curr. Oncol.
PD AUG 15
PY 2025
VL 32
IS 8
BP 
EP 
DI 10.3390/curroncol32080462
PG 13
WC Oncology
SC Oncology
GA 6NC8D
UT WOS:001557308300001
PM 40862831
DA 2026-01-16
ER

PT J
AU Zhu, ZX
   Chen, C
   Zheng, YF
   Gong, WL
   Chen, Z
   Fang, SL
   Shao, DH
   Sun, CX
AF Zhu, Zhi-xin
   Chen, Chen
   Zheng, Yong-feng
   Gong, Wei-li
   Chen, Zheng
   Fang, Shi-lei
   Shao, Dong-hua
   Sun, Cai-xia
TI Buccal Acupuncture Alleviates Postoperative Pain in Patients Undergoing Radical Resection of Gastrointestinal Cancers: A Randomized Controlled Pilot Study
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE buccal acupuncture; gastrointestinal cancers; acupuncture analgesia; postoperative pain; recovery quality; Chinese medicine
ID recovery; surgery; time
AB ObjectiveTo preliminarily investigate the effect of buccal acupuncture therapy on ameliorating postoperative pain and enhancing recovery quality among patients undergoing radical resection of gastrointestinal cancers. MethodsFifty-two participants were randomized at a 1:1 ratio to either the buccal acupuncture or the control group. The acupuncture protocol entailed targeting 5 predetermined acupoints [CA-2 (Upper jiao), CA-3 (Middle jiao), CA-4 (Lower jiao), CA-6 (back), and CA-7 (waist) and two adjustable acupoints [CA-1 (head) and CA-8 (sacrum)] on each side of the face. The outcomes included the Numeric Rating Scale (NRS) scores for each day within 7 days postoperatively, 15-Item Quality of Recovery Scale (QoR-15) scores, analgesics consumption during and after surgery, incidences of postoperative nausea and vomiting, and perioperative levels of interleukin-6 and glucose. Adverse events related to acupuncture were recorded. ResultsOf the initial 52 participants, 46 completed the study and were included in the analysis. Findings indicated that the buccal acupuncture group experienced significantly reduced resting NRS scores in post-anesthesia care unit and throughout the postoperative phase (P=0.001 and P=0.003, respectively), along with enhanced QoR-15 scores on the 3rd postoperative day (P=0.008), compared to the control group. No notable differences were identified in the remaining indicators (P>0.05). ConclusionBuccal acupuncture therapy demonstrated significant effectiveness in reducing postoperative pain and improving recovery quality for patients undergoing radical resection of gastrointestinal cancers, presenting a viable intervention without associated adverse outcomes. (Trial registration No. ChiCTR2200060441)
C1 [Zhu, Zhi-xin; Chen, Chen; Zheng, Yong-feng; Chen, Zheng; Fang, Shi-lei; Shao, Dong-hua; Sun, Cai-xia] Jiangsu Univ, Affiliated Peoples Hosp, Dept Anesthesiol, Zhenjiang 212002, Jiangsu, Peoples R China.
   [Gong, Wei-li] Jiangsu Univ, Affiliated Peoples Hosp, Dept Acupuncture & Moxibust, Zhenjiang 212002, Jiangsu, Peoples R China.
C3 Jiangsu University; Jiangsu University
RP Sun, CX (corresponding author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Anesthesiol, Zhenjiang 212002, Jiangsu, Peoples R China.
EM suncaixia_zj@126.com
FU Chinese Medical Development Plan Projects of Jiangsu Province [MS2021083]; Science and Technology Planning Social Development Project of Zhenjiang City [SH2022071]
CR Baumbach P, 2024, DTSCH ARZTEBL INT, V121, P0, DOI 10.3238/arztebl.m2023.0235
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Chen J, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1232754
   [中国中西医结合学会麻醉专业委员会 Chinese Society of Integrative Anesthesiology], 2021, 中华麻醉学杂志 CHINESE JOURNAL OF ANESTHESIOLOGY, V41, P1159
   Deng WG, 2021, ACUPUNCTURE ELECTRO, V47, P23, DOI 10.3727/036012921X16264625521754
   Ding XH, 2020, MED J NAT DEFEND FOR, V41, P379, DOI 10.16021/J.CNKI.1007-8622.2020.06.012
   Fregoso G, 2019, PAIN PHYSICIAN, V22, P479, DOI 10.36076/ppj/2019.22.479
   Hou YC, 2023, FRONT PSYCHIATRY, V14, P0, DOI 10.3389/fpsyt.2023.1095650
   Ismail SA, 2021, J PAIN RES, V14, P273, DOI 10.2147/JPR.S285322
   Jie Wangjun, 2017, ZHONG NAN DA XUE XUE BAO YI XUE BAN, V42, P517, DOI 10.11817/j.issn.1672-7347.2017.05.006
   [Jie Wangjun 颉旺军], 2016, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE 针灸推拿医学, V14, P131, DOI 10.1007/s11726-016-0913-7
   Kent ML, 2017, J PAIN, V18, P479, DOI 10.1016/j.jpain.2017.02.421
   Kwon OB, 2024, COMPLEMENT THER MED, V82, P0, DOI 10.1016/j.ctim.2024.103035
   Li R, 2022, SHANGHAI J TRADIT CHIN MED, V56, P59, DOI 10.16305/j.1007-1334.2022.2109090
   Liu Guo-Sheng, 2023, ZHONGGUO ZHEN JIU, V43, P743, DOI 10.13703/j.0255-2930.20220903-k0003
   Liu YH, 2023, LANCET REG HEALTH-W, V39, P0, DOI 10.1016/j.lanwpc.2023.100822
   Lv XC, 2023, INT J SURG, V109, P887, DOI 10.1097/JS9.0000000000000360
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, PST1, DOI 10.1089/acm.2010.1610
   Mariano ER, 2022, REGION ANESTH PAIN M, V47, P118, DOI 10.1136/rapm-2021-103083
   Mayhew D, 2019, ANAESTHESIA, V74, P373, DOI 10.1111/anae.14569
   Myles PS, 2018, BRIT J ANAESTH, V120, P705, DOI 10.1016/j.bja.2017.12.037
   Myles PS, 2022, BRIT J ANAESTH, V128, P1029, DOI 10.1016/j.bja.2022.03.009
   Pu RS, 2018, J ACUPUNCT TUINA SCI, V16, P229, DOI 10.1007/s11726-018-1055-x
   Small C, 2020, BJS-BRIT J SURG, V107, PE70, DOI 10.1002/bjs.11477
   Smarr KL, 2011, ARTHRIT CARE RES, V63, PS454, DOI 10.1002/acr.20556
   Strozyk S, 2020, GEBURTSH FRAUENHEILK, V80, P723, DOI 10.1055/a-1157-8996
   [苏丹 Su Dan], 2022, 临床麻醉学杂志 JOURNAL OF CLINICAL ANESTHESTOLOGY, V38, P29
   Usichenko TI, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.0517
   Walker EMK, 2016, BRIT J ANAESTH, V117, P758, DOI 10.1093/bja/aew381
   Wan L, 2020, CHIN J PAINOL, V16, P177
   Wang FH, 2023, CANCER COMMUN, V0, P0, DOI DOI 10.1002/cac2.12516
   Wang XQ, 2022, EXPLORE-NY, V18, P36, DOI 10.1016/j.explore.2021.09.007
   Wang YZ, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1211361
   Wang YZ, 2017, BUCCAL ACUPUNCTURE T, V0, P20
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Yi Y, 2024, J TRADIT CHIN MED, V44, P172, DOI 10.19852/j.cnki.jtcm.20231110.001
   Yue HY, 2023, J PAIN, V24, P2014, DOI 10.1016/j.jpain.2023.06.010
NR 37
TC 1
Z9 1
U1 5
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JUN 15
PY 2025
VL 31
IS 6
BP 558
EP 565
DI 10.1007/s11655-025-4128-y
EA MAR 2025
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 2QM5K
UT WOS:001444344800001
PM 40080251
DA 2026-01-16
ER

PT J
AU Huang, XM
   Cai, HX
   Zeng, W
   Zeng, XQ
   Xiao, XH
   Liu, Y
   Xu, YH
   Liu, XM
   Zhong, QH
AF Huang, Xiaomei
   Cai, Hanxue
   Zeng, Wen
   Zeng, Xueqin
   Xiao, Xinhong
   Liu, Yi
   Xu, Yanhong
   Liu, Xiaomei
   Zhong, Qinghua
TI Effect of auricular point acupressure combined with three-step analgesic therapy on cancer pain
SO SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO
LA English
DT Article
DE cancer pain; pain relief; auricular point pressing; three-step analgesic therapy
AB Introduction/Objective The objective was to evaluate the effect of auricular point pressing with beans combined with three-step analgesic therapy on cancer pain. Methods Sixty patients with cancer admitted to the Ganzhou Cancer Hospital from January to December 2021 were selected and randomly divided into experimental and control groups. The control group received three-step pain relief and routine care, while the experimental group was treated with auricular point acupressure combined with three-step analgesic therapy. The pain intensity was assessed by a numerical rating scale (NRS) at 0, 24, 48, and 72 h after treatment, and the incidence of adverse reactions was recorded. Results The NRS score of the experimental group was lower than that of the control group (Ftreatment = 105.521, p = 0.001). The difference in NRS scores before and 24, 48, and 72 h after treatment was statistically significant (Ftime = 335.521, p = 0.001). The number of eruption pain cases in the experimental group and the control group was found to be statistically significant (chi 2= 10.767, p = 0.001), and the occurrence of eruption pain in the control group was more severe than that in the experimental group (Z = -4.472, p = 0.001). The incidence of adverse reactions in the experimental and control groups was 3.33% and 30%, respectively, and the difference was statistically significant (chi 2= 12.738, p = 0.001). Conclusion The combination of auricular point pressing and three-step ladder analgesic therapy can significantly improve the pain of cancer patients.
C1 [Huang, Xiaomei; Cai, Hanxue; Zeng, Xueqin; Xiao, Xinhong; Liu, Yi; Xu, Yanhong] Ganzhou Canc Hosp, Dept Nursing, Ganzhou, Peoples R China.
   [Zeng, Wen; Liu, Xiaomei; Zhong, Qinghua] Ganzhou Canc Hosp, Dept Head & Neck Surg, 19 Huayuan Qian Rd, Ganzhou 341000, Peoples R China.
RP Zhong, QH (corresponding author), Ganzhou Canc Hosp, Dept Head & Neck Surg, 19 Huayuan Qian Rd, Ganzhou 341000, Peoples R China.
EM ping2023liu@163.com
FU Jiangxi Provincial Administration of Traditional Chinese Medicine [2020A0249]
CR Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Chen Y, 2020, MED. RECAPITUL., V26, P4112, DOI 10.1007/s11655-020-2850-z
   Chen Z, 2008, CHIN TCM MOXIBUST, V5, P392
   Corli O, 2019, CANCER MANAG RES, V11, P10337, DOI 10.2147/CMAR.S211818
   Fallon M, 2022, ANN ONCOL, V33, P1296, DOI 10.1016/j.annonc.2022.08.083
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Finkelstein S, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07694-7
   Fu QW, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05138-3
   Hansen JL, 2023, J CANCER SURVIV, V17, P646, DOI 10.1007/s11764-023-01354-9
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Jia PP, 2022, J MOD MED ONCOL, V30, P2097
   Jiang SL, 2023, TECHNOL HEALTH CARE, V31, P1119, DOI 10.3233/THC-220660
   Kawi J, 2024, COMPLEMENT THER MED, V81, P0, DOI 10.1016/j.ctim.2024.103030
   Li J, 2019, NURS PRACT RES, V16, P35
   Alarcón MDL, 2019, J GERIATR ONCOL, V10, P643, DOI 10.1016/j.jgo.2019.03.012
   Lou F, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000031826
   [鲁莹 Lu Ying], 2022, 中国病理生理杂志 CHINESE JOURNAL OF PATHOPHYSIOLOGY, V38, P364
   Lukkahatai N, 2024, PLOS ONE, V19, P0, DOI 10.1371/journal.pone.0311135
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W
   Sun JH, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0863-5
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   van de Castle B, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231198086
   Wu Y, 2016, J PLA NURS, V33, P1
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Yeh CH, 2014, HOLIST NURS PRACT, V28, P184, DOI 10.1097/HNP.0000000000000027
   Zhang Z, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000032310
   Zheng Xiaochun, 2017, ZHONGGUO ZHEN JIU, V37, P869, DOI 10.13703/j.0255-2930.2017.08.017
NR 30
TC 0
Z9 0
U1 3
U2 3
PU SRPSKO LEKARSKO DRUSTVO
PI BEOGRAD
PA UREDNISTVO CASOPISA SRPSKI ARHIV, UL DZORDZA VASINGTONA 19, BEOGRAD, 11000, SERBIA
SN 0370-8179
EI 
J9 SRP ARK CELOK LEK
JI Srp. Ark. Celok. Lek.
PD MAR-APR 15
PY 2025
VL 153
IS 3-4
BP 187
EP 192
DI 10.2298/SARH240919022H
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 4SJ4F
UT WOS:001525533500005
DA 2026-01-16
ER

PT J
AU Ge, XB
   Yue, GL
   Du, GZ
   Fang, X
AF Ge, Xiaobin
   Yue, Gonglei
   Du, Guangzhong
   Fang, Xue
TI Tiny needles, major benefits: acupuncture in child health
SO BMC PEDIATRICS
LA English
DT Article
DE Complementary and alternative medicine; Acupuncture therapy; Pediatrics; Disease spectrum; General Hospital
ID encephalitis; pain; management; attitudes; safety; stroke; ileus
AB ObjectiveTo retrospectively investigate the utilization patterns and clinical indications of acupuncture within the pediatric population in general hospitals from 2015 to 2020, including disease spectrum characteristics and relevance to pediatric subspecialties.MethodsThe clinical data of pediatric inpatients consulted by Acupuncture-Moxibustion and Tuina Department of Qilu Hospital of Shandong University was collected from January 1, 2015, to December 31, 2020. The data collected include the number of wards in which consultation was requested, the diseases that require consultation, the distribution of pediatric tertiary disciplines and the system of disease affiliation.ResultsThis study summarizes 55 types of pediatric diseases treated with acupuncture. The most common health issues addressed include peripheral facial paralysis, diarrhea, reduced limb mobility or decreased muscle strength, postoperative bloating, and Guillain-Barr & eacute; syndrome. Acupuncture is utilized across all pediatric subdisciplines, with notable applications in neurology, critical care medicine, general surgery, respiratory medicine, and orthopedics. The classification of diseases for acupuncture consultations primarily focuses on disorders of the nervous system, respiratory system, neoplasms, and digestive system (according to ICD-11).ConclusionsIn summary, acupuncture has a broad range of applications in the treatment of pediatric diseases and can serve as a valuable complementary and alternative therapy. The advancement of Traditional Chinese Medicine (TCM) acupuncture in general hospitals is closely linked to the involvement of pediatric practices. The findings of this study provide valuable insights for clinical practice, acupuncture education, pediatric healthcare systems, and social research.
C1 [Ge, Xiaobin; Yue, Gonglei; Du, Guangzhong] Shandong Univ, Qilu Hosp, Dept Acupuncture Moxibust & Tuina, Jinan, Peoples R China.
   [Fang, Xue] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Acupuncture, 42 Wenhua West Rd, Jinan 250011, Shandong, Peoples R China.
C3 Shandong University; Shandong University of Traditional Chinese Medicine
RP Fang, X (corresponding author), Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Acupuncture, 42 Wenhua West Rd, Jinan 250011, Shandong, Peoples R China.
EM fangxue0912@163.com
CR Abdullahi AM, 2020, CUREUS J MED SCIENCE, V12, P0, DOI 10.7759/cureus.11174
   Brittner M, 2016, CURR PROB PEDIATR AD, V46, P179, DOI 10.1016/j.cppeds.2015.12.005
   Carville S, 2012, BMJ-BRIT MED J, V345, P0, DOI 10.1136/bmj.e5765
   Chen YC, 2023, COMPLEMENT THER MED, V78, P0, DOI 10.1016/j.ctim.2023.102988
   Deng JJ, 2017, AM J CHINESE MED, V45, P737, DOI 10.1142/S0192415X17500392
   Ecevit A, 2011, J TRADIT CHIN MED, V31, P308, DOI 10.1016/S0254-6272(12)60009-0
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Franca RFO, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0628-1
   Ge Xiaobin, 2018, ZHONGGUO ZHEN JIU, V38, P211, DOI 10.13703/j.0255-2930.2018.02.029
   Gilbey P, 2015, PEDIATR ANESTH, V25, P603, DOI 10.1111/pan.12621
   Gold JI, 2009, EVID-BASED COMPL ALT, V6, P429, DOI 10.1093/ecam/nem181
   Gottschling S, 2008, PAIN, V137, P405, DOI 10.1016/j.pain.2007.10.004
   [胡琳娜 Hu Linna], 2010, 中国组织工程研究与临床康复 JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH, V14, P8662
   Keefe KR, 2018, LARYNGOSCOPE, V128, P2625, DOI 10.1002/lary.27231
   Kelly D, 2013, ADV EXP MED BIOL, V764, P133, DOI 10.1007/978-1-4614-4726-9_10
   Kim KS, 2006, PEDIATR ANESTH, V16, P1036, DOI 10.1111/j.1460-9592.2006.01927.x
   Lai SR, 2025, CLIN PEDIATR, V64, P719, DOI 10.1177/00099228241283279
   Li PP, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0121880
   Lima-De Armas B, 2016, REV NEUROLOGIA, V62, P239, DOI 10.33588/rn.6205.2015497
   Lin RH, 2017, EXP THER MED, V14, P2373, DOI 10.3892/etm.2017.4750
   Lin Y, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023953
   Mano KEJ, 2009, J ALTERN COMPLEM MED, V15, P661, DOI 10.1089/acm.2008.0449
   Piao HL, 2023, NEUROREHABILITATION, V53, P161, DOI 10.3233/NRE-230006
   Pintov S, 1997, PEDIATR NEUROL, V17, P129, DOI 10.1016/S0887-8994(97)00086-6
   Romero-García PA, 2024, HEALTHCARE-BASEL, V12, P0, DOI 10.3390/healthcare12151547
   Sertel S, 2009, EUR ARCH OTO-RHINO-L, V266, P919, DOI 10.1007/s00405-008-0851-1
   Skjeie H, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2015-009486
   [孙超 Sun Chao], 2021, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V62, P1343
   Tan L, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6611461
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
   Vather R, 2014, CLIN EXP PHARMACOL P, V41, P358, DOI 10.1111/1440-1681.12220
   Wang SY, 2017, MED ACUPUNCT, V29, P322, DOI 10.1089/acu.2017.1231
   Wen H, 1900, V06, V0, P92
   Wu S, 2009, PEDIATR CRIT CARE ME, V10, P291, DOI 10.1097/PCC.0b013e318198afd6
   Xu Kai-Sheng, 2014, ZHONGGUO ZHEN JIU, V34, P529
   Yan TB, 2009, J REHABIL MED, V41, P312, DOI 10.2340/16501977-0325
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Yao Y, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5549006
   Zhao JG, 2009, J NEUROL SCI, V276, P143, DOI 10.1016/j.jns.2008.09.018
   Ziodeen KA, 2018, COMPLEMENT THER MED, V37, P133, DOI 10.1016/j.ctim.2018.02.004
NR 41
TC 0
Z9 0
U1 2
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD APR 14
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12887-025-05586-9
PG 8
WC Pediatrics
SC Pediatrics
GA 1NW6K
UT WOS:001469477000003
PM 40223074
DA 2026-01-16
ER

PT J
AU Huang, H
   Su, M
   Liu, F
   Long, WB
AF Huang, Heng
   Su, Min
   Liu, Fei
   Long, Wenbo
TI Combination of acupoint herbal plaster and ear acupuncture for effective pain relief in patients after laparoscopic appendectomy
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Laparoscopic appendectomy; moxibustion/partitioned moxibustion; ear acupuncture; acute appendicitis; analgesia
ID cancer pain; appendicitis; metaanalysis; moxibustion; efficacy; points
AB Laparoscopic appendectomy effectively treats appendicitis and other related conditions. However, postoperative pain remains a major concern. This study elucidates the effect of traditional Chinese medicine (TCM) therapies on postoperative recovery of patients who had undergone laparoscopic appendectomy. The study encompassed 262 patients, including 41 controls and 221 TCM-treated patients. Quality control was monitored by two senior TCM physicians and one researcher. Postoperative outcomes included the length of hospitalization, antibiotic use, pain, analgesia and plasma drainage. No significant differences were observed between the groups concerning sex, age, acute appendicitis, postoperative complications and plasma drainage, except for pain and analgesia (both P<0.001). Moxibustion or partitioned moxibustion alone had no effect, compared with the control; however, ear acupuncture alone, acupoint herbal plaster + ear acupuncture, acupoint herbal plaster + moxibustion/partitioned moxibustion and acupoint herbal plaster + ear acupuncture + moxibustion/partitioned moxibustion exerted a significant effect. Pain index and analgesia duration were significantly lower for ear acupuncture alone than in the control group but remained higher than in the three acupoints herbal plaster-treated groups. The combination of acupoint herb plaster and ear acupuncture provided greater pain relief than ear acupuncture alone.
C1 [Huang, Heng; Liu, Fei] Southwest Med Univ, Affiliated Tradit Chinese Med Hosp, Dept Gen Surg, Hernia & Abdominal Wall Surg, Luzhou 646000, Sichuan, Peoples R China.
   [Su, Min] Southwest Med Univ, Affiliated Hosp, Ophthalmol Dept, Luzhou, Peoples R China.
   [Long, Wenbo] Southwest Med Univ, Affiliated Hosp, Pathol Dept, Luzhou, Peoples R China.
C3 Southwest Medical University; Southwest Medical University; Southwest Medical University
RP Long, WB (corresponding author), Southwest Med Univ, Affiliated Hosp, Pathol Dept, Luzhou, Peoples R China.
EM wenbolong@swmu.edu.cn
CR Athanasiou C, 2017, WORLD J SURG, V41, P3083, DOI 10.1007/s00268-017-4123-3
   Chae Y, 2013, J PAIN, V14, P215, DOI 10.1016/j.jpain.2012.11.011
   Chitnis SS, 2020, KOREAN J ANESTHESIOL, V73, P363, DOI 10.4097/kja.20323
   Doleman B, 2023, BRIT J ANAESTH, V130, P719, DOI 10.1016/j.bja.2023.02.041
   Faria M, 2024, J INTEGR MED-JIM, V22, P235, DOI 10.1016/j.joim.2024.03.002
   Gu QQ, 2023, J MINIM ACCESS SURG, V19, P348, DOI 10.4103/jmas.jmas_158_22
   HINES R, 1992, ANESTH ANALG, V74, P503
   Humes DJ, 2006, BMJ-BRIT MED J, V333, P530, DOI 10.1136/bmj.38940.664363.AE
   Jan AL, 2017, MED ACUPUNCT, V29, P276, DOI 10.1089/acu.2017.1237
   Li Y, 2023, J PAIN RES, V16, P515, DOI 10.2147/JPR.S396696
   Li Y, 2017, J CANCER RES THER, V13, P844, DOI 10.4103/jcrt.JCRT_709_17
   Liu W, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e25268
   Liu XL, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/657809
   Ma FJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021253
   Qingyi Z, 2021, J TRADIT CHIN MED, V41, P985, DOI 10.19852/j.cnki.jtcm.2021.06.017
   Ren ZQ, 2019, PAK J PHARM SCI, V32, P1375
   Shi YN, 2020, J IMMUNOL RES, V2020, P0, DOI 10.1155/2020/2383970
   Shou Y, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-4039-3
   Vas J, 2019, ACTA OBSTET GYN SCAN, V98, P1307, DOI 10.1111/aogs.13635
   Wang F, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021817
   Wang H, 2024, J. VIS. EXP., V18, P212
   Wang SY, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i39.5997
   Woo A, 2015, ANN PALLIAT MED, V4, P176, DOI 10.3978/j.issn.2224-5820.2015.09.04
   Yang MX, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.878371
   Yang MX, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170952
   Yi MM, 2024, ARCH ESP UROL, V77, P732, DOI 10.56434/j.arch.esp.urol.20247707.102
   Yu SY, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-018-2682-8
NR 27
TC 0
Z9 0
U1 5
U2 5
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
EI 
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD JUL-AUG 15
PY 2025
VL 38
IS 4
BP 
EP 
DI 10.36721/PJPS.2025.38.4.REG.13887.1
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 7GS4K
UT WOS:001570618900003
PM 40824014
DA 2026-01-16
ER

PT J
AU Huang, J
   Zhao, L
   Xie, Y
   Wang, C
   Yang, X
   Huang, H
   Zhang, D
AF Huang, Jianhao
   Zhao, LiuYang
   Xie, YuFeng
   Wang, Chi
   Yang, XinJing
   Huang, HaiFu
   Zhang, Dian
TI Investigating the Analgesic Mechanisms of Acupuncture for Cancer Pain: Insights
SO Journal of pain research
LA English
DT Journal Article
DE acupuncture; analgesic mechanism; cancer pain; deep learning; multimodal bioelectrical signals
AB PURPOSE: Cancer pain management remains a significant clinical challenge. While  acupuncture has shown potential in alleviating cancer pain, its underlying  mechanisms are not yet fully understood. This study investigates the  neurophysiological mechanisms underlying acupuncture's analgesic effects using  multimodal bioelectrical signal analysis. PATIENTS AND METHODS: Fifteen cancer  pain patients underwent acupuncture while wearing portable, multi-sensor devices  to capture bioelectrical signals. Pain levels were assessed using the Numerical  Rating Scale (NRS) before and during needle retention. Neurophysiological changes  were evaluated using Principal Component Analysis, Joint Time-Frequency Analysis,  power spectrum analysis, spectral analysis, and dynamic functional network  analysis. RESULTS: There was a significant reduction in NRS scores from  pre-treatment to the retention period, indicating pain relief. Principal  component analysis showed significant differences in bioelectrical signals  between these periods. Power spectrum analysis revealed decreased signal power  during retention. Functional network analysis demonstrated a reduction in  connectivity strength between electroencephalography and electromyography  signals. Spectral analysis identified distinct real-time and staged  characteristics of bioelectrical signals, with correlation analysis confirming a  positive relationship between NRS score changes and bioelectrical signal  alterations. CONCLUSION: Acupuncture alleviates cancer pain by reducing  functional connectivity between injured tissues and the brain, with immediate  effects. Prolonging needle retention may enhance therapeutic outcomes. These  findings provide new insights into the neurophysiological basis of acupuncture's  analgesic effects, supporting its role in cancer pain management.
C1 Department of Acupuncture and Moxibustion, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
   School of Computer and Software, Shenzhen University, Shenzhen, People's Republic of China.
   Department of Acupuncture and Moxibustion, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
   Faculty of Chinese Medicine and State Key Laboratory of Quality Research in 
   , Ganzhou Traditional Chinese Medicine Hospital, Ganzhou, People's Republic of China.
   Department of Acupuncture and Moxibustion, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
   Department of Acupuncture and Moxibustion, Shenzhen Hospital (Fu Tian) of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
   School of Computer and Software, Shenzhen University, Shenzhen, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD MAR 25
PY 2025
VL 18
IS 
BP 1435
EP 1450
DI 10.2147/JPR.S503975
PG 15
UT PubMed:40130202
PM 40130202
DA 2025-03-25
ER

PT J
AU Bulut, ÖÖ
   Özmen, M
   Al, Ali F
   Shaukat, I
   Bağcıer, F
AF Bulut, Özge Özpolat
   Özmen, Mevlüt
   Al Ali, Faisal
   Shaukat, Ismael
   Bağcıer, Fatih
TI Academic and societal impact of cancer pain research: a bibliometric and
SO Pain management
LA English
DT Journal Article
DE Cancer pain; altmetric analysis; bibliometric analysis; citation; social impact
AB BACKGROUND: Cancer-related pain affects quality of life despite advancements in  management. Bibliometric and altmetric analyses provide insights into the  academic and societal impact of research. OBJECTIVE: This study analyzed the top  100 most-cited articles on cancer-related pain using bibliometric and altmetric  indicators, exploring correlations between altmetric scores, citations per year,  and total citations. METHODS: A search of the Web of Science Core Collection  database was conducted on 2 November 2024, to identify articles related to cancer  pain published between 1975 and 2024. The top 100 most-cited articles were  selected based on total citation counts. Only English-language articles with  full-text access were included. Bibliometric data were collected. Altmetric  scores were retrieved using the Altmetric Explorer platform, and correlations  were assessed using Spearman's test. RESULTS: The 100 most-cited articles  appeared in 35 journals, with PAIN contributing the most (n = 19). Total  citations and citations per year showed a strong correlation (r = 0.64), but the  correlation between altmetric scores and total citations was weak (r = 0.18).  CONCLUSION: This study highlights the academic and societal impact of cancer pain  research. The weak correlation between citations and altmetric scores suggests a  need for better dissemination strategies to enhance public engagement.
C1 Clinic of Physical Medicine and Rehabilitation, Viransehir State Hospital, Sanliurfa, Turkey.
   Internal Medicine Residency Program, Rosalind Franklin University, Northwestern McHenry Hospital, McHenry, IL, USA.
   Internal Medicine Residency Program, Rosalind Franklin University, Northwestern McHenry Hospital, McHenry, IL, USA.
   Department of Medical Oncology, Northwestern McHenry Hospital Cancer Center, McHenry, IL, USA.
   Department of Physical Medicine and Rehabilitation, University of Health Sciences, Başakşehir çam and Sakura City Hospital, İstanbul, Turkey.
NR 0
TC 0
SN 1758-187
EI 1758-186
J9 Pain Manag
PD JUL 18
PY 2025
VL 15
IS 10
BP 693
EP 702
DI 10.1080/17581869.2025.2535270
PG 9
WC Bibliometrics; Humans; Cancer Pain; Biomedical Research; statistics & numerical data; Journal Impact Factor
UT PubMed:40678869
PM 40678869
DA 2025-07-18
ER

PT J
AU Qu, JY
   Peng, YC
   Shen, XF
   Xiong, J
   Wang, H
   Xiao, X
   Wang, YL
AF Qu, Jinyu
   Peng, Yingchun
   Shen, Xuefang
   Xiong, Jin
   Wang, Huan
   Xiao, Xiang
   Wang, Yili
TI Electroacupuncture of Guanyuan (CV4) Acupoint Improved Pelvic Inflammatory Disease Pain by Inhibiting Neuroinflammation and Sympathetic Activity
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article
DE electroacupuncture; Guanyuan acupoint; neuroinflammation; pelvic inflammatory disease; sympathetic activity
ID acupuncture; sensitization; mechanisms
AB Objective To investigate the underlying mechanisms through which electroacupuncture (EA) at the Guanyuan (CV4) acupoint inhibits sympathetic activity and neurogenic inflammatory responses to relieve pain in rats with pelvic inflammatory disease (PID). Methods Escherichia coli and Staphylococcus aureus were used to establish a PID rat model. EA was evaluated at frequencies of 2, 100, and 2/100 Hz, and 2/100 Hz was selected for subsequent investigation. The rats were randomly divided into the control, model, EA-guanyuan (2/100 Hz), and EA-nonsensitized groups (n = 6). Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were assessed using von Frey filaments. Hematoxylin and eosin staining was performed to evaluate the histopathology. The tyrosine hydroxylase (TH) expression was analyzed using immunofluorescence (IF) staining. The levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), transforming growth factor-beta 1 (TGF-beta 1), intercellular cell adhesion molecule-1 (ICAM-1), 5-hydroxytryptamine receptor 3 (5-HT3R), substance P (SP), hyaluronic acid (HA), and bradykinin (BK) were measured using an enzyme-linked immunosorbent assay (ELISA). Western blot analysis was performed to measure the expression of 5-HT3R, calcitonin gene-related peptide (CGRP), HA, Kininogen 1 (KNG1), prostaglandin I2 (PGI2), and trefoil factor 2 (TFF2). Transmission electron microscopy (TEM) was used to observe synaptic connections. Results EA at CV4 reduced the behavioral pain score (p < 0.05), increased MWT and TWL, and alleviated uterine tissue pathological damage in rats. EA at CV4 reduced the levels of 5-HT3R, CGRP, BK, HA, KNG1, PGI2SP, TGF-beta 1, ICAM-1, and TNF-alpha, and increased IL-2 levels (p < 0.05). Furthermore, EA at CV4 inhibited sympathetic activity by decreasing TH expression (p < 0.05). Additionally, EA at CV4 restored the synaptic connections between the pelvic nerves of the dorsal commissural neuron (DCN). Conclusion EA at CV4 alleviated the pathological damage and pain sensitization of uterine tissue in rats with PID by inhibiting sympathetic activity and neurogenic inflammatory response.
C1 [Qu, Jinyu; Peng, Yingchun; Shen, Xuefang; Xiong, Jin] Chengdu Med Coll, Affiliated Hosp 1, Dept Neurol, Chengdu, Peoples R China.
   [Wang, Huan; Wang, Yili] Chengdu Med Coll, Affiliated Hosp 1, Dept Rehabil Med, Chengdu, Peoples R China.
   [Xiao, Xiang] Chengdu Med Coll, Affiliated Hosp 1, Dept Nephrol, Chengdu, Peoples R China.
C3 Chengdu Medical College; Chengdu Medical College; Chengdu Medical College
RP Wang, YL (corresponding author), Chengdu Med Coll, Affiliated Hosp 1, Dept Rehabil Med, Chengdu, Peoples R China.; Xiao, X (corresponding author), Chengdu Med Coll, Affiliated Hosp 1, Dept Nephrol, Chengdu, Peoples R China.
EM 301397@cmc.edu.cn; wangyili@cmc.edu.cn
FU This study was supported by medical research project plan of Sichuan Province (S21099) and medical research project plan of Chengdu (2023382).
CR Unknown -, 1991, LABORATORY ANIMALS AND ANIMAL EXPERI (CHINESE), V0, P0
   Brunham RC, 2015, NEW ENGL J MED, V372, P2039, DOI 10.1056/NEJMra1411426
   Chen M, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.882214
   Cui X, 2023, J PAIN RES, V16, P2997, DOI 10.2147/JPR.S424841
   Cui X, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.822436
   DCosta VM, 2011, NATURE, V477, P457, DOI 10.1038/nature10388
   Doménech-García V, 2016, PAIN, V157, P1164, DOI 10.1097/j.pain.0000000000000497
   Engel M, 2013, FRONT CELL NEUROSCI, V7, P0, DOI 10.3389/fncel.2013.00076
   Favoni V, 2019, J HEADACHE PAIN, V20, P0, DOI 10.1186/s10194-019-0979-y
   Gao XY, 2021, PAIN, V162, P1068, DOI 10.1097/j.pain.0000000000002096
   Gomez R, 2011, PAIN, V152, P1548, DOI 10.1016/j.pain.2011.02.044
   Gustafsson JK, 2011, AM J PHYSIOL-GASTR L, V300, PG1080, DOI 10.1152/ajpgi.00349.2010
   Hillier SL, 2021, J INFECT DIS, V224, PS23, DOI 10.1093/infdis/jiab116
   Ji BY, 2017, BIOMED PHARMACOTHER, V94, P1057, DOI 10.1016/j.biopha.2017.08.042
   Ji H, 2022, GUIZHOU MED J (CHINESE), V46, P296
   Kanda H, 2017, ENEURO, V4, P0, DOI 10.1523/ENEURO.0064-17.2017
   KEEGAN JJ, 1948, ANAT RECORD, V102, P409, DOI 10.1002/ar.1091020403
   Kim DH, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-14359-z
   Li X, 2013, CHIN J EXP TRADIT MED FORM (CHINESE), V19, P225
   Liang Zhuo, 2021, ZHONGGUO ZHEN JIU, V41, P395, DOI 10.13703/j.0255-2930.20200329-k0003
   Lin YT, 2011, J NEUROINFLAMM, V8, P0, DOI 10.1186/1742-2094-8-126
   Lin YW, 2022, BRAIN BEHAV IMMUN, V100, P8, DOI 10.1016/j.bbi.2021.11.008
   Liu J, 2013, PURINERG SIGNAL, V9, P463, DOI 10.1007/s11302-013-9367-2
   Liu LZ, 2016, COMPLEMENT THER MED, V26, P28, DOI 10.1016/j.ctim.2016.02.013
   Liu ZF, 2018, HENAN TRADIT CHIN MED (CHINESE), V38, P1747
   Ozel S, 2011, ACUPUNCT MED, V29, P317, DOI 10.1136/acupmed-2011-010080
   Petrey AC, 2014, FRONT IMMUNOL, V5, P0, DOI 10.3389/fimmu.2014.00101
   Qin C, 2010, AM J PHYSIOL-GASTR L, V298, PG934, DOI 10.1152/ajpgi.00312.2009
   Ravel J, 2021, AM J OBSTET GYNECOL, V224, P251, DOI 10.1016/j.ajog.2020.10.019
   Savaris RF, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010285.pub3
   Schlievert PM, 2022, MICROBIOL SPECTR, V10, P0, DOI 10.1128/spectrum.00106-22
   Soper DE, 2010, OBSTET GYNECOL, V116, P419, DOI 10.1097/AOG.0b013e3181e92c54
   [王飞 Wang Fei], 2014, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V20, P304
   Wang YH, 2023, NEURAL PLAST, V2023, P0, DOI 10.1155/2023/8510213
   Wang YL, 2019, NEUROPEPTIDES, V77, P0, DOI 10.1016/j.npep.2019.101957
   Wu Dan, 2018, ZHEN CI YAN JIU, V43, P57, DOI 10.13702/j.1000-0607.160661
   [吴强 Wu Qiang], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P2001
   Wu Song, 2018, ZHONGGUO ZHEN JIU, V38, P1267, DOI 10.13703/j.0255-2930.2018.12.004
   Xu C, 2022, J TRADIT CHIN MED, V42, P965, DOI 10.19852/j.cnki.jtcm.20220928.003
   Yamakita S, 2023, MOL PAIN, V19, P0, DOI 10.1177/17448069231181973
   Yang Y, 2024, CHIN J INTEGR MED, V30, P152, DOI 10.1007/s11655-023-3565-8
   Yi YJ, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22041974
   Zeilhofer HU, 2012, ANNU REV PHARMACOL, V52, P111, DOI 10.1146/annurev-pharmtox-010611-134636
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2018, CHIN MED-UK, V13, P0, DOI 10.1186/s13020-018-0217-6
   Zhang ZY, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.812587
   Zheng XJ, 2018, J IMMUNOL, V200, P2941, DOI 10.4049/jimmunol.1701658
   Zieglgänsberger W, 2019, CELL TISSUE RES, V375, P227, DOI 10.1007/s00441-018-2922-y
   Zou W, 2021, J ETHNOPHARMACOL, V266, P0, DOI 10.1016/j.jep.2020.113405
NR 49
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 
EI 2050-4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
PD NOV 5
PY 2025
VL 13
IS 11
BP 
EP 
DI 10.1002/iid3.70299
PG 12
WC Immunology
SC Immunology
GA 9ME1X
UT WOS:001609664800001
PM 41194515
DA 2026-01-16
ER

PT J
AU Wang, Z
   Liu, C
   Pei, W
   Zhang, T
   Zhang, J
   Fan, W
   Wei, X
   Tu, J
   Wang, X
   Yang, N
AF Wang, Ze-Yi
   Liu, Cun-Zhi
   Pei, Wei
   Zhang, Tian-Zhen
   Zhang, Jing
   Fan, Wen-Wen
   Wei, Xiao-Ya
   Tu, Jian-Feng
   Wang, Lu
   Wang, Xu
   Yang, Na-Na
TI Investigating the efficacy of electroacupuncture for postoperative ileus in patients with colorectal cancer: study protocol for a multicentre clinical trial with neuroimaging assessment
SO BMJ Open
LA English
DT Article
DE Acupuncture; Colorectal surgery; COMPLEMENTARY MEDICINE; Functional bowel disorders; Functional Magnetic Resonance Imaging; Motility disorders
ID adult; adverse event; china; colorectal tumor; diagnostic imaging; electroacupuncture; etiology; female; human; ileus; laparoscopy; male; middle aged; multicenter study (topic); neuroimaging; nuclear magnetic resonance imaging; postoperative complication; procedures; randomized controlled trial (topic); surgery; therapy; treatment outcome; adult; colorectal neoplasms; electroacupuncture; female; humans; ileus; laparoscopy; magnetic resonance imaging; male; middle aged; multicenter studies as topic; neuroimaging; postoperative complications; randomized controlled trials as topic; treatment outcome
AB INTRODUCTION: Postoperative ileus (POI) is a prevalent complication following abdominal surgeries, significantly compromising patients' quality of life and imposing a socioeconomic burden. Electroacupuncture (EA), a widely used therapeutic approach in China, has shown promise as an effective intervention for POI. However, the neural mechanism underlying its therapeutic effects remains unclear. Thus, this study aims to evaluate the efficacy of EA treatment for POI and investigate its central mechanism by functional MRI (fMRI). METHODS AND ANALYSIS: This randomised controlled clinical trial will be conducted across three hospitals in China. A total of 50 eligible patients with colorectal cancer scheduled for elective laparoscopic surgery will be randomly assigned to either the EA or sham electroacupuncture (SA) group in a 1:1 ratio. All patients will undergo 5 sessions of 30 min EA or SA over 5 consecutive days post-surgery (once daily). Resting-state fMRI (rs-fMRI) scans will be performed at baseline and the end of treatment to examine brain functional changes related to EA treatment. The primary outcome is the time to first defecation. Secondary outcomes include the time to first flatus, ambulation, tolerability of semiliquid and solid food; length of postoperative hospital stay; severity of postoperative pain, abdominal distension and nausea; frequency of postoperative nausea and vomiting episodes; rate of readmission. Postoperative complications will be monitored and documented throughout the trial duration. Credibility and expectancy evaluation, along with blinding assessment, will be conducted after the first treatment session. Pearson/Spearman correlation analysis will be performed to determine the relationship between clinical variables and rs-fMRI metrics. ETHICS AND DISSEMINATION: This protocol has been approved by the ethics committees of Beijing University of Chinese Medicine (number 2024BZYLL0113), Cancer Hospital Chinese Academy of Medical Sciences (number 24/323-4603), Beijing Friendship Hospital Affiliated to Capital Medical University (number 2024-P2-081-01) and Beijing Chaoyang Huanxing Cancer Hospital (number 2024-011-02). Participants will sign the paper-based informed consent form before enrolment. The results will be disseminated through peer-reviewed publications. TRIAL REGISTRATION NUMBER: ITMCTR2024000504. © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
C1 Beijing University of Chinese Medicine, Wang, Zeyi, School of Acupuncture-Moxibustion and Tuina, Beijing, China
   Beijing University of Chinese Medicine, Liu, Cunzhi, School of Acupuncture-Moxibustion and Tuina, Beijing, China
   Pei, Wei, Department of Colorectal Surgery, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
   Capital Medical University, Zhang, Tianzhen, Department of General Surgery, Beijing, China, Beijing, China, Beijing, China
   Huanxing Cancer Hospital, Zhang, Jing, Department of Surgery, Beijing, Beijing, China
   Fan, Wenwen, Department of Radiology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
   Beijing University of Chinese Medicine, Wei, Xiaoya, School of Acupuncture-Moxibustion and Tuina, Beijing, China
   Beijing University of Chinese Medicine, Tu, Jianfeng, School of Acupuncture-Moxibustion and Tuina, Beijing, China
   Beijing University of Chinese Medicine, null, null, School of Acupuncture-Moxibustion and Tuina, Beijing, China
   Beijing University of Chinese Medicine, Wang, Xu, School of Life Sciences, Beijing, China
   Beijing University of Chinese Medicine, Yang, Nana, School of Acupuncture-Moxibustion and Tuina, Beijing, China
NR 0
TC 0
SN 20446055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2025
VL 15
IS 12
BP e108722
EP 
DI 10.1136/bmjopen-2025-108722
PG 0
UT PubMed:41475813
ER

PT J
AU Li, Y
   Xu, R
   Chen, M
   Zheng, K
   Nie, H
   Yin, C
   Liu, B
   Tai, Y
   Du, J
   Wang, J
   Fang, J
   Liu, B
AF Li, Yuanyuan
   Xu, Ruoyao
   Chen, Muyan
   Zheng, Kaige
   Nie, Huimin
   Yin, Chengyu
   Liu, Boyu
   Tai, Yan
   Du, Junying
   Wang, Jie
   Fang, Jianqiao
   Liu, Boyi
TI Electroacupuncture alleviates paclitaxel-induced peripheral neuropathy by reducing CCL2-mediated macrophage infiltration in sensory ganglia and sciatic nerve
SO Chinese Medicine (United Kingdom)
LA English
DT Article
DE Acupuncture; Chemotherapy; Macrophages; Neuropathy; Paclitaxel; Pain
ID monocyte chemotactic protein 1; paclitaxel; 4t1 cell line; animal experiment; animal model; animal tissue; antineoplastic activity; article; bagg albino mouse; c57bl 6 mouse; clinical effectiveness; cold hyperalgesia; controlled study; dose response; drug effect; drug efficacy; drug mechanism; electroacupuncture; female; flow cytometry; immunohistochemistry; in vivo study; intra epidermal nerve fiber; kunlun acupoint; m1 macrophage; m2 macrophage; macrophage; male; mechanical hyperalgesia; mouse; nerve fiber; nonhuman; peripheral neuropathy; sciatic nerve; sensory ganglion; sensory nerve cell; spinal ganglion; treatment outcome; tumor volume; tumor xenograft; zusanli acupoint
AB Background: Paclitaxel-induced peripheral neuropathy (PIPN) is prevalent among patients receiving paclitaxel chemotherapy, which results in sensory abnormality as well as neuropathic pain. Conventional medications lack effectiveness on PIPN. Clinical trials identified beneficial effects of acupuncture on PIPN among patients receiving chemotherapy. Here we explored the mechanisms underlying how acupuncture might alleviate PIPN. Methods: A mouse model of PIPN was established by repeated paclitaxel application. Electroacupuncture (EA) was applied at ST36 and BL60 acupoints of model mice. Immunostaining, flow cytometry, behavioral assay, in vivo imaging were utilized for effects determination and mechanism exploration. Results: EA ameliorated mechanical and cold pain hypersensitivities, reduced sensory neuron damage and improved loss in intra-epidermal nerve fibers (IENFs) in model mice. Macrophages infiltration were detected in DRG and sciatic nerve of model mice, which was reduced by EA. EA affected M1-like pro-inflammatory macrophage infiltration in DRG, whereas it did not affect M2-like macrophages. DRG neurons released chemoattractant CCL2 that recruited macrophages via CCR2 to DRG. EA reduced CCL2 overproduction by DRG neurons and reduced macrophage infiltration. Blocking CCR2 mimicked EAs anti-allodynic effect, whereas exogenously applying recombinant CCL2 reversed the ameliorative effect of EA on macrophage infiltration and abolished EAs anti-allodynia on model mice. EA ameliorated other signs of PIPN, including sensory neuron damage, sciatic nerve morphology impairment and IENFs loss. In mice inoculated with breast cancer cells, EA didnt affect paclitaxel-induced antitumor effect. Conclusions: These findings suggest EA alleviates PIPN by reducing CCL2/CCR2 mediated-pro-inflammatory macrophage infiltration into sensory ganglia as well as the sciatic nerve. Our study supports EA could be used as a potential non-pharmacological therapy for PIPN. © The Author(s) 2025.
C1 Zhejiang Chinese Medical University, Li, Yuanyuan, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Xu, Ruoyao, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Chen, Muyan, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Zheng, Kaige, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Nie, Huimin, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Yin, Chengyu, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Liu, Boyu, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Tai, Yan, Academy of Chinese Medical Sciences, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Du, Junying, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   The Second Affiliated Hospital Zhejiang University School of Medicine, Wang, Jie, Department of Rehabilitation in Traditional Chinese Medicine, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Fang, Jianqiao, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
   Zhejiang Chinese Medical University, Liu, Boyi, Department of Neurobiology and Acupuncture Research, Hangzhou, Zhejiang, China
CR Mody, 1900, 2016, V0, P0
   Forsyth, 1900, 1997, V0, P0
   Starobova, 1900, PATHOPHYSIOLOGY OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, V0, P10
   Brewer, 1900, CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: CURRENT STATUS AND PROGRESS, V0, P176-183
   Flatters, 1900, 2017, V0, P0
   Loprinzi, 1900, 2020, V0, P0
   Sisignano, 1900, MECHANISM-BASED TREATMENT FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHIC PAIN, V0, P694-707
   Jordan, 1900, SYSTEMIC ANTICANCER THERAPY-INDUCED PERIPHERAL AND CENTRAL NEUROTOXICITY: ESMO–EONS–EANO CLINICAL PRACTICE GUIDELINES FOR DIAGNOSIS, V0, P1306-1319
   Chen, 1900, REGULATION OF PAIN BY NEURO-IMMUNE INTERACTIONS BETWEEN MACROPHAGES AND NOCICEPTOR SENSORY NEURONS, V0, P17-25
   Ji, 1900, 2016, V0, P0
NR 10
TC 5
SN 19910150
EI 
J9 CHIN MED
JI Chin. Med
PD JUN 15
PY 2025
VL 20
IS 1
BP 
EP 
DI 10.1186/s13020-024-01023-8
PG 0
UT Scopus:10.1186/s13020-024-01023-8
ER

PT J
AU Wu, XY
   Lam, CS
   Chu, YS
   Deng, WS
   Chan, CWH
   Au, KY
   Man, SS
   Li, CK
   Zhong, CW
   Ho, L
   Cheung, YT
AF Wu, Xingyue
   Lam, Chun Sing
   Chu, Yau Shing
   Deng, Weishang
   Chan, Carmen Wing Han
   Au, Kwok Yin
   Man, Sze Shun
   Li, Chi Kong
   Zhong, Chenwen
   Ho, Leonard
   Cheung, Yin Ting
TI Efficacy of Traditional, Complementary, and Integrative Medicine in Pain and Psychological Distress Management for Pediatric Palliative Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Traditional; complementary; and integrative medicine; Pediatric palliative care; Pain; Psychological distress; Meta-Analyses; Systematic review
ID quality-of-life; music-therapy; consort extension; children; massage; anxiety; hypnosis; cancer; care
AB Context. Traditional, complementary, and integrative medicine (TCIM) is being increasingly used to manage symptoms in patients with palliative needs. However, there is a lack of evidence to guide its use in the pediatric palliative care (PPC) setting. Objectives. This study aimed to synthesize and evaluate the current evidence on the effectiveness of TCIM in reducing pain and psychological distress in PPC. Methods. Four English electronic databases were searched for randomized controlled trials (RCTs) published between January 2000 and August 2023. The standardized mean difference (SMD) was used to report the pooled magnitude of the treatment effect. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of the evidence for each treatment outcome. Results. Thirty RCTs were included. The interventions were massage (n = 9), music therapy (n = 6), hypnosis (n = 3), acupuncture, aromatherapy, and other TCIM modalities. Compared with the control interventions, music therapy significantly decreased pain (SMD:-1.07; 95% CI:-1.64 to-0.50; P< 0.05; I-2 = 72%) and relieved anxiety (SMD:-0.75; 95% CI:-1.35 to-0.15; P< 0.05; I-2 = 74%); massage significantly decreased pain (SMD:-0.74; 95% CI:-1.46 to-0.02; P< 0.05; I-2 = 83%) and relieved anxiety (SMD:-0.61; 95% CI:-1.21 to-0.01; P< 0.05; I2 = 71%). Hypnosis had significant effects on procedure-related anxiety, pain, and behavioral distress management (P< 0.05). The quality of evidence was rated as "moderate" for the efficacy of music therapy in alleviating pain and anxiety and "low" for the efficacy of all of the other interventions. Conclusions. Existing evidence supports the therapeutic benefits of music therapy, massage, and hypnosis on relieving pain and anxiety symptoms in the PPC setting, though the evidence is of low-to-moderate quality. (c) 2025 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.
C1 [Wu, Xingyue; Lam, Chun Sing; Chu, Yau Shing; Deng, Weishang; Cheung, Yin Ting] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Lo Kwee Seong Integrated Biomed Sci Bldg Area 39, Hong Kong, Peoples R China.
   [Chan, Carmen Wing Han] Chinese Univ Hong Kong, Fac Med, Nethersole Sch Nursing, Hong Kong, Peoples R China.
   [Au, Kwok Yin] Chinese Univ Hong Kong, Integrat Med Ctr, Shatin, Hong Kong, Peoples R China.
   [Man, Sze Shun] Hong Kong Childrens Hosp, Hong Kong, Peoples R China.
   [Li, Chi Kong] Chinese Univ Hong Kong, Fac Med, Dept Paediat, Shatin, Hong Kong, Peoples R China.
   [Zhong, Chenwen; Ho, Leonard] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong
RP Cheung, YT (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Lo Kwee Seong Integrated Biomed Sci Bldg Area 39, Hong Kong, Peoples R China.
EM yinting.cheung@cuhk.edu.hk
FU Hong Kong Health Bureau Chinese Medicine Development Fund [23B2/072]
CR Akard TF, 2021, J PALLIAT MED, V24, P680, DOI 10.1089/jpm.2020.0139
   Unknown -, 2023, TRADITIONAL, V0, P0
   Barker MM, 2019, JAMA PEDIATR, V173, P835, DOI 10.1001/jamapediatrics.2019.1712
   Beecham E, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010750.pub2
   Ben-Pazi H, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0175028
   Boon MH, 2021, J CLIN EPIDEMIOL, V135, P42, DOI 10.1016/j.jclinepi.2021.01.001
   Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Chen ZQ, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1097477
   Chong LA, 2018, J PALLIAT MED, V21, P1242, DOI 10.1089/jpm.2017.0626
   Connor SR, 2017, J PAIN SYMPTOM MANAG, V53, P171, DOI 10.1016/j.jpainsymman.2016.08.020
   Batalha LMD, 2013, J PEDIAT-BRAZIL, V89, P595, DOI 10.1016/j.jped.2013.03.022
   Duymaz T, 2020, ANN CLIN ANAL MED, V11, P115, DOI 10.4328/ACAM.6171
   Faraone Stephen V, 2008, P T, V33, P700
   Ferro F, 2021, EUR J PEDIATR, V180, P2389, DOI 10.1007/s00431-021-04164-2
   Field T, 2001, JOURNAL OF BODYWORK AND MOVEMENT THERAPIES, V5, P271, DOI 10.1054/jbmt.2001.0228
   Flyckt N, 2022, J PEDIATR REHAB MED, V15, P49, DOI 10.3233/PRM-210046
   Freedenberg VA, 2017, PEDIATR CARDIOL, V38, P1415, DOI 10.1007/s00246-017-1679-5
   Gurcan M, 2021, EUR J CANCER CARE, V30, P0, DOI 10.1111/ecc.13491
   Harrison TM, 2020, NURS RES, V69, PS36, DOI 10.1097/NNR.0000000000000459
   Hatem Thamine P, 2006, J PEDIATR (RIO J), V82, P186, DOI 10.2223/JPED.1473
   Haun Jolie N, 2009, INT J THER MASSAGE BODYWORK, V2, P7
   Higgins J, 2024, COCHRANE HDB SYSTEMA, V0, P0
   Higgins JPT, 2019, REVISED COCHRANE RISK-OF-BIAS TOOL FOR RANDOMIZED TRIALS (ROB 2), V0, P0
   Huang YL, 2021, J PERIANESTH NURS, V36, P243, DOI 10.1016/j.jopan.2020.08.004
   Mano KEJ, 2019, CLIN J PAIN, V35, P989, DOI 10.1097/AJP.0000000000000763
   Kammin V, 2024, PALLIATIVE MED, V38, P364, DOI 10.1177/02692163241230664
   Kodish I, 2011, PEDIATR CLIN N AM, V58, P55, DOI 10.1016/j.pcl.2010.10.002
   Koller D, 2012, J PEDIATR NURS, V27, P652, DOI 10.1016/j.pedn.2011.08.001
   Lam CS, 2022, BMJ PAEDIATR OPEN, V6, P0, DOI 10.1136/bmjpo-2022-001701
   Landier W, 2010, J PEDIATR NURS, V25, P566, DOI 10.1016/j.pedn.2010.01.009
   Lemanek KL, 2009, J PEDIATR PSYCHOL, V34, P1091, DOI 10.1093/jpepsy/jsp015
   Li J, 2019, COMPLEMENT THER MED, V46, P180, DOI 10.1016/j.ctim.2019.08.014
   Liberati A, 2009, ANN INTERN MED, V151, PW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Liossi C, 2006, HEALTH PSYCHOL, V25, P307, DOI 10.1037/0278-6133.25.3.307
   Liossi C, 2009, PAIN, V142, P255, DOI 10.1016/j.pain.2009.01.017
   Loizzo Alberto, 2009, OPEN BIOCHEM J, V3, P18, DOI 10.2174/1874091X00903010018
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03271-9
   Madden JR, 2010, J PEDIATR ONCOL NURS, V27, P133, DOI 10.1177/1043454209355452
   Mak C, 2018, DEV MED CHILD NEUROL, V60, P922, DOI 10.1111/dmcn.13923
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Marcus KL, 2022, J PAIN SYMPTOM MANAG, V63, P88, DOI 10.1016/j.jpainsymman.2021.07.010
   Marofi Maryam, 2015, IRAN J NURS MIDWIFERY RES, V20, P247
   Mehling WE, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/450150
   Namisango E, 2019, PATIENT, V12, P15, DOI 10.1007/s40271-018-0333-5
   National Hospice and Palliative Care Organization, 2022, STANDARDS OF PRACTICE FOR PEDIATRIC PALLIATIVE CARE, V0, P0
   Nilsson Stefan, 2011, COMPLEMENT THER CLIN PRACT, V17, P127, DOI 10.1016/j.ctcp.2010.11.003
   Nunns M, 2018, PSYCHO-ONCOLOGY, V27, P1889, DOI 10.1002/pon.4749
   Oh A, 2023, SEMIN PEDIATR NEUROL, V48, P0, DOI 10.1016/j.spen.2023.101085
   Ostojic K, 2022, DEV MED CHILD NEUROL, V64, P1507, DOI 10.1111/dmcn.15303
   Pai M, 2015, RARE DIS, V3, P0, DOI 10.1080/21675511.2015.1058463
   Park YL, 2019, HEALTH SYST REFORM, V5, P24, DOI 10.1080/23288604.2018.1539058
   Phipps S, 2012, PEDIATRICS, V129, PE762, DOI 10.1542/peds.2011-1816
   Phipps S, 2010, CANCER-AM CANCER SOC, V116, P3924, DOI 10.1002/cncr.25415
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Rajendran Tara, 2021, HARNESSING THE THERAPEUTIC POTENTIAL OF MUSIC, V0, P0
   Robb SL, 2017, J PEDIATR PSYCHOL, V42, P208, DOI 10.1093/jpepsy/jsw050
   Rodríguez-Rodríguez RC, 2022, GLOBAL HEALTH ACTION, V15, P0, DOI 10.1080/16549716.2022.2116774
   Ryan R, 2016, HOW TO GRADE THE QUALITY OF THE EVIDENCE, V0, P0
   Santa IND, 2021, COMPLEMENT THER MED, V59, P0, DOI 10.1016/j.ctim.2021.102725
   Staveski SL, 2018, PEDIATR CRIT CARE ME, V19, P725, DOI 10.1097/PCC.0000000000001615
   Stegemann Thomas, 2019, MEDICINES (BASEL), V6, P0, DOI 10.3390/medicines6010025
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   Ting BR, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11040991
   Ting JM, 2025, PEDIATR CARDIOL, V46, P1142, DOI 10.1007/s00246-024-03535-4
   Tomlinson D, 2011, SUPPORT CARE CANCER, V19, P1857, DOI 10.1007/s00520-010-1029-0
   Uggla L, 2018, ACTA PAEDIATR, V107, P1986, DOI 10.1111/apa.14515
   van der Heijden MJE, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0133608
   Wan X, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-135
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012564.pub2
   Yu HB, 2009, INT J NURS STUD, V46, P1423, DOI 10.1016/j.ijnurstu.2009.05.007
   Zhao FY, 2022, WORLD J ACUPUNCT-MOX, V32, P1, DOI 10.1016/j.wjam.2021.07.005
   Zhu YW, 2022, NEUROSCI BIOBEHAV R, V143, P0, DOI 10.1016/j.neubiorev.2022.104954
NR 75
TC 1
Z9 1
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY 15
PY 2025
VL 69
IS 5
BP e337
EP e358
DI 10.1016/j.jpainsymman.2025.01.002
EA APR 2025
PG 22
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 1OV2R
UT WOS:001470117300001
PM 39800142
DA 2026-01-16
ER

PT J
AU Cao, Y
   Bai, ZQ
AF Cao, Yong
   Bai, Zhiqiang
TI Evaluation of acupuncture on pain intensity and sleep quality in patients with neuropathic pain following spinal cord injury
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Spinal cord injury; neuropathic pain; acupuncture; pharmacotherapy; effect modification
AB Objective: To assess the efficacy of incorporating acupuncture into standard pharmacotherapy for neuropathic pain following spinal cord injury (SCI-NP) and investigate the potential influence of age and disease duration on this effect. Methods: We conducted a retrospective review of 312 patients with SCI-NP who were treated at Northwest University First Hospital from March 2022 to August 2024. According to the hospital information system, patients either received standard pharmacotherapy alone (control) or pharmacotherapy in conjunction with acupuncture (study). The duration of both regimens was four weeks. The main outcomes were changes in the Pain Rating Index (PRI), the Visual Analogue Scale (VAS), and the Present Pain Intensity (PPI). Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index, PSQI), inflammatory markers (Interleukin-1 beta, Interleukin-6, Tumor Necrosis Factor-alpha), immune indices (Immunoglobulin A, Immunoglobulin G), and adverse events. Results: The combination resulted in more significant decreases in PRI, VAS, and PPI, as well as more notable enhancements in PSQI, inflammatory markers, and immunoglobulin levels (all P<0.0001), compared to pharmacotherapy alone. The rates of adverse events were comparable between groups (P>0.05). Age-by-duration analysis revealed that in patients aged 40-50 years, an extended disease duration correlated with a diminished probability of pain improvement (P=0.018); conversely, no definitive association was found in individuals over 50 years (P=0.694). Conclusion: Adding acupuncture to conventional pharmacotherapy reduced pain, improved sleep quality, and shifted inflammatory and immune indices in a favorable direction, without an increase in adverse events. Treatment response varied by patient profile: among those aged 40 to 50 years, longer disease duration was linked to a lower likelihood of pain improvement, while no clear duration effect was seen in older patients.
C1 [Cao, Yong; Bai, Zhiqiang] Northwest Univ, Dept Rehabil, Hosp 1, 512 Xianning East Rd, Xian 710043, Shaanxi, Peoples R China.
C3 Northwest University Xi'an
RP Bai, ZQ (corresponding author), Northwest Univ, Dept Rehabil, Hosp 1, 512 Xianning East Rd, Xian 710043, Shaanxi, Peoples R China.
EM bai680320@163.com
CR Anjum A, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21207533
   Chen T, 2021, PAIN THER, V10, P1497, DOI 10.1007/s40122-021-00302-8
   Chen Y, 2023, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1093849
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Eli I, 2021, NEUROL CLIN, V39, P471, DOI 10.1016/j.ncl.2021.02.004
   Eller OC, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.991736
   Feng ZT, 2023, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1076993
   Ge SY, 2025, NEUROL SCI, V46, P3547, DOI 10.1007/s10072-025-08120-y
   He KL, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6297484
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Kannan P, 2022, THER ADV CHRONIC DIS, V13, P0, DOI 10.1177/20406223221078672
   Khosravaninezhad Y, 2025, EXPLORE-NY, V21, P0, DOI 10.1016/j.explore.2025.103192
   Kohno K, 2022, SCIENCE, V376, P86, DOI 10.1126/science.abf6805
   Kui WY, 2025, J PAIN RES, V18, P1115, DOI 10.2147/JPR.S506569
   Li XM, 2025, FRONT CELL NEUROSCI, V19, P0, DOI 10.3389/fncel.2025.1547524
   Liu CY, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3964-5
   Liu LY, 2024, J INTEGR MED-JIM, V22, P32, DOI 10.1016/j.joim.2024.01.005
   Lordache SD, 2023, ISR MED ASSOC J, V25, P286
   Ma X, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.940343
   Norrbrink C, 2011, ACUPUNCT MED, V29, P108, DOI 10.1136/aim.2010.003269
   Shi GX, 2025, J PAIN RES, V18, P663, DOI 10.2147/JPR.S486812
   Sun LT, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/5607898
   Wang N, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1092402
   Widerström-Noga E, 2023, DRUGS, V83, P1001, DOI 10.1007/s40265-023-01903-7
   Wu JM, 2024, FRONT NEUROSCI-SWITZ, V18, P0, DOI 10.3389/fnins.2024.1346635
   Wu WD, 2025, FRONT PHARMACOL, V16, P0, DOI 10.3389/fphar.2025.1588284
   Yang Y, 2022, SPINAL CORD, V60, P375, DOI 10.1038/s41393-022-00776-z
   Ye Y, 2024, CELL MOL NEUROBIOL, V44, P0, DOI 10.1007/s10571-024-01517-x
   Yuan M, 2022, FRONT AGING NEUROSCI, V14, P0, DOI 10.3389/fnagi.2022.913881
   Zhao HF, 2024, COMB CHEM HIGH T SCR, V27, P2951, DOI 10.2174/0113862073265007231108050338
   Zheng JY, 2024, J INTEGR MED-JIM, V22, P445, DOI 10.1016/j.joim.2024.06.004
   Zitser J, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0270095
NR 32
TC 0
Z9 0
U1 1
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2025
VL 17
IS 12
BP 9242
EP 9258
DI 10.62347/EKQG6497
PG 17
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA AK5YK
UT WOS:001650339800001
DA 2026-01-16
ER

PT J
AU Li, X
   Lampson, K
   Ahles, TA
   Root, JC
   Li, QS
   Li, Y
   Ahsan, A
   Mao, JJ
   Liou, KT
AF Li, Xiaotong
   Lampson, Kaitlin
   Ahles, Tim A
   Root, James C
   Li, Q Susan
   Li, Yuelin
   Ahsan, Anam
   Mao, Jun J
   Liou, Kevin T
TI Feasibility and Preliminary Effects of Acupuncture for Cognitive Dysfunction in
SO Current oncology (Toronto, Ont.)
LA English
DT Journal Article
DE acupuncture; cancer survivorship; cognitive dysfunction; feasibility; pilot study
AB (1) Background: This pilot study evaluates the feasibility and preliminary  effects of acupuncture for cancer-related cognitive dysfunction (CRCD) in cancer  survivors. (2) Methods: A randomized trial comparing real acupuncture (RA) to  sham acupuncture (SA) and waitlist control (WLC) among cancer survivors reporting  cognitive difficulties. Interventions were delivered weekly over 10 weeks.  Feasibility was evaluated by recruitment, treatment adherence, and assessment  completion. Subjective CRCD was assessed by the Functional Assessment of Cancer  Therapy-Cognitive Function-Perceived Cognitive Impairment subscale (FACT-Cog PCI)  and objective CRCD was assessed by the Hopkins Verbal Learning Test-Revised  (HVLT-R). (3) Results: 32 participants (57.1% of eligible patients) were  enrolled. All participants in acupuncture groups completed ≥8 of 10 treatments.  Assessment completion rate was 100% for all participants. From baseline to week  10, the RA group (n = 19) reported a clinically meaningful 17.3-point increase in  FACT-Cog PCI (95% confidence interval [CI] 12.5 to 22.1), compared to 9.7 points  (95% CI 2.8 to 16.7) in the SA group (n = 9), and 6.8 points (95% CI -3.7 to  17.2) in the WLC group (n = 4). In the subgroup analysis among patients with a  below-average baseline HVLT-R (T-score < 50), the RA group (n = 8) increased  FACT-Cog PCI scores by 20.4 (95% CI 13.6 to 27.3), compared to 11.1 points (95%  CI 0.6 to 21.5) in the SA group (n = 5). The improvements from RA persisted  through week 16 in both the total sample and the sub-group. Eleven mild adverse  events were reported, with pain and bleeding at the needling sites being the most  common. (4) Conclusions: The findings support the feasibility and safety of  conducting a randomized, placebo-controlled trial to evaluate acupuncture for  cognitive dysfunction in cancer survivors.
C1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer 
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
NR 0
TC 0
SN 1718-772
EI 1198-005
J9 Curr Oncol
PD JAN 24
PY 2025
VL 32
IS 1
BP 
EP 
DI 10.3390/curroncol32010027
PG 0
WC Humans; Acupuncture Therapy; methods; Pilot Projects; Male; Female; Cancer Survivors; psychology; Cognitive Dysfunction; therapy; Middle Aged; Feasibility Studies; Aged; Neoplasms; complications; Adult
UT PubMed:39851943
PM 39851943
DA 2025-01-24
ER

PT J
AU Zhang, Q
   Zhao, Y
   Cheng, GY
AF Zhang, Qi
   Zhao, Yue
   Cheng, Guang-Yu
TI Effect of negative mood, serum inflammatory factors, miR-155, and brain-derived neurotrophic factor
SO WORLD JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Syndrome differentiation acupuncture; Abdominal surgery; Depression; Negative mood; Serum inflammatory factor; Tiny RNA-155
ID depression
AB BACKGROUND Abdominal postoperative patients are susceptible to postoperative depression resulting from pain and stress, which can hinder their rehabilitation. Acupuncture has shown potential to relieve this condition. AIM To analyze the mechanism by which acupuncture relieves postoperative depression in patients post-abdominal surgery. METHODS Abdominal postoperative patients with depression between January 2015 and December 2023 at the First Affiliated Hospital of Heilongjiang University of Chinese Medicine were enrolled. Patients were divided into two groups using the random throwing method: Observation (250 cases, fluoxetine hydrochloride + acupuncture treatment) and control (250 cases, fluoxetine hydrochloride treatment). Changes in negative emotions Hamilton Depression Scale 24, serum inflammatory factors [tumor necrosis factor alpha, interleukin (IL)-1 beta, IL-6], miR-155 expression levels, and BDNF levels were assessed. RESULTS Significant improvements were observed in the observation group compared to the control group in all assessed parameters after six weeks (P < 0.05). This suggests that the combination of fluoxetine hydrochloride and acupuncture may be more effective in managing postoperative depression than medication alone. CONCLUSION Acupuncture complies with the principle of traditional Chinese medicine syndrome differentiation and ensures the pertinence and effectiveness of treatment. In addition, it not only actively improves depressive symptoms but also effectively regulates the serum level of inflammatory factors.
C1 [Zhang, Qi] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Prevent & Treatment Ctr, Harbin 150040, Heilongjiang, Peoples R China.
   [Zhao, Yue] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Med, Harbin 150040, Heilongjiang, Peoples R China.
   [Cheng, Guang-Yu] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Tradit Chinese Med Translat Med Res Ctr, 6 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine
RP Cheng, GY (corresponding author), Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Tradit Chinese Med Translat Med Res Ctr, 6 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
EM chengguangyu@hljucm.edu.cn
CR Colucci-DAmato L, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21207777
   Dai J, 2020, EUR REV MED PHARMACO, V24, P1398, DOI 10.26355/eurrev_202002_20197
   Kelly KM, 2021, BRAIN BEHAV IMMUN, V95, P106, DOI 10.1016/j.bbi.2021.02.019
   Li MX, 2020, COMPLEMENT THER MED, V50, P0, DOI 10.1016/j.ctim.2019.102202
   McAllister-Williams RH, 2006, BRIT J HOSP MED, V67, P60, DOI 10.12968/hmed.2006.67.2.20461
   Sardar M, 2022, COMPUT BIOL CHEM, V101, P0, DOI 10.1016/j.compbiolchem.2022.107774
   Shen DD, 2021, NEUROSCI LETT, V746, P0, DOI 10.1016/j.neulet.2020.135585
   Szoke-Kovacs Zsombor, 2020, NEUROPSYCHOPHARMACOL HUNG, V22, P4
   Yang NN, 2022, CURR NEUROPHARMACOL, V20, P738, DOI 10.2174/1570159X19666210609162809
   Yao L, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.518837
   Zimmerman M, 2013, J AFFECT DISORDERS, V150, P384, DOI 10.1016/j.jad.2013.04.028
NR 11
TC 2
Z9 2
U1 1
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2220-3206
EI 
J9 WORLD J PSYCHIATR
JI World J. Psychiatr.
PD FEB 19
PY 2025
VL 15
IS 2
BP 
EP 
DI 10.5498/wjp.v15.i2.99573
PG 8
WC Psychiatry
SC Psychiatry
GA U7J6L
UT WOS:001413514100003
PM 39974477
DA 2026-01-16
ER

PT J
AU Zhou, XY
   Wang, XY
   Zhang, YF
   Wang, XL
   Zhang, XX
   Liu, YY
   Li, PY
   Tian, YS
AF Zhou, Xing-Yu
   Wang, Xin-Yi
   Zhang, Yu-Fei
   Wang, Xiao-Long
   Zhang, Xiu-Xiu
   Liu, Yuan-Yuan
   Li, Peng-Yan
   Tian, Yuan-Sheng
TI [Clinical observation on treatment of patients with kidney-yang deficiency type
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupoint embedding therapy; Ankylosing spondylitis; Bushen Tongdu external treatment method; Kidney- yang deficiency; Ren Du Zhou-Tian moxibustion
AB OBJECTIVES: To observe and evaluate the effectiveness and safety of Bushen Tongdu  (reinforcing the kidney-yang and regulating the Governor Vessel) external  treatment for patients with kidney-yang deficiency type ankylosing spondylitis  (AS). METHODS: Patients with Kidney-yang deficiency type AS were randomly divided  into an observation group(36 cases, 4 cases dropped out) and a control group(36  cases, 3 cases dropped out). The observation group were received the Bushen  Tongdu external treatment which was a combination of Ren Du Zhou-Tian moxibustion  and acupoint embedding therapy, i.e. performing ginger-juice soaked nonwoven  separated moxibustion first at the back covering the region from Dazhui (GV14) to  Yaoshu (GV2) for 1 h, and then at the thoracoabdominal region covering the part  from Tiantu (CV22) to Zhongji (CV3) for 1 h, followed by performing acupoint  catgut embedding at one or two pairs of GV14, Shenshu (BL23), Dachangshu (BL25),  Xuehai (SP10), and Zusanli (ST36), once a week, for 8 weeks. The control group  received oral administration of salazosulfapyridine capsules (0.2 g/time), once a  day for 8 weeks. Changes of the patients' conditions were evaluated by using  traditional Chinese medicine (TCM) syndrome score (0 to 3 points for cold and  painful lower back, morning stiffness, limited lumbar movement, soreness and  weakness of waist and knees, etc.) and the total score (0 to 18 points), the Bath  ankylosing spondylitis disease activity index (BASDAI) score (0 to 10 points for  fatigue, physical discomfort caused by pain, swelling, or tenderness in the spine  and peripheral joints, duration and severity of morning stiffness, etc). The  therapeutic effect was assessed . The safety observation included fainting during  acupuncture or moxibustion treatment, burn, etc. The contents of serum  interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix  metalloproteinase-3 (MMP-3) were detected before and after the treatment.  RESULTS: After 8 weeks of treatment, the TCM syndrome score, total score, BASDA  score, contents of serum IL-6, TNF-α and MMP-3 were strikingly decreased in both  groups compared with those of their own pre-treatment (P<0.05), and the  therapeutic effect of the observation group was significantly superior to that of  the control group in lowering the scores of cold and painful lower back, weakness  in the lower back and knees, preference for warmth and aversion to cold, pain  worsened by cold, and total score, BASDA score, and contents of serum IL-6, TNF-α  and MMP-3 (P<0.05). The total effective rate of observation group was 90.63%  (29/32), which was higher (P<0.05) than that of control group (75.76%, 25/33).  CONCLUSIONS: The Bushen Tongdu external treatment method significantly improves  AS patients' TCM clinical symptoms, alleviates inflammatory reactions, and  demonstrates a significant efficacy with good safety.
C1 Department of Pain and Rheumatology, Henan Integrated Medicine Hospital, Zhengzhou 450004, China.
   Department of Pain and Rheumatology, Henan Integrated Medicine Hospital, Zhengzhou 450004, China.
   Department of Pain and Rheumatology, Henan Integrated Medicine Hospital, Zhengzhou 450004, China.
   School of Acupuncture-Moxibustion and Tuina, Henan University Of Chinese Medicine, Zhengzhou 450046.
   School of Acupuncture-Moxibustion and Tuina, Henan University Of Chinese Medicine, Zhengzhou 450046.
   School of Acupuncture-Moxibustion and Tuina, Henan University Of Chinese Medicine, Zhengzhou 450046.
   School of Acupuncture-Moxibustion and Tuina, Henan University Of Chinese Medicine, Zhengzhou 450046.
   Department of Pain and Rheumatology, Henan Integrated Medicine Hospital, Zhengzhou 450004, China. 1619166115@qq.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAR 10
PY 2025
VL 50
IS 2
BP 183
EP 189
DI 10.13702/j.1000-0607.20231040
PG 6
WC Humans; Spondylitis, Ankylosing; therapy; Female; Male; Adult; Acupuncture Points; Yang Deficiency; therapy; Middle Aged; Acupuncture Therapy; Young Adult; Drugs, Chinese Herbal; administration & dosage; Kidney; physiopathology; Treatment Outcome; Tumor Necrosis Factor-alpha; blood; Moxibustion; Interleukin-6; blood
UT PubMed:40059052
PM 40059052
DA 2025-03-10
ER

PT J
AU Zhang, JM
   Zhang, H
   Zheng, JF
   Niu, C
   Zhu, S
   Hu, HQ
   Lu, Y
   Zhu, MH
AF Zhang, Jiamin
   Zhang, Hao
   Zheng, Junfei
   Niu, Cong
   Zhu, Shu
   Hu, Haiqing
   Lu, Ye
   Zhu, Meihua
TI Safety and Effectiveness of Electroacupuncture During Colon Endoscopic Submucosal Dissection: A Randomized Controlled Trial
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE electroacupuncture; endoscopic submucosal dissection; propofol; remifentanil
ID acupuncture; pain; dexmedetomidine; sedation
AB Background: Endoscopic treatment of early colon neoplasms has evolved as a valid and less traumatic alternative to surgical resection. It can usually be performed with sedation on an outpatient basis. The present study was performed to determine the safety and effectiveness of electroacupuncture (EA) versus propofol sedation during endoscopic submucosal dissection (ESD) for early colon neoplasm. Methods: A total of 150 adult outpatients undergoing ESD were selected and divided into the EA combined with propofol group (EP group), remifentanil combined with propofol group (RP group), and propofol group (SP group), with 50 patients in each group. All patients received standard sedation with propofol. Acupuncture was performed before intravenous propofol injection in the EP group. A density wave of 1-3 mA, 2/100 hz current was administered for 20 min before the induction of anesthesia. The effectiveness of sedation was measured by satisfaction levels, and pain and sedation scores were measured by questionnaires. Respiratory and hemodynamic complications were monitored and compared as indices of safety. Results: Demographic data were comparable among the three groups. The total dose of propofol and the percentage of body movement in the EP group were lower than in the SP and RP groups (P<0.01). The incidence of hypotension and bradycardia in the SP and RP groups was higher than in the EP group. Patients who received the EA intervention showed a significant reduction in hypoxemia. The endoscopists felt that the procedure was more favorable in the EP group, but, there was no significant difference of patient satisfaction scores among three groups. Conclusion: Sedation with EA is effective and safe for patients undergoing ESD, and could improve the satisfaction levels of patients and gastroendoscopists.
C1 [Zhang, Jiamin; Zheng, Junfei; Niu, Cong; Zhu, Shu; Hu, Haiqing; Zhu, Meihua] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, Nanjing 210017, Jiangsu, Peoples R China.
   [Zhang, Hao] Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanjing 210011, Peoples R China.
   [Lu, Ye] Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Surg, Nanjing 210017, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing University of Chinese Medicine
RP Zhu, MH (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Anesthesiol, Nanjing 210017, Jiangsu, Peoples R China.; Lu, Y (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp 2, Dept Surg, Nanjing 210017, Jiangsu, Peoples R China.
EM zyyluyuanz@126.com; zhu_zmh@yeah.net
FU Science and Technology Project of Traditional Chinese Medicine Administration of Jiangsu Province [YB201822]
CR Ashikari K, 2021, J GASTROEN HEPATOL, V36, P1920, DOI 10.1111/jgh.15417
   Bhatt A, 2020, GASTROINTEST ENDOSC, V92, P1187, DOI 10.1016/j.gie.2020.07.005
   Chen H, 2018, MED SCI MONITOR, V24, P2946, DOI 10.12659/MSM.909995
   Choi GH, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011215.pub2
   Cilli F, 2019, AM J INFECT CONTROL, V47, P582, DOI 10.1016/j.ajic.2018.10.014
   Eberl S, 2020, ACUPUNCT MED, V38, P131, DOI 10.1136/acupmed-2017-011459
   Ishihara R, 2020, DIGEST ENDOSC, V32, P452, DOI 10.1111/den.13654
   Gan CYJ, 2021, ANZ J SURG, V91, PE375, DOI 10.1111/ans.16870
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kim JE, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003593
   Kim SH, 2022, J GASTROEN HEPATOL, V37, P558, DOI 10.1111/jgh.15718
   Lee Jun Kyu, 2017, KOREAN J GASTROENTEROL, V69, P55, DOI 10.4166/kjg.2017.69.1.55
   Lee S, 2023, THER ADV GASTROENTER, V16, P0, DOI 10.1177/17562848231189957
   Lewis J, 2017, EUR J PAIN, V21, P1007, DOI 10.1002/ejp.1001
   Li QY, 2023, PAIN THER, V12, P1355, DOI 10.1007/s40122-023-00549-3
   Li QY, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231192017
   Li Y, 2019, J TRADIT CHIN MED, V39, P740
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Lo MY, 2020, J FORMOS MED ASSOC, V119, P81, DOI 10.1016/j.jfma.2019.03.012
   Luo X, 2024, DRUG DES DEV THER, V18, P4551, DOI 10.2147/DDDT.S475749
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Maselli R, 2019, DIGEST LIVER DIS, V51, P391, DOI 10.1016/j.dld.2018.09.023
   Nascimento FF, 2019, J VET MED SCI, V81, P764, DOI 10.1292/jvms.18-0744
   Sasaki T, 2013, DIGEST ENDOSC, V25, P79, DOI 10.1111/den.12024
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Shetty GB, 2018, J ACUPUNCT MERIDIAN, V11, P153, DOI 10.1016/j.jams.2018.04.001
   Takeuchi Y, 2020, DIGESTION, V101, P450, DOI 10.1159/000500874
   Wan J, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21030968
   Wang Q, 2024, MOL PAIN, V20, P0, DOI 10.1177/17448069241254201
   Wu SY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019541
   Yahagi N, 2022, DIGEST ENDOSC, V34, P95, DOI 10.1111/den.14229
   Yang GZ, 2017, J ANESTH, V31, P156, DOI 10.1007/s00540-016-2258-2
   Ye EC, 2023, BRIT J CLIN PHARMACO, V89, P3401, DOI 10.1111/bcp.15839
NR 34
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2025
VL 18
IS 
BP 1221
EP 1229
DI 10.2147/JPR.S501941
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 0CW2T
UT WOS:001444351600001
PM 40104825
DA 2026-01-16
ER

PT J
AU Vella, R
   Giardino, A
   Pizzocaro, E
   Frigerio, I
   Bannone, E
   Vieni, S
   Butturini, G
AF Vella, Roberta
   Giardino, Alessandro
   Pizzocaro, Erica
   Frigerio, Isabella
   Bannone, Elisa
   Vieni, Salvatore
   Butturini, Giovanni
TI Unconventional Treatments for Pancreatic Cancer: A Systematic Review.
SO Cancers
LA English
DT Review
DE complementary medicine; pancreatic cancer; precision oncology; systematic review; unconventional treatment
AB OBJECTIVE: This study aims to review the existing literature on the efficacy and  safety of unconventional treatments among pancreatic cancer patients, including  the use of natural products, dietary supplements, probiotics, whole medical  systems, and body-based therapies. METHODS: An electronic, systematic, and  comprehensive literature review was conducted searching for studies up to  November 2024 following the PRISMA 2020 guidelines. Randomized controlled trials  and prospective and retrospective studies assessing the efficacy and safety of  unconventional treatments for pancreatic cancer were considered eligible. Data on  overall survival, quality of life, and treatment tolerability were extracted.  RESULTS: A total of 21 studies, providing data from 3095 patients, met the  inclusion criteria. Various types of unconventional treatments are used in  pancreatic cancer patients, including Chinese herbal medicine (CHM), mistletoe  extract (ME), curcumin, and electroacupuncture. Among these, the use of CHM and  curcumin concomitant with standard therapy was associated with survival and  quality-of-life benefits. Electroacupuncture reduced pancreatic cancer pain  intensity in a cost-effective manner. The data on ME are mixed and of  insufficient quality for drawing definitive conclusions. CONCLUSIONS: Some  unconventional treatments showed potential benefits in improving overall survival  and quality of life in pancreatic cancer patients within an integrative oncology  setting. Further high-quality studies are needed to provide robust, rigorous, and  ethical evidence to support their integration into future guidelines, ensuring a  holistic approach to cancer treatment.
C1 HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
   Department of Precision Medicine in Medical, Surgical, and Critical Care, 
   HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
   HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
   PhD School of Applied Medical-Surgical Sciences, University Tor Vergata, 00133 
   HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
   Collegium Medicum, SAN University, 90-012 Lodz, Poland.
   HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
   Department of Precision Medicine in Medical, Surgical, and Critical Care, (Me.Pre.C.C.), University of Palermo, 90133 Palermo, Italy.
   HPB Surgery, Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy.
NR 0
TC 0
SN 2072-669
EI 2072-669
J9 Cancers (Basel)
PD MAY 14
PY 2025
VL 17
IS 9
BP 
EP 
DI 10.3390/cancers17091437
PG 0
UT PubMed:40361364
PM 40361364
DA 2025-05-14
ER

PT J
AU Zhao, BB
   Jia, HL
   Zhang, SB
   Yang, YZ
   Li, B
   Shi, P
   Fang, GX
AF Zhao, Binbin
   Jia, Hongli
   Zhang, Subing
   Yang, Yuzi
   Li, Bing
   Shi, Pei
   Fang, Gongxi
TI Effect of ultrasound-guided needle knife combined with platelet-rich plasma infusion on lumbar muscle strain and prognostic evaluation
SO JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES
LA English
DT Article
DE Chronic lumbar muscle strain (CLMS); Ultrasound-guided needle knife (UGNK); Platelet-rich plasma (PRP); Quality of life (QOL); Lumbar function
ID low-back-pain; disability; questionnaire; degeneration; exercises; scale
AB The study evaluated the effectiveness of ultrasound-guided needle knife (UGNK) combined with platelet-rich plasma (PRP) infusion in treating chronic lumbar muscle strain (CLMS). Ninety-two patients with CLMS treated from January 2023 to January 2024 were randomly divided into a control group (CG, n = 46, simple local injection) and an observation group (OG, n = 46, UGNK with PRP infusion). The study compared treatment outcomes, lumbar range of motion, ultrasound findings, pain levels, lumbar function, serum inflammatory factors, and quality of life (QOL) before and after treatment. The effective rate in the OG (97.83 %) was significantly higher than in the CG (78.26 %, P < 0.05). After treatment, the OG showed a reduced lumbar range of motion, smaller hypoechoic areas, and lower pain scores (Present Pain Intensity [PPI], Visual Analog Scale [VAS], and Pain Rating Index [PRI]) compared to the CG (P < 0.05). The OG also had higher Japanese Orthopaedic Association (JOA) scores and lower Oswestry Disability Index (ODI) scores, indicating improved lumbar function (P < 0.05). Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and C-reactive protein (CRP) were lower in the OG, demonstrating reduced inflammation (P < 0.05). Additionally, QOL scores in the physiology, social relations, psychology, and environment domains were higher in the OG (P < 0.05). In conclusion, UGNK combined with PRP infusion effectively improves clinical symptoms, lumbar function, pain relief, inflammation reduction, and QOL in CLMS patients, suggesting a promising therapeutic approach.
C1 [Zhao, Binbin; Zhang, Subing] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Anesthesia Surg, Harbin City 150040, Heilongjiang Pr, Peoples R China.
   [Jia, Hongli] Northeast Agr Univ Hosp, Med Examinat Ctr, Harbin City 150006, Heilongjiang Pr, Peoples R China.
   [Yang, Yuzi] Harbin Fifth Hosp, Dept Plast Surg, Harbin City 150000, Heilongjiang Pr, Peoples R China.
   [Li, Bing] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Peripheral Vasc Dis, Harbin City 150040, Heilongjiang Pr, Peoples R China.
   [Shi, Pei] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Oncol, Harbin City 150040, Heilongjiang Pr, Peoples R China.
   [Fang, Gongxi] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Bone Injuries, Harbin City 150040, Heilongjiang Pr, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine
RP Fang, GX (corresponding author), Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Bone Injuries, Harbin City 150040, Heilongjiang Pr, Peoples R China.
EM cgaho@tzc.edu.cn
FU Heilongjiang research project on traditional Chinese medicine [ZHY2024-080]; Heilongjiang Health Commis-sion [20232121020210]
CR Alharbi HA, 2020, SAUDI J ANAESTH, V14, P343, DOI 10.4103/sja.SJA_34_20
   Araki M, 2021, J ORTHOP SCI, V26, P290, DOI 10.1016/j.jos.2020.02.019
   Chen L, 2022, CLINICAL TRIALS JOURNAL, V18, P123
   Dallaway A, 2020, AGING MALE, V23, P1583, DOI 10.1080/13685538.2021.1878130
   Eksi MS, 2022, J PEDIATR ORTHOP B, V31, P93, DOI 10.1097/BPB.0000000000000833
   Ellegård L, 2021, CLIN ENDOCRINOL, V95, P197, DOI 10.1111/cen.14448
   Enatsu Y, 2022, REPROD MED BIOL, V21, P0, DOI 10.1002/rmb2.12417
   Everts P, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21207794
   Fairbank JCT, 2014, J NEUROSURG-SPINE, V20, P83, DOI 10.3171/2013.9.SPINE13344
   Getzmann JM, 2023, SPINE, V48, P97, DOI 10.1097/BRS.0000000000004477
   Hayden JA, 2021, J PHYSIOTHER, V67, P252, DOI 10.1016/j.jphys.2021.09.004
   Hlaing SS, 2021, BMC MUSCULOSKEL DIS, V22, P0, DOI 10.1186/s12891-021-04858-6
   Karnik V, 2020, CAN J NEUROL SCI, V47, P336, DOI 10.1017/cjn.2020.13
   Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9
   LeBlanc L, 2021, SPINE, V46, P998
   Li X, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000041066
   Luo H, 2019, IMMEDIATE CURATIVE EFFECT OF THREE-WAY SEQUENTIAL TREATMENT OF LUMBAR INTERSPINOUS LIGAMENT INJURY, V0, P0
   Maïano C, 2019, PHYS THER, V99, P507, DOI 10.1093/ptj/pzz012
   Minetama M, 2023, SPINE J, V23, P1630, DOI 10.1016/j.spinee.2023.06.398
   Olkoski MM, 2021, J SPORT MED PHYS FIT, V61, P699, DOI 10.23736/S0022-4707.20.11265-9
   Ramirez-GarciaLuna JL, 2021, SURG TODAY, V51, P1530, DOI 10.1007/s00595-021-02275-9
   Schönnagel L, 2023, SPINE, V48, P1627, DOI 10.1097/BRS.0000000000004826
   Shafshak TS, 2021, JCR-J CLIN RHEUMATOL, V27, P282, DOI 10.1097/RHU.0000000000001320
   Sonmezer E, 2021, J BACK MUSCULOSKELET, V34, P69, DOI 10.3233/BMR-191810
   Stanuszek A, 2022, ARCH ORTHOP TRAUM SU, V142, P1375, DOI 10.1007/s00402-021-03754-x
   Tetreault L, 2017, EUR SPINE J, V26, P78, DOI 10.1007/s00586-016-4660-8
   The National Administration of Traditional Chinese Medicine, 1994, EFFICACY CRITERIA FOR DIAGNOSIS OF TCM SYNDROME, V0, P0
   van Dillen LR, 2021, JAMA NEUROL, V78, P385, DOI 10.1001/jamaneurol.2020.4821
   Zhang GL, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020519
   Zielinski MA, 2022, PAIN PHYSICIAN, V25, P29
NR 30
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1687-8507
EI 
J9 J RADIAT RES APPL SC
JI J. Radiat. Res. Appl. Sci.
PD SEP 15
PY 2025
VL 18
IS 3
BP 
EP 
DI 10.1016/j.jrras.2025.101562
EA MAY 2025
PG 7
WC Multidisciplinary Sciences; Radiology, Nuclear Medicine & Medical Imaging
SC Science & Technology - Other Topics; Radiology, Nuclear Medicine & Medical Imaging
GA 2XS4P
UT WOS:001493811600002
DA 2026-01-16
ER

PT J
AU Wan, RH
   Zheng, QH
   Zeng, XR
   Luo, YL
   Sun, LQ
   Chen, S
   Luo, FL
   Zhang, YP
   Zhu, ZY
   Chen, XY
   Zhao, YY
   Li, Y
AF Wan, Renhong
   Zheng, Qianhua
   Zeng, Xiaorui
   Luo, Yalan
   Sun, Luqiang
   Chen, Shuai
   Luo, Fangli
   Zhang, Yupeng
   Zhu, Ziyue
   Chen, Xinyun
   Zhao, Yuanyuan
   Li, Ying
TI Differential placebo effect of sham acupuncture for chronic pain: a network meta-analysis of randomized controlled trials
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Manual acupuncture; Sham acupuncture; Placebo; Chronic pain; Randomized controlled trial; Meta-analysis
ID tension-type headache; low-back-pain; knee osteoarthritis; needle acupuncture; multicenter; migraine; fibromyalgia; efficacy; devices; blind
AB BackgroundThe clinical effects of acupuncture are often underestimated due to the placebo effect of sham acupuncture. While multiple sham acupuncture methods have been used in clinical practice, it is challenging to select the appropriate sham acupuncture technique due to the lack of head-to-head trials.PurposeThe purpose of this study was to compare the differential placebo effects of diverse sham acupuncture interventions, providing evidence-based guidance for selecting optimal placebo controls in clinical practice.MethodPubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were systematically searched for randomized controlled trials comparing acupuncture with sham acupuncture for the treatment of chronic non-cancer pain (from inceptions to May 1, 2025). The primary outcome measure was pain variation, while secondary outcome measures included adverse events and the assessment of acupuncture blinding. Frequentist random-effect models were employed to perform indirect treatment comparison meta-analysis, and Confidence in Network Meta-Analysis (CINeMA) was utilized to evaluate the level of evidence.ResultsA total of 45 randomized controlled trials (RCTs) were included, involving 7 sham acupuncture methods and 8287 participants. Regarding pain variation, the difference was noted between the waiting treatment group (mean difference 1.86 (95% confidence interval 1.36 to 2.35), SUCRA 97.4%; moderate confidence of evidence) and manual acupuncture group was most pronounced, followed by the difference between the acupoint and no penetration group (mean difference 1.14 (95% confidence interval 0.74 to 1.55), SUCRA 73.6%; low confidence of evidence) and the nonacupoint and no penetration group (mean difference 1.00 (95% confidence interval 0.35 to 1.65), SUCRA 64.8%; low confidence of evidence). Additionally, the rate of adverse events was comparable among the aforementioned sham acupuncture groups, and the blinding procedure was successfully implemented in the trials.ConclusionsThe placebo effect of sham acupuncture is significant, among which the no penetration (acupoint or nonacupoint) groups exhibited the lowest placebo effect. Nevertheless, further head-to-head trials are warranted to obtain direct evidence.Systematic review registrationPROSPERO no. CRD42024535012.
C1 [Wan, Renhong; Zheng, Qianhua; Zeng, Xiaorui; Sun, Luqiang; Zhang, Yupeng; Zhu, Ziyue; Chen, Xinyun; Zhao, Yuanyuan; Li, Ying] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Luo, Yalan] Luzhou Longmatan TCM Hosp, Luzhou, Peoples R China.
   [Chen, Shuai] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
   [Luo, Fangli] North Sichuan Med Coll, Clin Med Coll Integrated Tradit Chinese & Western, Nanchong, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; North Sichuan Medical University
RP Li, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM liying@cdutcm.edu.cn
FU Chengdu University of Traditional Chinese Medicine "Xinglin Scholar"Team Project [XKTD2022008]; General Program of National Natural Science Foundation of China [82,474,659]; Sichuan Natural Science Foundation Youth Fund Project [24NSFSC4900]
CR Baelz GU, 2023, ACTA SCI-HEALTH SCI, V45, P0, DOI 10.4025/actascihealthsci.v45i1.61315
   BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Chen LX, 2013, JCR-J CLIN RHEUMATOL, V19, P308, DOI 10.1097/RHU.0b013e3182a21848
   Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   Maciel LYD, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1477-2
   Dyson-Hudson TA, 2007, ARCH PHYS MED REHAB, V88, P1276, DOI 10.1016/j.apmr.2007.06.014
   Endres HG, 2007, DTSCH ARZTEBL, V104, P0
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Fink M, 2002, FORSCH KOMP KLAS NAT, V9, P210, DOI 10.1159/000066030
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins J, 2024, COCHRANE HDB SYSTEMA, V0, P0
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Huang ZL, 2019, PAIN MED, V20, P2303, DOI 10.1093/pm/pnz167
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7
   Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263
   Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8
   Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kerr CE, 2011, CONSCIOUS COGN, V20, P784, DOI 10.1016/j.concog.2010.12.009
   Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4
   Lam WC, 2021, AM J MED, V134, P1286, DOI 10.1016/j.amjmed.2021.05.002
   Lathia AT, 2009, J ALTERN COMPLEM MED, V15, P613, DOI 10.1089/acm.2008.0272
   Lee YS, 2023, J EVID-BASED MED, V16, P82, DOI 10.1111/jebm.12524
   Li Bo, 2023, ZHONGGUO ZHEN JIU, V43, P654, DOI 10.13703/j.0255-2930.20221113-k0006
   Lin LL, 2018, CLIN REHABIL, V32, P1666, DOI 10.1177/0269215518790632
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Liu L, 2024, QJM-INT J MED, V117, P0, DOI 10.1093/qjmed/hcae094
   Lowe C, 2017, NEUROGASTROENT MOTIL, V29, P0, DOI 10.1111/nmo.13040
   Lu LM, 2024, ANN INTERN MED, V177, P0, DOI 10.7326/M23-2721
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Mayrink WC, 2018, J ACUPUNCT MERIDIAN, V11, P296, DOI 10.1016/j.jams.2018.07.003
   Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Miller E, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen080
   Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Nikolakopoulou A, 2020, PLOS MED, V17, P0, DOI 10.1371/journal.pmed.1003082
   Page Matthew J, 2021, BMJ, V372, Pn71, DOI 10.1016/j.ijsu.2021.105906
   Papakonstantinou T, 2020, CAMPBELL SYST REV, V16, P0, DOI 10.1002/cl2.1080
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Pei LX, 2020, MAYO CLIN PROC, V95, P1671, DOI 10.1016/j.mayocp.2020.01.042
   Qi LY, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.48817
   Qin C, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08971-9
   Qin ZS, 2018, J UROLOGY, V200, P815, DOI 10.1016/j.juro.2018.05.001
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Sun J, 2025, PAIN THER, V14, P737, DOI 10.1007/s40122-025-00713-x
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Takakura Nobuari, 2007, BMC COMPLEMENT ALTERN MED, V7, P31, DOI 10.1186/1472-6882-7-31
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Ugurlu FG, 2017, ACTA REUMATOL PORT, V42, P32
   Vas J, 2016, ACUPUNCT MED, V34, P257, DOI 10.1136/acupmed-2015-010950
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Wang Huaiyu, 2024, ZHONGGUO ZHEN JIU, V44, P411, DOI 10.13703/j.0255-2930.20230626-k0003
   Wang YY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/920353
   Wang Yu-Ting, 2024, ZHEN CI YAN JIU, V49, P875, DOI 10.13702/j.1000-0607.20230390
   White AR, 2000, CEPHALALGIA, V20, P632, DOI 10.1046/j.1468-2982.2000.00097.x
   White IR, 2011, STATA J, V11, P255, DOI 10.1177/1536867X1101100206
   White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Xu SB, 2020, BMJ-BRIT MED J, V368, P0, DOI 10.1136/bmj.m697
   Yang XY, 2022, J INTEGR COMPLEMENT, V28, P202, DOI 10.1089/jicm.2021.0128
   Yao HQ, 2024, BMJ-BRIT MED J, V384, P0, DOI 10.1136/bmj-2023-076410
   Zanette SD, 2008, CLIN RHEUMATOL, V27, P627, DOI 10.1007/s10067-007-0759-y
   Zeng D, 2022, EUR J PAIN, V26, P1006, DOI 10.1002/ejp.1924
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067476
   Zhao J, 2024, FRONT MED-PRC, V18, P678, DOI 10.1007/s11684-024-1073-7
   Zhao L, 2024, ANN INTERN MED, V177, P1330, DOI 10.7326/M23-2425
   Zheng H, 2022, NEUROLOGY, V99, PE1560, DOI 10.1212/WNL.0000000000200670
   Zheng H, 2015, ACUPUNCT MED, V33, P121, DOI 10.1136/acupmed-2014-010679
   Zieger A, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0268646
NR 81
TC 1
Z9 1
U1 9
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD SEP 1
PY 2025
VL 25
IS 1
BP 
EP 
DI 10.1186/s12906-025-05055-x
PG 16
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 6TL8F
UT WOS:001561619800006
PM 40890765
DA 2026-01-16
ER

PT J
AU Zhang, Q
   Zhao, Y
   Cheng, GY
AF Zhang, Qi
   Zhao, Yue
   Cheng, Guang-Yu
TI Effect of negative mood, serum inflammatory factors, miR-155, and brain-derived
SO World journal of psychiatry
LA English
DT Journal Article
DE Abdominal surgery; Depression; Negative mood; Serum inflammatory factor; Syndrome differentiation acupuncture; Tiny RNA-155
AB BACKGROUND: Abdominal postoperative patients are susceptible to postoperative  depression resulting from pain and stress, which can hinder their rehabilitation.  Acupuncture has shown potential to relieve this condition. AIM: To analyze the  mechanism by which acupuncture relieves postoperative depression in patients  post-abdominal surgery. METHODS: Abdominal postoperative patients with depression  between January 2015 and December 2023 at the First Affiliated Hospital of  Heilongjiang University of Chinese Medicine were enrolled. Patients were divided  into two groups using the random throwing method: Observation (250 cases,  fluoxetine hydrochloride + acupuncture treatment) and control (250 cases,  fluoxetine hydrochloride treatment). Changes in negative emotions Hamilton  Depression Scale 24, serum inflammatory factors [tumor necrosis factor α,  interleukin (IL)-1β, IL-6], miR-155 expression levels, and BDNF levels were  assessed. RESULTS: Significant improvements were observed in the observation  group compared to the control group in all assessed parameters after six weeks (P  < 0.05). This suggests that the combination of fluoxetine hydrochloride and  acupuncture may be more effective in managing postoperative depression than  medication alone. CONCLUSION: Acupuncture complies with the principle of  traditional Chinese medicine syndrome differentiation and ensures the pertinence  and effectiveness of treatment. In addition, it not only actively improves  depressive symptoms but also effectively regulates the serum level of  inflammatory factors.
C1 Prevention and Treatment Center, First Affiliated Hospital Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang Province, China.
   Department of Medical, First Affiliated Hospital Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang Province, China.
   Traditional Chinese Medicine Translational Medicine Research Center, First Affiliated Hospital Heilongjiang University of Chinese Medicine, Harbin 150040,Heilongjiang Province, China. chengguangyu@hljucm.edu.cn.
NR 0
TC 0
SN 2220-320
EI 2220-320
J9 World J Psychiatry
PD FEB 20
PY 2025
VL 15
IS 2
BP 99573
EP 99573
DI 10.5498/wjp.v15.i2.99573
PG 0
UT PubMed:39974477
PM 39974477
DA 2025-02-20
ER

PT J
AU Kiss, G
   Póth-Szebenyi, B
   Rózsa, T
   Könyves, L
   Gábor, G
AF Kiss, Gerda
   Poth-Szebenyi, Bettina
   Rozsa, Tamas
   Konyves, Laszlo
   Gabor, Gyorgy
TI Usage of low-level laser therapy in human and veterinary practice
SO MAGYAR ALLATORVOSOK LAPJA
LA Hungarian
DT Article
ID knee osteoarthritis; photobiomodulation; pain; musculoskeletal; irradiation; efficacy; rats; red; rehabilitation; acupuncture
AB The medicative affect of light has been known for several millennia. One of the latest findings in light terapies is Low-Level Laser Therapy (LLLT) which has become increasingly widespread in the recent years and its application is extremely broad from wound treatment and dentistry to physiotherapy and infertility management both in human and veterinary medicine. Its main effect is related to its ability to modulate cellular metabolism (enhancing ATP production, increasing intracellular Ca2+ concentration, enzymatic modulation) and its usage is fairly easy. As a consequence, experiments have been and are being carried out on almost all organ systems of the human and animal body in order to achieve better results with the most precise settings (wavelenght, power, time, frequence) and exact protocols. However, the current literature data is rather controversial about the efficacy of LLLT. Experiments on different species and disorders with different parameters and controls can be found which makes the data incomparable. More well established and detailed studies are needed to carry out and publish to make LLLT an affirmed complementary or, in the future, a primary therapeutic method. Although there are already a few summary studies on the subject, a high number of relevant publications appear every day, which shows the importance and topicality of LLLT. Our aim is shortly reviewing the experimental results published in the last 60 years since the finding of therapeutic laser sources in human and veterinary medicine around the world and to give an outlook on possible future applications, because low-level lasers are potential tools for the treatment of many severe diseases like tumors, or degenerative disorders like Alzheimer's- or Parkinson's disease.
C1 [Kiss, Gerda] Kharisz Vet Kft, Rakoczi U 152, Budapest, Hungary.
   [Poth-Szebenyi, Bettina] MATE, Kaposvari Campus, Kaposvari, Hungary.
   [Rozsa, Tamas] Safe Laser Trade Kft, Budapest, Hungary.
   [Konyves, Laszlo] Allatorvostudomanyi Egyet, Allathigieniai Allornany Egeszsegtani Tanszek & M, Budapest, Hungary.
   [Gabor, Gyorgy] Androvet Kft, Budapest, Hungary.
C3 Hungarian University of Agriculture & Life Sciences; University of Veterinary Medicine Budapest
RP Kiss, G (corresponding author), Kharisz Vet Kft, Rakoczi U 152, Budapest, Hungary.
EM khariszvet@gmail.com
CR Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4
   Ahmad MA, 2022, PHYSIOTHERAPY, V114, P85, DOI 10.1016/j.physio.2021.03.011
   Ahmed W, 2021, J EQUINE VET SCI, V98, P0, DOI 10.1016/j.jevs.2020.103363
   Akbar A, 2023, J PHOTOCH PHOTOBIO B, V248, P0, DOI 10.1016/j.jphotobiol.2023.112796
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103-011-0885-2
   Alves ED, 2019, J PHOTOCH PHOTOBIO B, V194, P6, DOI 10.1016/j.jphotobiol.2019.03.006
   Astuti SD, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e23253
   Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003
   BECKERMAN H, 1992, PHYS THER, V72, P483, DOI 10.1093/ptj/72.7.483
   Catalán J, 2020, THERIOGENOLOGY, V149, P88, DOI 10.1016/j.theriogenology.2020.03.024
   Cheung WKW, 2020, PHYSIOTHERAPY, V106, P24, DOI 10.1016/j.physio.2019.06.005
   Cho HJ, 2004, IN VIVO, V18, P585
   Corral-Baqués MI, 2009, LASER MED SCI, V24, P703, DOI 10.1007/s10103-008-0606-7
   de Almeida TG, 2019, LASER MED SCI, V34, P1001, DOI 10.1007/s10103-018-2690-7
   de Brito AA, 2020, J PHOTOCH PHOTOBIO B, V203, P0, DOI 10.1016/j.jphotobiol.2019.111731
   de Moraes MB, 2020, J ORAL MAXIL SURG, V78, P0, DOI 10.1016/j.joms.2020.05.018
   Draper WE, 2012, J SMALL ANIM PRACT, V53, P465, DOI 10.1111/j.1748-5827.2012.01242.x
   Dyson M, 1985, INTERNATIONAL CONGRESS LASER MEDIC SURGERY, V1, P215
   El Faham DA, 2018, LASER MED SCI, V33, P1105, DOI 10.1007/s10103-018-2476-y
   Enwemeka CS, 2020, J PHOTOCH PHOTOBIO B, V207, P0, DOI 10.1016/j.jphotobiol.2020.111891
   Farivar S, 2014, J LASERS MED SCI, V5, P58
   Fernandes GHC, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0121487
   Figurová M, 2016, PHOTOMED LASER SURG, V34, P53, DOI 10.1089/pho.2015.4013
   FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P229, DOI 10.1038/jid.1959.40
   Flemming K A, 1999, J WOUND CARE, V8, P111
   Fraga RS, 2020, J ORAL MAXIL SURG, V78, P0, DOI 10.1016/j.joms.2020.08.002
   Gagnon D, 2016, BMC VET RES, V12, P0, DOI 10.1186/s12917-016-0689-5
   GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5
   Ghamsari SM, 1996, BRIT VET J, V152, P583, DOI 10.1016/S0007-1935(96)80010-8
   Godine RL, 2014, PHOTOMED LASER SURG, V32, P1, DOI 10.1089/pho.2013.9867
   Grinsted A, 2019, EC GYNAECOL, V8, P875
   HALL J, 1994, BRIT J RHEUMATOL, V33, P142
   Hamblin MR, 2016, J BIOPHOTONICS, V9, P1122, DOI 10.1002/jbio.201670113
   Hamblin MR, 2006, PROC SPIE, V0, P0, DOI DOI 10.1117/12.646294
   Harrison KL, 2008, FERTIL STERIL, V90, PS321, DOI 10.1016/J.FERTNSTERT.2008.07.1670
   Harrison TM, 2023, FOWLERS ZOO WILD ANI, V10, P319, DOI 10.1016/B978-0-323-82852-9.00048-4
   Hasani A, 2020, LIFE SCI, V254, P0, DOI 10.1016/j.lfs.2020.117767
   Haussler KK, 2020, J EQUINE VET SCI, V86, P0, DOI 10.1016/j.jevs.2019.102891
   Jacobsen FM, 1997, PAIN, V73, P110
   John SS, 2020, J CRANIO MAXILL SURG, V48, P251, DOI 10.1016/j.jcms.2020.01.012
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x
   Kelkar M, 2023, J CRANIO MAXILL SURG, V51, P316, DOI 10.1016/j.jcms.2023.05.003
   Kheiri A, 2020, ARCH ORAL BIOL, V117, P0, DOI 10.1016/j.archoralbio.2020.104782
   KLEINKORT JA, 1984, AM J ACUPUNCTURE, V12, P51
   Kurach LM, 2015, VET SURG, V44, P988, DOI 10.1111/vsu.12407
   Laakso L, 1993, AUST J PHYSIOTHER, V39, P95, DOI 10.1016/S0004-9514(14)60473-6
   Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002
   Lorenzini L, 2010, RES VET SCI, V88, P159, DOI 10.1016/j.rvsc.2009.06.001
   Luna SPL, 2020, J EQUINE VET SCI, V85, P0, DOI 10.1016/j.jevs.2019.102846
   Medeiros DM, 2020, PHYS THER SPORT, V42, P124, DOI 10.1016/j.ptsp.2020.01.006
   Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918-13.2013
   Mester A, 2017, PHOTOMED LASER SURG, V35, P393, DOI 10.1089/pho.2017.4332
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002-9610(71)90482-X
   Millis DL, 2023, ANIMALS-BASEL, V13, P0, DOI 10.3390/ani13040667
   Milojevic Momir, 2003, MED PREGL, V56, P413, DOI 10.2298/MPNS0310413M
   Mirulla AI, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e22379
   MULCAHY D, 1995, INJURY, V26, P315, DOI 10.1016/0020-1383(95)00048-E
   Naseri P, 2017, LASER MED SCI, V32, P1971, DOI 10.1007/s10103-017-2296-5
   Ohshiro T, 1991, J CLIN LASER MED SURG, V9, P267
   Ohshiro T, 2005, LASER THER, V14, P121
   Ohshiro Toshio, 2012, LASER THER, V21, P97, DOI 10.5978/islsm.12-OR-05
   Ohshiro Toshio, 2012, LASER THER, V21, P275, DOI 10.5978/islsm.12-OR-16
   Olivieri L, 2015, VET DERMATOL, V26, P35, DOI 10.1111/vde.12170
   Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198
   Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8
   Oubiña G, 2019, PROG BIOPHYS MOL BIO, V145, P10, DOI 10.1016/j.pbiomolbio.2018.11.010
   Garcia GP, 2021, NEUROTRAUMA REP, V2, P548, DOI 10.1089/neur.2021.0005
   Petersen SL, 1999, EQUINE VET J, V31, P228, DOI 10.1111/j.2042-3306.1999.tb03177.x
   Pinheiro A L, 1997, J CLIN LASER MED SURG, V15, P181
   Pryor B, 2015, VET CLIN N AM-SMALL, V45, P45, DOI 10.1016/j.cvsm.2014.09.003
   Quiney L, 2020, J EQUINE VET SCI, V86, P0, DOI 10.1016/j.jevs.2019.102878
   Raja IS, 2024, BIOMATERIALS, V309, P0, DOI 10.1016/j.biomaterials.2024.122623
   Reusing MSde Oliveira, 2021, REVUE VETERINAIRE CLINIQUE, V56, P177, DOI 10.1016/j.anicom.2021.08.001
   Alves MBR, 2016, LASER MED SCI, V31, P695, DOI 10.1007/s10103-016-1911-1
   Roelandts R, 2002, J AM ACAD DERMATOL, V46, P926, DOI 10.1067/mjd.2002.121354
   Ryan T, 2007, IRISH VET J, V60, P295, DOI 10.1186/2046-0481-60-5-295
   Safian F, 2020, PHOTOBIOMOD PHOTOMED, V38, P222, DOI 10.1089/photob.2019.4773
   Saylan A, 2023, REV INT ANDROL, V21, P0, DOI 10.1016/j.androl.2022.04.001
   Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, P0, DOI 10.1186/1744-9081-5-46
   Shaver SL, 2009, J AVIAN MED SURG, V23, P209, DOI 10.1647/2008-038.1
   Siqueira AFP, 2016, LASER MED SCI, V31, P1245, DOI 10.1007/s10103-016-1966-z
   SKOBELKIN O K, 1991, LASER THERAPY, V3, P169
   de Lima VHS, 2020, ORAL ONCOL, V102, P0, DOI 10.1016/j.oraloncology.2019.104524
   Tadakuma Takushi, 1993, KEIO JOURNAL OF MEDICINE, V42, P180
   Tan Gang, 2022, PHOTODIAGNOSIS PHOTODYN THER, V40, P103093, DOI 10.1016/j.pdpdt.2022.103093
   Tanideh N, 2024, KNEE, V47, P208, DOI 10.1016/j.knee.2024.02.004
   Taylor DN, 2020, J CHIROPR MED, V19, P119, DOI 10.1016/j.jcm.2020.06.002
   Thiel H, 1986, J CAN CHIROPR ASS, V30, P133
   Tong SM, 2025, J PHOTOCH PHOTOBIO A, V459, P0, DOI 10.1016/j.jphotochem.2024.116085
   Tsai HW, 2020, GYNECOL ENDOCRINOL, V36, P734, DOI 10.1080/09513590.2020.1712694
   Walsh LJ, 1997, AUST DENT J, V42, P302, DOI 10.1111/j.1834-7819.1997.tb00134.x
   Walsh LJ, 1997, AUST DENT J, V42, P247, DOI 10.1111/j.1834-7819.1997.tb00129.x
   Wang HB, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e13821
   Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8
   Wilden L, 1998, J CLIN LASER MED SUR, V16, P159, DOI 10.1089/clm.1998.16.159
   Yuca Y, 2020, J CRANIO MAXILL SURG, V48, P308, DOI 10.1016/j.jcms.2020.01.017
   Yurtsever MÇ, 2020, J PHOTOCH PHOTOBIO B, V204, P0, DOI 10.1016/j.jphotobiol.2019.111742
   Zielinska P, 2023, J EQUINE VET SCI, V120, P0, DOI 10.1016/j.jevs.2022.104188
   Zipper R, 2022, J COMP EFFECT RES, V11, P843, DOI 10.2217/cer-2021-0281
NR 101
TC 0
Z9 0
U1 3
U2 3
PU MEZOGAZDA KIADO KFT
PI BUDAPEST
PA PO BOX 16, 1631 BUDAPEST, HUNGARY
SN 0025-004X
EI 
J9 MAGY ALLATORVOSOK
JI Magy. Allatorv. Lapja
PD JUL 15
PY 2025
VL 147
IS 7
BP 407
EP 427
DI 10.56385/magyallorv.2025.7.407-427
PG 21
WC Veterinary Sciences
SC Veterinary Sciences
GA 6AD7N
UT WOS:001548491800004
DA 2026-01-16
ER

PT J
AU Cheng, L
   Chen, Y
   Li, LJ
AF Cheng, Lan
   Chen, Yu
   Li, Lianjie
TI Crowned dens syndrome combined with cervical disc herniation: A case report and literature review
SO MEDICINE
LA English
DT Article
DE case report; cervical disc herniation; Crowned dens syndrome; neck pain; odontoid syndrome
AB Rationale:Crowned dens syndrome (CDS) is an unusual and frequently underdiagnosed cause of intense neck pain in older people due to the lack of awareness. The clinical presentation often mimics intracranial infections, which may result in unnecessary invasive procedures and the inappropriate use of antibiotics. The patient had a long-standing history of chronic neck pain, and the acute exacerbation was initially misdiagnosed as cervical disc herniation with suspected intracranial infection before the diagnosis of CDS was established.Patient concerns:We report the first case of an 80-year-old female patient who presented with severe suboccipital neck pain for 10 days, accompanied by restriction of rotational movement of the neck and low-grade fever.Diagnoses and interventions:Differentiating CDS from other potential causes of neck pain, such as degenerative cervical spondylosis, fracture, or metastatic spinal tumors, is challenging given the patient's history and clinical presentation. Initially, the patient was diagnosed with cervical spondylosis. However, treatment with pain-relief patches, acupuncture, and physiotherapy did not alleviate these symptoms. Diagnosis of intracranial infection based on laboratory tests and clinical symptoms cannot be ruled out. However, the antibiotics had no effect. Plain cervical computed tomography revealed typical calcification around the odontoid process. Increased levels of inflammatory markers can contribute to the final diagnosis of CDS. Radiography of the knee joints revealed calcium deposits in the cartilage and ligament tissues, with no apparent alteration, deformity, or destruction of the joints. This finding supported the diagnosis. After combined administration of celecoxib, colchicine, and a short course of corticosteroids, the patient's fever subsided rapidly, and both neck pain and restricted cervical mobility improved significantly. Inflammatory markers, including C-reactive protein and erythrocyte sedimentation rate, decreased rapidly and were within normal limits within 7 days.Outcomes:There was no indication of recurrence, and C-reactive protein and erythrocyte sedimentation rate levels returned to normal at the 2-week follow-up.Lessons:CDS should be considered in cases of acute pain in the neck or occipital regions. Moreover, prompt computed tomography of the cervical vertebrae may guide early diagnosis and avoid unnecessary invasive procedures or administration of antibiotics.
C1 [Cheng, Lan] Ningbo No 2 Hosp, Dept Cardiovasc Med, Ningbo, Zhejiang, Peoples R China.
   [Chen, Yu] Xiangshan Red Cross Taiwan Compatriot Hosp Med & H, Dept Neurosurg, Ningbo, Zhejiang, Peoples R China.
   [Li, Lianjie] Ningbo No 2 Hosp, Dept Neurosurg, 41 Xibei St, Ningbo 315000, Zhejiang, Peoples R China.
RP Li, LJ (corresponding author), Ningbo No 2 Hosp, Dept Neurosurg, 41 Xibei St, Ningbo 315000, Zhejiang, Peoples R China.
EM 1157202624@qq.com; 564600178@qq.com; 798095204@qq.com
CR Awisat A, 2020, CLIN RHEUMATOL, V39, P571, DOI 10.1007/s10067-019-04822-9
   BOUVET JP, 1985, ARTHRITIS RHEUM, V28, P1417, DOI 10.1002/art.1780281215
   Castellanos Gustavo, 2025, CUREUS, V17, Pe78158, DOI 10.7759/cureus.78158
   Ferraccioli G, 2023, RMD OPEN, V9, P0, DOI 10.1136/rmdopen-2023-003017
   Goto S, 2007, J BONE JOINT SURG AM, V89A, P2732, DOI 10.2106/JBJS.F.01322
   Haikal A, 2020, AM J MED, V133, PE32, DOI 10.1016/j.amjmed.2019.06.050
   Hamdan O, 2025, RHEUMATOL INT, V45, P0, DOI 10.1007/s00296-025-05884-6
   Huang P, 2022, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.528663
   Koda R, 2015, INTERNAL MED, V54, P2405, DOI 10.2169/internalmedicine.54.4571
   Morita S, 2025, CLIN CASE REP, V13, P0, DOI 10.1002/ccr3.70168
   Okumura N, 2025, J GEN FAM MED, V26, P267, DOI 10.1002/jgf2.780
   Palmowski A, 2025, CAN J EMERG MED, V27, P233, DOI 10.1007/s43678-024-00850-w
   Sakhamuru P, 2025, CUREUS, V17, P0
   Tang J, 2020, EXP THER MED, V20, P3853, DOI 10.3892/etm.2020.9128
   Wang SM, 2023, QUANT IMAG MED SURG, V13, P4984, DOI 10.21037/qims-22-1387
   Yang X, 2022, BONE JOINT J, V104B, P1242, DOI 10.1302/0301-620X.104B11.BJJ-2022-0657.R2
NR 16
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 31
PY 2025
VL 104
IS 44
BP 
EP 
DI 10.1097/MD.0000000000045039
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 9ZK4O
UT WOS:001618674700036
PM 41261598
DA 2026-01-16
ER

PT J
AU Hao, YB
   Liu, YL
   Wang, XM
   Cheng, K
   Tu, QY
   Dai, F
   Yang, XB
AF Hao, Ya-bo
   Liu, Yan-lin
   Wang, Xiao-mei
   Cheng, Kai
   Tu, Qing-yu
   Dai, Fei
   Yang, Xi-bing
TI Effects of Electroacupuncture at ST36 on Visceral Pain and Inflammatory Markers in IBS Rats
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article; Early Access
DE electroacupuncture; inflammatory biomarkers; visceral hypersensitivity; visceral pain; Zusanli
ID acupuncture; mechanisms; pathway; model
AB Background: Irritable bowel syndrome (IBS) is characterized by recurrent visceral pain associated with low-grade gut inflammation. Electroacupuncture (EA) at acupoint ST36 (Zusanli) is reputed to alleviate gastrointestinal disorders, but its effects on IBS-related visceral hypersensitivity and inflammation remain to be fully elucidated. This study evaluated whether EA at ST36 attenuates visceral pain and modulates key inflammatory mediators in the IBS rat model. Methods: Forty male rats were randomly assigned to Control, IBS model, IBS + EA, and IBS + Sham groups (n = 10 each). IBS was induced by intracolonic acetic acid enema combined with daily restraint stress for 1 week, validating the IBS-D model. EA was applied at bilateral ST36 (2/100 Hz alternating frequency, similar to 0.5 mA, 20 min) every other day for 2 weeks; sham treatment used superficial needling with no electrical current. Visceral pain was assessed by abdominal withdrawal reflex (AWR) scores and electromyographic responses to graded colorectal distension. Colonic tissues were analyzed for pro-inflammatory cytokines (interleukin-1 beta, IL-6, tumor necrosis factor-alpha) by ELISA and for the expression of pain or inflammation-related proteins (TRPV1 and nuclear factor kappa B, NF-kappa B) by Western blot analyses. Results: IBS model rats exhibited pronounced visceral hypersensitivity, with AWR scores significantly elevated (e.g., score 3 threshold volume reduced by similar to 40% vs. controls, p < 0.01). EA at ST36 markedly alleviated visceral pain, increasing pain threshold and reducing AWR scores by similar to 30%-50% compared to untreated IBS (p < 0.05). EA also significantly downregulated colonic IL-1 beta, IL-6, and TNF-alpha levels (by 45%-60% vs. IBS, p < 0.01) and reduced TRPV1 and NF-kappa B expression toward normal levels. Conclusion: EA at ST36 produced significant analgesic and anti-inflammatory effects in IBS model rats. Visceral hypersensitivity was blunted and colonic inflammatory biomarkers (cytokines, TRPV1, NF-kappa B) were suppressed by EA, suggesting that EA at ST36 modulates neuro-immune pathways to relieve IBS-related pain. These findings support the therapeutic potential of ST36-targeted electroacupuncture for managing IBS visceral pain via inflammatory mechanism attenuation.
C1 [Hao, Ya-bo; Liu, Yan-lin; Wang, Xiao-mei; Yang, Xi-bing] Jiaxing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Jiaxing, Zhejiang, Peoples R China.
   [Cheng, Kai] Jiaxing Hosp Tradit Chinese Med, Pediat Dept, Jiaxing, Zhejiang, Peoples R China.
   [Tu, Qing-yu] Jiaxing Hosp Tradit Chinese Med, Jiaxing, Zhejiang, Peoples R China.
   [Dai, Fei] Xi An Jiao Tong Univ, Affiliated Hosp 2, Div Gastroenterol, Xian, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Yang, XB (corresponding author), Jiaxing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Jiaxing, Zhejiang, Peoples R China.; Dai, F (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Div Gastroenterol, Xian, Shaanxi, Peoples R China.
EM feifeili001@outlook.com; yxb821018@163.com
CR Aggeletopoulou I, 2024, INT J MOL SCI, V25, P0, DOI 10.3390/ijms252212395
   Alam MJ, 2024, BIOELECTRON MED-US, V10, P0, DOI 10.1186/s42234-024-00158-1
   Alam MJ, 2023, BIOELECTRON MED-US, V9, P0, DOI 10.1186/s42234-023-00130-5
   Unknown -, 2021, J INFLAMM RES, V14, P393, DOI 10.2147/JIR.S306309
   Black CJ, 2021, FRONTLINE GASTROENTE, V12, P303, DOI 10.1136/flgastro-2019-101298
   Bonaz Bruno, 2020, BIOELECTRON MED, V6, P15, DOI 10.1186/s42234-020-00051-7
   Canavan C, 2014, CLIN EPIDEMIOL, V6, P71, DOI 10.2147/CLEP.S40245
   Carothers AM, 2010, CANCER RES, V70, P4433, DOI 10.1158/0008-5472.CAN-09-4289
   Chen Longtu, 2017, ANESTH PAIN MED, V7, Pe42747, DOI 10.5812/aapm.42747
   Chen Y, 2021, J INFLAMM RES, V14, P325, DOI 10.2147/JIR.S285146
   Chu D, 2011, INT J COLORECTAL DIS, V26, P569, DOI 10.1007/s00384-010-1087-2
   Enck P, 2016, NAT REV DIS PRIMERS, V2, P0, DOI 10.1038/nrdp.2016.14
   Fan HQ, 2025, SCI REP-UK, V15, P0, DOI 10.1038/s41598-025-91883-3
   Guo J, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.918652
   Guo XJ, 2024, NEUROMODULATION, V27, P295, DOI 10.1016/j.neurom.2023.08.010
   Huyghe JR, 2021, GUT, V70, P1325, DOI 10.1136/gutjnl-2020-321534
   Kang XL, 2024, DIGEST DIS SCI, V69, P1143, DOI 10.1007/s10620-024-08288-x
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Papale AJ, 2024, J CLIN MED, V13, P0, DOI 10.3390/jcm13226948
   Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189
   Tang Y, 2025, J PAIN RES, V18, P2175, DOI 10.2147/JPR.S483750
   Wu SY, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-96
   Xiang Y, 2018, J PAIN RES, V11, P83, DOI 10.2147/JPR.S152743
   Yang JP, 2006, WORLD J GASTROENTERO, V12, P2781, DOI 10.3748/wjg.v12.i17.2781
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yang YZ, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1251470
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang SP, 2023, FRONT PAIN RES, V4, P0, DOI 10.3389/fpain.2023.1202590
   Zhou J, 2025, PLOS ONE, V20, P0, DOI 10.1371/journal.pone.0314678
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
EI 1365-2982
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD DEC 18
PY 2025
VL 0
IS 
BP 
EP 
DI 10.1111/nmo.70195
EA DEC 2025
PG 14
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA Z7815
UT WOS:001642955500001
PM 41413920
DA 2026-01-16
ER

PT J
AU Meng, HSL
   Yu, H
   Gang, SH
   Bo, A
   Wang, ZL
AF Meng, Husileng
   Yu, Hong
   Gang, Suhe
   Bo, Agula
   Wang, Zhanli
TI Therapeutic effects of Mongolian medical warm acupuncture on neuropathic pain via gut microbiota and inflammatory pathway regulation in a chronic constriction injury rat model
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Mongolian medical warm acupuncture; neuropathic pain; chronic constriction injury; gut microbiota; inflammation
AB The study was designed to determine whether Mongolian medical warm acupuncture (MMWA) can alleviate neuropathic pain through regulating gut microbiota and inflammation-related pathways in the chronic constriction injury (CCI) rat model. Rats were randomly divided into three groups: sham, model, and treatment. A bilateral chronic constriction injury (CCI) was induced to establish a rat model of neuropathic pain. Rats in the treatment group received MMWA at the Heyi and Shen acupoints once daily for seven consecutive days. Pain-related behaviors were evaluated using mechanical pain threshold and thermal withdrawal latency measurements. The mRNA levels of c-fos in spinal dorsal horns were determined using real-time PCR. Gut microbiota was analyzed by 16S ribosomal RNA sequencing. Interleukin (IL)-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha were evaluated by enzyme-linked immunosorbent assay (ELISA) analysis. MMWA could relieve behavioral symptoms (P<0.01). MMWA intervention significantly suppressed the expression of c-fos in CCI rats (P<0.05). The relative abundance of gut bacteria was disturbed in CCI rats, with the microbiota disorder ameliorated by MMWA. KEGG enrichment analysis revealed that changes in gut microbiota were associated with the pentose and glucuronate interconversion pathway and secondary bile acid biosynthesis. The concentrations of IL-1 beta, IL-6, and TNF-alpha in CCI rats were increased (P<0.05), an effect that was reversed by MMWA intervention (P<0.05). The current study indicated that the MMWA could effectively alleviate neuropathic pain by modulating gut microbiota and inhibiting inflammation in the CCI rat model, suggesting that gut microbiota could be a promising potential biological target for treating neuropathic pain.
C1 [Meng, Husileng; Gang, Suhe; Bo, Agula] Inner Mongolia Med Univ, Mongolian Med Sch, 5 Xinhua St, Hohhot, Peoples R China.
   [Yu, Hong; Bo, Agula; Wang, Zhanli] Baotou Med Coll, Affiliated Hosp 2, Inner Mongolia Key Lab Dis Related Biomarkers, 30 Hudemulin Ave, Baotou, Peoples R China.
C3 Inner Mongolia Medical University; Baotou Medical College
RP Bo, A (corresponding author), Inner Mongolia Med Univ, Mongolian Med Sch, 5 Xinhua St, Hohhot, Peoples R China.; Bo, A; Wang, ZL (corresponding author), Baotou Med Coll, Affiliated Hosp 2, Inner Mongolia Key Lab Dis Related Biomarkers, 30 Hudemulin Ave, Baotou, Peoples R China.
EM agula372000@126.com; wang.zhanli@hotmail.com
FU National Natural Science Foundation of China [82460987, 82074577, 82260092]; Natural Science Foundation of Inner Mongolia Autonomous Region of China [2023ZD01, 2023QN08065]
CR Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Cavalli E, 2019, INT J IMMUNOPATH PH, V33, P0, DOI 10.1177/2058738419838383
   Chen P, 2021, MOL BRAIN, V14, P0, DOI 10.1186/s13041-021-00765-y
   Cruz-Mendoza F, 2022, BRAIN SCI, V12, P0, DOI 10.3390/brainsci12060687
   Ding WH, 2021, ANESTH ANALG, V132, P1146, DOI 10.1213/ANE.0000000000005155
   Ellis RJ, 2022, J PAIN, V23, P318, DOI 10.1016/j.jpain.2021.08.006
   Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019
   Gula A, 2019, ACUPUNCT MED, V37, P301, DOI 10.1136/acupmed-2016-011243
   Han JL, 2011, MED SCI MONITOR, V17, PRA164, DOI 10.12659/MSM.881842
   Hua DY, 2022, FRONT MOL NEUROSCI, V14, P0, DOI 10.3389/fnmol.2021.806700
   Huang XC, 2016, J ETHNOPHARMACOL, V186, P234, DOI 10.1016/j.jep.2016.03.067
   Jing YL, 2021, MICROBIOME, V9, P0, DOI 10.1186/s40168-021-01007-y
   Kakoty V, 2021, NEUROSCI LETT, V753, P0, DOI 10.1016/j.neulet.2021.135865
   Lanza M, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10102756
   Li RL, 2022, FRONT PHYSIOL, V13, P0, DOI 10.3389/fphys.2022.813626
   Lian NQ, 2021, J PAIN RES, V14, P681, DOI 10.2147/JPR.S288289
   Lin BB, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-020-01170-x
   Lin H, 2021, CIRC-HEART FAIL, V14, P1136, DOI 10.1161/CIRCHEARTFAILURE.120.008220
   Liu CS, 2019, FRONT MICROBIOL, V10, P0, DOI 10.3389/fmicb.2019.00825
   Morreale C, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11060971
   Pane K, 2022, NEUROBIOL DIS, V170, P0, DOI 10.1016/j.nbd.2022.105773
   Rowin J, 2019, MUSCLE NERVE, V60, P124, DOI 10.1002/mus.26510
   Runa A, 2021, ANN PALLIAT MED, V10, P5541, DOI 10.21037/apm-21-925
   Saiyin Chao-Ke-Tu, 2021, ZHEN CI YAN JIU, V46, P742, DOI 10.13702/j.1000-0607.200761
   Shen CL, 2022, J NUTR BIOCHEM, V100, P0, DOI 10.1016/j.jnutbio.2021.108904
   Shui L, 2020, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00078
   Takagi T, 2016, BRIT J NUTR, V116, P1199, DOI 10.1017/S0007114516003068
   van Hecke O, 2014, PAIN, V155, P654, DOI 10.1016/j.pain.2013.11.013
   Wang C, 2023, INT IMMUNOPHARMACOL, V125, P0, DOI 10.1016/j.intimp.2023.111170
   Wu Y, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.830439
   Yu H, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0267843
   Yu JW, 2021, MOL DIVERS, V25, P233, DOI 10.1007/s11030-020-10055-9
   Yu XD, 2017, ACUPUNCT MED, V35, P142, DOI 10.1136/acupmed-2016-011063
   Yu Y, 2019, AM J PHYSIOL-GASTR L, V317, PG275, DOI 10.1152/ajpgi.00016.2019
   Zhang WG, 2021, MOL MED REP, V23, P0, DOI 10.3892/mmr.2021.11870
   Zhang X, 2021, J PAIN RES, V14, P2083, DOI 10.2147/JPR.S317204
   Zhao X, 2012, NEUROPHARMACOLOGY, V62, P843, DOI 10.1016/j.neuropharm.2011.08.050
   Zheng DW, 2020, ADV MATER, V32, P0, DOI 10.1002/adma.202004529
   Zheng SJ, 2021, BRAIN BEHAV, V11, P0, DOI 10.1002/brb3.2036
   Zhou F, 2021, MOL PAIN, V17, P0, DOI 10.1177/1744806921996520
NR 40
TC 0
Z9 0
U1 0
U2 0
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PD JUN 15
PY 2025
VL 77
IS 3
BP 225
EP 236
DI 10.2298/ABS250531018M
PG 12
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA AN1GV
UT WOS:001652051700002
DA 2026-01-16
ER

